
  <!doctype html>
  <html lang="en">
  <head>
  <meta charset="UTF-8">
  <title>CPAT Report</title>
  <link rel="stylesheet" href="./css/modest.css">
  </head>
  <body>
  
<h1>CPAT Report</h1>
<blockquote>
<p>Report Time: Fri Mar 18 17:35:32 2022</p>
<p>Biogeographic Group: Oceanian</p>
<h2>Pharmacogenomics Summary</h2>
<p>CPAT calculated the effect scores of the drugs of interest in the five phenotype categories based on the genotypes obtained from the analysis. Evidence levels 1A, 1B, 2, 3, and 4 are used to indicate the degree of influence of a drug on a particular drug response.</p>
</blockquote>
  

  <table width= "400" border="1">
    <tr>
      <th>Evidence</th><th>Toxicity</th><th>Dosage</th><th>Toxicity</th><th>Efficacy</th><th>Metabolism/PK</th><th>Other</th>
    </tr>
    <tr>
      <td bgcolor="#55B979"><font color="white"><b>Level 1A</b></font></td><td>warfarin; mercaptopurine; phenytoin; azathioprine; fluvastatin; simvastatin; atorvastatin; rasburicase; fluorouracil; capecitabine; efavirenz; sevoflurane; rosuvastatin; lovastatin; pravastatin; succinylcholine; halothane; methoxyflurane; isoflurane; desflurane; enflurane; acenocoumarol; methotrexate; opioids; heroin; aspirin; gemcitabine; carboplatin; docetaxel; cisplatin</td><<td>warfarin; mercaptopurine; azathioprine; acenocoumarol; phenprocoumon</td><td>atorvastatin; fluorouracil; methotrexate; Platinum compounds; ribavirin; peginterferon alfa-2b; Tumor necrosis factor alpha (TNF-alpha) inhibitors; peginterferon alfa-2a; telaprevir; boceprevir</td><td>phenytoin; fluvastatin; simvastatin; efavirenz; rosuvastatin; lovastatin; pravastatin; tacrolimus; celecoxib; oxycodone; ibuprofen; meloxicam; siponimod; flurbiprofen; lornoxicam; tenoxicam; piroxicam; lovastatin acid; pitavastatin; simvastatin acid</td><td></td>
    </tr>
    <tr>
      <td bgcolor="#55B979"><font color="white"><b>Level 1B</b></font></td><td>cyclophosphamide; olanzapine; ethanol; Platinum compounds; antipsychotics; nicotine; tegafur; doxorubicin; ribavirin; peginterferon alfa-2b; thioguanine; paclitaxel; thalidomide; risperidone; irinotecan; cytarabine; Drugs For Treatment Of Tuberculosis; tacrolimus; leucovorin; isoniazid; clozapine; hmg coa reductase inhibitors; cocaine; phenprocoumon; fentanyl; sorafenib; idarubicin; methamphetamine; methadone; ritonavir; acetaminophen</td><<td>tacrolimus; fentanyl; methadone; valproic acid</td><td>warfarin; simvastatin; rosuvastatin; pravastatin; gemcitabine; carboplatin; docetaxel; cisplatin; cyclophosphamide; ethanol; antipsychotics; nicotine; doxorubicin; thalidomide; risperidone; irinotecan; cytarabine; leucovorin; hmg coa reductase inhibitors; sorafenib; idarubicin; citalopram; atenolol; paroxetine; imatinib; escitalopram; radiotherapy; antidepressants; oxaliplatin; bupropion; varenicline; venlafaxine; hydrochlorothiazide; lithium; methylphenidate; pemetrexed; interferon beta-1a; interferon beta-1b; deferasirox; interferons; fenofibrate; Selective serotonin reuptake inhibitors; adalimumab; etanercept; sofosbuvir; infliximab; metformin</td><td>atorvastatin; methotrexate; nicotine; fentanyl; nevirapine; losartan; cotinine</td><td></td>
    </tr>
    <tr>
      <td bgcolor="#3F72D8"><font color="white"><b>Level 2</b></font></td><td>sunitinib; exemestane; nevirapine; letrozole; citalopram; morphine; etoposide; atenolol; gefitinib; bleomycin; paroxetine; imatinib; cyclosporine; everolimus; amiodarone; vincristine; escitalopram; levodopa; mycophenolate mofetil; remifentanil; rifampin; anastrozole; atazanavir; Ace Inhibitors, Plain; radiotherapy; fludarabine; gemtuzumab ozogamicin; antidepressants; oxaliplatin; Antiinflammatory agents, non-steroids; sirolimus; hormonal contraceptives for systemic use; nelfinavir; verapamil; Antivirals for treatment of HIV infections, combinations; Tumor necrosis factor alpha (TNF-alpha) inhibitors; glibenclamide; Pyrazolones; propionic acid derivatives; diclofenac; valproic acid; didanosine; bupropion; varenicline; tenofovir disoproxil fumarate; taxanes; clomipramine; nefazodone; venlafaxine; enalapril; hydrochlorothiazide; dexamethasone; pyrazinamide; carbamazepine; quetiapine; celecoxib; Bisphosphonates; nortriptyline; Dabigatran; fluvoxamine</td><<td>opioids; paroxetine; carbamazepine; sufentanil</td><td>phenytoin; azathioprine; fluvastatin; capecitabine; efavirenz; sevoflurane; lovastatin; aspirin; olanzapine; paclitaxel; clozapine; phenprocoumon; fentanyl; methadone; sunitinib; letrozole; morphine; etoposide; cyclosporine; everolimus; vincristine; remifentanil; anastrozole; Ace Inhibitors, Plain; nelfinavir; clomipramine; nefazodone; enalapril; dexamethasone; quetiapine; Bisphosphonates; daunorubicin; cetuximab; trastuzumab; sertraline; tamoxifen; allopurinol; epirubicin; corticosteroids; losartan; sulfonamides, urea derivatives; metoprolol; mirtazapine; bevacizumab; fluoxetine; anthracyclines and related substances; carvedilol; pitrakinra; ledipasvir; repaglinide; calcium channel blockers; rituximab; rivastigmine; mitoxantrone; clodronate; ustekinumab; glucocorticoids; folic acid; candesartan; mycophenolic acid; certolizumab pegol; ketorolac; perindopril; montelukast; lisinopril; omeprazole; chlorthalidone; milnacipran; nifedipine; prasugrel; dexrazoxane; voxilaprevir; vitamin b-complex, plain; velpatasvir; pegaptanib; benazepril; cladribine; diuretics; simeprevir; irbesartan; naltrexone; modafinil; atomoxetine; dobutamine; duloxetine; Drugs used in nicotine dependence</td><td>cyclophosphamide; thioguanine; phenprocoumon; methadone; exemestane; imatinib; cyclosporine; atazanavir; nelfinavir; diclofenac; carbamazepine; deferasirox; oxcarbazepine; lamotrigine; metformin; omeprazole; lopinavir; zafirlukast; Vitamin K1</td><td></td>
    </tr>
    <tr>
      <td bgcolor="#F5C344"><font color="white"><b>Level 3</b></font></td><td>codeine; cerivastatin; trifluoperazine; fluphenazine; chlorpromazine; thioridazine; cannabinoids; haloperidol; tramadol; buprenorphine; aripiprazole; platinum; daunorubicin; propofol; desloratadine; dalcetrapib; lithium; asparaginase; glimepiride; glipizide; Thiazides, plain; nitrous oxide; dapsone; cetuximab; trastuzumab; Farglitazar; sertraline; tamoxifen; allopurinol; Beta Blocking Agents; timolol; prednisone; dolasetron; epirubicin; granisetron; lenalidomide; caffeine; amisulpride; selegiline; amantadine; Anticholinergics; prednisolone; deferiprone; Dopamine agonists; corticosteroids; methylphenidate; triamcinolone; sumatriptan; Analgesics; rosiglitazone; Ergot alkaloids; ethambutol; losartan; pemetrexed; liothyronine; sulfonamides, urea derivatives; dextroamphetamine; antineoplastic agents; Antibiotics; ciprofloxacin; sufentanil; paliperidone; interferon beta-1a; chloramphenicol; oseltamivir; interferon beta-1b; thiazolidinediones; peginterferon alfa-2a; pegaspargase; temsirolimus; rivaroxaban; apixaban; sulfamethoxazole; protease inhibitors; metoprolol; amphetamine; Opium alkaloids and derivatives; mirtazapine; methylene blue; zoledronate; methylprednisolone; nitrofurantoin; ritodrine; interferon alfa-2a, recombinant; phenazopyridine; egfr inhibitors; dimercaprol; deferasirox; iloperidone; indomethacin; volatile anesthetics; sulfasalazine; clavulanate; phenobarbital; oxycodone; glatiramer acetate; Antithyroid Preparations; muraglitazar; amoxicillin; bevacizumab; Dihydropyridine derivatives; hydrocodone; sulfametopyrazine; sulfamethoxazole / trimethoprim; sulfadoxine</td><<td>phenytoin; simvastatin; atorvastatin; methotrexate; docetaxel; cyclophosphamide; ethanol; antipsychotics; nicotine; doxorubicin; ribavirin; thioguanine; paclitaxel; sunitinib; morphine; imatinib; cyclosporine; levodopa; mycophenolate mofetil; remifentanil; sirolimus; codeine; buprenorphine; propofol; selegiline; amantadine; Anticholinergics; Dopamine agonists; oxycodone; bevacizumab; purine analogues; antiepileptics; lamotrigine; SN-38; interferon alfa-2b, recombinant; meperidine; pentazocine; mephenytoin; catecholamines; fexofenadine; rocuronium; carvedilol</td><td>opioids; tacrolimus; ritonavir; exemestane; gefitinib; levodopa; mycophenolate mofetil; gemtuzumab ozogamicin; verapamil; valproic acid; taxanes; carbamazepine; celecoxib; nortriptyline; fluvoxamine; trifluoperazine; chlorpromazine; haloperidol; tramadol; buprenorphine; aripiprazole; propofol; dalcetrapib; Thiazides, plain; Beta Blocking Agents; prednisone; granisetron; lenalidomide; amisulpride; deferiprone; Analgesics; rosiglitazone; antineoplastic agents; sufentanil; paliperidone; amphetamine; methylene blue; interferon alfa-2a, recombinant; volatile anesthetics; sulfasalazine; phenobarbital; oxycodone; leflunomide; purine analogues; interferon alfa-2b, recombinant; rocuronium; tocilizumab; ondansetron; pioglitazone; donepezil; hydroxyurea; Enzymes; trifluridine; tipiracil hydrochloride; alendronate; benzodiazepine derivatives; maraviroc; lonafarnib; risedronate; etidronic acid; tiludronate; galantamine; Opioid anesthetics; Other general anesthetics; desipramine; sildenafil; Vitamin B-complex, Incl. Combinations; cyanocobalamin; l-methylfolate; insulin recombinant; zinc acetate; Antihypertensives; Pertussis vaccines; pazopanib; salvianolic acid b; conjugated estrogens; rabeprazole; lansoprazole; zileuton; medroxyprogesterone; ivacaftor; Antihypertensives And Diuretics In Combination; calcium; Drugs used in alcohol dependence; abiraterone; captopril; salbutamol; erlotinib; imidapril; fluticasone propionate; doxepin; perphenazine; disulfiram; quinapril; spironolactone; acetylcysteine; trandolapril; panitumumab; selective beta-2-adrenoreceptor agonists; Beta blocking agents, selective; fluindione; nimodipine; Angiotensin II Antagonists; thyrotropin alfa; follitropin beta; urofollitropin; digoxin; bromperidol; nemonapride; nitrendipine; bucindolol; acamprosate; deleobuvir; bumetanide; ibuprofen; torasemide; faldaprevir; furosemide; gliclazide; lurasidone; axitinib; rofecoxib; lamivudine; Hepatitis vaccines; lopinavir; zidovudine; terbutaline; creatine; butorphanol; angiotensin II; agomelatine; highly active antiretroviral therapy (haart); latanoprost; lumefantrine; prochlorperazine; pramipexole; ticagrelor; cangrelor; vinorelbine; ziprasidone; raloxifene; daclatasvir; curcumin; liraglutide; pantoprazole; bisoprolol</td><td>warfarin; gemcitabine; docetaxel; olanzapine; ethanol; risperidone; irinotecan; ritonavir; acetaminophen; morphine; etoposide; everolimus; rifampin; anastrozole; sirolimus; valproic acid; quetiapine; Dabigatran; tramadol; granisetron; caffeine; sufentanil; temsirolimus; rivaroxaban; apixaban; sulfasalazine; tenofovir; clopidogrel; SN-38; fexofenadine; telaprevir; folic acid; mycophenolic acid; montelukast; maraviroc; sildenafil; pazopanib; lansoprazole; erlotinib; nimodipine; digoxin; lumefantrine; ticagrelor; amlodipine; midazolam; acetaldehyde; daptomycin; voriconazole; bilirubin; topotecan; tolbutamide; silibinin; dolutegravir; o-desmethyltramadol; telmisartan; temozolomide; letermovir; cilostazol; amprenavir; tipifarnib; 3,4-methylenedioxymethamphetamine; etravirine; dicloxacillin; dextropropoxyphene; busulfan; S-EDDP; (R)-methadone; talinolol; vardenafil; difluorodeoxyuridine; ceftriaxone; dipyrone; fesoterodine; desmethylnaproxen; tapentadol; l-phenylalanine; carbocisteine; oxazepam</td><td>phenytoin; simvastatin; atorvastatin; fluorouracil; efavirenz; acenocoumarol; methotrexate; opioids; heroin; aspirin; gemcitabine; docetaxel; olanzapine; ethanol; nicotine; tegafur; doxorubicin; risperidone; irinotecan; cytarabine; tacrolimus; clozapine; hmg coa reductase inhibitors; cocaine; fentanyl; methamphetamine; methadone; ritonavir; acetaminophen; exemestane; nevirapine; letrozole; morphine; paroxetine; imatinib; mycophenolate mofetil; rifampin; anastrozole; atazanavir; Antiinflammatory agents, non-steroids; sirolimus; verapamil; valproic acid; quetiapine; thioridazine; aripiprazole; lithium; prednisone; amisulpride; sumatriptan; Analgesics; Ergot alkaloids; losartan; paliperidone; amphetamine; mirtazapine; metformin; repaglinide; nifedipine; ondansetron; digoxin; pitavastatin; midazolam; 3,4-methylenedioxymethamphetamine; dicloxacillin; talinolol; nilotinib; mitotane; trimipramine; triglycerides; topiramate; rhodamine 123; memantine; dasatinib; coumarin; ataluren; antithymocyte globulin; debrisoquine; dexmedetomidine; l-tryptophan; indinavir; hdl cholesterol; estradiol; doxorubicinol; zonisamide</td>
    </tr>
    <tr>
      <td bgcolor="#B64641"><font color="white"><b>Level 4</b></font></td><td></td><<td></td><td></td><td></td><td></td>
    </tr>
  </table>
<h2>Pharmacogenomics Details</h2>
<h3>Diplotypes predicted by CPAT</h3>
<table width= "400" border="1">
<tr><th>ID</th><th>Gene</th><th>Variant</th><th>Drug</th><th>Phenotypes</th><th>EvidenceLevel</th><th>Alleles</th><th>PhenotypeCategory</th><th>Annotation</th><th>Function</th></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183620959>0</a></td><td>G6PD</td><td>G6PD A- 202A_376G</td><td>methylene blue</td><td>Anemia, Hemolytic;Hemolysis;Protein Deficiency</td><td>3</td><td>B (wildtype)</td><td>Efficacy</td><td>Male patients with the B (wildtype) haplotype who are treated with methylene blue 1) may be more likely to respond to treatment for methemoglobinemia 2) may have a reduced risk of drug-induced hemolysis as compared to patients with the A- 202A_376G haplotype (hemizygous for the G6PD A- variant). Other genetic and clinical factors may also influence a patient's response to methylene blue treatment and risk of hemolysis.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183620959>1</a></td><td>G6PD</td><td>G6PD B (wildtype)</td><td>methylene blue</td><td>Anemia, Hemolytic;Hemolysis;Protein Deficiency</td><td>3</td><td>B (wildtype)</td><td>Efficacy</td><td>Male patients with the B (wildtype) haplotype who are treated with methylene blue 1) may be more likely to respond to treatment for methemoglobinemia 2) may have a reduced risk of drug-induced hemolysis as compared to patients with the A- 202A_376G haplotype (hemizygous for the G6PD A- variant). Other genetic and clinical factors may also influence a patient's response to methylene blue treatment and risk of hemolysis.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183491318>2</a></td><td>CYP3A4</td><td>CYP3A4*1</td><td>atorvastatin</td><td>Hyperlipidemias</td><td>3</td><td>*1/*1</td><td>Efficacy</td><td>Patients with the *1/*1 diplotype and Hyperlipidemia may have a reduced response to atorvastatin treatment (determined by a lower reduction in total cholesterol) as compared to patients with the *1/*1G or *1G/*1G diplotype. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183491318>3</a></td><td>CYP3A4</td><td>CYP3A4*1G</td><td>atorvastatin</td><td>Hyperlipidemias</td><td>3</td><td>*1/*1</td><td>Efficacy</td><td>Patients with the *1/*1 diplotype and Hyperlipidemia may have a reduced response to atorvastatin treatment (determined by a lower reduction in total cholesterol) as compared to patients with the *1/*1G or *1G/*1G diplotype. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183491310>4</a></td><td>CYP3A4</td><td>CYP3A4*1</td><td>simvastatin</td><td>Hyperlipidemias</td><td>3</td><td>*1/*1</td><td>Efficacy</td><td>Patients with the *1/*1 diplotype and Hyperlipidemia may have a reduced response to simvastatin treatment as compared to patients with the *1/*4 genotype. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183491310>5</a></td><td>CYP3A4</td><td>CYP3A4*4</td><td>simvastatin</td><td>Hyperlipidemias</td><td>3</td><td>*1/*1</td><td>Efficacy</td><td>Patients with the *1/*1 diplotype and Hyperlipidemia may have a reduced response to simvastatin treatment as compared to patients with the *1/*4 genotype. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183615041>6</a></td><td>CYP2B6</td><td>CYP2B6*1</td><td>mirtazapine</td><td>Depression</td><td>3</td><td>*5/*6</td><td>Efficacy</td><td>Patients with the CYP2B6 *5/*6 genotype and depression may have a decreased response when treated with mirtazapine as compared to patients with the CYP2B6 *6/*6 genotype. Other genetic and clinical factors may also influence response to mirtazapine.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183615041>7</a></td><td>CYP2B6</td><td>CYP2B6*4</td><td>mirtazapine</td><td>Depression</td><td>3</td><td>*5/*6</td><td>Efficacy</td><td>Patients with the CYP2B6 *5/*6 genotype and depression may have a decreased response when treated with mirtazapine as compared to patients with the CYP2B6 *6/*6 genotype. Other genetic and clinical factors may also influence response to mirtazapine.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183615041>8</a></td><td>CYP2B6</td><td>CYP2B6*5</td><td>mirtazapine</td><td>Depression</td><td>3</td><td>*5/*6</td><td>Efficacy</td><td>Patients with the CYP2B6 *5/*6 genotype and depression may have a decreased response when treated with mirtazapine as compared to patients with the CYP2B6 *6/*6 genotype. Other genetic and clinical factors may also influence response to mirtazapine.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183615041>9</a></td><td>CYP2B6</td><td>CYP2B6*6</td><td>mirtazapine</td><td>Depression</td><td>3</td><td>*5/*6</td><td>Efficacy</td><td>Patients with the CYP2B6 *5/*6 genotype and depression may have a decreased response when treated with mirtazapine as compared to patients with the CYP2B6 *6/*6 genotype. Other genetic and clinical factors may also influence response to mirtazapine.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183615041>10</a></td><td>CYP2B6</td><td>CYP2B6*7</td><td>mirtazapine</td><td>Depression</td><td>3</td><td>*5/*6</td><td>Efficacy</td><td>Patients with the CYP2B6 *5/*6 genotype and depression may have a decreased response when treated with mirtazapine as compared to patients with the CYP2B6 *6/*6 genotype. Other genetic and clinical factors may also influence response to mirtazapine.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1154221922>11</a></td><td>ABCG2</td><td>rs2231142</td><td>rosuvastatin</td><td>Hypercholesterolemia;Myocardial Infarction</td><td>2A</td><td>GG</td><td>Efficacy</td><td>Patients with the rs2231142 GG genotype and who are treated with rosuvastatin may have a reduced response to treatment as determined by a lower reduction in LDL-C as compared to patients with the GT or TT genotypes. Other genetic and clinical factors may also influence response to rosuvastatin.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449565060>12</a></td><td>ABCG2</td><td>rs2231142</td><td>gemcitabine</td><td>Carcinoma, Non-Small-Cell Lung</td><td>3</td><td>GG</td><td>Efficacy</td><td>Patients with the GG genotype and non-small cell lung cancer may have shorter progression-free survival, and decreased severity of thrombocytopenia, as compared to patients with the GT and TT genotypes. There was no association between genotype and overall survival, or severity of neutropenia. Other clinical and genetic factors may also influence response to, and risk of thrombocytopenia in patients with non-small cell lung cancer who are treated with gemcitabine.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450375746>13</a></td><td>ABCG2</td><td>rs4148155</td><td>allopurinol</td><td></td><td>3</td><td>GG</td><td>Efficacy</td><td>Patients with the GG genotype may have a decreased response to allopurinol as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to allopurinol.s</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444686824>14</a></td><td>ABCG2</td><td>rs2231142</td><td>sulfasalazine</td><td>Arthritis, Rheumatoid</td><td>3</td><td>GG</td><td>Efficacy</td><td>Patients with the GG genotype and rheumatoid arthritis may have a lower likelihood of achieving remission when treated with sulfasalazine as compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence response to sulfasalazine.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444686803>15</a></td><td>ABCG2</td><td>rs2231142</td><td>capecitabine</td><td>Colorectal Neoplasms</td><td>4</td><td>GG</td><td>Efficacy</td><td>Patients with the GG genotype and and colorectal cancer who are receiving FOLFOX/XELOX regimens may have a poorer response rate as compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence response to chemotherapy regimens.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444686803>16</a></td><td>ABCG2</td><td>rs2231142</td><td>fluorouracil</td><td>Colorectal Neoplasms</td><td>4</td><td>GG</td><td>Efficacy</td><td>Patients with the GG genotype and and colorectal cancer who are receiving FOLFOX/XELOX regimens may have a poorer response rate as compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence response to chemotherapy regimens.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444686803>17</a></td><td>ABCG2</td><td>rs2231142</td><td>leucovorin</td><td>Colorectal Neoplasms</td><td>4</td><td>GG</td><td>Efficacy</td><td>Patients with the GG genotype and and colorectal cancer who are receiving FOLFOX/XELOX regimens may have a poorer response rate as compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence response to chemotherapy regimens.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444686803>18</a></td><td>ABCG2</td><td>rs2231142</td><td>oxaliplatin</td><td>Colorectal Neoplasms</td><td>4</td><td>GG</td><td>Efficacy</td><td>Patients with the GG genotype and and colorectal cancer who are receiving FOLFOX/XELOX regimens may have a poorer response rate as compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence response to chemotherapy regimens.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447672998>19</a></td><td>VKORC1</td><td>rs9923231</td><td>warfarin</td><td>time to therapeutic inr</td><td>2A</td><td>CT</td><td>Efficacy</td><td>Patients with the rs9923231 CT genotype may require shorter time to therapeutic INR when treated with warfarin as compared with patients with genotype CC. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence the response to warfarin.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447673015>20</a></td><td>VKORC1</td><td>rs9923231</td><td>warfarin</td><td>time in therapeutic range</td><td>2A</td><td>CT</td><td>Efficacy</td><td>Patients with the rs9923231 CT genotype may spent less time in INR therapeutic range (TTR) when treated with warfarin as compared with patients with genotype CC. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence the response to warfarin.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444700860>21</a></td><td>ABCG2</td><td>rs7699188</td><td>fluorouracil</td><td>Colorectal Neoplasms</td><td>3</td><td>GG</td><td>Efficacy</td><td>Patients with the GG genotype may have decreased tumor response rate and decreased risk of grade 3-4 nonhematological toxicity when treated with fluorouracil, irinotecan and leucovorin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to fluorouracil, irinotecan and leucovorin.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444700860>22</a></td><td>ABCG2</td><td>rs7699188</td><td>irinotecan</td><td>Colorectal Neoplasms</td><td>3</td><td>GG</td><td>Efficacy</td><td>Patients with the GG genotype may have decreased tumor response rate and decreased risk of grade 3-4 nonhematological toxicity when treated with fluorouracil, irinotecan and leucovorin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to fluorouracil, irinotecan and leucovorin.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444700860>23</a></td><td>ABCG2</td><td>rs7699188</td><td>leucovorin</td><td>Colorectal Neoplasms</td><td>3</td><td>GG</td><td>Efficacy</td><td>Patients with the GG genotype may have decreased tumor response rate and decreased risk of grade 3-4 nonhematological toxicity when treated with fluorouracil, irinotecan and leucovorin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to fluorouracil, irinotecan and leucovorin.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451135140>24</a></td><td>CYP3A4</td><td>CYP3A4*1</td><td>sufentanil</td><td></td><td>3</td><td>*1/*1</td><td>Efficacy</td><td>Patients with the *1/*1 genotype may have a decreased analgesic response to sufentanil as compared to patients with the *1G/*1G genotype. Other genetic and clinical factors may also affect a patient's response to sufentanil.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451135140>25</a></td><td>CYP3A4</td><td>CYP3A4*1G</td><td>sufentanil</td><td></td><td>3</td><td>*1/*1</td><td>Efficacy</td><td>Patients with the *1/*1 genotype may have a decreased analgesic response to sufentanil as compared to patients with the *1G/*1G genotype. Other genetic and clinical factors may also affect a patient's response to sufentanil.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183620959>26</a></td><td>G6PD</td><td>G6PD A- 202A_376G</td><td>methylene blue</td><td>Anemia, Hemolytic;Hemolysis;Protein Deficiency</td><td>3</td><td>B (wildtype)</td><td>Toxicity</td><td>Male patients with the B (wildtype) haplotype who are treated with methylene blue 1) may be more likely to respond to treatment for methemoglobinemia 2) may have a reduced risk of drug-induced hemolysis as compared to patients with the A- 202A_376G haplotype (hemizygous for the G6PD A- variant). Other genetic and clinical factors may also influence a patient's response to methylene blue treatment and risk of hemolysis.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183620959>27</a></td><td>G6PD</td><td>G6PD B (wildtype)</td><td>methylene blue</td><td>Anemia, Hemolytic;Hemolysis;Protein Deficiency</td><td>3</td><td>B (wildtype)</td><td>Toxicity</td><td>Male patients with the B (wildtype) haplotype who are treated with methylene blue 1) may be more likely to respond to treatment for methemoglobinemia 2) may have a reduced risk of drug-induced hemolysis as compared to patients with the A- 202A_376G haplotype (hemizygous for the G6PD A- variant). Other genetic and clinical factors may also influence a patient's response to methylene blue treatment and risk of hemolysis.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183620032>28</a></td><td>G6PD</td><td>G6PD A- 202A_376G</td><td>glibenclamide</td><td>Anemia, Hemolytic</td><td>3</td><td>B (wildtype)</td><td>Toxicity</td><td>Male patients with the wildtype B haplotype who are treated with glibenclamide may have a reduced risk of hemolysis or hemolytic anemia as compared to patients with the A-202A_376G haplotype. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolytic anemia.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183620032>29</a></td><td>G6PD</td><td>G6PD B (wildtype)</td><td>glibenclamide</td><td>Anemia, Hemolytic</td><td>3</td><td>B (wildtype)</td><td>Toxicity</td><td>Male patients with the wildtype B haplotype who are treated with glibenclamide may have a reduced risk of hemolysis or hemolytic anemia as compared to patients with the A-202A_376G haplotype. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolytic anemia.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183621000>30</a></td><td>G6PD</td><td>G6PD A- 202A_376G</td><td>rasburicase</td><td>Hemolysis;Methemoglobinemia</td><td>1A</td><td>B (wildtype)</td><td>Toxicity</td><td>Patients with one X-chromosome and the reference B (wildtype) allele (non-deficient, class IV) who are treated with rasburicase may have a decreased risk of methemoglobinemia and/or hemolysis as compared to patients with a deficient class I-III allele. Patients with two X-chromosomes and two copies of the reference B allele (non-deficient, class IV) who are treated with rasburicase may have a decreased risk of methemoglobinemia and/or hemolysis as compared to patients with a deficient class I-III allele. Patients with two X-chromosomes, one copy of the reference B allele (non-deficient, class IV) and one deficient class I-III allele who are treated with rasburicase have an unknown risk of methemoglobinemia and/or hemolysis as compared to patients with two copies of the reference B allele (non-deficient, class IV). Other genetic and clinical factors may also influence risk of drug-induced hemolysis.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183621000>31</a></td><td>G6PD</td><td>G6PD B (wildtype)</td><td>rasburicase</td><td>Hemolysis;Methemoglobinemia</td><td>1A</td><td>B (wildtype)</td><td>Toxicity</td><td>Patients with one X-chromosome and the reference B (wildtype) allele (non-deficient, class IV) who are treated with rasburicase may have a decreased risk of methemoglobinemia and/or hemolysis as compared to patients with a deficient class I-III allele. Patients with two X-chromosomes and two copies of the reference B allele (non-deficient, class IV) who are treated with rasburicase may have a decreased risk of methemoglobinemia and/or hemolysis as compared to patients with a deficient class I-III allele. Patients with two X-chromosomes, one copy of the reference B allele (non-deficient, class IV) and one deficient class I-III allele who are treated with rasburicase have an unknown risk of methemoglobinemia and/or hemolysis as compared to patients with two copies of the reference B allele (non-deficient, class IV). Other genetic and clinical factors may also influence risk of drug-induced hemolysis.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183621000>32</a></td><td>G6PD</td><td>G6PD Mediterranean</td><td>rasburicase</td><td>Hemolysis;Methemoglobinemia</td><td>1A</td><td>B (wildtype)</td><td>Toxicity</td><td>Patients with one X-chromosome and the reference B (wildtype) allele (non-deficient, class IV) who are treated with rasburicase may have a decreased risk of methemoglobinemia and/or hemolysis as compared to patients with a deficient class I-III allele. Patients with two X-chromosomes and two copies of the reference B allele (non-deficient, class IV) who are treated with rasburicase may have a decreased risk of methemoglobinemia and/or hemolysis as compared to patients with a deficient class I-III allele. Patients with two X-chromosomes, one copy of the reference B allele (non-deficient, class IV) and one deficient class I-III allele who are treated with rasburicase have an unknown risk of methemoglobinemia and/or hemolysis as compared to patients with two copies of the reference B allele (non-deficient, class IV). Other genetic and clinical factors may also influence risk of drug-induced hemolysis.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183621000>33</a></td><td>G6PD</td><td>Dallas</td><td>rasburicase</td><td>Hemolysis;Methemoglobinemia</td><td>1A</td><td>B (wildtype)</td><td>Toxicity</td><td>Patients with one X-chromosome and the reference B (wildtype) allele (non-deficient, class IV) who are treated with rasburicase may have a decreased risk of methemoglobinemia and/or hemolysis as compared to patients with a deficient class I-III allele. Patients with two X-chromosomes and two copies of the reference B allele (non-deficient, class IV) who are treated with rasburicase may have a decreased risk of methemoglobinemia and/or hemolysis as compared to patients with a deficient class I-III allele. Patients with two X-chromosomes, one copy of the reference B allele (non-deficient, class IV) and one deficient class I-III allele who are treated with rasburicase have an unknown risk of methemoglobinemia and/or hemolysis as compared to patients with two copies of the reference B allele (non-deficient, class IV). Other genetic and clinical factors may also influence risk of drug-induced hemolysis.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183621000>34</a></td><td>G6PD</td><td>Panama</td><td>rasburicase</td><td>Hemolysis;Methemoglobinemia</td><td>1A</td><td>B (wildtype)</td><td>Toxicity</td><td>Patients with one X-chromosome and the reference B (wildtype) allele (non-deficient, class IV) who are treated with rasburicase may have a decreased risk of methemoglobinemia and/or hemolysis as compared to patients with a deficient class I-III allele. Patients with two X-chromosomes and two copies of the reference B allele (non-deficient, class IV) who are treated with rasburicase may have a decreased risk of methemoglobinemia and/or hemolysis as compared to patients with a deficient class I-III allele. Patients with two X-chromosomes, one copy of the reference B allele (non-deficient, class IV) and one deficient class I-III allele who are treated with rasburicase have an unknown risk of methemoglobinemia and/or hemolysis as compared to patients with two copies of the reference B allele (non-deficient, class IV). Other genetic and clinical factors may also influence risk of drug-induced hemolysis.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183621000>35</a></td><td>G6PD</td><td>Sassari</td><td>rasburicase</td><td>Hemolysis;Methemoglobinemia</td><td>1A</td><td>B (wildtype)</td><td>Toxicity</td><td>Patients with one X-chromosome and the reference B (wildtype) allele (non-deficient, class IV) who are treated with rasburicase may have a decreased risk of methemoglobinemia and/or hemolysis as compared to patients with a deficient class I-III allele. Patients with two X-chromosomes and two copies of the reference B allele (non-deficient, class IV) who are treated with rasburicase may have a decreased risk of methemoglobinemia and/or hemolysis as compared to patients with a deficient class I-III allele. Patients with two X-chromosomes, one copy of the reference B allele (non-deficient, class IV) and one deficient class I-III allele who are treated with rasburicase have an unknown risk of methemoglobinemia and/or hemolysis as compared to patients with two copies of the reference B allele (non-deficient, class IV). Other genetic and clinical factors may also influence risk of drug-induced hemolysis.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183621000>36</a></td><td>G6PD</td><td>Cagliari</td><td>rasburicase</td><td>Hemolysis;Methemoglobinemia</td><td>1A</td><td>B (wildtype)</td><td>Toxicity</td><td>Patients with one X-chromosome and the reference B (wildtype) allele (non-deficient, class IV) who are treated with rasburicase may have a decreased risk of methemoglobinemia and/or hemolysis as compared to patients with a deficient class I-III allele. Patients with two X-chromosomes and two copies of the reference B allele (non-deficient, class IV) who are treated with rasburicase may have a decreased risk of methemoglobinemia and/or hemolysis as compared to patients with a deficient class I-III allele. Patients with two X-chromosomes, one copy of the reference B allele (non-deficient, class IV) and one deficient class I-III allele who are treated with rasburicase have an unknown risk of methemoglobinemia and/or hemolysis as compared to patients with two copies of the reference B allele (non-deficient, class IV). Other genetic and clinical factors may also influence risk of drug-induced hemolysis.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183621000>37</a></td><td>G6PD</td><td>Birmingham</td><td>rasburicase</td><td>Hemolysis;Methemoglobinemia</td><td>1A</td><td>B (wildtype)</td><td>Toxicity</td><td>Patients with one X-chromosome and the reference B (wildtype) allele (non-deficient, class IV) who are treated with rasburicase may have a decreased risk of methemoglobinemia and/or hemolysis as compared to patients with a deficient class I-III allele. Patients with two X-chromosomes and two copies of the reference B allele (non-deficient, class IV) who are treated with rasburicase may have a decreased risk of methemoglobinemia and/or hemolysis as compared to patients with a deficient class I-III allele. Patients with two X-chromosomes, one copy of the reference B allele (non-deficient, class IV) and one deficient class I-III allele who are treated with rasburicase have an unknown risk of methemoglobinemia and/or hemolysis as compared to patients with two copies of the reference B allele (non-deficient, class IV). Other genetic and clinical factors may also influence risk of drug-induced hemolysis.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184000346>38</a></td><td>G6PD</td><td>G6PD A- 202A_376G</td><td>nitrofurantoin</td><td>Anemia, Hemolytic;Hemolysis</td><td>3</td><td>B (wildtype)</td><td>Toxicity</td><td>Male patients with the B (wildtype) haplotype (not associated with G6PD deficiency) who are treated with nitrofurantoin may have a reduced, but not absent, risk of hemolysis as compared to patients with the A-202A_376G haplotype (hemizygous for the A- variant, associated with G6PD deficiency). Please note: all studies reported an association with G6PD deficiency but did not genotype or characterize the G6PD variant, here we are representing this association under the A- variant which is associated with G6PD deficiency, with the B (wildtype) haplotype representing G6PD non-deficient. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184000346>39</a></td><td>G6PD</td><td>G6PD B (wildtype)</td><td>nitrofurantoin</td><td>Anemia, Hemolytic;Hemolysis</td><td>3</td><td>B (wildtype)</td><td>Toxicity</td><td>Male patients with the B (wildtype) haplotype (not associated with G6PD deficiency) who are treated with nitrofurantoin may have a reduced, but not absent, risk of hemolysis as compared to patients with the A-202A_376G haplotype (hemizygous for the A- variant, associated with G6PD deficiency). Please note: all studies reported an association with G6PD deficiency but did not genotype or characterize the G6PD variant, here we are representing this association under the A- variant which is associated with G6PD deficiency, with the B (wildtype) haplotype representing G6PD non-deficient. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184000380>40</a></td><td>G6PD</td><td>G6PD B (wildtype)</td><td>phenazopyridine</td><td>Anemia, Hemolytic;Hemolysis</td><td>3</td><td>B (wildtype)</td><td>Toxicity</td><td>Male patients with the B (wildtype) haplotype (not associated with G6PD deficiency) who are treated with phenazopyridine may have a reduced, but not absent, risk of hemolytic anemia as compared to patients with the Mediterranean haplotype (hemizygous for the Mediterranean variant, associated with G6PD deficiency). Please note: all studies reported an association with G6PD deficiency but did not genotype or characterize the G6PD variant, here we are representing this association under the Mediterranean variant which is associated with G6PD deficiency, with the B (wildtype) haplotype representing G6PD non-deficient. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184000380>41</a></td><td>G6PD</td><td>G6PD Mediterranean Haplotype</td><td>phenazopyridine</td><td>Anemia, Hemolytic;Hemolysis</td><td>3</td><td>B (wildtype)</td><td>Toxicity</td><td>Male patients with the B (wildtype) haplotype (not associated with G6PD deficiency) who are treated with phenazopyridine may have a reduced, but not absent, risk of hemolytic anemia as compared to patients with the Mediterranean haplotype (hemizygous for the Mediterranean variant, associated with G6PD deficiency). Please note: all studies reported an association with G6PD deficiency but did not genotype or characterize the G6PD variant, here we are representing this association under the Mediterranean variant which is associated with G6PD deficiency, with the B (wildtype) haplotype representing G6PD non-deficient. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183944118>42</a></td><td>G6PD</td><td>G6PD A- 202A_376G</td><td>mefloquine</td><td>Malaria</td><td>4</td><td>B (wildtype)</td><td>Toxicity</td><td>Male patients with the B haplotype (wildtype, associated with normal G6PD activity) who are treated with mefloquine 1) may have a reduced risk of pulmonary damage 2) may have a similar risk of hemolysis as compared to patients with the A-202A_376G haplotype (hemizygous for the G6PD A- variant, associated with G6PD deficiency). Other genetic and clinical factors may also influence a patient's response to mefloquine treatment and risk of toxicity.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183944118>43</a></td><td>G6PD</td><td>G6PD B (wildtype)</td><td>mefloquine</td><td>Malaria</td><td>4</td><td>B (wildtype)</td><td>Toxicity</td><td>Male patients with the B haplotype (wildtype, associated with normal G6PD activity) who are treated with mefloquine 1) may have a reduced risk of pulmonary damage 2) may have a similar risk of hemolysis as compared to patients with the A-202A_376G haplotype (hemizygous for the G6PD A- variant, associated with G6PD deficiency). Other genetic and clinical factors may also influence a patient's response to mefloquine treatment and risk of toxicity.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184516153>44</a></td><td>G6PD</td><td>G6PD B (wildtype)</td><td>aspirin</td><td>Hemolysis</td><td>3</td><td>B (wildtype)</td><td>Toxicity</td><td>Male children with the B (wildtype) genotype (not associated with G6PD deficiency) and systemic arthritis who are treated with a high dose of aspirin may have a reduced risk of hemolysis as compared to children hemizygous for the G6PD Mediterranean variant (associated with G6PD deficiency). Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184516153>45</a></td><td>G6PD</td><td>G6PD Mediterranean</td><td>aspirin</td><td>Hemolysis</td><td>3</td><td>B (wildtype)</td><td>Toxicity</td><td>Male children with the B (wildtype) genotype (not associated with G6PD deficiency) and systemic arthritis who are treated with a high dose of aspirin may have a reduced risk of hemolysis as compared to children hemizygous for the G6PD Mediterranean variant (associated with G6PD deficiency). Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184516153>46</a></td><td>G6PD</td><td>Dallas</td><td>aspirin</td><td>Hemolysis</td><td>3</td><td>B (wildtype)</td><td>Toxicity</td><td>Male children with the B (wildtype) genotype (not associated with G6PD deficiency) and systemic arthritis who are treated with a high dose of aspirin may have a reduced risk of hemolysis as compared to children hemizygous for the G6PD Mediterranean variant (associated with G6PD deficiency). Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184516153>47</a></td><td>G6PD</td><td>Panama</td><td>aspirin</td><td>Hemolysis</td><td>3</td><td>B (wildtype)</td><td>Toxicity</td><td>Male children with the B (wildtype) genotype (not associated with G6PD deficiency) and systemic arthritis who are treated with a high dose of aspirin may have a reduced risk of hemolysis as compared to children hemizygous for the G6PD Mediterranean variant (associated with G6PD deficiency). Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184516153>48</a></td><td>G6PD</td><td>Sassari</td><td>aspirin</td><td>Hemolysis</td><td>3</td><td>B (wildtype)</td><td>Toxicity</td><td>Male children with the B (wildtype) genotype (not associated with G6PD deficiency) and systemic arthritis who are treated with a high dose of aspirin may have a reduced risk of hemolysis as compared to children hemizygous for the G6PD Mediterranean variant (associated with G6PD deficiency). Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184516153>49</a></td><td>G6PD</td><td>Cagliari</td><td>aspirin</td><td>Hemolysis</td><td>3</td><td>B (wildtype)</td><td>Toxicity</td><td>Male children with the B (wildtype) genotype (not associated with G6PD deficiency) and systemic arthritis who are treated with a high dose of aspirin may have a reduced risk of hemolysis as compared to children hemizygous for the G6PD Mediterranean variant (associated with G6PD deficiency). Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184516153>50</a></td><td>G6PD</td><td>Birmingham</td><td>aspirin</td><td>Hemolysis</td><td>3</td><td>B (wildtype)</td><td>Toxicity</td><td>Male children with the B (wildtype) genotype (not associated with G6PD deficiency) and systemic arthritis who are treated with a high dose of aspirin may have a reduced risk of hemolysis as compared to children hemizygous for the G6PD Mediterranean variant (associated with G6PD deficiency). Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183705354>51</a></td><td>G6PD</td><td>G6PD A- 202A_376G</td><td>dimercaprol</td><td>Hemolysis;Lead Poisoning, Nervous System, Childhood</td><td>3</td><td>B (wildtype)</td><td>Toxicity</td><td>Male children with lead poisoning and the B (wildtype) haplotype (not associated with G6PD deficiency) who are treated with dimercaprol may have a reduced risk of hemolysis as compared to children with the A- 202A_376G haplotype (hemizygous for the A- variant, associated with G6PD deficiency). Please note: the A- G6PD variant was determined by electrophoresis rather than genotyping and here is represented by the A- 202_376G haplotype, with the B (wildtype) haplotype representing G6PD non-deficient. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183705354>52</a></td><td>G6PD</td><td>G6PD B (wildtype)</td><td>dimercaprol</td><td>Hemolysis;Lead Poisoning, Nervous System, Childhood</td><td>3</td><td>B (wildtype)</td><td>Toxicity</td><td>Male children with lead poisoning and the B (wildtype) haplotype (not associated with G6PD deficiency) who are treated with dimercaprol may have a reduced risk of hemolysis as compared to children with the A- 202A_376G haplotype (hemizygous for the A- variant, associated with G6PD deficiency). Please note: the A- G6PD variant was determined by electrophoresis rather than genotyping and here is represented by the A- 202_376G haplotype, with the B (wildtype) haplotype representing G6PD non-deficient. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183705307>53</a></td><td>G6PD</td><td>G6PD B (wildtype)</td><td>ciprofloxacin</td><td>Anemia, Hemolytic</td><td>3</td><td>B (wildtype)</td><td>Toxicity</td><td>Male patients with the B (wildtype) haplotype (not associated with G6PD deficiency) who are treated with ciprofloxacin may have a reduced risk of hemolytic anemia as compared to patients hemizygous for the Mediterranean variant (associated with G6PD deficiency). Please note: this study did not report genotyping, but reported the patient to have Mediterranean G6PD deficiency, therefore here we are representing this association under the Mediterranean variant. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183705307>54</a></td><td>G6PD</td><td>G6PD Mediterranean Haplotype</td><td>ciprofloxacin</td><td>Anemia, Hemolytic</td><td>3</td><td>B (wildtype)</td><td>Toxicity</td><td>Male patients with the B (wildtype) haplotype (not associated with G6PD deficiency) who are treated with ciprofloxacin may have a reduced risk of hemolytic anemia as compared to patients hemizygous for the Mediterranean variant (associated with G6PD deficiency). Please note: this study did not report genotyping, but reported the patient to have Mediterranean G6PD deficiency, therefore here we are representing this association under the Mediterranean variant. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183705307>55</a></td><td>G6PD</td><td>G6PD Mediterranean</td><td>ciprofloxacin</td><td>Anemia, Hemolytic</td><td>3</td><td>B (wildtype)</td><td>Toxicity</td><td>Male patients with the B (wildtype) haplotype (not associated with G6PD deficiency) who are treated with ciprofloxacin may have a reduced risk of hemolytic anemia as compared to patients hemizygous for the Mediterranean variant (associated with G6PD deficiency). Please note: this study did not report genotyping, but reported the patient to have Mediterranean G6PD deficiency, therefore here we are representing this association under the Mediterranean variant. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183705307>56</a></td><td>G6PD</td><td>Dallas</td><td>ciprofloxacin</td><td>Anemia, Hemolytic</td><td>3</td><td>B (wildtype)</td><td>Toxicity</td><td>Male patients with the B (wildtype) haplotype (not associated with G6PD deficiency) who are treated with ciprofloxacin may have a reduced risk of hemolytic anemia as compared to patients hemizygous for the Mediterranean variant (associated with G6PD deficiency). Please note: this study did not report genotyping, but reported the patient to have Mediterranean G6PD deficiency, therefore here we are representing this association under the Mediterranean variant. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183705307>57</a></td><td>G6PD</td><td>Panama</td><td>ciprofloxacin</td><td>Anemia, Hemolytic</td><td>3</td><td>B (wildtype)</td><td>Toxicity</td><td>Male patients with the B (wildtype) haplotype (not associated with G6PD deficiency) who are treated with ciprofloxacin may have a reduced risk of hemolytic anemia as compared to patients hemizygous for the Mediterranean variant (associated with G6PD deficiency). Please note: this study did not report genotyping, but reported the patient to have Mediterranean G6PD deficiency, therefore here we are representing this association under the Mediterranean variant. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183705307>58</a></td><td>G6PD</td><td>Sassari</td><td>ciprofloxacin</td><td>Anemia, Hemolytic</td><td>3</td><td>B (wildtype)</td><td>Toxicity</td><td>Male patients with the B (wildtype) haplotype (not associated with G6PD deficiency) who are treated with ciprofloxacin may have a reduced risk of hemolytic anemia as compared to patients hemizygous for the Mediterranean variant (associated with G6PD deficiency). Please note: this study did not report genotyping, but reported the patient to have Mediterranean G6PD deficiency, therefore here we are representing this association under the Mediterranean variant. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183705307>59</a></td><td>G6PD</td><td>Cagliari</td><td>ciprofloxacin</td><td>Anemia, Hemolytic</td><td>3</td><td>B (wildtype)</td><td>Toxicity</td><td>Male patients with the B (wildtype) haplotype (not associated with G6PD deficiency) who are treated with ciprofloxacin may have a reduced risk of hemolytic anemia as compared to patients hemizygous for the Mediterranean variant (associated with G6PD deficiency). Please note: this study did not report genotyping, but reported the patient to have Mediterranean G6PD deficiency, therefore here we are representing this association under the Mediterranean variant. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183705307>60</a></td><td>G6PD</td><td>Birmingham</td><td>ciprofloxacin</td><td>Anemia, Hemolytic</td><td>3</td><td>B (wildtype)</td><td>Toxicity</td><td>Male patients with the B (wildtype) haplotype (not associated with G6PD deficiency) who are treated with ciprofloxacin may have a reduced risk of hemolytic anemia as compared to patients hemizygous for the Mediterranean variant (associated with G6PD deficiency). Please note: this study did not report genotyping, but reported the patient to have Mediterranean G6PD deficiency, therefore here we are representing this association under the Mediterranean variant. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183705226>61</a></td><td>G6PD</td><td>G6PD A- 202A_376G</td><td>chloroquine</td><td>Anemia, Hemolytic</td><td>4</td><td>B (wildtype)</td><td>Toxicity</td><td>Male patients with the B (wildtype) haplotype (not associated with G6PD deficiency) who are treated with a high dose of chloroquine may have a reduced risk of hemolytic anemia as compared to patients with the Mediterranean or A-202A_376G haplotype (hemizygous for variants associated with G6PD deficiency). Most studies show no association with increased risk with normal chloroquine dosage. Please note: all studies reported an association with G6PD deficiency but only one reported genotyping, here we are representing this association under the Mediterranean or A- haplotype which is associated with G6PD deficiency, with the B (wildtype) haplotype representing G6PD non-deficient. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183705226>62</a></td><td>G6PD</td><td>G6PD B (wildtype)</td><td>chloroquine</td><td>Anemia, Hemolytic</td><td>4</td><td>B (wildtype)</td><td>Toxicity</td><td>Male patients with the B (wildtype) haplotype (not associated with G6PD deficiency) who are treated with a high dose of chloroquine may have a reduced risk of hemolytic anemia as compared to patients with the Mediterranean or A-202A_376G haplotype (hemizygous for variants associated with G6PD deficiency). Most studies show no association with increased risk with normal chloroquine dosage. Please note: all studies reported an association with G6PD deficiency but only one reported genotyping, here we are representing this association under the Mediterranean or A- haplotype which is associated with G6PD deficiency, with the B (wildtype) haplotype representing G6PD non-deficient. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183705226>63</a></td><td>G6PD</td><td>G6PD Mediterranean Haplotype</td><td>chloroquine</td><td>Anemia, Hemolytic</td><td>4</td><td>B (wildtype)</td><td>Toxicity</td><td>Male patients with the B (wildtype) haplotype (not associated with G6PD deficiency) who are treated with a high dose of chloroquine may have a reduced risk of hemolytic anemia as compared to patients with the Mediterranean or A-202A_376G haplotype (hemizygous for variants associated with G6PD deficiency). Most studies show no association with increased risk with normal chloroquine dosage. Please note: all studies reported an association with G6PD deficiency but only one reported genotyping, here we are representing this association under the Mediterranean or A- haplotype which is associated with G6PD deficiency, with the B (wildtype) haplotype representing G6PD non-deficient. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183705226>64</a></td><td>G6PD</td><td>G6PD Mediterranean</td><td>chloroquine</td><td>Anemia, Hemolytic</td><td>4</td><td>B (wildtype)</td><td>Toxicity</td><td>Male patients with the B (wildtype) haplotype (not associated with G6PD deficiency) who are treated with a high dose of chloroquine may have a reduced risk of hemolytic anemia as compared to patients with the Mediterranean or A-202A_376G haplotype (hemizygous for variants associated with G6PD deficiency). Most studies show no association with increased risk with normal chloroquine dosage. Please note: all studies reported an association with G6PD deficiency but only one reported genotyping, here we are representing this association under the Mediterranean or A- haplotype which is associated with G6PD deficiency, with the B (wildtype) haplotype representing G6PD non-deficient. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183705226>65</a></td><td>G6PD</td><td>Dallas</td><td>chloroquine</td><td>Anemia, Hemolytic</td><td>4</td><td>B (wildtype)</td><td>Toxicity</td><td>Male patients with the B (wildtype) haplotype (not associated with G6PD deficiency) who are treated with a high dose of chloroquine may have a reduced risk of hemolytic anemia as compared to patients with the Mediterranean or A-202A_376G haplotype (hemizygous for variants associated with G6PD deficiency). Most studies show no association with increased risk with normal chloroquine dosage. Please note: all studies reported an association with G6PD deficiency but only one reported genotyping, here we are representing this association under the Mediterranean or A- haplotype which is associated with G6PD deficiency, with the B (wildtype) haplotype representing G6PD non-deficient. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183705226>66</a></td><td>G6PD</td><td>Panama</td><td>chloroquine</td><td>Anemia, Hemolytic</td><td>4</td><td>B (wildtype)</td><td>Toxicity</td><td>Male patients with the B (wildtype) haplotype (not associated with G6PD deficiency) who are treated with a high dose of chloroquine may have a reduced risk of hemolytic anemia as compared to patients with the Mediterranean or A-202A_376G haplotype (hemizygous for variants associated with G6PD deficiency). Most studies show no association with increased risk with normal chloroquine dosage. Please note: all studies reported an association with G6PD deficiency but only one reported genotyping, here we are representing this association under the Mediterranean or A- haplotype which is associated with G6PD deficiency, with the B (wildtype) haplotype representing G6PD non-deficient. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183705226>67</a></td><td>G6PD</td><td>Sassari</td><td>chloroquine</td><td>Anemia, Hemolytic</td><td>4</td><td>B (wildtype)</td><td>Toxicity</td><td>Male patients with the B (wildtype) haplotype (not associated with G6PD deficiency) who are treated with a high dose of chloroquine may have a reduced risk of hemolytic anemia as compared to patients with the Mediterranean or A-202A_376G haplotype (hemizygous for variants associated with G6PD deficiency). Most studies show no association with increased risk with normal chloroquine dosage. Please note: all studies reported an association with G6PD deficiency but only one reported genotyping, here we are representing this association under the Mediterranean or A- haplotype which is associated with G6PD deficiency, with the B (wildtype) haplotype representing G6PD non-deficient. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183705226>68</a></td><td>G6PD</td><td>Cagliari</td><td>chloroquine</td><td>Anemia, Hemolytic</td><td>4</td><td>B (wildtype)</td><td>Toxicity</td><td>Male patients with the B (wildtype) haplotype (not associated with G6PD deficiency) who are treated with a high dose of chloroquine may have a reduced risk of hemolytic anemia as compared to patients with the Mediterranean or A-202A_376G haplotype (hemizygous for variants associated with G6PD deficiency). Most studies show no association with increased risk with normal chloroquine dosage. Please note: all studies reported an association with G6PD deficiency but only one reported genotyping, here we are representing this association under the Mediterranean or A- haplotype which is associated with G6PD deficiency, with the B (wildtype) haplotype representing G6PD non-deficient. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183705226>69</a></td><td>G6PD</td><td>Birmingham</td><td>chloroquine</td><td>Anemia, Hemolytic</td><td>4</td><td>B (wildtype)</td><td>Toxicity</td><td>Male patients with the B (wildtype) haplotype (not associated with G6PD deficiency) who are treated with a high dose of chloroquine may have a reduced risk of hemolytic anemia as compared to patients with the Mediterranean or A-202A_376G haplotype (hemizygous for variants associated with G6PD deficiency). Most studies show no association with increased risk with normal chloroquine dosage. Please note: all studies reported an association with G6PD deficiency but only one reported genotyping, here we are representing this association under the Mediterranean or A- haplotype which is associated with G6PD deficiency, with the B (wildtype) haplotype representing G6PD non-deficient. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183705086>70</a></td><td>G6PD</td><td>G6PD A- 202A_376G</td><td>chloramphenicol</td><td>Anemia, Hemolytic;Hemolysis</td><td>3</td><td>B (wildtype)</td><td>Toxicity</td><td>Male patients with typhoid fever and the B (wildtype) haplotype (not associated with G6PD deficiency) who are treated with chloramphenicol may have a reduced, but not absent, risk of hemolysis as compared to patients with the A-202A_376G haplotype (hemizygous for the A- variant, associated with G6PD deficiency). Please note: all studies reported an association with G6PD deficiency but did not genotype or characterize the G6PD variant, here we are representing this association under the A- variant which is associated with G6PD deficiency, with the B (wildtype) haplotype representing G6PD non-deficient. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183705086>71</a></td><td>G6PD</td><td>G6PD B (wildtype)</td><td>chloramphenicol</td><td>Anemia, Hemolytic;Hemolysis</td><td>3</td><td>B (wildtype)</td><td>Toxicity</td><td>Male patients with typhoid fever and the B (wildtype) haplotype (not associated with G6PD deficiency) who are treated with chloramphenicol may have a reduced, but not absent, risk of hemolysis as compared to patients with the A-202A_376G haplotype (hemizygous for the A- variant, associated with G6PD deficiency). Please note: all studies reported an association with G6PD deficiency but did not genotype or characterize the G6PD variant, here we are representing this association under the A- variant which is associated with G6PD deficiency, with the B (wildtype) haplotype representing G6PD non-deficient. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451496100>72</a></td><td>G6PD</td><td>G6PD B (wildtype)</td><td>sulfamethoxazole</td><td>Hemolysis</td><td>3</td><td>B (wildtype)</td><td>Toxicity</td><td>Patients with one X-chromosome and the G6PD B (wildtype) allele (non-deficient, class IV) who are treated with sulfamethoxazole may have a decreased risk of hemolysis as compared to patients with a deficient class II allele. Patients with two X-chromosomes and two copies of the B allele who are treated with sulfamethoxazole may have a decreased risk of hemolysis as compared to patients with a deficient class II allele. Patients with two X-chromosomes, one copy of the B allele and one deficient class II allele who are treated with sulfamethoxazole have an unknown risk of hemolysis as compared to patients with two copies of the B allele. Other genetic and clinical factors may also influence risk of sulfamethoxazole-induced hemolysis.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451496100>73</a></td><td>G6PD</td><td>G6PD Canton</td><td>sulfamethoxazole</td><td>Hemolysis</td><td>3</td><td>B (wildtype)</td><td>Toxicity</td><td>Patients with one X-chromosome and the G6PD B (wildtype) allele (non-deficient, class IV) who are treated with sulfamethoxazole may have a decreased risk of hemolysis as compared to patients with a deficient class II allele. Patients with two X-chromosomes and two copies of the B allele who are treated with sulfamethoxazole may have a decreased risk of hemolysis as compared to patients with a deficient class II allele. Patients with two X-chromosomes, one copy of the B allele and one deficient class II allele who are treated with sulfamethoxazole have an unknown risk of hemolysis as compared to patients with two copies of the B allele. Other genetic and clinical factors may also influence risk of sulfamethoxazole-induced hemolysis.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451496100>74</a></td><td>G6PD</td><td>Taiwan-Hakka</td><td>sulfamethoxazole</td><td>Hemolysis</td><td>3</td><td>B (wildtype)</td><td>Toxicity</td><td>Patients with one X-chromosome and the G6PD B (wildtype) allele (non-deficient, class IV) who are treated with sulfamethoxazole may have a decreased risk of hemolysis as compared to patients with a deficient class II allele. Patients with two X-chromosomes and two copies of the B allele who are treated with sulfamethoxazole may have a decreased risk of hemolysis as compared to patients with a deficient class II allele. Patients with two X-chromosomes, one copy of the B allele and one deficient class II allele who are treated with sulfamethoxazole have an unknown risk of hemolysis as compared to patients with two copies of the B allele. Other genetic and clinical factors may also influence risk of sulfamethoxazole-induced hemolysis.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451496100>75</a></td><td>G6PD</td><td>Gifu-like</td><td>sulfamethoxazole</td><td>Hemolysis</td><td>3</td><td>B (wildtype)</td><td>Toxicity</td><td>Patients with one X-chromosome and the G6PD B (wildtype) allele (non-deficient, class IV) who are treated with sulfamethoxazole may have a decreased risk of hemolysis as compared to patients with a deficient class II allele. Patients with two X-chromosomes and two copies of the B allele who are treated with sulfamethoxazole may have a decreased risk of hemolysis as compared to patients with a deficient class II allele. Patients with two X-chromosomes, one copy of the B allele and one deficient class II allele who are treated with sulfamethoxazole have an unknown risk of hemolysis as compared to patients with two copies of the B allele. Other genetic and clinical factors may also influence risk of sulfamethoxazole-induced hemolysis.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451496100>76</a></td><td>G6PD</td><td>Agrigento-like</td><td>sulfamethoxazole</td><td>Hemolysis</td><td>3</td><td>B (wildtype)</td><td>Toxicity</td><td>Patients with one X-chromosome and the G6PD B (wildtype) allele (non-deficient, class IV) who are treated with sulfamethoxazole may have a decreased risk of hemolysis as compared to patients with a deficient class II allele. Patients with two X-chromosomes and two copies of the B allele who are treated with sulfamethoxazole may have a decreased risk of hemolysis as compared to patients with a deficient class II allele. Patients with two X-chromosomes, one copy of the B allele and one deficient class II allele who are treated with sulfamethoxazole have an unknown risk of hemolysis as compared to patients with two copies of the B allele. Other genetic and clinical factors may also influence risk of sulfamethoxazole-induced hemolysis.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449718248>77</a></td><td>ABCG2</td><td>rs2231142</td><td>cyclophosphamide</td><td>Breast Neoplasms</td><td>3</td><td>GG</td><td>Toxicity</td><td>Patients with the GG genotype and breast cancer may have a decreased risk for anemia when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the GT genotype. Other genetic and clinical factors may also influence risk for anemia in patients taking FAC chemotherapy.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449718248>78</a></td><td>ABCG2</td><td>rs2231142</td><td>doxorubicin</td><td>Breast Neoplasms</td><td>3</td><td>GG</td><td>Toxicity</td><td>Patients with the GG genotype and breast cancer may have a decreased risk for anemia when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the GT genotype. Other genetic and clinical factors may also influence risk for anemia in patients taking FAC chemotherapy.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449718248>79</a></td><td>ABCG2</td><td>rs2231142</td><td>fluorouracil</td><td>Breast Neoplasms</td><td>3</td><td>GG</td><td>Toxicity</td><td>Patients with the GG genotype and breast cancer may have a decreased risk for anemia when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the GT genotype. Other genetic and clinical factors may also influence risk for anemia in patients taking FAC chemotherapy.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183620032>80</a></td><td>G6PD</td><td>G6PD A- 202A_376G</td><td>glibenclamide</td><td>Anemia, Hemolytic</td><td>3</td><td>B (wildtype)/B (wildtype)</td><td>Toxicity</td><td>Female patients with the wildtype B/ B diplotype who are treated with glibenclamide may have a reduced risk of hemolysis or hemolytic anemia as compared to patients with the wildtype B/ B diplotype. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolytic anemia.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183620032>81</a></td><td>G6PD</td><td>G6PD B (wildtype)</td><td>glibenclamide</td><td>Anemia, Hemolytic</td><td>3</td><td>B (wildtype)/B (wildtype)</td><td>Toxicity</td><td>Female patients with the wildtype B/ B diplotype who are treated with glibenclamide may have a reduced risk of hemolysis or hemolytic anemia as compared to patients with the wildtype B/ B diplotype. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolytic anemia.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183614716>82</a></td><td>ABCG2</td><td>rs2231142</td><td>efavirenz</td><td>HIV Infections</td><td>3</td><td>GG</td><td>Toxicity</td><td>Patients with the GG genotype and HIV infection who are treated with efavirenz may have a reduced risk of abnormal dreams as compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence a patient's risk of efavirenz-induced side effects.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449565060>83</a></td><td>ABCG2</td><td>rs2231142</td><td>gemcitabine</td><td>Carcinoma, Non-Small-Cell Lung</td><td>3</td><td>GG</td><td>Toxicity</td><td>Patients with the GG genotype and non-small cell lung cancer may have shorter progression-free survival, and decreased severity of thrombocytopenia, as compared to patients with the GT and TT genotypes. There was no association between genotype and overall survival, or severity of neutropenia. Other clinical and genetic factors may also influence response to, and risk of thrombocytopenia in patients with non-small cell lung cancer who are treated with gemcitabine.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184000346>84</a></td><td>G6PD</td><td>G6PD A- 202A_376G</td><td>nitrofurantoin</td><td>Anemia, Hemolytic;Hemolysis</td><td>3</td><td>B (wildtype)/B (wildtype)</td><td>Toxicity</td><td>Female patients with the B/B wildtype diplotype (not associated with G6PD deficiency) who are treated with nitrofurantoin may have a reduced, but not absent, risk of hemolysis as compared to patients with the A-202A_376G/A-202A_376G diplotype (homozygous for the A- variant, associated with G6PD deficiency). Please note: all studies reported an association with G6PD deficiency but did not genotype or characterize the G6PD variant, here we are representing this association under the A- variant which is associated with G6PD deficiency, with the B (wildtype) haplotype representing G6PD non-deficient. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184000346>85</a></td><td>G6PD</td><td>G6PD B (wildtype)</td><td>nitrofurantoin</td><td>Anemia, Hemolytic;Hemolysis</td><td>3</td><td>B (wildtype)/B (wildtype)</td><td>Toxicity</td><td>Female patients with the B/B wildtype diplotype (not associated with G6PD deficiency) who are treated with nitrofurantoin may have a reduced, but not absent, risk of hemolysis as compared to patients with the A-202A_376G/A-202A_376G diplotype (homozygous for the A- variant, associated with G6PD deficiency). Please note: all studies reported an association with G6PD deficiency but did not genotype or characterize the G6PD variant, here we are representing this association under the A- variant which is associated with G6PD deficiency, with the B (wildtype) haplotype representing G6PD non-deficient. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184000380>86</a></td><td>G6PD</td><td>G6PD B (wildtype)</td><td>phenazopyridine</td><td>Anemia, Hemolytic;Hemolysis</td><td>3</td><td>B (wildtype)/B (wildtype)</td><td>Toxicity</td><td>Female patients with the B/B wildtype diplotype (not associated with G6PD deficiency) who are treated with phenazopyridine may have a reduced, but not absent, risk of hemolytic anemia as compared to patients with the Mediterranean/Mediterranean diplotype (homozygous for the Mediterranean variant, associated with G6PD deficiency). Please note: all studies reported an association with G6PD deficiency but did not genotype or characterize the G6PD variant, here we are representing this association under the Mediterranean variant which is associated with G6PD deficiency, with the B (wildtype) haplotype representing G6PD non-deficient. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184000380>87</a></td><td>G6PD</td><td>G6PD Mediterranean Haplotype</td><td>phenazopyridine</td><td>Anemia, Hemolytic;Hemolysis</td><td>3</td><td>B (wildtype)/B (wildtype)</td><td>Toxicity</td><td>Female patients with the B/B wildtype diplotype (not associated with G6PD deficiency) who are treated with phenazopyridine may have a reduced, but not absent, risk of hemolytic anemia as compared to patients with the Mediterranean/Mediterranean diplotype (homozygous for the Mediterranean variant, associated with G6PD deficiency). Please note: all studies reported an association with G6PD deficiency but did not genotype or characterize the G6PD variant, here we are representing this association under the Mediterranean variant which is associated with G6PD deficiency, with the B (wildtype) haplotype representing G6PD non-deficient. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184642788>88</a></td><td>G6PD</td><td>G6PD A- 202A_376G</td><td>sulfasalazine</td><td>Hemolysis</td><td>3</td><td>B (wildtype)/B (wildtype)</td><td>Toxicity</td><td>Female patients with the B/B wildtype diplotype (not associated with G6PD deficiency) who are treated with sulfasalazine may have a reduced risk of hemolysis as compared to patients with genotypes conferring G6PD deficiency (e.g. homozygous for the A-). Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184642788>89</a></td><td>G6PD</td><td>G6PD B (wildtype)</td><td>sulfasalazine</td><td>Hemolysis</td><td>3</td><td>B (wildtype)/B (wildtype)</td><td>Toxicity</td><td>Female patients with the B/B wildtype diplotype (not associated with G6PD deficiency) who are treated with sulfasalazine may have a reduced risk of hemolysis as compared to patients with genotypes conferring G6PD deficiency (e.g. homozygous for the A-). Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183680699>90</a></td><td>TPMT</td><td>TPMT*1</td><td>azathioprine</td><td>Transplantation</td><td>3</td><td>*1/*1</td><td>Toxicity</td><td>Patients with the TPMT *1/*1 genotype and heart transplantation who are treated with azathioprine may have a decreased, but not absent, risk of severe rejection as compared to patients with the TPMT *1/*2 or *1/*3A or *1/*3C genotype. Other genetic and clinical factors may also impact the risk for organ rejection.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183680699>91</a></td><td>TPMT</td><td>TPMT*2</td><td>azathioprine</td><td>Transplantation</td><td>3</td><td>*1/*1</td><td>Toxicity</td><td>Patients with the TPMT *1/*1 genotype and heart transplantation who are treated with azathioprine may have a decreased, but not absent, risk of severe rejection as compared to patients with the TPMT *1/*2 or *1/*3A or *1/*3C genotype. Other genetic and clinical factors may also impact the risk for organ rejection.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183680699>92</a></td><td>TPMT</td><td>TPMT*3A</td><td>azathioprine</td><td>Transplantation</td><td>3</td><td>*1/*1</td><td>Toxicity</td><td>Patients with the TPMT *1/*1 genotype and heart transplantation who are treated with azathioprine may have a decreased, but not absent, risk of severe rejection as compared to patients with the TPMT *1/*2 or *1/*3A or *1/*3C genotype. Other genetic and clinical factors may also impact the risk for organ rejection.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183680699>93</a></td><td>TPMT</td><td>TPMT*3C</td><td>azathioprine</td><td>Transplantation</td><td>3</td><td>*1/*1</td><td>Toxicity</td><td>Patients with the TPMT *1/*1 genotype and heart transplantation who are treated with azathioprine may have a decreased, but not absent, risk of severe rejection as compared to patients with the TPMT *1/*2 or *1/*3A or *1/*3C genotype. Other genetic and clinical factors may also impact the risk for organ rejection.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184746746>94</a></td><td>TPMT</td><td>TPMT*1</td><td>mercaptopurine</td><td></td><td>3</td><td>*1/*1</td><td>Toxicity</td><td>Patients with the *1/*1 genotype 1) may have increased inactivation of thiopurines due to normal TPMT activity and 2) may have a decreased risk for toxicity when receiving thiopurine drugs and purine analogues as compared to patients with a non-functional allele (e.g. *5, *10). Patients with the *1/*1 genotype may still be at risk for toxicity when taking thiopurine drugs and purine analogues based upon their genotypes. Other genetic and clinical factors may also influence a patient's risk for toxicity.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184746746>95</a></td><td>TPMT</td><td>TPMT*1</td><td>thioguanine</td><td></td><td>3</td><td>*1/*1</td><td>Toxicity</td><td>Patients with the *1/*1 genotype 1) may have increased inactivation of thiopurines due to normal TPMT activity and 2) may have a decreased risk for toxicity when receiving thiopurine drugs and purine analogues as compared to patients with a non-functional allele (e.g. *5, *10). Patients with the *1/*1 genotype may still be at risk for toxicity when taking thiopurine drugs and purine analogues based upon their genotypes. Other genetic and clinical factors may also influence a patient's risk for toxicity.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184746746>96</a></td><td>TPMT</td><td>TPMT*5</td><td>mercaptopurine</td><td></td><td>3</td><td>*1/*1</td><td>Toxicity</td><td>Patients with the *1/*1 genotype 1) may have increased inactivation of thiopurines due to normal TPMT activity and 2) may have a decreased risk for toxicity when receiving thiopurine drugs and purine analogues as compared to patients with a non-functional allele (e.g. *5, *10). Patients with the *1/*1 genotype may still be at risk for toxicity when taking thiopurine drugs and purine analogues based upon their genotypes. Other genetic and clinical factors may also influence a patient's risk for toxicity.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184746746>97</a></td><td>TPMT</td><td>TPMT*5</td><td>thioguanine</td><td></td><td>3</td><td>*1/*1</td><td>Toxicity</td><td>Patients with the *1/*1 genotype 1) may have increased inactivation of thiopurines due to normal TPMT activity and 2) may have a decreased risk for toxicity when receiving thiopurine drugs and purine analogues as compared to patients with a non-functional allele (e.g. *5, *10). Patients with the *1/*1 genotype may still be at risk for toxicity when taking thiopurine drugs and purine analogues based upon their genotypes. Other genetic and clinical factors may also influence a patient's risk for toxicity.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184746746>98</a></td><td>TPMT</td><td>TPMT*10</td><td>mercaptopurine</td><td></td><td>3</td><td>*1/*1</td><td>Toxicity</td><td>Patients with the *1/*1 genotype 1) may have increased inactivation of thiopurines due to normal TPMT activity and 2) may have a decreased risk for toxicity when receiving thiopurine drugs and purine analogues as compared to patients with a non-functional allele (e.g. *5, *10). Patients with the *1/*1 genotype may still be at risk for toxicity when taking thiopurine drugs and purine analogues based upon their genotypes. Other genetic and clinical factors may also influence a patient's risk for toxicity.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184746746>99</a></td><td>TPMT</td><td>TPMT*10</td><td>thioguanine</td><td></td><td>3</td><td>*1/*1</td><td>Toxicity</td><td>Patients with the *1/*1 genotype 1) may have increased inactivation of thiopurines due to normal TPMT activity and 2) may have a decreased risk for toxicity when receiving thiopurine drugs and purine analogues as compared to patients with a non-functional allele (e.g. *5, *10). Patients with the *1/*1 genotype may still be at risk for toxicity when taking thiopurine drugs and purine analogues based upon their genotypes. Other genetic and clinical factors may also influence a patient's risk for toxicity.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184746746>100</a></td><td>TPMT</td><td>TPMT*13</td><td>mercaptopurine</td><td></td><td>3</td><td>*1/*1</td><td>Toxicity</td><td>Patients with the *1/*1 genotype 1) may have increased inactivation of thiopurines due to normal TPMT activity and 2) may have a decreased risk for toxicity when receiving thiopurine drugs and purine analogues as compared to patients with a non-functional allele (e.g. *5, *10). Patients with the *1/*1 genotype may still be at risk for toxicity when taking thiopurine drugs and purine analogues based upon their genotypes. Other genetic and clinical factors may also influence a patient's risk for toxicity.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184746746>101</a></td><td>TPMT</td><td>TPMT*13</td><td>thioguanine</td><td></td><td>3</td><td>*1/*1</td><td>Toxicity</td><td>Patients with the *1/*1 genotype 1) may have increased inactivation of thiopurines due to normal TPMT activity and 2) may have a decreased risk for toxicity when receiving thiopurine drugs and purine analogues as compared to patients with a non-functional allele (e.g. *5, *10). Patients with the *1/*1 genotype may still be at risk for toxicity when taking thiopurine drugs and purine analogues based upon their genotypes. Other genetic and clinical factors may also influence a patient's risk for toxicity.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184746746>102</a></td><td>TPMT</td><td>TPMT*15</td><td>mercaptopurine</td><td></td><td>3</td><td>*1/*1</td><td>Toxicity</td><td>Patients with the *1/*1 genotype 1) may have increased inactivation of thiopurines due to normal TPMT activity and 2) may have a decreased risk for toxicity when receiving thiopurine drugs and purine analogues as compared to patients with a non-functional allele (e.g. *5, *10). Patients with the *1/*1 genotype may still be at risk for toxicity when taking thiopurine drugs and purine analogues based upon their genotypes. Other genetic and clinical factors may also influence a patient's risk for toxicity.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184746746>103</a></td><td>TPMT</td><td>TPMT*15</td><td>thioguanine</td><td></td><td>3</td><td>*1/*1</td><td>Toxicity</td><td>Patients with the *1/*1 genotype 1) may have increased inactivation of thiopurines due to normal TPMT activity and 2) may have a decreased risk for toxicity when receiving thiopurine drugs and purine analogues as compared to patients with a non-functional allele (e.g. *5, *10). Patients with the *1/*1 genotype may still be at risk for toxicity when taking thiopurine drugs and purine analogues based upon their genotypes. Other genetic and clinical factors may also influence a patient's risk for toxicity.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184746746>104</a></td><td>TPMT</td><td>TPMT*19</td><td>mercaptopurine</td><td></td><td>3</td><td>*1/*1</td><td>Toxicity</td><td>Patients with the *1/*1 genotype 1) may have increased inactivation of thiopurines due to normal TPMT activity and 2) may have a decreased risk for toxicity when receiving thiopurine drugs and purine analogues as compared to patients with a non-functional allele (e.g. *5, *10). Patients with the *1/*1 genotype may still be at risk for toxicity when taking thiopurine drugs and purine analogues based upon their genotypes. Other genetic and clinical factors may also influence a patient's risk for toxicity.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184746746>105</a></td><td>TPMT</td><td>TPMT*19</td><td>thioguanine</td><td></td><td>3</td><td>*1/*1</td><td>Toxicity</td><td>Patients with the *1/*1 genotype 1) may have increased inactivation of thiopurines due to normal TPMT activity and 2) may have a decreased risk for toxicity when receiving thiopurine drugs and purine analogues as compared to patients with a non-functional allele (e.g. *5, *10). Patients with the *1/*1 genotype may still be at risk for toxicity when taking thiopurine drugs and purine analogues based upon their genotypes. Other genetic and clinical factors may also influence a patient's risk for toxicity.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184746746>106</a></td><td>TPMT</td><td>TPMT*24</td><td>mercaptopurine</td><td></td><td>3</td><td>*1/*1</td><td>Toxicity</td><td>Patients with the *1/*1 genotype 1) may have increased inactivation of thiopurines due to normal TPMT activity and 2) may have a decreased risk for toxicity when receiving thiopurine drugs and purine analogues as compared to patients with a non-functional allele (e.g. *5, *10). Patients with the *1/*1 genotype may still be at risk for toxicity when taking thiopurine drugs and purine analogues based upon their genotypes. Other genetic and clinical factors may also influence a patient's risk for toxicity.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184746746>107</a></td><td>TPMT</td><td>TPMT*24</td><td>thioguanine</td><td></td><td>3</td><td>*1/*1</td><td>Toxicity</td><td>Patients with the *1/*1 genotype 1) may have increased inactivation of thiopurines due to normal TPMT activity and 2) may have a decreased risk for toxicity when receiving thiopurine drugs and purine analogues as compared to patients with a non-functional allele (e.g. *5, *10). Patients with the *1/*1 genotype may still be at risk for toxicity when taking thiopurine drugs and purine analogues based upon their genotypes. Other genetic and clinical factors may also influence a patient's risk for toxicity.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184746746>108</a></td><td>TPMT</td><td>TPMT*25</td><td>mercaptopurine</td><td></td><td>3</td><td>*1/*1</td><td>Toxicity</td><td>Patients with the *1/*1 genotype 1) may have increased inactivation of thiopurines due to normal TPMT activity and 2) may have a decreased risk for toxicity when receiving thiopurine drugs and purine analogues as compared to patients with a non-functional allele (e.g. *5, *10). Patients with the *1/*1 genotype may still be at risk for toxicity when taking thiopurine drugs and purine analogues based upon their genotypes. Other genetic and clinical factors may also influence a patient's risk for toxicity.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184746746>109</a></td><td>TPMT</td><td>TPMT*25</td><td>thioguanine</td><td></td><td>3</td><td>*1/*1</td><td>Toxicity</td><td>Patients with the *1/*1 genotype 1) may have increased inactivation of thiopurines due to normal TPMT activity and 2) may have a decreased risk for toxicity when receiving thiopurine drugs and purine analogues as compared to patients with a non-functional allele (e.g. *5, *10). Patients with the *1/*1 genotype may still be at risk for toxicity when taking thiopurine drugs and purine analogues based upon their genotypes. Other genetic and clinical factors may also influence a patient's risk for toxicity.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184746746>110</a></td><td>TPMT</td><td>TPMT*26</td><td>mercaptopurine</td><td></td><td>3</td><td>*1/*1</td><td>Toxicity</td><td>Patients with the *1/*1 genotype 1) may have increased inactivation of thiopurines due to normal TPMT activity and 2) may have a decreased risk for toxicity when receiving thiopurine drugs and purine analogues as compared to patients with a non-functional allele (e.g. *5, *10). Patients with the *1/*1 genotype may still be at risk for toxicity when taking thiopurine drugs and purine analogues based upon their genotypes. Other genetic and clinical factors may also influence a patient's risk for toxicity.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184746746>111</a></td><td>TPMT</td><td>TPMT*26</td><td>thioguanine</td><td></td><td>3</td><td>*1/*1</td><td>Toxicity</td><td>Patients with the *1/*1 genotype 1) may have increased inactivation of thiopurines due to normal TPMT activity and 2) may have a decreased risk for toxicity when receiving thiopurine drugs and purine analogues as compared to patients with a non-functional allele (e.g. *5, *10). Patients with the *1/*1 genotype may still be at risk for toxicity when taking thiopurine drugs and purine analogues based upon their genotypes. Other genetic and clinical factors may also influence a patient's risk for toxicity.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184746746>112</a></td><td>TPMT</td><td>TPMT*27</td><td>mercaptopurine</td><td></td><td>3</td><td>*1/*1</td><td>Toxicity</td><td>Patients with the *1/*1 genotype 1) may have increased inactivation of thiopurines due to normal TPMT activity and 2) may have a decreased risk for toxicity when receiving thiopurine drugs and purine analogues as compared to patients with a non-functional allele (e.g. *5, *10). Patients with the *1/*1 genotype may still be at risk for toxicity when taking thiopurine drugs and purine analogues based upon their genotypes. Other genetic and clinical factors may also influence a patient's risk for toxicity.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184746746>113</a></td><td>TPMT</td><td>TPMT*27</td><td>thioguanine</td><td></td><td>3</td><td>*1/*1</td><td>Toxicity</td><td>Patients with the *1/*1 genotype 1) may have increased inactivation of thiopurines due to normal TPMT activity and 2) may have a decreased risk for toxicity when receiving thiopurine drugs and purine analogues as compared to patients with a non-functional allele (e.g. *5, *10). Patients with the *1/*1 genotype may still be at risk for toxicity when taking thiopurine drugs and purine analogues based upon their genotypes. Other genetic and clinical factors may also influence a patient's risk for toxicity.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184746746>114</a></td><td>TPMT</td><td>TPMT*28</td><td>mercaptopurine</td><td></td><td>3</td><td>*1/*1</td><td>Toxicity</td><td>Patients with the *1/*1 genotype 1) may have increased inactivation of thiopurines due to normal TPMT activity and 2) may have a decreased risk for toxicity when receiving thiopurine drugs and purine analogues as compared to patients with a non-functional allele (e.g. *5, *10). Patients with the *1/*1 genotype may still be at risk for toxicity when taking thiopurine drugs and purine analogues based upon their genotypes. Other genetic and clinical factors may also influence a patient's risk for toxicity.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184746746>115</a></td><td>TPMT</td><td>TPMT*28</td><td>thioguanine</td><td></td><td>3</td><td>*1/*1</td><td>Toxicity</td><td>Patients with the *1/*1 genotype 1) may have increased inactivation of thiopurines due to normal TPMT activity and 2) may have a decreased risk for toxicity when receiving thiopurine drugs and purine analogues as compared to patients with a non-functional allele (e.g. *5, *10). Patients with the *1/*1 genotype may still be at risk for toxicity when taking thiopurine drugs and purine analogues based upon their genotypes. Other genetic and clinical factors may also influence a patient's risk for toxicity.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184746746>116</a></td><td>TPMT</td><td>TPMT*30</td><td>mercaptopurine</td><td></td><td>3</td><td>*1/*1</td><td>Toxicity</td><td>Patients with the *1/*1 genotype 1) may have increased inactivation of thiopurines due to normal TPMT activity and 2) may have a decreased risk for toxicity when receiving thiopurine drugs and purine analogues as compared to patients with a non-functional allele (e.g. *5, *10). Patients with the *1/*1 genotype may still be at risk for toxicity when taking thiopurine drugs and purine analogues based upon their genotypes. Other genetic and clinical factors may also influence a patient's risk for toxicity.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184746746>117</a></td><td>TPMT</td><td>TPMT*30</td><td>thioguanine</td><td></td><td>3</td><td>*1/*1</td><td>Toxicity</td><td>Patients with the *1/*1 genotype 1) may have increased inactivation of thiopurines due to normal TPMT activity and 2) may have a decreased risk for toxicity when receiving thiopurine drugs and purine analogues as compared to patients with a non-functional allele (e.g. *5, *10). Patients with the *1/*1 genotype may still be at risk for toxicity when taking thiopurine drugs and purine analogues based upon their genotypes. Other genetic and clinical factors may also influence a patient's risk for toxicity.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184746746>118</a></td><td>TPMT</td><td>TPMT*31</td><td>mercaptopurine</td><td></td><td>3</td><td>*1/*1</td><td>Toxicity</td><td>Patients with the *1/*1 genotype 1) may have increased inactivation of thiopurines due to normal TPMT activity and 2) may have a decreased risk for toxicity when receiving thiopurine drugs and purine analogues as compared to patients with a non-functional allele (e.g. *5, *10). Patients with the *1/*1 genotype may still be at risk for toxicity when taking thiopurine drugs and purine analogues based upon their genotypes. Other genetic and clinical factors may also influence a patient's risk for toxicity.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184746746>119</a></td><td>TPMT</td><td>TPMT*31</td><td>thioguanine</td><td></td><td>3</td><td>*1/*1</td><td>Toxicity</td><td>Patients with the *1/*1 genotype 1) may have increased inactivation of thiopurines due to normal TPMT activity and 2) may have a decreased risk for toxicity when receiving thiopurine drugs and purine analogues as compared to patients with a non-functional allele (e.g. *5, *10). Patients with the *1/*1 genotype may still be at risk for toxicity when taking thiopurine drugs and purine analogues based upon their genotypes. Other genetic and clinical factors may also influence a patient's risk for toxicity.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184746746>120</a></td><td>TPMT</td><td>TPMT*32</td><td>mercaptopurine</td><td></td><td>3</td><td>*1/*1</td><td>Toxicity</td><td>Patients with the *1/*1 genotype 1) may have increased inactivation of thiopurines due to normal TPMT activity and 2) may have a decreased risk for toxicity when receiving thiopurine drugs and purine analogues as compared to patients with a non-functional allele (e.g. *5, *10). Patients with the *1/*1 genotype may still be at risk for toxicity when taking thiopurine drugs and purine analogues based upon their genotypes. Other genetic and clinical factors may also influence a patient's risk for toxicity.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184746746>121</a></td><td>TPMT</td><td>TPMT*32</td><td>thioguanine</td><td></td><td>3</td><td>*1/*1</td><td>Toxicity</td><td>Patients with the *1/*1 genotype 1) may have increased inactivation of thiopurines due to normal TPMT activity and 2) may have a decreased risk for toxicity when receiving thiopurine drugs and purine analogues as compared to patients with a non-functional allele (e.g. *5, *10). Patients with the *1/*1 genotype may still be at risk for toxicity when taking thiopurine drugs and purine analogues based upon their genotypes. Other genetic and clinical factors may also influence a patient's risk for toxicity.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184746746>122</a></td><td>TPMT</td><td>TPMT*33</td><td>mercaptopurine</td><td></td><td>3</td><td>*1/*1</td><td>Toxicity</td><td>Patients with the *1/*1 genotype 1) may have increased inactivation of thiopurines due to normal TPMT activity and 2) may have a decreased risk for toxicity when receiving thiopurine drugs and purine analogues as compared to patients with a non-functional allele (e.g. *5, *10). Patients with the *1/*1 genotype may still be at risk for toxicity when taking thiopurine drugs and purine analogues based upon their genotypes. Other genetic and clinical factors may also influence a patient's risk for toxicity.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184746746>123</a></td><td>TPMT</td><td>TPMT*33</td><td>thioguanine</td><td></td><td>3</td><td>*1/*1</td><td>Toxicity</td><td>Patients with the *1/*1 genotype 1) may have increased inactivation of thiopurines due to normal TPMT activity and 2) may have a decreased risk for toxicity when receiving thiopurine drugs and purine analogues as compared to patients with a non-functional allele (e.g. *5, *10). Patients with the *1/*1 genotype may still be at risk for toxicity when taking thiopurine drugs and purine analogues based upon their genotypes. Other genetic and clinical factors may also influence a patient's risk for toxicity.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184746746>124</a></td><td>TPMT</td><td>TPMT*34</td><td>mercaptopurine</td><td></td><td>3</td><td>*1/*1</td><td>Toxicity</td><td>Patients with the *1/*1 genotype 1) may have increased inactivation of thiopurines due to normal TPMT activity and 2) may have a decreased risk for toxicity when receiving thiopurine drugs and purine analogues as compared to patients with a non-functional allele (e.g. *5, *10). Patients with the *1/*1 genotype may still be at risk for toxicity when taking thiopurine drugs and purine analogues based upon their genotypes. Other genetic and clinical factors may also influence a patient's risk for toxicity.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184746746>125</a></td><td>TPMT</td><td>TPMT*34</td><td>thioguanine</td><td></td><td>3</td><td>*1/*1</td><td>Toxicity</td><td>Patients with the *1/*1 genotype 1) may have increased inactivation of thiopurines due to normal TPMT activity and 2) may have a decreased risk for toxicity when receiving thiopurine drugs and purine analogues as compared to patients with a non-functional allele (e.g. *5, *10). Patients with the *1/*1 genotype may still be at risk for toxicity when taking thiopurine drugs and purine analogues based upon their genotypes. Other genetic and clinical factors may also influence a patient's risk for toxicity.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184746746>126</a></td><td>TPMT</td><td>TPMT*37</td><td>mercaptopurine</td><td></td><td>3</td><td>*1/*1</td><td>Toxicity</td><td>Patients with the *1/*1 genotype 1) may have increased inactivation of thiopurines due to normal TPMT activity and 2) may have a decreased risk for toxicity when receiving thiopurine drugs and purine analogues as compared to patients with a non-functional allele (e.g. *5, *10). Patients with the *1/*1 genotype may still be at risk for toxicity when taking thiopurine drugs and purine analogues based upon their genotypes. Other genetic and clinical factors may also influence a patient's risk for toxicity.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184746746>127</a></td><td>TPMT</td><td>TPMT*37</td><td>thioguanine</td><td></td><td>3</td><td>*1/*1</td><td>Toxicity</td><td>Patients with the *1/*1 genotype 1) may have increased inactivation of thiopurines due to normal TPMT activity and 2) may have a decreased risk for toxicity when receiving thiopurine drugs and purine analogues as compared to patients with a non-functional allele (e.g. *5, *10). Patients with the *1/*1 genotype may still be at risk for toxicity when taking thiopurine drugs and purine analogues based upon their genotypes. Other genetic and clinical factors may also influence a patient's risk for toxicity.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184653758>128</a></td><td>TPMT</td><td>TPMT*1</td><td>azathioprine</td><td>Lupus Erythematosus, Systemic;Precursor Cell Lymphoblastic Leukemia-Lymphoma</td><td>4</td><td>*1/*1</td><td>Toxicity</td><td>Patients with the *1/*1 genotype 1) may have increased inactivation of thiopurines due to normal TPMT activity and 2) may have a decreased risk for toxicity when receiving thiopurine drugs and purine analogues as compared to patients with a non-functional allele (e.g. *6, *7, *8). Patients with the *1/*1 genotype may still be at risk for toxicity when taking thiopurine drugs and purine analogues based upon their genotypes. Other genetic and clinical factors may also influence a patient's risk for toxicity.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184653758>129</a></td><td>TPMT</td><td>TPMT*1</td><td>mercaptopurine</td><td>Lupus Erythematosus, Systemic;Precursor Cell Lymphoblastic Leukemia-Lymphoma</td><td>4</td><td>*1/*1</td><td>Toxicity</td><td>Patients with the *1/*1 genotype 1) may have increased inactivation of thiopurines due to normal TPMT activity and 2) may have a decreased risk for toxicity when receiving thiopurine drugs and purine analogues as compared to patients with a non-functional allele (e.g. *6, *7, *8). Patients with the *1/*1 genotype may still be at risk for toxicity when taking thiopurine drugs and purine analogues based upon their genotypes. Other genetic and clinical factors may also influence a patient's risk for toxicity.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184653758>130</a></td><td>TPMT</td><td>TPMT*1</td><td>purine analogues</td><td>Lupus Erythematosus, Systemic;Precursor Cell Lymphoblastic Leukemia-Lymphoma</td><td>4</td><td>*1/*1</td><td>Toxicity</td><td>Patients with the *1/*1 genotype 1) may have increased inactivation of thiopurines due to normal TPMT activity and 2) may have a decreased risk for toxicity when receiving thiopurine drugs and purine analogues as compared to patients with a non-functional allele (e.g. *6, *7, *8). Patients with the *1/*1 genotype may still be at risk for toxicity when taking thiopurine drugs and purine analogues based upon their genotypes. Other genetic and clinical factors may also influence a patient's risk for toxicity.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184653758>131</a></td><td>TPMT</td><td>TPMT*1</td><td>thioguanine</td><td>Lupus Erythematosus, Systemic;Precursor Cell Lymphoblastic Leukemia-Lymphoma</td><td>4</td><td>*1/*1</td><td>Toxicity</td><td>Patients with the *1/*1 genotype 1) may have increased inactivation of thiopurines due to normal TPMT activity and 2) may have a decreased risk for toxicity when receiving thiopurine drugs and purine analogues as compared to patients with a non-functional allele (e.g. *6, *7, *8). Patients with the *1/*1 genotype may still be at risk for toxicity when taking thiopurine drugs and purine analogues based upon their genotypes. Other genetic and clinical factors may also influence a patient's risk for toxicity.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184653758>132</a></td><td>TPMT</td><td>TPMT*6</td><td>azathioprine</td><td>Lupus Erythematosus, Systemic;Precursor Cell Lymphoblastic Leukemia-Lymphoma</td><td>4</td><td>*1/*1</td><td>Toxicity</td><td>Patients with the *1/*1 genotype 1) may have increased inactivation of thiopurines due to normal TPMT activity and 2) may have a decreased risk for toxicity when receiving thiopurine drugs and purine analogues as compared to patients with a non-functional allele (e.g. *6, *7, *8). Patients with the *1/*1 genotype may still be at risk for toxicity when taking thiopurine drugs and purine analogues based upon their genotypes. Other genetic and clinical factors may also influence a patient's risk for toxicity.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184653758>133</a></td><td>TPMT</td><td>TPMT*6</td><td>mercaptopurine</td><td>Lupus Erythematosus, Systemic;Precursor Cell Lymphoblastic Leukemia-Lymphoma</td><td>4</td><td>*1/*1</td><td>Toxicity</td><td>Patients with the *1/*1 genotype 1) may have increased inactivation of thiopurines due to normal TPMT activity and 2) may have a decreased risk for toxicity when receiving thiopurine drugs and purine analogues as compared to patients with a non-functional allele (e.g. *6, *7, *8). Patients with the *1/*1 genotype may still be at risk for toxicity when taking thiopurine drugs and purine analogues based upon their genotypes. Other genetic and clinical factors may also influence a patient's risk for toxicity.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184653758>134</a></td><td>TPMT</td><td>TPMT*6</td><td>purine analogues</td><td>Lupus Erythematosus, Systemic;Precursor Cell Lymphoblastic Leukemia-Lymphoma</td><td>4</td><td>*1/*1</td><td>Toxicity</td><td>Patients with the *1/*1 genotype 1) may have increased inactivation of thiopurines due to normal TPMT activity and 2) may have a decreased risk for toxicity when receiving thiopurine drugs and purine analogues as compared to patients with a non-functional allele (e.g. *6, *7, *8). Patients with the *1/*1 genotype may still be at risk for toxicity when taking thiopurine drugs and purine analogues based upon their genotypes. Other genetic and clinical factors may also influence a patient's risk for toxicity.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184653758>135</a></td><td>TPMT</td><td>TPMT*6</td><td>thioguanine</td><td>Lupus Erythematosus, Systemic;Precursor Cell Lymphoblastic Leukemia-Lymphoma</td><td>4</td><td>*1/*1</td><td>Toxicity</td><td>Patients with the *1/*1 genotype 1) may have increased inactivation of thiopurines due to normal TPMT activity and 2) may have a decreased risk for toxicity when receiving thiopurine drugs and purine analogues as compared to patients with a non-functional allele (e.g. *6, *7, *8). Patients with the *1/*1 genotype may still be at risk for toxicity when taking thiopurine drugs and purine analogues based upon their genotypes. Other genetic and clinical factors may also influence a patient's risk for toxicity.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184653758>136</a></td><td>TPMT</td><td>TPMT*7</td><td>azathioprine</td><td>Lupus Erythematosus, Systemic;Precursor Cell Lymphoblastic Leukemia-Lymphoma</td><td>4</td><td>*1/*1</td><td>Toxicity</td><td>Patients with the *1/*1 genotype 1) may have increased inactivation of thiopurines due to normal TPMT activity and 2) may have a decreased risk for toxicity when receiving thiopurine drugs and purine analogues as compared to patients with a non-functional allele (e.g. *6, *7, *8). Patients with the *1/*1 genotype may still be at risk for toxicity when taking thiopurine drugs and purine analogues based upon their genotypes. Other genetic and clinical factors may also influence a patient's risk for toxicity.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184653758>137</a></td><td>TPMT</td><td>TPMT*7</td><td>mercaptopurine</td><td>Lupus Erythematosus, Systemic;Precursor Cell Lymphoblastic Leukemia-Lymphoma</td><td>4</td><td>*1/*1</td><td>Toxicity</td><td>Patients with the *1/*1 genotype 1) may have increased inactivation of thiopurines due to normal TPMT activity and 2) may have a decreased risk for toxicity when receiving thiopurine drugs and purine analogues as compared to patients with a non-functional allele (e.g. *6, *7, *8). Patients with the *1/*1 genotype may still be at risk for toxicity when taking thiopurine drugs and purine analogues based upon their genotypes. Other genetic and clinical factors may also influence a patient's risk for toxicity.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184653758>138</a></td><td>TPMT</td><td>TPMT*7</td><td>purine analogues</td><td>Lupus Erythematosus, Systemic;Precursor Cell Lymphoblastic Leukemia-Lymphoma</td><td>4</td><td>*1/*1</td><td>Toxicity</td><td>Patients with the *1/*1 genotype 1) may have increased inactivation of thiopurines due to normal TPMT activity and 2) may have a decreased risk for toxicity when receiving thiopurine drugs and purine analogues as compared to patients with a non-functional allele (e.g. *6, *7, *8). Patients with the *1/*1 genotype may still be at risk for toxicity when taking thiopurine drugs and purine analogues based upon their genotypes. Other genetic and clinical factors may also influence a patient's risk for toxicity.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184653758>139</a></td><td>TPMT</td><td>TPMT*7</td><td>thioguanine</td><td>Lupus Erythematosus, Systemic;Precursor Cell Lymphoblastic Leukemia-Lymphoma</td><td>4</td><td>*1/*1</td><td>Toxicity</td><td>Patients with the *1/*1 genotype 1) may have increased inactivation of thiopurines due to normal TPMT activity and 2) may have a decreased risk for toxicity when receiving thiopurine drugs and purine analogues as compared to patients with a non-functional allele (e.g. *6, *7, *8). Patients with the *1/*1 genotype may still be at risk for toxicity when taking thiopurine drugs and purine analogues based upon their genotypes. Other genetic and clinical factors may also influence a patient's risk for toxicity.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184653758>140</a></td><td>TPMT</td><td>TPMT*8</td><td>azathioprine</td><td>Lupus Erythematosus, Systemic;Precursor Cell Lymphoblastic Leukemia-Lymphoma</td><td>4</td><td>*1/*1</td><td>Toxicity</td><td>Patients with the *1/*1 genotype 1) may have increased inactivation of thiopurines due to normal TPMT activity and 2) may have a decreased risk for toxicity when receiving thiopurine drugs and purine analogues as compared to patients with a non-functional allele (e.g. *6, *7, *8). Patients with the *1/*1 genotype may still be at risk for toxicity when taking thiopurine drugs and purine analogues based upon their genotypes. Other genetic and clinical factors may also influence a patient's risk for toxicity.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184653758>141</a></td><td>TPMT</td><td>TPMT*8</td><td>mercaptopurine</td><td>Lupus Erythematosus, Systemic;Precursor Cell Lymphoblastic Leukemia-Lymphoma</td><td>4</td><td>*1/*1</td><td>Toxicity</td><td>Patients with the *1/*1 genotype 1) may have increased inactivation of thiopurines due to normal TPMT activity and 2) may have a decreased risk for toxicity when receiving thiopurine drugs and purine analogues as compared to patients with a non-functional allele (e.g. *6, *7, *8). Patients with the *1/*1 genotype may still be at risk for toxicity when taking thiopurine drugs and purine analogues based upon their genotypes. Other genetic and clinical factors may also influence a patient's risk for toxicity.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184653758>142</a></td><td>TPMT</td><td>TPMT*8</td><td>purine analogues</td><td>Lupus Erythematosus, Systemic;Precursor Cell Lymphoblastic Leukemia-Lymphoma</td><td>4</td><td>*1/*1</td><td>Toxicity</td><td>Patients with the *1/*1 genotype 1) may have increased inactivation of thiopurines due to normal TPMT activity and 2) may have a decreased risk for toxicity when receiving thiopurine drugs and purine analogues as compared to patients with a non-functional allele (e.g. *6, *7, *8). Patients with the *1/*1 genotype may still be at risk for toxicity when taking thiopurine drugs and purine analogues based upon their genotypes. Other genetic and clinical factors may also influence a patient's risk for toxicity.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184653758>143</a></td><td>TPMT</td><td>TPMT*8</td><td>thioguanine</td><td>Lupus Erythematosus, Systemic;Precursor Cell Lymphoblastic Leukemia-Lymphoma</td><td>4</td><td>*1/*1</td><td>Toxicity</td><td>Patients with the *1/*1 genotype 1) may have increased inactivation of thiopurines due to normal TPMT activity and 2) may have a decreased risk for toxicity when receiving thiopurine drugs and purine analogues as compared to patients with a non-functional allele (e.g. *6, *7, *8). Patients with the *1/*1 genotype may still be at risk for toxicity when taking thiopurine drugs and purine analogues based upon their genotypes. Other genetic and clinical factors may also influence a patient's risk for toxicity.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184653758>144</a></td><td>TPMT</td><td>TPMT*11</td><td>azathioprine</td><td>Lupus Erythematosus, Systemic;Precursor Cell Lymphoblastic Leukemia-Lymphoma</td><td>4</td><td>*1/*1</td><td>Toxicity</td><td>Patients with the *1/*1 genotype 1) may have increased inactivation of thiopurines due to normal TPMT activity and 2) may have a decreased risk for toxicity when receiving thiopurine drugs and purine analogues as compared to patients with a non-functional allele (e.g. *6, *7, *8). Patients with the *1/*1 genotype may still be at risk for toxicity when taking thiopurine drugs and purine analogues based upon their genotypes. Other genetic and clinical factors may also influence a patient's risk for toxicity.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184653758>145</a></td><td>TPMT</td><td>TPMT*11</td><td>mercaptopurine</td><td>Lupus Erythematosus, Systemic;Precursor Cell Lymphoblastic Leukemia-Lymphoma</td><td>4</td><td>*1/*1</td><td>Toxicity</td><td>Patients with the *1/*1 genotype 1) may have increased inactivation of thiopurines due to normal TPMT activity and 2) may have a decreased risk for toxicity when receiving thiopurine drugs and purine analogues as compared to patients with a non-functional allele (e.g. *6, *7, *8). Patients with the *1/*1 genotype may still be at risk for toxicity when taking thiopurine drugs and purine analogues based upon their genotypes. Other genetic and clinical factors may also influence a patient's risk for toxicity.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184653758>146</a></td><td>TPMT</td><td>TPMT*11</td><td>purine analogues</td><td>Lupus Erythematosus, Systemic;Precursor Cell Lymphoblastic Leukemia-Lymphoma</td><td>4</td><td>*1/*1</td><td>Toxicity</td><td>Patients with the *1/*1 genotype 1) may have increased inactivation of thiopurines due to normal TPMT activity and 2) may have a decreased risk for toxicity when receiving thiopurine drugs and purine analogues as compared to patients with a non-functional allele (e.g. *6, *7, *8). Patients with the *1/*1 genotype may still be at risk for toxicity when taking thiopurine drugs and purine analogues based upon their genotypes. Other genetic and clinical factors may also influence a patient's risk for toxicity.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184653758>147</a></td><td>TPMT</td><td>TPMT*11</td><td>thioguanine</td><td>Lupus Erythematosus, Systemic;Precursor Cell Lymphoblastic Leukemia-Lymphoma</td><td>4</td><td>*1/*1</td><td>Toxicity</td><td>Patients with the *1/*1 genotype 1) may have increased inactivation of thiopurines due to normal TPMT activity and 2) may have a decreased risk for toxicity when receiving thiopurine drugs and purine analogues as compared to patients with a non-functional allele (e.g. *6, *7, *8). Patients with the *1/*1 genotype may still be at risk for toxicity when taking thiopurine drugs and purine analogues based upon their genotypes. Other genetic and clinical factors may also influence a patient's risk for toxicity.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184653758>148</a></td><td>TPMT</td><td>TPMT*14</td><td>azathioprine</td><td>Lupus Erythematosus, Systemic;Precursor Cell Lymphoblastic Leukemia-Lymphoma</td><td>4</td><td>*1/*1</td><td>Toxicity</td><td>Patients with the *1/*1 genotype 1) may have increased inactivation of thiopurines due to normal TPMT activity and 2) may have a decreased risk for toxicity when receiving thiopurine drugs and purine analogues as compared to patients with a non-functional allele (e.g. *6, *7, *8). Patients with the *1/*1 genotype may still be at risk for toxicity when taking thiopurine drugs and purine analogues based upon their genotypes. Other genetic and clinical factors may also influence a patient's risk for toxicity.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184653758>149</a></td><td>TPMT</td><td>TPMT*14</td><td>mercaptopurine</td><td>Lupus Erythematosus, Systemic;Precursor Cell Lymphoblastic Leukemia-Lymphoma</td><td>4</td><td>*1/*1</td><td>Toxicity</td><td>Patients with the *1/*1 genotype 1) may have increased inactivation of thiopurines due to normal TPMT activity and 2) may have a decreased risk for toxicity when receiving thiopurine drugs and purine analogues as compared to patients with a non-functional allele (e.g. *6, *7, *8). Patients with the *1/*1 genotype may still be at risk for toxicity when taking thiopurine drugs and purine analogues based upon their genotypes. Other genetic and clinical factors may also influence a patient's risk for toxicity.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184653758>150</a></td><td>TPMT</td><td>TPMT*14</td><td>purine analogues</td><td>Lupus Erythematosus, Systemic;Precursor Cell Lymphoblastic Leukemia-Lymphoma</td><td>4</td><td>*1/*1</td><td>Toxicity</td><td>Patients with the *1/*1 genotype 1) may have increased inactivation of thiopurines due to normal TPMT activity and 2) may have a decreased risk for toxicity when receiving thiopurine drugs and purine analogues as compared to patients with a non-functional allele (e.g. *6, *7, *8). Patients with the *1/*1 genotype may still be at risk for toxicity when taking thiopurine drugs and purine analogues based upon their genotypes. Other genetic and clinical factors may also influence a patient's risk for toxicity.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184653758>151</a></td><td>TPMT</td><td>TPMT*14</td><td>thioguanine</td><td>Lupus Erythematosus, Systemic;Precursor Cell Lymphoblastic Leukemia-Lymphoma</td><td>4</td><td>*1/*1</td><td>Toxicity</td><td>Patients with the *1/*1 genotype 1) may have increased inactivation of thiopurines due to normal TPMT activity and 2) may have a decreased risk for toxicity when receiving thiopurine drugs and purine analogues as compared to patients with a non-functional allele (e.g. *6, *7, *8). Patients with the *1/*1 genotype may still be at risk for toxicity when taking thiopurine drugs and purine analogues based upon their genotypes. Other genetic and clinical factors may also influence a patient's risk for toxicity.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184653758>152</a></td><td>TPMT</td><td>TPMT*16</td><td>azathioprine</td><td>Lupus Erythematosus, Systemic;Precursor Cell Lymphoblastic Leukemia-Lymphoma</td><td>4</td><td>*1/*1</td><td>Toxicity</td><td>Patients with the *1/*1 genotype 1) may have increased inactivation of thiopurines due to normal TPMT activity and 2) may have a decreased risk for toxicity when receiving thiopurine drugs and purine analogues as compared to patients with a non-functional allele (e.g. *6, *7, *8). Patients with the *1/*1 genotype may still be at risk for toxicity when taking thiopurine drugs and purine analogues based upon their genotypes. Other genetic and clinical factors may also influence a patient's risk for toxicity.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184653758>153</a></td><td>TPMT</td><td>TPMT*16</td><td>mercaptopurine</td><td>Lupus Erythematosus, Systemic;Precursor Cell Lymphoblastic Leukemia-Lymphoma</td><td>4</td><td>*1/*1</td><td>Toxicity</td><td>Patients with the *1/*1 genotype 1) may have increased inactivation of thiopurines due to normal TPMT activity and 2) may have a decreased risk for toxicity when receiving thiopurine drugs and purine analogues as compared to patients with a non-functional allele (e.g. *6, *7, *8). Patients with the *1/*1 genotype may still be at risk for toxicity when taking thiopurine drugs and purine analogues based upon their genotypes. Other genetic and clinical factors may also influence a patient's risk for toxicity.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184653758>154</a></td><td>TPMT</td><td>TPMT*16</td><td>purine analogues</td><td>Lupus Erythematosus, Systemic;Precursor Cell Lymphoblastic Leukemia-Lymphoma</td><td>4</td><td>*1/*1</td><td>Toxicity</td><td>Patients with the *1/*1 genotype 1) may have increased inactivation of thiopurines due to normal TPMT activity and 2) may have a decreased risk for toxicity when receiving thiopurine drugs and purine analogues as compared to patients with a non-functional allele (e.g. *6, *7, *8). Patients with the *1/*1 genotype may still be at risk for toxicity when taking thiopurine drugs and purine analogues based upon their genotypes. Other genetic and clinical factors may also influence a patient's risk for toxicity.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184653758>155</a></td><td>TPMT</td><td>TPMT*16</td><td>thioguanine</td><td>Lupus Erythematosus, Systemic;Precursor Cell Lymphoblastic Leukemia-Lymphoma</td><td>4</td><td>*1/*1</td><td>Toxicity</td><td>Patients with the *1/*1 genotype 1) may have increased inactivation of thiopurines due to normal TPMT activity and 2) may have a decreased risk for toxicity when receiving thiopurine drugs and purine analogues as compared to patients with a non-functional allele (e.g. *6, *7, *8). Patients with the *1/*1 genotype may still be at risk for toxicity when taking thiopurine drugs and purine analogues based upon their genotypes. Other genetic and clinical factors may also influence a patient's risk for toxicity.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184653758>156</a></td><td>TPMT</td><td>TPMT*17</td><td>azathioprine</td><td>Lupus Erythematosus, Systemic;Precursor Cell Lymphoblastic Leukemia-Lymphoma</td><td>4</td><td>*1/*1</td><td>Toxicity</td><td>Patients with the *1/*1 genotype 1) may have increased inactivation of thiopurines due to normal TPMT activity and 2) may have a decreased risk for toxicity when receiving thiopurine drugs and purine analogues as compared to patients with a non-functional allele (e.g. *6, *7, *8). Patients with the *1/*1 genotype may still be at risk for toxicity when taking thiopurine drugs and purine analogues based upon their genotypes. Other genetic and clinical factors may also influence a patient's risk for toxicity.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184653758>157</a></td><td>TPMT</td><td>TPMT*17</td><td>mercaptopurine</td><td>Lupus Erythematosus, Systemic;Precursor Cell Lymphoblastic Leukemia-Lymphoma</td><td>4</td><td>*1/*1</td><td>Toxicity</td><td>Patients with the *1/*1 genotype 1) may have increased inactivation of thiopurines due to normal TPMT activity and 2) may have a decreased risk for toxicity when receiving thiopurine drugs and purine analogues as compared to patients with a non-functional allele (e.g. *6, *7, *8). Patients with the *1/*1 genotype may still be at risk for toxicity when taking thiopurine drugs and purine analogues based upon their genotypes. Other genetic and clinical factors may also influence a patient's risk for toxicity.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184653758>158</a></td><td>TPMT</td><td>TPMT*17</td><td>purine analogues</td><td>Lupus Erythematosus, Systemic;Precursor Cell Lymphoblastic Leukemia-Lymphoma</td><td>4</td><td>*1/*1</td><td>Toxicity</td><td>Patients with the *1/*1 genotype 1) may have increased inactivation of thiopurines due to normal TPMT activity and 2) may have a decreased risk for toxicity when receiving thiopurine drugs and purine analogues as compared to patients with a non-functional allele (e.g. *6, *7, *8). Patients with the *1/*1 genotype may still be at risk for toxicity when taking thiopurine drugs and purine analogues based upon their genotypes. Other genetic and clinical factors may also influence a patient's risk for toxicity.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184653758>159</a></td><td>TPMT</td><td>TPMT*17</td><td>thioguanine</td><td>Lupus Erythematosus, Systemic;Precursor Cell Lymphoblastic Leukemia-Lymphoma</td><td>4</td><td>*1/*1</td><td>Toxicity</td><td>Patients with the *1/*1 genotype 1) may have increased inactivation of thiopurines due to normal TPMT activity and 2) may have a decreased risk for toxicity when receiving thiopurine drugs and purine analogues as compared to patients with a non-functional allele (e.g. *6, *7, *8). Patients with the *1/*1 genotype may still be at risk for toxicity when taking thiopurine drugs and purine analogues based upon their genotypes. Other genetic and clinical factors may also influence a patient's risk for toxicity.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184653758>160</a></td><td>TPMT</td><td>TPMT*18</td><td>azathioprine</td><td>Lupus Erythematosus, Systemic;Precursor Cell Lymphoblastic Leukemia-Lymphoma</td><td>4</td><td>*1/*1</td><td>Toxicity</td><td>Patients with the *1/*1 genotype 1) may have increased inactivation of thiopurines due to normal TPMT activity and 2) may have a decreased risk for toxicity when receiving thiopurine drugs and purine analogues as compared to patients with a non-functional allele (e.g. *6, *7, *8). Patients with the *1/*1 genotype may still be at risk for toxicity when taking thiopurine drugs and purine analogues based upon their genotypes. Other genetic and clinical factors may also influence a patient's risk for toxicity.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184653758>161</a></td><td>TPMT</td><td>TPMT*18</td><td>mercaptopurine</td><td>Lupus Erythematosus, Systemic;Precursor Cell Lymphoblastic Leukemia-Lymphoma</td><td>4</td><td>*1/*1</td><td>Toxicity</td><td>Patients with the *1/*1 genotype 1) may have increased inactivation of thiopurines due to normal TPMT activity and 2) may have a decreased risk for toxicity when receiving thiopurine drugs and purine analogues as compared to patients with a non-functional allele (e.g. *6, *7, *8). Patients with the *1/*1 genotype may still be at risk for toxicity when taking thiopurine drugs and purine analogues based upon their genotypes. Other genetic and clinical factors may also influence a patient's risk for toxicity.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184653758>162</a></td><td>TPMT</td><td>TPMT*18</td><td>purine analogues</td><td>Lupus Erythematosus, Systemic;Precursor Cell Lymphoblastic Leukemia-Lymphoma</td><td>4</td><td>*1/*1</td><td>Toxicity</td><td>Patients with the *1/*1 genotype 1) may have increased inactivation of thiopurines due to normal TPMT activity and 2) may have a decreased risk for toxicity when receiving thiopurine drugs and purine analogues as compared to patients with a non-functional allele (e.g. *6, *7, *8). Patients with the *1/*1 genotype may still be at risk for toxicity when taking thiopurine drugs and purine analogues based upon their genotypes. Other genetic and clinical factors may also influence a patient's risk for toxicity.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184653758>163</a></td><td>TPMT</td><td>TPMT*18</td><td>thioguanine</td><td>Lupus Erythematosus, Systemic;Precursor Cell Lymphoblastic Leukemia-Lymphoma</td><td>4</td><td>*1/*1</td><td>Toxicity</td><td>Patients with the *1/*1 genotype 1) may have increased inactivation of thiopurines due to normal TPMT activity and 2) may have a decreased risk for toxicity when receiving thiopurine drugs and purine analogues as compared to patients with a non-functional allele (e.g. *6, *7, *8). Patients with the *1/*1 genotype may still be at risk for toxicity when taking thiopurine drugs and purine analogues based upon their genotypes. Other genetic and clinical factors may also influence a patient's risk for toxicity.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184653758>164</a></td><td>TPMT</td><td>TPMT*20</td><td>azathioprine</td><td>Lupus Erythematosus, Systemic;Precursor Cell Lymphoblastic Leukemia-Lymphoma</td><td>4</td><td>*1/*1</td><td>Toxicity</td><td>Patients with the *1/*1 genotype 1) may have increased inactivation of thiopurines due to normal TPMT activity and 2) may have a decreased risk for toxicity when receiving thiopurine drugs and purine analogues as compared to patients with a non-functional allele (e.g. *6, *7, *8). Patients with the *1/*1 genotype may still be at risk for toxicity when taking thiopurine drugs and purine analogues based upon their genotypes. Other genetic and clinical factors may also influence a patient's risk for toxicity.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184653758>165</a></td><td>TPMT</td><td>TPMT*20</td><td>mercaptopurine</td><td>Lupus Erythematosus, Systemic;Precursor Cell Lymphoblastic Leukemia-Lymphoma</td><td>4</td><td>*1/*1</td><td>Toxicity</td><td>Patients with the *1/*1 genotype 1) may have increased inactivation of thiopurines due to normal TPMT activity and 2) may have a decreased risk for toxicity when receiving thiopurine drugs and purine analogues as compared to patients with a non-functional allele (e.g. *6, *7, *8). Patients with the *1/*1 genotype may still be at risk for toxicity when taking thiopurine drugs and purine analogues based upon their genotypes. Other genetic and clinical factors may also influence a patient's risk for toxicity.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184653758>166</a></td><td>TPMT</td><td>TPMT*20</td><td>purine analogues</td><td>Lupus Erythematosus, Systemic;Precursor Cell Lymphoblastic Leukemia-Lymphoma</td><td>4</td><td>*1/*1</td><td>Toxicity</td><td>Patients with the *1/*1 genotype 1) may have increased inactivation of thiopurines due to normal TPMT activity and 2) may have a decreased risk for toxicity when receiving thiopurine drugs and purine analogues as compared to patients with a non-functional allele (e.g. *6, *7, *8). Patients with the *1/*1 genotype may still be at risk for toxicity when taking thiopurine drugs and purine analogues based upon their genotypes. Other genetic and clinical factors may also influence a patient's risk for toxicity.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184653758>167</a></td><td>TPMT</td><td>TPMT*20</td><td>thioguanine</td><td>Lupus Erythematosus, Systemic;Precursor Cell Lymphoblastic Leukemia-Lymphoma</td><td>4</td><td>*1/*1</td><td>Toxicity</td><td>Patients with the *1/*1 genotype 1) may have increased inactivation of thiopurines due to normal TPMT activity and 2) may have a decreased risk for toxicity when receiving thiopurine drugs and purine analogues as compared to patients with a non-functional allele (e.g. *6, *7, *8). Patients with the *1/*1 genotype may still be at risk for toxicity when taking thiopurine drugs and purine analogues based upon their genotypes. Other genetic and clinical factors may also influence a patient's risk for toxicity.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184653758>168</a></td><td>TPMT</td><td>TPMT*21</td><td>azathioprine</td><td>Lupus Erythematosus, Systemic;Precursor Cell Lymphoblastic Leukemia-Lymphoma</td><td>4</td><td>*1/*1</td><td>Toxicity</td><td>Patients with the *1/*1 genotype 1) may have increased inactivation of thiopurines due to normal TPMT activity and 2) may have a decreased risk for toxicity when receiving thiopurine drugs and purine analogues as compared to patients with a non-functional allele (e.g. *6, *7, *8). Patients with the *1/*1 genotype may still be at risk for toxicity when taking thiopurine drugs and purine analogues based upon their genotypes. Other genetic and clinical factors may also influence a patient's risk for toxicity.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184653758>169</a></td><td>TPMT</td><td>TPMT*21</td><td>mercaptopurine</td><td>Lupus Erythematosus, Systemic;Precursor Cell Lymphoblastic Leukemia-Lymphoma</td><td>4</td><td>*1/*1</td><td>Toxicity</td><td>Patients with the *1/*1 genotype 1) may have increased inactivation of thiopurines due to normal TPMT activity and 2) may have a decreased risk for toxicity when receiving thiopurine drugs and purine analogues as compared to patients with a non-functional allele (e.g. *6, *7, *8). Patients with the *1/*1 genotype may still be at risk for toxicity when taking thiopurine drugs and purine analogues based upon their genotypes. Other genetic and clinical factors may also influence a patient's risk for toxicity.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184653758>170</a></td><td>TPMT</td><td>TPMT*21</td><td>purine analogues</td><td>Lupus Erythematosus, Systemic;Precursor Cell Lymphoblastic Leukemia-Lymphoma</td><td>4</td><td>*1/*1</td><td>Toxicity</td><td>Patients with the *1/*1 genotype 1) may have increased inactivation of thiopurines due to normal TPMT activity and 2) may have a decreased risk for toxicity when receiving thiopurine drugs and purine analogues as compared to patients with a non-functional allele (e.g. *6, *7, *8). Patients with the *1/*1 genotype may still be at risk for toxicity when taking thiopurine drugs and purine analogues based upon their genotypes. Other genetic and clinical factors may also influence a patient's risk for toxicity.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184653758>171</a></td><td>TPMT</td><td>TPMT*21</td><td>thioguanine</td><td>Lupus Erythematosus, Systemic;Precursor Cell Lymphoblastic Leukemia-Lymphoma</td><td>4</td><td>*1/*1</td><td>Toxicity</td><td>Patients with the *1/*1 genotype 1) may have increased inactivation of thiopurines due to normal TPMT activity and 2) may have a decreased risk for toxicity when receiving thiopurine drugs and purine analogues as compared to patients with a non-functional allele (e.g. *6, *7, *8). Patients with the *1/*1 genotype may still be at risk for toxicity when taking thiopurine drugs and purine analogues based upon their genotypes. Other genetic and clinical factors may also influence a patient's risk for toxicity.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184653758>172</a></td><td>TPMT</td><td>TPMT*22</td><td>azathioprine</td><td>Lupus Erythematosus, Systemic;Precursor Cell Lymphoblastic Leukemia-Lymphoma</td><td>4</td><td>*1/*1</td><td>Toxicity</td><td>Patients with the *1/*1 genotype 1) may have increased inactivation of thiopurines due to normal TPMT activity and 2) may have a decreased risk for toxicity when receiving thiopurine drugs and purine analogues as compared to patients with a non-functional allele (e.g. *6, *7, *8). Patients with the *1/*1 genotype may still be at risk for toxicity when taking thiopurine drugs and purine analogues based upon their genotypes. Other genetic and clinical factors may also influence a patient's risk for toxicity.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184653758>173</a></td><td>TPMT</td><td>TPMT*22</td><td>mercaptopurine</td><td>Lupus Erythematosus, Systemic;Precursor Cell Lymphoblastic Leukemia-Lymphoma</td><td>4</td><td>*1/*1</td><td>Toxicity</td><td>Patients with the *1/*1 genotype 1) may have increased inactivation of thiopurines due to normal TPMT activity and 2) may have a decreased risk for toxicity when receiving thiopurine drugs and purine analogues as compared to patients with a non-functional allele (e.g. *6, *7, *8). Patients with the *1/*1 genotype may still be at risk for toxicity when taking thiopurine drugs and purine analogues based upon their genotypes. Other genetic and clinical factors may also influence a patient's risk for toxicity.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184653758>174</a></td><td>TPMT</td><td>TPMT*22</td><td>purine analogues</td><td>Lupus Erythematosus, Systemic;Precursor Cell Lymphoblastic Leukemia-Lymphoma</td><td>4</td><td>*1/*1</td><td>Toxicity</td><td>Patients with the *1/*1 genotype 1) may have increased inactivation of thiopurines due to normal TPMT activity and 2) may have a decreased risk for toxicity when receiving thiopurine drugs and purine analogues as compared to patients with a non-functional allele (e.g. *6, *7, *8). Patients with the *1/*1 genotype may still be at risk for toxicity when taking thiopurine drugs and purine analogues based upon their genotypes. Other genetic and clinical factors may also influence a patient's risk for toxicity.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184653758>175</a></td><td>TPMT</td><td>TPMT*22</td><td>thioguanine</td><td>Lupus Erythematosus, Systemic;Precursor Cell Lymphoblastic Leukemia-Lymphoma</td><td>4</td><td>*1/*1</td><td>Toxicity</td><td>Patients with the *1/*1 genotype 1) may have increased inactivation of thiopurines due to normal TPMT activity and 2) may have a decreased risk for toxicity when receiving thiopurine drugs and purine analogues as compared to patients with a non-functional allele (e.g. *6, *7, *8). Patients with the *1/*1 genotype may still be at risk for toxicity when taking thiopurine drugs and purine analogues based upon their genotypes. Other genetic and clinical factors may also influence a patient's risk for toxicity.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184653758>176</a></td><td>TPMT</td><td>TPMT*23</td><td>azathioprine</td><td>Lupus Erythematosus, Systemic;Precursor Cell Lymphoblastic Leukemia-Lymphoma</td><td>4</td><td>*1/*1</td><td>Toxicity</td><td>Patients with the *1/*1 genotype 1) may have increased inactivation of thiopurines due to normal TPMT activity and 2) may have a decreased risk for toxicity when receiving thiopurine drugs and purine analogues as compared to patients with a non-functional allele (e.g. *6, *7, *8). Patients with the *1/*1 genotype may still be at risk for toxicity when taking thiopurine drugs and purine analogues based upon their genotypes. Other genetic and clinical factors may also influence a patient's risk for toxicity.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184653758>177</a></td><td>TPMT</td><td>TPMT*23</td><td>mercaptopurine</td><td>Lupus Erythematosus, Systemic;Precursor Cell Lymphoblastic Leukemia-Lymphoma</td><td>4</td><td>*1/*1</td><td>Toxicity</td><td>Patients with the *1/*1 genotype 1) may have increased inactivation of thiopurines due to normal TPMT activity and 2) may have a decreased risk for toxicity when receiving thiopurine drugs and purine analogues as compared to patients with a non-functional allele (e.g. *6, *7, *8). Patients with the *1/*1 genotype may still be at risk for toxicity when taking thiopurine drugs and purine analogues based upon their genotypes. Other genetic and clinical factors may also influence a patient's risk for toxicity.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184653758>178</a></td><td>TPMT</td><td>TPMT*23</td><td>purine analogues</td><td>Lupus Erythematosus, Systemic;Precursor Cell Lymphoblastic Leukemia-Lymphoma</td><td>4</td><td>*1/*1</td><td>Toxicity</td><td>Patients with the *1/*1 genotype 1) may have increased inactivation of thiopurines due to normal TPMT activity and 2) may have a decreased risk for toxicity when receiving thiopurine drugs and purine analogues as compared to patients with a non-functional allele (e.g. *6, *7, *8). Patients with the *1/*1 genotype may still be at risk for toxicity when taking thiopurine drugs and purine analogues based upon their genotypes. Other genetic and clinical factors may also influence a patient's risk for toxicity.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184653758>179</a></td><td>TPMT</td><td>TPMT*23</td><td>thioguanine</td><td>Lupus Erythematosus, Systemic;Precursor Cell Lymphoblastic Leukemia-Lymphoma</td><td>4</td><td>*1/*1</td><td>Toxicity</td><td>Patients with the *1/*1 genotype 1) may have increased inactivation of thiopurines due to normal TPMT activity and 2) may have a decreased risk for toxicity when receiving thiopurine drugs and purine analogues as compared to patients with a non-functional allele (e.g. *6, *7, *8). Patients with the *1/*1 genotype may still be at risk for toxicity when taking thiopurine drugs and purine analogues based upon their genotypes. Other genetic and clinical factors may also influence a patient's risk for toxicity.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183705354>180</a></td><td>G6PD</td><td>G6PD A- 202A_376G</td><td>dimercaprol</td><td>Hemolysis;Lead Poisoning, Nervous System, Childhood</td><td>3</td><td>B (wildtype)/B (wildtype)</td><td>Toxicity</td><td>Female children with lead poisoning and the B/B (wildtype) diplotype (not associated with G6PD deficiency) who are treated with dimercaprol may have a reduced risk of hemolysis as compared to children with the A- 202A_376G diplotype (hemizygous for the A- variant, associated with G6PD deficiency). Please note: the A- G6PD variant was determined by electrophoresis rather than genotyping and here is represented by the A- 202_376G haplotype, with the B (wildtype) haplotype representing G6PD non-deficient. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183705354>181</a></td><td>G6PD</td><td>G6PD B (wildtype)</td><td>dimercaprol</td><td>Hemolysis;Lead Poisoning, Nervous System, Childhood</td><td>3</td><td>B (wildtype)/B (wildtype)</td><td>Toxicity</td><td>Female children with lead poisoning and the B/B (wildtype) diplotype (not associated with G6PD deficiency) who are treated with dimercaprol may have a reduced risk of hemolysis as compared to children with the A- 202A_376G diplotype (hemizygous for the A- variant, associated with G6PD deficiency). Please note: the A- G6PD variant was determined by electrophoresis rather than genotyping and here is represented by the A- 202_376G haplotype, with the B (wildtype) haplotype representing G6PD non-deficient. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183705307>182</a></td><td>G6PD</td><td>G6PD B (wildtype)</td><td>ciprofloxacin</td><td>Anemia, Hemolytic</td><td>3</td><td>B (wildtype)/B (wildtype)</td><td>Toxicity</td><td>Female patients with the B (wildtype)/B (wildtype) haplotype (not associated with G6PD deficiency) who are treated with ciprofloxacin may have a reduced risk of hemolytic anemia as compared to patients with the Mediterranean/Mediterranean genotype (homozygous for the Mediterranean variant, associated with G6PD deficiency). Please note: this study did not report genotyping, but reported the patient to have Mediterranean G6PD deficiency, therefore here we are representing this association under the Mediterranean variant. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183705307>183</a></td><td>G6PD</td><td>G6PD Mediterranean Haplotype</td><td>ciprofloxacin</td><td>Anemia, Hemolytic</td><td>3</td><td>B (wildtype)/B (wildtype)</td><td>Toxicity</td><td>Female patients with the B (wildtype)/B (wildtype) haplotype (not associated with G6PD deficiency) who are treated with ciprofloxacin may have a reduced risk of hemolytic anemia as compared to patients with the Mediterranean/Mediterranean genotype (homozygous for the Mediterranean variant, associated with G6PD deficiency). Please note: this study did not report genotyping, but reported the patient to have Mediterranean G6PD deficiency, therefore here we are representing this association under the Mediterranean variant. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183705307>184</a></td><td>G6PD</td><td>G6PD Mediterranean</td><td>ciprofloxacin</td><td>Anemia, Hemolytic</td><td>3</td><td>B (wildtype)/B (wildtype)</td><td>Toxicity</td><td>Female patients with the B (wildtype)/B (wildtype) haplotype (not associated with G6PD deficiency) who are treated with ciprofloxacin may have a reduced risk of hemolytic anemia as compared to patients with the Mediterranean/Mediterranean genotype (homozygous for the Mediterranean variant, associated with G6PD deficiency). Please note: this study did not report genotyping, but reported the patient to have Mediterranean G6PD deficiency, therefore here we are representing this association under the Mediterranean variant. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183705307>185</a></td><td>G6PD</td><td>Dallas</td><td>ciprofloxacin</td><td>Anemia, Hemolytic</td><td>3</td><td>B (wildtype)/B (wildtype)</td><td>Toxicity</td><td>Female patients with the B (wildtype)/B (wildtype) haplotype (not associated with G6PD deficiency) who are treated with ciprofloxacin may have a reduced risk of hemolytic anemia as compared to patients with the Mediterranean/Mediterranean genotype (homozygous for the Mediterranean variant, associated with G6PD deficiency). Please note: this study did not report genotyping, but reported the patient to have Mediterranean G6PD deficiency, therefore here we are representing this association under the Mediterranean variant. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183705307>186</a></td><td>G6PD</td><td>Panama</td><td>ciprofloxacin</td><td>Anemia, Hemolytic</td><td>3</td><td>B (wildtype)/B (wildtype)</td><td>Toxicity</td><td>Female patients with the B (wildtype)/B (wildtype) haplotype (not associated with G6PD deficiency) who are treated with ciprofloxacin may have a reduced risk of hemolytic anemia as compared to patients with the Mediterranean/Mediterranean genotype (homozygous for the Mediterranean variant, associated with G6PD deficiency). Please note: this study did not report genotyping, but reported the patient to have Mediterranean G6PD deficiency, therefore here we are representing this association under the Mediterranean variant. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183705307>187</a></td><td>G6PD</td><td>Sassari</td><td>ciprofloxacin</td><td>Anemia, Hemolytic</td><td>3</td><td>B (wildtype)/B (wildtype)</td><td>Toxicity</td><td>Female patients with the B (wildtype)/B (wildtype) haplotype (not associated with G6PD deficiency) who are treated with ciprofloxacin may have a reduced risk of hemolytic anemia as compared to patients with the Mediterranean/Mediterranean genotype (homozygous for the Mediterranean variant, associated with G6PD deficiency). Please note: this study did not report genotyping, but reported the patient to have Mediterranean G6PD deficiency, therefore here we are representing this association under the Mediterranean variant. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183705307>188</a></td><td>G6PD</td><td>Cagliari</td><td>ciprofloxacin</td><td>Anemia, Hemolytic</td><td>3</td><td>B (wildtype)/B (wildtype)</td><td>Toxicity</td><td>Female patients with the B (wildtype)/B (wildtype) haplotype (not associated with G6PD deficiency) who are treated with ciprofloxacin may have a reduced risk of hemolytic anemia as compared to patients with the Mediterranean/Mediterranean genotype (homozygous for the Mediterranean variant, associated with G6PD deficiency). Please note: this study did not report genotyping, but reported the patient to have Mediterranean G6PD deficiency, therefore here we are representing this association under the Mediterranean variant. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183705307>189</a></td><td>G6PD</td><td>Birmingham</td><td>ciprofloxacin</td><td>Anemia, Hemolytic</td><td>3</td><td>B (wildtype)/B (wildtype)</td><td>Toxicity</td><td>Female patients with the B (wildtype)/B (wildtype) haplotype (not associated with G6PD deficiency) who are treated with ciprofloxacin may have a reduced risk of hemolytic anemia as compared to patients with the Mediterranean/Mediterranean genotype (homozygous for the Mediterranean variant, associated with G6PD deficiency). Please note: this study did not report genotyping, but reported the patient to have Mediterranean G6PD deficiency, therefore here we are representing this association under the Mediterranean variant. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183705226>190</a></td><td>G6PD</td><td>G6PD A- 202A_376G</td><td>chloroquine</td><td>Anemia, Hemolytic</td><td>4</td><td>B (wildtype)/B (wildtype)</td><td>Toxicity</td><td>Female patients with the B/B (wildtype) diplotype (not associated with G6PD deficiency) who are treated with a high dose of chloroquine may have a reduced risk of hemolytic anemia as compared to patients with the Mediterranean/Mediterranean or A-202A_376G/A-202A_376G diplotype (homozygous for a variant associated with G6PD deficiency). Most studies show no association with increased risk with normal chloroquine dosage. Please note: all studies reported an association with G6PD deficiency but only one reported genotyping, here we are representing this association under the Mediterranean or A- haplotype which is associated with G6PD deficiency, with the B (wildtype) haplotype representing G6PD non-deficient. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183705226>191</a></td><td>G6PD</td><td>G6PD B (wildtype)</td><td>chloroquine</td><td>Anemia, Hemolytic</td><td>4</td><td>B (wildtype)/B (wildtype)</td><td>Toxicity</td><td>Female patients with the B/B (wildtype) diplotype (not associated with G6PD deficiency) who are treated with a high dose of chloroquine may have a reduced risk of hemolytic anemia as compared to patients with the Mediterranean/Mediterranean or A-202A_376G/A-202A_376G diplotype (homozygous for a variant associated with G6PD deficiency). Most studies show no association with increased risk with normal chloroquine dosage. Please note: all studies reported an association with G6PD deficiency but only one reported genotyping, here we are representing this association under the Mediterranean or A- haplotype which is associated with G6PD deficiency, with the B (wildtype) haplotype representing G6PD non-deficient. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183705226>192</a></td><td>G6PD</td><td>G6PD Mediterranean Haplotype</td><td>chloroquine</td><td>Anemia, Hemolytic</td><td>4</td><td>B (wildtype)/B (wildtype)</td><td>Toxicity</td><td>Female patients with the B/B (wildtype) diplotype (not associated with G6PD deficiency) who are treated with a high dose of chloroquine may have a reduced risk of hemolytic anemia as compared to patients with the Mediterranean/Mediterranean or A-202A_376G/A-202A_376G diplotype (homozygous for a variant associated with G6PD deficiency). Most studies show no association with increased risk with normal chloroquine dosage. Please note: all studies reported an association with G6PD deficiency but only one reported genotyping, here we are representing this association under the Mediterranean or A- haplotype which is associated with G6PD deficiency, with the B (wildtype) haplotype representing G6PD non-deficient. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183705226>193</a></td><td>G6PD</td><td>G6PD Mediterranean</td><td>chloroquine</td><td>Anemia, Hemolytic</td><td>4</td><td>B (wildtype)/B (wildtype)</td><td>Toxicity</td><td>Female patients with the B/B (wildtype) diplotype (not associated with G6PD deficiency) who are treated with a high dose of chloroquine may have a reduced risk of hemolytic anemia as compared to patients with the Mediterranean/Mediterranean or A-202A_376G/A-202A_376G diplotype (homozygous for a variant associated with G6PD deficiency). Most studies show no association with increased risk with normal chloroquine dosage. Please note: all studies reported an association with G6PD deficiency but only one reported genotyping, here we are representing this association under the Mediterranean or A- haplotype which is associated with G6PD deficiency, with the B (wildtype) haplotype representing G6PD non-deficient. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183705226>194</a></td><td>G6PD</td><td>Dallas</td><td>chloroquine</td><td>Anemia, Hemolytic</td><td>4</td><td>B (wildtype)/B (wildtype)</td><td>Toxicity</td><td>Female patients with the B/B (wildtype) diplotype (not associated with G6PD deficiency) who are treated with a high dose of chloroquine may have a reduced risk of hemolytic anemia as compared to patients with the Mediterranean/Mediterranean or A-202A_376G/A-202A_376G diplotype (homozygous for a variant associated with G6PD deficiency). Most studies show no association with increased risk with normal chloroquine dosage. Please note: all studies reported an association with G6PD deficiency but only one reported genotyping, here we are representing this association under the Mediterranean or A- haplotype which is associated with G6PD deficiency, with the B (wildtype) haplotype representing G6PD non-deficient. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183705226>195</a></td><td>G6PD</td><td>Panama</td><td>chloroquine</td><td>Anemia, Hemolytic</td><td>4</td><td>B (wildtype)/B (wildtype)</td><td>Toxicity</td><td>Female patients with the B/B (wildtype) diplotype (not associated with G6PD deficiency) who are treated with a high dose of chloroquine may have a reduced risk of hemolytic anemia as compared to patients with the Mediterranean/Mediterranean or A-202A_376G/A-202A_376G diplotype (homozygous for a variant associated with G6PD deficiency). Most studies show no association with increased risk with normal chloroquine dosage. Please note: all studies reported an association with G6PD deficiency but only one reported genotyping, here we are representing this association under the Mediterranean or A- haplotype which is associated with G6PD deficiency, with the B (wildtype) haplotype representing G6PD non-deficient. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183705226>196</a></td><td>G6PD</td><td>Sassari</td><td>chloroquine</td><td>Anemia, Hemolytic</td><td>4</td><td>B (wildtype)/B (wildtype)</td><td>Toxicity</td><td>Female patients with the B/B (wildtype) diplotype (not associated with G6PD deficiency) who are treated with a high dose of chloroquine may have a reduced risk of hemolytic anemia as compared to patients with the Mediterranean/Mediterranean or A-202A_376G/A-202A_376G diplotype (homozygous for a variant associated with G6PD deficiency). Most studies show no association with increased risk with normal chloroquine dosage. Please note: all studies reported an association with G6PD deficiency but only one reported genotyping, here we are representing this association under the Mediterranean or A- haplotype which is associated with G6PD deficiency, with the B (wildtype) haplotype representing G6PD non-deficient. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183705226>197</a></td><td>G6PD</td><td>Cagliari</td><td>chloroquine</td><td>Anemia, Hemolytic</td><td>4</td><td>B (wildtype)/B (wildtype)</td><td>Toxicity</td><td>Female patients with the B/B (wildtype) diplotype (not associated with G6PD deficiency) who are treated with a high dose of chloroquine may have a reduced risk of hemolytic anemia as compared to patients with the Mediterranean/Mediterranean or A-202A_376G/A-202A_376G diplotype (homozygous for a variant associated with G6PD deficiency). Most studies show no association with increased risk with normal chloroquine dosage. Please note: all studies reported an association with G6PD deficiency but only one reported genotyping, here we are representing this association under the Mediterranean or A- haplotype which is associated with G6PD deficiency, with the B (wildtype) haplotype representing G6PD non-deficient. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183705226>198</a></td><td>G6PD</td><td>Birmingham</td><td>chloroquine</td><td>Anemia, Hemolytic</td><td>4</td><td>B (wildtype)/B (wildtype)</td><td>Toxicity</td><td>Female patients with the B/B (wildtype) diplotype (not associated with G6PD deficiency) who are treated with a high dose of chloroquine may have a reduced risk of hemolytic anemia as compared to patients with the Mediterranean/Mediterranean or A-202A_376G/A-202A_376G diplotype (homozygous for a variant associated with G6PD deficiency). Most studies show no association with increased risk with normal chloroquine dosage. Please note: all studies reported an association with G6PD deficiency but only one reported genotyping, here we are representing this association under the Mediterranean or A- haplotype which is associated with G6PD deficiency, with the B (wildtype) haplotype representing G6PD non-deficient. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183705086>199</a></td><td>G6PD</td><td>G6PD A- 202A_376G</td><td>chloramphenicol</td><td>Anemia, Hemolytic;Hemolysis</td><td>3</td><td>B (wildtype)/B (wildtype)</td><td>Toxicity</td><td>Female patients with typhoid fever and the B/B wildtype diplotype (not associated with G6PD deficiency) who are treated with chloramphenicol may have a reduced, but not absent, risk of hemolysis as compared to patients with the A-202A_376G/A-202A_376G diplotype (homozygous for the A- variant, associated with G6PD deficiency). Please note: all studies reported an association with G6PD deficiency but did not genotype or characterize the G6PD variant, here we are representing this association under the A- variant which is associated with G6PD deficiency, with the B (wildtype) haplotype representing G6PD non-deficient. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183705086>200</a></td><td>G6PD</td><td>G6PD B (wildtype)</td><td>chloramphenicol</td><td>Anemia, Hemolytic;Hemolysis</td><td>3</td><td>B (wildtype)/B (wildtype)</td><td>Toxicity</td><td>Female patients with typhoid fever and the B/B wildtype diplotype (not associated with G6PD deficiency) who are treated with chloramphenicol may have a reduced, but not absent, risk of hemolysis as compared to patients with the A-202A_376G/A-202A_376G diplotype (homozygous for the A- variant, associated with G6PD deficiency). Please note: all studies reported an association with G6PD deficiency but did not genotype or characterize the G6PD variant, here we are representing this association under the A- variant which is associated with G6PD deficiency, with the B (wildtype) haplotype representing G6PD non-deficient. Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444607466>201</a></td><td>CYP2C9</td><td>CYP2C9*1</td><td>olanzapine</td><td>Hypotension</td><td>3</td><td>*1/*1</td><td>Toxicity</td><td>Individuals with the *1/*1 genotype were less likely to experience hypotension when receiving olanzapine as compared to individuals with the *1/*3, *2/*3 or *3/*6 genotype. Other genetic and clinical factors may also influence likelihood of hypotension when receiving olanzapine.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444607466>202</a></td><td>CYP2C9</td><td>CYP2C9*2</td><td>olanzapine</td><td>Hypotension</td><td>3</td><td>*1/*1</td><td>Toxicity</td><td>Individuals with the *1/*1 genotype were less likely to experience hypotension when receiving olanzapine as compared to individuals with the *1/*3, *2/*3 or *3/*6 genotype. Other genetic and clinical factors may also influence likelihood of hypotension when receiving olanzapine.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444607466>203</a></td><td>CYP2C9</td><td>CYP2C9*3</td><td>olanzapine</td><td>Hypotension</td><td>3</td><td>*1/*1</td><td>Toxicity</td><td>Individuals with the *1/*1 genotype were less likely to experience hypotension when receiving olanzapine as compared to individuals with the *1/*3, *2/*3 or *3/*6 genotype. Other genetic and clinical factors may also influence likelihood of hypotension when receiving olanzapine.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444607466>204</a></td><td>CYP2C9</td><td>CYP2C9*6</td><td>olanzapine</td><td>Hypotension</td><td>3</td><td>*1/*1</td><td>Toxicity</td><td>Individuals with the *1/*1 genotype were less likely to experience hypotension when receiving olanzapine as compared to individuals with the *1/*3, *2/*3 or *3/*6 genotype. Other genetic and clinical factors may also influence likelihood of hypotension when receiving olanzapine.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444666110>205</a></td><td>ABCG2</td><td>rs2231142</td><td>sunitinib</td><td>Neoplasms</td><td>3</td><td>GG</td><td>Toxicity</td><td>Patients with the GG genotype may decreased likelihood of toxicity when treated with sunitinib as compared to patients with the TT genotype. Other genetic and clinical factors may also influence sunitinib toxicity.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444666533>206</a></td><td>CYP3A4</td><td>CYP3A4*1</td><td>paclitaxel</td><td>Breast Neoplasms;Ovarian Neoplasms</td><td>3</td><td>*1/*1</td><td>Toxicity</td><td>Patients with the *1/*1 genotype and breast or ovarian cancer may have a decreased risk for neuropathy when treated with paclitaxel as compared to patients with the *1/*8 or *1/*20 genotype. This drug-gene pair has been assigned a no recommendation by DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence risk for neuropathy.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444666533>207</a></td><td>CYP3A4</td><td>CYP3A4*8</td><td>paclitaxel</td><td>Breast Neoplasms;Ovarian Neoplasms</td><td>3</td><td>*1/*1</td><td>Toxicity</td><td>Patients with the *1/*1 genotype and breast or ovarian cancer may have a decreased risk for neuropathy when treated with paclitaxel as compared to patients with the *1/*8 or *1/*20 genotype. This drug-gene pair has been assigned a no recommendation by DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence risk for neuropathy.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444666533>208</a></td><td>CYP3A4</td><td>CYP3A4*20</td><td>paclitaxel</td><td>Breast Neoplasms;Ovarian Neoplasms</td><td>3</td><td>*1/*1</td><td>Toxicity</td><td>Patients with the *1/*1 genotype and breast or ovarian cancer may have a decreased risk for neuropathy when treated with paclitaxel as compared to patients with the *1/*8 or *1/*20 genotype. This drug-gene pair has been assigned a no recommendation by DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence risk for neuropathy.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444607507>209</a></td><td>TPMT</td><td>TPMT*1</td><td>olanzapine</td><td>Fatigue</td><td>3</td><td>*1/*1</td><td>Toxicity</td><td>Individuals with the *1/*1 genotype may have an decreased likelihood of fatigue when receiving olanzapine as compared to individuals with the *1/*3A or *1/*3C genotype. Other genetic and clinical factors may also influence risk for fatigue when receiving olanzapine.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444607507>210</a></td><td>TPMT</td><td>TPMT*3A</td><td>olanzapine</td><td>Fatigue</td><td>3</td><td>*1/*1</td><td>Toxicity</td><td>Individuals with the *1/*1 genotype may have an decreased likelihood of fatigue when receiving olanzapine as compared to individuals with the *1/*3A or *1/*3C genotype. Other genetic and clinical factors may also influence risk for fatigue when receiving olanzapine.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444607507>211</a></td><td>TPMT</td><td>TPMT*3C</td><td>olanzapine</td><td>Fatigue</td><td>3</td><td>*1/*1</td><td>Toxicity</td><td>Individuals with the *1/*1 genotype may have an decreased likelihood of fatigue when receiving olanzapine as compared to individuals with the *1/*3A or *1/*3C genotype. Other genetic and clinical factors may also influence risk for fatigue when receiving olanzapine.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184986540>212</a></td><td>CYP2C9</td><td>CYP2C9*1</td><td>sulfonamides, urea derivatives</td><td>Diabetes Mellitus, Type 2</td><td>3</td><td>*1/*1</td><td>Toxicity</td><td>Elderly patients with the *1/*1 genotype and Type II diabetes mellitus who are administered sulfonylureas may have a decreased risk of hypoglycemia as compared to patients who are heterozygous or homozygous for the *2 or *3 allele. Other clinical and genetic factors may also affect the risk of hypoglycemia in elderly patients administered sulfonamides.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184986540>213</a></td><td>CYP2C9</td><td>CYP2C9*2</td><td>sulfonamides, urea derivatives</td><td>Diabetes Mellitus, Type 2</td><td>3</td><td>*1/*1</td><td>Toxicity</td><td>Elderly patients with the *1/*1 genotype and Type II diabetes mellitus who are administered sulfonylureas may have a decreased risk of hypoglycemia as compared to patients who are heterozygous or homozygous for the *2 or *3 allele. Other clinical and genetic factors may also affect the risk of hypoglycemia in elderly patients administered sulfonamides.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184986540>214</a></td><td>CYP2C9</td><td>CYP2C9*3</td><td>sulfonamides, urea derivatives</td><td>Diabetes Mellitus, Type 2</td><td>3</td><td>*1/*1</td><td>Toxicity</td><td>Elderly patients with the *1/*1 genotype and Type II diabetes mellitus who are administered sulfonylureas may have a decreased risk of hypoglycemia as compared to patients who are heterozygous or homozygous for the *2 or *3 allele. Other clinical and genetic factors may also affect the risk of hypoglycemia in elderly patients administered sulfonamides.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444700860>215</a></td><td>ABCG2</td><td>rs7699188</td><td>fluorouracil</td><td>Colorectal Neoplasms</td><td>3</td><td>GG</td><td>Toxicity</td><td>Patients with the GG genotype may have decreased tumor response rate and decreased risk of grade 3-4 nonhematological toxicity when treated with fluorouracil, irinotecan and leucovorin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to fluorouracil, irinotecan and leucovorin.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444700860>216</a></td><td>ABCG2</td><td>rs7699188</td><td>irinotecan</td><td>Colorectal Neoplasms</td><td>3</td><td>GG</td><td>Toxicity</td><td>Patients with the GG genotype may have decreased tumor response rate and decreased risk of grade 3-4 nonhematological toxicity when treated with fluorouracil, irinotecan and leucovorin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to fluorouracil, irinotecan and leucovorin.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444700860>217</a></td><td>ABCG2</td><td>rs7699188</td><td>leucovorin</td><td>Colorectal Neoplasms</td><td>3</td><td>GG</td><td>Toxicity</td><td>Patients with the GG genotype may have decreased tumor response rate and decreased risk of grade 3-4 nonhematological toxicity when treated with fluorouracil, irinotecan and leucovorin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to fluorouracil, irinotecan and leucovorin.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447963662>218</a></td><td>ABCG2</td><td>rs2231142</td><td>gefitinib</td><td>Lung Neoplasms</td><td>4</td><td>GG</td><td>Toxicity</td><td>Patients with the GG genotype and lung cancer may have a decreased risk of diarrhea when treated with gefitinib as compared to patients with the GT genotype. However, multiple studies find no association between this polymorphism and gefitinib-related diarrhea or other adverse effects. Other genetic and clinical factors may also influence risk of diarrhea.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448616179>219</a></td><td>TPMT</td><td>TPMT*1</td><td>cisplatin</td><td>Ototoxicity</td><td>3</td><td>*1/*1</td><td>Toxicity</td><td>Patients with the TPMT *1/*1 genotype, may have a decreased risk of ototoxicity when treated with cisplatin as compared to patients with the *1/*3A or *3A/*3A genotypes. Other clinical and genetic factors may also influence risk of ototoxicity in patients who are treated with cisplatin.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448616179>220</a></td><td>TPMT</td><td>TPMT*3A</td><td>cisplatin</td><td>Ototoxicity</td><td>3</td><td>*1/*1</td><td>Toxicity</td><td>Patients with the TPMT *1/*1 genotype, may have a decreased risk of ototoxicity when treated with cisplatin as compared to patients with the *1/*3A or *3A/*3A genotypes. Other clinical and genetic factors may also influence risk of ototoxicity in patients who are treated with cisplatin.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448423466>221</a></td><td>CYP3A5</td><td>CYP3A5*1</td><td>carboplatin</td><td>Ovarian Neoplasms</td><td>3</td><td>*3/*3</td><td>Toxicity</td><td>Patients with the CYP3A5*3/*3 genotype and epithelial ovarian cancer may have a decreased risk for leukopenia or neutropenia when treated with carboplatin and paclitaxel as compared to patients with the CYP3A4*1/*3 genotype. Other genetic and clinical factors may also influence risk of leukopenia or neutropenia in patients taking carboplatin and paclitaxel.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448423466>222</a></td><td>CYP3A5</td><td>CYP3A5*1</td><td>paclitaxel</td><td>Ovarian Neoplasms</td><td>3</td><td>*3/*3</td><td>Toxicity</td><td>Patients with the CYP3A5*3/*3 genotype and epithelial ovarian cancer may have a decreased risk for leukopenia or neutropenia when treated with carboplatin and paclitaxel as compared to patients with the CYP3A4*1/*3 genotype. Other genetic and clinical factors may also influence risk of leukopenia or neutropenia in patients taking carboplatin and paclitaxel.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448423466>223</a></td><td>CYP3A5</td><td>CYP3A5*3</td><td>carboplatin</td><td>Ovarian Neoplasms</td><td>3</td><td>*3/*3</td><td>Toxicity</td><td>Patients with the CYP3A5*3/*3 genotype and epithelial ovarian cancer may have a decreased risk for leukopenia or neutropenia when treated with carboplatin and paclitaxel as compared to patients with the CYP3A4*1/*3 genotype. Other genetic and clinical factors may also influence risk of leukopenia or neutropenia in patients taking carboplatin and paclitaxel.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448423466>224</a></td><td>CYP3A5</td><td>CYP3A5*3</td><td>paclitaxel</td><td>Ovarian Neoplasms</td><td>3</td><td>*3/*3</td><td>Toxicity</td><td>Patients with the CYP3A5*3/*3 genotype and epithelial ovarian cancer may have a decreased risk for leukopenia or neutropenia when treated with carboplatin and paclitaxel as compared to patients with the CYP3A4*1/*3 genotype. Other genetic and clinical factors may also influence risk of leukopenia or neutropenia in patients taking carboplatin and paclitaxel.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449005135>225</a></td><td>CYP3A5</td><td>CYP3A5*1</td><td>cyclosporine</td><td>Kidney Transplantation;transplant rejection</td><td>4</td><td>*3/*3</td><td>Toxicity</td><td>Recipients of kidney transplants who are administered cyclosporine or tacrolimus and who receive kidneys from donors with the CYP3A5 *3/*3 genotype may have a decreased likelihood of transplant rejection as compared to kidneys from donors with the CYP3A5 *1/3A and *3/*3 genotypes. Other clinical and genetic factors may also influence risk of transplant rejection in recipients of kidneys who are administered tacrolimus and cyclosporine.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449005135>226</a></td><td>CYP3A5</td><td>CYP3A5*1</td><td>tacrolimus</td><td>Kidney Transplantation;transplant rejection</td><td>4</td><td>*3/*3</td><td>Toxicity</td><td>Recipients of kidney transplants who are administered cyclosporine or tacrolimus and who receive kidneys from donors with the CYP3A5 *3/*3 genotype may have a decreased likelihood of transplant rejection as compared to kidneys from donors with the CYP3A5 *1/3A and *3/*3 genotypes. Other clinical and genetic factors may also influence risk of transplant rejection in recipients of kidneys who are administered tacrolimus and cyclosporine.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449005135>227</a></td><td>CYP3A5</td><td>CYP3A5*3</td><td>cyclosporine</td><td>Kidney Transplantation;transplant rejection</td><td>4</td><td>*3/*3</td><td>Toxicity</td><td>Recipients of kidney transplants who are administered cyclosporine or tacrolimus and who receive kidneys from donors with the CYP3A5 *3/*3 genotype may have a decreased likelihood of transplant rejection as compared to kidneys from donors with the CYP3A5 *1/3A and *3/*3 genotypes. Other clinical and genetic factors may also influence risk of transplant rejection in recipients of kidneys who are administered tacrolimus and cyclosporine.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449005135>228</a></td><td>CYP3A5</td><td>CYP3A5*3</td><td>tacrolimus</td><td>Kidney Transplantation;transplant rejection</td><td>4</td><td>*3/*3</td><td>Toxicity</td><td>Recipients of kidney transplants who are administered cyclosporine or tacrolimus and who receive kidneys from donors with the CYP3A5 *3/*3 genotype may have a decreased likelihood of transplant rejection as compared to kidneys from donors with the CYP3A5 *1/3A and *3/*3 genotypes. Other clinical and genetic factors may also influence risk of transplant rejection in recipients of kidneys who are administered tacrolimus and cyclosporine.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451140140>229</a></td><td>CYP2C9</td><td>CYP2C9*1</td><td>indomethacin</td><td></td><td>3</td><td>*1/*1</td><td>Toxicity</td><td>Patients with the *1/*1 diplotype may have decreased toxicity when treated with indomethacin as compared to patients with *1/*3 or *3/*3 diplotype. This drug-variant pair has been assigned a no recommendation by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence toxicity to indomethacin.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451140140>230</a></td><td>CYP2C9</td><td>CYP2C9*3</td><td>indomethacin</td><td></td><td>3</td><td>*1/*1</td><td>Toxicity</td><td>Patients with the *1/*1 diplotype may have decreased toxicity when treated with indomethacin as compared to patients with *1/*3 or *3/*3 diplotype. This drug-variant pair has been assigned a no recommendation by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence toxicity to indomethacin.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451135160>231</a></td><td>CYP3A4</td><td>CYP3A4*1</td><td>sufentanil</td><td>Respiratory Insufficiency</td><td>3</td><td>*1/*1</td><td>Toxicity</td><td>Patients with the *1/*1 genotype may have a decreased risk of developing respiratory depression when treated with sufentanil as compared to patients with the *1G/*1G genotype. Other genetic and clinical factors may also affect a patient's risk of respiratory depression when treated with sufentanil.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451135160>232</a></td><td>CYP3A4</td><td>CYP3A4*1G</td><td>sufentanil</td><td>Respiratory Insufficiency</td><td>3</td><td>*1/*1</td><td>Toxicity</td><td>Patients with the *1/*1 genotype may have a decreased risk of developing respiratory depression when treated with sufentanil as compared to patients with the *1G/*1G genotype. Other genetic and clinical factors may also affect a patient's risk of respiratory depression when treated with sufentanil.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451237820>233</a></td><td>CYP3A4</td><td>CYP3A4*1</td><td>sufentanil</td><td></td><td>3</td><td>*1</td><td>Metabolism/PK</td><td>Patients with two copies of the *1 allele or one copy of the *1 allele in combination with one copy of the *1G allele may have increased plasma concentrations of sufentanil as compared to patients with two copies of the *1G allele. Other genetic and clinical factors may also affect sufentanil plasma concentrations. This annotation only covers the pharmacokinetic relationship between CYP3A4 and sufentanil and does not include evidence about clinical outcomes.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451237820>234</a></td><td>CYP3A4</td><td>CYP3A4*1G</td><td>sufentanil</td><td></td><td>3</td><td>*1</td><td>Metabolism/PK</td><td>Patients with two copies of the *1 allele or one copy of the *1 allele in combination with one copy of the *1G allele may have increased plasma concentrations of sufentanil as compared to patients with two copies of the *1G allele. Other genetic and clinical factors may also affect sufentanil plasma concentrations. This annotation only covers the pharmacokinetic relationship between CYP3A4 and sufentanil and does not include evidence about clinical outcomes.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450112801>235</a></td><td>ABCG2</td><td>rs13137622</td><td>methotrexate</td><td>Osteosarcoma</td><td>3</td><td>GG</td><td>Metabolism/PK</td><td>Patients with osteosarcoma and the GG genotype may have decreased clearance of methotrexate as compared to patients with the GT or TT genotypes. This variant was highly correlated with rs13120400 in the study analysis. Other genetic and clinical factors may also affect clearance of methotrexate in patients.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447986938>236</a></td><td>CYP3A5</td><td>CYP3A5*1</td><td>midazolam</td><td></td><td>3</td><td>*3/*3</td><td>Metabolism/PK</td><td>Patients with the CYP3A5 *3/*3 genotype who are administered midazolam may have slower clearance rates, and decreased metabolism of midazolam as compared to patients with the CYP3A5 *1/*3 or *1/*1 genotypes, although this is contradicted in one study. Other clinical and genetic factors may also influence clearance and metabolism of midazolam.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447986938>237</a></td><td>CYP3A5</td><td>CYP3A5*3</td><td>midazolam</td><td></td><td>3</td><td>*3/*3</td><td>Metabolism/PK</td><td>Patients with the CYP3A5 *3/*3 genotype who are administered midazolam may have slower clearance rates, and decreased metabolism of midazolam as compared to patients with the CYP3A5 *1/*3 or *1/*1 genotypes, although this is contradicted in one study. Other clinical and genetic factors may also influence clearance and metabolism of midazolam.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448428239>238</a></td><td>CYP2C9</td><td>CYP2C9*1</td><td>valproic acid</td><td>Bipolar Disorder;Psychotic Disorders</td><td>3</td><td>*1/*1</td><td>Metabolism/PK</td><td>Patients with the *1/*1 genotype and bipolar disorder and other psychotic disorders may have increased dose of valproic acid compared to patients with the *1/*2 and *1/*3 genotypes. However, dose-adjusted and absolute serum concentrations were not found to differ by genotype. Other clinical and genetic factors may affect required dose of valproic acid.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448428239>239</a></td><td>CYP2C9</td><td>CYP2C9*2</td><td>valproic acid</td><td>Bipolar Disorder;Psychotic Disorders</td><td>3</td><td>*1/*1</td><td>Metabolism/PK</td><td>Patients with the *1/*1 genotype and bipolar disorder and other psychotic disorders may have increased dose of valproic acid compared to patients with the *1/*2 and *1/*3 genotypes. However, dose-adjusted and absolute serum concentrations were not found to differ by genotype. Other clinical and genetic factors may affect required dose of valproic acid.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448428239>240</a></td><td>CYP2C9</td><td>CYP2C9*3</td><td>valproic acid</td><td>Bipolar Disorder;Psychotic Disorders</td><td>3</td><td>*1/*1</td><td>Metabolism/PK</td><td>Patients with the *1/*1 genotype and bipolar disorder and other psychotic disorders may have increased dose of valproic acid compared to patients with the *1/*2 and *1/*3 genotypes. However, dose-adjusted and absolute serum concentrations were not found to differ by genotype. Other clinical and genetic factors may affect required dose of valproic acid.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1446907373>241</a></td><td>CYP3A5</td><td>CYP3A5*1</td><td>cilostazol</td><td></td><td>3</td><td>*3/*3</td><td>Metabolism/PK</td><td>Patients with the CYP3A5 *3/*3 may have a decreased metabolism of cilostazol as compared to patients with the CYP3A5 *1/*1 diplotype. Other clinical and genetic factors may also influence metabolism of cilostazol.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1446907373>242</a></td><td>CYP3A5</td><td>CYP3A5*3</td><td>cilostazol</td><td></td><td>3</td><td>*3/*3</td><td>Metabolism/PK</td><td>Patients with the CYP3A5 *3/*3 may have a decreased metabolism of cilostazol as compared to patients with the CYP3A5 *1/*1 diplotype. Other clinical and genetic factors may also influence metabolism of cilostazol.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449309910>243</a></td><td>CYP3A5</td><td>CYP3A5*1</td><td>tacrolimus</td><td>Nephrotic Syndrome</td><td>3</td><td>*3/*3</td><td>Metabolism/PK</td><td>Pediatric patients with nephrotic syndrome and the *3/*3 diplotype may have decreased clearance of tacrolimus as compared to patients with the *1/*1 or *1/*3 diplotypes. Other clinical and genetic factors may also influence clearance of tacrolimus in patients with nephrotic syndrome.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449309910>244</a></td><td>CYP3A5</td><td>CYP3A5*3</td><td>tacrolimus</td><td>Nephrotic Syndrome</td><td>3</td><td>*3/*3</td><td>Metabolism/PK</td><td>Pediatric patients with nephrotic syndrome and the *3/*3 diplotype may have decreased clearance of tacrolimus as compared to patients with the *1/*1 or *1/*3 diplotypes. Other clinical and genetic factors may also influence clearance of tacrolimus in patients with nephrotic syndrome.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450812401>245</a></td><td>CYP3A5</td><td>CYP3A5*1</td><td>nimodipine</td><td></td><td>3</td><td>*3/*3</td><td>Metabolism/PK</td><td>Patients with the *3/*3 genotype may have increased exposure to nimodipine as compared to patient with the *1/*1 or *1/*3 genotypes. Other genetic and clinical factors may also affect a patient's exposure to nimodipine.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450812401>246</a></td><td>CYP3A5</td><td>CYP3A5*3</td><td>nimodipine</td><td></td><td>3</td><td>*3/*3</td><td>Metabolism/PK</td><td>Patients with the *3/*3 genotype may have increased exposure to nimodipine as compared to patient with the *1/*1 or *1/*3 genotypes. Other genetic and clinical factors may also affect a patient's exposure to nimodipine.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450812594>247</a></td><td>CYP3A5</td><td>CYP3A5*1</td><td>dextropropoxyphene</td><td></td><td>3</td><td>*3/*3</td><td>Metabolism/PK</td><td>Patients with the *3/*3 genotype may have an increased exposure to dextropropoxyphene as compared to patients with the *1/*3 genotype. Other genetic and clinical factors may also affect a patient't exposure to dextropropoxyphene.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450812594>248</a></td><td>CYP3A5</td><td>CYP3A5*3</td><td>dextropropoxyphene</td><td></td><td>3</td><td>*3/*3</td><td>Metabolism/PK</td><td>Patients with the *3/*3 genotype may have an increased exposure to dextropropoxyphene as compared to patients with the *1/*3 genotype. Other genetic and clinical factors may also affect a patient't exposure to dextropropoxyphene.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450371828>249</a></td><td>CYP3A5</td><td>CYP3A5*1</td><td>maraviroc</td><td>HIV Infections</td><td>3</td><td>*3/*3</td><td>Metabolism/PK</td><td>Patients with HIV and the CYP3A5 *3/*3 genotype (designated as poor metabolizers) may have increased plasma concentrations of maraviroc as compared to patients with the *1/*1 genotype. However, there is no significant association of this genotype with response to maraviroc. Additionally, analysis of other cohorts in the same study found contradictory data with regards to maraviroc concentrations. Other genetic and clinical factors may also affect plasma concentrations of maraviroc in patients.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450371828>250</a></td><td>CYP3A5</td><td>CYP3A5*3</td><td>maraviroc</td><td>HIV Infections</td><td>3</td><td>*3/*3</td><td>Metabolism/PK</td><td>Patients with HIV and the CYP3A5 *3/*3 genotype (designated as poor metabolizers) may have increased plasma concentrations of maraviroc as compared to patients with the *1/*1 genotype. However, there is no significant association of this genotype with response to maraviroc. Additionally, analysis of other cohorts in the same study found contradictory data with regards to maraviroc concentrations. Other genetic and clinical factors may also affect plasma concentrations of maraviroc in patients.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450371828>251</a></td><td>CYP3A5</td><td>CYP3A5*6</td><td>maraviroc</td><td>HIV Infections</td><td>3</td><td>*3/*3</td><td>Metabolism/PK</td><td>Patients with HIV and the CYP3A5 *3/*3 genotype (designated as poor metabolizers) may have increased plasma concentrations of maraviroc as compared to patients with the *1/*1 genotype. However, there is no significant association of this genotype with response to maraviroc. Additionally, analysis of other cohorts in the same study found contradictory data with regards to maraviroc concentrations. Other genetic and clinical factors may also affect plasma concentrations of maraviroc in patients.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450371828>252</a></td><td>CYP3A5</td><td>CYP3A5*7</td><td>maraviroc</td><td>HIV Infections</td><td>3</td><td>*3/*3</td><td>Metabolism/PK</td><td>Patients with HIV and the CYP3A5 *3/*3 genotype (designated as poor metabolizers) may have increased plasma concentrations of maraviroc as compared to patients with the *1/*1 genotype. However, there is no significant association of this genotype with response to maraviroc. Additionally, analysis of other cohorts in the same study found contradictory data with regards to maraviroc concentrations. Other genetic and clinical factors may also affect plasma concentrations of maraviroc in patients.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451147643>253</a></td><td>CYP3A4</td><td>CYP3A4*1</td><td>fesoterodine</td><td></td><td>3</td><td>*1/*1</td><td>Metabolism/PK</td><td>Patients with the *1/*1 genotype may have decreased clearance of fesoterodine as compared to patients carrying at least one copy of the *3, *20 or *22 alleles. This annotation only covers the pharmacokinetic relationship between CYP3A4 genotypes and fesoterodine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect clearance of fesoterodine.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451147643>254</a></td><td>CYP3A4</td><td>CYP3A4*3</td><td>fesoterodine</td><td></td><td>3</td><td>*1/*1</td><td>Metabolism/PK</td><td>Patients with the *1/*1 genotype may have decreased clearance of fesoterodine as compared to patients carrying at least one copy of the *3, *20 or *22 alleles. This annotation only covers the pharmacokinetic relationship between CYP3A4 genotypes and fesoterodine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect clearance of fesoterodine.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451147643>255</a></td><td>CYP3A4</td><td>CYP3A4*20</td><td>fesoterodine</td><td></td><td>3</td><td>*1/*1</td><td>Metabolism/PK</td><td>Patients with the *1/*1 genotype may have decreased clearance of fesoterodine as compared to patients carrying at least one copy of the *3, *20 or *22 alleles. This annotation only covers the pharmacokinetic relationship between CYP3A4 genotypes and fesoterodine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect clearance of fesoterodine.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451147643>256</a></td><td>CYP3A4</td><td>CYP3A4*22</td><td>fesoterodine</td><td></td><td>3</td><td>*1/*1</td><td>Metabolism/PK</td><td>Patients with the *1/*1 genotype may have decreased clearance of fesoterodine as compared to patients carrying at least one copy of the *3, *20 or *22 alleles. This annotation only covers the pharmacokinetic relationship between CYP3A4 genotypes and fesoterodine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect clearance of fesoterodine.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1043880357>257</a></td><td>VKORC1</td><td>rs11150606</td><td>warfarin</td><td></td><td>3</td><td>CT</td><td>Dosage</td><td>Patients with the rs11150606 CT genotype may require decreased dose of warfarin as compared to patients with the TT genotype. Other clinical or genetic factors may also influence warfarin dose.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655385012>258</a></td><td>VKORC1</td><td>rs9923231</td><td>warfarin</td><td></td><td>1A</td><td>CT</td><td>Dosage</td><td>Patients with the rs9923231 CT genotype may require a decreased dose of warfarin as compared to patients with the CC genotype or an increased dose as compared to patients with the TT genotype. Other genetic and clinical factors may also influence warfarin dose requirement.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/981204044>259</a></td><td>VKORC1</td><td>rs9923231</td><td>acenocoumarol</td><td></td><td>1A</td><td>CT</td><td>Dosage</td><td>Patients with the rs9923231 CT genotype may require a decreased dose of acenocoumarol as compared to patients with the CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence acenocoumarol dose requirements.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451237940>260</a></td><td>VKORC1</td><td>rs9923231</td><td>phenprocoumon</td><td></td><td>1A</td><td>CT</td><td>Dosage</td><td>Patients with the rs9923231 CT genotype may require a lower dose when treated with phenprocoumon as compared to patients with the CC genotype. Other genetic and clinical factors may also influence phenprocoumon dose.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/981203808>261</a></td><td>CYP3A5</td><td>CYP3A5*1</td><td>tacrolimus</td><td>hematopoietic stem cell transplantation;Kidney Transplantation;transplant rejection</td><td>4</td><td>*3</td><td>Efficacy</td><td>Patients who are recipients of a kidney or hematopoietic stem cell transplant and have the *3 allele in combination with another no function allele may have a decreased risk of transplant rejection when treated with tacrolimus as compared to patients with a no function allele in combination with a normal function allele or patients with two normal function alleles, while patients with the *3 allele in combination with a normal function allele may have a decreased risk of transplant rejection as compared to patients with two normal function alleles. However, the majority of studies have failed to find this association. Other genetic and clinical factors may also affect a patient's risk of transplant rejection when treated with tacrolimus.</td><td>No</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/981203808>262</a></td><td>CYP3A5</td><td>CYP3A5*3</td><td>tacrolimus</td><td>hematopoietic stem cell transplantation;Kidney Transplantation;transplant rejection</td><td>4</td><td>*3</td><td>Efficacy</td><td>Patients who are recipients of a kidney or hematopoietic stem cell transplant and have the *3 allele in combination with another no function allele may have a decreased risk of transplant rejection when treated with tacrolimus as compared to patients with a no function allele in combination with a normal function allele or patients with two normal function alleles, while patients with the *3 allele in combination with a normal function allele may have a decreased risk of transplant rejection as compared to patients with two normal function alleles. However, the majority of studies have failed to find this association. Other genetic and clinical factors may also affect a patient's risk of transplant rejection when treated with tacrolimus.</td><td>No</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184563800>263</a></td><td>G6PD</td><td>G6PD B (wildtype)</td><td>sulfamethoxazole / trimethoprim</td><td>Anemia, Hemolytic;Hemolysis</td><td>4</td><td>B (wildtype)</td><td>Toxicity</td><td>The current evidence base suggests that there is no significant association between the G6PD B (wildtype) variant and risk of hemolytic anemia when treated with sulfamethoxazole and trimethoprim. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of hemolytic anemia when treated with sulfamethoxazole and trimethoprim.</td><td>No</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184563800>264</a></td><td>G6PD</td><td>G6PD Canton</td><td>sulfamethoxazole / trimethoprim</td><td>Anemia, Hemolytic;Hemolysis</td><td>4</td><td>B (wildtype)</td><td>Toxicity</td><td>The current evidence base suggests that there is no significant association between the G6PD B (wildtype) variant and risk of hemolytic anemia when treated with sulfamethoxazole and trimethoprim. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of hemolytic anemia when treated with sulfamethoxazole and trimethoprim.</td><td>No</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184563800>265</a></td><td>G6PD</td><td>Taiwan-Hakka</td><td>sulfamethoxazole / trimethoprim</td><td>Anemia, Hemolytic;Hemolysis</td><td>4</td><td>B (wildtype)</td><td>Toxicity</td><td>The current evidence base suggests that there is no significant association between the G6PD B (wildtype) variant and risk of hemolytic anemia when treated with sulfamethoxazole and trimethoprim. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of hemolytic anemia when treated with sulfamethoxazole and trimethoprim.</td><td>No</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184563800>266</a></td><td>G6PD</td><td>Gifu-like</td><td>sulfamethoxazole / trimethoprim</td><td>Anemia, Hemolytic;Hemolysis</td><td>4</td><td>B (wildtype)</td><td>Toxicity</td><td>The current evidence base suggests that there is no significant association between the G6PD B (wildtype) variant and risk of hemolytic anemia when treated with sulfamethoxazole and trimethoprim. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of hemolytic anemia when treated with sulfamethoxazole and trimethoprim.</td><td>No</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184563800>267</a></td><td>G6PD</td><td>Agrigento-like</td><td>sulfamethoxazole / trimethoprim</td><td>Anemia, Hemolytic;Hemolysis</td><td>4</td><td>B (wildtype)</td><td>Toxicity</td><td>The current evidence base suggests that there is no significant association between the G6PD B (wildtype) variant and risk of hemolytic anemia when treated with sulfamethoxazole and trimethoprim. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of hemolytic anemia when treated with sulfamethoxazole and trimethoprim.</td><td>No</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184568404>268</a></td><td>G6PD</td><td>G6PD B (wildtype)</td><td>sulfametopyrazine</td><td>Hemolysis</td><td>4</td><td>B (wildtype)</td><td>Toxicity</td><td>The current evidence base suggests that there is no significant association between the G6PD B (wildtype) variant and risk of hemolytic anemia when treated with sulfametopyrazine. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of hemolytic anemia when treated with sulfametopyrazine.</td><td>No</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184568404>269</a></td><td>G6PD</td><td>G6PD Mediterranean</td><td>sulfametopyrazine</td><td>Hemolysis</td><td>4</td><td>B (wildtype)</td><td>Toxicity</td><td>The current evidence base suggests that there is no significant association between the G6PD B (wildtype) variant and risk of hemolytic anemia when treated with sulfametopyrazine. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of hemolytic anemia when treated with sulfametopyrazine.</td><td>No</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184568404>270</a></td><td>G6PD</td><td>Dallas</td><td>sulfametopyrazine</td><td>Hemolysis</td><td>4</td><td>B (wildtype)</td><td>Toxicity</td><td>The current evidence base suggests that there is no significant association between the G6PD B (wildtype) variant and risk of hemolytic anemia when treated with sulfametopyrazine. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of hemolytic anemia when treated with sulfametopyrazine.</td><td>No</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184568404>271</a></td><td>G6PD</td><td>Panama</td><td>sulfametopyrazine</td><td>Hemolysis</td><td>4</td><td>B (wildtype)</td><td>Toxicity</td><td>The current evidence base suggests that there is no significant association between the G6PD B (wildtype) variant and risk of hemolytic anemia when treated with sulfametopyrazine. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of hemolytic anemia when treated with sulfametopyrazine.</td><td>No</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184568404>272</a></td><td>G6PD</td><td>Sassari</td><td>sulfametopyrazine</td><td>Hemolysis</td><td>4</td><td>B (wildtype)</td><td>Toxicity</td><td>The current evidence base suggests that there is no significant association between the G6PD B (wildtype) variant and risk of hemolytic anemia when treated with sulfametopyrazine. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of hemolytic anemia when treated with sulfametopyrazine.</td><td>No</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184568404>273</a></td><td>G6PD</td><td>Cagliari</td><td>sulfametopyrazine</td><td>Hemolysis</td><td>4</td><td>B (wildtype)</td><td>Toxicity</td><td>The current evidence base suggests that there is no significant association between the G6PD B (wildtype) variant and risk of hemolytic anemia when treated with sulfametopyrazine. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of hemolytic anemia when treated with sulfametopyrazine.</td><td>No</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184568404>274</a></td><td>G6PD</td><td>Birmingham</td><td>sulfametopyrazine</td><td>Hemolysis</td><td>4</td><td>B (wildtype)</td><td>Toxicity</td><td>The current evidence base suggests that there is no significant association between the G6PD B (wildtype) variant and risk of hemolytic anemia when treated with sulfametopyrazine. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of hemolytic anemia when treated with sulfametopyrazine.</td><td>No</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451336047>275</a></td><td>CYP3A5</td><td>CYP3A5*1</td><td>olanzapine</td><td>somnolence</td><td>3</td><td>*3</td><td>Toxicity</td><td>Patients carrying the CYP3A5*3 allele in combination with a normal or no function allele may have a decreased likelihood of developing somnolence when treated with olanzapine as compared to patients carrying two normal function alleles. Other genetic and clinical factors may also influence likelihood of olanzapine-induced somnolence.</td><td>No</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451336047>276</a></td><td>CYP3A5</td><td>CYP3A5*3</td><td>olanzapine</td><td>somnolence</td><td>3</td><td>*3</td><td>Toxicity</td><td>Patients carrying the CYP3A5*3 allele in combination with a normal or no function allele may have a decreased likelihood of developing somnolence when treated with olanzapine as compared to patients carrying two normal function alleles. Other genetic and clinical factors may also influence likelihood of olanzapine-induced somnolence.</td><td>No</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/981203790>277</a></td><td>CYP3A5</td><td>CYP3A5*1</td><td>tacrolimus</td><td>nephrotoxicity</td><td>4</td><td>*3</td><td>Toxicity</td><td>Patients with the CYP3A5*3 allele in combination with another *3 allele who are treated with tacrolimus may have a decreased but not absent, risk of nephrotoxicity as compared to patients with two CYP3A5*1 alleles or the combination of the *1 and *3 allele. However, a number of studies show an increased risk of nephrotoxicity for patients with two *3 alleles, and a similar number of studies show no association as compared to an association considering both direction. Other genetic and clinical factors may also influence a patient's risk for drug-induced nephrotoxicity.</td><td>No</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/981203790>278</a></td><td>CYP3A5</td><td>CYP3A5*3</td><td>tacrolimus</td><td>nephrotoxicity</td><td>4</td><td>*3</td><td>Toxicity</td><td>Patients with the CYP3A5*3 allele in combination with another *3 allele who are treated with tacrolimus may have a decreased but not absent, risk of nephrotoxicity as compared to patients with two CYP3A5*1 alleles or the combination of the *1 and *3 allele. However, a number of studies show an increased risk of nephrotoxicity for patients with two *3 alleles, and a similar number of studies show no association as compared to an association considering both direction. Other genetic and clinical factors may also influence a patient's risk for drug-induced nephrotoxicity.</td><td>No</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451476500>279</a></td><td>ABCG2</td><td>rs2231142</td><td>methotrexate</td><td>Burkitt Lymphoma;Drug Toxicity;Lymphoma, T-Cell;Osteosarcoma;Precursor Cell Lymphoblastic Leukemia-Lymphoma</td><td>4</td><td>GG</td><td>Toxicity</td><td>The current evidence base suggests that there is no significant association between the rs2231142 GG genotype and risk of experiencing drug toxicity when treated with methotrexate in patients with acute lymphoblastic leukemia (ALL). However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of experiencing drug toxicity when treated with methotrexate.</td><td>No</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451228960>280</a></td><td>CYP3A5</td><td>CYP3A5*1</td><td>methadone</td><td></td><td>4</td><td>*3</td><td>Metabolism/PK</td><td>Patients carrying the *3 allele in combination with another no function allele may have increased concentrations of methadone as compared to patients with two normal function alleles or a normal function allele in combination with a no function allele. However, other studies have failed to find this association and a case study has described this association in the opposite direction. Other genetic and clinical factors may also affect methadone concentrations. This annotation only covers the pharmacokinetic relationship between CYP3A5 and methadone and does not include evidence about clinical outcomes.</td><td>No</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451228960>281</a></td><td>CYP3A5</td><td>CYP3A5*3</td><td>methadone</td><td></td><td>4</td><td>*3</td><td>Metabolism/PK</td><td>Patients carrying the *3 allele in combination with another no function allele may have increased concentrations of methadone as compared to patients with two normal function alleles or a normal function allele in combination with a no function allele. However, other studies have failed to find this association and a case study has described this association in the opposite direction. Other genetic and clinical factors may also affect methadone concentrations. This annotation only covers the pharmacokinetic relationship between CYP3A5 and methadone and does not include evidence about clinical outcomes.</td><td>No</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183615177>282</a></td><td>CYP3A5</td><td>CYP3A5*1</td><td>amlodipine</td><td></td><td>3</td><td>*3</td><td>Metabolism/PK</td><td>Patients carrying at least one copy of the *3 allele may have decreased metabolism of amlodipine as compared to patients with the *1/*1 genotype. However, one study failed to find an association between the *3 allele and amlodipine clearance. This annotation only covers the pharmacokinetic relationship between CYP3A5 genotypes and amlodipine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect amlodipine metabolism.</td><td>No</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183615177>283</a></td><td>CYP3A5</td><td>CYP3A5*3</td><td>amlodipine</td><td></td><td>3</td><td>*3</td><td>Metabolism/PK</td><td>Patients carrying at least one copy of the *3 allele may have decreased metabolism of amlodipine as compared to patients with the *1/*1 genotype. However, one study failed to find an association between the *3 allele and amlodipine clearance. This annotation only covers the pharmacokinetic relationship between CYP3A5 genotypes and amlodipine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect amlodipine metabolism.</td><td>No</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183615177>284</a></td><td>CYP3A5</td><td>CYP3A5*6</td><td>amlodipine</td><td></td><td>3</td><td>*3</td><td>Metabolism/PK</td><td>Patients carrying at least one copy of the *3 allele may have decreased metabolism of amlodipine as compared to patients with the *1/*1 genotype. However, one study failed to find an association between the *3 allele and amlodipine clearance. This annotation only covers the pharmacokinetic relationship between CYP3A5 genotypes and amlodipine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect amlodipine metabolism.</td><td>No</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183615177>285</a></td><td>CYP3A5</td><td>CYP3A5*7</td><td>amlodipine</td><td></td><td>3</td><td>*3</td><td>Metabolism/PK</td><td>Patients carrying at least one copy of the *3 allele may have decreased metabolism of amlodipine as compared to patients with the *1/*1 genotype. However, one study failed to find an association between the *3 allele and amlodipine clearance. This annotation only covers the pharmacokinetic relationship between CYP3A5 genotypes and amlodipine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect amlodipine metabolism.</td><td>No</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451410221>286</a></td><td>CYP3A5</td><td>CYP3A5*1</td><td>everolimus</td><td>Breast Neoplasms;heart transplantation;Kidney Neoplasms;Kidney Transplantation;lung transplantation;Neuroendocrine Tumors</td><td>3</td><td>*3</td><td>Metabolism/PK</td><td>Patients carrying the CYP3A5*3 allele in combination with another no function allele may have decreased clearance of everolimus as compared to patients carrying two normal function alleles or a normal function allele in combination with a no function allele. Patients carrying the *3 allele in combination with a normal function allele may have decreased clearance of everolimus as compared to patients carrying two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP3A5 and everolimus and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence everolimus metabolism.</td><td>No</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451410221>287</a></td><td>CYP3A5</td><td>CYP3A5*3</td><td>everolimus</td><td>Breast Neoplasms;heart transplantation;Kidney Neoplasms;Kidney Transplantation;lung transplantation;Neuroendocrine Tumors</td><td>3</td><td>*3</td><td>Metabolism/PK</td><td>Patients carrying the CYP3A5*3 allele in combination with another no function allele may have decreased clearance of everolimus as compared to patients carrying two normal function alleles or a normal function allele in combination with a no function allele. Patients carrying the *3 allele in combination with a normal function allele may have decreased clearance of everolimus as compared to patients carrying two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP3A5 and everolimus and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence everolimus metabolism.</td><td>No</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/981203936>288</a></td><td>CYP3A5</td><td>CYP3A5*1</td><td>sirolimus</td><td>Transplantation</td><td>3</td><td>*3</td><td>Metabolism/PK</td><td>Patients with the *3 allele in combination with another no function allele may have decreased metabolism of sirolimus as compared to patients with the *3 allele in combination with a normal function allele or patients with two normal function alleles. Other genetic and clinical factors may also influence a patient's sirolimus' metabolism. This annotation only covers the pharmacokinetic relationship between CYP3A5 and sirolimus and does not include evidence about clinical outcomes.</td><td>No</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/981203936>289</a></td><td>CYP3A5</td><td>CYP3A5*3</td><td>sirolimus</td><td>Transplantation</td><td>3</td><td>*3</td><td>Metabolism/PK</td><td>Patients with the *3 allele in combination with another no function allele may have decreased metabolism of sirolimus as compared to patients with the *3 allele in combination with a normal function allele or patients with two normal function alleles. Other genetic and clinical factors may also influence a patient's sirolimus' metabolism. This annotation only covers the pharmacokinetic relationship between CYP3A5 and sirolimus and does not include evidence about clinical outcomes.</td><td>No</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451214480>290</a></td><td>CYP3A5</td><td>CYP3A5*1</td><td>tacrolimus</td><td>heart transplantation;hematopoietic stem cell transplantation;Kidney Transplantation;lung transplantation</td><td>1A</td><td>*3</td><td>Metabolism/PK</td><td>The CYP3A5*3 allele has been assigned as a no function allele by CPIC. Patients who are recipients of a kidney, heart, lung or hematopoietic stem cell transplant or a liver transplant with the same CYP3A5 genotype as the recipient and who carry the *3 allele in combination with another no function allele may have decreased metabolism of tacrolimus as compared to patients carrying two normal function alleles or a normal function allele in combination with a no function allele. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP3A5 and tacrolimus and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect tacrolimus metabolism.</td><td>No</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451214480>291</a></td><td>CYP3A5</td><td>CYP3A5*3</td><td>tacrolimus</td><td>heart transplantation;hematopoietic stem cell transplantation;Kidney Transplantation;lung transplantation</td><td>1A</td><td>*3</td><td>Metabolism/PK</td><td>The CYP3A5*3 allele has been assigned as a no function allele by CPIC. Patients who are recipients of a kidney, heart, lung or hematopoietic stem cell transplant or a liver transplant with the same CYP3A5 genotype as the recipient and who carry the *3 allele in combination with another no function allele may have decreased metabolism of tacrolimus as compared to patients carrying two normal function alleles or a normal function allele in combination with a no function allele. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP3A5 and tacrolimus and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect tacrolimus metabolism.</td><td>No</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451214480>292</a></td><td>CYP3A5</td><td>CYP3A5*6</td><td>tacrolimus</td><td>heart transplantation;hematopoietic stem cell transplantation;Kidney Transplantation;lung transplantation</td><td>1A</td><td>*3</td><td>Metabolism/PK</td><td>The CYP3A5*3 allele has been assigned as a no function allele by CPIC. Patients who are recipients of a kidney, heart, lung or hematopoietic stem cell transplant or a liver transplant with the same CYP3A5 genotype as the recipient and who carry the *3 allele in combination with another no function allele may have decreased metabolism of tacrolimus as compared to patients carrying two normal function alleles or a normal function allele in combination with a no function allele. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP3A5 and tacrolimus and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect tacrolimus metabolism.</td><td>No</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451214480>293</a></td><td>CYP3A5</td><td>CYP3A5*7</td><td>tacrolimus</td><td>heart transplantation;hematopoietic stem cell transplantation;Kidney Transplantation;lung transplantation</td><td>1A</td><td>*3</td><td>Metabolism/PK</td><td>The CYP3A5*3 allele has been assigned as a no function allele by CPIC. Patients who are recipients of a kidney, heart, lung or hematopoietic stem cell transplant or a liver transplant with the same CYP3A5 genotype as the recipient and who carry the *3 allele in combination with another no function allele may have decreased metabolism of tacrolimus as compared to patients carrying two normal function alleles or a normal function allele in combination with a no function allele. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP3A5 and tacrolimus and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect tacrolimus metabolism.</td><td>No</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451241780>294</a></td><td>CYP3A5</td><td>CYP3A5*1</td><td>tacrolimus</td><td>liver transplantation</td><td>1B</td><td>*3</td><td>Metabolism/PK</td><td>Patients who receive a liver transplant from a donor with the CYP3A5*3 allele in combination with another no function allele may have decreased metabolism of tacrolimus as compared to patients who receive a liver transplant from a donor with a no function allele in combination with a normal function allele or a donor with two normal function alleles, while patients who receive a liver transplant from a donor with the *3 allele in combination with a normal function allele may have decreased metabolism of tacrolimus as compared to patients who receive a liver transplant from a donor with two normal function alleles. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP3A5 and tacrolimus and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect tacrolimus metabolism.</td><td>No</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451241780>295</a></td><td>CYP3A5</td><td>CYP3A5*3</td><td>tacrolimus</td><td>liver transplantation</td><td>1B</td><td>*3</td><td>Metabolism/PK</td><td>Patients who receive a liver transplant from a donor with the CYP3A5*3 allele in combination with another no function allele may have decreased metabolism of tacrolimus as compared to patients who receive a liver transplant from a donor with a no function allele in combination with a normal function allele or a donor with two normal function alleles, while patients who receive a liver transplant from a donor with the *3 allele in combination with a normal function allele may have decreased metabolism of tacrolimus as compared to patients who receive a liver transplant from a donor with two normal function alleles. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP3A5 and tacrolimus and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect tacrolimus metabolism.</td><td>No</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184999911>296</a></td><td>CYP3A5</td><td>CYP3A5*1</td><td>tacrolimus</td><td>liver transplantation</td><td>1B</td><td>*3</td><td>Metabolism/PK</td><td>Patients undergoing a liver transplant who have the CYP3A5*3 allele in combination with another no function allele may have decreased metabolism of tacrolimus as compared to patients with two normal function alleles or a normal function allele in combination with a no function allele, while patients who have the *3 allele in combination with a normal function allele may have decreased metabolism of tacrolimus as compared to patients with two normal function alleles. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP3A5 and tacrolimus and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect tacrolimus metabolism.</td><td>No</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184999911>297</a></td><td>CYP3A5</td><td>CYP3A5*3</td><td>tacrolimus</td><td>liver transplantation</td><td>1B</td><td>*3</td><td>Metabolism/PK</td><td>Patients undergoing a liver transplant who have the CYP3A5*3 allele in combination with another no function allele may have decreased metabolism of tacrolimus as compared to patients with two normal function alleles or a normal function allele in combination with a no function allele, while patients who have the *3 allele in combination with a normal function allele may have decreased metabolism of tacrolimus as compared to patients with two normal function alleles. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP3A5 and tacrolimus and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect tacrolimus metabolism.</td><td>No</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444607496>298</a></td><td>CYP3A5</td><td>CYP3A5*1</td><td>olanzapine</td><td></td><td>4</td><td>*3</td><td>Metabolism/PK</td><td>Patients carrying the CYP3A5*3 allele in combination with a no function allele may have decreased exposure to olanzapine as compared to patients carrying two normal function alleles or a normal function allele in combination with a no function allele. Patients carrying the *3 allele in combination with a normal function allele may have increased exposure to olanzapine as compared to patients carrying two no function alleles. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP3A5 and olanzapine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence exposure to olanzapine.</td><td>No</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444607496>299</a></td><td>CYP3A5</td><td>CYP3A5*3</td><td>olanzapine</td><td></td><td>4</td><td>*3</td><td>Metabolism/PK</td><td>Patients carrying the CYP3A5*3 allele in combination with a no function allele may have decreased exposure to olanzapine as compared to patients carrying two normal function alleles or a normal function allele in combination with a no function allele. Patients carrying the *3 allele in combination with a normal function allele may have increased exposure to olanzapine as compared to patients carrying two no function alleles. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP3A5 and olanzapine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence exposure to olanzapine.</td><td>No</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1185000451>300</a></td><td>CYP3A5</td><td>CYP3A5*1</td><td>atazanavir</td><td>HIV Infections</td><td>3</td><td>*3</td><td>Metabolism/PK</td><td>Individuals with one *3 allele in combination with one functional (*1) allele may metabolize atazanavir more rapidly as compared to individuals with any combination of two non-functional alleles (*3, *6, or *7) alleles, but may metabolize atazanavir more slowly as compared to individuals with the *1/*1 genotype. Please note: this association was only significant in White subjects and is for atazanavir boosted with ritonavir, which inhibits CYP3A5. Other clinical and genetic factors may also influence the rate of atazanavir metabolism.</td><td>No</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1185000451>301</a></td><td>CYP3A5</td><td>CYP3A5*1</td><td>ritonavir</td><td>HIV Infections</td><td>3</td><td>*3</td><td>Metabolism/PK</td><td>Individuals with one *3 allele in combination with one functional (*1) allele may metabolize atazanavir more rapidly as compared to individuals with any combination of two non-functional alleles (*3, *6, or *7) alleles, but may metabolize atazanavir more slowly as compared to individuals with the *1/*1 genotype. Please note: this association was only significant in White subjects and is for atazanavir boosted with ritonavir, which inhibits CYP3A5. Other clinical and genetic factors may also influence the rate of atazanavir metabolism.</td><td>No</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1185000451>302</a></td><td>CYP3A5</td><td>CYP3A5*3</td><td>atazanavir</td><td>HIV Infections</td><td>3</td><td>*3</td><td>Metabolism/PK</td><td>Individuals with one *3 allele in combination with one functional (*1) allele may metabolize atazanavir more rapidly as compared to individuals with any combination of two non-functional alleles (*3, *6, or *7) alleles, but may metabolize atazanavir more slowly as compared to individuals with the *1/*1 genotype. Please note: this association was only significant in White subjects and is for atazanavir boosted with ritonavir, which inhibits CYP3A5. Other clinical and genetic factors may also influence the rate of atazanavir metabolism.</td><td>No</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1185000451>303</a></td><td>CYP3A5</td><td>CYP3A5*3</td><td>ritonavir</td><td>HIV Infections</td><td>3</td><td>*3</td><td>Metabolism/PK</td><td>Individuals with one *3 allele in combination with one functional (*1) allele may metabolize atazanavir more rapidly as compared to individuals with any combination of two non-functional alleles (*3, *6, or *7) alleles, but may metabolize atazanavir more slowly as compared to individuals with the *1/*1 genotype. Please note: this association was only significant in White subjects and is for atazanavir boosted with ritonavir, which inhibits CYP3A5. Other clinical and genetic factors may also influence the rate of atazanavir metabolism.</td><td>No</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1185000451>304</a></td><td>CYP3A5</td><td>CYP3A5*6</td><td>atazanavir</td><td>HIV Infections</td><td>3</td><td>*3</td><td>Metabolism/PK</td><td>Individuals with one *3 allele in combination with one functional (*1) allele may metabolize atazanavir more rapidly as compared to individuals with any combination of two non-functional alleles (*3, *6, or *7) alleles, but may metabolize atazanavir more slowly as compared to individuals with the *1/*1 genotype. Please note: this association was only significant in White subjects and is for atazanavir boosted with ritonavir, which inhibits CYP3A5. Other clinical and genetic factors may also influence the rate of atazanavir metabolism.</td><td>No</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1185000451>305</a></td><td>CYP3A5</td><td>CYP3A5*6</td><td>ritonavir</td><td>HIV Infections</td><td>3</td><td>*3</td><td>Metabolism/PK</td><td>Individuals with one *3 allele in combination with one functional (*1) allele may metabolize atazanavir more rapidly as compared to individuals with any combination of two non-functional alleles (*3, *6, or *7) alleles, but may metabolize atazanavir more slowly as compared to individuals with the *1/*1 genotype. Please note: this association was only significant in White subjects and is for atazanavir boosted with ritonavir, which inhibits CYP3A5. Other clinical and genetic factors may also influence the rate of atazanavir metabolism.</td><td>No</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1185000451>306</a></td><td>CYP3A5</td><td>CYP3A5*7</td><td>atazanavir</td><td>HIV Infections</td><td>3</td><td>*3</td><td>Metabolism/PK</td><td>Individuals with one *3 allele in combination with one functional (*1) allele may metabolize atazanavir more rapidly as compared to individuals with any combination of two non-functional alleles (*3, *6, or *7) alleles, but may metabolize atazanavir more slowly as compared to individuals with the *1/*1 genotype. Please note: this association was only significant in White subjects and is for atazanavir boosted with ritonavir, which inhibits CYP3A5. Other clinical and genetic factors may also influence the rate of atazanavir metabolism.</td><td>No</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1185000451>307</a></td><td>CYP3A5</td><td>CYP3A5*7</td><td>ritonavir</td><td>HIV Infections</td><td>3</td><td>*3</td><td>Metabolism/PK</td><td>Individuals with one *3 allele in combination with one functional (*1) allele may metabolize atazanavir more rapidly as compared to individuals with any combination of two non-functional alleles (*3, *6, or *7) alleles, but may metabolize atazanavir more slowly as compared to individuals with the *1/*1 genotype. Please note: this association was only significant in White subjects and is for atazanavir boosted with ritonavir, which inhibits CYP3A5. Other clinical and genetic factors may also influence the rate of atazanavir metabolism.</td><td>No</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447813861>308</a></td><td>CYP3A5</td><td>CYP3A5*1</td><td>atazanavir</td><td></td><td>3</td><td>*3</td><td>Metabolism/PK</td><td>Individuals with one *3 allele in combination with one functional (*1) allele may metabolize atazanavir more rapidly as compared to individuals with any combination of two non-functional alleles (*3, *6, or *7) alleles, but may metabolize atazanavir more slowly as compared to individuals with the *1/*1 genotype, although this is contradicted in one study. Please note: this association was only significant in White subjects and is for atazanavir alone without ritonavir, which inhibits CYP3A5. Other clinical and genetic factors may also influence the rate of atazanavir metabolism.</td><td>No</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447813861>309</a></td><td>CYP3A5</td><td>CYP3A5*3</td><td>atazanavir</td><td></td><td>3</td><td>*3</td><td>Metabolism/PK</td><td>Individuals with one *3 allele in combination with one functional (*1) allele may metabolize atazanavir more rapidly as compared to individuals with any combination of two non-functional alleles (*3, *6, or *7) alleles, but may metabolize atazanavir more slowly as compared to individuals with the *1/*1 genotype, although this is contradicted in one study. Please note: this association was only significant in White subjects and is for atazanavir alone without ritonavir, which inhibits CYP3A5. Other clinical and genetic factors may also influence the rate of atazanavir metabolism.</td><td>No</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447813861>310</a></td><td>CYP3A5</td><td>CYP3A5*6</td><td>atazanavir</td><td></td><td>3</td><td>*3</td><td>Metabolism/PK</td><td>Individuals with one *3 allele in combination with one functional (*1) allele may metabolize atazanavir more rapidly as compared to individuals with any combination of two non-functional alleles (*3, *6, or *7) alleles, but may metabolize atazanavir more slowly as compared to individuals with the *1/*1 genotype, although this is contradicted in one study. Please note: this association was only significant in White subjects and is for atazanavir alone without ritonavir, which inhibits CYP3A5. Other clinical and genetic factors may also influence the rate of atazanavir metabolism.</td><td>No</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447813861>311</a></td><td>CYP3A5</td><td>CYP3A5*7</td><td>atazanavir</td><td></td><td>3</td><td>*3</td><td>Metabolism/PK</td><td>Individuals with one *3 allele in combination with one functional (*1) allele may metabolize atazanavir more rapidly as compared to individuals with any combination of two non-functional alleles (*3, *6, or *7) alleles, but may metabolize atazanavir more slowly as compared to individuals with the *1/*1 genotype, although this is contradicted in one study. Please note: this association was only significant in White subjects and is for atazanavir alone without ritonavir, which inhibits CYP3A5. Other clinical and genetic factors may also influence the rate of atazanavir metabolism.</td><td>No</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449165704>312</a></td><td>CYP3A5</td><td>CYP3A5*1</td><td>cyclosporine</td><td>Kidney Transplantation</td><td>3</td><td>*3</td><td>Metabolism/PK</td><td>Patients who are recipients of a kidney transplant and who carry the *3 allele in combination with another no function allele may have increased metabolism of cyclosporine as compared to patients carrying two normal function alleles or a normal function allele in combination with a no function allele. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP3A5 and cyclosporine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect cyclosporine metabolism.</td><td>No</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449165704>313</a></td><td>CYP3A5</td><td>CYP3A5*3</td><td>cyclosporine</td><td>Kidney Transplantation</td><td>3</td><td>*3</td><td>Metabolism/PK</td><td>Patients who are recipients of a kidney transplant and who carry the *3 allele in combination with another no function allele may have increased metabolism of cyclosporine as compared to patients carrying two normal function alleles or a normal function allele in combination with a no function allele. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP3A5 and cyclosporine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect cyclosporine metabolism.</td><td>No</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449713943>314</a></td><td>CYP3A5</td><td>CYP3A5*1</td><td>fentanyl</td><td>Pain;Pain, Postoperative</td><td>3</td><td>*3</td><td>Metabolism/PK</td><td>Patients with two copies of the CYP3A5*3 allele or one copy of the *3 allele in combination with one copy of the *1 or *6 alleles may have decreased metabolism of fentanyl as compared to patients with two copies of the *1 allele. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP3A5 and fentanyl and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence fentanyl metabolism.</td><td>No</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449713943>315</a></td><td>CYP3A5</td><td>CYP3A5*3</td><td>fentanyl</td><td>Pain;Pain, Postoperative</td><td>3</td><td>*3</td><td>Metabolism/PK</td><td>Patients with two copies of the CYP3A5*3 allele or one copy of the *3 allele in combination with one copy of the *1 or *6 alleles may have decreased metabolism of fentanyl as compared to patients with two copies of the *1 allele. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP3A5 and fentanyl and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence fentanyl metabolism.</td><td>No</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449713943>316</a></td><td>CYP3A5</td><td>CYP3A5*6</td><td>fentanyl</td><td>Pain;Pain, Postoperative</td><td>3</td><td>*3</td><td>Metabolism/PK</td><td>Patients with two copies of the CYP3A5*3 allele or one copy of the *3 allele in combination with one copy of the *1 or *6 alleles may have decreased metabolism of fentanyl as compared to patients with two copies of the *1 allele. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP3A5 and fentanyl and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence fentanyl metabolism.</td><td>No</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451207862>317</a></td><td>CYP3A5</td><td>CYP3A5*1</td><td>Dabigatran</td><td></td><td>3</td><td>*3</td><td>Metabolism/PK</td><td>Patients carrying the *3 allele in combination with another no function or a normal function allele may have increased exposure to dabigatran as compared to patients with two normal function alleles. Other genetic and clinical factors may also affect a patient's exposure to dabigatran. This annotation only covers the pharmacokinetic relationship between CYP3A5 and dabigatran and does not include evidence about clinical outcomes.</td><td>No</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451207862>318</a></td><td>CYP3A5</td><td>CYP3A5*3</td><td>Dabigatran</td><td></td><td>3</td><td>*3</td><td>Metabolism/PK</td><td>Patients carrying the *3 allele in combination with another no function or a normal function allele may have increased exposure to dabigatran as compared to patients with two normal function alleles. Other genetic and clinical factors may also affect a patient's exposure to dabigatran. This annotation only covers the pharmacokinetic relationship between CYP3A5 and dabigatran and does not include evidence about clinical outcomes.</td><td>No</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451410200>319</a></td><td>CYP3A4</td><td>CYP3A4*1</td><td>everolimus</td><td>Breast Neoplasms;Kidney Neoplasms;Kidney Transplantation;Neuroendocrine Tumors</td><td>4</td><td>*1</td><td>Metabolism/PK</td><td>The current evidence base suggests that there is not significant association between the CYP3A4*1 allele and everolimus concentrations or metabolism. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP3A4 and everolimus and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence everolimus metabolism.</td><td>No</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451410200>320</a></td><td>CYP3A4</td><td>CYP3A4*22</td><td>everolimus</td><td>Breast Neoplasms;Kidney Neoplasms;Kidney Transplantation;Neuroendocrine Tumors</td><td>4</td><td>*1</td><td>Metabolism/PK</td><td>The current evidence base suggests that there is not significant association between the CYP3A4*1 allele and everolimus concentrations or metabolism. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP3A4 and everolimus and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence everolimus metabolism.</td><td>No</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451553602>321</a></td><td>ABCG2</td><td>rs2231142</td><td>methotrexate</td><td>Burkitt Lymphoma;Lymphoma, T-Cell;Osteosarcoma;Precursor Cell Lymphoblastic Leukemia-Lymphoma</td><td>4</td><td>GG</td><td>Metabolism/PK</td><td>The current evidence base suggests that there is no significant association between the rs2231142 GG genotype and exposure to methotrexate. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs2231142 and methotrexate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence methotrexate exposure.</td><td>No</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655387053>322</a></td><td>CYP3A5</td><td>CYP3A5*1</td><td>cyclosporine</td><td>Kidney Transplantation</td><td>3</td><td>*3</td><td>Dosage</td><td>Patients who are recipients of a kidney transplant and who carry the *3 allele in combination with another no function allele may have decreased cyclosporine dose requirements as compared to patients carrying two normal function alleles or a normal function allele in combination with a no function allele. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect cyclosporine dose requirements.</td><td>No</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655387053>323</a></td><td>CYP3A5</td><td>CYP3A5*3</td><td>cyclosporine</td><td>Kidney Transplantation</td><td>3</td><td>*3</td><td>Dosage</td><td>Patients who are recipients of a kidney transplant and who carry the *3 allele in combination with another no function allele may have decreased cyclosporine dose requirements as compared to patients carrying two normal function alleles or a normal function allele in combination with a no function allele. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect cyclosporine dose requirements.</td><td>No</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451241700>324</a></td><td>CYP3A5</td><td>CYP3A5*1</td><td>tacrolimus</td><td>liver transplantation</td><td>2A</td><td>*3</td><td>Dosage</td><td>Patients who are recipients of a liver transplant from a donor with the CYP3A5*3 allele in combination with another no function allele may require decreased doses of tacrolimus as compared to patients who receive a liver transplant from a donor with the CYP3A5*3 allele in combination with a normal function allele or a donor with two normal function alleles, while patients who are recipients of a liver transplant from a donor with the CYP3A5*3 allele in combination with a normal function allele may require decreased doses of tacrolimus as compared to patients who receive a liver transplant from a donor with two normal function alleles. Other genetic and clinical factors may also affect tacrolimus dose requirements.</td><td>No</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451241700>325</a></td><td>CYP3A5</td><td>CYP3A5*3</td><td>tacrolimus</td><td>liver transplantation</td><td>2A</td><td>*3</td><td>Dosage</td><td>Patients who are recipients of a liver transplant from a donor with the CYP3A5*3 allele in combination with another no function allele may require decreased doses of tacrolimus as compared to patients who receive a liver transplant from a donor with the CYP3A5*3 allele in combination with a normal function allele or a donor with two normal function alleles, while patients who are recipients of a liver transplant from a donor with the CYP3A5*3 allele in combination with a normal function allele may require decreased doses of tacrolimus as compared to patients who receive a liver transplant from a donor with two normal function alleles. Other genetic and clinical factors may also affect tacrolimus dose requirements.</td><td>No</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/981203719>326</a></td><td>CYP3A5</td><td>CYP3A5*1</td><td>tacrolimus</td><td>heart transplantation;hemopoietic stem cell transplant;Kidney Transplantation;liver transplantation;lung transplantation</td><td>1A</td><td>*3</td><td>Dosage</td><td>The CYP3A5*3 allele has been assigned as a no function allele by CPIC. Patients receiving a kidney, heart, lung, or hematopoietic stem cell transplant or patients receiving a liver transplant where the donor and recipient CYP3A5 genotypes are identical and who carry the CYP3A5*3 allele in combination with another no function allele may have decreased tacrolimus dose requirements as compared to patients carrying two normal function alleles or a normal function allele in combination with a no function allele. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect tacrolimus dose requirements.</td><td>No</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/981203719>327</a></td><td>CYP3A5</td><td>CYP3A5*3</td><td>tacrolimus</td><td>heart transplantation;hemopoietic stem cell transplant;Kidney Transplantation;liver transplantation;lung transplantation</td><td>1A</td><td>*3</td><td>Dosage</td><td>The CYP3A5*3 allele has been assigned as a no function allele by CPIC. Patients receiving a kidney, heart, lung, or hematopoietic stem cell transplant or patients receiving a liver transplant where the donor and recipient CYP3A5 genotypes are identical and who carry the CYP3A5*3 allele in combination with another no function allele may have decreased tacrolimus dose requirements as compared to patients carrying two normal function alleles or a normal function allele in combination with a no function allele. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect tacrolimus dose requirements.</td><td>No</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/981203719>328</a></td><td>CYP3A5</td><td>CYP3A5*6</td><td>tacrolimus</td><td>heart transplantation;hemopoietic stem cell transplant;Kidney Transplantation;liver transplantation;lung transplantation</td><td>1A</td><td>*3</td><td>Dosage</td><td>The CYP3A5*3 allele has been assigned as a no function allele by CPIC. Patients receiving a kidney, heart, lung, or hematopoietic stem cell transplant or patients receiving a liver transplant where the donor and recipient CYP3A5 genotypes are identical and who carry the CYP3A5*3 allele in combination with another no function allele may have decreased tacrolimus dose requirements as compared to patients carrying two normal function alleles or a normal function allele in combination with a no function allele. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect tacrolimus dose requirements.</td><td>No</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/981203719>329</a></td><td>CYP3A5</td><td>CYP3A5*7</td><td>tacrolimus</td><td>heart transplantation;hemopoietic stem cell transplant;Kidney Transplantation;liver transplantation;lung transplantation</td><td>1A</td><td>*3</td><td>Dosage</td><td>The CYP3A5*3 allele has been assigned as a no function allele by CPIC. Patients receiving a kidney, heart, lung, or hematopoietic stem cell transplant or patients receiving a liver transplant where the donor and recipient CYP3A5 genotypes are identical and who carry the CYP3A5*3 allele in combination with another no function allele may have decreased tacrolimus dose requirements as compared to patients carrying two normal function alleles or a normal function allele in combination with a no function allele. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect tacrolimus dose requirements.</td><td>No</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451243216>330</a></td><td>CYP3A5</td><td>CYP3A5*1</td><td>tacrolimus</td><td>liver transplantation</td><td>2A</td><td>*3</td><td>Dosage</td><td>Patients who are recipients of a liver transplant and have have the CYP3A5*3 allele in combination with another no function allele may require a decreased dose of tacrolimus as compared to patients with a no function allele in combination with a normal function allele or two normal function alleles, while patients who have the CYP3A5*3 allele in combination with a normal function allele may require a decreased dose of tacrolimus as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect tacrolimus dose requirements.</td><td>No</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451243216>331</a></td><td>CYP3A5</td><td>CYP3A5*3</td><td>tacrolimus</td><td>liver transplantation</td><td>2A</td><td>*3</td><td>Dosage</td><td>Patients who are recipients of a liver transplant and have have the CYP3A5*3 allele in combination with another no function allele may require a decreased dose of tacrolimus as compared to patients with a no function allele in combination with a normal function allele or two normal function alleles, while patients who have the CYP3A5*3 allele in combination with a normal function allele may require a decreased dose of tacrolimus as compared to patients with two normal function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect tacrolimus dose requirements.</td><td>No</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451286280>332</a></td><td>CYP3A5</td><td>CYP3A5*1</td><td>sirolimus</td><td></td><td>3</td><td>*3</td><td>Dosage</td><td>Patients with the *3 allele in combination with another no function allele may require lower doses of sirolimus as compared to patients with the *3 allele in combination with a normal function allele or a patients with two normal function alleles. Other genetic and clinical factors may also affect sirolimus dose requirements.</td><td>No</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451286280>333</a></td><td>CYP3A5</td><td>CYP3A5*3</td><td>sirolimus</td><td></td><td>3</td><td>*3</td><td>Dosage</td><td>Patients with the *3 allele in combination with another no function allele may require lower doses of sirolimus as compared to patients with the *3 allele in combination with a normal function allele or a patients with two normal function alleles. Other genetic and clinical factors may also affect sirolimus dose requirements.</td><td>No</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451337408>334</a></td><td>CYP2C9</td><td>CYP2C9*1</td><td>sulfonamides, urea derivatives</td><td>Diabetes Mellitus</td><td>3</td><td>*1</td><td>Efficacy</td><td>Patients carrying the CYP2C9*1 allele in combination with another normal function allele may have decreased response to sulfonylureas as compared to patients carrying two decreased or no function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to sulfonylureas.</td><td>Normal</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451337408>335</a></td><td>CYP2C9</td><td>CYP2C9*2</td><td>sulfonamides, urea derivatives</td><td>Diabetes Mellitus</td><td>3</td><td>*1</td><td>Efficacy</td><td>Patients carrying the CYP2C9*1 allele in combination with another normal function allele may have decreased response to sulfonylureas as compared to patients carrying two decreased or no function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to sulfonylureas.</td><td>Normal</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451337408>336</a></td><td>CYP2C9</td><td>CYP2C9*3</td><td>sulfonamides, urea derivatives</td><td>Diabetes Mellitus</td><td>3</td><td>*1</td><td>Efficacy</td><td>Patients carrying the CYP2C9*1 allele in combination with another normal function allele may have decreased response to sulfonylureas as compared to patients carrying two decreased or no function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to sulfonylureas.</td><td>Normal</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/982037603>337</a></td><td>CYP2C9</td><td>CYP2C9*1</td><td>clopidogrel</td><td>Acute coronary syndrome;Coronary Artery Disease</td><td>4</td><td>*1</td><td>Efficacy</td><td>Patients carrying the CYP2C9*1 allele in combination with another normal function allele may have 1) increased inhibition of platelet aggregation and 2) decreased, but not absent, risk of high on-clopidogrel platelet reactivity and poor responder status as compared to patients with two decreased or no function alleles or a decreased function allele in combination with a no function allele. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to clopidogrel.</td><td>Normal</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/982037603>338</a></td><td>CYP2C9</td><td>CYP2C9*2</td><td>clopidogrel</td><td>Acute coronary syndrome;Coronary Artery Disease</td><td>4</td><td>*1</td><td>Efficacy</td><td>Patients carrying the CYP2C9*1 allele in combination with another normal function allele may have 1) increased inhibition of platelet aggregation and 2) decreased, but not absent, risk of high on-clopidogrel platelet reactivity and poor responder status as compared to patients with two decreased or no function alleles or a decreased function allele in combination with a no function allele. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to clopidogrel.</td><td>Normal</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/982037603>339</a></td><td>CYP2C9</td><td>CYP2C9*3</td><td>clopidogrel</td><td>Acute coronary syndrome;Coronary Artery Disease</td><td>4</td><td>*1</td><td>Efficacy</td><td>Patients carrying the CYP2C9*1 allele in combination with another normal function allele may have 1) increased inhibition of platelet aggregation and 2) decreased, but not absent, risk of high on-clopidogrel platelet reactivity and poor responder status as compared to patients with two decreased or no function alleles or a decreased function allele in combination with a no function allele. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to clopidogrel.</td><td>Normal</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447672622>340</a></td><td>CYP2C9</td><td>CYP2C9*1</td><td>warfarin</td><td></td><td>4</td><td>*1</td><td>Efficacy</td><td>The current evidence base suggests that there is no significant association between the CYP2C9*1 allele and time to reach therapeutic INR in patients treated with warfarin. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence time to reach therapeutic INR when treated with warfarin.</td><td>Normal</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447672622>341</a></td><td>CYP2C9</td><td>CYP2C9*2</td><td>warfarin</td><td></td><td>4</td><td>*1</td><td>Efficacy</td><td>The current evidence base suggests that there is no significant association between the CYP2C9*1 allele and time to reach therapeutic INR in patients treated with warfarin. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence time to reach therapeutic INR when treated with warfarin.</td><td>Normal</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447672622>342</a></td><td>CYP2C9</td><td>CYP2C9*3</td><td>warfarin</td><td></td><td>4</td><td>*1</td><td>Efficacy</td><td>The current evidence base suggests that there is no significant association between the CYP2C9*1 allele and time to reach therapeutic INR in patients treated with warfarin. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence time to reach therapeutic INR when treated with warfarin.</td><td>Normal</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447672600>343</a></td><td>CYP2C9</td><td>CYP2C9*1</td><td>warfarin</td><td>Atrial Fibrillation;heart valve replacement</td><td>2A</td><td>*1</td><td>Efficacy</td><td>Patients with CYP2C9*1 allele in combination with another normal function allele may require less time to achieve stable dose when treated with warfarin as compared to patients carrying two decreased or no function alleles or a normal or decreased function allele in combination with a no function allele. However, conflicting evidence has been reported. Other genetic or clinical factors may also influence the time to achieve warfarin stable dose.</td><td>Normal</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447672600>344</a></td><td>CYP2C9</td><td>CYP2C9*2</td><td>warfarin</td><td>Atrial Fibrillation;heart valve replacement</td><td>2A</td><td>*1</td><td>Efficacy</td><td>Patients with CYP2C9*1 allele in combination with another normal function allele may require less time to achieve stable dose when treated with warfarin as compared to patients carrying two decreased or no function alleles or a normal or decreased function allele in combination with a no function allele. However, conflicting evidence has been reported. Other genetic or clinical factors may also influence the time to achieve warfarin stable dose.</td><td>Normal</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447672600>345</a></td><td>CYP2C9</td><td>CYP2C9*3</td><td>warfarin</td><td>Atrial Fibrillation;heart valve replacement</td><td>2A</td><td>*1</td><td>Efficacy</td><td>Patients with CYP2C9*1 allele in combination with another normal function allele may require less time to achieve stable dose when treated with warfarin as compared to patients carrying two decreased or no function alleles or a normal or decreased function allele in combination with a no function allele. However, conflicting evidence has been reported. Other genetic or clinical factors may also influence the time to achieve warfarin stable dose.</td><td>Normal</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447672600>346</a></td><td>CYP2C9</td><td>CYP2C9*13</td><td>warfarin</td><td>Atrial Fibrillation;heart valve replacement</td><td>2A</td><td>*1</td><td>Efficacy</td><td>Patients with CYP2C9*1 allele in combination with another normal function allele may require less time to achieve stable dose when treated with warfarin as compared to patients carrying two decreased or no function alleles or a normal or decreased function allele in combination with a no function allele. However, conflicting evidence has been reported. Other genetic or clinical factors may also influence the time to achieve warfarin stable dose.</td><td>Normal</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447672600>347</a></td><td>CYP2C9</td><td>CYP2C9*14</td><td>warfarin</td><td>Atrial Fibrillation;heart valve replacement</td><td>2A</td><td>*1</td><td>Efficacy</td><td>Patients with CYP2C9*1 allele in combination with another normal function allele may require less time to achieve stable dose when treated with warfarin as compared to patients carrying two decreased or no function alleles or a normal or decreased function allele in combination with a no function allele. However, conflicting evidence has been reported. Other genetic or clinical factors may also influence the time to achieve warfarin stable dose.</td><td>Normal</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447672640>348</a></td><td>CYP2C9</td><td>CYP2C9*1</td><td>warfarin</td><td></td><td>4</td><td>*1</td><td>Efficacy</td><td>The current evidence base suggests that there is no significant association between the CYP2C9*1 allele and time in therapeutic INR range in patients treated with warfarin. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence time in therapeutic INR range when treated with warfarin.</td><td>Normal</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447672640>349</a></td><td>CYP2C9</td><td>CYP2C9*2</td><td>warfarin</td><td></td><td>4</td><td>*1</td><td>Efficacy</td><td>The current evidence base suggests that there is no significant association between the CYP2C9*1 allele and time in therapeutic INR range in patients treated with warfarin. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence time in therapeutic INR range when treated with warfarin.</td><td>Normal</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447672640>350</a></td><td>CYP2C9</td><td>CYP2C9*3</td><td>warfarin</td><td></td><td>4</td><td>*1</td><td>Efficacy</td><td>The current evidence base suggests that there is no significant association between the CYP2C9*1 allele and time in therapeutic INR range in patients treated with warfarin. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence time in therapeutic INR range when treated with warfarin.</td><td>Normal</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451638880>351</a></td><td>CYP2C9</td><td>CYP2C9*1</td><td>ketorolac</td><td>Pain, Postoperative</td><td>3</td><td>*1</td><td>Efficacy</td><td>Patients with two copies of the CYP2C9*1 allele may have a decreased analgesic response to ketorolac as compared to patients carrying two decreased function alleles, two no function alleles, a no function allele in combination with a normal or decreased function allele or a normal function allele in combination with a decreased function allele. Other genetic and clinical factors may also influence response to ketorolac.</td><td>Normal</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451638880>352</a></td><td>CYP2C9</td><td>CYP2C9*2</td><td>ketorolac</td><td>Pain, Postoperative</td><td>3</td><td>*1</td><td>Efficacy</td><td>Patients with two copies of the CYP2C9*1 allele may have a decreased analgesic response to ketorolac as compared to patients carrying two decreased function alleles, two no function alleles, a no function allele in combination with a normal or decreased function allele or a normal function allele in combination with a decreased function allele. Other genetic and clinical factors may also influence response to ketorolac.</td><td>Normal</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451638880>353</a></td><td>CYP2C9</td><td>CYP2C9*3</td><td>ketorolac</td><td>Pain, Postoperative</td><td>3</td><td>*1</td><td>Efficacy</td><td>Patients with two copies of the CYP2C9*1 allele may have a decreased analgesic response to ketorolac as compared to patients carrying two decreased function alleles, two no function alleles, a no function allele in combination with a normal or decreased function allele or a normal function allele in combination with a decreased function allele. Other genetic and clinical factors may also influence response to ketorolac.</td><td>Normal</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451245764>354</a></td><td>NUDT15</td><td>NUDT15*1</td><td>mercaptopurine</td><td>Leukopenia</td><td>3</td><td>*1</td><td>Toxicity</td><td>Patients with the NUDT15*1 allele in combination with another normal function allele may be at a decreased risk of developing leukopenia when treated with mercaptopurine as compared to patients with a normal function allele in combination with an uncertain function allele. Other genetic and clinical factors may also affect a patient's risk of developing mercaptopurine-induced leukopenia.</td><td>Normal</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451245764>355</a></td><td>NUDT15</td><td>NUDT15*4</td><td>mercaptopurine</td><td>Leukopenia</td><td>3</td><td>*1</td><td>Toxicity</td><td>Patients with the NUDT15*1 allele in combination with another normal function allele may be at a decreased risk of developing leukopenia when treated with mercaptopurine as compared to patients with a normal function allele in combination with an uncertain function allele. Other genetic and clinical factors may also affect a patient's risk of developing mercaptopurine-induced leukopenia.</td><td>Normal</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451245764>356</a></td><td>NUDT15</td><td>NUDT15*5</td><td>mercaptopurine</td><td>Leukopenia</td><td>3</td><td>*1</td><td>Toxicity</td><td>Patients with the NUDT15*1 allele in combination with another normal function allele may be at a decreased risk of developing leukopenia when treated with mercaptopurine as compared to patients with a normal function allele in combination with an uncertain function allele. Other genetic and clinical factors may also affect a patient's risk of developing mercaptopurine-induced leukopenia.</td><td>Normal</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451245764>357</a></td><td>NUDT15</td><td>NUDT15*6</td><td>mercaptopurine</td><td>Leukopenia</td><td>3</td><td>*1</td><td>Toxicity</td><td>Patients with the NUDT15*1 allele in combination with another normal function allele may be at a decreased risk of developing leukopenia when treated with mercaptopurine as compared to patients with a normal function allele in combination with an uncertain function allele. Other genetic and clinical factors may also affect a patient's risk of developing mercaptopurine-induced leukopenia.</td><td>Normal</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451245800>358</a></td><td>NUDT15</td><td>NUDT15*1</td><td>mercaptopurine</td><td>Neutropenia</td><td>3</td><td>*1</td><td>Toxicity</td><td>Patients with the *1 allele in combination with another normal function allele may be at a decreased risk of developing neutropenia when treated with mercaptopurine as compared to patients with a normal function allele in combination with an uncertain function allele. Other genetic and clinical factors may also affect risk of developing mercaptopurine-induced neutropenia.</td><td>Normal</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451245800>359</a></td><td>NUDT15</td><td>NUDT15*6</td><td>mercaptopurine</td><td>Neutropenia</td><td>3</td><td>*1</td><td>Toxicity</td><td>Patients with the *1 allele in combination with another normal function allele may be at a decreased risk of developing neutropenia when treated with mercaptopurine as compared to patients with a normal function allele in combination with an uncertain function allele. Other genetic and clinical factors may also affect risk of developing mercaptopurine-induced neutropenia.</td><td>Normal</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/981238501>360</a></td><td>CYP2C9</td><td>CYP2C9*1</td><td>phenytoin</td><td>Epilepsy</td><td>1A</td><td>*1</td><td>Toxicity</td><td>The CYP2C9*1 allele is assigned as a normal function allele by CPIC. Patients carrying the CYP2C9*1 allele in combination with another normal function allele may have a decreased, but not absent, risk of drug toxicity when treated with phenytoin as compared to patients with a no function allele in combination with a normal or decreased function allele or two no or decreased function alleles. Patients carrying the CYP2C9*1 allele in combination with another normal function allele may have a similar risk of drug toxicity when treated with phenytoin as compared to patients carrying a decreased function allele in combination with a normal function allele. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity when treated with phenytoin.</td><td>Normal</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/981238501>361</a></td><td>CYP2C9</td><td>CYP2C9*2</td><td>phenytoin</td><td>Epilepsy</td><td>1A</td><td>*1</td><td>Toxicity</td><td>The CYP2C9*1 allele is assigned as a normal function allele by CPIC. Patients carrying the CYP2C9*1 allele in combination with another normal function allele may have a decreased, but not absent, risk of drug toxicity when treated with phenytoin as compared to patients with a no function allele in combination with a normal or decreased function allele or two no or decreased function alleles. Patients carrying the CYP2C9*1 allele in combination with another normal function allele may have a similar risk of drug toxicity when treated with phenytoin as compared to patients carrying a decreased function allele in combination with a normal function allele. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity when treated with phenytoin.</td><td>Normal</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/981238501>362</a></td><td>CYP2C9</td><td>CYP2C9*3</td><td>phenytoin</td><td>Epilepsy</td><td>1A</td><td>*1</td><td>Toxicity</td><td>The CYP2C9*1 allele is assigned as a normal function allele by CPIC. Patients carrying the CYP2C9*1 allele in combination with another normal function allele may have a decreased, but not absent, risk of drug toxicity when treated with phenytoin as compared to patients with a no function allele in combination with a normal or decreased function allele or two no or decreased function alleles. Patients carrying the CYP2C9*1 allele in combination with another normal function allele may have a similar risk of drug toxicity when treated with phenytoin as compared to patients carrying a decreased function allele in combination with a normal function allele. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity when treated with phenytoin.</td><td>Normal</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449188570>363</a></td><td>CYP2C9</td><td>CYP2C9*1</td><td>acenocoumarol</td><td>over-anticoagulation</td><td>1B</td><td>*1</td><td>Toxicity</td><td>Patients carrying CYP2C9*1 allele in combination with another normal function allele may have decreased risk of over-anticoagulation when treated with acenocoumarol as compared to patients carrying at least one copy of a decreased function or no function allele. However, conflicting evidence has been reported. This drug-variant pair has been assigned a no recommendation by DPWG, as it was determined to be not clinically actionable.Other genetic and clinical factors may also influence the toxicity to acenocoumarol.</td><td>Normal</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449188570>364</a></td><td>CYP2C9</td><td>CYP2C9*2</td><td>acenocoumarol</td><td>over-anticoagulation</td><td>1B</td><td>*1</td><td>Toxicity</td><td>Patients carrying CYP2C9*1 allele in combination with another normal function allele may have decreased risk of over-anticoagulation when treated with acenocoumarol as compared to patients carrying at least one copy of a decreased function or no function allele. However, conflicting evidence has been reported. This drug-variant pair has been assigned a no recommendation by DPWG, as it was determined to be not clinically actionable.Other genetic and clinical factors may also influence the toxicity to acenocoumarol.</td><td>Normal</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449188570>365</a></td><td>CYP2C9</td><td>CYP2C9*3</td><td>acenocoumarol</td><td>over-anticoagulation</td><td>1B</td><td>*1</td><td>Toxicity</td><td>Patients carrying CYP2C9*1 allele in combination with another normal function allele may have decreased risk of over-anticoagulation when treated with acenocoumarol as compared to patients carrying at least one copy of a decreased function or no function allele. However, conflicting evidence has been reported. This drug-variant pair has been assigned a no recommendation by DPWG, as it was determined to be not clinically actionable.Other genetic and clinical factors may also influence the toxicity to acenocoumarol.</td><td>Normal</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449269868>366</a></td><td>CYP2C9</td><td>CYP2C9*1</td><td>acenocoumarol</td><td>Hemorrhage</td><td>2A</td><td>*1</td><td>Toxicity</td><td>The CYP2C9*1 allele is assigned as a normal function allele by CPIC. Patients carrying CYP2C9*1 allele in combination with another normal function allele may have a decreased risk of bleeding when treated with acenocoumarol as compared to patients carrying at least one copy of a decreased function or no function allele. However, conflicting evidence has been reported. This drug-variant pair has been assigned a no recommendation by DPWG, as it was determined to be not clinically actionable.Other genetic and clinical factors may also influence the risk of bleeding when treated with acenocoumarol.</td><td>Normal</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449269868>367</a></td><td>CYP2C9</td><td>CYP2C9*2</td><td>acenocoumarol</td><td>Hemorrhage</td><td>2A</td><td>*1</td><td>Toxicity</td><td>The CYP2C9*1 allele is assigned as a normal function allele by CPIC. Patients carrying CYP2C9*1 allele in combination with another normal function allele may have a decreased risk of bleeding when treated with acenocoumarol as compared to patients carrying at least one copy of a decreased function or no function allele. However, conflicting evidence has been reported. This drug-variant pair has been assigned a no recommendation by DPWG, as it was determined to be not clinically actionable.Other genetic and clinical factors may also influence the risk of bleeding when treated with acenocoumarol.</td><td>Normal</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449269868>368</a></td><td>CYP2C9</td><td>CYP2C9*3</td><td>acenocoumarol</td><td>Hemorrhage</td><td>2A</td><td>*1</td><td>Toxicity</td><td>The CYP2C9*1 allele is assigned as a normal function allele by CPIC. Patients carrying CYP2C9*1 allele in combination with another normal function allele may have a decreased risk of bleeding when treated with acenocoumarol as compared to patients carrying at least one copy of a decreased function or no function allele. However, conflicting evidence has been reported. This drug-variant pair has been assigned a no recommendation by DPWG, as it was determined to be not clinically actionable.Other genetic and clinical factors may also influence the risk of bleeding when treated with acenocoumarol.</td><td>Normal</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451448820>369</a></td><td>NUDT15</td><td>NUDT15*1</td><td>mercaptopurine</td><td>Leukopenia;Neutropenia</td><td>1A</td><td>*1</td><td>Toxicity</td><td>The NUDT15*1 allele is assigned as a normal function allele by CPIC. Patients with the *1 allele in combination with another normal function allele may be at a decreased risk of developing leukopenia or neutropenia when treated with mercaptopurine as compared to patients with two no function alleles or a normal function allele in combination with an no function allele. Other genetic and clinical factors may also affect risk of developing mercaptopurine-induced leukopenia or neutropenia.</td><td>Normal</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451448820>370</a></td><td>NUDT15</td><td>NUDT15*2</td><td>mercaptopurine</td><td>Leukopenia;Neutropenia</td><td>1A</td><td>*1</td><td>Toxicity</td><td>The NUDT15*1 allele is assigned as a normal function allele by CPIC. Patients with the *1 allele in combination with another normal function allele may be at a decreased risk of developing leukopenia or neutropenia when treated with mercaptopurine as compared to patients with two no function alleles or a normal function allele in combination with an no function allele. Other genetic and clinical factors may also affect risk of developing mercaptopurine-induced leukopenia or neutropenia.</td><td>Normal</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451448820>371</a></td><td>NUDT15</td><td>NUDT15*3</td><td>mercaptopurine</td><td>Leukopenia;Neutropenia</td><td>1A</td><td>*1</td><td>Toxicity</td><td>The NUDT15*1 allele is assigned as a normal function allele by CPIC. Patients with the *1 allele in combination with another normal function allele may be at a decreased risk of developing leukopenia or neutropenia when treated with mercaptopurine as compared to patients with two no function alleles or a normal function allele in combination with an no function allele. Other genetic and clinical factors may also affect risk of developing mercaptopurine-induced leukopenia or neutropenia.</td><td>Normal</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184648909>372</a></td><td>TPMT</td><td>TPMT*1</td><td>mercaptopurine</td><td></td><td>1A</td><td>*1</td><td>Toxicity</td><td>The TPMT*1 allele is assigned as a normal allele by CPIC. Patients carrying the TPMT*1 allele in combination with another normal function allele may have decreased likelihood of toxicity when treated with mercaptopurine as compared to patients with one or two no function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence mercaptopurine toxicity.</td><td>Normal</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184648909>373</a></td><td>TPMT</td><td>TPMT*2</td><td>mercaptopurine</td><td></td><td>1A</td><td>*1</td><td>Toxicity</td><td>The TPMT*1 allele is assigned as a normal allele by CPIC. Patients carrying the TPMT*1 allele in combination with another normal function allele may have decreased likelihood of toxicity when treated with mercaptopurine as compared to patients with one or two no function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence mercaptopurine toxicity.</td><td>Normal</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184648909>374</a></td><td>TPMT</td><td>TPMT*3A</td><td>mercaptopurine</td><td></td><td>1A</td><td>*1</td><td>Toxicity</td><td>The TPMT*1 allele is assigned as a normal allele by CPIC. Patients carrying the TPMT*1 allele in combination with another normal function allele may have decreased likelihood of toxicity when treated with mercaptopurine as compared to patients with one or two no function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence mercaptopurine toxicity.</td><td>Normal</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184648909>375</a></td><td>TPMT</td><td>TPMT*3B</td><td>mercaptopurine</td><td></td><td>1A</td><td>*1</td><td>Toxicity</td><td>The TPMT*1 allele is assigned as a normal allele by CPIC. Patients carrying the TPMT*1 allele in combination with another normal function allele may have decreased likelihood of toxicity when treated with mercaptopurine as compared to patients with one or two no function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence mercaptopurine toxicity.</td><td>Normal</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184648909>376</a></td><td>TPMT</td><td>TPMT*3C</td><td>mercaptopurine</td><td></td><td>1A</td><td>*1</td><td>Toxicity</td><td>The TPMT*1 allele is assigned as a normal allele by CPIC. Patients carrying the TPMT*1 allele in combination with another normal function allele may have decreased likelihood of toxicity when treated with mercaptopurine as compared to patients with one or two no function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence mercaptopurine toxicity.</td><td>Normal</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184648909>377</a></td><td>TPMT</td><td>TPMT*4</td><td>mercaptopurine</td><td></td><td>1A</td><td>*1</td><td>Toxicity</td><td>The TPMT*1 allele is assigned as a normal allele by CPIC. Patients carrying the TPMT*1 allele in combination with another normal function allele may have decreased likelihood of toxicity when treated with mercaptopurine as compared to patients with one or two no function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence mercaptopurine toxicity.</td><td>Normal</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184648909>378</a></td><td>TPMT</td><td>TPMT*9</td><td>mercaptopurine</td><td></td><td>1A</td><td>*1</td><td>Toxicity</td><td>The TPMT*1 allele is assigned as a normal allele by CPIC. Patients carrying the TPMT*1 allele in combination with another normal function allele may have decreased likelihood of toxicity when treated with mercaptopurine as compared to patients with one or two no function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence mercaptopurine toxicity.</td><td>Normal</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184648909>379</a></td><td>TPMT</td><td>TPMT*12</td><td>mercaptopurine</td><td></td><td>1A</td><td>*1</td><td>Toxicity</td><td>The TPMT*1 allele is assigned as a normal allele by CPIC. Patients carrying the TPMT*1 allele in combination with another normal function allele may have decreased likelihood of toxicity when treated with mercaptopurine as compared to patients with one or two no function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence mercaptopurine toxicity.</td><td>Normal</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451678600>380</a></td><td>CYP2C9</td><td>CYP2C9*1</td><td>fluvastatin</td><td></td><td>1A</td><td>*1</td><td>Toxicity</td><td>The CYP2C9*1 allele is assigned as a normal function allele by CPIC. Patients carrying CYP2C9*1 allele in combination with another normal function allele may have decreased likelihood of adverse events when treated with fluvastatin as compared to patients carrying at least one copy of a decreased function or no function allele. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence the toxicity of fluvastatin.</td><td>Normal</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451678600>381</a></td><td>CYP2C9</td><td>CYP2C9*2</td><td>fluvastatin</td><td></td><td>1A</td><td>*1</td><td>Toxicity</td><td>The CYP2C9*1 allele is assigned as a normal function allele by CPIC. Patients carrying CYP2C9*1 allele in combination with another normal function allele may have decreased likelihood of adverse events when treated with fluvastatin as compared to patients carrying at least one copy of a decreased function or no function allele. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence the toxicity of fluvastatin.</td><td>Normal</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451678600>382</a></td><td>CYP2C9</td><td>CYP2C9*3</td><td>fluvastatin</td><td></td><td>1A</td><td>*1</td><td>Toxicity</td><td>The CYP2C9*1 allele is assigned as a normal function allele by CPIC. Patients carrying CYP2C9*1 allele in combination with another normal function allele may have decreased likelihood of adverse events when treated with fluvastatin as compared to patients carrying at least one copy of a decreased function or no function allele. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence the toxicity of fluvastatin.</td><td>Normal</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447672658>383</a></td><td>CYP2C9</td><td>CYP2C9*1</td><td>warfarin</td><td>over-anticoagulation</td><td>1A</td><td>*1</td><td>Toxicity</td><td>The CYP2C9*1 allele is assigned as a normal function allele by CPIC. Patients carrying CYP2C9*1 allele in combination with another normal function allele may have decreased risk of over-anticoagulation when treated with warfarin as compared to patients carrying at least one copy of a decreased or no function allele. Other genetic and clinical factors may also influence the toxicity to warfarin.</td><td>Normal</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447672658>384</a></td><td>CYP2C9</td><td>CYP2C9*2</td><td>warfarin</td><td>over-anticoagulation</td><td>1A</td><td>*1</td><td>Toxicity</td><td>The CYP2C9*1 allele is assigned as a normal function allele by CPIC. Patients carrying CYP2C9*1 allele in combination with another normal function allele may have decreased risk of over-anticoagulation when treated with warfarin as compared to patients carrying at least one copy of a decreased or no function allele. Other genetic and clinical factors may also influence the toxicity to warfarin.</td><td>Normal</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447672658>385</a></td><td>CYP2C9</td><td>CYP2C9*3</td><td>warfarin</td><td>over-anticoagulation</td><td>1A</td><td>*1</td><td>Toxicity</td><td>The CYP2C9*1 allele is assigned as a normal function allele by CPIC. Patients carrying CYP2C9*1 allele in combination with another normal function allele may have decreased risk of over-anticoagulation when treated with warfarin as compared to patients carrying at least one copy of a decreased or no function allele. Other genetic and clinical factors may also influence the toxicity to warfarin.</td><td>Normal</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447672658>386</a></td><td>CYP2C9</td><td>CYP2C9*5</td><td>warfarin</td><td>over-anticoagulation</td><td>1A</td><td>*1</td><td>Toxicity</td><td>The CYP2C9*1 allele is assigned as a normal function allele by CPIC. Patients carrying CYP2C9*1 allele in combination with another normal function allele may have decreased risk of over-anticoagulation when treated with warfarin as compared to patients carrying at least one copy of a decreased or no function allele. Other genetic and clinical factors may also influence the toxicity to warfarin.</td><td>Normal</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447672658>387</a></td><td>CYP2C9</td><td>CYP2C9*6</td><td>warfarin</td><td>over-anticoagulation</td><td>1A</td><td>*1</td><td>Toxicity</td><td>The CYP2C9*1 allele is assigned as a normal function allele by CPIC. Patients carrying CYP2C9*1 allele in combination with another normal function allele may have decreased risk of over-anticoagulation when treated with warfarin as compared to patients carrying at least one copy of a decreased or no function allele. Other genetic and clinical factors may also influence the toxicity to warfarin.</td><td>Normal</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447672658>388</a></td><td>CYP2C9</td><td>CYP2C9*11</td><td>warfarin</td><td>over-anticoagulation</td><td>1A</td><td>*1</td><td>Toxicity</td><td>The CYP2C9*1 allele is assigned as a normal function allele by CPIC. Patients carrying CYP2C9*1 allele in combination with another normal function allele may have decreased risk of over-anticoagulation when treated with warfarin as compared to patients carrying at least one copy of a decreased or no function allele. Other genetic and clinical factors may also influence the toxicity to warfarin.</td><td>Normal</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447672988>389</a></td><td>CYP2C9</td><td>CYP2C9*1</td><td>warfarin</td><td>Hemorrhage</td><td>1A</td><td>*1</td><td>Toxicity</td><td>The CYP2C9*1 allele is assigned as a normal function allele by CPIC. Patients carrying CYP2C9*1 allele in combination with another normal function allele may have a decreased risk of bleeding when treated with warfarin as compared to patients carrying at least one copy of a decreased or no function allele. Other genetic and clinical factors may also influence the risk of warfarin-induced bleeding.</td><td>Normal</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447672988>390</a></td><td>CYP2C9</td><td>CYP2C9*2</td><td>warfarin</td><td>Hemorrhage</td><td>1A</td><td>*1</td><td>Toxicity</td><td>The CYP2C9*1 allele is assigned as a normal function allele by CPIC. Patients carrying CYP2C9*1 allele in combination with another normal function allele may have a decreased risk of bleeding when treated with warfarin as compared to patients carrying at least one copy of a decreased or no function allele. Other genetic and clinical factors may also influence the risk of warfarin-induced bleeding.</td><td>Normal</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447672988>391</a></td><td>CYP2C9</td><td>CYP2C9*3</td><td>warfarin</td><td>Hemorrhage</td><td>1A</td><td>*1</td><td>Toxicity</td><td>The CYP2C9*1 allele is assigned as a normal function allele by CPIC. Patients carrying CYP2C9*1 allele in combination with another normal function allele may have a decreased risk of bleeding when treated with warfarin as compared to patients carrying at least one copy of a decreased or no function allele. Other genetic and clinical factors may also influence the risk of warfarin-induced bleeding.</td><td>Normal</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447672988>392</a></td><td>CYP2C9</td><td>CYP2C9*5</td><td>warfarin</td><td>Hemorrhage</td><td>1A</td><td>*1</td><td>Toxicity</td><td>The CYP2C9*1 allele is assigned as a normal function allele by CPIC. Patients carrying CYP2C9*1 allele in combination with another normal function allele may have a decreased risk of bleeding when treated with warfarin as compared to patients carrying at least one copy of a decreased or no function allele. Other genetic and clinical factors may also influence the risk of warfarin-induced bleeding.</td><td>Normal</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447672988>393</a></td><td>CYP2C9</td><td>CYP2C9*6</td><td>warfarin</td><td>Hemorrhage</td><td>1A</td><td>*1</td><td>Toxicity</td><td>The CYP2C9*1 allele is assigned as a normal function allele by CPIC. Patients carrying CYP2C9*1 allele in combination with another normal function allele may have a decreased risk of bleeding when treated with warfarin as compared to patients carrying at least one copy of a decreased or no function allele. Other genetic and clinical factors may also influence the risk of warfarin-induced bleeding.</td><td>Normal</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447672988>394</a></td><td>CYP2C9</td><td>CYP2C9*11</td><td>warfarin</td><td>Hemorrhage</td><td>1A</td><td>*1</td><td>Toxicity</td><td>The CYP2C9*1 allele is assigned as a normal function allele by CPIC. Patients carrying CYP2C9*1 allele in combination with another normal function allele may have a decreased risk of bleeding when treated with warfarin as compared to patients carrying at least one copy of a decreased or no function allele. Other genetic and clinical factors may also influence the risk of warfarin-induced bleeding.</td><td>Normal</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451237240>395</a></td><td>TPMT</td><td>TPMT*1</td><td>azathioprine</td><td>Leukopenia;Myelosuppression</td><td>1A</td><td>*1</td><td>Toxicity</td><td>Patients carrying the TPMT*1 allele in combination with another normal function allele may have decreased likelihood of myelosuppression when treated with azathioprine as compared to patients with one or two no function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence azathioprine toxicity.</td><td>Normal</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451237240>396</a></td><td>TPMT</td><td>TPMT*2</td><td>azathioprine</td><td>Leukopenia;Myelosuppression</td><td>1A</td><td>*1</td><td>Toxicity</td><td>Patients carrying the TPMT*1 allele in combination with another normal function allele may have decreased likelihood of myelosuppression when treated with azathioprine as compared to patients with one or two no function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence azathioprine toxicity.</td><td>Normal</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451237240>397</a></td><td>TPMT</td><td>TPMT*3A</td><td>azathioprine</td><td>Leukopenia;Myelosuppression</td><td>1A</td><td>*1</td><td>Toxicity</td><td>Patients carrying the TPMT*1 allele in combination with another normal function allele may have decreased likelihood of myelosuppression when treated with azathioprine as compared to patients with one or two no function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence azathioprine toxicity.</td><td>Normal</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451237240>398</a></td><td>TPMT</td><td>TPMT*3B</td><td>azathioprine</td><td>Leukopenia;Myelosuppression</td><td>1A</td><td>*1</td><td>Toxicity</td><td>Patients carrying the TPMT*1 allele in combination with another normal function allele may have decreased likelihood of myelosuppression when treated with azathioprine as compared to patients with one or two no function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence azathioprine toxicity.</td><td>Normal</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451237240>399</a></td><td>TPMT</td><td>TPMT*3C</td><td>azathioprine</td><td>Leukopenia;Myelosuppression</td><td>1A</td><td>*1</td><td>Toxicity</td><td>Patients carrying the TPMT*1 allele in combination with another normal function allele may have decreased likelihood of myelosuppression when treated with azathioprine as compared to patients with one or two no function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence azathioprine toxicity.</td><td>Normal</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451229340>400</a></td><td>CYP2C9</td><td>CYP2C9*1</td><td>methadone</td><td></td><td>4</td><td>*1</td><td>Metabolism/PK</td><td>Patients carrying the *1 allele in combination with another normal function allele may have decreased concentrations of methadone as compared to patients with a normal function allele in combination with a decreased function allele or patients with a normal function allele in combination with a no function allele. However, multiple studies have failed to find this association. Other genetic and clinical factors may also affect methadone concentrations. This annotation only covers the pharmacokinetic relationship between CYP2C9 and methadone and does not include evidence about clinical outcomes.</td><td>Normal</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451229340>401</a></td><td>CYP2C9</td><td>CYP2C9*2</td><td>methadone</td><td></td><td>4</td><td>*1</td><td>Metabolism/PK</td><td>Patients carrying the *1 allele in combination with another normal function allele may have decreased concentrations of methadone as compared to patients with a normal function allele in combination with a decreased function allele or patients with a normal function allele in combination with a no function allele. However, multiple studies have failed to find this association. Other genetic and clinical factors may also affect methadone concentrations. This annotation only covers the pharmacokinetic relationship between CYP2C9 and methadone and does not include evidence about clinical outcomes.</td><td>Normal</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451229340>402</a></td><td>CYP2C9</td><td>CYP2C9*3</td><td>methadone</td><td></td><td>4</td><td>*1</td><td>Metabolism/PK</td><td>Patients carrying the *1 allele in combination with another normal function allele may have decreased concentrations of methadone as compared to patients with a normal function allele in combination with a decreased function allele or patients with a normal function allele in combination with a no function allele. However, multiple studies have failed to find this association. Other genetic and clinical factors may also affect methadone concentrations. This annotation only covers the pharmacokinetic relationship between CYP2C9 and methadone and does not include evidence about clinical outcomes.</td><td>Normal</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/982047500>403</a></td><td>CYP2C9</td><td>CYP2C9*1</td><td>phenytoin</td><td>Epilepsy</td><td>1A</td><td>*1</td><td>Metabolism/PK</td><td>The CYP2C9*1 allele has been assigned as a normal function allele by CPIC. Patients carrying the *1 allele in combination with another normal function allele may have increased metabolism/clearance of phenytoin as compared to patients with a normal function allele in combination with a no or decreased function allele, two no or decreased function alleles, or one decreased function allele in combination with a no function allele. This annotation only covers the pharmacokinetic relationship between CYP2C9 and phenytoin and does not include evidence about clinical outcomes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence phenytoin metabolism.</td><td>Normal</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/982047500>404</a></td><td>CYP2C9</td><td>CYP2C9*2</td><td>phenytoin</td><td>Epilepsy</td><td>1A</td><td>*1</td><td>Metabolism/PK</td><td>The CYP2C9*1 allele has been assigned as a normal function allele by CPIC. Patients carrying the *1 allele in combination with another normal function allele may have increased metabolism/clearance of phenytoin as compared to patients with a normal function allele in combination with a no or decreased function allele, two no or decreased function alleles, or one decreased function allele in combination with a no function allele. This annotation only covers the pharmacokinetic relationship between CYP2C9 and phenytoin and does not include evidence about clinical outcomes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence phenytoin metabolism.</td><td>Normal</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/982047500>405</a></td><td>CYP2C9</td><td>CYP2C9*3</td><td>phenytoin</td><td>Epilepsy</td><td>1A</td><td>*1</td><td>Metabolism/PK</td><td>The CYP2C9*1 allele has been assigned as a normal function allele by CPIC. Patients carrying the *1 allele in combination with another normal function allele may have increased metabolism/clearance of phenytoin as compared to patients with a normal function allele in combination with a no or decreased function allele, two no or decreased function alleles, or one decreased function allele in combination with a no function allele. This annotation only covers the pharmacokinetic relationship between CYP2C9 and phenytoin and does not include evidence about clinical outcomes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence phenytoin metabolism.</td><td>Normal</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/982047500>406</a></td><td>CYP2C9</td><td>CYP2C9*5</td><td>phenytoin</td><td>Epilepsy</td><td>1A</td><td>*1</td><td>Metabolism/PK</td><td>The CYP2C9*1 allele has been assigned as a normal function allele by CPIC. Patients carrying the *1 allele in combination with another normal function allele may have increased metabolism/clearance of phenytoin as compared to patients with a normal function allele in combination with a no or decreased function allele, two no or decreased function alleles, or one decreased function allele in combination with a no function allele. This annotation only covers the pharmacokinetic relationship between CYP2C9 and phenytoin and does not include evidence about clinical outcomes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence phenytoin metabolism.</td><td>Normal</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/982047500>407</a></td><td>CYP2C9</td><td>CYP2C9*6</td><td>phenytoin</td><td>Epilepsy</td><td>1A</td><td>*1</td><td>Metabolism/PK</td><td>The CYP2C9*1 allele has been assigned as a normal function allele by CPIC. Patients carrying the *1 allele in combination with another normal function allele may have increased metabolism/clearance of phenytoin as compared to patients with a normal function allele in combination with a no or decreased function allele, two no or decreased function alleles, or one decreased function allele in combination with a no function allele. This annotation only covers the pharmacokinetic relationship between CYP2C9 and phenytoin and does not include evidence about clinical outcomes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence phenytoin metabolism.</td><td>Normal</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/982047500>408</a></td><td>CYP2C9</td><td>CYP2C9*8</td><td>phenytoin</td><td>Epilepsy</td><td>1A</td><td>*1</td><td>Metabolism/PK</td><td>The CYP2C9*1 allele has been assigned as a normal function allele by CPIC. Patients carrying the *1 allele in combination with another normal function allele may have increased metabolism/clearance of phenytoin as compared to patients with a normal function allele in combination with a no or decreased function allele, two no or decreased function alleles, or one decreased function allele in combination with a no function allele. This annotation only covers the pharmacokinetic relationship between CYP2C9 and phenytoin and does not include evidence about clinical outcomes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence phenytoin metabolism.</td><td>Normal</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/982047500>409</a></td><td>CYP2C9</td><td>CYP2C9*11</td><td>phenytoin</td><td>Epilepsy</td><td>1A</td><td>*1</td><td>Metabolism/PK</td><td>The CYP2C9*1 allele has been assigned as a normal function allele by CPIC. Patients carrying the *1 allele in combination with another normal function allele may have increased metabolism/clearance of phenytoin as compared to patients with a normal function allele in combination with a no or decreased function allele, two no or decreased function alleles, or one decreased function allele in combination with a no function allele. This annotation only covers the pharmacokinetic relationship between CYP2C9 and phenytoin and does not include evidence about clinical outcomes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence phenytoin metabolism.</td><td>Normal</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/982047500>410</a></td><td>CYP2C9</td><td>CYP2C9*13</td><td>phenytoin</td><td>Epilepsy</td><td>1A</td><td>*1</td><td>Metabolism/PK</td><td>The CYP2C9*1 allele has been assigned as a normal function allele by CPIC. Patients carrying the *1 allele in combination with another normal function allele may have increased metabolism/clearance of phenytoin as compared to patients with a normal function allele in combination with a no or decreased function allele, two no or decreased function alleles, or one decreased function allele in combination with a no function allele. This annotation only covers the pharmacokinetic relationship between CYP2C9 and phenytoin and does not include evidence about clinical outcomes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence phenytoin metabolism.</td><td>Normal</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/982047500>411</a></td><td>CYP2C9</td><td>CYP2C9*14</td><td>phenytoin</td><td>Epilepsy</td><td>1A</td><td>*1</td><td>Metabolism/PK</td><td>The CYP2C9*1 allele has been assigned as a normal function allele by CPIC. Patients carrying the *1 allele in combination with another normal function allele may have increased metabolism/clearance of phenytoin as compared to patients with a normal function allele in combination with a no or decreased function allele, two no or decreased function alleles, or one decreased function allele in combination with a no function allele. This annotation only covers the pharmacokinetic relationship between CYP2C9 and phenytoin and does not include evidence about clinical outcomes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence phenytoin metabolism.</td><td>Normal</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/982047500>412</a></td><td>CYP2C9</td><td>CYP2C9*16</td><td>phenytoin</td><td>Epilepsy</td><td>1A</td><td>*1</td><td>Metabolism/PK</td><td>The CYP2C9*1 allele has been assigned as a normal function allele by CPIC. Patients carrying the *1 allele in combination with another normal function allele may have increased metabolism/clearance of phenytoin as compared to patients with a normal function allele in combination with a no or decreased function allele, two no or decreased function alleles, or one decreased function allele in combination with a no function allele. This annotation only covers the pharmacokinetic relationship between CYP2C9 and phenytoin and does not include evidence about clinical outcomes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence phenytoin metabolism.</td><td>Normal</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/982047500>413</a></td><td>CYP2C9</td><td>CYP2C9*29</td><td>phenytoin</td><td>Epilepsy</td><td>1A</td><td>*1</td><td>Metabolism/PK</td><td>The CYP2C9*1 allele has been assigned as a normal function allele by CPIC. Patients carrying the *1 allele in combination with another normal function allele may have increased metabolism/clearance of phenytoin as compared to patients with a normal function allele in combination with a no or decreased function allele, two no or decreased function alleles, or one decreased function allele in combination with a no function allele. This annotation only covers the pharmacokinetic relationship between CYP2C9 and phenytoin and does not include evidence about clinical outcomes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence phenytoin metabolism.</td><td>Normal</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/982047500>414</a></td><td>CYP2C9</td><td>CYP2C9*31</td><td>phenytoin</td><td>Epilepsy</td><td>1A</td><td>*1</td><td>Metabolism/PK</td><td>The CYP2C9*1 allele has been assigned as a normal function allele by CPIC. Patients carrying the *1 allele in combination with another normal function allele may have increased metabolism/clearance of phenytoin as compared to patients with a normal function allele in combination with a no or decreased function allele, two no or decreased function alleles, or one decreased function allele in combination with a no function allele. This annotation only covers the pharmacokinetic relationship between CYP2C9 and phenytoin and does not include evidence about clinical outcomes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence phenytoin metabolism.</td><td>Normal</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/982047500>415</a></td><td>CYP2C9</td><td>CYP2C9*33</td><td>phenytoin</td><td>Epilepsy</td><td>1A</td><td>*1</td><td>Metabolism/PK</td><td>The CYP2C9*1 allele has been assigned as a normal function allele by CPIC. Patients carrying the *1 allele in combination with another normal function allele may have increased metabolism/clearance of phenytoin as compared to patients with a normal function allele in combination with a no or decreased function allele, two no or decreased function alleles, or one decreased function allele in combination with a no function allele. This annotation only covers the pharmacokinetic relationship between CYP2C9 and phenytoin and does not include evidence about clinical outcomes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence phenytoin metabolism.</td><td>Normal</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/982047500>416</a></td><td>CYP2C9</td><td>CYP2C9*37</td><td>phenytoin</td><td>Epilepsy</td><td>1A</td><td>*1</td><td>Metabolism/PK</td><td>The CYP2C9*1 allele has been assigned as a normal function allele by CPIC. Patients carrying the *1 allele in combination with another normal function allele may have increased metabolism/clearance of phenytoin as compared to patients with a normal function allele in combination with a no or decreased function allele, two no or decreased function alleles, or one decreased function allele in combination with a no function allele. This annotation only covers the pharmacokinetic relationship between CYP2C9 and phenytoin and does not include evidence about clinical outcomes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence phenytoin metabolism.</td><td>Normal</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/982047500>417</a></td><td>CYP2C9</td><td>CYP2C9*39</td><td>phenytoin</td><td>Epilepsy</td><td>1A</td><td>*1</td><td>Metabolism/PK</td><td>The CYP2C9*1 allele has been assigned as a normal function allele by CPIC. Patients carrying the *1 allele in combination with another normal function allele may have increased metabolism/clearance of phenytoin as compared to patients with a normal function allele in combination with a no or decreased function allele, two no or decreased function alleles, or one decreased function allele in combination with a no function allele. This annotation only covers the pharmacokinetic relationship between CYP2C9 and phenytoin and does not include evidence about clinical outcomes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence phenytoin metabolism.</td><td>Normal</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/982047500>418</a></td><td>CYP2C9</td><td>CYP2C9*42</td><td>phenytoin</td><td>Epilepsy</td><td>1A</td><td>*1</td><td>Metabolism/PK</td><td>The CYP2C9*1 allele has been assigned as a normal function allele by CPIC. Patients carrying the *1 allele in combination with another normal function allele may have increased metabolism/clearance of phenytoin as compared to patients with a normal function allele in combination with a no or decreased function allele, two no or decreased function alleles, or one decreased function allele in combination with a no function allele. This annotation only covers the pharmacokinetic relationship between CYP2C9 and phenytoin and does not include evidence about clinical outcomes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence phenytoin metabolism.</td><td>Normal</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/982047500>419</a></td><td>CYP2C9</td><td>CYP2C9*43</td><td>phenytoin</td><td>Epilepsy</td><td>1A</td><td>*1</td><td>Metabolism/PK</td><td>The CYP2C9*1 allele has been assigned as a normal function allele by CPIC. Patients carrying the *1 allele in combination with another normal function allele may have increased metabolism/clearance of phenytoin as compared to patients with a normal function allele in combination with a no or decreased function allele, two no or decreased function alleles, or one decreased function allele in combination with a no function allele. This annotation only covers the pharmacokinetic relationship between CYP2C9 and phenytoin and does not include evidence about clinical outcomes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence phenytoin metabolism.</td><td>Normal</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/982047500>420</a></td><td>CYP2C9</td><td>CYP2C9*45</td><td>phenytoin</td><td>Epilepsy</td><td>1A</td><td>*1</td><td>Metabolism/PK</td><td>The CYP2C9*1 allele has been assigned as a normal function allele by CPIC. Patients carrying the *1 allele in combination with another normal function allele may have increased metabolism/clearance of phenytoin as compared to patients with a normal function allele in combination with a no or decreased function allele, two no or decreased function alleles, or one decreased function allele in combination with a no function allele. This annotation only covers the pharmacokinetic relationship between CYP2C9 and phenytoin and does not include evidence about clinical outcomes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence phenytoin metabolism.</td><td>Normal</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/982047500>421</a></td><td>CYP2C9</td><td>CYP2C9*50</td><td>phenytoin</td><td>Epilepsy</td><td>1A</td><td>*1</td><td>Metabolism/PK</td><td>The CYP2C9*1 allele has been assigned as a normal function allele by CPIC. Patients carrying the *1 allele in combination with another normal function allele may have increased metabolism/clearance of phenytoin as compared to patients with a normal function allele in combination with a no or decreased function allele, two no or decreased function alleles, or one decreased function allele in combination with a no function allele. This annotation only covers the pharmacokinetic relationship between CYP2C9 and phenytoin and does not include evidence about clinical outcomes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence phenytoin metabolism.</td><td>Normal</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/982047500>422</a></td><td>CYP2C9</td><td>CYP2C9*52</td><td>phenytoin</td><td>Epilepsy</td><td>1A</td><td>*1</td><td>Metabolism/PK</td><td>The CYP2C9*1 allele has been assigned as a normal function allele by CPIC. Patients carrying the *1 allele in combination with another normal function allele may have increased metabolism/clearance of phenytoin as compared to patients with a normal function allele in combination with a no or decreased function allele, two no or decreased function alleles, or one decreased function allele in combination with a no function allele. This annotation only covers the pharmacokinetic relationship between CYP2C9 and phenytoin and does not include evidence about clinical outcomes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence phenytoin metabolism.</td><td>Normal</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/982047500>423</a></td><td>CYP2C9</td><td>CYP2C9*55</td><td>phenytoin</td><td>Epilepsy</td><td>1A</td><td>*1</td><td>Metabolism/PK</td><td>The CYP2C9*1 allele has been assigned as a normal function allele by CPIC. Patients carrying the *1 allele in combination with another normal function allele may have increased metabolism/clearance of phenytoin as compared to patients with a normal function allele in combination with a no or decreased function allele, two no or decreased function alleles, or one decreased function allele in combination with a no function allele. This annotation only covers the pharmacokinetic relationship between CYP2C9 and phenytoin and does not include evidence about clinical outcomes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence phenytoin metabolism.</td><td>Normal</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451231100>424</a></td><td>CYP2C9</td><td>CYP2C9*1</td><td>siponimod</td><td></td><td>1A</td><td>*1</td><td>Metabolism/PK</td><td>The CYP2C9*1 allele is assigned as a normal function allele by CPIC. Patients carrying the CYP2C9*1 allele in combination with another normal function allele may have increased metabolism and decreased plasma concentrations of siponimod as compared to patients carrying at least one decreased or no function alleles. Other genetic and clinical factors may also influence the metabolism of siponimod. This annotation only covers the pharmacokinetic relationship between CYP2C9 and siponimod and does not include evidence about clinical outcomes.</td><td>Normal</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451231100>425</a></td><td>CYP2C9</td><td>CYP2C9*2</td><td>siponimod</td><td></td><td>1A</td><td>*1</td><td>Metabolism/PK</td><td>The CYP2C9*1 allele is assigned as a normal function allele by CPIC. Patients carrying the CYP2C9*1 allele in combination with another normal function allele may have increased metabolism and decreased plasma concentrations of siponimod as compared to patients carrying at least one decreased or no function alleles. Other genetic and clinical factors may also influence the metabolism of siponimod. This annotation only covers the pharmacokinetic relationship between CYP2C9 and siponimod and does not include evidence about clinical outcomes.</td><td>Normal</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451231100>426</a></td><td>CYP2C9</td><td>CYP2C9*3</td><td>siponimod</td><td></td><td>1A</td><td>*1</td><td>Metabolism/PK</td><td>The CYP2C9*1 allele is assigned as a normal function allele by CPIC. Patients carrying the CYP2C9*1 allele in combination with another normal function allele may have increased metabolism and decreased plasma concentrations of siponimod as compared to patients carrying at least one decreased or no function alleles. Other genetic and clinical factors may also influence the metabolism of siponimod. This annotation only covers the pharmacokinetic relationship between CYP2C9 and siponimod and does not include evidence about clinical outcomes.</td><td>Normal</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451516322>427</a></td><td>CYP2C9</td><td>CYP2C9*1</td><td>phenprocoumon</td><td></td><td>3</td><td>*1</td><td>Metabolism/PK</td><td>Patients carrying the CYP2C9*1 allele in combination with another normal function allele may have increased metabolism of phenprocoumon as compared to patients with two decreased or no function alleles; a normal function allele in combination with a decreased or no function allele; or a decreased function allele in combination with a no function allele. This annotation only covers the pharmacokinetic relationship between CYP2C9 and phenprocoumon and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence phenprocoumon metabolism.</td><td>Normal</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451516322>428</a></td><td>CYP2C9</td><td>CYP2C9*2</td><td>phenprocoumon</td><td></td><td>3</td><td>*1</td><td>Metabolism/PK</td><td>Patients carrying the CYP2C9*1 allele in combination with another normal function allele may have increased metabolism of phenprocoumon as compared to patients with two decreased or no function alleles; a normal function allele in combination with a decreased or no function allele; or a decreased function allele in combination with a no function allele. This annotation only covers the pharmacokinetic relationship between CYP2C9 and phenprocoumon and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence phenprocoumon metabolism.</td><td>Normal</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451516322>429</a></td><td>CYP2C9</td><td>CYP2C9*3</td><td>phenprocoumon</td><td></td><td>3</td><td>*1</td><td>Metabolism/PK</td><td>Patients carrying the CYP2C9*1 allele in combination with another normal function allele may have increased metabolism of phenprocoumon as compared to patients with two decreased or no function alleles; a normal function allele in combination with a decreased or no function allele; or a decreased function allele in combination with a no function allele. This annotation only covers the pharmacokinetic relationship between CYP2C9 and phenprocoumon and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence phenprocoumon metabolism.</td><td>Normal</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451666740>430</a></td><td>CYP2C9</td><td>CYP2C9*1</td><td>fluvastatin</td><td></td><td>1A</td><td>*1</td><td>Metabolism/PK</td><td>The CYP2C9*1 allele is assigned as a normal function allele by CPIC. Patients carrying CYP2C9*1 allele in combination with another normal function allele may have increased metabolism of fluvastatin as compared to patients carrying at least one copy of a decreased function or no function allele. Other genetic and clinical factors may also influence the metabolism of fluvastatin. This annotation only covers the pharmacokinetic relationship between CYP2C9 and fluvastatin and does not include evidence about clinical outcomes.</td><td>Normal</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451666740>431</a></td><td>CYP2C9</td><td>CYP2C9*2</td><td>fluvastatin</td><td></td><td>1A</td><td>*1</td><td>Metabolism/PK</td><td>The CYP2C9*1 allele is assigned as a normal function allele by CPIC. Patients carrying CYP2C9*1 allele in combination with another normal function allele may have increased metabolism of fluvastatin as compared to patients carrying at least one copy of a decreased function or no function allele. Other genetic and clinical factors may also influence the metabolism of fluvastatin. This annotation only covers the pharmacokinetic relationship between CYP2C9 and fluvastatin and does not include evidence about clinical outcomes.</td><td>Normal</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451666740>432</a></td><td>CYP2C9</td><td>CYP2C9*3</td><td>fluvastatin</td><td></td><td>1A</td><td>*1</td><td>Metabolism/PK</td><td>The CYP2C9*1 allele is assigned as a normal function allele by CPIC. Patients carrying CYP2C9*1 allele in combination with another normal function allele may have increased metabolism of fluvastatin as compared to patients carrying at least one copy of a decreased function or no function allele. Other genetic and clinical factors may also influence the metabolism of fluvastatin. This annotation only covers the pharmacokinetic relationship between CYP2C9 and fluvastatin and does not include evidence about clinical outcomes.</td><td>Normal</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183615090>433</a></td><td>CYP2C9</td><td>CYP2C9*1</td><td>losartan</td><td></td><td>3</td><td>*1</td><td>Metabolism/PK</td><td>Patients carrying CYP2C9*1 allele in combination with another normal function allele may have increased metabolism of losartan as compared to patients with a normal function allele in combination with a no function allele (e.g. *1/*3, *1/*6, *1/*13) or a decreased function allele in combination with a no function allele (e.g. *5/*6) or two decreased function alleles (e.g. *5/*8) or a normal function allele in combination with a decreased function allele (e.g. *1/*5). However, findings show that the presence of a combination of a normal and decreased function allele might not significantly affect the metabolism as compared to two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP2C9 and losartan and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of losartan.</td><td>Normal</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183615090>434</a></td><td>CYP2C9</td><td>CYP2C9*2</td><td>losartan</td><td></td><td>3</td><td>*1</td><td>Metabolism/PK</td><td>Patients carrying CYP2C9*1 allele in combination with another normal function allele may have increased metabolism of losartan as compared to patients with a normal function allele in combination with a no function allele (e.g. *1/*3, *1/*6, *1/*13) or a decreased function allele in combination with a no function allele (e.g. *5/*6) or two decreased function alleles (e.g. *5/*8) or a normal function allele in combination with a decreased function allele (e.g. *1/*5). However, findings show that the presence of a combination of a normal and decreased function allele might not significantly affect the metabolism as compared to two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP2C9 and losartan and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of losartan.</td><td>Normal</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183615090>435</a></td><td>CYP2C9</td><td>CYP2C9*3</td><td>losartan</td><td></td><td>3</td><td>*1</td><td>Metabolism/PK</td><td>Patients carrying CYP2C9*1 allele in combination with another normal function allele may have increased metabolism of losartan as compared to patients with a normal function allele in combination with a no function allele (e.g. *1/*3, *1/*6, *1/*13) or a decreased function allele in combination with a no function allele (e.g. *5/*6) or two decreased function alleles (e.g. *5/*8) or a normal function allele in combination with a decreased function allele (e.g. *1/*5). However, findings show that the presence of a combination of a normal and decreased function allele might not significantly affect the metabolism as compared to two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP2C9 and losartan and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of losartan.</td><td>Normal</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183615090>436</a></td><td>CYP2C9</td><td>CYP2C9*5</td><td>losartan</td><td></td><td>3</td><td>*1</td><td>Metabolism/PK</td><td>Patients carrying CYP2C9*1 allele in combination with another normal function allele may have increased metabolism of losartan as compared to patients with a normal function allele in combination with a no function allele (e.g. *1/*3, *1/*6, *1/*13) or a decreased function allele in combination with a no function allele (e.g. *5/*6) or two decreased function alleles (e.g. *5/*8) or a normal function allele in combination with a decreased function allele (e.g. *1/*5). However, findings show that the presence of a combination of a normal and decreased function allele might not significantly affect the metabolism as compared to two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP2C9 and losartan and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of losartan.</td><td>Normal</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183615090>437</a></td><td>CYP2C9</td><td>CYP2C9*6</td><td>losartan</td><td></td><td>3</td><td>*1</td><td>Metabolism/PK</td><td>Patients carrying CYP2C9*1 allele in combination with another normal function allele may have increased metabolism of losartan as compared to patients with a normal function allele in combination with a no function allele (e.g. *1/*3, *1/*6, *1/*13) or a decreased function allele in combination with a no function allele (e.g. *5/*6) or two decreased function alleles (e.g. *5/*8) or a normal function allele in combination with a decreased function allele (e.g. *1/*5). However, findings show that the presence of a combination of a normal and decreased function allele might not significantly affect the metabolism as compared to two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP2C9 and losartan and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of losartan.</td><td>Normal</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183615090>438</a></td><td>CYP2C9</td><td>CYP2C9*8</td><td>losartan</td><td></td><td>3</td><td>*1</td><td>Metabolism/PK</td><td>Patients carrying CYP2C9*1 allele in combination with another normal function allele may have increased metabolism of losartan as compared to patients with a normal function allele in combination with a no function allele (e.g. *1/*3, *1/*6, *1/*13) or a decreased function allele in combination with a no function allele (e.g. *5/*6) or two decreased function alleles (e.g. *5/*8) or a normal function allele in combination with a decreased function allele (e.g. *1/*5). However, findings show that the presence of a combination of a normal and decreased function allele might not significantly affect the metabolism as compared to two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP2C9 and losartan and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of losartan.</td><td>Normal</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183615090>439</a></td><td>CYP2C9</td><td>CYP2C9*13</td><td>losartan</td><td></td><td>3</td><td>*1</td><td>Metabolism/PK</td><td>Patients carrying CYP2C9*1 allele in combination with another normal function allele may have increased metabolism of losartan as compared to patients with a normal function allele in combination with a no function allele (e.g. *1/*3, *1/*6, *1/*13) or a decreased function allele in combination with a no function allele (e.g. *5/*6) or two decreased function alleles (e.g. *5/*8) or a normal function allele in combination with a decreased function allele (e.g. *1/*5). However, findings show that the presence of a combination of a normal and decreased function allele might not significantly affect the metabolism as compared to two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP2C9 and losartan and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of losartan.</td><td>Normal</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183615090>440</a></td><td>CYP2C9</td><td>CYP2C9*59</td><td>losartan</td><td></td><td>3</td><td>*1</td><td>Metabolism/PK</td><td>Patients carrying CYP2C9*1 allele in combination with another normal function allele may have increased metabolism of losartan as compared to patients with a normal function allele in combination with a no function allele (e.g. *1/*3, *1/*6, *1/*13) or a decreased function allele in combination with a no function allele (e.g. *5/*6) or two decreased function alleles (e.g. *5/*8) or a normal function allele in combination with a decreased function allele (e.g. *1/*5). However, findings show that the presence of a combination of a normal and decreased function allele might not significantly affect the metabolism as compared to two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP2C9 and losartan and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of losartan.</td><td>Normal</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183615090>441</a></td><td>CYP2C9</td><td>CYP2C9*62</td><td>losartan</td><td></td><td>3</td><td>*1</td><td>Metabolism/PK</td><td>Patients carrying CYP2C9*1 allele in combination with another normal function allele may have increased metabolism of losartan as compared to patients with a normal function allele in combination with a no function allele (e.g. *1/*3, *1/*6, *1/*13) or a decreased function allele in combination with a no function allele (e.g. *5/*6) or two decreased function alleles (e.g. *5/*8) or a normal function allele in combination with a decreased function allele (e.g. *1/*5). However, findings show that the presence of a combination of a normal and decreased function allele might not significantly affect the metabolism as compared to two normal function alleles. This annotation only covers the pharmacokinetic relationship between CYP2C9 and losartan and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of losartan.</td><td>Normal</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444842106>442</a></td><td>CYP2C9</td><td>CYP2C9*1</td><td>flurbiprofen</td><td></td><td>1A</td><td>*1</td><td>Metabolism/PK</td><td>The CYP2C9*1 allele has been assigned as a normal function allele by CPIC. Patients carrying the CYP2C9*1 allele in combination with another normal function allele may have increased metabolism of flurbiprofen as compared to patients carrying at least one copy of a decreased or no function allele. Other genetic and clinical factors may also influence flurbiprofen metabolism. This annotation only covers the pharmacokinetic relationship between CYP2C9 and flurbiprofen and does not include evidence about clinical outcomes.</td><td>Normal</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444842106>443</a></td><td>CYP2C9</td><td>CYP2C9*2</td><td>flurbiprofen</td><td></td><td>1A</td><td>*1</td><td>Metabolism/PK</td><td>The CYP2C9*1 allele has been assigned as a normal function allele by CPIC. Patients carrying the CYP2C9*1 allele in combination with another normal function allele may have increased metabolism of flurbiprofen as compared to patients carrying at least one copy of a decreased or no function allele. Other genetic and clinical factors may also influence flurbiprofen metabolism. This annotation only covers the pharmacokinetic relationship between CYP2C9 and flurbiprofen and does not include evidence about clinical outcomes.</td><td>Normal</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444842106>444</a></td><td>CYP2C9</td><td>CYP2C9*3</td><td>flurbiprofen</td><td></td><td>1A</td><td>*1</td><td>Metabolism/PK</td><td>The CYP2C9*1 allele has been assigned as a normal function allele by CPIC. Patients carrying the CYP2C9*1 allele in combination with another normal function allele may have increased metabolism of flurbiprofen as compared to patients carrying at least one copy of a decreased or no function allele. Other genetic and clinical factors may also influence flurbiprofen metabolism. This annotation only covers the pharmacokinetic relationship between CYP2C9 and flurbiprofen and does not include evidence about clinical outcomes.</td><td>Normal</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444842106>445</a></td><td>CYP2C9</td><td>CYP2C9*29</td><td>flurbiprofen</td><td></td><td>1A</td><td>*1</td><td>Metabolism/PK</td><td>The CYP2C9*1 allele has been assigned as a normal function allele by CPIC. Patients carrying the CYP2C9*1 allele in combination with another normal function allele may have increased metabolism of flurbiprofen as compared to patients carrying at least one copy of a decreased or no function allele. Other genetic and clinical factors may also influence flurbiprofen metabolism. This annotation only covers the pharmacokinetic relationship between CYP2C9 and flurbiprofen and does not include evidence about clinical outcomes.</td><td>Normal</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183703296>446</a></td><td>CYP2C9</td><td>CYP2C9*1</td><td>lornoxicam</td><td></td><td>1A</td><td>*1</td><td>Metabolism/PK</td><td>The CYP2C9*1 allele is assigned as a normal function allele by CPIC. Patients carrying the CYP2C9*1 allele in combination with another normal function allele may have increased metabolism of lornoxicam as compared to patients with at lease one decreased or no function allele. Other genetic and clinical factors may also affect lornoxicam metabolism. This annotation only covers the pharmacokinetic relationship between CYP2C9 and lornoxicam and does not include evidence about clinical outcomes.</td><td>Normal</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183703296>447</a></td><td>CYP2C9</td><td>CYP2C9*3</td><td>lornoxicam</td><td></td><td>1A</td><td>*1</td><td>Metabolism/PK</td><td>The CYP2C9*1 allele is assigned as a normal function allele by CPIC. Patients carrying the CYP2C9*1 allele in combination with another normal function allele may have increased metabolism of lornoxicam as compared to patients with at lease one decreased or no function allele. Other genetic and clinical factors may also affect lornoxicam metabolism. This annotation only covers the pharmacokinetic relationship between CYP2C9 and lornoxicam and does not include evidence about clinical outcomes.</td><td>Normal</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183703296>448</a></td><td>CYP2C9</td><td>CYP2C9*13</td><td>lornoxicam</td><td></td><td>1A</td><td>*1</td><td>Metabolism/PK</td><td>The CYP2C9*1 allele is assigned as a normal function allele by CPIC. Patients carrying the CYP2C9*1 allele in combination with another normal function allele may have increased metabolism of lornoxicam as compared to patients with at lease one decreased or no function allele. Other genetic and clinical factors may also affect lornoxicam metabolism. This annotation only covers the pharmacokinetic relationship between CYP2C9 and lornoxicam and does not include evidence about clinical outcomes.</td><td>Normal</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451092460>449</a></td><td>CYP2C9</td><td>CYP2C9*1</td><td>tenoxicam</td><td></td><td>1A</td><td>*1</td><td>Metabolism/PK</td><td>The CYP2C9*1 allele has been assigned as a normal function allele by CPIC. Patients carrying the *1 allele in combination with another normal function allele may have increased metabolism of tenoxicam as compared to patients carrying two decreased or no function alleles or a normal function allele in combination with a decreased or no function allele. This annotation only covers the pharmacokinetic relationship between CYP2C9 and tenoxicam and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect tenoxicam metabolism.</td><td>Normal</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451092460>450</a></td><td>CYP2C9</td><td>CYP2C9*2</td><td>tenoxicam</td><td></td><td>1A</td><td>*1</td><td>Metabolism/PK</td><td>The CYP2C9*1 allele has been assigned as a normal function allele by CPIC. Patients carrying the *1 allele in combination with another normal function allele may have increased metabolism of tenoxicam as compared to patients carrying two decreased or no function alleles or a normal function allele in combination with a decreased or no function allele. This annotation only covers the pharmacokinetic relationship between CYP2C9 and tenoxicam and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect tenoxicam metabolism.</td><td>Normal</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451092460>451</a></td><td>CYP2C9</td><td>CYP2C9*3</td><td>tenoxicam</td><td></td><td>1A</td><td>*1</td><td>Metabolism/PK</td><td>The CYP2C9*1 allele has been assigned as a normal function allele by CPIC. Patients carrying the *1 allele in combination with another normal function allele may have increased metabolism of tenoxicam as compared to patients carrying two decreased or no function alleles or a normal function allele in combination with a decreased or no function allele. This annotation only covers the pharmacokinetic relationship between CYP2C9 and tenoxicam and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect tenoxicam metabolism.</td><td>Normal</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451092541>452</a></td><td>CYP2C9</td><td>CYP2C9*1</td><td>piroxicam</td><td></td><td>1A</td><td>*1</td><td>Metabolism/PK</td><td>The CYP2C9*1 allele is assigned as a normal function allele by CPIC. Patients carrying the CYP2C9*1 allele in combination with another normal function allele may have increased metabolism of piroxicam as compared to patients carrying at least one copy of a decreased or no function allele. Other genetic and clinical factors may also affect piroxicam metabolism. This annotation only covers the pharmacokinetic relationship between CYP2C9 and piroxicam and does not include evidence about clinical outcomes.</td><td>Normal</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451092541>453</a></td><td>CYP2C9</td><td>CYP2C9*2</td><td>piroxicam</td><td></td><td>1A</td><td>*1</td><td>Metabolism/PK</td><td>The CYP2C9*1 allele is assigned as a normal function allele by CPIC. Patients carrying the CYP2C9*1 allele in combination with another normal function allele may have increased metabolism of piroxicam as compared to patients carrying at least one copy of a decreased or no function allele. Other genetic and clinical factors may also affect piroxicam metabolism. This annotation only covers the pharmacokinetic relationship between CYP2C9 and piroxicam and does not include evidence about clinical outcomes.</td><td>Normal</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451092541>454</a></td><td>CYP2C9</td><td>CYP2C9*3</td><td>piroxicam</td><td></td><td>1A</td><td>*1</td><td>Metabolism/PK</td><td>The CYP2C9*1 allele is assigned as a normal function allele by CPIC. Patients carrying the CYP2C9*1 allele in combination with another normal function allele may have increased metabolism of piroxicam as compared to patients carrying at least one copy of a decreased or no function allele. Other genetic and clinical factors may also affect piroxicam metabolism. This annotation only covers the pharmacokinetic relationship between CYP2C9 and piroxicam and does not include evidence about clinical outcomes.</td><td>Normal</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451092677>455</a></td><td>CYP2C9</td><td>CYP2C9*1</td><td>meloxicam</td><td></td><td>1A</td><td>*1</td><td>Metabolism/PK</td><td>The CYP2C9*1 allele is assigned as a normal function allele by CPIC. Patients carrying the CYP2C9*1 allele in combination with another normal function allele may have increased metabolism of meloxicam as compared to patients carrying at least one copy of a decreased or no function allele. Other genetic and clinical factors may also affect meloxicam metabolism. This annotation only covers the pharmacokinetic relationship between CYP2C9 and meloxicam and does not include evidence about clinical outcomes.</td><td>Normal</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451092677>456</a></td><td>CYP2C9</td><td>CYP2C9*2</td><td>meloxicam</td><td></td><td>1A</td><td>*1</td><td>Metabolism/PK</td><td>The CYP2C9*1 allele is assigned as a normal function allele by CPIC. Patients carrying the CYP2C9*1 allele in combination with another normal function allele may have increased metabolism of meloxicam as compared to patients carrying at least one copy of a decreased or no function allele. Other genetic and clinical factors may also affect meloxicam metabolism. This annotation only covers the pharmacokinetic relationship between CYP2C9 and meloxicam and does not include evidence about clinical outcomes.</td><td>Normal</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451092677>457</a></td><td>CYP2C9</td><td>CYP2C9*3</td><td>meloxicam</td><td></td><td>1A</td><td>*1</td><td>Metabolism/PK</td><td>The CYP2C9*1 allele is assigned as a normal function allele by CPIC. Patients carrying the CYP2C9*1 allele in combination with another normal function allele may have increased metabolism of meloxicam as compared to patients carrying at least one copy of a decreased or no function allele. Other genetic and clinical factors may also affect meloxicam metabolism. This annotation only covers the pharmacokinetic relationship between CYP2C9 and meloxicam and does not include evidence about clinical outcomes.</td><td>Normal</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451092677>458</a></td><td>CYP2C9</td><td>CYP2C9*13</td><td>meloxicam</td><td></td><td>1A</td><td>*1</td><td>Metabolism/PK</td><td>The CYP2C9*1 allele is assigned as a normal function allele by CPIC. Patients carrying the CYP2C9*1 allele in combination with another normal function allele may have increased metabolism of meloxicam as compared to patients carrying at least one copy of a decreased or no function allele. Other genetic and clinical factors may also affect meloxicam metabolism. This annotation only covers the pharmacokinetic relationship between CYP2C9 and meloxicam and does not include evidence about clinical outcomes.</td><td>Normal</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451092720>459</a></td><td>CYP2C9</td><td>CYP2C9*1</td><td>ibuprofen</td><td></td><td>1A</td><td>*1</td><td>Metabolism/PK</td><td>The CYP2C9*1 allele is assigned as a normal function allele by CPIC. Patients carrying CYP2C9*1 allele in combination with another normal function allele may have increased metabolism of ibuprofen as compared to patients carrying at least one copy of a decreased or no function allele. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence metabolism of ibuprofen. This annotation only covers the pharmacokinetic relationship between CYP2C9 and ibuprofen and does not include evidence about clinical outcomes.</td><td>Normal</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451092720>460</a></td><td>CYP2C9</td><td>CYP2C9*2</td><td>ibuprofen</td><td></td><td>1A</td><td>*1</td><td>Metabolism/PK</td><td>The CYP2C9*1 allele is assigned as a normal function allele by CPIC. Patients carrying CYP2C9*1 allele in combination with another normal function allele may have increased metabolism of ibuprofen as compared to patients carrying at least one copy of a decreased or no function allele. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence metabolism of ibuprofen. This annotation only covers the pharmacokinetic relationship between CYP2C9 and ibuprofen and does not include evidence about clinical outcomes.</td><td>Normal</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451092720>461</a></td><td>CYP2C9</td><td>CYP2C9*3</td><td>ibuprofen</td><td></td><td>1A</td><td>*1</td><td>Metabolism/PK</td><td>The CYP2C9*1 allele is assigned as a normal function allele by CPIC. Patients carrying CYP2C9*1 allele in combination with another normal function allele may have increased metabolism of ibuprofen as compared to patients carrying at least one copy of a decreased or no function allele. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence metabolism of ibuprofen. This annotation only covers the pharmacokinetic relationship between CYP2C9 and ibuprofen and does not include evidence about clinical outcomes.</td><td>Normal</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451139160>462</a></td><td>CYP2C9</td><td>CYP2C9*1</td><td>naproxen</td><td></td><td>4</td><td>*1</td><td>Metabolism/PK</td><td>Patients carrying the *1 allele in addition to another normal function allele may have increased metabolism of naproxen as compared to patients carrying at least one copy of a decreased function or no function allele. This drug-variant pair has been assigned a no recommendation by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence the metabolism of naproxen. This annotation only covers the pharmacokinetic relationship between CYP2C9 and naproxen and does not include evidence about clinical outcomes.</td><td>Normal</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451139160>463</a></td><td>CYP2C9</td><td>CYP2C9*2</td><td>naproxen</td><td></td><td>4</td><td>*1</td><td>Metabolism/PK</td><td>Patients carrying the *1 allele in addition to another normal function allele may have increased metabolism of naproxen as compared to patients carrying at least one copy of a decreased function or no function allele. This drug-variant pair has been assigned a no recommendation by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence the metabolism of naproxen. This annotation only covers the pharmacokinetic relationship between CYP2C9 and naproxen and does not include evidence about clinical outcomes.</td><td>Normal</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451139160>464</a></td><td>CYP2C9</td><td>CYP2C9*3</td><td>naproxen</td><td></td><td>4</td><td>*1</td><td>Metabolism/PK</td><td>Patients carrying the *1 allele in addition to another normal function allele may have increased metabolism of naproxen as compared to patients carrying at least one copy of a decreased function or no function allele. This drug-variant pair has been assigned a no recommendation by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence the metabolism of naproxen. This annotation only covers the pharmacokinetic relationship between CYP2C9 and naproxen and does not include evidence about clinical outcomes.</td><td>Normal</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451139160>465</a></td><td>CYP2C9</td><td>CYP2C9*29</td><td>naproxen</td><td></td><td>4</td><td>*1</td><td>Metabolism/PK</td><td>Patients carrying the *1 allele in addition to another normal function allele may have increased metabolism of naproxen as compared to patients carrying at least one copy of a decreased function or no function allele. This drug-variant pair has been assigned a no recommendation by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence the metabolism of naproxen. This annotation only covers the pharmacokinetic relationship between CYP2C9 and naproxen and does not include evidence about clinical outcomes.</td><td>Normal</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451236700>466</a></td><td>CYP2C9</td><td>CYP2C9*1</td><td>celecoxib</td><td></td><td>1A</td><td>*1</td><td>Metabolism/PK</td><td>The CYP2C9*1 allele is assigned as a normal function allele by CPIC. Patients carrying CYP2C9*1 allele in combination with another normal function allele may have increased metabolism of celecoxib as compared to patients carrying at least one copy of a decreased function or no function allele. Other genetic and clinical factors may also influence the metabolism of celecoxib. This annotation only covers the pharmacokinetic relationship between CYP2C9 and celecoxib and does not include evidence about clinical outcomes.</td><td>Normal</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451236700>467</a></td><td>CYP2C9</td><td>CYP2C9*2</td><td>celecoxib</td><td></td><td>1A</td><td>*1</td><td>Metabolism/PK</td><td>The CYP2C9*1 allele is assigned as a normal function allele by CPIC. Patients carrying CYP2C9*1 allele in combination with another normal function allele may have increased metabolism of celecoxib as compared to patients carrying at least one copy of a decreased function or no function allele. Other genetic and clinical factors may also influence the metabolism of celecoxib. This annotation only covers the pharmacokinetic relationship between CYP2C9 and celecoxib and does not include evidence about clinical outcomes.</td><td>Normal</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451236700>468</a></td><td>CYP2C9</td><td>CYP2C9*3</td><td>celecoxib</td><td></td><td>1A</td><td>*1</td><td>Metabolism/PK</td><td>The CYP2C9*1 allele is assigned as a normal function allele by CPIC. Patients carrying CYP2C9*1 allele in combination with another normal function allele may have increased metabolism of celecoxib as compared to patients carrying at least one copy of a decreased function or no function allele. Other genetic and clinical factors may also influence the metabolism of celecoxib. This annotation only covers the pharmacokinetic relationship between CYP2C9 and celecoxib and does not include evidence about clinical outcomes.</td><td>Normal</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451236700>469</a></td><td>CYP2C9</td><td>CYP2C9*13</td><td>celecoxib</td><td></td><td>1A</td><td>*1</td><td>Metabolism/PK</td><td>The CYP2C9*1 allele is assigned as a normal function allele by CPIC. Patients carrying CYP2C9*1 allele in combination with another normal function allele may have increased metabolism of celecoxib as compared to patients carrying at least one copy of a decreased function or no function allele. Other genetic and clinical factors may also influence the metabolism of celecoxib. This annotation only covers the pharmacokinetic relationship between CYP2C9 and celecoxib and does not include evidence about clinical outcomes.</td><td>Normal</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450809583>470</a></td><td>CYP2C9</td><td>CYP2C9*1</td><td>tolbutamide</td><td></td><td>3</td><td>*1</td><td>Metabolism/PK</td><td>Patients carrying the *1 allele in combination with another normal function allele may have increased clearance of tolbutamide as compared to patients with a normal function allele in combination with a no function allele (e.g. *1/*3) or a decreased function allele in combination with a no function allele (e.g. *2/*3) or two no function alleles (e.g. *3/*3). This drug-variant pair has been assigned a no recommendation by DPWG, as it was determined to be not clinically actionable. This annotation only covers the pharmacokinetic relationship between CYP2C9 and tolbutamide and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect tolbutamide clearance.</td><td>Normal</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450809583>471</a></td><td>CYP2C9</td><td>CYP2C9*2</td><td>tolbutamide</td><td></td><td>3</td><td>*1</td><td>Metabolism/PK</td><td>Patients carrying the *1 allele in combination with another normal function allele may have increased clearance of tolbutamide as compared to patients with a normal function allele in combination with a no function allele (e.g. *1/*3) or a decreased function allele in combination with a no function allele (e.g. *2/*3) or two no function alleles (e.g. *3/*3). This drug-variant pair has been assigned a no recommendation by DPWG, as it was determined to be not clinically actionable. This annotation only covers the pharmacokinetic relationship between CYP2C9 and tolbutamide and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect tolbutamide clearance.</td><td>Normal</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450809583>472</a></td><td>CYP2C9</td><td>CYP2C9*3</td><td>tolbutamide</td><td></td><td>3</td><td>*1</td><td>Metabolism/PK</td><td>Patients carrying the *1 allele in combination with another normal function allele may have increased clearance of tolbutamide as compared to patients with a normal function allele in combination with a no function allele (e.g. *1/*3) or a decreased function allele in combination with a no function allele (e.g. *2/*3) or two no function alleles (e.g. *3/*3). This drug-variant pair has been assigned a no recommendation by DPWG, as it was determined to be not clinically actionable. This annotation only covers the pharmacokinetic relationship between CYP2C9 and tolbutamide and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect tolbutamide clearance.</td><td>Normal</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450809583>473</a></td><td>CYP2C9</td><td>CYP2C9*62</td><td>tolbutamide</td><td></td><td>3</td><td>*1</td><td>Metabolism/PK</td><td>Patients carrying the *1 allele in combination with another normal function allele may have increased clearance of tolbutamide as compared to patients with a normal function allele in combination with a no function allele (e.g. *1/*3) or a decreased function allele in combination with a no function allele (e.g. *2/*3) or two no function alleles (e.g. *3/*3). This drug-variant pair has been assigned a no recommendation by DPWG, as it was determined to be not clinically actionable. This annotation only covers the pharmacokinetic relationship between CYP2C9 and tolbutamide and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect tolbutamide clearance.</td><td>Normal</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449565774>474</a></td><td>CYP2C9</td><td>CYP2C9*1</td><td>phenytoin</td><td></td><td>3</td><td>*1</td><td>Metabolism/PK</td><td>Patients carrying the CYP2C9*1 allele may have an increased rate of phenytoin clearance as compared to patients carrying the CYP2C9*19 or *36 allele, and a decreased rate of phenytoin clearance as compared to patients carrying the CYP2C9*27, *40, *41, *47, *49, *51, *53, *54 or *56 allele. Other genetic or clinical factors may also affect the clearance rate of phenytoin in a patient. This annotation only covers the pharmacokinetic relationship between CYP2C9 and phenytoin and does not include evidence about clinical outcomes.</td><td>Normal</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449565774>475</a></td><td>CYP2C9</td><td>CYP2C9*19</td><td>phenytoin</td><td></td><td>3</td><td>*1</td><td>Metabolism/PK</td><td>Patients carrying the CYP2C9*1 allele may have an increased rate of phenytoin clearance as compared to patients carrying the CYP2C9*19 or *36 allele, and a decreased rate of phenytoin clearance as compared to patients carrying the CYP2C9*27, *40, *41, *47, *49, *51, *53, *54 or *56 allele. Other genetic or clinical factors may also affect the clearance rate of phenytoin in a patient. This annotation only covers the pharmacokinetic relationship between CYP2C9 and phenytoin and does not include evidence about clinical outcomes.</td><td>Normal</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449565774>476</a></td><td>CYP2C9</td><td>CYP2C9*27</td><td>phenytoin</td><td></td><td>3</td><td>*1</td><td>Metabolism/PK</td><td>Patients carrying the CYP2C9*1 allele may have an increased rate of phenytoin clearance as compared to patients carrying the CYP2C9*19 or *36 allele, and a decreased rate of phenytoin clearance as compared to patients carrying the CYP2C9*27, *40, *41, *47, *49, *51, *53, *54 or *56 allele. Other genetic or clinical factors may also affect the clearance rate of phenytoin in a patient. This annotation only covers the pharmacokinetic relationship between CYP2C9 and phenytoin and does not include evidence about clinical outcomes.</td><td>Normal</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449565774>477</a></td><td>CYP2C9</td><td>CYP2C9*36</td><td>phenytoin</td><td></td><td>3</td><td>*1</td><td>Metabolism/PK</td><td>Patients carrying the CYP2C9*1 allele may have an increased rate of phenytoin clearance as compared to patients carrying the CYP2C9*19 or *36 allele, and a decreased rate of phenytoin clearance as compared to patients carrying the CYP2C9*27, *40, *41, *47, *49, *51, *53, *54 or *56 allele. Other genetic or clinical factors may also affect the clearance rate of phenytoin in a patient. This annotation only covers the pharmacokinetic relationship between CYP2C9 and phenytoin and does not include evidence about clinical outcomes.</td><td>Normal</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449565774>478</a></td><td>CYP2C9</td><td>CYP2C9*40</td><td>phenytoin</td><td></td><td>3</td><td>*1</td><td>Metabolism/PK</td><td>Patients carrying the CYP2C9*1 allele may have an increased rate of phenytoin clearance as compared to patients carrying the CYP2C9*19 or *36 allele, and a decreased rate of phenytoin clearance as compared to patients carrying the CYP2C9*27, *40, *41, *47, *49, *51, *53, *54 or *56 allele. Other genetic or clinical factors may also affect the clearance rate of phenytoin in a patient. This annotation only covers the pharmacokinetic relationship between CYP2C9 and phenytoin and does not include evidence about clinical outcomes.</td><td>Normal</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449565774>479</a></td><td>CYP2C9</td><td>CYP2C9*41</td><td>phenytoin</td><td></td><td>3</td><td>*1</td><td>Metabolism/PK</td><td>Patients carrying the CYP2C9*1 allele may have an increased rate of phenytoin clearance as compared to patients carrying the CYP2C9*19 or *36 allele, and a decreased rate of phenytoin clearance as compared to patients carrying the CYP2C9*27, *40, *41, *47, *49, *51, *53, *54 or *56 allele. Other genetic or clinical factors may also affect the clearance rate of phenytoin in a patient. This annotation only covers the pharmacokinetic relationship between CYP2C9 and phenytoin and does not include evidence about clinical outcomes.</td><td>Normal</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449565774>480</a></td><td>CYP2C9</td><td>CYP2C9*47</td><td>phenytoin</td><td></td><td>3</td><td>*1</td><td>Metabolism/PK</td><td>Patients carrying the CYP2C9*1 allele may have an increased rate of phenytoin clearance as compared to patients carrying the CYP2C9*19 or *36 allele, and a decreased rate of phenytoin clearance as compared to patients carrying the CYP2C9*27, *40, *41, *47, *49, *51, *53, *54 or *56 allele. Other genetic or clinical factors may also affect the clearance rate of phenytoin in a patient. This annotation only covers the pharmacokinetic relationship between CYP2C9 and phenytoin and does not include evidence about clinical outcomes.</td><td>Normal</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449565774>481</a></td><td>CYP2C9</td><td>CYP2C9*49</td><td>phenytoin</td><td></td><td>3</td><td>*1</td><td>Metabolism/PK</td><td>Patients carrying the CYP2C9*1 allele may have an increased rate of phenytoin clearance as compared to patients carrying the CYP2C9*19 or *36 allele, and a decreased rate of phenytoin clearance as compared to patients carrying the CYP2C9*27, *40, *41, *47, *49, *51, *53, *54 or *56 allele. Other genetic or clinical factors may also affect the clearance rate of phenytoin in a patient. This annotation only covers the pharmacokinetic relationship between CYP2C9 and phenytoin and does not include evidence about clinical outcomes.</td><td>Normal</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449565774>482</a></td><td>CYP2C9</td><td>CYP2C9*51</td><td>phenytoin</td><td></td><td>3</td><td>*1</td><td>Metabolism/PK</td><td>Patients carrying the CYP2C9*1 allele may have an increased rate of phenytoin clearance as compared to patients carrying the CYP2C9*19 or *36 allele, and a decreased rate of phenytoin clearance as compared to patients carrying the CYP2C9*27, *40, *41, *47, *49, *51, *53, *54 or *56 allele. Other genetic or clinical factors may also affect the clearance rate of phenytoin in a patient. This annotation only covers the pharmacokinetic relationship between CYP2C9 and phenytoin and does not include evidence about clinical outcomes.</td><td>Normal</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449565774>483</a></td><td>CYP2C9</td><td>CYP2C9*53</td><td>phenytoin</td><td></td><td>3</td><td>*1</td><td>Metabolism/PK</td><td>Patients carrying the CYP2C9*1 allele may have an increased rate of phenytoin clearance as compared to patients carrying the CYP2C9*19 or *36 allele, and a decreased rate of phenytoin clearance as compared to patients carrying the CYP2C9*27, *40, *41, *47, *49, *51, *53, *54 or *56 allele. Other genetic or clinical factors may also affect the clearance rate of phenytoin in a patient. This annotation only covers the pharmacokinetic relationship between CYP2C9 and phenytoin and does not include evidence about clinical outcomes.</td><td>Normal</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449565774>484</a></td><td>CYP2C9</td><td>CYP2C9*54</td><td>phenytoin</td><td></td><td>3</td><td>*1</td><td>Metabolism/PK</td><td>Patients carrying the CYP2C9*1 allele may have an increased rate of phenytoin clearance as compared to patients carrying the CYP2C9*19 or *36 allele, and a decreased rate of phenytoin clearance as compared to patients carrying the CYP2C9*27, *40, *41, *47, *49, *51, *53, *54 or *56 allele. Other genetic or clinical factors may also affect the clearance rate of phenytoin in a patient. This annotation only covers the pharmacokinetic relationship between CYP2C9 and phenytoin and does not include evidence about clinical outcomes.</td><td>Normal</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449565774>485</a></td><td>CYP2C9</td><td>CYP2C9*56</td><td>phenytoin</td><td></td><td>3</td><td>*1</td><td>Metabolism/PK</td><td>Patients carrying the CYP2C9*1 allele may have an increased rate of phenytoin clearance as compared to patients carrying the CYP2C9*19 or *36 allele, and a decreased rate of phenytoin clearance as compared to patients carrying the CYP2C9*27, *40, *41, *47, *49, *51, *53, *54 or *56 allele. Other genetic or clinical factors may also affect the clearance rate of phenytoin in a patient. This annotation only covers the pharmacokinetic relationship between CYP2C9 and phenytoin and does not include evidence about clinical outcomes.</td><td>Normal</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451148920>486</a></td><td>CYP2C9</td><td>CYP2C9*1</td><td>warfarin</td><td></td><td>3</td><td>*1</td><td>Metabolism/PK</td><td>Patients carrying the *1 allele in addition to another normal function allele may have increased metabolism of warfarin as compared to patients with at least one copy of a decreased or no function allele. Other genetic and clinical factors may also affect warfarin metabolism. This annotation only covers the pharmacokinetic relationship between CYP2C9 and warfarin and does not include evidence about clinical outcomes.</td><td>Normal</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451148920>487</a></td><td>CYP2C9</td><td>CYP2C9*29</td><td>warfarin</td><td></td><td>3</td><td>*1</td><td>Metabolism/PK</td><td>Patients carrying the *1 allele in addition to another normal function allele may have increased metabolism of warfarin as compared to patients with at least one copy of a decreased or no function allele. Other genetic and clinical factors may also affect warfarin metabolism. This annotation only covers the pharmacokinetic relationship between CYP2C9 and warfarin and does not include evidence about clinical outcomes.</td><td>Normal</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/982033279>488</a></td><td>CYP2C9</td><td>CYP2C9*1</td><td>acenocoumarol</td><td></td><td>1B</td><td>*1</td><td>Dosage</td><td>Patients carrying CYP2C9*1 allele in combination with another normal function allele may require a higher dose of acenocoumarol as compared to patients carrying at least one copy of a decreased function or no function allele. However, conflicting evidence has been reported. This drug-variant pair has been assigned a no recommendation by DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence the required dose of acenocoumarol.</td><td>Normal</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/982033279>489</a></td><td>CYP2C9</td><td>CYP2C9*2</td><td>acenocoumarol</td><td></td><td>1B</td><td>*1</td><td>Dosage</td><td>Patients carrying CYP2C9*1 allele in combination with another normal function allele may require a higher dose of acenocoumarol as compared to patients carrying at least one copy of a decreased function or no function allele. However, conflicting evidence has been reported. This drug-variant pair has been assigned a no recommendation by DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence the required dose of acenocoumarol.</td><td>Normal</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/982033279>490</a></td><td>CYP2C9</td><td>CYP2C9*3</td><td>acenocoumarol</td><td></td><td>1B</td><td>*1</td><td>Dosage</td><td>Patients carrying CYP2C9*1 allele in combination with another normal function allele may require a higher dose of acenocoumarol as compared to patients carrying at least one copy of a decreased function or no function allele. However, conflicting evidence has been reported. This drug-variant pair has been assigned a no recommendation by DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence the required dose of acenocoumarol.</td><td>Normal</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451448900>491</a></td><td>NUDT15</td><td>NUDT15*1</td><td>mercaptopurine</td><td></td><td>3</td><td>*1</td><td>Dosage</td><td>Patients carrying the NUDT15*1 allele in combination with another normal function allele may tolerate increased doses of mercaptopurine as compared to patients with an uncertain function allele in combination with a normal or no function allele. Other genetic and clinical factors may also affect mercaptopurine dosing.</td><td>Normal</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451448900>492</a></td><td>NUDT15</td><td>NUDT15*4</td><td>mercaptopurine</td><td></td><td>3</td><td>*1</td><td>Dosage</td><td>Patients carrying the NUDT15*1 allele in combination with another normal function allele may tolerate increased doses of mercaptopurine as compared to patients with an uncertain function allele in combination with a normal or no function allele. Other genetic and clinical factors may also affect mercaptopurine dosing.</td><td>Normal</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451448900>493</a></td><td>NUDT15</td><td>NUDT15*5</td><td>mercaptopurine</td><td></td><td>3</td><td>*1</td><td>Dosage</td><td>Patients carrying the NUDT15*1 allele in combination with another normal function allele may tolerate increased doses of mercaptopurine as compared to patients with an uncertain function allele in combination with a normal or no function allele. Other genetic and clinical factors may also affect mercaptopurine dosing.</td><td>Normal</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451448900>494</a></td><td>NUDT15</td><td>NUDT15*6</td><td>mercaptopurine</td><td></td><td>3</td><td>*1</td><td>Dosage</td><td>Patients carrying the NUDT15*1 allele in combination with another normal function allele may tolerate increased doses of mercaptopurine as compared to patients with an uncertain function allele in combination with a normal or no function allele. Other genetic and clinical factors may also affect mercaptopurine dosing.</td><td>Normal</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448635217>495</a></td><td>NUDT15</td><td>NUDT15*1</td><td>mercaptopurine</td><td>Precursor Cell Lymphoblastic Leukemia-Lymphoma</td><td>1A</td><td>*1</td><td>Dosage</td><td>The NUDT15*1 allele is assigned as a normal function allele by CPIC. Patients carrying the NUDT15*1 allele in combination with another normal function allele may tolerate increased doses of mercaptopurine as compared to patients with two no function alleles or a no function allele in combination with a normal function allele. Other genetic and clinical factors may also affect mercaptopurine dosing.</td><td>Normal</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448635217>496</a></td><td>NUDT15</td><td>NUDT15*2</td><td>mercaptopurine</td><td>Precursor Cell Lymphoblastic Leukemia-Lymphoma</td><td>1A</td><td>*1</td><td>Dosage</td><td>The NUDT15*1 allele is assigned as a normal function allele by CPIC. Patients carrying the NUDT15*1 allele in combination with another normal function allele may tolerate increased doses of mercaptopurine as compared to patients with two no function alleles or a no function allele in combination with a normal function allele. Other genetic and clinical factors may also affect mercaptopurine dosing.</td><td>Normal</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448635217>497</a></td><td>NUDT15</td><td>NUDT15*3</td><td>mercaptopurine</td><td>Precursor Cell Lymphoblastic Leukemia-Lymphoma</td><td>1A</td><td>*1</td><td>Dosage</td><td>The NUDT15*1 allele is assigned as a normal function allele by CPIC. Patients carrying the NUDT15*1 allele in combination with another normal function allele may tolerate increased doses of mercaptopurine as compared to patients with two no function alleles or a no function allele in combination with a normal function allele. Other genetic and clinical factors may also affect mercaptopurine dosing.</td><td>Normal</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451516314>498</a></td><td>CYP2C9</td><td>CYP2C9*1</td><td>phenprocoumon</td><td></td><td>3</td><td>*1</td><td>Dosage</td><td>Patients carrying the CYP2C9*1 allele in combination with another normal function allele may require an increased dose of phenprocoumon as compared to patients with two decreased or no function alleles or a normal function allele in combination with a decreased or no function allele. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence phenprocoumon dose requirements.</td><td>Normal</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451516314>499</a></td><td>CYP2C9</td><td>CYP2C9*2</td><td>phenprocoumon</td><td></td><td>3</td><td>*1</td><td>Dosage</td><td>Patients carrying the CYP2C9*1 allele in combination with another normal function allele may require an increased dose of phenprocoumon as compared to patients with two decreased or no function alleles or a normal function allele in combination with a decreased or no function allele. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence phenprocoumon dose requirements.</td><td>Normal</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451516314>500</a></td><td>CYP2C9</td><td>CYP2C9*3</td><td>phenprocoumon</td><td></td><td>3</td><td>*1</td><td>Dosage</td><td>Patients carrying the CYP2C9*1 allele in combination with another normal function allele may require an increased dose of phenprocoumon as compared to patients with two decreased or no function alleles or a normal function allele in combination with a decreased or no function allele. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence phenprocoumon dose requirements.</td><td>Normal</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/981238341>501</a></td><td>CYP2C9</td><td>CYP2C9*1</td><td>warfarin</td><td>Cardiovascular Diseases</td><td>1A</td><td>*1</td><td>Dosage</td><td>The CYP2C9*1 allele is assigned as a normal function allele by CPIC. Patients carrying the CYP2C9*1 allele in combination with another normal function allele may require a higher dose of warfarin as compared to patients carrying at least one copy of a decreased or no function allele. Other genetic and clinical factors may also influence warfarin dose.</td><td>Normal</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/981238341>502</a></td><td>CYP2C9</td><td>CYP2C9*2</td><td>warfarin</td><td>Cardiovascular Diseases</td><td>1A</td><td>*1</td><td>Dosage</td><td>The CYP2C9*1 allele is assigned as a normal function allele by CPIC. Patients carrying the CYP2C9*1 allele in combination with another normal function allele may require a higher dose of warfarin as compared to patients carrying at least one copy of a decreased or no function allele. Other genetic and clinical factors may also influence warfarin dose.</td><td>Normal</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/981238341>503</a></td><td>CYP2C9</td><td>CYP2C9*3</td><td>warfarin</td><td>Cardiovascular Diseases</td><td>1A</td><td>*1</td><td>Dosage</td><td>The CYP2C9*1 allele is assigned as a normal function allele by CPIC. Patients carrying the CYP2C9*1 allele in combination with another normal function allele may require a higher dose of warfarin as compared to patients carrying at least one copy of a decreased or no function allele. Other genetic and clinical factors may also influence warfarin dose.</td><td>Normal</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/981238341>504</a></td><td>CYP2C9</td><td>CYP2C9*4</td><td>warfarin</td><td>Cardiovascular Diseases</td><td>1A</td><td>*1</td><td>Dosage</td><td>The CYP2C9*1 allele is assigned as a normal function allele by CPIC. Patients carrying the CYP2C9*1 allele in combination with another normal function allele may require a higher dose of warfarin as compared to patients carrying at least one copy of a decreased or no function allele. Other genetic and clinical factors may also influence warfarin dose.</td><td>Normal</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/981238341>505</a></td><td>CYP2C9</td><td>CYP2C9*5</td><td>warfarin</td><td>Cardiovascular Diseases</td><td>1A</td><td>*1</td><td>Dosage</td><td>The CYP2C9*1 allele is assigned as a normal function allele by CPIC. Patients carrying the CYP2C9*1 allele in combination with another normal function allele may require a higher dose of warfarin as compared to patients carrying at least one copy of a decreased or no function allele. Other genetic and clinical factors may also influence warfarin dose.</td><td>Normal</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/981238341>506</a></td><td>CYP2C9</td><td>CYP2C9*6</td><td>warfarin</td><td>Cardiovascular Diseases</td><td>1A</td><td>*1</td><td>Dosage</td><td>The CYP2C9*1 allele is assigned as a normal function allele by CPIC. Patients carrying the CYP2C9*1 allele in combination with another normal function allele may require a higher dose of warfarin as compared to patients carrying at least one copy of a decreased or no function allele. Other genetic and clinical factors may also influence warfarin dose.</td><td>Normal</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/981238341>507</a></td><td>CYP2C9</td><td>CYP2C9*8</td><td>warfarin</td><td>Cardiovascular Diseases</td><td>1A</td><td>*1</td><td>Dosage</td><td>The CYP2C9*1 allele is assigned as a normal function allele by CPIC. Patients carrying the CYP2C9*1 allele in combination with another normal function allele may require a higher dose of warfarin as compared to patients carrying at least one copy of a decreased or no function allele. Other genetic and clinical factors may also influence warfarin dose.</td><td>Normal</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/981238341>508</a></td><td>CYP2C9</td><td>CYP2C9*11</td><td>warfarin</td><td>Cardiovascular Diseases</td><td>1A</td><td>*1</td><td>Dosage</td><td>The CYP2C9*1 allele is assigned as a normal function allele by CPIC. Patients carrying the CYP2C9*1 allele in combination with another normal function allele may require a higher dose of warfarin as compared to patients carrying at least one copy of a decreased or no function allele. Other genetic and clinical factors may also influence warfarin dose.</td><td>Normal</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451237200>509</a></td><td>TPMT</td><td>TPMT*1</td><td>mercaptopurine</td><td>dose reduction</td><td>1A</td><td>*1</td><td>Dosage</td><td>The TPMT*1 allele is assigned as a normal allele by CPIC. Patients carrying the TPMT*1 allele in combination with another normal function allele may have decreased likelihood of dose reduction when treated with mercaptopurine as compared to patients with one or two no function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence mercaptopurine dosage.</td><td>Normal</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451237200>510</a></td><td>TPMT</td><td>TPMT*2</td><td>mercaptopurine</td><td>dose reduction</td><td>1A</td><td>*1</td><td>Dosage</td><td>The TPMT*1 allele is assigned as a normal allele by CPIC. Patients carrying the TPMT*1 allele in combination with another normal function allele may have decreased likelihood of dose reduction when treated with mercaptopurine as compared to patients with one or two no function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence mercaptopurine dosage.</td><td>Normal</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451237200>511</a></td><td>TPMT</td><td>TPMT*3A</td><td>mercaptopurine</td><td>dose reduction</td><td>1A</td><td>*1</td><td>Dosage</td><td>The TPMT*1 allele is assigned as a normal allele by CPIC. Patients carrying the TPMT*1 allele in combination with another normal function allele may have decreased likelihood of dose reduction when treated with mercaptopurine as compared to patients with one or two no function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence mercaptopurine dosage.</td><td>Normal</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451237200>512</a></td><td>TPMT</td><td>TPMT*3B</td><td>mercaptopurine</td><td>dose reduction</td><td>1A</td><td>*1</td><td>Dosage</td><td>The TPMT*1 allele is assigned as a normal allele by CPIC. Patients carrying the TPMT*1 allele in combination with another normal function allele may have decreased likelihood of dose reduction when treated with mercaptopurine as compared to patients with one or two no function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence mercaptopurine dosage.</td><td>Normal</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451237200>513</a></td><td>TPMT</td><td>TPMT*3C</td><td>mercaptopurine</td><td>dose reduction</td><td>1A</td><td>*1</td><td>Dosage</td><td>The TPMT*1 allele is assigned as a normal allele by CPIC. Patients carrying the TPMT*1 allele in combination with another normal function allele may have decreased likelihood of dose reduction when treated with mercaptopurine as compared to patients with one or two no function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence mercaptopurine dosage.</td><td>Normal</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451237200>514</a></td><td>TPMT</td><td>TPMT*9</td><td>mercaptopurine</td><td>dose reduction</td><td>1A</td><td>*1</td><td>Dosage</td><td>The TPMT*1 allele is assigned as a normal allele by CPIC. Patients carrying the TPMT*1 allele in combination with another normal function allele may have decreased likelihood of dose reduction when treated with mercaptopurine as compared to patients with one or two no function alleles. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence mercaptopurine dosage.</td><td>Normal</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451237326>515</a></td><td>TPMT</td><td>TPMT*1</td><td>azathioprine</td><td>dose reduction</td><td>1A</td><td>*1</td><td>Dosage</td><td>Patients carrying the *1 allele in combination with another normal function allele may have decreased likelihood of dose reduction when treated with azathioprine as compared to patients with one or two no function alleles. Other genetic and clinical factors may also influence azathioprine dosage.</td><td>Normal</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451237326>516</a></td><td>TPMT</td><td>TPMT*2</td><td>azathioprine</td><td>dose reduction</td><td>1A</td><td>*1</td><td>Dosage</td><td>Patients carrying the *1 allele in combination with another normal function allele may have decreased likelihood of dose reduction when treated with azathioprine as compared to patients with one or two no function alleles. Other genetic and clinical factors may also influence azathioprine dosage.</td><td>Normal</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451237326>517</a></td><td>TPMT</td><td>TPMT*3A</td><td>azathioprine</td><td>dose reduction</td><td>1A</td><td>*1</td><td>Dosage</td><td>Patients carrying the *1 allele in combination with another normal function allele may have decreased likelihood of dose reduction when treated with azathioprine as compared to patients with one or two no function alleles. Other genetic and clinical factors may also influence azathioprine dosage.</td><td>Normal</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451237326>518</a></td><td>TPMT</td><td>TPMT*3B</td><td>azathioprine</td><td>dose reduction</td><td>1A</td><td>*1</td><td>Dosage</td><td>Patients carrying the *1 allele in combination with another normal function allele may have decreased likelihood of dose reduction when treated with azathioprine as compared to patients with one or two no function alleles. Other genetic and clinical factors may also influence azathioprine dosage.</td><td>Normal</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451237326>519</a></td><td>TPMT</td><td>TPMT*3C</td><td>azathioprine</td><td>dose reduction</td><td>1A</td><td>*1</td><td>Dosage</td><td>Patients carrying the *1 allele in combination with another normal function allele may have decreased likelihood of dose reduction when treated with azathioprine as compared to patients with one or two no function alleles. Other genetic and clinical factors may also influence azathioprine dosage.</td><td>Normal</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451353040>520</a></td><td>VKORC1</td><td>rs72547529</td><td>warfarin</td><td></td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype may require increased dose of warfarin as compared to patients with the CC genotype. This variant (VKORC1 Val66Met) is associated with warfarin resistance. Other genetic and clinical factors may also influence warfarin dose requirement.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448640327>521</a></td><td>TPMT</td><td>TPMT*1</td><td>fluorouracil</td><td>Neoplasms</td><td>3</td><td>*1/*1</td><td>Efficacy</td><td>Patients with the *1/*1 genotype and cancer may have an increased response to fluoropyrimidine-based chemotherapy as compared to those with the *1/*3B or *1/*3C genotype. Other genetic and clinical factors may also influence a patient's response to fluoropyrimidine-based chemotherapy.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448640327>522</a></td><td>TPMT</td><td>TPMT*3B</td><td>fluorouracil</td><td>Neoplasms</td><td>3</td><td>*1/*1</td><td>Efficacy</td><td>Patients with the *1/*1 genotype and cancer may have an increased response to fluoropyrimidine-based chemotherapy as compared to those with the *1/*3B or *1/*3C genotype. Other genetic and clinical factors may also influence a patient's response to fluoropyrimidine-based chemotherapy.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448640327>523</a></td><td>TPMT</td><td>TPMT*3C</td><td>fluorouracil</td><td>Neoplasms</td><td>3</td><td>*1/*1</td><td>Efficacy</td><td>Patients with the *1/*1 genotype and cancer may have an increased response to fluoropyrimidine-based chemotherapy as compared to those with the *1/*3B or *1/*3C genotype. Other genetic and clinical factors may also influence a patient's response to fluoropyrimidine-based chemotherapy.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1043859462>524</a></td><td>CYP2C9</td><td>CYP2C9*1</td><td>doxepin</td><td></td><td>3</td><td>*1/*1</td><td>Efficacy</td><td>Patients with the CYP2C9*1/*1 genotype may have an increased clearance of doxepin as compared to patients with the CYP2C9*3/*3 genotype. Other genetic and clinical factors may also influence a patient's response to doxepin.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1043859462>525</a></td><td>CYP2C9</td><td>CYP2C9*3</td><td>doxepin</td><td></td><td>3</td><td>*1/*1</td><td>Efficacy</td><td>Patients with the CYP2C9*1/*1 genotype may have an increased clearance of doxepin as compared to patients with the CYP2C9*3/*3 genotype. Other genetic and clinical factors may also influence a patient's response to doxepin.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449717941>526</a></td><td>ABCG2</td><td>rs2231142</td><td>Opioid anesthetics</td><td></td><td>3</td><td>GG</td><td>Efficacy</td><td>Patients with the GG genotype may have a longer recovery time from general anesthesia as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's recovery time from general anesthesia.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449717941>527</a></td><td>ABCG2</td><td>rs2231142</td><td>Other general anesthetics</td><td></td><td>3</td><td>GG</td><td>Efficacy</td><td>Patients with the GG genotype may have a longer recovery time from general anesthesia as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's recovery time from general anesthesia.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449717941>528</a></td><td>ABCG2</td><td>rs2231142</td><td>volatile anesthetics</td><td></td><td>3</td><td>GG</td><td>Efficacy</td><td>Patients with the GG genotype may have a longer recovery time from general anesthesia as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's recovery time from general anesthesia.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450375734>529</a></td><td>ABCG2</td><td>rs4148157</td><td>allopurinol</td><td></td><td>3</td><td>GG</td><td>Efficacy</td><td>Patients with the GG genotype may have an increased response to allopurinol as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's response to allopurinol.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655385272>530</a></td><td>ABCG2</td><td>rs17731538</td><td>methotrexate</td><td>Psoriasis</td><td>3</td><td>GG</td><td>Efficacy</td><td>Patients with the GG genotype and psoriasis who are treated with methotrexate may be more likely to have improvement in psoriasis area or severity as compared to patients with the AG genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444673379>531</a></td><td>ABCG2</td><td>rs12505410</td><td>imatinib</td><td>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</td><td>3</td><td>GG</td><td>Efficacy</td><td>Patients with the GG genotype and chronic myelogenous leukemia may have a greater chance of achieving major molecular response when treated with imatinib as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to imatinib.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447982582>532</a></td><td>ABCG2</td><td>rs2231142</td><td>allopurinol</td><td>Gout</td><td>3</td><td>GG</td><td>Efficacy</td><td>Patients with the GG genotype and gout may have increased response when treated with allopurinol as compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence allopurinol response.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450371828>533</a></td><td>CYP3A5</td><td>CYP3A5*1</td><td>maraviroc</td><td>HIV Infections</td><td>3</td><td>*3/*3</td><td>Efficacy</td><td>Patients with HIV and the CYP3A5 *3/*3 genotype (designated as poor metabolizers) may have increased plasma concentrations of maraviroc as compared to patients with the *1/*1 genotype. However, there is no significant association of this genotype with response to maraviroc. Additionally, analysis of other cohorts in the same study found contradictory data with regards to maraviroc concentrations. Other genetic and clinical factors may also affect plasma concentrations of maraviroc in patients.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450371828>534</a></td><td>CYP3A5</td><td>CYP3A5*3</td><td>maraviroc</td><td>HIV Infections</td><td>3</td><td>*3/*3</td><td>Efficacy</td><td>Patients with HIV and the CYP3A5 *3/*3 genotype (designated as poor metabolizers) may have increased plasma concentrations of maraviroc as compared to patients with the *1/*1 genotype. However, there is no significant association of this genotype with response to maraviroc. Additionally, analysis of other cohorts in the same study found contradictory data with regards to maraviroc concentrations. Other genetic and clinical factors may also affect plasma concentrations of maraviroc in patients.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450371828>535</a></td><td>CYP3A5</td><td>CYP3A5*6</td><td>maraviroc</td><td>HIV Infections</td><td>3</td><td>*3/*3</td><td>Efficacy</td><td>Patients with HIV and the CYP3A5 *3/*3 genotype (designated as poor metabolizers) may have increased plasma concentrations of maraviroc as compared to patients with the *1/*1 genotype. However, there is no significant association of this genotype with response to maraviroc. Additionally, analysis of other cohorts in the same study found contradictory data with regards to maraviroc concentrations. Other genetic and clinical factors may also affect plasma concentrations of maraviroc in patients.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450371828>536</a></td><td>CYP3A5</td><td>CYP3A5*7</td><td>maraviroc</td><td>HIV Infections</td><td>3</td><td>*3/*3</td><td>Efficacy</td><td>Patients with HIV and the CYP3A5 *3/*3 genotype (designated as poor metabolizers) may have increased plasma concentrations of maraviroc as compared to patients with the *1/*1 genotype. However, there is no significant association of this genotype with response to maraviroc. Additionally, analysis of other cohorts in the same study found contradictory data with regards to maraviroc concentrations. Other genetic and clinical factors may also affect plasma concentrations of maraviroc in patients.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183491278>537</a></td><td>CYP3A5</td><td>CYP3A5*1</td><td>atorvastatin</td><td>Myalgia unspecified</td><td>3</td><td>*3/*3</td><td>Toxicity</td><td>Patients with the *3/*3 genotype who are treated with atorvastatin 1) may have a decreased response to treatment as compared to patients with the *1/*3 and *1/*1 genotype 2) may have an increased risk of myalgia and a greater degree of muscle damage as compared to patients with the *1/*3 genotype. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183491278>538</a></td><td>CYP3A5</td><td>CYP3A5*3</td><td>atorvastatin</td><td>Myalgia unspecified</td><td>3</td><td>*3/*3</td><td>Toxicity</td><td>Patients with the *3/*3 genotype who are treated with atorvastatin 1) may have a decreased response to treatment as compared to patients with the *1/*3 and *1/*1 genotype 2) may have an increased risk of myalgia and a greater degree of muscle damage as compared to patients with the *1/*3 genotype. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449165034>539</a></td><td>ABCG2</td><td>rs2231142</td><td>methotrexate</td><td>Arthritis, Rheumatoid</td><td>3</td><td>GG</td><td>Toxicity</td><td>Patients with the GG genotype and rheumatoid arthritis who are taking methotrexate may have an increased risk for adverse events as compared to patients with the TT genotype. Other genetic and clinical factors may also influence methotrexate toxicity.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449269910>540</a></td><td>VKORC1</td><td>rs9923231</td><td>warfarin</td><td>Hemorrhage</td><td>2A</td><td>CT</td><td>Toxicity</td><td>Patients with the rs9923231 CT genotype may have an increased risk of bleeding when treated with warfarin as compared to patients with the CC genotypes. However, conflicting evidence has been reported. Other clinical and genetic factors may also influence risk of warfarin-induced bleeding.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184516188>541</a></td><td>G6PD</td><td>G6PD B (wildtype)</td><td>sulfadoxine</td><td>Hemolysis</td><td>3</td><td>B (wildtype)/B (wildtype)</td><td>Toxicity</td><td>Female patients homozygous for the B (wildtype) haplotype (not associated with G6PD deficiency) who are treated with sulfadoxine may have increased survival of red blood cells as compared to patients hemizygous for the Mediterranean variant (associated with G6PD deficiency). Please note: this study did not report genotyping. Other genetic and clinical factors may also influence red blood cell survival.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184516188>542</a></td><td>G6PD</td><td>G6PD Mediterranean</td><td>sulfadoxine</td><td>Hemolysis</td><td>3</td><td>B (wildtype)/B (wildtype)</td><td>Toxicity</td><td>Female patients homozygous for the B (wildtype) haplotype (not associated with G6PD deficiency) who are treated with sulfadoxine may have increased survival of red blood cells as compared to patients hemizygous for the Mediterranean variant (associated with G6PD deficiency). Please note: this study did not report genotyping. Other genetic and clinical factors may also influence red blood cell survival.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184516188>543</a></td><td>G6PD</td><td>Dallas</td><td>sulfadoxine</td><td>Hemolysis</td><td>3</td><td>B (wildtype)/B (wildtype)</td><td>Toxicity</td><td>Female patients homozygous for the B (wildtype) haplotype (not associated with G6PD deficiency) who are treated with sulfadoxine may have increased survival of red blood cells as compared to patients hemizygous for the Mediterranean variant (associated with G6PD deficiency). Please note: this study did not report genotyping. Other genetic and clinical factors may also influence red blood cell survival.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184516188>544</a></td><td>G6PD</td><td>Panama</td><td>sulfadoxine</td><td>Hemolysis</td><td>3</td><td>B (wildtype)/B (wildtype)</td><td>Toxicity</td><td>Female patients homozygous for the B (wildtype) haplotype (not associated with G6PD deficiency) who are treated with sulfadoxine may have increased survival of red blood cells as compared to patients hemizygous for the Mediterranean variant (associated with G6PD deficiency). Please note: this study did not report genotyping. Other genetic and clinical factors may also influence red blood cell survival.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184516188>545</a></td><td>G6PD</td><td>Sassari</td><td>sulfadoxine</td><td>Hemolysis</td><td>3</td><td>B (wildtype)/B (wildtype)</td><td>Toxicity</td><td>Female patients homozygous for the B (wildtype) haplotype (not associated with G6PD deficiency) who are treated with sulfadoxine may have increased survival of red blood cells as compared to patients hemizygous for the Mediterranean variant (associated with G6PD deficiency). Please note: this study did not report genotyping. Other genetic and clinical factors may also influence red blood cell survival.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184516188>546</a></td><td>G6PD</td><td>Cagliari</td><td>sulfadoxine</td><td>Hemolysis</td><td>3</td><td>B (wildtype)/B (wildtype)</td><td>Toxicity</td><td>Female patients homozygous for the B (wildtype) haplotype (not associated with G6PD deficiency) who are treated with sulfadoxine may have increased survival of red blood cells as compared to patients hemizygous for the Mediterranean variant (associated with G6PD deficiency). Please note: this study did not report genotyping. Other genetic and clinical factors may also influence red blood cell survival.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184516188>547</a></td><td>G6PD</td><td>Birmingham</td><td>sulfadoxine</td><td>Hemolysis</td><td>3</td><td>B (wildtype)/B (wildtype)</td><td>Toxicity</td><td>Female patients homozygous for the B (wildtype) haplotype (not associated with G6PD deficiency) who are treated with sulfadoxine may have increased survival of red blood cells as compared to patients hemizygous for the Mediterranean variant (associated with G6PD deficiency). Please note: this study did not report genotyping. Other genetic and clinical factors may also influence red blood cell survival.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184516153>548</a></td><td>G6PD</td><td>G6PD B (wildtype)</td><td>aspirin</td><td>Hemolysis</td><td>3</td><td>B (wildtype)/B (wildtype)</td><td>Toxicity</td><td>Female children with the B/B (wildtype) genotype (not associated with G6PD deficiency) and systemic arthritis who are treated with a high dose of aspirin may have an increased risk of hemolysis as compared to children homozygous for the G6PD Mediterranean variant (associated with G6PD deficiency). Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184516153>549</a></td><td>G6PD</td><td>G6PD Mediterranean</td><td>aspirin</td><td>Hemolysis</td><td>3</td><td>B (wildtype)/B (wildtype)</td><td>Toxicity</td><td>Female children with the B/B (wildtype) genotype (not associated with G6PD deficiency) and systemic arthritis who are treated with a high dose of aspirin may have an increased risk of hemolysis as compared to children homozygous for the G6PD Mediterranean variant (associated with G6PD deficiency). Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184516153>550</a></td><td>G6PD</td><td>Dallas</td><td>aspirin</td><td>Hemolysis</td><td>3</td><td>B (wildtype)/B (wildtype)</td><td>Toxicity</td><td>Female children with the B/B (wildtype) genotype (not associated with G6PD deficiency) and systemic arthritis who are treated with a high dose of aspirin may have an increased risk of hemolysis as compared to children homozygous for the G6PD Mediterranean variant (associated with G6PD deficiency). Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184516153>551</a></td><td>G6PD</td><td>Panama</td><td>aspirin</td><td>Hemolysis</td><td>3</td><td>B (wildtype)/B (wildtype)</td><td>Toxicity</td><td>Female children with the B/B (wildtype) genotype (not associated with G6PD deficiency) and systemic arthritis who are treated with a high dose of aspirin may have an increased risk of hemolysis as compared to children homozygous for the G6PD Mediterranean variant (associated with G6PD deficiency). Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184516153>552</a></td><td>G6PD</td><td>Sassari</td><td>aspirin</td><td>Hemolysis</td><td>3</td><td>B (wildtype)/B (wildtype)</td><td>Toxicity</td><td>Female children with the B/B (wildtype) genotype (not associated with G6PD deficiency) and systemic arthritis who are treated with a high dose of aspirin may have an increased risk of hemolysis as compared to children homozygous for the G6PD Mediterranean variant (associated with G6PD deficiency). Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184516153>553</a></td><td>G6PD</td><td>Cagliari</td><td>aspirin</td><td>Hemolysis</td><td>3</td><td>B (wildtype)/B (wildtype)</td><td>Toxicity</td><td>Female children with the B/B (wildtype) genotype (not associated with G6PD deficiency) and systemic arthritis who are treated with a high dose of aspirin may have an increased risk of hemolysis as compared to children homozygous for the G6PD Mediterranean variant (associated with G6PD deficiency). Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184516153>554</a></td><td>G6PD</td><td>Birmingham</td><td>aspirin</td><td>Hemolysis</td><td>3</td><td>B (wildtype)/B (wildtype)</td><td>Toxicity</td><td>Female children with the B/B (wildtype) genotype (not associated with G6PD deficiency) and systemic arthritis who are treated with a high dose of aspirin may have an increased risk of hemolysis as compared to children homozygous for the G6PD Mediterranean variant (associated with G6PD deficiency). Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449747954>555</a></td><td>CYP3A5</td><td>CYP3A5*1</td><td>tacrolimus</td><td>Kidney Transplantation</td><td>3</td><td>*3/*3</td><td>Toxicity</td><td>Recipients of kidney transplants who are administered tacrolimus and who receive kidneys from donors with the CYP3A5 *3/*3 genotype may have a higher likelihood of nephrotoxicity as compared to kidneys from donors with the CYP3A5 *1/*1 or *1/*3 genotypes. Other clinical and genetic factors may also influence risk of nephrotoxicity.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449747954>556</a></td><td>CYP3A5</td><td>CYP3A5*3</td><td>tacrolimus</td><td>Kidney Transplantation</td><td>3</td><td>*3/*3</td><td>Toxicity</td><td>Recipients of kidney transplants who are administered tacrolimus and who receive kidneys from donors with the CYP3A5 *3/*3 genotype may have a higher likelihood of nephrotoxicity as compared to kidneys from donors with the CYP3A5 *1/*1 or *1/*3 genotypes. Other clinical and genetic factors may also influence risk of nephrotoxicity.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447673005>557</a></td><td>VKORC1</td><td>rs9923231</td><td>warfarin</td><td>over-anticoagulation</td><td>1B</td><td>CT</td><td>Toxicity</td><td>Patients with the rs9923231 CT genotype may have increased risk of over-anticoagulation when treated with warfarin as compared with patients with genotype CC. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence the toxicity to warfarin.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449716378>558</a></td><td>CYP3A5</td><td>CYP3A5*1</td><td>fentanyl</td><td>Neoplasms;Pain</td><td>3</td><td>*3/*3</td><td>Toxicity</td><td>Patients with the *3/*3 genotype may be at an increased risk of experiencing adverse events as a result of taking fentanyl as compared to patients with the *1/*1 and *1/*3 genotypes. Other genetic and clinical factors may also affect a patient's risk of experiencing adverse events.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449716378>559</a></td><td>CYP3A5</td><td>CYP3A5*3</td><td>fentanyl</td><td>Neoplasms;Pain</td><td>3</td><td>*3/*3</td><td>Toxicity</td><td>Patients with the *3/*3 genotype may be at an increased risk of experiencing adverse events as a result of taking fentanyl as compared to patients with the *1/*1 and *1/*3 genotypes. Other genetic and clinical factors may also affect a patient's risk of experiencing adverse events.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451243628>560</a></td><td>VKORC1</td><td>rs9923231</td><td>acenocoumarol</td><td>Hemorrhage</td><td>3</td><td>CT</td><td>Toxicity</td><td>Patients with the CT genotype who are treated with acenocoumarol may have an increased risk of Hemorrhage as compared to the CC genotypes. Other clinical and genetic factors may also influence risk of hemorrhage in patients administered acetacoumarol.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451243676>561</a></td><td>VKORC1</td><td>rs9923231</td><td>phenprocoumon</td><td>Hemorrhage;over-anticoagulation;time above therapeutic range</td><td>2A</td><td>CT</td><td>Toxicity</td><td>Patients with the CT genotype may have an increased risk of adverse events (bleeding, over-anticoagulation or increased time above therapeutic range) when treated with phenprocoumon as compared to patients with the CC genotype. Other clinical and genetic factors may also influence risk of adverse events to phenprocoumon.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451139080>562</a></td><td>CYP2C9</td><td>CYP2C9*1</td><td>dipyrone</td><td></td><td>3</td><td>*1/*1</td><td>Metabolism/PK</td><td>Patients with the *1/*1 diplotype may have increased metabolism as compared to patients carrying the *3 allele. Other genetic and clinical factors may also influence the metabolism of dipyrone.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451139080>563</a></td><td>CYP2C9</td><td>CYP2C9*3</td><td>dipyrone</td><td></td><td>3</td><td>*1/*1</td><td>Metabolism/PK</td><td>Patients with the *1/*1 diplotype may have increased metabolism as compared to patients carrying the *3 allele. Other genetic and clinical factors may also influence the metabolism of dipyrone.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450112778>564</a></td><td>ABCG2</td><td>rs12505410</td><td>methotrexate</td><td>Osteosarcoma</td><td>3</td><td>GG</td><td>Metabolism/PK</td><td>Patients with osteosarcoma and the GG genotype may have increased clearance of methotrexate as compared to patients with the GT or TT genotypes. This variant was highly correlated with rs13120400 in the study analysis. Other genetic and clinical factors may also affect clearance of methotrexate in patients.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183689931>565</a></td><td>CYP3A4</td><td>CYP3A4*1</td><td>tacrolimus</td><td>heart transplantation;Kidney Transplantation;laparoscopic sleeve gastrectomy;liver transplantation;lung transplantation</td><td>1B</td><td>*1</td><td>Metabolism/PK</td><td>Patients carrying two copies of the CYP3A4*1 allele may have decreased metabolism of tacrolimus as compared to patients carrying two copies of the *1B, *1G or *18B alleles or one copy of the *1 allele in combination with one copy of the *1G or *18 alleles. Patients carrying two copies of the CYP3A4*1 allele may have increased metabolism of tacrolimus as compared to patients carrying two copies of the *22 allele or one copy of the *1 allele in combination with one copy of the *20 or *22 alleles. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP3A4 and tacrolimus and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence tacrolimus metabolism.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183689931>566</a></td><td>CYP3A4</td><td>CYP3A4*1G</td><td>tacrolimus</td><td>heart transplantation;Kidney Transplantation;laparoscopic sleeve gastrectomy;liver transplantation;lung transplantation</td><td>1B</td><td>*1</td><td>Metabolism/PK</td><td>Patients carrying two copies of the CYP3A4*1 allele may have decreased metabolism of tacrolimus as compared to patients carrying two copies of the *1B, *1G or *18B alleles or one copy of the *1 allele in combination with one copy of the *1G or *18 alleles. Patients carrying two copies of the CYP3A4*1 allele may have increased metabolism of tacrolimus as compared to patients carrying two copies of the *22 allele or one copy of the *1 allele in combination with one copy of the *20 or *22 alleles. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP3A4 and tacrolimus and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence tacrolimus metabolism.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183689931>567</a></td><td>CYP3A4</td><td>CYP3A4*18</td><td>tacrolimus</td><td>heart transplantation;Kidney Transplantation;laparoscopic sleeve gastrectomy;liver transplantation;lung transplantation</td><td>1B</td><td>*1</td><td>Metabolism/PK</td><td>Patients carrying two copies of the CYP3A4*1 allele may have decreased metabolism of tacrolimus as compared to patients carrying two copies of the *1B, *1G or *18B alleles or one copy of the *1 allele in combination with one copy of the *1G or *18 alleles. Patients carrying two copies of the CYP3A4*1 allele may have increased metabolism of tacrolimus as compared to patients carrying two copies of the *22 allele or one copy of the *1 allele in combination with one copy of the *20 or *22 alleles. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP3A4 and tacrolimus and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence tacrolimus metabolism.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183689931>568</a></td><td>CYP3A4</td><td>CYP3A4*20</td><td>tacrolimus</td><td>heart transplantation;Kidney Transplantation;laparoscopic sleeve gastrectomy;liver transplantation;lung transplantation</td><td>1B</td><td>*1</td><td>Metabolism/PK</td><td>Patients carrying two copies of the CYP3A4*1 allele may have decreased metabolism of tacrolimus as compared to patients carrying two copies of the *1B, *1G or *18B alleles or one copy of the *1 allele in combination with one copy of the *1G or *18 alleles. Patients carrying two copies of the CYP3A4*1 allele may have increased metabolism of tacrolimus as compared to patients carrying two copies of the *22 allele or one copy of the *1 allele in combination with one copy of the *20 or *22 alleles. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP3A4 and tacrolimus and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence tacrolimus metabolism.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183689931>569</a></td><td>CYP3A4</td><td>CYP3A4*22</td><td>tacrolimus</td><td>heart transplantation;Kidney Transplantation;laparoscopic sleeve gastrectomy;liver transplantation;lung transplantation</td><td>1B</td><td>*1</td><td>Metabolism/PK</td><td>Patients carrying two copies of the CYP3A4*1 allele may have decreased metabolism of tacrolimus as compared to patients carrying two copies of the *1B, *1G or *18B alleles or one copy of the *1 allele in combination with one copy of the *1G or *18 alleles. Patients carrying two copies of the CYP3A4*1 allele may have increased metabolism of tacrolimus as compared to patients carrying two copies of the *22 allele or one copy of the *1 allele in combination with one copy of the *20 or *22 alleles. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP3A4 and tacrolimus and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence tacrolimus metabolism.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1156738774>570</a></td><td>ABCG2</td><td>rs2231142</td><td>simvastatin</td><td></td><td>3</td><td>GG</td><td>Metabolism/PK</td><td>Patients with the rs2231142 GG genotype may have reduced exposure to simvastatin as compared to patients with the TT genotype. This annotation only covers the pharmacokinetic relationship between rs2231142 and simvastatin and does not include evidence about clinical outcomes. This drug-variant pair has been assigned a no recommendation by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence exposure to simvastatin.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1156076089>571</a></td><td>ABCG2</td><td>rs2231142</td><td>fluvastatin</td><td></td><td>3</td><td>GG</td><td>Metabolism/PK</td><td>Patients with the GG genotype may have reduced exposure to fluvastatin as compared to patients with the TT genotype. This drug-variant pair has been assigned a no recommendation by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence a patient's exposure to fluvastatin. This annotation only covers the pharmacokinetic relationship between rs2231142 and fluvastatin and does not include evidence about clinical outcomes.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448821500>572</a></td><td>ABCG2</td><td>rs2231142</td><td>tenofovir</td><td>HIV Infections</td><td>3</td><td>GG</td><td>Metabolism/PK</td><td>Patients with the GG genotype and HIV may have decreased area under the concentration-time curve (AUC) of tenofovir as compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence AUC of tenofovir.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448995134>573</a></td><td>ABCG2</td><td>rs2231142</td><td>dolutegravir</td><td>HIV Infections</td><td>3</td><td>GG</td><td>Metabolism/PK</td><td>Patients with the GG genotype may have decreased plasma concentrations of dolutegravir as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to dolutegravir.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449269612>574</a></td><td>ABCG2</td><td>rs2231142</td><td>apixaban</td><td>Atrial Fibrillation</td><td>3</td><td>GG</td><td>Metabolism/PK</td><td>Patients atrial fibrillation and the GG genotype may have increased clearance and decreased concentrations of apixaban as compared to patients with the TT genotype. Other clinical and genetic factors may also influence clearance and concentrations of apixaban in patients with atrial fibrillation.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449164352>575</a></td><td>CYP3A4</td><td>CYP3A4*1</td><td>sildenafil</td><td>Heart Failure</td><td>3</td><td>*1/*1</td><td>Metabolism/PK</td><td>Patients with the *1/*1 genotype and heart failure may have decreased concentrations of sildenafil as compared to patients with the *1/*22 genotype. Other genetic and clinical factors may also influence sildenafil concentrations.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449164352>576</a></td><td>CYP3A4</td><td>CYP3A4*22</td><td>sildenafil</td><td>Heart Failure</td><td>3</td><td>*1/*1</td><td>Metabolism/PK</td><td>Patients with the *1/*1 genotype and heart failure may have decreased concentrations of sildenafil as compared to patients with the *1/*22 genotype. Other genetic and clinical factors may also influence sildenafil concentrations.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449157113>577</a></td><td>TPMT</td><td>TPMT*1</td><td>thioguanine</td><td>Crohn Disease</td><td>3</td><td>*1/*1</td><td>Metabolism/PK</td><td>Patients with Crohn's disease and the TPMT *1/*1 diplotype may have decreased plasma concentrations of 6-thioguanine during thiopurine treatment as compared to patients with the *1/*3A or *1/*3C diplotypes. Other genetic and clinical factors may also affect plasma concentrations of 6-thioguanine during thiopurine treatment.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449157113>578</a></td><td>TPMT</td><td>TPMT*3A</td><td>thioguanine</td><td>Crohn Disease</td><td>3</td><td>*1/*1</td><td>Metabolism/PK</td><td>Patients with Crohn's disease and the TPMT *1/*1 diplotype may have decreased plasma concentrations of 6-thioguanine during thiopurine treatment as compared to patients with the *1/*3A or *1/*3C diplotypes. Other genetic and clinical factors may also affect plasma concentrations of 6-thioguanine during thiopurine treatment.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449157113>579</a></td><td>TPMT</td><td>TPMT*3C</td><td>thioguanine</td><td>Crohn Disease</td><td>3</td><td>*1/*1</td><td>Metabolism/PK</td><td>Patients with Crohn's disease and the TPMT *1/*1 diplotype may have decreased plasma concentrations of 6-thioguanine during thiopurine treatment as compared to patients with the *1/*3A or *1/*3C diplotypes. Other genetic and clinical factors may also affect plasma concentrations of 6-thioguanine during thiopurine treatment.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444700509>580</a></td><td>ABCG2</td><td>rs2231142</td><td>imatinib</td><td></td><td>3</td><td>GG</td><td>Metabolism/PK</td><td>Patients with the GG genotype and Neoplasms might have an increased metabolism of imatinib as compared to patients with the GT genotype. Patients with GG genotype may have a decreased sensitivity to dasatinib or imatinib or nilotinib as compared to patients with TT genotype. The association is based on in-vitro finding in K562 cells. Other genetic and clinical factors may also influence a patient's response to dasatinib, imatinib or nilotinib.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1446899372>581</a></td><td>ABCG2</td><td>rs2231142</td><td>sulfasalazine</td><td></td><td>3</td><td>GG</td><td>Metabolism/PK</td><td>Patients with the GG genotype may have improved clearance and metabolism of sulfasalazine as compared to patients with the GT and TT genotypes. Other clinical and genetic factors may also influence clearance and metabolism of sulfasalazine.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444665995>582</a></td><td>CYP2C9</td><td>CYP2C9*1</td><td>diclofenac</td><td></td><td>3</td><td>*1/*1</td><td>Metabolism/PK</td><td>Individuals with the *1/*1 genotype may have increased metabolism of diclofenac as compared to individuals with the *1/*3 or *1/*8 genotype. This drug-variant pair has been assigned a no recommendation by CPIC, as it was determined to be not clinically actionable. This annotation only covers the pharmacokinetic relationship between CYP2C9 and diclofenac and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of diclofenac.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444665995>583</a></td><td>CYP2C9</td><td>CYP2C9*3</td><td>diclofenac</td><td></td><td>3</td><td>*1/*1</td><td>Metabolism/PK</td><td>Individuals with the *1/*1 genotype may have increased metabolism of diclofenac as compared to individuals with the *1/*3 or *1/*8 genotype. This drug-variant pair has been assigned a no recommendation by CPIC, as it was determined to be not clinically actionable. This annotation only covers the pharmacokinetic relationship between CYP2C9 and diclofenac and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of diclofenac.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444665995>584</a></td><td>CYP2C9</td><td>CYP2C9*8</td><td>diclofenac</td><td></td><td>3</td><td>*1/*1</td><td>Metabolism/PK</td><td>Individuals with the *1/*1 genotype may have increased metabolism of diclofenac as compared to individuals with the *1/*3 or *1/*8 genotype. This drug-variant pair has been assigned a no recommendation by CPIC, as it was determined to be not clinically actionable. This annotation only covers the pharmacokinetic relationship between CYP2C9 and diclofenac and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of diclofenac.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1446899749>585</a></td><td>CYP3A4</td><td>CYP3A4*1</td><td>simvastatin</td><td>Hypercholesterolemia</td><td>3</td><td>*1/*1</td><td>Metabolism/PK</td><td>Patients with the CYP3A4 *1/*1 diplotype may have decreased plasma concentrations of simvastatin as compared to patients with the CYP3A4 *1/*22 or *22/*22 diplotypes, but there appears to be no association with response. Other clinical and genetic factors may also influence plasma concentrations of simvastatin.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1446899749>586</a></td><td>CYP3A4</td><td>CYP3A4*22</td><td>simvastatin</td><td>Hypercholesterolemia</td><td>3</td><td>*1/*1</td><td>Metabolism/PK</td><td>Patients with the CYP3A4 *1/*1 diplotype may have decreased plasma concentrations of simvastatin as compared to patients with the CYP3A4 *1/*22 or *22/*22 diplotypes, but there appears to be no association with response. Other clinical and genetic factors may also influence plasma concentrations of simvastatin.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448099454>587</a></td><td>ABCG2</td><td>rs72552713</td><td>sulfasalazine</td><td></td><td>3</td><td>GG</td><td>Metabolism/PK</td><td>Patients with the GG genotype may have increased clearance of sulfasalazine as compared to patients with the AG genotype. Other clinical and genetic factors may also influence clearance of sulfasalazine. Please note: the evidence is from a single individual who was compound heterozygote at rs72552713 (AG) and rs2231142 (AG).</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448123060>588</a></td><td>CYP2C9</td><td>CYP2C9*1</td><td>zafirlukast</td><td></td><td>3</td><td>*1/*1</td><td>Metabolism/PK</td><td>Patients with CYP2C9 *1/*1 genotype may have increased clearance and decreased exposure to zafirlukast as compared to CYP2C9 *1/*3 or CYP2C9 *1/*13. Other genetic and clinical factors may also influence the pharmacokinetics of zafirlukast.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448123060>589</a></td><td>CYP2C9</td><td>CYP2C9*3</td><td>zafirlukast</td><td></td><td>3</td><td>*1/*1</td><td>Metabolism/PK</td><td>Patients with CYP2C9 *1/*1 genotype may have increased clearance and decreased exposure to zafirlukast as compared to CYP2C9 *1/*3 or CYP2C9 *1/*13. Other genetic and clinical factors may also influence the pharmacokinetics of zafirlukast.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448123060>590</a></td><td>CYP2C9</td><td>CYP2C9*13</td><td>zafirlukast</td><td></td><td>3</td><td>*1/*1</td><td>Metabolism/PK</td><td>Patients with CYP2C9 *1/*1 genotype may have increased clearance and decreased exposure to zafirlukast as compared to CYP2C9 *1/*3 or CYP2C9 *1/*13. Other genetic and clinical factors may also influence the pharmacokinetics of zafirlukast.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448567803>591</a></td><td>CYP3A4</td><td>CYP3A4*1</td><td>sirolimus</td><td></td><td>4</td><td>*1/*1</td><td>Metabolism/PK</td><td>In human liver microsomes, the *1/*1 genotype is associated with increased metabolism of sirolimus as compared to the *1/*22 or *22/*22 genotype. No significant associations have been seen in analyses in patients. Other genetic and clinical factors may also influence metabolism of sirolimus.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448567803>592</a></td><td>CYP3A4</td><td>CYP3A4*22</td><td>sirolimus</td><td></td><td>4</td><td>*1/*1</td><td>Metabolism/PK</td><td>In human liver microsomes, the *1/*1 genotype is associated with increased metabolism of sirolimus as compared to the *1/*22 or *22/*22 genotype. No significant associations have been seen in analyses in patients. Other genetic and clinical factors may also influence metabolism of sirolimus.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451666660>593</a></td><td>ABCG2</td><td>rs2231142</td><td>rosuvastatin</td><td></td><td>1A</td><td>GG</td><td>Metabolism/PK</td><td>The T allele of this variant, when measured on the plus chromosomal strand, is assigned decreased function by CPIC. Patients with the rs2231142 GG genotype may have decreased plasma concentrations of rosuvastatin when treated with rosuvastatin as compared to patients with the TT or GT genotype. Other genetic and clinical factors may also influence the metabolism of rosuvastatin. This annotation only covers the pharmacokinetic relationship between rs2231142 and rosuvastatin and does not include evidence about clinical outcomes.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447981313>594</a></td><td>ABCG2</td><td>rs4148157</td><td>topotecan</td><td>Brain Neoplasms</td><td>3</td><td>GG</td><td>Metabolism/PK</td><td>Infants and children with the GG genotype and brain tumors may have decreased absorption and lower concentrations of topotecan compared to patients with the AA and AG genotypes. Other genetic and clinical factors may affect pharmacokinetics of topotecan.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448100487>595</a></td><td>ABCG2</td><td>rs2231142</td><td>lamotrigine</td><td>Epilepsy</td><td>3</td><td>GG</td><td>Metabolism/PK</td><td>Patients with the rs2231142 GG genotype and epilepsy may have decreased concentrations of lamotrigine compared to patients with the GT and TT genotypes. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs2231142 and lamotrigine and does not include evidence about clinical outcomes. Other factors may affect lamotrigine concentrations.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448519686>596</a></td><td>CYP3A4</td><td>CYP3A4*1</td><td>exemestane</td><td>Breast Neoplasms</td><td>3</td><td>*1/*1</td><td>Metabolism/PK</td><td>Patients with the CYP3A4*1/*1 genotype and breast cancer may have decreased concentrations of exemestane as compared to patients with the *1/*22 genotype. Other genetic and clinical factors may also influence exemestane concentrations.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448519686>597</a></td><td>CYP3A4</td><td>CYP3A4*22</td><td>exemestane</td><td>Breast Neoplasms</td><td>3</td><td>*1/*1</td><td>Metabolism/PK</td><td>Patients with the CYP3A4*1/*1 genotype and breast cancer may have decreased concentrations of exemestane as compared to patients with the *1/*22 genotype. Other genetic and clinical factors may also influence exemestane concentrations.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448426877>598</a></td><td>CYP3A5</td><td>CYP3A5*1</td><td>granisetron</td><td></td><td>3</td><td>*3/*3</td><td>Metabolism/PK</td><td>Patients with CYP3A5*3/*3 had a significantly lower granisetron clearance and increased exposure as compared to patients with *1/*1 or *1/*3 in pregnant women with nausea and vomiting. Other genetic and clinical factors may also influence the metabolism of granisetron.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448426877>599</a></td><td>CYP3A5</td><td>CYP3A5*3</td><td>granisetron</td><td></td><td>3</td><td>*3/*3</td><td>Metabolism/PK</td><td>Patients with CYP3A5*3/*3 had a significantly lower granisetron clearance and increased exposure as compared to patients with *1/*1 or *1/*3 in pregnant women with nausea and vomiting. Other genetic and clinical factors may also influence the metabolism of granisetron.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450931850>600</a></td><td>CYP3A4</td><td>CYP3A4*1</td><td>fentanyl</td><td></td><td>3</td><td>*1</td><td>Metabolism/PK</td><td>Patients with two copies of the CYP3A4*1 allele may have decreased exposure to fentanyl as compared to patients carrying at least one copy of the *3, *20 or *22 alleles or those carrying two copies of the *1G allele. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP3A4 and fentanyl and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect a patient's exposure to fentanyl.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450931850>601</a></td><td>CYP3A4</td><td>CYP3A4*1G</td><td>fentanyl</td><td></td><td>3</td><td>*1</td><td>Metabolism/PK</td><td>Patients with two copies of the CYP3A4*1 allele may have decreased exposure to fentanyl as compared to patients carrying at least one copy of the *3, *20 or *22 alleles or those carrying two copies of the *1G allele. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP3A4 and fentanyl and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect a patient's exposure to fentanyl.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450931850>602</a></td><td>CYP3A4</td><td>CYP3A4*3</td><td>fentanyl</td><td></td><td>3</td><td>*1</td><td>Metabolism/PK</td><td>Patients with two copies of the CYP3A4*1 allele may have decreased exposure to fentanyl as compared to patients carrying at least one copy of the *3, *20 or *22 alleles or those carrying two copies of the *1G allele. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP3A4 and fentanyl and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect a patient's exposure to fentanyl.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450931850>603</a></td><td>CYP3A4</td><td>CYP3A4*20</td><td>fentanyl</td><td></td><td>3</td><td>*1</td><td>Metabolism/PK</td><td>Patients with two copies of the CYP3A4*1 allele may have decreased exposure to fentanyl as compared to patients carrying at least one copy of the *3, *20 or *22 alleles or those carrying two copies of the *1G allele. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP3A4 and fentanyl and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect a patient's exposure to fentanyl.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450931850>604</a></td><td>CYP3A4</td><td>CYP3A4*22</td><td>fentanyl</td><td></td><td>3</td><td>*1</td><td>Metabolism/PK</td><td>Patients with two copies of the CYP3A4*1 allele may have decreased exposure to fentanyl as compared to patients carrying at least one copy of the *3, *20 or *22 alleles or those carrying two copies of the *1G allele. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between CYP3A4 and fentanyl and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect a patient's exposure to fentanyl.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451112120>605</a></td><td>CYP4F2</td><td>CYP4F2*1</td><td>Vitamin K1</td><td></td><td>3</td><td>*1/*1</td><td>Metabolism/PK</td><td>Patients with the *1/*1 genotype may have decreased exposure to vitamin K1 as compared to patients with the *1/*3 or *3/*3 genotypes. Other genetic and clinical factors may also affect a patient's exposure to vitamin K1.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451112120>606</a></td><td>CYP4F2</td><td>CYP4F2*3</td><td>Vitamin K1</td><td></td><td>3</td><td>*1/*1</td><td>Metabolism/PK</td><td>Patients with the *1/*1 genotype may have decreased exposure to vitamin K1 as compared to patients with the *1/*3 or *3/*3 genotypes. Other genetic and clinical factors may also affect a patient's exposure to vitamin K1.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451116107>607</a></td><td>CYP3A4</td><td>CYP3A4*1</td><td>lopinavir</td><td>HIV Infections</td><td>3</td><td>*1/*1</td><td>Metabolism/PK</td><td>Patients with HIV infections and the *1/*1 genotype may have increased clearance of lopinavir as compared to patients with the *22/*22 genotype. However, one study failed to find this association. Other genetic and clinical factors may also affect lopinavir pharmacokinetics.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451116107>608</a></td><td>CYP3A4</td><td>CYP3A4*22</td><td>lopinavir</td><td>HIV Infections</td><td>3</td><td>*1/*1</td><td>Metabolism/PK</td><td>Patients with HIV infections and the *1/*1 genotype may have increased clearance of lopinavir as compared to patients with the *22/*22 genotype. However, one study failed to find this association. Other genetic and clinical factors may also affect lopinavir pharmacokinetics.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451147700>609</a></td><td>CYP3A4</td><td>CYP3A4*1</td><td>imatinib</td><td></td><td>3</td><td>*1/*1</td><td>Metabolism/PK</td><td>Patients with the *1/*1 genotype may have decreased exposure to imatinib as compared to patients carrying at least one copy of the *3, *20 or *22 alleles. This annotation only covers the pharmacokinetic relationship between CYP3A4 genotypes and imatinib and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect a patient's exposure to imatinib.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451147700>610</a></td><td>CYP3A4</td><td>CYP3A4*3</td><td>imatinib</td><td></td><td>3</td><td>*1/*1</td><td>Metabolism/PK</td><td>Patients with the *1/*1 genotype may have decreased exposure to imatinib as compared to patients carrying at least one copy of the *3, *20 or *22 alleles. This annotation only covers the pharmacokinetic relationship between CYP3A4 genotypes and imatinib and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect a patient's exposure to imatinib.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451147700>611</a></td><td>CYP3A4</td><td>CYP3A4*20</td><td>imatinib</td><td></td><td>3</td><td>*1/*1</td><td>Metabolism/PK</td><td>Patients with the *1/*1 genotype may have decreased exposure to imatinib as compared to patients carrying at least one copy of the *3, *20 or *22 alleles. This annotation only covers the pharmacokinetic relationship between CYP3A4 genotypes and imatinib and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect a patient's exposure to imatinib.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451147700>612</a></td><td>CYP3A4</td><td>CYP3A4*22</td><td>imatinib</td><td></td><td>3</td><td>*1/*1</td><td>Metabolism/PK</td><td>Patients with the *1/*1 genotype may have decreased exposure to imatinib as compared to patients carrying at least one copy of the *3, *20 or *22 alleles. This annotation only covers the pharmacokinetic relationship between CYP3A4 genotypes and imatinib and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect a patient's exposure to imatinib.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451147720>613</a></td><td>CYP3A4</td><td>CYP3A4*1</td><td>quetiapine</td><td></td><td>3</td><td>*1/*1</td><td>Metabolism/PK</td><td>Patients with the *1/*1 genotype may have decreased exposure to quetiapine as compared to patients carrying at least one copy of the *3, *20 or *22 alleles. This annotation only covers the pharmacokinetic relationship between CYP3A4 genotypes and quetiapine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect a patient's exposure to quetiapine.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451147720>614</a></td><td>CYP3A4</td><td>CYP3A4*3</td><td>quetiapine</td><td></td><td>3</td><td>*1/*1</td><td>Metabolism/PK</td><td>Patients with the *1/*1 genotype may have decreased exposure to quetiapine as compared to patients carrying at least one copy of the *3, *20 or *22 alleles. This annotation only covers the pharmacokinetic relationship between CYP3A4 genotypes and quetiapine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect a patient's exposure to quetiapine.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451147720>615</a></td><td>CYP3A4</td><td>CYP3A4*20</td><td>quetiapine</td><td></td><td>3</td><td>*1/*1</td><td>Metabolism/PK</td><td>Patients with the *1/*1 genotype may have decreased exposure to quetiapine as compared to patients carrying at least one copy of the *3, *20 or *22 alleles. This annotation only covers the pharmacokinetic relationship between CYP3A4 genotypes and quetiapine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect a patient's exposure to quetiapine.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451147720>616</a></td><td>CYP3A4</td><td>CYP3A4*22</td><td>quetiapine</td><td></td><td>3</td><td>*1/*1</td><td>Metabolism/PK</td><td>Patients with the *1/*1 genotype may have decreased exposure to quetiapine as compared to patients carrying at least one copy of the *3, *20 or *22 alleles. This annotation only covers the pharmacokinetic relationship between CYP3A4 genotypes and quetiapine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect a patient's exposure to quetiapine.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451567040>617</a></td><td>CYP3A4</td><td>CYP3A4*1</td><td>oxycodone</td><td></td><td>3</td><td>*1</td><td>Metabolism/PK</td><td>Patients with two copies of the CYP3A4*1 allele may have increased clearance of oxycodone as compared to patients carrying the *2, *3, *4, *5, *6, *7, *8, *9, *10, *11, *12, *13, *14, *15, *16, *17, *18, *19, *20, *21, *22, *23, *24, *26, *28, *29, *30, *31, *32, *33 or *34 alleles. This annotation only covers the pharmacokinetic relationship between CYP3A4 and oxycodone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence oxycodone clearance.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451567040>618</a></td><td>CYP3A4</td><td>CYP3A4*2</td><td>oxycodone</td><td></td><td>3</td><td>*1</td><td>Metabolism/PK</td><td>Patients with two copies of the CYP3A4*1 allele may have increased clearance of oxycodone as compared to patients carrying the *2, *3, *4, *5, *6, *7, *8, *9, *10, *11, *12, *13, *14, *15, *16, *17, *18, *19, *20, *21, *22, *23, *24, *26, *28, *29, *30, *31, *32, *33 or *34 alleles. This annotation only covers the pharmacokinetic relationship between CYP3A4 and oxycodone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence oxycodone clearance.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451567040>619</a></td><td>CYP3A4</td><td>CYP3A4*3</td><td>oxycodone</td><td></td><td>3</td><td>*1</td><td>Metabolism/PK</td><td>Patients with two copies of the CYP3A4*1 allele may have increased clearance of oxycodone as compared to patients carrying the *2, *3, *4, *5, *6, *7, *8, *9, *10, *11, *12, *13, *14, *15, *16, *17, *18, *19, *20, *21, *22, *23, *24, *26, *28, *29, *30, *31, *32, *33 or *34 alleles. This annotation only covers the pharmacokinetic relationship between CYP3A4 and oxycodone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence oxycodone clearance.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451567040>620</a></td><td>CYP3A4</td><td>CYP3A4*4</td><td>oxycodone</td><td></td><td>3</td><td>*1</td><td>Metabolism/PK</td><td>Patients with two copies of the CYP3A4*1 allele may have increased clearance of oxycodone as compared to patients carrying the *2, *3, *4, *5, *6, *7, *8, *9, *10, *11, *12, *13, *14, *15, *16, *17, *18, *19, *20, *21, *22, *23, *24, *26, *28, *29, *30, *31, *32, *33 or *34 alleles. This annotation only covers the pharmacokinetic relationship between CYP3A4 and oxycodone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence oxycodone clearance.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451567040>621</a></td><td>CYP3A4</td><td>CYP3A4*5</td><td>oxycodone</td><td></td><td>3</td><td>*1</td><td>Metabolism/PK</td><td>Patients with two copies of the CYP3A4*1 allele may have increased clearance of oxycodone as compared to patients carrying the *2, *3, *4, *5, *6, *7, *8, *9, *10, *11, *12, *13, *14, *15, *16, *17, *18, *19, *20, *21, *22, *23, *24, *26, *28, *29, *30, *31, *32, *33 or *34 alleles. This annotation only covers the pharmacokinetic relationship between CYP3A4 and oxycodone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence oxycodone clearance.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451567040>622</a></td><td>CYP3A4</td><td>CYP3A4*6</td><td>oxycodone</td><td></td><td>3</td><td>*1</td><td>Metabolism/PK</td><td>Patients with two copies of the CYP3A4*1 allele may have increased clearance of oxycodone as compared to patients carrying the *2, *3, *4, *5, *6, *7, *8, *9, *10, *11, *12, *13, *14, *15, *16, *17, *18, *19, *20, *21, *22, *23, *24, *26, *28, *29, *30, *31, *32, *33 or *34 alleles. This annotation only covers the pharmacokinetic relationship between CYP3A4 and oxycodone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence oxycodone clearance.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451567040>623</a></td><td>CYP3A4</td><td>CYP3A4*7</td><td>oxycodone</td><td></td><td>3</td><td>*1</td><td>Metabolism/PK</td><td>Patients with two copies of the CYP3A4*1 allele may have increased clearance of oxycodone as compared to patients carrying the *2, *3, *4, *5, *6, *7, *8, *9, *10, *11, *12, *13, *14, *15, *16, *17, *18, *19, *20, *21, *22, *23, *24, *26, *28, *29, *30, *31, *32, *33 or *34 alleles. This annotation only covers the pharmacokinetic relationship between CYP3A4 and oxycodone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence oxycodone clearance.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451567040>624</a></td><td>CYP3A4</td><td>CYP3A4*8</td><td>oxycodone</td><td></td><td>3</td><td>*1</td><td>Metabolism/PK</td><td>Patients with two copies of the CYP3A4*1 allele may have increased clearance of oxycodone as compared to patients carrying the *2, *3, *4, *5, *6, *7, *8, *9, *10, *11, *12, *13, *14, *15, *16, *17, *18, *19, *20, *21, *22, *23, *24, *26, *28, *29, *30, *31, *32, *33 or *34 alleles. This annotation only covers the pharmacokinetic relationship between CYP3A4 and oxycodone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence oxycodone clearance.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451567040>625</a></td><td>CYP3A4</td><td>CYP3A4*9</td><td>oxycodone</td><td></td><td>3</td><td>*1</td><td>Metabolism/PK</td><td>Patients with two copies of the CYP3A4*1 allele may have increased clearance of oxycodone as compared to patients carrying the *2, *3, *4, *5, *6, *7, *8, *9, *10, *11, *12, *13, *14, *15, *16, *17, *18, *19, *20, *21, *22, *23, *24, *26, *28, *29, *30, *31, *32, *33 or *34 alleles. This annotation only covers the pharmacokinetic relationship between CYP3A4 and oxycodone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence oxycodone clearance.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451567040>626</a></td><td>CYP3A4</td><td>CYP3A4*10</td><td>oxycodone</td><td></td><td>3</td><td>*1</td><td>Metabolism/PK</td><td>Patients with two copies of the CYP3A4*1 allele may have increased clearance of oxycodone as compared to patients carrying the *2, *3, *4, *5, *6, *7, *8, *9, *10, *11, *12, *13, *14, *15, *16, *17, *18, *19, *20, *21, *22, *23, *24, *26, *28, *29, *30, *31, *32, *33 or *34 alleles. This annotation only covers the pharmacokinetic relationship between CYP3A4 and oxycodone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence oxycodone clearance.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451567040>627</a></td><td>CYP3A4</td><td>CYP3A4*11</td><td>oxycodone</td><td></td><td>3</td><td>*1</td><td>Metabolism/PK</td><td>Patients with two copies of the CYP3A4*1 allele may have increased clearance of oxycodone as compared to patients carrying the *2, *3, *4, *5, *6, *7, *8, *9, *10, *11, *12, *13, *14, *15, *16, *17, *18, *19, *20, *21, *22, *23, *24, *26, *28, *29, *30, *31, *32, *33 or *34 alleles. This annotation only covers the pharmacokinetic relationship between CYP3A4 and oxycodone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence oxycodone clearance.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451567040>628</a></td><td>CYP3A4</td><td>CYP3A4*12</td><td>oxycodone</td><td></td><td>3</td><td>*1</td><td>Metabolism/PK</td><td>Patients with two copies of the CYP3A4*1 allele may have increased clearance of oxycodone as compared to patients carrying the *2, *3, *4, *5, *6, *7, *8, *9, *10, *11, *12, *13, *14, *15, *16, *17, *18, *19, *20, *21, *22, *23, *24, *26, *28, *29, *30, *31, *32, *33 or *34 alleles. This annotation only covers the pharmacokinetic relationship between CYP3A4 and oxycodone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence oxycodone clearance.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451567040>629</a></td><td>CYP3A4</td><td>CYP3A4*13</td><td>oxycodone</td><td></td><td>3</td><td>*1</td><td>Metabolism/PK</td><td>Patients with two copies of the CYP3A4*1 allele may have increased clearance of oxycodone as compared to patients carrying the *2, *3, *4, *5, *6, *7, *8, *9, *10, *11, *12, *13, *14, *15, *16, *17, *18, *19, *20, *21, *22, *23, *24, *26, *28, *29, *30, *31, *32, *33 or *34 alleles. This annotation only covers the pharmacokinetic relationship between CYP3A4 and oxycodone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence oxycodone clearance.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451567040>630</a></td><td>CYP3A4</td><td>CYP3A4*14</td><td>oxycodone</td><td></td><td>3</td><td>*1</td><td>Metabolism/PK</td><td>Patients with two copies of the CYP3A4*1 allele may have increased clearance of oxycodone as compared to patients carrying the *2, *3, *4, *5, *6, *7, *8, *9, *10, *11, *12, *13, *14, *15, *16, *17, *18, *19, *20, *21, *22, *23, *24, *26, *28, *29, *30, *31, *32, *33 or *34 alleles. This annotation only covers the pharmacokinetic relationship between CYP3A4 and oxycodone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence oxycodone clearance.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451567040>631</a></td><td>CYP3A4</td><td>CYP3A4*15</td><td>oxycodone</td><td></td><td>3</td><td>*1</td><td>Metabolism/PK</td><td>Patients with two copies of the CYP3A4*1 allele may have increased clearance of oxycodone as compared to patients carrying the *2, *3, *4, *5, *6, *7, *8, *9, *10, *11, *12, *13, *14, *15, *16, *17, *18, *19, *20, *21, *22, *23, *24, *26, *28, *29, *30, *31, *32, *33 or *34 alleles. This annotation only covers the pharmacokinetic relationship between CYP3A4 and oxycodone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence oxycodone clearance.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451567040>632</a></td><td>CYP3A4</td><td>CYP3A4*16</td><td>oxycodone</td><td></td><td>3</td><td>*1</td><td>Metabolism/PK</td><td>Patients with two copies of the CYP3A4*1 allele may have increased clearance of oxycodone as compared to patients carrying the *2, *3, *4, *5, *6, *7, *8, *9, *10, *11, *12, *13, *14, *15, *16, *17, *18, *19, *20, *21, *22, *23, *24, *26, *28, *29, *30, *31, *32, *33 or *34 alleles. This annotation only covers the pharmacokinetic relationship between CYP3A4 and oxycodone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence oxycodone clearance.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451567040>633</a></td><td>CYP3A4</td><td>CYP3A4*17</td><td>oxycodone</td><td></td><td>3</td><td>*1</td><td>Metabolism/PK</td><td>Patients with two copies of the CYP3A4*1 allele may have increased clearance of oxycodone as compared to patients carrying the *2, *3, *4, *5, *6, *7, *8, *9, *10, *11, *12, *13, *14, *15, *16, *17, *18, *19, *20, *21, *22, *23, *24, *26, *28, *29, *30, *31, *32, *33 or *34 alleles. This annotation only covers the pharmacokinetic relationship between CYP3A4 and oxycodone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence oxycodone clearance.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451567040>634</a></td><td>CYP3A4</td><td>CYP3A4*18</td><td>oxycodone</td><td></td><td>3</td><td>*1</td><td>Metabolism/PK</td><td>Patients with two copies of the CYP3A4*1 allele may have increased clearance of oxycodone as compared to patients carrying the *2, *3, *4, *5, *6, *7, *8, *9, *10, *11, *12, *13, *14, *15, *16, *17, *18, *19, *20, *21, *22, *23, *24, *26, *28, *29, *30, *31, *32, *33 or *34 alleles. This annotation only covers the pharmacokinetic relationship between CYP3A4 and oxycodone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence oxycodone clearance.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451567040>635</a></td><td>CYP3A4</td><td>CYP3A4*19</td><td>oxycodone</td><td></td><td>3</td><td>*1</td><td>Metabolism/PK</td><td>Patients with two copies of the CYP3A4*1 allele may have increased clearance of oxycodone as compared to patients carrying the *2, *3, *4, *5, *6, *7, *8, *9, *10, *11, *12, *13, *14, *15, *16, *17, *18, *19, *20, *21, *22, *23, *24, *26, *28, *29, *30, *31, *32, *33 or *34 alleles. This annotation only covers the pharmacokinetic relationship between CYP3A4 and oxycodone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence oxycodone clearance.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451567040>636</a></td><td>CYP3A4</td><td>CYP3A4*20</td><td>oxycodone</td><td></td><td>3</td><td>*1</td><td>Metabolism/PK</td><td>Patients with two copies of the CYP3A4*1 allele may have increased clearance of oxycodone as compared to patients carrying the *2, *3, *4, *5, *6, *7, *8, *9, *10, *11, *12, *13, *14, *15, *16, *17, *18, *19, *20, *21, *22, *23, *24, *26, *28, *29, *30, *31, *32, *33 or *34 alleles. This annotation only covers the pharmacokinetic relationship between CYP3A4 and oxycodone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence oxycodone clearance.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451567040>637</a></td><td>CYP3A4</td><td>CYP3A4*21</td><td>oxycodone</td><td></td><td>3</td><td>*1</td><td>Metabolism/PK</td><td>Patients with two copies of the CYP3A4*1 allele may have increased clearance of oxycodone as compared to patients carrying the *2, *3, *4, *5, *6, *7, *8, *9, *10, *11, *12, *13, *14, *15, *16, *17, *18, *19, *20, *21, *22, *23, *24, *26, *28, *29, *30, *31, *32, *33 or *34 alleles. This annotation only covers the pharmacokinetic relationship between CYP3A4 and oxycodone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence oxycodone clearance.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451567040>638</a></td><td>CYP3A4</td><td>CYP3A4*22</td><td>oxycodone</td><td></td><td>3</td><td>*1</td><td>Metabolism/PK</td><td>Patients with two copies of the CYP3A4*1 allele may have increased clearance of oxycodone as compared to patients carrying the *2, *3, *4, *5, *6, *7, *8, *9, *10, *11, *12, *13, *14, *15, *16, *17, *18, *19, *20, *21, *22, *23, *24, *26, *28, *29, *30, *31, *32, *33 or *34 alleles. This annotation only covers the pharmacokinetic relationship between CYP3A4 and oxycodone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence oxycodone clearance.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451567040>639</a></td><td>CYP3A4</td><td>CYP3A4*23</td><td>oxycodone</td><td></td><td>3</td><td>*1</td><td>Metabolism/PK</td><td>Patients with two copies of the CYP3A4*1 allele may have increased clearance of oxycodone as compared to patients carrying the *2, *3, *4, *5, *6, *7, *8, *9, *10, *11, *12, *13, *14, *15, *16, *17, *18, *19, *20, *21, *22, *23, *24, *26, *28, *29, *30, *31, *32, *33 or *34 alleles. This annotation only covers the pharmacokinetic relationship between CYP3A4 and oxycodone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence oxycodone clearance.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451567040>640</a></td><td>CYP3A4</td><td>CYP3A4*24</td><td>oxycodone</td><td></td><td>3</td><td>*1</td><td>Metabolism/PK</td><td>Patients with two copies of the CYP3A4*1 allele may have increased clearance of oxycodone as compared to patients carrying the *2, *3, *4, *5, *6, *7, *8, *9, *10, *11, *12, *13, *14, *15, *16, *17, *18, *19, *20, *21, *22, *23, *24, *26, *28, *29, *30, *31, *32, *33 or *34 alleles. This annotation only covers the pharmacokinetic relationship between CYP3A4 and oxycodone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence oxycodone clearance.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451567040>641</a></td><td>CYP3A4</td><td>CYP3A4*26</td><td>oxycodone</td><td></td><td>3</td><td>*1</td><td>Metabolism/PK</td><td>Patients with two copies of the CYP3A4*1 allele may have increased clearance of oxycodone as compared to patients carrying the *2, *3, *4, *5, *6, *7, *8, *9, *10, *11, *12, *13, *14, *15, *16, *17, *18, *19, *20, *21, *22, *23, *24, *26, *28, *29, *30, *31, *32, *33 or *34 alleles. This annotation only covers the pharmacokinetic relationship between CYP3A4 and oxycodone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence oxycodone clearance.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451567040>642</a></td><td>CYP3A4</td><td>CYP3A4*28</td><td>oxycodone</td><td></td><td>3</td><td>*1</td><td>Metabolism/PK</td><td>Patients with two copies of the CYP3A4*1 allele may have increased clearance of oxycodone as compared to patients carrying the *2, *3, *4, *5, *6, *7, *8, *9, *10, *11, *12, *13, *14, *15, *16, *17, *18, *19, *20, *21, *22, *23, *24, *26, *28, *29, *30, *31, *32, *33 or *34 alleles. This annotation only covers the pharmacokinetic relationship between CYP3A4 and oxycodone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence oxycodone clearance.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451567040>643</a></td><td>CYP3A4</td><td>CYP3A4*29</td><td>oxycodone</td><td></td><td>3</td><td>*1</td><td>Metabolism/PK</td><td>Patients with two copies of the CYP3A4*1 allele may have increased clearance of oxycodone as compared to patients carrying the *2, *3, *4, *5, *6, *7, *8, *9, *10, *11, *12, *13, *14, *15, *16, *17, *18, *19, *20, *21, *22, *23, *24, *26, *28, *29, *30, *31, *32, *33 or *34 alleles. This annotation only covers the pharmacokinetic relationship between CYP3A4 and oxycodone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence oxycodone clearance.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451567040>644</a></td><td>CYP3A4</td><td>CYP3A4*30</td><td>oxycodone</td><td></td><td>3</td><td>*1</td><td>Metabolism/PK</td><td>Patients with two copies of the CYP3A4*1 allele may have increased clearance of oxycodone as compared to patients carrying the *2, *3, *4, *5, *6, *7, *8, *9, *10, *11, *12, *13, *14, *15, *16, *17, *18, *19, *20, *21, *22, *23, *24, *26, *28, *29, *30, *31, *32, *33 or *34 alleles. This annotation only covers the pharmacokinetic relationship between CYP3A4 and oxycodone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence oxycodone clearance.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451567040>645</a></td><td>CYP3A4</td><td>CYP3A4*31</td><td>oxycodone</td><td></td><td>3</td><td>*1</td><td>Metabolism/PK</td><td>Patients with two copies of the CYP3A4*1 allele may have increased clearance of oxycodone as compared to patients carrying the *2, *3, *4, *5, *6, *7, *8, *9, *10, *11, *12, *13, *14, *15, *16, *17, *18, *19, *20, *21, *22, *23, *24, *26, *28, *29, *30, *31, *32, *33 or *34 alleles. This annotation only covers the pharmacokinetic relationship between CYP3A4 and oxycodone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence oxycodone clearance.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451567040>646</a></td><td>CYP3A4</td><td>CYP3A4*32</td><td>oxycodone</td><td></td><td>3</td><td>*1</td><td>Metabolism/PK</td><td>Patients with two copies of the CYP3A4*1 allele may have increased clearance of oxycodone as compared to patients carrying the *2, *3, *4, *5, *6, *7, *8, *9, *10, *11, *12, *13, *14, *15, *16, *17, *18, *19, *20, *21, *22, *23, *24, *26, *28, *29, *30, *31, *32, *33 or *34 alleles. This annotation only covers the pharmacokinetic relationship between CYP3A4 and oxycodone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence oxycodone clearance.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451567040>647</a></td><td>CYP3A4</td><td>CYP3A4*33</td><td>oxycodone</td><td></td><td>3</td><td>*1</td><td>Metabolism/PK</td><td>Patients with two copies of the CYP3A4*1 allele may have increased clearance of oxycodone as compared to patients carrying the *2, *3, *4, *5, *6, *7, *8, *9, *10, *11, *12, *13, *14, *15, *16, *17, *18, *19, *20, *21, *22, *23, *24, *26, *28, *29, *30, *31, *32, *33 or *34 alleles. This annotation only covers the pharmacokinetic relationship between CYP3A4 and oxycodone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence oxycodone clearance.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451567040>648</a></td><td>CYP3A4</td><td>CYP3A4*34</td><td>oxycodone</td><td></td><td>3</td><td>*1</td><td>Metabolism/PK</td><td>Patients with two copies of the CYP3A4*1 allele may have increased clearance of oxycodone as compared to patients carrying the *2, *3, *4, *5, *6, *7, *8, *9, *10, *11, *12, *13, *14, *15, *16, *17, *18, *19, *20, *21, *22, *23, *24, *26, *28, *29, *30, *31, *32, *33 or *34 alleles. This annotation only covers the pharmacokinetic relationship between CYP3A4 and oxycodone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence oxycodone clearance.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451353040>649</a></td><td>VKORC1</td><td>rs72547529</td><td>warfarin</td><td></td><td>3</td><td>CT</td><td>Dosage</td><td>Patients with the CT genotype may require increased dose of warfarin as compared to patients with the CC genotype. This variant (VKORC1 Val66Met) is associated with warfarin resistance. Other genetic and clinical factors may also influence warfarin dose requirement.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/981239556>650</a></td><td>VKORC1</td><td>rs104894541</td><td>warfarin</td><td></td><td>3</td><td>CT</td><td>Dosage</td><td>Patients with the CT genotype may be resistant to warfarin, requiring an increased dose of warfarin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence warfarin dose.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449715423>651</a></td><td>CYP3A4</td><td>CYP3A4*1</td><td>sufentanil</td><td>Pain</td><td>3</td><td>*1</td><td>Dosage</td><td>Patients with two copies of the *1 allele or one copy of the *1 allele in combination with one copy of the *1G allele may have increased sufentanil dose requirements as compared to patients with two copies of the *1G allele. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect a patient's sufentanil dose requirements.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449715423>652</a></td><td>CYP3A4</td><td>CYP3A4*1G</td><td>sufentanil</td><td>Pain</td><td>3</td><td>*1</td><td>Dosage</td><td>Patients with two copies of the *1 allele or one copy of the *1 allele in combination with one copy of the *1G allele may have increased sufentanil dose requirements as compared to patients with two copies of the *1G allele. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect a patient's sufentanil dose requirements.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1445296897>653</a></td><td>CYP2C9</td><td>CYP2C9*1</td><td>warfarin</td><td></td><td>3</td><td>*1/*1</td><td>Dosage</td><td>Patients with CYP2C9*1/*1 may require significantly higher dose of warfarin as compared to patients with CYP2C9 *59/*59 or CYP2C9 *1/*59. Other genetic and clinical factors may also influence the dose of warfarin.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1445296897>654</a></td><td>CYP2C9</td><td>CYP2C9*59</td><td>warfarin</td><td></td><td>3</td><td>*1/*1</td><td>Dosage</td><td>Patients with CYP2C9*1/*1 may require significantly higher dose of warfarin as compared to patients with CYP2C9 *59/*59 or CYP2C9 *1/*59. Other genetic and clinical factors may also influence the dose of warfarin.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1185002363>655</a></td><td>VKORC1</td><td>rs55894764</td><td>acenocoumarol</td><td></td><td>3</td><td>CT</td><td>Dosage</td><td>Patients with the CT genotype may require increased dose of acenocoumarol as compared to patients with the CC genotype. Other clinical or genetic factors may also influence acenocoumarol dose.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1185002369>656</a></td><td>VKORC1</td><td>rs17878544</td><td>acenocoumarol</td><td></td><td>3</td><td>CT</td><td>Dosage</td><td>Patients with the CT genotype may require increased dose of acenocoumarol as compared to patients with the TT genotype. Other clinical or genetic factors may also influence acenocoumarol dose.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448428239>657</a></td><td>CYP2C9</td><td>CYP2C9*1</td><td>valproic acid</td><td>Bipolar Disorder;Psychotic Disorders</td><td>3</td><td>*1/*1</td><td>Dosage</td><td>Patients with the *1/*1 genotype and bipolar disorder and other psychotic disorders may have increased dose of valproic acid compared to patients with the *1/*2 and *1/*3 genotypes. However, dose-adjusted and absolute serum concentrations were not found to differ by genotype. Other clinical and genetic factors may affect required dose of valproic acid.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448428239>658</a></td><td>CYP2C9</td><td>CYP2C9*2</td><td>valproic acid</td><td>Bipolar Disorder;Psychotic Disorders</td><td>3</td><td>*1/*1</td><td>Dosage</td><td>Patients with the *1/*1 genotype and bipolar disorder and other psychotic disorders may have increased dose of valproic acid compared to patients with the *1/*2 and *1/*3 genotypes. However, dose-adjusted and absolute serum concentrations were not found to differ by genotype. Other clinical and genetic factors may affect required dose of valproic acid.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448428239>659</a></td><td>CYP2C9</td><td>CYP2C9*3</td><td>valproic acid</td><td>Bipolar Disorder;Psychotic Disorders</td><td>3</td><td>*1/*1</td><td>Dosage</td><td>Patients with the *1/*1 genotype and bipolar disorder and other psychotic disorders may have increased dose of valproic acid compared to patients with the *1/*2 and *1/*3 genotypes. However, dose-adjusted and absolute serum concentrations were not found to differ by genotype. Other clinical and genetic factors may affect required dose of valproic acid.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655384733>660</a></td><td>VKORC1</td><td>rs7294</td><td>warfarin</td><td></td><td>1B</td><td>CT</td><td>Dosage</td><td>Patients with the rs7294 CT genotype may require a higher dose of warfarin as compared to patients with the CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect warfarin dose requirements.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449003986>661</a></td><td>CYP3A5</td><td>CYP3A5*1</td><td>oxycodone</td><td></td><td>3</td><td>*3/*3</td><td>Dosage</td><td>Patients with the *3/*3 genotype may require an increased dose of oxycodone as compared to patients with the *1/*1 or *1/*3 genotypes. However, another study failed to find an association. Other genetic and clinical factors may influence a patient's oxycodone dose requirements.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449003986>662</a></td><td>CYP3A5</td><td>CYP3A5*3</td><td>oxycodone</td><td></td><td>3</td><td>*3/*3</td><td>Dosage</td><td>Patients with the *3/*3 genotype may require an increased dose of oxycodone as compared to patients with the *1/*1 or *1/*3 genotypes. However, another study failed to find an association. Other genetic and clinical factors may influence a patient's oxycodone dose requirements.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451251080>663</a></td><td>CYP3A4</td><td>CYP3A4*1</td><td>tacrolimus</td><td>Kidney Transplantation;Organ Transplantation</td><td>2A</td><td>*1</td><td>Dosage</td><td>Patients who are recipients of an organ transplant and carry two copies of the CYP3A4*1 allele may require an increased dose of tacrolimus as compared to patients with two copies of the *3 or *22 alleles or one copy of the 1* allele in combination with one copy of the *3 or *22 alleles. Other genetic and clinical factors may also influence tacrolimus dose.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451251080>664</a></td><td>CYP3A4</td><td>CYP3A4*3</td><td>tacrolimus</td><td>Kidney Transplantation;Organ Transplantation</td><td>2A</td><td>*1</td><td>Dosage</td><td>Patients who are recipients of an organ transplant and carry two copies of the CYP3A4*1 allele may require an increased dose of tacrolimus as compared to patients with two copies of the *3 or *22 alleles or one copy of the 1* allele in combination with one copy of the *3 or *22 alleles. Other genetic and clinical factors may also influence tacrolimus dose.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451251080>665</a></td><td>CYP3A4</td><td>CYP3A4*20</td><td>tacrolimus</td><td>Kidney Transplantation;Organ Transplantation</td><td>2A</td><td>*1</td><td>Dosage</td><td>Patients who are recipients of an organ transplant and carry two copies of the CYP3A4*1 allele may require an increased dose of tacrolimus as compared to patients with two copies of the *3 or *22 alleles or one copy of the 1* allele in combination with one copy of the *3 or *22 alleles. Other genetic and clinical factors may also influence tacrolimus dose.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451251080>666</a></td><td>CYP3A4</td><td>CYP3A4*22</td><td>tacrolimus</td><td>Kidney Transplantation;Organ Transplantation</td><td>2A</td><td>*1</td><td>Dosage</td><td>Patients who are recipients of an organ transplant and carry two copies of the CYP3A4*1 allele may require an increased dose of tacrolimus as compared to patients with two copies of the *3 or *22 alleles or one copy of the 1* allele in combination with one copy of the *3 or *22 alleles. Other genetic and clinical factors may also influence tacrolimus dose.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449296086>667</a></td><td>CYP3A4</td><td>CYP3A4*1</td><td>fentanyl</td><td>Pain, Postoperative</td><td>2A</td><td>*1</td><td>Dosage</td><td>Patients with two copies of the CYP3A4*1 allele or one copy of the CYP3A4*1 allele in combination with one copy of the CYP3A4*1G allele may require an increased dose of fentanyl to manage postoperative pain as compared to patients with two copies of the CYP3A4*1G allele or two copies of the CYP3A4*18 allele. However, this association was only seen at one timepoint and conflicting evidence has been reported. Other genetic and clinical factors may also affect fentanyl dosage requirements.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449296086>668</a></td><td>CYP3A4</td><td>CYP3A4*1G</td><td>fentanyl</td><td>Pain, Postoperative</td><td>2A</td><td>*1</td><td>Dosage</td><td>Patients with two copies of the CYP3A4*1 allele or one copy of the CYP3A4*1 allele in combination with one copy of the CYP3A4*1G allele may require an increased dose of fentanyl to manage postoperative pain as compared to patients with two copies of the CYP3A4*1G allele or two copies of the CYP3A4*18 allele. However, this association was only seen at one timepoint and conflicting evidence has been reported. Other genetic and clinical factors may also affect fentanyl dosage requirements.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449296086>669</a></td><td>CYP3A4</td><td>CYP3A4*18</td><td>fentanyl</td><td>Pain, Postoperative</td><td>2A</td><td>*1</td><td>Dosage</td><td>Patients with two copies of the CYP3A4*1 allele or one copy of the CYP3A4*1 allele in combination with one copy of the CYP3A4*1G allele may require an increased dose of fentanyl to manage postoperative pain as compared to patients with two copies of the CYP3A4*1G allele or two copies of the CYP3A4*18 allele. However, this association was only seen at one timepoint and conflicting evidence has been reported. Other genetic and clinical factors may also affect fentanyl dosage requirements.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451135188>670</a></td><td>CYP3A5</td><td>CYP3A5*1</td><td>sufentanil</td><td></td><td>3</td><td>*3/*3</td><td>Dosage</td><td>Patients with the *3/*3 genotype may have increased dose requirements of sufentanil as compared to patients with the *1/*1 genotype. Other genetic and clinical factors may also affect a patient's sufentanil dose requirements.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451135188>671</a></td><td>CYP3A5</td><td>CYP3A5*3</td><td>sufentanil</td><td></td><td>3</td><td>*3/*3</td><td>Dosage</td><td>Patients with the *3/*3 genotype may have increased dose requirements of sufentanil as compared to patients with the *1/*1 genotype. Other genetic and clinical factors may also affect a patient's sufentanil dose requirements.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183491278>672</a></td><td>CYP3A5</td><td>CYP3A5*1</td><td>atorvastatin</td><td>Myalgia unspecified</td><td>3</td><td>*3/*3</td><td>Efficacy</td><td>Patients with the *3/*3 genotype who are treated with atorvastatin 1) may have a decreased response to treatment as compared to patients with the *1/*3 and *1/*1 genotype 2) may have an increased risk of myalgia and a greater degree of muscle damage as compared to patients with the *1/*3 genotype. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183491278>673</a></td><td>CYP3A5</td><td>CYP3A5*3</td><td>atorvastatin</td><td>Myalgia unspecified</td><td>3</td><td>*3/*3</td><td>Efficacy</td><td>Patients with the *3/*3 genotype who are treated with atorvastatin 1) may have a decreased response to treatment as compared to patients with the *1/*3 and *1/*1 genotype 2) may have an increased risk of myalgia and a greater degree of muscle damage as compared to patients with the *1/*3 genotype. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1445585748>674</a></td><td>VKORC1</td><td>rs7294</td><td>acenocoumarol</td><td></td><td>3</td><td>CT</td><td>Dosage</td><td>Patients with the CT genotype may require a increased dose of phenprocoumon or acenocoumarol as compared to patients with the CC genotype and a decreased dose as compared to the TT genotype, although this has been contradicted in some studies. Other genetic and clinical factors may also influence a patient's phenprocoumon or acenocoumarol dose requirement.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1445585748>675</a></td><td>VKORC1</td><td>rs7294</td><td>phenprocoumon</td><td></td><td>3</td><td>CT</td><td>Dosage</td><td>Patients with the CT genotype may require a increased dose of phenprocoumon or acenocoumarol as compared to patients with the CC genotype and a decreased dose as compared to the TT genotype, although this has been contradicted in some studies. Other genetic and clinical factors may also influence a patient's phenprocoumon or acenocoumarol dose requirement.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447946219>676</a></td><td>ABCG2</td><td>rs2231135</td><td>methotrexate</td><td>Osteosarcoma</td><td>3</td><td>GG</td><td>Toxicity</td><td>No patients with the GG genotype were available for analysis, but patients with the AG genotype and osteosarcoma may be at increased risk for mucositis when receiving methotrexate, as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of mucositis in patients receiving methotrexate.</td><td>Unknown</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184516188>677</a></td><td>G6PD</td><td>G6PD B (wildtype)</td><td>sulfadoxine</td><td>Hemolysis</td><td>3</td><td>B (wildtype)</td><td>Toxicity</td><td>Male patients with the B (wildtype) haplotype (not associated with G6PD deficiency) who are treated with sulfadoxine may have increased survival of red blood cells as compared to patients hemizygous for the Mediterranean variant (associated with G6PD deficiency). Please note: this study did not report genotyping. Other genetic and clinical factors may also influence red blood cell survival.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184516188>678</a></td><td>G6PD</td><td>G6PD Mediterranean</td><td>sulfadoxine</td><td>Hemolysis</td><td>3</td><td>B (wildtype)</td><td>Toxicity</td><td>Male patients with the B (wildtype) haplotype (not associated with G6PD deficiency) who are treated with sulfadoxine may have increased survival of red blood cells as compared to patients hemizygous for the Mediterranean variant (associated with G6PD deficiency). Please note: this study did not report genotyping. Other genetic and clinical factors may also influence red blood cell survival.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184516188>679</a></td><td>G6PD</td><td>Dallas</td><td>sulfadoxine</td><td>Hemolysis</td><td>3</td><td>B (wildtype)</td><td>Toxicity</td><td>Male patients with the B (wildtype) haplotype (not associated with G6PD deficiency) who are treated with sulfadoxine may have increased survival of red blood cells as compared to patients hemizygous for the Mediterranean variant (associated with G6PD deficiency). Please note: this study did not report genotyping. Other genetic and clinical factors may also influence red blood cell survival.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184516188>680</a></td><td>G6PD</td><td>Panama</td><td>sulfadoxine</td><td>Hemolysis</td><td>3</td><td>B (wildtype)</td><td>Toxicity</td><td>Male patients with the B (wildtype) haplotype (not associated with G6PD deficiency) who are treated with sulfadoxine may have increased survival of red blood cells as compared to patients hemizygous for the Mediterranean variant (associated with G6PD deficiency). Please note: this study did not report genotyping. Other genetic and clinical factors may also influence red blood cell survival.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184516188>681</a></td><td>G6PD</td><td>Sassari</td><td>sulfadoxine</td><td>Hemolysis</td><td>3</td><td>B (wildtype)</td><td>Toxicity</td><td>Male patients with the B (wildtype) haplotype (not associated with G6PD deficiency) who are treated with sulfadoxine may have increased survival of red blood cells as compared to patients hemizygous for the Mediterranean variant (associated with G6PD deficiency). Please note: this study did not report genotyping. Other genetic and clinical factors may also influence red blood cell survival.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184516188>682</a></td><td>G6PD</td><td>Cagliari</td><td>sulfadoxine</td><td>Hemolysis</td><td>3</td><td>B (wildtype)</td><td>Toxicity</td><td>Male patients with the B (wildtype) haplotype (not associated with G6PD deficiency) who are treated with sulfadoxine may have increased survival of red blood cells as compared to patients hemizygous for the Mediterranean variant (associated with G6PD deficiency). Please note: this study did not report genotyping. Other genetic and clinical factors may also influence red blood cell survival.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184516188>683</a></td><td>G6PD</td><td>Birmingham</td><td>sulfadoxine</td><td>Hemolysis</td><td>3</td><td>B (wildtype)</td><td>Toxicity</td><td>Male patients with the B (wildtype) haplotype (not associated with G6PD deficiency) who are treated with sulfadoxine may have increased survival of red blood cells as compared to patients hemizygous for the Mediterranean variant (associated with G6PD deficiency). Please note: this study did not report genotyping. Other genetic and clinical factors may also influence red blood cell survival.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184642788>684</a></td><td>G6PD</td><td>G6PD A- 202A_376G</td><td>sulfasalazine</td><td>Hemolysis</td><td>3</td><td>B (wildtype)</td><td>Toxicity</td><td>Male patients with the B (wildtype) haplotype (not associated with G6PD deficiency) who are treated with sulfasalazine may have a reduced risk of hemolysis as compared to patients with variants conferring G6PD deficiency (e.g. hemizygous for the A- variant). Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184642788>685</a></td><td>G6PD</td><td>G6PD B (wildtype)</td><td>sulfasalazine</td><td>Hemolysis</td><td>3</td><td>B (wildtype)</td><td>Toxicity</td><td>Male patients with the B (wildtype) haplotype (not associated with G6PD deficiency) who are treated with sulfasalazine may have a reduced risk of hemolysis as compared to patients with variants conferring G6PD deficiency (e.g. hemizygous for the A- variant). Other genetic and clinical factors may also influence a patient's risk of drug-induced hemolysis.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184746746>686</a></td><td>TPMT</td><td>TPMT*1</td><td>mercaptopurine</td><td></td><td>3</td><td>*1/*1</td><td>Dosage</td><td>Patients with the *1/*1 genotype 1) may have increased inactivation of thiopurines due to normal TPMT activity and 2) may have a decreased risk for toxicity when receiving thiopurine drugs and purine analogues as compared to patients with a non-functional allele (e.g. *5, *10). Patients with the *1/*1 genotype may still be at risk for toxicity when taking thiopurine drugs and purine analogues based upon their genotypes. Other genetic and clinical factors may also influence a patient's risk for toxicity.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184746746>687</a></td><td>TPMT</td><td>TPMT*1</td><td>thioguanine</td><td></td><td>3</td><td>*1/*1</td><td>Dosage</td><td>Patients with the *1/*1 genotype 1) may have increased inactivation of thiopurines due to normal TPMT activity and 2) may have a decreased risk for toxicity when receiving thiopurine drugs and purine analogues as compared to patients with a non-functional allele (e.g. *5, *10). Patients with the *1/*1 genotype may still be at risk for toxicity when taking thiopurine drugs and purine analogues based upon their genotypes. Other genetic and clinical factors may also influence a patient's risk for toxicity.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184746746>688</a></td><td>TPMT</td><td>TPMT*5</td><td>mercaptopurine</td><td></td><td>3</td><td>*1/*1</td><td>Dosage</td><td>Patients with the *1/*1 genotype 1) may have increased inactivation of thiopurines due to normal TPMT activity and 2) may have a decreased risk for toxicity when receiving thiopurine drugs and purine analogues as compared to patients with a non-functional allele (e.g. *5, *10). Patients with the *1/*1 genotype may still be at risk for toxicity when taking thiopurine drugs and purine analogues based upon their genotypes. Other genetic and clinical factors may also influence a patient's risk for toxicity.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184746746>689</a></td><td>TPMT</td><td>TPMT*5</td><td>thioguanine</td><td></td><td>3</td><td>*1/*1</td><td>Dosage</td><td>Patients with the *1/*1 genotype 1) may have increased inactivation of thiopurines due to normal TPMT activity and 2) may have a decreased risk for toxicity when receiving thiopurine drugs and purine analogues as compared to patients with a non-functional allele (e.g. *5, *10). Patients with the *1/*1 genotype may still be at risk for toxicity when taking thiopurine drugs and purine analogues based upon their genotypes. Other genetic and clinical factors may also influence a patient's risk for toxicity.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184746746>690</a></td><td>TPMT</td><td>TPMT*10</td><td>mercaptopurine</td><td></td><td>3</td><td>*1/*1</td><td>Dosage</td><td>Patients with the *1/*1 genotype 1) may have increased inactivation of thiopurines due to normal TPMT activity and 2) may have a decreased risk for toxicity when receiving thiopurine drugs and purine analogues as compared to patients with a non-functional allele (e.g. *5, *10). Patients with the *1/*1 genotype may still be at risk for toxicity when taking thiopurine drugs and purine analogues based upon their genotypes. Other genetic and clinical factors may also influence a patient's risk for toxicity.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184746746>691</a></td><td>TPMT</td><td>TPMT*10</td><td>thioguanine</td><td></td><td>3</td><td>*1/*1</td><td>Dosage</td><td>Patients with the *1/*1 genotype 1) may have increased inactivation of thiopurines due to normal TPMT activity and 2) may have a decreased risk for toxicity when receiving thiopurine drugs and purine analogues as compared to patients with a non-functional allele (e.g. *5, *10). Patients with the *1/*1 genotype may still be at risk for toxicity when taking thiopurine drugs and purine analogues based upon their genotypes. Other genetic and clinical factors may also influence a patient's risk for toxicity.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184746746>692</a></td><td>TPMT</td><td>TPMT*13</td><td>mercaptopurine</td><td></td><td>3</td><td>*1/*1</td><td>Dosage</td><td>Patients with the *1/*1 genotype 1) may have increased inactivation of thiopurines due to normal TPMT activity and 2) may have a decreased risk for toxicity when receiving thiopurine drugs and purine analogues as compared to patients with a non-functional allele (e.g. *5, *10). Patients with the *1/*1 genotype may still be at risk for toxicity when taking thiopurine drugs and purine analogues based upon their genotypes. Other genetic and clinical factors may also influence a patient's risk for toxicity.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184746746>693</a></td><td>TPMT</td><td>TPMT*13</td><td>thioguanine</td><td></td><td>3</td><td>*1/*1</td><td>Dosage</td><td>Patients with the *1/*1 genotype 1) may have increased inactivation of thiopurines due to normal TPMT activity and 2) may have a decreased risk for toxicity when receiving thiopurine drugs and purine analogues as compared to patients with a non-functional allele (e.g. *5, *10). Patients with the *1/*1 genotype may still be at risk for toxicity when taking thiopurine drugs and purine analogues based upon their genotypes. Other genetic and clinical factors may also influence a patient's risk for toxicity.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184746746>694</a></td><td>TPMT</td><td>TPMT*15</td><td>mercaptopurine</td><td></td><td>3</td><td>*1/*1</td><td>Dosage</td><td>Patients with the *1/*1 genotype 1) may have increased inactivation of thiopurines due to normal TPMT activity and 2) may have a decreased risk for toxicity when receiving thiopurine drugs and purine analogues as compared to patients with a non-functional allele (e.g. *5, *10). Patients with the *1/*1 genotype may still be at risk for toxicity when taking thiopurine drugs and purine analogues based upon their genotypes. Other genetic and clinical factors may also influence a patient's risk for toxicity.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184746746>695</a></td><td>TPMT</td><td>TPMT*15</td><td>thioguanine</td><td></td><td>3</td><td>*1/*1</td><td>Dosage</td><td>Patients with the *1/*1 genotype 1) may have increased inactivation of thiopurines due to normal TPMT activity and 2) may have a decreased risk for toxicity when receiving thiopurine drugs and purine analogues as compared to patients with a non-functional allele (e.g. *5, *10). Patients with the *1/*1 genotype may still be at risk for toxicity when taking thiopurine drugs and purine analogues based upon their genotypes. Other genetic and clinical factors may also influence a patient's risk for toxicity.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184746746>696</a></td><td>TPMT</td><td>TPMT*19</td><td>mercaptopurine</td><td></td><td>3</td><td>*1/*1</td><td>Dosage</td><td>Patients with the *1/*1 genotype 1) may have increased inactivation of thiopurines due to normal TPMT activity and 2) may have a decreased risk for toxicity when receiving thiopurine drugs and purine analogues as compared to patients with a non-functional allele (e.g. *5, *10). Patients with the *1/*1 genotype may still be at risk for toxicity when taking thiopurine drugs and purine analogues based upon their genotypes. Other genetic and clinical factors may also influence a patient's risk for toxicity.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184746746>697</a></td><td>TPMT</td><td>TPMT*19</td><td>thioguanine</td><td></td><td>3</td><td>*1/*1</td><td>Dosage</td><td>Patients with the *1/*1 genotype 1) may have increased inactivation of thiopurines due to normal TPMT activity and 2) may have a decreased risk for toxicity when receiving thiopurine drugs and purine analogues as compared to patients with a non-functional allele (e.g. *5, *10). Patients with the *1/*1 genotype may still be at risk for toxicity when taking thiopurine drugs and purine analogues based upon their genotypes. Other genetic and clinical factors may also influence a patient's risk for toxicity.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184746746>698</a></td><td>TPMT</td><td>TPMT*24</td><td>mercaptopurine</td><td></td><td>3</td><td>*1/*1</td><td>Dosage</td><td>Patients with the *1/*1 genotype 1) may have increased inactivation of thiopurines due to normal TPMT activity and 2) may have a decreased risk for toxicity when receiving thiopurine drugs and purine analogues as compared to patients with a non-functional allele (e.g. *5, *10). Patients with the *1/*1 genotype may still be at risk for toxicity when taking thiopurine drugs and purine analogues based upon their genotypes. Other genetic and clinical factors may also influence a patient's risk for toxicity.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184746746>699</a></td><td>TPMT</td><td>TPMT*24</td><td>thioguanine</td><td></td><td>3</td><td>*1/*1</td><td>Dosage</td><td>Patients with the *1/*1 genotype 1) may have increased inactivation of thiopurines due to normal TPMT activity and 2) may have a decreased risk for toxicity when receiving thiopurine drugs and purine analogues as compared to patients with a non-functional allele (e.g. *5, *10). Patients with the *1/*1 genotype may still be at risk for toxicity when taking thiopurine drugs and purine analogues based upon their genotypes. Other genetic and clinical factors may also influence a patient's risk for toxicity.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184746746>700</a></td><td>TPMT</td><td>TPMT*25</td><td>mercaptopurine</td><td></td><td>3</td><td>*1/*1</td><td>Dosage</td><td>Patients with the *1/*1 genotype 1) may have increased inactivation of thiopurines due to normal TPMT activity and 2) may have a decreased risk for toxicity when receiving thiopurine drugs and purine analogues as compared to patients with a non-functional allele (e.g. *5, *10). Patients with the *1/*1 genotype may still be at risk for toxicity when taking thiopurine drugs and purine analogues based upon their genotypes. Other genetic and clinical factors may also influence a patient's risk for toxicity.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184746746>701</a></td><td>TPMT</td><td>TPMT*25</td><td>thioguanine</td><td></td><td>3</td><td>*1/*1</td><td>Dosage</td><td>Patients with the *1/*1 genotype 1) may have increased inactivation of thiopurines due to normal TPMT activity and 2) may have a decreased risk for toxicity when receiving thiopurine drugs and purine analogues as compared to patients with a non-functional allele (e.g. *5, *10). Patients with the *1/*1 genotype may still be at risk for toxicity when taking thiopurine drugs and purine analogues based upon their genotypes. Other genetic and clinical factors may also influence a patient's risk for toxicity.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184746746>702</a></td><td>TPMT</td><td>TPMT*26</td><td>mercaptopurine</td><td></td><td>3</td><td>*1/*1</td><td>Dosage</td><td>Patients with the *1/*1 genotype 1) may have increased inactivation of thiopurines due to normal TPMT activity and 2) may have a decreased risk for toxicity when receiving thiopurine drugs and purine analogues as compared to patients with a non-functional allele (e.g. *5, *10). Patients with the *1/*1 genotype may still be at risk for toxicity when taking thiopurine drugs and purine analogues based upon their genotypes. Other genetic and clinical factors may also influence a patient's risk for toxicity.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184746746>703</a></td><td>TPMT</td><td>TPMT*26</td><td>thioguanine</td><td></td><td>3</td><td>*1/*1</td><td>Dosage</td><td>Patients with the *1/*1 genotype 1) may have increased inactivation of thiopurines due to normal TPMT activity and 2) may have a decreased risk for toxicity when receiving thiopurine drugs and purine analogues as compared to patients with a non-functional allele (e.g. *5, *10). Patients with the *1/*1 genotype may still be at risk for toxicity when taking thiopurine drugs and purine analogues based upon their genotypes. Other genetic and clinical factors may also influence a patient's risk for toxicity.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184746746>704</a></td><td>TPMT</td><td>TPMT*27</td><td>mercaptopurine</td><td></td><td>3</td><td>*1/*1</td><td>Dosage</td><td>Patients with the *1/*1 genotype 1) may have increased inactivation of thiopurines due to normal TPMT activity and 2) may have a decreased risk for toxicity when receiving thiopurine drugs and purine analogues as compared to patients with a non-functional allele (e.g. *5, *10). Patients with the *1/*1 genotype may still be at risk for toxicity when taking thiopurine drugs and purine analogues based upon their genotypes. Other genetic and clinical factors may also influence a patient's risk for toxicity.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184746746>705</a></td><td>TPMT</td><td>TPMT*27</td><td>thioguanine</td><td></td><td>3</td><td>*1/*1</td><td>Dosage</td><td>Patients with the *1/*1 genotype 1) may have increased inactivation of thiopurines due to normal TPMT activity and 2) may have a decreased risk for toxicity when receiving thiopurine drugs and purine analogues as compared to patients with a non-functional allele (e.g. *5, *10). Patients with the *1/*1 genotype may still be at risk for toxicity when taking thiopurine drugs and purine analogues based upon their genotypes. Other genetic and clinical factors may also influence a patient's risk for toxicity.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184746746>706</a></td><td>TPMT</td><td>TPMT*28</td><td>mercaptopurine</td><td></td><td>3</td><td>*1/*1</td><td>Dosage</td><td>Patients with the *1/*1 genotype 1) may have increased inactivation of thiopurines due to normal TPMT activity and 2) may have a decreased risk for toxicity when receiving thiopurine drugs and purine analogues as compared to patients with a non-functional allele (e.g. *5, *10). Patients with the *1/*1 genotype may still be at risk for toxicity when taking thiopurine drugs and purine analogues based upon their genotypes. Other genetic and clinical factors may also influence a patient's risk for toxicity.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184746746>707</a></td><td>TPMT</td><td>TPMT*28</td><td>thioguanine</td><td></td><td>3</td><td>*1/*1</td><td>Dosage</td><td>Patients with the *1/*1 genotype 1) may have increased inactivation of thiopurines due to normal TPMT activity and 2) may have a decreased risk for toxicity when receiving thiopurine drugs and purine analogues as compared to patients with a non-functional allele (e.g. *5, *10). Patients with the *1/*1 genotype may still be at risk for toxicity when taking thiopurine drugs and purine analogues based upon their genotypes. Other genetic and clinical factors may also influence a patient's risk for toxicity.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184746746>708</a></td><td>TPMT</td><td>TPMT*30</td><td>mercaptopurine</td><td></td><td>3</td><td>*1/*1</td><td>Dosage</td><td>Patients with the *1/*1 genotype 1) may have increased inactivation of thiopurines due to normal TPMT activity and 2) may have a decreased risk for toxicity when receiving thiopurine drugs and purine analogues as compared to patients with a non-functional allele (e.g. *5, *10). Patients with the *1/*1 genotype may still be at risk for toxicity when taking thiopurine drugs and purine analogues based upon their genotypes. Other genetic and clinical factors may also influence a patient's risk for toxicity.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184746746>709</a></td><td>TPMT</td><td>TPMT*30</td><td>thioguanine</td><td></td><td>3</td><td>*1/*1</td><td>Dosage</td><td>Patients with the *1/*1 genotype 1) may have increased inactivation of thiopurines due to normal TPMT activity and 2) may have a decreased risk for toxicity when receiving thiopurine drugs and purine analogues as compared to patients with a non-functional allele (e.g. *5, *10). Patients with the *1/*1 genotype may still be at risk for toxicity when taking thiopurine drugs and purine analogues based upon their genotypes. Other genetic and clinical factors may also influence a patient's risk for toxicity.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184746746>710</a></td><td>TPMT</td><td>TPMT*31</td><td>mercaptopurine</td><td></td><td>3</td><td>*1/*1</td><td>Dosage</td><td>Patients with the *1/*1 genotype 1) may have increased inactivation of thiopurines due to normal TPMT activity and 2) may have a decreased risk for toxicity when receiving thiopurine drugs and purine analogues as compared to patients with a non-functional allele (e.g. *5, *10). Patients with the *1/*1 genotype may still be at risk for toxicity when taking thiopurine drugs and purine analogues based upon their genotypes. Other genetic and clinical factors may also influence a patient's risk for toxicity.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184746746>711</a></td><td>TPMT</td><td>TPMT*31</td><td>thioguanine</td><td></td><td>3</td><td>*1/*1</td><td>Dosage</td><td>Patients with the *1/*1 genotype 1) may have increased inactivation of thiopurines due to normal TPMT activity and 2) may have a decreased risk for toxicity when receiving thiopurine drugs and purine analogues as compared to patients with a non-functional allele (e.g. *5, *10). Patients with the *1/*1 genotype may still be at risk for toxicity when taking thiopurine drugs and purine analogues based upon their genotypes. Other genetic and clinical factors may also influence a patient's risk for toxicity.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184746746>712</a></td><td>TPMT</td><td>TPMT*32</td><td>mercaptopurine</td><td></td><td>3</td><td>*1/*1</td><td>Dosage</td><td>Patients with the *1/*1 genotype 1) may have increased inactivation of thiopurines due to normal TPMT activity and 2) may have a decreased risk for toxicity when receiving thiopurine drugs and purine analogues as compared to patients with a non-functional allele (e.g. *5, *10). Patients with the *1/*1 genotype may still be at risk for toxicity when taking thiopurine drugs and purine analogues based upon their genotypes. Other genetic and clinical factors may also influence a patient's risk for toxicity.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184746746>713</a></td><td>TPMT</td><td>TPMT*32</td><td>thioguanine</td><td></td><td>3</td><td>*1/*1</td><td>Dosage</td><td>Patients with the *1/*1 genotype 1) may have increased inactivation of thiopurines due to normal TPMT activity and 2) may have a decreased risk for toxicity when receiving thiopurine drugs and purine analogues as compared to patients with a non-functional allele (e.g. *5, *10). Patients with the *1/*1 genotype may still be at risk for toxicity when taking thiopurine drugs and purine analogues based upon their genotypes. Other genetic and clinical factors may also influence a patient's risk for toxicity.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184746746>714</a></td><td>TPMT</td><td>TPMT*33</td><td>mercaptopurine</td><td></td><td>3</td><td>*1/*1</td><td>Dosage</td><td>Patients with the *1/*1 genotype 1) may have increased inactivation of thiopurines due to normal TPMT activity and 2) may have a decreased risk for toxicity when receiving thiopurine drugs and purine analogues as compared to patients with a non-functional allele (e.g. *5, *10). Patients with the *1/*1 genotype may still be at risk for toxicity when taking thiopurine drugs and purine analogues based upon their genotypes. Other genetic and clinical factors may also influence a patient's risk for toxicity.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184746746>715</a></td><td>TPMT</td><td>TPMT*33</td><td>thioguanine</td><td></td><td>3</td><td>*1/*1</td><td>Dosage</td><td>Patients with the *1/*1 genotype 1) may have increased inactivation of thiopurines due to normal TPMT activity and 2) may have a decreased risk for toxicity when receiving thiopurine drugs and purine analogues as compared to patients with a non-functional allele (e.g. *5, *10). Patients with the *1/*1 genotype may still be at risk for toxicity when taking thiopurine drugs and purine analogues based upon their genotypes. Other genetic and clinical factors may also influence a patient's risk for toxicity.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184746746>716</a></td><td>TPMT</td><td>TPMT*34</td><td>mercaptopurine</td><td></td><td>3</td><td>*1/*1</td><td>Dosage</td><td>Patients with the *1/*1 genotype 1) may have increased inactivation of thiopurines due to normal TPMT activity and 2) may have a decreased risk for toxicity when receiving thiopurine drugs and purine analogues as compared to patients with a non-functional allele (e.g. *5, *10). Patients with the *1/*1 genotype may still be at risk for toxicity when taking thiopurine drugs and purine analogues based upon their genotypes. Other genetic and clinical factors may also influence a patient's risk for toxicity.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184746746>717</a></td><td>TPMT</td><td>TPMT*34</td><td>thioguanine</td><td></td><td>3</td><td>*1/*1</td><td>Dosage</td><td>Patients with the *1/*1 genotype 1) may have increased inactivation of thiopurines due to normal TPMT activity and 2) may have a decreased risk for toxicity when receiving thiopurine drugs and purine analogues as compared to patients with a non-functional allele (e.g. *5, *10). Patients with the *1/*1 genotype may still be at risk for toxicity when taking thiopurine drugs and purine analogues based upon their genotypes. Other genetic and clinical factors may also influence a patient's risk for toxicity.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184746746>718</a></td><td>TPMT</td><td>TPMT*37</td><td>mercaptopurine</td><td></td><td>3</td><td>*1/*1</td><td>Dosage</td><td>Patients with the *1/*1 genotype 1) may have increased inactivation of thiopurines due to normal TPMT activity and 2) may have a decreased risk for toxicity when receiving thiopurine drugs and purine analogues as compared to patients with a non-functional allele (e.g. *5, *10). Patients with the *1/*1 genotype may still be at risk for toxicity when taking thiopurine drugs and purine analogues based upon their genotypes. Other genetic and clinical factors may also influence a patient's risk for toxicity.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184746746>719</a></td><td>TPMT</td><td>TPMT*37</td><td>thioguanine</td><td></td><td>3</td><td>*1/*1</td><td>Dosage</td><td>Patients with the *1/*1 genotype 1) may have increased inactivation of thiopurines due to normal TPMT activity and 2) may have a decreased risk for toxicity when receiving thiopurine drugs and purine analogues as compared to patients with a non-functional allele (e.g. *5, *10). Patients with the *1/*1 genotype may still be at risk for toxicity when taking thiopurine drugs and purine analogues based upon their genotypes. Other genetic and clinical factors may also influence a patient's risk for toxicity.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184653758>720</a></td><td>TPMT</td><td>TPMT*1</td><td>azathioprine</td><td>Lupus Erythematosus, Systemic;Precursor Cell Lymphoblastic Leukemia-Lymphoma</td><td>4</td><td>*1/*1</td><td>Dosage</td><td>Patients with the *1/*1 genotype 1) may have increased inactivation of thiopurines due to normal TPMT activity and 2) may have a decreased risk for toxicity when receiving thiopurine drugs and purine analogues as compared to patients with a non-functional allele (e.g. *6, *7, *8). Patients with the *1/*1 genotype may still be at risk for toxicity when taking thiopurine drugs and purine analogues based upon their genotypes. Other genetic and clinical factors may also influence a patient's risk for toxicity.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184653758>721</a></td><td>TPMT</td><td>TPMT*1</td><td>mercaptopurine</td><td>Lupus Erythematosus, Systemic;Precursor Cell Lymphoblastic Leukemia-Lymphoma</td><td>4</td><td>*1/*1</td><td>Dosage</td><td>Patients with the *1/*1 genotype 1) may have increased inactivation of thiopurines due to normal TPMT activity and 2) may have a decreased risk for toxicity when receiving thiopurine drugs and purine analogues as compared to patients with a non-functional allele (e.g. *6, *7, *8). Patients with the *1/*1 genotype may still be at risk for toxicity when taking thiopurine drugs and purine analogues based upon their genotypes. Other genetic and clinical factors may also influence a patient's risk for toxicity.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184653758>722</a></td><td>TPMT</td><td>TPMT*1</td><td>purine analogues</td><td>Lupus Erythematosus, Systemic;Precursor Cell Lymphoblastic Leukemia-Lymphoma</td><td>4</td><td>*1/*1</td><td>Dosage</td><td>Patients with the *1/*1 genotype 1) may have increased inactivation of thiopurines due to normal TPMT activity and 2) may have a decreased risk for toxicity when receiving thiopurine drugs and purine analogues as compared to patients with a non-functional allele (e.g. *6, *7, *8). Patients with the *1/*1 genotype may still be at risk for toxicity when taking thiopurine drugs and purine analogues based upon their genotypes. Other genetic and clinical factors may also influence a patient's risk for toxicity.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184653758>723</a></td><td>TPMT</td><td>TPMT*1</td><td>thioguanine</td><td>Lupus Erythematosus, Systemic;Precursor Cell Lymphoblastic Leukemia-Lymphoma</td><td>4</td><td>*1/*1</td><td>Dosage</td><td>Patients with the *1/*1 genotype 1) may have increased inactivation of thiopurines due to normal TPMT activity and 2) may have a decreased risk for toxicity when receiving thiopurine drugs and purine analogues as compared to patients with a non-functional allele (e.g. *6, *7, *8). Patients with the *1/*1 genotype may still be at risk for toxicity when taking thiopurine drugs and purine analogues based upon their genotypes. Other genetic and clinical factors may also influence a patient's risk for toxicity.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184653758>724</a></td><td>TPMT</td><td>TPMT*6</td><td>azathioprine</td><td>Lupus Erythematosus, Systemic;Precursor Cell Lymphoblastic Leukemia-Lymphoma</td><td>4</td><td>*1/*1</td><td>Dosage</td><td>Patients with the *1/*1 genotype 1) may have increased inactivation of thiopurines due to normal TPMT activity and 2) may have a decreased risk for toxicity when receiving thiopurine drugs and purine analogues as compared to patients with a non-functional allele (e.g. *6, *7, *8). Patients with the *1/*1 genotype may still be at risk for toxicity when taking thiopurine drugs and purine analogues based upon their genotypes. Other genetic and clinical factors may also influence a patient's risk for toxicity.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184653758>725</a></td><td>TPMT</td><td>TPMT*6</td><td>mercaptopurine</td><td>Lupus Erythematosus, Systemic;Precursor Cell Lymphoblastic Leukemia-Lymphoma</td><td>4</td><td>*1/*1</td><td>Dosage</td><td>Patients with the *1/*1 genotype 1) may have increased inactivation of thiopurines due to normal TPMT activity and 2) may have a decreased risk for toxicity when receiving thiopurine drugs and purine analogues as compared to patients with a non-functional allele (e.g. *6, *7, *8). Patients with the *1/*1 genotype may still be at risk for toxicity when taking thiopurine drugs and purine analogues based upon their genotypes. Other genetic and clinical factors may also influence a patient's risk for toxicity.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184653758>726</a></td><td>TPMT</td><td>TPMT*6</td><td>purine analogues</td><td>Lupus Erythematosus, Systemic;Precursor Cell Lymphoblastic Leukemia-Lymphoma</td><td>4</td><td>*1/*1</td><td>Dosage</td><td>Patients with the *1/*1 genotype 1) may have increased inactivation of thiopurines due to normal TPMT activity and 2) may have a decreased risk for toxicity when receiving thiopurine drugs and purine analogues as compared to patients with a non-functional allele (e.g. *6, *7, *8). Patients with the *1/*1 genotype may still be at risk for toxicity when taking thiopurine drugs and purine analogues based upon their genotypes. Other genetic and clinical factors may also influence a patient's risk for toxicity.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184653758>727</a></td><td>TPMT</td><td>TPMT*6</td><td>thioguanine</td><td>Lupus Erythematosus, Systemic;Precursor Cell Lymphoblastic Leukemia-Lymphoma</td><td>4</td><td>*1/*1</td><td>Dosage</td><td>Patients with the *1/*1 genotype 1) may have increased inactivation of thiopurines due to normal TPMT activity and 2) may have a decreased risk for toxicity when receiving thiopurine drugs and purine analogues as compared to patients with a non-functional allele (e.g. *6, *7, *8). Patients with the *1/*1 genotype may still be at risk for toxicity when taking thiopurine drugs and purine analogues based upon their genotypes. Other genetic and clinical factors may also influence a patient's risk for toxicity.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184653758>728</a></td><td>TPMT</td><td>TPMT*7</td><td>azathioprine</td><td>Lupus Erythematosus, Systemic;Precursor Cell Lymphoblastic Leukemia-Lymphoma</td><td>4</td><td>*1/*1</td><td>Dosage</td><td>Patients with the *1/*1 genotype 1) may have increased inactivation of thiopurines due to normal TPMT activity and 2) may have a decreased risk for toxicity when receiving thiopurine drugs and purine analogues as compared to patients with a non-functional allele (e.g. *6, *7, *8). Patients with the *1/*1 genotype may still be at risk for toxicity when taking thiopurine drugs and purine analogues based upon their genotypes. Other genetic and clinical factors may also influence a patient's risk for toxicity.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184653758>729</a></td><td>TPMT</td><td>TPMT*7</td><td>mercaptopurine</td><td>Lupus Erythematosus, Systemic;Precursor Cell Lymphoblastic Leukemia-Lymphoma</td><td>4</td><td>*1/*1</td><td>Dosage</td><td>Patients with the *1/*1 genotype 1) may have increased inactivation of thiopurines due to normal TPMT activity and 2) may have a decreased risk for toxicity when receiving thiopurine drugs and purine analogues as compared to patients with a non-functional allele (e.g. *6, *7, *8). Patients with the *1/*1 genotype may still be at risk for toxicity when taking thiopurine drugs and purine analogues based upon their genotypes. Other genetic and clinical factors may also influence a patient's risk for toxicity.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184653758>730</a></td><td>TPMT</td><td>TPMT*7</td><td>purine analogues</td><td>Lupus Erythematosus, Systemic;Precursor Cell Lymphoblastic Leukemia-Lymphoma</td><td>4</td><td>*1/*1</td><td>Dosage</td><td>Patients with the *1/*1 genotype 1) may have increased inactivation of thiopurines due to normal TPMT activity and 2) may have a decreased risk for toxicity when receiving thiopurine drugs and purine analogues as compared to patients with a non-functional allele (e.g. *6, *7, *8). Patients with the *1/*1 genotype may still be at risk for toxicity when taking thiopurine drugs and purine analogues based upon their genotypes. Other genetic and clinical factors may also influence a patient's risk for toxicity.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184653758>731</a></td><td>TPMT</td><td>TPMT*7</td><td>thioguanine</td><td>Lupus Erythematosus, Systemic;Precursor Cell Lymphoblastic Leukemia-Lymphoma</td><td>4</td><td>*1/*1</td><td>Dosage</td><td>Patients with the *1/*1 genotype 1) may have increased inactivation of thiopurines due to normal TPMT activity and 2) may have a decreased risk for toxicity when receiving thiopurine drugs and purine analogues as compared to patients with a non-functional allele (e.g. *6, *7, *8). Patients with the *1/*1 genotype may still be at risk for toxicity when taking thiopurine drugs and purine analogues based upon their genotypes. Other genetic and clinical factors may also influence a patient's risk for toxicity.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184653758>732</a></td><td>TPMT</td><td>TPMT*8</td><td>azathioprine</td><td>Lupus Erythematosus, Systemic;Precursor Cell Lymphoblastic Leukemia-Lymphoma</td><td>4</td><td>*1/*1</td><td>Dosage</td><td>Patients with the *1/*1 genotype 1) may have increased inactivation of thiopurines due to normal TPMT activity and 2) may have a decreased risk for toxicity when receiving thiopurine drugs and purine analogues as compared to patients with a non-functional allele (e.g. *6, *7, *8). Patients with the *1/*1 genotype may still be at risk for toxicity when taking thiopurine drugs and purine analogues based upon their genotypes. Other genetic and clinical factors may also influence a patient's risk for toxicity.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184653758>733</a></td><td>TPMT</td><td>TPMT*8</td><td>mercaptopurine</td><td>Lupus Erythematosus, Systemic;Precursor Cell Lymphoblastic Leukemia-Lymphoma</td><td>4</td><td>*1/*1</td><td>Dosage</td><td>Patients with the *1/*1 genotype 1) may have increased inactivation of thiopurines due to normal TPMT activity and 2) may have a decreased risk for toxicity when receiving thiopurine drugs and purine analogues as compared to patients with a non-functional allele (e.g. *6, *7, *8). Patients with the *1/*1 genotype may still be at risk for toxicity when taking thiopurine drugs and purine analogues based upon their genotypes. Other genetic and clinical factors may also influence a patient's risk for toxicity.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184653758>734</a></td><td>TPMT</td><td>TPMT*8</td><td>purine analogues</td><td>Lupus Erythematosus, Systemic;Precursor Cell Lymphoblastic Leukemia-Lymphoma</td><td>4</td><td>*1/*1</td><td>Dosage</td><td>Patients with the *1/*1 genotype 1) may have increased inactivation of thiopurines due to normal TPMT activity and 2) may have a decreased risk for toxicity when receiving thiopurine drugs and purine analogues as compared to patients with a non-functional allele (e.g. *6, *7, *8). Patients with the *1/*1 genotype may still be at risk for toxicity when taking thiopurine drugs and purine analogues based upon their genotypes. Other genetic and clinical factors may also influence a patient's risk for toxicity.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184653758>735</a></td><td>TPMT</td><td>TPMT*8</td><td>thioguanine</td><td>Lupus Erythematosus, Systemic;Precursor Cell Lymphoblastic Leukemia-Lymphoma</td><td>4</td><td>*1/*1</td><td>Dosage</td><td>Patients with the *1/*1 genotype 1) may have increased inactivation of thiopurines due to normal TPMT activity and 2) may have a decreased risk for toxicity when receiving thiopurine drugs and purine analogues as compared to patients with a non-functional allele (e.g. *6, *7, *8). Patients with the *1/*1 genotype may still be at risk for toxicity when taking thiopurine drugs and purine analogues based upon their genotypes. Other genetic and clinical factors may also influence a patient's risk for toxicity.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184653758>736</a></td><td>TPMT</td><td>TPMT*11</td><td>azathioprine</td><td>Lupus Erythematosus, Systemic;Precursor Cell Lymphoblastic Leukemia-Lymphoma</td><td>4</td><td>*1/*1</td><td>Dosage</td><td>Patients with the *1/*1 genotype 1) may have increased inactivation of thiopurines due to normal TPMT activity and 2) may have a decreased risk for toxicity when receiving thiopurine drugs and purine analogues as compared to patients with a non-functional allele (e.g. *6, *7, *8). Patients with the *1/*1 genotype may still be at risk for toxicity when taking thiopurine drugs and purine analogues based upon their genotypes. Other genetic and clinical factors may also influence a patient's risk for toxicity.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184653758>737</a></td><td>TPMT</td><td>TPMT*11</td><td>mercaptopurine</td><td>Lupus Erythematosus, Systemic;Precursor Cell Lymphoblastic Leukemia-Lymphoma</td><td>4</td><td>*1/*1</td><td>Dosage</td><td>Patients with the *1/*1 genotype 1) may have increased inactivation of thiopurines due to normal TPMT activity and 2) may have a decreased risk for toxicity when receiving thiopurine drugs and purine analogues as compared to patients with a non-functional allele (e.g. *6, *7, *8). Patients with the *1/*1 genotype may still be at risk for toxicity when taking thiopurine drugs and purine analogues based upon their genotypes. Other genetic and clinical factors may also influence a patient's risk for toxicity.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184653758>738</a></td><td>TPMT</td><td>TPMT*11</td><td>purine analogues</td><td>Lupus Erythematosus, Systemic;Precursor Cell Lymphoblastic Leukemia-Lymphoma</td><td>4</td><td>*1/*1</td><td>Dosage</td><td>Patients with the *1/*1 genotype 1) may have increased inactivation of thiopurines due to normal TPMT activity and 2) may have a decreased risk for toxicity when receiving thiopurine drugs and purine analogues as compared to patients with a non-functional allele (e.g. *6, *7, *8). Patients with the *1/*1 genotype may still be at risk for toxicity when taking thiopurine drugs and purine analogues based upon their genotypes. Other genetic and clinical factors may also influence a patient's risk for toxicity.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184653758>739</a></td><td>TPMT</td><td>TPMT*11</td><td>thioguanine</td><td>Lupus Erythematosus, Systemic;Precursor Cell Lymphoblastic Leukemia-Lymphoma</td><td>4</td><td>*1/*1</td><td>Dosage</td><td>Patients with the *1/*1 genotype 1) may have increased inactivation of thiopurines due to normal TPMT activity and 2) may have a decreased risk for toxicity when receiving thiopurine drugs and purine analogues as compared to patients with a non-functional allele (e.g. *6, *7, *8). Patients with the *1/*1 genotype may still be at risk for toxicity when taking thiopurine drugs and purine analogues based upon their genotypes. Other genetic and clinical factors may also influence a patient's risk for toxicity.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184653758>740</a></td><td>TPMT</td><td>TPMT*14</td><td>azathioprine</td><td>Lupus Erythematosus, Systemic;Precursor Cell Lymphoblastic Leukemia-Lymphoma</td><td>4</td><td>*1/*1</td><td>Dosage</td><td>Patients with the *1/*1 genotype 1) may have increased inactivation of thiopurines due to normal TPMT activity and 2) may have a decreased risk for toxicity when receiving thiopurine drugs and purine analogues as compared to patients with a non-functional allele (e.g. *6, *7, *8). Patients with the *1/*1 genotype may still be at risk for toxicity when taking thiopurine drugs and purine analogues based upon their genotypes. Other genetic and clinical factors may also influence a patient's risk for toxicity.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184653758>741</a></td><td>TPMT</td><td>TPMT*14</td><td>mercaptopurine</td><td>Lupus Erythematosus, Systemic;Precursor Cell Lymphoblastic Leukemia-Lymphoma</td><td>4</td><td>*1/*1</td><td>Dosage</td><td>Patients with the *1/*1 genotype 1) may have increased inactivation of thiopurines due to normal TPMT activity and 2) may have a decreased risk for toxicity when receiving thiopurine drugs and purine analogues as compared to patients with a non-functional allele (e.g. *6, *7, *8). Patients with the *1/*1 genotype may still be at risk for toxicity when taking thiopurine drugs and purine analogues based upon their genotypes. Other genetic and clinical factors may also influence a patient's risk for toxicity.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184653758>742</a></td><td>TPMT</td><td>TPMT*14</td><td>purine analogues</td><td>Lupus Erythematosus, Systemic;Precursor Cell Lymphoblastic Leukemia-Lymphoma</td><td>4</td><td>*1/*1</td><td>Dosage</td><td>Patients with the *1/*1 genotype 1) may have increased inactivation of thiopurines due to normal TPMT activity and 2) may have a decreased risk for toxicity when receiving thiopurine drugs and purine analogues as compared to patients with a non-functional allele (e.g. *6, *7, *8). Patients with the *1/*1 genotype may still be at risk for toxicity when taking thiopurine drugs and purine analogues based upon their genotypes. Other genetic and clinical factors may also influence a patient's risk for toxicity.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184653758>743</a></td><td>TPMT</td><td>TPMT*14</td><td>thioguanine</td><td>Lupus Erythematosus, Systemic;Precursor Cell Lymphoblastic Leukemia-Lymphoma</td><td>4</td><td>*1/*1</td><td>Dosage</td><td>Patients with the *1/*1 genotype 1) may have increased inactivation of thiopurines due to normal TPMT activity and 2) may have a decreased risk for toxicity when receiving thiopurine drugs and purine analogues as compared to patients with a non-functional allele (e.g. *6, *7, *8). Patients with the *1/*1 genotype may still be at risk for toxicity when taking thiopurine drugs and purine analogues based upon their genotypes. Other genetic and clinical factors may also influence a patient's risk for toxicity.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184653758>744</a></td><td>TPMT</td><td>TPMT*16</td><td>azathioprine</td><td>Lupus Erythematosus, Systemic;Precursor Cell Lymphoblastic Leukemia-Lymphoma</td><td>4</td><td>*1/*1</td><td>Dosage</td><td>Patients with the *1/*1 genotype 1) may have increased inactivation of thiopurines due to normal TPMT activity and 2) may have a decreased risk for toxicity when receiving thiopurine drugs and purine analogues as compared to patients with a non-functional allele (e.g. *6, *7, *8). Patients with the *1/*1 genotype may still be at risk for toxicity when taking thiopurine drugs and purine analogues based upon their genotypes. Other genetic and clinical factors may also influence a patient's risk for toxicity.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184653758>745</a></td><td>TPMT</td><td>TPMT*16</td><td>mercaptopurine</td><td>Lupus Erythematosus, Systemic;Precursor Cell Lymphoblastic Leukemia-Lymphoma</td><td>4</td><td>*1/*1</td><td>Dosage</td><td>Patients with the *1/*1 genotype 1) may have increased inactivation of thiopurines due to normal TPMT activity and 2) may have a decreased risk for toxicity when receiving thiopurine drugs and purine analogues as compared to patients with a non-functional allele (e.g. *6, *7, *8). Patients with the *1/*1 genotype may still be at risk for toxicity when taking thiopurine drugs and purine analogues based upon their genotypes. Other genetic and clinical factors may also influence a patient's risk for toxicity.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184653758>746</a></td><td>TPMT</td><td>TPMT*16</td><td>purine analogues</td><td>Lupus Erythematosus, Systemic;Precursor Cell Lymphoblastic Leukemia-Lymphoma</td><td>4</td><td>*1/*1</td><td>Dosage</td><td>Patients with the *1/*1 genotype 1) may have increased inactivation of thiopurines due to normal TPMT activity and 2) may have a decreased risk for toxicity when receiving thiopurine drugs and purine analogues as compared to patients with a non-functional allele (e.g. *6, *7, *8). Patients with the *1/*1 genotype may still be at risk for toxicity when taking thiopurine drugs and purine analogues based upon their genotypes. Other genetic and clinical factors may also influence a patient's risk for toxicity.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184653758>747</a></td><td>TPMT</td><td>TPMT*16</td><td>thioguanine</td><td>Lupus Erythematosus, Systemic;Precursor Cell Lymphoblastic Leukemia-Lymphoma</td><td>4</td><td>*1/*1</td><td>Dosage</td><td>Patients with the *1/*1 genotype 1) may have increased inactivation of thiopurines due to normal TPMT activity and 2) may have a decreased risk for toxicity when receiving thiopurine drugs and purine analogues as compared to patients with a non-functional allele (e.g. *6, *7, *8). Patients with the *1/*1 genotype may still be at risk for toxicity when taking thiopurine drugs and purine analogues based upon their genotypes. Other genetic and clinical factors may also influence a patient's risk for toxicity.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184653758>748</a></td><td>TPMT</td><td>TPMT*17</td><td>azathioprine</td><td>Lupus Erythematosus, Systemic;Precursor Cell Lymphoblastic Leukemia-Lymphoma</td><td>4</td><td>*1/*1</td><td>Dosage</td><td>Patients with the *1/*1 genotype 1) may have increased inactivation of thiopurines due to normal TPMT activity and 2) may have a decreased risk for toxicity when receiving thiopurine drugs and purine analogues as compared to patients with a non-functional allele (e.g. *6, *7, *8). Patients with the *1/*1 genotype may still be at risk for toxicity when taking thiopurine drugs and purine analogues based upon their genotypes. Other genetic and clinical factors may also influence a patient's risk for toxicity.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184653758>749</a></td><td>TPMT</td><td>TPMT*17</td><td>mercaptopurine</td><td>Lupus Erythematosus, Systemic;Precursor Cell Lymphoblastic Leukemia-Lymphoma</td><td>4</td><td>*1/*1</td><td>Dosage</td><td>Patients with the *1/*1 genotype 1) may have increased inactivation of thiopurines due to normal TPMT activity and 2) may have a decreased risk for toxicity when receiving thiopurine drugs and purine analogues as compared to patients with a non-functional allele (e.g. *6, *7, *8). Patients with the *1/*1 genotype may still be at risk for toxicity when taking thiopurine drugs and purine analogues based upon their genotypes. Other genetic and clinical factors may also influence a patient's risk for toxicity.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184653758>750</a></td><td>TPMT</td><td>TPMT*17</td><td>purine analogues</td><td>Lupus Erythematosus, Systemic;Precursor Cell Lymphoblastic Leukemia-Lymphoma</td><td>4</td><td>*1/*1</td><td>Dosage</td><td>Patients with the *1/*1 genotype 1) may have increased inactivation of thiopurines due to normal TPMT activity and 2) may have a decreased risk for toxicity when receiving thiopurine drugs and purine analogues as compared to patients with a non-functional allele (e.g. *6, *7, *8). Patients with the *1/*1 genotype may still be at risk for toxicity when taking thiopurine drugs and purine analogues based upon their genotypes. Other genetic and clinical factors may also influence a patient's risk for toxicity.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184653758>751</a></td><td>TPMT</td><td>TPMT*17</td><td>thioguanine</td><td>Lupus Erythematosus, Systemic;Precursor Cell Lymphoblastic Leukemia-Lymphoma</td><td>4</td><td>*1/*1</td><td>Dosage</td><td>Patients with the *1/*1 genotype 1) may have increased inactivation of thiopurines due to normal TPMT activity and 2) may have a decreased risk for toxicity when receiving thiopurine drugs and purine analogues as compared to patients with a non-functional allele (e.g. *6, *7, *8). Patients with the *1/*1 genotype may still be at risk for toxicity when taking thiopurine drugs and purine analogues based upon their genotypes. Other genetic and clinical factors may also influence a patient's risk for toxicity.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184653758>752</a></td><td>TPMT</td><td>TPMT*18</td><td>azathioprine</td><td>Lupus Erythematosus, Systemic;Precursor Cell Lymphoblastic Leukemia-Lymphoma</td><td>4</td><td>*1/*1</td><td>Dosage</td><td>Patients with the *1/*1 genotype 1) may have increased inactivation of thiopurines due to normal TPMT activity and 2) may have a decreased risk for toxicity when receiving thiopurine drugs and purine analogues as compared to patients with a non-functional allele (e.g. *6, *7, *8). Patients with the *1/*1 genotype may still be at risk for toxicity when taking thiopurine drugs and purine analogues based upon their genotypes. Other genetic and clinical factors may also influence a patient's risk for toxicity.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184653758>753</a></td><td>TPMT</td><td>TPMT*18</td><td>mercaptopurine</td><td>Lupus Erythematosus, Systemic;Precursor Cell Lymphoblastic Leukemia-Lymphoma</td><td>4</td><td>*1/*1</td><td>Dosage</td><td>Patients with the *1/*1 genotype 1) may have increased inactivation of thiopurines due to normal TPMT activity and 2) may have a decreased risk for toxicity when receiving thiopurine drugs and purine analogues as compared to patients with a non-functional allele (e.g. *6, *7, *8). Patients with the *1/*1 genotype may still be at risk for toxicity when taking thiopurine drugs and purine analogues based upon their genotypes. Other genetic and clinical factors may also influence a patient's risk for toxicity.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184653758>754</a></td><td>TPMT</td><td>TPMT*18</td><td>purine analogues</td><td>Lupus Erythematosus, Systemic;Precursor Cell Lymphoblastic Leukemia-Lymphoma</td><td>4</td><td>*1/*1</td><td>Dosage</td><td>Patients with the *1/*1 genotype 1) may have increased inactivation of thiopurines due to normal TPMT activity and 2) may have a decreased risk for toxicity when receiving thiopurine drugs and purine analogues as compared to patients with a non-functional allele (e.g. *6, *7, *8). Patients with the *1/*1 genotype may still be at risk for toxicity when taking thiopurine drugs and purine analogues based upon their genotypes. Other genetic and clinical factors may also influence a patient's risk for toxicity.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184653758>755</a></td><td>TPMT</td><td>TPMT*18</td><td>thioguanine</td><td>Lupus Erythematosus, Systemic;Precursor Cell Lymphoblastic Leukemia-Lymphoma</td><td>4</td><td>*1/*1</td><td>Dosage</td><td>Patients with the *1/*1 genotype 1) may have increased inactivation of thiopurines due to normal TPMT activity and 2) may have a decreased risk for toxicity when receiving thiopurine drugs and purine analogues as compared to patients with a non-functional allele (e.g. *6, *7, *8). Patients with the *1/*1 genotype may still be at risk for toxicity when taking thiopurine drugs and purine analogues based upon their genotypes. Other genetic and clinical factors may also influence a patient's risk for toxicity.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184653758>756</a></td><td>TPMT</td><td>TPMT*20</td><td>azathioprine</td><td>Lupus Erythematosus, Systemic;Precursor Cell Lymphoblastic Leukemia-Lymphoma</td><td>4</td><td>*1/*1</td><td>Dosage</td><td>Patients with the *1/*1 genotype 1) may have increased inactivation of thiopurines due to normal TPMT activity and 2) may have a decreased risk for toxicity when receiving thiopurine drugs and purine analogues as compared to patients with a non-functional allele (e.g. *6, *7, *8). Patients with the *1/*1 genotype may still be at risk for toxicity when taking thiopurine drugs and purine analogues based upon their genotypes. Other genetic and clinical factors may also influence a patient's risk for toxicity.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184653758>757</a></td><td>TPMT</td><td>TPMT*20</td><td>mercaptopurine</td><td>Lupus Erythematosus, Systemic;Precursor Cell Lymphoblastic Leukemia-Lymphoma</td><td>4</td><td>*1/*1</td><td>Dosage</td><td>Patients with the *1/*1 genotype 1) may have increased inactivation of thiopurines due to normal TPMT activity and 2) may have a decreased risk for toxicity when receiving thiopurine drugs and purine analogues as compared to patients with a non-functional allele (e.g. *6, *7, *8). Patients with the *1/*1 genotype may still be at risk for toxicity when taking thiopurine drugs and purine analogues based upon their genotypes. Other genetic and clinical factors may also influence a patient's risk for toxicity.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184653758>758</a></td><td>TPMT</td><td>TPMT*20</td><td>purine analogues</td><td>Lupus Erythematosus, Systemic;Precursor Cell Lymphoblastic Leukemia-Lymphoma</td><td>4</td><td>*1/*1</td><td>Dosage</td><td>Patients with the *1/*1 genotype 1) may have increased inactivation of thiopurines due to normal TPMT activity and 2) may have a decreased risk for toxicity when receiving thiopurine drugs and purine analogues as compared to patients with a non-functional allele (e.g. *6, *7, *8). Patients with the *1/*1 genotype may still be at risk for toxicity when taking thiopurine drugs and purine analogues based upon their genotypes. Other genetic and clinical factors may also influence a patient's risk for toxicity.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184653758>759</a></td><td>TPMT</td><td>TPMT*20</td><td>thioguanine</td><td>Lupus Erythematosus, Systemic;Precursor Cell Lymphoblastic Leukemia-Lymphoma</td><td>4</td><td>*1/*1</td><td>Dosage</td><td>Patients with the *1/*1 genotype 1) may have increased inactivation of thiopurines due to normal TPMT activity and 2) may have a decreased risk for toxicity when receiving thiopurine drugs and purine analogues as compared to patients with a non-functional allele (e.g. *6, *7, *8). Patients with the *1/*1 genotype may still be at risk for toxicity when taking thiopurine drugs and purine analogues based upon their genotypes. Other genetic and clinical factors may also influence a patient's risk for toxicity.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184653758>760</a></td><td>TPMT</td><td>TPMT*21</td><td>azathioprine</td><td>Lupus Erythematosus, Systemic;Precursor Cell Lymphoblastic Leukemia-Lymphoma</td><td>4</td><td>*1/*1</td><td>Dosage</td><td>Patients with the *1/*1 genotype 1) may have increased inactivation of thiopurines due to normal TPMT activity and 2) may have a decreased risk for toxicity when receiving thiopurine drugs and purine analogues as compared to patients with a non-functional allele (e.g. *6, *7, *8). Patients with the *1/*1 genotype may still be at risk for toxicity when taking thiopurine drugs and purine analogues based upon their genotypes. Other genetic and clinical factors may also influence a patient's risk for toxicity.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184653758>761</a></td><td>TPMT</td><td>TPMT*21</td><td>mercaptopurine</td><td>Lupus Erythematosus, Systemic;Precursor Cell Lymphoblastic Leukemia-Lymphoma</td><td>4</td><td>*1/*1</td><td>Dosage</td><td>Patients with the *1/*1 genotype 1) may have increased inactivation of thiopurines due to normal TPMT activity and 2) may have a decreased risk for toxicity when receiving thiopurine drugs and purine analogues as compared to patients with a non-functional allele (e.g. *6, *7, *8). Patients with the *1/*1 genotype may still be at risk for toxicity when taking thiopurine drugs and purine analogues based upon their genotypes. Other genetic and clinical factors may also influence a patient's risk for toxicity.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184653758>762</a></td><td>TPMT</td><td>TPMT*21</td><td>purine analogues</td><td>Lupus Erythematosus, Systemic;Precursor Cell Lymphoblastic Leukemia-Lymphoma</td><td>4</td><td>*1/*1</td><td>Dosage</td><td>Patients with the *1/*1 genotype 1) may have increased inactivation of thiopurines due to normal TPMT activity and 2) may have a decreased risk for toxicity when receiving thiopurine drugs and purine analogues as compared to patients with a non-functional allele (e.g. *6, *7, *8). Patients with the *1/*1 genotype may still be at risk for toxicity when taking thiopurine drugs and purine analogues based upon their genotypes. Other genetic and clinical factors may also influence a patient's risk for toxicity.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184653758>763</a></td><td>TPMT</td><td>TPMT*21</td><td>thioguanine</td><td>Lupus Erythematosus, Systemic;Precursor Cell Lymphoblastic Leukemia-Lymphoma</td><td>4</td><td>*1/*1</td><td>Dosage</td><td>Patients with the *1/*1 genotype 1) may have increased inactivation of thiopurines due to normal TPMT activity and 2) may have a decreased risk for toxicity when receiving thiopurine drugs and purine analogues as compared to patients with a non-functional allele (e.g. *6, *7, *8). Patients with the *1/*1 genotype may still be at risk for toxicity when taking thiopurine drugs and purine analogues based upon their genotypes. Other genetic and clinical factors may also influence a patient's risk for toxicity.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184653758>764</a></td><td>TPMT</td><td>TPMT*22</td><td>azathioprine</td><td>Lupus Erythematosus, Systemic;Precursor Cell Lymphoblastic Leukemia-Lymphoma</td><td>4</td><td>*1/*1</td><td>Dosage</td><td>Patients with the *1/*1 genotype 1) may have increased inactivation of thiopurines due to normal TPMT activity and 2) may have a decreased risk for toxicity when receiving thiopurine drugs and purine analogues as compared to patients with a non-functional allele (e.g. *6, *7, *8). Patients with the *1/*1 genotype may still be at risk for toxicity when taking thiopurine drugs and purine analogues based upon their genotypes. Other genetic and clinical factors may also influence a patient's risk for toxicity.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184653758>765</a></td><td>TPMT</td><td>TPMT*22</td><td>mercaptopurine</td><td>Lupus Erythematosus, Systemic;Precursor Cell Lymphoblastic Leukemia-Lymphoma</td><td>4</td><td>*1/*1</td><td>Dosage</td><td>Patients with the *1/*1 genotype 1) may have increased inactivation of thiopurines due to normal TPMT activity and 2) may have a decreased risk for toxicity when receiving thiopurine drugs and purine analogues as compared to patients with a non-functional allele (e.g. *6, *7, *8). Patients with the *1/*1 genotype may still be at risk for toxicity when taking thiopurine drugs and purine analogues based upon their genotypes. Other genetic and clinical factors may also influence a patient's risk for toxicity.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184653758>766</a></td><td>TPMT</td><td>TPMT*22</td><td>purine analogues</td><td>Lupus Erythematosus, Systemic;Precursor Cell Lymphoblastic Leukemia-Lymphoma</td><td>4</td><td>*1/*1</td><td>Dosage</td><td>Patients with the *1/*1 genotype 1) may have increased inactivation of thiopurines due to normal TPMT activity and 2) may have a decreased risk for toxicity when receiving thiopurine drugs and purine analogues as compared to patients with a non-functional allele (e.g. *6, *7, *8). Patients with the *1/*1 genotype may still be at risk for toxicity when taking thiopurine drugs and purine analogues based upon their genotypes. Other genetic and clinical factors may also influence a patient's risk for toxicity.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184653758>767</a></td><td>TPMT</td><td>TPMT*22</td><td>thioguanine</td><td>Lupus Erythematosus, Systemic;Precursor Cell Lymphoblastic Leukemia-Lymphoma</td><td>4</td><td>*1/*1</td><td>Dosage</td><td>Patients with the *1/*1 genotype 1) may have increased inactivation of thiopurines due to normal TPMT activity and 2) may have a decreased risk for toxicity when receiving thiopurine drugs and purine analogues as compared to patients with a non-functional allele (e.g. *6, *7, *8). Patients with the *1/*1 genotype may still be at risk for toxicity when taking thiopurine drugs and purine analogues based upon their genotypes. Other genetic and clinical factors may also influence a patient's risk for toxicity.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184653758>768</a></td><td>TPMT</td><td>TPMT*23</td><td>azathioprine</td><td>Lupus Erythematosus, Systemic;Precursor Cell Lymphoblastic Leukemia-Lymphoma</td><td>4</td><td>*1/*1</td><td>Dosage</td><td>Patients with the *1/*1 genotype 1) may have increased inactivation of thiopurines due to normal TPMT activity and 2) may have a decreased risk for toxicity when receiving thiopurine drugs and purine analogues as compared to patients with a non-functional allele (e.g. *6, *7, *8). Patients with the *1/*1 genotype may still be at risk for toxicity when taking thiopurine drugs and purine analogues based upon their genotypes. Other genetic and clinical factors may also influence a patient's risk for toxicity.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184653758>769</a></td><td>TPMT</td><td>TPMT*23</td><td>mercaptopurine</td><td>Lupus Erythematosus, Systemic;Precursor Cell Lymphoblastic Leukemia-Lymphoma</td><td>4</td><td>*1/*1</td><td>Dosage</td><td>Patients with the *1/*1 genotype 1) may have increased inactivation of thiopurines due to normal TPMT activity and 2) may have a decreased risk for toxicity when receiving thiopurine drugs and purine analogues as compared to patients with a non-functional allele (e.g. *6, *7, *8). Patients with the *1/*1 genotype may still be at risk for toxicity when taking thiopurine drugs and purine analogues based upon their genotypes. Other genetic and clinical factors may also influence a patient's risk for toxicity.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184653758>770</a></td><td>TPMT</td><td>TPMT*23</td><td>purine analogues</td><td>Lupus Erythematosus, Systemic;Precursor Cell Lymphoblastic Leukemia-Lymphoma</td><td>4</td><td>*1/*1</td><td>Dosage</td><td>Patients with the *1/*1 genotype 1) may have increased inactivation of thiopurines due to normal TPMT activity and 2) may have a decreased risk for toxicity when receiving thiopurine drugs and purine analogues as compared to patients with a non-functional allele (e.g. *6, *7, *8). Patients with the *1/*1 genotype may still be at risk for toxicity when taking thiopurine drugs and purine analogues based upon their genotypes. Other genetic and clinical factors may also influence a patient's risk for toxicity.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184653758>771</a></td><td>TPMT</td><td>TPMT*23</td><td>thioguanine</td><td>Lupus Erythematosus, Systemic;Precursor Cell Lymphoblastic Leukemia-Lymphoma</td><td>4</td><td>*1/*1</td><td>Dosage</td><td>Patients with the *1/*1 genotype 1) may have increased inactivation of thiopurines due to normal TPMT activity and 2) may have a decreased risk for toxicity when receiving thiopurine drugs and purine analogues as compared to patients with a non-functional allele (e.g. *6, *7, *8). Patients with the *1/*1 genotype may still be at risk for toxicity when taking thiopurine drugs and purine analogues based upon their genotypes. Other genetic and clinical factors may also influence a patient's risk for toxicity.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183621972>772</a></td><td>CYP2C9</td><td>CYP2C9*1</td><td>trimipramine</td><td></td><td>3</td><td>*1/*1</td><td>Other</td><td>Patients with the CYP2C9*1/*1, CYP2D6*1/*1 and CYP2C19*1/*1 combined diplotype may have increased metabolism of trimipramine as compared to patients with the CYP2C9*3/*3 diplotype. Other genetic and clinical factors may also influence a patient's metabolism of trimipramine.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183621972>773</a></td><td>CYP2C9</td><td>CYP2C9*3</td><td>trimipramine</td><td></td><td>3</td><td>*1/*1</td><td>Other</td><td>Patients with the CYP2C9*1/*1, CYP2D6*1/*1 and CYP2C19*1/*1 combined diplotype may have increased metabolism of trimipramine as compared to patients with the CYP2C9*3/*3 diplotype. Other genetic and clinical factors may also influence a patient's metabolism of trimipramine.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183689961>774</a></td><td>CYP3A4</td><td>CYP3A4*1</td><td>tacrolimus</td><td>liver transplantation</td><td>3</td><td>*1/*1</td><td>Other</td><td>Patients with the CYP3A4 *1/*1 diplotype undergoing organ transplant who received a donor liver with the *1/*1 diplotype may have a decreased risk of acute cellular rejection when treated with tacrolimus as compared to patients with the *1/*1G or *1G/*1G diplotype who received a donor liver with the *1/*1G or *1G/*1G diplotype. Other genetic and clinical factors may also influence incidence of acute cellular rejection.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183689961>775</a></td><td>CYP3A4</td><td>CYP3A4*1G</td><td>tacrolimus</td><td>liver transplantation</td><td>3</td><td>*1/*1</td><td>Other</td><td>Patients with the CYP3A4 *1/*1 diplotype undergoing organ transplant who received a donor liver with the *1/*1 diplotype may have a decreased risk of acute cellular rejection when treated with tacrolimus as compared to patients with the *1/*1G or *1G/*1G diplotype who received a donor liver with the *1/*1G or *1G/*1G diplotype. Other genetic and clinical factors may also influence incidence of acute cellular rejection.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183614989>776</a></td><td>CYP2B6</td><td>CYP2B6*1</td><td>mirtazapine</td><td>Depression</td><td>3</td><td>*5/*6</td><td>Other</td><td>Patients with the CYP2B6 *5/*6 genotype and depression may have decreased metabolism of mirtazapine as compared to patients with the CYP2B6 *6/*6 genotype. Other genetic and clinical factors may also influence metabolism of mirtazapine.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183614989>777</a></td><td>CYP2B6</td><td>CYP2B6*4</td><td>mirtazapine</td><td>Depression</td><td>3</td><td>*5/*6</td><td>Other</td><td>Patients with the CYP2B6 *5/*6 genotype and depression may have decreased metabolism of mirtazapine as compared to patients with the CYP2B6 *6/*6 genotype. Other genetic and clinical factors may also influence metabolism of mirtazapine.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183614989>778</a></td><td>CYP2B6</td><td>CYP2B6*5</td><td>mirtazapine</td><td>Depression</td><td>3</td><td>*5/*6</td><td>Other</td><td>Patients with the CYP2B6 *5/*6 genotype and depression may have decreased metabolism of mirtazapine as compared to patients with the CYP2B6 *6/*6 genotype. Other genetic and clinical factors may also influence metabolism of mirtazapine.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183614989>779</a></td><td>CYP2B6</td><td>CYP2B6*6</td><td>mirtazapine</td><td>Depression</td><td>3</td><td>*5/*6</td><td>Other</td><td>Patients with the CYP2B6 *5/*6 genotype and depression may have decreased metabolism of mirtazapine as compared to patients with the CYP2B6 *6/*6 genotype. Other genetic and clinical factors may also influence metabolism of mirtazapine.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183614989>780</a></td><td>CYP2B6</td><td>CYP2B6*7</td><td>mirtazapine</td><td>Depression</td><td>3</td><td>*5/*6</td><td>Other</td><td>Patients with the CYP2B6 *5/*6 genotype and depression may have decreased metabolism of mirtazapine as compared to patients with the CYP2B6 *6/*6 genotype. Other genetic and clinical factors may also influence metabolism of mirtazapine.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1155598159>781</a></td><td>ABCG2</td><td>rs2231142</td><td>atorvastatin</td><td></td><td>3</td><td>GG</td><td>Other</td><td>Patients with the GG genotype may have lower plasma concentrations of atorvastatin as compared to patients with the TT genotype. This drug-variant pair has been assigned a no recommendation by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence pharmacokinetics of atorvastatin.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449188545>782</a></td><td>VKORC1</td><td>rs7294</td><td>acenocoumarol</td><td></td><td>3</td><td>CT</td><td>Other</td><td>Patients with the CT genotype may have a decreased likelihood of hemorrhage when treated with acenocoumarol as compared to patients with the TT genotypes and increased likelihood as compared to patients with the CC genotypes. Other clinical and genetic factors may also influence risk of hemorrhage in patients administered acenocoumarol.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444700495>783</a></td><td>ABCG2</td><td>rs41282401</td><td>dasatinib</td><td></td><td>3</td><td>GG</td><td>Other</td><td>Patients with GG genotype may have a decreased sensitivity to dasatinib or imatinib or nilotinib as compared to patients with CC genotype. The association is based on in-vitro finding in K562 cells. Other genetic and clinical factors may also influence a patient's response to dasatinib, imatinib or nilotinib.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444700495>784</a></td><td>ABCG2</td><td>rs41282401</td><td>imatinib</td><td></td><td>3</td><td>GG</td><td>Other</td><td>Patients with GG genotype may have a decreased sensitivity to dasatinib or imatinib or nilotinib as compared to patients with CC genotype. The association is based on in-vitro finding in K562 cells. Other genetic and clinical factors may also influence a patient's response to dasatinib, imatinib or nilotinib.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444700495>785</a></td><td>ABCG2</td><td>rs41282401</td><td>nilotinib</td><td></td><td>3</td><td>GG</td><td>Other</td><td>Patients with GG genotype may have a decreased sensitivity to dasatinib or imatinib or nilotinib as compared to patients with CC genotype. The association is based on in-vitro finding in K562 cells. Other genetic and clinical factors may also influence a patient's response to dasatinib, imatinib or nilotinib.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444700502>786</a></td><td>ABCG2</td><td>rs1061018</td><td>dasatinib</td><td></td><td>3</td><td>GG</td><td>Other</td><td>Patients with GG genotype may have an increased sensitivity to dasatinib or imatinib or nilotinib as compared to patients with AA genotype. The association is based on in-vitro finding in K562 cells. Other genetic and clinical factors may also influence a patient's response to dasatinib, imatinib or nilotinib.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444700502>787</a></td><td>ABCG2</td><td>rs1061018</td><td>imatinib</td><td></td><td>3</td><td>GG</td><td>Other</td><td>Patients with GG genotype may have an increased sensitivity to dasatinib or imatinib or nilotinib as compared to patients with AA genotype. The association is based on in-vitro finding in K562 cells. Other genetic and clinical factors may also influence a patient's response to dasatinib, imatinib or nilotinib.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444700502>788</a></td><td>ABCG2</td><td>rs1061018</td><td>nilotinib</td><td></td><td>3</td><td>GG</td><td>Other</td><td>Patients with GG genotype may have an increased sensitivity to dasatinib or imatinib or nilotinib as compared to patients with AA genotype. The association is based on in-vitro finding in K562 cells. Other genetic and clinical factors may also influence a patient's response to dasatinib, imatinib or nilotinib.</td><td>Uncertain</td></tr>
</table>
<h3>Genotypes called by VCF</h3>
<table width= "400" border="1">
<tr><th>ID</th><th>Gene</th><th>Variant</th><th>Drug</th><th>Phenotypes</th><th>EvidenceLevel</th><th>Alleles</th><th>PhenotypeCategory</th><th>Annotation</th><th>Function</th></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451290960>0</a></td><td>KCNJ11</td><td>rs5219</td><td>gliclazide</td><td>Diabetes Mellitus</td><td>3</td><td>CC</td><td>Efficacy</td><td>Patients with diabetes mellitus and the CC genotype who are taking gliclazide may have decreased response as compared to patients with the TT genotype. Other clinical and genetic factors may also influence response to gliclazide in patients with diabetes mellitus.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451356520>1</a></td><td>SLCO1B1</td><td>rs4149056</td><td>simvastatin</td><td></td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype may have decreased lipid-lowering response to simvastatin as compared to patients with the TT genotype. However, conflicting evidence has been reported. The effect size may be small. Other genetic and clinical factors may also influence response to simvastatin.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451357763>2</a></td><td>CSMD1</td><td>rs6990851</td><td>anastrozole</td><td>Breast Neoplasms</td><td>3</td><td>AA</td><td>Efficacy</td><td>Patients with breast cancer and the rs6990851 AA genotype may have a decreased response to anastrozole as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence response to anastrozole.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451121940>3</a></td><td>ERCC1</td><td>rs11615</td><td>cisplatin</td><td>Esophageal Neoplasms;Ovarian Neoplasms;Stomach Neoplasms</td><td>3</td><td>AA</td><td>Efficacy</td><td>Patients with the rs11615 AA genotype may have a decreased response to cisplatin as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to cisplatin.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/981201443>4</a></td><td>NOS3</td><td>rs2070744</td><td>Antihypertensives</td><td>Hypertension</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype may have a decreased but not absent risk of resistant hypertension when treated with antihypertensive drugs including diuretics as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to antihypertensives.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/981201443>5</a></td><td>NOS3</td><td>rs2070744</td><td>Antihypertensives And Diuretics In Combination</td><td>Hypertension</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype may have a decreased but not absent risk of resistant hypertension when treated with antihypertensive drugs including diuretics as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to antihypertensives.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/981201443>6</a></td><td>NOS3</td><td>rs2070744</td><td>diuretics</td><td>Hypertension</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype may have a decreased but not absent risk of resistant hypertension when treated with antihypertensive drugs including diuretics as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to antihypertensives.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/981202103>7</a></td><td>YEATS4</td><td>rs7297610</td><td>hydrochlorothiazide</td><td>Essential hypertension;Hypertension</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the rs7297610 CT genotype and hypertension who are treated with hydrochlorothiazide may have a decreased response as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to hydrochlorothiazide.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/981204864>8</a></td><td>MTHFR</td><td>rs1801131</td><td>capecitabine</td><td>Neoplasms</td><td>3</td><td>TT</td><td>Efficacy</td><td>Patients with the TT genotype who have cancer may have a decreased response to fluoropyrimidine-based chemotherapy as compared to patients with the GG or GT genotypes. However, there is conflicting evidence with regards to the association between this variant and event-free survival. Fluoropyrimidines are often used in combination chemotherapy such as FOLFOX (fluorouracil, leucovorin and oxaliplatin). Other genetic and clinical factors may also influence response to fluoropyrimidine-based chemotherapy.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/981204864>9</a></td><td>MTHFR</td><td>rs1801131</td><td>fluorouracil</td><td>Neoplasms</td><td>3</td><td>TT</td><td>Efficacy</td><td>Patients with the TT genotype who have cancer may have a decreased response to fluoropyrimidine-based chemotherapy as compared to patients with the GG or GT genotypes. However, there is conflicting evidence with regards to the association between this variant and event-free survival. Fluoropyrimidines are often used in combination chemotherapy such as FOLFOX (fluorouracil, leucovorin and oxaliplatin). Other genetic and clinical factors may also influence response to fluoropyrimidine-based chemotherapy.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/981204864>10</a></td><td>MTHFR</td><td>rs1801131</td><td>leucovorin</td><td>Neoplasms</td><td>3</td><td>TT</td><td>Efficacy</td><td>Patients with the TT genotype who have cancer may have a decreased response to fluoropyrimidine-based chemotherapy as compared to patients with the GG or GT genotypes. However, there is conflicting evidence with regards to the association between this variant and event-free survival. Fluoropyrimidines are often used in combination chemotherapy such as FOLFOX (fluorouracil, leucovorin and oxaliplatin). Other genetic and clinical factors may also influence response to fluoropyrimidine-based chemotherapy.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/981204864>11</a></td><td>MTHFR</td><td>rs1801131</td><td>oxaliplatin</td><td>Neoplasms</td><td>3</td><td>TT</td><td>Efficacy</td><td>Patients with the TT genotype who have cancer may have a decreased response to fluoropyrimidine-based chemotherapy as compared to patients with the GG or GT genotypes. However, there is conflicting evidence with regards to the association between this variant and event-free survival. Fluoropyrimidines are often used in combination chemotherapy such as FOLFOX (fluorouracil, leucovorin and oxaliplatin). Other genetic and clinical factors may also influence response to fluoropyrimidine-based chemotherapy.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/981238910>12</a></td><td>KCNJ11</td><td>rs5219</td><td>metformin</td><td>Diabetes Mellitus, Type 2</td><td>3</td><td>CC</td><td>Efficacy</td><td>Patients with the CC genotype and Type 2 Diabetes who are treated with metformin and sulfonamides, urea derivatives may have a decreased likelihood of treatment failure as compared to patients with the TT genotype. This association with response was not seen in a separate study in patients treated with sulfonamides, urea derivatives. Other genetic and clinical factors may also influence a patient's response to treatment.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/981238910>13</a></td><td>KCNJ11</td><td>rs5219</td><td>sulfonamides, urea derivatives</td><td>Diabetes Mellitus, Type 2</td><td>3</td><td>CC</td><td>Efficacy</td><td>Patients with the CC genotype and Type 2 Diabetes who are treated with metformin and sulfonamides, urea derivatives may have a decreased likelihood of treatment failure as compared to patients with the TT genotype. This association with response was not seen in a separate study in patients treated with sulfonamides, urea derivatives. Other genetic and clinical factors may also influence a patient's response to treatment.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/981345285>14</a></td><td>XRCC1</td><td>rs25487</td><td>cyclophosphamide</td><td>Neoplasms;Ovarian Neoplasms</td><td>4</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype may have 1) decreased survival and 2) decreased risk of severe neutropenia when treated with cyclophosphamide-containing chemotherapy regimens as compared to patients with the CC genotype. However, all studies evaluated also included platinum drugs which may interact with this variant. Other genetic and clinical factors may also influence response to treatment.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447943646>15</a></td><td>CHAT</td><td>rs2177370</td><td>galantamine</td><td>Alzheimer Disease</td><td>3</td><td>GG</td><td>Efficacy</td><td>Patients with the GG genotype and Alzheimer's disease may have decreased response to galantamine compared to patients with the AA or AG genotype. Other genetic and clinical factors may also impact the metabolism of galantamine.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448100396>16</a></td><td>CERS6</td><td>rs13393173</td><td>Tumor necrosis factor alpha (TNF-alpha) inhibitors</td><td>Arthritis, Rheumatoid</td><td>3</td><td>AA</td><td>Efficacy</td><td>Rheumatoid Arthritis patients with the genotype AA may be less likely to respond to TNF inhibitors compared with patients with genotype GG. Other genetic and clinical factors may also influence a patient's response.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448104131>17</a></td><td>LDLR</td><td>rs14158</td><td>peginterferon alfa-2a</td><td>Hepatitis C, Chronic;HIV Infections</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype who are co-infected with chronic hepatitis C, genotype 1 or 4, and HIV may have a decreased likelihood of sustained virological response when treated with pegylated interferon and ribavirin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence likelihood of sustained virological response.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448104131>18</a></td><td>LDLR</td><td>rs14158</td><td>peginterferon alfa-2b</td><td>Hepatitis C, Chronic;HIV Infections</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype who are co-infected with chronic hepatitis C, genotype 1 or 4, and HIV may have a decreased likelihood of sustained virological response when treated with pegylated interferon and ribavirin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence likelihood of sustained virological response.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448104131>19</a></td><td>LDLR</td><td>rs14158</td><td>ribavirin</td><td>Hepatitis C, Chronic;HIV Infections</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype who are co-infected with chronic hepatitis C, genotype 1 or 4, and HIV may have a decreased likelihood of sustained virological response when treated with pegylated interferon and ribavirin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence likelihood of sustained virological response.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449155614>20</a></td><td>LY96</td><td>rs11465996</td><td>Tumor necrosis factor alpha (TNF-alpha) inhibitors</td><td>Psoriasis</td><td>3</td><td>CG</td><td>Efficacy</td><td>Patients with the CG genotype and psoriasis may have a poorer response when treated with TNF-inhibitors as compared to patients with the CC genotype. Other genetic and clinical factors may also influence TNF-inhibitor response.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449155643>21</a></td><td>TLR9</td><td>rs352139</td><td>Tumor necrosis factor alpha (TNF-alpha) inhibitors</td><td>Psoriasis</td><td>3</td><td>CC</td><td>Efficacy</td><td>Patients with the CC genotype and psoriasis may have a poorer response when treated with TNF-inhibitors as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence TNF-inhibitor response.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449713682>22</a></td><td>ERBB2</td><td>rs1136201</td><td>carboplatin</td><td>Breast Neoplasms</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype and breast cancer may have a decreased response to treatment with carboplatin, docetaxel and trastuzumab as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to carboplatin, docetaxel and trastuzumab.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449713682>23</a></td><td>ERBB2</td><td>rs1136201</td><td>docetaxel</td><td>Breast Neoplasms</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype and breast cancer may have a decreased response to treatment with carboplatin, docetaxel and trastuzumab as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to carboplatin, docetaxel and trastuzumab.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449713682>24</a></td><td>ERBB2</td><td>rs1136201</td><td>trastuzumab</td><td>Breast Neoplasms</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype and breast cancer may have a decreased response to treatment with carboplatin, docetaxel and trastuzumab as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to carboplatin, docetaxel and trastuzumab.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450814923>25</a></td><td>PPARG</td><td>rs1801282</td><td>pioglitazone</td><td>Diabetes Mellitus, Type 2</td><td>3</td><td>CC</td><td>Efficacy</td><td>Patients with Type II diabetes and the CC genotype may have a decreased response to pioglitazone as compared to patients with the CG genotype. However, another study found no association between this variant and response to pioglitazone. Other genetic and clinical factors may also affect a patient's response to pioglitazone.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449005047>26</a></td><td>CYP3A4</td><td>rs2740574</td><td>lumefantrine</td><td>Malaria</td><td>3</td><td>TT</td><td>Efficacy</td><td>Pregnant patients with malaria and the TT genotype may have lower concentrations and worse response to lumefantrine as compared to patients with the CT or CC genotypes. Other clinical and genetic factors may also influence concentrations and response to lumefantrine.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449168307>27</a></td><td>-</td><td>rs4437856</td><td>duloxetine</td><td>Depressive Disorder, Major</td><td>3</td><td>AC</td><td>Efficacy</td><td>Patients with the AC genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449168314>28</a></td><td>-</td><td>rs2419128</td><td>duloxetine</td><td>Depressive Disorder, Major</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449168621>29</a></td><td>ANO2</td><td>rs61908410</td><td>duloxetine</td><td>Depressive Disorder, Major</td><td>3</td><td>TT</td><td>Efficacy</td><td>Patients with the TT genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450376133>30</a></td><td>TAOK3</td><td>rs795484</td><td>morphine</td><td>Pain, Postoperative</td><td>3</td><td>CC</td><td>Efficacy</td><td>Patients with the CC genotype may require a decreased dose of morphine as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's morphine dosage requirements.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183491380>31</a></td><td>ABCB1</td><td>rs1922242</td><td>fluvastatin</td><td>Hypercholesterolemia</td><td>3</td><td>AT</td><td>Efficacy</td><td>Patients with the AT genotype and Hypercholesterolemia may have a reduced response to fluvastatin (a lower change in LDL-cholesterol levels) as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to fluvastatin treatment.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/982030732>32</a></td><td>CYP1A2</td><td>rs762551</td><td>clopidogrel</td><td></td><td>3</td><td>AC</td><td>Efficacy</td><td>Patients with the AC genotype may have decreased on-treatment platelet reactivity when treated with clopidogrel as compared to patients with the CC genotype. However, another study found no association with risk of major adverse cardiac events. Other genetic and clinical factors may influence a patient's response to clopidogrel.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183491359>33</a></td><td>CETP</td><td>rs4783961</td><td>fluvastatin</td><td>Hypercholesterolemia</td><td>3</td><td>AA</td><td>Efficacy</td><td>Patients with the AA genotype and Hypercholesterolemia may have a reduced response to fluvastatin treatment (determined by a lower change in HDL-C levels) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to fluvastatin treatment.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183491403>34</a></td><td>ADAMTS1</td><td>rs428785</td><td>pravastatin</td><td>Coronary Disease;Myocardial Infarction</td><td>3</td><td>CG</td><td>Efficacy</td><td>Patients with the CG genotype may benefit less from pravastatin treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183630246>35</a></td><td>RRM1</td><td>rs1042858</td><td>gemcitabine</td><td>Breast Neoplasms</td><td>4</td><td>AA</td><td>Efficacy</td><td>Patients with the AA genotype combined with the G allele at rs9937 and breast cancer who are treated with gemcitabine may have a reduced risk of side effects including neutropenia as compared to patients with the GG genotype. This association was not seen in a seperate study in patients with pancreatic cancer. Other genetic and clinical factors may also influence a patient's response to gemcitabine treatment.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183617832>36</a></td><td>HTR1A</td><td>rs6295</td><td>paroxetine</td><td>Panic Disorder</td><td>3</td><td>CC</td><td>Efficacy</td><td>Patients with the rs6295 CC genotype may have decreased response when treated with paroxetine as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to paroxetine.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183615621>37</a></td><td>PRCP</td><td>rs2229437</td><td>benazepril</td><td>Hypertension</td><td>3</td><td>GT</td><td>Efficacy</td><td>Patients with the GT genotype and hypertension may have a decreased response when treated with benazepril as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to benazepril.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183699226>38</a></td><td>AKT1</td><td>rs2494752</td><td>carboplatin</td><td>Carcinoma, Non-Small-Cell Lung</td><td>3</td><td>GG</td><td>Efficacy</td><td>Patients with the GG genotype who are treated with carboplatin or cisplatin may have decreased risk of progression of disease as compared to patients with the AG genotype. Other genetic and clinical factors may also influence a patients response to carboplatin or cisplatin.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183699226>39</a></td><td>AKT1</td><td>rs2494752</td><td>cisplatin</td><td>Carcinoma, Non-Small-Cell Lung</td><td>3</td><td>GG</td><td>Efficacy</td><td>Patients with the GG genotype who are treated with carboplatin or cisplatin may have decreased risk of progression of disease as compared to patients with the AG genotype. Other genetic and clinical factors may also influence a patients response to carboplatin or cisplatin.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1043880802>40</a></td><td>SLCO1B1</td><td>rs4149056</td><td>pravastatin</td><td></td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the rs4149056 CT genotype who are treated with pravastatin may have a smaller reduction in LDL and total cholesterol as compared to patients with the TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183615261>41</a></td><td>HTR3A</td><td>rs2276302</td><td>clozapine</td><td>Schizophrenia</td><td>3</td><td>AA</td><td>Efficacy</td><td>Patients with the AA genotype and schizophrenia may may be less likely to respond to treatment with clozapine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to clozapine.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183615424>42</a></td><td>TNFRSF1A</td><td>rs767455</td><td>adalimumab</td><td>Arthritis, Psoriatic</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype and psoriatic arthritis may have a decreased response after 3 months of treatment with adalimumab, etanercept or infliximab as compared to patients with the TT genotype. No significant associations were seen after 6 months of treatment. Other genetic and clinical factors may also influence response to adalimumab, etanercept or infliximab.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183615424>43</a></td><td>TNFRSF1A</td><td>rs767455</td><td>etanercept</td><td>Arthritis, Psoriatic</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype and psoriatic arthritis may have a decreased response after 3 months of treatment with adalimumab, etanercept or infliximab as compared to patients with the TT genotype. No significant associations were seen after 6 months of treatment. Other genetic and clinical factors may also influence response to adalimumab, etanercept or infliximab.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183615424>44</a></td><td>TNFRSF1A</td><td>rs767455</td><td>infliximab</td><td>Arthritis, Psoriatic</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype and psoriatic arthritis may have a decreased response after 3 months of treatment with adalimumab, etanercept or infliximab as compared to patients with the TT genotype. No significant associations were seen after 6 months of treatment. Other genetic and clinical factors may also influence response to adalimumab, etanercept or infliximab.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183614600>45</a></td><td>CYP11B2</td><td>rs1799998</td><td>candesartan</td><td>Hypertension</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype and hypertension may be less likely to respond to treatment with candesartan as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to candesartan.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183700230>46</a></td><td>RRM2</td><td>rs1130609</td><td>cladribine</td><td>Leukemia, Myeloid, Acute</td><td>3</td><td>GT</td><td>Efficacy</td><td>Patients with the GT genotype and acute myeloid leukemia who are treated with cytarabine and cladribine may have poorer overall survival as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine and cladribine treatment.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183700230>47</a></td><td>RRM2</td><td>rs1130609</td><td>cytarabine</td><td>Leukemia, Myeloid, Acute</td><td>3</td><td>GT</td><td>Efficacy</td><td>Patients with the GT genotype and acute myeloid leukemia who are treated with cytarabine and cladribine may have poorer overall survival as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine and cladribine treatment.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183700488>48</a></td><td>CETP</td><td>rs1532624</td><td>hmg coa reductase inhibitors</td><td>Hyperlipidemias</td><td>3</td><td>AA</td><td>Efficacy</td><td>Patients with the AA genotype may have decreased response to hmg coa reductase inhibitors in people with Hyperlipidemias as compared to patients with genotype CC. Other genetic and clinical factors may also influence a patient's response to hmg coa reductase inhibitors.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1148480056>49</a></td><td>CYP2E1</td><td>rs2070676</td><td>cisplatin</td><td>Ovarian Neoplasms</td><td>3</td><td>CC</td><td>Efficacy</td><td>Female patients with the CC genotype and Ovarian Neoplasms who are treated with cisplatin and cyclophosphamide may have a decreased risk for severe emesis as compared to patients with the GC genotype. However, no association was found with progression-free survival or overall survival. Other genetic and clinical factors may also influence a patient's risk for severe emesis.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1148480056>50</a></td><td>CYP2E1</td><td>rs2070676</td><td>cyclophosphamide</td><td>Ovarian Neoplasms</td><td>3</td><td>CC</td><td>Efficacy</td><td>Female patients with the CC genotype and Ovarian Neoplasms who are treated with cisplatin and cyclophosphamide may have a decreased risk for severe emesis as compared to patients with the GC genotype. However, no association was found with progression-free survival or overall survival. Other genetic and clinical factors may also influence a patient's risk for severe emesis.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451398281>51</a></td><td>ADRB1</td><td>rs1801253</td><td>bucindolol</td><td>Heart Failure</td><td>3</td><td>CG</td><td>Efficacy</td><td>Patients with heart failure and the rs1801253 CG genotype may have a decreased response to bucindolol as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to bucindolol.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183532599>52</a></td><td>SCARB1</td><td>rs5888</td><td>atorvastatin</td><td>Hypercholesterolemia</td><td>3</td><td>GG</td><td>Efficacy</td><td>Patients with the GG genotype and Hypercholesterolemia who are treated with atorvastatin may have a reduced response to treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183631564>53</a></td><td>HRH4</td><td>rs4483927</td><td>risperidone</td><td>Schizophrenia</td><td>3</td><td>TT</td><td>Efficacy</td><td>Patients with the TT genotype and schizophrenia may have a poorer response when treated with risperidone as compared to patients with the GT or GG genotype. However, another study failed to find an association between this variant and response to risperidone. Other genetic and clinical factors may also influence response to risperidone.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451398287>54</a></td><td>MC4R</td><td>rs489693</td><td>paliperidone</td><td>Weight gain</td><td>3</td><td>AC</td><td>Efficacy</td><td>Patients with the rs489693 AC genotype may be at a decreased risk of experiencing weight gain when treated with paliperidone as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of experiencing weight gain when treated with paliperidone.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183690892>55</a></td><td>ABCB1</td><td>rs1045642</td><td>lamivudine</td><td>HIV Infections</td><td>3</td><td>AA</td><td>Efficacy</td><td>Patients with the AA genotype and HIV may have a decreased risk of virological failure when receiving highly active antiretroviral therapy (HAART), as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence risk of virological failure on HAART.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183690892>56</a></td><td>ABCB1</td><td>rs1045642</td><td>lopinavir</td><td>HIV Infections</td><td>3</td><td>AA</td><td>Efficacy</td><td>Patients with the AA genotype and HIV may have a decreased risk of virological failure when receiving highly active antiretroviral therapy (HAART), as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence risk of virological failure on HAART.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183690892>57</a></td><td>ABCB1</td><td>rs1045642</td><td>ritonavir</td><td>HIV Infections</td><td>3</td><td>AA</td><td>Efficacy</td><td>Patients with the AA genotype and HIV may have a decreased risk of virological failure when receiving highly active antiretroviral therapy (HAART), as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence risk of virological failure on HAART.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183690892>58</a></td><td>ABCB1</td><td>rs1045642</td><td>zidovudine</td><td>HIV Infections</td><td>3</td><td>AA</td><td>Efficacy</td><td>Patients with the AA genotype and HIV may have a decreased risk of virological failure when receiving highly active antiretroviral therapy (HAART), as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence risk of virological failure on HAART.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183680546>59</a></td><td>IFNL3</td><td>rs12979860</td><td>boceprevir</td><td>Hepatitis C, Chronic</td><td>1A</td><td>CT</td><td>Efficacy</td><td>Patients with the rs12979860 CT genotype and hepatitis C infection may have decreased response to triple therapy (boceprevir, peginterferon alfa-2a/2b and ribavirin) as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to boceprevir-peginterferon based therapy.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183680546>60</a></td><td>IFNL4</td><td>rs12979860</td><td>boceprevir</td><td>Hepatitis C, Chronic</td><td>1A</td><td>CT</td><td>Efficacy</td><td>Patients with the rs12979860 CT genotype and hepatitis C infection may have decreased response to triple therapy (boceprevir, peginterferon alfa-2a/2b and ribavirin) as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to boceprevir-peginterferon based therapy.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183680546>61</a></td><td>IFNL3</td><td>rs12979860</td><td>peginterferon alfa-2a</td><td>Hepatitis C, Chronic</td><td>1A</td><td>CT</td><td>Efficacy</td><td>Patients with the rs12979860 CT genotype and hepatitis C infection may have decreased response to triple therapy (boceprevir, peginterferon alfa-2a/2b and ribavirin) as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to boceprevir-peginterferon based therapy.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183680546>62</a></td><td>IFNL4</td><td>rs12979860</td><td>peginterferon alfa-2a</td><td>Hepatitis C, Chronic</td><td>1A</td><td>CT</td><td>Efficacy</td><td>Patients with the rs12979860 CT genotype and hepatitis C infection may have decreased response to triple therapy (boceprevir, peginterferon alfa-2a/2b and ribavirin) as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to boceprevir-peginterferon based therapy.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183680546>63</a></td><td>IFNL3</td><td>rs12979860</td><td>peginterferon alfa-2b</td><td>Hepatitis C, Chronic</td><td>1A</td><td>CT</td><td>Efficacy</td><td>Patients with the rs12979860 CT genotype and hepatitis C infection may have decreased response to triple therapy (boceprevir, peginterferon alfa-2a/2b and ribavirin) as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to boceprevir-peginterferon based therapy.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183680546>64</a></td><td>IFNL4</td><td>rs12979860</td><td>peginterferon alfa-2b</td><td>Hepatitis C, Chronic</td><td>1A</td><td>CT</td><td>Efficacy</td><td>Patients with the rs12979860 CT genotype and hepatitis C infection may have decreased response to triple therapy (boceprevir, peginterferon alfa-2a/2b and ribavirin) as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to boceprevir-peginterferon based therapy.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183680546>65</a></td><td>IFNL3</td><td>rs12979860</td><td>ribavirin</td><td>Hepatitis C, Chronic</td><td>1A</td><td>CT</td><td>Efficacy</td><td>Patients with the rs12979860 CT genotype and hepatitis C infection may have decreased response to triple therapy (boceprevir, peginterferon alfa-2a/2b and ribavirin) as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to boceprevir-peginterferon based therapy.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183680546>66</a></td><td>IFNL4</td><td>rs12979860</td><td>ribavirin</td><td>Hepatitis C, Chronic</td><td>1A</td><td>CT</td><td>Efficacy</td><td>Patients with the rs12979860 CT genotype and hepatitis C infection may have decreased response to triple therapy (boceprevir, peginterferon alfa-2a/2b and ribavirin) as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to boceprevir-peginterferon based therapy.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/982031330>67</a></td><td>-</td><td>rs2826494</td><td>lithium</td><td>Bipolar Disorder</td><td>3</td><td>GC</td><td>Efficacy</td><td>Patients with the GC genotype and Bipolar Disorder may be less likely to respond to lithium as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to lithium.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/982045124>68</a></td><td>VKORC1</td><td>rs9934438</td><td>fluindione</td><td>Thromboembolism</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with AG genotypes may have decreased the time to achieve a first INR within the therapeutic range and shorter time to have over-anticoagulation (INR >4) risk when compared to patients with GG genotypes. Other genetic and clinical factors may also influence a patient's response to therapy.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183697531>69</a></td><td>SLC19A1</td><td>rs1051266</td><td>irinotecan</td><td>Colorectal Neoplasms</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype and metastatic colorectal cancer may have decreased rapid response to treatment containing irinotecan as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to irinotecan based treatment.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183697570>70</a></td><td>ABCB1</td><td>rs1045642</td><td>tamoxifen</td><td>Breast Neoplasms</td><td>3</td><td>AA</td><td>Efficacy</td><td>Women with the AA genotype and breast cancer may have a decreased chance of disease recurrence when treated with tamoxifen as compared to patients with the AG genotype. Other genetic and clinical factors may also influence breast cancer recurrence.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183491298>71</a></td><td>MAD1L1</td><td>rs1801368</td><td>carboplatin</td><td>Ovarian Neoplasms</td><td>3</td><td>TT</td><td>Efficacy</td><td>Patients with the TT genotype and Ovarian Neoplasms who are treated with carboplatin and paclitaxel may have lower decreased biochemical response, cytoreduction, and sensitivity to the induction chemotherapy as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to carboplatin and paclitaxel.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183491298>72</a></td><td>MAD1L1</td><td>rs1801368</td><td>paclitaxel</td><td>Ovarian Neoplasms</td><td>3</td><td>TT</td><td>Efficacy</td><td>Patients with the TT genotype and Ovarian Neoplasms who are treated with carboplatin and paclitaxel may have lower decreased biochemical response, cytoreduction, and sensitivity to the induction chemotherapy as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to carboplatin and paclitaxel.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183533882>73</a></td><td>LPL</td><td>rs328</td><td>pravastatin</td><td></td><td>3</td><td>CC</td><td>Efficacy</td><td>Patients with the CC genotype who are treated with pravastatin may have a reduced response (less decrease in total cholesterol) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183614701>74</a></td><td>REEP5</td><td>rs153549</td><td>citalopram</td><td>Depressive Disorder, Major</td><td>3</td><td>GG</td><td>Efficacy</td><td>Patients with the GG genotype and major depressive disorder may be less likely to respond when treated with citalopram, fluoxetine, paroxetine or sertraline as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to citalopram, fluoxetine, paroxetine or sertraline.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183614701>75</a></td><td>REEP5</td><td>rs153549</td><td>fluoxetine</td><td>Depressive Disorder, Major</td><td>3</td><td>GG</td><td>Efficacy</td><td>Patients with the GG genotype and major depressive disorder may be less likely to respond when treated with citalopram, fluoxetine, paroxetine or sertraline as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to citalopram, fluoxetine, paroxetine or sertraline.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183614701>76</a></td><td>REEP5</td><td>rs153549</td><td>paroxetine</td><td>Depressive Disorder, Major</td><td>3</td><td>GG</td><td>Efficacy</td><td>Patients with the GG genotype and major depressive disorder may be less likely to respond when treated with citalopram, fluoxetine, paroxetine or sertraline as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to citalopram, fluoxetine, paroxetine or sertraline.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183614701>77</a></td><td>REEP5</td><td>rs153549</td><td>sertraline</td><td>Depressive Disorder, Major</td><td>3</td><td>GG</td><td>Efficacy</td><td>Patients with the GG genotype and major depressive disorder may be less likely to respond when treated with citalopram, fluoxetine, paroxetine or sertraline as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to citalopram, fluoxetine, paroxetine or sertraline.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183594148>78</a></td><td>ACE</td><td>rs4291</td><td>amlodipine</td><td>Hypertension</td><td>3</td><td>AT</td><td>Efficacy</td><td>Patients with the AT genotype and hypertension may have decreased fasting glucose levels when treated with amlodipine, chlorthalidone or lisinopril as compared to patients with the TT genotype. Other genetic and clinical factors may also influence fasting glucose levels.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183594148>79</a></td><td>ACE</td><td>rs4291</td><td>chlorthalidone</td><td>Hypertension</td><td>3</td><td>AT</td><td>Efficacy</td><td>Patients with the AT genotype and hypertension may have decreased fasting glucose levels when treated with amlodipine, chlorthalidone or lisinopril as compared to patients with the TT genotype. Other genetic and clinical factors may also influence fasting glucose levels.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183594148>80</a></td><td>ACE</td><td>rs4291</td><td>lisinopril</td><td>Hypertension</td><td>3</td><td>AT</td><td>Efficacy</td><td>Patients with the AT genotype and hypertension may have decreased fasting glucose levels when treated with amlodipine, chlorthalidone or lisinopril as compared to patients with the TT genotype. Other genetic and clinical factors may also influence fasting glucose levels.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183700483>81</a></td><td>PPARA</td><td>rs9626730</td><td>fenofibrate</td><td></td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype may have decreased reduction in fasting IL-2 when treated with fenofibrate as compared to patients with genotype TT. Other genetic and clinical factors may also influence a patient's response to fenofibrate.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/982009415>82</a></td><td>KCNH2</td><td>rs1137617</td><td>calcium channel blockers</td><td>Essential hypertension</td><td>3</td><td>GG</td><td>Efficacy</td><td>Patients with the GG genotype with essential hypertension who are treated with calcium channel blockers may have smaller reductions in diastolic blood pressure and mean arterial pressure as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's response to antihypertensive treatments.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/982009415>83</a></td><td>KCNH2</td><td>rs1137617</td><td>nitrendipine</td><td>Essential hypertension</td><td>3</td><td>GG</td><td>Efficacy</td><td>Patients with the GG genotype with essential hypertension who are treated with calcium channel blockers may have smaller reductions in diastolic blood pressure and mean arterial pressure as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's response to antihypertensive treatments.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/981239773>84</a></td><td>IFNL3</td><td>rs8099917</td><td>interferons</td><td>Hepatitis C, Chronic</td><td>1B</td><td>GT</td><td>Efficacy</td><td>Patients with the rs8099917 GT genotype and chronic hepatitis C infection may have decreased response (lower SVR) to peginterferon alfa and ribavirin therapy as compared to patients with the TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to peginterferon alfa and ribavirin therapy. Please note that this SNP has been found to be in high LD with rs12979860 which is also associated with response to pegIFN-alpha/ribavirin.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/981239773>85</a></td><td>IFNL3</td><td>rs8099917</td><td>peginterferon alfa-2a</td><td>Hepatitis C, Chronic</td><td>1B</td><td>GT</td><td>Efficacy</td><td>Patients with the rs8099917 GT genotype and chronic hepatitis C infection may have decreased response (lower SVR) to peginterferon alfa and ribavirin therapy as compared to patients with the TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to peginterferon alfa and ribavirin therapy. Please note that this SNP has been found to be in high LD with rs12979860 which is also associated with response to pegIFN-alpha/ribavirin.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/981239773>86</a></td><td>IFNL3</td><td>rs8099917</td><td>peginterferon alfa-2b</td><td>Hepatitis C, Chronic</td><td>1B</td><td>GT</td><td>Efficacy</td><td>Patients with the rs8099917 GT genotype and chronic hepatitis C infection may have decreased response (lower SVR) to peginterferon alfa and ribavirin therapy as compared to patients with the TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to peginterferon alfa and ribavirin therapy. Please note that this SNP has been found to be in high LD with rs12979860 which is also associated with response to pegIFN-alpha/ribavirin.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/981239773>87</a></td><td>IFNL3</td><td>rs8099917</td><td>ribavirin</td><td>Hepatitis C, Chronic</td><td>1B</td><td>GT</td><td>Efficacy</td><td>Patients with the rs8099917 GT genotype and chronic hepatitis C infection may have decreased response (lower SVR) to peginterferon alfa and ribavirin therapy as compared to patients with the TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to peginterferon alfa and ribavirin therapy. Please note that this SNP has been found to be in high LD with rs12979860 which is also associated with response to pegIFN-alpha/ribavirin.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/982034831>88</a></td><td>ABCB1</td><td>rs1045642</td><td>oxaliplatin</td><td>Colorectal Neoplasms</td><td>3</td><td>AA</td><td>Efficacy</td><td>Patients with the AA genotype and colorectal cancer may have a shorter period of recurrence-free survival when treated with oxaliplatin-based chemotherapy as compared to patients with the AG genotype. Other genetic and clinical factors may also influence a patient's response to treatment.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1043858975>89</a></td><td>TBXA2R</td><td>rs4523</td><td>aspirin</td><td></td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype may have a decreased, but not absent, risk for aspirin resistance as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for aspirin resistance.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1043859494>90</a></td><td>HTR2C</td><td>rs6318</td><td>escitalopram</td><td>neuropathic pain</td><td>3</td><td>G</td><td>Efficacy</td><td>Patients with one X-chromosome, neuropathic pain and the G genotype may have decreased pain relief when treated with escitalopram as compared to patients with the C genotype. Other genetic and clinical factors may also influence a patient's response to escitalopram.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183491055>91</a></td><td>P2RY12</td><td>rs6787801</td><td>cangrelor</td><td></td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype may have lower ADP-induced peak platelet aggregation when exposed to cangrelor as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to cangrelor.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183491262>92</a></td><td>SLC6A4</td><td>rs1042173</td><td>ondansetron</td><td>Alcoholism</td><td>3</td><td>CC</td><td>Efficacy</td><td>Patients with the CC genotype who are treated with ondansetron may have decreased treatment response among patients carrying the SLC6A4 promoter length polymorphism long/long genotype as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to ondansetron.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183615273>93</a></td><td>ERCC1</td><td>rs11615</td><td>fluorouracil</td><td>Colorectal Neoplasms</td><td>3</td><td>AA</td><td>Efficacy</td><td>Patients with the AA genotype and colorectal cancer may have decreased overall and progression-free survival time when treated with FOLFOX (fluorouracil, leucovorin, oxaliplatin) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence overall and progression-free survival time.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183615273>94</a></td><td>ERCC1</td><td>rs11615</td><td>leucovorin</td><td>Colorectal Neoplasms</td><td>3</td><td>AA</td><td>Efficacy</td><td>Patients with the AA genotype and colorectal cancer may have decreased overall and progression-free survival time when treated with FOLFOX (fluorouracil, leucovorin, oxaliplatin) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence overall and progression-free survival time.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183615273>95</a></td><td>ERCC1</td><td>rs11615</td><td>oxaliplatin</td><td>Colorectal Neoplasms</td><td>3</td><td>AA</td><td>Efficacy</td><td>Patients with the AA genotype and colorectal cancer may have decreased overall and progression-free survival time when treated with FOLFOX (fluorouracil, leucovorin, oxaliplatin) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence overall and progression-free survival time.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183614766>96</a></td><td>CASP7</td><td>rs1127687</td><td>paclitaxel</td><td>Carcinoma, Non-Small-Cell Lung</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype and non-small cell lung cancer may have reduced progression-free survival time when treated with platinum compounds in combination with paclitaxel as compared to patients with the GG genotype. Other genetic and clinical factors may also influence progression-free survival time.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183614766>97</a></td><td>CASP7</td><td>rs1127687</td><td>Platinum compounds</td><td>Carcinoma, Non-Small-Cell Lung</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype and non-small cell lung cancer may have reduced progression-free survival time when treated with platinum compounds in combination with paclitaxel as compared to patients with the GG genotype. Other genetic and clinical factors may also influence progression-free survival time.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183631787>98</a></td><td>GRK5</td><td>rs915120</td><td>citalopram</td><td>Depressive Disorder</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype may have decreased likelihood of remission at 8 weeks when treated with citalopram or escitalopram in people with depression as compared to patients with the TT genotype. However, this association did not reach genome-wide level of significance in the GWAS study (P<10-7). Other genetic or clinical factors may also influence a patient's response to citalopram or escitalopram.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183631787>99</a></td><td>GRK5</td><td>rs915120</td><td>escitalopram</td><td>Depressive Disorder</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype may have decreased likelihood of remission at 8 weeks when treated with citalopram or escitalopram in people with depression as compared to patients with the TT genotype. However, this association did not reach genome-wide level of significance in the GWAS study (P<10-7). Other genetic or clinical factors may also influence a patient's response to citalopram or escitalopram.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183679843>100</a></td><td>SERPINA3</td><td>rs17091162</td><td>antineoplastic agents</td><td>Pancreatic Neoplasms</td><td>3</td><td>AC</td><td>Efficacy</td><td>Patients with the AC genotype may have decreased survival when treated with antineoplastic agents in people with Pancreatic Neoplasms as compared to patients with genotype AA. Other genetic and clinical factors may also influence a patient's response to antineoplastic agents.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183680526>101</a></td><td>COMT</td><td>rs13306278</td><td>Selective serotonin reuptake inhibitors</td><td>Depressive Disorder, Major</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype may have decreased likelihood of remission when treated with Selective serotonin reuptake inhibitors in people with Depressive Disorder as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to Selective serotonin reuptake inhibitors.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450814647>102</a></td><td>HTR2A</td><td>rs2770296</td><td>bupropion</td><td>Depressive Disorder, Major</td><td>3</td><td>TT</td><td>Efficacy</td><td>Patients with the TT genotype may have a decreased response to bupropion in the treatment of major depressive disorder, as measured by a reduction in HAMD scores, as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to bupropion.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/982031517>103</a></td><td>-</td><td>rs352428</td><td>citalopram</td><td>Depressive Disorder, Major</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype and depression may be less likely to respond to citalopram or escitalopram as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to citalopram or escitalopram.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/982031517>104</a></td><td>-</td><td>rs352428</td><td>escitalopram</td><td>Depressive Disorder, Major</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype and depression may be less likely to respond to citalopram or escitalopram as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to citalopram or escitalopram.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183491822>105</a></td><td>F3</td><td>rs3917643</td><td>simvastatin</td><td>Myocardial Ischemia</td><td>3</td><td>TT</td><td>Efficacy</td><td>Patients with the TT genotype and stable ischemic heart disease may have a reduced response to simvastatin as compared to patients with the CT genotype. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/982031241>106</a></td><td>SLCO1C1</td><td>rs3794271</td><td>Tumor necrosis factor alpha (TNF-alpha) inhibitors</td><td>Arthritis, Psoriatic;Arthritis, Rheumatoid</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype may have decreased response to TNF inhibitors as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to TNF inhibitor treatment.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/982045137>107</a></td><td>NEUROD1</td><td>rs1801262</td><td>repaglinide</td><td>Diabetes Mellitus</td><td>3</td><td>CC</td><td>Efficacy</td><td>Patients with CC genotypes may have worse response for fasting and postprandial plasma glucose in diabetic patients treated with repaglinide when compared to patients with CT + TT genotypes. Other genetic and clinical factors may also influence a patient's response to therapy.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1043880066>108</a></td><td>IL10</td><td>rs1800872</td><td>cyclosporine</td><td>Kidney Transplantation</td><td>3</td><td>GT</td><td>Efficacy</td><td>Patients with the TG genotype and Kidney Transplantation may have a decreased risk for biopsy-proven acute rejection (BPAR) at 12 month post-transplant when treated with cyclosporine and mycophenolate mofetil as compared to patients with TT genotype. Other genetic and clinical factors may also influence a patient's risk for biopsy-proven acute rejection.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1043880066>109</a></td><td>IL10</td><td>rs1800872</td><td>mycophenolate mofetil</td><td>Kidney Transplantation</td><td>3</td><td>GT</td><td>Efficacy</td><td>Patients with the TG genotype and Kidney Transplantation may have a decreased risk for biopsy-proven acute rejection (BPAR) at 12 month post-transplant when treated with cyclosporine and mycophenolate mofetil as compared to patients with TT genotype. Other genetic and clinical factors may also influence a patient's risk for biopsy-proven acute rejection.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183632195>110</a></td><td>ABCB1</td><td>rs1045642</td><td>ondansetron</td><td>Postoperative Nausea and Vomiting;Vomiting</td><td>3</td><td>AA</td><td>Efficacy</td><td>Patients with the rs1045642 AA genotype may have decreased likelihood of nausea and vomiting shortly after being treated with ondansetron as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence response to ondansetron.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449168072>111</a></td><td>-</td><td>rs2933304</td><td>duloxetine</td><td>Depressive Disorder, Major</td><td>3</td><td>GT</td><td>Efficacy</td><td>Patients with the GT genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/982030971>112</a></td><td>P2RY12</td><td>rs9859552</td><td>cangrelor</td><td></td><td>3</td><td>GT</td><td>Efficacy</td><td>No information is reported for the GT genotype. However, patients with the TT genotype may have less inhibition of platelet aggregation with crangrelor as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to cangrelor.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/982031308>113</a></td><td>DRD1</td><td>rs4532</td><td>lithium</td><td>Bipolar Disorder</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype and Bipolar Disorder may have a decreased response to lithium as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to treatment.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/982031034>114</a></td><td>P2RY12</td><td>rs6809699</td><td>clopidogrel</td><td>Coronary Artery Disease</td><td>3</td><td>CC</td><td>Efficacy</td><td>Patients with the CC genotype and treated with clopidogrel may have 1) an average aggregation 2) decreased, but not absent, risk of non-response as compared to patients with the AA genotype. However, contradictory findings exist. Other genetic and clinical factors may also influence a patient's response to clopidogrel.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1043858872>115</a></td><td>ZNF423</td><td>rs8060157</td><td>raloxifene</td><td>Breast Neoplasms</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype may have decreased risk of occurrence of breast cancer during SERM (selective estrogen receptor modulators) therapy when treated with raloxifene or tamoxifen in people with Breast Neoplasms as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to SERM therapy.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1043858872>116</a></td><td>ZNF423</td><td>rs8060157</td><td>tamoxifen</td><td>Breast Neoplasms</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype may have decreased risk of occurrence of breast cancer during SERM (selective estrogen receptor modulators) therapy when treated with raloxifene or tamoxifen in people with Breast Neoplasms as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to SERM therapy.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183614547>117</a></td><td>RHBDF2</td><td>rs12948783</td><td>fentanyl</td><td>Neoplasms</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype may have lower pain relief to opioids in cancer patients as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to opioids.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183614547>118</a></td><td>RHBDF2</td><td>rs12948783</td><td>morphine</td><td>Neoplasms</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype may have lower pain relief to opioids in cancer patients as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to opioids.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183614547>119</a></td><td>RHBDF2</td><td>rs12948783</td><td>opioids</td><td>Neoplasms</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype may have lower pain relief to opioids in cancer patients as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to opioids.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183614547>120</a></td><td>RHBDF2</td><td>rs12948783</td><td>oxycodone</td><td>Neoplasms</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype may have lower pain relief to opioids in cancer patients as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to opioids.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/982032734>121</a></td><td>GSK3B</td><td>rs6438552</td><td>lithium</td><td>Bipolar Disorder</td><td>3</td><td>GA</td><td>Efficacy</td><td>Patients with the GA genotype and Bipolar Disorder may be less likely to respond to lithium as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to lithium.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183614696>122</a></td><td>REEP5</td><td>rs153560</td><td>citalopram</td><td>Depressive Disorder, Major</td><td>3</td><td>AA</td><td>Efficacy</td><td>Patients with the AA genotype and major depressive disorder may be less likely to respond when treated with citalopram, fluoxetine, paroxetine or sertraline as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to citalopram, fluoxetine, paroxetine or sertraline.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183614696>123</a></td><td>REEP5</td><td>rs153560</td><td>fluoxetine</td><td>Depressive Disorder, Major</td><td>3</td><td>AA</td><td>Efficacy</td><td>Patients with the AA genotype and major depressive disorder may be less likely to respond when treated with citalopram, fluoxetine, paroxetine or sertraline as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to citalopram, fluoxetine, paroxetine or sertraline.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183614696>124</a></td><td>REEP5</td><td>rs153560</td><td>paroxetine</td><td>Depressive Disorder, Major</td><td>3</td><td>AA</td><td>Efficacy</td><td>Patients with the AA genotype and major depressive disorder may be less likely to respond when treated with citalopram, fluoxetine, paroxetine or sertraline as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to citalopram, fluoxetine, paroxetine or sertraline.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183614696>125</a></td><td>REEP5</td><td>rs153560</td><td>sertraline</td><td>Depressive Disorder, Major</td><td>3</td><td>AA</td><td>Efficacy</td><td>Patients with the AA genotype and major depressive disorder may be less likely to respond when treated with citalopram, fluoxetine, paroxetine or sertraline as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to citalopram, fluoxetine, paroxetine or sertraline.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183545767>126</a></td><td>APOA1</td><td>rs964184</td><td>fenofibrate</td><td>Hypertriglyceridemia</td><td>3</td><td>CC</td><td>Efficacy</td><td>Patients with the CC genotype and hypertriglyceridemia may have a decreased response when treated with fenofibrate as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to fenofibrate.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183624306>127</a></td><td>DRD3</td><td>rs324026</td><td>duloxetine</td><td>Anxiety Disorders</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype and Anxiety Disorders who are treated with duloxetine may have decreased response to duloxetine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to duloxetine.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183624313>128</a></td><td>DRD3</td><td>rs324023</td><td>duloxetine</td><td>Anxiety Disorders</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype and Anxiety Disorders who are treated with duloxetine may have decreased response to duloxetine as compared to patients with the CC or TT genotype. Other genetic and clinical factors may also influence a patient's response to duloxetine.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183624328>129</a></td><td>DRD3</td><td>rs167770</td><td>duloxetine</td><td>Anxiety Disorders</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype and Anxiety Disorders who are treated with duloxetine may have decreased response to duloxetine as compared to patients with the AA or GG genotype. Other genetic and clinical factors may also influence a patient's response to duloxetine.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1043880608>130</a></td><td>SLCO1B1</td><td>rs2306283</td><td>atorvastatin</td><td>Hypercholesterolemia</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype and Hypercholesterolemia who are treated with atorvastatin may have less reduction in LDL as compared to patients with the GG genotype. However, one study found no association with LDL levels. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183614752>131</a></td><td>TGFBR3</td><td>rs12082710</td><td>antidepressants</td><td>Depression</td><td>3</td><td>CC</td><td>Efficacy</td><td>Patients with the CC genotype and depression may be less likely to respond to antidepressant treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to antidepressants.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183615150>132</a></td><td>AGT</td><td>rs7079</td><td>benazepril</td><td>Hypertension</td><td>3</td><td>GG</td><td>Efficacy</td><td>Patients with the GG genotype and hypertension may have smaller decreases in systolic and diastolic blood pressure when treated with benazepril as compared to patients with the TT genotype. Other genetic and clinical factors may also influence change in systolic and diastrolic blood pressure.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183615213>133</a></td><td>MTHFR</td><td>rs1801133</td><td>benazepril</td><td>Hypertension</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype and hypertension may have a smaller decrease in diastolic blood pressure when treated with benazepril as compared to patients with the AA genotype. No significant differences in systolic blood pressure were seen. Other genetic and clinical factors may also influence change in diastolic blood pressure.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/982031956>134</a></td><td>IL4R</td><td>rs8832</td><td>pitrakinra</td><td>Asthma</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype and Asthma may be less likely to respond when treated with pitrakinra as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to pitrakinra.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183564845>135</a></td><td>AGTR1</td><td>rs5186</td><td>candesartan</td><td>Heart Failure</td><td>3</td><td>AC</td><td>Efficacy</td><td>Patients with the AC genotype and heart failure may have a decreased response when treated with candesartan as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to candesartan.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183614706>136</a></td><td>CRP</td><td>rs1417938</td><td>fenofibrate</td><td>Metabolic Syndrome</td><td>3</td><td>AT</td><td>Efficacy</td><td>Patients with the AT genotype and metabolic syndrome may have a decreased response when treated with fenofibrate as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to fenofibrate.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183614771>137</a></td><td>CASP7</td><td>rs1127687</td><td>gemcitabine</td><td>Carcinoma, Non-Small-Cell Lung</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype and non-small cell lung cancer may have reduced progression-free survival time when treated with platinum compounds in combination with gemcitabine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence progression-free survival time.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183614771>138</a></td><td>CASP7</td><td>rs1127687</td><td>Platinum compounds</td><td>Carcinoma, Non-Small-Cell Lung</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype and non-small cell lung cancer may have reduced progression-free survival time when treated with platinum compounds in combination with gemcitabine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence progression-free survival time.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183615288>139</a></td><td>HTR3A</td><td>rs1062613</td><td>clozapine</td><td>Schizophrenia</td><td>3</td><td>CC</td><td>Efficacy</td><td>Patients with the CC genotype and schizophrenia may be less likely to respond to treatment with clozapine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to clozapine.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183615373>140</a></td><td>NOD2</td><td>rs2066844</td><td>tacrolimus</td><td>Kidney Transplantation</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype who underwent kidney transplantation may have a shorter post-transplantation hospital stay when treated with tacrolimus as compared to patients with the CC genotype. Other genetic and clinical factors may also influence length of post-transplantation hospital stay.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183554425>141</a></td><td>CASP7</td><td>rs7921977</td><td>docetaxel</td><td>Carcinoma, Non-Small-Cell Lung</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype and non-small cell lung cancer may have reduced progression-free survival time when treated with platinum compounds in combination with either docetaxel, gemcitabine, paclitaxel or vinorelbine, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence progression-free survival time.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183554425>142</a></td><td>CASP7</td><td>rs7921977</td><td>gemcitabine</td><td>Carcinoma, Non-Small-Cell Lung</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype and non-small cell lung cancer may have reduced progression-free survival time when treated with platinum compounds in combination with either docetaxel, gemcitabine, paclitaxel or vinorelbine, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence progression-free survival time.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183554425>143</a></td><td>CASP7</td><td>rs7921977</td><td>paclitaxel</td><td>Carcinoma, Non-Small-Cell Lung</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype and non-small cell lung cancer may have reduced progression-free survival time when treated with platinum compounds in combination with either docetaxel, gemcitabine, paclitaxel or vinorelbine, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence progression-free survival time.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183554425>144</a></td><td>CASP7</td><td>rs7921977</td><td>Platinum compounds</td><td>Carcinoma, Non-Small-Cell Lung</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype and non-small cell lung cancer may have reduced progression-free survival time when treated with platinum compounds in combination with either docetaxel, gemcitabine, paclitaxel or vinorelbine, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence progression-free survival time.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183554425>145</a></td><td>CASP7</td><td>rs7921977</td><td>vinorelbine</td><td>Carcinoma, Non-Small-Cell Lung</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype and non-small cell lung cancer may have reduced progression-free survival time when treated with platinum compounds in combination with either docetaxel, gemcitabine, paclitaxel or vinorelbine, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence progression-free survival time.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183632091>146</a></td><td>PRKCA</td><td>rs4791040</td><td>hydrochlorothiazide</td><td>Hypertension</td><td>3</td><td>TT</td><td>Efficacy</td><td>Patients with the TT genotype and hypertension who are treated with hydrochlorothiazide may have decreased reduction of diastolic blood pressure as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also influence a patient's response to hydrochlorothiazide treatment.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449716207>147</a></td><td>-</td><td>rs13093031</td><td>fentanyl</td><td>Pain, Postoperative</td><td>3</td><td>AA</td><td>Efficacy</td><td>Patients with the AA genotype may have a decreased response to fentanyl as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to fentanyl.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449750773>148</a></td><td>RASSF1</td><td>rs2236947</td><td>cetuximab</td><td>Colorectal Neoplasms</td><td>3</td><td>AC</td><td>Efficacy</td><td>Patients with the AC genotype and colorectal cancer may have decreased overall survival time when treated with cetuximab as compared to patients with the CC genotype. Other genetic and clinical factors may also influence overall survival time.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449750843>149</a></td><td>NCAM1</td><td>rs2303377</td><td>duloxetine</td><td>Depressive Disorder, Major</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype and major depressive disorder may have a poorer response to treatment with duloxetine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence duloxetine response.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449169675>150</a></td><td>UGT1A6</td><td>rs1105879</td><td>aspirin</td><td>Colonic Neoplasms</td><td>3</td><td>AC</td><td>Efficacy</td><td>Patients with the AC genotype may not experience a reduced risk of developing colonic cancer when taking aspirin as compared to patients with the AA genotype who are taking aspirin. Other genetic and clinical factors may also affect the protective effect of aspirin on a patient's risk of developing colonic cancer.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451408023>151</a></td><td>COMT</td><td>rs6269</td><td>butorphanol</td><td></td><td>3</td><td>GG</td><td>Efficacy</td><td>Patients with the rs6269 GG genotype may have a decreased analgesic response to butorphanol as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also influence response to butorphanol.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450930536>152</a></td><td>XIRP2</td><td>rs7606603</td><td>atenolol</td><td>Hypertension</td><td>3</td><td>CC</td><td>Efficacy</td><td>Patients with hypertension and the CC genotype may have a decreased systolic blood pressure response to atenolol as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to atenolol.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450821128>153</a></td><td>CYP4A11</td><td>rs3890011</td><td>spironolactone</td><td>Hypertension</td><td>3</td><td>CC</td><td>Efficacy</td><td>Patients with hypertension and the CC genotype may have a decreased response to spironolactone, as measured by changes in systolic and diastolic blood pressure, as compared to patients with the CG or GG genotypes. Other genetic or clinical factors may also affect a patient's response to spironolactone.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450928486>154</a></td><td>HTT</td><td>rs362267</td><td>risperidone</td><td>Schizophrenia</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with schizophrenia and the CT genotype may have a decreased response to risperidone as compared to patients with the CC genotype. However, this association lost significance following correction for multiple testing. Other genetic or clinical factors may also affect a patient's response to risperidone.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450928486>155</a></td><td>MSANTD1</td><td>rs362267</td><td>risperidone</td><td>Schizophrenia</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with schizophrenia and the CT genotype may have a decreased response to risperidone as compared to patients with the CC genotype. However, this association lost significance following correction for multiple testing. Other genetic or clinical factors may also affect a patient's response to risperidone.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450820863>156</a></td><td>DRD2</td><td>rs1079597</td><td>prochlorperazine</td><td>Nausea</td><td>3</td><td>CC</td><td>Efficacy</td><td>Patients with the CC genotype may have a decreased incidence of nausea following treatment with prochlorperazine as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also affect a patient's response to prochlorperazine.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449167420>157</a></td><td>ETFDH</td><td>rs11559290</td><td>methylphenidate</td><td>Attention Deficit Disorder with Hyperactivity</td><td>3</td><td>TT</td><td>Efficacy</td><td>Patients with the TT genotype and Attention Deficit Disorder with Hyperactivity may have a decreased response to treatment with methylphenidate as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's response to methylphenidate.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449167431>158</a></td><td>NFIB</td><td>rs7858</td><td>methylphenidate</td><td>Attention Deficit Disorder with Hyperactivity</td><td>3</td><td>TT</td><td>Efficacy</td><td>Patients with the TT genotype and Attention Deficit Disorder with Hyperactivity may have a decreased response to treatment with methylphenidate as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's response to methylphenidate.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449167442>159</a></td><td>ARHGEF28</td><td>rs929740</td><td>methylphenidate</td><td>Attention Deficit Disorder with Hyperactivity</td><td>3</td><td>AA</td><td>Efficacy</td><td>Patients with the AA genotype and Attention Deficit Disorder with Hyperactivity may have a decreased response to treatment with methylphenidate as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's response to methylphenidate.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449168385>160</a></td><td>-</td><td>rs7625956</td><td>duloxetine</td><td>Depressive Disorder, Major</td><td>3</td><td>AA</td><td>Efficacy</td><td>Patients with the AA genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's response to duloxetine.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449168392>161</a></td><td>-</td><td>rs4858478</td><td>duloxetine</td><td>Depressive Disorder, Major</td><td>3</td><td>AA</td><td>Efficacy</td><td>Patients with the AA genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's response to duloxetine.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449168412>162</a></td><td>-</td><td>rs10007051</td><td>duloxetine</td><td>Depressive Disorder, Major</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449168419>163</a></td><td>-</td><td>rs11933890</td><td>duloxetine</td><td>Depressive Disorder, Major</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449168426>164</a></td><td>-</td><td>rs62319299</td><td>duloxetine</td><td>Depressive Disorder, Major</td><td>3</td><td>AC</td><td>Efficacy</td><td>Patients with the AC genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449168433>165</a></td><td>-</td><td>rs56229625</td><td>duloxetine</td><td>Depressive Disorder, Major</td><td>3</td><td>GT</td><td>Efficacy</td><td>Patients with the GT genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449168440>166</a></td><td>-</td><td>rs55881666</td><td>duloxetine</td><td>Depressive Disorder, Major</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449168447>167</a></td><td>TTC37</td><td>rs12657120</td><td>duloxetine</td><td>Depressive Disorder, Major</td><td>3</td><td>CG</td><td>Efficacy</td><td>Patients with the CG genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451409133>168</a></td><td>CETP</td><td>rs708272</td><td>rosuvastatin</td><td></td><td>3</td><td>AA</td><td>Efficacy</td><td>Patients with the rs708272 AA genotype may have a decreased response to rosuvastatin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to rosuvastatin.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449155310>169</a></td><td>SLCO1B3</td><td>rs4149117</td><td>sunitinib</td><td>Gastrointestinal Stromal Tumors</td><td>3</td><td>GG</td><td>Efficacy</td><td>Patients with the GG genotype and gastrointestinal stromal tumors (GIST) may have shorter overall survival times when treated with sunitinib as compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence overall survival time.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450373854>170</a></td><td>KCNJ6</td><td>rs6517442</td><td>morphine</td><td>Pain</td><td>3</td><td>TT</td><td>Efficacy</td><td>Patients with the TT genotype may have a decreased analgesic response to morphine as compared to patients with the CC or CT genotypes. Other genetic or clinical factors may also affect a patient's response to morphine.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450928430>171</a></td><td>HTT</td><td>rs362306</td><td>risperidone</td><td>Schizophrenia</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with schizophrenia and the AG genotype may have a decreased response to risperidone as compared to patients with the GG genotype. However, this association lost significance following correction for multiple testing. Other genetic or clinical factors may also affect a patient's response to risperidone.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450928430>172</a></td><td>MSANTD1</td><td>rs362306</td><td>risperidone</td><td>Schizophrenia</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with schizophrenia and the AG genotype may have a decreased response to risperidone as compared to patients with the GG genotype. However, this association lost significance following correction for multiple testing. Other genetic or clinical factors may also affect a patient's response to risperidone.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449296320>173</a></td><td>CPA6</td><td>rs2162145</td><td>metformin</td><td>Diabetes Mellitus, Type 2</td><td>3</td><td>CC</td><td>Efficacy</td><td>Patients with the CC genotype may have decreased response to metformin in people with type 2 Diabetes Mellitus as compared to patients with genotype TT or CT. Other genetic and clinical factors may also influence the response to metformin.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449296326>174</a></td><td>NBEA</td><td>rs57081354</td><td>metformin</td><td>Diabetes Mellitus, Type 2</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype may have decreased response to metformin in people with type 2 Diabetes Mellitus as compared to patients with genotype TT. Other genetic and clinical factors may also influence the response to metformin.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451410280>175</a></td><td>MTOR</td><td>rs2024627</td><td>everolimus</td><td>Breast Neoplasms;Kidney Neoplasms;Neuroendocrine Tumors</td><td>3</td><td>CC</td><td>Efficacy</td><td>Patients with the rs2024627 CC genotype and cancer may have a decreased likelihood of progression-free survival when treated with everolimus as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence likelihood of progression-free survival when treated with everolimus.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451412140>176</a></td><td>MUTYH</td><td>rs3219489</td><td>cisplatin</td><td>Carcinoma, Squamous Cell;progression-free survival</td><td>3</td><td>GG</td><td>Efficacy</td><td>Patients with the rs3219489 GG genotype and oral squamous cell carcinoma may have a decreased likelihood of progression-free survival when treated with a combination of cisplatin, fluorouracil and radiotherapy. as compared to patients with the CC genotype. Other genetic and clinical factors may also influence likelihood of progression-free survival when treated with cisplatin, fluorouracil and radiotherapy.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451412140>177</a></td><td>MUTYH</td><td>rs3219489</td><td>fluorouracil</td><td>Carcinoma, Squamous Cell;progression-free survival</td><td>3</td><td>GG</td><td>Efficacy</td><td>Patients with the rs3219489 GG genotype and oral squamous cell carcinoma may have a decreased likelihood of progression-free survival when treated with a combination of cisplatin, fluorouracil and radiotherapy. as compared to patients with the CC genotype. Other genetic and clinical factors may also influence likelihood of progression-free survival when treated with cisplatin, fluorouracil and radiotherapy.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451412140>178</a></td><td>MUTYH</td><td>rs3219489</td><td>radiotherapy</td><td>Carcinoma, Squamous Cell;progression-free survival</td><td>3</td><td>GG</td><td>Efficacy</td><td>Patients with the rs3219489 GG genotype and oral squamous cell carcinoma may have a decreased likelihood of progression-free survival when treated with a combination of cisplatin, fluorouracil and radiotherapy. as compared to patients with the CC genotype. Other genetic and clinical factors may also influence likelihood of progression-free survival when treated with cisplatin, fluorouracil and radiotherapy.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450376139>179</a></td><td>TAOK3</td><td>rs1277441</td><td>morphine</td><td>Pain, Postoperative</td><td>3</td><td>AA</td><td>Efficacy</td><td>Patients with the AA genotype may require a decreased dose of morphine as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's morphine dosage requirements.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655385462>180</a></td><td>ABCB1</td><td>rs1045642</td><td>methotrexate</td><td>Arthritis, Rheumatoid</td><td>3</td><td>AA</td><td>Efficacy</td><td>Patients with the rs1045642 AA genotype and rheumatoid arthritis who are treated with methotrexate may have a decreased risk of drug toxicity as compared to patients with the AG or GG genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity when treated with methotrexate.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655385579>181</a></td><td>NOS3</td><td>rs2070744</td><td>Antihypertensives And Diuretics In Combination</td><td></td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype who are treated with antihypertensive drugs may have a decreased, but not absent, risk for resistance as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for resistance.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655385705>182</a></td><td>BDNF</td><td>rs61888800</td><td>antidepressants</td><td>Depression;Depressive Disorder, Major</td><td>3</td><td>GT</td><td>Efficacy</td><td>Patients with the GT genotype with major depressive disorder may experience a lesser response when treated with desipramine or fluoxetine compared to patients with GG genotypes. Other genetic and clinical factors may also influence response to antidepressants.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655385705>183</a></td><td>BDNF</td><td>rs61888800</td><td>desipramine</td><td>Depression;Depressive Disorder, Major</td><td>3</td><td>GT</td><td>Efficacy</td><td>Patients with the GT genotype with major depressive disorder may experience a lesser response when treated with desipramine or fluoxetine compared to patients with GG genotypes. Other genetic and clinical factors may also influence response to antidepressants.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655385705>184</a></td><td>BDNF</td><td>rs61888800</td><td>fluoxetine</td><td>Depression;Depressive Disorder, Major</td><td>3</td><td>GT</td><td>Efficacy</td><td>Patients with the GT genotype with major depressive disorder may experience a lesser response when treated with desipramine or fluoxetine compared to patients with GG genotypes. Other genetic and clinical factors may also influence response to antidepressants.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655385763>185</a></td><td>TCF7L2</td><td>rs290487</td><td>repaglinide</td><td>Diabetes Mellitus, Type 2</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype may have lower response to repaglinide in people with Diabetes Mellitus, Type 2 as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's repsonse.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655386104>186</a></td><td>PPARD</td><td>rs6922548</td><td>docetaxel</td><td>Prostatic Neoplasms</td><td>3</td><td>AA</td><td>Efficacy</td><td>Patients with the AA genotype may have decreased chance of response to treatment with docetaxel and thalidomide as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence treatment response.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655386104>187</a></td><td>PPARD</td><td>rs6922548</td><td>thalidomide</td><td>Prostatic Neoplasms</td><td>3</td><td>AA</td><td>Efficacy</td><td>Patients with the AA genotype may have decreased chance of response to treatment with docetaxel and thalidomide as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence treatment response.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655386161>188</a></td><td>PPARD</td><td>rs2016520</td><td>docetaxel</td><td>Prostatic Neoplasms</td><td>3</td><td>TT</td><td>Efficacy</td><td>Patients with the TT genotype may have decreased chance of response to treatment with docetaxel and thalidomide as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also influence treatment response.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655386161>189</a></td><td>PPARD</td><td>rs2016520</td><td>thalidomide</td><td>Prostatic Neoplasms</td><td>3</td><td>TT</td><td>Efficacy</td><td>Patients with the TT genotype may have decreased chance of response to treatment with docetaxel and thalidomide as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also influence treatment response.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655386166>190</a></td><td>PPARD</td><td>rs1883322</td><td>docetaxel</td><td>Prostatic Neoplasms</td><td>3</td><td>TT</td><td>Efficacy</td><td>Patients with the TT genotype may have decreased chance of response to treatment with docetaxel and thalidomide as compared to patients with the CT or CC genotypes. Other genetic and clinical factors may also influence treatment response.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655386166>191</a></td><td>PPARD</td><td>rs1883322</td><td>thalidomide</td><td>Prostatic Neoplasms</td><td>3</td><td>TT</td><td>Efficacy</td><td>Patients with the TT genotype may have decreased chance of response to treatment with docetaxel and thalidomide as compared to patients with the CT or CC genotypes. Other genetic and clinical factors may also influence treatment response.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655386212>192</a></td><td>KCNJ6</td><td>rs2070995</td><td>Analgesics</td><td>Pain</td><td>3</td><td>CC</td><td>Efficacy</td><td>Patients with the CC genotype and post-operative pain may be less likely to require rescue analgesic administration as compared to patients with the TT genotype. Additionally, patients with the CC genotype who are addicted to heroin may require a decreased dose of methadone as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's chance for requiring a rescue analgesic and dose of methadone.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655386856>193</a></td><td>SERPINE1</td><td>rs2227631</td><td>antidepressants</td><td>Depressive Disorder, Major</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype and genotype GG or AG at rs1799889 with major depressive disorder may be less likely to respond to citalopram and fluoxetine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for non-response to antidepressants.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655386856>194</a></td><td>SERPINE1</td><td>rs2227631</td><td>citalopram</td><td>Depressive Disorder, Major</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype and genotype GG or AG at rs1799889 with major depressive disorder may be less likely to respond to citalopram and fluoxetine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for non-response to antidepressants.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655386856>195</a></td><td>SERPINE1</td><td>rs2227631</td><td>fluoxetine</td><td>Depressive Disorder, Major</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype and genotype GG or AG at rs1799889 with major depressive disorder may be less likely to respond to citalopram and fluoxetine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for non-response to antidepressants.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655386657>196</a></td><td>XRCC1</td><td>rs25487</td><td>Platinum compounds</td><td>Neoplasms</td><td>2B</td><td>CT</td><td>Efficacy</td><td>Patients with cancer and the rs25487 CT genotype may have decreased response when treated with platinum-based therapies as compared to patients with the CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to platinum-based regimens.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655387014>197</a></td><td>NOS3</td><td>rs2070744</td><td>cyclophosphamide</td><td>Breast Neoplasms</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype and breast cancer who are not treated with a adjuvant cyclophophamide-based regimens may have shorter disease-free survival as compared to patients with the CC genotype. Other genetic and clinical factors may also influence disease-free survival.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655387014>198</a></td><td>NOS3</td><td>rs2070744</td><td>doxorubicin</td><td>Breast Neoplasms</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype and breast cancer who are not treated with a adjuvant cyclophophamide-based regimens may have shorter disease-free survival as compared to patients with the CC genotype. Other genetic and clinical factors may also influence disease-free survival.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655387014>199</a></td><td>NOS3</td><td>rs2070744</td><td>fluorouracil</td><td>Breast Neoplasms</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype and breast cancer who are not treated with a adjuvant cyclophophamide-based regimens may have shorter disease-free survival as compared to patients with the CC genotype. Other genetic and clinical factors may also influence disease-free survival.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655387014>200</a></td><td>NOS3</td><td>rs2070744</td><td>methotrexate</td><td>Breast Neoplasms</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype and breast cancer who are not treated with a adjuvant cyclophophamide-based regimens may have shorter disease-free survival as compared to patients with the CC genotype. Other genetic and clinical factors may also influence disease-free survival.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/769171582>201</a></td><td>GSK3B</td><td>rs334558</td><td>citalopram</td><td>Depressive Disorder, Major</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype and Major Depressive Disorder who are treated with fluoxetine and citalopram may have less improvement in symptoms as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to fluoxetine and citalopram.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/769171582>202</a></td><td>GSK3B</td><td>rs334558</td><td>fluoxetine</td><td>Depressive Disorder, Major</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype and Major Depressive Disorder who are treated with fluoxetine and citalopram may have less improvement in symptoms as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to fluoxetine and citalopram.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/637879637>203</a></td><td>ITPA</td><td>rs1127354</td><td>azathioprine</td><td>Lupus Erythematosus, Systemic</td><td>3</td><td>CC</td><td>Efficacy</td><td>Patients with the CC genotype may experience less response to azathiopurine treatment for SLE as compared to patients with the AA or AC genotype. Other genetic and clinical factors may also influence a patient's likelihood of response.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/637879637>204</a></td><td>ITPA</td><td>rs1127354</td><td>purine analogues</td><td>Lupus Erythematosus, Systemic</td><td>3</td><td>CC</td><td>Efficacy</td><td>Patients with the CC genotype may experience less response to azathiopurine treatment for SLE as compared to patients with the AA or AC genotype. Other genetic and clinical factors may also influence a patient's likelihood of response.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/637879957>205</a></td><td>PON1</td><td>rs854555</td><td>Tumor necrosis factor alpha (TNF-alpha) inhibitors</td><td>Arthritis, Rheumatoid</td><td>3</td><td>AC</td><td>Efficacy</td><td>Rheumatoid Arthritis patients with the AC genotype may be less likely to respond to TNF inhibitors compared to a patient with the genotype CC. Other genetic and clinical factors may also influence a patient's response.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/637879967>206</a></td><td>PON1</td><td>rs854547</td><td>Tumor necrosis factor alpha (TNF-alpha) inhibitors</td><td>Arthritis, Rheumatoid</td><td>3</td><td>AG</td><td>Efficacy</td><td>Rheumatoid Arthritis patients with the genotype AG may be less likely to respond to TNF inhibitors compared to a patient with genotype GG. Other genetic and clinical factors may also influence a patient's response.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/637879997>207</a></td><td>GBP6</td><td>rs928655</td><td>Tumor necrosis factor alpha (TNF-alpha) inhibitors</td><td>Arthritis, Rheumatoid</td><td>3</td><td>AA</td><td>Efficacy</td><td>Rheumatoid Arthritis patients with genotype AA may be less likely to respond to TNF inhibitors compared to patients with genotype GG. Other genetic and clinical factors may also influence a patient's response.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655384485>208</a></td><td>CCND1</td><td>rs9344</td><td>cetuximab</td><td>Colorectal Neoplasms</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype may have decreased survival when treated with cetuximab as compared to patients with the AA genotypes, however the data is from small studies and there is contradictory data. Other genetic and clinical factors may also influence response to cetuximab.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655384510>209</a></td><td>CREB1</td><td>rs7569963</td><td>antidepressants</td><td>Depression</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype may have decreased likelihood of remission on anti-depressants as compared to patients with the GG genotype. Male patients with the AG genotype and depression who are treated with citalopram may have a decreased, but not absent, risk of suicidal ideation as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to antidepressants.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655384510>210</a></td><td>METTL21A</td><td>rs7569963</td><td>antidepressants</td><td>Depression</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype may have decreased likelihood of remission on anti-depressants as compared to patients with the GG genotype. Male patients with the AG genotype and depression who are treated with citalopram may have a decreased, but not absent, risk of suicidal ideation as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to antidepressants.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655384510>211</a></td><td>CREB1</td><td>rs7569963</td><td>citalopram</td><td>Depression</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype may have decreased likelihood of remission on anti-depressants as compared to patients with the GG genotype. Male patients with the AG genotype and depression who are treated with citalopram may have a decreased, but not absent, risk of suicidal ideation as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to antidepressants.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655384510>212</a></td><td>METTL21A</td><td>rs7569963</td><td>citalopram</td><td>Depression</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype may have decreased likelihood of remission on anti-depressants as compared to patients with the GG genotype. Male patients with the AG genotype and depression who are treated with citalopram may have a decreased, but not absent, risk of suicidal ideation as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to antidepressants.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655384539>213</a></td><td>ABCB1</td><td>rs2032582</td><td>cyclosporine</td><td>Colitis, Ulcerative</td><td>3</td><td>AC</td><td>Efficacy</td><td>Patients with the AC genotype may have a decreased risk of resistance to cyclosporine compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of resistance to cyclosporine.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/637880425>214</a></td><td>HTR2A</td><td>rs7997012</td><td>citalopram</td><td>Depression;Depressive Disorder</td><td>3</td><td>GG</td><td>Efficacy</td><td>Patients with the rs7997012 GG genotype and depression who are treated with citalopram may be less likely to have improvement in symptoms as compared to patients with the AA or AG genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to citalopram.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655384679>215</a></td><td>PTGS2</td><td>rs20417</td><td>rofecoxib</td><td></td><td>3</td><td>CG</td><td>Efficacy</td><td>Patients with the CG genotype may have poorer pain relief response to rofecoxib as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to rofecoxib.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655384772>216</a></td><td>HTR1A</td><td>rs6295</td><td>antidepressants</td><td>Depressive Disorder;Depressive Disorder, Major</td><td>3</td><td>CC</td><td>Efficacy</td><td>Patients with the CC genotype may have a decreased likelihood of response to antidepressants as compared to patients with the GG or CG genotype. Other genetic and clinical factors may also influence response to antidepressants.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655384772>217</a></td><td>HTR1A</td><td>rs6295</td><td>fluvoxamine</td><td>Depressive Disorder;Depressive Disorder, Major</td><td>3</td><td>CC</td><td>Efficacy</td><td>Patients with the CC genotype may have a decreased likelihood of response to antidepressants as compared to patients with the GG or CG genotype. Other genetic and clinical factors may also influence response to antidepressants.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655384772>218</a></td><td>HTR1A</td><td>rs6295</td><td>paroxetine</td><td>Depressive Disorder;Depressive Disorder, Major</td><td>3</td><td>CC</td><td>Efficacy</td><td>Patients with the CC genotype may have a decreased likelihood of response to antidepressants as compared to patients with the GG or CG genotype. Other genetic and clinical factors may also influence response to antidepressants.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655384772>219</a></td><td>HTR1A</td><td>rs6295</td><td>Selective serotonin reuptake inhibitors</td><td>Depressive Disorder;Depressive Disorder, Major</td><td>3</td><td>CC</td><td>Efficacy</td><td>Patients with the CC genotype may have a decreased likelihood of response to antidepressants as compared to patients with the GG or CG genotype. Other genetic and clinical factors may also influence response to antidepressants.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655384772>220</a></td><td>HTR1A</td><td>rs6295</td><td>sertraline</td><td>Depressive Disorder;Depressive Disorder, Major</td><td>3</td><td>CC</td><td>Efficacy</td><td>Patients with the CC genotype may have a decreased likelihood of response to antidepressants as compared to patients with the GG or CG genotype. Other genetic and clinical factors may also influence response to antidepressants.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655384809>221</a></td><td>SLC22A1</td><td>rs622342</td><td>metformin</td><td>Diabetes Mellitus</td><td>3</td><td>AC</td><td>Efficacy</td><td>Patients with the AC genotype and the GG genotype at rs2289669 who have diabetes may have a poorer response to metformin, as measured by a smaller reduction in HbA1c levels, as compared to patients with the AA genotype. Although contradictory information exists for this association, and may be dependent on the absence of an A allele at rs2289669. Other genetic and clinical factors may also influence a patient's reduction in HbA1c levels with metformin treatment.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655384866>222</a></td><td>DTNBP1</td><td>rs909706</td><td>haloperidol</td><td>Schizophrenia</td><td>3</td><td>CC</td><td>Efficacy</td><td>Patients with the CC genotype and Schizophrenia may have a reduced response to haloperidol as compared to patients with the CT genotype. Results were suggestive of an association. Other genetic and clinical factors may also influence a patient's response to haloperidol.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655384938>223</a></td><td>LTC4S</td><td>rs730012</td><td>montelukast</td><td>Asthma</td><td>3</td><td>AC</td><td>Efficacy</td><td>Patients with the AC genotype and asthma who are treated with montelukast may have a decreased, but not absent, risk of asthma exacerbations as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of asthma exacerbations with montelukast treatment.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655384962>224</a></td><td>DRD3</td><td>rs6280</td><td>olanzapine</td><td>Schizophrenia</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype and schizophrenia who are treated with olanzapine may have reduced positive symptom improvement and positive symptom remission as compared to patients with the CC genotypes. Other genetic and clinical factors may also influence a patient's response to olanzapine.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655384979>225</a></td><td>RGS4</td><td>rs2842030</td><td>risperidone</td><td>Schizophrenia</td><td>3</td><td>TT</td><td>Efficacy</td><td>Patients with the TT genotype may have poorer response to risperidone than to perphenazine, quetiapine, and ziprasidone treatment in people with schizophrenia compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655384991>226</a></td><td>SLC14A2</td><td>rs3745009</td><td>nifedipine</td><td>Hypertension</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the GA genotype who are treated with nifedipine may have smaller mean changes in systolic and diastolic blood pressure as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to nifedipine treatment.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655385037>227</a></td><td>DRD3</td><td>rs6280</td><td>pramipexole</td><td>Parkinson Disease</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype may have lower response rate to pramipexole in Chinese patients with Parkinson's disease than TT allele carriers. Other genetic and clinical factors may also influence a patient's response.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655385050>228</a></td><td>RGS4</td><td>rs2661319</td><td>risperidone</td><td>Schizophrenia</td><td>3</td><td>CC</td><td>Efficacy</td><td>Patients with the CC genotype and schizophrenia who are treated with risperidone may have less improvement in symptoms as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to risperidone.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655385062>229</a></td><td>AKT1</td><td>rs2494732</td><td>risperidone</td><td>Schizophrenia</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype and schizophrenia may have a decreased response to risperidone compared to patients with the TT genotype. However, another study failed to find an association between this variant and response to risperidone. Other genetic and clinical factors may also influence a patient's response to risperidone.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655385067>230</a></td><td>AKT1</td><td>rs3803300</td><td>risperidone</td><td>Schizophrenia</td><td>3</td><td>CC</td><td>Efficacy</td><td>Patients with the CC genotype and schizophrenia may have a decrease response to risperidone as compared to patients with the CT or TT genotype. Please note this association did not reach statistical significance in one study, while another study failed to find an association. Other genetic and clinical factors may also influence a patient's response to risperidone.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655385072>231</a></td><td>COMT</td><td>rs165599</td><td>risperidone</td><td>Schizophrenia</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype and schizophrenia who are treated with risperidone may have less improvement in symptoms as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to risperidone.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655385139>232</a></td><td>KCNJ11</td><td>rs5219</td><td>repaglinide</td><td>Diabetes Mellitus, Type 2</td><td>3</td><td>CC</td><td>Efficacy</td><td>Patients with the CC genotype are less likely to respond to repaglinide than patients with the CT or TT genotype in T2DM patients. Other genetic and clinical factors may also influence a patient's response.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655385295>233</a></td><td>ADRB1</td><td>rs1801253</td><td>metoprolol</td><td>Hypertension</td><td>3</td><td>CG</td><td>Efficacy</td><td>Patients with the CG genotype may have weaker response to metoprolol compared to CC genotype carriers. Other genetic and clinical factors may also influence the patient's response to metoprolol.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449748511>234</a></td><td>ABCB1</td><td>rs1128503</td><td>tacrolimus</td><td>Nephrotic Syndrome</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype and nephrotic syndrome may have a decreased response when treated with tacrolimus as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to tacrolimus treatment in patients with nephrotic syndrome.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/827832280>235</a></td><td>ADRB1</td><td>rs1801253</td><td>metoprolol</td><td></td><td>3</td><td>CG</td><td>Efficacy</td><td>Patients with the CG genotype may have a decreased response to metoprolol as compared to patients with the CC genotype. However, some studies have failed to find an association. Other genetic and clinical factors may also influence a patient's response to metoprolol.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/827847738>236</a></td><td>ABCC3</td><td>rs9895420</td><td>methotrexate</td><td>Precursor Cell Lymphoblastic Leukemia-Lymphoma</td><td>3</td><td>AT</td><td>Efficacy</td><td>Patients with the AT genotype may have decreased event free survival when treated with methotrexate as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/827847744>237</a></td><td>GALNT14</td><td>rs9679162</td><td>cisplatin</td><td>Carcinoma, Hepatocellular;Liver Neoplasms</td><td>3</td><td>GT</td><td>Efficacy</td><td>Patients with the rs9679162 GT genotype and Liver Neoplasms may decreased response to cisplatin, fluorouracil and mitoxantrone chemotherapy as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to cisplatin, fluorouracil and mitoxantrone chemotherapy.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/827847744>238</a></td><td>GALNT14</td><td>rs9679162</td><td>fluorouracil</td><td>Carcinoma, Hepatocellular;Liver Neoplasms</td><td>3</td><td>GT</td><td>Efficacy</td><td>Patients with the rs9679162 GT genotype and Liver Neoplasms may decreased response to cisplatin, fluorouracil and mitoxantrone chemotherapy as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to cisplatin, fluorouracil and mitoxantrone chemotherapy.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/827847744>239</a></td><td>GALNT14</td><td>rs9679162</td><td>mitoxantrone</td><td>Carcinoma, Hepatocellular;Liver Neoplasms</td><td>3</td><td>GT</td><td>Efficacy</td><td>Patients with the rs9679162 GT genotype and Liver Neoplasms may decreased response to cisplatin, fluorouracil and mitoxantrone chemotherapy as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to cisplatin, fluorouracil and mitoxantrone chemotherapy.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/978608464>240</a></td><td>MTHFR</td><td>rs1801133</td><td>methotrexate</td><td>Graft vs Host Disease;Leukemia;Leukemia, Myelogenous, Chronic, BCR-ABL Positive</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype and leukemia who undergo hematopoietic cell transplant and are treated with methotrexate may have a decreased risk of Graft vs Host disease as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk Graft vs Host disease and efficacy of methotrexate treatment. This drug-variant pair has been assigned a no recommendation by DPWG, as it was determined to be not clinically actionable.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/981202609>241</a></td><td>ATIC</td><td>rs4673993</td><td>methotrexate</td><td>Arthritis, Rheumatoid</td><td>2B</td><td>CT</td><td>Efficacy</td><td>Patients with the rs4673993 CT genotype and Rheumatoid Arthritis may have decreased response when treated with methotrexate as compared to patients with the CC genotype. Other genetic and clinical factors may also influence methotrexate response.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/981240029>242</a></td><td>KCNJ11</td><td>rs5219</td><td>sulfonamides, urea derivatives</td><td>Diabetes Mellitus, Type 2</td><td>3</td><td>CC</td><td>Efficacy</td><td>Patients with CC genotype and Type 2 diabetes may have a poorer response (smaller decrease in HbA1c) when receiving treatment with sulfonylureas as compared to patients with genotype CT or TT. Other genetic or clinical factors may also influence a patient's response to sulfonylureas.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/981204116>243</a></td><td>ABCB1</td><td>rs2032582</td><td>tacrolimus</td><td>Colitis, Ulcerative;Kidney Transplantation</td><td>3</td><td>AC</td><td>Efficacy</td><td>Patients with AC genotype may have lower success rate in achieving short-term remission when treated with tacrolimus in people with ulcerative colitis as compared to patients with the AA genotype. However, a different study contradicts this finding. Other genetic or clinical factors may influence response to tacrolimus.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/981238288>244</a></td><td>ABCB1</td><td>rs2032582</td><td>efavirenz</td><td>HIV Infections</td><td>4</td><td>AC</td><td>Efficacy</td><td>Patients with the AC genotype may have decreased likelihood of emerging viral drug resistance when exposed to efavirenz in people with HIV Infections as compared to patients with the CC genotype.This varaint is not associated with plasma exposure of efavirenz. Other genetic and clinical factors may also influence the response to efavirenz.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/981475450>245</a></td><td>EGFR</td><td>rs121434569</td><td>erlotinib</td><td>Adenocarcinoma;Carcinoma, Non-Small-Cell Lung;Drug Resistance;Lung Neoplasms</td><td>2B</td><td>CC</td><td>Efficacy</td><td>Patients with the somatic rs121434569 CC genotype (i.e. lacking the somatic T790M mutation) in combination with an activating EGFR mutation (e.g. L858R or exon 19 deletion) may have decreased likelihood of acquired resistance to erlotinib as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect response to erlotinib.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/981203578>246</a></td><td>DRD3</td><td>rs6280</td><td>clozapine</td><td>Schizophrenia</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype and Schizophrenia who are treated with clozapine may have a poorer response to treatment as compared to patients with the TT genotype. Please note; this association was not found in a meta-analysis. Other genetic and clinical factors may also influence a patient's response to clozapine treatment.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/981204272>247</a></td><td>ABCB1</td><td>rs1045642</td><td>paclitaxel</td><td>Breast Neoplasms</td><td>3</td><td>AA</td><td>Efficacy</td><td>Genotype AA may be associated with decreased disease control rate and lower overall survival rate when treated with paclitaxel in Asians with metastatic breast cancer as compared to genotype GG. However, contradictory findings have been reported and no association have been reported for Caucasians. Other genetic and clinical factors may influence the response to paclitaxel.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/981204306>248</a></td><td>ABCB1</td><td>rs1045642</td><td>phenytoin</td><td>Epilepsy</td><td>3</td><td>AA</td><td>Efficacy</td><td>Patients with epilepsy and the AA genotype may have decreased likelihood of drug resistance when treated with phenytoin as compared to patients with the AG or GG genotypes. However, other studies have failed to find this association. Other genetic or clinical factors may influence a patient's response to phenytoin.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449004567>249</a></td><td>ABCB1</td><td>rs1045642</td><td>oxcarbazepine</td><td>Epilepsy</td><td>3</td><td>AA</td><td>Efficacy</td><td>Patients with epilepsy and the AA genotype may have decreased concentrations of oxcarbazepine and worse response as compared to patients with the AG and GG genotypes. Other clinical and genetic factors may also influence exposure to and response to oxcarbazepine in patients with epilepsy.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449144304>250</a></td><td>-</td><td>rs1611259</td><td>lithium</td><td>Bipolar Disorder</td><td>3</td><td>TT</td><td>Efficacy</td><td>Patients with the TT genotype and bipolar affective disorder may have a decreased response to lithium as compared to patients with the CT or CC genotypes. Other genetic and clinical factors may also influence a patient's response to lithium when treating bipolar affective disorder.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449144322>251</a></td><td>MYO1H</td><td>rs7959663</td><td>lithium</td><td>Bipolar Disorder</td><td>3</td><td>CC</td><td>Efficacy</td><td>Patients with the CC genotype and bipolar affective disorder may have a decreased response to lithium as compared to patients with the CG or GG genotypes. Other genetic and clinical factors may also influence a patient's response to lithium when treating bipolar affective disorder.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449752771>252</a></td><td>PIN1</td><td>rs2233678</td><td>oxaliplatin</td><td>Colorectal Neoplasms</td><td>3</td><td>CG</td><td>Efficacy</td><td>Patients with the CG genotype and colorectal cancer may have decreased survival times when treated with oxaliplatin-based treatments as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to oxaliplatin-based treatments.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450928473>253</a></td><td>CYP1B1</td><td>rs10012</td><td>risperidone</td><td>Schizophrenia</td><td>3</td><td>CG</td><td>Efficacy</td><td>Patients with schizophrenia and the CG genotype may have a decreased response to risperidone as compared to patients with the GG genotype. However, this association lost significance following correction for multiple testing. Other genetic or clinical factors may also affect a patient's response to risperidone.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450928522>254</a></td><td>DRD3</td><td>rs6280</td><td>risperidone</td><td>Schizophrenia</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with schizophrenia and the CT genotype may have a decreased response to risperidone as compared to patients with the TT genotype. However, this association lost significance following correction for multiple testing. Other genetic or clinical factors may also affect a patient's response to risperidone.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449748502>255</a></td><td>ABCB1</td><td>rs2032582</td><td>tacrolimus</td><td>Nephrotic Syndrome</td><td>3</td><td>AC</td><td>Efficacy</td><td>Patients with the AC genotype and nephrotic syndrome may have a decreased response when treated with tacrolimus as compared to patients with the AA, AT or TT genotype. Other genetic and clinical factors may also influence response to tacrolimus treatment in patients with nephrotic syndrome.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450814929>256</a></td><td>PTPRD</td><td>rs17584499</td><td>pioglitazone</td><td>Diabetes Mellitus, Type 2</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with Type II diabetes and the CT genotype may have a decreased response to pioglitazone as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to pioglitazone.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450928454>257</a></td><td>CYP1B1</td><td>rs1056827</td><td>risperidone</td><td>Schizophrenia</td><td>3</td><td>AC</td><td>Efficacy</td><td>Patients with schizophrenia and the AC genotype may have a decreased response to risperidone as compared to patients with the CC genotype. However, this association lost significance following correction for multiple testing. Other genetic or clinical factors may also affect a patient's response to risperidone.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450373616>258</a></td><td>NQO1</td><td>rs10517</td><td>imatinib</td><td>Gastrointestinal Stromal Tumors</td><td>3</td><td>GG</td><td>Efficacy</td><td>Patients with the GG genotype and gastrointestinal stromal tumors may have decreased progression-free survival times when treated with imatinib as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence progression-free survival times in patients receiving imatinib.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449168065>259</a></td><td>NRXN1</td><td>rs4971678</td><td>duloxetine</td><td>Depressive Disorder, Major</td><td>3</td><td>AT</td><td>Efficacy</td><td>Patients with the AT genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449168321>260</a></td><td>-</td><td>rs12094644</td><td>duloxetine</td><td>Depressive Disorder, Major</td><td>3</td><td>AT</td><td>Efficacy</td><td>Patients with the AT genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450930548>261</a></td><td>TXNDC11</td><td>rs3784921</td><td>hydrochlorothiazide</td><td>Hypertension</td><td>3</td><td>GT</td><td>Efficacy</td><td>Patients with hypertension and the GT genotype may have a decreased systolic blood pressure response to hydrochlorothiazide as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to hydrochlorothiazide.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450929786>262</a></td><td>ABCB1</td><td>rs1045642</td><td>fentanyl</td><td>Pain</td><td>4</td><td>AA</td><td>Efficacy</td><td>Patients with the AA genotype may have a decreased response to fentanyl as compared to patients with the AG or GG genotypes. However, another study did not find an association between this variant and response to fentanyl. Other genetic and clinical factors may also affect a patient's response to fentanyl.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183704353>263</a></td><td>TNFAIP3</td><td>rs6920220</td><td>methotrexate</td><td></td><td>3</td><td>GG</td><td>Efficacy</td><td>Patients with the GG genotype may have decreased likelihood of discontinuation of methotrexate in people with Arthritis as compared to patients with genotype AA or AG. Other genetic and clinical factors may also influence the response to methotrexate.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183704316>264</a></td><td>VEGFA</td><td>rs699947</td><td>sildenafil</td><td>Erectile Dysfunction</td><td>3</td><td>AC</td><td>Efficacy</td><td>Patients with the AC genotype may have decreased response to sildenafil in men with Erectile Dysfunction as compared to patients with genotype CC. Other genetic and clinical factors may also influence the response to sildenafil.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183888959>265</a></td><td>IFNL3</td><td>rs8099917</td><td>peginterferon alfa-2a</td><td>Hepatitis C, Chronic</td><td>2A</td><td>GT</td><td>Efficacy</td><td>Patients with the rs8099917 GT genotype may have lower response rates (SVR) to triple therapy (telaprevir, peginterferon alfa-2a/b and ribavirin) in people with Hepatitis C genotype 1 as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to HCV triple therapy.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183888959>266</a></td><td>IFNL3</td><td>rs8099917</td><td>peginterferon alfa-2b</td><td>Hepatitis C, Chronic</td><td>2A</td><td>GT</td><td>Efficacy</td><td>Patients with the rs8099917 GT genotype may have lower response rates (SVR) to triple therapy (telaprevir, peginterferon alfa-2a/b and ribavirin) in people with Hepatitis C genotype 1 as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to HCV triple therapy.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183888959>267</a></td><td>IFNL3</td><td>rs8099917</td><td>ribavirin</td><td>Hepatitis C, Chronic</td><td>2A</td><td>GT</td><td>Efficacy</td><td>Patients with the rs8099917 GT genotype may have lower response rates (SVR) to triple therapy (telaprevir, peginterferon alfa-2a/b and ribavirin) in people with Hepatitis C genotype 1 as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to HCV triple therapy.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183888959>268</a></td><td>IFNL3</td><td>rs8099917</td><td>telaprevir</td><td>Hepatitis C, Chronic</td><td>2A</td><td>GT</td><td>Efficacy</td><td>Patients with the rs8099917 GT genotype may have lower response rates (SVR) to triple therapy (telaprevir, peginterferon alfa-2a/b and ribavirin) in people with Hepatitis C genotype 1 as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to HCV triple therapy.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183888969>269</a></td><td>IFNL3</td><td>rs12979860</td><td>peginterferon alfa-2a</td><td>Hepatitis C, Chronic</td><td>1A</td><td>CT</td><td>Efficacy</td><td>Patients with the rs12979860 CT genotype and hepatitis C infection may have lower response rates (SVR) to triple therapy (telaprevir, peginterferon alfa-2a/b and ribavirin) as compared to patients with the CC genotype. However, conflicting evidence has been reported. The impact of IL28B genotype may be dampened in patients with prior PegIFN/RBV treatment failure. Other genetic and clinical factors may also influence response to HCV triple therapy.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183888969>270</a></td><td>IFNL4</td><td>rs12979860</td><td>peginterferon alfa-2a</td><td>Hepatitis C, Chronic</td><td>1A</td><td>CT</td><td>Efficacy</td><td>Patients with the rs12979860 CT genotype and hepatitis C infection may have lower response rates (SVR) to triple therapy (telaprevir, peginterferon alfa-2a/b and ribavirin) as compared to patients with the CC genotype. However, conflicting evidence has been reported. The impact of IL28B genotype may be dampened in patients with prior PegIFN/RBV treatment failure. Other genetic and clinical factors may also influence response to HCV triple therapy.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183888969>271</a></td><td>IFNL3</td><td>rs12979860</td><td>peginterferon alfa-2b</td><td>Hepatitis C, Chronic</td><td>1A</td><td>CT</td><td>Efficacy</td><td>Patients with the rs12979860 CT genotype and hepatitis C infection may have lower response rates (SVR) to triple therapy (telaprevir, peginterferon alfa-2a/b and ribavirin) as compared to patients with the CC genotype. However, conflicting evidence has been reported. The impact of IL28B genotype may be dampened in patients with prior PegIFN/RBV treatment failure. Other genetic and clinical factors may also influence response to HCV triple therapy.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183888969>272</a></td><td>IFNL4</td><td>rs12979860</td><td>peginterferon alfa-2b</td><td>Hepatitis C, Chronic</td><td>1A</td><td>CT</td><td>Efficacy</td><td>Patients with the rs12979860 CT genotype and hepatitis C infection may have lower response rates (SVR) to triple therapy (telaprevir, peginterferon alfa-2a/b and ribavirin) as compared to patients with the CC genotype. However, conflicting evidence has been reported. The impact of IL28B genotype may be dampened in patients with prior PegIFN/RBV treatment failure. Other genetic and clinical factors may also influence response to HCV triple therapy.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183888969>273</a></td><td>IFNL3</td><td>rs12979860</td><td>ribavirin</td><td>Hepatitis C, Chronic</td><td>1A</td><td>CT</td><td>Efficacy</td><td>Patients with the rs12979860 CT genotype and hepatitis C infection may have lower response rates (SVR) to triple therapy (telaprevir, peginterferon alfa-2a/b and ribavirin) as compared to patients with the CC genotype. However, conflicting evidence has been reported. The impact of IL28B genotype may be dampened in patients with prior PegIFN/RBV treatment failure. Other genetic and clinical factors may also influence response to HCV triple therapy.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183888969>274</a></td><td>IFNL4</td><td>rs12979860</td><td>ribavirin</td><td>Hepatitis C, Chronic</td><td>1A</td><td>CT</td><td>Efficacy</td><td>Patients with the rs12979860 CT genotype and hepatitis C infection may have lower response rates (SVR) to triple therapy (telaprevir, peginterferon alfa-2a/b and ribavirin) as compared to patients with the CC genotype. However, conflicting evidence has been reported. The impact of IL28B genotype may be dampened in patients with prior PegIFN/RBV treatment failure. Other genetic and clinical factors may also influence response to HCV triple therapy.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183888969>275</a></td><td>IFNL3</td><td>rs12979860</td><td>telaprevir</td><td>Hepatitis C, Chronic</td><td>1A</td><td>CT</td><td>Efficacy</td><td>Patients with the rs12979860 CT genotype and hepatitis C infection may have lower response rates (SVR) to triple therapy (telaprevir, peginterferon alfa-2a/b and ribavirin) as compared to patients with the CC genotype. However, conflicting evidence has been reported. The impact of IL28B genotype may be dampened in patients with prior PegIFN/RBV treatment failure. Other genetic and clinical factors may also influence response to HCV triple therapy.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183888969>276</a></td><td>IFNL4</td><td>rs12979860</td><td>telaprevir</td><td>Hepatitis C, Chronic</td><td>1A</td><td>CT</td><td>Efficacy</td><td>Patients with the rs12979860 CT genotype and hepatitis C infection may have lower response rates (SVR) to triple therapy (telaprevir, peginterferon alfa-2a/b and ribavirin) as compared to patients with the CC genotype. However, conflicting evidence has been reported. The impact of IL28B genotype may be dampened in patients with prior PegIFN/RBV treatment failure. Other genetic and clinical factors may also influence response to HCV triple therapy.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184134160>277</a></td><td>CMPK1</td><td>rs11211524</td><td>gemcitabine</td><td>Neoplasms</td><td>3</td><td>CC</td><td>Efficacy</td><td>Patients with the CC genotype and solid tumors, may have decreased response to gemcitabine compared to the AA and AC genotypes. Other genetic and clinical factors may also influence a patient's response to gemcitabine.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183704292>278</a></td><td>-</td><td>rs7186128</td><td>cisplatin</td><td></td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype may have decreased overall survival when treated with cisplatin and irinotecan in people with Carcinoma, Small Cell as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to cisplatin and irinotecan.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183704292>279</a></td><td>-</td><td>rs7186128</td><td>irinotecan</td><td></td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype may have decreased overall survival when treated with cisplatin and irinotecan in people with Carcinoma, Small Cell as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to cisplatin and irinotecan.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183704358>280</a></td><td>SLC22A16</td><td>rs6907567</td><td>cyclophosphamide</td><td>Breast Neoplasms</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype may have decreased risk for neutropenia and a decreased likelihood of dose delay when treated with cyclophosphamide, doxorubicin and fluorouracil, as compared to patients with AA genotypes. Other genetic and clinical factors may also influence risk for dose delay and toxicity in patients taking cyclophosphamide, doxorubicin and fluorouracil.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183704358>281</a></td><td>SLC22A16</td><td>rs6907567</td><td>doxorubicin</td><td>Breast Neoplasms</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype may have decreased risk for neutropenia and a decreased likelihood of dose delay when treated with cyclophosphamide, doxorubicin and fluorouracil, as compared to patients with AA genotypes. Other genetic and clinical factors may also influence risk for dose delay and toxicity in patients taking cyclophosphamide, doxorubicin and fluorouracil.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183704358>282</a></td><td>SLC22A16</td><td>rs6907567</td><td>fluorouracil</td><td>Breast Neoplasms</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype may have decreased risk for neutropenia and a decreased likelihood of dose delay when treated with cyclophosphamide, doxorubicin and fluorouracil, as compared to patients with AA genotypes. Other genetic and clinical factors may also influence risk for dose delay and toxicity in patients taking cyclophosphamide, doxorubicin and fluorouracil.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183702417>283</a></td><td>IFNL3</td><td>rs8103142</td><td>peginterferon alfa-2a</td><td>Hepatitis C</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype may have decreased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to patients with genotype TT. Other genetic or clinical factors may also influence the response to peginterferon and ribavirin therapy.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183702417>284</a></td><td>IFNL3</td><td>rs8103142</td><td>peginterferon alfa-2b</td><td>Hepatitis C</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype may have decreased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to patients with genotype TT. Other genetic or clinical factors may also influence the response to peginterferon and ribavirin therapy.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183702417>285</a></td><td>IFNL3</td><td>rs8103142</td><td>ribavirin</td><td>Hepatitis C</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype may have decreased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to patients with genotype TT. Other genetic or clinical factors may also influence the response to peginterferon and ribavirin therapy.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183704409>286</a></td><td>HTR2A</td><td>rs6311</td><td>antipsychotics</td><td>tardive dyskinesia</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype may have decreased risk of tardive dyskinesia when treated with antipsychotics in people with Schizophrenia as compared to patients with genotypes TT. Other genetic and clinical factors may also influence the risk of toxicity to antipsychotics.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444703154>287</a></td><td>BCL2</td><td>rs1800477</td><td>interferons</td><td>Hepatitis C</td><td>3</td><td>CC</td><td>Efficacy</td><td>Patients with the CC genotype and Hepatitis C who are treated with interferons and ribavirin may have decreased, but not absent, risk for non-response as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to interferons and ribavirin.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444703154>288</a></td><td>BCL2</td><td>rs1800477</td><td>ribavirin</td><td>Hepatitis C</td><td>3</td><td>CC</td><td>Efficacy</td><td>Patients with the CC genotype and Hepatitis C who are treated with interferons and ribavirin may have decreased, but not absent, risk for non-response as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to interferons and ribavirin.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444703571>289</a></td><td>-</td><td>rs4982133</td><td>methotrexate</td><td>Arthritis, Rheumatoid</td><td>4</td><td>CC</td><td>Efficacy</td><td>Patients with the CC genotype and Rheumatoid Arthritis who are treated with methotrexate may have a poorer response to treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate treatment.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444700822>290</a></td><td>CFAP44</td><td>rs13064411</td><td>hmg coa reductase inhibitors</td><td></td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype may have decreased response to hmg coa reductase inhibitors as compared to patients with AA genotype. Other genetic and clinical factors may also influence a patient's response to hmg coa reductase inhibitors.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450371701>291</a></td><td>FCGR3A</td><td>rs396991</td><td>tocilizumab</td><td>Arthritis, Rheumatoid</td><td>3</td><td>AC</td><td>Efficacy</td><td>Patients with rheumatoid arthritis and the AC genotype may have a decreased response to tocilizumab as compared to patients with the AA genotype. Other genetic or clinical factors may also affect a patient's response to tocilizumab.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1445401205>292</a></td><td>ABCB1</td><td>rs1128503</td><td>imatinib</td><td>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype and chronic myeloid leukemia may have a poorer response to imatinib treatment as compared to patients with the GG genotype, although this is contradicted in one study. Other genetic and clinical factors may also influence response to imatinib.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444608441>293</a></td><td>DRD3</td><td>rs6280</td><td>methylphenidate</td><td>Autism Spectrum Disorder</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype and autism spectrum disorders may have a poorer tolerance for methylphenidate treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence tolerability for methylphenidate treatment.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444703393>294</a></td><td>GDNF</td><td>rs2216711</td><td>paroxetine</td><td>Depressive Disorder, Major</td><td>3</td><td>AG</td><td>Efficacy</td><td>Female patients with the AG genotype and major depression may have decreased response to paroxetine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to paroxetine.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1445400792>295</a></td><td>FDPS</td><td>rs11264359</td><td>atorvastatin</td><td>Coronary Disease;Osteoporosis</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype may have a decrease in bone density when treated with atorvastatin, as compared to those with the AA genotype. Other genetic and clinical factors may also influence a patient's response.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1445400792>296</a></td><td>FDPS</td><td>rs11264359</td><td>Bisphosphonates</td><td>Coronary Disease;Osteoporosis</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype may have a decrease in bone density when treated with atorvastatin, as compared to those with the AA genotype. Other genetic and clinical factors may also influence a patient's response.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1445400917>297</a></td><td>DBH</td><td>rs1611115</td><td>naltrexone</td><td>Alcoholism</td><td>3</td><td>CC</td><td>Efficacy</td><td>Patients with the CC genotype who are alcohol-dependent may have a poorer response to treatment with naltrexone as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence response to naltrexone.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1446902912>298</a></td><td>-</td><td>rs1104514</td><td>atenolol</td><td>Hypertension</td><td>3</td><td>GG</td><td>Efficacy</td><td>Patients with the GG genotype may have decreased response to atenolol in hypertensive patients as compared to patients with genotype AA or AG. Other genetic and clinical factors may also influence the response to atenolol.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444704048>299</a></td><td>GDNF</td><td>rs2973049</td><td>paroxetine</td><td>Depressive Disorder, Major</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype and major depression may have decreased response to paroxetine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to paroxetine.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444680101>300</a></td><td>OPRD1</td><td>rs581111</td><td>buprenorphine</td><td>Opioid-Related Disorders</td><td>4</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype who are opioid-dependent may have a poorer response to treatment with buprenorphine as compared to patients with the GG genotype. Literature evidence currently indicates that this finding is only significant in women. Other genetic and clinical factors may also influence response to buprenorphine.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1446896644>301</a></td><td>BDNF</td><td>rs6265</td><td>olanzapine</td><td>Schizophrenia</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype and schizophrenia may have a poorer response when treated with olanzapine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to olanzapine.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1446897502>302</a></td><td>-</td><td>rs1364805</td><td>montelukast</td><td>Asthma</td><td>3</td><td>GG</td><td>Efficacy</td><td>Patients with asthma and the GG genotype may have a decreased response to montelukast as compared to patients with the GT or TT genotypes. Other clinical and genetic factors may also affect response to montelukast in patients with asthma.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444704928>303</a></td><td>GPR83</td><td>rs3758785</td><td>hydrochlorothiazide</td><td>Essential hypertension</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype may have decreased response to hydrochlorothiazide in people with essential hypertension as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to hydrochlorothiazide.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444607408>304</a></td><td>ABCB1</td><td>rs1045642</td><td>imatinib</td><td>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</td><td>3</td><td>AA</td><td>Efficacy</td><td>Patients with the AA genotype and chronic myeloid leukemia may have a decreased likelihood of achieving complete molecular response when treated with imatinib, as compared to patients with the GG genotype. However, this was only significant in an exclusively Caucasian population. Additionally, no significant results were seen when considering major molecular response. Other genetic and clinical factors may also influence likelihood of achieving complete molecular response.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444607420>305</a></td><td>CREB1</td><td>rs889895</td><td>antidepressants</td><td>Depressive Disorder, Major</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype and major depressive disorder may be less likely to enter remission when treated with antidepressants, as compared to patients with the GG genotype. Other genetic and clinical factors may also influence likelihood of remission from major depressive disorder.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444686836>306</a></td><td>IL10</td><td>rs1800871</td><td>tacrolimus</td><td>Kidney Transplantation</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype who are undergoing kidney transplantation may have a lower chance of achieving target concentrations of tacrolimus as compared to patients with the AA genotype. Other genetic and clinical factors, such as the CYP3A5*3 allele, may also influence a patient achieving target concentrations of tacrolimus.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447673027>307</a></td><td>VKORC1</td><td>rs9934438</td><td>warfarin</td><td></td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype may have decreased time in therapeutic range of INR (TTR) when treated with warfarin as compared to genotype GG. Other genetic and clinical factors may also influence the response to warfarin.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444930642>308</a></td><td>IFNL3</td><td>rs12979860</td><td>ledipasvir</td><td>Hepatitis C, Chronic</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with Hepatitis C and the rs12979860 CT genotype may have a decreased response to ledipasvir and sofosbuvir as compared to patients with the CC genotype. Other genetic and clinical factors may also influence the response to ledipasvir and sofosbuvir.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444930642>309</a></td><td>IFNL4</td><td>rs12979860</td><td>ledipasvir</td><td>Hepatitis C, Chronic</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with Hepatitis C and the rs12979860 CT genotype may have a decreased response to ledipasvir and sofosbuvir as compared to patients with the CC genotype. Other genetic and clinical factors may also influence the response to ledipasvir and sofosbuvir.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444930642>310</a></td><td>IFNL3</td><td>rs12979860</td><td>sofosbuvir</td><td>Hepatitis C, Chronic</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with Hepatitis C and the rs12979860 CT genotype may have a decreased response to ledipasvir and sofosbuvir as compared to patients with the CC genotype. Other genetic and clinical factors may also influence the response to ledipasvir and sofosbuvir.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444930642>311</a></td><td>IFNL4</td><td>rs12979860</td><td>sofosbuvir</td><td>Hepatitis C, Chronic</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with Hepatitis C and the rs12979860 CT genotype may have a decreased response to ledipasvir and sofosbuvir as compared to patients with the CC genotype. Other genetic and clinical factors may also influence the response to ledipasvir and sofosbuvir.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447672998>312</a></td><td>VKORC1</td><td>rs9923231</td><td>warfarin</td><td>time to therapeutic inr</td><td>2A</td><td>CT</td><td>Efficacy</td><td>Patients with the rs9923231 CT genotype may require shorter time to therapeutic INR when treated with warfarin as compared with patients with genotype CC. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence the response to warfarin.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447673015>313</a></td><td>VKORC1</td><td>rs9923231</td><td>warfarin</td><td>time in therapeutic range</td><td>2A</td><td>CT</td><td>Efficacy</td><td>Patients with the rs9923231 CT genotype may spent less time in INR therapeutic range (TTR) when treated with warfarin as compared with patients with genotype CC. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence the response to warfarin.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444608053>314</a></td><td>GSTA1</td><td>rs3957357</td><td>doxorubicin</td><td>Sarcoma</td><td>3</td><td>GG</td><td>Efficacy</td><td>Patients with the GG genotype and soft tissue sarcoma may have a shorter progression-free survival time when treated with doxorubicin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence progression-free survival time.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1446906363>315</a></td><td>DRD2</td><td>rs6277</td><td>aripiprazole</td><td>Schizophrenia</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the genotype AG may have decreased response to aripiprazole in people with Schizophrenia as compared to patients with genotype AA. Though this association was found not statistically significant. Other genetic and clinical factors may also influence the response to aripiprazole.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447814424>316</a></td><td>CHAT</td><td>rs3793790</td><td>donepezil</td><td>Alzheimer Disease</td><td>3</td><td>AA</td><td>Efficacy</td><td>Patients with the AA genotype and Alzheimer Disease may have decreased response to donepezil, galantamine, or rivastigmine as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's response to donezepil, galantamine, and rivastigmine.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447814424>317</a></td><td>CHAT</td><td>rs3793790</td><td>galantamine</td><td>Alzheimer Disease</td><td>3</td><td>AA</td><td>Efficacy</td><td>Patients with the AA genotype and Alzheimer Disease may have decreased response to donepezil, galantamine, or rivastigmine as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's response to donezepil, galantamine, and rivastigmine.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447814424>318</a></td><td>CHAT</td><td>rs3793790</td><td>rivastigmine</td><td>Alzheimer Disease</td><td>3</td><td>AA</td><td>Efficacy</td><td>Patients with the AA genotype and Alzheimer Disease may have decreased response to donepezil, galantamine, or rivastigmine as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's response to donezepil, galantamine, and rivastigmine.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447814450>319</a></td><td>SELE</td><td>rs3917412</td><td>capecitabine</td><td>Colonic Neoplasms</td><td>3</td><td>CC</td><td>Efficacy</td><td>Patients with CC genotype and Colonic Neoplasms may have decreased response to capecitabine, leucovorin, oxaliplatin, or fluorouracil (FOLFOX and CAPOX) as compared to people with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's response to capecitabine, leucovorin, oxaliplatin, and fluorouracil.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447814450>320</a></td><td>SELE</td><td>rs3917412</td><td>fluorouracil</td><td>Colonic Neoplasms</td><td>3</td><td>CC</td><td>Efficacy</td><td>Patients with CC genotype and Colonic Neoplasms may have decreased response to capecitabine, leucovorin, oxaliplatin, or fluorouracil (FOLFOX and CAPOX) as compared to people with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's response to capecitabine, leucovorin, oxaliplatin, and fluorouracil.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447814450>321</a></td><td>SELE</td><td>rs3917412</td><td>leucovorin</td><td>Colonic Neoplasms</td><td>3</td><td>CC</td><td>Efficacy</td><td>Patients with CC genotype and Colonic Neoplasms may have decreased response to capecitabine, leucovorin, oxaliplatin, or fluorouracil (FOLFOX and CAPOX) as compared to people with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's response to capecitabine, leucovorin, oxaliplatin, and fluorouracil.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447814450>322</a></td><td>SELE</td><td>rs3917412</td><td>oxaliplatin</td><td>Colonic Neoplasms</td><td>3</td><td>CC</td><td>Efficacy</td><td>Patients with CC genotype and Colonic Neoplasms may have decreased response to capecitabine, leucovorin, oxaliplatin, or fluorouracil (FOLFOX and CAPOX) as compared to people with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's response to capecitabine, leucovorin, oxaliplatin, and fluorouracil.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444686850>323</a></td><td>SLC22A1</td><td>rs683369</td><td>imatinib</td><td>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</td><td>3</td><td>CG</td><td>Efficacy</td><td>Patients with the CG genotype and chronic myeloid leukemia may have decreased clearance of imatinib, as well as decreased event-free survival time, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence clearance of imatinib and event-free survival time.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444687039>324</a></td><td>TNFRSF1A</td><td>rs4149570</td><td>Tumor necrosis factor alpha (TNF-alpha) inhibitors</td><td>Crohn Disease;Inflammatory Bowel Diseases</td><td>3</td><td>CC</td><td>Efficacy</td><td>Patients with the CC genotype and inflammatory bowel disease, or specifically Crohn's disease, may have a poorer response to anti-TNF therapy as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447814165>325</a></td><td>VEGFA</td><td>rs1570360</td><td>sorafenib</td><td>Carcinoma, Renal Cell</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype may have unfavorable progression-free survival when treated with sorafenib in people with Carcinoma, Renal Cell as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to sorafenib.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447943597>326</a></td><td>ABCB1</td><td>rs1045642</td><td>venlafaxine</td><td>Depressive Disorder;Narcolepsy</td><td>3</td><td>AA</td><td>Efficacy</td><td>Patients with genotype AA and depressive disorder may have decreased response to venlafaxine compared to patients with genotype GG. Patients with AA genotype and narcolepsy were not found to have different response to venlafaxine compared to patients with other genotypes. Other clinical and genetic factors also may affect response to venlafaxine.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447943608>327</a></td><td>ABCB1</td><td>rs1045642</td><td>Selective serotonin reuptake inhibitors</td><td>Depressive Disorder</td><td>3</td><td>AA</td><td>Efficacy</td><td>Patients with the AA genotype and depressive disorder may have decreased response to serotonin reuptake inhibitors compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to selective serotonin inhibitors.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447943700>328</a></td><td>ABCB1</td><td>rs1045642</td><td>modafinil</td><td>Narcolepsy</td><td>3</td><td>AA</td><td>Efficacy</td><td>Patients with genotype AA and narcolepsy may have decreased response to modafinil compared to patients with genotype AG. Other clinical and genetic factors may affect a patient's response to modafinil.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447944813>329</a></td><td>ST13</td><td>rs138337</td><td>corticosteroids</td><td>Asthma</td><td>3</td><td>GG</td><td>Efficacy</td><td>Patients with the GG genotype and asthma may have a decreased response when treated with inhaled corticosteroids as compared to patients with the AA and AG genotypes. Other genetic and clinical factors may also influence response to corticosteroids in asthmatics.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447676781>330</a></td><td>IFNL3</td><td>rs8099917</td><td>peginterferon alfa-2a</td><td>Hepatitis C</td><td>3</td><td>GT</td><td>Efficacy</td><td>Patients with genotype GT may have decreased response to simeprevir plus peginterferon and ribavirin therapy in treatment-nave patients and relapsers as compared to patients with genotype TT. Other genetic and clinical factors may also influence the response to simeprevir/pegintron therapy.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447676781>331</a></td><td>IFNL3</td><td>rs8099917</td><td>peginterferon alfa-2b</td><td>Hepatitis C</td><td>3</td><td>GT</td><td>Efficacy</td><td>Patients with genotype GT may have decreased response to simeprevir plus peginterferon and ribavirin therapy in treatment-nave patients and relapsers as compared to patients with genotype TT. Other genetic and clinical factors may also influence the response to simeprevir/pegintron therapy.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447676781>332</a></td><td>IFNL3</td><td>rs8099917</td><td>ribavirin</td><td>Hepatitis C</td><td>3</td><td>GT</td><td>Efficacy</td><td>Patients with genotype GT may have decreased response to simeprevir plus peginterferon and ribavirin therapy in treatment-nave patients and relapsers as compared to patients with genotype TT. Other genetic and clinical factors may also influence the response to simeprevir/pegintron therapy.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447676781>333</a></td><td>IFNL3</td><td>rs8099917</td><td>simeprevir</td><td>Hepatitis C</td><td>3</td><td>GT</td><td>Efficacy</td><td>Patients with genotype GT may have decreased response to simeprevir plus peginterferon and ribavirin therapy in treatment-nave patients and relapsers as compared to patients with genotype TT. Other genetic and clinical factors may also influence the response to simeprevir/pegintron therapy.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447946098>334</a></td><td>IL13</td><td>rs1295686</td><td>Hepatitis vaccines</td><td></td><td>3</td><td>CC</td><td>Efficacy</td><td>Patients with the CC genotype may be at decreased risk for non-immune response to the hepatitis B vaccine, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of non-immune response in patients receiving the hepatitis B vaccine.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444667668>335</a></td><td>PTGFR</td><td>rs3753380</td><td>latanoprost</td><td>Glaucoma, Open-Angle</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the rs3753380 CT genotype and open angle glaucoma may have a decreased response to latanoprost compared to patients with genotype CC. Other genetic and clinical factors may affect response to latanoprost.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1445400992>336</a></td><td>MDM4</td><td>rs1563828</td><td>docetaxel</td><td>Breast Neoplasms</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype and breast cancer may have a poorer response when treated with docetaxel and epirubicin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to docetaxel and epirubicin treatment.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1445400992>337</a></td><td>MDM4</td><td>rs1563828</td><td>epirubicin</td><td>Breast Neoplasms</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype and breast cancer may have a poorer response when treated with docetaxel and epirubicin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to docetaxel and epirubicin treatment.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447943640>338</a></td><td>CHAT</td><td>rs2177370</td><td>donepezil</td><td>Alzheimer Disease</td><td>3</td><td>GG</td><td>Efficacy</td><td>Patients with the GG genotype and Alzheimer's disease may have decreased response to donepezil compared to patients with the AA or AG genotype. Other genetic and clinical factors may also impact the metabolism of donezepil.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447943653>339</a></td><td>CHAT</td><td>rs2177370</td><td>rivastigmine</td><td>Alzheimer Disease</td><td>3</td><td>GG</td><td>Efficacy</td><td>Patients with the GG genotype and Alzheimer's disease may have decreased response to rivastigmine compared to patients with the AA or AG genotype. Other genetic and clinical factors may also impact the metabolism of rivastigmine.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447944806>340</a></td><td>ST13</td><td>rs138335</td><td>corticosteroids</td><td>Asthma</td><td>3</td><td>GG</td><td>Efficacy</td><td>Patients with the GG genotype and asthma may have a decreased response when treated with inhaled corticosteroids as compared to patients with the CC and CG genotypes. Other genetic and clinical factors may also influence response to corticosteroids in asthmatics.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444704373>341</a></td><td>-</td><td>rs446112</td><td>etoposide</td><td></td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype may have decreased resistance to etoposide as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to etoposide.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444686927>342</a></td><td>IL1RN</td><td>rs4251961</td><td>Tumor necrosis factor alpha (TNF-alpha) inhibitors</td><td>Colitis, Ulcerative</td><td>3</td><td>CC</td><td>Efficacy</td><td>Patients with the CC genotype and ulcerative colitis may have a poorer response to anti-TNF therapy as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444700589>343</a></td><td>RRAS2</td><td>rs11023197</td><td>tamoxifen</td><td>Breast Neoplasms</td><td>3</td><td>GG</td><td>Efficacy</td><td>Patients with the GG genotype and breast neoplasms may have a decreased frequency of relapse when treated with tamoxifen as compared to patients with the AA genotype. Other genetic and clinical factors may also effect patients' risk for frequency of relapse.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444668597>344</a></td><td>FTO</td><td>rs9939609</td><td>interferon alfa-2a, recombinant</td><td>Hepatitis C, Chronic;HIV Infections</td><td>3</td><td>AT</td><td>Efficacy</td><td>Patients with genotype AT may have lower likelihood of achieving successful virologic response to pegylated-interferon-alpha plus ribavirin in patients coinfected with HIV/HCV as compared to patients with genotype TT. Other genetic and clinical factors may also influence the response to pegylated-interferon-alpha plus ribavirin therapy.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444668597>345</a></td><td>FTO</td><td>rs9939609</td><td>interferon alfa-2b, recombinant</td><td>Hepatitis C, Chronic;HIV Infections</td><td>3</td><td>AT</td><td>Efficacy</td><td>Patients with genotype AT may have lower likelihood of achieving successful virologic response to pegylated-interferon-alpha plus ribavirin in patients coinfected with HIV/HCV as compared to patients with genotype TT. Other genetic and clinical factors may also influence the response to pegylated-interferon-alpha plus ribavirin therapy.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444668597>346</a></td><td>FTO</td><td>rs9939609</td><td>ribavirin</td><td>Hepatitis C, Chronic;HIV Infections</td><td>3</td><td>AT</td><td>Efficacy</td><td>Patients with genotype AT may have lower likelihood of achieving successful virologic response to pegylated-interferon-alpha plus ribavirin in patients coinfected with HIV/HCV as compared to patients with genotype TT. Other genetic and clinical factors may also influence the response to pegylated-interferon-alpha plus ribavirin therapy.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448601910>347</a></td><td>SLC6A2</td><td>rs2242446</td><td>venlafaxine</td><td>Depressive Disorder, Major</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype and major depressive disorder may have an decreased response to venlafaxine compared to patients with the CC genotype. Other clinical and genetic factors affect response to venlafaxine.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448602210>348</a></td><td>HTR1B</td><td>rs9361233</td><td>fluoxetine</td><td>Depressive Disorder, Major</td><td>3</td><td>CT</td><td>Efficacy</td><td>Children with the CT genotype and major depressive disorder may respond worse to fluoxetine therapy compared to patients with the CC and TT genotypes. Other clinical and genetic factors may affect response to fluoxetine.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444686958>349</a></td><td>TLR2</td><td>rs1816702</td><td>Tumor necrosis factor alpha (TNF-alpha) inhibitors</td><td>Crohn Disease</td><td>3</td><td>CC</td><td>Efficacy</td><td>Patients with the CC genotype and Crohn's disease, may have a poorer response to anti-TNF therapy as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1445619585>350</a></td><td>ANKFN1</td><td>rs9915451</td><td>hydrochlorothiazide</td><td>Essential hypertension</td><td>3</td><td>GG</td><td>Efficacy</td><td>Patients with the GG genotype and essential hypertension may have a decreased response when treated with hydrochlorothiazide as compared to patients with the AG and AA genotypes. Other genetic and clinical factors may also influence response to hydrochlorothiazide in patients with essential hypertension.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444607348>351</a></td><td>-</td><td>rs478437</td><td>tamoxifen</td><td></td><td>3</td><td>TT</td><td>Efficacy</td><td>In lymphoblastoid cell lines, the TT genotype was associated with decreased sensitivity to tamoxifen, as compared to the CC genotype. Other genetic or clinical factors may affect sensitivity to tamoxifen.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444607366>352</a></td><td>E2F7</td><td>rs310786</td><td>tamoxifen</td><td></td><td>3</td><td>TT</td><td>Efficacy</td><td>In lymphoblastoid cell lines, the TT genotype was associated with decreased sensitivity to tamoxifen, as compared to the CC genotype. Other genetic or clinical factors may affect sensitivity to tamoxifen.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184986585>353</a></td><td>ATP7B</td><td>rs9535828</td><td>Platinum compounds</td><td>Lung Neoplasms</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype and lung cancer may have a decreased response as compared to patients with the AA genotype. Other clinical and genetic factors may affect response to platinum compounds in patients with lung cancer.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444686969>354</a></td><td>TLR2</td><td>rs11938228</td><td>Tumor necrosis factor alpha (TNF-alpha) inhibitors</td><td>Inflammatory Bowel Diseases;Psoriasis</td><td>3</td><td>AA</td><td>Efficacy</td><td>Patients with the AA genotype and inflammatory bowel disease or psoriasis, may have a poorer response to anti-TNF therapy as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444686990>355</a></td><td>IL17A</td><td>rs2275913</td><td>Tumor necrosis factor alpha (TNF-alpha) inhibitors</td><td>Colitis, Ulcerative;Inflammatory Bowel Diseases</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype and inflammatory bowel disease, or specifically ulcerative colitis, may have a poorer response to anti-TNF therapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444687004>356</a></td><td>IL6</td><td>rs10499563</td><td>Tumor necrosis factor alpha (TNF-alpha) inhibitors</td><td>Colitis, Ulcerative;Inflammatory Bowel Diseases</td><td>3</td><td>TT</td><td>Efficacy</td><td>Patients with the TT genotype and inflammatory bowel disease, or specifically ulcerative colitis, may have a poorer response to anti-TNF therapy as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444705206>357</a></td><td>CRHR2</td><td>rs2270007</td><td>citalopram</td><td>Depressive Disorder, Major</td><td>3</td><td>CC</td><td>Efficacy</td><td>Patients with the CC genotype and major depression may have decreased response to citalopram as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to citalopram.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184999957>358</a></td><td>CYP3A5</td><td>rs776746</td><td>tacrolimus</td><td>transplant rejection</td><td>4</td><td>CC</td><td>Efficacy</td><td>Patients who are recipients of a liver transplantation from a donor with the CC (CYP3A5 *3/*3) genotype and are treated with tacrolimus may have a decreased, but not absent, risk of transplant rejection as compared to patients with the CT or TT genotype (*1/*3 or *1/*1). Other genetic and clinical factors may also influence a patient's response to tacrolimus treatment and risk of transplant rejection.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184747857>359</a></td><td>MYLIP</td><td>rs9370867</td><td>atorvastatin</td><td>Hypercholesterolemia</td><td>3</td><td>GG</td><td>Efficacy</td><td>Patients with the GG genotype and hypercholesterolemia who are treated with atorvastatin may have decreased LDL-C responses and are less likely to achieve LDL-C levels of less than 130mg/dl as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to atorvastatin.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444703985>360</a></td><td>DRD2</td><td>rs2734833</td><td>Selective serotonin reuptake inhibitors</td><td>Depressive Disorder, Major</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype and major depression may have early decrease in the percentage of HAMD scores when treated with Selective serotonin reuptake inhibitors as compared to patients with the AA genotype or may have late decrease in the percentage of HAMD scores when treated with Selective serotonin reuptake inhibitors as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to Selective serotonin reuptake inhibitors.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1185003565>361</a></td><td>FCGR3A</td><td>rs396991</td><td>trastuzumab</td><td>Breast Neoplasms</td><td>3</td><td>AC</td><td>Efficacy</td><td>Patients with the AC genotype may have decreased response to trastuzumab and shorter progression-free survival in people with Breast cancer as compared to patients with genotype CC. Other genetic or clinical factors may also influence the response to trastuzumab.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184986578>362</a></td><td>ATP7B</td><td>rs9535826</td><td>Platinum compounds</td><td>Lung Neoplasms</td><td>3</td><td>GT</td><td>Efficacy</td><td>Patients with the GT genotype and lung cancer may have a decreased response to platinum compounds as compared to patients with the GG genotype. Other clinical and genetic factors may also influence response to platinum compounds in patients with lung cancer.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444607704>363</a></td><td>UGT1A6</td><td>rs6759892</td><td>deferiprone</td><td>beta-Thalassemia</td><td>3</td><td>GT</td><td>Efficacy</td><td>Patients with the GT genotype and beta-thalassemia may have a worse response, but also a decreased risk for experiencing adverse drug reactions, when treated with deferiprone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response or risk for adverse events in patients receiving deferiprone.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444666756>364</a></td><td>PAX4</td><td>rs6467136</td><td>rosiglitazone</td><td>Diabetes Mellitus, Type 2</td><td>3</td><td>GG</td><td>Efficacy</td><td>Patients with the GG genotype and type 2 diabetes may have a poorer response when treated with rosiglitazone as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence response to rosiglitazone</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444666803>365</a></td><td>SLC19A1</td><td>rs3788189</td><td>pemetrexed</td><td>Carcinoma, Non-Small-Cell Lung;Mesothelioma</td><td>3</td><td>GT</td><td>Efficacy</td><td>Patients with the GT genotype and lung cancer may have a shorter overall survival time when treated with pemetrexed as compared to patients with the TT genotype. Other genetic and clinical factors may also influence overall survival time.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184988834>366</a></td><td>HLA-G</td><td>rs1063320</td><td>hmg coa reductase inhibitors</td><td>Asthma</td><td>3</td><td>GG</td><td>Efficacy</td><td>Patients with asthma and the GG genotype may have a decreased likelihood of asthma-related exacerbations when exposed to HMG-CoA reductase inhibitors (statins) as compared to patients with the CC genotype. Other clinical and environmental factors may also influence likelihood of asthma-related exacerbations in patients taking statins.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449003839>367</a></td><td>CDH2</td><td>rs8094439</td><td>methadone</td><td></td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG and GG genotypes who are taking methadone may have a decreased response as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to methadone treatment.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449003845>368</a></td><td>CDH2</td><td>rs17446819</td><td>methadone</td><td></td><td>3</td><td>AC</td><td>Efficacy</td><td>Patients with the AA and AC genotypes who are taking methadone may have a decreased response as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to methadone treatment.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444666376>369</a></td><td>AGT</td><td>rs5051</td><td>benazepril</td><td>Hypertension</td><td>3</td><td>TT</td><td>Efficacy</td><td>Patients with the TT genotype and hypertension may have a poorer response to treatment with benazepril or imidapril as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to benazepril or imidapril.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444666376>370</a></td><td>AGT</td><td>rs5051</td><td>imidapril</td><td>Hypertension</td><td>3</td><td>TT</td><td>Efficacy</td><td>Patients with the TT genotype and hypertension may have a poorer response to treatment with benazepril or imidapril as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to benazepril or imidapril.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444702822>371</a></td><td>ABCB1</td><td>rs1045642</td><td>phenobarbital</td><td>Epilepsy</td><td>3</td><td>AA</td><td>Efficacy</td><td>Patients with genotype AA may have decreased likelihood to be phenobarbital resistant in epilepsy patients as compared to patients with genotype GG or AG. Other genetic and clinical factors may also influence the response to phenobarbital.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444703529>372</a></td><td>EIF2AK4</td><td>rs2412459</td><td>olanzapine</td><td>Schizophrenia</td><td>3</td><td>TT</td><td>Efficacy</td><td>Patients with the TT genotype and Schizophrenia may have decreased response to olanzapine, quetiapine, risperidone or ziprasidone as compared to patients with the CT genotype. Other genetic and clinical factors may also influence a patient's response to olanzapine, quetiapine, risperidone or ziprasidone.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444703529>373</a></td><td>EIF2AK4</td><td>rs2412459</td><td>quetiapine</td><td>Schizophrenia</td><td>3</td><td>TT</td><td>Efficacy</td><td>Patients with the TT genotype and Schizophrenia may have decreased response to olanzapine, quetiapine, risperidone or ziprasidone as compared to patients with the CT genotype. Other genetic and clinical factors may also influence a patient's response to olanzapine, quetiapine, risperidone or ziprasidone.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444703529>374</a></td><td>EIF2AK4</td><td>rs2412459</td><td>risperidone</td><td>Schizophrenia</td><td>3</td><td>TT</td><td>Efficacy</td><td>Patients with the TT genotype and Schizophrenia may have decreased response to olanzapine, quetiapine, risperidone or ziprasidone as compared to patients with the CT genotype. Other genetic and clinical factors may also influence a patient's response to olanzapine, quetiapine, risperidone or ziprasidone.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444703529>375</a></td><td>EIF2AK4</td><td>rs2412459</td><td>ziprasidone</td><td>Schizophrenia</td><td>3</td><td>TT</td><td>Efficacy</td><td>Patients with the TT genotype and Schizophrenia may have decreased response to olanzapine, quetiapine, risperidone or ziprasidone as compared to patients with the CT genotype. Other genetic and clinical factors may also influence a patient's response to olanzapine, quetiapine, risperidone or ziprasidone.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444703560>376</a></td><td>PTPRM</td><td>rs6506569</td><td>methotrexate</td><td>Arthritis, Rheumatoid</td><td>4</td><td>CC</td><td>Efficacy</td><td>Patients with the CC genotype and Rheumatoid Arthritis who are treated with methotrexate may have a poorer response to treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate treatment.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444700536>377</a></td><td>-</td><td>rs10792367</td><td>hydrochlorothiazide</td><td>Hypertension</td><td>3</td><td>GG</td><td>Efficacy</td><td>Patients with the GG genotype and hypertension may have less blood pressure (BP) reduction when treated with hydrochlorothiazide as compared to patients with the CC genotype. Other genetic and clinical factors may also effect patients response to hydrochlorothiazide.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444702771>378</a></td><td>ALDH5A1</td><td>rs2760118</td><td>methadone</td><td>Opioid-Related Disorders</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype who are opioid-dependent may have a poorer response when treated with methadone as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to methadone.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444666681>379</a></td><td>WIF1</td><td>rs10878232</td><td>Platinum compounds</td><td>Carcinoma, Non-Small-Cell Lung</td><td>3</td><td>GG</td><td>Efficacy</td><td>Patients with the GG genotype and non-small-cell lung cancer may have a shorter survival time when treated with platinum-based chemotherapy as compared to patients with the TT genotype. Other genetic and clinical factors may also influence survival time in patients receiving platinum-based chemotherapy.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444702664>380</a></td><td>TRAF1</td><td>rs3761847</td><td>adalimumab</td><td>Arthritis, Rheumatoid</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype may have decreased response to anti-Tumor necrosis factor alpha (TNF-alpha) treatments in people with Arthritis, Rheumatoid as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to anti-TNF treatments.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444702664>381</a></td><td>TRAF1</td><td>rs3761847</td><td>etanercept</td><td>Arthritis, Rheumatoid</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype may have decreased response to anti-Tumor necrosis factor alpha (TNF-alpha) treatments in people with Arthritis, Rheumatoid as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to anti-TNF treatments.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444702664>382</a></td><td>TRAF1</td><td>rs3761847</td><td>infliximab</td><td>Arthritis, Rheumatoid</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype may have decreased response to anti-Tumor necrosis factor alpha (TNF-alpha) treatments in people with Arthritis, Rheumatoid as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to anti-TNF treatments.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444702664>383</a></td><td>TRAF1</td><td>rs3761847</td><td>Tumor necrosis factor alpha (TNF-alpha) inhibitors</td><td>Arthritis, Rheumatoid</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype may have decreased response to anti-Tumor necrosis factor alpha (TNF-alpha) treatments in people with Arthritis, Rheumatoid as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to anti-TNF treatments.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1446897485>384</a></td><td>VEGFA</td><td>rs699947</td><td>bevacizumab</td><td>Colorectal Neoplasms</td><td>3</td><td>AC</td><td>Efficacy</td><td>Patients with colorectal cancer and the AC genotype may have a reduced response to bevacizumab, capecitabine, fluorouracil, irinotecan, leucovorin, or oxaliplatin as compared to patients with the CC genotype. Other clinical and genetic factors may also affect response to chemotherapy in people with colorectal cancer.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1446897485>385</a></td><td>VEGFA</td><td>rs699947</td><td>capecitabine</td><td>Colorectal Neoplasms</td><td>3</td><td>AC</td><td>Efficacy</td><td>Patients with colorectal cancer and the AC genotype may have a reduced response to bevacizumab, capecitabine, fluorouracil, irinotecan, leucovorin, or oxaliplatin as compared to patients with the CC genotype. Other clinical and genetic factors may also affect response to chemotherapy in people with colorectal cancer.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1446897485>386</a></td><td>VEGFA</td><td>rs699947</td><td>fluorouracil</td><td>Colorectal Neoplasms</td><td>3</td><td>AC</td><td>Efficacy</td><td>Patients with colorectal cancer and the AC genotype may have a reduced response to bevacizumab, capecitabine, fluorouracil, irinotecan, leucovorin, or oxaliplatin as compared to patients with the CC genotype. Other clinical and genetic factors may also affect response to chemotherapy in people with colorectal cancer.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1446897485>387</a></td><td>VEGFA</td><td>rs699947</td><td>irinotecan</td><td>Colorectal Neoplasms</td><td>3</td><td>AC</td><td>Efficacy</td><td>Patients with colorectal cancer and the AC genotype may have a reduced response to bevacizumab, capecitabine, fluorouracil, irinotecan, leucovorin, or oxaliplatin as compared to patients with the CC genotype. Other clinical and genetic factors may also affect response to chemotherapy in people with colorectal cancer.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1446897485>388</a></td><td>VEGFA</td><td>rs699947</td><td>leucovorin</td><td>Colorectal Neoplasms</td><td>3</td><td>AC</td><td>Efficacy</td><td>Patients with colorectal cancer and the AC genotype may have a reduced response to bevacizumab, capecitabine, fluorouracil, irinotecan, leucovorin, or oxaliplatin as compared to patients with the CC genotype. Other clinical and genetic factors may also affect response to chemotherapy in people with colorectal cancer.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1446897485>389</a></td><td>VEGFA</td><td>rs699947</td><td>oxaliplatin</td><td>Colorectal Neoplasms</td><td>3</td><td>AC</td><td>Efficacy</td><td>Patients with colorectal cancer and the AC genotype may have a reduced response to bevacizumab, capecitabine, fluorouracil, irinotecan, leucovorin, or oxaliplatin as compared to patients with the CC genotype. Other clinical and genetic factors may also affect response to chemotherapy in people with colorectal cancer.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184749208>390</a></td><td>ABCB1</td><td>rs1045642</td><td>vincristine</td><td>Precursor Cell Lymphoblastic Leukemia-Lymphoma</td><td>3</td><td>AA</td><td>Efficacy</td><td>Patients with the AA genotype and acute lymphoblastic leukemia who are treated with vincristine may have a decreased likelihood of event-free survival as compared to patients with the GG genotype. This association was not replicated in a second cohort. Other genetic and clinical factors may also influence a patient's response to vincristine treatment.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1446897495>391</a></td><td>VEGFA</td><td>rs3025039</td><td>bevacizumab</td><td>Breast Neoplasms;Colorectal Neoplasms</td><td>3</td><td>TT</td><td>Efficacy</td><td>Patients with colorectal or breast cancer and the TT genotype may have a worse response to bevacizumab-based treatment regimens as compared to patients with the CC and CT genotype, although this is contradicted in one study. Other clinical and genetic factors may also influence response to bevacizumab-based treatment regimens in patients with cancer.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1446908615>392</a></td><td>AGT</td><td>rs11122576</td><td>amlodipine</td><td></td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype may have a decreased, but not absent, risk for Coronary Disease when treated with chlorthalidone or lisinopril as compared to patients with the CT genotype who are treated with amlodipine. Other genetic and clinical factors may also influence a patient's response to treatment and risk for Coronary Disease.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1446908615>393</a></td><td>AGT</td><td>rs11122576</td><td>chlorthalidone</td><td></td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype may have a decreased, but not absent, risk for Coronary Disease when treated with chlorthalidone or lisinopril as compared to patients with the CT genotype who are treated with amlodipine. Other genetic and clinical factors may also influence a patient's response to treatment and risk for Coronary Disease.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1446908615>394</a></td><td>AGT</td><td>rs11122576</td><td>lisinopril</td><td></td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype may have a decreased, but not absent, risk for Coronary Disease when treated with chlorthalidone or lisinopril as compared to patients with the CT genotype who are treated with amlodipine. Other genetic and clinical factors may also influence a patient's response to treatment and risk for Coronary Disease.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444673002>395</a></td><td>SLC12A3</td><td>rs1529927</td><td>bumetanide</td><td></td><td>3</td><td>GG</td><td>Efficacy</td><td>Patients with the GG genotype may have a poorer response to treatment with loop diuretics as compared to those with the CC genotype. Other genetic and clinical factors may also influence response to loop diuretics.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444673002>396</a></td><td>SLC12A3</td><td>rs1529927</td><td>furosemide</td><td></td><td>3</td><td>GG</td><td>Efficacy</td><td>Patients with the GG genotype may have a poorer response to treatment with loop diuretics as compared to those with the CC genotype. Other genetic and clinical factors may also influence response to loop diuretics.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444673002>397</a></td><td>SLC12A3</td><td>rs1529927</td><td>torasemide</td><td></td><td>3</td><td>GG</td><td>Efficacy</td><td>Patients with the GG genotype may have a poorer response to treatment with loop diuretics as compared to those with the CC genotype. Other genetic and clinical factors may also influence response to loop diuretics.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444700983>398</a></td><td>NOS3</td><td>rs1799983</td><td>Ace Inhibitors, Plain</td><td>Heart Failure</td><td>3</td><td>GG</td><td>Efficacy</td><td>Patients with the GG genotype may have decreased risk of emergency department visits when treated with Ace Inhibitors, Plain, Angiotensin II Antagonists, Beta Blocking Agents, digoxin, diuretics or spironolactone in people with Heart Failureas compared to patients with genotype TT or GT. Other genetic or clinical factors may also influence the outcome of heart failure patients.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444700983>399</a></td><td>NOS3</td><td>rs1799983</td><td>Angiotensin II Antagonists</td><td>Heart Failure</td><td>3</td><td>GG</td><td>Efficacy</td><td>Patients with the GG genotype may have decreased risk of emergency department visits when treated with Ace Inhibitors, Plain, Angiotensin II Antagonists, Beta Blocking Agents, digoxin, diuretics or spironolactone in people with Heart Failureas compared to patients with genotype TT or GT. Other genetic or clinical factors may also influence the outcome of heart failure patients.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444700983>400</a></td><td>NOS3</td><td>rs1799983</td><td>Beta Blocking Agents</td><td>Heart Failure</td><td>3</td><td>GG</td><td>Efficacy</td><td>Patients with the GG genotype may have decreased risk of emergency department visits when treated with Ace Inhibitors, Plain, Angiotensin II Antagonists, Beta Blocking Agents, digoxin, diuretics or spironolactone in people with Heart Failureas compared to patients with genotype TT or GT. Other genetic or clinical factors may also influence the outcome of heart failure patients.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444700983>401</a></td><td>NOS3</td><td>rs1799983</td><td>digoxin</td><td>Heart Failure</td><td>3</td><td>GG</td><td>Efficacy</td><td>Patients with the GG genotype may have decreased risk of emergency department visits when treated with Ace Inhibitors, Plain, Angiotensin II Antagonists, Beta Blocking Agents, digoxin, diuretics or spironolactone in people with Heart Failureas compared to patients with genotype TT or GT. Other genetic or clinical factors may also influence the outcome of heart failure patients.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444700983>402</a></td><td>NOS3</td><td>rs1799983</td><td>diuretics</td><td>Heart Failure</td><td>3</td><td>GG</td><td>Efficacy</td><td>Patients with the GG genotype may have decreased risk of emergency department visits when treated with Ace Inhibitors, Plain, Angiotensin II Antagonists, Beta Blocking Agents, digoxin, diuretics or spironolactone in people with Heart Failureas compared to patients with genotype TT or GT. Other genetic or clinical factors may also influence the outcome of heart failure patients.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444700983>403</a></td><td>NOS3</td><td>rs1799983</td><td>spironolactone</td><td>Heart Failure</td><td>3</td><td>GG</td><td>Efficacy</td><td>Patients with the GG genotype may have decreased risk of emergency department visits when treated with Ace Inhibitors, Plain, Angiotensin II Antagonists, Beta Blocking Agents, digoxin, diuretics or spironolactone in people with Heart Failureas compared to patients with genotype TT or GT. Other genetic or clinical factors may also influence the outcome of heart failure patients.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451506740>404</a></td><td>-</td><td>rs139945292</td><td>Beta Blocking Agents</td><td></td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the rs139945292 CT genotype may have decreased blood pressure reduction after treatment with beta blocking agents as compared to patients with the CC genotype. Other genetic and clinical factors may also influence the response to beta-blocking agents.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444673046>405</a></td><td>HRH3</td><td>rs3787429</td><td>risperidone</td><td>Schizophrenia</td><td>3</td><td>CC</td><td>Efficacy</td><td>Patients with the CC genotype and schizophrenia may have a poorer response when treated with risperidone as compared to patients with the TT genotype. However, another study found no association between this variant and response to riperidone in patients with schizophrenia. Other genetic and clinical factors may also influence response to risperidone.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444876859>406</a></td><td>IFNL3</td><td>rs12979860</td><td>deleobuvir</td><td>Hepatitis C, Chronic</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype may have decreased response to deleobuvir and faldaprevir in people with Hepatitis C genotype 1 as compared to patients with genotype CC. Other genetic and clinical factors may also influence the response to deleobuvir and faldaprevir.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444876859>407</a></td><td>IFNL4</td><td>rs12979860</td><td>deleobuvir</td><td>Hepatitis C, Chronic</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype may have decreased response to deleobuvir and faldaprevir in people with Hepatitis C genotype 1 as compared to patients with genotype CC. Other genetic and clinical factors may also influence the response to deleobuvir and faldaprevir.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444876859>408</a></td><td>IFNL3</td><td>rs12979860</td><td>faldaprevir</td><td>Hepatitis C, Chronic</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype may have decreased response to deleobuvir and faldaprevir in people with Hepatitis C genotype 1 as compared to patients with genotype CC. Other genetic and clinical factors may also influence the response to deleobuvir and faldaprevir.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444876859>409</a></td><td>IFNL4</td><td>rs12979860</td><td>faldaprevir</td><td>Hepatitis C, Chronic</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype may have decreased response to deleobuvir and faldaprevir in people with Hepatitis C genotype 1 as compared to patients with genotype CC. Other genetic and clinical factors may also influence the response to deleobuvir and faldaprevir.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1446900938>410</a></td><td>DHFR</td><td>rs408626</td><td>methotrexate</td><td>Precursor Cell Lymphoblastic Leukemia-Lymphoma</td><td>3</td><td>CC</td><td>Efficacy</td><td>Patients with acute lymphoblastic leukemia and the CC genotype may have a decreased risk of leukopenia, as compared to patients with the TT genotypes, but may also experience decreased rates of event-free survival, and overall survival rates as compared to patients with the TT genotypes. Other clinical and genetic factors may also affect risk of leukopenia, as well as event-free survival, and overall survival rates in patients with acute lymphoblastic leukemia.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444673412>411</a></td><td>ABCG2</td><td>rs2725252</td><td>imatinib</td><td>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</td><td>3</td><td>AA</td><td>Efficacy</td><td>Patients with the AA genotype and chronic myelogenous leukemia may have a lower chance of achieving major molecular response when treated with imatinib as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence response to imatinib.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444700874>412</a></td><td>DBH</td><td>rs1611115</td><td>levodopa</td><td>Cocaine-Related Disorders</td><td>3</td><td>CC</td><td>Efficacy</td><td>Patients with the CC genotype may have a decreased response to levodopa in people with cocaine-related disorders as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's response to levodopa.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444702778>413</a></td><td>CCL2</td><td>rs2857657</td><td>risperidone</td><td>Schizophrenia</td><td>3</td><td>CG</td><td>Efficacy</td><td>Patients with the CG genotype and schizophrenia may have a poorer response when treated with risperidone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to risperidone.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444703258>414</a></td><td>DRD2</td><td>rs4460839</td><td>Selective serotonin reuptake inhibitors</td><td>Depressive Disorder, Major</td><td>3</td><td>TT</td><td>Efficacy</td><td>Patients with the TT genotype and major depression who are treated with Selective serotonin reuptake inhibitors may have late decrease in the percentage of HAMD scores as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to Selective serotonin reuptake inhibitors.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1445402085>415</a></td><td>HTR1A</td><td>rs6295</td><td>clozapine</td><td>Schizophrenia</td><td>3</td><td>CC</td><td>Efficacy</td><td>Patients with the CC genotype and schizophrenia may have a poorer response when treated with clozapine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to clozapine.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448100067>416</a></td><td>STAT3</td><td>rs4796793</td><td>interferons</td><td>Carcinoma, Renal Cell</td><td>3</td><td>CG</td><td>Efficacy</td><td>Patients with the CG genotype and renal cell carcinoma may have a decreased response to treatment with interferon alfa (IFN-alpha) therapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to IFN-alpha therapy.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448100194>417</a></td><td>-</td><td>rs2831440</td><td>antidepressants</td><td>Depressive Disorder, Major</td><td>3</td><td>GT</td><td>Efficacy</td><td>Patients with the GT genotype and major depressive disorder may have decreased response to antidepressants compared to patients with the TT genotype. Other factors may affect response to antidepressants.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448522760>418</a></td><td>MAP3K1</td><td>rs96844</td><td>Tumor necrosis factor alpha (TNF-alpha) inhibitors</td><td>Psoriasis</td><td>3</td><td>AA</td><td>Efficacy</td><td>Patients with the AA genotype and psoriasis may have a poorer response to treatment with anti-TNF drugs as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence response to anti-TNF drugs.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448602934>419</a></td><td>CYP2R1</td><td>rs10741657</td><td>peginterferon alfa-2b</td><td>Hepatitis C, Chronic</td><td>3</td><td>GG</td><td>Efficacy</td><td>Patients with the GG genotype may have decreased sustained virological response (svr) when treated with peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to patients with genotype AA or AG. Other genetic and clinical factors may influence the response to peginterferon alpha and ribavirin.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448602934>420</a></td><td>CYP2R1</td><td>rs10741657</td><td>ribavirin</td><td>Hepatitis C, Chronic</td><td>3</td><td>GG</td><td>Efficacy</td><td>Patients with the GG genotype may have decreased sustained virological response (svr) when treated with peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to patients with genotype AA or AG. Other genetic and clinical factors may influence the response to peginterferon alpha and ribavirin.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448612776>421</a></td><td>CLNK</td><td>rs13144136</td><td>Antihypertensives</td><td>Hypertension</td><td>3</td><td>GT</td><td>Efficacy</td><td>Patients with the GT genotype and hypertension may have a decreased response to antihypertensives compared to patients with the GG genotype. Other clinical and genetic factors may affect response to antihypertensive therapy.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447981289>422</a></td><td>UGT2B7</td><td>rs4292394</td><td>methadone</td><td>Opioid-Related Disorders</td><td>3</td><td>CG</td><td>Efficacy</td><td>Patients with the CG genotype who are undergoing methadone maintenance treatment may have decreased severity of opiate withdrawal symptoms as compared to patients with the GG genotype. Other genetic and clinical factors may also influence opiate withdrawal symptoms in patients receiving methadone.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448102470>423</a></td><td>IFNL3</td><td>rs8105790</td><td>peginterferon alfa-2a</td><td>Hepatitis C, Chronic</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype and chronic hepatitis C may have a decreased likelihood of sustained virological response when treated with peginterferon-alpha and ribavirin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to peginterferon-alpha and ribavirin treatment.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448102470>424</a></td><td>IFNL3</td><td>rs8105790</td><td>peginterferon alfa-2b</td><td>Hepatitis C, Chronic</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype and chronic hepatitis C may have a decreased likelihood of sustained virological response when treated with peginterferon-alpha and ribavirin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to peginterferon-alpha and ribavirin treatment.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448102470>425</a></td><td>IFNL3</td><td>rs8105790</td><td>ribavirin</td><td>Hepatitis C, Chronic</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype and chronic hepatitis C may have a decreased likelihood of sustained virological response when treated with peginterferon-alpha and ribavirin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to peginterferon-alpha and ribavirin treatment.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448427405>426</a></td><td>VEGFA</td><td>rs3025039</td><td>bevacizumab</td><td>Breast Neoplasms</td><td>3</td><td>TT</td><td>Efficacy</td><td>Patients with the TT genotype and breast cancer may have poorer overall survival times when treated with bevacizumab (in combination with chemotherapy) as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence response to bevacizumab.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448522766>427</a></td><td>IL12B</td><td>rs2546890</td><td>Tumor necrosis factor alpha (TNF-alpha) inhibitors</td><td>Psoriasis</td><td>3</td><td>GG</td><td>Efficacy</td><td>Patients with the GG genotype and psoriasis may have a poorer response to treatment with anti-TNF drugs as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to anti-TNF drugs.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448102463>428</a></td><td>IFNL3</td><td>rs7248668</td><td>peginterferon alfa-2a</td><td>Hepatitis C, Chronic</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype and chronic hepatitis C may have a decreased likelihood of sustained virological response when treated with peginterferon-alpha and ribavirin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to peginterferon-alpha and ribavirin treatment.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448102463>429</a></td><td>IFNL3</td><td>rs7248668</td><td>peginterferon alfa-2b</td><td>Hepatitis C, Chronic</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype and chronic hepatitis C may have a decreased likelihood of sustained virological response when treated with peginterferon-alpha and ribavirin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to peginterferon-alpha and ribavirin treatment.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448102463>430</a></td><td>IFNL3</td><td>rs7248668</td><td>ribavirin</td><td>Hepatitis C, Chronic</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype and chronic hepatitis C may have a decreased likelihood of sustained virological response when treated with peginterferon-alpha and ribavirin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to peginterferon-alpha and ribavirin treatment.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450815160>431</a></td><td>TJP1</td><td>rs785423</td><td>risperidone</td><td>Schizophrenia</td><td>3</td><td>GG</td><td>Efficacy</td><td>Patients with schizophrenia and the GG genotype may have a decreased response to risperidone as compared to patients with the AA or AG genotypes. Other genetic or clinical factors may also affect a patient's response to risperidone.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447949632>432</a></td><td>VDR</td><td>rs1540339</td><td>selective beta-2-adrenoreceptor agonists</td><td>Asthma</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with CT genotype may have decreased response to selective beta-2-adrenoreceptor agonists in people with asthma as compared to patients with genotype TT. Other genetic and clinical factors may also influence the risk of response to selective beta-2-adrenoreceptor agonists.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447964250>433</a></td><td>ADGRL3</td><td>rs1947275</td><td>methylphenidate</td><td>Attention Deficit Disorder with Hyperactivity</td><td>3</td><td>CC</td><td>Efficacy</td><td>Patients with the CC genotype and ADHD may have a slower response when treated with methylphenidate as compared to patients with the CT and TT genotypes. Other genetic and clinical factors may also influence the speed of efficacy of methylphenidate.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447962737>434</a></td><td>LDLR</td><td>rs688</td><td>lovastatin</td><td></td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype may have a smaller decrease in total cholesterol when treated with lovastatin as compared to patients with the CC or TT genotype. Other genetic and clinical factors may also influence total cholesterol levels.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447979493>435</a></td><td>VEGFA</td><td>rs2010963</td><td>sorafenib</td><td>Carcinoma, Hepatocellular</td><td>3</td><td>GG</td><td>Efficacy</td><td>Patients with the GG genotype may have decreased progression-free survival and decreased overall survival when treated with sorafenib in people with Hepatocellular Carcinoma as compared to patients with genotype CC or CG. Other genetic and clinical factors may also influence the response to sorafenib.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447979514>436</a></td><td>NOS3</td><td>rs1799983</td><td>sorafenib</td><td>Carcinoma, Hepatocellular</td><td>3</td><td>GG</td><td>Efficacy</td><td>Patients with the GG genotype may have decreased progression-free survival and decreased overall survival when treated with sorafenib in people with Hepatocellular Carcinoma as compared to patients with genotype GT or TT. Other genetic and clinical factors may also influence the response to sorafenib.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448102497>437</a></td><td>-</td><td>rs8113007</td><td>peginterferon alfa-2b</td><td>Hepatitis C;HIV Infections</td><td>3</td><td>AT</td><td>Efficacy</td><td>Patients with the AT genotype and hepatitis C or HIV may have a decreased likelihood of sustained virological response to peginterferon-alpha and ribavirin treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to peginterferon-alpha and ribavirin treatment.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448102497>438</a></td><td>-</td><td>rs8113007</td><td>ribavirin</td><td>Hepatitis C;HIV Infections</td><td>3</td><td>AT</td><td>Efficacy</td><td>Patients with the AT genotype and hepatitis C or HIV may have a decreased likelihood of sustained virological response to peginterferon-alpha and ribavirin treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to peginterferon-alpha and ribavirin treatment.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448102666>439</a></td><td>-</td><td>rs2498804</td><td>carboplatin</td><td>Carcinoma, Non-Small-Cell Lung</td><td>3</td><td>AC</td><td>Efficacy</td><td>Patients with the AC genotype and non-small-cell lung cancer may have a decreased risk of distant disease progression when treated with platinum-based chemotherapy as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for disease progression.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448102666>440</a></td><td>-</td><td>rs2498804</td><td>cisplatin</td><td>Carcinoma, Non-Small-Cell Lung</td><td>3</td><td>AC</td><td>Efficacy</td><td>Patients with the AC genotype and non-small-cell lung cancer may have a decreased risk of distant disease progression when treated with platinum-based chemotherapy as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for disease progression.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448125544>441</a></td><td>HIF1A</td><td>rs11549465</td><td>axitinib</td><td></td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with CT genotype may have decreased progression-free survival when treated with axitinib or sorafenib in people with Carcinoma, Renal Cell as compared to patients with genotype CC. Other genetic and clinical factors may also influence the response to axitinib and sorafenib.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448125544>442</a></td><td>HIF1A</td><td>rs11549465</td><td>sorafenib</td><td></td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with CT genotype may have decreased progression-free survival when treated with axitinib or sorafenib in people with Carcinoma, Renal Cell as compared to patients with genotype CC. Other genetic and clinical factors may also influence the response to axitinib and sorafenib.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448102477>443</a></td><td>IFNL3</td><td>rs28416813</td><td>peginterferon alfa-2a</td><td>Hepatitis C, Chronic;HIV Infections</td><td>3</td><td>CG</td><td>Efficacy</td><td>Patients with the CG genotype and chronic hepatitis C or HIV may have a decreased likelihood of sustained virological response when treated with peginterferon-alpha and ribavirin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to peginterferon-alpha and ribavirin treatment.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448102477>444</a></td><td>IFNL3</td><td>rs28416813</td><td>peginterferon alfa-2b</td><td>Hepatitis C, Chronic;HIV Infections</td><td>3</td><td>CG</td><td>Efficacy</td><td>Patients with the CG genotype and chronic hepatitis C or HIV may have a decreased likelihood of sustained virological response when treated with peginterferon-alpha and ribavirin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to peginterferon-alpha and ribavirin treatment.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448102477>445</a></td><td>IFNL3</td><td>rs28416813</td><td>ribavirin</td><td>Hepatitis C, Chronic;HIV Infections</td><td>3</td><td>CG</td><td>Efficacy</td><td>Patients with the CG genotype and chronic hepatitis C or HIV may have a decreased likelihood of sustained virological response when treated with peginterferon-alpha and ribavirin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to peginterferon-alpha and ribavirin treatment.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447960468>446</a></td><td>RRM1</td><td>rs183484</td><td>gemcitabine</td><td>Neoplasms</td><td>3</td><td>AC</td><td>Efficacy</td><td>Patients with the AC genotype and cancer may have shorter progression-free survival times when treated with gemcitabine as compared to patients with the AA or CC genotype. No significant association with overall survival times has been found. Other genetic and clinical factors may also influence progression-free survival in patients receiving gemcitabine.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447981158>447</a></td><td>UGT2B7</td><td>rs6600879</td><td>methadone</td><td>Opioid-Related Disorders</td><td>3</td><td>CG</td><td>Efficacy</td><td>Patients with the CG genotype who are undergoing methadone maintenance treatment may have decreased severity of opiate withdrawal symptoms as compared to patients with the GG genotype. Other genetic and clinical factors may also influence opiate withdrawal symptoms in patients receiving methadone.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447981207>448</a></td><td>UGT2B7</td><td>rs6600880</td><td>methadone</td><td>Opioid-Related Disorders</td><td>3</td><td>AT</td><td>Efficacy</td><td>Patients with the AT genotype who are undergoing methadone maintenance treatment may have decreased severity of opiate withdrawal symptoms as compared to patients with the AA genotype. Other genetic and clinical factors may also influence opiate withdrawal symptoms in patients receiving methadone.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447981222>449</a></td><td>UGT2B7</td><td>rs4554144</td><td>methadone</td><td>Opioid-Related Disorders</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype who are undergoing methadone maintenance treatment may have decreased severity of opiate withdrawal symptoms as compared to patients with the TT genotype. Other genetic and clinical factors may also influence opiate withdrawal symptoms in patients receiving methadone.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447981250>450</a></td><td>UGT2B7</td><td>rs11940316</td><td>methadone</td><td>Opioid-Related Disorders</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype who are undergoing methadone maintenance treatment may have decreased severity of opiate withdrawal symptoms as compared to patients with the CC genotype. Other genetic and clinical factors may also influence opiate withdrawal symptoms in patients receiving methadone.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447981259>451</a></td><td>UGT2B7</td><td>rs7438135</td><td>methadone</td><td>Opioid-Related Disorders</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype who are undergoing methadone maintenance treatment may have decreased severity of opiate withdrawal symptoms as compared to patients with the AA genotype. Other genetic and clinical factors may also influence opiate withdrawal symptoms in patients receiving methadone.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447981268>452</a></td><td>UGT2B7</td><td>rs7662029</td><td>methadone</td><td>Opioid-Related Disorders</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype who are undergoing methadone maintenance treatment may have decreased severity of opiate withdrawal symptoms as compared to patients with the GG genotype. Other genetic and clinical factors may also influence opiate withdrawal symptoms in patients receiving methadone.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448103846>453</a></td><td>PTGS2</td><td>rs5275</td><td>capecitabine</td><td>Colorectal Neoplasms</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype and colorectal cancer may have shorter progression-free survival times when treated with capecitabine and oxaliplatin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence progression-free survival time.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448103846>454</a></td><td>PTGS2</td><td>rs5275</td><td>oxaliplatin</td><td>Colorectal Neoplasms</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype and colorectal cancer may have shorter progression-free survival times when treated with capecitabine and oxaliplatin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence progression-free survival time.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448103973>455</a></td><td>IGF2BP2</td><td>rs1470579</td><td>repaglinide</td><td>Diabetes Mellitus, Type 2</td><td>3</td><td>AC</td><td>Efficacy</td><td>Patients with the AC genotype and type 2 diabetes may have a decreased response to treatment with repaglinide as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to repaglinide.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448104005>456</a></td><td>SLC6A3</td><td>rs2975226</td><td>clozapine</td><td>Schizophrenia</td><td>3</td><td>TT</td><td>Efficacy</td><td>Patients with the TT genotype and schizophrenia may have a decreased response to treatment with clozapine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to clozapine.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448104029>457</a></td><td>-</td><td>rs2808630</td><td>rosuvastatin</td><td>Coronary Disease</td><td>3</td><td>TT</td><td>Efficacy</td><td>Patients with the TT genotype and coronary disease may have poorer cardiovascular outcomes when treated with rosuvastatin as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence cardiovascular outcomes.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447953123>458</a></td><td>HOTAIR</td><td>rs7958904</td><td>Platinum compounds</td><td>Lung Neoplasms</td><td>3</td><td>CG</td><td>Efficacy</td><td>Patients with the CG genotype and lung cancer may have a decreased response to platinum compounds as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to platinum compounds.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447953328>459</a></td><td>CTNNB1</td><td>rs4135385</td><td>cyclophosphamide</td><td>Multiple Myeloma</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype and multiple myeloma may have a decreased response to cyclophosphamide, dexamethasone, and thalidomide as compared to patients with the AG and GG genotypes. They may also be at decreased risk for neutropenia when treated with lenalidomide. Other genetic and clinical factors may also influence a patient's response to cyclophosphamide, dexamethasone, and thalidomide, and risk of neutropenia when treated with lenalidomide.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447953328>460</a></td><td>CTNNB1</td><td>rs4135385</td><td>dexamethasone</td><td>Multiple Myeloma</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype and multiple myeloma may have a decreased response to cyclophosphamide, dexamethasone, and thalidomide as compared to patients with the AG and GG genotypes. They may also be at decreased risk for neutropenia when treated with lenalidomide. Other genetic and clinical factors may also influence a patient's response to cyclophosphamide, dexamethasone, and thalidomide, and risk of neutropenia when treated with lenalidomide.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447953328>461</a></td><td>CTNNB1</td><td>rs4135385</td><td>lenalidomide</td><td>Multiple Myeloma</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype and multiple myeloma may have a decreased response to cyclophosphamide, dexamethasone, and thalidomide as compared to patients with the AG and GG genotypes. They may also be at decreased risk for neutropenia when treated with lenalidomide. Other genetic and clinical factors may also influence a patient's response to cyclophosphamide, dexamethasone, and thalidomide, and risk of neutropenia when treated with lenalidomide.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447953328>462</a></td><td>CTNNB1</td><td>rs4135385</td><td>thalidomide</td><td>Multiple Myeloma</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype and multiple myeloma may have a decreased response to cyclophosphamide, dexamethasone, and thalidomide as compared to patients with the AG and GG genotypes. They may also be at decreased risk for neutropenia when treated with lenalidomide. Other genetic and clinical factors may also influence a patient's response to cyclophosphamide, dexamethasone, and thalidomide, and risk of neutropenia when treated with lenalidomide.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447953340>463</a></td><td>CTNNB1</td><td>rs4533622</td><td>lenalidomide</td><td>Multiple Myeloma</td><td>3</td><td>AC</td><td>Efficacy</td><td>Patients with the AC genotype and multiple myeloma may have a decreased response to thalidomide as compared to patients with the AA genotype. However, they may also be at decreased risk for neutropenia when treated with lenalidomide compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to thalidomide and risk of neutropenia when treated with lenalidomide.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447953340>464</a></td><td>CTNNB1</td><td>rs4533622</td><td>thalidomide</td><td>Multiple Myeloma</td><td>3</td><td>AC</td><td>Efficacy</td><td>Patients with the AC genotype and multiple myeloma may have a decreased response to thalidomide as compared to patients with the AA genotype. However, they may also be at decreased risk for neutropenia when treated with lenalidomide compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to thalidomide and risk of neutropenia when treated with lenalidomide.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447960211>465</a></td><td>ABCB1</td><td>rs1045642</td><td>Platinum compounds</td><td>Carcinoma, Non-Small-Cell Lung</td><td>3</td><td>AA</td><td>Efficacy</td><td>Patients with the AA genotype and non-small-cell lung cancer may have a poorer response to platinum-based chemotherapy as compared to patients with the GG genotype. This was only seen in those of Asian ethnicity. Other genetic and clinical factors may also influence response to platinum-based chemotherapy.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447960656>466</a></td><td>AGTR1</td><td>rs5186</td><td>losartan</td><td>Liver Cirrhosis</td><td>3</td><td>AC</td><td>Efficacy</td><td>Patients with the AC genotype and cirrhosis may have a smaller decrease of hepatic venous pressure gradient when treated with losartan as compared to patients with the AA genotype. Other genetic and clinical factors may also influence hepatic venous pressure gradient.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447981474>467</a></td><td>TENT4A</td><td>rs274713</td><td>gemcitabine</td><td>Pancreatic Neoplasms</td><td>3</td><td>GT</td><td>Efficacy</td><td>Patients with the GT genotype and pancreatic cancer may have a shorter overall survival time when treated with gemcitabine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence overall survival time in patients with pancreatic cancer.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447983137>468</a></td><td>-</td><td>rs12143842</td><td>amlodipine</td><td></td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype and hypertension who are treated with amlodipine may have a decreased, but not absent, risk for stroke as compared to patients with C allele who are treated with chlorthalidone or lisinopril. Other genetic and clinical factors may also influence a patient's response to treatment and risk of stroke.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447983137>469</a></td><td>-</td><td>rs12143842</td><td>chlorthalidone</td><td></td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype and hypertension who are treated with amlodipine may have a decreased, but not absent, risk for stroke as compared to patients with C allele who are treated with chlorthalidone or lisinopril. Other genetic and clinical factors may also influence a patient's response to treatment and risk of stroke.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447983137>470</a></td><td>-</td><td>rs12143842</td><td>lisinopril</td><td></td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype and hypertension who are treated with amlodipine may have a decreased, but not absent, risk for stroke as compared to patients with C allele who are treated with chlorthalidone or lisinopril. Other genetic and clinical factors may also influence a patient's response to treatment and risk of stroke.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447960257>471</a></td><td>CFH</td><td>rs1061170</td><td>photodynamic therapy</td><td>Macular Degeneration</td><td>4</td><td>TT</td><td>Efficacy</td><td>Patients with the TT genotype and age-related macular degeneration may have a poorer response to treatment with photodynamic therapy as compared to patients with the CC or CT genotype. However, other studies have found no association between this genotype and photodynamic therapy response. Other genetic and clinical factors may also influence response to photodynamic therapy.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447963644>472</a></td><td>DRD1</td><td>rs265976</td><td>clozapine</td><td>Schizophrenia</td><td>3</td><td>GT</td><td>Efficacy</td><td>Patients with the GT genotype and schizophrenia may have a poorer response when treated with clozapine as compared to patients with the GG or TT genotype. Other genetic and clinical factors may also influence response to clozapine.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448097768>473</a></td><td>RRM1</td><td>rs232043</td><td>cisplatin</td><td>Carcinoma, Non-Small-Cell Lung</td><td>3</td><td>AA</td><td>Efficacy</td><td>Patients with non-small cell lung cancer and the AA genotype may have a decreased response to cisplatin and gemcitabine as compared to the AG and GG genotypes. Please note: the association was only significant when combining the effect of the AA genotype at rs232043 with the CC genotype at rs4492666 (CMPK1). Other clinical and genetic factors may also influence response to cisplatin and gemcitabine in patients with non-small cell lung cancer.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448097768>474</a></td><td>RRM1</td><td>rs232043</td><td>gemcitabine</td><td>Carcinoma, Non-Small-Cell Lung</td><td>3</td><td>AA</td><td>Efficacy</td><td>Patients with non-small cell lung cancer and the AA genotype may have a decreased response to cisplatin and gemcitabine as compared to the AG and GG genotypes. Please note: the association was only significant when combining the effect of the AA genotype at rs232043 with the CC genotype at rs4492666 (CMPK1). Other clinical and genetic factors may also influence response to cisplatin and gemcitabine in patients with non-small cell lung cancer.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447980897>475</a></td><td>CFTR</td><td>rs77010898</td><td>curcumin</td><td>Cystic Fibrosis</td><td>3</td><td>GG</td><td>Efficacy</td><td>Patients with the rs77010898 GG genotype and cystic fibrosis may not receive benefit when treated with ivacaftor and curcumin as compared to patients with the AA and AG genotypes. Other genetic and clinical factors may also influence the efficacy of ivacaftor and curcumin.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447980897>476</a></td><td>CFTR</td><td>rs77010898</td><td>ivacaftor</td><td>Cystic Fibrosis</td><td>3</td><td>GG</td><td>Efficacy</td><td>Patients with the rs77010898 GG genotype and cystic fibrosis may not receive benefit when treated with ivacaftor and curcumin as compared to patients with the AA and AG genotypes. Other genetic and clinical factors may also influence the efficacy of ivacaftor and curcumin.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447963798>477</a></td><td>GRK4</td><td>rs1801058</td><td>metoprolol</td><td>hypertensive nephrosclerosis</td><td>3</td><td>CT</td><td>Efficacy</td><td>Women with the CT genotype and hypertensive nephrosclerosis may have a poorer response to treatment with metoprolol as compared to patients with the CC genotype. No significant results were seen for men. Other genetic and clinical factors may also influence response to metoprolol.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447963432>478</a></td><td>AGT</td><td>rs699</td><td>Ace Inhibitors, Plain</td><td>Hypertension</td><td>3</td><td>GG</td><td>Efficacy</td><td>Patients with the GG genotype and hypertension may have a decreased risk of stroke when treated with ACE inhibitors as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence risk of stroke.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448266177>479</a></td><td>-</td><td>rs4273729</td><td>peginterferon alfa-2a</td><td>Hepatitis C, Chronic</td><td>3</td><td>CG</td><td>Efficacy</td><td>Patients with genotype CG may have poorer rapid virological response (rvr) and sustained virological response (svr) to peginterferon/RBV in people with Hepatitis C, Chronic as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to peginterferon/RBV therapy.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448266177>480</a></td><td>-</td><td>rs4273729</td><td>peginterferon alfa-2b</td><td>Hepatitis C, Chronic</td><td>3</td><td>CG</td><td>Efficacy</td><td>Patients with genotype CG may have poorer rapid virological response (rvr) and sustained virological response (svr) to peginterferon/RBV in people with Hepatitis C, Chronic as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to peginterferon/RBV therapy.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448266177>481</a></td><td>-</td><td>rs4273729</td><td>ribavirin</td><td>Hepatitis C, Chronic</td><td>3</td><td>CG</td><td>Efficacy</td><td>Patients with genotype CG may have poorer rapid virological response (rvr) and sustained virological response (svr) to peginterferon/RBV in people with Hepatitis C, Chronic as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to peginterferon/RBV therapy.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448526040>482</a></td><td>OPRM1</td><td>rs10485058</td><td>methadone</td><td>Opioid-Related Disorders</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the rs10485058 AG genotype who are opioid-dependent may have a decreased response to treatment with methadone as compared to patients with the AA genotype. However, conflicting evidence has been reported. This drug-variant pair has been assigned a no recommendation by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence methadone response.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447960599>483</a></td><td>AGTR1</td><td>rs5186</td><td>nitrendipine</td><td>Hypertension</td><td>3</td><td>AC</td><td>Efficacy</td><td>Patients with the AC genotype and hypertension may have a lesser reduction in pulse wave velocity when treated with nitrendipine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence pulse wave velocity.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447961389>484</a></td><td>-</td><td>rs2056527</td><td>nicotine</td><td>Tobacco Use Disorder</td><td>3</td><td>CT</td><td>Efficacy</td><td>Smokers with the CT genotype who are treated with nicotine gum or nicotine patches may have a poorer likelihood of abstinence as compared to patients with the CC genotype. Other genetic and clinical factors may also influence likelihood of smoking abstinence.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447949639>485</a></td><td>VDR</td><td>rs2239179</td><td>selective beta-2-adrenoreceptor agonists</td><td>Asthma</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with CT genotype may have decreased response to selective beta-2-adrenoreceptor agonists in people with asthma as compared to patients with genotype TT. Other genetic and clinical factors may also influence the risk of response to selective beta-2-adrenoreceptor agonists.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448104059>486</a></td><td>SLC6A2</td><td>rs5569</td><td>methylphenidate</td><td>Attention Deficit Disorder with Hyperactivity</td><td>4</td><td>AG</td><td>Efficacy</td><td>Pediatric patients with the AG genotype and ADHD may have a poorer response when treated with methylphenidate as compared to patients with the GG genotype. However, contradictory evidence exists for this association. Studies used different scales to analyze improvement, e.g. CGI-I, ARS-IV, and other. Other genetic and clinical factors may also influence response to methylphenidate.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448102439>487</a></td><td>IFNL3</td><td>rs11881222</td><td>peginterferon alfa-2a</td><td>Hepatitis C;HIV Infections</td><td>2A</td><td>AG</td><td>Efficacy</td><td>Patients with the rs11881222 AG genotype and hepatitis C or HIV may have a poorer response to treatment with peginterferon-alpha and ribavirin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to peginterferon-alpha and ribavirin treatment.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448102439>488</a></td><td>IFNL3</td><td>rs11881222</td><td>peginterferon alfa-2b</td><td>Hepatitis C;HIV Infections</td><td>2A</td><td>AG</td><td>Efficacy</td><td>Patients with the rs11881222 AG genotype and hepatitis C or HIV may have a poorer response to treatment with peginterferon-alpha and ribavirin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to peginterferon-alpha and ribavirin treatment.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448102439>489</a></td><td>IFNL3</td><td>rs11881222</td><td>ribavirin</td><td>Hepatitis C;HIV Infections</td><td>2A</td><td>AG</td><td>Efficacy</td><td>Patients with the rs11881222 AG genotype and hepatitis C or HIV may have a poorer response to treatment with peginterferon-alpha and ribavirin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to peginterferon-alpha and ribavirin treatment.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448531868>490</a></td><td>PEAR1</td><td>rs4661012</td><td>ticagrelor</td><td></td><td>3</td><td>GT</td><td>Efficacy</td><td>People with the GT genotype may have decreased inhibition of platelet aggregation when taking ticagrelor compared to people with the GG genotype. Other clinical and genetic factors may affect response to ticagrelor.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447960327>491</a></td><td>RAF1</td><td>rs11710163</td><td>carboplatin</td><td>Carcinoma, Non-Small-Cell Lung</td><td>3</td><td>AA</td><td>Efficacy</td><td>Patients with the AA genotype and non-small-cell lung cancer may have poorer overall survival times when treated with platinum agents in combination with either gemcitabine or taxanes, as compared to patients with the AG genotype. Other genetic and clinical factors may also influence overall survival times in non-small-cell lung cancer patients.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447960327>492</a></td><td>RAF1</td><td>rs11710163</td><td>cisplatin</td><td>Carcinoma, Non-Small-Cell Lung</td><td>3</td><td>AA</td><td>Efficacy</td><td>Patients with the AA genotype and non-small-cell lung cancer may have poorer overall survival times when treated with platinum agents in combination with either gemcitabine or taxanes, as compared to patients with the AG genotype. Other genetic and clinical factors may also influence overall survival times in non-small-cell lung cancer patients.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447960327>493</a></td><td>RAF1</td><td>rs11710163</td><td>docetaxel</td><td>Carcinoma, Non-Small-Cell Lung</td><td>3</td><td>AA</td><td>Efficacy</td><td>Patients with the AA genotype and non-small-cell lung cancer may have poorer overall survival times when treated with platinum agents in combination with either gemcitabine or taxanes, as compared to patients with the AG genotype. Other genetic and clinical factors may also influence overall survival times in non-small-cell lung cancer patients.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447960327>494</a></td><td>RAF1</td><td>rs11710163</td><td>gemcitabine</td><td>Carcinoma, Non-Small-Cell Lung</td><td>3</td><td>AA</td><td>Efficacy</td><td>Patients with the AA genotype and non-small-cell lung cancer may have poorer overall survival times when treated with platinum agents in combination with either gemcitabine or taxanes, as compared to patients with the AG genotype. Other genetic and clinical factors may also influence overall survival times in non-small-cell lung cancer patients.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447960327>495</a></td><td>RAF1</td><td>rs11710163</td><td>paclitaxel</td><td>Carcinoma, Non-Small-Cell Lung</td><td>3</td><td>AA</td><td>Efficacy</td><td>Patients with the AA genotype and non-small-cell lung cancer may have poorer overall survival times when treated with platinum agents in combination with either gemcitabine or taxanes, as compared to patients with the AG genotype. Other genetic and clinical factors may also influence overall survival times in non-small-cell lung cancer patients.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448097711>496</a></td><td>CMPK1</td><td>rs4492666</td><td>cisplatin</td><td>Carcinoma, Non-Small-Cell Lung</td><td>3</td><td>CC</td><td>Efficacy</td><td>Patients with non-small cell lung cancer and the CC genotype may have a worse response to cisplatin and gemcitabine as compared to patients with the AA or AC genotypes. Other clinical and genetic factors may also influence response to cisplatin and gemcitabine in patients with non-small cell lung cancer.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448097711>497</a></td><td>CMPK1</td><td>rs4492666</td><td>gemcitabine</td><td>Carcinoma, Non-Small-Cell Lung</td><td>3</td><td>CC</td><td>Efficacy</td><td>Patients with non-small cell lung cancer and the CC genotype may have a worse response to cisplatin and gemcitabine as compared to patients with the AA or AC genotypes. Other clinical and genetic factors may also influence response to cisplatin and gemcitabine in patients with non-small cell lung cancer.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448097718>498</a></td><td>RRM1</td><td>rs2284449</td><td>cisplatin</td><td>Carcinoma, Non-Small-Cell Lung</td><td>3</td><td>TT</td><td>Efficacy</td><td>Patients with non-small cell lung cancer and the TT genotype may have a worse response to cisplatin and gemcitabine as compared to patients with the CC or CT genotypes. Please note: no association was found between overall survival and the TT genotype at rs2284449 alone, but an association was found when combining the effect of the TT genotype at rs2284449 with the CC genotype at rs4492666 (CMPK1) in patients treated with gemcitabine/cisplatin. Other clinical and genetic factors may also influence response to gemcitabine and cisplatin in patients with non-small cell lung cancer.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448097718>499</a></td><td>RRM1</td><td>rs2284449</td><td>gemcitabine</td><td>Carcinoma, Non-Small-Cell Lung</td><td>3</td><td>TT</td><td>Efficacy</td><td>Patients with non-small cell lung cancer and the TT genotype may have a worse response to cisplatin and gemcitabine as compared to patients with the CC or CT genotypes. Please note: no association was found between overall survival and the TT genotype at rs2284449 alone, but an association was found when combining the effect of the TT genotype at rs2284449 with the CC genotype at rs4492666 (CMPK1) in patients treated with gemcitabine/cisplatin. Other clinical and genetic factors may also influence response to gemcitabine and cisplatin in patients with non-small cell lung cancer.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447953102>500</a></td><td>-</td><td>rs10514475</td><td>Selective serotonin reuptake inhibitors</td><td>Depression</td><td>3</td><td>GG</td><td>Efficacy</td><td>Patients with the GG genotype and depression may have a decreased response to selective serotonin reuptake inhibitors as compared to patients with the AA and AG genotypes. Other genetic and clinical factors may also influence a patient's respond to SSRIs.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448100229>501</a></td><td>LDLR</td><td>rs1433099</td><td>pravastatin</td><td>Vascular Diseases</td><td>3</td><td>CC</td><td>Efficacy</td><td>Patients with the CC genotype and vascular diseases may have a poorer response to pravastatin treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also influence pravastatin response.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447962744>502</a></td><td>LDLR</td><td>rs5925</td><td>lovastatin</td><td></td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype may have a smaller decrease in total cholesterol when treated with lovastatin as compared to patients with the CC or TT genotype. Other genetic and clinical factors may also influence total cholesterol levels.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448100661>503</a></td><td>LRMDA</td><td>rs10509373</td><td>tamoxifen</td><td>Breast Neoplasms</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype and breast cancer may have shorter recurrence-free survival times when treated with tamoxifen as compared to patients with the TT genotype. Other genetic and clinical factors may also influence recurrence-free survival time.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448100687>504</a></td><td>GALR1</td><td>rs2717162</td><td>bupropion</td><td>Tobacco Use Disorder</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype who are addicted to smoking may have a poorer response to treatment with bupropion as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to bupropion treatment.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447953284>505</a></td><td>REV3L</td><td>rs462779</td><td>cisplatin</td><td>Osteosarcoma</td><td>3</td><td>AA</td><td>Efficacy</td><td>Patients with the AA genotype and osteosarcoma may have a decreased response to cisplatin as compared to patients with the AG and GG genotypes. Other genetic and clinical factors may also influence a patient's response to cisplatin.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447981282>506</a></td><td>UGT2B7</td><td>rs7439366</td><td>methadone</td><td>Opioid-Related Disorders</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype who are undergoing methadone maintenance treatment may have decreased severity of opiate withdrawal symptoms as compared to patients with the CC genotype. Other genetic and clinical factors may also influence opiate withdrawal symptoms in patients receiving methadone.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447981275>507</a></td><td>UGT2B7</td><td>rs7668258</td><td>methadone</td><td>Opioid-Related Disorders</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the rs7668258 CT genotype who are undergoing methadone maintenance treatment may have decreased severity of opiate withdrawal symptoms as compared to patients with the CC genotype. Other genetic and clinical factors may also influence opiate withdrawal symptoms when treated with methadone.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448102294>508</a></td><td>GSTA1</td><td>rs3957357</td><td>cyclophosphamide</td><td>Lymphoma, Large B-Cell, Diffuse</td><td>3</td><td>GG</td><td>Efficacy</td><td>Patients with the GG genotype and diffuse large B-cell lymphoma may have a shorter event-free survival time when treated with the R-CHOP chemotherapy regimen as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence event-free survival time.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448102294>509</a></td><td>GSTA1</td><td>rs3957357</td><td>doxorubicin</td><td>Lymphoma, Large B-Cell, Diffuse</td><td>3</td><td>GG</td><td>Efficacy</td><td>Patients with the GG genotype and diffuse large B-cell lymphoma may have a shorter event-free survival time when treated with the R-CHOP chemotherapy regimen as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence event-free survival time.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448102294>510</a></td><td>GSTA1</td><td>rs3957357</td><td>prednisone</td><td>Lymphoma, Large B-Cell, Diffuse</td><td>3</td><td>GG</td><td>Efficacy</td><td>Patients with the GG genotype and diffuse large B-cell lymphoma may have a shorter event-free survival time when treated with the R-CHOP chemotherapy regimen as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence event-free survival time.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448102294>511</a></td><td>GSTA1</td><td>rs3957357</td><td>rituximab</td><td>Lymphoma, Large B-Cell, Diffuse</td><td>3</td><td>GG</td><td>Efficacy</td><td>Patients with the GG genotype and diffuse large B-cell lymphoma may have a shorter event-free survival time when treated with the R-CHOP chemotherapy regimen as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence event-free survival time.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448102294>512</a></td><td>GSTA1</td><td>rs3957357</td><td>vincristine</td><td>Lymphoma, Large B-Cell, Diffuse</td><td>3</td><td>GG</td><td>Efficacy</td><td>Patients with the GG genotype and diffuse large B-cell lymphoma may have a shorter event-free survival time when treated with the R-CHOP chemotherapy regimen as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence event-free survival time.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449144364>513</a></td><td>-</td><td>rs1611255</td><td>lithium</td><td>Bipolar Disorder</td><td>3</td><td>AA</td><td>Efficacy</td><td>Patients with the AA genotype and bipolar affective disorder may have a decreased response to lithium as compared to patients with the AC or CC genotypes. Other genetic and clinical factors may also influence a patient's response to lithium when treating bipolar affective disorder.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447960633>514</a></td><td>AGTR1</td><td>rs5186</td><td>angiotensin II</td><td></td><td>3</td><td>AC</td><td>Efficacy</td><td>Patients with the AC genotype may have a smaller decrease in glomerular filtration rate (GFR) when treated with losartan as compared to patients with the AA genotype. Other genetic and clinical factors may also influence GFR.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447981296>515</a></td><td>UGT2B7</td><td>rs6600893</td><td>methadone</td><td>Opioid-Related Disorders</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype who are undergoing methadone maintenance treatment may have decreased severity of opiate withdrawal symptoms as compared to patients with the CC genotype. Other genetic and clinical factors may also influence opiate withdrawal symptoms in patients receiving methadone.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448100437>516</a></td><td>ATG5</td><td>rs510432</td><td>adalimumab</td><td>Inflammatory Bowel Diseases</td><td>3</td><td>CC</td><td>Efficacy</td><td>Patients with the CC genotype and inflammatory bowel disease may have decreased response to adalimumab compared to patients with the CT and TT genotypes. Other factors may affect response to adalimumab.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448100451>517</a></td><td>-</td><td>rs10945919</td><td>Tumor necrosis factor alpha (TNF-alpha) inhibitors</td><td>Arthritis, Rheumatoid</td><td>3</td><td>GG</td><td>Efficacy</td><td>Rheumatoid Arthritis patients with the genotype GG may be less likely to respond to TNF inhibitors compared with patients with genotype AA. Other genetic and clinical factors may also influence a patient's response.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448101202>518</a></td><td>SLC29A1</td><td>rs760370</td><td>peginterferon alfa-2a</td><td>Hepatitis C, Chronic</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype and chronic hepatitis C may be less likely to have rapid virological response when treated with pegylated interferon-ribavirin therapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence likelihood of rapid virological response.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448101202>519</a></td><td>SLC29A1</td><td>rs760370</td><td>peginterferon alfa-2b</td><td>Hepatitis C, Chronic</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype and chronic hepatitis C may be less likely to have rapid virological response when treated with pegylated interferon-ribavirin therapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence likelihood of rapid virological response.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448101202>520</a></td><td>SLC29A1</td><td>rs760370</td><td>ribavirin</td><td>Hepatitis C, Chronic</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype and chronic hepatitis C may be less likely to have rapid virological response when treated with pegylated interferon-ribavirin therapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence likelihood of rapid virological response.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448102446>521</a></td><td>IFNL3</td><td>rs4803219</td><td>peginterferon alfa-2a</td><td>Hepatitis C, Chronic</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype and chronic hepatitis C may have a decreased likelihood of virological response when treated with peginterferon-alpha and ribavirin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to peginterferon-alpha and ribavirin treatment.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448102446>522</a></td><td>IFNL3</td><td>rs4803219</td><td>peginterferon alfa-2b</td><td>Hepatitis C, Chronic</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype and chronic hepatitis C may have a decreased likelihood of virological response when treated with peginterferon-alpha and ribavirin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to peginterferon-alpha and ribavirin treatment.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448102446>523</a></td><td>IFNL3</td><td>rs4803219</td><td>ribavirin</td><td>Hepatitis C, Chronic</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype and chronic hepatitis C may have a decreased likelihood of virological response when treated with peginterferon-alpha and ribavirin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to peginterferon-alpha and ribavirin treatment.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448612662>524</a></td><td>UGT1A10</td><td>rs2741049</td><td>oxcarbazepine</td><td>Epilepsy;Seizures</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype and seizures may have decreased response to oxcarbazepine compared to patients with the CC genotypes. Other clinical and genetic factors may affect response to oxcarbazepine.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448612662>525</a></td><td>UGT1A7</td><td>rs2741049</td><td>oxcarbazepine</td><td>Epilepsy;Seizures</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype and seizures may have decreased response to oxcarbazepine compared to patients with the CC genotypes. Other clinical and genetic factors may affect response to oxcarbazepine.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448612662>526</a></td><td>UGT1A8</td><td>rs2741049</td><td>oxcarbazepine</td><td>Epilepsy;Seizures</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype and seizures may have decreased response to oxcarbazepine compared to patients with the CC genotypes. Other clinical and genetic factors may affect response to oxcarbazepine.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448612662>527</a></td><td>UGT1A9</td><td>rs2741049</td><td>oxcarbazepine</td><td>Epilepsy;Seizures</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype and seizures may have decreased response to oxcarbazepine compared to patients with the CC genotypes. Other clinical and genetic factors may affect response to oxcarbazepine.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447960937>528</a></td><td>DRD2</td><td>rs1799732</td><td>nicotine</td><td>Tobacco Use Disorder</td><td>3</td><td>GG</td><td>Efficacy</td><td>Patients with the GG genotype who are tobacco dependent may have a lower likelihood of abstinence when treated with nicotine replacement therapy as compared to patients with the G/del or del/del genotype. Other genetic and clinical factors may also influence smoking cessation.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449147609>529</a></td><td>CYP3A4</td><td>rs2740574</td><td>buprenorphine</td><td>Pain</td><td>3</td><td>TT</td><td>Efficacy</td><td>Patients with the CT or TT genotypes who are taking buprenorphine for pain may have a decreased analgesic response as compared to patients with the CC genotype. Other genetic and clinical factors may also influence analgesic response to buprenorphine.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448257290>530</a></td><td>ASPH</td><td>rs4379440</td><td>warfarin</td><td></td><td>3</td><td>GT</td><td>Efficacy</td><td>Patients with the GT genotype may have decreased time in therapeutic range (TTR) when treated with warfarin as compared to patients with genotype GG. Other genetic and clinical factors may influence the response to warfarin.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447982843>531</a></td><td>-</td><td>rs6924995</td><td>simvastatin</td><td>Hypercholesterolemia</td><td>3</td><td>G</td><td>Efficacy</td><td>Patients with the G allele may have decreased expression of LDLR as compared to patients with the A allele. This may affect the efficacy of simvastatin therapy. Other genetic and clinical factors may affect LDLR expression related to statin treatment.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448636111>532</a></td><td>EGFR</td><td>rs11506105</td><td>peginterferon alfa-2a</td><td>Hepatitis C, Chronic</td><td>3</td><td>GG</td><td>Efficacy</td><td>Patients with the GG genotype may have decreased rapid virological response (rvr), complete early virologic response (cEVR) and sustained virological response (svr) when treated with peginterferon alfa-2/RBV in people with Hepatitis C, Chronic as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to peginterferon alfa-2/RBV.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448636111>533</a></td><td>EGFR</td><td>rs11506105</td><td>peginterferon alfa-2b</td><td>Hepatitis C, Chronic</td><td>3</td><td>GG</td><td>Efficacy</td><td>Patients with the GG genotype may have decreased rapid virological response (rvr), complete early virologic response (cEVR) and sustained virological response (svr) when treated with peginterferon alfa-2/RBV in people with Hepatitis C, Chronic as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to peginterferon alfa-2/RBV.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448636111>534</a></td><td>EGFR</td><td>rs11506105</td><td>ribavirin</td><td>Hepatitis C, Chronic</td><td>3</td><td>GG</td><td>Efficacy</td><td>Patients with the GG genotype may have decreased rapid virological response (rvr), complete early virologic response (cEVR) and sustained virological response (svr) when treated with peginterferon alfa-2/RBV in people with Hepatitis C, Chronic as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to peginterferon alfa-2/RBV.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448100117>535</a></td><td>FHIT</td><td>rs49411</td><td>antidepressants</td><td>Depressive Disorder, Major</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with major depressive disorder and the CT genotype may have decreased response to antidepressants compared to patients with the TT genotype. Other factors may affect response to antidepressants.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448100173>536</a></td><td>PARP11</td><td>rs2532560</td><td>antidepressants</td><td>Depressive Disorder, Major</td><td>3</td><td>AA</td><td>Efficacy</td><td>Patients with the AA genotype and major depressive disorder may have decreased response to antidepressants compared to patients with the GG genotype. Other factors may affect response to antidepressants.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448100180>537</a></td><td>NBEA</td><td>rs9315310</td><td>antidepressants</td><td>Depressive Disorder, Major</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype and major depressive disorder may have decreased response to antidepressants compared to patients with the TT genotype. Other factors may affect response to antidepressants.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447990855>538</a></td><td>RBFOX1</td><td>rs6500843</td><td>antineoplastic agents</td><td>Breast Neoplasms</td><td>3</td><td>GG</td><td>Efficacy</td><td>Women with the GG genotype and breast cancer who are treated with antineoplastic agents may be associated with worse survival as compared to women with the AA genotype. Other clinical and genetic factors may also influence survival rates in women with breast cancer.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448568208>539</a></td><td>EGFR</td><td>rs2227983</td><td>cetuximab</td><td>Head and Neck Neoplasms</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype may have decreased progression-free survival when treated with cetuximab in people with Head and Neck Neoplasms as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to cetuximab.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448632491>540</a></td><td>CD33</td><td>rs35112940</td><td>gemtuzumab ozogamicin</td><td>Leukemia, Myeloid, Acute</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype may have decreased overall survival when treated with gemtuzumab ozogamicin in children with Leukemia, Myeloid, Acute as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to gemtuzumab ozogamicin.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447949088>541</a></td><td>HLA-DPA1</td><td>rs3077</td><td>peginterferon alfa-2b</td><td>Hepatitis B, Chronic</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with AG genotype may have decreased virological response to peginterferon alfa-2b with or without entecavir in patients with HBeAg-negative chronic hepatitis B as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to peginterferon alfa-2b.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448126020>542</a></td><td>KDR</td><td>rs1870377</td><td>sorafenib</td><td>Carcinoma, Hepatocellular</td><td>3</td><td>AT</td><td>Efficacy</td><td>Patients with genotype AT may have decreased progression-free survival and overral survival when treated with sorafenib in people with Carcinoma, Hepatocellular as compared to patients with genotype TT. Other genetic and clinical factors may also influence the response to sorafenib.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448532363>543</a></td><td>IFNL3</td><td>rs8099917</td><td>ledipasvir</td><td>Hepatitis C, Chronic</td><td>3</td><td>GT</td><td>Efficacy</td><td>Patients with genotype GT may have decreased sustained virological response (SVR) to ledipasvir and sofosbuvir in people with Hepatitis C genotype 1 as compared to patients with genotypes TT. Other genetic and clinical factors may also influence the response to ledipasvir and sofosbuvir.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448532363>544</a></td><td>IFNL4</td><td>rs8099917</td><td>ledipasvir</td><td>Hepatitis C, Chronic</td><td>3</td><td>GT</td><td>Efficacy</td><td>Patients with genotype GT may have decreased sustained virological response (SVR) to ledipasvir and sofosbuvir in people with Hepatitis C genotype 1 as compared to patients with genotypes TT. Other genetic and clinical factors may also influence the response to ledipasvir and sofosbuvir.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448532363>545</a></td><td>IFNL3</td><td>rs8099917</td><td>sofosbuvir</td><td>Hepatitis C, Chronic</td><td>3</td><td>GT</td><td>Efficacy</td><td>Patients with genotype GT may have decreased sustained virological response (SVR) to ledipasvir and sofosbuvir in people with Hepatitis C genotype 1 as compared to patients with genotypes TT. Other genetic and clinical factors may also influence the response to ledipasvir and sofosbuvir.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448532363>546</a></td><td>IFNL4</td><td>rs8099917</td><td>sofosbuvir</td><td>Hepatitis C, Chronic</td><td>3</td><td>GT</td><td>Efficacy</td><td>Patients with genotype GT may have decreased sustained virological response (SVR) to ledipasvir and sofosbuvir in people with Hepatitis C genotype 1 as compared to patients with genotypes TT. Other genetic and clinical factors may also influence the response to ledipasvir and sofosbuvir.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448112486>547</a></td><td>CD69</td><td>rs11052877</td><td>tocilizumab</td><td>Arthritis, Rheumatoid</td><td>3</td><td>GG</td><td>Efficacy</td><td>Patients with the GG genotype and rheumatoid arthritis may have a decreased response to tocilizumab compared to patients with the AA and AG genotypes. Other clinical and genetic factors may affect response to tocilizumab.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448112493>548</a></td><td>GALNT18</td><td>rs4910008</td><td>tocilizumab</td><td>Arthritis, Rheumatoid</td><td>3</td><td>TT</td><td>Efficacy</td><td>Patients with the TT genotype and rheumatoid arthritis may have decreased response to tocilizumab compared to patients with the CC genotype. Other genetic and clinical factors may affect response to tocilizumab.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/982043234>549</a></td><td>AKR1C3</td><td>rs1937840</td><td>docetaxel</td><td>Breast Neoplasms</td><td>3</td><td>CG</td><td>Efficacy</td><td>Patients with breast cancer and the rs1937840 CG genotype may have a decreased response to treatment with docetaxel and doxorubicin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to treatment with docetaxel and doxorubicin.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/982043234>550</a></td><td>AKR1C3</td><td>rs1937840</td><td>doxorubicin</td><td>Breast Neoplasms</td><td>3</td><td>CG</td><td>Efficacy</td><td>Patients with breast cancer and the rs1937840 CG genotype may have a decreased response to treatment with docetaxel and doxorubicin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to treatment with docetaxel and doxorubicin.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1043873018>551</a></td><td>GRIK4</td><td>rs12800734</td><td>antidepressants</td><td>Depressive Disorder</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype may have decreased likelihood of remission when treated with antidepressants in people with Depressive Disorder as compared to patients with GG genotype. Other clinical or genetic factors may also influence a patient's response to antidepressants.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1446898324>552</a></td><td>CYP2B6</td><td>rs2279343</td><td>bupropion</td><td>Tobacco Use Disorder</td><td>3</td><td>AG</td><td>Efficacy</td><td>Individuals with tobacco use disorder and the AG genotype may have a decreased response to bupropion as compared to individuals with the AA genotype, although this is contradicted in one study. Other clinical and genetic factors may also affect response to bupropion in individuals with tobacco use disorder.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1446899639>553</a></td><td>ECT2L</td><td>rs11155012</td><td>anthracyclines and related substances</td><td>Breast Neoplasms</td><td>3</td><td>AA</td><td>Efficacy</td><td>Women with breast cancer and the AA genotype may have a decreased likelihood of survival when treated with anthracyclines and related substances as compared to women with the AG or GG genotypes. Other clinical and genetic factors may also influence likelihood of survival in women with breast cancer who are treated with anthracyclines and related substances.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448112600>554</a></td><td>CSNK2A3</td><td>rs7937567</td><td>cisplatin</td><td>Urinary Bladder Neoplasms</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype and bladder cancer may have reduced response to cisplatin-based therapy compared to patients with the GG genotype. However, replication studies did not find an association. Other clinical and genetic factors may affect response to cisplatin-based therapies.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448112600>555</a></td><td>GALNT18</td><td>rs7937567</td><td>cisplatin</td><td>Urinary Bladder Neoplasms</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype and bladder cancer may have reduced response to cisplatin-based therapy compared to patients with the GG genotype. However, replication studies did not find an association. Other clinical and genetic factors may affect response to cisplatin-based therapies.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448112614>556</a></td><td>RARS</td><td>rs244898</td><td>cisplatin</td><td>Urinary Bladder Neoplasms</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype and bladder cancer may have a decreased response to cisplatin-based therapies compared to patients with the TT genotype. Replication studies did not confirm these results. Other clinical and genetic factors may affect response to cisplatin-based therapies.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/982030854>557</a></td><td>COMT</td><td>rs9606186</td><td>risperidone</td><td>Schizophrenia</td><td>3</td><td>CG</td><td>Efficacy</td><td>Patients with the rs9606186 CG genotype and Schizophrenia may be less likely to respond when treated with risperidone as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may influence response to risperidone.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447990913>558</a></td><td>MGAT4A</td><td>rs885036</td><td>bevacizumab</td><td>Colorectal Neoplasms</td><td>3</td><td>GG</td><td>Efficacy</td><td>The GG genotype in patients with colorectal cancer who are treated with bevacizumab, capecitabine and oxaliplatin may be associated with decreased progression-free survival as compared to patients with the AG or AA genotypes. Other clinical and genetic factors may also influence length of progression-free survival in patients with colorectal cancer.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447990913>559</a></td><td>MGAT4A</td><td>rs885036</td><td>capecitabine</td><td>Colorectal Neoplasms</td><td>3</td><td>GG</td><td>Efficacy</td><td>The GG genotype in patients with colorectal cancer who are treated with bevacizumab, capecitabine and oxaliplatin may be associated with decreased progression-free survival as compared to patients with the AG or AA genotypes. Other clinical and genetic factors may also influence length of progression-free survival in patients with colorectal cancer.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447990913>560</a></td><td>MGAT4A</td><td>rs885036</td><td>oxaliplatin</td><td>Colorectal Neoplasms</td><td>3</td><td>GG</td><td>Efficacy</td><td>The GG genotype in patients with colorectal cancer who are treated with bevacizumab, capecitabine and oxaliplatin may be associated with decreased progression-free survival as compared to patients with the AG or AA genotypes. Other clinical and genetic factors may also influence length of progression-free survival in patients with colorectal cancer.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447943591>561</a></td><td>ABCB1</td><td>rs1045642</td><td>agomelatine</td><td>Depressive Disorder</td><td>3</td><td>AA</td><td>Efficacy</td><td>Patients with the AA genotype and depressive disorder may have a decreased response to agomelatine, as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to agomelatine.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448100125>562</a></td><td>MTRF1L</td><td>rs766127</td><td>antidepressants</td><td>Depressive Disorder, Major</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with major depressive disorder and the AG genotype may have decreased response to antidepressants compared to patients with the GG genotype. Other factors may affect response to antidepressants.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448259106>563</a></td><td>ACE</td><td>rs4291</td><td>captopril</td><td>Alzheimer Disease</td><td>3</td><td>AT</td><td>Efficacy</td><td>Patients with the AT genotype and Alzheimer's Disease may have increasing creatinine levels when taking captopril compared to patients with the AT genotype. Other clinical and genetic factors may affect creatinine levels in patients with Alzheimer's Disease.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449164443>564</a></td><td>IFNL3</td><td>rs12979860</td><td>peginterferon alfa-2a</td><td>Myeloproliferative Disorders</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype may have decreased hematologic response to interferon-alpha treatment in patients with myeloproliferative neoplasms as compared to patients with genotypes CC. Other genetic and clinical factors may also influence the response to interferon-alpha.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449164443>565</a></td><td>IFNL4</td><td>rs12979860</td><td>peginterferon alfa-2a</td><td>Myeloproliferative Disorders</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype may have decreased hematologic response to interferon-alpha treatment in patients with myeloproliferative neoplasms as compared to patients with genotypes CC. Other genetic and clinical factors may also influence the response to interferon-alpha.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449164443>566</a></td><td>IFNL3</td><td>rs12979860</td><td>peginterferon alfa-2b</td><td>Myeloproliferative Disorders</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype may have decreased hematologic response to interferon-alpha treatment in patients with myeloproliferative neoplasms as compared to patients with genotypes CC. Other genetic and clinical factors may also influence the response to interferon-alpha.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449164443>567</a></td><td>IFNL4</td><td>rs12979860</td><td>peginterferon alfa-2b</td><td>Myeloproliferative Disorders</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype may have decreased hematologic response to interferon-alpha treatment in patients with myeloproliferative neoplasms as compared to patients with genotypes CC. Other genetic and clinical factors may also influence the response to interferon-alpha.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450945347>568</a></td><td>HSD3B1</td><td>rs1047303</td><td>glucocorticoids</td><td>Asthma</td><td>3</td><td>AA</td><td>Efficacy</td><td>Patients with the AA genotype may have poorer response to glucocorticoid treatment and lower lung function in glucocortioid-dependent severe asthma as compared to patients with the CC genotype. Other genetic and clinical factors may also impact the response to glucocorticoid treatment in severe asthma.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447521683>569</a></td><td>APOE</td><td>rs7412</td><td>warfarin</td><td></td><td>3</td><td>CT</td><td>Efficacy</td><td>African-American patients with the CT genotype (carriers of E2) may require a shorter duration of time to reach a stable warfarin dose as compared to African-American patients with the CC genotype (especially those who are APOE E3/E3, also having rs429358 TT). Other genetic and clinical factors may also influence the response to warfarin.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451100080>570</a></td><td>-</td><td>rs6487504</td><td>Antihypertensives</td><td>Hypertension</td><td>3</td><td>TT</td><td>Efficacy</td><td>Patients with the TT genotype and hypertension may be less likely to respond to antihypertensives than patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's response to antihypertensives.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451151380>571</a></td><td>TP53</td><td>rs1042522</td><td>Platinum compounds</td><td>overall survival</td><td>3</td><td>CG</td><td>Efficacy</td><td>Patients with the CG genotype may have decreased response when treated with platinum drugs as compared to patients with the CC genotype although evidence is contradictory. Other genetic and clinical factors may also influence a patient's response to platinum drugs.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451245360>572</a></td><td>SLC19A1</td><td>rs1051266</td><td>methotrexate</td><td>Arthritis, Rheumatoid</td><td>2A</td><td>CT</td><td>Efficacy</td><td>Patients with the rs1051266 CT genotype and rheumatoid arthritis may have decreased response when treated with methotrexate as compared to patients with the TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence methotrexate response.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451250540>573</a></td><td>EGFR</td><td>rs121434569</td><td>gefitinib</td><td>Carcinoma, Non-Small-Cell Lung;Drug Resistance</td><td>2B</td><td>CC</td><td>Efficacy</td><td>Patients with the somatic rs121434569 CC genotype (i.e. lacking the somatic T790M mutation) in combination with an activating EGFR mutation (e.g. L858R or exon 19 deletion) may have decreased likelihood of acquired resistance to gefitinib as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence response to gefitinib.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450811960>574</a></td><td>OPRM1</td><td>rs648007</td><td>ethanol</td><td></td><td>3</td><td>GG</td><td>Efficacy</td><td>Patients with the GG genotype may have decreased subjective responses to alcohol as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's response to alcohol.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450930542>575</a></td><td>-</td><td>rs16872401</td><td>atenolol</td><td>Hypertension</td><td>3</td><td>TT</td><td>Efficacy</td><td>Patients with hypertension and the TT genotype may have a decreased systolic blood pressure response to atenolol as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's response to atenolol.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449167228>576</a></td><td>CORO7</td><td>rs3810818</td><td>methylphenidate</td><td>Attention Deficit Disorder with Hyperactivity</td><td>3</td><td>CC</td><td>Efficacy</td><td>Patients with the CC genotype and Attention Deficit Disorder with Hyperactivity may have a decreased response to treatment with methylphenidate as compared to patients who carry the A allele. Other genetic and clinical factors may also affect a patient's response to methylphenidate.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449168454>577</a></td><td>TTC37</td><td>rs4639250</td><td>duloxetine</td><td>Depressive Disorder, Major</td><td>3</td><td>CG</td><td>Efficacy</td><td>Patients with the CG genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449168461>578</a></td><td>TREML4</td><td>rs9369266</td><td>duloxetine</td><td>Depressive Disorder, Major</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449168468>579</a></td><td>TREML4</td><td>rs13204353</td><td>duloxetine</td><td>Depressive Disorder, Major</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449168565>580</a></td><td>ANO2</td><td>rs17724464</td><td>duloxetine</td><td>Depressive Disorder, Major</td><td>3</td><td>GG</td><td>Efficacy</td><td>Patients with the GG genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449168586>581</a></td><td>ANO2</td><td>rs61908406</td><td>duloxetine</td><td>Depressive Disorder, Major</td><td>3</td><td>GG</td><td>Efficacy</td><td>Patients with the GG genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449168614>582</a></td><td>ANO2</td><td>rs61908409</td><td>duloxetine</td><td>Depressive Disorder, Major</td><td>3</td><td>CC</td><td>Efficacy</td><td>Patients with the CC genotype may have a decreased response to treatment with duloxetine for major depressive disorder as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450814192>583</a></td><td>OPRM1</td><td>rs671531</td><td>highly active antiretroviral therapy (haart)</td><td>HIV Infections</td><td>3</td><td>GG</td><td>Efficacy</td><td>Hispanic patients with the GG genotype may have a smaller decrease in viral load following the initiation of HAART as compared to Hispanic patients with the AA or AG genotypes. This association was not seen in European or African American patients. Other genetic or clinical factors may also affect a patient's response to HAART.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450813875>584</a></td><td>CYP2B6</td><td>rs8109525</td><td>bupropion</td><td>Tobacco Use Disorder</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype may be less likely to quit smoking by weeks 9-12 of bupropion treatment as compared to patients with the GG genotype. Other genetic or clinical factors may also affect response to bupropion.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450811954>585</a></td><td>OPRM1</td><td>rs548646</td><td>ethanol</td><td></td><td>3</td><td>CC</td><td>Efficacy</td><td>Patients with the CC genotype may have decreased subjective responses to alcohol as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's response to alcohol.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450811978>586</a></td><td>OPRM1</td><td>rs2075572</td><td>ethanol</td><td></td><td>3</td><td>CC</td><td>Efficacy</td><td>Patients with the CC genotype may have decreased subjective responses to alcohol as compared to patients with the CG or GG genotypes. Other genetic and clinical factors may also affect a patient's response to alcohol.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450811984>587</a></td><td>OPRM1</td><td>rs681243</td><td>ethanol</td><td></td><td>3</td><td>CC</td><td>Efficacy</td><td>Patients with the CC genotype may have decreased subjective responses to alcohol as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's response to alcohol.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450815104>588</a></td><td>TJP1</td><td>rs813676</td><td>risperidone</td><td>Schizophrenia</td><td>3</td><td>CC</td><td>Efficacy</td><td>Patients with schizophrenia and the CC genotype may have a decreased response to risperidone as compared to patients with the CT or TT genotypes. Other genetic or clinical factors may also affect a patient's response to risperidone.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450815154>589</a></td><td>TJP1</td><td>rs711355</td><td>risperidone</td><td>Schizophrenia</td><td>3</td><td>CC</td><td>Efficacy</td><td>Patients with schizophrenia and the CC genotype may have a decreased response to risperidone as compared to patients with the CT or TT genotypes. Other genetic or clinical factors may also affect a patient's response to risperidone.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450824473>590</a></td><td>OPRM1</td><td>rs3778150</td><td>ethanol</td><td></td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype may have a decreased response to ethanol as compared to patients with the TT genotype. Other genetic or clinical factors may also affect a patient's response to ethanol.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449311670>591</a></td><td>ABCB1</td><td>rs1128503</td><td>propofol</td><td></td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype who are undergoing surgery may have a decreased response to propofol and remifentanil administered as anesthesia as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to propofol and remifentanil.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449311670>592</a></td><td>ABCB1</td><td>rs1128503</td><td>remifentanil</td><td></td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype who are undergoing surgery may have a decreased response to propofol and remifentanil administered as anesthesia as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to propofol and remifentanil.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450931960>593</a></td><td>GNB3</td><td>rs5441</td><td>sertraline</td><td>Depressive Disorder, Major</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with major depressive disorder and the AG genotype may be less likely to respond to sertraline as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to sertraline.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450931960>594</a></td><td>P3H3</td><td>rs5441</td><td>sertraline</td><td>Depressive Disorder, Major</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with major depressive disorder and the AG genotype may be less likely to respond to sertraline as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to sertraline.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451103260>595</a></td><td>SLCO1B3</td><td>rs4149117</td><td>mycophenolic acid</td><td>chronic lung allograft dysfunction;lung transplantation</td><td>3</td><td>GG</td><td>Efficacy</td><td>Patients with the GG genotype who are treated with mycophenolic acid following lung transplantation may have a decreased risk of developing chronic lung allograft dysfunction (CLAD) as compared to patients with the GT or TT genotypes. Other genetic and clinical factors may also affect response to mycophenolic acid in lung transplant patients.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451103320>596</a></td><td>SLCO1B3</td><td>rs4149117</td><td>mycophenolic acid</td><td>lung transplantation;transplant rejection</td><td>3</td><td>GG</td><td>Efficacy</td><td>Patients with the GG genotype who are treated with mycophenolic acid following lung transplantation may be at a decreased risk of transplant rejection as compared to patients with the GT or TT genotypes. Other genetic and clinical factors may also affect response to mycophenolic acid. in lung transplant patients.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451103340>597</a></td><td>SLCO1B3</td><td>rs7311358</td><td>mycophenolic acid</td><td>lung transplantation;transplant rejection</td><td>3</td><td>AA</td><td>Efficacy</td><td>Patients with the AA genotype who are treated with mycophenolic acid following lung transplantation may be at a decreased risk of transplant rejection as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect response to mycophenolic acid. in lung transplant patients.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451103360>598</a></td><td>SLCO1B3</td><td>rs7311358</td><td>mycophenolic acid</td><td>chronic lung allograft dysfunction;lung transplantation</td><td>3</td><td>AA</td><td>Efficacy</td><td>Patients with the AA genotype who are treated with mycophenolic acid following lung transplantation may have a decreased risk of developing chronic lung allograft dysfunction (CLAD) as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect response to mycophenolic acid in lung transplant patients.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451107360>599</a></td><td>ADRB2</td><td>rs1042714</td><td>atenolol</td><td>Tachycardia</td><td>3</td><td>CG</td><td>Efficacy</td><td>Patients with the CG genotype may have a decreased response to atenolol or metoprolol, as measured by a smaller decrease in heart rate, as compared to patients with the CC genotype. Note that this association was only found in patients of European descent and not in African American or Hispanic patients. Other genetic and clinical factors may also affect. a patient's response to atenolol or metoprolol.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451107360>600</a></td><td>ADRB2</td><td>rs1042714</td><td>metoprolol</td><td>Tachycardia</td><td>3</td><td>CG</td><td>Efficacy</td><td>Patients with the CG genotype may have a decreased response to atenolol or metoprolol, as measured by a smaller decrease in heart rate, as compared to patients with the CC genotype. Note that this association was only found in patients of European descent and not in African American or Hispanic patients. Other genetic and clinical factors may also affect. a patient's response to atenolol or metoprolol.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451121780>601</a></td><td>OPRD1</td><td>rs581111</td><td>oxycodone</td><td></td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype may have decreased subjective positive effects from oxycodone as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's subjective response to oxycodone.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451124486>602</a></td><td>UGT2B7</td><td>rs7439366</td><td>morphine</td><td>Pain</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype may have a decreased analgesic response to morphine as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to morphine.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451124808>603</a></td><td>-</td><td>rs6025211</td><td>cisplatin</td><td>Liver Neoplasms</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with liver cancer and the CT genotype may have decreased overall survival when treated with a combination of cisplatin, fluorouracil and mitoxantrone as compared to patients with the CC or TT genotypes. Other genetic and clinical factors may also affect a patient's response to chemotherapy.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451124808>604</a></td><td>-</td><td>rs6025211</td><td>fluorouracil</td><td>Liver Neoplasms</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with liver cancer and the CT genotype may have decreased overall survival when treated with a combination of cisplatin, fluorouracil and mitoxantrone as compared to patients with the CC or TT genotypes. Other genetic and clinical factors may also affect a patient's response to chemotherapy.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451124808>605</a></td><td>-</td><td>rs6025211</td><td>mitoxantrone</td><td>Liver Neoplasms</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with liver cancer and the CT genotype may have decreased overall survival when treated with a combination of cisplatin, fluorouracil and mitoxantrone as compared to patients with the CC or TT genotypes. Other genetic and clinical factors may also affect a patient's response to chemotherapy.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451124852>606</a></td><td>GALNT14</td><td>rs9679162</td><td>cisplatin</td><td>Liver Neoplasms</td><td>3</td><td>GT</td><td>Efficacy</td><td>Patients with liver cancer and the GT genotype may have decreased overall survival when treated with cisplatin and fluorouracil as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to chemotherapy.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451124852>607</a></td><td>GALNT14</td><td>rs9679162</td><td>fluorouracil</td><td>Liver Neoplasms</td><td>3</td><td>GT</td><td>Efficacy</td><td>Patients with liver cancer and the GT genotype may have decreased overall survival when treated with cisplatin and fluorouracil as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to chemotherapy.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451124880>608</a></td><td>GALNT14</td><td>rs9679162</td><td>sorafenib</td><td>Hepatitis C;Liver Neoplasms</td><td>3</td><td>GT</td><td>Efficacy</td><td>Patients with liver cancer, anti-HCV antibodies and the GT genotype may have a decreased overall survival when treated with sorafenib as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to sorafenib.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451126312>609</a></td><td>MOBP</td><td>rs616147</td><td>creatine</td><td>Amyotrophic Lateral Sclerosis</td><td>3</td><td>GG</td><td>Efficacy</td><td>Patients with ALS and the GG genotype may have a decreased response to treatment with creatine as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's response to creatine.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451131735>610</a></td><td>IKBKB</td><td>rs2272733</td><td>gefitinib</td><td>Carcinoma, Non-Small-Cell Lung;Exanthema</td><td>3</td><td>CC</td><td>Efficacy</td><td>Patients with non-small cell lung cancer and the CC genotype may be at a decreased risk of developing skin rash when treated with gefitinib as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's risk of gefitinib-induced skin rash.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451133765>611</a></td><td>ABCB1</td><td>rs1045642</td><td>morphine</td><td>Pain</td><td>3</td><td>AA</td><td>Efficacy</td><td>Patients with neuropathic pain and the rs1045642 AA genotype may have a decreased response to combined therapy with morphine and nortriptyline as compared to patients with the GG genotype. Other genetic and clinical factors may also affect response to morphine and nortriptyline.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451133765>612</a></td><td>ABCB1</td><td>rs1045642</td><td>nortriptyline</td><td>Pain</td><td>3</td><td>AA</td><td>Efficacy</td><td>Patients with neuropathic pain and the rs1045642 AA genotype may have a decreased response to combined therapy with morphine and nortriptyline as compared to patients with the GG genotype. Other genetic and clinical factors may also affect response to morphine and nortriptyline.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451217440>613</a></td><td>IFNL3</td><td>rs12979860</td><td>peginterferon alfa-2a</td><td>Hepatitis B, Chronic</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with hepatitis B and the CT genotype may have a decreased response to treatment with peginterferon-alpha 2a and/or 2b as compared to patients with the TT genotype. However, one study found this association in the opposite direction, while another failed to find an association. Other genetic and clinical factors may also affect a patient's response to treatment peginterferon-alpha 2a and/or 2b</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451217440>614</a></td><td>IFNL4</td><td>rs12979860</td><td>peginterferon alfa-2a</td><td>Hepatitis B, Chronic</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with hepatitis B and the CT genotype may have a decreased response to treatment with peginterferon-alpha 2a and/or 2b as compared to patients with the TT genotype. However, one study found this association in the opposite direction, while another failed to find an association. Other genetic and clinical factors may also affect a patient's response to treatment peginterferon-alpha 2a and/or 2b</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451217520>615</a></td><td>IFNL3</td><td>rs12979860</td><td>sofosbuvir</td><td>Hepatitis C, Chronic</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype may have a decreased response to treatment with sofosbuvir and ribavirin as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to treatment with sofosbuvir and ribavirin.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451217520>616</a></td><td>IFNL4</td><td>rs12979860</td><td>sofosbuvir</td><td>Hepatitis C, Chronic</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype may have a decreased response to treatment with sofosbuvir and ribavirin as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to treatment with sofosbuvir and ribavirin.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451217560>617</a></td><td>IFNL3</td><td>rs12979860</td><td>interferons</td><td>Hepatitis C</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype may have a decreased response to treatment with interferons and ribavirin as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to treatment with interferons and ribavirin.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451217560>618</a></td><td>IFNL4</td><td>rs12979860</td><td>interferons</td><td>Hepatitis C</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype may have a decreased response to treatment with interferons and ribavirin as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to treatment with interferons and ribavirin.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451217540>619</a></td><td>IFNL3</td><td>rs12979860</td><td>interferons</td><td>Hepatitis C</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with a HCV genotype I infection and the rs12979860 CT genotype may have a decreased response to treatment with interferons as compared to patients with the CC genotype. However, this association was not found in patients with HCV genotype II infections. Other genetic and clinical factors may also affect response to treatment with interferons.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451217540>620</a></td><td>IFNL4</td><td>rs12979860</td><td>interferons</td><td>Hepatitis C</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with a HCV genotype I infection and the rs12979860 CT genotype may have a decreased response to treatment with interferons as compared to patients with the CC genotype. However, this association was not found in patients with HCV genotype II infections. Other genetic and clinical factors may also affect response to treatment with interferons.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451282140>621</a></td><td>CYP19A1</td><td>rs4646</td><td>tamoxifen</td><td>Breast Neoplasms</td><td>3</td><td>CC</td><td>Efficacy</td><td>Pre-menopausal women with the CC genotype and breast cancer may have decreased disease free survival when treated with tamoxifen as compared to patients with the AA and AC genotypes. Other genetic and clinical factors may also influence response to tamoxifen.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/981419532>622</a></td><td>COQ2</td><td>rs4693075</td><td>atorvastatin</td><td>Muscular Diseases</td><td>3</td><td>CC</td><td>Toxicity</td><td>Patients with the CC genotype may have decreased risk of statin-related muscle symptoms as compared to patients with genotype GG or CG. Other genetic and clinical factors may also influence a patient's risk of toxicity.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/981419532>623</a></td><td>COQ2</td><td>rs4693075</td><td>hmg coa reductase inhibitors</td><td>Muscular Diseases</td><td>3</td><td>CC</td><td>Toxicity</td><td>Patients with the CC genotype may have decreased risk of statin-related muscle symptoms as compared to patients with genotype GG or CG. Other genetic and clinical factors may also influence a patient's risk of toxicity.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/981419532>624</a></td><td>COQ2</td><td>rs4693075</td><td>rosuvastatin</td><td>Muscular Diseases</td><td>3</td><td>CC</td><td>Toxicity</td><td>Patients with the CC genotype may have decreased risk of statin-related muscle symptoms as compared to patients with genotype GG or CG. Other genetic and clinical factors may also influence a patient's risk of toxicity.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451226212>625</a></td><td>COMT</td><td>rs740603</td><td>buprenorphine</td><td>Neonatal Abstinence Syndrome</td><td>3</td><td>AG</td><td>Toxicity</td><td>Infants who have been exposed to buprenorphine in utero and who are born to women with the rs740603 AG genotype may be less likely to require medication to treat neonatal abstinence syndrome as compared to infants born to women with the GG genotype. Be aware that this annotation is on the mother's genotype, even though the phenotype is observed in the infant and that this was not a statistically significant association. Other genetic and clinical factors may also affect severity of neonatal abstinence syndrome.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451226220>626</a></td><td>COMT</td><td>rs740603</td><td>methadone</td><td>Neonatal Abstinence Syndrome</td><td>3</td><td>AG</td><td>Toxicity</td><td>Infants who have been exposed to methadone in utero and who are born to women with the AG genotype may be less likely to require medication to treat neonatal abstinence syndrome as compared to infants born to women with the GG genotype. Be aware that this annotation is on the mother's genotype, even though the phenotype is observed in the infant and that this was not a statistically significant association. Other genetic and clinical factors may also affect severity of neonatal abstinence syndrome.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450930839>627</a></td><td>CHRNB4</td><td>rs1948</td><td>nicotine</td><td>Tobacco Use Disorder</td><td>3</td><td>AG</td><td>Toxicity</td><td>Patients with the AG genotype may have decreased severity of nicotine dependence, as measured by FTND score, as compared to patients with the GG genotype. Other genetic and clinical factors may also affect severity of nicotine dependence.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451151506>628</a></td><td>ARID4A</td><td>rs61974485</td><td>ethanol</td><td>Alcoholism</td><td>3</td><td>CC</td><td>Toxicity</td><td>Patients with the CC genotype may be at a decreased risk of developing alcoholism as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451356356>629</a></td><td>NECTIN4</td><td>rs11265549</td><td>methadone</td><td>Opioid-Related Disorders;Pruritus</td><td>3</td><td>GG</td><td>Toxicity</td><td>Patients with opioid dependence and the rs11265549 GG genotype may be less likely to experience skin irritation when receiving methadone maintenance therapy (MMT) as compared to patients with the AA genotype. Other genetic and clinical factors may also influence the likelihood of experiencing kin irritation when receiving MMT.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451240740>630</a></td><td>TMEM43</td><td>rs2228001</td><td>cisplatin</td><td>Neutropenia;Urinary Bladder Neoplasms</td><td>3</td><td>TT</td><td>Toxicity</td><td>Patients with bladder cancer and the TT genotype may be at a decreased risk of developing neutropenia when treated with cisplatin as compared to patients with the GG or GT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia when treated with cisplatin.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451240740>631</a></td><td>XPC</td><td>rs2228001</td><td>cisplatin</td><td>Neutropenia;Urinary Bladder Neoplasms</td><td>3</td><td>TT</td><td>Toxicity</td><td>Patients with bladder cancer and the TT genotype may be at a decreased risk of developing neutropenia when treated with cisplatin as compared to patients with the GG or GT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia when treated with cisplatin.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451240746>632</a></td><td>TMEM43</td><td>rs2228001</td><td>cisplatin</td><td>Drug Toxicity;Urinary Bladder Neoplasms</td><td>3</td><td>TT</td><td>Toxicity</td><td>Patients with bladder cancer and the TT genotype may be at a decreased risk of experiencing drug toxicity when treated with cisplatin as compared to patients with the GG or GT genotypes. Other genetic and clinical factors may also affect a patient's risk of drug toxicity when treated with cisplatin.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451240746>633</a></td><td>XPC</td><td>rs2228001</td><td>cisplatin</td><td>Drug Toxicity;Urinary Bladder Neoplasms</td><td>3</td><td>TT</td><td>Toxicity</td><td>Patients with bladder cancer and the TT genotype may be at a decreased risk of experiencing drug toxicity when treated with cisplatin as compared to patients with the GG or GT genotypes. Other genetic and clinical factors may also affect a patient's risk of drug toxicity when treated with cisplatin.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451277440>634</a></td><td>HTR2C</td><td>rs1414334</td><td>risperidone</td><td>Metabolic Syndrome</td><td>3</td><td>G</td><td>Toxicity</td><td>Patients with one X-chromosome and the G genotype who are treated with risperidone may have a decreased risk of developing metabolic syndrome as compared to patients with the C genotype. This gene is on the X chromosome and males have only one allele. Other genetic and clinical factors may also influence a patient's risk for developing metabolic syndrome.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451277440>635</a></td><td>HTR2C</td><td>rs1414334</td><td>risperidone</td><td>Metabolic Syndrome</td><td>3</td><td>GG</td><td>Toxicity</td><td>Patients with two X-chromosomes and the GG genotype who are treated with risperidone may have a decreased, but not absent, risk of developing metabolic syndrome as compared to patients with the CG and CC genotype. Other genetic and clinical factors may also influence a patient's risk for developing metabolic syndrome. This gene is on the X chromosome therefore some individuals may have only one allele.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448256712>636</a></td><td>UGT1A9</td><td>rs7574296</td><td>sorafenib</td><td>Carcinoma, Hepatocellular;hand-foot syndrome</td><td>3</td><td>AG</td><td>Toxicity</td><td>Patients with the AG genotype may have decreased risk of hand-foot syndrome when treated with sorafenib in people with Carcinoma, Hepatocellular as compared to patients with genotype AA. Other genetic and clinical factors may also influence the toxicity to sorafenib.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451328325>637</a></td><td>LPA</td><td>rs10455872</td><td>hmg coa reductase inhibitors</td><td>Coronary Artery Disease</td><td>3</td><td>AA</td><td>Toxicity</td><td>Patients with the rs10455872 AA genotype may have a decreased risk of Coronary Artery Disease when treated with statins as compared to patients with genotype AG or GG. Other clinical and genetic factors may also influence the risk of coronary artery disease when treated with statins.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451336100>638</a></td><td>ABCB1</td><td>rs3842</td><td>olanzapine</td><td>Arrhythmias, Cardiac</td><td>3</td><td>CT</td><td>Toxicity</td><td>Patients with the rs3842 CT genotype may have a decreased likelihood of developing palpitations when treated with olanzapine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence likelihood of developing olanzapine-induced palpitations.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451352146>639</a></td><td>ABCB1</td><td>rs1045642</td><td>opioids</td><td>Low Back Pain</td><td>3</td><td>AA</td><td>Toxicity</td><td>Patients with the rs1045642 AA genotype may be less likely to experience nausea when treated with opioids as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence likelihood of experiencing nausea when treated with opioids.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450813849>640</a></td><td>HTR3B</td><td>rs3758987</td><td>nicotine</td><td>Tobacco Use Disorder</td><td>3</td><td>CT</td><td>Toxicity</td><td>Patients with the CT genotype may be less likely to have relapsed before 52 weeks of nicotine abstinence as compared to patients with the TT genotype. Other genetic or clinical factors may also affect time to relapse in patients who are quitting smoking.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/981201549>641</a></td><td>ADORA2A</td><td>rs2298383</td><td>caffeine</td><td></td><td>3</td><td>CT</td><td>Toxicity</td><td>Patients with the CT genotype may have decreased anxiety when exposed to caffeine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patients response to caffeine.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/981202334>642</a></td><td>CYP2B6</td><td>rs3745274</td><td>cyclophosphamide</td><td>Hepatic Veno-Occlusive Disease;Transplantation</td><td>3</td><td>GT</td><td>Toxicity</td><td>Leukemia patients who are recipients of HLA-identical hematopoietic stem cell transplantation from donors with the GT genotype may have a decreased risk of developing veno-occlusive disease of the liver when treated with cyclophosphamide as compared to donor cells with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for venoocclusive disease of the liver.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/981202562>643</a></td><td>CYP2C19</td><td>rs4244285</td><td>cyclophosphamide</td><td>Lupus Erythematosus, Systemic</td><td>3</td><td>AA</td><td>Toxicity</td><td>Patients with the AA genotype and Systemic Lupus Erythematosus who are treated with cyclophosphamide may have decreased metabolism of cyclophosphamide, leading to lower concentrations of the active metabolite and a decreased risk of toxicity (ovarian, gastrointestinal, or hematological) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for cyclophosphamide-induced toxicity.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/981345285>644</a></td><td>XRCC1</td><td>rs25487</td><td>cyclophosphamide</td><td>Neoplasms;Ovarian Neoplasms</td><td>4</td><td>CT</td><td>Toxicity</td><td>Patients with the CT genotype may have 1) decreased survival and 2) decreased risk of severe neutropenia when treated with cyclophosphamide-containing chemotherapy regimens as compared to patients with the CC genotype. However, all studies evaluated also included platinum drugs which may interact with this variant. Other genetic and clinical factors may also influence response to treatment.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448616845>645</a></td><td>CDA</td><td>rs2072671</td><td>capecitabine</td><td>Neoplasms</td><td>3</td><td>AC</td><td>Toxicity</td><td>Patients with cancer and the AC genotype who are treated with capecitabine may have a decreased (but not absent) incidence of adverse events, including hand-foot syndrome, as compared to patients with the AA genotype, however this is contradicted in some studies. Other clinical and genetic factors may also influence risk of adverse events in patients who are administered capecitabine.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448616870>646</a></td><td>UMPS</td><td>rs2279199</td><td>capecitabine</td><td>Nausea;Vomiting</td><td>3</td><td>CT</td><td>Toxicity</td><td>Patients with cancer and the CT genotype who are treated with capecitabine may have a decreased (but not absent) risk of nausea and vomiting as compared to patients with the TT genotype. Other clinical and genetic factors may also influence risk of nausea and vomiting in patients with cancer who are treated with capecitabine.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449566691>647</a></td><td>SLC31A1</td><td>rs10817464</td><td>Platinum compounds</td><td>Anemia;Leukopenia;Nausea;Neutropenia;Thrombocytopenia;Vomiting</td><td>3</td><td>TT</td><td>Toxicity</td><td>Patients with the TT genotype and non-small cell lung cancer who are treated with platinum compounds may have decreased severity of drug toxicity (nausea, vomiting) and hematologic toxicity (leukopenia, neutropenia, anemia, and thrombocytopenia) as compared to patients with the CC or CT genotype. Other clinical and genetic factors may also influence toxicity in patients with non-small cell lung cancer who are treated with platinum compounds.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450820971>648</a></td><td>CHRNA4</td><td>rs3787138</td><td>nicotine</td><td>Tobacco Use Disorder</td><td>3</td><td>AA</td><td>Toxicity</td><td>Patients with the AA genotype may have a decreased severity of nicotine withdrawal, as indicated by a lower Minnesota Nicotine Withdrawal Scale score, as compared to patients with the GG genotype. Other genetic and clinical factors may also affect the severity of a patient's nicotine withdrawal symptoms.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450376188>649</a></td><td>KCNJ11</td><td>rs5219</td><td>tacrolimus</td><td>Diabetes Mellitus, Type 2</td><td>3</td><td>CC</td><td>Toxicity</td><td>Patients with the CC genotype who are undergoing kidney or heart transplants may have a decreased risk for developing new-onset diabetes after transplantation (NODAT) when treated with tacrolimus as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence the risk for developing NODAT.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450935917>650</a></td><td>XPO1</td><td>rs4430924</td><td>Drugs For Treatment Of Tuberculosis</td><td>Drug Toxicity;Tuberculosis</td><td>3</td><td>AG</td><td>Toxicity</td><td>Patients with the AG genotype may be at a decreased risk of developing hepatotoxicity when treated with anti-tuberculosis (anti-TB) drugs as compared to patients with the AA genotype. Note that this association was only observed in a subgroup analysis of patients with probable hepatotoxicity. Other genetic and clinical factors may also affect a patient's risk of developing anti-TB drug-induced hepatotoxicity.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183700536>651</a></td><td>CDKN2B-AS1</td><td>rs10757274</td><td>Antiinflammatory agents, non-steroids</td><td>Acute coronary syndrome</td><td>3</td><td>AG</td><td>Toxicity</td><td>Patients with the AG genotype may have decreased likelihood of Acute coronary syndrome when exposed to Antiinflammatory agents, non-steroids in people with Acute coronary syndrome as compared to patients with genotype GG. Other genetic and clinical factors may also influence a patient's risk of toxicity to NSAIDs.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1043880644>652</a></td><td>ABO</td><td>rs495828</td><td>Ace Inhibitors, Plain</td><td></td><td>3</td><td>GG</td><td>Toxicity</td><td>Patients with the GG genotype may have a decreased, but not absent, risk for angiotensin-converting enzyme inhibitors-induced cough when treated with Ace Inhibitors as compared to patients with the TT or TG genotype. Other genetic and clinical factors may also influence a patient's risk for angiotensin-converting enzyme inhibitors-induced cough.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183632170>653</a></td><td>SULT2B1</td><td>rs10426377</td><td>anthracyclines and related substances</td><td>Neoplasms</td><td>4</td><td>AC</td><td>Toxicity</td><td>Patients with the AC genotype may have decreased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with the CC genotype, although this is contradicted in one study. Other genetic and clinical factors may also influence a patient's response to anthracyclines.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183693433>654</a></td><td>XDH</td><td>rs1594160</td><td>didanosine</td><td>HIV Infections</td><td>3</td><td>CC</td><td>Toxicity</td><td>Patients with the CC genotype and HIV may have a reduced risk of developing noncirrhotic portal hypertension when treated with didanosine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of noncirrhotic portal hypertension.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183533945>655</a></td><td>ABCC2</td><td>rs3740066</td><td>irinotecan</td><td>Carcinoma, Non-Small-Cell Lung</td><td>3</td><td>CT</td><td>Toxicity</td><td>Patients with the CT genotype and non-small cell lung cancer may have a decreased risk of diarrhea when treated with irinotecan as compared to patients with the CC genotype. No association has been seen for neutropenia. Other genetic and clinical factors may also influence risk of diarrhea.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183604793>656</a></td><td>SACM1L</td><td>rs2245705</td><td>bupropion</td><td>Depressive Disorder, Major</td><td>3</td><td>CC</td><td>Toxicity</td><td>Patients with the CC genotype and major depressive disorder may have decreased sexual side-effects when treated with bupropion as compared to patients with the TT genotype. Other genetic and clinical factors may also influence sexual side-effects.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183614761>657</a></td><td>ABCB1</td><td>rs1128503</td><td>sirolimus</td><td>Kidney Transplantation</td><td>3</td><td>AG</td><td>Toxicity</td><td>Patients with the AG genotype who underwent kidney transplantation may have decreased triglyceride levels when treated with sirolimus as compared to patients with the AA genotype. Other genetic and clinical factors may also influence triglyceride levels.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451398340>658</a></td><td>MC4R</td><td>rs17782313</td><td>quetiapine</td><td>Weight gain</td><td>3</td><td>CT</td><td>Toxicity</td><td>Patients with the rs17782313 CT genotype may be at a decreased risk of experiencing weight gain when treated with quetiapine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of experiencing weight gain when treated with quetiapine.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1148480056>659</a></td><td>CYP2E1</td><td>rs2070676</td><td>cisplatin</td><td>Ovarian Neoplasms</td><td>3</td><td>CC</td><td>Toxicity</td><td>Female patients with the CC genotype and Ovarian Neoplasms who are treated with cisplatin and cyclophosphamide may have a decreased risk for severe emesis as compared to patients with the GC genotype. However, no association was found with progression-free survival or overall survival. Other genetic and clinical factors may also influence a patient's risk for severe emesis.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1148480056>660</a></td><td>CYP2E1</td><td>rs2070676</td><td>cyclophosphamide</td><td>Ovarian Neoplasms</td><td>3</td><td>CC</td><td>Toxicity</td><td>Female patients with the CC genotype and Ovarian Neoplasms who are treated with cisplatin and cyclophosphamide may have a decreased risk for severe emesis as compared to patients with the GC genotype. However, no association was found with progression-free survival or overall survival. Other genetic and clinical factors may also influence a patient's risk for severe emesis.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451398293>661</a></td><td>MC4R</td><td>rs17782313</td><td>paliperidone</td><td>Weight gain</td><td>3</td><td>CT</td><td>Toxicity</td><td>Patients with the rs17782313 CT genotype may be at a decreased risk of experiencing weight gain when treated with paliperidone as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of experiencing weight gain when treated with paliperidone.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1143176298>662</a></td><td>ABCB1</td><td>rs1045642</td><td>simvastatin</td><td>Hypercholesterolemia;Myalgia unspecified</td><td>3</td><td>AA</td><td>Toxicity</td><td>Patients with the AA genotype and Hypercholesterolemia who are treated with simvastatin may have a reduced risk of developing myalgia as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of simvastatin-induced myalgia.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183629480>663</a></td><td>GRIN2B</td><td>rs1806201</td><td>risperidone</td><td>Drug Toxicity</td><td>3</td><td>AG</td><td>Toxicity</td><td>Patients with the AG genotype who are treated with risperidone may have a decreased likelihood of adverse reactions as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of adverse reactions when treated with risperidone.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451398307>664</a></td><td>MC4R</td><td>rs489693</td><td>haloperidol</td><td>Hypertriglyceridemia;schizoaffective disorder;Schizophrenia;Weight gain</td><td>3</td><td>AC</td><td>Toxicity</td><td>Patients with the rs489693 AC genotype may have a decreased likelihood of experiencing side effects, such as weight gain and hypertriglyceridemia, when treated with haloperidol as compared to patients with the AA genotype. Other genetic and clinical factors may also influence the likelihood of side effects when treated with haloperidol.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451398314>665</a></td><td>MC4R</td><td>rs489693</td><td>quetiapine</td><td>Hypertriglyceridemia;schizoaffective disorder;Schizophrenia;Weight gain</td><td>3</td><td>AC</td><td>Toxicity</td><td>Patients with the rs489693 AC genotype may have a decreased likelihood of experiencing side effects, such as weight gain and hypertriglyceridemia, when treated with haloperidol as compared to patients with the AA genotype. Other genetic and clinical factors may also influence the likelihood of side effects when treated with haloperidol.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183693438>666</a></td><td>XDH</td><td>rs1429376</td><td>didanosine</td><td>HIV Infections</td><td>3</td><td>CC</td><td>Toxicity</td><td>Patients with the CC genotype and HIV may have a reduced risk of developing noncirrhotic portal hypertension when treated with didanosine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of noncirrhotic portal hypertension.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451398347>667</a></td><td>MC4R</td><td>rs489693</td><td>risperidone</td><td>Weight gain</td><td>3</td><td>AC</td><td>Toxicity</td><td>Patients with the rs489693 AC genotype may be at a decreased risk of experiencing side effects, such as weight gain and hypertriglyceridemia, when treated with risperidone as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of experiencing side effects when treated with risperidone.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451398299>668</a></td><td>MC4R</td><td>rs17782313</td><td>risperidone</td><td>Weight gain</td><td>3</td><td>CT</td><td>Toxicity</td><td>Patients with the rs17782313 CT genotype may be at a decreased risk of experiencing weight gain when treated with risperidone as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of experiencing weight gain when treated with risperidone.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451403428>669</a></td><td>DRD2</td><td>rs1079596</td><td>opioids</td><td>Opioid-Related Disorders</td><td>3</td><td>CC</td><td>Toxicity</td><td>Patients with the rs1079596 CC genotype may have a decreased risk of developing opioid dependence when exposed to opioids as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence risk of developing opioid dependence.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1043880649>670</a></td><td>-</td><td>rs4459610</td><td>Ace Inhibitors, Plain</td><td>Cough</td><td>3</td><td>AT</td><td>Toxicity</td><td>Patients with the AT genotype who are treated with ACE inhibitors may have a decreased, but not absent, risk for cough as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for cough.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183631545>671</a></td><td>-</td><td>rs879207</td><td>carboplatin</td><td>Ovarian Neoplasms</td><td>3</td><td>GG</td><td>Toxicity</td><td>Patients with the GG genotype and ovarian cancer may have a decreased risk of neurotoxicity when treated with carboplatin in combination with either docetaxel or paclitaxel, as compared to patients with the AG genotype. Other genetic and clinical factors may also influence risk of neurotoxicity.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183631545>672</a></td><td>-</td><td>rs879207</td><td>docetaxel</td><td>Ovarian Neoplasms</td><td>3</td><td>GG</td><td>Toxicity</td><td>Patients with the GG genotype and ovarian cancer may have a decreased risk of neurotoxicity when treated with carboplatin in combination with either docetaxel or paclitaxel, as compared to patients with the AG genotype. Other genetic and clinical factors may also influence risk of neurotoxicity.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183631545>673</a></td><td>-</td><td>rs879207</td><td>paclitaxel</td><td>Ovarian Neoplasms</td><td>3</td><td>GG</td><td>Toxicity</td><td>Patients with the GG genotype and ovarian cancer may have a decreased risk of neurotoxicity when treated with carboplatin in combination with either docetaxel or paclitaxel, as compared to patients with the AG genotype. Other genetic and clinical factors may also influence risk of neurotoxicity.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451398380>674</a></td><td>MC4R</td><td>rs489693</td><td>amisulpride</td><td>Hypertriglyceridemia;Weight gain</td><td>3</td><td>AC</td><td>Toxicity</td><td>Patients with the rs489693 AC genotype may be at a decreased risk of experiencing side effects, such as weight gain and hypertriglyceridemia, when treated with amisulpride as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of experiencing side effects when treated with amisulpride.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183684132>675</a></td><td>SLC22A12</td><td>rs11231825</td><td>cytarabine</td><td>Leukemia, Myeloid, Acute</td><td>3</td><td>CC</td><td>Toxicity</td><td>Patients with the CC genotype may have a decreased likelihood of fever when treated with cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183684132>676</a></td><td>SLC22A12</td><td>rs11231825</td><td>fludarabine</td><td>Leukemia, Myeloid, Acute</td><td>3</td><td>CC</td><td>Toxicity</td><td>Patients with the CC genotype may have a decreased likelihood of fever when treated with cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183684132>677</a></td><td>SLC22A12</td><td>rs11231825</td><td>gemtuzumab ozogamicin</td><td>Leukemia, Myeloid, Acute</td><td>3</td><td>CC</td><td>Toxicity</td><td>Patients with the CC genotype may have a decreased likelihood of fever when treated with cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183684132>678</a></td><td>SLC22A12</td><td>rs11231825</td><td>idarubicin</td><td>Leukemia, Myeloid, Acute</td><td>3</td><td>CC</td><td>Toxicity</td><td>Patients with the CC genotype may have a decreased likelihood of fever when treated with cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451398387>679</a></td><td>MC4R</td><td>rs17782313</td><td>amisulpride</td><td>Weight gain</td><td>3</td><td>CT</td><td>Toxicity</td><td>Patients with the rs17782313 CT genotype may be at a decreased risk of experiencing weight gain when treated with amisulpride as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of experiencing weight gain when treated with amisulpride.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451398394>680</a></td><td>MC4R</td><td>rs489693</td><td>aripiprazole</td><td>Weight gain</td><td>3</td><td>AC</td><td>Toxicity</td><td>Patients with the rs489693 AC genotype may have a decreased likelihood of experiencing weight gain when treated with aripiprazole as compared to patients with the AA genotype. Other genetic and clinical factors may also influence the likelihood of experiencing weight gain when treated with aripiprazole.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451403437>681</a></td><td>DRD3</td><td>rs2654754</td><td>opioids</td><td>Opioid-Related Disorders</td><td>3</td><td>AA</td><td>Toxicity</td><td>Patients with the rs2654754 AA genotype may have a decreased risk of developing opioid dependence when exposed to opioids as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence risk of developing opioid dependence.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451403500>682</a></td><td>OPRM1</td><td>rs510769</td><td>opioids</td><td>Opioid-Related Disorders</td><td>3</td><td>CT</td><td>Toxicity</td><td>Patients with the rs510769 CT genotype may have a decreased risk of developing opioid dependence when exposed to opioids as compared to patients with the CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of developing opioid dependence.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451403467>683</a></td><td>TACR1</td><td>rs735668</td><td>opioids</td><td>Opioid-Related Disorders</td><td>3</td><td>CC</td><td>Toxicity</td><td>Patients with the rs735668 CC genotype may have a decreased risk of developing opioid dependence when exposed to opioids as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of developing opioid dependence.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1043880654>684</a></td><td>-</td><td>rs4267385</td><td>Ace Inhibitors, Plain</td><td>Cough</td><td>3</td><td>CT</td><td>Toxicity</td><td>Patients with the CT genotype and homozygous carrier for the GG genotype for rs4343 who are treated with ACE inhibitors may have a decreased, but not absent, risk for cough as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for cough.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183602693>685</a></td><td>SACM1L</td><td>rs2742423</td><td>bupropion</td><td>Depressive Disorder, Major</td><td>3</td><td>GG</td><td>Toxicity</td><td>Patients with the GG genotype and major depressive disorder may have decreased sexual side-effects when treated with bupropion as compared to patients with the AA genotype. Other genetic and clinical factors may also influence sexual side-effects.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183604439>686</a></td><td>SACM1L</td><td>rs2251954</td><td>bupropion</td><td>Depressive Disorder, Major</td><td>3</td><td>CC</td><td>Toxicity</td><td>Patients with the CC genotype and major depressive disorder may have decreased sexual side-effects when treated with bupropion as compared to patients with the TT genotype. Other genetic and clinical factors may also influence sexual side-effects.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183614726>687</a></td><td>HTR2A</td><td>rs6313</td><td>efavirenz</td><td>HIV Infections</td><td>3</td><td>AG</td><td>Toxicity</td><td>Patients with the AG genotype and HIV infection who are treated with efavirenz may have a decreased risk of sadness as a side effect as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of efavirenz-induced side effects.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183629475>688</a></td><td>GRIN2B</td><td>rs1806201</td><td>quetiapine</td><td>Drug Toxicity</td><td>3</td><td>AG</td><td>Toxicity</td><td>Patients with the AG genotype who are treated with quetiapine may have a decreased likelihood of neurological adverse reactions and sleepiness as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of adverse reactions when treated with quetiapine.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451403621>689</a></td><td>CYP2D6</td><td>rs1065852</td><td>opioids</td><td>Opioid-Related Disorders</td><td>3</td><td>AG</td><td>Toxicity</td><td>Patients with the rs1065852 AG genotype may have a decreased risk of developing opioid dependence when exposed to opioids as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of developing opioid dependence.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183679863>690</a></td><td>ABCC4</td><td>rs1678387</td><td>Bisphosphonates</td><td>Osteonecrosis</td><td>3</td><td>CC</td><td>Toxicity</td><td>Patients with the CC genotype may have decreased likelihood of Osteonecrosis when treated with Bisphosphonates as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity to bisphosphonates.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451403600>691</a></td><td>CYP2A7P1</td><td>rs3745274</td><td>opioids</td><td>Opioid-Related Disorders</td><td>3</td><td>GT</td><td>Toxicity</td><td>Patients with the rs3745274 GT genotype may have a decreased risk of developing opioid dependence when exposed to opioids as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of developing opioid dependence.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451403600>692</a></td><td>CYP2B6</td><td>rs3745274</td><td>opioids</td><td>Opioid-Related Disorders</td><td>3</td><td>GT</td><td>Toxicity</td><td>Patients with the rs3745274 GT genotype may have a decreased risk of developing opioid dependence when exposed to opioids as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of developing opioid dependence.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183614830>693</a></td><td>CYP2D6</td><td>rs1065852</td><td>iloperidone</td><td>Schizophrenia</td><td>3</td><td>AG</td><td>Toxicity</td><td>Patients with the AG genotype and schizophrenia may have a decreased QTc interval when treated with iloperidone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence QTc interval.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183629489>694</a></td><td>HTR2A</td><td>rs6313</td><td>risperidone</td><td>Drug Toxicity</td><td>3</td><td>AG</td><td>Toxicity</td><td>Patients with the AG genotype who are treated with risperidone may have a reduced, but not absent, risk of cardiovascular adverse events as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of risperidone-induced adverse reactions.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1043858698>695</a></td><td>TBXA2R</td><td>rs1131882</td><td>aspirin</td><td>Asthma</td><td>3</td><td>AG</td><td>Toxicity</td><td>Patients with the AG genotype and asthma may have a decreased, but not absent, risk for aspirin-intolerant asthma as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for aspirin-intolerant asthma.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183603016>696</a></td><td>SACM1L</td><td>rs2742417</td><td>bupropion</td><td>Depressive Disorder, Major</td><td>3</td><td>TT</td><td>Toxicity</td><td>Patients with the TT genotype and major depressive disorder may have decreased sexual side-effects when treated with bupropion as compared to patients with the CC genotype. Other genetic and clinical factors may also influence sexual side-effects.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449713231>697</a></td><td>IRF6</td><td>rs2205986</td><td>interferon beta-1a</td><td>drug-induced liver injury;Multiple Sclerosis</td><td>3</td><td>AA</td><td>Toxicity</td><td>Patients with the AA genotype and multiple sclerosis may have a decreased risk of developing drug-induced liver injury following treatment with interferon beta as compared to multiple sclerosis patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing drug-induced liver injury following interferon beta treatment.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449713231>698</a></td><td>IRF6</td><td>rs2205986</td><td>interferon beta-1b</td><td>drug-induced liver injury;Multiple Sclerosis</td><td>3</td><td>AA</td><td>Toxicity</td><td>Patients with the AA genotype and multiple sclerosis may have a decreased risk of developing drug-induced liver injury following treatment with interferon beta as compared to multiple sclerosis patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing drug-induced liver injury following interferon beta treatment.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449752810>699</a></td><td>HLA-DRB1</td><td>rs701829</td><td>dapsone</td><td>Drug Hypersensitivity</td><td>3</td><td>CC</td><td>Toxicity</td><td>Patients with the CC genotype and who carry the HLA-B*13:01 allele may be at a decreased risk of experiencing hypersensitivity to dapsone as compared to HLA-B*13:01-positive patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's risk of experiencing dapsone hypersensitivity.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/981419550>700</a></td><td>RYR2</td><td>rs2819742</td><td>cerivastatin</td><td>Rhabdomyolysis</td><td>3</td><td>AG</td><td>Toxicity</td><td>Patients with the AG genotype may have a reduced risk of cerivastatin-associated rhabdomyolysis as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1157877076>701</a></td><td>CYP3A5</td><td>rs776746</td><td>sunitinib</td><td>Carcinoma, Renal Cell</td><td>3</td><td>CC</td><td>Toxicity</td><td>Patients with the CC genotype and Carcinoma who are treated with sunitinib may have a decreased, but not absent, risk for dose reductions due to toxicity as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to sunitinib.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183491354>702</a></td><td>SLC6A5</td><td>rs2298826</td><td>haloperidol</td><td>Schizophrenia</td><td>3</td><td>GG</td><td>Toxicity</td><td>Patients with the GG genotype and Schizophrenia who are treated with haloperidol may have a decreased risk for rapid rise of motor side effects at the beginning of the treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for treatment side effects.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183618859>703</a></td><td>HTR2A</td><td>rs6313</td><td>paroxetine</td><td>Depression</td><td>3</td><td>AG</td><td>Toxicity</td><td>Patients with the AG genotype and depression who are treated with paroxetine may have a reduced risk of adverse drug reactions as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of adverse reactions.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183603158>704</a></td><td>SACM1L</td><td>rs2742390</td><td>bupropion</td><td>Depressive Disorder, Major</td><td>3</td><td>AA</td><td>Toxicity</td><td>Patients with the AA genotype and major depressive disorder may have decreased sexual side-effects when treated with bupropion as compared to patients with the GG genotype. Other genetic and clinical factors may also influence sexual side-effects.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/982031045>705</a></td><td>NOS3</td><td>rs1799983</td><td>aspirin</td><td>Coronary Artery Disease</td><td>3</td><td>GG</td><td>Toxicity</td><td>Male patients with the GG genotype and Coronary Artery Disease may have a decreased, but not absent, risk of in-stent restenosis when treated with aspirin, Beta Blocking Agents, clopidogrel and hmg coa reductase inhibitors as compared to male patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of in-stent restenosis.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/982031045>706</a></td><td>NOS3</td><td>rs1799983</td><td>Beta Blocking Agents</td><td>Coronary Artery Disease</td><td>3</td><td>GG</td><td>Toxicity</td><td>Male patients with the GG genotype and Coronary Artery Disease may have a decreased, but not absent, risk of in-stent restenosis when treated with aspirin, Beta Blocking Agents, clopidogrel and hmg coa reductase inhibitors as compared to male patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of in-stent restenosis.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/982031045>707</a></td><td>NOS3</td><td>rs1799983</td><td>clopidogrel</td><td>Coronary Artery Disease</td><td>3</td><td>GG</td><td>Toxicity</td><td>Male patients with the GG genotype and Coronary Artery Disease may have a decreased, but not absent, risk of in-stent restenosis when treated with aspirin, Beta Blocking Agents, clopidogrel and hmg coa reductase inhibitors as compared to male patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of in-stent restenosis.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/982031045>708</a></td><td>NOS3</td><td>rs1799983</td><td>hmg coa reductase inhibitors</td><td>Coronary Artery Disease</td><td>3</td><td>GG</td><td>Toxicity</td><td>Male patients with the GG genotype and Coronary Artery Disease may have a decreased, but not absent, risk of in-stent restenosis when treated with aspirin, Beta Blocking Agents, clopidogrel and hmg coa reductase inhibitors as compared to male patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of in-stent restenosis.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1043858733>709</a></td><td>HNMT</td><td>rs1050891</td><td>aspirin</td><td></td><td>3</td><td>GG</td><td>Toxicity</td><td>Patients with the GG genotype may have a decreased risk of acetylsalicylic acid-intolerant chronic urticaria as compared to the AA genotype. Other genetic and clinical factors may also influence a patient's risk for aspirin sensitivity.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183602849>710</a></td><td>SACM1L</td><td>rs2742421</td><td>bupropion</td><td>Depressive Disorder, Major</td><td>3</td><td>GG</td><td>Toxicity</td><td>Patients with the GG genotype and major depressive disorder may have decreased sexual side-effects when treated with bupropion as compared to patients with the TT genotype. Other genetic and clinical factors may also influence sexual side-effects.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183631559>711</a></td><td>SOX10</td><td>rs139887</td><td>carboplatin</td><td>Ovarian Neoplasms</td><td>3</td><td>CC</td><td>Toxicity</td><td>Patients with the CC genotype and ovarian cancer may have a decreased risk of neurotoxicity when treated with carboplatin in combination with either docetaxel or paclitaxel, as compared to patients with the CG genotype. Other genetic and clinical factors may also influence risk of neurotoxicity.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183631559>712</a></td><td>SOX10</td><td>rs139887</td><td>docetaxel</td><td>Ovarian Neoplasms</td><td>3</td><td>CC</td><td>Toxicity</td><td>Patients with the CC genotype and ovarian cancer may have a decreased risk of neurotoxicity when treated with carboplatin in combination with either docetaxel or paclitaxel, as compared to patients with the CG genotype. Other genetic and clinical factors may also influence risk of neurotoxicity.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183631559>713</a></td><td>SOX10</td><td>rs139887</td><td>paclitaxel</td><td>Ovarian Neoplasms</td><td>3</td><td>CC</td><td>Toxicity</td><td>Patients with the CC genotype and ovarian cancer may have a decreased risk of neurotoxicity when treated with carboplatin in combination with either docetaxel or paclitaxel, as compared to patients with the CG genotype. Other genetic and clinical factors may also influence risk of neurotoxicity.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449003934>714</a></td><td>EHMT2</td><td>rs652888</td><td>Antithyroid Preparations</td><td>Agranulocytosis</td><td>3</td><td>AA</td><td>Toxicity</td><td>Patients with the AA genotype may have a decreased risk of developing agranulocytosis when treated with antithyroid preparations as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence a patient's risk of developing agranulocytosis when treated with antithyroid preparations.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449752825>715</a></td><td>HLA-DRB1</td><td>rs17211071</td><td>dapsone</td><td>Drug Hypersensitivity</td><td>3</td><td>GG</td><td>Toxicity</td><td>Patients with the GG genotype and who carry the HLA-B*13:01 allele may be at a decreased risk of experiencing hypersensitivity to dapsone as compared to HLA-B*13:01-positive patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's risk of experiencing dapsone hypersensitivity.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449005372>716</a></td><td>SH2B1</td><td>rs3888190</td><td>amisulpride</td><td>Bipolar Disorder;Depressive Disorder;Psychotic Disorders;schizoaffective disorder</td><td>3</td><td>AC</td><td>Toxicity</td><td>Patients with bipolar, depressive, psychotic, or schizoaffective disorders and the AC genotype who are administered amisulpride, aripiprazole, clozapine, olanzapine, quetiapine, paliperidone, risperidone, lithium, valproate or/and mirtazapine may have smaller elevations of LDL cholesterol concentrations as compared to patients with the CC genotype. Other clinical and genetic factors may also influence LDL concentrations in patients administered these medications.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449005372>717</a></td><td>SH2B1</td><td>rs3888190</td><td>aripiprazole</td><td>Bipolar Disorder;Depressive Disorder;Psychotic Disorders;schizoaffective disorder</td><td>3</td><td>AC</td><td>Toxicity</td><td>Patients with bipolar, depressive, psychotic, or schizoaffective disorders and the AC genotype who are administered amisulpride, aripiprazole, clozapine, olanzapine, quetiapine, paliperidone, risperidone, lithium, valproate or/and mirtazapine may have smaller elevations of LDL cholesterol concentrations as compared to patients with the CC genotype. Other clinical and genetic factors may also influence LDL concentrations in patients administered these medications.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449005372>718</a></td><td>SH2B1</td><td>rs3888190</td><td>clozapine</td><td>Bipolar Disorder;Depressive Disorder;Psychotic Disorders;schizoaffective disorder</td><td>3</td><td>AC</td><td>Toxicity</td><td>Patients with bipolar, depressive, psychotic, or schizoaffective disorders and the AC genotype who are administered amisulpride, aripiprazole, clozapine, olanzapine, quetiapine, paliperidone, risperidone, lithium, valproate or/and mirtazapine may have smaller elevations of LDL cholesterol concentrations as compared to patients with the CC genotype. Other clinical and genetic factors may also influence LDL concentrations in patients administered these medications.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449005372>719</a></td><td>SH2B1</td><td>rs3888190</td><td>lithium</td><td>Bipolar Disorder;Depressive Disorder;Psychotic Disorders;schizoaffective disorder</td><td>3</td><td>AC</td><td>Toxicity</td><td>Patients with bipolar, depressive, psychotic, or schizoaffective disorders and the AC genotype who are administered amisulpride, aripiprazole, clozapine, olanzapine, quetiapine, paliperidone, risperidone, lithium, valproate or/and mirtazapine may have smaller elevations of LDL cholesterol concentrations as compared to patients with the CC genotype. Other clinical and genetic factors may also influence LDL concentrations in patients administered these medications.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449005372>720</a></td><td>SH2B1</td><td>rs3888190</td><td>mirtazapine</td><td>Bipolar Disorder;Depressive Disorder;Psychotic Disorders;schizoaffective disorder</td><td>3</td><td>AC</td><td>Toxicity</td><td>Patients with bipolar, depressive, psychotic, or schizoaffective disorders and the AC genotype who are administered amisulpride, aripiprazole, clozapine, olanzapine, quetiapine, paliperidone, risperidone, lithium, valproate or/and mirtazapine may have smaller elevations of LDL cholesterol concentrations as compared to patients with the CC genotype. Other clinical and genetic factors may also influence LDL concentrations in patients administered these medications.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449005372>721</a></td><td>SH2B1</td><td>rs3888190</td><td>olanzapine</td><td>Bipolar Disorder;Depressive Disorder;Psychotic Disorders;schizoaffective disorder</td><td>3</td><td>AC</td><td>Toxicity</td><td>Patients with bipolar, depressive, psychotic, or schizoaffective disorders and the AC genotype who are administered amisulpride, aripiprazole, clozapine, olanzapine, quetiapine, paliperidone, risperidone, lithium, valproate or/and mirtazapine may have smaller elevations of LDL cholesterol concentrations as compared to patients with the CC genotype. Other clinical and genetic factors may also influence LDL concentrations in patients administered these medications.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449005372>722</a></td><td>SH2B1</td><td>rs3888190</td><td>paliperidone</td><td>Bipolar Disorder;Depressive Disorder;Psychotic Disorders;schizoaffective disorder</td><td>3</td><td>AC</td><td>Toxicity</td><td>Patients with bipolar, depressive, psychotic, or schizoaffective disorders and the AC genotype who are administered amisulpride, aripiprazole, clozapine, olanzapine, quetiapine, paliperidone, risperidone, lithium, valproate or/and mirtazapine may have smaller elevations of LDL cholesterol concentrations as compared to patients with the CC genotype. Other clinical and genetic factors may also influence LDL concentrations in patients administered these medications.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449005372>723</a></td><td>SH2B1</td><td>rs3888190</td><td>quetiapine</td><td>Bipolar Disorder;Depressive Disorder;Psychotic Disorders;schizoaffective disorder</td><td>3</td><td>AC</td><td>Toxicity</td><td>Patients with bipolar, depressive, psychotic, or schizoaffective disorders and the AC genotype who are administered amisulpride, aripiprazole, clozapine, olanzapine, quetiapine, paliperidone, risperidone, lithium, valproate or/and mirtazapine may have smaller elevations of LDL cholesterol concentrations as compared to patients with the CC genotype. Other clinical and genetic factors may also influence LDL concentrations in patients administered these medications.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449005372>724</a></td><td>SH2B1</td><td>rs3888190</td><td>risperidone</td><td>Bipolar Disorder;Depressive Disorder;Psychotic Disorders;schizoaffective disorder</td><td>3</td><td>AC</td><td>Toxicity</td><td>Patients with bipolar, depressive, psychotic, or schizoaffective disorders and the AC genotype who are administered amisulpride, aripiprazole, clozapine, olanzapine, quetiapine, paliperidone, risperidone, lithium, valproate or/and mirtazapine may have smaller elevations of LDL cholesterol concentrations as compared to patients with the CC genotype. Other clinical and genetic factors may also influence LDL concentrations in patients administered these medications.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449005372>725</a></td><td>SH2B1</td><td>rs3888190</td><td>valproic acid</td><td>Bipolar Disorder;Depressive Disorder;Psychotic Disorders;schizoaffective disorder</td><td>3</td><td>AC</td><td>Toxicity</td><td>Patients with bipolar, depressive, psychotic, or schizoaffective disorders and the AC genotype who are administered amisulpride, aripiprazole, clozapine, olanzapine, quetiapine, paliperidone, risperidone, lithium, valproate or/and mirtazapine may have smaller elevations of LDL cholesterol concentrations as compared to patients with the CC genotype. Other clinical and genetic factors may also influence LDL concentrations in patients administered these medications.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450820963>726</a></td><td>CHRNA4</td><td>rs6090378</td><td>nicotine</td><td>Tobacco Use Disorder</td><td>3</td><td>AA</td><td>Toxicity</td><td>Patients with the AA genotype may have a decreased severity of nicotine dependence, as indicated by a lower Fagerstrom Test for Nicotine Dependence score, as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect the severity of a patient's nicotine dependence.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449004504>727</a></td><td>MEG3</td><td>rs10132552</td><td>Platinum compounds</td><td>Anemia;Dermatitis;Leukopenia;mucositis;Myelosuppression;Neutropenia;Thrombocytopenia</td><td>3</td><td>CT</td><td>Toxicity</td><td>Patients with nasopharyngeal cancer and the CT genotype may have a decreased risk of anemia as compared to the CC genotype. There was no association with risk of Dermatitis, Leukopenia, mucositis, Myelosuppression, Neutropenia and Thrombocytopenia. Other clinical and genetic factors may also influence risk of myelossuppression and neutropenia in patients with nasopharyngeal cancer who are treated with platinum compounds and radiotherapy.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449004504>728</a></td><td>MEG3</td><td>rs10132552</td><td>radiotherapy</td><td>Anemia;Dermatitis;Leukopenia;mucositis;Myelosuppression;Neutropenia;Thrombocytopenia</td><td>3</td><td>CT</td><td>Toxicity</td><td>Patients with nasopharyngeal cancer and the CT genotype may have a decreased risk of anemia as compared to the CC genotype. There was no association with risk of Dermatitis, Leukopenia, mucositis, Myelosuppression, Neutropenia and Thrombocytopenia. Other clinical and genetic factors may also influence risk of myelossuppression and neutropenia in patients with nasopharyngeal cancer who are treated with platinum compounds and radiotherapy.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450813869>729</a></td><td>-</td><td>rs11969064</td><td>azathioprine</td><td>Inflammatory Bowel Diseases;Myelosuppression</td><td>3</td><td>CC</td><td>Toxicity</td><td>Patients with the CC genotype may have decreased risk for thiopurine-induced myelosuppression in patients With inflammatory bowel disease as compared to patients with genotype TT or CT. Other genetic and clinical factors may also influence a patient's risk for toxicity.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450813869>730</a></td><td>-</td><td>rs11969064</td><td>mercaptopurine</td><td>Inflammatory Bowel Diseases;Myelosuppression</td><td>3</td><td>CC</td><td>Toxicity</td><td>Patients with the CC genotype may have decreased risk for thiopurine-induced myelosuppression in patients With inflammatory bowel disease as compared to patients with genotype TT or CT. Other genetic and clinical factors may also influence a patient's risk for toxicity.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450813869>731</a></td><td>-</td><td>rs11969064</td><td>thioguanine</td><td>Inflammatory Bowel Diseases;Myelosuppression</td><td>3</td><td>CC</td><td>Toxicity</td><td>Patients with the CC genotype may have decreased risk for thiopurine-induced myelosuppression in patients With inflammatory bowel disease as compared to patients with genotype TT or CT. Other genetic and clinical factors may also influence a patient's risk for toxicity.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449296290>732</a></td><td>CYP1A2</td><td>rs762551</td><td>caffeine</td><td>insomnia</td><td>3</td><td>AC</td><td>Toxicity</td><td>Patients with the AC genotype may be less likely to experience insomnia as a result of consuming caffeine as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's likelihood of experiencing insomnia due to caffeine.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450932703>733</a></td><td>ARRB2</td><td>rs1045280</td><td>buprenorphine</td><td>adverse events;Opioid-Related Disorders</td><td>3</td><td>CT</td><td>Toxicity</td><td>Patients with the CT genotype and who are being treated with buprenorphine with optional fentanyl and tramadol for prescription opioid dependence may less likely to experience adverse events as compared to patients with the TT genotype. Other genetic and clinical factors may also affect the incidence of adverse events during treatment for opioid dependence.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450932703>734</a></td><td>ARRB2</td><td>rs1045280</td><td>fentanyl</td><td>adverse events;Opioid-Related Disorders</td><td>3</td><td>CT</td><td>Toxicity</td><td>Patients with the CT genotype and who are being treated with buprenorphine with optional fentanyl and tramadol for prescription opioid dependence may less likely to experience adverse events as compared to patients with the TT genotype. Other genetic and clinical factors may also affect the incidence of adverse events during treatment for opioid dependence.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450932703>735</a></td><td>ARRB2</td><td>rs1045280</td><td>tramadol</td><td>adverse events;Opioid-Related Disorders</td><td>3</td><td>CT</td><td>Toxicity</td><td>Patients with the CT genotype and who are being treated with buprenorphine with optional fentanyl and tramadol for prescription opioid dependence may less likely to experience adverse events as compared to patients with the TT genotype. Other genetic and clinical factors may also affect the incidence of adverse events during treatment for opioid dependence.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450813988>736</a></td><td>BDNF</td><td>rs6265</td><td>methamphetamine</td><td>methamphetamine dependence</td><td>3</td><td>CT</td><td>Toxicity</td><td>Patients with the CT genotype may be less likely to respond to treatment for methamphetamine dependence as compared to patients with the CC genotype. This association was only observed in patients of European ancestry. Other genetic or clinical factors may also affect a patient's response to treatment for methamphetamine dependence.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449718277>737</a></td><td>ABCC2</td><td>rs2273697</td><td>cyclophosphamide</td><td>Breast Neoplasms</td><td>3</td><td>AG</td><td>Toxicity</td><td>Patients with AG genotype and breast cancer may have a decreased risk of anemia when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the GG genotype. Other genetic and clinical factors may also affect the risk for anemia in patients taking FAC chemotherapy.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449718277>738</a></td><td>ABCC2</td><td>rs2273697</td><td>doxorubicin</td><td>Breast Neoplasms</td><td>3</td><td>AG</td><td>Toxicity</td><td>Patients with AG genotype and breast cancer may have a decreased risk of anemia when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the GG genotype. Other genetic and clinical factors may also affect the risk for anemia in patients taking FAC chemotherapy.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449718277>739</a></td><td>ABCC2</td><td>rs2273697</td><td>fluorouracil</td><td>Breast Neoplasms</td><td>3</td><td>AG</td><td>Toxicity</td><td>Patients with AG genotype and breast cancer may have a decreased risk of anemia when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the GG genotype. Other genetic and clinical factors may also affect the risk for anemia in patients taking FAC chemotherapy.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449718289>740</a></td><td>ATM</td><td>rs1801516</td><td>cyclophosphamide</td><td>Breast Neoplasms</td><td>3</td><td>GG</td><td>Toxicity</td><td>Patients with GG genotype and breast cancer may have a decreased risk of nausea and vomiting when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also affect the risk for nausea and vomiting in patients taking FAC chemotherapy.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449718289>741</a></td><td>ATM</td><td>rs1801516</td><td>doxorubicin</td><td>Breast Neoplasms</td><td>3</td><td>GG</td><td>Toxicity</td><td>Patients with GG genotype and breast cancer may have a decreased risk of nausea and vomiting when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also affect the risk for nausea and vomiting in patients taking FAC chemotherapy.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449718289>742</a></td><td>ATM</td><td>rs1801516</td><td>fluorouracil</td><td>Breast Neoplasms</td><td>3</td><td>GG</td><td>Toxicity</td><td>Patients with GG genotype and breast cancer may have a decreased risk of nausea and vomiting when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also affect the risk for nausea and vomiting in patients taking FAC chemotherapy.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449718317>743</a></td><td>ERCC1</td><td>rs11615</td><td>cyclophosphamide</td><td>Breast Neoplasms</td><td>3</td><td>AA</td><td>Toxicity</td><td>Patients with AA genotype and breast cancer may have a decreased risk of anemia and nephrotoxicity when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also affect the risk for anemia and nephrotoxicity in patients taking FAC chemotherapy.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449718317>744</a></td><td>ERCC1</td><td>rs11615</td><td>doxorubicin</td><td>Breast Neoplasms</td><td>3</td><td>AA</td><td>Toxicity</td><td>Patients with AA genotype and breast cancer may have a decreased risk of anemia and nephrotoxicity when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also affect the risk for anemia and nephrotoxicity in patients taking FAC chemotherapy.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449718317>745</a></td><td>ERCC1</td><td>rs11615</td><td>fluorouracil</td><td>Breast Neoplasms</td><td>3</td><td>AA</td><td>Toxicity</td><td>Patients with AA genotype and breast cancer may have a decreased risk of anemia and nephrotoxicity when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also affect the risk for anemia and nephrotoxicity in patients taking FAC chemotherapy.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449718343>746</a></td><td>ABCB1</td><td>rs1045642</td><td>cyclophosphamide</td><td>Breast Neoplasms</td><td>3</td><td>AA</td><td>Toxicity</td><td>Patients with the AA genotype and breast cancer may have a decreased risk for anemia when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for anemia in patients taking FAC chemotherapy.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449718343>747</a></td><td>ABCB1</td><td>rs1045642</td><td>doxorubicin</td><td>Breast Neoplasms</td><td>3</td><td>AA</td><td>Toxicity</td><td>Patients with the AA genotype and breast cancer may have a decreased risk for anemia when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for anemia in patients taking FAC chemotherapy.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449718343>748</a></td><td>ABCB1</td><td>rs1045642</td><td>fluorouracil</td><td>Breast Neoplasms</td><td>3</td><td>AA</td><td>Toxicity</td><td>Patients with the AA genotype and breast cancer may have a decreased risk for anemia when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for anemia in patients taking FAC chemotherapy.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451411220>749</a></td><td>KCNMA1</td><td>rs2253201</td><td>Ace Inhibitors, Plain</td><td>Angioedema</td><td>3</td><td>AA</td><td>Toxicity</td><td>Patients with the rs2253201 AA genotype may be at a decreased risk of developing angioedema when treated with ACE inhibitors as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence risk of developing angioedema when treated with ACE inhibitors.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450373745>750</a></td><td>CDA</td><td>rs471760</td><td>gemcitabine</td><td>Neutropenia;Pancreatic Neoplasms</td><td>3</td><td>AG</td><td>Toxicity</td><td>Patients with pancreatic cancer and the AG genotype may be at a decreased risk of developing neutropenia as a result of gemcitabine treatment as compared to patients with the GG genotype. Note that this variant is in high LD with rs2072671 (see clinical annotation 981188379). Other genetic or clinical factors may also affect a patient's risk of developing neutropenia as a result of gemcitabine treatment.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450811273>751</a></td><td>CHRNA4</td><td>rs1044394</td><td>ethanol</td><td>Alcoholism</td><td>3</td><td>GG</td><td>Toxicity</td><td>Patients with the GG genotype may be at a decreased risk of developing alcoholism as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655385462>752</a></td><td>ABCB1</td><td>rs1045642</td><td>methotrexate</td><td>Arthritis, Rheumatoid</td><td>3</td><td>AA</td><td>Toxicity</td><td>Patients with the rs1045642 AA genotype and rheumatoid arthritis who are treated with methotrexate may have a decreased risk of drug toxicity as compared to patients with the AG or GG genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity when treated with methotrexate.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655385475>753</a></td><td>MTHFR</td><td>rs4846051</td><td>methotrexate</td><td>Arthritis, Rheumatoid;Drug Toxicity</td><td>3</td><td>AA</td><td>Toxicity</td><td>Patients with the AA genotype with Rheumatoid Arthritis who are treated with methotrexate may have a lower drug toxicity score as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's level of methotrexate induced toxicity.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655385613>754</a></td><td>HTR2A</td><td>rs7997012</td><td>olanzapine</td><td></td><td>3</td><td>GG</td><td>Toxicity</td><td>Patients with the GG genotype and psychiatric disorders who are treated with olanzapine may have a decreased, but not absent, risk for more side effects as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for side effects with olanzapine treatment.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655385977>755</a></td><td>NCF4</td><td>rs1883112</td><td>doxorubicin</td><td>Neoplasms</td><td>3</td><td>AG</td><td>Toxicity</td><td>Cancer patients with the AG genotype who are treated with doxorubicin or idarubicin may have a decreased, but not absent, risk for cardiotoxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for cardiotoxicity.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655385977>756</a></td><td>NCF4</td><td>rs1883112</td><td>idarubicin</td><td>Neoplasms</td><td>3</td><td>AG</td><td>Toxicity</td><td>Cancer patients with the AG genotype who are treated with doxorubicin or idarubicin may have a decreased, but not absent, risk for cardiotoxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for cardiotoxicity.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655385997>757</a></td><td>SLIT1</td><td>rs2784917</td><td>etoposide</td><td></td><td>3</td><td>GG</td><td>Toxicity</td><td>Patients with the GG genotype may have lower risk of toxicity with etoposide compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655385674>758</a></td><td>HTR2C</td><td>rs1414334</td><td>clozapine</td><td>Metabolic Syndrome;Schizophrenia</td><td>3</td><td>G</td><td>Toxicity</td><td>Patients with one X-chromosome and the G genotype who are treated with clozapine may have a decreased risk of developing metabolic syndrome as compared to patients with the C genotype. This gene is on the X chromosome and males have only one allele. Other genetic and clinical factors may also influence a patient's risk for developing metabolic syndrome.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655385674>759</a></td><td>HTR2C</td><td>rs1414334</td><td>clozapine</td><td>Metabolic Syndrome;Schizophrenia</td><td>3</td><td>GG</td><td>Toxicity</td><td>Patients with two X-chromosomes and the GG genotype who are treated with clozapine may have a decreased, but not absent, risk of developing metabolic syndrome as compared to patients with the CG and CC genotype. Other genetic and clinical factors may also influence a patient's risk for developing metabolic syndrome. This gene is on the X chromosome therefore some individuals may have only one allele.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655386436>760</a></td><td>MTHFR</td><td>rs1801131</td><td>methotrexate</td><td>Arthritis, Rheumatoid</td><td>3</td><td>TT</td><td>Toxicity</td><td>Patients with the rs1801131 TT genotype and Rheumatoid Arthritis who are treated with methotrexate may have a decreased, but not absent, risk of drug toxicity and adverse events as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk for adverse events with methotrexate treatment.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655386002>761</a></td><td>-</td><td>rs6539870</td><td>etoposide</td><td></td><td>3</td><td>AG</td><td>Toxicity</td><td>Patients with the AG genotype may have lower risk of toxicity with etoposide compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655386801>762</a></td><td>GSTA1</td><td>rs3957357</td><td>cisplatin</td><td>Anemia;Ovarian Neoplasms</td><td>3</td><td>GG</td><td>Toxicity</td><td>Patients with the GG genotype may have decreased risk for anemia when treated with cisplatin and cyclophosphamide as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence response to cisplatin regimens.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655386801>763</a></td><td>GSTA1</td><td>rs3957357</td><td>cyclophosphamide</td><td>Anemia;Ovarian Neoplasms</td><td>3</td><td>GG</td><td>Toxicity</td><td>Patients with the GG genotype may have decreased risk for anemia when treated with cisplatin and cyclophosphamide as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence response to cisplatin regimens.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655386830>764</a></td><td>CDA</td><td>rs60369023</td><td>gemcitabine</td><td>Neoplasms;Neutropenia</td><td>3</td><td>GG</td><td>Toxicity</td><td>Patients with the GG genotype and cancer who are treated with gemcitabine 1) may have increased clearance of gemcitabine 2) may have decreased severity of Neutropenia as compared to patients with AA genotype. Other genetic and clinical factors may also influence gemcitabine clearance and severity of neutropenia.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655386244>765</a></td><td>ABCB1</td><td>rs1045642</td><td>nevirapine</td><td>HIV Infections;Toxic liver disease</td><td>3</td><td>AA</td><td>Toxicity</td><td>Patients with the rs1045642 AA genotype and HIV-1 infection who are treated with nevirapine may have a decreased, but not absent, risk for nevirapine hepatotoxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of hepatotoxicity with nevirapine treatment.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655386612>766</a></td><td>XPC</td><td>rs2228001</td><td>cisplatin</td><td>Neoplasms;Osteosarcoma;Ototoxicity;Testicular Neoplasms</td><td>3</td><td>TT</td><td>Toxicity</td><td>Patients with the TT genotype may have a decreased, but not non-existent, risk for ototoxicity with cisplatin treatment as compared to patients with the GG or GT genotypes. However, another study failed to find this association. Other genetic and clinical factors may also influence a patient's risk for ototoxicity when treated with cisplatin.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655387839>767</a></td><td>MTHFR</td><td>rs1801131</td><td>nitrous oxide</td><td></td><td>3</td><td>TT</td><td>Toxicity</td><td>Patients with the TT genotype may have lower homocysteine levels after nitrous oxide anesthesia as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's homocysteine levels after nitrous oxide exposure.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/699639249>768</a></td><td>CYP3A5</td><td>rs776746</td><td>paclitaxel</td><td></td><td>3</td><td>CC</td><td>Toxicity</td><td>Patients with the CC genotype may have decreased but not absent risk of neurotoxicity when treated with paclitaxel as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of toxicity with paclitaxel.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/613976848>769</a></td><td>BAG6</td><td>rs750332</td><td>carbamazepine</td><td></td><td>3</td><td>TT</td><td>Toxicity</td><td>Patients with the TT genotype who are treated with carbamazepine may have a decreased, but not absent, risk of Stevens-Johnson syndrome as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence a patient's risk for Stevens-Johnson syndrome with carbamazepine treatment.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/613976848>770</a></td><td>PRRC2A</td><td>rs750332</td><td>carbamazepine</td><td></td><td>3</td><td>TT</td><td>Toxicity</td><td>Patients with the TT genotype who are treated with carbamazepine may have a decreased, but not absent, risk of Stevens-Johnson syndrome as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence a patient's risk for Stevens-Johnson syndrome with carbamazepine treatment.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/619523389>771</a></td><td>KCNH2</td><td>rs12720441</td><td>amiodarone</td><td>Torsades de Pointes</td><td>3</td><td>GG</td><td>Toxicity</td><td>Patients with the GG genotype may have decreased risk for Torsades de Point when treated with amiodarone as compared to patients with the AA or AG genotype. Patients with the GG genotype may still be at risk for adverse events when taking amiodarone based on their genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/637880078>772</a></td><td>LRP2</td><td>rs2075252</td><td>cisplatin</td><td>Neoplasms</td><td>4</td><td>CC</td><td>Toxicity</td><td>Patients with the CC genotype treated with cisplatin may have a reduced but not non-existent risk for hearing loss as compared to patients with the CT or TT genotype. However, other studies have failed to find an association. Other genetic and clinical factors may also influence a patient's chance of adverse events.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655384510>773</a></td><td>CREB1</td><td>rs7569963</td><td>antidepressants</td><td>Depression</td><td>3</td><td>AG</td><td>Toxicity</td><td>Patients with the AG genotype may have decreased likelihood of remission on anti-depressants as compared to patients with the GG genotype. Male patients with the AG genotype and depression who are treated with citalopram may have a decreased, but not absent, risk of suicidal ideation as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to antidepressants.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655384510>774</a></td><td>METTL21A</td><td>rs7569963</td><td>antidepressants</td><td>Depression</td><td>3</td><td>AG</td><td>Toxicity</td><td>Patients with the AG genotype may have decreased likelihood of remission on anti-depressants as compared to patients with the GG genotype. Male patients with the AG genotype and depression who are treated with citalopram may have a decreased, but not absent, risk of suicidal ideation as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to antidepressants.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655384510>775</a></td><td>CREB1</td><td>rs7569963</td><td>citalopram</td><td>Depression</td><td>3</td><td>AG</td><td>Toxicity</td><td>Patients with the AG genotype may have decreased likelihood of remission on anti-depressants as compared to patients with the GG genotype. Male patients with the AG genotype and depression who are treated with citalopram may have a decreased, but not absent, risk of suicidal ideation as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to antidepressants.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655384510>776</a></td><td>METTL21A</td><td>rs7569963</td><td>citalopram</td><td>Depression</td><td>3</td><td>AG</td><td>Toxicity</td><td>Patients with the AG genotype may have decreased likelihood of remission on anti-depressants as compared to patients with the GG genotype. Male patients with the AG genotype and depression who are treated with citalopram may have a decreased, but not absent, risk of suicidal ideation as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to antidepressants.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/652779372>777</a></td><td>CBR3</td><td>rs1056892</td><td>anthracyclines and related substances</td><td>Heart Failure;Neoplasms</td><td>3</td><td>AA</td><td>Toxicity</td><td>Patients with the AA genotype may have decreased risk of cardiac damage after anthracycline exposure as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655384578>778</a></td><td>CYP3A4</td><td>rs2740574</td><td>docetaxel</td><td>Neoplasms</td><td>3</td><td>TT</td><td>Toxicity</td><td>Patients with the TT genotype may have decreased clearance of docetaxel and a decreased risk of an infusion-related reaction as compared to patients with the CC or CT genotype. These patients may experience a decreased risk of neurotoxicity with docetaxel treatment, though reports conflict. Other genetic and clinical factors may also influence clearance of and reactions to docetaxel.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655384635>779</a></td><td>UGT1A9</td><td>rs58597806</td><td>propofol</td><td></td><td>3</td><td>GG</td><td>Toxicity</td><td>Patients with the GG genotype may have decreased but not non-existent risk of adverse effects when treated with propofol as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence response to propofol.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655384902>780</a></td><td>CYP1A2</td><td>rs762551</td><td>leflunomide</td><td>Arthritis, Rheumatoid</td><td>4</td><td>AC</td><td>Toxicity</td><td>Patients with the AC genotype and rheumatoid arthritis who are treated with leflunomide may have a decreased, but not absent, risk of toxicity as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity with leflunomide treatment.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655385082>781</a></td><td>APOC3</td><td>rs2854117</td><td>ritonavir</td><td>HIV Infections;Hyperlipidemias</td><td>3</td><td>CC</td><td>Toxicity</td><td>Patients with the CC genotype and HIV who are treated with ritonavir may have lower triglyceride levels (lower risk of Hypertriglyceridemia) as compared to patients with the TC or TT genotype. Patients with the CC genotype may still be at risk for toxicity when taking ritonavir. Other genetic and clinical factors may also influence a patient's triglyceride levels.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451414840>782</a></td><td>ABCB1</td><td>rs1045642</td><td>oseltamivir</td><td></td><td>3</td><td>AA</td><td>Toxicity</td><td>Patients with the rs1045642 AA genotype and acute respiratory diseases and suspected influenza infection may have decreased risk of side effects when treated with oseltamivir as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence risk of oseltamivir side effects.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450373628>783</a></td><td>SLC19A1</td><td>rs12659</td><td>imatinib</td><td>Gastrointestinal Stromal Tumors</td><td>3</td><td>AG</td><td>Toxicity</td><td>Patients with the AG genotype and gastrointestinal stromal tumors may have a decreased risk for toxicity when treated with imatinib as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk for toxicity in patients receiving imatinib.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450373634>784</a></td><td>SLC19A1</td><td>rs1051266</td><td>imatinib</td><td>Gastrointestinal Stromal Tumors</td><td>3</td><td>CT</td><td>Toxicity</td><td>Patients with the CT genotype and gastrointestinal stromal tumors may have a decreased risk for toxicity when treated with imatinib as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk for toxicity in patients receiving imatinib.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/827847751>785</a></td><td>IDO1</td><td>rs9657182</td><td>interferon alfa-2a, recombinant</td><td>Hepatitis C, Chronic</td><td>3</td><td>CT</td><td>Toxicity</td><td>Patients with the CT genotype may have decreased, but not absent, risk for moderate or severe depression when treated with peginterferon alfa-2b or recombinant interferon alfa-2a as compared to patients with the CC genotypes. Other genetic and clinical factors may also influence a patient's risk for drug side effects.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/827847751>786</a></td><td>IDO1</td><td>rs9657182</td><td>peginterferon alfa-2b</td><td>Hepatitis C, Chronic</td><td>3</td><td>CT</td><td>Toxicity</td><td>Patients with the CT genotype may have decreased, but not absent, risk for moderate or severe depression when treated with peginterferon alfa-2b or recombinant interferon alfa-2a as compared to patients with the CC genotypes. Other genetic and clinical factors may also influence a patient's risk for drug side effects.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/827848555>787</a></td><td>SLC10A2</td><td>rs9514091</td><td>anthracyclines and related substances</td><td>Neoplasms</td><td>4</td><td>AG</td><td>Toxicity</td><td>Patients with the AG genotype may have decreased but not absent risk for cardiotoxicity when exposed to anthracyclines for pediatric cancer as compared to patients with the GG genotype, although this is contradicted in one study. Other genetic and clinical factors may also influence risk for cardiotoxicity.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/981188379>788</a></td><td>CDA</td><td>rs2072671</td><td>gemcitabine</td><td>Carcinoma, Non-Small-Cell Lung;Mesothelioma;Pancreatic Neoplasms</td><td>3</td><td>AC</td><td>Toxicity</td><td>Patients with the AC genotype who are treated with gemcitabine may have a decreased risk of toxicity when compared to patients with the AA genotype. Other genetic and clinical factors may also influence the risk of adverse events in cancer patients administered gemcitabine.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/981201333>789</a></td><td>EGFR</td><td>rs2227983</td><td>egfr inhibitors</td><td>Carcinoma, Non-Small-Cell Lung;Colorectal Neoplasms;Neoplasms;Pancreatic Neoplasms</td><td>3</td><td>AG</td><td>Toxicity</td><td>Patients with the AG genotype may have a decreased but not absent risk for rash when treated with EGFR inhibitors, such as erlotinib, as compared to patients with the GG genotypes. No significant association is found between this variant and cetuximab or panitumumab response. Other genetic and clinical factors may also influence a patient's risk for toxicity.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451416408>790</a></td><td>HTR2A</td><td>rs6311</td><td>antidepressants</td><td>adverse events;Bipolar Disorder;Depression;Depressive Disorder, Major</td><td>3</td><td>CT</td><td>Toxicity</td><td>Patients with the rs6311 CT genotype may be at a decreased risk of experiencing side effects when treated with antidepressants as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of side effects when treated with antidepressants.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451416422>791</a></td><td>HTR2A</td><td>rs6313</td><td>antidepressants</td><td>adverse events;Bipolar Disorder;Depression;Depressive Disorder, Major</td><td>3</td><td>AG</td><td>Toxicity</td><td>Patients with the rs6313 AG genotype may be at a decreased risk of experiencing side effects when treated with antidepressants as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of side effects when treated with antidepressants.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451416946>792</a></td><td>CDA</td><td>rs2072671</td><td>gemcitabine</td><td>Nausea;Pancreatic Neoplasms</td><td>3</td><td>AC</td><td>Toxicity</td><td>Patients with pancreatic cancer and the rs2072671 AC genotype may have a decreased risk of experiencing nausea when treated with FOLFIRINOX as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of experiencing nausea when treated with FOLFIRINOX.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451416946>793</a></td><td>CDA</td><td>rs2072671</td><td>paclitaxel</td><td>Nausea;Pancreatic Neoplasms</td><td>3</td><td>AC</td><td>Toxicity</td><td>Patients with pancreatic cancer and the rs2072671 AC genotype may have a decreased risk of experiencing nausea when treated with FOLFIRINOX as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of experiencing nausea when treated with FOLFIRINOX.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/981220481>794</a></td><td>MTHFR</td><td>rs1801133</td><td>cisplatin</td><td>Neoplasms</td><td>3</td><td>AG</td><td>Toxicity</td><td>Patients with AG genotype may have a decreased risk of drug toxicity when treated with platinum drugs as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity when receiving platinum-based chemotherapy.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/981220481>795</a></td><td>MTHFR</td><td>rs1801133</td><td>oxaliplatin</td><td>Neoplasms</td><td>3</td><td>AG</td><td>Toxicity</td><td>Patients with AG genotype may have a decreased risk of drug toxicity when treated with platinum drugs as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity when receiving platinum-based chemotherapy.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/981220481>796</a></td><td>MTHFR</td><td>rs1801133</td><td>Platinum compounds</td><td>Neoplasms</td><td>3</td><td>AG</td><td>Toxicity</td><td>Patients with AG genotype may have a decreased risk of drug toxicity when treated with platinum drugs as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity when receiving platinum-based chemotherapy.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/981204466>797</a></td><td>ABCB1</td><td>rs1045642</td><td>capecitabine</td><td>Neoplasms</td><td>3</td><td>AA</td><td>Toxicity</td><td>Patients with AA genotype may have decreased risk of hand-foot syndrome when treated with capecitabine in people with Colorectal Neoplasms as compared to patients with genotype GG. Genotypes AG + GG are not associated with decreased clinical outcome when treated with capecitabine, cisplatin, docetaxel, epirubicin and gemcitabine in people with Pancreatic Neoplasms as compared to genotype AA. Other genetic and clinical factors may influence the response to capecitabine.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/981203618>798</a></td><td>DPYD</td><td>rs67376798</td><td>fluorouracil</td><td>Neoplasms</td><td>1A</td><td>TT</td><td>Toxicity</td><td>The A allele of this variant, when measured on plus chromosomal strand, is assigned decreased function by CPIC. Patients with the TT genotype and cancer who are treated with fluorouracil, a fluoropyrimidine-based chemotherapy, may have decreased, but not absent, risk and reduced severity of drug toxicity as compared to patients with the AA or AT genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/981203518>799</a></td><td>ADORA2A</td><td>rs5751876</td><td>caffeine</td><td>Anxiety Disorders</td><td>3</td><td>CT</td><td>Toxicity</td><td>Individuals with the CT genotype may be less likely to experience anxiety when exposed to caffeine as compared to individuals with the TT genotype. Other genetic and clinical factors may also influence an individual's response to caffeine.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451263877>800</a></td><td>CACNA1S</td><td>rs1800559</td><td>enflurane</td><td>Malignant Hyperthermia</td><td>1A</td><td>CC</td><td>Toxicity</td><td>Patients with the rs1800559 CC genotype may have a decreased, but not absent, risk for malignant hyperthermia when treated with enflurane as compared to patients with the TT genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451263966>801</a></td><td>CACNA1S</td><td>rs1800559</td><td>methoxyflurane</td><td></td><td>1A</td><td>CC</td><td>Toxicity</td><td>Patients with the rs1800559 CC genotype may have a decreased, but not absent, risk for malignant hyperthermia when treated with methoxyflurane as compared to patients with the TT genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451263973>802</a></td><td>CACNA1S</td><td>rs1800559</td><td>sevoflurane</td><td>Malignant Hyperthermia</td><td>1A</td><td>CC</td><td>Toxicity</td><td>Patients with the rs1800559 CC genotype may have a decreased risk for malignant hyperthermia when treated with sevoflurane as compared to patients with the TT genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451263980>803</a></td><td>CACNA1S</td><td>rs1800559</td><td>halothane</td><td>Malignant Hyperthermia</td><td>1A</td><td>CC</td><td>Toxicity</td><td>Patients with the rs1800559 CC genotype may have a decreased, but not absent, risk for malignant hyperthermia when treated with halothane as compared to patients with the CT or TT genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451263986>804</a></td><td>CACNA1S</td><td>rs1800559</td><td>isoflurane</td><td>Malignant Hyperthermia</td><td>1A</td><td>CC</td><td>Toxicity</td><td>Patients with the rs1800559 CC genotype may have a decreased, but not absent, risk for malignant hyperthermia when treated with isoflurane as compared to patients with the TT genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451264020>805</a></td><td>CACNA1S</td><td>rs1800559</td><td>succinylcholine</td><td>Malignant Hyperthermia</td><td>1A</td><td>CC</td><td>Toxicity</td><td>Patients with the rs1800559 CC genotype may have a decreased, but not absent, risk for malignant hyperthermia when treated with succinylcholine as compared to patients with the TT genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451274090>806</a></td><td>DPYD</td><td>rs67376798</td><td>capecitabine</td><td>Neoplasms</td><td>1A</td><td>TT</td><td>Toxicity</td><td>The A allele of rs67376798, when measured on plus chromosomal strand, is assigned decreased function by CPIC. Patients with the TT genotype and cancer who are treated with capecitabine, a fluoropyrimidine-based chemotherapy, may have decreased, but not absent, risk and reduced severity of drug toxicity as compared to patients with the AA or AT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/981419540>807</a></td><td>COQ2</td><td>rs6535454</td><td>atorvastatin</td><td>Muscular Diseases</td><td>3</td><td>GG</td><td>Toxicity</td><td>Patients with the GG genotype may have decreased risk of statin intolerance, defined primarily as muscle symptoms when treated with hmg coa reductase inhibitors as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's risk to statin.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/981419540>808</a></td><td>COQ2</td><td>rs6535454</td><td>hmg coa reductase inhibitors</td><td>Muscular Diseases</td><td>3</td><td>GG</td><td>Toxicity</td><td>Patients with the GG genotype may have decreased risk of statin intolerance, defined primarily as muscle symptoms when treated with hmg coa reductase inhibitors as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's risk to statin.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/981419540>809</a></td><td>COQ2</td><td>rs6535454</td><td>rosuvastatin</td><td>Muscular Diseases</td><td>3</td><td>GG</td><td>Toxicity</td><td>Patients with the GG genotype may have decreased risk of statin intolerance, defined primarily as muscle symptoms when treated with hmg coa reductase inhibitors as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's risk to statin.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449004239>810</a></td><td>-</td><td>rs1829346</td><td>Platinum compounds</td><td>Nasopharyngeal Neoplasms</td><td>3</td><td>AC</td><td>Toxicity</td><td>Patients with nasopharyngeal cancer and the AC genotype who are treated with platinum compounds and radiotherapy may have a decreased risk of dermatitis as compared to patients with the AA genotype. Other clinical and genetic factors may also influence the risk of dermatitis in patients with cancer who are treated with platinum compounds and radiotherapy.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449004239>811</a></td><td>-</td><td>rs1829346</td><td>radiotherapy</td><td>Nasopharyngeal Neoplasms</td><td>3</td><td>AC</td><td>Toxicity</td><td>Patients with nasopharyngeal cancer and the AC genotype who are treated with platinum compounds and radiotherapy may have a decreased risk of dermatitis as compared to patients with the AA genotype. Other clinical and genetic factors may also influence the risk of dermatitis in patients with cancer who are treated with platinum compounds and radiotherapy.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449004245>812</a></td><td>-</td><td>rs36080650</td><td>Platinum compounds</td><td>Nasopharyngeal Neoplasms</td><td>3</td><td>CT</td><td>Toxicity</td><td>Patients with the CT genotype and nasopharyngeal cancer who are treated with platinum compounds and radiotherapy may have a decreased risk of dermatitis as compared to patients with the CC genotype. Other clinical and genetic factors may also influence the risk of dermatitis in patients with cancer who are treated with platinum compounds and radiotherapy.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449004245>813</a></td><td>-</td><td>rs36080650</td><td>radiotherapy</td><td>Nasopharyngeal Neoplasms</td><td>3</td><td>CT</td><td>Toxicity</td><td>Patients with the CT genotype and nasopharyngeal cancer who are treated with platinum compounds and radiotherapy may have a decreased risk of dermatitis as compared to patients with the CC genotype. Other clinical and genetic factors may also influence the risk of dermatitis in patients with cancer who are treated with platinum compounds and radiotherapy.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449004528>814</a></td><td>-</td><td>rs2027701</td><td>Platinum compounds</td><td>Anemia;Dermatitis;Leukopenia;mucositis;Myelosuppression;Neutropenia;Thrombocytopenia</td><td>3</td><td>GG</td><td>Toxicity</td><td>Patients with nasopharyngeal cancer and the GG genotype may have a decreased risk of neutropenia when treated with radiotherapy and platinum compounds as compared to patients with the AA genotype. There was no association with risk of Anemia, Dermatitis, Leukopenia, mucositis, Myelosuppression and Thrombocytopenia. Other clinical and genetic factors may also influence risk of neutropenia in patients with nasopharyngeal cancer who are treated with platinum compounds and radiotherapy.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449004528>815</a></td><td>-</td><td>rs2027701</td><td>radiotherapy</td><td>Anemia;Dermatitis;Leukopenia;mucositis;Myelosuppression;Neutropenia;Thrombocytopenia</td><td>3</td><td>GG</td><td>Toxicity</td><td>Patients with nasopharyngeal cancer and the GG genotype may have a decreased risk of neutropenia when treated with radiotherapy and platinum compounds as compared to patients with the AA genotype. There was no association with risk of Anemia, Dermatitis, Leukopenia, mucositis, Myelosuppression and Thrombocytopenia. Other clinical and genetic factors may also influence risk of neutropenia in patients with nasopharyngeal cancer who are treated with platinum compounds and radiotherapy.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449564196>816</a></td><td>HSP90AB1</td><td>rs6929249</td><td>bevacizumab</td><td>Hypertension</td><td>3</td><td>AA</td><td>Toxicity</td><td>Patients with the AA genotype may have a decreased risk of developing hypertension as a result of bevacizumab treatment as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing hypertension as a result of bevacizumab treatment.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449163252>817</a></td><td>BCL2L11</td><td>rs724710</td><td>corticosteroids</td><td>Precursor Cell Lymphoblastic Leukemia-Lymphoma</td><td>3</td><td>CT</td><td>Toxicity</td><td>High-risk pediatric patients with acute lymphoblastic leukemia who have the CT genotype may have a decreased risk for osteonecrosis when treated with corticosteroids as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for osteonecrosis.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449163306>818</a></td><td>BCL2L11</td><td>rs2241843</td><td>corticosteroids</td><td>Precursor Cell Lymphoblastic Leukemia-Lymphoma</td><td>3</td><td>AC</td><td>Toxicity</td><td>Pediatric patients with the AC genotype and acute lymphoblastic leukemia may have a decreased risk for osteonecrosis when treated with corticosteroids as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk for osteonecrosis.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449164746>819</a></td><td>SLC22A5</td><td>rs274558</td><td>imatinib</td><td>Gastrointestinal Stromal Tumors</td><td>3</td><td>AG</td><td>Toxicity</td><td>Patients with the AG genotype and gastrointestinal stromal tumors (GIST) may have a decreased risk for periorbital edema when treated with imatinib as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for periorbital edema.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449170150>820</a></td><td>-</td><td>rs2734583</td><td>allopurinol</td><td>drug reaction with eosinophilia and systemic symptoms;Stevens-Johnson Syndrome</td><td>3</td><td>AA</td><td>Toxicity</td><td>Patients with the AA genotype who are treated with allopurinol may have a decreased risk of DRESS Syndrome or Stevens-Johnson Syndrome as compared to patients with the AG or GG genotypes. Please note: the AG and GG genotypes were found to be in high linkage disequilibrium with an allele known to be associated with SCARs, HLA*58:01. Other clinical and genetic factors may also influence risk of DRESS Syndrome or Stevens-Johnson Syndrome in patients administered allopurinol.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450931522>821</a></td><td>PNPLA3</td><td>rs738409</td><td>ethanol</td><td>Alcoholism</td><td>3</td><td>CC</td><td>Toxicity</td><td>Patients with the CC genotype may have a decreased risk of developing alcoholism as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451605946>822</a></td><td>GLP1R</td><td>rs2268639</td><td>olanzapine</td><td>Schizophrenia;Weight gain</td><td>3</td><td>AT</td><td>Toxicity</td><td>Patients with schizophrenia and the rs2268639 AT genotype who are treated with olanzapine may have less weight gain as compared to patients with the TT genotype. Other genetic and clinical factors may also influence likelihood and severity of weight gain when treated with olanzapine.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450374881>823</a></td><td>ABCB1</td><td>rs2032582</td><td>methylphenidate</td><td>Attention Deficit Disorder with Hyperactivity</td><td>3</td><td>AC</td><td>Toxicity</td><td>Patients with the AC genotype and attention deficit disorder with hyperactivity who are treated with methylphenidate may have lower adverse drug reaction scores (ADR scores using Barkley Stimulant Side Effect Rating Scale (BSSERS)) as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to methylphenidate.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450375035>824</a></td><td>CYP3A</td><td>rs2740574</td><td>bleomycin</td><td>Alopecia;Testicular Neoplasms</td><td>3</td><td>TT</td><td>Toxicity</td><td>Patients with testicular cancer and the TT genotype may have a decreased risk of developing alopecia as a result of treatment with bleomycin, cisplatin and etoposide as compared to patients with the GT genotype. Other genetic and clinical factors may also affect a patient's risk of developing alopecia as a result of treatment with bleomycin, cisplatin and etoposide.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450375035>825</a></td><td>CYP3A4</td><td>rs2740574</td><td>bleomycin</td><td>Alopecia;Testicular Neoplasms</td><td>3</td><td>TT</td><td>Toxicity</td><td>Patients with testicular cancer and the TT genotype may have a decreased risk of developing alopecia as a result of treatment with bleomycin, cisplatin and etoposide as compared to patients with the GT genotype. Other genetic and clinical factors may also affect a patient's risk of developing alopecia as a result of treatment with bleomycin, cisplatin and etoposide.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450375035>826</a></td><td>CYP3A</td><td>rs2740574</td><td>cisplatin</td><td>Alopecia;Testicular Neoplasms</td><td>3</td><td>TT</td><td>Toxicity</td><td>Patients with testicular cancer and the TT genotype may have a decreased risk of developing alopecia as a result of treatment with bleomycin, cisplatin and etoposide as compared to patients with the GT genotype. Other genetic and clinical factors may also affect a patient's risk of developing alopecia as a result of treatment with bleomycin, cisplatin and etoposide.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450375035>827</a></td><td>CYP3A4</td><td>rs2740574</td><td>cisplatin</td><td>Alopecia;Testicular Neoplasms</td><td>3</td><td>TT</td><td>Toxicity</td><td>Patients with testicular cancer and the TT genotype may have a decreased risk of developing alopecia as a result of treatment with bleomycin, cisplatin and etoposide as compared to patients with the GT genotype. Other genetic and clinical factors may also affect a patient's risk of developing alopecia as a result of treatment with bleomycin, cisplatin and etoposide.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450375035>828</a></td><td>CYP3A</td><td>rs2740574</td><td>etoposide</td><td>Alopecia;Testicular Neoplasms</td><td>3</td><td>TT</td><td>Toxicity</td><td>Patients with testicular cancer and the TT genotype may have a decreased risk of developing alopecia as a result of treatment with bleomycin, cisplatin and etoposide as compared to patients with the GT genotype. Other genetic and clinical factors may also affect a patient's risk of developing alopecia as a result of treatment with bleomycin, cisplatin and etoposide.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450375035>829</a></td><td>CYP3A4</td><td>rs2740574</td><td>etoposide</td><td>Alopecia;Testicular Neoplasms</td><td>3</td><td>TT</td><td>Toxicity</td><td>Patients with testicular cancer and the TT genotype may have a decreased risk of developing alopecia as a result of treatment with bleomycin, cisplatin and etoposide as compared to patients with the GT genotype. Other genetic and clinical factors may also affect a patient's risk of developing alopecia as a result of treatment with bleomycin, cisplatin and etoposide.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449270973>830</a></td><td>TOP2A</td><td>rs181501757</td><td>cyclophosphamide</td><td>Breast Neoplasms;Neutropenia</td><td>3</td><td>GG</td><td>Toxicity</td><td>Patients with breast cancer and the GG genotype may have a decreased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449270973>831</a></td><td>TOP2A</td><td>rs181501757</td><td>epirubicin</td><td>Breast Neoplasms;Neutropenia</td><td>3</td><td>GG</td><td>Toxicity</td><td>Patients with breast cancer and the GG genotype may have a decreased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449270973>832</a></td><td>TOP2A</td><td>rs181501757</td><td>fluorouracil</td><td>Breast Neoplasms;Neutropenia</td><td>3</td><td>GG</td><td>Toxicity</td><td>Patients with breast cancer and the GG genotype may have a decreased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449157600>833</a></td><td>NOTCH4</td><td>rs367398</td><td>allopurinol</td><td>severe cutaneous adverse reactions</td><td>3</td><td>AG</td><td>Toxicity</td><td>Patients with the AG genotype who are administered allopurinol may have a decreased risk of severe cutaneous adverse reactions (SCAR) when treated with allopurinol as compared to patients with the GG genotype. Other clinical and genetic factors may also influence risk of SCAR in patients administered allopurinol.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450813534>834</a></td><td>CYP2A13</td><td>rs1709083</td><td>nicotine</td><td>Tobacco Use Disorder</td><td>3</td><td>CC</td><td>Toxicity</td><td>Patients with the CC genotype may have less severe nicotine dependence as compared to patients with the CG genotype, as measured by mean number of cigarettes smoked per day. However, analysis of other measurements did not find a significant association. Other genetic and clinical factors may also affect the severity of nicotine dependence.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449752818>835</a></td><td>HLA-DRB1</td><td>rs201929247</td><td>dapsone</td><td>Drug Hypersensitivity</td><td>3</td><td>GG</td><td>Toxicity</td><td>Patients with the GG genotype and who carry the HLA-B*13:01 allele may be at a decreased risk of experiencing hypersensitivity to dapsone as compared to HLA-B*13:01-positive patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's risk of experiencing dapsone hypersensitivity.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450823626>836</a></td><td>KAT2B</td><td>rs9829896</td><td>amphetamine</td><td>Substance-Related Disorders</td><td>3</td><td>AC</td><td>Toxicity</td><td>Patients with the AC genotype may be at a decreased risk of developing drug dependence as compared to patients with the AA genotype. Note that this association was only found in African American subjects, and not in European Americans. Other genetic or clinical factors may also affect a patient's risk of developing drug dependence.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450823626>837</a></td><td>KAT2B</td><td>rs9829896</td><td>cannabinoids</td><td>Substance-Related Disorders</td><td>3</td><td>AC</td><td>Toxicity</td><td>Patients with the AC genotype may be at a decreased risk of developing drug dependence as compared to patients with the AA genotype. Note that this association was only found in African American subjects, and not in European Americans. Other genetic or clinical factors may also affect a patient's risk of developing drug dependence.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450823626>838</a></td><td>KAT2B</td><td>rs9829896</td><td>cocaine</td><td>Substance-Related Disorders</td><td>3</td><td>AC</td><td>Toxicity</td><td>Patients with the AC genotype may be at a decreased risk of developing drug dependence as compared to patients with the AA genotype. Note that this association was only found in African American subjects, and not in European Americans. Other genetic or clinical factors may also affect a patient's risk of developing drug dependence.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450823626>839</a></td><td>KAT2B</td><td>rs9829896</td><td>opioids</td><td>Substance-Related Disorders</td><td>3</td><td>AC</td><td>Toxicity</td><td>Patients with the AC genotype may be at a decreased risk of developing drug dependence as compared to patients with the AA genotype. Note that this association was only found in African American subjects, and not in European Americans. Other genetic or clinical factors may also affect a patient's risk of developing drug dependence.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183704339>840</a></td><td>-</td><td>rs6977820</td><td>antipsychotics</td><td>Schizophrenia;tardive dyskinesia</td><td>3</td><td>CC</td><td>Toxicity</td><td>Patients with the CC genotype may have decreased likelihood of tardive dyskinesia when treated with antipsychotics in people with Schizophrenia as compared to patients with genotype TT or CT. Other genetic and clinical factors may also influence the risk of toxicity to antipsychotics.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184348872>841</a></td><td>GLP1R</td><td>rs2268639</td><td>clozapine</td><td>Schizophrenia;Weight gain</td><td>3</td><td>AT</td><td>Toxicity</td><td>Patients with schizophrenia and the rs2268639 AT genotype who are treated with clozapine may have less weight gain as compared to patients with the TT genotype. Other genetic and clinical factors may also influence likelihood and severity of weight gain when treated with clozapine.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184348774>842</a></td><td>LIG3</td><td>rs1052536</td><td>cisplatin</td><td>Ovarian Neoplasms</td><td>3</td><td>TT</td><td>Toxicity</td><td>Patients with the TT genotype and ovarian cancer who are treated with chemotherapy involving cisplatin and cyclophosphamide may have a reduced, but not absent, risk of grade 3-4 neutropenia as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity when treated with chemotherapy.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184348774>843</a></td><td>LIG3</td><td>rs1052536</td><td>cyclophosphamide</td><td>Ovarian Neoplasms</td><td>3</td><td>TT</td><td>Toxicity</td><td>Patients with the TT genotype and ovarian cancer who are treated with chemotherapy involving cisplatin and cyclophosphamide may have a reduced, but not absent, risk of grade 3-4 neutropenia as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity when treated with chemotherapy.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183704267>844</a></td><td>SLC10A2</td><td>rs7319981</td><td>anthracyclines and related substances</td><td>Neoplasms</td><td>4</td><td>AA</td><td>Toxicity</td><td>Patients with the AA genotype may have decreased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with genotype GG, although this is contradicted in one study. Other genetic and clinical factors may also influence the toxicity to anthracyclines.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183703760>845</a></td><td>HAS3</td><td>rs2232228</td><td>anthracyclines and related substances</td><td>Cardiomyopathies</td><td>3</td><td>GG</td><td>Toxicity</td><td>Patients with genotype GG may have decreased cardiomyopathy risk when exposed to high-dose (> 250 mg/m2) anthracyclines in children with Neoplasms as compared to patients with genotype AA or AG. Other genetic or clinical factors may also influence a patient's risk of toxicity to anthracyclines.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183863989>846</a></td><td>-</td><td>rs9936750</td><td>capecitabine</td><td>Neoplasms</td><td>3</td><td>TT</td><td>Toxicity</td><td>Patients with the TT genotype who are treated with capecitabine may have a decreased, but not absent, risk for capecitabine-induced toxicity as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for severe capecitabine toxicity.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184514240>847</a></td><td>TANC1</td><td>rs264663</td><td>radiotherapy</td><td>Prostatic Neoplasms</td><td>3</td><td>CC</td><td>Toxicity</td><td>Patients with the CC genotype and prostate cancer who are treated with radiotherapy may have a reduced risk of late stage toxicity as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of radiotherapy-induced toxicity.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183704330>848</a></td><td>AGT</td><td>rs699</td><td>Antiinflammatory agents, non-steroids</td><td></td><td>3</td><td>GG</td><td>Toxicity</td><td>Patients with the GG genotype may have decreased likelihood of Acute coronary syndrome when exposed to Antiinflammatory agents, non-steroids (NSAIDs) in people with Acute coronary syndrome as compared to patients with genotype AA or AG. Other genetic and clinical factors may also influence the response to NSAIDs.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184348736>849</a></td><td>RAD52</td><td>rs11226</td><td>cisplatin</td><td>Ovarian Neoplasms</td><td>4</td><td>AG</td><td>Toxicity</td><td>Patients with the AG genotype and ovarian cancer who are treated with chemotherapy involving cisplatin and cyclophosphamide may have a reduced, but not absent, risk of grade 3-4 neutropenia as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity when treated with chemotherapy.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184348736>850</a></td><td>RAD52</td><td>rs11226</td><td>cyclophosphamide</td><td>Ovarian Neoplasms</td><td>4</td><td>AG</td><td>Toxicity</td><td>Patients with the AG genotype and ovarian cancer who are treated with chemotherapy involving cisplatin and cyclophosphamide may have a reduced, but not absent, risk of grade 3-4 neutropenia as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity when treated with chemotherapy.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450931583>851</a></td><td>HTR2A</td><td>rs6311</td><td>citalopram</td><td>Depressive Disorder, Major;Nausea;Vomiting</td><td>3</td><td>CT</td><td>Toxicity</td><td>Patients with major depressive disorder and the CT genotype may be less likely to experience nausea and vomiting when treated with citalopram as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's likelihood of experiencing citalopram-induced nausea and vomiting.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451637100>852</a></td><td>WBP2NL</td><td>rs9620007</td><td>codeine</td><td>adverse events</td><td>3</td><td>CG</td><td>Toxicity</td><td>Patients with the rs9620007 CG genotype may be at a decreased risk of experiencing adverse events when treated with codeine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of adverse events when treated with codeine.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183705783>853</a></td><td>RYR1</td><td>rs118192167</td><td>desflurane</td><td>Malignant Hyperthermia</td><td>1A</td><td>AA</td><td>Toxicity</td><td>Patients with the rs118192167 AA genotype may have a decreased, but not absent, risk for malignant hyperthermia based on this variant when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and/or succinylcholine as compared to patients with the GG or AG genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183705783>854</a></td><td>RYR1</td><td>rs118192167</td><td>enflurane</td><td>Malignant Hyperthermia</td><td>1A</td><td>AA</td><td>Toxicity</td><td>Patients with the rs118192167 AA genotype may have a decreased, but not absent, risk for malignant hyperthermia based on this variant when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and/or succinylcholine as compared to patients with the GG or AG genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183705783>855</a></td><td>RYR1</td><td>rs118192167</td><td>halothane</td><td>Malignant Hyperthermia</td><td>1A</td><td>AA</td><td>Toxicity</td><td>Patients with the rs118192167 AA genotype may have a decreased, but not absent, risk for malignant hyperthermia based on this variant when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and/or succinylcholine as compared to patients with the GG or AG genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183705783>856</a></td><td>RYR1</td><td>rs118192167</td><td>isoflurane</td><td>Malignant Hyperthermia</td><td>1A</td><td>AA</td><td>Toxicity</td><td>Patients with the rs118192167 AA genotype may have a decreased, but not absent, risk for malignant hyperthermia based on this variant when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and/or succinylcholine as compared to patients with the GG or AG genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183705783>857</a></td><td>RYR1</td><td>rs118192167</td><td>methoxyflurane</td><td>Malignant Hyperthermia</td><td>1A</td><td>AA</td><td>Toxicity</td><td>Patients with the rs118192167 AA genotype may have a decreased, but not absent, risk for malignant hyperthermia based on this variant when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and/or succinylcholine as compared to patients with the GG or AG genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183705783>858</a></td><td>RYR1</td><td>rs118192167</td><td>sevoflurane</td><td>Malignant Hyperthermia</td><td>1A</td><td>AA</td><td>Toxicity</td><td>Patients with the rs118192167 AA genotype may have a decreased, but not absent, risk for malignant hyperthermia based on this variant when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and/or succinylcholine as compared to patients with the GG or AG genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183705783>859</a></td><td>RYR1</td><td>rs118192167</td><td>succinylcholine</td><td>Malignant Hyperthermia</td><td>1A</td><td>AA</td><td>Toxicity</td><td>Patients with the rs118192167 AA genotype may have a decreased, but not absent, risk for malignant hyperthermia based on this variant when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and/or succinylcholine as compared to patients with the GG or AG genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183704358>860</a></td><td>SLC22A16</td><td>rs6907567</td><td>cyclophosphamide</td><td>Breast Neoplasms</td><td>3</td><td>AG</td><td>Toxicity</td><td>Patients with the AG genotype may have decreased risk for neutropenia and a decreased likelihood of dose delay when treated with cyclophosphamide, doxorubicin and fluorouracil, as compared to patients with AA genotypes. Other genetic and clinical factors may also influence risk for dose delay and toxicity in patients taking cyclophosphamide, doxorubicin and fluorouracil.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183704358>861</a></td><td>SLC22A16</td><td>rs6907567</td><td>doxorubicin</td><td>Breast Neoplasms</td><td>3</td><td>AG</td><td>Toxicity</td><td>Patients with the AG genotype may have decreased risk for neutropenia and a decreased likelihood of dose delay when treated with cyclophosphamide, doxorubicin and fluorouracil, as compared to patients with AA genotypes. Other genetic and clinical factors may also influence risk for dose delay and toxicity in patients taking cyclophosphamide, doxorubicin and fluorouracil.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183704358>862</a></td><td>SLC22A16</td><td>rs6907567</td><td>fluorouracil</td><td>Breast Neoplasms</td><td>3</td><td>AG</td><td>Toxicity</td><td>Patients with the AG genotype may have decreased risk for neutropenia and a decreased likelihood of dose delay when treated with cyclophosphamide, doxorubicin and fluorouracil, as compared to patients with AA genotypes. Other genetic and clinical factors may also influence risk for dose delay and toxicity in patients taking cyclophosphamide, doxorubicin and fluorouracil.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451637200>863</a></td><td>SEPTIN3</td><td>rs739296</td><td>hydrocodone</td><td>adverse events</td><td>3</td><td>AG</td><td>Toxicity</td><td>Patients with the rs739296 AG genotype may be at a decreased risk of experiencing adverse events when treated with hydrocodone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of adverse events when treated with hydrocodone.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451637200>864</a></td><td>WBP2NL</td><td>rs739296</td><td>hydrocodone</td><td>adverse events</td><td>3</td><td>AG</td><td>Toxicity</td><td>Patients with the rs739296 AG genotype may be at a decreased risk of experiencing adverse events when treated with hydrocodone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of adverse events when treated with hydrocodone.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1185000205>865</a></td><td>CYP3A5</td><td>rs776746</td><td>tacrolimus</td><td>Neurotoxicity Syndromes</td><td>4</td><td>CC</td><td>Toxicity</td><td>Patients with the CC genotype (CYP3A5 *3/*3) undergoing organ transplantation may have a decreased risk for neurotoxicity when treated with tacrolimus as compared to patients with the CT (*1/*3) genotype. Other genetic and clinical factors may also influence risk for neurotoxicity in patients receiving tacrolimus.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444700830>866</a></td><td>PTGER2</td><td>rs1353411</td><td>aspirin</td><td>Asthma</td><td>3</td><td>AG</td><td>Toxicity</td><td>Patients with the AG genotype and asthma may have a decreased, but not absent, risk for aspirin-intolerant asthma when exposed to aspirin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1445401008>867</a></td><td>CACNA1S</td><td>rs1800559</td><td>desflurane</td><td>Malignant Hyperthermia</td><td>1A</td><td>CC</td><td>Toxicity</td><td>Patients with the rs1800559 CC genotype may have a decreased, but not absent, risk for malignant hyperthermia when treated with desflurane as compared to patients with the TT genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451637183>868</a></td><td>SEPTIN3</td><td>rs739296</td><td>codeine</td><td>adverse events</td><td>3</td><td>AG</td><td>Toxicity</td><td>Patients with the rs739296 AG genotype may be at a decreased risk of experiencing adverse events when treated with codeine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of adverse events when treated with codeine.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451637183>869</a></td><td>WBP2NL</td><td>rs739296</td><td>codeine</td><td>adverse events</td><td>3</td><td>AG</td><td>Toxicity</td><td>Patients with the rs739296 AG genotype may be at a decreased risk of experiencing adverse events when treated with codeine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of adverse events when treated with codeine.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451637220>870</a></td><td>SEPTIN3</td><td>rs739296</td><td>oxycodone</td><td>adverse events</td><td>3</td><td>AG</td><td>Toxicity</td><td>Patients with the rs739296 AG genotype may be at a decreased risk of experiencing adverse events when treated with codeine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of adverse events when treated with codeine.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451637220>871</a></td><td>WBP2NL</td><td>rs739296</td><td>oxycodone</td><td>adverse events</td><td>3</td><td>AG</td><td>Toxicity</td><td>Patients with the rs739296 AG genotype may be at a decreased risk of experiencing adverse events when treated with codeine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of adverse events when treated with codeine.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451637280>872</a></td><td>SEPTIN3</td><td>rs739296</td><td>tramadol</td><td>adverse events</td><td>3</td><td>AG</td><td>Toxicity</td><td>Patients with the rs739296 AG genotype may be at a decreased risk of experiencing adverse events when treated with tramadol as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of adverse events when treated with tramadol.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451637280>873</a></td><td>WBP2NL</td><td>rs739296</td><td>tramadol</td><td>adverse events</td><td>3</td><td>AG</td><td>Toxicity</td><td>Patients with the rs739296 AG genotype may be at a decreased risk of experiencing adverse events when treated with tramadol as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of adverse events when treated with tramadol.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451476360>874</a></td><td>ERCC1</td><td>rs11615</td><td>cisplatin</td><td>mucositis;Osteosarcoma</td><td>3</td><td>AA</td><td>Toxicity</td><td>Patients with osteosarcoma and the rs11615 AA genotype may have a decreased risk of developing mucositis when treated with cisplatin and doxorubicin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of developing mucositis when treated with cisplatin and doxorubicin.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451476360>875</a></td><td>ERCC1</td><td>rs11615</td><td>doxorubicin</td><td>mucositis;Osteosarcoma</td><td>3</td><td>AA</td><td>Toxicity</td><td>Patients with osteosarcoma and the rs11615 AA genotype may have a decreased risk of developing mucositis when treated with cisplatin and doxorubicin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of developing mucositis when treated with cisplatin and doxorubicin.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444680131>876</a></td><td>HOMER1</td><td>rs4704559</td><td>levodopa</td><td>Parkinson Disease</td><td>3</td><td>AG</td><td>Toxicity</td><td>Patients with the AG genotype and Parkinson's disease may have a decreased risk for adverse reactions, including hallucinations and dyskinesia, when treated with levodopa as compared to patients with the AA genotype. Other genetic and clinical factors may also influence adverse effects in patients taking levodopa.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444704032>877</a></td><td>PTGES</td><td>rs2302821</td><td>celecoxib</td><td>Colorectal Neoplasms</td><td>3</td><td>AA</td><td>Toxicity</td><td>Patients with the AA genotype and Colorectal Neoplasms who are treated with celecoxib may have decreased, but not absent, risk for cardiovascular toxicity and symptoms as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to celecoxib.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451476520>878</a></td><td>CYBA</td><td>rs4673</td><td>cisplatin</td><td>Anemia;mucositis;Osteosarcoma</td><td>3</td><td>AG</td><td>Toxicity</td><td>Patients with osteosarcoma and the rs4673 AG genotype may be at a decreased risk of experiencing side effects when treated with cisplatin and doxorubicin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of experiencing side effects when treated with cisplating and doxorubicin.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451476520>879</a></td><td>CYBA</td><td>rs4673</td><td>doxorubicin</td><td>Anemia;mucositis;Osteosarcoma</td><td>3</td><td>AG</td><td>Toxicity</td><td>Patients with osteosarcoma and the rs4673 AG genotype may be at a decreased risk of experiencing side effects when treated with cisplatin and doxorubicin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of experiencing side effects when treated with cisplating and doxorubicin.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1446897533>880</a></td><td>TNFRSF11B</td><td>rs2073618</td><td>anastrozole</td><td>Breast Neoplasms</td><td>3</td><td>CG</td><td>Toxicity</td><td>Patients with breast cancer and the CG genotype may have a decreased likelihood of aromatase inhibitor-associated musculoskeletal syndrome, metabolic bone disease, or osteoporosis when treated with anastrozole or letrozole as compared to CC genotypes. Other clinical and genetic factors may also affect risk of musculoskeletal syndromes and bone diseases in patients who are taking anastrozole or letrozole.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1446897533>881</a></td><td>TNFRSF11B</td><td>rs2073618</td><td>letrozole</td><td>Breast Neoplasms</td><td>3</td><td>CG</td><td>Toxicity</td><td>Patients with breast cancer and the CG genotype may have a decreased likelihood of aromatase inhibitor-associated musculoskeletal syndrome, metabolic bone disease, or osteoporosis when treated with anastrozole or letrozole as compared to CC genotypes. Other clinical and genetic factors may also affect risk of musculoskeletal syndromes and bone diseases in patients who are taking anastrozole or letrozole.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1446899949>882</a></td><td>ATP7B</td><td>rs1061472</td><td>carboplatin</td><td>Ovarian Neoplasms</td><td>3</td><td>CT</td><td>Toxicity</td><td>Women with ovarian cancer and the CT genotype may have a decreased likelihood of gastrointestinal toxicity when exposed to carboplatin and taxanes, as compared to women with the TT genotype. Other clinical and genetic factors may also influence the likelihood of gastrointestinal toxicity in women with ovarian cancer who are administered carboplatin and taxanes.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1446899949>883</a></td><td>ATP7B</td><td>rs1061472</td><td>taxanes</td><td>Ovarian Neoplasms</td><td>3</td><td>CT</td><td>Toxicity</td><td>Women with ovarian cancer and the CT genotype may have a decreased likelihood of gastrointestinal toxicity when exposed to carboplatin and taxanes, as compared to women with the TT genotype. Other clinical and genetic factors may also influence the likelihood of gastrointestinal toxicity in women with ovarian cancer who are administered carboplatin and taxanes.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444608238>884</a></td><td>DRD1</td><td>rs4532</td><td>dextroamphetamine</td><td>Attention Deficit Disorder with Hyperactivity</td><td>3</td><td>CT</td><td>Toxicity</td><td>Patients with the CT genotype and attention deficit hyperactivity disorder (ADHD) may have a decreased severity of social withdrawal or nausea when treated with methylphenidate or dextroamphetamine, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence social withdrawal or nausea in patients receiving methylphenidate or dextroamphetamine.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444608238>885</a></td><td>DRD1</td><td>rs4532</td><td>methylphenidate</td><td>Attention Deficit Disorder with Hyperactivity</td><td>3</td><td>CT</td><td>Toxicity</td><td>Patients with the CT genotype and attention deficit hyperactivity disorder (ADHD) may have a decreased severity of social withdrawal or nausea when treated with methylphenidate or dextroamphetamine, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence social withdrawal or nausea in patients receiving methylphenidate or dextroamphetamine.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444703951>886</a></td><td>-</td><td>rs495828</td><td>enalapril</td><td>Hypertension</td><td>3</td><td>GG</td><td>Toxicity</td><td>Patients with the GG genotype and Hypertension who are treated with enalapril may have decreased, but not absent, risk for Cough as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to enalapril.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444704795>887</a></td><td>COL26A1</td><td>rs10279545</td><td>aspirin</td><td></td><td>3</td><td>CC</td><td>Toxicity</td><td>Patients with the CC genotype may have decreased, but not absent, risk for asthma as compared to patients with the TT gneotype. Other genetic and clinical factors may also influence a patient's response to aspirin.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444706890>888</a></td><td>DRD2</td><td>rs4436578</td><td>clozapine</td><td>Schizophrenia</td><td>3</td><td>TT</td><td>Toxicity</td><td>Patients with the TT genotype and Schizophrenia may have decreased risk for body weight gain when treated with clozapine, olanzapine or risperidone as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to clozapine, olanzapine or risperidone.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444706890>889</a></td><td>DRD2</td><td>rs4436578</td><td>olanzapine</td><td>Schizophrenia</td><td>3</td><td>TT</td><td>Toxicity</td><td>Patients with the TT genotype and Schizophrenia may have decreased risk for body weight gain when treated with clozapine, olanzapine or risperidone as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to clozapine, olanzapine or risperidone.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444706890>890</a></td><td>DRD2</td><td>rs4436578</td><td>risperidone</td><td>Schizophrenia</td><td>3</td><td>TT</td><td>Toxicity</td><td>Patients with the TT genotype and Schizophrenia may have decreased risk for body weight gain when treated with clozapine, olanzapine or risperidone as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to clozapine, olanzapine or risperidone.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1445401420>891</a></td><td>UGT1A</td><td>rs11563250</td><td>irinotecan</td><td>Colorectal Neoplasms</td><td>3</td><td>AG</td><td>Toxicity</td><td>Patients with the AG genotype and metastatic colorectal cancer may have a decreased risk of neutropenia when treated with irinotecan as compared to patients with the AA genotype. Other genetic and clinical factors, such as rs8175347, may also influence risk for neutropenia.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451504300>892</a></td><td>BCHE</td><td>rs568724445</td><td>succinylcholine</td><td>Apnea</td><td>3</td><td>CC</td><td>Toxicity</td><td>Patients with the rs568724445 CC genotype may be at a decreased risk of experiencing apnea following administration of succinylcholine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of experiencing apnea following administration of succinylcholine.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1446908002>893</a></td><td>CYP2B6</td><td>rs4802101</td><td>cyclophosphamide</td><td>Lupus erythematosus</td><td>3</td><td>CC</td><td>Toxicity</td><td>Patients with the CC genotype may have decreased metabolism of cyclophosphamide, resulting in decreased concentrations of active cyclophosphamide metabolites, and decreased risk of gastrointestinal toxicity, or leukopenia, as compared to patients with the CT or TT genotypes. Other clinical and genetic factors may also influence metabolism of cyclophosphamide, as well as risk of toxicity in patients with lupus.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444700639>894</a></td><td>PTGIR</td><td>rs1126510</td><td>aspirin</td><td>Asthma</td><td>3</td><td>AG</td><td>Toxicity</td><td>Patients with the AG genotype and asthma may have decreased, but not absent, risk of aspirin-intolerant asthma when exposed to aspirin as compared to patients with the AA genotype. Other genetic and clinical factors may also effect patients' response to aspirin.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1446906335>895</a></td><td>GRIA3</td><td>rs4825476</td><td>citalopram</td><td>Depression;suicide</td><td>3</td><td>AA</td><td>Toxicity</td><td>Patients with the AA genotype may have decreased risk of treatment-emergent suicidal ideation when treated with citalopram in people with depression as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to citalopram.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447813873>896</a></td><td>ESR1</td><td>rs4870061</td><td>letrozole</td><td>Breast Neoplasms</td><td>3</td><td>CT</td><td>Toxicity</td><td>Women with the CT genotype and breast neoplasms may have less bone mineral loss when taking letrozole as compared to women with the TT genotype. Other genetic and clinical factors may also influence a patient's response to letrozole.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447814397>897</a></td><td>ESR1</td><td>rs9322335</td><td>exemestane</td><td>Breast Neoplasms</td><td>3</td><td>CT</td><td>Toxicity</td><td>Patients with the CT genotype and Breast Neoplasms may be at decreased risk for bone mineral density loss when treated with letrozole and/or exemestane as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk for bone mineral density loss.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447814397>898</a></td><td>ESR1</td><td>rs9322335</td><td>letrozole</td><td>Breast Neoplasms</td><td>3</td><td>CT</td><td>Toxicity</td><td>Patients with the CT genotype and Breast Neoplasms may be at decreased risk for bone mineral density loss when treated with letrozole and/or exemestane as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk for bone mineral density loss.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1446897166>899</a></td><td>IL1B</td><td>rs16944</td><td>antipsychotics</td><td>Schizophrenia</td><td>3</td><td>GG</td><td>Toxicity</td><td>Patients with the GG genotype and schizophrenia may have lower weight gain when treated with antipsychotics as compared to patients with the AG genotype. Other genetic and clinical factors may also influence weight gain in patients taking antipsychotics.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1446897184>900</a></td><td>IL1B</td><td>rs4849127</td><td>antipsychotics</td><td>Schizophrenia</td><td>3</td><td>GG</td><td>Toxicity</td><td>Patients with the GG genotype and schizophrenia may have lower weight gain when treated with antipsychotics as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence weight gain in patients taking antipsychotics.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447673759>901</a></td><td>RYR1</td><td>rs118192178</td><td>desflurane</td><td>Malignant Hyperthermia</td><td>1A</td><td>CC</td><td>Toxicity</td><td>Patients with the rs118192178 CC genotype may have a decreased, but not absent, risk for malignant hyperthermia based on this variant when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and/or succinylcholine as compared to patients with the CT, CG, GG or TT genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447673759>902</a></td><td>RYR1</td><td>rs118192178</td><td>enflurane</td><td>Malignant Hyperthermia</td><td>1A</td><td>CC</td><td>Toxicity</td><td>Patients with the rs118192178 CC genotype may have a decreased, but not absent, risk for malignant hyperthermia based on this variant when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and/or succinylcholine as compared to patients with the CT, CG, GG or TT genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447673759>903</a></td><td>RYR1</td><td>rs118192178</td><td>halothane</td><td>Malignant Hyperthermia</td><td>1A</td><td>CC</td><td>Toxicity</td><td>Patients with the rs118192178 CC genotype may have a decreased, but not absent, risk for malignant hyperthermia based on this variant when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and/or succinylcholine as compared to patients with the CT, CG, GG or TT genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447673759>904</a></td><td>RYR1</td><td>rs118192178</td><td>isoflurane</td><td>Malignant Hyperthermia</td><td>1A</td><td>CC</td><td>Toxicity</td><td>Patients with the rs118192178 CC genotype may have a decreased, but not absent, risk for malignant hyperthermia based on this variant when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and/or succinylcholine as compared to patients with the CT, CG, GG or TT genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447673759>905</a></td><td>RYR1</td><td>rs118192178</td><td>methoxyflurane</td><td>Malignant Hyperthermia</td><td>1A</td><td>CC</td><td>Toxicity</td><td>Patients with the rs118192178 CC genotype may have a decreased, but not absent, risk for malignant hyperthermia based on this variant when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and/or succinylcholine as compared to patients with the CT, CG, GG or TT genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447673759>906</a></td><td>RYR1</td><td>rs118192178</td><td>sevoflurane</td><td>Malignant Hyperthermia</td><td>1A</td><td>CC</td><td>Toxicity</td><td>Patients with the rs118192178 CC genotype may have a decreased, but not absent, risk for malignant hyperthermia based on this variant when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and/or succinylcholine as compared to patients with the CT, CG, GG or TT genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447673759>907</a></td><td>RYR1</td><td>rs118192178</td><td>succinylcholine</td><td>Malignant Hyperthermia</td><td>1A</td><td>CC</td><td>Toxicity</td><td>Patients with the rs118192178 CC genotype may have a decreased, but not absent, risk for malignant hyperthermia based on this variant when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and/or succinylcholine as compared to patients with the CT, CG, GG or TT genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447673778>908</a></td><td>RYR1</td><td>rs193922818</td><td>desflurane</td><td>Malignant Hyperthermia</td><td>1A</td><td>GG</td><td>Toxicity</td><td>Patients with the rs193922818 GG genotype may have a decreased, but not absent, risk for malignant hyperthermia based on this variant when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and/or succinylcholine as compared to patients with AG or AA genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447673778>909</a></td><td>RYR1</td><td>rs193922818</td><td>enflurane</td><td>Malignant Hyperthermia</td><td>1A</td><td>GG</td><td>Toxicity</td><td>Patients with the rs193922818 GG genotype may have a decreased, but not absent, risk for malignant hyperthermia based on this variant when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and/or succinylcholine as compared to patients with AG or AA genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447673778>910</a></td><td>RYR1</td><td>rs193922818</td><td>halothane</td><td>Malignant Hyperthermia</td><td>1A</td><td>GG</td><td>Toxicity</td><td>Patients with the rs193922818 GG genotype may have a decreased, but not absent, risk for malignant hyperthermia based on this variant when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and/or succinylcholine as compared to patients with AG or AA genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447673778>911</a></td><td>RYR1</td><td>rs193922818</td><td>isoflurane</td><td>Malignant Hyperthermia</td><td>1A</td><td>GG</td><td>Toxicity</td><td>Patients with the rs193922818 GG genotype may have a decreased, but not absent, risk for malignant hyperthermia based on this variant when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and/or succinylcholine as compared to patients with AG or AA genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447673778>912</a></td><td>RYR1</td><td>rs193922818</td><td>methoxyflurane</td><td>Malignant Hyperthermia</td><td>1A</td><td>GG</td><td>Toxicity</td><td>Patients with the rs193922818 GG genotype may have a decreased, but not absent, risk for malignant hyperthermia based on this variant when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and/or succinylcholine as compared to patients with AG or AA genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447673778>913</a></td><td>RYR1</td><td>rs193922818</td><td>sevoflurane</td><td>Malignant Hyperthermia</td><td>1A</td><td>GG</td><td>Toxicity</td><td>Patients with the rs193922818 GG genotype may have a decreased, but not absent, risk for malignant hyperthermia based on this variant when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and/or succinylcholine as compared to patients with AG or AA genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447673778>914</a></td><td>RYR1</td><td>rs193922818</td><td>succinylcholine</td><td>Malignant Hyperthermia</td><td>1A</td><td>GG</td><td>Toxicity</td><td>Patients with the rs193922818 GG genotype may have a decreased, but not absent, risk for malignant hyperthermia based on this variant when treated with volatile anesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane) and/or succinylcholine as compared to patients with AG or AA genotype. Other genetic or clinical factors may also influence the risk for malignant hyperthermia.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444686789>915</a></td><td>CYP2B6</td><td>rs3745274</td><td>imatinib</td><td>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</td><td>3</td><td>GT</td><td>Toxicity</td><td>Patients with the GT genotype and chronic myeloid leukemia may have a 1) a better response to treatment with imatinib as compared to patients with the TT genotype, 2) a decreased risk of developing cytogenetic resistance to imatinib as compared to patients with the GG or TT genotype, and 3) a decreased risk for side effects as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response, resistance and risk of side effects in patients taking imatinib.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1445401281>916</a></td><td>ABCC4</td><td>rs7317112</td><td>methotrexate</td><td>Precursor Cell Lymphoblastic Leukemia-Lymphoma</td><td>3</td><td>AG</td><td>Toxicity</td><td>Patients with the AG genotype and acute lymphoblastic leukemia may have a decreased risk for mucositis when treated with methotrexate as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of mucositis.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448602871>917</a></td><td>CES1</td><td>rs2244613</td><td>capecitabine</td><td>Drug Toxicity</td><td>3</td><td>TT</td><td>Toxicity</td><td>Patients with the TT genotype may have decreased risk of overall capecitabine-related toxicity in cancer patients as compared to patients with the GG genotype. Other genetic and clinical factors may also influence the toxicity to capecitabine.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448602883>918</a></td><td>CES1P1</td><td>rs7187684</td><td>capecitabine</td><td>Drug Toxicity</td><td>3</td><td>CC</td><td>Toxicity</td><td>Patients with the CC genotype may have decreased risk of overall capecitabine-related toxicity in cancer patients as compared to patients with the TT genotype. Other genetic and clinical factors may also influence the toxicity to capecitabine.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1446897191>919</a></td><td>BDNF</td><td>rs6265</td><td>antipsychotics</td><td>Schizophrenia</td><td>3</td><td>CT</td><td>Toxicity</td><td>Patients with the CT genotype and schizophrenia may have lower weight gain when treated with antipsychotics as compared to patients with the CC genotype. Other genetic and clinical factors may also influence weight gain in patients taking antipsychotics.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1446897696>920</a></td><td>ABCB1</td><td>rs2032582</td><td>sunitinib</td><td>Carcinoma, Renal Cell;Neutropenia</td><td>3</td><td>AC</td><td>Toxicity</td><td>Patients with renal cell carcinoma and the AC genotypes may have a decreased risk of adverse events, including hand-foot syndrome, hypertension, or neutropenia when treated with sunitinib as compared to patients with the CC genotype. Other clinical and genetic factors may also influence risk of adverse events in patients with renal cell carcinoma who are treated with sunitinib.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451638961>921</a></td><td>ABCB1</td><td>rs1128503</td><td>paclitaxel</td><td>Breast Neoplasms;Peripheral Nervous System Diseases</td><td>3</td><td>AG</td><td>Toxicity</td><td>Patients with the rs1128503 AG genotype may have decreased severity of peripheral neuropathy when treated with paclitaxel as compared to patients with the AA genotype. Other genetic and clinical factors may also influence severity of peripheral neuropathy when treated with paclitaxel.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444703668>922</a></td><td>-</td><td>rs642990</td><td>gemcitabine</td><td></td><td>3</td><td>CT</td><td>Toxicity</td><td>Patients with the CT genotype may have decreased risk for neutropenia when treated with gemcitabine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to gemcitabine.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448604316>923</a></td><td>C3</td><td>rs2277984</td><td>clozapine</td><td>Metabolic Syndrome</td><td>3</td><td>TT</td><td>Toxicity</td><td>Patients with the TT genotype and schizophrenia may have decreased fasting triglyceride levels, that may reduce susceptibility to metabolic syndrome, when treated with clozapine as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence fasting triglyceride levels and metabolic syndrome.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444607373>924</a></td><td>E2F7</td><td>rs310786</td><td>tamoxifen</td><td>Breast Neoplasms</td><td>3</td><td>TT</td><td>Toxicity</td><td>Women with the TT genotype and breast cancer may have decreased lumbar bone loss when treated with tamoxifen as compared to women with the CC genotype. Other genetic and clinical factors may also influence lumbar bone loss in women taking tamoxifen.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184987048>925</a></td><td>ABCB1</td><td>rs10267099</td><td>atenolol</td><td>Hypertension</td><td>3</td><td>AA</td><td>Toxicity</td><td>Patients with genotype AA and hypertension may have a decreased risk of hypercholesteremia when administered atenolol as compared to patients with the AG and GG genotypes. Other clinical and genetic factors may also influence risk of hypercholesteremia upon administration of atenolol in patients with hypertension.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444700445>926</a></td><td>TRAF3IP2</td><td>rs76228616</td><td>nevirapine</td><td>HIV Infections</td><td>3</td><td>GG</td><td>Toxicity</td><td>Patients with the GG genotype may have decreased risk of developing Steven-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN) when treated with nevirapine as compared to patients with the CC or CG genotype. Other genetic and clinical factors may also influence the risk of toxicity to nevirapine.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444703107>927</a></td><td>ALG10</td><td>rs1705772</td><td>gemcitabine</td><td></td><td>3</td><td>AG</td><td>Toxicity</td><td>Patients with the AG genotype who are treated with gemcitabine may have a decreased, but not absent, risk for toxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444667912>928</a></td><td>SOD2</td><td>rs4880</td><td>valproic acid</td><td>Epilepsy</td><td>3</td><td>AA</td><td>Toxicity</td><td>Patients with genotype AA and epilepsy may have a decreased risk of drug toxicity when taking valproic acid as compared to patients with the GG genotype. Other clinical and genetic factors may also affect risk of drug toxicity when taking valproic acid.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184987008>929</a></td><td>GALNT2</td><td>rs2144297</td><td>atenolol</td><td>Hypertension</td><td>3</td><td>CT</td><td>Toxicity</td><td>Patients with genotype CT and hypertension may have a greater reduction in HDL-C when administered atenolol as compared to patients with genotype CC. Other clinical and genetic factors may also influence changes in HDL-C upon administration of atenolol in patients with hypertension.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184987041>930</a></td><td>ABCB1</td><td>rs3213619</td><td>atenolol</td><td>Hypertension</td><td>3</td><td>AA</td><td>Toxicity</td><td>Patients with the AA genotype and hypertension may have a decreased risk of hypercholesteremia when administered atenolol as compared to patients with the AG and GG genotypes. Other clinical and genetic factors may also influence risk of hypercholesteremia upon administration of atenolol in patients with hypertension.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1185000225>931</a></td><td>CYP3A5</td><td>rs776746</td><td>tacrolimus</td><td>Infection</td><td>3</td><td>CC</td><td>Toxicity</td><td>Patients with the CC genotype (CYP3A5 *3/*3) undergoing organ transplantation may have a decreased risk for infections when treated with tacrolimus as compared to patients with the CT or TT (*1/*3 or *1/*1) genotype. Other genetic and clinical factors may also influence risk for infections in patients receiving tacrolimus.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444704426>932</a></td><td>SLC28A1</td><td>rs2290271</td><td>anthracyclines and related substances</td><td></td><td>4</td><td>AC</td><td>Toxicity</td><td>Patients with genotype AC may have decreased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with genotype AA, although this is contradicted in one study. Other genetic and clinical factors may also influence the toxicity to anthracyclines.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444607704>933</a></td><td>UGT1A6</td><td>rs6759892</td><td>deferiprone</td><td>beta-Thalassemia</td><td>3</td><td>GT</td><td>Toxicity</td><td>Patients with the GT genotype and beta-thalassemia may have a worse response, but also a decreased risk for experiencing adverse drug reactions, when treated with deferiprone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response or risk for adverse events in patients receiving deferiprone.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444607775>934</a></td><td>DHFR</td><td>rs442767</td><td>pemetrexed</td><td>Carcinoma, Non-Small-Cell Lung</td><td>3</td><td>GT</td><td>Toxicity</td><td>Patients with the GT genotype and non-small-cell lung cancer may be at decreased risk for experiencing fatigue when treated with pemetrexed, as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for fatigue when receiving pemetrexed.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444666770>935</a></td><td>DHFR</td><td>rs1650697</td><td>pemetrexed</td><td>Carcinoma, Non-Small-Cell Lung;Mesothelioma</td><td>3</td><td>GG</td><td>Toxicity</td><td>Patients with the GG genotype and lung cancer may have a decreased risk for experiencing drug toxicity when treated with pemetrexed as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence risk for drug toxicity.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444667512>936</a></td><td>HLA-DPB1</td><td>rs1042136</td><td>aspirin</td><td>aspirin-induced asthma;Asthma</td><td>3</td><td>AA</td><td>Toxicity</td><td>Patients with asthma and the AA genotype may have a decreased risk of aspirin induced asthma as compared to people with the AC or CC genotype. Other genetic and clinical factors may also influence a patient's risk of asthma.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444704881>937</a></td><td>ABCB1</td><td>rs1045642</td><td>methylprednisolone</td><td>Kidney Transplantation</td><td>3</td><td>AA</td><td>Toxicity</td><td>Patients with the AA genotype and Kidney Transplantation may have decreased, but not absent, risk of Osteonecrosis when treated with methylprednisolone and prednisolone as compared to patients with the GG or GA genotype. Other genetic and clinical factors may also influence a patient's methylprednisolone and prednisolone.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444704881>938</a></td><td>ABCB1</td><td>rs1045642</td><td>prednisolone</td><td>Kidney Transplantation</td><td>3</td><td>AA</td><td>Toxicity</td><td>Patients with the AA genotype and Kidney Transplantation may have decreased, but not absent, risk of Osteonecrosis when treated with methylprednisolone and prednisolone as compared to patients with the GG or GA genotype. Other genetic and clinical factors may also influence a patient's methylprednisolone and prednisolone.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444608189>939</a></td><td>ENOSF1</td><td>rs2612091</td><td>capecitabine</td><td>Neoplasms</td><td>3</td><td>TT</td><td>Toxicity</td><td>Patients with the TT genotype and cancer may have a decreased risk for experiencing drug toxicity, particularly hand-foot syndrome, when treated with capecitabine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for experiencing drug toxicity when treated with capecitabine.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444608201>940</a></td><td>ENOSF1</td><td>rs2741171</td><td>capecitabine</td><td>Colorectal Neoplasms</td><td>3</td><td>CC</td><td>Toxicity</td><td>Patients with the CC genotype and colorectal cancer may have a decreased risk for experiencing drug toxicity, particularly hand-foot syndrome, when treated with capecitabine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk for experiencing drug toxicity when treated with capecitabine.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444608231>941</a></td><td>GRIN1</td><td>rs1126442</td><td>methamphetamine</td><td>Psychotic Disorders</td><td>3</td><td>AG</td><td>Toxicity</td><td>Individuals with the AG genotype who are addicted to methamphetamine may be less likely to experience psychosis when taking methamphetamine, as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for psychosis when taking methamphetamine.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444667432>942</a></td><td>CHIA</td><td>rs3818822</td><td>aspirin</td><td>aspirin-induced asthma</td><td>3</td><td>GG</td><td>Toxicity</td><td>Patients with asthma and the GG genotype may have a decreased risk of aspirin induced asthma as compared to people with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's risk of asthma.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1446899708>943</a></td><td>KCNIP4</td><td>rs6838116</td><td>Ace Inhibitors, Plain</td><td></td><td>3</td><td>CC</td><td>Toxicity</td><td>Patients with the CC genotype may be less likely to experience ACE inhibitor induced cough when taking ACE inhibitors as compared to patients with the AC and AA genotype. Other clinical and genetic factors may also influence likelihood of ACE inhibitor induced cough in patients who are taking ACE inhibitors.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1446899729>944</a></td><td>KCNIP4</td><td>rs145489027</td><td>Ace Inhibitors, Plain</td><td></td><td>3</td><td>GG</td><td>Toxicity</td><td>Patients with the GG genotype may be less likely to experience ACE inhibitor induced cough when taking ACE inhibitors as compared to patients with the AG and AA genotype, although this is contradicted in one study. Other clinical and genetic factors may also influence likelihood of ACE inhibitor induced cough in patients who are taking ACE inhibitors.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1446899890>945</a></td><td>GSR</td><td>rs3594</td><td>carboplatin</td><td>Ovarian Neoplasms</td><td>3</td><td>AC</td><td>Toxicity</td><td>Women with ovarian cancer and the AC genotype may have a decreased likelihood of gastrointestinal toxicity when exposed to carboplatin and taxanes, such as paclitaxel and docetaxel, as compared to women with the CC genotype. Other clinical and genetic factors may also influence likelihood of gastrointestinal toxicity in women with ovarian cancer who are administered carboplatin and taxanes.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1446899890>946</a></td><td>GSR</td><td>rs3594</td><td>taxanes</td><td>Ovarian Neoplasms</td><td>3</td><td>AC</td><td>Toxicity</td><td>Women with ovarian cancer and the AC genotype may have a decreased likelihood of gastrointestinal toxicity when exposed to carboplatin and taxanes, such as paclitaxel and docetaxel, as compared to women with the CC genotype. Other clinical and genetic factors may also influence likelihood of gastrointestinal toxicity in women with ovarian cancer who are administered carboplatin and taxanes.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1446899905>947</a></td><td>ATP7B</td><td>rs1801249</td><td>carboplatin</td><td>Ovarian Neoplasms</td><td>3</td><td>GG</td><td>Toxicity</td><td>Women with ovarian cancer and the GG genotype may have a decreased likelihood of gastrointestinal toxicity when exposed to carboplatin and taxanes, such as paclitaxel and docetaxel, as compared to women with the AA genotype. Other clinical and genetic factors may also influence likelihood of gastrointestinal toxicity in women with ovarian cancer who are administered carboplatin and taxanes.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1446899905>948</a></td><td>ATP7B</td><td>rs1801249</td><td>taxanes</td><td>Ovarian Neoplasms</td><td>3</td><td>GG</td><td>Toxicity</td><td>Women with ovarian cancer and the GG genotype may have a decreased likelihood of gastrointestinal toxicity when exposed to carboplatin and taxanes, such as paclitaxel and docetaxel, as compared to women with the AA genotype. Other clinical and genetic factors may also influence likelihood of gastrointestinal toxicity in women with ovarian cancer who are administered carboplatin and taxanes.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444607789>949</a></td><td>HTR3B</td><td>rs1176744</td><td>paroxetine</td><td>Mental Disorders</td><td>4</td><td>AC</td><td>Toxicity</td><td>Patients with the AC genotype and Mental Disorders who are treated with paroxetine may have a decreased risk of nausea as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to paroxetine.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444694616>950</a></td><td>ABCB1</td><td>rs1045642</td><td>tacrolimus</td><td>Kidney Transplantation</td><td>3</td><td>AA</td><td>Toxicity</td><td>Patients with the AA genotype who are undergoing kidney transplantation may have a decreased risk of hypokalemia when treated with tacrolimus as compared to patients with the AG genotype. Other genetic and clinical factors may also influence risk of hypokalemia.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444694609>951</a></td><td>ABCB1</td><td>rs1045642</td><td>tacrolimus</td><td>Kidney Transplantation</td><td>4</td><td>AA</td><td>Toxicity</td><td>Patients with the AA genotype who are undergoing kidney transplantation and are treated with tacrolimus may have decreased risk of experiencing transplant rejection as compared to patients with the AG genotype. However, the majority of studies find no association between this polymorphism and risk for transplant rejection. Other genetic and clinical factors may also influence risk of transplant rejection.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1445401406>952</a></td><td>ABCB1</td><td>rs1045642</td><td>sunitinib</td><td>Carcinoma, Renal Cell</td><td>3</td><td>AA</td><td>Toxicity</td><td>Patients with the AA genotype and renal cell carcinoma may have a lower risk for adverse effects when treated with sunitinib as compared to patients with the GG genotype. One study found no association between this SNP and thrombocytopenia, neutropenia, anemia or hand-food syndrome. Other genetic and clinical factors may also influence risk for sunitinib toxicities.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1446908587>953</a></td><td>-</td><td>rs2292997</td><td>fluorouracil</td><td>Colorectal Neoplasms</td><td>3</td><td>GG</td><td>Toxicity</td><td>Patients with the GG genotype and Colorectal Neoplasms who are treated with fluorouracil, irinotecan and leucovorin may have a decreased, but not absent, risk for Neutropenia as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's risk for Neutropenia.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1446908587>954</a></td><td>-</td><td>rs2292997</td><td>irinotecan</td><td>Colorectal Neoplasms</td><td>3</td><td>GG</td><td>Toxicity</td><td>Patients with the GG genotype and Colorectal Neoplasms who are treated with fluorouracil, irinotecan and leucovorin may have a decreased, but not absent, risk for Neutropenia as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's risk for Neutropenia.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1446908587>955</a></td><td>-</td><td>rs2292997</td><td>leucovorin</td><td>Colorectal Neoplasms</td><td>3</td><td>GG</td><td>Toxicity</td><td>Patients with the GG genotype and Colorectal Neoplasms who are treated with fluorouracil, irinotecan and leucovorin may have a decreased, but not absent, risk for Neutropenia as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's risk for Neutropenia.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444700916>956</a></td><td>THBD</td><td>rs1042580</td><td>warfarin</td><td></td><td>3</td><td>CT</td><td>Toxicity</td><td>Patients with the CT genotype may have decreased risk of Hemorrhage in patients with mechanical cardiac valves treated with warfarin as compared to patients with genotype TT. Other genetic or clinical factors may also influence the risk of toxicity to warfarin.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444700970>957</a></td><td>PRKCE</td><td>rs11125035</td><td>radiotherapy</td><td></td><td>3</td><td>AT</td><td>Toxicity</td><td>Patients with the AT genotype may have decreased risk of Esophagitis when treated with radiotherapy as compared to patients with genotype AA. Other genetic or clinical factors may also influence the risk of toxicity to radiotherapy.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1445401824>958</a></td><td>CYP2C8</td><td>rs1113129</td><td>paclitaxel</td><td>Breast Neoplasms</td><td>3</td><td>CC</td><td>Toxicity</td><td>Patients with the CC genotype and breast cancer may have a decreased risk for anemia when treated with paclitaxel as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence risk for anemia.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1446900938>959</a></td><td>DHFR</td><td>rs408626</td><td>methotrexate</td><td>Precursor Cell Lymphoblastic Leukemia-Lymphoma</td><td>3</td><td>CC</td><td>Toxicity</td><td>Patients with acute lymphoblastic leukemia and the CC genotype may have a decreased risk of leukopenia, as compared to patients with the TT genotypes, but may also experience decreased rates of event-free survival, and overall survival rates as compared to patients with the TT genotypes. Other clinical and genetic factors may also affect risk of leukopenia, as well as event-free survival, and overall survival rates in patients with acute lymphoblastic leukemia.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1446901291>960</a></td><td>CXCL8</td><td>rs1126647</td><td>sunitinib</td><td>Carcinoma, Renal Cell</td><td>3</td><td>AT</td><td>Toxicity</td><td>Patients with renal cell carcinoma and the AT genotype may have a decreased likelihood of hypertension when taking sunitinib as compared to patients with the TT genotype. Other clinical and genetic factors may also affect likelihood of hypertension in renal cell carcinoma patients who are treated with sunitinib.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1185000213>961</a></td><td>CYP3A5</td><td>rs776746</td><td>tacrolimus</td><td>Hypertension</td><td>4</td><td>CC</td><td>Toxicity</td><td>Patients with the CC genotype (CYP3A5 *3/*3) undergoing kidney transplantation may have decreased systolic and diastolic blood pressure when treated with tacrolimus as compared to patients with the CT or TT (*1/*3 or *1/*1) genotype. However, the majority of studies show no association between the CC genotype and blood pressure. Other genetic and clinical factors may also influence changes in blood pressure in patients receiving tacrolimus.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1185000260>962</a></td><td>CYP3A5</td><td>rs776746</td><td>tacrolimus</td><td>Toxic liver disease</td><td>3</td><td>CC</td><td>Toxicity</td><td>Patients with the CC genotype (CYP3A5 *3/*3) undergoing liver transplantation who are treated with tacrolimus may have a decreased, but not absent, risk of experiencing calcineurin-inhibitor induced hepatic toxicity as compared to patients with the CT or TT genotype (*1/*3 or *1/*1). Other genetic and clinical factors may also influence a patient's risk for hepatic toxicity.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1185000350>963</a></td><td>UGT1A1</td><td>rs10929303</td><td>atazanavir</td><td>HIV Infections;nephrolithiasis</td><td>3</td><td>CC</td><td>Toxicity</td><td>Patients with the CC genotype and HIV may have a decreased risk of nephrolithiasis when treated with atazanavir and ritonavir as compared to patients with the CT and TT genotypes. Other genetic and clinical factors may also affect risk of nephrolithiasis in patients with HIV who are taking atazanavir and ritonavir.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1185000350>964</a></td><td>UGT1A1</td><td>rs10929303</td><td>ritonavir</td><td>HIV Infections;nephrolithiasis</td><td>3</td><td>CC</td><td>Toxicity</td><td>Patients with the CC genotype and HIV may have a decreased risk of nephrolithiasis when treated with atazanavir and ritonavir as compared to patients with the CT and TT genotypes. Other genetic and clinical factors may also affect risk of nephrolithiasis in patients with HIV who are taking atazanavir and ritonavir.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1185000362>965</a></td><td>UGT1A1</td><td>rs1042640</td><td>atazanavir</td><td>HIV Infections;nephrolithiasis</td><td>3</td><td>CC</td><td>Toxicity</td><td>Patients with the CC genotype and HIV may have a decreased risk of nephrolithiasis when treated with atazanavir and ritonavir as compared to patients with the CG and GG genotypes. Other genetic and clinical factors may also affect risk of nephrolithiasis in patients with HIV who are taking atazanavir and ritonavir.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1185000362>966</a></td><td>UGT1A1</td><td>rs1042640</td><td>ritonavir</td><td>HIV Infections;nephrolithiasis</td><td>3</td><td>CC</td><td>Toxicity</td><td>Patients with the CC genotype and HIV may have a decreased risk of nephrolithiasis when treated with atazanavir and ritonavir as compared to patients with the CG and GG genotypes. Other genetic and clinical factors may also affect risk of nephrolithiasis in patients with HIV who are taking atazanavir and ritonavir.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1185000369>967</a></td><td>UGT1A1</td><td>rs8330</td><td>atazanavir</td><td>HIV Infections;nephrolithiasis</td><td>3</td><td>CC</td><td>Toxicity</td><td>Patients with the CC genotype and HIV may have a decreased risk of nephrolithiasis when treated with atazanavir and ritonavir as compared to patients with the CG and GG genotypes. Other genetic and clinical factors may also affect risk of nephrolithiasis in patients with HIV who are taking atazanavir and ritonavir.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1185000369>968</a></td><td>UGT1A1</td><td>rs8330</td><td>ritonavir</td><td>HIV Infections;nephrolithiasis</td><td>3</td><td>CC</td><td>Toxicity</td><td>Patients with the CC genotype and HIV may have a decreased risk of nephrolithiasis when treated with atazanavir and ritonavir as compared to patients with the CG and GG genotypes. Other genetic and clinical factors may also affect risk of nephrolithiasis in patients with HIV who are taking atazanavir and ritonavir.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444700867>969</a></td><td>VDR</td><td>rs1544410</td><td>peginterferon alfa-2a</td><td>Hepatitis C</td><td>3</td><td>CT</td><td>Toxicity</td><td>Patients with the CT genotype and Hepatitis C may have a decreased, but not absent, risk for anemia when treated with peginterferon alfa-2a and ribavirin compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for anemia.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444700867>970</a></td><td>VDR</td><td>rs1544410</td><td>ribavirin</td><td>Hepatitis C</td><td>3</td><td>CT</td><td>Toxicity</td><td>Patients with the CT genotype and Hepatitis C may have a decreased, but not absent, risk for anemia when treated with peginterferon alfa-2a and ribavirin compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for anemia.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444704089>971</a></td><td>AQP2</td><td>rs296766</td><td>thiazolidinediones</td><td>Diabetes Mellitus, Type 2</td><td>3</td><td>CC</td><td>Toxicity</td><td>Patients with the CC genotype and Diabetes Mellitus, Type 2 who are treated with thiazolidinediones may have decreased, but not absent, risk for edema as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to thiazolidinediones.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1445401296>972</a></td><td>CAMK1D</td><td>rs10752271</td><td>losartan</td><td>Essential hypertension</td><td>3</td><td>AA</td><td>Toxicity</td><td>Patients with the AA genotype and hypertension may have a smaller decrease in blood pressure when treated with losartan as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence blood pressure.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1445401303>973</a></td><td>CAMK1D</td><td>rs10737062</td><td>losartan</td><td>Essential hypertension</td><td>3</td><td>AA</td><td>Toxicity</td><td>Patients with the AA genotype and hypertension may have a smaller decrease in blood pressure when treated with losartan as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence blood pressure.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448427005>974</a></td><td>ABCB1</td><td>rs1128503</td><td>gefitinib</td><td>Carcinoma, Non-Small-Cell Lung</td><td>3</td><td>AG</td><td>Toxicity</td><td>Patients with the AG genotype and non-small cell lung cancer may have a decreased risk for diarrhea and skin rash when treated with gefitinib as compared to patients with the AA genotype. Other genetic and clinical factors may also influence drug toxicity risk in patients receiving gefitinib.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448423703>975</a></td><td>FBXL19</td><td>rs10782001</td><td>Tumor necrosis factor alpha (TNF-alpha) inhibitors</td><td>Psoriasis</td><td>3</td><td>AA</td><td>Toxicity</td><td>Patients with the AA genotype and psoriasis may have a decreased risk for paradoxical psoriasiform reactions when treated with TNF-inhibitors as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for paradoxical psoriasiform reactions.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448532002>976</a></td><td>-</td><td>rs149104283</td><td>clozapine</td><td>Neutropenia</td><td>3</td><td>CC</td><td>Toxicity</td><td>Patients with the CC genotype may have decreased risk of clozapine-induced Neutropenia in people with Schizophrenia as compared to patients with genotype GG. Other genetic and clinical factors may also influence the toxicity to clozapine.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449565416>977</a></td><td>CYP2C9</td><td>rs544027339</td><td>phenytoin</td><td>Drug Toxicity</td><td>3</td><td>GG</td><td>Toxicity</td><td>Patients with the GG genotype may have a decreased risk of developing phenytoin toxicity as a result of phenytoin treatment as compared to patients with the GT and TT genotypes. This observation has only been seen in combination with rs1029359343 in a compound heterozygote patient. Other genetic and clinical factors may also affect a patient's risk of developing phenytoin toxicity.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451510621>978</a></td><td>ABCB1</td><td>rs1045642</td><td>rivaroxaban</td><td></td><td>3</td><td>AA</td><td>Toxicity</td><td>Patients with the rs1045642 AA genotype may have decreased risk of Thromboembolism when treated with rivaroxaban as compared to patients with genotype GG. Other genetic and clinical factors may also influence the toxicity to rivaroxaban.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451510641>979</a></td><td>ABCB1</td><td>rs4148738</td><td>apixaban</td><td></td><td>3</td><td>CT</td><td>Toxicity</td><td>Patients with the rs4148738 CT genotype may have decreased risk of bleeding when treated with apixaban as compared to patients with the CC genotype. Other genetic and clinical factors may also influence the toxicity to apixaban.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448632697>980</a></td><td>PNPLA3</td><td>rs738409</td><td>asparaginase</td><td>Precursor Cell Lymphoblastic Leukemia-Lymphoma</td><td>3</td><td>CC</td><td>Toxicity</td><td>Patients with the CC genotype may have decreased risk of hepatotoxicity when treated with remission induction therapy (including asparaginase) in children with acute lymphoblastic leukemia (ALL) as compared to patients with genotype GG or CG. Other genetic and clinical factors may also influence the risk of toxicity to remission induction therapy.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448632697>981</a></td><td>PNPLA3</td><td>rs738409</td><td>cyclophosphamide</td><td>Precursor Cell Lymphoblastic Leukemia-Lymphoma</td><td>3</td><td>CC</td><td>Toxicity</td><td>Patients with the CC genotype may have decreased risk of hepatotoxicity when treated with remission induction therapy (including asparaginase) in children with acute lymphoblastic leukemia (ALL) as compared to patients with genotype GG or CG. Other genetic and clinical factors may also influence the risk of toxicity to remission induction therapy.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448632697>982</a></td><td>PNPLA3</td><td>rs738409</td><td>daunorubicin</td><td>Precursor Cell Lymphoblastic Leukemia-Lymphoma</td><td>3</td><td>CC</td><td>Toxicity</td><td>Patients with the CC genotype may have decreased risk of hepatotoxicity when treated with remission induction therapy (including asparaginase) in children with acute lymphoblastic leukemia (ALL) as compared to patients with genotype GG or CG. Other genetic and clinical factors may also influence the risk of toxicity to remission induction therapy.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448632697>983</a></td><td>PNPLA3</td><td>rs738409</td><td>prednisolone</td><td>Precursor Cell Lymphoblastic Leukemia-Lymphoma</td><td>3</td><td>CC</td><td>Toxicity</td><td>Patients with the CC genotype may have decreased risk of hepatotoxicity when treated with remission induction therapy (including asparaginase) in children with acute lymphoblastic leukemia (ALL) as compared to patients with genotype GG or CG. Other genetic and clinical factors may also influence the risk of toxicity to remission induction therapy.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448632697>984</a></td><td>PNPLA3</td><td>rs738409</td><td>vincristine</td><td>Precursor Cell Lymphoblastic Leukemia-Lymphoma</td><td>3</td><td>CC</td><td>Toxicity</td><td>Patients with the CC genotype may have decreased risk of hepatotoxicity when treated with remission induction therapy (including asparaginase) in children with acute lymphoblastic leukemia (ALL) as compared to patients with genotype GG or CG. Other genetic and clinical factors may also influence the risk of toxicity to remission induction therapy.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447981289>985</a></td><td>UGT2B7</td><td>rs4292394</td><td>methadone</td><td>Opioid-Related Disorders</td><td>3</td><td>CG</td><td>Toxicity</td><td>Patients with the CG genotype who are undergoing methadone maintenance treatment may have decreased severity of opiate withdrawal symptoms as compared to patients with the GG genotype. Other genetic and clinical factors may also influence opiate withdrawal symptoms in patients receiving methadone.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447983050>986</a></td><td>EIF3A</td><td>rs7091672</td><td>Platinum compounds</td><td>Carcinoma, Non-Small-Cell Lung</td><td>3</td><td>CC</td><td>Toxicity</td><td>Patients with the CC genotype and non-small-cell lung carcinoma may have decreased risk of toxicities, including anemia, leukopenia, thrombocytopenia, toxic liver disease, and vomiting when treated with platinum compounds compared to patients with the TT genotype. Other genetic and clinical factors may affect risk of toxicities with platinum compound treatment.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447986967>987</a></td><td>PRKCB</td><td>rs11649514</td><td>atenolol</td><td>Hyperglycemia</td><td>3</td><td>GG</td><td>Toxicity</td><td>Patients with the GG genotype and essential hypertension who are administered atenolol may have a decreased likelihood of developing hyperglycemia as compared to patients with the GT or TT genotype. Other clinical and genetic factors also influence the likelihood that patients with essential hypertension will develop hyperglycemia.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450373755>988</a></td><td>SLC28A1</td><td>rs12148896</td><td>gemcitabine</td><td>Neutropenia;Pancreatic Neoplasms</td><td>3</td><td>AA</td><td>Toxicity</td><td>Patients with pancreatic cancer and the AA genotype may be at a decreased risk of developing neutropenia as a result of gemcitabine treatment as compared to patients with the GG genotype. Note that this variant is in high LD with rs3825876 (see clinical annotation 1450373761). Other genetic or clinical factors may also affect a patient's risk of developing neutropenia as a result of gemcitabine treatment.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448265174>989</a></td><td>LGALS3</td><td>rs11125</td><td>Antibiotics</td><td>Hypersensitivity</td><td>3</td><td>AA</td><td>Toxicity</td><td>Patients with the AA genotype may have a decreased, but not absent, risk for an immediate reaction to beta-lactam antibiotics as compared to patients with the AT or TT genotype. Other genetic and clinical factors may also influence risk for an immediate reaction to beta-lactam antibiotics.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449715919>990</a></td><td>ABCB1</td><td>rs2032582</td><td>fentanyl</td><td>Pain, Postoperative;Respiratory Insufficiency</td><td>3</td><td>AC</td><td>Toxicity</td><td>Patients with the AC genotype may have a decreased likelihood of experiencing respiratory depression as a result of fentanyl as compared to patients with the AA genotype. Other genetic and clinical factors may also affect the likelihood of a patient developing respiratory depression as a result of fentanyl.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449715928>991</a></td><td>ABCB1</td><td>rs1128503</td><td>fentanyl</td><td>Pain, Postoperative;Respiratory Insufficiency</td><td>3</td><td>AG</td><td>Toxicity</td><td>Patients with the AG genotype may have a decreased likelihood of experiencing respiratory depression as a result of fentanyl as compared to patients with the AA genotype. Other genetic and clinical factors may also affect the likelihood of a patient developing respiratory depression as a result of fentanyl.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448102306>992</a></td><td>CYBA</td><td>rs4673</td><td>doxorubicin</td><td>Neoplasms</td><td>3</td><td>AG</td><td>Toxicity</td><td>Cancer patients with the AG genotype may have a longer overall and event-free survival time as compared to patients with the AA genotype when treated with anthracyclines. Other genetic and clinical factors may also influence survival times.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448102306>993</a></td><td>CYBA</td><td>rs4673</td><td>idarubicin</td><td>Neoplasms</td><td>3</td><td>AG</td><td>Toxicity</td><td>Cancer patients with the AG genotype may have a longer overall and event-free survival time as compared to patients with the AA genotype when treated with anthracyclines. Other genetic and clinical factors may also influence survival times.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448103875>994</a></td><td>ESR1</td><td>rs2234693</td><td>methamphetamine</td><td>Psychotic Disorders</td><td>3</td><td>CT</td><td>Toxicity</td><td>Patients with the CT genotype and who are addicted to methamphetamines may have a decreased risk for methamphetamine-induced psychosis as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for methamphetamine-induced psychosis.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447981158>995</a></td><td>UGT2B7</td><td>rs6600879</td><td>methadone</td><td>Opioid-Related Disorders</td><td>3</td><td>CG</td><td>Toxicity</td><td>Patients with the CG genotype who are undergoing methadone maintenance treatment may have decreased severity of opiate withdrawal symptoms as compared to patients with the GG genotype. Other genetic and clinical factors may also influence opiate withdrawal symptoms in patients receiving methadone.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447981207>996</a></td><td>UGT2B7</td><td>rs6600880</td><td>methadone</td><td>Opioid-Related Disorders</td><td>3</td><td>AT</td><td>Toxicity</td><td>Patients with the AT genotype who are undergoing methadone maintenance treatment may have decreased severity of opiate withdrawal symptoms as compared to patients with the AA genotype. Other genetic and clinical factors may also influence opiate withdrawal symptoms in patients receiving methadone.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447981222>997</a></td><td>UGT2B7</td><td>rs4554144</td><td>methadone</td><td>Opioid-Related Disorders</td><td>3</td><td>CT</td><td>Toxicity</td><td>Patients with the CT genotype who are undergoing methadone maintenance treatment may have decreased severity of opiate withdrawal symptoms as compared to patients with the TT genotype. Other genetic and clinical factors may also influence opiate withdrawal symptoms in patients receiving methadone.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447981250>998</a></td><td>UGT2B7</td><td>rs11940316</td><td>methadone</td><td>Opioid-Related Disorders</td><td>3</td><td>CT</td><td>Toxicity</td><td>Patients with the CT genotype who are undergoing methadone maintenance treatment may have decreased severity of opiate withdrawal symptoms as compared to patients with the CC genotype. Other genetic and clinical factors may also influence opiate withdrawal symptoms in patients receiving methadone.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447981259>999</a></td><td>UGT2B7</td><td>rs7438135</td><td>methadone</td><td>Opioid-Related Disorders</td><td>3</td><td>AG</td><td>Toxicity</td><td>Patients with the AG genotype who are undergoing methadone maintenance treatment may have decreased severity of opiate withdrawal symptoms as compared to patients with the AA genotype. Other genetic and clinical factors may also influence opiate withdrawal symptoms in patients receiving methadone.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447981268>1000</a></td><td>UGT2B7</td><td>rs7662029</td><td>methadone</td><td>Opioid-Related Disorders</td><td>3</td><td>AG</td><td>Toxicity</td><td>Patients with the AG genotype who are undergoing methadone maintenance treatment may have decreased severity of opiate withdrawal symptoms as compared to patients with the GG genotype. Other genetic and clinical factors may also influence opiate withdrawal symptoms in patients receiving methadone.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448099430>1001</a></td><td>-</td><td>rs80223967</td><td>cyclophosphamide</td><td>Osteonecrosis;Precursor Cell Lymphoblastic Leukemia-Lymphoma</td><td>3</td><td>AA</td><td>Toxicity</td><td>Pediatric patients with acute lymphoblastic leukemia and the AA genotype may have a decreased risk of osteonecrosis when treated with cyclophosphamide, cytarabine, daunorubicin, dexamethasone, doxorubicin, methotrexate, pegaspargase, prednisone, thioguanine and vincristine as compared to patients with the AG or GG genotypes. Other clinical and genetic factors may also influence the risk of osteonecrosis in patients with acute lymphoblastic leukemia.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448099430>1002</a></td><td>-</td><td>rs80223967</td><td>cytarabine</td><td>Osteonecrosis;Precursor Cell Lymphoblastic Leukemia-Lymphoma</td><td>3</td><td>AA</td><td>Toxicity</td><td>Pediatric patients with acute lymphoblastic leukemia and the AA genotype may have a decreased risk of osteonecrosis when treated with cyclophosphamide, cytarabine, daunorubicin, dexamethasone, doxorubicin, methotrexate, pegaspargase, prednisone, thioguanine and vincristine as compared to patients with the AG or GG genotypes. Other clinical and genetic factors may also influence the risk of osteonecrosis in patients with acute lymphoblastic leukemia.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448099430>1003</a></td><td>-</td><td>rs80223967</td><td>daunorubicin</td><td>Osteonecrosis;Precursor Cell Lymphoblastic Leukemia-Lymphoma</td><td>3</td><td>AA</td><td>Toxicity</td><td>Pediatric patients with acute lymphoblastic leukemia and the AA genotype may have a decreased risk of osteonecrosis when treated with cyclophosphamide, cytarabine, daunorubicin, dexamethasone, doxorubicin, methotrexate, pegaspargase, prednisone, thioguanine and vincristine as compared to patients with the AG or GG genotypes. Other clinical and genetic factors may also influence the risk of osteonecrosis in patients with acute lymphoblastic leukemia.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448099430>1004</a></td><td>-</td><td>rs80223967</td><td>dexamethasone</td><td>Osteonecrosis;Precursor Cell Lymphoblastic Leukemia-Lymphoma</td><td>3</td><td>AA</td><td>Toxicity</td><td>Pediatric patients with acute lymphoblastic leukemia and the AA genotype may have a decreased risk of osteonecrosis when treated with cyclophosphamide, cytarabine, daunorubicin, dexamethasone, doxorubicin, methotrexate, pegaspargase, prednisone, thioguanine and vincristine as compared to patients with the AG or GG genotypes. Other clinical and genetic factors may also influence the risk of osteonecrosis in patients with acute lymphoblastic leukemia.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448099430>1005</a></td><td>-</td><td>rs80223967</td><td>doxorubicin</td><td>Osteonecrosis;Precursor Cell Lymphoblastic Leukemia-Lymphoma</td><td>3</td><td>AA</td><td>Toxicity</td><td>Pediatric patients with acute lymphoblastic leukemia and the AA genotype may have a decreased risk of osteonecrosis when treated with cyclophosphamide, cytarabine, daunorubicin, dexamethasone, doxorubicin, methotrexate, pegaspargase, prednisone, thioguanine and vincristine as compared to patients with the AG or GG genotypes. Other clinical and genetic factors may also influence the risk of osteonecrosis in patients with acute lymphoblastic leukemia.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448099430>1006</a></td><td>-</td><td>rs80223967</td><td>methotrexate</td><td>Osteonecrosis;Precursor Cell Lymphoblastic Leukemia-Lymphoma</td><td>3</td><td>AA</td><td>Toxicity</td><td>Pediatric patients with acute lymphoblastic leukemia and the AA genotype may have a decreased risk of osteonecrosis when treated with cyclophosphamide, cytarabine, daunorubicin, dexamethasone, doxorubicin, methotrexate, pegaspargase, prednisone, thioguanine and vincristine as compared to patients with the AG or GG genotypes. Other clinical and genetic factors may also influence the risk of osteonecrosis in patients with acute lymphoblastic leukemia.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448099430>1007</a></td><td>-</td><td>rs80223967</td><td>pegaspargase</td><td>Osteonecrosis;Precursor Cell Lymphoblastic Leukemia-Lymphoma</td><td>3</td><td>AA</td><td>Toxicity</td><td>Pediatric patients with acute lymphoblastic leukemia and the AA genotype may have a decreased risk of osteonecrosis when treated with cyclophosphamide, cytarabine, daunorubicin, dexamethasone, doxorubicin, methotrexate, pegaspargase, prednisone, thioguanine and vincristine as compared to patients with the AG or GG genotypes. Other clinical and genetic factors may also influence the risk of osteonecrosis in patients with acute lymphoblastic leukemia.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448099430>1008</a></td><td>-</td><td>rs80223967</td><td>prednisone</td><td>Osteonecrosis;Precursor Cell Lymphoblastic Leukemia-Lymphoma</td><td>3</td><td>AA</td><td>Toxicity</td><td>Pediatric patients with acute lymphoblastic leukemia and the AA genotype may have a decreased risk of osteonecrosis when treated with cyclophosphamide, cytarabine, daunorubicin, dexamethasone, doxorubicin, methotrexate, pegaspargase, prednisone, thioguanine and vincristine as compared to patients with the AG or GG genotypes. Other clinical and genetic factors may also influence the risk of osteonecrosis in patients with acute lymphoblastic leukemia.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448099430>1009</a></td><td>-</td><td>rs80223967</td><td>thioguanine</td><td>Osteonecrosis;Precursor Cell Lymphoblastic Leukemia-Lymphoma</td><td>3</td><td>AA</td><td>Toxicity</td><td>Pediatric patients with acute lymphoblastic leukemia and the AA genotype may have a decreased risk of osteonecrosis when treated with cyclophosphamide, cytarabine, daunorubicin, dexamethasone, doxorubicin, methotrexate, pegaspargase, prednisone, thioguanine and vincristine as compared to patients with the AG or GG genotypes. Other clinical and genetic factors may also influence the risk of osteonecrosis in patients with acute lymphoblastic leukemia.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448099430>1010</a></td><td>-</td><td>rs80223967</td><td>vincristine</td><td>Osteonecrosis;Precursor Cell Lymphoblastic Leukemia-Lymphoma</td><td>3</td><td>AA</td><td>Toxicity</td><td>Pediatric patients with acute lymphoblastic leukemia and the AA genotype may have a decreased risk of osteonecrosis when treated with cyclophosphamide, cytarabine, daunorubicin, dexamethasone, doxorubicin, methotrexate, pegaspargase, prednisone, thioguanine and vincristine as compared to patients with the AG or GG genotypes. Other clinical and genetic factors may also influence the risk of osteonecrosis in patients with acute lymphoblastic leukemia.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448256881>1011</a></td><td>ABCB1</td><td>rs1128503</td><td>Platinum compounds</td><td>Carcinoma, Non-Small-Cell Lung</td><td>3</td><td>AG</td><td>Toxicity</td><td>Patients with the AG genotype and non-small cell lung cancer may have reduced risk of toxicities when treated with platinum-based chemotherapy compared to patients with the AA genotype. Other clinical and genetic factors may affect risk of toxicities in response to platinum-based chemotherapies.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447963011>1012</a></td><td>ITPA</td><td>rs1127354</td><td>mercaptopurine</td><td>Myelosuppression;Precursor Cell Lymphoblastic Leukemia-Lymphoma</td><td>4</td><td>CC</td><td>Toxicity</td><td>Patients with the CC genotype and acute lymphoblastic leukemia may have a decreased risk of myelosuppression when treated with mercaptopurine as compared to patients with the AA or AC genotype. Other genetic and clinical factors may also influence risk of myelosuppression.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447953072>1013</a></td><td>TYMS</td><td>rs183205964</td><td>capecitabine</td><td>Neoplasms</td><td>3</td><td>GG</td><td>Toxicity</td><td>Patients with the GG genotype and cancer may have a decreased risk of discontinuation of therapy due to severe toxicity when treated with capecitabine, fluorouracil, and tegafur as compared to patients with the CC or CG genotype. Other genetic and clinical factors may also influence a patient's risk of side effects when treated with drug fluoropyrimidine patients.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447953072>1014</a></td><td>TYMS</td><td>rs183205964</td><td>fluorouracil</td><td>Neoplasms</td><td>3</td><td>GG</td><td>Toxicity</td><td>Patients with the GG genotype and cancer may have a decreased risk of discontinuation of therapy due to severe toxicity when treated with capecitabine, fluorouracil, and tegafur as compared to patients with the CC or CG genotype. Other genetic and clinical factors may also influence a patient's risk of side effects when treated with drug fluoropyrimidine patients.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447953072>1015</a></td><td>TYMS</td><td>rs183205964</td><td>tegafur</td><td>Neoplasms</td><td>3</td><td>GG</td><td>Toxicity</td><td>Patients with the GG genotype and cancer may have a decreased risk of discontinuation of therapy due to severe toxicity when treated with capecitabine, fluorouracil, and tegafur as compared to patients with the CC or CG genotype. Other genetic and clinical factors may also influence a patient's risk of side effects when treated with drug fluoropyrimidine patients.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447953328>1016</a></td><td>CTNNB1</td><td>rs4135385</td><td>cyclophosphamide</td><td>Multiple Myeloma</td><td>3</td><td>AG</td><td>Toxicity</td><td>Patients with the AG genotype and multiple myeloma may have a decreased response to cyclophosphamide, dexamethasone, and thalidomide as compared to patients with the AG and GG genotypes. They may also be at decreased risk for neutropenia when treated with lenalidomide. Other genetic and clinical factors may also influence a patient's response to cyclophosphamide, dexamethasone, and thalidomide, and risk of neutropenia when treated with lenalidomide.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447953328>1017</a></td><td>CTNNB1</td><td>rs4135385</td><td>dexamethasone</td><td>Multiple Myeloma</td><td>3</td><td>AG</td><td>Toxicity</td><td>Patients with the AG genotype and multiple myeloma may have a decreased response to cyclophosphamide, dexamethasone, and thalidomide as compared to patients with the AG and GG genotypes. They may also be at decreased risk for neutropenia when treated with lenalidomide. Other genetic and clinical factors may also influence a patient's response to cyclophosphamide, dexamethasone, and thalidomide, and risk of neutropenia when treated with lenalidomide.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447953328>1018</a></td><td>CTNNB1</td><td>rs4135385</td><td>lenalidomide</td><td>Multiple Myeloma</td><td>3</td><td>AG</td><td>Toxicity</td><td>Patients with the AG genotype and multiple myeloma may have a decreased response to cyclophosphamide, dexamethasone, and thalidomide as compared to patients with the AG and GG genotypes. They may also be at decreased risk for neutropenia when treated with lenalidomide. Other genetic and clinical factors may also influence a patient's response to cyclophosphamide, dexamethasone, and thalidomide, and risk of neutropenia when treated with lenalidomide.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447953328>1019</a></td><td>CTNNB1</td><td>rs4135385</td><td>thalidomide</td><td>Multiple Myeloma</td><td>3</td><td>AG</td><td>Toxicity</td><td>Patients with the AG genotype and multiple myeloma may have a decreased response to cyclophosphamide, dexamethasone, and thalidomide as compared to patients with the AG and GG genotypes. They may also be at decreased risk for neutropenia when treated with lenalidomide. Other genetic and clinical factors may also influence a patient's response to cyclophosphamide, dexamethasone, and thalidomide, and risk of neutropenia when treated with lenalidomide.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447953340>1020</a></td><td>CTNNB1</td><td>rs4533622</td><td>lenalidomide</td><td>Multiple Myeloma</td><td>3</td><td>AC</td><td>Toxicity</td><td>Patients with the AC genotype and multiple myeloma may have a decreased response to thalidomide as compared to patients with the AA genotype. However, they may also be at decreased risk for neutropenia when treated with lenalidomide compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to thalidomide and risk of neutropenia when treated with lenalidomide.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447953340>1021</a></td><td>CTNNB1</td><td>rs4533622</td><td>thalidomide</td><td>Multiple Myeloma</td><td>3</td><td>AC</td><td>Toxicity</td><td>Patients with the AC genotype and multiple myeloma may have a decreased response to thalidomide as compared to patients with the AA genotype. However, they may also be at decreased risk for neutropenia when treated with lenalidomide compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to thalidomide and risk of neutropenia when treated with lenalidomide.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447959508>1022</a></td><td>SOD2</td><td>rs4880</td><td>asparaginase</td><td>Precursor Cell Lymphoblastic Leukemia-Lymphoma</td><td>3</td><td>AA</td><td>Toxicity</td><td>Patients with the AA genotype and acute lymphoblastic leukemia (ALL) may have a decreased risk for hepatotoxicity when treated with asparaginase as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for hepatotoxicity.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447960582>1023</a></td><td>GGH</td><td>rs719235</td><td>methotrexate</td><td>Arthritis, Rheumatoid</td><td>3</td><td>AC</td><td>Toxicity</td><td>Patients with the AC genotype and rheumatoid arthritis may have a decreased risk of bone marrow toxicity when treated with methotrexate as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of bone marrow toxicity.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447960204>1024</a></td><td>ADRB2</td><td>rs1042714</td><td>atenolol</td><td>Hypertension</td><td>3</td><td>CG</td><td>Toxicity</td><td>Patients with the CG genotype and hypertension may have a decreased risk of developing hypertriglyceridemia when treated with atenolol or metoprolol as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of hypertriglyceridemia.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447960204>1025</a></td><td>ADRB2</td><td>rs1042714</td><td>metoprolol</td><td>Hypertension</td><td>3</td><td>CG</td><td>Toxicity</td><td>Patients with the CG genotype and hypertension may have a decreased risk of developing hypertriglyceridemia when treated with atenolol or metoprolol as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of hypertriglyceridemia.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448531661>1026</a></td><td>ABCC1</td><td>rs17501331</td><td>irinotecan</td><td>Colorectal Neoplasms;Neutropenia</td><td>3</td><td>AG</td><td>Toxicity</td><td>Patients with the AG genotype and colorectal neoplasms may have decreased severity of neutropenia compared to patients with the AA genotype when taking irinotecan. Other clinical and genetic factors may affect severity of neutropenia when taking irinotecan.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450931410>1027</a></td><td>PIP5K1C</td><td>rs2074957</td><td>ethanol</td><td>Alcoholism</td><td>3</td><td>TT</td><td>Toxicity</td><td>Patients with the TT genotype may be at a decreased risk of developing alcoholism as compared to patients with the CC or CT genotypes. This association was found in patients of African ancestry in the discovery cohort and was not replicated in either the replication cohort or in patients or European ancestry. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448107277>1028</a></td><td>HCG22</td><td>rs3873352</td><td>triamcinolone</td><td>Retinal Diseases</td><td>3</td><td>CC</td><td>Toxicity</td><td>Patients with retinal disease and the CC genotype may have decreased intraocular pressure when treated with triamcinolone as compared to patients with the CG or GG genotypes. Other clinical and genetic factors may also influence changes in intraocular pressure in patients with retinal disease.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448098213>1029</a></td><td>NR1I3</td><td>rs9725457</td><td>docetaxel</td><td>Anemia;Nasopharyngeal Neoplasms</td><td>3</td><td>AG</td><td>Toxicity</td><td>Patients with nasopharyngeal cancer and the AG genotype who are treated with docetaxel may have less severe anemia as compared to patients with the AA genotypes. Other clinical and genetic factors may also influence severity of anemia in patients with nasopharyngeal cancer.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447980706>1030</a></td><td>CYP3A4</td><td>rs4646437</td><td>methadone</td><td>Heroin Dependence</td><td>3</td><td>GG</td><td>Toxicity</td><td>Patients with the GG genotype who are heroin dependent may have less severe side effects when treated with methadone as compared to patients with the AA genotype. Other genetic and clinical factors may also influence side effects in patients receiving methadone.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448112052>1031</a></td><td>HTR1B</td><td>rs6296</td><td>citalopram</td><td>Anxiety Disorders;Depressive Disorder, Major</td><td>3</td><td>CG</td><td>Toxicity</td><td>Patients with the CG genotype and anxiety disorder or major depression may have decreased risk of becoming agitated when taking citalopram compared to patients with the CC genotype. Other clinical and genetic factors may affect risk of becoming agitated when taking citalopram.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447964002>1032</a></td><td>PPARG</td><td>rs1801282</td><td>olanzapine</td><td>Schizophrenia</td><td>3</td><td>CC</td><td>Toxicity</td><td>Patients with the CC genotype and schizophrenia may have lower weight gain when treated with olanzapine as compared to patients with the CG genotype. Other genetic and clinical factors may also influence weight gain.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448258734>1033</a></td><td>SLCO1B1</td><td>rs2306283</td><td>sorafenib</td><td>Diarrhea</td><td>3</td><td>AG</td><td>Toxicity</td><td>Patients with the AG genotype may have decreased likelihood of developing Diarrhea when treated with sorafenib as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to sorafenib.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448256091>1034</a></td><td>GNMT</td><td>rs10948059</td><td>mercaptopurine</td><td>Precursor Cell Lymphoblastic Leukemia-Lymphoma</td><td>3</td><td>CT</td><td>Toxicity</td><td>Patients with the CT genotype may have decreased risk of hematological toxicity when treated with mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to patients with genotype CC.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448097600>1035</a></td><td>UGT1A3</td><td>rs3806596</td><td>atazanavir</td><td>HIV Infections;Hyperbilirubinemia</td><td>3</td><td>CT</td><td>Toxicity</td><td>Patients with HIV and the CT genotype may be less likely to develop hyperbilirubinemia when administered atazanavir and ritonavir as compared to patients with the CC genotypes. Please note: the CC genotype was only significantly associated with likelihood of hyperbilirubinemia when it was part of a haplotype with 4 other UGT1A variants: rs17868323 GG and rs17863778 AA, rs7586110 GG (UGT1A7) and UGT1A1 *28/*28. Other clinical and genetic factors may also influence a patient's likelihood of developing hyperbilirubinemia in patients with HIV who were administered atazanavir and ritonavir.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448097600>1036</a></td><td>UGT1A3</td><td>rs3806596</td><td>ritonavir</td><td>HIV Infections;Hyperbilirubinemia</td><td>3</td><td>CT</td><td>Toxicity</td><td>Patients with HIV and the CT genotype may be less likely to develop hyperbilirubinemia when administered atazanavir and ritonavir as compared to patients with the CC genotypes. Please note: the CC genotype was only significantly associated with likelihood of hyperbilirubinemia when it was part of a haplotype with 4 other UGT1A variants: rs17868323 GG and rs17863778 AA, rs7586110 GG (UGT1A7) and UGT1A1 *28/*28. Other clinical and genetic factors may also influence a patient's likelihood of developing hyperbilirubinemia in patients with HIV who were administered atazanavir and ritonavir.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447983057>1037</a></td><td>EIF3A</td><td>rs4752219</td><td>Platinum compounds</td><td>Carcinoma, Non-Small-Cell Lung</td><td>3</td><td>TT</td><td>Toxicity</td><td>Patients with the TT genotype and non-small-cell lung carcinoma may have decreased risk of toxicities, including anemia, leukopenia, thrombocytopenia, toxic liver disease, and vomiting when treated with platinum compounds compared to patients with the CC genotype. Other genetic and clinical factors may affect risk of toxicities with platinum compound treatment.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447983064>1038</a></td><td>EIF3A</td><td>rs4752220</td><td>Platinum compounds</td><td>Carcinoma, Non-Small-Cell Lung</td><td>3</td><td>GG</td><td>Toxicity</td><td>Patients with the GG genotype and non-small-cell lung carcinoma may have decreased risk of toxicities, including anemia, leukopenia, thrombocytopenia, toxic liver disease, and vomiting when treated with platinum compounds compared to patients with the AA genotype. Other genetic and clinical factors may affect risk of toxicities with platinum compound treatment.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448256718>1039</a></td><td>VEGFA</td><td>rs3025040</td><td>sorafenib</td><td>Carcinoma, Hepatocellular;hand-foot syndrome</td><td>3</td><td>TT</td><td>Toxicity</td><td>Patients with the TT genotype may have decreased risk of hand-foot syndrome when treated with sorafenib in people with Carcinoma, Hepatocellular as compared to patients with genotype CC. Other genetic and clinical factors may also influence the toxicity to sorafenib.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447963701>1040</a></td><td>CYP3A4</td><td>rs2740574</td><td>tamoxifen</td><td>Breast Neoplasms</td><td>3</td><td>TT</td><td>Toxicity</td><td>Patients with the TT genotype and breast cancer may have a decreased risk of developing endometrial cancer following tamoxifen treatment as compared to patients with the CT genotype. Other genetic and clinical factors may also influence risk of endometrial cancer.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447983217>1041</a></td><td>CPA2</td><td>rs199695765</td><td>asparaginase</td><td>Pancreatitis;Precursor Cell Lymphoblastic Leukemia-Lymphoma</td><td>3</td><td>CC</td><td>Toxicity</td><td>Patients with the CC genotype may have decreased risk of Pancreatitis when treated with asparaginase in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to patients with genotype TT or CT. Other genetic and clinical factors may also influence the risk of toxicity to asparaginase.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448428108>1042</a></td><td>GRIK3</td><td>rs1334802</td><td>antipsychotics</td><td>Psychotic Disorders</td><td>3</td><td>TT</td><td>Toxicity</td><td>Patients with the TT genotype and first episode psychosis (FEP) may have a decreased risk for extrapyramidal symptoms when treated with antipsychotics as compared to patients with the CT genotype. Other genetic and clinical factors may also influence risk of extrapyramidal symptoms.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448531802>1043</a></td><td>ABCC1</td><td>rs3743527</td><td>irinotecan</td><td>Colorectal Neoplasms</td><td>3</td><td>CT</td><td>Toxicity</td><td>Patients with the CT genotype and colorectal neoplasms may have deceased severity of neutropenia when taking irinotecan compared to patients with the CC genotype. Other clinical and genetic factors may affect severity of neutropenia when taking irinotecan.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450932374>1044</a></td><td>MTHFR</td><td>rs1801131</td><td>capecitabine</td><td>Neoplasms</td><td>3</td><td>TT</td><td>Toxicity</td><td>Patients with cancer and the TT genotype may be at a decreased risk of experiencing drug toxicity when treated with fluoropyrimidine-based chemotherapy as compared to patients with the GG genotype. However, other studies have not found an association between this variant and toxic side effects of fluoropyrimidine-based chemotherapy. Other genetic and clinical factors may also affect a patient's risk of experiencing fluoropyrimidine-based chemotherapy-related toxicity.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450932374>1045</a></td><td>MTHFR</td><td>rs1801131</td><td>fluorouracil</td><td>Neoplasms</td><td>3</td><td>TT</td><td>Toxicity</td><td>Patients with cancer and the TT genotype may be at a decreased risk of experiencing drug toxicity when treated with fluoropyrimidine-based chemotherapy as compared to patients with the GG genotype. However, other studies have not found an association between this variant and toxic side effects of fluoropyrimidine-based chemotherapy. Other genetic and clinical factors may also affect a patient's risk of experiencing fluoropyrimidine-based chemotherapy-related toxicity.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450932374>1046</a></td><td>MTHFR</td><td>rs1801131</td><td>leucovorin</td><td>Neoplasms</td><td>3</td><td>TT</td><td>Toxicity</td><td>Patients with cancer and the TT genotype may be at a decreased risk of experiencing drug toxicity when treated with fluoropyrimidine-based chemotherapy as compared to patients with the GG genotype. However, other studies have not found an association between this variant and toxic side effects of fluoropyrimidine-based chemotherapy. Other genetic and clinical factors may also affect a patient's risk of experiencing fluoropyrimidine-based chemotherapy-related toxicity.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450932374>1047</a></td><td>MTHFR</td><td>rs1801131</td><td>oxaliplatin</td><td>Neoplasms</td><td>3</td><td>TT</td><td>Toxicity</td><td>Patients with cancer and the TT genotype may be at a decreased risk of experiencing drug toxicity when treated with fluoropyrimidine-based chemotherapy as compared to patients with the GG genotype. However, other studies have not found an association between this variant and toxic side effects of fluoropyrimidine-based chemotherapy. Other genetic and clinical factors may also affect a patient's risk of experiencing fluoropyrimidine-based chemotherapy-related toxicity.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447983071>1048</a></td><td>EIF3A</td><td>rs1409314</td><td>Platinum compounds</td><td>Carcinoma, Non-Small-Cell Lung</td><td>3</td><td>GG</td><td>Toxicity</td><td>Patients with the GG genotype and non-small-cell lung carcinoma may have decreased risk of toxicities, including anemia, leukopenia, thrombocytopenia, toxic liver disease, and vomiting when treated with platinum compounds compared to patients with the AA genotype. Other genetic and clinical factors may affect risk of toxicities with platinum compound treatment.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447983078>1049</a></td><td>EIF3A</td><td>rs10510050</td><td>Platinum compounds</td><td>Carcinoma, Non-Small-Cell Lung</td><td>3</td><td>GG</td><td>Toxicity</td><td>Patients with the GG genotype and non-small-cell lung carcinoma may have decreased risk of toxicities, including thrombocytopenia, toxic liver disease, and vomiting when treated with platinum compounds compared to patients with the AA genotype. Other genetic and clinical factors may affect risk of toxicities with platinum compound treatment.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447981346>1050</a></td><td>FOLH1</td><td>rs61886492</td><td>mercaptopurine</td><td>Precursor Cell Lymphoblastic Leukemia-Lymphoma</td><td>3</td><td>GG</td><td>Toxicity</td><td>Pediatric patients with the GG genotype and acute lymphoblastic leukemia may have a decreased risk for hematological toxicity when treated with mercaptopurine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence mercaptopurine-mediated hematological toxicity.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447981346>1051</a></td><td>FOLH1</td><td>rs61886492</td><td>methotrexate</td><td>Precursor Cell Lymphoblastic Leukemia-Lymphoma</td><td>3</td><td>GG</td><td>Toxicity</td><td>Pediatric patients with the GG genotype and acute lymphoblastic leukemia may have a decreased risk for hematological toxicity when treated with mercaptopurine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence mercaptopurine-mediated hematological toxicity.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448265581>1052</a></td><td>AGBL4</td><td>rs320003</td><td>rifampin</td><td>Tuberculosis</td><td>3</td><td>AG</td><td>Toxicity</td><td>Patients with the AG genotype and tuberculosis may be at decreased risk of drug-induced liver toxicity when taking rifampicin compared to patients with the GG genotype. This SNP was identified in a GWAS study and maintained significance in combination with a replication study. Other genetic and clinical factors may affect response to rifampicin.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1445401427>1053</a></td><td>SLC28A2</td><td>rs11854484</td><td>peginterferon alfa-2b</td><td>Hepatitis C</td><td>3</td><td>CT</td><td>Toxicity</td><td>Patients with the CT genotype and hepatitis C may have a decreased risk for anemia when treated with protease inhibitors plus ribavirin and peginterferon, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk for anemia.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1445401427>1054</a></td><td>SLC28A2</td><td>rs11854484</td><td>protease inhibitors</td><td>Hepatitis C</td><td>3</td><td>CT</td><td>Toxicity</td><td>Patients with the CT genotype and hepatitis C may have a decreased risk for anemia when treated with protease inhibitors plus ribavirin and peginterferon, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk for anemia.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1445401427>1055</a></td><td>SLC28A2</td><td>rs11854484</td><td>ribavirin</td><td>Hepatitis C</td><td>3</td><td>CT</td><td>Toxicity</td><td>Patients with the CT genotype and hepatitis C may have a decreased risk for anemia when treated with protease inhibitors plus ribavirin and peginterferon, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk for anemia.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447962613>1056</a></td><td>PROX1</td><td>rs340874</td><td>atenolol</td><td>Hypertension</td><td>3</td><td>TT</td><td>Toxicity</td><td>Patients with the TT genotype and hypertension may have a lower increase in fasting glucose when treated with atenolol as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence fasting glucose levels.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447981282>1057</a></td><td>UGT2B7</td><td>rs7439366</td><td>methadone</td><td>Opioid-Related Disorders</td><td>3</td><td>CT</td><td>Toxicity</td><td>Patients with the CT genotype who are undergoing methadone maintenance treatment may have decreased severity of opiate withdrawal symptoms as compared to patients with the CC genotype. Other genetic and clinical factors may also influence opiate withdrawal symptoms in patients receiving methadone.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447981296>1058</a></td><td>UGT2B7</td><td>rs6600893</td><td>methadone</td><td>Opioid-Related Disorders</td><td>3</td><td>CT</td><td>Toxicity</td><td>Patients with the CT genotype who are undergoing methadone maintenance treatment may have decreased severity of opiate withdrawal symptoms as compared to patients with the CC genotype. Other genetic and clinical factors may also influence opiate withdrawal symptoms in patients receiving methadone.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448101163>1059</a></td><td>CHRNA5</td><td>rs660652</td><td>nicotine</td><td>Pain;Tobacco Use Disorder</td><td>3</td><td>AG</td><td>Toxicity</td><td>Patients with the AG genotype who are in chronic pain and receive opioid medications for treatment may be at decreased risk for nicotine addiction as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of opiate addiction.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448101163>1060</a></td><td>CHRNA5</td><td>rs660652</td><td>Opium alkaloids and derivatives</td><td>Pain;Tobacco Use Disorder</td><td>3</td><td>AG</td><td>Toxicity</td><td>Patients with the AG genotype who are in chronic pain and receive opioid medications for treatment may be at decreased risk for nicotine addiction as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of opiate addiction.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448101175>1061</a></td><td>CHRNB2</td><td>rs2072660</td><td>nicotine</td><td>Tobacco Use Disorder</td><td>3</td><td>CC</td><td>Toxicity</td><td>Patients with the CC genotype may have a decreased risk for smoking addiction as compared to patients with the TT genotype. Other genetic and clinical factors may also influence smoking addiction.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448615614>1062</a></td><td>CACNA1C</td><td>rs10774053</td><td>ritodrine</td><td>adverse events;Premature Birth</td><td>3</td><td>AG</td><td>Toxicity</td><td>Women with premature births and the AG genotype who are treated with ritodrine may have a decreased likelihood of adverse events as compared to women with premature birth and the GG genotype. Other clinical and genetic factors may also influence the likelihood of adverse events in women with premature labor who are treated with ritodrine.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447990245>1063</a></td><td>RYR1</td><td>rs118204423</td><td>succinylcholine</td><td>Malignant Hyperthermia</td><td>3</td><td>GG</td><td>Toxicity</td><td>Patients with the GG genotype may not develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype CG and CC. Other genetic or clinical factors may also influence whether a patient develops malignant hyperthermia. *Please note: The C allele is NOT designated as MHS causative by the European Malignant Hyperthermia Group.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447990245>1064</a></td><td>RYR1</td><td>rs118204423</td><td>volatile anesthetics</td><td>Malignant Hyperthermia</td><td>3</td><td>GG</td><td>Toxicity</td><td>Patients with the GG genotype may not develop Malignant Hyperthermia when treated with inhalational anaesthetics (desflurane, enflurane, halothane, isoflurane, methoxyflurane, sevoflurane), either alone or in conjunction with a depolarizing muscle relaxant (specifically, succinylcholine) as compared to patients with genotype CG and CC. Other genetic or clinical factors may also influence whether a patient develops malignant hyperthermia. *Please note: The C allele is NOT designated as MHS causative by the European Malignant Hyperthermia Group.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448097574>1065</a></td><td>UGT1A7</td><td>rs17868323</td><td>atazanavir</td><td>HIV Infections;Hyperbilirubinemia</td><td>3</td><td>GT</td><td>Toxicity</td><td>Patients with HIV and the GT genotype may be less likely to develop hyperbilirubinemia when administered atazanavir and ritonavir as compared to patients with the GG genotypes. Please note: the GG genotype was only significantly associated with likelihood of hyperbilirubinemia when it was combined with the rs7586110 GG and rs17863778 AA (UGT1A7), rs3806596 CC (UGT1A3) and UGT1A1 *28/*28. Other clinical and genetic factors may also influence a patient's likelihood of developing hyperbilirubinemia in patients with HIV who were administered atazanavir and ritonavir.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448097574>1066</a></td><td>UGT1A7</td><td>rs17868323</td><td>ritonavir</td><td>HIV Infections;Hyperbilirubinemia</td><td>3</td><td>GT</td><td>Toxicity</td><td>Patients with HIV and the GT genotype may be less likely to develop hyperbilirubinemia when administered atazanavir and ritonavir as compared to patients with the GG genotypes. Please note: the GG genotype was only significantly associated with likelihood of hyperbilirubinemia when it was combined with the rs7586110 GG and rs17863778 AA (UGT1A7), rs3806596 CC (UGT1A3) and UGT1A1 *28/*28. Other clinical and genetic factors may also influence a patient's likelihood of developing hyperbilirubinemia in patients with HIV who were administered atazanavir and ritonavir.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448097587>1067</a></td><td>UGT1A7</td><td>rs17863778</td><td>atazanavir</td><td>HIV Infections;Hyperbilirubinemia</td><td>3</td><td>AC</td><td>Toxicity</td><td>Patients with HIV and the AC genotype may be more less to develop hyperbilirubinemia when administered atazanavir and ritonavir as compared to patients with the AC or CC genotypes. Please note: the AA genotype was only significantly associated with likelihood of hyperbilirubinemia when it was part of a haplotype with 4 other UGT1A variants: rs7586110 GG, rs17868323 GG (UGT1A7), rs3806596 CC (UGT1A3) and UGT1A1 *28/*28. Other clinical and genetic factors may also influence a patient's likelihood of developing hyperbilirubinemia in patients with HIV who were administered atazanavir and ritonavir.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448097587>1068</a></td><td>UGT1A7</td><td>rs17863778</td><td>ritonavir</td><td>HIV Infections;Hyperbilirubinemia</td><td>3</td><td>AC</td><td>Toxicity</td><td>Patients with HIV and the AC genotype may be more less to develop hyperbilirubinemia when administered atazanavir and ritonavir as compared to patients with the AC or CC genotypes. Please note: the AA genotype was only significantly associated with likelihood of hyperbilirubinemia when it was part of a haplotype with 4 other UGT1A variants: rs7586110 GG, rs17868323 GG (UGT1A7), rs3806596 CC (UGT1A3) and UGT1A1 *28/*28. Other clinical and genetic factors may also influence a patient's likelihood of developing hyperbilirubinemia in patients with HIV who were administered atazanavir and ritonavir.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448099059>1069</a></td><td>-</td><td>rs1891059</td><td>cyclophosphamide</td><td>Osteonecrosis;Precursor Cell Lymphoblastic Leukemia-Lymphoma</td><td>3</td><td>GG</td><td>Toxicity</td><td>Pediatric patients with acute lymphoblastic leukemia (ALL) and the GG genotype may have a decreased risk of developing osteonecrosis when treated with cyclophosphamide, cytarabine, daunorubicin, dexamethasone, doxorubicin, methotrexate, pegaspargase, prednisone, thioguanine and vincristine as compared to pediatric ALL patients with the AG or AA genotypes. Other clinical and genetic factors may also influence the risk of developing osteonecrosis in pediatric ALL patients.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448099059>1070</a></td><td>-</td><td>rs1891059</td><td>cytarabine</td><td>Osteonecrosis;Precursor Cell Lymphoblastic Leukemia-Lymphoma</td><td>3</td><td>GG</td><td>Toxicity</td><td>Pediatric patients with acute lymphoblastic leukemia (ALL) and the GG genotype may have a decreased risk of developing osteonecrosis when treated with cyclophosphamide, cytarabine, daunorubicin, dexamethasone, doxorubicin, methotrexate, pegaspargase, prednisone, thioguanine and vincristine as compared to pediatric ALL patients with the AG or AA genotypes. Other clinical and genetic factors may also influence the risk of developing osteonecrosis in pediatric ALL patients.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448099059>1071</a></td><td>-</td><td>rs1891059</td><td>daunorubicin</td><td>Osteonecrosis;Precursor Cell Lymphoblastic Leukemia-Lymphoma</td><td>3</td><td>GG</td><td>Toxicity</td><td>Pediatric patients with acute lymphoblastic leukemia (ALL) and the GG genotype may have a decreased risk of developing osteonecrosis when treated with cyclophosphamide, cytarabine, daunorubicin, dexamethasone, doxorubicin, methotrexate, pegaspargase, prednisone, thioguanine and vincristine as compared to pediatric ALL patients with the AG or AA genotypes. Other clinical and genetic factors may also influence the risk of developing osteonecrosis in pediatric ALL patients.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448099059>1072</a></td><td>-</td><td>rs1891059</td><td>dexamethasone</td><td>Osteonecrosis;Precursor Cell Lymphoblastic Leukemia-Lymphoma</td><td>3</td><td>GG</td><td>Toxicity</td><td>Pediatric patients with acute lymphoblastic leukemia (ALL) and the GG genotype may have a decreased risk of developing osteonecrosis when treated with cyclophosphamide, cytarabine, daunorubicin, dexamethasone, doxorubicin, methotrexate, pegaspargase, prednisone, thioguanine and vincristine as compared to pediatric ALL patients with the AG or AA genotypes. Other clinical and genetic factors may also influence the risk of developing osteonecrosis in pediatric ALL patients.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448099059>1073</a></td><td>-</td><td>rs1891059</td><td>doxorubicin</td><td>Osteonecrosis;Precursor Cell Lymphoblastic Leukemia-Lymphoma</td><td>3</td><td>GG</td><td>Toxicity</td><td>Pediatric patients with acute lymphoblastic leukemia (ALL) and the GG genotype may have a decreased risk of developing osteonecrosis when treated with cyclophosphamide, cytarabine, daunorubicin, dexamethasone, doxorubicin, methotrexate, pegaspargase, prednisone, thioguanine and vincristine as compared to pediatric ALL patients with the AG or AA genotypes. Other clinical and genetic factors may also influence the risk of developing osteonecrosis in pediatric ALL patients.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448099059>1074</a></td><td>-</td><td>rs1891059</td><td>methotrexate</td><td>Osteonecrosis;Precursor Cell Lymphoblastic Leukemia-Lymphoma</td><td>3</td><td>GG</td><td>Toxicity</td><td>Pediatric patients with acute lymphoblastic leukemia (ALL) and the GG genotype may have a decreased risk of developing osteonecrosis when treated with cyclophosphamide, cytarabine, daunorubicin, dexamethasone, doxorubicin, methotrexate, pegaspargase, prednisone, thioguanine and vincristine as compared to pediatric ALL patients with the AG or AA genotypes. Other clinical and genetic factors may also influence the risk of developing osteonecrosis in pediatric ALL patients.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448099059>1075</a></td><td>-</td><td>rs1891059</td><td>pegaspargase</td><td>Osteonecrosis;Precursor Cell Lymphoblastic Leukemia-Lymphoma</td><td>3</td><td>GG</td><td>Toxicity</td><td>Pediatric patients with acute lymphoblastic leukemia (ALL) and the GG genotype may have a decreased risk of developing osteonecrosis when treated with cyclophosphamide, cytarabine, daunorubicin, dexamethasone, doxorubicin, methotrexate, pegaspargase, prednisone, thioguanine and vincristine as compared to pediatric ALL patients with the AG or AA genotypes. Other clinical and genetic factors may also influence the risk of developing osteonecrosis in pediatric ALL patients.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448099059>1076</a></td><td>-</td><td>rs1891059</td><td>prednisone</td><td>Osteonecrosis;Precursor Cell Lymphoblastic Leukemia-Lymphoma</td><td>3</td><td>GG</td><td>Toxicity</td><td>Pediatric patients with acute lymphoblastic leukemia (ALL) and the GG genotype may have a decreased risk of developing osteonecrosis when treated with cyclophosphamide, cytarabine, daunorubicin, dexamethasone, doxorubicin, methotrexate, pegaspargase, prednisone, thioguanine and vincristine as compared to pediatric ALL patients with the AG or AA genotypes. Other clinical and genetic factors may also influence the risk of developing osteonecrosis in pediatric ALL patients.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448099059>1077</a></td><td>-</td><td>rs1891059</td><td>thioguanine</td><td>Osteonecrosis;Precursor Cell Lymphoblastic Leukemia-Lymphoma</td><td>3</td><td>GG</td><td>Toxicity</td><td>Pediatric patients with acute lymphoblastic leukemia (ALL) and the GG genotype may have a decreased risk of developing osteonecrosis when treated with cyclophosphamide, cytarabine, daunorubicin, dexamethasone, doxorubicin, methotrexate, pegaspargase, prednisone, thioguanine and vincristine as compared to pediatric ALL patients with the AG or AA genotypes. Other clinical and genetic factors may also influence the risk of developing osteonecrosis in pediatric ALL patients.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448099059>1078</a></td><td>-</td><td>rs1891059</td><td>vincristine</td><td>Osteonecrosis;Precursor Cell Lymphoblastic Leukemia-Lymphoma</td><td>3</td><td>GG</td><td>Toxicity</td><td>Pediatric patients with acute lymphoblastic leukemia (ALL) and the GG genotype may have a decreased risk of developing osteonecrosis when treated with cyclophosphamide, cytarabine, daunorubicin, dexamethasone, doxorubicin, methotrexate, pegaspargase, prednisone, thioguanine and vincristine as compared to pediatric ALL patients with the AG or AA genotypes. Other clinical and genetic factors may also influence the risk of developing osteonecrosis in pediatric ALL patients.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448615137>1079</a></td><td>ABCB1</td><td>rs1045642</td><td>anastrozole</td><td>Arthralgia;Breast Neoplasms</td><td>3</td><td>AA</td><td>Toxicity</td><td>Postmenopausal women with HR+ breast cancer and the AA genotype may be less likely to experience arthralgia when treated with anastrozole as compared to women with the AG or GG genotypes. Other clinical and genetic factors may also influence the likelihood of experiencing arthralgia in postmenopausal women with HR+ breast cancer who are treated with anastrozole.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448098293>1080</a></td><td>NR1I3</td><td>rs10538494</td><td>docetaxel</td><td>Anemia;Nasopharyngeal Neoplasms</td><td>3</td><td>AT</td><td>Toxicity</td><td>Patients with nasopharyngeal cancer and the AT genotype who are treated with docetaxel may have a decreased severity of neutropenia as compared to patients with the TT genotype. Other clinical and genetic factors may also influence severity of neutropenia in patients with nasopharyngeal cancer who are treated with docetaxel.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448098304>1081</a></td><td>NR1I2</td><td>rs3732359</td><td>docetaxel</td><td>Anemia;Nasopharyngeal Neoplasms</td><td>3</td><td>AG</td><td>Toxicity</td><td>Patients with nasopharyngeal cancer and the AG genotype may have less severe anemia when treated with docetaxel as compared to patients with the AA genotype. Other clinical and genetic factors may also influence the severity of anemia in patients with nasopharyngeal cancer who are treated with docetaxel.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448098315>1082</a></td><td>NR1I2</td><td>rs3732360</td><td>docetaxel</td><td>Anemia;Nasopharyngeal Neoplasms</td><td>3</td><td>CT</td><td>Toxicity</td><td>Patients with nasopharyngeal cancer and the CT genotype may have less severe anemia who are treated with docetaxel as compared to patients with the TT genotype. Other clinical and genetic factors may also influence severity of anemia in patients with nasopharyngeal cancer who are treated with docetaxel.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448098320>1083</a></td><td>NR1I2</td><td>rs3814058</td><td>docetaxel</td><td>Anemia;Nasopharyngeal Neoplasms</td><td>3</td><td>CT</td><td>Toxicity</td><td>Patients with nasopharyngeal cancer and the CT genotype may have less severe anemia as compared to patients with the CC or TT genotype who are treated with docetaxel. Other clinical and genetic factors may also influence severity of anemia in patients with nasopharyngeal cancer who are treated with docetaxel.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448099112>1084</a></td><td>BMP7</td><td>rs79085477</td><td>cyclophosphamide</td><td>Osteonecrosis;Precursor Cell Lymphoblastic Leukemia-Lymphoma</td><td>3</td><td>CC</td><td>Toxicity</td><td>Pediatric patients with acute lymphoblastic leukemia (ALL) and the CC genotype may have an decreased risk of developing osteonecrosis when treated with cyclophosphamide, cytarabine, daunorubicin, dexamethasone, doxorubicin, methotrexate, pegaspargase, prednisone, thioguanine and vincristine as compared to pediatric ALL patients with the CT or TT genotypes. Other clinical and genetic factors may also influence the risk of developing osteonecrosis in pediatric ALL patients.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448099112>1085</a></td><td>BMP7</td><td>rs79085477</td><td>cytarabine</td><td>Osteonecrosis;Precursor Cell Lymphoblastic Leukemia-Lymphoma</td><td>3</td><td>CC</td><td>Toxicity</td><td>Pediatric patients with acute lymphoblastic leukemia (ALL) and the CC genotype may have an decreased risk of developing osteonecrosis when treated with cyclophosphamide, cytarabine, daunorubicin, dexamethasone, doxorubicin, methotrexate, pegaspargase, prednisone, thioguanine and vincristine as compared to pediatric ALL patients with the CT or TT genotypes. Other clinical and genetic factors may also influence the risk of developing osteonecrosis in pediatric ALL patients.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448099112>1086</a></td><td>BMP7</td><td>rs79085477</td><td>daunorubicin</td><td>Osteonecrosis;Precursor Cell Lymphoblastic Leukemia-Lymphoma</td><td>3</td><td>CC</td><td>Toxicity</td><td>Pediatric patients with acute lymphoblastic leukemia (ALL) and the CC genotype may have an decreased risk of developing osteonecrosis when treated with cyclophosphamide, cytarabine, daunorubicin, dexamethasone, doxorubicin, methotrexate, pegaspargase, prednisone, thioguanine and vincristine as compared to pediatric ALL patients with the CT or TT genotypes. Other clinical and genetic factors may also influence the risk of developing osteonecrosis in pediatric ALL patients.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448099112>1087</a></td><td>BMP7</td><td>rs79085477</td><td>dexamethasone</td><td>Osteonecrosis;Precursor Cell Lymphoblastic Leukemia-Lymphoma</td><td>3</td><td>CC</td><td>Toxicity</td><td>Pediatric patients with acute lymphoblastic leukemia (ALL) and the CC genotype may have an decreased risk of developing osteonecrosis when treated with cyclophosphamide, cytarabine, daunorubicin, dexamethasone, doxorubicin, methotrexate, pegaspargase, prednisone, thioguanine and vincristine as compared to pediatric ALL patients with the CT or TT genotypes. Other clinical and genetic factors may also influence the risk of developing osteonecrosis in pediatric ALL patients.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448099112>1088</a></td><td>BMP7</td><td>rs79085477</td><td>doxorubicin</td><td>Osteonecrosis;Precursor Cell Lymphoblastic Leukemia-Lymphoma</td><td>3</td><td>CC</td><td>Toxicity</td><td>Pediatric patients with acute lymphoblastic leukemia (ALL) and the CC genotype may have an decreased risk of developing osteonecrosis when treated with cyclophosphamide, cytarabine, daunorubicin, dexamethasone, doxorubicin, methotrexate, pegaspargase, prednisone, thioguanine and vincristine as compared to pediatric ALL patients with the CT or TT genotypes. Other clinical and genetic factors may also influence the risk of developing osteonecrosis in pediatric ALL patients.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448099112>1089</a></td><td>BMP7</td><td>rs79085477</td><td>methotrexate</td><td>Osteonecrosis;Precursor Cell Lymphoblastic Leukemia-Lymphoma</td><td>3</td><td>CC</td><td>Toxicity</td><td>Pediatric patients with acute lymphoblastic leukemia (ALL) and the CC genotype may have an decreased risk of developing osteonecrosis when treated with cyclophosphamide, cytarabine, daunorubicin, dexamethasone, doxorubicin, methotrexate, pegaspargase, prednisone, thioguanine and vincristine as compared to pediatric ALL patients with the CT or TT genotypes. Other clinical and genetic factors may also influence the risk of developing osteonecrosis in pediatric ALL patients.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448099112>1090</a></td><td>BMP7</td><td>rs79085477</td><td>pegaspargase</td><td>Osteonecrosis;Precursor Cell Lymphoblastic Leukemia-Lymphoma</td><td>3</td><td>CC</td><td>Toxicity</td><td>Pediatric patients with acute lymphoblastic leukemia (ALL) and the CC genotype may have an decreased risk of developing osteonecrosis when treated with cyclophosphamide, cytarabine, daunorubicin, dexamethasone, doxorubicin, methotrexate, pegaspargase, prednisone, thioguanine and vincristine as compared to pediatric ALL patients with the CT or TT genotypes. Other clinical and genetic factors may also influence the risk of developing osteonecrosis in pediatric ALL patients.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448099112>1091</a></td><td>BMP7</td><td>rs79085477</td><td>prednisone</td><td>Osteonecrosis;Precursor Cell Lymphoblastic Leukemia-Lymphoma</td><td>3</td><td>CC</td><td>Toxicity</td><td>Pediatric patients with acute lymphoblastic leukemia (ALL) and the CC genotype may have an decreased risk of developing osteonecrosis when treated with cyclophosphamide, cytarabine, daunorubicin, dexamethasone, doxorubicin, methotrexate, pegaspargase, prednisone, thioguanine and vincristine as compared to pediatric ALL patients with the CT or TT genotypes. Other clinical and genetic factors may also influence the risk of developing osteonecrosis in pediatric ALL patients.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448099112>1092</a></td><td>BMP7</td><td>rs79085477</td><td>thioguanine</td><td>Osteonecrosis;Precursor Cell Lymphoblastic Leukemia-Lymphoma</td><td>3</td><td>CC</td><td>Toxicity</td><td>Pediatric patients with acute lymphoblastic leukemia (ALL) and the CC genotype may have an decreased risk of developing osteonecrosis when treated with cyclophosphamide, cytarabine, daunorubicin, dexamethasone, doxorubicin, methotrexate, pegaspargase, prednisone, thioguanine and vincristine as compared to pediatric ALL patients with the CT or TT genotypes. Other clinical and genetic factors may also influence the risk of developing osteonecrosis in pediatric ALL patients.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448099112>1093</a></td><td>BMP7</td><td>rs79085477</td><td>vincristine</td><td>Osteonecrosis;Precursor Cell Lymphoblastic Leukemia-Lymphoma</td><td>3</td><td>CC</td><td>Toxicity</td><td>Pediatric patients with acute lymphoblastic leukemia (ALL) and the CC genotype may have an decreased risk of developing osteonecrosis when treated with cyclophosphamide, cytarabine, daunorubicin, dexamethasone, doxorubicin, methotrexate, pegaspargase, prednisone, thioguanine and vincristine as compared to pediatric ALL patients with the CT or TT genotypes. Other clinical and genetic factors may also influence the risk of developing osteonecrosis in pediatric ALL patients.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448099162>1094</a></td><td>HNF4A</td><td>rs3746574</td><td>docetaxel</td><td>Anemia;Nasopharyngeal Neoplasms</td><td>3</td><td>TT</td><td>Toxicity</td><td>Patients with nasopharyngeal cancer and the TT genotype may have less severe anemia when treated with docetaxel as compared to patients with the CT genotype. Other clinical and genetic factors may also influence severity of anemia in patients with nasopharyngeal cancer who are treated with docetaxel.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448099178>1095</a></td><td>HNF4A</td><td>rs6130615</td><td>docetaxel</td><td>Anemia;Nasopharyngeal Neoplasms</td><td>3</td><td>CT</td><td>Toxicity</td><td>Patients with nasopharyngeal cancer and the CT genotype may have less severe anemia when treated with docetaxel as compared to patients with the TT genotype. Other clinical and genetic factors may also influence severity of anemia in patients with nasopharyngeal cancer who are treated with docetaxel.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449140069>1096</a></td><td>NR1I2</td><td>rs6785049</td><td>sirolimus</td><td>gastrointestinal toxicity;Myelosuppression;Urinary Bladder Neoplasms</td><td>3</td><td>AG</td><td>Toxicity</td><td>Patients with the AG genotype and bladder cancer who are treated with temsirolimus may have decreased exposure to temsirolimus or sirolimus as compared to patients with the GG genotype, and decreased likelihood of bone marrow and gastrointestinal toxicities, or other adverse events as compared to patients with the AA genotypes. Other clinical and genetic factors may also influence metabolism of and likelihood of adverse events with temsirolimus or sirolimus in patients with bladder cancer.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449140069>1097</a></td><td>NR1I2</td><td>rs6785049</td><td>temsirolimus</td><td>gastrointestinal toxicity;Myelosuppression;Urinary Bladder Neoplasms</td><td>3</td><td>AG</td><td>Toxicity</td><td>Patients with the AG genotype and bladder cancer who are treated with temsirolimus may have decreased exposure to temsirolimus or sirolimus as compared to patients with the GG genotype, and decreased likelihood of bone marrow and gastrointestinal toxicities, or other adverse events as compared to patients with the AA genotypes. Other clinical and genetic factors may also influence metabolism of and likelihood of adverse events with temsirolimus or sirolimus in patients with bladder cancer.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/982030836>1098</a></td><td>UGT1A1</td><td>rs10929302</td><td>irinotecan</td><td>Neutropenia</td><td>2A</td><td>AG</td><td>Toxicity</td><td>Patients with the rs10929302 AG genotype may have decreased risk of neutropenia when treated with irinotecan as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence irinotecan-related toxicity.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448616890>1099</a></td><td>SLC22A7</td><td>rs2270860</td><td>capecitabine</td><td>Drug Toxicity;Neoplasms</td><td>3</td><td>CT</td><td>Toxicity</td><td>Patients with the CT genotype and colorectal cancer who are treated with capecitabine may have a decreased, but not absent, risk of drug toxicity as compared to patients with the TT genotype. Other clinical and genetic factors may also influence drug toxicity in patients with colorectal cancer who are treated with capecitabine.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448634065>1100</a></td><td>COMT</td><td>rs4646316</td><td>cisplatin</td><td>Neoplasms;nephrotoxicity</td><td>3</td><td>CT</td><td>Toxicity</td><td>The CT genotype may be associated with decreased likelihood of nephrotoxicity when treated with cisplatin as compared to theTT genotype. Other clinical and genetic factors may influence likelihood of nephrotoxicity in patients treated with cisplatin.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183700517>1101</a></td><td>NOS2</td><td>rs11080344</td><td>isoniazid</td><td>Toxic liver disease;Tuberculosis</td><td>3</td><td>TC</td><td>Toxicity</td><td>Patients with the TC genotype may have decreased likelihood of Toxic liver disease when treated with isoniazid and rifampin in people with Tuberculosis as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity to isoniazid and rifampin.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183700517>1102</a></td><td>NOS2</td><td>rs11080344</td><td>rifampin</td><td>Toxic liver disease;Tuberculosis</td><td>3</td><td>TC</td><td>Toxicity</td><td>Patients with the TC genotype may have decreased likelihood of Toxic liver disease when treated with isoniazid and rifampin in people with Tuberculosis as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity to isoniazid and rifampin.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444704963>1103</a></td><td>ADORA2A</td><td>rs3761422</td><td>caffeine</td><td>Anxiety Disorders</td><td>3</td><td>CT</td><td>Toxicity</td><td>People with the CT genotype may have decreased Anxiety Disorders when exposed to caffeine as compared to patients with genotype TT. Other genetic and clinical factors may also influence the anxiogenic effect of caffeine.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449003940>1104</a></td><td>-</td><td>rs111618861</td><td>Antithyroid Preparations</td><td>Agranulocytosis</td><td>3</td><td>A/A</td><td>Toxicity</td><td>Patients with the A/A genotype may have a decreased risk of developing agranulocytosis when treated with antithyroid preparations as compared to patients with the A/del or del/del genotypes. Other genetic and clinical factors may also influence a patient's risk of developing agranulocytosis when treated with antithyroid preparations.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450944540>1105</a></td><td>ABCB1</td><td>rs1128503</td><td>cyclosporine</td><td>hematopoietic stem cell transplantation;Neurotoxicity Syndromes</td><td>3</td><td>AG</td><td>Toxicity</td><td>Patients with the AG genotype may be at a decreased risk of developing neurotoxicity after receiving cyclosporine following hematopoietic stem cell transplant as compared to patients with the GG genotype. However, this association was not statistically significant. Other genetic and clinical factors may also affect a patient's rick of developing neurotoxicity following cyclosporine treatment.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/637880087>1106</a></td><td>SLC22A2</td><td>rs316019</td><td>cisplatin</td><td>Neoplasms</td><td>3</td><td>AC</td><td>Toxicity</td><td>Patients with the AC genotype may have reduced but not non-existent risk of nephrotoxicity, as measured by serum creatinine, in response to cisplatin treatment as compared to patients with the CC genotype however studies with other biomarkers showed conflicting results. Other genetic and clinical factors may also influence a patient's risk for toxicity.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451544980>1107</a></td><td>CNIH3</td><td>rs10799590</td><td>opioids</td><td>Opioid-Related Disorders</td><td>3</td><td>AG</td><td>Toxicity</td><td>Patients with the rs10799590 AG genotype may have a decreased risk of developing opioid dependence when exposed to opioids as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of developing opioid dependence.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451151340>1108</a></td><td>TP53</td><td>rs1042522</td><td>antineoplastic agents</td><td>Drug Toxicity</td><td>3</td><td>CG</td><td>Toxicity</td><td>Patients with the CG genotype may have decreased but not absent risk for toxicity when treated with antineoplastic agents as compared to patients with the GG genotype although . Other genetic and clinical factors may also influence a patient's response to antineoplastic agents.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450930833>1109</a></td><td>CHRNB4</td><td>rs7178270</td><td>nicotine</td><td>Tobacco Use Disorder</td><td>3</td><td>CG</td><td>Toxicity</td><td>Patients with the CG genotype may have decreased severity of nicotine dependence, as measured by FTND score, as compared to patients with the CC genotype. Other genetic and clinical factors may also affect severity of nicotine dependence.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450812253>1110</a></td><td>CSNK1E</td><td>rs1534891</td><td>heroin</td><td>Heroin Dependence</td><td>3</td><td>CT</td><td>Toxicity</td><td>Patients with the CT genotype may be at a decreased risk of developing heroin dependence as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of developing heroin dependence.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449190104>1111</a></td><td>ABCB1</td><td>rs1045642</td><td>antineoplastic agents</td><td>Neoplasms</td><td>3</td><td>AA</td><td>Toxicity</td><td>Patients with the AA genotype and receiving chemotherapy treatment may have decreased severity of nausea as compared to patients with the AG genotype. Other genetic and clinical factors may also affect the severity of nausea following chemotherapy treatment.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449271003>1112</a></td><td>PIK3R2</td><td>rs117341846</td><td>cyclophosphamide</td><td>Breast Neoplasms;Neutropenia</td><td>3</td><td>CC</td><td>Toxicity</td><td>Patients with breast cancer and the CC genotype may have a decreased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449271003>1113</a></td><td>PIK3R2</td><td>rs117341846</td><td>epirubicin</td><td>Breast Neoplasms;Neutropenia</td><td>3</td><td>CC</td><td>Toxicity</td><td>Patients with breast cancer and the CC genotype may have a decreased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449271003>1114</a></td><td>PIK3R2</td><td>rs117341846</td><td>fluorouracil</td><td>Breast Neoplasms;Neutropenia</td><td>3</td><td>CC</td><td>Toxicity</td><td>Patients with breast cancer and the CC genotype may have a decreased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450936592>1115</a></td><td>AQP1</td><td>rs1049305</td><td>cisplatin</td><td>Anemia;Mesothelioma</td><td>3</td><td>CG</td><td>Toxicity</td><td>Patients with malignant mesothelioma and the CG genotype may be at a decreased risk of developing anemia when treated with cisplatin-based chemotherapy as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing anemia when treated with cisplatin-based chemotherapy.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449270985>1116</a></td><td>INSR</td><td>rs41412545</td><td>cyclophosphamide</td><td>Breast Neoplasms;Neutropenia</td><td>3</td><td>CC</td><td>Toxicity</td><td>Patients with breast cancer and the CC genotype may have a decreased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the AA or AC genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449270985>1117</a></td><td>INSR</td><td>rs41412545</td><td>epirubicin</td><td>Breast Neoplasms;Neutropenia</td><td>3</td><td>CC</td><td>Toxicity</td><td>Patients with breast cancer and the CC genotype may have a decreased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the AA or AC genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449270985>1118</a></td><td>INSR</td><td>rs41412545</td><td>fluorouracil</td><td>Breast Neoplasms;Neutropenia</td><td>3</td><td>CC</td><td>Toxicity</td><td>Patients with breast cancer and the CC genotype may have a decreased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the AA or AC genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449270991>1119</a></td><td>PIK3R2</td><td>rs118129530</td><td>cyclophosphamide</td><td>Breast Neoplasms;Neutropenia</td><td>3</td><td>GG</td><td>Toxicity</td><td>Patients with breast cancer and the GG genotype may have a decreased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449270991>1120</a></td><td>PIK3R2</td><td>rs118129530</td><td>epirubicin</td><td>Breast Neoplasms;Neutropenia</td><td>3</td><td>GG</td><td>Toxicity</td><td>Patients with breast cancer and the GG genotype may have a decreased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449270991>1121</a></td><td>PIK3R2</td><td>rs118129530</td><td>fluorouracil</td><td>Breast Neoplasms;Neutropenia</td><td>3</td><td>GG</td><td>Toxicity</td><td>Patients with breast cancer and the GG genotype may have a decreased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450807362>1122</a></td><td>OPRM1</td><td>rs2075572</td><td>heroin</td><td>Heroin Dependence</td><td>3</td><td>CC</td><td>Toxicity</td><td>Patients with the CC genotype may be at a decreased risk of developing heroin dependence as compared to patients with the CG or GG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing heroin dependence.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450823123>1123</a></td><td>OPRM1</td><td>rs562859</td><td>heroin</td><td>Heroin Dependence</td><td>3</td><td>TT</td><td>Toxicity</td><td>Patients with the TT genotype may be at a decreased risk of developing heroin dependence as compared to patients with the CC or CT genotypes. Other genetic or clinical factors may also affect a patient's risk of developing heroin dependence.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449003926>1124</a></td><td>HLA-B</td><td>rs1071816</td><td>Antithyroid Preparations</td><td>Agranulocytosis</td><td>3</td><td>TT</td><td>Toxicity</td><td>Patients with the TT genotype may have a decreased risk of developing agranulocytosis when treated with antithyroid preparations as compared to patients with the CT or CC genotypes. Other genetic and clinical factors may also influence a patient's risk of developing agranulocytosis when treated with antithyroid preparations.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450809956>1125</a></td><td>OPRM1</td><td>rs2075572</td><td>methamphetamine</td><td>methamphetamine dependence</td><td>3</td><td>CC</td><td>Toxicity</td><td>Patients with the CC genotype may be at a decreased risk of developing methamphetamine dependence as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing methamphetamine dependence.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451114072>1126</a></td><td>APOB</td><td>rs679899</td><td>warfarin</td><td>heart valve replacement;Hemorrhage</td><td>3</td><td>AA</td><td>Toxicity</td><td>Patients with the AA genotype and receiving warfarin following cardiac valve replacement may have a decreased risk of bleeding at therapeutic INR as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's risk of bleeding while receiving warfarin therapy.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451120724>1127</a></td><td>-</td><td>rs62097526</td><td>antipsychotics</td><td>Weight gain</td><td>3</td><td>TT</td><td>Toxicity</td><td>Patients with the rs62097526 TT genotype may gain less weight during treatment with antipsychotics as compared to patients with the GG or GT genotypes. Other genetic and clinical factors may also affect weight gain during treatment with antipsychotics.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451129800>1128</a></td><td>CACNA1C</td><td>rs1034936</td><td>ethanol</td><td>Alcoholism;Bipolar Disorder</td><td>3</td><td>CT</td><td>Toxicity</td><td>Patients with bipolar disorder and the CT genotype may be at a decreased risk of developing alcohol dependence as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's risk of developing alcohol dependence.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451131840>1129</a></td><td>NFKBIA</td><td>rs2233409</td><td>gefitinib</td><td>Carcinoma, Non-Small-Cell Lung;Diarrhea</td><td>3</td><td>GG</td><td>Toxicity</td><td>Patients with non-small cell lung cancer and the GG genotype may be at a decreased risk of developing diarrhea when treated with gefitinib as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of gefitinib-induced diarrhea.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451131858>1130</a></td><td>TAB2</td><td>rs577001</td><td>gefitinib</td><td>Diarrhea</td><td>3</td><td>CT</td><td>Toxicity</td><td>Patients with non-small cell lung cancer and the CT genotype may be at a decreased risk of developing diarrhea when treated with gefitinib as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of gefitinib-induced diarrhea.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451145100>1131</a></td><td>CHRNA5</td><td>rs588765</td><td>cocaine</td><td>Cocaine-Related Disorders</td><td>3</td><td>CT</td><td>Toxicity</td><td>Patients with the CT genotype may be at a decreased risk of cocaine dependence as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of developing cocaine dependence.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451146140>1132</a></td><td>TH</td><td>rs10770141</td><td>opioids</td><td>Opioid-Related Disorders</td><td>3</td><td>GG</td><td>Toxicity</td><td>Patients with the GG genotype may be at a decreased risk of developing opioid dependence as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing opioid dependence.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451149980>1133</a></td><td>PDE4B</td><td>rs6421482</td><td>ethanol</td><td>Alcoholism</td><td>3</td><td>AG</td><td>Toxicity</td><td>Patients with the AG genotype may be at a decreased risk of developing alcoholism as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451149992>1134</a></td><td>GCKR</td><td>rs1260326</td><td>ethanol</td><td>Alcoholism</td><td>3</td><td>CT</td><td>Toxicity</td><td>Patients with the CT genotype may be at a decreased risk of developing alcoholism as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451149998>1135</a></td><td>-</td><td>rs494904</td><td>ethanol</td><td>Alcoholism</td><td>3</td><td>CT</td><td>Toxicity</td><td>Patients with the CT genotype may be at a decreased risk of developing alcoholism as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451150020>1136</a></td><td>-</td><td>rs9679319</td><td>ethanol</td><td>Alcoholism</td><td>3</td><td>GT</td><td>Toxicity</td><td>Patients with the GT genotype may be at a decreased risk of developing alcoholism as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451150046>1137</a></td><td>-</td><td>rs2673136</td><td>ethanol</td><td>Alcoholism</td><td>3</td><td>AG</td><td>Toxicity</td><td>Patients with the AG genotype may be at a decreased risk of developing alcoholism as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451150060>1138</a></td><td>CADM2</td><td>rs62250713</td><td>ethanol</td><td>Alcoholism</td><td>3</td><td>GG</td><td>Toxicity</td><td>Patients with the GG genotype may be at a decreased risk of developing alcoholism as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451151460>1139</a></td><td>DPP6</td><td>rs2533200</td><td>ethanol</td><td>Alcoholism</td><td>3</td><td>CG</td><td>Toxicity</td><td>Patients with the CG genotype may be at a decreased risk of developing alcoholism as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451151466>1140</a></td><td>-</td><td>rs2582405</td><td>ethanol</td><td>Alcoholism</td><td>3</td><td>CC</td><td>Toxicity</td><td>Patients with the CC genotype may be at a decreased risk of developing alcoholism as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451151500>1141</a></td><td>-</td><td>rs6589386</td><td>ethanol</td><td>Alcoholism</td><td>3</td><td>CT</td><td>Toxicity</td><td>Patients with the CT genotype may be at a decreased risk of developing alcoholism as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451151512>1142</a></td><td>-</td><td>rs8008020</td><td>ethanol</td><td>Alcoholism</td><td>3</td><td>CC</td><td>Toxicity</td><td>Patients with the CC genotype may be at a decreased risk of developing alcoholism as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451266120>1143</a></td><td>DPYD</td><td>rs67376798</td><td>tegafur</td><td>Neoplasms</td><td>1A</td><td>TT</td><td>Toxicity</td><td>Patients with the rs67376798 TT genotype and cancer who are treated with tegafur, a fluoropyrimidine, may have a decreased, but not absent, risk of drug toxicity as compared to patients with the AT or AA genotype. This drug-variant pair has been assigned a no recommendation by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence response to fluoropyrimidine-based chemotherapy.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451356386>1144</a></td><td>NECTIN4</td><td>rs11265549</td><td>methadone</td><td>Opioid-Related Disorders</td><td>3</td><td>GG</td><td>Metabolism/PK</td><td>Patients with opioid dependence and the rs11265549 GG genotype may have increased concentrations of methadone when receiving methadone maintenance therapy (MMT) as compared to patients with the AA genotype. This annotation only covers the pharmacokinetic relationship between rs11265549 and methadone and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence methadone concetrations.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451244700>1145</a></td><td>SLCO1B1</td><td>rs4149056</td><td>fluvastatin</td><td></td><td>1A</td><td>CT</td><td>Metabolism/PK</td><td>Patients with the rs4149056 CT genotype may have increased concentrations of fluvastatin as compared to patients with the TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect fluvastatin concentrations. This annotation only covers the pharmacokinetic relationship between rs4149056 and fluvastatin and does not include evidence about clinical outcomes.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450936284>1146</a></td><td>SULT1A1</td><td>rs758145522</td><td>acetaminophen</td><td></td><td>3</td><td>AA</td><td>Metabolism/PK</td><td>Patients with the AA genotype may have increased sulfation of acetaminophen as compared to patients with the AT or TT genotypes. Other genetic and clinical factors may also affect acetaminophen sulfation.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449005041>1147</a></td><td>CYP3A</td><td>rs776746</td><td>lumefantrine</td><td>Malaria</td><td>3</td><td>CC</td><td>Metabolism/PK</td><td>Pregnant patients infected with malaria and the CC genotype may have elevated concentrations of lumefantrine as compared to patients with the CT or TT genotypes. There is no association with response. Other clinical and genetic factors may also influence concentrations of lumefantrine.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449005041>1148</a></td><td>CYP3A5</td><td>rs776746</td><td>lumefantrine</td><td>Malaria</td><td>3</td><td>CC</td><td>Metabolism/PK</td><td>Pregnant patients infected with malaria and the CC genotype may have elevated concentrations of lumefantrine as compared to patients with the CT or TT genotypes. There is no association with response. Other clinical and genetic factors may also influence concentrations of lumefantrine.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449005041>1149</a></td><td>ZSCAN25</td><td>rs776746</td><td>lumefantrine</td><td>Malaria</td><td>3</td><td>CC</td><td>Metabolism/PK</td><td>Pregnant patients infected with malaria and the CC genotype may have elevated concentrations of lumefantrine as compared to patients with the CT or TT genotypes. There is no association with response. Other clinical and genetic factors may also influence concentrations of lumefantrine.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450044809>1150</a></td><td>ABCC2</td><td>rs2273697</td><td>ceftriaxone</td><td>Central Nervous System Infections</td><td>3</td><td>AG</td><td>Metabolism/PK</td><td>Patients with central nervous system infections and the AG genotype may have increased cerebrospinal fluid (CSF) concentrations of ceftriaxone as compared to patients with the GG genotype. Other genetic and clinical factors may also affect CSF concentrations of ceftriaxone.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450112772>1151</a></td><td>UGT1A1</td><td>rs4148324</td><td>methotrexate</td><td>Osteosarcoma</td><td>3</td><td>GT</td><td>Metabolism/PK</td><td>Patients with osteosarcoma and the GT genotype may have decreased clearance of methotrexate as compared to patients with the TT genotype. This variant is identified in the paper as being located in the UGT1A gene. Other genetic and clinical factors may also affect clearance of methotrexate in patients.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450112772>1152</a></td><td>UGT1A10</td><td>rs4148324</td><td>methotrexate</td><td>Osteosarcoma</td><td>3</td><td>GT</td><td>Metabolism/PK</td><td>Patients with osteosarcoma and the GT genotype may have decreased clearance of methotrexate as compared to patients with the TT genotype. This variant is identified in the paper as being located in the UGT1A gene. Other genetic and clinical factors may also affect clearance of methotrexate in patients.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450112772>1153</a></td><td>UGT1A3</td><td>rs4148324</td><td>methotrexate</td><td>Osteosarcoma</td><td>3</td><td>GT</td><td>Metabolism/PK</td><td>Patients with osteosarcoma and the GT genotype may have decreased clearance of methotrexate as compared to patients with the TT genotype. This variant is identified in the paper as being located in the UGT1A gene. Other genetic and clinical factors may also affect clearance of methotrexate in patients.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450112772>1154</a></td><td>UGT1A4</td><td>rs4148324</td><td>methotrexate</td><td>Osteosarcoma</td><td>3</td><td>GT</td><td>Metabolism/PK</td><td>Patients with osteosarcoma and the GT genotype may have decreased clearance of methotrexate as compared to patients with the TT genotype. This variant is identified in the paper as being located in the UGT1A gene. Other genetic and clinical factors may also affect clearance of methotrexate in patients.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450112772>1155</a></td><td>UGT1A5</td><td>rs4148324</td><td>methotrexate</td><td>Osteosarcoma</td><td>3</td><td>GT</td><td>Metabolism/PK</td><td>Patients with osteosarcoma and the GT genotype may have decreased clearance of methotrexate as compared to patients with the TT genotype. This variant is identified in the paper as being located in the UGT1A gene. Other genetic and clinical factors may also affect clearance of methotrexate in patients.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450112772>1156</a></td><td>UGT1A6</td><td>rs4148324</td><td>methotrexate</td><td>Osteosarcoma</td><td>3</td><td>GT</td><td>Metabolism/PK</td><td>Patients with osteosarcoma and the GT genotype may have decreased clearance of methotrexate as compared to patients with the TT genotype. This variant is identified in the paper as being located in the UGT1A gene. Other genetic and clinical factors may also affect clearance of methotrexate in patients.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450112772>1157</a></td><td>UGT1A7</td><td>rs4148324</td><td>methotrexate</td><td>Osteosarcoma</td><td>3</td><td>GT</td><td>Metabolism/PK</td><td>Patients with osteosarcoma and the GT genotype may have decreased clearance of methotrexate as compared to patients with the TT genotype. This variant is identified in the paper as being located in the UGT1A gene. Other genetic and clinical factors may also affect clearance of methotrexate in patients.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450112772>1158</a></td><td>UGT1A8</td><td>rs4148324</td><td>methotrexate</td><td>Osteosarcoma</td><td>3</td><td>GT</td><td>Metabolism/PK</td><td>Patients with osteosarcoma and the GT genotype may have decreased clearance of methotrexate as compared to patients with the TT genotype. This variant is identified in the paper as being located in the UGT1A gene. Other genetic and clinical factors may also affect clearance of methotrexate in patients.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450112772>1159</a></td><td>UGT1A9</td><td>rs4148324</td><td>methotrexate</td><td>Osteosarcoma</td><td>3</td><td>GT</td><td>Metabolism/PK</td><td>Patients with osteosarcoma and the GT genotype may have decreased clearance of methotrexate as compared to patients with the TT genotype. This variant is identified in the paper as being located in the UGT1A gene. Other genetic and clinical factors may also affect clearance of methotrexate in patients.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450936260>1160</a></td><td>SULT1A1</td><td>rs767487725</td><td>tapentadol</td><td></td><td>3</td><td>AA</td><td>Metabolism/PK</td><td>Patients with the AA genotype may have increased sulfation of tapentadol as compared to patients with the AC or CC genotypes. Other genetic and clinical factors may also affect tapentadol sulfation.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183697592>1161</a></td><td>SLCO1B1</td><td>rs2306283</td><td>methotrexate</td><td>Precursor Cell Lymphoblastic Leukemia-Lymphoma</td><td>3</td><td>AG</td><td>Metabolism/PK</td><td>Patients with the rs2306283 AG genotype may have increased exposure to methotrexate as compared to patients with the GG genotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs2306283 and methotrexate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence methotrexate exposure.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449169484>1162</a></td><td>UGT2B7</td><td>rs7668258</td><td>valproic acid</td><td>Epilepsy</td><td>3</td><td>CT</td><td>Metabolism/PK</td><td>Patients with the CT genotype and epilepsy who are treated with valproic acid may have increased concentrations of valproic acid as compared to patients with the CC genotypes, although this is contradicted in two studies. Other clinical and genetic factors may also influence concentrations of valproic acid in patients epilepsy.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448820584>1163</a></td><td>C6</td><td>rs9200</td><td>tacrolimus</td><td>liver transplantation</td><td>3</td><td>TT</td><td>Metabolism/PK</td><td>Patients undergoing liver transplantation with the TT genotype may have increased dose-adjusted trough concentrations of tacrolimus as compared to patients with the CC or CT genotype. Other genetic and clinical factors, such as CYP3A5*3, may also influence dose-adjusted trough concentrations of tacrolimus.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448820590>1164</a></td><td>C6</td><td>rs10052999</td><td>tacrolimus</td><td>liver transplantation</td><td>3</td><td>CT</td><td>Metabolism/PK</td><td>Patients undergoing liver transplantation whose donor livers have the CT genotype may have increased dose-adjusted trough concentrations of tacrolimus as compared to patients with the CC or TT genotype. Other genetic and clinical factors, such as CYP3A5*3, may also influence dose-adjusted trough concentrations of tacrolimus.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655387949>1165</a></td><td>SLCO1B1</td><td>rs4149056</td><td>methotrexate</td><td>Osteosarcoma;Precursor Cell Lymphoblastic Leukemia-Lymphoma</td><td>3</td><td>CT</td><td>Metabolism/PK</td><td>Pediatric patients with the rs4149056 CT genotype and cancers may have decreased clearance of methotrexate as compared to patients with the TT genotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs4149056 and methotrexate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence clearance of methotrexate.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655384578>1166</a></td><td>CYP3A4</td><td>rs2740574</td><td>docetaxel</td><td>Neoplasms</td><td>3</td><td>TT</td><td>Metabolism/PK</td><td>Patients with the TT genotype may have decreased clearance of docetaxel and a decreased risk of an infusion-related reaction as compared to patients with the CC or CT genotype. These patients may experience a decreased risk of neurotoxicity with docetaxel treatment, though reports conflict. Other genetic and clinical factors may also influence clearance of and reactions to docetaxel.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451244800>1167</a></td><td>SLCO1B1</td><td>rs4149056</td><td>atorvastatin</td><td></td><td>1A</td><td>CT</td><td>Metabolism/PK</td><td>Patients with the CT genotype may have increased exposure to atorvastatin as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's exposure to atorvastatin. This annotation only covers the pharmacokinetic relationship between rs4149056 and atorvastatin and does not include evidence about clinical outcomes.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/981204286>1168</a></td><td>ABCB1</td><td>rs1045642</td><td>cyclosporine</td><td>Transplantation</td><td>3</td><td>AA</td><td>Metabolism/PK</td><td>Patients with genotype AA may have increased intracellular and blood concentrations of cyclosporine in people with Transplantation as compared to patients with genotype GG. However, contradictory findings have been reported. Other genetic and clinical factors may also influence the concentration of cyclosporine.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449162866>1169</a></td><td>ABCB1</td><td>rs1045642</td><td>tramadol</td><td></td><td>3</td><td>AA</td><td>Metabolism/PK</td><td>Patients with the AA genotype may have an increased exposure to tramadol as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence a patient's exposure to tramadol.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449169595>1170</a></td><td>AGTR1</td><td>rs5186</td><td>atorvastatin</td><td></td><td>3</td><td>AC</td><td>Metabolism/PK</td><td>Subjects with the AC genotype may have an increased exposure to atorvastatin as compared to individuals with the AA or CC genotypes. Other clinical and genetic factors may also influence exposure to atorvastatin.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449165794>1171</a></td><td>SUMO4</td><td>rs237025</td><td>tacrolimus</td><td>liver transplantation</td><td>3</td><td>AG</td><td>Metabolism/PK</td><td>Patients who are undergoing liver transplantation and receive a liver from a DONOR with the AG genotype may have increased concentrations of tacrolimus as compared to patients who receive a liver from a DONOR with the AA genotype. Other genetic and clinical factors, such as CYP3A5*3, may also influence tacrolimus concentrations.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449140229>1172</a></td><td>ABCB1</td><td>rs1128503</td><td>sirolimus</td><td>Urinary Bladder Neoplasms</td><td>3</td><td>AG</td><td>Metabolism/PK</td><td>Patients with the AG genotype and bladder cancer may have increased exposure to sirolimus and temsirolimus as compared to patients with the GG genotypes. Other clinical and genetic factors may also influence exposure to sirolimus and temsirolimus in patients with bladder cancer.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449140229>1173</a></td><td>ABCB1</td><td>rs1128503</td><td>temsirolimus</td><td>Urinary Bladder Neoplasms</td><td>3</td><td>AG</td><td>Metabolism/PK</td><td>Patients with the AG genotype and bladder cancer may have increased exposure to sirolimus and temsirolimus as compared to patients with the GG genotypes. Other clinical and genetic factors may also influence exposure to sirolimus and temsirolimus in patients with bladder cancer.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449645366>1174</a></td><td>SULT1A3</td><td>rs767263838</td><td>morphine</td><td></td><td>3</td><td>TT</td><td>Metabolism/PK</td><td>Patients with the TT genotype may have an increased rate of sulfation of morphine as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect morphine sulfation in patients.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449645372>1175</a></td><td>SULT1A3</td><td>rs767263838</td><td>tapentadol</td><td></td><td>3</td><td>TT</td><td>Metabolism/PK</td><td>Patients with the TT genotype may have an increased rate of sulfation of tapentadol as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect tapentadol sulfation in patients.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449157957>1176</a></td><td>CYP24A1</td><td>rs2585428</td><td>deferasirox</td><td>beta-Thalassemia</td><td>3</td><td>TT</td><td>Metabolism/PK</td><td>Patients with the TT genotype and beta-thalassemia may have decreased metabolism of deferasirox as compared to patients with the CC genotype. Other genetic and clinical factors may also influence deferasirox metabolism.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449157963>1177</a></td><td>CYP24A1</td><td>rs2248359</td><td>deferasirox</td><td>beta-Thalassemia</td><td>3</td><td>TT</td><td>Metabolism/PK</td><td>Patients with the TT genotype and beta-thalassemia may have decreased metabolism of deferasirox as compared to patients with the CC genotype. Other genetic and clinical factors may also influence deferasirox metabolism.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450936272>1178</a></td><td>SULT1A1</td><td>rs758145522</td><td>desmethylnaproxen</td><td></td><td>3</td><td>AA</td><td>Metabolism/PK</td><td>Patients with the AA genotype may have increased sulfation of O-desmethylnaproxen as compared to patients with the AT or TT genotypes. Other genetic and clinical factors may also affect O-desmethylnaproxen sulfation.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444700796>1179</a></td><td>CYP2C19</td><td>rs12768009</td><td>nevirapine</td><td>HIV Infections</td><td>3</td><td>AA</td><td>Metabolism/PK</td><td>Patients with the AA genotype and HIV who are treated with nevirapine may have decreased clearance of nevirapine as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's response to nevirapine.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444704074>1180</a></td><td>AHR</td><td>rs4410790</td><td>olanzapine</td><td>Psychotic Disorders</td><td>3</td><td>CT</td><td>Metabolism/PK</td><td>Patients with the CT genotype may have decreased metabolism of olanzapine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's metabolism of olanzapine.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1445402163>1181</a></td><td>HSD11B1</td><td>rs846908</td><td>tacrolimus</td><td>Kidney Transplantation</td><td>3</td><td>GG</td><td>Metabolism/PK</td><td>Patients with the GG genotype who are undergoing kidney transplantation may have higher concentrations of tacrolimus as compared to patients with the AA genotype. However, this was only significant in patients who were CYP3A5 expressers (CYP3A5 *1/*1 or *1/*3). Other genetic and clinical factors, such as CYP3A5 variants, may also influence concentrations of tacrolimus.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1445402175>1182</a></td><td>HSD11B1</td><td>rs4844880</td><td>tacrolimus</td><td>Kidney Transplantation</td><td>3</td><td>TT</td><td>Metabolism/PK</td><td>Patients with the TT genotype who are undergoing kidney transplantation may have higher concentrations of tacrolimus as compared to patients with the AA genotype. However, this was only significant in patients who were CYP3A5 expressers (CYP3A5 *1/*1 or *1/*3). Other genetic and clinical factors, such as CYP3A5 variants, may also influence concentrations of tacrolimus.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1445402182>1183</a></td><td>HSD11B1</td><td>rs846910</td><td>tacrolimus</td><td>Kidney Transplantation</td><td>3</td><td>GG</td><td>Metabolism/PK</td><td>Patients with the GG genotype who are undergoing kidney transplantation may have higher concentrations of tacrolimus as compared to patients with the AA genotype. However, this was only significant in patients who were CYP3A5 expressers (CYP3A5 *1/*1 or *1/*3). Other genetic and clinical factors, such as CYP3A5 variants, may also influence concentrations of tacrolimus.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444704921>1184</a></td><td>ABCC2</td><td>rs3740066</td><td>carbamazepine</td><td>Epilepsy</td><td>3</td><td>CT</td><td>Metabolism/PK</td><td>Patients with the CT genotype may have decreased metabolism of carbamazepine in men with Epilepsy as compared to patients with genotype CC. This association was only significant in male patients. Other genetic and clinical factors may also influence the metabolism of carbamazepine.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1445401439>1185</a></td><td>CYP2C9</td><td>rs1934969</td><td>phenytoin</td><td>Epilepsy</td><td>3</td><td>TT</td><td>Metabolism/PK</td><td>Patients with the TT genotype and epilepsy may have increased dose-adjusted trough concentrations of phenytoin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence dose-adjusted trough concentrations of phenytoin.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444666550>1186</a></td><td>ABCC2</td><td>rs2273697</td><td>deferasirox</td><td>beta-Thalassemia</td><td>3</td><td>AG</td><td>Metabolism/PK</td><td>Patients with the AG genotype and beta-thalassemia may have increased concentrations of deferasirox as compared to patients with the GG genotype. Other genetic and clinical factors may also influence concentrations of deferasirox.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1446906328>1187</a></td><td>NR1I2</td><td>rs4688040</td><td>carbamazepine</td><td>Epilepsy</td><td>3</td><td>GG</td><td>Metabolism/PK</td><td>Patients with the GG genotype may have decreased metabolism of carbamazepine in people with Epilepsy as compared to patients with genotype TT or GT. Other genetic and clinical factors may also influence metabolism of carbamazepine.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444686850>1188</a></td><td>SLC22A1</td><td>rs683369</td><td>imatinib</td><td>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</td><td>3</td><td>CG</td><td>Metabolism/PK</td><td>Patients with the CG genotype and chronic myeloid leukemia may have decreased clearance of imatinib, as well as decreased event-free survival time, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence clearance of imatinib and event-free survival time.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444686843>1189</a></td><td>CYP3A4</td><td>rs4646437</td><td>tacrolimus</td><td>Kidney Transplantation;liver transplantation;Proteinuria</td><td>2A</td><td>GG</td><td>Metabolism/PK</td><td>Patients with the rs4646437 GG genotype may have increased dose-adjusted trough concentrations of tacrolimus as compared to patients with the AA or AG genotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs4646437 and tacrolimus and does not include evidence about clinical outcomes. Other genetic and clinical factors, such as the CYP3A5*3 allele, may also influence concentrations of tacrolimus.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447943693>1190</a></td><td>DRD3</td><td>rs6280</td><td>quetiapine</td><td></td><td>3</td><td>CT</td><td>Metabolism/PK</td><td>People with CT genotype may have decreased clearance of quetiapine compared with people with genotype TT. Other genetic and clinical factors may affect a person's clearance of quetiapine.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447943739>1191</a></td><td>ABCB1</td><td>rs1128503</td><td>efavirenz</td><td>HIV Infections</td><td>4</td><td>AG</td><td>Metabolism/PK</td><td>Patients with AG genotype and HIV may have increased concentrations of efavirenz in plasma compared to patients with AA genotype. However, this association was not significant and has not been found in other studies. Other clinical and genetic factors may affect efavirenz concentrations.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444700896>1192</a></td><td>CYP3A5</td><td>rs776746</td><td>quetiapine</td><td></td><td>3</td><td>CC</td><td>Metabolism/PK</td><td>Patients with the CC genotype may have decreased metabolism of quetiapine as compared to CT or TT genotype. Other genetic and clinical factors may also influence a patient's response to quetiapine.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444694511>1193</a></td><td>ABCB1</td><td>rs2032582</td><td>tacrolimus</td><td>Kidney Transplantation;liver transplantation</td><td>4</td><td>AC</td><td>Metabolism/PK</td><td>Patients with the AC genotype who are undergoing organ transplantation may have decreased metabolism and dose requirements of tacrolimus, as compared to patients with the CC genotype. However, the majority of studies have found no association between this polymorphism and metabolism or dose of tacrolimus. Other genetic and clinical factors, such as CYP3A5*3, may also influence metabolism and dose of tacrolimus.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448594289>1194</a></td><td>CYP2B6</td><td>rs2279343</td><td>propofol</td><td></td><td>4</td><td>AG</td><td>Metabolism/PK</td><td>Patients with the AG genotype who undergo anesthesia with propofol may have decreased clearance of the drug as compared to patients with the GG genotype. However, a different study found no association for the CYP2B6*4, *6 and *7 haplotypes - this SNP defines the *4 haplotype, and appears in combination with other SNPs in the *6 and *7 haplotypes. Other genetic and clinical factors may also influence propofol clearance.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444706124>1195</a></td><td>SLCO1B1</td><td>rs11045872</td><td>methotrexate</td><td>Precursor Cell Lymphoblastic Leukemia-Lymphoma</td><td>3</td><td>AA</td><td>Metabolism/PK</td><td>Pediatric patients with ALL and the AA genotype may have decreased clearance of methotrexate as compared to patients with the GG genotype. Other genetic and clinical factors may influence also a patient's clearance of methotrexate.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444704914>1196</a></td><td>ABCB1</td><td>rs1045642</td><td>etoposide</td><td>Precursor Cell Lymphoblastic Leukemia-Lymphoma</td><td>3</td><td>AA</td><td>Metabolism/PK</td><td>Patients with the AA genotype and Precursor Cell Lymphoblastic Leukemia-Lymphoma may have decreased metabolism of etoposide as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to etoposide.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444703473>1197</a></td><td>CYP3A5</td><td>rs776746</td><td>vardenafil</td><td></td><td>3</td><td>CC</td><td>Metabolism/PK</td><td>Male patients with the CC genotype may have decreased clearance of vardenafil as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to vardenafil.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444607716>1198</a></td><td>ABCB1</td><td>rs2032582</td><td>ritonavir</td><td>HIV Infections</td><td>3</td><td>AC</td><td>Metabolism/PK</td><td>Patients with the AC genotype who are treated with ritonavir may have a increased intracellular/plasma trough concentration as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to ritonavir.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444666342>1199</a></td><td>ORM2</td><td>rs2250242</td><td>docetaxel</td><td>Prostatic Neoplasms</td><td>3</td><td>AG</td><td>Metabolism/PK</td><td>Patients with the AG genotype and prostate cancer may have decreased clearance of docetaxel as compared to patients with the AA genotype. Other genetic and clinical factors may also influence clearance of docetaxel.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444666564>1200</a></td><td>CYP1A2</td><td>rs762551</td><td>deferasirox</td><td>beta-Thalassemia</td><td>3</td><td>AC</td><td>Metabolism/PK</td><td>Patients with the AC genotype and beta-thalassemia may have increased concentrations of deferasirox as compared to patients with the AA genotype. Other genetic and clinical factors may also influence concentrations of deferasirox.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444666571>1201</a></td><td>CYP1A2</td><td>rs2470890</td><td>deferasirox</td><td>beta-Thalassemia</td><td>3</td><td>CT</td><td>Metabolism/PK</td><td>Patients with the CT genotype and beta-thalassemia may have increased concentrations of deferasirox as compared to patients with the TT genotype. Other genetic and clinical factors may also influence concentrations of deferasirox.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1446896596>1202</a></td><td>CYP1A2</td><td>rs2472304</td><td>erlotinib</td><td></td><td>3</td><td>AG</td><td>Metabolism/PK</td><td>Patients with the AG genotype may have increased concentrations of erlotinib as compared to patients with the GG genotype. Other genetic and clinical factors may also influence concentrations of erlotinib.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444703076>1203</a></td><td>CYP2C19</td><td>rs4244285</td><td>etravirine</td><td>HIV Infections</td><td>3</td><td>AA</td><td>Metabolism/PK</td><td>Patients with the AA genotype who are treated with etravirine may have a decreased etravirine clearance as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's etravirine clearance.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1445401186>1204</a></td><td>NAT1</td><td>rs13253389</td><td>cotinine</td><td></td><td>3</td><td>AG</td><td>Metabolism/PK</td><td>Patients with the AG genotype may have increased concentrations of cotinine when exposed to secondhand smoke as compared to patients with the AA genotype. Other genetic and clinical factors may also influence levels of cotinine in patients exposed to secondhand smoke.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444703273>1205</a></td><td>ABCC4</td><td>rs3742106</td><td>tenofovir</td><td>HIV Infections</td><td>3</td><td>AC</td><td>Metabolism/PK</td><td>Patients with genotype AC may have increased mean plasma concentrations of tenofovir in people with HIV as compared to patients with genotype AA. Other genetic and clinical factors may also affect tenofovir plasma concentrations.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448613237>1206</a></td><td>IL3</td><td>rs181781</td><td>tacrolimus</td><td>Kidney Transplantation</td><td>3</td><td>AG</td><td>Metabolism/PK</td><td>Patients with the AG genotype and kidney transplantation may have increased exposure (Concentration/Dose) to tacrolimus compared to patients with the GG genotypes. Other clinical and genetic factors may affect exposure to tacrolimus.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448532196>1207</a></td><td>ABCB1</td><td>rs1045642</td><td>rivaroxaban</td><td></td><td>3</td><td>AA</td><td>Metabolism/PK</td><td>People with the AA genotype may have increased exposure to rivaroxaban compared to people with the GG genotype when assessed in conjunction with the rs2032582 SNP. Other clinical and genetic factor may affect exposure to rivaroxaban.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448532202>1208</a></td><td>ABCB1</td><td>rs2032582</td><td>Dabigatran</td><td></td><td>3</td><td>AC</td><td>Metabolism/PK</td><td>People with the AC genotype may have increased exposure to dabigatran compared to patients with the CC genotype when assessed in conjunction with a variant at position rs1045642. Other clinical and genetic factors may affect exposure to dabigatran.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448532211>1209</a></td><td>ABCB1</td><td>rs2032582</td><td>rivaroxaban</td><td></td><td>3</td><td>AC</td><td>Metabolism/PK</td><td>People with the AC genotype may have increased exposure to rivaroxaban compared to patients with the CC genotype, when assessed in conjunction with a variant at position rs1045642. Other clinical and genetic factors may affect exposure to rivaroxaban.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448624874>1210</a></td><td>N6AMT1</td><td>rs2254638</td><td>clopidogrel</td><td>major adverse cardiac events (mace)</td><td>3</td><td>AG</td><td>Metabolism/PK</td><td>Patients with the AG genotype may have decreased metabolism and increased risk of major adverse cardiac events (mace) when treated with clopidogrel in people with Coronary Artery Disease as compared patients with genotype AA. Other genetic and clinical factors may also influence the response to clopidogrel.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448125853>1211</a></td><td>CYP3A5</td><td>rs776746</td><td>imatinib</td><td>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</td><td>3</td><td>CC</td><td>Metabolism/PK</td><td>Patients with the CC genotype and chronic myeloid leukemia have have increased trough concentrations of imatinib compared to patients with the CT and TT genotypes. Other genetic and clinical factors may affect concentrations of imatinib.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449296314>1212</a></td><td>MTHFR</td><td>rs1801133</td><td>folic acid</td><td></td><td>3</td><td>AG</td><td>Metabolism/PK</td><td>Patients with the AG genotype may have decreased metabolism of folic acid as compared to patients with the GG genotype. Other genetic and clinical factors may also affect folic acid metabolism in patients. This annotation only covers the pharmacokinetic relationship between rs1801133 and folic acid and does not include evidence about clinical outcomes. This drug-variant pair has been assigned a no recommendation by DPWG, as it was determined to be not clinically actionable.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447961194>1213</a></td><td>CYP2B6</td><td>rs8192719</td><td>efavirenz</td><td>HIV Infections</td><td>3</td><td>CT</td><td>Metabolism/PK</td><td>Patients with the CT genotype and HIV may have increased concentrations of efavirenz as compared to patients with the CC genotype. Other genetic and clinical factors, such as rs3745274, may also influence concentrations of efavirenz.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448266413>1214</a></td><td>NR1I2</td><td>rs1523130</td><td>risperidone</td><td>Bipolar Disorder;Depression;Substance-Related Disorders</td><td>3</td><td>CC</td><td>Metabolism/PK</td><td>Patients with the CC genotype and psychiatric disorders may have decreased clearance of risperidone compared to patients with the CT or TT genotypes. Other clinical and genetic factors may affect clearance of risperidone.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447983940>1215</a></td><td>CYP1A2</td><td>rs762551</td><td>carbamazepine</td><td>Epilepsy</td><td>3</td><td>AC</td><td>Metabolism/PK</td><td>Pediatric patients with epilepsy and the AC genotype may have decreased clearance of carbamazepine as compared to pediatric patients with epilepsy and the AA genotypes. Other clinical and genetic factors may also influence clearance of carbamazepine in pediatric patients with epilepsy.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447960218>1216</a></td><td>ABCB1</td><td>rs1045642</td><td>voriconazole</td><td></td><td>3</td><td>AA</td><td>Metabolism/PK</td><td>Patients with the AA genotype may have decreased clearance of voriconazole as compared to patients with the GG genotype. Other genetic and clinical factors, such as variants within the CYP2C19 gene, may also influence metabolism of voriconazole.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448531652>1217</a></td><td>ABCC1</td><td>rs6498588</td><td>SN-38</td><td>Colorectal Neoplasms</td><td>3</td><td>TT</td><td>Metabolism/PK</td><td>Patients with the TT genotype and colorectal neoplasm may have increased exposure to SN-38 compared to patients with the AA genotype. Other clinical and genetic factors may affect exposure to SN-38.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448097455>1218</a></td><td>NR1I2</td><td>rs10934498</td><td>irinotecan</td><td>Colonic Neoplasms</td><td>3</td><td>AA</td><td>Metabolism/PK</td><td>Patients with the AA genotype and colonic neoplasms may have decreased area under the curve of irinotecan-based therapy as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence the AUC of irinotecan.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448100786>1219</a></td><td>VDR</td><td>rs4516035</td><td>midazolam</td><td></td><td>3</td><td>CC</td><td>Metabolism/PK</td><td>Patients with the CC genotype may have decreased clearance of midazolam as compared to patients with the CT or TT genotype. This SNP is present in the VDR gene, and the VDR protein is known to transcriptionally regulate intestinal CYP3A4 expression. Other genetic and clinical factors may also influence clearance of midazolam.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448532190>1220</a></td><td>ABCB1</td><td>rs1045642</td><td>Dabigatran</td><td></td><td>3</td><td>AA</td><td>Metabolism/PK</td><td>People with the AA genotype may have increased exposure to dabigatran compared to patients with the GG genotype, when also assessed with the rs2032582 allele. Other clinical and genetic factors may affect exposure to dabigatran.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447981372>1221</a></td><td>CDA</td><td>rs4655226</td><td>difluorodeoxyuridine</td><td>Neoplasms</td><td>3</td><td>CT</td><td>Metabolism/PK</td><td>Patients with the CT genotype and cancer may have decreased clearance of 2',2'- difluorodeoxyuridine (dFdU; a metabolite of gemcitabine) when treated with gemcitabine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence metabolism of gemcitabine.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448263578>1222</a></td><td>SLC22A1</td><td>rs628031</td><td>lamotrigine</td><td>Epilepsy</td><td>3</td><td>AG</td><td>Metabolism/PK</td><td>Patients with the rs628031 AG genotype and epilepsy may have increased concentrations of lamotrigine compared to patients with the GG genotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs628031 and lamotrigine and does not include evidence about clinical outcomes. Other genetic and clinical factors may affect response to lamotrigine.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448100955>1223</a></td><td>CES1</td><td>rs8192935</td><td>Dabigatran</td><td>Atrial Fibrillation</td><td>3</td><td>AG</td><td>Metabolism/PK</td><td>Patients with the AG genotype and atrial fibrillation may have increased trough plasma concentrations of dabigatran compared to patients with the GG genotype. Other clinical factors may affect plasma concentrations of dabigatran.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448100471>1224</a></td><td>CYP24A1</td><td>rs2585428</td><td>telaprevir</td><td>Hepatitis C</td><td>3</td><td>TT</td><td>Metabolism/PK</td><td>Patients with the TT genotype and Hepatitis C may have increased trough concentrations of telaprevir compared to patients with the CC and CT genotypes. Other factors may affect trough concentrations of telaprevir.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448100347>1225</a></td><td>SLCO1B1</td><td>rs4149056</td><td>ticagrelor</td><td>Acute coronary syndrome</td><td>3</td><td>CT</td><td>Metabolism/PK</td><td>Patients with the CT genotype and acute coronary syndrome may have increased concentrations of ticagrelor compared to patients with the TT genotype. Other factors may affect concentrations of ticagrelor.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448100354>1226</a></td><td>SLCO1B1</td><td>rs113681054</td><td>ticagrelor</td><td>Acute coronary syndrome</td><td>3</td><td>CT</td><td>Metabolism/PK</td><td>Patients with the CT genotype and acute coronary syndrome may have increased concentrations of ticagrelor compared to patients with the TT genotype. Other factors may affect concentrations of ticagrelor.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447990578>1227</a></td><td>SLCO1B1</td><td>rs2306283</td><td>mycophenolic acid</td><td>Kidney Transplantation</td><td>3</td><td>AG</td><td>Metabolism/PK</td><td>Kidney transplant patients with the AG genotype may have reduced clearance rates of mycophenolic acid as compared to patients with the GG genotype. Other clinical and genetic factors may also influence clearance rates of mycophenolic acid in patients with kidney transplants.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448099022>1228</a></td><td>GSTA1</td><td>rs3957357</td><td>busulfan</td><td>Transplantation</td><td>3</td><td>GG</td><td>Metabolism/PK</td><td>Pediatric patients with the GG genotype who are undergoing hematopoietic stem cell transplantation may have decreased clearance of busulfan as compared to patients with the AA genotype. Other genetic and clinical factors may also influence busulfan clearance.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448603625>1229</a></td><td>IL10</td><td>rs1800896</td><td>tacrolimus</td><td>Transplantation</td><td>4</td><td>TT</td><td>Metabolism/PK</td><td>Patients with the TT genotype who are undergoing lung transplantation may have increased dose-adjusted trough concentrations of tacrolimus as compared to patients with the CT genotype. However, no significant results were seen in a cohort of kidney transplant patients. Other genetic and clinical factors, such as the CYP3A5*3 variant, may also influence tacrolimus concentrations.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449140085>1230</a></td><td>ABCB1</td><td>rs2032582</td><td>sirolimus</td><td>hematopoietic stem cell transplantation;Kidney Transplantation;Urinary Bladder Neoplasms</td><td>3</td><td>AC</td><td>Metabolism/PK</td><td>Patients with the AC genotype and bladder cancer may have decreased metabolism of temsirolimus or sirolimus as compared to patients with the CC genotype, although this is contradicted in one study. Other clinical and genetic factors may also influence metabolism of temsirolimus or sirolimus.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449140085>1231</a></td><td>ABCB1</td><td>rs2032582</td><td>temsirolimus</td><td>hematopoietic stem cell transplantation;Kidney Transplantation;Urinary Bladder Neoplasms</td><td>3</td><td>AC</td><td>Metabolism/PK</td><td>Patients with the AC genotype and bladder cancer may have decreased metabolism of temsirolimus or sirolimus as compared to patients with the CC genotype, although this is contradicted in one study. Other clinical and genetic factors may also influence metabolism of temsirolimus or sirolimus.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444706201>1232</a></td><td>SLCO1B1</td><td>rs4149032</td><td>rifampin</td><td>Tuberculosis</td><td>3</td><td>CC</td><td>Metabolism/PK</td><td>Tuberculosis patients with the CC genotype may have increased rifampicin exposure when treated with ethambutol, isoniazid, pyrazinamide and rifampin in people with Tuberculosis as compared to patients with the TT or TC genotypes. Other genetic and clinical factors may influence also a patient's exposure to rifampicin.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444694588>1233</a></td><td>ABCB1</td><td>rs1045642</td><td>tacrolimus</td><td>Organ Transplantation</td><td>4</td><td>AA</td><td>Metabolism/PK</td><td>Patients with the AA genotype who are undergoing organ transplantation, or who have other diseases, may have decreased clearance and dose requirements of tacrolimus, as compared to patients with the AG or GG genotype. However, the vast majority of studies find no association between this SNP and clearance or dose of tacrolimus. Other genetic and clinical factors, such as CYP3A5*3, may also influence clearance and dose of tacrolimus.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450935200>1234</a></td><td>CYP3A4</td><td>rs2740574</td><td>cyclosporine</td><td>Kidney Transplantation</td><td>3</td><td>TT</td><td>Metabolism/PK</td><td>Patients with the rs2740574 TT genotype and who are treated with cyclosporine following kidney transplantation may have increased blood concentrations of cyclosporine as compared to patients with the rs2740574 CC or CT genotypes. This annotation only covers the pharmacokinetic relationship between rs2740574 and cyclosporine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect blood concentrations of cyclosporine.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450936266>1235</a></td><td>SULT1A1</td><td>rs767487725</td><td>desmethylnaproxen</td><td></td><td>3</td><td>AA</td><td>Metabolism/PK</td><td>Patients with the AA genotype may have increased sulfation of O-desmethylnaproxen as compared to patients with the AC or CC genotypes. Other genetic and clinical factors may also affect O-desmethylnaproxen sulfation.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450936278>1236</a></td><td>SULT1A1</td><td>rs758145522</td><td>tapentadol</td><td></td><td>3</td><td>AA</td><td>Metabolism/PK</td><td>Patients with the AA genotype may have increased sulfation of tapentadol as compared to patients with the AT or TT genotypes. Other genetic and clinical factors may also affect tapentadol sulfation.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450936254>1237</a></td><td>SULT1A1</td><td>rs767487725</td><td>acetaminophen</td><td></td><td>3</td><td>AA</td><td>Metabolism/PK</td><td>Patients with the AA genotype may have increased sulfation of acetaminophen as compared to patients with the AC or CC genotypes. Other genetic and clinical factors may also affect acetaminophen sulfation.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449645356>1238</a></td><td>SULT1A3</td><td>rs767263838</td><td>acetaminophen</td><td></td><td>3</td><td>TT</td><td>Metabolism/PK</td><td>Patients with the TT genotype may have an increased rate of sulfation of acetaminophen as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect acetaminophen sulfation in patients.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449266582>1239</a></td><td>UGT2B7</td><td>rs7439366</td><td>(R)-methadone</td><td>Opioid-Related Disorders</td><td>3</td><td>CT</td><td>Metabolism/PK</td><td>Patients with the CT genotype who are receiving methadone maintenance therapy may have increased plasma concentrations of methadone as compared to patients with the CC or TT genotypes. Other genetic and clinical factors may also affect plasma concentrations of methadone.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449266582>1240</a></td><td>UGT2B7</td><td>rs7439366</td><td>methadone</td><td>Opioid-Related Disorders</td><td>3</td><td>CT</td><td>Metabolism/PK</td><td>Patients with the CT genotype who are receiving methadone maintenance therapy may have increased plasma concentrations of methadone as compared to patients with the CC or TT genotypes. Other genetic and clinical factors may also affect plasma concentrations of methadone.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449266582>1241</a></td><td>UGT2B7</td><td>rs7439366</td><td>S-EDDP</td><td>Opioid-Related Disorders</td><td>3</td><td>CT</td><td>Metabolism/PK</td><td>Patients with the CT genotype who are receiving methadone maintenance therapy may have increased plasma concentrations of methadone as compared to patients with the CC or TT genotypes. Other genetic and clinical factors may also affect plasma concentrations of methadone.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451105180>1242</a></td><td>SLCO1B1</td><td>rs4149032</td><td>letermovir</td><td></td><td>3</td><td>CC</td><td>Metabolism/PK</td><td>Patients with the CC genotype may have an increased AUC of letermovir as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's exposure to letermovir.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451105200>1243</a></td><td>SLCO1B1</td><td>rs4149056</td><td>letermovir</td><td></td><td>3</td><td>CT</td><td>Metabolism/PK</td><td>Patients with the CT genotype may have an increased AUC of letermovir as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's exposure to letermovir.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451116049>1244</a></td><td>CYP3A</td><td>rs776746</td><td>lopinavir</td><td>HIV Infections</td><td>3</td><td>CC</td><td>Metabolism/PK</td><td>Patients with HIV infections and the CC genotype may have increased trough concentrations of lopinavir as compared to patients with the TT genotype. Note that this association was only found in patients of European descent, and not in African American or Hispanic patients. Other genetic and clinical factors may also affect concentrations of lopinavir in patients.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451116049>1245</a></td><td>CYP3A5</td><td>rs776746</td><td>lopinavir</td><td>HIV Infections</td><td>3</td><td>CC</td><td>Metabolism/PK</td><td>Patients with HIV infections and the CC genotype may have increased trough concentrations of lopinavir as compared to patients with the TT genotype. Note that this association was only found in patients of European descent, and not in African American or Hispanic patients. Other genetic and clinical factors may also affect concentrations of lopinavir in patients.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451116049>1246</a></td><td>ZSCAN25</td><td>rs776746</td><td>lopinavir</td><td>HIV Infections</td><td>3</td><td>CC</td><td>Metabolism/PK</td><td>Patients with HIV infections and the CC genotype may have increased trough concentrations of lopinavir as compared to patients with the TT genotype. Note that this association was only found in patients of European descent, and not in African American or Hispanic patients. Other genetic and clinical factors may also affect concentrations of lopinavir in patients.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451553580>1247</a></td><td>ABCB1</td><td>rs1045642</td><td>methotrexate</td><td>Burkitt Lymphoma;Lymphoma, T-Cell;Precursor Cell Lymphoblastic Leukemia-Lymphoma</td><td>3</td><td>AA</td><td>Metabolism/PK</td><td>Patients with the rs1045642 AA genotype may have increased concentrations of methotrexate as compared to patients with the GG genotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs1045642 and methotrexate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence methotrexate concentrations.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449311190>1248</a></td><td>SLCO1B1</td><td>rs4149056</td><td>mercaptopurine</td><td>Precursor Cell Lymphoblastic Leukemia-Lymphoma</td><td>3</td><td>CT</td><td>Dosage</td><td>Patients with the CT genotype and Precursor Cell Lymphoblastic Leukemia-Lymphoma may need a decreased dose of mercaptopurine, or methotrexate, as compared to children with the TT genotype. Other clinical and genetic factors may also influence dose of mercaptopurine or methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449311190>1249</a></td><td>SLCO1B1</td><td>rs4149056</td><td>methotrexate</td><td>Precursor Cell Lymphoblastic Leukemia-Lymphoma</td><td>3</td><td>CT</td><td>Dosage</td><td>Patients with the CT genotype and Precursor Cell Lymphoblastic Leukemia-Lymphoma may need a decreased dose of mercaptopurine, or methotrexate, as compared to children with the TT genotype. Other clinical and genetic factors may also influence dose of mercaptopurine or methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451356840>1250</a></td><td>NFKBIA</td><td>rs696</td><td>sufentanil</td><td>Pain, Postoperative</td><td>3</td><td>CT</td><td>Dosage</td><td>Patients with the rs696 CT genotype may require decreased doses of sufentanil as compared to patients with the TT genotype. Other genetic and clinical factors may also influence sufentanil dosage requirements.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451352140>1251</a></td><td>KCNJ6</td><td>rs6517442</td><td>opioids</td><td>Low Back Pain</td><td>3</td><td>TT</td><td>Dosage</td><td>Patients with the rs6517442 TT genotype may have decreased opioid dose requirements as compared to patients with the CC genotype. Other genetic and clinical factors may also affect opioid dose requirements.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451253880>1252</a></td><td>EPHX1</td><td>rs1051740</td><td>carbamazepine</td><td>Epilepsy</td><td>3</td><td>CT</td><td>Dosage</td><td>Patients with the CT genotype and Epilepsy may require a decreased dose of carbamazepine as compared to patients with the the CC genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence metabolism and dose of carbamazepine.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450934061>1253</a></td><td>ABCB1</td><td>rs28656907</td><td>imatinib</td><td>Drug Toxicity;Gastrointestinal Stromal Tumors</td><td>3</td><td>CT</td><td>Dosage</td><td>Patients with the CT genotype may be more likely to require a dose reduction of imatinib due to drug toxicity as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's imatinib dose requirements.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450934061>1254</a></td><td>RUNDC3B</td><td>rs28656907</td><td>imatinib</td><td>Drug Toxicity;Gastrointestinal Stromal Tumors</td><td>3</td><td>CT</td><td>Dosage</td><td>Patients with the CT genotype may be more likely to require a dose reduction of imatinib due to drug toxicity as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's imatinib dose requirements.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451354640>1255</a></td><td>TPH2</td><td>rs1386493</td><td>methadone</td><td>Heroin Dependence</td><td>3</td><td>AG</td><td>Dosage</td><td>Patients with heroin dependence and the rs1386493 AG genotype may require decreased doses of methadone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence methadone dosage requirements.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/981201770>1256</a></td><td>SLCO1B3</td><td>rs4149117</td><td>mycophenolate mofetil</td><td>Kidney Transplantation</td><td>3</td><td>GG</td><td>Dosage</td><td>Patients with the GG genotype who are renal transplant recipients and are treated with mycophenolate mofetil: 1) may have an increased risk of adverse drug reactions 2) may have decreased exposure to active mycophenolic acid as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for drug-induced toxicity and exposure to mycophenolic acid.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450376133>1257</a></td><td>TAOK3</td><td>rs795484</td><td>morphine</td><td>Pain, Postoperative</td><td>3</td><td>CC</td><td>Dosage</td><td>Patients with the CC genotype may require a decreased dose of morphine as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's morphine dosage requirements.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/982032567>1258</a></td><td>ANKK1</td><td>rs7118900</td><td>methadone</td><td>Heroin Dependence;Opioid-Related Disorders</td><td>3</td><td>AG</td><td>Dosage</td><td>Patients with the AG genotype and heroin addiction may require a lower dose of methadone when undergoing methadone maintenance treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence methadone dose required for effective treatment.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183574175>1259</a></td><td>-</td><td>rs2952768</td><td>buprenorphine</td><td></td><td>3</td><td>CT</td><td>Dosage</td><td>Patients with the CT genotype may have decreased opioid analgesic requirements after surgery as compared to patients with the CC genotype. Other genetic and clinical factors may influence a patient's opioid dose requirement.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183574175>1260</a></td><td>-</td><td>rs2952768</td><td>fentanyl</td><td></td><td>3</td><td>CT</td><td>Dosage</td><td>Patients with the CT genotype may have decreased opioid analgesic requirements after surgery as compared to patients with the CC genotype. Other genetic and clinical factors may influence a patient's opioid dose requirement.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183574175>1261</a></td><td>-</td><td>rs2952768</td><td>meperidine</td><td></td><td>3</td><td>CT</td><td>Dosage</td><td>Patients with the CT genotype may have decreased opioid analgesic requirements after surgery as compared to patients with the CC genotype. Other genetic and clinical factors may influence a patient's opioid dose requirement.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183574175>1262</a></td><td>-</td><td>rs2952768</td><td>morphine</td><td></td><td>3</td><td>CT</td><td>Dosage</td><td>Patients with the CT genotype may have decreased opioid analgesic requirements after surgery as compared to patients with the CC genotype. Other genetic and clinical factors may influence a patient's opioid dose requirement.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183574175>1263</a></td><td>-</td><td>rs2952768</td><td>opioids</td><td></td><td>3</td><td>CT</td><td>Dosage</td><td>Patients with the CT genotype may have decreased opioid analgesic requirements after surgery as compared to patients with the CC genotype. Other genetic and clinical factors may influence a patient's opioid dose requirement.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183574175>1264</a></td><td>-</td><td>rs2952768</td><td>pentazocine</td><td></td><td>3</td><td>CT</td><td>Dosage</td><td>Patients with the CT genotype may have decreased opioid analgesic requirements after surgery as compared to patients with the CC genotype. Other genetic and clinical factors may influence a patient's opioid dose requirement.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/982030369>1265</a></td><td>-</td><td>rs12777823</td><td>warfarin</td><td></td><td>1A</td><td>AA</td><td>Dosage</td><td>Patients with the rs12777823 AA genotype may require a lower dose of warfarin in African Americans as compared to patients with the GG genotype. Other genetic and clinical factors may also influence warfarin dosage.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1043873028>1266</a></td><td>CYP2C9</td><td>rs12782374</td><td>phenytoin</td><td>Epilepsy</td><td>3</td><td>AA</td><td>Dosage</td><td>Patients with the AA genotype may require decreased dose of phenytoin in people with Epilepsy as compared to patients with genotype GG. The Allele A is associated with decreased expression of CYP2C9 when treated with phenytoin in HepG2 cells. Other clinical or genetic factors may also influence a patient's dose of phenytoin.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655387745>1267</a></td><td>CYP2C19</td><td>rs11188072</td><td>mephenytoin</td><td></td><td>3</td><td>CC</td><td>Dosage</td><td>Patients with the CC genotype who are treated with mephenytoin may require a decreased dose as compared to patients with the TT genotype. Other genetic factors, including other CYP2C19 alleles *17 rs12248560, *2 rs4244285,*3 rs4986893, and clinical factors may also influence a patient's required dose and should be taken into consideration.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1157877076>1268</a></td><td>CYP3A5</td><td>rs776746</td><td>sunitinib</td><td>Carcinoma, Renal Cell</td><td>3</td><td>CC</td><td>Dosage</td><td>Patients with the CC genotype and Carcinoma who are treated with sunitinib may have a decreased, but not absent, risk for dose reductions due to toxicity as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to sunitinib.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450929025>1269</a></td><td>TAOK3</td><td>rs1277441</td><td>opioids</td><td>Pain</td><td>3</td><td>AA</td><td>Dosage</td><td>Patients with the AA genotype may have decreased opioid dose requirements as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's opioid dose requirements.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450934049>1270</a></td><td>CYP1A2</td><td>rs762551</td><td>imatinib</td><td>Gastrointestinal Stromal Tumors</td><td>3</td><td>AC</td><td>Dosage</td><td>Patients with the AC genotype may be less likely to require a dose reduction of imatinib due to toxicity as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's imatinib dosing requirements.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450376139>1271</a></td><td>TAOK3</td><td>rs1277441</td><td>morphine</td><td>Pain, Postoperative</td><td>3</td><td>AA</td><td>Dosage</td><td>Patients with the AA genotype may require a decreased dose of morphine as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's morphine dosage requirements.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449188526>1272</a></td><td>CALU</td><td>rs1043550</td><td>acenocoumarol</td><td></td><td>3</td><td>AG</td><td>Dosage</td><td>Patients with the AG genotype may require a lower dose of acenocoumarol as compared to patients with the GG genotype and a higher dose as compared to the AA genotypes. Other clinical and genetic factors may also affect dose of acenocoumarol.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655385392>1273</a></td><td>VKORC1</td><td>rs9934438</td><td>warfarin</td><td></td><td>1B</td><td>AG</td><td>Dosage</td><td>Patients with the rs9934438 AG genotype may require a lower dose of warfarin as compared to patients with the GG genotype, and a higher dose as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other clinical and genetic factors may also influence warfarin dose requirements.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655386028>1274</a></td><td>ABCB1</td><td>rs1045642</td><td>fexofenadine</td><td></td><td>3</td><td>AA</td><td>Dosage</td><td>Healthy individuals with the AA genotype who are treated with fexofenadine may have lower plasma drug levels as compared to healthy individuals with the AG or GG genotype. Another study found no association with fexofenadine plasma concentrations. Other genetic and clinical factors may also influence plasma concentrations of fexofenadine and dose requirements.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655386310>1275</a></td><td>PIK3CA</td><td>rs870995</td><td>docetaxel</td><td>Carcinoma, Non-Small-Cell Lung</td><td>3</td><td>AA</td><td>Dosage</td><td>Patients with the AA genotype may have decreased clearance of docetaxel compared to patients with the CC genotype. Other genetic and clinical factors may also influence docetaxel clearance.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655386324>1276</a></td><td>XRCC4</td><td>rs1382368</td><td>docetaxel</td><td>Carcinoma, Non-Small-Cell Lung</td><td>3</td><td>CT</td><td>Dosage</td><td>Patients with the CT genotype may have increased clearance of docetaxel compared to patients with the CC genotype, or decreased clearance of docetaxel compared to patients with the TT genotype. Other genetic and clinical factors may also influence docetaxel clearance.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/637879785>1277</a></td><td>EPHX1</td><td>rs1131873</td><td>warfarin</td><td></td><td>4</td><td>AG</td><td>Dosage</td><td>Patients with the AG genotype may require a lower dose of warfarin than patients with the GG genotype however there have been conflicting results regarding the association of this SNP with warfarin dose. Other genetic and clinical factors may also influence warfarin dose requirements.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655384546>1278</a></td><td>ABCB1</td><td>rs1128503</td><td>cyclosporine</td><td>Kidney Transplantation;Myasthenia Gravis</td><td>3</td><td>AG</td><td>Dosage</td><td>Patients with the AG genotype and myasthenia gravis or organ transplantation may have reduced clearance of cyclosporine as compared to patients with the GG genotype, or increased clearance as compared to patients with the AA genotype, and therefore may require an adjusted dose of the drug. Patients with the AG genotype may also have an increased risk of infection as compared to those with the GG genotype. Other genetic and clinical factors may also influence clearance and dose of cyclosporine.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655385028>1279</a></td><td>VKORC1</td><td>rs8050894</td><td>warfarin</td><td></td><td>1B</td><td>CG</td><td>Dosage</td><td>Patients with the rs8050894 CG genotype may require a lower dose of warfarin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence warfarin dosage requirements.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655385012>1280</a></td><td>VKORC1</td><td>rs9923231</td><td>warfarin</td><td></td><td>1A</td><td>CT</td><td>Dosage</td><td>Patients with the rs9923231 CT genotype may require a decreased dose of warfarin as compared to patients with the CC genotype or an increased dose as compared to patients with the TT genotype. Other genetic and clinical factors may also influence warfarin dose requirement.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655385016>1281</a></td><td>STX4</td><td>rs10871454</td><td>warfarin</td><td></td><td>3</td><td>CT</td><td>Dosage</td><td>Patients with the CT genotype who are treated with warfarin may require a lower dose as compared to patients with the CC genotype.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/827831435>1282</a></td><td>ABCB1</td><td>rs2032582</td><td>cyclosporine</td><td></td><td>3</td><td>AC</td><td>Dosage</td><td>Patients with the AC genotype may have higher blood trough concentrations of cyclosporine compared to patients with the CC genotype, and may have lower blood trough concentrations of cyclosporine compared to patients with the AA genotype, and may require dose adjustments. Other genetic and clinical factors may also influence cyclosporine blood concentrations.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/981201937>1283</a></td><td>GGCX</td><td>rs12714145</td><td>warfarin</td><td></td><td>4</td><td>CT</td><td>Dosage</td><td>Genotype CT may be associated with decreased dose of warfarin as compared to genotype TT, and increased dose as compared to genotype CC, although this is contradicted in most studies. Other genetic and clinical factors may influence a patient's dose of warfarin.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/981237907>1284</a></td><td>ITPA</td><td>rs1127354</td><td>interferon alfa-2b, recombinant</td><td>Hepatitis C, Chronic</td><td>3</td><td>CC</td><td>Dosage</td><td>Patients with the CC genotype and chronic hepatitis C may require a dose reduction of ribavirin when treated with recombinant interferon alfa-2b and ribavirin, or recombinant interferon alfa-2b, ribavirin and telaprevir, as compared to patients with the AC and AA genotype. Other genetic and clinical factors may also influence a patient's risk for response to ribavirin.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/981237907>1285</a></td><td>ITPA</td><td>rs1127354</td><td>ribavirin</td><td>Hepatitis C, Chronic</td><td>3</td><td>CC</td><td>Dosage</td><td>Patients with the CC genotype and chronic hepatitis C may require a dose reduction of ribavirin when treated with recombinant interferon alfa-2b and ribavirin, or recombinant interferon alfa-2b, ribavirin and telaprevir, as compared to patients with the AC and AA genotype. Other genetic and clinical factors may also influence a patient's risk for response to ribavirin.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/981204044>1286</a></td><td>VKORC1</td><td>rs9923231</td><td>acenocoumarol</td><td></td><td>1A</td><td>CT</td><td>Dosage</td><td>Patients with the rs9923231 CT genotype may require a decreased dose of acenocoumarol as compared to patients with the CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence acenocoumarol dose requirements.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/981203545>1287</a></td><td>DRD2</td><td>rs6275</td><td>methadone</td><td>Heroin Dependence</td><td>3</td><td>AG</td><td>Dosage</td><td>Patients with the rs6275 AG genotype and Heroin Dependence may require a decreased dose of methadone as compared to patients with the GG genotype or may require an increased dose of methadone as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence methadone dose requirements.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449716764>1288</a></td><td>ABCB1</td><td>rs1128503</td><td>fentanyl</td><td>Pain;Pain, Postoperative</td><td>3</td><td>AG</td><td>Dosage</td><td>Patients with the AG genotype may have an increased response to fentanyl and may therefore require a decreased dose as compared to patients with the AA genotype. However, one study failed to find a significant relationship between this variant and dose of fentanyl. Other genetic and clinical factors may also affect a patient's response to fentanyl and their dosage requirements.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450929804>1289</a></td><td>ABCB1</td><td>rs1045642</td><td>morphine</td><td>Pain;Pain, Postoperative</td><td>4</td><td>AA</td><td>Dosage</td><td>Patients with the AA genotype may have decreased morphine dose requirements as compared to patients with the AG or GG genotypes. However, the majority of studies have not found an association between this variant and morphine dosing. Other genetic and clinical factors may also affect a patient's morphine dose requirements.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444703380>1290</a></td><td>CYP4F2</td><td>rs2189784</td><td>warfarin</td><td></td><td>3</td><td>AG</td><td>Dosage</td><td>Patients with the AG genotype who are treated with warfarin may have decreased time to achieve therapeutic international normalized ratio as compared to patients with the AA genotype or may have increased time to achieve therapeutic international normalized ratio as compared to patients with the GG genotype. However, another study reported no association with dose of warfarin. Other genetic and clinical factors may also influence a patient's response to warfarin.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444680138>1291</a></td><td>GGCX</td><td>rs2592551</td><td>warfarin</td><td>Atrial Fibrillation</td><td>3</td><td>GG</td><td>Dosage</td><td>Patients with the GG genotype and atrial fibrillation may require a lower dose of warfarin as compared to patients with the AA or AG genotype. Other genetic and clinical factors, such as variations in the VKORC1 and CYP2C9 genes, may also influence dose of warfarin.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1446899616>1292</a></td><td>CYP3A5</td><td>rs776746</td><td>cyclosporine</td><td>liver transplantation</td><td>3</td><td>CC</td><td>Dosage</td><td>Patients who are recipients of a liver transplantation from a donor with the CC (CYP3A5 *3/*3) genotype who is also CYP3A4 low or intermediate expressers may have decreased metabolism of cyclosporine resulting in increased exposure, and may require a lower dose as compared to patients who receive a liver transplantation from a donor with the CT or TT (*1/*3 or *1/*1) genotype, regardless of CYP3A4 expresser status. However, this is contradicted in one study. Other genetic and clinical factors, such as recipient genotype, may also influence a patient's cyclosporine dose requirement.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444694544>1293</a></td><td>IL10</td><td>rs1800896</td><td>tacrolimus</td><td>liver transplantation</td><td>3</td><td>TT</td><td>Dosage</td><td>Patients undergoing liver transplantation who receive a donor liver with the TT genotype may require a decreased dose of tacrolimus as compared to patients who receive a donor liver with the CT genotype. Other genetic and clinical factors, such as CYP3A5*3, may also influence dose of tacrolimus.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444694511>1294</a></td><td>ABCB1</td><td>rs2032582</td><td>tacrolimus</td><td>Kidney Transplantation;liver transplantation</td><td>4</td><td>AC</td><td>Dosage</td><td>Patients with the AC genotype who are undergoing organ transplantation may have decreased metabolism and dose requirements of tacrolimus, as compared to patients with the CC genotype. However, the majority of studies have found no association between this polymorphism and metabolism or dose of tacrolimus. Other genetic and clinical factors, such as CYP3A5*3, may also influence metabolism and dose of tacrolimus.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444704833>1295</a></td><td>ABCB1</td><td>rs1045642</td><td>opioids</td><td>Pain;Pain, Postoperative</td><td>3</td><td>AA</td><td>Dosage</td><td>Patients with the AA genotype may have decreased opioid dose requirements as compared to patients with the AG or GG genotypes. However, several studies have failed to find an association between this variant and opioid dose requirements. Other genetic and clinical factors may also influence opioid dose requirements.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184997925>1296</a></td><td>NR1I3</td><td>rs2501873</td><td>warfarin</td><td></td><td>4</td><td>CT</td><td>Dosage</td><td>Patients with the CT genotype and any allele of rs3212198 who are treated with warfarin may require a lower dose as compared to patients with the TT genotype and rs3212198 T allele. The variant combination of rs2501873 and rs3212198 explained 1.7% of the overall interindividual variability in warfarin dose requirements among one study in a multivariate regression analysis. Other genetic and clinical factors may also influence a patient's dose of warfarin.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444607325>1297</a></td><td>CFH</td><td>rs1061170</td><td>bevacizumab</td><td>Macular Degeneration</td><td>3</td><td>TT</td><td>Dosage</td><td>Patients with the TT genotype and age-related macular degeneration may require a fewer number of bevacizumab injections as compared to those with the CT genotype. Other genetic and clinical factors may also influence number of injections of bevacizumab.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1446899176>1298</a></td><td>NQO1</td><td>rs10517</td><td>warfarin</td><td></td><td>3</td><td>GG</td><td>Dosage</td><td>Patients with the GG genotype may require a decreased dose of warfarin as compared to patients with the AA and GG genotypes. Other clinical and genetic factors may also influence dose of warfarin.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444933020>1299</a></td><td>CYP2B6</td><td>rs3745274</td><td>propofol</td><td></td><td>3</td><td>GT</td><td>Dosage</td><td>Patients under general anaesthesia with genotypes GT may need decreased dose of propofol as compared to patients with genotype GG. Other genetic and clinical factors may also influence the dose of propofol.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1446903563>1300</a></td><td>-</td><td>rs12461964</td><td>nicotine</td><td>Tobacco Use Disorder</td><td>3</td><td>AG</td><td>Dosage</td><td>Individuals who smoke and have the AG genotype may have decreased rates of nicotine clearance, and as a consequence may smoke less when compared to individuals who smoke and have the GG genotypes, and increased rates of metabolism as compared to patients with the AA genotype. Other clinical and genetic factors may also influence nicotine clearance rates in smokers.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1445401915>1301</a></td><td>ABCB1</td><td>rs1045642</td><td>carbamazepine</td><td>Epilepsy</td><td>4</td><td>AA</td><td>Dosage</td><td>Patients with the AA genotype and epilepsy may need a decreased dose carbamazepine as compared to patients with the AG genotype. However, multiple studies have shown no association with dose or concentrations of carbamazepine. Other genetic and clinical factors may also influence dose requirements and concentrations of carbamazepine.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1445401880>1302</a></td><td>CYP3A5</td><td>rs776746</td><td>carbamazepine</td><td>Epilepsy</td><td>3</td><td>CC</td><td>Dosage</td><td>Patients with the CC genotype (CYP3A5 *3/*3) and epilepsy may have decreased clearance and increased concentrations of carbamazepine, and require lower doses of the drug, as compared to patients with the CT (*1/*3) or TT (*1/*1) genotype. Other genetic and clinical factors may also influence dose or concentrations of carbamazepine.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448267381>1303</a></td><td>STX1B</td><td>rs72800847</td><td>warfarin</td><td>heart valve replacement</td><td>3</td><td>AG</td><td>Dosage</td><td>Patients with the AG genotype and heart valve replacement may require lower dose of warfarin compared to patients with the GG genotype. Other clinical and genetic factors affect warfarin dose.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448267389>1304</a></td><td>CYP1A1</td><td>rs3826041</td><td>warfarin</td><td>heart valve replacement</td><td>3</td><td>AC</td><td>Dosage</td><td>Patients with the AC genotype and heart valve replacement may require decreased dose of warfarin compared to patients with the CC genotype. Other clinical and genetic factors affect warfarin dose.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447960436>1305</a></td><td>ADRB1</td><td>rs1801253</td><td>catecholamines</td><td>Coronary Artery Disease</td><td>3</td><td>CG</td><td>Dosage</td><td>Patients with the CG genotype and coronary artery disease may require a reduced dose of catecholamines as compared to patients with the GG genotype, and an increased dose as compared to patients with the CC genotype. Other genetic and clinical factors may also influence required dose of catecholamines.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447964091>1306</a></td><td>CYP3A4</td><td>rs2740574</td><td>atorvastatin</td><td></td><td>3</td><td>TT</td><td>Dosage</td><td>Patients with the TT genotype may be more likely to require a decrease in dose or switch to a different drug when treated with atorvastatin or simvastatin as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence dose of simvastatin or atorvastatin, or likelihood of switching to a different drug.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447964091>1307</a></td><td>CYP3A4</td><td>rs2740574</td><td>simvastatin</td><td></td><td>3</td><td>TT</td><td>Dosage</td><td>Patients with the TT genotype may be more likely to require a decrease in dose or switch to a different drug when treated with atorvastatin or simvastatin as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence dose of simvastatin or atorvastatin, or likelihood of switching to a different drug.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447983818>1308</a></td><td>ABCB1</td><td>rs1045642</td><td>antipsychotics</td><td>Schizophrenia</td><td>3</td><td>AA</td><td>Dosage</td><td>Patients with the AA genotype and schizophrenia who responded to treatment with antipsychotics may require a decreased dose of antipsychotics as compared to patients with the GG genotype. Other genetic and clinical factors may also influence dose of antipsychotics.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447984146>1309</a></td><td>ABCB1</td><td>rs2032582</td><td>antipsychotics</td><td>Schizophrenia</td><td>3</td><td>AC</td><td>Dosage</td><td>Patients with the AC genotype and schizophrenia who responded to treatment with antipsychotics may require a decreased dose of antipsychotics as compared to patients with the CC genotype, or an increased dose as compared to patients with the AA genotype. Other genetic and clinical factors may also influence dose of antipsychotics.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447960411>1310</a></td><td>PROC</td><td>rs1799808</td><td>phenprocoumon</td><td></td><td>3</td><td>CT</td><td>Dosage</td><td>Patients with the CT genotype may require a decreased dose of phenprocoumon as compared to patients with the CC genotype. Other genetic and clinical factors may also influence dosage of phenprocoumon.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448101086>1311</a></td><td>SLC22A1</td><td>rs622342</td><td>amantadine</td><td>Parkinson Disease</td><td>3</td><td>AC</td><td>Dosage</td><td>Patients with the AC genotype and Parkinson disease may require increased doses of anti-Parkinsonian drugs and may have an increased risk of mortality as compared to patients with the AA genotype, and require decreased doses and have a decreased risk of mortality as compared to patients with the CC genotype. Other genetic and clinical factors may also influence dose of anti-Parkinsonian drugs and risk of mortality.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448101086>1312</a></td><td>SLC22A1</td><td>rs622342</td><td>Anticholinergics</td><td>Parkinson Disease</td><td>3</td><td>AC</td><td>Dosage</td><td>Patients with the AC genotype and Parkinson disease may require increased doses of anti-Parkinsonian drugs and may have an increased risk of mortality as compared to patients with the AA genotype, and require decreased doses and have a decreased risk of mortality as compared to patients with the CC genotype. Other genetic and clinical factors may also influence dose of anti-Parkinsonian drugs and risk of mortality.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448101086>1313</a></td><td>SLC22A1</td><td>rs622342</td><td>Dopamine agonists</td><td>Parkinson Disease</td><td>3</td><td>AC</td><td>Dosage</td><td>Patients with the AC genotype and Parkinson disease may require increased doses of anti-Parkinsonian drugs and may have an increased risk of mortality as compared to patients with the AA genotype, and require decreased doses and have a decreased risk of mortality as compared to patients with the CC genotype. Other genetic and clinical factors may also influence dose of anti-Parkinsonian drugs and risk of mortality.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448101086>1314</a></td><td>SLC22A1</td><td>rs622342</td><td>levodopa</td><td>Parkinson Disease</td><td>3</td><td>AC</td><td>Dosage</td><td>Patients with the AC genotype and Parkinson disease may require increased doses of anti-Parkinsonian drugs and may have an increased risk of mortality as compared to patients with the AA genotype, and require decreased doses and have a decreased risk of mortality as compared to patients with the CC genotype. Other genetic and clinical factors may also influence dose of anti-Parkinsonian drugs and risk of mortality.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448101086>1315</a></td><td>SLC22A1</td><td>rs622342</td><td>selegiline</td><td>Parkinson Disease</td><td>3</td><td>AC</td><td>Dosage</td><td>Patients with the AC genotype and Parkinson disease may require increased doses of anti-Parkinsonian drugs and may have an increased risk of mortality as compared to patients with the AA genotype, and require decreased doses and have a decreased risk of mortality as compared to patients with the CC genotype. Other genetic and clinical factors may also influence dose of anti-Parkinsonian drugs and risk of mortality.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448633935>1316</a></td><td>CYP4F11</td><td>rs1060467</td><td>warfarin</td><td></td><td>3</td><td>AG</td><td>Dosage</td><td>Patients with the AG genotype and who are treated with warfarin may require increased dose as compared to patients with the GG genotypes and decreased dose as compared to those with the AA genotype. Other clinical and genetic factors may also influence dose of warfarin.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448257270>1317</a></td><td>NEDD4</td><td>rs2288344</td><td>warfarin</td><td></td><td>3</td><td>TT</td><td>Dosage</td><td>Patients with the TT genotype may require decreased dose of warfarin as compared to patients with genotype GG or GT. Other genetic and clinical factors may also influence the dose of warfarin.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1043880392>1318</a></td><td>CYP2C9</td><td>rs4918758</td><td>warfarin</td><td></td><td>3</td><td>CC</td><td>Dosage</td><td>Patients with the CC genotype may require decreased dose of warfarin in mechanical heart valve replacement patients when treated with warfarin as compared to patients with the TT genotype. Other clinical or genetic factors may also influence warfarin dose.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444694588>1319</a></td><td>ABCB1</td><td>rs1045642</td><td>tacrolimus</td><td>Organ Transplantation</td><td>4</td><td>AA</td><td>Dosage</td><td>Patients with the AA genotype who are undergoing organ transplantation, or who have other diseases, may have decreased clearance and dose requirements of tacrolimus, as compared to patients with the AG or GG genotype. However, the vast majority of studies find no association between this SNP and clearance or dose of tacrolimus. Other genetic and clinical factors, such as CYP3A5*3, may also influence clearance and dose of tacrolimus.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450820507>1320</a></td><td>CACNA1E</td><td>rs3845446</td><td>fentanyl</td><td>Pain, Postoperative</td><td>3</td><td>CT</td><td>Dosage</td><td>Patients with postoperative pain and the CT genotype may have decreased fentanyl dose requirements as compared to patients with the TT genotype. However, another study failed to find a significant association between this variant and fentanyl dose requirements. Other genetic or clinical factors may also affect a patient's fentanyl dose requirements.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/613978931>1321</a></td><td>SCN1A</td><td>rs3812718</td><td>carbamazepine</td><td>Epilepsy</td><td>2B</td><td>CT</td><td>Dosage</td><td>Patients with the rs3812718 CT genotype who are treated with carbamazepine may require a higher dose as compared to patients with the CC genotype but a lower dose as compared to patients with the TT genotype. Other genetic and clinical factors may also influence dose of carbamazepine.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183704228>1322</a></td><td>VKORC1</td><td>rs9934438</td><td>acenocoumarol</td><td></td><td>2A</td><td>AG</td><td>Dosage</td><td>Patients with the rs9934438 AG genotype may require decreased dose of acenocoumarol as compared to patients with genotype GG. Other genetic and clinical factors may also influence the dose of acenocoumarol.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655385024>1323</a></td><td>VKORC1</td><td>rs2359612</td><td>warfarin</td><td></td><td>1B</td><td>AG</td><td>Dosage</td><td>Patients with the rs2359612 AG genotype may require a decreased dose of warfarin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence dose of warfarin.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450929222>1324</a></td><td>ABCB1</td><td>rs1045642</td><td>fentanyl</td><td>Pain;Pain, Postoperative</td><td>3</td><td>AA</td><td>Dosage</td><td>Patients with the rs1045642 AA genotype may have decreased fentanyl dose requirements as compared to patients with the AG or GG genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect fentanyl dose requirements.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451237940>1325</a></td><td>VKORC1</td><td>rs9923231</td><td>phenprocoumon</td><td></td><td>1A</td><td>CT</td><td>Dosage</td><td>Patients with the rs9923231 CT genotype may require a lower dose when treated with phenprocoumon as compared to patients with the CC genotype. Other genetic and clinical factors may also influence phenprocoumon dose.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449171009>1326</a></td><td>CYP3A4</td><td>rs2740574</td><td>buprenorphine</td><td>Opioid-Related Disorders</td><td>3</td><td>TT</td><td>Dosage</td><td>Patients with opioid-related disorders and the rs2740574 TT genotype (CYP3A4*1/*1) may require a decreased dose of buprenorphine to prevent withdrawal symptoms as compared to patients with the rs2740574 CT or CC genotype (CYP3A4*1B). Other genetic and clinical factors may also influence dosage of buprenorphine in patients with opioid-related disorders.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450929810>1327</a></td><td>ABCB1</td><td>rs1045642</td><td>oxycodone</td><td>Pain</td><td>3</td><td>AA</td><td>Dosage</td><td>Patients with the AA genotype may have decreased oxycodone dose requirements as compared to patients with the AG or GG genotypes. However, another study did not find an association between this variant and oxycodone dosing. Other genetic and clinical factors may also affect a patient's oxycodone dose requirements.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450929037>1328</a></td><td>TAOK3</td><td>rs795484</td><td>opioids</td><td>Pain</td><td>3</td><td>CC</td><td>Dosage</td><td>Patients with the CC genotype may have decreased opioid dose requirements as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's opioid dose requirements.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450929792>1329</a></td><td>ABCB1</td><td>rs1045642</td><td>methadone</td><td>Pain</td><td>3</td><td>AA</td><td>Dosage</td><td>Patients with the rs1045642 AA genotype and who are receiving methadone for analgesia may required a decreased dose as compared to patients with the AG or GG genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect methadone dose requirements for analgesia.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451118760>1330</a></td><td>ABCB1</td><td>rs1045642</td><td>remifentanil</td><td></td><td>3</td><td>AA</td><td>Dosage</td><td>Patients with the AA genotype may have decreased remifentanil requirements as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's remifentanil requirements.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451138494>1331</a></td><td>OPRD1</td><td>rs204047</td><td>methadone</td><td></td><td>3</td><td>GT</td><td>Dosage</td><td>Patients with the GT genotype may require decreased doses of methadone when undergoing methadone maintenance treatment (MMT) as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's dose requirements when receiving MMT.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451149000>1332</a></td><td>SLC6A4</td><td>rs1042173</td><td>morphine</td><td>Pain</td><td>3</td><td>CC</td><td>Dosage</td><td>Patients with cancer pain and the CC genotype may have decreased morphine dose requirements as compared to patients with the AA or AC genotypes. Other genetic and clinical factors may also affect a patient's morphine dose requirements.</td><td>Decreased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451358900>1333</a></td><td>SLCO1B1</td><td>rs4149056</td><td>rosuvastatin</td><td></td><td>4</td><td>CT</td><td>Efficacy</td><td>The current evidence base suggests that there is no association between the rs4149056 CT genotype and the LDL-lowering response to rosuvastatin. Some studies report an association, however the majority of the studies documented no association. Other genetic and clinical factors may also influence response to rosuvastatin.</td><td>No</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451254826>1334</a></td><td>SLC19A1</td><td>rs1051266</td><td>methotrexate</td><td>Neoplasms;Precursor Cell Lymphoblastic Leukemia-Lymphoma</td><td>4</td><td>CT</td><td>Efficacy</td><td>The current evidence base suggests that there is no significant association between the rs1051266 CT genotype and response to methotrexate in patients with neoplasms. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to methotrexate.</td><td>No</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183697575>1335</a></td><td>MTHFR</td><td>rs1801131</td><td>methotrexate</td><td>Precursor Cell Lymphoblastic Leukemia-Lymphoma</td><td>4</td><td>TT</td><td>Efficacy</td><td>The current evidence base suggests that there is no significant association between the rs1801131 TT genotype and response to methotrexate in patients with blood cancers. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to methotrexate.</td><td>No</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/981201895>1336</a></td><td>ABCB1</td><td>rs1045642</td><td>antiepileptics</td><td>Epilepsies, Partial;Epilepsy;Epilepsy, Generalized</td><td>4</td><td>AA</td><td>Efficacy</td><td>The current evidence base suggests that there is no significant association between the rs1045642 AA genotype and likelihood of drug resistance when treated with antiepileptics. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence likelihood of drug resistance when treated with antiepileptics.</td><td>No</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451416400>1337</a></td><td>HTR2A</td><td>rs6311</td><td>antidepressants</td><td>Bipolar Disorder;Depression;Depressive Disorder, Major</td><td>4</td><td>CT</td><td>Efficacy</td><td>The current evidence base suggests that there is no significant association between the rs6311 CT genotype and response to antidepressants. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to antidepressants.</td><td>No</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451621742>1338</a></td><td>ABCB1</td><td>rs1045642</td><td>methotrexate</td><td>Arthritis, Juvenile Rheumatoid;Arthritis, Rheumatoid</td><td>4</td><td>AA</td><td>Efficacy</td><td>The current evidence base suggests that there is no significant association between the rs1045642 AA genotype and response to methotrexate in patients with rheumatoid arthritis. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to methotrexate.</td><td>No</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1445401168>1339</a></td><td>HTR2A</td><td>rs6313</td><td>antidepressants</td><td>Bipolar Disorder;Depression;Depressive Disorder, Major</td><td>4</td><td>AG</td><td>Efficacy</td><td>The current evidence base suggests there that is no significant association between the rs6313 AG genotype and response to antidepressants. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to antidepressants.</td><td>No</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444673170>1340</a></td><td>VEGFA</td><td>rs699947</td><td>docetaxel</td><td>Breast Neoplasms</td><td>4</td><td>AC</td><td>Efficacy</td><td>Current literature evidence finds no significant effect of the AC genotype on progression-free survival time in patients taking docetaxel.</td><td>No</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444672826>1341</a></td><td>ABCB1</td><td>rs1045642</td><td>pantoprazole</td><td>Helicobacter Infections</td><td>4</td><td>AA</td><td>Efficacy</td><td>The current evidence base suggests that there is no significant association between the rs1045642 AA genotype and eradication of Helicobacter infection when treated with pantoprazole. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence likelihood of response to pantoprazole.</td><td>No</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451544841>1342</a></td><td>ADRB1</td><td>rs1801253</td><td>Beta Blocking Agents</td><td>Cardiomyopathy, Dilated;Heart Failure</td><td>4</td><td>CG</td><td>Efficacy</td><td>The current evidence base suggests that there is no significant association between the rs1801253 CG genotype and response to beta-blockers. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to beta-blockers.</td><td>No</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451553595>1343</a></td><td>ABCB1</td><td>rs1045642</td><td>methotrexate</td><td>Precursor Cell Lymphoblastic Leukemia-Lymphoma</td><td>4</td><td>AA</td><td>Efficacy</td><td>The current evidence base suggests that there is no significant association between the rs1045642 AA genotype and response to methotrexate in patients with acute lymphoblastic leukemia (ALL). However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to methotrexate.</td><td>No</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451254820>1344</a></td><td>SLC19A1</td><td>rs1051266</td><td>methotrexate</td><td>Neoplasms</td><td>4</td><td>CT</td><td>Toxicity</td><td>The current evidence base suggests that there is no significant association between the rs1051266 CT genotype and risk of drug toxicity when treated with methotrexate in patients with neoplasms. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity when treated with methotrexate.</td><td>No</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183698868>1345</a></td><td>UGT1A1</td><td>rs4124874</td><td>irinotecan</td><td>Lymphoma;Neoplasms</td><td>4</td><td>GT</td><td>Toxicity</td><td>The current evidence base suggests that there is no significant association between the rs4124874 GT genotype and risk of adverse effects when treated with irinotecan. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of adverse effects when treated with irinotecan.</td><td>No</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449165169>1346</a></td><td>ABCC2</td><td>rs2273697</td><td>methotrexate</td><td>Arthritis, Rheumatoid</td><td>4</td><td>AG</td><td>Toxicity</td><td>The current evidence base suggests that there is no significant association between the rs2273697 AG genotype and risk of drug toxicity in patients with rheumatoid arthritis and treated with methorexate. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity when treated with methotrexate.</td><td>No</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449165158>1347</a></td><td>ABCB1</td><td>rs1128503</td><td>methotrexate</td><td>Arthritis, Rheumatoid</td><td>4</td><td>AG</td><td>Toxicity</td><td>The current evidence base suggests that there is no significant association between the rs1128503 AG genotype and risk of drug toxicity in patients with rheumatoid arthritis and treated with methotrexate. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity when treated with methotrexate.</td><td>No</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655387942>1348</a></td><td>SLCO1B1</td><td>rs11045879</td><td>methotrexate</td><td>Lymphoma;Osteosarcoma;Precursor Cell Lymphoblastic Leukemia-Lymphoma</td><td>4</td><td>CT</td><td>Toxicity</td><td>The current evidence base suggests that there is no significant association between the rs11045879 CT genotype and risk of drug toxicity when treated with methotrexate. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity when treated with methotrexate.</td><td>No</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/699639332>1349</a></td><td>MTHFR</td><td>rs1801131</td><td>methotrexate</td><td>Burkitt Lymphoma;Lymphoma, Non-Hodgkin;Lymphoma, T-Cell;Precursor Cell Lymphoblastic Leukemia-Lymphoma</td><td>4</td><td>TT</td><td>Toxicity</td><td>The current evidence base suggests that there is no significant association between the rs1801131 TT genotype and risk of drug toxicity when treated with methotrexate. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity when treated with methotrexate.</td><td>No</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451289660>1350</a></td><td>DPYD</td><td>rs59086055</td><td>fluorouracil</td><td>Neoplasms</td><td>1A</td><td>GG</td><td>Toxicity</td><td>The A allele of rs59086055 is assigned a no function allele by CPIC. Patients with GG genotype and cancer who are treated with fluorouracil and leucovorin may have a decreased, but not absent, risk of drug toxicity as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence risk of drug toxicity.</td><td>No</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/981238562>1351</a></td><td>SLC19A1</td><td>rs1051266</td><td>methotrexate</td><td>Burkitt Lymphoma;Leukemia;Lymphoma, T-Cell;Neoplasms;Osteosarcoma;Precursor Cell Lymphoblastic Leukemia-Lymphoma</td><td>4</td><td>CT</td><td>Metabolism/PK</td><td>The current evidence base suggests that there is no significant association between the rs1051266 CT genotype and methotrexate concentrations in patients with neoplasms. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs1051266 and methotrexate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence methotrexate concentrations.</td><td>No</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/982031741>1352</a></td><td>UGT2B7</td><td>rs7439366</td><td>valproic acid</td><td>Epilepsy</td><td>4</td><td>CT</td><td>Metabolism/PK</td><td>The current evidence base suggests that there is no significant association between the rs7439366 CT genotype and concentrations of valproic acid. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs7439366 and valproic acid and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence valproic acid concentrations.</td><td>No</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448100313>1353</a></td><td>UGT2B7</td><td>rs28365063</td><td>lamotrigine</td><td>Epilepsy</td><td>4</td><td>AG</td><td>Metabolism/PK</td><td>The current evidence base suggests that there is no significant association between the rs28365063 AG genotype and concentrations of lamotrigine. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs28365063 and lamotrigine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence lamotrigine concentrations.</td><td>No</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451408000>1354</a></td><td>COMT</td><td>rs6269</td><td>morphine</td><td>Neoplasms;Pain;Pain, Postoperative</td><td>4</td><td>GG</td><td>Dosage</td><td>The current evidence base suggests that there is no significant association between the rs6269 GG genotype and morphine dose requirements. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence morphine dose requirements.</td><td>No</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451464245>1355</a></td><td>MTHFR</td><td>rs1801131</td><td>methotrexate</td><td>Precursor Cell Lymphoblastic Leukemia-Lymphoma</td><td>4</td><td>TT</td><td>Dosage</td><td>The current evidence base suggests that there is no significant association between the rs1801131 TT genotype and methotrexate dosage in patients with ALL. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence methotrexate dose requirements.</td><td>No</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450811641>1356</a></td><td>ABCB1</td><td>rs1128503</td><td>methadone</td><td>Heroin Dependence;Opioid-Related Disorders</td><td>4</td><td>AG</td><td>Dosage</td><td>The current evidence base suggests that there is no significant association between the rs1128503 AG genotype and methadone dose requirements. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence methadone dose requirements.</td><td>No</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450929798>1357</a></td><td>ABCB1</td><td>rs1045642</td><td>methadone</td><td>Heroin Dependence;Opioid-Related Disorders</td><td>4</td><td>AA</td><td>Dosage</td><td>The current evidence base suggests that there is no significant association between rs1045642 AA genotype and methadone dose requirements. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence methadone dose requirements.</td><td>No</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449575656>1358</a></td><td>DPYD</td><td>rs59086055</td><td>fluorouracil</td><td></td><td>1A</td><td>GG</td><td>Other</td><td>The A allele of rs59086055 is assigned as no function by CPIC. The GG genotype may have increased catalytic activity of DPYD as compared to the AG or AA genotypes. Other clinical and genetic factors may also influence catalytic activity of DPYD.</td><td>No</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447989706>1359</a></td><td>DPYD</td><td>rs1801266</td><td>fluorouracil</td><td></td><td>1A</td><td>GG</td><td>Other</td><td>The A allele of rs1801266 is assigned no function by CPIC. Patients with the GG genotype may have increased DPYD activity as compared to those with the AA or AG genotype. Other genetic and clinical factors may also influence catalytic activity of DPYD.</td><td>No</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/981201981>1360</a></td><td>DPYD</td><td>rs1801265</td><td>fluorouracil</td><td>Neoplasms</td><td>1A</td><td>AG</td><td>Toxicity</td><td>Both variants of rs1801265 are assigned normal function by CPIC. Patients with the AG genotype and cancer who are treated with fluorouracil, a fluoropyrimidine-based chemotherapy, may not have altered risk of drug toxicity as compared to patients with the AA or GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity.</td><td>Normal</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451287240>1361</a></td><td>DPYD</td><td>rs1801265</td><td>capecitabine</td><td>Neoplasms</td><td>1A</td><td>AG</td><td>Toxicity</td><td>Both variants of rs1801265 are assigned normal function by CPIC. Patients with the AG genotype and cancer who are treated with capecitabine, a fluoropyrimidine-based chemotherapy, may not have altered risk of drug toxicity as compared to patients with the AA or GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity.</td><td>Normal</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450815092>1362</a></td><td>PPA2</td><td>rs2636697</td><td>risperidone</td><td>Schizophrenia</td><td>3</td><td>AA</td><td>Efficacy</td><td>Patients with schizophrenia and the AA genotype may have an increased response to risperidone as compared to patients with the AG or GG genotypes. Other genetic or clinical factors may also affect a patient's response to risperidone.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451351240>1363</a></td><td>OPRM1</td><td>rs79910351</td><td>fentanyl</td><td></td><td>3</td><td>CC</td><td>Efficacy</td><td>Patients with the rs79910351 CC genotype may have an increased response to fentanyl as compared to patients with the TT genotype. Other genetic and clinical factors may also affect response to fentanyl.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451351260>1364</a></td><td>OPRM1</td><td>rs79910351</td><td>remifentanil</td><td></td><td>3</td><td>CC</td><td>Efficacy</td><td>Patients with the rs79910351 CC genotype may have an increased response to remifentanil as compared to patients with the TT genotype. Other genetic and clinical factors may also affect response to remifentanil.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450375701>1365</a></td><td>GREM2</td><td>rs4659982</td><td>allopurinol</td><td></td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype may have an increased response to allopurinol as compared to patients with the AA, AT or TT genotypes. Other genetic and clinical factors may also affect a patient's response to allopurinol.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451357783>1366</a></td><td>DLG2</td><td>rs2449598</td><td>anastrozole</td><td>Breast Neoplasms</td><td>3</td><td>GG</td><td>Efficacy</td><td>Patients with breast cancer and the rs2449598 GG genotype may have an increased response to anastrozole as compared to patients with the GT or TT genotypes. Other genetic and clinical factors may also influence response to anastrozole.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451237983>1367</a></td><td>HTR7</td><td>rs7905446</td><td>antidepressants</td><td>Depression</td><td>3</td><td>GT</td><td>Efficacy</td><td>Patients with depression and the GT genotype may have an increased response to antidepressants as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to antidepressants.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451237983>1368</a></td><td>RPP30</td><td>rs7905446</td><td>antidepressants</td><td>Depression</td><td>3</td><td>GT</td><td>Efficacy</td><td>Patients with depression and the GT genotype may have an increased response to antidepressants as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to antidepressants.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451238020>1369</a></td><td>HTR7</td><td>rs7905446</td><td>paroxetine</td><td>Bipolar Disorder</td><td>3</td><td>GT</td><td>Efficacy</td><td>Patients with bipolar disorder and the GT genotype may have an increased response to paroxetine as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to paroxetine.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451238020>1370</a></td><td>RPP30</td><td>rs7905446</td><td>paroxetine</td><td>Bipolar Disorder</td><td>3</td><td>GT</td><td>Efficacy</td><td>Patients with bipolar disorder and the GT genotype may have an increased response to paroxetine as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to paroxetine.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451238040>1371</a></td><td>HTR7</td><td>rs7905446</td><td>escitalopram</td><td>Depression</td><td>3</td><td>GT</td><td>Efficacy</td><td>Patients with depression and the GT genotype may have an increased response to escitalopram as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to escitalopram.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451238040>1372</a></td><td>RPP30</td><td>rs7905446</td><td>escitalopram</td><td>Depression</td><td>3</td><td>GT</td><td>Efficacy</td><td>Patients with depression and the GT genotype may have an increased response to escitalopram as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to escitalopram.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451245960>1373</a></td><td>LPA</td><td>rs10455872</td><td>rosuvastatin</td><td></td><td>3</td><td>AA</td><td>Efficacy</td><td>Patients with the AA genotype may have an increased response to rosuvastatin as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's response to rosuvastatin.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449716213>1374</a></td><td>-</td><td>rs6961071</td><td>fentanyl</td><td>Pain, Postoperative</td><td>3</td><td>GG</td><td>Efficacy</td><td>Patients with the GG genotype may have an increased response to fentanyl as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's response to fentanyl.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/827836551>1375</a></td><td>PTGS2</td><td>rs20417</td><td>ibuprofen</td><td></td><td>3</td><td>CG</td><td>Efficacy</td><td>Patients with the CG genotype may have increased pain relief when treated with ibuprofen as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to ibuprofen.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/827847725>1376</a></td><td>DSCAM</td><td>rs9981861</td><td>carboplatin</td><td>Carcinoma, Non-Small-Cell Lung;Neoplasms</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype may have increased survival when treated with carboplatin and paclitaxel as compared to patients with the TT genotypes. Other genetic and clinical factors may also influence survival.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/827847725>1377</a></td><td>DSCAM</td><td>rs9981861</td><td>paclitaxel</td><td>Carcinoma, Non-Small-Cell Lung;Neoplasms</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype may have increased survival when treated with carboplatin and paclitaxel as compared to patients with the TT genotypes. Other genetic and clinical factors may also influence survival.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/827847759>1378</a></td><td>DRD3</td><td>rs963468</td><td>duloxetine</td><td>Anxiety Disorders</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype may have increased response to duloxetine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to duloxetine treatment.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/981201455>1379</a></td><td>CACNG2</td><td>rs2284017</td><td>lithium</td><td>Bipolar Disorder</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype may have increased response to lithium as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to treatment.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/981202440>1380</a></td><td>FCGR3A</td><td>rs396991</td><td>cetuximab</td><td>Neoplasms</td><td>3</td><td>AC</td><td>Efficacy</td><td>Patients with the AC genotype with cancer who are treated with cetuximab may have better response and treatment outcome as compared to patients with the CC genotype or may have poorer response and treatment outcome as compared to patients with the AA genotype. However, other studies have found no association between this variant and response to cetuximab. Other genetic and clinical factors may also influence a patient's response to therapy.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/981202551>1381</a></td><td>CYP2C19</td><td>rs4244285</td><td>cyclophosphamide</td><td>Breast Neoplasms</td><td>3</td><td>AA</td><td>Efficacy</td><td>Patients with the AA genotype and Breast Cancer who are treated with cyclophosphamide and doxorubicin may have an increased risk of poorer outcome as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to treatment.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/981202551>1382</a></td><td>CYP2C19</td><td>rs4244285</td><td>doxorubicin</td><td>Breast Neoplasms</td><td>3</td><td>AA</td><td>Efficacy</td><td>Patients with the AA genotype and Breast Cancer who are treated with cyclophosphamide and doxorubicin may have an increased risk of poorer outcome as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to treatment.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/981204525>1383</a></td><td>MTHFR</td><td>rs1801131</td><td>bevacizumab</td><td>Neoplasms</td><td>3</td><td>TT</td><td>Efficacy</td><td>Genotype TT may be associated with overall survival and progression free survival in cancer patients treated with pemetrexed and a few other anticancer drugs as compared to genotype GG and GT. However, contradictory findings (better and poorer responses) have been reported. Other genetic and clinical factors may influence a patient's response to pemetrexed.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/981204525>1384</a></td><td>MTHFR</td><td>rs1801131</td><td>carboplatin</td><td>Neoplasms</td><td>3</td><td>TT</td><td>Efficacy</td><td>Genotype TT may be associated with overall survival and progression free survival in cancer patients treated with pemetrexed and a few other anticancer drugs as compared to genotype GG and GT. However, contradictory findings (better and poorer responses) have been reported. Other genetic and clinical factors may influence a patient's response to pemetrexed.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/981204525>1385</a></td><td>MTHFR</td><td>rs1801131</td><td>cisplatin</td><td>Neoplasms</td><td>3</td><td>TT</td><td>Efficacy</td><td>Genotype TT may be associated with overall survival and progression free survival in cancer patients treated with pemetrexed and a few other anticancer drugs as compared to genotype GG and GT. However, contradictory findings (better and poorer responses) have been reported. Other genetic and clinical factors may influence a patient's response to pemetrexed.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/981204525>1386</a></td><td>MTHFR</td><td>rs1801131</td><td>cyanocobalamin</td><td>Neoplasms</td><td>3</td><td>TT</td><td>Efficacy</td><td>Genotype TT may be associated with overall survival and progression free survival in cancer patients treated with pemetrexed and a few other anticancer drugs as compared to genotype GG and GT. However, contradictory findings (better and poorer responses) have been reported. Other genetic and clinical factors may influence a patient's response to pemetrexed.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/981204525>1387</a></td><td>MTHFR</td><td>rs1801131</td><td>folic acid</td><td>Neoplasms</td><td>3</td><td>TT</td><td>Efficacy</td><td>Genotype TT may be associated with overall survival and progression free survival in cancer patients treated with pemetrexed and a few other anticancer drugs as compared to genotype GG and GT. However, contradictory findings (better and poorer responses) have been reported. Other genetic and clinical factors may influence a patient's response to pemetrexed.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/981204525>1388</a></td><td>MTHFR</td><td>rs1801131</td><td>pemetrexed</td><td>Neoplasms</td><td>3</td><td>TT</td><td>Efficacy</td><td>Genotype TT may be associated with overall survival and progression free survival in cancer patients treated with pemetrexed and a few other anticancer drugs as compared to genotype GG and GT. However, contradictory findings (better and poorer responses) have been reported. Other genetic and clinical factors may influence a patient's response to pemetrexed.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/981238092>1389</a></td><td>ABCB1</td><td>rs2032582</td><td>antiepileptics</td><td>Epilepsy</td><td>3</td><td>AC</td><td>Efficacy</td><td>Patients with genotype AC may have increased likelihood of drug resistance when treated with antiepileptics and carbamazepine in people with Epilepsy as compared to patients with genotype CC. However, contradictory findings have been reported. Genotype AC is not associated with dose of carbamazepine. Other genetic and clinical factors may also influence a patient's response to carbamazepine.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/981238092>1390</a></td><td>ABCB1</td><td>rs2032582</td><td>carbamazepine</td><td>Epilepsy</td><td>3</td><td>AC</td><td>Efficacy</td><td>Patients with genotype AC may have increased likelihood of drug resistance when treated with antiepileptics and carbamazepine in people with Epilepsy as compared to patients with genotype CC. However, contradictory findings have been reported. Genotype AC is not associated with dose of carbamazepine. Other genetic and clinical factors may also influence a patient's response to carbamazepine.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/981345277>1391</a></td><td>XRCC1</td><td>rs25487</td><td>fluorouracil</td><td>Colonic Neoplasms;Colorectal Neoplasms;Neoplasms;Rectal Neoplasms;Uterine Cervical Neoplasms</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype and cancer may have decreased response to fluorouracil-containing chemotherapy regimens, as well as an increased risk for and an earlier onset of sensory neuropathy, as compared to patients with the CC genotype. However, all studies evaluated also included other treatments (platinum drugs or radiotherapy) which may interact with this variant. Other genetic and clinical factors may also influence response to treatment.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448100389>1392</a></td><td>EPM2A</td><td>rs1415744</td><td>chlorpromazine</td><td>Schizophrenia</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype and schizophrenia may have increased response to chlorpromazine, clozapine, haloperidol, olanzapine, quetiapine, risperidone, or trifluoperazine compared to patients with the TT genotype. Other factors may affect response to these drugs.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448100389>1393</a></td><td>EPM2A</td><td>rs1415744</td><td>clozapine</td><td>Schizophrenia</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype and schizophrenia may have increased response to chlorpromazine, clozapine, haloperidol, olanzapine, quetiapine, risperidone, or trifluoperazine compared to patients with the TT genotype. Other factors may affect response to these drugs.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448100389>1394</a></td><td>EPM2A</td><td>rs1415744</td><td>haloperidol</td><td>Schizophrenia</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype and schizophrenia may have increased response to chlorpromazine, clozapine, haloperidol, olanzapine, quetiapine, risperidone, or trifluoperazine compared to patients with the TT genotype. Other factors may affect response to these drugs.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448100389>1395</a></td><td>EPM2A</td><td>rs1415744</td><td>olanzapine</td><td>Schizophrenia</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype and schizophrenia may have increased response to chlorpromazine, clozapine, haloperidol, olanzapine, quetiapine, risperidone, or trifluoperazine compared to patients with the TT genotype. Other factors may affect response to these drugs.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448100389>1396</a></td><td>EPM2A</td><td>rs1415744</td><td>quetiapine</td><td>Schizophrenia</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype and schizophrenia may have increased response to chlorpromazine, clozapine, haloperidol, olanzapine, quetiapine, risperidone, or trifluoperazine compared to patients with the TT genotype. Other factors may affect response to these drugs.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448100389>1397</a></td><td>EPM2A</td><td>rs1415744</td><td>risperidone</td><td>Schizophrenia</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype and schizophrenia may have increased response to chlorpromazine, clozapine, haloperidol, olanzapine, quetiapine, risperidone, or trifluoperazine compared to patients with the TT genotype. Other factors may affect response to these drugs.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448100389>1398</a></td><td>EPM2A</td><td>rs1415744</td><td>trifluoperazine</td><td>Schizophrenia</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype and schizophrenia may have increased response to chlorpromazine, clozapine, haloperidol, olanzapine, quetiapine, risperidone, or trifluoperazine compared to patients with the TT genotype. Other factors may affect response to these drugs.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448100404>1399</a></td><td>CRP</td><td>rs1130864</td><td>adalimumab</td><td></td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype and inflammatory bowel disease may have increased response to adalimumab compared to patients with the GG genotype. Other factors may affect response to adalimumab.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449155625>1400</a></td><td>TLR5</td><td>rs5744174</td><td>ustekinumab</td><td>Psoriasis</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype and psoriasis may have a better response when treated with ustekinumab as compared to patients with the AA genotype. Other genetic and clinical factors may also influence ustekinumab response.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449155631>1401</a></td><td>IL1B</td><td>rs1143627</td><td>Tumor necrosis factor alpha (TNF-alpha) inhibitors</td><td>Psoriasis</td><td>3</td><td>AA</td><td>Efficacy</td><td>Patients with the AA genotype and psoriasis may have a better response when treated with TNF-inhibitors or ustekinumab as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence TNF-inhibitor or ustekinumab response.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449155631>1402</a></td><td>IL1B</td><td>rs1143627</td><td>ustekinumab</td><td>Psoriasis</td><td>3</td><td>AA</td><td>Efficacy</td><td>Patients with the AA genotype and psoriasis may have a better response when treated with TNF-inhibitors or ustekinumab as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence TNF-inhibitor or ustekinumab response.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449164603>1403</a></td><td>NCF4</td><td>rs1883112</td><td>idarubicin</td><td>Leukemia, Myeloid, Acute</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype and acute myeloid leukemia may be more likely to have complete remission when treated with idarubicin as compared to patients with the GG genotype, or less likely as compared to patients with the AA genotype. Other genetic and clinical factors may also influence likelihood of complete remission.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449713660>1404</a></td><td>RNF8</td><td>rs2284922</td><td>carboplatin</td><td>Breast Neoplasms</td><td>3</td><td>AA</td><td>Efficacy</td><td>Patients with the AA genotype and breast cancer may have an increased response to treatment with carboplatin, docetaxel and trastuzumab as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to carboplatin, docetaxel and trastuzumab.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449713660>1405</a></td><td>RNF8</td><td>rs2284922</td><td>docetaxel</td><td>Breast Neoplasms</td><td>3</td><td>AA</td><td>Efficacy</td><td>Patients with the AA genotype and breast cancer may have an increased response to treatment with carboplatin, docetaxel and trastuzumab as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to carboplatin, docetaxel and trastuzumab.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449713660>1406</a></td><td>RNF8</td><td>rs2284922</td><td>trastuzumab</td><td>Breast Neoplasms</td><td>3</td><td>AA</td><td>Efficacy</td><td>Patients with the AA genotype and breast cancer may have an increased response to treatment with carboplatin, docetaxel and trastuzumab as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to carboplatin, docetaxel and trastuzumab.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450373589>1407</a></td><td>SLC22A1</td><td>rs628031</td><td>imatinib</td><td>Neoplasms</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype and cancer may have increased clearance of imatinib, as well as a decreased response and decreased risk for toxicity when treated with imatinib as compared to patients with the GG genotype. However, one study failed to find an association between this variant and imatinib toxicity. Other genetic and clinical factors may also influence clearance, response, and risk for toxicity in patients receiving imatinib.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450373595>1408</a></td><td>ABCB4</td><td>rs1202283</td><td>imatinib</td><td>Gastrointestinal Stromal Tumors</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype and gastrointestinal stromal tumors may have increased progression-free survival when treated with imatinib as compared to patients with the GG genotype. Other genetic and clinical factors may also influence progression-free survival in patients receiving imatinib.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450373604>1409</a></td><td>ABCC2</td><td>rs2273697</td><td>imatinib</td><td>Gastrointestinal Stromal Tumors</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype and gastrointestinal stromal tumors may have increased progression-free survival times when treated with imatinib as compared to patients with the GG genotype. Other genetic and clinical factors may also influence progression-free survival tumes in patients receiving imatinib.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449004733>1410</a></td><td>ABCC2</td><td>rs2273697</td><td>cisplatin</td><td>Mesothelioma</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with mesothelioma and the AG genotype may have improved overall and progression-free survival when treated with cisplatin and pemetrexed as compared to patients with the GG genotype. Other clinical and genetic factors may also influence survival in patients with mesothelioma who are treated with cisplatin and premetrexed.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449004733>1411</a></td><td>ABCC2</td><td>rs2273697</td><td>pemetrexed</td><td>Mesothelioma</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with mesothelioma and the AG genotype may have improved overall and progression-free survival when treated with cisplatin and pemetrexed as compared to patients with the GG genotype. Other clinical and genetic factors may also influence survival in patients with mesothelioma who are treated with cisplatin and premetrexed.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449718259>1412</a></td><td>SLC22A16</td><td>rs714368</td><td>cyclophosphamide</td><td>Breast Neoplasms</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype may have increased risk for nausea, but a decreased likelihood of dose delay, when treated with cyclophosphamide, doxorubicin and fluorouracil, as compared to patients with TT genotype. Other genetic and clinical factors may also influence risk for dose delay and toxicity in patients taking cyclophosphamide, doxorubicin and fluorouracil.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449718259>1413</a></td><td>SLC22A16</td><td>rs714368</td><td>doxorubicin</td><td>Breast Neoplasms</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype may have increased risk for nausea, but a decreased likelihood of dose delay, when treated with cyclophosphamide, doxorubicin and fluorouracil, as compared to patients with TT genotype. Other genetic and clinical factors may also influence risk for dose delay and toxicity in patients taking cyclophosphamide, doxorubicin and fluorouracil.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449718259>1414</a></td><td>SLC22A16</td><td>rs714368</td><td>fluorouracil</td><td>Breast Neoplasms</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype may have increased risk for nausea, but a decreased likelihood of dose delay, when treated with cyclophosphamide, doxorubicin and fluorouracil, as compared to patients with TT genotype. Other genetic and clinical factors may also influence risk for dose delay and toxicity in patients taking cyclophosphamide, doxorubicin and fluorouracil.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449167568>1415</a></td><td>PYROXD2</td><td>rs1061115</td><td>methylphenidate</td><td>Attention Deficit Disorder with Hyperactivity</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to methylphenidate</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450375674>1416</a></td><td>NTNG1</td><td>rs61816456</td><td>allopurinol</td><td></td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype may have an increased response to allopurinol as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to allopurinol.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450375680>1417</a></td><td>GREM2</td><td>rs77567654</td><td>allopurinol</td><td></td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype may have an increased response to allopurinol as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to allopurinol.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450375686>1418</a></td><td>GREM2</td><td>rs10802887</td><td>allopurinol</td><td></td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype may have an increased response to allopurinol as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to allopurinol.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449715584>1419</a></td><td>UGT2B7</td><td>rs4587017</td><td>fentanyl</td><td>Pain, Postoperative</td><td>3</td><td>GT</td><td>Efficacy</td><td>Patients with the GT genotype may have an increased response to fentanyl as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to fentanyl.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/982030998>1420</a></td><td>MAP3K5</td><td>rs9376230</td><td>hydroxyurea</td><td>Thalassemia</td><td>3</td><td>AA</td><td>Efficacy</td><td>Patients with the AA genotype and Thalassemia may be more likely to respond to hydroxyurea treatment as compared to genotype AC. Other genetic and clinical factors may also influence a patient's response to treatment.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/982040494>1421</a></td><td>BDNF</td><td>rs6265</td><td>paroxetine</td><td>Depressive Disorder, Major</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype and Depressive Disorder may be more likely to respond to paroxetine as compared to patients with the TT genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to paroxetine.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1043880476>1422</a></td><td>AGTR1</td><td>rs5186</td><td>Ace Inhibitors, Plain</td><td>Coronary Artery Disease</td><td>3</td><td>CA</td><td>Efficacy</td><td>Patients with the CA genotype and Coronary Artery Disease may have an increased major cardiovascular events rate when treated with Ace Inhibitors as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for major cardiovascular events.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1127092670>1423</a></td><td>UST</td><td>rs2500535</td><td>nortriptyline</td><td>Depressive Disorder, Major</td><td>3</td><td>GG</td><td>Efficacy</td><td>Patients with the GG genotype and major depressive disorder who are treated with nortriptyline may have increased improvement of depression symptoms as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to nortriptyline.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1153928101>1424</a></td><td>NQO2</td><td>rs1143684</td><td>cyclophosphamide</td><td>Breast Neoplasms</td><td>3</td><td>TT</td><td>Efficacy</td><td>Patients with the TT genotype and Breast Neoplasms who are ER-ve/PR-ve negative and treated with cyclophosphamide and doxorubicin may have better prognosis (overall survival and progression-free survival) as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence a patient's treatment prognosis.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1153928101>1425</a></td><td>NQO2</td><td>rs1143684</td><td>doxorubicin</td><td>Breast Neoplasms</td><td>3</td><td>TT</td><td>Efficacy</td><td>Patients with the TT genotype and Breast Neoplasms who are ER-ve/PR-ve negative and treated with cyclophosphamide and doxorubicin may have better prognosis (overall survival and progression-free survival) as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence a patient's treatment prognosis.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183491157>1426</a></td><td>CYP3A5</td><td>rs776746</td><td>lovastatin</td><td>Arteriosclerosis</td><td>3</td><td>CC</td><td>Efficacy</td><td>Patients with the CC genotype and Arteriosclerosis who are treated with lovastatin may have a better response to treatment (measured by higher reductions in total cholesterol) as compared to patients with the CT genotype. Other genetic and clinical factors may also influence a patient's response to statin treatment.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183614605>1427</a></td><td>CYP11B2</td><td>rs1799998</td><td>benazepril</td><td>Essential hypertension</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype and hypertension may have a greater decrease in diastolic blood pressure when treated with benazepril or imidapril as compared to patients with the GG genotype. No significant effects on systolic blood pressure were seen. Other genetic and clinical factors may also influence diastolic blood pressure response.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183614605>1428</a></td><td>CYP11B2</td><td>rs1799998</td><td>imidapril</td><td>Essential hypertension</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype and hypertension may have a greater decrease in diastolic blood pressure when treated with benazepril or imidapril as compared to patients with the GG genotype. No significant effects on systolic blood pressure were seen. Other genetic and clinical factors may also influence diastolic blood pressure response.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183630286>1429</a></td><td>SLC19A1</td><td>rs12659</td><td>carboplatin</td><td>Uterine Cervical Neoplasms</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype and cervical cancer who are treated with carboplatin, cisplatin and fluorouracil may have a reduced response to treatment as compared to patients with the GG genotype or may have a better response to treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to platinum-based neoadjuvant treatment.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183630286>1430</a></td><td>SLC19A1</td><td>rs12659</td><td>cisplatin</td><td>Uterine Cervical Neoplasms</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype and cervical cancer who are treated with carboplatin, cisplatin and fluorouracil may have a reduced response to treatment as compared to patients with the GG genotype or may have a better response to treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to platinum-based neoadjuvant treatment.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183630286>1431</a></td><td>SLC19A1</td><td>rs12659</td><td>fluorouracil</td><td>Uterine Cervical Neoplasms</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype and cervical cancer who are treated with carboplatin, cisplatin and fluorouracil may have a reduced response to treatment as compared to patients with the GG genotype or may have a better response to treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to platinum-based neoadjuvant treatment.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183700522>1432</a></td><td>DHFR</td><td>rs1105525</td><td>methotrexate</td><td>Precursor Cell Lymphoblastic Leukemia-Lymphoma</td><td>3</td><td>CC</td><td>Efficacy</td><td>Patients with the CC genotype may have increased event free survival when treated with methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to patients with genotype TT or TC. Other genetic and clinical factors may also influence a patient's response to methotrexate.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/982031855>1433</a></td><td>CHRNA5</td><td>rs588765</td><td>Drugs used in nicotine dependence</td><td>Tobacco Use Disorder</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype may have increased chance of achieving 6 month abstinence if prescribed NRT (nicotine replacement therapy) when treated with Drugs used in nicotine dependence as compared to patients with the CC genotype. However this has been contradicted in some studies.Other clinical and genetic factors may also influence response to smoking cessation therapies.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/982031855>1434</a></td><td>CHRNA5</td><td>rs588765</td><td>nicotine</td><td>Tobacco Use Disorder</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype may have increased chance of achieving 6 month abstinence if prescribed NRT (nicotine replacement therapy) when treated with Drugs used in nicotine dependence as compared to patients with the CC genotype. However this has been contradicted in some studies.Other clinical and genetic factors may also influence response to smoking cessation therapies.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/982031855>1435</a></td><td>CHRNA5</td><td>rs588765</td><td>varenicline</td><td>Tobacco Use Disorder</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype may have increased chance of achieving 6 month abstinence if prescribed NRT (nicotine replacement therapy) when treated with Drugs used in nicotine dependence as compared to patients with the CC genotype. However this has been contradicted in some studies.Other clinical and genetic factors may also influence response to smoking cessation therapies.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451398106>1436</a></td><td>FKBP5</td><td>rs4713916</td><td>fluoxetine</td><td>Mood Disorders</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with mood disorders and the rs4713916 AG genotype may have an increased response to fluoxetine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to fluoxetine.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183689409>1437</a></td><td>TNF</td><td>rs1799724</td><td>Tumor necrosis factor alpha (TNF-alpha) inhibitors</td><td>Arthritis, Rheumatoid;Crohn Disease;Psoriasis;Spondylitis, Ankylosing</td><td>4</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype and inflammatory diseases may have increased response to anti-TNFalpha treatment as compared to patients with the CC genotype. However, both conflicting and non-significant evidence exists for this association. Other genetic and clinical factors may also influence a patient's response to tumor necrosis factor alpha inhibitors.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451398120>1438</a></td><td>FKBP5</td><td>rs4713916</td><td>mirtazapine</td><td>Mood Disorders</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with mood disorders and the rs4713916 AG genotype may have an increased response to mirtazapine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to mirtazapine.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183614499>1439</a></td><td>MTHFR</td><td>rs1801133</td><td>disulfiram</td><td>Cocaine-Related Disorders</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype and cocaine dependence may have an increased response when treated with disulfiram as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to disulfiram.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183631404>1440</a></td><td>SV2C</td><td>rs11960832</td><td>olanzapine</td><td>Schizophrenia</td><td>3</td><td>CC</td><td>Efficacy</td><td>Patients with the CC genotype and schizophrenia may have a better response when treated with olanzapine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to olanzapine.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183700527>1441</a></td><td>PTPRC</td><td>rs10919563</td><td>adalimumab</td><td>Arthritis, Rheumatoid</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype may have increased response to adalimumab, etanercept or infliximab in people with Arthritis, Rheumatoid as compared to patients with genotype AA. However, contradictory evidence has also been reported. Other genetic and clinical factors may also influence a patient's response to anti-TNF biologics.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183700527>1442</a></td><td>PTPRC</td><td>rs10919563</td><td>etanercept</td><td>Arthritis, Rheumatoid</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype may have increased response to adalimumab, etanercept or infliximab in people with Arthritis, Rheumatoid as compared to patients with genotype AA. However, contradictory evidence has also been reported. Other genetic and clinical factors may also influence a patient's response to anti-TNF biologics.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183700527>1443</a></td><td>PTPRC</td><td>rs10919563</td><td>infliximab</td><td>Arthritis, Rheumatoid</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype may have increased response to adalimumab, etanercept or infliximab in people with Arthritis, Rheumatoid as compared to patients with genotype AA. However, contradictory evidence has also been reported. Other genetic and clinical factors may also influence a patient's response to anti-TNF biologics.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183700527>1444</a></td><td>PTPRC</td><td>rs10919563</td><td>Tumor necrosis factor alpha (TNF-alpha) inhibitors</td><td>Arthritis, Rheumatoid</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype may have increased response to adalimumab, etanercept or infliximab in people with Arthritis, Rheumatoid as compared to patients with genotype AA. However, contradictory evidence has also been reported. Other genetic and clinical factors may also influence a patient's response to anti-TNF biologics.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/982032727>1445</a></td><td>NR1D1</td><td>rs2071427</td><td>lithium</td><td>Bipolar Disorder</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype and Bipolar Disorder may be more likely to respond to lithium as compared to patients with the CC genotype. However, contradictory findings have been reported. Other genetic and clinical factors may also influence a patient's response to lithium.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/982032727>1446</a></td><td>THRA</td><td>rs2071427</td><td>lithium</td><td>Bipolar Disorder</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype and Bipolar Disorder may be more likely to respond to lithium as compared to patients with the CC genotype. However, contradictory findings have been reported. Other genetic and clinical factors may also influence a patient's response to lithium.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/982037796>1447</a></td><td>LEPR</td><td>rs1137101</td><td>simvastatin</td><td>Coronary Disease</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype and coronary heart disease may have a reduced response to treatment with smaller increases in HDL-C levels when treated with simvastatin as compared to patients with the GG genotype or may have a better response to treatment with higher increases in HDL-C levels when treated with simvastatin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to treatment.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1043859380>1448</a></td><td>MC1R</td><td>rs2228478</td><td>desipramine</td><td>Depressive Disorder, Major</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype and Depressive Disorder may have an increased likelihood of remission when treated with desipramine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to desipramine.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183492035>1449</a></td><td>APOA5</td><td>rs662799</td><td>atorvastatin</td><td>Hyperlipidemias</td><td>3</td><td>AA</td><td>Efficacy</td><td>Patients with the rs662799 AA genotype and Hyperlipidemia who are treated with atorvastatin, lovastatin or simvastatin may have a higher reduction in LDL-cholesterol as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence response to statin treatment.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183492035>1450</a></td><td>APOA5</td><td>rs662799</td><td>lovastatin</td><td>Hyperlipidemias</td><td>3</td><td>AA</td><td>Efficacy</td><td>Patients with the rs662799 AA genotype and Hyperlipidemia who are treated with atorvastatin, lovastatin or simvastatin may have a higher reduction in LDL-cholesterol as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence response to statin treatment.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183492035>1451</a></td><td>APOA5</td><td>rs662799</td><td>simvastatin</td><td>Hyperlipidemias</td><td>3</td><td>AA</td><td>Efficacy</td><td>Patients with the rs662799 AA genotype and Hyperlipidemia who are treated with atorvastatin, lovastatin or simvastatin may have a higher reduction in LDL-cholesterol as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence response to statin treatment.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1043858965>1452</a></td><td>AGTR1</td><td>rs5186</td><td>captopril</td><td>Diabetes Mellitus, Type 2</td><td>3</td><td>AC</td><td>Efficacy</td><td>Patients with the AC genotype and type 2 diabetes may have an increased response when treated with captopril as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to captopril.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183632145>1453</a></td><td>WNK1</td><td>rs880054</td><td>hydrochlorothiazide</td><td>Hypertension</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype may have increased reduction in systolic blood pressure (SBP) when treated with hydrochlorothiazide in people with Hypertension as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to hydrochlorothiazide.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183533955>1454</a></td><td>IL4R</td><td>rs3024530</td><td>pitrakinra</td><td>Asthma</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype and asthma may have a higher frequency of asthma exacerbations when treated with pitrakinra as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to pitrakinra.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183601914>1455</a></td><td>CRP</td><td>rs3091244</td><td>fenofibrate</td><td>Metabolic Syndrome</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype and metabolic syndrome may have an increased response when treated with fenofibrate as compared to patients with the AA or AT genotype. Other genetic and clinical factors may also influence response to fenofibrate.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183617644>1456</a></td><td>CYP1A2</td><td>rs2472304</td><td>paroxetine</td><td>Depressive Disorder, Major</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype and major depressive disorder who are treated with paroxetine may be more likely to experience remission as compared to patients with the GG genotype or may be less likely to experience remission as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to paroxetine treatment.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183697540>1457</a></td><td>SLCO1B1</td><td>rs2306283</td><td>irinotecan</td><td>Colorectal Neoplasms</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype and metastatic colorectal cancer may have 1) increased rapid response to treatment containing irinotecan, 2) longer progression free survival, and 3) greater irinotecan-related time to treatment failure as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to irinotecan based treatment.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183698831>1458</a></td><td>IL6</td><td>rs1800795</td><td>fenofibrate</td><td>Cardiovascular Diseases</td><td>3</td><td>CG</td><td>Efficacy</td><td>Patients with the CG genotype who have a high risk of cardiovascular disease may have a better anti-inflammatory response when treated with fenofibrate as compared to patients with the GG genotype. Other genetic and clinical factors may also influence the anti-inflammatory action of fenofibrate.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183617724>1459</a></td><td>FKBP5</td><td>rs4713916</td><td>antidepressants</td><td>Depressive Disorder;Mood Disorders</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype may have a better response to antidepressants as compared to patients with the GG genotype or may have a reduced response to antidepressants as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to antidepressant treatment.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183617724>1460</a></td><td>FKBP5</td><td>rs4713916</td><td>Selective serotonin reuptake inhibitors</td><td>Depressive Disorder;Mood Disorders</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype may have a better response to antidepressants as compared to patients with the GG genotype or may have a reduced response to antidepressants as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to antidepressant treatment.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183700248>1461</a></td><td>RRM1</td><td>rs2898950</td><td>cladribine</td><td>Leukemia, Myeloid, Acute</td><td>3</td><td>CC</td><td>Efficacy</td><td>Patients with the CC genotype and acute myeloid leukemia who are treated with cytarabine and cladribine may be more likely to have a complete response to the first course of remission induction therapy as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine and cladribine treatment.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183700248>1462</a></td><td>RRM1</td><td>rs2898950</td><td>cytarabine</td><td>Leukemia, Myeloid, Acute</td><td>3</td><td>CC</td><td>Efficacy</td><td>Patients with the CC genotype and acute myeloid leukemia who are treated with cytarabine and cladribine may be more likely to have a complete response to the first course of remission induction therapy as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine and cladribine treatment.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183700253>1463</a></td><td>RRM1</td><td>rs1561876</td><td>cladribine</td><td>Leukemia, Myeloid, Acute</td><td>3</td><td>AA</td><td>Efficacy</td><td>Patients with the AA genotype and acute myeloid leukemia who are treated with cytarabine and cladribine may have a better response to treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine and cladribine treatment.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183700253>1464</a></td><td>RRM1</td><td>rs1561876</td><td>cytarabine</td><td>Leukemia, Myeloid, Acute</td><td>3</td><td>AA</td><td>Efficacy</td><td>Patients with the AA genotype and acute myeloid leukemia who are treated with cytarabine and cladribine may have a better response to treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine and cladribine treatment.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/982030990>1465</a></td><td>MAP3K5</td><td>rs9483947</td><td>hydroxyurea</td><td>Thalassemia</td><td>3</td><td>TT</td><td>Efficacy</td><td>Patients with the TT genotype and Thalassemia may be more likely to respond to hydroxyurea treatment as compared to genotype CT. Other genetic and clinical factors may also influence a patient's response to treatment.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183607656>1466</a></td><td>ABCA1</td><td>rs2230808</td><td>fenofibrate</td><td>Hypertriglyceridemia</td><td>3</td><td>CC</td><td>Efficacy</td><td>Patients with the CC genotype and hypertriglyceridemia may have an increased response when treated with fenofibrate as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to fenofibrate.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183614504>1467</a></td><td>F12</td><td>rs1801020</td><td>Enzymes</td><td>Stroke</td><td>3</td><td>GG</td><td>Efficacy</td><td>Patients with the GG genotype who have had a stroke may have an increased risk of in-hospital death when treated with tissue plasminogen activator as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence risk of in-hospital death.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183614802>1468</a></td><td>IL4R</td><td>rs1110470</td><td>pitrakinra</td><td>Asthma</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype and asthma may have a higher frequency of asthma exacerbations when treated with pitrakinra as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to pitrakinra.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1146391450>1469</a></td><td>FKBP5</td><td>rs4713916</td><td>corticosteroids</td><td>Crohn Disease</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype and Crohn Disease who are treated with corticosteroids may have an increased likelihood of responsiveness as compared to patients with GG genotype. Other genetic and clinical factors may also influence a patient's response to corticosteroids.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183492249>1470</a></td><td>APOE</td><td>rs7412</td><td>atorvastatin</td><td>Coronary Disease;Hyperlipidemias</td><td>2B</td><td>CT</td><td>Efficacy</td><td>Patients with the rs7412 CT genotype may have increased response to atorvastatin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to atorvastatin treatment.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183680531>1471</a></td><td>SLC30A8</td><td>rs13266634</td><td>repaglinide</td><td>Diabetes Mellitus, Type 2</td><td>3</td><td>TT</td><td>Efficacy</td><td>Patients with the TT genotype may have increased response to repaglinide in people with Diabetes Mellitus, Type 2 as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to repaglinide.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/982032721>1472</a></td><td>-</td><td>rs2769605</td><td>lithium</td><td>Bipolar Disorder</td><td>3</td><td>TT</td><td>Efficacy</td><td>Patients with the TT genotype and Bipolar Disorder may be more likely to respond to lithium or valproic acid as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to lithium.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/982032721>1473</a></td><td>-</td><td>rs2769605</td><td>valproic acid</td><td>Bipolar Disorder</td><td>3</td><td>TT</td><td>Efficacy</td><td>Patients with the TT genotype and Bipolar Disorder may be more likely to respond to lithium or valproic acid as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to lithium.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/982037753>1474</a></td><td>LEPR</td><td>rs1137101</td><td>simvastatin</td><td>Hyperlipidemias</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype and hypercholesterolemia may have a better response to treatment with increased reductions in total cholesterol when treated with simvastatin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to treatment.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/982038273>1475</a></td><td>HTR2A</td><td>rs7997012</td><td>venlafaxine</td><td>Anxiety Disorders</td><td>3</td><td>GG</td><td>Efficacy</td><td>Patients with the GG genotype may be more likely to respond to venlafaxine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to venlafaxine.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183698841>1476</a></td><td>SLC22A4</td><td>rs1050152</td><td>imatinib</td><td>Gastrointestinal Stromal Tumors;Leukemia, Myelogenous, Chronic, BCR-ABL Positive</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype and cancer may have a better response to treatment with imatinib as compared to patients with the TT genotype. Other genetic and clinical factors may also influence time to progression.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1043858882>1477</a></td><td>VDR</td><td>rs731236</td><td>calcium</td><td></td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype may have increased risk of bone fractures when treated with Calcium as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to calcium.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1043873003>1478</a></td><td>PPARA</td><td>rs135550</td><td>fenofibrate</td><td></td><td>3</td><td>TT</td><td>Efficacy</td><td>Patients with the TT genotype may have increased reduction in fasting LDL-C when treated with fenofibrate as compared to patients with the CC or CT genotype. Other clinical or genetic factors may also influence a patient's response to fenofibrate.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183491385>1479</a></td><td>CETP</td><td>rs5882</td><td>fluvastatin</td><td>Hypercholesterolemia</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype and Hypercholesterolemia may have a better response to fluvastatin (a higher change in triglycerides) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to fluvastatin treatment.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183700493>1480</a></td><td>GATA4</td><td>rs13273672</td><td>Drugs used in alcohol dependence</td><td>Alcoholism</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype may have increased time to relapse when treated with Drugs used in alcohol dependence in people with Alcoholism as compared to patients with genotypes CC. Other genetic and clinical factors may also influence a patient's response.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1050579065>1481</a></td><td>MTTP</td><td>rs1800591</td><td>pravastatin</td><td>Coronary Artery Disease</td><td>3</td><td>TT</td><td>Efficacy</td><td>Patients with the TT genotype who are treated with pravastatin may be more likely to benefit from treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183490994>1482</a></td><td>PDE4D</td><td>rs702553</td><td>diuretics</td><td>Nephrosclerosis</td><td>3</td><td>AT</td><td>Efficacy</td><td>Patients with the AT genotype and Nephrosclerosis may have a higher baseline mean arterial blood pressure when treated with diuretics as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to diuretics.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183492181>1483</a></td><td>APOE</td><td>rs7412</td><td>pravastatin</td><td></td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype (carriers of APOE E2) who are treated with pravastatin may have a better response (increased reduction in LDL-cholesterol) as compared to patients with the CC genotype (non-carriers of APOE E2). Other genetic and clinical factors may also influence a patient's response to pravastatin treatment.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1142234402>1484</a></td><td>ABCB1</td><td>rs1045642</td><td>simvastatin</td><td></td><td>4</td><td>AA</td><td>Efficacy</td><td>Patients with the AA genotype who are treated with simvastatin may have a better response to treatment (measured by a higher reduction in total cholesterol) compared to patients with the GG genotype. In another study no association was seen. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1150414901>1485</a></td><td>ABCB1</td><td>rs2032582</td><td>simvastatin</td><td>Hypercholesterolemia</td><td>3</td><td>AC</td><td>Efficacy</td><td>Patients with the AC genotype who are treated with simvastatin may have a better response (as measured by higher reductions in total cholesterol) as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/982034869>1486</a></td><td>ABCB1</td><td>rs1128503</td><td>oxaliplatin</td><td>Colorectal Neoplasms</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype and colorectal cancer may have an increased overall survival period when treated with oxaliplatin-based chemotherapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to treatment.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/982037811>1487</a></td><td>CETP</td><td>rs708272</td><td>pravastatin</td><td>Coronary Artery Disease</td><td>3</td><td>AA</td><td>Efficacy</td><td>Patients with the AA genotype and Coronary Artery Disease may be less likely to benefit from treatment with pravastatin and have an increased risk of death or cardiovascular disease events as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to statin treatment.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/982040619>1488</a></td><td>ABCB1</td><td>rs2032582</td><td>cyclosporine</td><td>Kidney Transplantation</td><td>3</td><td>AC</td><td>Efficacy</td><td>Patients with the AC genotype may have an increased risk of biopsy-proven acute rejection at 12 month post-transplant when treated with cyclosporine and mycophenolate mofetil as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to mycophenolate mofetil.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/982040619>1489</a></td><td>ABCB1</td><td>rs2032582</td><td>mycophenolate mofetil</td><td>Kidney Transplantation</td><td>3</td><td>AC</td><td>Efficacy</td><td>Patients with the AC genotype may have an increased risk of biopsy-proven acute rejection at 12 month post-transplant when treated with cyclosporine and mycophenolate mofetil as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to mycophenolate mofetil.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1043858877>1490</a></td><td>-</td><td>rs10030044</td><td>raloxifene</td><td>Breast Neoplasms</td><td>3</td><td>GT</td><td>Efficacy</td><td>Patients with the GT genotype may have increased risk of occurrence of breast cancer during SERM (selective estrogen receptor modulators) therapy when treated with raloxifene or tamoxifen in people with Breast Neoplasms as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients response to SERM therapy.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1043858877>1491</a></td><td>-</td><td>rs10030044</td><td>tamoxifen</td><td>Breast Neoplasms</td><td>3</td><td>GT</td><td>Efficacy</td><td>Patients with the GT genotype may have increased risk of occurrence of breast cancer during SERM (selective estrogen receptor modulators) therapy when treated with raloxifene or tamoxifen in people with Breast Neoplasms as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patients response to SERM therapy.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1043873013>1492</a></td><td>ALDH1A2</td><td>rs12903202</td><td>Bisphosphonates</td><td>Osteonecrosis</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype may have increased likelihood of Osteonecrosis when treated with Bisphosphonates as compared to patients with the GG genotype. Other clinical or genetic factors may also influence a patient's risk of toxicity to bisphosphonates.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1043880426>1493</a></td><td>SCAP</td><td>rs12487736</td><td>simvastatin</td><td>Hypercholesterolemia</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype and Hypercholesterolemia may have a better response to simvastatin treatment as compared to patients with the the TT genotype. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1157204541>1494</a></td><td>HTR3A</td><td>rs1150226</td><td>clozapine</td><td>Schizophrenia</td><td>3</td><td>GG</td><td>Efficacy</td><td>Patients with the GG genotype as part of a haplotype rs2276302-rs1062613-rs1150226 and Schizophrenia who are treated with clozapine may have an increased response as compared to patients with the AA genotype as part of a haplotype rs2276302-rs1062613-rs1150226. However, only a trend of association is reported. Other genetic and clinical factors may also influence a patient's response to clozapine.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183491364>1495</a></td><td>MTHFR</td><td>rs1801133</td><td>folic acid</td><td></td><td>3</td><td>AG</td><td>Efficacy</td><td>Female patients with the AG genotype and Migraine who are treated with folic acid and a vitamin b-complex may have a decreased severity of pain greater reduction in homocysteine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's severity of pain. This drug-variant pair has been assigned a no recommendation by DPWG, as it was determined to be not clinically actionable.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183491364>1496</a></td><td>MTHFR</td><td>rs1801133</td><td>vitamin b-complex, plain</td><td></td><td>3</td><td>AG</td><td>Efficacy</td><td>Female patients with the AG genotype and Migraine who are treated with folic acid and a vitamin b-complex may have a decreased severity of pain greater reduction in homocysteine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's severity of pain. This drug-variant pair has been assigned a no recommendation by DPWG, as it was determined to be not clinically actionable.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1043859020>1497</a></td><td>AGT</td><td>rs5051</td><td>atenolol</td><td>Hypertension</td><td>3</td><td>TT</td><td>Efficacy</td><td>Patients with the TT genotype and hypertension may have a greater decrease in systolic blood pressure when treated with atenolol as compared to patients with the CC genotype. No significant change in diastolic blood pressure was seen between genotypes. Other genetic and clinical factors may also influence change in systolic blood pressure.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183491390>1498</a></td><td>CETP</td><td>rs5882</td><td>simvastatin</td><td>Hypercholesterolemia</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype who have Hypercholesterolemia may have a better response to simvastatin (a greater decrease in triglyceride levels and higher increase in HDL-cholesterol levels) as compared to patients with the GG genotype, or may have a reduced response to simvastatin (a lower decrease in triglyceride levels and lower increase in HDL-cholesterol levels) as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183614711>1499</a></td><td>ZNF804A</td><td>rs1344706</td><td>antipsychotics</td><td>Schizophrenia</td><td>3</td><td>CC</td><td>Efficacy</td><td>Patients with the CC genotype and schizophrenia may have a better response when treated with antipsychotics as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to antipsychotics.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183533961>1500</a></td><td>CYP3A4</td><td>rs2740574</td><td>amlodipine</td><td>Hypertension</td><td>4</td><td>TT</td><td>Efficacy</td><td>Women with the TT genotype and hypertension may have an increased likelihood of reaching a target mean arterial pressure of <= 107 mm Hg when treated with amlodipine as compared to women with the CC genotype. No significant associations were seen when considering a target mean arterial pressure of <= 92 mm Hg, or when considering men or men and women together. Other genetic and clinical factors may also influence response to amlodipine.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183632073>1501</a></td><td>-</td><td>rs238</td><td>hydrochlorothiazide</td><td>Hypertension</td><td>3</td><td>GG</td><td>Efficacy</td><td>Patients with the GG genotype and hypertension who are treated with hydrochlorothiazide may have slightly increased reduction of systolic blood pressure as compared to patients with the AA or the AG genotypes. Other genetic and clinical factors may also influence a patient's response to hydrochlorothiazide treatment.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183632190>1502</a></td><td>ABCB1</td><td>rs1045642</td><td>anthracyclines and related substances</td><td>Breast Neoplasms</td><td>3</td><td>AA</td><td>Efficacy</td><td>Patients with the AA genotype may have increased likelihood of complete response when treated with anthracyclines and related substances and taxanes in people with Breast Neoplasms as compared to patients with the GG or AG genotype. Other genetic and clinical factors may also influence a patient's response to anthracyclines and related substances and taxanes.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183632190>1503</a></td><td>ABCB1</td><td>rs1045642</td><td>taxanes</td><td>Breast Neoplasms</td><td>3</td><td>AA</td><td>Efficacy</td><td>Patients with the AA genotype may have increased likelihood of complete response when treated with anthracyclines and related substances and taxanes in people with Breast Neoplasms as compared to patients with the GG or AG genotype. Other genetic and clinical factors may also influence a patient's response to anthracyclines and related substances and taxanes.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183680415>1504</a></td><td>IL1B</td><td>rs16944</td><td>lansoprazole</td><td>Helicobacter Infections</td><td>3</td><td>GG</td><td>Efficacy</td><td>Patients with the GG genotype who are infected with Helicobacter pylori (H. pylori) may have an increased chance of eradication failure when treated with lansoprazole, omeprazole, or rabeprazole, as compared to patients with the AA or AG genotype. Patients also received amoxicillin and clarithromycin. However, several studies have found no association between rs16944 genotype and H. pylori eradication in patients taking these drugs. Other genetic and clinical factors may also influence eradication rate of H. pylori.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183680415>1505</a></td><td>IL1B</td><td>rs16944</td><td>omeprazole</td><td>Helicobacter Infections</td><td>3</td><td>GG</td><td>Efficacy</td><td>Patients with the GG genotype who are infected with Helicobacter pylori (H. pylori) may have an increased chance of eradication failure when treated with lansoprazole, omeprazole, or rabeprazole, as compared to patients with the AA or AG genotype. Patients also received amoxicillin and clarithromycin. However, several studies have found no association between rs16944 genotype and H. pylori eradication in patients taking these drugs. Other genetic and clinical factors may also influence eradication rate of H. pylori.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183680415>1506</a></td><td>IL1B</td><td>rs16944</td><td>rabeprazole</td><td>Helicobacter Infections</td><td>3</td><td>GG</td><td>Efficacy</td><td>Patients with the GG genotype who are infected with Helicobacter pylori (H. pylori) may have an increased chance of eradication failure when treated with lansoprazole, omeprazole, or rabeprazole, as compared to patients with the AA or AG genotype. Patients also received amoxicillin and clarithromycin. However, several studies have found no association between rs16944 genotype and H. pylori eradication in patients taking these drugs. Other genetic and clinical factors may also influence eradication rate of H. pylori.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1043858722>1507</a></td><td>NTRK1</td><td>rs2768759</td><td>aspirin</td><td></td><td>3</td><td>CC</td><td>Efficacy</td><td>Patients with the CC genotype may have an increased residual platelet aggregation to collagen and epinephrine when treated with aspirin as compared to the AA genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183491792>1508</a></td><td>CXCL5</td><td>rs352046</td><td>hmg coa reductase inhibitors</td><td>Acute coronary syndrome</td><td>3</td><td>CC</td><td>Efficacy</td><td>Patients with the CC genotype and Acute coronary syndrome who are treated with statins may have an increased response to treatment as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence a patient's response to statin treatment.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183605282>1509</a></td><td>IL4R</td><td>rs2239347</td><td>pitrakinra</td><td>Asthma</td><td>3</td><td>AC</td><td>Efficacy</td><td>Patients with the AC genotype and asthma may have a higher frequency of asthma exacerbations when treated with pitrakinra as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to pitrakinra.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183607013>1510</a></td><td>KCNQ1</td><td>rs2237895</td><td>repaglinide</td><td>Diabetes Mellitus, Type 2</td><td>3</td><td>AC</td><td>Efficacy</td><td>Patients with the AC genotype an type 2 diabetes may have an increased response when treated with repaglinide as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to repaglinide.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/982044867>1511</a></td><td>CCND1</td><td>rs9344</td><td>fluorouracil</td><td>Colonic Neoplasms</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with colonic neoplasms and the rs9344 AG genotype may have increased time-to-tumor recurrence when treated with fluorouracil as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to fluorouracil.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1051394394>1512</a></td><td>MTTP</td><td>rs1800591</td><td>atorvastatin</td><td>Hyperlipoproteinemia Type II</td><td>3</td><td>TT</td><td>Efficacy</td><td>Men with the TT genotype and Hyperlipoproteinemia Type II who are treated with atorvastatin may have higher decreases in triglyceride levels as compared to patients with the GT or GG genotype. No association with atorvastatin response was seen in women. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1139265477>1513</a></td><td>ABCB1</td><td>rs1045642</td><td>atorvastatin</td><td>Coronary Artery Disease</td><td>3</td><td>AA</td><td>Efficacy</td><td>Patients with the AA genotype who are treated with atorvastatin may have a better response to treatment (as measured by an increased reduction in LDL-cholesterol or total cholesterol) compared to patients with the GG genotype. Some studies find no association. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183617623>1514</a></td><td>CYP1A2</td><td>rs2470890</td><td>paroxetine</td><td>Depressive Disorder, Major</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype and major depressive disorder who are treated with paroxetine may be less likely to experience remission as compared to patients with the TT genotype or may be more likely to experience remission as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to paroxetine treatment.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1043880170>1515</a></td><td>CETP</td><td>rs708272</td><td>simvastatin</td><td>Hypercholesterolemia;Hyperlipoproteinemia Type II</td><td>4</td><td>AA</td><td>Efficacy</td><td>Patients with the AA genotype and hypercholesterolemia who are treated with simvastatin may have an increased risk of cardiovascular disease events as compared to patients with the AG or GG genotype. Another study found no association with response to simvastatin. Other genetic and clinical factors may also influence a patient's response to statin treatment.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183614476>1516</a></td><td>IL4R</td><td>rs1805010</td><td>pitrakinra</td><td>Asthma</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype and asthma may have a higher frequency of asthma exacerbations when treated with pitrakinra as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to pitrakinra.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/982030862>1517</a></td><td>GABRA6</td><td>rs1992647</td><td>antidepressants</td><td>Depressive Disorder, Major</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype and Major Depressive Disorder may be more likely to respond to anti-depressant treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to anti-depressant treatment.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/982030862>1518</a></td><td>GABRA6</td><td>rs1992647</td><td>Selective serotonin reuptake inhibitors</td><td>Depressive Disorder, Major</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype and Major Depressive Disorder may be more likely to respond to anti-depressant treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to anti-depressant treatment.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/982030862>1519</a></td><td>GABRA6</td><td>rs1992647</td><td>venlafaxine</td><td>Depressive Disorder, Major</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype and Major Depressive Disorder may be more likely to respond to anti-depressant treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to anti-depressant treatment.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/982031346>1520</a></td><td>OR52J2P</td><td>rs2499984</td><td>lithium</td><td>Bipolar Disorder</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype and Bipolar Disorder may be more likely to respond to lithium as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to lithium.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/982031346>1521</a></td><td>OR52J3</td><td>rs2499984</td><td>lithium</td><td>Bipolar Disorder</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype and Bipolar Disorder may be more likely to respond to lithium as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to lithium.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/982029578>1522</a></td><td>VEGFA</td><td>rs699947</td><td>ranibizumab</td><td>Macular Degeneration</td><td>4</td><td>AC</td><td>Efficacy</td><td>Patients with the AC genotype and Macular Degeneration who are treated with ranibizumab may have an early response to treatment compared to patients with the AA genotype. No association with response was found in other studies. Other genetic and clinical factors may also influence a patient's response to ranibizumab treatment.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/982030916>1523</a></td><td>GAL</td><td>rs948854</td><td>antidepressants</td><td>Depressive Disorder, Major</td><td>3</td><td>TT</td><td>Efficacy</td><td>Female patients with the TT genotype and depression who are treated with antidepressants, benzodiazepine derivatives, mirtazapine or selective serotonin reuptake inhibitors may be more likely to respond to antidepressant treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to antidepressants.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/982030916>1524</a></td><td>GAL</td><td>rs948854</td><td>benzodiazepine derivatives</td><td>Depressive Disorder, Major</td><td>3</td><td>TT</td><td>Efficacy</td><td>Female patients with the TT genotype and depression who are treated with antidepressants, benzodiazepine derivatives, mirtazapine or selective serotonin reuptake inhibitors may be more likely to respond to antidepressant treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to antidepressants.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/982030916>1525</a></td><td>GAL</td><td>rs948854</td><td>mirtazapine</td><td>Depressive Disorder, Major</td><td>3</td><td>TT</td><td>Efficacy</td><td>Female patients with the TT genotype and depression who are treated with antidepressants, benzodiazepine derivatives, mirtazapine or selective serotonin reuptake inhibitors may be more likely to respond to antidepressant treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to antidepressants.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/982030916>1526</a></td><td>GAL</td><td>rs948854</td><td>Selective serotonin reuptake inhibitors</td><td>Depressive Disorder, Major</td><td>3</td><td>TT</td><td>Efficacy</td><td>Female patients with the TT genotype and depression who are treated with antidepressants, benzodiazepine derivatives, mirtazapine or selective serotonin reuptake inhibitors may be more likely to respond to antidepressant treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to antidepressants.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1043858606>1527</a></td><td>BDNF</td><td>rs6265</td><td>antidepressants</td><td>Depressive Disorder</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype and Depressive Disorder may be more likely to respond to paroxetine or antidepressants as compared to patients with the CC or TT genotype. However, contradictory findings have been reported. Other genetic and clinical factors may also influence a patient's response to anti-depressants.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1043858606>1528</a></td><td>BDNF</td><td>rs6265</td><td>citalopram</td><td>Depressive Disorder</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype and Depressive Disorder may be more likely to respond to paroxetine or antidepressants as compared to patients with the CC or TT genotype. However, contradictory findings have been reported. Other genetic and clinical factors may also influence a patient's response to anti-depressants.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1043858606>1529</a></td><td>BDNF</td><td>rs6265</td><td>paroxetine</td><td>Depressive Disorder</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype and Depressive Disorder may be more likely to respond to paroxetine or antidepressants as compared to patients with the CC or TT genotype. However, contradictory findings have been reported. Other genetic and clinical factors may also influence a patient's response to anti-depressants.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1043859269>1530</a></td><td>P2RY12</td><td>rs6787801</td><td>clopidogrel</td><td></td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype undergoing percutaneous coronary intervention who are CYP2C19*1/*1 carriers may have an increased risk for high on-treatment platelet reactivity when treated with clopidogrel as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to clopidogrel.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1043880214>1531</a></td><td>MMP3</td><td>rs35068180</td><td>pravastatin</td><td>Coronary Artery Disease</td><td>3</td><td>AA</td><td>Efficacy</td><td>Patients with the AA genotype and Coronary Artery Disease may be more likely to benefit from pravastatin treatment as compared to patients with the del/del genotype. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1043880229>1532</a></td><td>MMP3</td><td>rs35068180</td><td>chlorthalidone</td><td>Hypertension</td><td>3</td><td>AA</td><td>Efficacy</td><td>Patients with the AA genotype and hypertension may have an increased risk of stroke when treated with lisinopril as compared to patients with the AA genotype treated with chlorthalidone. Other genetic and clinical factors may also influence a patient's response to treatment and risk of stroke.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1043880229>1533</a></td><td>MMP3</td><td>rs35068180</td><td>lisinopril</td><td>Hypertension</td><td>3</td><td>AA</td><td>Efficacy</td><td>Patients with the AA genotype and hypertension may have an increased risk of stroke when treated with lisinopril as compared to patients with the AA genotype treated with chlorthalidone. Other genetic and clinical factors may also influence a patient's response to treatment and risk of stroke.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1043880823>1534</a></td><td>CYP7A1</td><td>rs3808607</td><td>atorvastatin</td><td></td><td>3</td><td>TT</td><td>Efficacy</td><td>Patients with the TT genotype may have an increased response to atorvastatin as compared to patients with the GG or GT genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to atorvastatin.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1048764135>1535</a></td><td>IL1B</td><td>rs16944</td><td>pravastatin</td><td></td><td>3</td><td>GG</td><td>Efficacy</td><td>Patients with the GG genotype who are treated with pravastatin may 1) have lower IL1B serum levels, and 2) be more likely to benefit from pravastatin treatment in terms of improvement in coronary function, as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183491140>1536</a></td><td>CYP3A5</td><td>rs776746</td><td>atorvastatin</td><td></td><td>3</td><td>CC</td><td>Efficacy</td><td>Patients with the CC genotype who are treated with atorvastatin may have a better response to treatment as compared to patients with the TT genotype. Conflicting evidence was seen by population type. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1043880192>1537</a></td><td>CETP</td><td>rs708272</td><td>atorvastatin</td><td></td><td>4</td><td>AA</td><td>Efficacy</td><td>Patients with the AA genotype who are treated with atorvastatin may have a decreased response to treatment and an increased risk of cardiovascular disease events as compared to patients with the GG genotype. However, these results were not statistically significant and there are contradictory studies. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183491775>1538</a></td><td>MTHFR</td><td>rs1801133</td><td>pravastatin</td><td>Coronary Artery Disease;Myocardial Infarction</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype and Hypertension who are treated with pravastatin may have an increased risk of nonfatal myocardial infarction and fatal coronary heart disease as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to pravastatin treatment.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183492030>1539</a></td><td>GABRA1</td><td>rs2279020</td><td>carbamazepine</td><td>Epilepsy</td><td>3</td><td>GA</td><td>Efficacy</td><td>Patients with the GA genotype and Epilepsy who are treated with carbamazepine, phenytoin or valproic acid may have increased risk for drug-resistance as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for drug-resistance.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183492030>1540</a></td><td>GABRA1</td><td>rs2279020</td><td>phenytoin</td><td>Epilepsy</td><td>3</td><td>GA</td><td>Efficacy</td><td>Patients with the GA genotype and Epilepsy who are treated with carbamazepine, phenytoin or valproic acid may have increased risk for drug-resistance as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for drug-resistance.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183492030>1541</a></td><td>GABRA1</td><td>rs2279020</td><td>valproic acid</td><td>Epilepsy</td><td>3</td><td>GA</td><td>Efficacy</td><td>Patients with the GA genotype and Epilepsy who are treated with carbamazepine, phenytoin or valproic acid may have increased risk for drug-resistance as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for drug-resistance.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183492128>1542</a></td><td>APOE</td><td>rs7412</td><td>fluvastatin</td><td></td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype (carriers of E2) who are treated with fluvastatin may have a better response (increased reduction in LDL-cholesterol or change in HDL) as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to statin treatment.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183614624>1543</a></td><td>SCN1A</td><td>rs3812718</td><td>carbamazepine</td><td>Epilepsy</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype and epilepsy who are treated with carbamazepine may be more likely to respond to treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to carbamazepine.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183614591>1544</a></td><td>SCN1A</td><td>rs2298771</td><td>carbamazepine</td><td>Epilepsy</td><td>4</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype and epilepsy who are treated with carbamazepine may have a decreased likelihood of a good response as compared to patients with the TT genotype, although most studies have found no association with response. Other genetic and clinical factors may also influence a patient's response to carbamazepine treatment.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183614591>1545</a></td><td>SCN1A</td><td>rs2298771</td><td>oxcarbazepine</td><td>Epilepsy</td><td>4</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype and epilepsy who are treated with carbamazepine may have a decreased likelihood of a good response as compared to patients with the TT genotype, although most studies have found no association with response. Other genetic and clinical factors may also influence a patient's response to carbamazepine treatment.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183615573>1546</a></td><td>AGT</td><td>rs699</td><td>irbesartan</td><td>Hypertension;Hypertrophy, Left Ventricular</td><td>3</td><td>GG</td><td>Efficacy</td><td>Patients with the rs699 GG genotype may have an increased response to irbesartan as compared to patients with the AA or AG genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to irbesartan.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/982031323>1547</a></td><td>GSK3B</td><td>rs334558</td><td>lithium</td><td>Bipolar Disorder</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype and Bipolar Disorder may be more likely to respond to lithium as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to lithium.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/982047849>1548</a></td><td>DRD3</td><td>rs6280</td><td>paroxetine</td><td>Depressive Disorder, Major</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype and major depressive disorder may have a better response when treated with paroxetine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to paroxetine.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1043872993>1549</a></td><td>XRCC3</td><td>rs861539</td><td>Platinum compounds</td><td>Carcinoma, Non-Small-Cell Lung</td><td>3</td><td>AA</td><td>Efficacy</td><td>Patients with the AA genotype and non-small cell lung cancer may have an improved response when treated with platinum compounds as compared to patients with the GG genotype, although this is contradicted in one study. Other clinical or genetic factors may also influence a patient's response to platinum compounds in people with non-small cell lung cancer.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1043876904>1550</a></td><td>CRHR1</td><td>rs242941</td><td>fluoxetine</td><td>Anxiety Disorders;Depressive Disorder, Major</td><td>3</td><td>CC</td><td>Efficacy</td><td>Patients with the CC genotype and major depression and high anxiety may have an increased response to fluoxetine treatment as compared to patients with the AA or AC genotype. Other genetic and clinical factors may also influence a patient's response to fluoxetine.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1043880664>1551</a></td><td>OPRM1</td><td>rs510769</td><td>amphetamine</td><td></td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype may have increased Stimulation and Euphoria scores after amphetamine exposure as compared to patients with the TT genotype.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183533981>1552</a></td><td>GABRA1</td><td>rs2290732</td><td>carbamazepine</td><td>Epilepsy</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype and epilepsy may have increased retention rates when treated with carbamazepine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence retention rate of carbamazepine.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183614845>1553</a></td><td>ADRB2</td><td>rs1042714</td><td>enalapril</td><td>Hypertrophy, Left Ventricular</td><td>3</td><td>CG</td><td>Efficacy</td><td>Patients with the CG genotype and left ventricular hypertrophy may have a greater percent reduction in left ventricular mass index when treated with enalapril as compared to patients with the CC genotype. Other genetic and clinical factors may also influence reduction in left ventricular mass index.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183615415>1554</a></td><td>TNFRSF1A</td><td>rs767455</td><td>Tumor necrosis factor alpha (TNF-alpha) inhibitors</td><td>Arthritis, Rheumatoid</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype and rheumatoid arthritis may have an increased response to treatment with anti-TNF therapy as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183615582>1555</a></td><td>AGT</td><td>rs699</td><td>atenolol</td><td>Hypertension;Hypertrophy, Left Ventricular</td><td>3</td><td>GG</td><td>Efficacy</td><td>Patients with the rs699 GG genotype may have an increased response to atenolol as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to atenolol.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183614486>1556</a></td><td>ADRB1</td><td>rs1801253</td><td>dobutamine</td><td></td><td>3</td><td>CG</td><td>Efficacy</td><td>Healthy males with the CG genotype may have smaller increases in fractional shortening and systolic blood pressure when given dobutamine, as compared to healthy males with the CC genotype. No significant differences were seen for heart rate. Other genetic and clinical factors may also influence fractional shortening and systolic blood pressure.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183614881>1557</a></td><td>IL4R</td><td>rs1029489</td><td>pitrakinra</td><td>Asthma</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype and asthma may have a higher frequency of asthma exacerbations when treated with pitrakinra as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to pitrakinra.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183614970>1558</a></td><td>APOE</td><td>rs7412</td><td>fenofibrate</td><td>Hypertriglyceridemia</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype (carriers of E2) and hypertriglyceridemia may have an increased response when treated with fenofibrate as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to fenofibrate.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/982040598>1559</a></td><td>CYP2C19</td><td>rs4244285</td><td>prasugrel</td><td>Acute coronary syndrome</td><td>3</td><td>AA</td><td>Efficacy</td><td>Patients with the AA genotype who are treated with prasugrel may have a higher rate of high on-treatment platelet reactivity at 1 month of treatment as compared to patients with the GG genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to prasugrel.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183631465>1560</a></td><td>PPARA</td><td>rs4823613</td><td>simvastatin</td><td></td><td>3</td><td>AA</td><td>Efficacy</td><td>Patients with the AA genotype may have a reduced response to simvastatin treatment (a lower reduction in total cholesterol and LDL-cholesterol) as compared to patients with the GG genotype. A separate larger study found no association. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183632078>1561</a></td><td>-</td><td>rs2776546</td><td>hydrochlorothiazide</td><td>Hypertension</td><td>3</td><td>AA</td><td>Efficacy</td><td>Patients with the AA genotype and hypertension who are treated with hydrochlorothiazide may have greater reduction of diastolic blood pressure as compared to patients with the AC or CC genotypes. Other genetic and clinical factors may also influence a patient's response to hydrochlorothiazide treatment.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451407981>1562</a></td><td>COMT</td><td>rs6269</td><td>morphine</td><td></td><td>3</td><td>GG</td><td>Efficacy</td><td>Patients with the rs6269 GG genotype may have an increased analgesic response to morphine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to morphine.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449566673>1563</a></td><td>SLC31A1</td><td>rs4979223</td><td>Platinum compounds</td><td>overall survival;Thrombocytopenia</td><td>3</td><td>AC</td><td>Efficacy</td><td>Patients with the AC genotype and non-small cell lung cancer who are treated with platinum compounds may have increased severity of thrombocytopenia, and decresed likelihood of overall survival as compared to patients with the AC genotype. Other clinical and genetic factors may also influence severity of thrombocytopenia and overall survival in patients with non-small lung cancer.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450929015>1564</a></td><td>TAOK3</td><td>rs1277441</td><td>opioids</td><td>Pain</td><td>3</td><td>AA</td><td>Efficacy</td><td>Patients with the AA genotype may have an increased analgesic response to opioids as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to opioids and their opioid dose requirements.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450929816>1565</a></td><td>ABCB1</td><td>rs1045642</td><td>tramadol</td><td>Fractures, Bone;Pain;Pain, Postoperative</td><td>3</td><td>AA</td><td>Efficacy</td><td>Patients with the rs1045642 AA genotype may have an increased analgesic response to tramadol as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to tramadol.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449167300>1566</a></td><td>ARHGAP12</td><td>rs2799018</td><td>methylphenidate</td><td>Attention Deficit Disorder with Hyperactivity</td><td>3</td><td>TT</td><td>Efficacy</td><td>Patients with the TT genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients who do not carry the T allele. Other genetic and clinical factors may also affect a patient's response to methylphenidate.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449167350>1567</a></td><td>CMTM8</td><td>rs4627790</td><td>methylphenidate</td><td>Attention Deficit Disorder with Hyperactivity</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to methylphenidate.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451409141>1568</a></td><td>CETP</td><td>rs5882</td><td>rosuvastatin</td><td></td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the rs5882 AG genotype may have an increased response to rosuvastatin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to rosuvastatin.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449156029>1569</a></td><td>CHRNA5</td><td>rs503464</td><td>bupropion</td><td>Tobacco Use Disorder</td><td>3</td><td>AT</td><td>Efficacy</td><td>Patients with the AT genotype may have 1) an increased risk of nicotine dependence and 2) an increased response to smoking cessation therapies as compared to patients with the TT genotype. Other genetic and clinical factors may also affect nicotine dependence and smoking cessation.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449156029>1570</a></td><td>CHRNA5</td><td>rs503464</td><td>nicotine</td><td>Tobacco Use Disorder</td><td>3</td><td>AT</td><td>Efficacy</td><td>Patients with the AT genotype may have 1) an increased risk of nicotine dependence and 2) an increased response to smoking cessation therapies as compared to patients with the TT genotype. Other genetic and clinical factors may also affect nicotine dependence and smoking cessation.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449156029>1571</a></td><td>CHRNA5</td><td>rs503464</td><td>varenicline</td><td>Tobacco Use Disorder</td><td>3</td><td>AT</td><td>Efficacy</td><td>Patients with the AT genotype may have 1) an increased risk of nicotine dependence and 2) an increased response to smoking cessation therapies as compared to patients with the TT genotype. Other genetic and clinical factors may also affect nicotine dependence and smoking cessation.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449168684>1572</a></td><td>-</td><td>rs10771999</td><td>duloxetine</td><td>Depressive Disorder, Major</td><td>3</td><td>GG</td><td>Efficacy</td><td>Patients with the GG genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the CC and CG genotypes. Other genetic and clinical factors may also affect a patient's response to duloxetine.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450933017>1573</a></td><td>VDR</td><td>rs731236</td><td>deferasirox</td><td>beta-Thalassemia</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with beta-thalassemia and the AG genotype may have a decreased response to deferasirox, as measured by higher liver stiffness values, as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to deferasirox.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450813881>1574</a></td><td>HYKK</td><td>rs7164594</td><td>varenicline</td><td>Tobacco Use Disorder</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype may be more likely to quit smoking by weeks 9-12 of varenicline treatment as compared to patients with the CC genotype. Other genetic or clinical factors may also affect response to varenicline.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449565066>1575</a></td><td>SLC29A3</td><td>rs780668</td><td>gemcitabine</td><td>Carcinoma, Non-Small-Cell Lung</td><td>4</td><td>TT</td><td>Efficacy</td><td>Patients with the TT genotype and non-small cell lung cancer who are treated with gemcitabine may have longer overall survival as compared to patients with the CC genotypes. There was no association between genotype and progression-free survival, or with risk of neutropenia and thrombocytopenia. Other clinical and genetic factors may also influence overall survival in patients with non-small cell lung cancer who are treated with gemcitabine.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449296332>1576</a></td><td>PRPF31</td><td>rs254271</td><td>metformin</td><td>Diabetes Mellitus, Type 2</td><td>3</td><td>GG</td><td>Efficacy</td><td>Patients with the GG genotype may have increased response to metformin in people with type 2 Diabetes Mellitus as compared to patients with genotype CC or CG. Other genetic and clinical factors may also influence the response to metformin.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449004841>1577</a></td><td>SLCO1B1</td><td>rs4149056</td><td>methotrexate</td><td>Precursor Cell Lymphoblastic Leukemia-Lymphoma</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with precursor cell lymphoblastic leukemia-lymphoma and the rs4149056 CT genotype may have an increased response to methotrexate as compared to patients with the CC genotype. However, conflicting evidence has been reported. Other clinical and genetic factors may also influence response to methotrexate.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450373489>1578</a></td><td>OPRM1</td><td>rs3192723</td><td>methadone</td><td>Heroin Dependence</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype may have an increased response to methadone in the treatment of heroin dependence as compared to patients with the CC genotype. Note that although this variant is located in MTRF1L, it is discussed in the study as being an OPRM1 SNP. Other genetic and clinical factors may also affect a patient's response to methadone when being treated for heroin dependence.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450932995>1579</a></td><td>UGT1A1</td><td>rs887829</td><td>deferasirox</td><td>beta-Thalassemia</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with beta-thalassemia and the CT genotype may have an increased response to deferasirox, as measured by lower liver stiffness values, as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to deferasirox.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450929031>1580</a></td><td>TAOK3</td><td>rs795484</td><td>opioids</td><td>Pain</td><td>3</td><td>CC</td><td>Efficacy</td><td>Patients with the CC genotype may have an increased analgesic response to opioids as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to opioids.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451412100>1581</a></td><td>APEX1</td><td>rs1760944</td><td>cisplatin</td><td>Carcinoma, Squamous Cell;overall survival</td><td>3</td><td>GT</td><td>Efficacy</td><td>Patients with the rs1760944 GT genotype and oral squamous cell carcinoma may have an increased likelihood of overall survival when treated with a combination of cisplatin, fluorouracil and radiotherapy. as compared to patients with the GG genotype. Other genetic and clinical factors may also influence likelihood of overall survival when treated with cisplatin, fluorouracil and radiotherapy.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451412100>1582</a></td><td>OSGEP</td><td>rs1760944</td><td>cisplatin</td><td>Carcinoma, Squamous Cell;overall survival</td><td>3</td><td>GT</td><td>Efficacy</td><td>Patients with the rs1760944 GT genotype and oral squamous cell carcinoma may have an increased likelihood of overall survival when treated with a combination of cisplatin, fluorouracil and radiotherapy. as compared to patients with the GG genotype. Other genetic and clinical factors may also influence likelihood of overall survival when treated with cisplatin, fluorouracil and radiotherapy.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451412100>1583</a></td><td>APEX1</td><td>rs1760944</td><td>fluorouracil</td><td>Carcinoma, Squamous Cell;overall survival</td><td>3</td><td>GT</td><td>Efficacy</td><td>Patients with the rs1760944 GT genotype and oral squamous cell carcinoma may have an increased likelihood of overall survival when treated with a combination of cisplatin, fluorouracil and radiotherapy. as compared to patients with the GG genotype. Other genetic and clinical factors may also influence likelihood of overall survival when treated with cisplatin, fluorouracil and radiotherapy.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451412100>1584</a></td><td>OSGEP</td><td>rs1760944</td><td>fluorouracil</td><td>Carcinoma, Squamous Cell;overall survival</td><td>3</td><td>GT</td><td>Efficacy</td><td>Patients with the rs1760944 GT genotype and oral squamous cell carcinoma may have an increased likelihood of overall survival when treated with a combination of cisplatin, fluorouracil and radiotherapy. as compared to patients with the GG genotype. Other genetic and clinical factors may also influence likelihood of overall survival when treated with cisplatin, fluorouracil and radiotherapy.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451412100>1585</a></td><td>APEX1</td><td>rs1760944</td><td>radiotherapy</td><td>Carcinoma, Squamous Cell;overall survival</td><td>3</td><td>GT</td><td>Efficacy</td><td>Patients with the rs1760944 GT genotype and oral squamous cell carcinoma may have an increased likelihood of overall survival when treated with a combination of cisplatin, fluorouracil and radiotherapy. as compared to patients with the GG genotype. Other genetic and clinical factors may also influence likelihood of overall survival when treated with cisplatin, fluorouracil and radiotherapy.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451412100>1586</a></td><td>OSGEP</td><td>rs1760944</td><td>radiotherapy</td><td>Carcinoma, Squamous Cell;overall survival</td><td>3</td><td>GT</td><td>Efficacy</td><td>Patients with the rs1760944 GT genotype and oral squamous cell carcinoma may have an increased likelihood of overall survival when treated with a combination of cisplatin, fluorouracil and radiotherapy. as compared to patients with the GG genotype. Other genetic and clinical factors may also influence likelihood of overall survival when treated with cisplatin, fluorouracil and radiotherapy.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449748187>1587</a></td><td>KIF6</td><td>rs20455</td><td>simvastatin</td><td>Hypercholesterolemia</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype may have an increased lipid-lowering response to simvastatin as compared to patients with the GG genotype. However, one study found no association between this variant and response to simvastatin. Other genetic and clinical factors may also affect a patient's response to simvastatin.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450812748>1588</a></td><td>CHRNA7</td><td>rs2337980</td><td>nicotine</td><td></td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype may show no change in performance in attention-related tasks when given nicotine vs placebo as compared to patients with the CC genotype, who may show an improved performance when given nicotine vs placebo. Other genetic and clinical factors may also affect a patient's response to nicotine.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655385404>1589</a></td><td>LDLR</td><td>rs688</td><td>atenolol</td><td>Hypertension</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype may have more effective lowering of systolic blood pressure with atenolol as compared to patients with genotype TT. Other genetic and clinical factors may also influence a patient's likelihood of response.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655385418>1590</a></td><td>COMT</td><td>rs165599</td><td>bupropion</td><td>Tobacco Use Disorder</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype may have an increased chance of response to bupropion treatment for smoking cessation as compared to patients with the GG genotype. Patients with the AG genotype may still be at risk for non-response to bupropion treatment based on their genotype. Other genetic and clinical factors may also influence a patient's chance of response.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655385604>1591</a></td><td>CYP1A2</td><td>rs762551</td><td>olanzapine</td><td></td><td>3</td><td>AC</td><td>Efficacy</td><td>Patients with the AC genotype and psychiatric disorders who are treated with olanzapine may have an increased response to olanzapine based on not decreased mean dose-/body weight-normalized olanzapine serum concentrations as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to olanzapine.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655385701>1592</a></td><td>ABCB1</td><td>rs1045642</td><td>efavirenz</td><td>HIV Infections</td><td>3</td><td>AA</td><td>Efficacy</td><td>Patients with the AA genotype and HIV who are treated with nelfinavir and efavirenz: 1) May have increased CD4-cell count as compared to patients with the GA and GG genotype 2) May have increased virologic response as compared to patients with the GA and GG genotype 3) May have an increased risk for toxicity-related failure as compared to patients with the GA and GG genotype 4) May have a decreased, but not absent, risk of hepatotoxicity as compared to patients with the GA and GG genotype. Other genetic and clinical factors may also influence a patient's drug response or risk for toxicity.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655385701>1593</a></td><td>ABCB1</td><td>rs1045642</td><td>nelfinavir</td><td>HIV Infections</td><td>3</td><td>AA</td><td>Efficacy</td><td>Patients with the AA genotype and HIV who are treated with nelfinavir and efavirenz: 1) May have increased CD4-cell count as compared to patients with the GA and GG genotype 2) May have increased virologic response as compared to patients with the GA and GG genotype 3) May have an increased risk for toxicity-related failure as compared to patients with the GA and GG genotype 4) May have a decreased, but not absent, risk of hepatotoxicity as compared to patients with the GA and GG genotype. Other genetic and clinical factors may also influence a patient's drug response or risk for toxicity.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655386099>1594</a></td><td>CHST3</td><td>rs730720</td><td>docetaxel</td><td>Prostatic Neoplasms</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype may have an increased chance of response to treatment with docetaxel and thalidomide as compared to patients with the TT genotypes. Other genetic and clinical factors may also influence treatment response.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655386099>1595</a></td><td>CHST3</td><td>rs730720</td><td>thalidomide</td><td>Prostatic Neoplasms</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype may have an increased chance of response to treatment with docetaxel and thalidomide as compared to patients with the TT genotypes. Other genetic and clinical factors may also influence treatment response.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655386114>1596</a></td><td>CHST3</td><td>rs4148950</td><td>docetaxel</td><td>Prostatic Neoplasms</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype may have an 1) increased chance of response to treatment with docetaxel and thalidomide 2) increased risk of toxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence treatment response.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655386114>1597</a></td><td>CHST3</td><td>rs4148950</td><td>thalidomide</td><td>Prostatic Neoplasms</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype may have an 1) increased chance of response to treatment with docetaxel and thalidomide 2) increased risk of toxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence treatment response.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655386120>1598</a></td><td>CHST3</td><td>rs4148947</td><td>docetaxel</td><td>Prostatic Neoplasms</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype may have an increased chance of response to treatment with docetaxel and thalidomide as compared to patients with the CC genotype. Other genetic and clinical factors may also influence treatment response.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655386120>1599</a></td><td>CHST3</td><td>rs4148947</td><td>thalidomide</td><td>Prostatic Neoplasms</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype may have an increased chance of response to treatment with docetaxel and thalidomide as compared to patients with the CC genotype. Other genetic and clinical factors may also influence treatment response.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655386126>1600</a></td><td>CHST3</td><td>rs4148945</td><td>docetaxel</td><td>Prostatic Neoplasms</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype may have an 1) increased chance of response to treatment with docetaxel and thalidomide 2) increased risk of toxicity as compared to patients with the TT genotype. Other genetic and clinical factors may also influence treatment response.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655386126>1601</a></td><td>CHST3</td><td>rs4148945</td><td>thalidomide</td><td>Prostatic Neoplasms</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype may have an 1) increased chance of response to treatment with docetaxel and thalidomide 2) increased risk of toxicity as compared to patients with the TT genotype. Other genetic and clinical factors may also influence treatment response.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655386131>1602</a></td><td>CHST3</td><td>rs4148943</td><td>docetaxel</td><td>Prostatic Neoplasms</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype may have an increased chance of response to treatment with docetaxel and thalidomide as compared to patients with the TT genotype. Other genetic and clinical factors may also influence treatment response.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655386131>1603</a></td><td>CHST3</td><td>rs4148943</td><td>thalidomide</td><td>Prostatic Neoplasms</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype may have an increased chance of response to treatment with docetaxel and thalidomide as compared to patients with the TT genotype. Other genetic and clinical factors may also influence treatment response.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655386136>1604</a></td><td>PPARD</td><td>rs3734254</td><td>docetaxel</td><td>Prostatic Neoplasms</td><td>3</td><td>TT</td><td>Efficacy</td><td>Patients with the TT genotype may have an increased chance of response to treatment with docetaxel and thalidomide as compared to patients with the CC genotype. Other genetic and clinical factors may also influence treatment response.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655386136>1605</a></td><td>PPARD</td><td>rs3734254</td><td>thalidomide</td><td>Prostatic Neoplasms</td><td>3</td><td>TT</td><td>Efficacy</td><td>Patients with the TT genotype may have an increased chance of response to treatment with docetaxel and thalidomide as compared to patients with the CC genotype. Other genetic and clinical factors may also influence treatment response.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655386171>1606</a></td><td>CHST3</td><td>rs1871450</td><td>docetaxel</td><td>Prostatic Neoplasms</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AA genotype may have an 1) increased chance of response to treatment with docetaxel and thalidomide 2) increased risk of toxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence treatment response.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655386171>1607</a></td><td>CHST3</td><td>rs1871450</td><td>thalidomide</td><td>Prostatic Neoplasms</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AA genotype may have an 1) increased chance of response to treatment with docetaxel and thalidomide 2) increased risk of toxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence treatment response.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655386191>1608</a></td><td>CHST3</td><td>rs12418</td><td>docetaxel</td><td>Prostatic Neoplasms</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype may have an increased chance of response to treatment with docetaxel and thalidomide as compared to patients with the GG genotype. Other genetic and clinical factors may also influence treatment response.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655386191>1609</a></td><td>CHST3</td><td>rs12418</td><td>thalidomide</td><td>Prostatic Neoplasms</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype may have an increased chance of response to treatment with docetaxel and thalidomide as compared to patients with the GG genotype. Other genetic and clinical factors may also influence treatment response.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655386873>1610</a></td><td>VDR</td><td>rs731236</td><td>clodronate</td><td>Osteitis Deformans</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype and Osteitis Deformans may have increased likelihood of resistance when treated with clodronate compared to patients with genotype GG, or may have decreased likelihood of resistance when treated with clodronate compared to patients with genotype AA. Other genetic and clinical factors may also influence resistance to clodronate.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655386888>1611</a></td><td>IL1B</td><td>rs16944</td><td>Bisphosphonates</td><td>Osteitis Deformans</td><td>3</td><td>GG</td><td>Efficacy</td><td>Patients with the GG genotype and Paget's disease of bone who are treated with bisphosphonates may have an increased risk of resistance as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's risk for resistance to bisphosphonates.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655386888>1612</a></td><td>IL1B</td><td>rs16944</td><td>clodronate</td><td>Osteitis Deformans</td><td>3</td><td>GG</td><td>Efficacy</td><td>Patients with the GG genotype and Paget's disease of bone who are treated with bisphosphonates may have an increased risk of resistance as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's risk for resistance to bisphosphonates.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655386888>1613</a></td><td>IL1B</td><td>rs16944</td><td>etidronic acid</td><td>Osteitis Deformans</td><td>3</td><td>GG</td><td>Efficacy</td><td>Patients with the GG genotype and Paget's disease of bone who are treated with bisphosphonates may have an increased risk of resistance as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's risk for resistance to bisphosphonates.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655386888>1614</a></td><td>IL1B</td><td>rs16944</td><td>risedronate</td><td>Osteitis Deformans</td><td>3</td><td>GG</td><td>Efficacy</td><td>Patients with the GG genotype and Paget's disease of bone who are treated with bisphosphonates may have an increased risk of resistance as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's risk for resistance to bisphosphonates.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655386888>1615</a></td><td>IL1B</td><td>rs16944</td><td>tiludronate</td><td>Osteitis Deformans</td><td>3</td><td>GG</td><td>Efficacy</td><td>Patients with the GG genotype and Paget's disease of bone who are treated with bisphosphonates may have an increased risk of resistance as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's risk for resistance to bisphosphonates.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655387009>1616</a></td><td>NOS3</td><td>rs1799983</td><td>cyclophosphamide</td><td>Breast Neoplasms</td><td>3</td><td>GG</td><td>Efficacy</td><td>Patients with the GG genotype 1) may have longer disease-free survival when treated with cyclophosphamide-based regimens 2) may have shorter disease-free survival when not treated with cyclophosphamide-based regimens, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence disease-free survival.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655387009>1617</a></td><td>NOS3</td><td>rs1799983</td><td>doxorubicin</td><td>Breast Neoplasms</td><td>3</td><td>GG</td><td>Efficacy</td><td>Patients with the GG genotype 1) may have longer disease-free survival when treated with cyclophosphamide-based regimens 2) may have shorter disease-free survival when not treated with cyclophosphamide-based regimens, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence disease-free survival.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655387009>1618</a></td><td>NOS3</td><td>rs1799983</td><td>fluorouracil</td><td>Breast Neoplasms</td><td>3</td><td>GG</td><td>Efficacy</td><td>Patients with the GG genotype 1) may have longer disease-free survival when treated with cyclophosphamide-based regimens 2) may have shorter disease-free survival when not treated with cyclophosphamide-based regimens, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence disease-free survival.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655387009>1619</a></td><td>NOS3</td><td>rs1799983</td><td>methotrexate</td><td>Breast Neoplasms</td><td>3</td><td>GG</td><td>Efficacy</td><td>Patients with the GG genotype 1) may have longer disease-free survival when treated with cyclophosphamide-based regimens 2) may have shorter disease-free survival when not treated with cyclophosphamide-based regimens, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence disease-free survival.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655387027>1620</a></td><td>CDA</td><td>rs532545</td><td>cytarabine</td><td>Leukemia, Myeloid, Acute;Neoplasms</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the genotype CT who are treated with cytarabine may have increased toxicity as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's survival when treated with cytarabine.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655387221>1621</a></td><td>DRD3</td><td>rs6280</td><td>risperidone</td><td>Autistic Disorder</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype may have greater reductions in Autism Treatment Evaluation Checklist (ATEC) scores, indicating improved symptoms and response to risperidone in Children with Autism, than TT homozygotes. Other genetic and clinical factors may also influence a patient's response.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655387229>1622</a></td><td>ABCB1</td><td>rs1128503</td><td>risperidone</td><td>Autistic Disorder</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype may have lower Autism Treatment Evaluation Checklist (ATEC) scores, indicating improved symptoms and response to risperidone in Children with Autism, than patients with the GG homozygotes. Other genetic and clinical factors may also influence a patient's response.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655387237>1623</a></td><td>HTR2A</td><td>rs6311</td><td>risperidone</td><td>Autistic Disorder</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype may have lower Autism Treatment Evaluation Checklist (ATEC) scores than CC homozygotes, indicating improved symptoms and response to risperidone in children with autism as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655387821>1624</a></td><td>TYMS</td><td>rs2853539</td><td>methotrexate</td><td>Arthritis, Rheumatoid</td><td>3</td><td>GG</td><td>Efficacy</td><td>Patients with the GG genotype and rheumatoid arthritis who are treated with methotrexate may be more likely to have improvement in disease activity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655388510>1625</a></td><td>DRD2</td><td>rs1799732</td><td>antipsychotics</td><td>Schizophrenia</td><td>3</td><td>G/G</td><td>Efficacy</td><td>Patients with the G/G genotype and Schizophrenia who are treated with antipsychotics 1) may have an increased response 2) may have decreased time until response, compared to patients with the del/del or G/del genotype. Please note that there is contradictory evidence from studies that report no association with this allele and response to antipsychotics. Other genetic and clinical factors may also influence a patient's response to antipsychotics.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655388510>1626</a></td><td>DRD2</td><td>rs1799732</td><td>aripiprazole</td><td>Schizophrenia</td><td>3</td><td>G/G</td><td>Efficacy</td><td>Patients with the G/G genotype and Schizophrenia who are treated with antipsychotics 1) may have an increased response 2) may have decreased time until response, compared to patients with the del/del or G/del genotype. Please note that there is contradictory evidence from studies that report no association with this allele and response to antipsychotics. Other genetic and clinical factors may also influence a patient's response to antipsychotics.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655388510>1627</a></td><td>DRD2</td><td>rs1799732</td><td>bromperidol</td><td>Schizophrenia</td><td>3</td><td>G/G</td><td>Efficacy</td><td>Patients with the G/G genotype and Schizophrenia who are treated with antipsychotics 1) may have an increased response 2) may have decreased time until response, compared to patients with the del/del or G/del genotype. Please note that there is contradictory evidence from studies that report no association with this allele and response to antipsychotics. Other genetic and clinical factors may also influence a patient's response to antipsychotics.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655388510>1628</a></td><td>DRD2</td><td>rs1799732</td><td>chlorpromazine</td><td>Schizophrenia</td><td>3</td><td>G/G</td><td>Efficacy</td><td>Patients with the G/G genotype and Schizophrenia who are treated with antipsychotics 1) may have an increased response 2) may have decreased time until response, compared to patients with the del/del or G/del genotype. Please note that there is contradictory evidence from studies that report no association with this allele and response to antipsychotics. Other genetic and clinical factors may also influence a patient's response to antipsychotics.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655388510>1629</a></td><td>DRD2</td><td>rs1799732</td><td>clozapine</td><td>Schizophrenia</td><td>3</td><td>G/G</td><td>Efficacy</td><td>Patients with the G/G genotype and Schizophrenia who are treated with antipsychotics 1) may have an increased response 2) may have decreased time until response, compared to patients with the del/del or G/del genotype. Please note that there is contradictory evidence from studies that report no association with this allele and response to antipsychotics. Other genetic and clinical factors may also influence a patient's response to antipsychotics.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655388510>1630</a></td><td>DRD2</td><td>rs1799732</td><td>nemonapride</td><td>Schizophrenia</td><td>3</td><td>G/G</td><td>Efficacy</td><td>Patients with the G/G genotype and Schizophrenia who are treated with antipsychotics 1) may have an increased response 2) may have decreased time until response, compared to patients with the del/del or G/del genotype. Please note that there is contradictory evidence from studies that report no association with this allele and response to antipsychotics. Other genetic and clinical factors may also influence a patient's response to antipsychotics.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655388510>1631</a></td><td>DRD2</td><td>rs1799732</td><td>olanzapine</td><td>Schizophrenia</td><td>3</td><td>G/G</td><td>Efficacy</td><td>Patients with the G/G genotype and Schizophrenia who are treated with antipsychotics 1) may have an increased response 2) may have decreased time until response, compared to patients with the del/del or G/del genotype. Please note that there is contradictory evidence from studies that report no association with this allele and response to antipsychotics. Other genetic and clinical factors may also influence a patient's response to antipsychotics.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655388510>1632</a></td><td>DRD2</td><td>rs1799732</td><td>risperidone</td><td>Schizophrenia</td><td>3</td><td>G/G</td><td>Efficacy</td><td>Patients with the G/G genotype and Schizophrenia who are treated with antipsychotics 1) may have an increased response 2) may have decreased time until response, compared to patients with the del/del or G/del genotype. Please note that there is contradictory evidence from studies that report no association with this allele and response to antipsychotics. Other genetic and clinical factors may also influence a patient's response to antipsychotics.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/699639336>1633</a></td><td>MTHFR</td><td>rs1801131</td><td>methotrexate</td><td>Arthritis, Rheumatoid</td><td>3</td><td>TT</td><td>Efficacy</td><td>Patients with the TT genotype and Rheumatoid Arthritis who are treated with methotrexate may have an increased likelihood of methotrexate response as compared to patients with the GT and GG genotypes. This association has been contradicted by at least one study, and other studies have found no association of this variant with methotrexate efficacy. Other genetic and clinical factors may also influence a patient's response to methotrexate treatment.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/699642190>1634</a></td><td>TPH2</td><td>rs10879346</td><td>antidepressants</td><td>Depressive Disorder, Major</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype who are treated with antidepressants may have more improvement in symptoms as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to antidepressants.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/699642190>1635</a></td><td>TPH2</td><td>rs10879346</td><td>mirtazapine</td><td>Depressive Disorder, Major</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype who are treated with antidepressants may have more improvement in symptoms as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to antidepressants.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/699642190>1636</a></td><td>TPH2</td><td>rs10879346</td><td>venlafaxine</td><td>Depressive Disorder, Major</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype who are treated with antidepressants may have more improvement in symptoms as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to antidepressants.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655386945>1637</a></td><td>CRHR2</td><td>rs7793837</td><td>salbutamol</td><td>Asthma</td><td>3</td><td>AA</td><td>Efficacy</td><td>Patients with the AA genotype and asthma who are treated with short-acting beta2-antagonists may have a better response (increased acute bronchodilation) as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to short-acting beta2-antagonists.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/613979021>1638</a></td><td>ADRB2</td><td>rs1042714</td><td>carvedilol</td><td>Heart Failure</td><td>3</td><td>CG</td><td>Efficacy</td><td>Patients with the CG genotype and heart failure may have a poorer response to carvedilol treatment as compared to patients with the GG genotype and a better response as compared to patients with the CC genotype. Patients with the CG genotype may still be at risk for non-response to carvedilol treatment based on their genotype. Other genetic and clinical factors may also influence a patient's chance of response.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/619523400>1639</a></td><td>RRM1</td><td>rs9937</td><td>gemcitabine</td><td>Neoplasms</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype with cancer who are treated with gemcitabine 1) may be less likely to experience neutropenia and 2) may have increased progression-free survival (PFS) as compared to patients with the AA genotype. However, one study found no association with PFS for this variant. Other genetic and clinical factors may also influence a patient's risk of toxicity and response to gemcitabine.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/637879937>1640</a></td><td>C9orf72</td><td>rs3849942</td><td>Tumor necrosis factor alpha (TNF-alpha) inhibitors</td><td>Arthritis, Rheumatoid</td><td>3</td><td>CC</td><td>Efficacy</td><td>Rheumatoid Arthritis patients with the CC genotype may be more likely to respond to TNF inhibitors compared to patients with genotypes CT or TT. Other genetic and clinical factors may also influence a patient's response.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/637879952>1641</a></td><td>MOB3B</td><td>rs7046653</td><td>Tumor necrosis factor alpha (TNF-alpha) inhibitors</td><td>Arthritis, Rheumatoid</td><td>3</td><td>GG</td><td>Efficacy</td><td>Rheumatoid Arthritis patients with the GG genotype may be more likely to respond to TNF inhibitors compared to patients with genotypes AA or AG. Other genetic and clinical factors may also influence a patient's response.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/637879962>1642</a></td><td>PON1</td><td>rs854548</td><td>Tumor necrosis factor alpha (TNF-alpha) inhibitors</td><td>Arthritis, Rheumatoid</td><td>3</td><td>GG</td><td>Efficacy</td><td>Rheumatoid Arthritis patients with the genotype GG may be more likely to respond to TNF inhibitors compared to patients with genotypes AA or AG. Other genetic and clinical factors may also influence a patient's response.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/637879992>1643</a></td><td>MOB3B</td><td>rs868856</td><td>Tumor necrosis factor alpha (TNF-alpha) inhibitors</td><td>Arthritis, Rheumatoid</td><td>3</td><td>GG</td><td>Efficacy</td><td>Rheumatoid Arthritis patients with the GG genotype may be more likely to respond to TNF inhibitors compared to a patient with the genotype AA or AG. Other genetic and clinical factors may also influence a patient's response.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/619523395>1644</a></td><td>FDPS</td><td>rs2297480</td><td>Bisphosphonates</td><td>Osteoporosis;Osteoporosis, Postmenopausal</td><td>3</td><td>GT</td><td>Efficacy</td><td>Patients with the GT genotype may have an increased chance of response to bisphosphonate treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's chance of response.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/652472012>1645</a></td><td>BDKRB1</td><td>rs12050217</td><td>perindopril</td><td>Coronary Artery Disease</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype who are treated with perindopril may have an increased risk for cardiac events as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for cardiac events when taking perindopril.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655384529>1646</a></td><td>DTNBP1</td><td>rs742105</td><td>clozapine</td><td>Schizophrenia</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype and Schizophrenia may have an increased response to clozapine compared to patients with a CC genotype. Other genetic and clinical factors may also influence a patient's response to clozapine.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655384534>1647</a></td><td>SOD2</td><td>rs4880</td><td>cyclophosphamide</td><td>Breast Neoplasms</td><td>3</td><td>AA</td><td>Efficacy</td><td>Patients with the AA genotype and breast cancer who are treated with cyclophosphamide may have increased survival as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's survival when treated with cyclophosphamide.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655384563>1648</a></td><td>FKBP5</td><td>rs3800373</td><td>antidepressants</td><td>Depression</td><td>3</td><td>AC</td><td>Efficacy</td><td>Patients with the AC genotype and depression who are treated with antidepressants may be more likely to have improvement in symptoms as compared to patients with the AA genotype. However, contradictory findings have been reported. Other genetic and clinical factors may also influence a patient's response to antidepressants.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655384568>1649</a></td><td>FKBP5</td><td>rs1360780</td><td>antidepressants</td><td>Depression</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype may 1) have increased response to antidepressants 2) have increased risk for suicide ideation with paroxetine, venlafaxine, clomipramine, lithium, liothyronine or nefazodone as compared to patients with the CC genotype. However, contradictory findings regarding an association of the opposite allele or no association with response have been reported. Other genetic and clinical factors may also influence a patient's response to antidepressants.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655384568>1650</a></td><td>FKBP5</td><td>rs1360780</td><td>citalopram</td><td>Depression</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype may 1) have increased response to antidepressants 2) have increased risk for suicide ideation with paroxetine, venlafaxine, clomipramine, lithium, liothyronine or nefazodone as compared to patients with the CC genotype. However, contradictory findings regarding an association of the opposite allele or no association with response have been reported. Other genetic and clinical factors may also influence a patient's response to antidepressants.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655384568>1651</a></td><td>FKBP5</td><td>rs1360780</td><td>clomipramine</td><td>Depression</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype may 1) have increased response to antidepressants 2) have increased risk for suicide ideation with paroxetine, venlafaxine, clomipramine, lithium, liothyronine or nefazodone as compared to patients with the CC genotype. However, contradictory findings regarding an association of the opposite allele or no association with response have been reported. Other genetic and clinical factors may also influence a patient's response to antidepressants.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655384568>1652</a></td><td>FKBP5</td><td>rs1360780</td><td>lithium</td><td>Depression</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype may 1) have increased response to antidepressants 2) have increased risk for suicide ideation with paroxetine, venlafaxine, clomipramine, lithium, liothyronine or nefazodone as compared to patients with the CC genotype. However, contradictory findings regarding an association of the opposite allele or no association with response have been reported. Other genetic and clinical factors may also influence a patient's response to antidepressants.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655384568>1653</a></td><td>FKBP5</td><td>rs1360780</td><td>nefazodone</td><td>Depression</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype may 1) have increased response to antidepressants 2) have increased risk for suicide ideation with paroxetine, venlafaxine, clomipramine, lithium, liothyronine or nefazodone as compared to patients with the CC genotype. However, contradictory findings regarding an association of the opposite allele or no association with response have been reported. Other genetic and clinical factors may also influence a patient's response to antidepressants.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655384568>1654</a></td><td>FKBP5</td><td>rs1360780</td><td>paroxetine</td><td>Depression</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype may 1) have increased response to antidepressants 2) have increased risk for suicide ideation with paroxetine, venlafaxine, clomipramine, lithium, liothyronine or nefazodone as compared to patients with the CC genotype. However, contradictory findings regarding an association of the opposite allele or no association with response have been reported. Other genetic and clinical factors may also influence a patient's response to antidepressants.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655384568>1655</a></td><td>FKBP5</td><td>rs1360780</td><td>venlafaxine</td><td>Depression</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype may 1) have increased response to antidepressants 2) have increased risk for suicide ideation with paroxetine, venlafaxine, clomipramine, lithium, liothyronine or nefazodone as compared to patients with the CC genotype. However, contradictory findings regarding an association of the opposite allele or no association with response have been reported. Other genetic and clinical factors may also influence a patient's response to antidepressants.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655384674>1656</a></td><td>FCGR3A</td><td>rs396991</td><td>rituximab</td><td></td><td>3</td><td>AC</td><td>Efficacy</td><td>Lymphoma patients with the AC genotype who are treated with rituximab may be more likely to have tumor shrinkage as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to rituximab.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655384621>1657</a></td><td>KIF6</td><td>rs20455</td><td>pravastatin</td><td>Coronary Disease;Myocardial Infarction</td><td>2B</td><td>AG</td><td>Efficacy</td><td>Patients with the rs20455 AG genotype may be more likely to benefit from pravastatin treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to pravastatin treatment.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655384975>1658</a></td><td>RGS4</td><td>rs2842030</td><td>olanzapine</td><td>Schizophrenia</td><td>3</td><td>TT</td><td>Efficacy</td><td>Patients with the TT genotype and schizophrenia may be more likely to have improvement in symptoms when treated with olanzapine and perphanazine rather than quetiapine, risperidone, or ziprasidone as compared to patients with the GT or GG genotype. Other genetic and clinical factors may also influence a patient's response to perphanazine.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655384975>1659</a></td><td>RGS4</td><td>rs2842030</td><td>perphenazine</td><td>Schizophrenia</td><td>3</td><td>TT</td><td>Efficacy</td><td>Patients with the TT genotype and schizophrenia may be more likely to have improvement in symptoms when treated with olanzapine and perphanazine rather than quetiapine, risperidone, or ziprasidone as compared to patients with the GT or GG genotype. Other genetic and clinical factors may also influence a patient's response to perphanazine.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655384930>1660</a></td><td>ALOX5</td><td>rs2115819</td><td>montelukast</td><td>Asthma</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype and Asthma may not have an increased response to montelukast treatment, based on no change in Forced expiratory volume in one second (FEV1) response to montelukast at 6 month of treatment, compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to montelukast.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655384934>1661</a></td><td>LTA4H</td><td>rs2660845</td><td>montelukast</td><td>Asthma</td><td>3</td><td>GG</td><td>Efficacy</td><td>Patients with the GG genotype and asthma who are treated with montelukast may have an increased risk of asthma exacerbations as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of asthma exacerbations with montelukast treatment.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655384950>1662</a></td><td>HTR2A</td><td>rs6313</td><td>olanzapine</td><td>Alzheimer Disease</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype and Alzheimer disease may have increased risk for treatment-resistance to olanzapine or risperidone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to olanzapine or risperidone.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655384950>1663</a></td><td>HTR2A</td><td>rs6313</td><td>risperidone</td><td>Alzheimer Disease</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype and Alzheimer disease may have increased risk for treatment-resistance to olanzapine or risperidone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to olanzapine or risperidone.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655384987>1664</a></td><td>SLC14A2</td><td>rs1123617</td><td>nifedipine</td><td>Hypertension</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the GA genotype who are treated with nifedepine may have larger changes in systolic and diastolic blood pressures compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to nifedipine.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655385077>1665</a></td><td>GRM3</td><td>rs724226</td><td>risperidone</td><td>Schizophrenia</td><td>3</td><td>GG</td><td>Efficacy</td><td>Patients with the GG genotype and schizophrenia who are treated with risperidone may have more improvement in symptoms as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to risperidone.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655385110>1666</a></td><td>CRHR2</td><td>rs2267715</td><td>salbutamol</td><td>Asthma</td><td>3</td><td>AA</td><td>Efficacy</td><td>Patients with the AA genotype may have increased response to salbutamol in people with Asthma as compare to patients with the GG genotype. However, contradictory finding has been reported. Other genetic and clinical factors may also influence the bronchodilator response.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655385110>1667</a></td><td>CRHR2</td><td>rs2267715</td><td>selective beta-2-adrenoreceptor agonists</td><td>Asthma</td><td>3</td><td>AA</td><td>Efficacy</td><td>Patients with the AA genotype may have increased response to salbutamol in people with Asthma as compare to patients with the GG genotype. However, contradictory finding has been reported. Other genetic and clinical factors may also influence the bronchodilator response.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655385262>1668</a></td><td>ABCC1</td><td>rs2238476</td><td>methotrexate</td><td>Psoriasis</td><td>3</td><td>GG</td><td>Efficacy</td><td>Patients with the GG genotype and psoriasis who are treated with methotrexate: 1) may be more likely to have a reduction in psoriasis area or disease severity 2) may have an increased risk of toxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate and risk of toxicity.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655385352>1669</a></td><td>CYP2D6</td><td>rs3892097</td><td>metoprolol</td><td></td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with CT genotype may have higher plasma concentrations of metoprolol and have greater reductions in heart rate, diastolic blood pressure, and mean arterial pressure when treated with metoprolol as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to metoprolol. Please check other variants for PM phenotype.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655385115>1670</a></td><td>CRHR2</td><td>rs2284220</td><td>salbutamol</td><td>Asthma</td><td>4</td><td>AA</td><td>Efficacy</td><td>Patients with the AA genotype may have increased response to salbutamol in people with Asthma as compared to patients with the GG or AG genotype. However, the association is significant only in one of the three cohorts tested. Other genetic and clinical factors may also influence the bronchodilator response.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655385115>1671</a></td><td>CRHR2</td><td>rs2284220</td><td>selective beta-2-adrenoreceptor agonists</td><td>Asthma</td><td>4</td><td>AA</td><td>Efficacy</td><td>Patients with the AA genotype may have increased response to salbutamol in people with Asthma as compared to patients with the GG or AG genotype. However, the association is significant only in one of the three cohorts tested. Other genetic and clinical factors may also influence the bronchodilator response.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655385120>1672</a></td><td>CRHR2</td><td>rs255100</td><td>salbutamol</td><td>Asthma</td><td>4</td><td>TT</td><td>Efficacy</td><td>Patients with the TT genotype may have increased response to salbutamol in people with Asthma as compared to patients with the AA or AT genotype. However, the association is significant only in one of the three cohorts tested. Other genetic and clinical factors may also influence the bronchodilator response.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655385120>1673</a></td><td>CRHR2</td><td>rs255100</td><td>selective beta-2-adrenoreceptor agonists</td><td>Asthma</td><td>4</td><td>TT</td><td>Efficacy</td><td>Patients with the TT genotype may have increased response to salbutamol in people with Asthma as compared to patients with the AA or AT genotype. However, the association is significant only in one of the three cohorts tested. Other genetic and clinical factors may also influence the bronchodilator response.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450373100>1674</a></td><td>HTR7</td><td>rs7905446</td><td>Selective serotonin reuptake inhibitors</td><td>Depression</td><td>3</td><td>GT</td><td>Efficacy</td><td>Patients with the GT genotype may have an increased response to selective serotonin reuptake inhibitors as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to selective serotonin reuptake inhibitors.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450375692>1675</a></td><td>GREM2</td><td>rs1934341</td><td>allopurinol</td><td></td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype may have an increased response to allopurinol as compared to patients with the CC, CG or GG genotypes. Other genetic and clinical factors may also affect a patient's response to allopurinol.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/827830327>1676</a></td><td>DDRGK1</td><td>rs1127354</td><td>azathioprine</td><td>Inflammatory Bowel Diseases</td><td>3</td><td>CC</td><td>Efficacy</td><td>Patients with the CC genotype may experience a greater response to azathiopurine treatment for inflammatory bowel disease as compared to patients with the AA or AC genotype. Patients with the CC genotype may still be at risk for non-response to azathioprine. Other genetic and clinical factors may also influence a patient's chance of response.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/827830327>1677</a></td><td>ITPA</td><td>rs1127354</td><td>azathioprine</td><td>Inflammatory Bowel Diseases</td><td>3</td><td>CC</td><td>Efficacy</td><td>Patients with the CC genotype may experience a greater response to azathiopurine treatment for inflammatory bowel disease as compared to patients with the AA or AC genotype. Patients with the CC genotype may still be at risk for non-response to azathioprine. Other genetic and clinical factors may also influence a patient's chance of response.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/827849109>1678</a></td><td>HLA-DQA1</td><td>rs9272105</td><td>interferon beta-1a</td><td></td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype may have increased risk for developing neutralizing anti-IFN-beta antibodies (i.e. increased risk of treatment failure) when treated with interferon-beta therapy as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to interferon-beta therapy.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/827849109>1679</a></td><td>HLA-DQA1</td><td>rs9272105</td><td>interferon beta-1b</td><td></td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype may have increased risk for developing neutralizing anti-IFN-beta antibodies (i.e. increased risk of treatment failure) when treated with interferon-beta therapy as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to interferon-beta therapy.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/981201864>1680</a></td><td>P2RY12</td><td>rs2046934</td><td>clopidogrel</td><td>Acute coronary syndrome;Angina Pectoris</td><td>4</td><td>AA</td><td>Efficacy</td><td>Patients with the AA genotype may have increased response to clopidogrel ( increased platelet activation to ADP) as compared to patients with the GG or AG genotype. However, the majority of the literature suggests this variant is not significantly associated with response to clopidogrel. Other genetic and clinical factors may influence a patient's response to clopidogrel.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/981202068>1681</a></td><td>PON1</td><td>rs662</td><td>clopidogrel</td><td>Angina Pectoris;Coronary Artery Disease;Myocardial Infarction;Myocardial Ischemia;Thrombosis</td><td>4</td><td>CC</td><td>Efficacy</td><td>Patients with the CC genotype who are treated with clopidogrel 1) may have higher levels of active metabolite, resulting in increased platelet inhibition and better response 2) may have a decreased, but not absent, risk of stent thrombosis, target vessel revascularization or cardiovascular secondary events, as compared to patients with the CT or TT genotype. A large number of studies report contradictory findings. Other genetic and clinical factors may also influence a patient's response to clopidogrel.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/981202261>1682</a></td><td>ABCC2</td><td>rs3740066</td><td>antiepileptics</td><td>Epilepsy</td><td>4</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype and Epilepsy who are treated with antiepileptics may have an increased risk of drug resistance as compared to patients with the CC genotype. Most studies find no association. Other genetic and clinical factors may also influence a patient's response to antiepileptics.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451416434>1683</a></td><td>HTR2A</td><td>rs7997012</td><td>antidepressants</td><td>Bipolar Disorder;Depression;Depressive Disorder, Major</td><td>3</td><td>GG</td><td>Efficacy</td><td>Patients with the rs7997012 GG genotype may have an increased response to antidepressants as compared to patients with the AA or AG genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to antidepressants.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/981204026>1684</a></td><td>SLC19A1</td><td>rs9977268</td><td>methotrexate</td><td>Arthritis, Rheumatoid</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype and Rheumatoid Arthritis who are treated with methotrexate may have an increased likelihood of treatment being ineffective as compared to patients with the CC genotype or may have an increased likelihood of treatment being effective as compared to patients with the TT genotype. This association was not statistically significant after Bonferroni correction. Other genetic and clinical factors may also influence a patient's response to methotrexate treatment.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/981204433>1685</a></td><td>ABCB1</td><td>rs1045642</td><td>dexamethasone</td><td>Multiple Myeloma</td><td>3</td><td>AA</td><td>Efficacy</td><td>Patients with the AA genotype may have increased survival when treated with dexamethasone, doxorubicin and vincristine in people with Multiple Myeloma as compared to patients with genotype GG. Other genetic and clinical factors may influence the patient's response to dexamethasone, doxorubicin and vincristine.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/981204433>1686</a></td><td>ABCB1</td><td>rs1045642</td><td>doxorubicin</td><td>Multiple Myeloma</td><td>3</td><td>AA</td><td>Efficacy</td><td>Patients with the AA genotype may have increased survival when treated with dexamethasone, doxorubicin and vincristine in people with Multiple Myeloma as compared to patients with genotype GG. Other genetic and clinical factors may influence the patient's response to dexamethasone, doxorubicin and vincristine.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/981204433>1687</a></td><td>ABCB1</td><td>rs1045642</td><td>vincristine</td><td>Multiple Myeloma</td><td>3</td><td>AA</td><td>Efficacy</td><td>Patients with the AA genotype may have increased survival when treated with dexamethasone, doxorubicin and vincristine in people with Multiple Myeloma as compared to patients with genotype GG. Other genetic and clinical factors may influence the patient's response to dexamethasone, doxorubicin and vincristine.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/981238041>1688</a></td><td>ABCB1</td><td>rs2032582</td><td>dexamethasone</td><td>Multiple Myeloma</td><td>3</td><td>AC</td><td>Efficacy</td><td>Patients with the AC genotype are associated with increased overall survival when treated with dexamethasone, doxorubicin and vincristine in people with Multiple Myeloma as compared to patients with the CC genotype. Other genetic and clinical factors may also influence patient's response to the therapy.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/981238041>1689</a></td><td>ABCB1</td><td>rs2032582</td><td>doxorubicin</td><td>Multiple Myeloma</td><td>3</td><td>AC</td><td>Efficacy</td><td>Patients with the AC genotype are associated with increased overall survival when treated with dexamethasone, doxorubicin and vincristine in people with Multiple Myeloma as compared to patients with the CC genotype. Other genetic and clinical factors may also influence patient's response to the therapy.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/981238041>1690</a></td><td>ABCB1</td><td>rs2032582</td><td>vincristine</td><td>Multiple Myeloma</td><td>3</td><td>AC</td><td>Efficacy</td><td>Patients with the AC genotype are associated with increased overall survival when treated with dexamethasone, doxorubicin and vincristine in people with Multiple Myeloma as compared to patients with the CC genotype. Other genetic and clinical factors may also influence patient's response to the therapy.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/981204345>1691</a></td><td>ABCB1</td><td>rs1045642</td><td>carbamazepine</td><td>Epilepsy</td><td>4</td><td>AA</td><td>Efficacy</td><td>Patient with genotype AA may have increased likelihood of drug resistance when treated with antiepileptics and carbamazepine in people with Epilepsy as compared to patients with genotype GG. However, contradictory findings have been reported. Other genetic and clinical factors may also influence response to carbamazepine.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/981204107>1692</a></td><td>PTGS2</td><td>rs20417</td><td>aspirin</td><td>Coronary Artery Disease</td><td>3</td><td>CG</td><td>Efficacy</td><td>Patients with the CG genotype may have decreased risk of Coronary Disease when treated with aspirin as compared to patients with the CC genotype. However, Allele G may be associated with increased risk of Coronary Disease in people not taking aspirin as compared to allele C. Other genetic and clinical factors may influence patient's response to aspirin.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/981204361>1693</a></td><td>ABCB1</td><td>rs1045642</td><td>clopidogrel</td><td>Acute coronary syndrome;Myocardial Infarction</td><td>3</td><td>AA</td><td>Efficacy</td><td>People with AA genotype may have an increased risk of major adverse cardiovascular events (MACE such as cardiovascular death, myocardial infarction, or stroke) when treated with clopidogrel in people with Acute coronary syndrome or myocardial Infarction as compared to people with genotypes GG or AG. Contradictory findings have been reported in the literature. Other genetic and clinical factors may also impact the response to clopidogrel.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/981204137>1694</a></td><td>ABCB1</td><td>rs2032582</td><td>antiepileptics</td><td>Epilepsy</td><td>4</td><td>AC</td><td>Efficacy</td><td>Patients with genotype AC may have increased likelihood of drug resistance when treated with antiepileptics and carbamazepine in people with Epilepsy as compared to patients with genotype CC. However, contradictory findings have been reported. Other genetic and clinical factors may also influence a patient's response to antiepileptics.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/981204403>1695</a></td><td>ABCB1</td><td>rs1045642</td><td>cisplatin</td><td>Esophageal Neoplasms</td><td>4</td><td>AA</td><td>Efficacy</td><td>Patients with the AA genotype may have a decreased risk of lymph node metastases and increased survival rate when treated with cisplatin and fluorouracil in people with Esophageal Neoplasms as compared to patients with genotype GG. Other genetic and clinical factors may also influence patients' response to cisplatin and fluorouracil.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/981204403>1696</a></td><td>ABCB1</td><td>rs1045642</td><td>fluorouracil</td><td>Esophageal Neoplasms</td><td>4</td><td>AA</td><td>Efficacy</td><td>Patients with the AA genotype may have a decreased risk of lymph node metastases and increased survival rate when treated with cisplatin and fluorouracil in people with Esophageal Neoplasms as compared to patients with genotype GG. Other genetic and clinical factors may also influence patients' response to cisplatin and fluorouracil.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449140273>1697</a></td><td>TMEM167A</td><td>rs2075685</td><td>fluorouracil</td><td>Stomach Neoplasms</td><td>3</td><td>GT</td><td>Efficacy</td><td>Patients with the GT genotype and stomach cancer may have improved response to fluorouracil, platinum compounds, or radiotherapy as compared to patients with the TT genotypes and worse response as compared to patients with the GG genotype. Other clinical and genetic factors may also influence response to fluorouracil, platinum compounds, or radiotherapy in patients with stomach cancer.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449140273>1698</a></td><td>XRCC4</td><td>rs2075685</td><td>fluorouracil</td><td>Stomach Neoplasms</td><td>3</td><td>GT</td><td>Efficacy</td><td>Patients with the GT genotype and stomach cancer may have improved response to fluorouracil, platinum compounds, or radiotherapy as compared to patients with the TT genotypes and worse response as compared to patients with the GG genotype. Other clinical and genetic factors may also influence response to fluorouracil, platinum compounds, or radiotherapy in patients with stomach cancer.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449140273>1699</a></td><td>TMEM167A</td><td>rs2075685</td><td>Platinum compounds</td><td>Stomach Neoplasms</td><td>3</td><td>GT</td><td>Efficacy</td><td>Patients with the GT genotype and stomach cancer may have improved response to fluorouracil, platinum compounds, or radiotherapy as compared to patients with the TT genotypes and worse response as compared to patients with the GG genotype. Other clinical and genetic factors may also influence response to fluorouracil, platinum compounds, or radiotherapy in patients with stomach cancer.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449140273>1700</a></td><td>XRCC4</td><td>rs2075685</td><td>Platinum compounds</td><td>Stomach Neoplasms</td><td>3</td><td>GT</td><td>Efficacy</td><td>Patients with the GT genotype and stomach cancer may have improved response to fluorouracil, platinum compounds, or radiotherapy as compared to patients with the TT genotypes and worse response as compared to patients with the GG genotype. Other clinical and genetic factors may also influence response to fluorouracil, platinum compounds, or radiotherapy in patients with stomach cancer.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449140273>1701</a></td><td>TMEM167A</td><td>rs2075685</td><td>radiotherapy</td><td>Stomach Neoplasms</td><td>3</td><td>GT</td><td>Efficacy</td><td>Patients with the GT genotype and stomach cancer may have improved response to fluorouracil, platinum compounds, or radiotherapy as compared to patients with the TT genotypes and worse response as compared to patients with the GG genotype. Other clinical and genetic factors may also influence response to fluorouracil, platinum compounds, or radiotherapy in patients with stomach cancer.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449140273>1702</a></td><td>XRCC4</td><td>rs2075685</td><td>radiotherapy</td><td>Stomach Neoplasms</td><td>3</td><td>GT</td><td>Efficacy</td><td>Patients with the GT genotype and stomach cancer may have improved response to fluorouracil, platinum compounds, or radiotherapy as compared to patients with the TT genotypes and worse response as compared to patients with the GG genotype. Other clinical and genetic factors may also influence response to fluorouracil, platinum compounds, or radiotherapy in patients with stomach cancer.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449144292>1703</a></td><td>-</td><td>rs324899</td><td>lithium</td><td>Bipolar Disorder</td><td>3</td><td>GG</td><td>Efficacy</td><td>Patients with the GG genotype and bipolar affective disorder may have an increased response to lithium as compared to patients with the AG or AA genotypes. Other genetic and clinical factors may also influence a patient's response to lithium when treating bipolar affective disorder.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449004229>1704</a></td><td>SCN1A</td><td>rs2298771</td><td>carbamazepine</td><td>Epilepsy</td><td>4</td><td>CT</td><td>Efficacy</td><td>Patients with epilepsy and the CT genotype who are treated with mono or combination anti-epileptic therapy (carbamazepine, oxcarbazepine, clobazam, ethosuximide, lamotrigine, levetiracetam, or valproic acid), may have an improved response as compared to patients with the TT genotypes and a worse response as compared to patients with the CC genotype, although this is contradicted in four studies. Other clinical and genetic factors may also influence response of epileptic patients to anti-epileptic drugs.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449004229>1705</a></td><td>SCN1A</td><td>rs2298771</td><td>clobazam</td><td>Epilepsy</td><td>4</td><td>CT</td><td>Efficacy</td><td>Patients with epilepsy and the CT genotype who are treated with mono or combination anti-epileptic therapy (carbamazepine, oxcarbazepine, clobazam, ethosuximide, lamotrigine, levetiracetam, or valproic acid), may have an improved response as compared to patients with the TT genotypes and a worse response as compared to patients with the CC genotype, although this is contradicted in four studies. Other clinical and genetic factors may also influence response of epileptic patients to anti-epileptic drugs.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449004229>1706</a></td><td>SCN1A</td><td>rs2298771</td><td>ethosuximide</td><td>Epilepsy</td><td>4</td><td>CT</td><td>Efficacy</td><td>Patients with epilepsy and the CT genotype who are treated with mono or combination anti-epileptic therapy (carbamazepine, oxcarbazepine, clobazam, ethosuximide, lamotrigine, levetiracetam, or valproic acid), may have an improved response as compared to patients with the TT genotypes and a worse response as compared to patients with the CC genotype, although this is contradicted in four studies. Other clinical and genetic factors may also influence response of epileptic patients to anti-epileptic drugs.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449004229>1707</a></td><td>SCN1A</td><td>rs2298771</td><td>lamotrigine</td><td>Epilepsy</td><td>4</td><td>CT</td><td>Efficacy</td><td>Patients with epilepsy and the CT genotype who are treated with mono or combination anti-epileptic therapy (carbamazepine, oxcarbazepine, clobazam, ethosuximide, lamotrigine, levetiracetam, or valproic acid), may have an improved response as compared to patients with the TT genotypes and a worse response as compared to patients with the CC genotype, although this is contradicted in four studies. Other clinical and genetic factors may also influence response of epileptic patients to anti-epileptic drugs.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449004229>1708</a></td><td>SCN1A</td><td>rs2298771</td><td>levetiracetam</td><td>Epilepsy</td><td>4</td><td>CT</td><td>Efficacy</td><td>Patients with epilepsy and the CT genotype who are treated with mono or combination anti-epileptic therapy (carbamazepine, oxcarbazepine, clobazam, ethosuximide, lamotrigine, levetiracetam, or valproic acid), may have an improved response as compared to patients with the TT genotypes and a worse response as compared to patients with the CC genotype, although this is contradicted in four studies. Other clinical and genetic factors may also influence response of epileptic patients to anti-epileptic drugs.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449004229>1709</a></td><td>SCN1A</td><td>rs2298771</td><td>oxcarbazepine</td><td>Epilepsy</td><td>4</td><td>CT</td><td>Efficacy</td><td>Patients with epilepsy and the CT genotype who are treated with mono or combination anti-epileptic therapy (carbamazepine, oxcarbazepine, clobazam, ethosuximide, lamotrigine, levetiracetam, or valproic acid), may have an improved response as compared to patients with the TT genotypes and a worse response as compared to patients with the CC genotype, although this is contradicted in four studies. Other clinical and genetic factors may also influence response of epileptic patients to anti-epileptic drugs.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449004229>1710</a></td><td>SCN1A</td><td>rs2298771</td><td>valproic acid</td><td>Epilepsy</td><td>4</td><td>CT</td><td>Efficacy</td><td>Patients with epilepsy and the CT genotype who are treated with mono or combination anti-epileptic therapy (carbamazepine, oxcarbazepine, clobazam, ethosuximide, lamotrigine, levetiracetam, or valproic acid), may have an improved response as compared to patients with the TT genotypes and a worse response as compared to patients with the CC genotype, although this is contradicted in four studies. Other clinical and genetic factors may also influence response of epileptic patients to anti-epileptic drugs.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449144328>1711</a></td><td>-</td><td>rs66486766</td><td>lithium</td><td>Bipolar Disorder</td><td>3</td><td>GG</td><td>Efficacy</td><td>Patients with the GG genotype and bipolar affective disorder may have an increased response to lithium as compared to patients with the AG or AA genotypes. Other genetic and clinical factors may also influence a patient's response to lithium when treating bipolar affective disorder.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449144346>1712</a></td><td>ZNF804A</td><td>rs62200793</td><td>lithium</td><td>Bipolar Disorder</td><td>3</td><td>TT</td><td>Efficacy</td><td>Patients with the TT genotype and bipolar affective disorder may have an increased response to lithium as compared to patients with the CT or CC genotypes. Other genetic and clinical factors may also influence a patient's response to lithium when treating bipolar affective disorder.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449144352>1713</a></td><td>-</td><td>rs7588746</td><td>lithium</td><td>Bipolar Disorder</td><td>3</td><td>GG</td><td>Efficacy</td><td>Patients with the GG genotype and bipolar affective disorder may have an increased response to lithium as compared to patients with the AG or AA genotypes. Other genetic and clinical factors may also influence a patient's response to lithium when treating bipolar affective disorder.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450814653>1714</a></td><td>DBH</td><td>rs2873804</td><td>bupropion</td><td>Depressive Disorder, Major</td><td>3</td><td>CC</td><td>Efficacy</td><td>Patients with the CC genotype may have an increased response to bupropion in the treatment of major depressive disorder, as measured by a reduction in HAMD scores, as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's response to bupropion.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450928460>1715</a></td><td>UGT1A10</td><td>rs6706232</td><td>risperidone</td><td>Schizophrenia</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with schizophrenia and the AG genotype may have an increased response to risperidone as compared to patients with the GG genotype. However, this association lost significance following correction for multiple testing. Other genetic or clinical factors may also affect a patient's response to risperidone.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450928460>1716</a></td><td>UGT1A3</td><td>rs6706232</td><td>risperidone</td><td>Schizophrenia</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with schizophrenia and the AG genotype may have an increased response to risperidone as compared to patients with the GG genotype. However, this association lost significance following correction for multiple testing. Other genetic or clinical factors may also affect a patient's response to risperidone.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450928460>1717</a></td><td>UGT1A4</td><td>rs6706232</td><td>risperidone</td><td>Schizophrenia</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with schizophrenia and the AG genotype may have an increased response to risperidone as compared to patients with the GG genotype. However, this association lost significance following correction for multiple testing. Other genetic or clinical factors may also affect a patient's response to risperidone.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450928460>1718</a></td><td>UGT1A5</td><td>rs6706232</td><td>risperidone</td><td>Schizophrenia</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with schizophrenia and the AG genotype may have an increased response to risperidone as compared to patients with the GG genotype. However, this association lost significance following correction for multiple testing. Other genetic or clinical factors may also affect a patient's response to risperidone.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450928460>1719</a></td><td>UGT1A6</td><td>rs6706232</td><td>risperidone</td><td>Schizophrenia</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with schizophrenia and the AG genotype may have an increased response to risperidone as compared to patients with the GG genotype. However, this association lost significance following correction for multiple testing. Other genetic or clinical factors may also affect a patient's response to risperidone.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450928460>1720</a></td><td>UGT1A7</td><td>rs6706232</td><td>risperidone</td><td>Schizophrenia</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with schizophrenia and the AG genotype may have an increased response to risperidone as compared to patients with the GG genotype. However, this association lost significance following correction for multiple testing. Other genetic or clinical factors may also affect a patient's response to risperidone.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450928460>1721</a></td><td>UGT1A8</td><td>rs6706232</td><td>risperidone</td><td>Schizophrenia</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with schizophrenia and the AG genotype may have an increased response to risperidone as compared to patients with the GG genotype. However, this association lost significance following correction for multiple testing. Other genetic or clinical factors may also affect a patient's response to risperidone.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450928460>1722</a></td><td>UGT1A9</td><td>rs6706232</td><td>risperidone</td><td>Schizophrenia</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with schizophrenia and the AG genotype may have an increased response to risperidone as compared to patients with the GG genotype. However, this association lost significance following correction for multiple testing. Other genetic or clinical factors may also affect a patient's response to risperidone.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450928608>1723</a></td><td>NTRK1</td><td>rs2768759</td><td>aspirin</td><td></td><td>3</td><td>CC</td><td>Efficacy</td><td>Patients with the CC genotype may have higher platelet aggregation when treated with antiplatelet drugs as compared to patients with the AA genotype. However, one study failed to find an association between this variant and platelet aggregation. Other genetic or clinical factors may also affect a patient's response to antiplatelet drugs.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450928608>1724</a></td><td>PEAR1</td><td>rs2768759</td><td>aspirin</td><td></td><td>3</td><td>CC</td><td>Efficacy</td><td>Patients with the CC genotype may have higher platelet aggregation when treated with antiplatelet drugs as compared to patients with the AA genotype. However, one study failed to find an association between this variant and platelet aggregation. Other genetic or clinical factors may also affect a patient's response to antiplatelet drugs.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450928608>1725</a></td><td>NTRK1</td><td>rs2768759</td><td>prasugrel</td><td></td><td>3</td><td>CC</td><td>Efficacy</td><td>Patients with the CC genotype may have higher platelet aggregation when treated with antiplatelet drugs as compared to patients with the AA genotype. However, one study failed to find an association between this variant and platelet aggregation. Other genetic or clinical factors may also affect a patient's response to antiplatelet drugs.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450928608>1726</a></td><td>PEAR1</td><td>rs2768759</td><td>prasugrel</td><td></td><td>3</td><td>CC</td><td>Efficacy</td><td>Patients with the CC genotype may have higher platelet aggregation when treated with antiplatelet drugs as compared to patients with the AA genotype. However, one study failed to find an association between this variant and platelet aggregation. Other genetic or clinical factors may also affect a patient's response to antiplatelet drugs.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450812333>1727</a></td><td>DRD2</td><td>rs6277</td><td>nicotine</td><td></td><td>3</td><td>AG</td><td>Efficacy</td><td>Male patients with the AG genotype may have an increased response to nicotine (assessed by nicotine reward, perception, mood or reinforcement or physiological responses to nicotine) as compared to male patients with the GG genotype. This association was not found in female patients. Other genetic and clinical factors may also affect a patient's response to nicotine.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449269473>1728</a></td><td>UGT2B7</td><td>rs7439366</td><td>oxycodone</td><td>Pain</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype may have an increased response to oxycodone as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to oxycodone.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1145231686>1729</a></td><td>ABCB1</td><td>rs2032582</td><td>pravastatin</td><td>Acute coronary syndrome;Hyperlipoproteinemia Type II</td><td>3</td><td>AC</td><td>Efficacy</td><td>Patients with the rs2032582 AC genotype who are treated with pravastatin may have a reduced response (as measured by lower reductions in LDL-cholesterol) as compared to patients with the CC genotype, or may have a better response (as measured by higher reductions in LDL-cholesterol) as compared to patients with the AA, AT or TT genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to pravastatin treatment.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448636814>1730</a></td><td>RPTOR</td><td>rs9906827</td><td>everolimus</td><td>pneumonitis;progression-free survival</td><td>3</td><td>TT</td><td>Efficacy</td><td>Patients with the TT genotype and breast cancer who are treated with everolimus may have increased likelihood of progression-free survival and decreased likelihood of pneumonitis as compared to patients with the CC genotypes. Other clinical and genetic factors may also influence the likelihood of progression-free survival or pneumonitis in women with breast cancer who are treated with everolimus.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449564951>1731</a></td><td>KCNJ11</td><td>rs5219</td><td>sulfonamides, urea derivatives</td><td>Diabetes Mellitus</td><td>3</td><td>CC</td><td>Efficacy</td><td>Patients with diabetes mellitus and the CC genotype who are taking sulfonylureas may have worse response as compared to patients with the CT or TT genotypes, although no association with response is also reported, and one found that the heterozygous genotype had an improved response as compared to both homozygous genotypes. Other clinical and genetic factors may also influence response to sulfonylureas in patients with diabetes mellitus.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449564957>1732</a></td><td>ABCC8</td><td>rs757110</td><td>sulfonamides, urea derivatives</td><td>Diabetes Mellitus</td><td>3</td><td>AA</td><td>Efficacy</td><td>Patients with the AA genotype and diabetes mellitus may have an improved response to sulfonylureas as compared to the AC genotype. However, another study did not find any association between this variant and response to sulfonylureas. Other clinical and genetic factors may also influence response to sulfonylureas in patients with diabetes mellitus.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449564957>1733</a></td><td>KCNJ11</td><td>rs757110</td><td>sulfonamides, urea derivatives</td><td>Diabetes Mellitus</td><td>3</td><td>AA</td><td>Efficacy</td><td>Patients with the AA genotype and diabetes mellitus may have an improved response to sulfonylureas as compared to the AC genotype. However, another study did not find any association between this variant and response to sulfonylureas. Other clinical and genetic factors may also influence response to sulfonylureas in patients with diabetes mellitus.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449564963>1734</a></td><td>BCHE</td><td>rs1803274</td><td>donepezil</td><td>Alzheimer Disease;cognitive dysfunction</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype and and Alzheimer Disease may have an improved response to donepezil (slower cognitive decline) as compared to patients with the TT genotypes, and worse response as compared to CC genotype. This is contradicted by another study which showed the opposite, and another which showed no association between genotype and response to donepezil in patients with Alzheimer Disease. Other clinical and genetic factors may also influence response to donepezil in patients with Alzheimer Disease.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450928505>1735</a></td><td>COMT</td><td>rs4818</td><td>risperidone</td><td>Schizophrenia</td><td>3</td><td>GG</td><td>Efficacy</td><td>Patients with schizophrenia and the GG genotype may have an increased response to risperidone as compared to patients with the CC genotype. However, this association lost significance following correction for multiple testing. Other genetic or clinical factors may also affect a patient's response to risperidone.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450933062>1736</a></td><td>SH3BP2</td><td>rs6920220</td><td>Tumor necrosis factor alpha (TNF-alpha) inhibitors</td><td>Arthritis, Psoriatic;Psoriasis</td><td>3</td><td>GG</td><td>Efficacy</td><td>Patients with the GG genotype may have an increased response to anti-TNF drugs, as measured by an increase in quality of life scores, as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to anti-TNF drugs.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450933062>1737</a></td><td>TNFAIP3</td><td>rs6920220</td><td>Tumor necrosis factor alpha (TNF-alpha) inhibitors</td><td>Arthritis, Psoriatic;Psoriasis</td><td>3</td><td>GG</td><td>Efficacy</td><td>Patients with the GG genotype may have an increased response to anti-TNF drugs, as measured by an increase in quality of life scores, as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to anti-TNF drugs.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449004548>1738</a></td><td>UGT2B7</td><td>rs7439366</td><td>oxcarbazepine</td><td>Epilepsy</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with epilepsy and the CT genotype may have a worse response to oxcarbazepine as compared to patients with the TT genotype and an improved response as compared to patients with the CC genotype. There is no association with concentrations, or dose of carbamazepine. Other clinical and genetic factors may also influence response to oxcarbazepine in people with epilepsy.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449752787>1739</a></td><td>PIN1</td><td>rs2233678</td><td>irinotecan</td><td>Colorectal Neoplasms</td><td>3</td><td>CG</td><td>Efficacy</td><td>Patients with the CG genotype and colorectal cancer may have increased survival times when treated with irinotecan-based treatments as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to irinotecan-based treatments.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449168670>1740</a></td><td>-</td><td>rs10771997</td><td>duloxetine</td><td>Depressive Disorder, Major</td><td>3</td><td>CC</td><td>Efficacy</td><td>Patients with the CC genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's response to duloxetine.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449168677>1741</a></td><td>-</td><td>rs10771998</td><td>duloxetine</td><td>Depressive Disorder, Major</td><td>3</td><td>GG</td><td>Efficacy</td><td>Patients with the GG genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's response to duloxetine.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449752561>1742</a></td><td>MDM2</td><td>rs1690924</td><td>Platinum compounds</td><td>Carcinoma, Non-Small-Cell Lung</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with cancer and the CT genotype may have an increased overall survival time when treated with platinum-based chemotherapy as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to platinum-based chemotherapy.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449752602>1743</a></td><td>SLC19A1</td><td>rs1051266</td><td>Platinum compounds</td><td>Carcinoma, Non-Small-Cell Lung</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with lung cancer and the CT genotype may have an increased progression-free survival time when treated with platinum-based chemotherapy as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to platinum-based chemotherapy.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450376443>1744</a></td><td>SLC6A2</td><td>rs28386840</td><td>methylphenidate</td><td>Attention Deficit Disorder with Hyperactivity</td><td>3</td><td>AT</td><td>Efficacy</td><td>Pediatric patients with the AT genotype and ADHD may have a better response when treated with methylphenidate as compared to patients with the AA genotype. However, contradictory evidence exists for this association. Studies used different scales to analyze improvement, e.g. CGI-I, ARS-IV, and other. Other genetic and clinical factors may also influence response to methylphenidate.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449140279>1745</a></td><td>XRCC4</td><td>rs10040363</td><td>fluorouracil</td><td>Stomach Neoplasms</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype and stomach cancer may have an improved response to fluorouracil, platinum compounds or radiotherapy as compared to patients with the GG genotypes and a worse response as compared to patients with the AA genotype. Other clinical and genetic factors may also influence response to fluorouracil, platinum compounds or radiotherapy in patients with stomach cancer.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449140279>1746</a></td><td>XRCC4</td><td>rs10040363</td><td>Platinum compounds</td><td>Stomach Neoplasms</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype and stomach cancer may have an improved response to fluorouracil, platinum compounds or radiotherapy as compared to patients with the GG genotypes and a worse response as compared to patients with the AA genotype. Other clinical and genetic factors may also influence response to fluorouracil, platinum compounds or radiotherapy in patients with stomach cancer.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449140279>1747</a></td><td>XRCC4</td><td>rs10040363</td><td>radiotherapy</td><td>Stomach Neoplasms</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype and stomach cancer may have an improved response to fluorouracil, platinum compounds or radiotherapy as compared to patients with the GG genotypes and a worse response as compared to patients with the AA genotype. Other clinical and genetic factors may also influence response to fluorouracil, platinum compounds or radiotherapy in patients with stomach cancer.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/827864250>1748</a></td><td>CRHR1</td><td>rs1876828</td><td>corticosteroids</td><td>Asthma</td><td>3</td><td>TT</td><td>Efficacy</td><td>Patients with the TT genotype may have increased response to corticosteroids compared to patients with the CT or CC genotypes. Other genetic and clinical factors may also influence a patient's response to corticosteroids.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449310001>1749</a></td><td>NELFCD</td><td>rs2273359</td><td>diuretics</td><td>Hypertension</td><td>3</td><td>CG</td><td>Efficacy</td><td>Patients with the CG genotype and hypertension may have an improved response to diuretics, hydrochlorothiazides, or thiazides as compared to patients with the CG genotype. Other clinical and genetic factors may also influence response to anti-hypertensives in patients with hypertension.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449310001>1750</a></td><td>NELFCD</td><td>rs2273359</td><td>hydrochlorothiazide</td><td>Hypertension</td><td>3</td><td>CG</td><td>Efficacy</td><td>Patients with the CG genotype and hypertension may have an improved response to diuretics, hydrochlorothiazides, or thiazides as compared to patients with the CG genotype. Other clinical and genetic factors may also influence response to anti-hypertensives in patients with hypertension.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449310001>1751</a></td><td>NELFCD</td><td>rs2273359</td><td>Thiazides, plain</td><td>Hypertension</td><td>3</td><td>CG</td><td>Efficacy</td><td>Patients with the CG genotype and hypertension may have an improved response to diuretics, hydrochlorothiazides, or thiazides as compared to patients with the CG genotype. Other clinical and genetic factors may also influence response to anti-hypertensives in patients with hypertension.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449716764>1752</a></td><td>ABCB1</td><td>rs1128503</td><td>fentanyl</td><td>Pain;Pain, Postoperative</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype may have an increased response to fentanyl and may therefore require a decreased dose as compared to patients with the AA genotype. However, one study failed to find a significant relationship between this variant and dose of fentanyl. Other genetic and clinical factors may also affect a patient's response to fentanyl and their dosage requirements.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451635027>1753</a></td><td>CCND1</td><td>rs9344</td><td>methotrexate</td><td>Precursor Cell Lymphoblastic Leukemia-Lymphoma</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with acute lymphoblastic leukemia (ALL) and the rs9344 AG genotype may have an increased response to methotrexate as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to methotrexate.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451635034>1754</a></td><td>CCND1</td><td>rs9344</td><td>cisplatin</td><td>Osteosarcoma</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with osteosarcoma and the rs9344 AG genotype may have an increased response to combination therapy of cisplatin, doxorubicin and methotrexate as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to combination therapy of cisplatin, doxorubicin and methotrexate.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451635034>1755</a></td><td>CCND1</td><td>rs9344</td><td>doxorubicin</td><td>Osteosarcoma</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with osteosarcoma and the rs9344 AG genotype may have an increased response to combination therapy of cisplatin, doxorubicin and methotrexate as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to combination therapy of cisplatin, doxorubicin and methotrexate.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451635034>1756</a></td><td>CCND1</td><td>rs9344</td><td>methotrexate</td><td>Osteosarcoma</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with osteosarcoma and the rs9344 AG genotype may have an increased response to combination therapy of cisplatin, doxorubicin and methotrexate as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to combination therapy of cisplatin, doxorubicin and methotrexate.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450375716>1757</a></td><td>TRIB2</td><td>rs10193126</td><td>allopurinol</td><td></td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype may have an increased response to allopurinol as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to allopurinol.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450375722>1758</a></td><td>TBL1XR1</td><td>rs57449396</td><td>allopurinol</td><td></td><td>3</td><td>CC</td><td>Efficacy</td><td>Patients with the CC genotype may have an increased response to allopurinol as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's response to allopurinol.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449004876>1759</a></td><td>SLC19A1</td><td>rs2838958</td><td>methotrexate</td><td>Precursor Cell Lymphoblastic Leukemia-Lymphoma</td><td>3</td><td>AG</td><td>Efficacy</td><td>Pediatric patients with precursor cell lymphoblastic leukemia-lymphoma and the AG genotype may have improved response to methotrexate as compared to patients with the AA genotype. Other clinical and genetic factors may also influence response to methotrexate in pediatric patients with precursor cell lymphoblastic leukemia-lymphoma.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449005393>1760</a></td><td>ABCB1</td><td>rs1128503</td><td>remifentanil</td><td>tonsillectomy</td><td>3</td><td>AG</td><td>Efficacy</td><td>Pediatric patients undergoing surgery with the AG genotype may have an increased likelihood of adverse events, as well as a worse response to sevoflurane and remifentanil as compared to patients with the GG genotype. Other clinical and genetic factors may also influence response to sevoflurane and remifentanil.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449005393>1761</a></td><td>ABCB1</td><td>rs1128503</td><td>sevoflurane</td><td>tonsillectomy</td><td>3</td><td>AG</td><td>Efficacy</td><td>Pediatric patients undergoing surgery with the AG genotype may have an increased likelihood of adverse events, as well as a worse response to sevoflurane and remifentanil as compared to patients with the GG genotype. Other clinical and genetic factors may also influence response to sevoflurane and remifentanil.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183702959>1762</a></td><td>BDNF-AS</td><td>rs10501087</td><td>antipsychotics</td><td>Schizophrenia</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype and schizophrenia may show greater resistance to treatment with antipsychotics as compared to patients with the TT genotype. Other genetic and clinical factors may also influence resistance to antipsychotics.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183702964>1763</a></td><td>BDNF</td><td>rs6265</td><td>antipsychotics</td><td>Schizophrenia</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype and schizophrenia may show greater resistance to treatment with antipsychotics as compared to patients with the CC genotype. Other genetic and clinical factors may also influence resistance to antipsychotics.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183704404>1764</a></td><td>CD84</td><td>rs6427528</td><td>etanercept</td><td>Arthritis, Rheumatoid;Psoriasis</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype may have increased response to etanercept in people with Arthritis, Rheumatoid or Psoriasis as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to etanercept.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183704302>1765</a></td><td>DYNC2H1</td><td>rs716274</td><td>etoposide</td><td></td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype may have increased risk of Death when treated with etoposide and Platinum compounds in people with Carcinoma, Small Cell as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to etoposide and Platinum compounds.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183704302>1766</a></td><td>DYNC2H1</td><td>rs716274</td><td>Platinum compounds</td><td></td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype may have increased risk of Death when treated with etoposide and Platinum compounds in people with Carcinoma, Small Cell as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to etoposide and Platinum compounds.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183704372>1767</a></td><td>STK39</td><td>rs6749447</td><td>losartan</td><td></td><td>3</td><td>TT</td><td>Efficacy</td><td>Patients with the TT genotype may have increased reduction in ambulatory blood pressure when treated with losartan in men with Hypertension as compared to patients with genotype GG or GT. Other genetic and clinical factors may also influence the response to losartan.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184233161>1768</a></td><td>NR3C2</td><td>rs5522</td><td>enalapril</td><td>Hypertension</td><td>3</td><td>TT</td><td>Efficacy</td><td>Patients with the TT genotype and hypertension may have a greater reduction in diastolic blood pressure when treated with enalapril as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence a patient's response to enalapril.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184348713>1769</a></td><td>ADH1C</td><td>rs698</td><td>cisplatin</td><td>Ovarian Neoplasms</td><td>3</td><td>CC</td><td>Efficacy</td><td>Patients with the CC genotype and ovarian cancer who are treated with chemotherapy involving cisplatin and cyclophosphamide may be more likely to have a complete response to treatment as compared to patients with the CT genotype. Other genetic and clinical factors may also influence a patient's response to chemotherapy.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184348713>1770</a></td><td>ADH1C</td><td>rs698</td><td>cyclophosphamide</td><td>Ovarian Neoplasms</td><td>3</td><td>CC</td><td>Efficacy</td><td>Patients with the CC genotype and ovarian cancer who are treated with chemotherapy involving cisplatin and cyclophosphamide may be more likely to have a complete response to treatment as compared to patients with the CT genotype. Other genetic and clinical factors may also influence a patient's response to chemotherapy.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183702969>1771</a></td><td>BDNF</td><td>rs11030104</td><td>antipsychotics</td><td>Schizophrenia</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype and schizophrenia may show greater resistance to treatment with antipsychotics as compared to patients with the AA genotype. Other genetic and clinical factors may also influence resistance to antipsychotics.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183848125>1772</a></td><td>CES1P1</td><td>rs3785161</td><td>clopidogrel</td><td>Coronary Disease</td><td>3</td><td>CA</td><td>Efficacy</td><td>Patients with the CA genotype and Coronary Disease who are treated with clopidogrel may have an increased on-treatment platelet activity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for high on-treatment platelet activity.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184134274>1773</a></td><td>ABCB1</td><td>rs1045642</td><td>morphine</td><td>Pain</td><td>3</td><td>AA</td><td>Efficacy</td><td>Patients with the AA genotype may have increased pain reduction when treated with morphine in cancer patients as compared to patients with genotype AG or GG. Other genetic and clinical factors may also influence response to morphine.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184472721>1774</a></td><td>SLC29A1</td><td>rs760370</td><td>gemcitabine</td><td>Neoplasms</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with cancer and the AG genotype may have increased response to gemcitabine as compared to patients with the GG genotype. However, this has been contradicted in some studies. Other genetic and clinical factors may also influence response to gemcitabine.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183704390>1775</a></td><td>EPB41</td><td>rs6702335</td><td>bupropion</td><td>Tobacco Use Disorder</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype may have increased abstinence when treated with bupropion or nicotine in men with Tobacco Use Disorder as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to bupropion or nicotine.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183704390>1776</a></td><td>EPB41</td><td>rs6702335</td><td>nicotine</td><td>Tobacco Use Disorder</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype may have increased abstinence when treated with bupropion or nicotine in men with Tobacco Use Disorder as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to bupropion or nicotine.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183703019>1777</a></td><td>ADRA2A</td><td>rs1800544</td><td>methylphenidate</td><td>Attention Deficit Disorder with Hyperactivity</td><td>4</td><td>CG</td><td>Efficacy</td><td>Patients (mainly pediatric patients) with the CG genotype and attention deficit hyperactivity disorder (ADHD) may have a better response to methylphenidate treatment as compared to patients with the CC genotype. However, contradictory evidence exists for this association. Studies used different scales to analyze improvement, e.g. CGI-I, ARS-IV, and other. Other genetic and clinical factors may also influence response to methylphenidate.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449162249>1778</a></td><td>-</td><td>rs2562456</td><td>ketorolac</td><td></td><td>3</td><td>TT</td><td>Efficacy</td><td>Patients with the TT genotype who are treated with ketorolac and undergo oral surgery may have a faster analgesic onset as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to ketorolac.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451476060>1779</a></td><td>CCND1</td><td>rs9344</td><td>cisplatin</td><td>Osteosarcoma</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with osteosarcoma and the rs9344 AG genotype may have an increased likelihood of progression-free survival when treated with cisplatin, doxorubicin and methotrexate as compared to patients with the AA genotype. Other genetic and clinical factors may also influence likelihood of progression-free survival when treated with cisplatin, doxorubicin and methotrexate.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451476060>1780</a></td><td>CCND1</td><td>rs9344</td><td>doxorubicin</td><td>Osteosarcoma</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with osteosarcoma and the rs9344 AG genotype may have an increased likelihood of progression-free survival when treated with cisplatin, doxorubicin and methotrexate as compared to patients with the AA genotype. Other genetic and clinical factors may also influence likelihood of progression-free survival when treated with cisplatin, doxorubicin and methotrexate.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451476060>1781</a></td><td>CCND1</td><td>rs9344</td><td>methotrexate</td><td>Osteosarcoma</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with osteosarcoma and the rs9344 AG genotype may have an increased likelihood of progression-free survival when treated with cisplatin, doxorubicin and methotrexate as compared to patients with the AA genotype. Other genetic and clinical factors may also influence likelihood of progression-free survival when treated with cisplatin, doxorubicin and methotrexate.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183703000>1782</a></td><td>VEGFA</td><td>rs2010963</td><td>cyclophosphamide</td><td>Prostatic Neoplasms</td><td>3</td><td>GG</td><td>Efficacy</td><td>Patients with the GG genotype and prostate cancer may have longer progression-free survival time when treated with cyclophosphamide as compared to patients with the CC genotype. Other genetic and clinical factors may also influence length of progression-free survival.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444668236>1783</a></td><td>-</td><td>rs10747673</td><td>metformin</td><td>Diabetes Mellitus</td><td>3</td><td>GG</td><td>Efficacy</td><td>In healthy volunteers as well as patients with diabetes mellitus the GG genotype may be associated with a decreased secretory clearance of metformin, leading to increased exposure and a corresponding decrease in HbA1c levels, which is indicative of improved metformin efficacy, as compared to patients with the AG or AA genotypes. Other clinical and genetic factors may also influence metformin clearance and efficacy in patients with diabetes mellitus.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444673084>1784</a></td><td>SLC22A5</td><td>rs2631367</td><td>imatinib</td><td>Gastrointestinal Stromal Tumors</td><td>3</td><td>CG</td><td>Efficacy</td><td>Patients with the CG genotype and gastrointestinal stromal tumors may have a longer time to progression when treated with imatinib as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to imatinib treatment.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444673156>1785</a></td><td>FCGR3A</td><td>rs396991</td><td>adalimumab</td><td>Psoriasis</td><td>3</td><td>AC</td><td>Efficacy</td><td>Patients with the AC genotype and psoriasis may have a better response to treatment with anti-TNF therapy as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444673156>1786</a></td><td>FCGR3A</td><td>rs396991</td><td>etanercept</td><td>Psoriasis</td><td>3</td><td>AC</td><td>Efficacy</td><td>Patients with the AC genotype and psoriasis may have a better response to treatment with anti-TNF therapy as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444673156>1787</a></td><td>FCGR3A</td><td>rs396991</td><td>infliximab</td><td>Psoriasis</td><td>3</td><td>AC</td><td>Efficacy</td><td>Patients with the AC genotype and psoriasis may have a better response to treatment with anti-TNF therapy as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1445401125>1788</a></td><td>ERCC1</td><td>rs11615</td><td>capecitabine</td><td>Rectal Neoplasms</td><td>3</td><td>AA</td><td>Efficacy</td><td>Patients with the AA genotype and rectal cancer may have a better response to capecitabine-based chemoradiotherapy as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence response to capecitabine-based chemoradiotherapy.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1445401125>1789</a></td><td>ERCC1</td><td>rs11615</td><td>radiotherapy</td><td>Rectal Neoplasms</td><td>3</td><td>AA</td><td>Efficacy</td><td>Patients with the AA genotype and rectal cancer may have a better response to capecitabine-based chemoradiotherapy as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence response to capecitabine-based chemoradiotherapy.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1445737062>1790</a></td><td>NOS3</td><td>rs1799983</td><td>anthracyclines and related substances</td><td>Neoplasms;Ovarian Neoplasms;Stomach Neoplasms</td><td>3</td><td>GG</td><td>Efficacy</td><td>Patients with the GG genotype and breast cancer, stomach cancer, or other cancer may have an improved response (increased disease free survival or overall survival) when treated with a chemotherapy regimen that includes anthracyclines and related substances, platinum compounds, nucleoside inhibitors or folate analog metabolite inhibitors IF CYCLOPHOSPHAMIDE IS GIVEN AS AN ADJUVANT as compared to patients with the TT genotype. However, this is contradicted in one study. Other genetic and clinical factors may also influence a patient's response to chemotherapy regimens.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1445737062>1791</a></td><td>NOS3</td><td>rs1799983</td><td>cyclophosphamide</td><td>Neoplasms;Ovarian Neoplasms;Stomach Neoplasms</td><td>3</td><td>GG</td><td>Efficacy</td><td>Patients with the GG genotype and breast cancer, stomach cancer, or other cancer may have an improved response (increased disease free survival or overall survival) when treated with a chemotherapy regimen that includes anthracyclines and related substances, platinum compounds, nucleoside inhibitors or folate analog metabolite inhibitors IF CYCLOPHOSPHAMIDE IS GIVEN AS AN ADJUVANT as compared to patients with the TT genotype. However, this is contradicted in one study. Other genetic and clinical factors may also influence a patient's response to chemotherapy regimens.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1445737062>1792</a></td><td>NOS3</td><td>rs1799983</td><td>doxorubicin</td><td>Neoplasms;Ovarian Neoplasms;Stomach Neoplasms</td><td>3</td><td>GG</td><td>Efficacy</td><td>Patients with the GG genotype and breast cancer, stomach cancer, or other cancer may have an improved response (increased disease free survival or overall survival) when treated with a chemotherapy regimen that includes anthracyclines and related substances, platinum compounds, nucleoside inhibitors or folate analog metabolite inhibitors IF CYCLOPHOSPHAMIDE IS GIVEN AS AN ADJUVANT as compared to patients with the TT genotype. However, this is contradicted in one study. Other genetic and clinical factors may also influence a patient's response to chemotherapy regimens.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1445737062>1793</a></td><td>NOS3</td><td>rs1799983</td><td>epirubicin</td><td>Neoplasms;Ovarian Neoplasms;Stomach Neoplasms</td><td>3</td><td>GG</td><td>Efficacy</td><td>Patients with the GG genotype and breast cancer, stomach cancer, or other cancer may have an improved response (increased disease free survival or overall survival) when treated with a chemotherapy regimen that includes anthracyclines and related substances, platinum compounds, nucleoside inhibitors or folate analog metabolite inhibitors IF CYCLOPHOSPHAMIDE IS GIVEN AS AN ADJUVANT as compared to patients with the TT genotype. However, this is contradicted in one study. Other genetic and clinical factors may also influence a patient's response to chemotherapy regimens.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1445737062>1794</a></td><td>NOS3</td><td>rs1799983</td><td>fluorouracil</td><td>Neoplasms;Ovarian Neoplasms;Stomach Neoplasms</td><td>3</td><td>GG</td><td>Efficacy</td><td>Patients with the GG genotype and breast cancer, stomach cancer, or other cancer may have an improved response (increased disease free survival or overall survival) when treated with a chemotherapy regimen that includes anthracyclines and related substances, platinum compounds, nucleoside inhibitors or folate analog metabolite inhibitors IF CYCLOPHOSPHAMIDE IS GIVEN AS AN ADJUVANT as compared to patients with the TT genotype. However, this is contradicted in one study. Other genetic and clinical factors may also influence a patient's response to chemotherapy regimens.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1445737062>1795</a></td><td>NOS3</td><td>rs1799983</td><td>methotrexate</td><td>Neoplasms;Ovarian Neoplasms;Stomach Neoplasms</td><td>3</td><td>GG</td><td>Efficacy</td><td>Patients with the GG genotype and breast cancer, stomach cancer, or other cancer may have an improved response (increased disease free survival or overall survival) when treated with a chemotherapy regimen that includes anthracyclines and related substances, platinum compounds, nucleoside inhibitors or folate analog metabolite inhibitors IF CYCLOPHOSPHAMIDE IS GIVEN AS AN ADJUVANT as compared to patients with the TT genotype. However, this is contradicted in one study. Other genetic and clinical factors may also influence a patient's response to chemotherapy regimens.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1445737062>1796</a></td><td>NOS3</td><td>rs1799983</td><td>oxaliplatin</td><td>Neoplasms;Ovarian Neoplasms;Stomach Neoplasms</td><td>3</td><td>GG</td><td>Efficacy</td><td>Patients with the GG genotype and breast cancer, stomach cancer, or other cancer may have an improved response (increased disease free survival or overall survival) when treated with a chemotherapy regimen that includes anthracyclines and related substances, platinum compounds, nucleoside inhibitors or folate analog metabolite inhibitors IF CYCLOPHOSPHAMIDE IS GIVEN AS AN ADJUVANT as compared to patients with the TT genotype. However, this is contradicted in one study. Other genetic and clinical factors may also influence a patient's response to chemotherapy regimens.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1445737062>1797</a></td><td>NOS3</td><td>rs1799983</td><td>Platinum compounds</td><td>Neoplasms;Ovarian Neoplasms;Stomach Neoplasms</td><td>3</td><td>GG</td><td>Efficacy</td><td>Patients with the GG genotype and breast cancer, stomach cancer, or other cancer may have an improved response (increased disease free survival or overall survival) when treated with a chemotherapy regimen that includes anthracyclines and related substances, platinum compounds, nucleoside inhibitors or folate analog metabolite inhibitors IF CYCLOPHOSPHAMIDE IS GIVEN AS AN ADJUVANT as compared to patients with the TT genotype. However, this is contradicted in one study. Other genetic and clinical factors may also influence a patient's response to chemotherapy regimens.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444930850>1798</a></td><td>IFNL3</td><td>rs12979860</td><td>peginterferon alfa-2a</td><td>Hepatitis C, Chronic</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with CT genotype may have decreased response to simeprevir and peginterferon alfa-2a, peginterferon alfa-2b, ribavirin therapy in people with Hepatitis C, Chronic as compared to patients with genotype CC. However, RVR and SVR rates were higher in simeprevir treatment group than placebo for all genotypes suggesting the role of IFNL3 genotype is modest for simeprevir therapy as compare to PEG-IFN/RBV therapy. Other genetic and clinical factors may also influence the response to simeprevir based therapy.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444930850>1799</a></td><td>IFNL4</td><td>rs12979860</td><td>peginterferon alfa-2a</td><td>Hepatitis C, Chronic</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with CT genotype may have decreased response to simeprevir and peginterferon alfa-2a, peginterferon alfa-2b, ribavirin therapy in people with Hepatitis C, Chronic as compared to patients with genotype CC. However, RVR and SVR rates were higher in simeprevir treatment group than placebo for all genotypes suggesting the role of IFNL3 genotype is modest for simeprevir therapy as compare to PEG-IFN/RBV therapy. Other genetic and clinical factors may also influence the response to simeprevir based therapy.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444930850>1800</a></td><td>IFNL3</td><td>rs12979860</td><td>peginterferon alfa-2b</td><td>Hepatitis C, Chronic</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with CT genotype may have decreased response to simeprevir and peginterferon alfa-2a, peginterferon alfa-2b, ribavirin therapy in people with Hepatitis C, Chronic as compared to patients with genotype CC. However, RVR and SVR rates were higher in simeprevir treatment group than placebo for all genotypes suggesting the role of IFNL3 genotype is modest for simeprevir therapy as compare to PEG-IFN/RBV therapy. Other genetic and clinical factors may also influence the response to simeprevir based therapy.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444930850>1801</a></td><td>IFNL4</td><td>rs12979860</td><td>peginterferon alfa-2b</td><td>Hepatitis C, Chronic</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with CT genotype may have decreased response to simeprevir and peginterferon alfa-2a, peginterferon alfa-2b, ribavirin therapy in people with Hepatitis C, Chronic as compared to patients with genotype CC. However, RVR and SVR rates were higher in simeprevir treatment group than placebo for all genotypes suggesting the role of IFNL3 genotype is modest for simeprevir therapy as compare to PEG-IFN/RBV therapy. Other genetic and clinical factors may also influence the response to simeprevir based therapy.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444930850>1802</a></td><td>IFNL3</td><td>rs12979860</td><td>ribavirin</td><td>Hepatitis C, Chronic</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with CT genotype may have decreased response to simeprevir and peginterferon alfa-2a, peginterferon alfa-2b, ribavirin therapy in people with Hepatitis C, Chronic as compared to patients with genotype CC. However, RVR and SVR rates were higher in simeprevir treatment group than placebo for all genotypes suggesting the role of IFNL3 genotype is modest for simeprevir therapy as compare to PEG-IFN/RBV therapy. Other genetic and clinical factors may also influence the response to simeprevir based therapy.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444930850>1803</a></td><td>IFNL4</td><td>rs12979860</td><td>ribavirin</td><td>Hepatitis C, Chronic</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with CT genotype may have decreased response to simeprevir and peginterferon alfa-2a, peginterferon alfa-2b, ribavirin therapy in people with Hepatitis C, Chronic as compared to patients with genotype CC. However, RVR and SVR rates were higher in simeprevir treatment group than placebo for all genotypes suggesting the role of IFNL3 genotype is modest for simeprevir therapy as compare to PEG-IFN/RBV therapy. Other genetic and clinical factors may also influence the response to simeprevir based therapy.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444930850>1804</a></td><td>IFNL3</td><td>rs12979860</td><td>simeprevir</td><td>Hepatitis C, Chronic</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with CT genotype may have decreased response to simeprevir and peginterferon alfa-2a, peginterferon alfa-2b, ribavirin therapy in people with Hepatitis C, Chronic as compared to patients with genotype CC. However, RVR and SVR rates were higher in simeprevir treatment group than placebo for all genotypes suggesting the role of IFNL3 genotype is modest for simeprevir therapy as compare to PEG-IFN/RBV therapy. Other genetic and clinical factors may also influence the response to simeprevir based therapy.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444930850>1805</a></td><td>IFNL4</td><td>rs12979860</td><td>simeprevir</td><td>Hepatitis C, Chronic</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with CT genotype may have decreased response to simeprevir and peginterferon alfa-2a, peginterferon alfa-2b, ribavirin therapy in people with Hepatitis C, Chronic as compared to patients with genotype CC. However, RVR and SVR rates were higher in simeprevir treatment group than placebo for all genotypes suggesting the role of IFNL3 genotype is modest for simeprevir therapy as compare to PEG-IFN/RBV therapy. Other genetic and clinical factors may also influence the response to simeprevir based therapy.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1445401179>1806</a></td><td>VEGFA</td><td>rs1570360</td><td>cyclophosphamide</td><td>Prostatic Neoplasms</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype and prostate cancer may have longer progression-free survival time when treated with docetaxel plus oral metronomic cyclophosphamide as compared to patients with the AA genotype. Other genetic and clinical factors may also influence progression-free survival time.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1445401179>1807</a></td><td>VEGFA</td><td>rs1570360</td><td>docetaxel</td><td>Prostatic Neoplasms</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype and prostate cancer may have longer progression-free survival time when treated with docetaxel plus oral metronomic cyclophosphamide as compared to patients with the AA genotype. Other genetic and clinical factors may also influence progression-free survival time.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1445722592>1808</a></td><td>PON1</td><td>rs662</td><td>epirubicin</td><td>Neoplasms;Stomach Neoplasms</td><td>3</td><td>CC</td><td>Efficacy</td><td>Patients with the CC genotype and cancer, including cancer of the stomach, may have an increased response when treated with epirubicin, fluorouracil, and oxaliplatin as compared to patients with the CT and TT genotypes. Other genetic and clinical factors may also influence response to epirubicin, fluorouracil, and oxaliplatin in patients with cancer.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1445722592>1809</a></td><td>PON1</td><td>rs662</td><td>fluorouracil</td><td>Neoplasms;Stomach Neoplasms</td><td>3</td><td>CC</td><td>Efficacy</td><td>Patients with the CC genotype and cancer, including cancer of the stomach, may have an increased response when treated with epirubicin, fluorouracil, and oxaliplatin as compared to patients with the CT and TT genotypes. Other genetic and clinical factors may also influence response to epirubicin, fluorouracil, and oxaliplatin in patients with cancer.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1445722592>1810</a></td><td>PON1</td><td>rs662</td><td>oxaliplatin</td><td>Neoplasms;Stomach Neoplasms</td><td>3</td><td>CC</td><td>Efficacy</td><td>Patients with the CC genotype and cancer, including cancer of the stomach, may have an increased response when treated with epirubicin, fluorouracil, and oxaliplatin as compared to patients with the CT and TT genotypes. Other genetic and clinical factors may also influence response to epirubicin, fluorouracil, and oxaliplatin in patients with cancer.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450375752>1811</a></td><td>ABCG2</td><td>rs10011796</td><td>allopurinol</td><td></td><td>4</td><td>CC</td><td>Efficacy</td><td>Patients with the CC genotype may have an increased response to allopurinol as compared to patients with the CT or TT genotypes. However, another study found no association. Other genetic and clinical factors may also affect a patient's response to allopurinol.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444700382>1812</a></td><td>FKBP5</td><td>rs1360780</td><td>clozapine</td><td>Schizophrenia</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype and Schizophrenia who are treated with clozapine may have an increased response to clozapine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to clozapine.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444700605>1813</a></td><td>ALOX12</td><td>rs11078659</td><td>celecoxib</td><td>Colorectal Neoplasms</td><td>3</td><td>AA</td><td>Efficacy</td><td>Patients with the AA genotype with colorectal neoplasms who are treated with celecoxib may have an increased risk of adenoma recurrence as compared to patients with the GG genotype. Other genetic and clinical factors may also effect patients' risk for adenoma recurrence.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444701024>1814</a></td><td>NOS3</td><td>rs2070744</td><td>sildenafil</td><td>Erectile Dysfunction</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype may have increased response to sildenafil in men with post-operative Erectile Dysfunction as compared to patients with genotype TT. Other genetic or clinical factors may also influence the response to sildenafil.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1445400945>1815</a></td><td>NOS3</td><td>rs1799983</td><td>salvianolic acid b</td><td>Coronary Disease</td><td>3</td><td>GG</td><td>Efficacy</td><td>Patients with the GG genotype and coronary heart disease may have a better response to treatment with salvianolate as compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence response to salvianolate.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444703869>1816</a></td><td>SLCO1B1</td><td>rs4149081</td><td>simvastatin</td><td>Coronary Disease</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype and Coronary Disease who are treated with simvastatin may have higher LDL-C reduction as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to simvastatin.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444703578>1817</a></td><td>-</td><td>rs2650972</td><td>methotrexate</td><td>Arthritis, Rheumatoid</td><td>4</td><td>CC</td><td>Efficacy</td><td>Patients with the CC genotype and Rheumatoid Arthritis who are treated with methotrexate may have a better response to treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate treatment.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1446902920>1818</a></td><td>-</td><td>rs10739150</td><td>atenolol</td><td>Hypertension</td><td>3</td><td>GG</td><td>Efficacy</td><td>Patients with the GG genotype may have increased response to atenolol in hypertensive patients as compared to patients with genotype TT. Other genetic and clinical factors may also influence the response to atenolol.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1446902927>1819</a></td><td>PTPRD</td><td>rs4742610</td><td>trandolapril</td><td>Hypertension</td><td>3</td><td>TC</td><td>Efficacy</td><td>Patients with the TC genotype may have higher risk for resistant hypertension in whites and Hispanics patients treated with verapamil and trandolapril as compared to patients with genotype CC. Other genetic and clinical factors may also influence the response to verapamil.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1446902927>1820</a></td><td>PTPRD</td><td>rs4742610</td><td>verapamil</td><td>Hypertension</td><td>3</td><td>TC</td><td>Efficacy</td><td>Patients with the TC genotype may have higher risk for resistant hypertension in whites and Hispanics patients treated with verapamil and trandolapril as compared to patients with genotype CC. Other genetic and clinical factors may also influence the response to verapamil.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451493693>1821</a></td><td>AGTR1</td><td>rs5186</td><td>irbesartan</td><td>Hypertension;Hypertrophy, Left Ventricular</td><td>3</td><td>AC</td><td>Efficacy</td><td>Patients with the rs5186 AC genotype may have an increased response to irbesartan as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to irbesartan.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1445400873>1822</a></td><td>NOS3</td><td>rs1799983</td><td>daunorubicin</td><td>Leukemia, Myeloid, Acute</td><td>3</td><td>GG</td><td>Efficacy</td><td>Patients with acute myeloid leukemia and the GG genotype may have increased survival time when treated with daunorubicin as compared to patients with the GT or TT genotype. Other genetic and clinical factors may also influence response to daunorubicin.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1446897540>1823</a></td><td>TNFSF11</td><td>rs7984870</td><td>anastrozole</td><td>Breast Neoplasms</td><td>3</td><td>CC</td><td>Efficacy</td><td>Patients with breast cancer and the CC genotype may have an increased likelihood of Aromatase inhibitor-associated musculoskeletal syndrome, metabolic bone diseases, and osteoporosis when treated with anastrozole or letrozole as compared to patients with the CG and GG genotypes.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1446897540>1824</a></td><td>TNFSF11</td><td>rs7984870</td><td>letrozole</td><td>Breast Neoplasms</td><td>3</td><td>CC</td><td>Efficacy</td><td>Patients with breast cancer and the CC genotype may have an increased likelihood of Aromatase inhibitor-associated musculoskeletal syndrome, metabolic bone diseases, and osteoporosis when treated with anastrozole or letrozole as compared to patients with the CG and GG genotypes.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1446897710>1825</a></td><td>ABCB1</td><td>rs2032582</td><td>sunitinib</td><td>Carcinoma, Renal Cell</td><td>3</td><td>AC</td><td>Efficacy</td><td>Patients with renal cell carcinoma and the AC genotype may have an increased overall survival as compared to the AA or AT genotypes. Other clinical and genetic factors may also influence response to sunitinib in patients with renal cell carcinoma.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444704936>1826</a></td><td>GPR83</td><td>rs3758785</td><td>candesartan</td><td>Essential hypertension</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype may have increased response to candesartan in people with essential hypertension as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to candesartan.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444843402>1827</a></td><td>ABCC1</td><td>rs3784864</td><td>methotrexate</td><td>Arthritis, Rheumatoid</td><td>3</td><td>AA</td><td>Efficacy</td><td>Patients with the AA genotype may have increased response to methotrexate in people with Arthritis, Rheumatoid as compared to genotype GG or AG. Other genetic and clinical factors may also influence the response to methotrexate.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444668444>1828</a></td><td>LPA</td><td>rs10455872</td><td>hmg coa reductase inhibitors</td><td>Coronary Artery Disease</td><td>3</td><td>AA</td><td>Efficacy</td><td>Patients with the rs10455872 AA genotype may have an improved response to statins as compared to patients with the AG and GG genotypes. Other clinical and genetic factors may also influence response to statins.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444703936>1829</a></td><td>NT5C3A</td><td>rs3750117</td><td>cytarabine</td><td>Leukemia, Myeloid, Acute</td><td>3</td><td>GG</td><td>Efficacy</td><td>Patients with the GG genotype and Leukemia who are treated with cytarabine and idarubicin may have increased risk for induction failure as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine and idarubicin.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444703936>1830</a></td><td>NT5C3A</td><td>rs3750117</td><td>idarubicin</td><td>Leukemia, Myeloid, Acute</td><td>3</td><td>GG</td><td>Efficacy</td><td>Patients with the GG genotype and Leukemia who are treated with cytarabine and idarubicin may have increased risk for induction failure as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine and idarubicin.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444703702>1831</a></td><td>HTR2A</td><td>rs6313</td><td>fluvoxamine</td><td>Depressive Disorder, Major</td><td>4</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype who are treated with fluvoxamine or paroxetine may have a slower score reduction for the in Somatic anxiety item of HAM-D as compared to patients with the AA genotype or may have a faster score reduction for the in Somatic anxiety item of HAM-D as compared to patients with the GG genotype. However, no association regarding response was found with the overall HAM-D score. Other genetic and clinical factors may also influence a patient's response to fluvoxamine or paroxetine.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444703702>1832</a></td><td>HTR2A</td><td>rs6313</td><td>paroxetine</td><td>Depressive Disorder, Major</td><td>4</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype who are treated with fluvoxamine or paroxetine may have a slower score reduction for the in Somatic anxiety item of HAM-D as compared to patients with the AA genotype or may have a faster score reduction for the in Somatic anxiety item of HAM-D as compared to patients with the GG genotype. However, no association regarding response was found with the overall HAM-D score. Other genetic and clinical factors may also influence a patient's response to fluvoxamine or paroxetine.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444703739>1833</a></td><td>HTR2A</td><td>rs6313</td><td>fluvoxamine</td><td>Depressive Disorder, Major</td><td>4</td><td>AG</td><td>Efficacy</td><td>Patients with the GG genotype who are treated with fluvoxamine or paroxetine may have a faster score reduction for the in Delusion and Activity scores item of HAM-D as compared to patients with the AA genotype or may have a slower score reduction for the in Delusion and Activity scores item of HAM-D as compared to patients with the GG genotype. However, no association regarding response was found with the overall HAM-D score. Other genetic and clinical factors may also influence a patient's response to fluvoxamine or paroxetine.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444703739>1834</a></td><td>HTR2A</td><td>rs6313</td><td>paroxetine</td><td>Depressive Disorder, Major</td><td>4</td><td>AG</td><td>Efficacy</td><td>Patients with the GG genotype who are treated with fluvoxamine or paroxetine may have a faster score reduction for the in Delusion and Activity scores item of HAM-D as compared to patients with the AA genotype or may have a slower score reduction for the in Delusion and Activity scores item of HAM-D as compared to patients with the GG genotype. However, no association regarding response was found with the overall HAM-D score. Other genetic and clinical factors may also influence a patient's response to fluvoxamine or paroxetine.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1446906412>1835</a></td><td>TANC2</td><td>rs2429427</td><td>calcium channel blockers</td><td>Hypertension</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with genotype AG may have increased response to calcium channel blockers in people with Hypertension as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to calcium channel blockers.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444666601>1836</a></td><td>XPA</td><td>rs1800975</td><td>Platinum compounds</td><td>Carcinoma, Non-Small-Cell Lung</td><td>3</td><td>CC</td><td>Efficacy</td><td>Patients with the CC genotype and non-small-cell lung cancer may have a better response to treatment with platinum-based chemotherapy as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence response to platinum-based chemotherapy.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444666608>1837</a></td><td>ERCC4</td><td>rs1799801</td><td>Platinum compounds</td><td>Carcinoma, Non-Small-Cell Lung</td><td>3</td><td>CC</td><td>Efficacy</td><td>Patients with the CC genotype and non-small-cell lung cancer may have a better response to treatment with platinum-based chemotherapy as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to platinum-based chemotherapy.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444673184>1838</a></td><td>VEGFA</td><td>rs35864111</td><td>docetaxel</td><td>Breast Neoplasms</td><td>3</td><td>GG</td><td>Efficacy</td><td>Patients with the GG genotype and breast cancer may have a longer progression-free survival time when treated with docetaxel as compared to patients with the del/del genotype. Other genetic and clinical factors may also influence progression-free survival time.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1446906350>1839</a></td><td>FSHR</td><td>rs6166</td><td>follitropin beta</td><td>Infertility, Female;Ovarian hyperstimulation syndrome</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype may have good response to controlled ovarian hyperstimulation when treated with follitropin beta, thyrotropin alfa and urofollitropin as compared to patients with genotype CC. Other genetic and clinical factors may also influence the response to controlled ovarian hyperstimulation.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1446906350>1840</a></td><td>FSHR</td><td>rs6166</td><td>thyrotropin alfa</td><td>Infertility, Female;Ovarian hyperstimulation syndrome</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype may have good response to controlled ovarian hyperstimulation when treated with follitropin beta, thyrotropin alfa and urofollitropin as compared to patients with genotype CC. Other genetic and clinical factors may also influence the response to controlled ovarian hyperstimulation.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1446906350>1841</a></td><td>FSHR</td><td>rs6166</td><td>urofollitropin</td><td>Infertility, Female;Ovarian hyperstimulation syndrome</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype may have good response to controlled ovarian hyperstimulation when treated with follitropin beta, thyrotropin alfa and urofollitropin as compared to patients with genotype CC. Other genetic and clinical factors may also influence the response to controlled ovarian hyperstimulation.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444706209>1842</a></td><td>SLCO1B1</td><td>rs4149036</td><td>atorvastatin</td><td></td><td>3</td><td>AC</td><td>Efficacy</td><td>Patients with the AC genotype may have increased response to atorvastatin as compared to patients with the AA genotype. Other genetic and clinical factors may influence also a patient's atorvastatin response.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444706830>1843</a></td><td>SLC1A1</td><td>rs3087879</td><td>Selective serotonin reuptake inhibitors</td><td>Obsessive-Compulsive Disorder</td><td>3</td><td>CC</td><td>Efficacy</td><td>Patients with the CC genotype and Obsessive-Compulsive Disorder may have increased severity of pharmacological resistance when treated with Selective serotonin reuptake inhibitors as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to Selective serotonin reuptake inhibitors.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444930908>1844</a></td><td>IFNL3</td><td>rs12979860</td><td>daclatasvir</td><td>Hepatitis C, Chronic</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with genotype CT may have decreased response to daclatasvir, peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to patients with the CC genotype. SVR24 rates are higher in patients treated with the combination of daclatasvir and pegIFN-alfa/RBV than those receiving pegIFN-alfa/RBV alone across all genotypes regardless of viral subtypes. Other genetic and clinical factors may also influence the response to daclatasvir therapy.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444930908>1845</a></td><td>IFNL4</td><td>rs12979860</td><td>daclatasvir</td><td>Hepatitis C, Chronic</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with genotype CT may have decreased response to daclatasvir, peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to patients with the CC genotype. SVR24 rates are higher in patients treated with the combination of daclatasvir and pegIFN-alfa/RBV than those receiving pegIFN-alfa/RBV alone across all genotypes regardless of viral subtypes. Other genetic and clinical factors may also influence the response to daclatasvir therapy.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444930908>1846</a></td><td>IFNL3</td><td>rs12979860</td><td>peginterferon alfa-2a</td><td>Hepatitis C, Chronic</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with genotype CT may have decreased response to daclatasvir, peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to patients with the CC genotype. SVR24 rates are higher in patients treated with the combination of daclatasvir and pegIFN-alfa/RBV than those receiving pegIFN-alfa/RBV alone across all genotypes regardless of viral subtypes. Other genetic and clinical factors may also influence the response to daclatasvir therapy.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444930908>1847</a></td><td>IFNL4</td><td>rs12979860</td><td>peginterferon alfa-2a</td><td>Hepatitis C, Chronic</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with genotype CT may have decreased response to daclatasvir, peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to patients with the CC genotype. SVR24 rates are higher in patients treated with the combination of daclatasvir and pegIFN-alfa/RBV than those receiving pegIFN-alfa/RBV alone across all genotypes regardless of viral subtypes. Other genetic and clinical factors may also influence the response to daclatasvir therapy.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444930908>1848</a></td><td>IFNL3</td><td>rs12979860</td><td>peginterferon alfa-2b</td><td>Hepatitis C, Chronic</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with genotype CT may have decreased response to daclatasvir, peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to patients with the CC genotype. SVR24 rates are higher in patients treated with the combination of daclatasvir and pegIFN-alfa/RBV than those receiving pegIFN-alfa/RBV alone across all genotypes regardless of viral subtypes. Other genetic and clinical factors may also influence the response to daclatasvir therapy.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444930908>1849</a></td><td>IFNL4</td><td>rs12979860</td><td>peginterferon alfa-2b</td><td>Hepatitis C, Chronic</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with genotype CT may have decreased response to daclatasvir, peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to patients with the CC genotype. SVR24 rates are higher in patients treated with the combination of daclatasvir and pegIFN-alfa/RBV than those receiving pegIFN-alfa/RBV alone across all genotypes regardless of viral subtypes. Other genetic and clinical factors may also influence the response to daclatasvir therapy.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444930908>1850</a></td><td>IFNL3</td><td>rs12979860</td><td>ribavirin</td><td>Hepatitis C, Chronic</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with genotype CT may have decreased response to daclatasvir, peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to patients with the CC genotype. SVR24 rates are higher in patients treated with the combination of daclatasvir and pegIFN-alfa/RBV than those receiving pegIFN-alfa/RBV alone across all genotypes regardless of viral subtypes. Other genetic and clinical factors may also influence the response to daclatasvir therapy.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444930908>1851</a></td><td>IFNL4</td><td>rs12979860</td><td>ribavirin</td><td>Hepatitis C, Chronic</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with genotype CT may have decreased response to daclatasvir, peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to patients with the CC genotype. SVR24 rates are higher in patients treated with the combination of daclatasvir and pegIFN-alfa/RBV than those receiving pegIFN-alfa/RBV alone across all genotypes regardless of viral subtypes. Other genetic and clinical factors may also influence the response to daclatasvir therapy.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1445401260>1852</a></td><td>SLCO1B1</td><td>rs2306283</td><td>rocuronium</td><td></td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype who are placed under anesthesia may have an increased response to rocuronium as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to rocuronium.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447813720>1853</a></td><td>-</td><td>rs75222709</td><td>lithium</td><td>Bipolar Disorder</td><td>3</td><td>TT</td><td>Efficacy</td><td>Individuals with the TT genotype and bipolar disorder may have improved response to lithium as compared to individuals with the GT or GG genotype. Other clinical and genetic factors may also influence response to lithium in individuals with bipolar disorder.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447813969>1854</a></td><td>MTHFR</td><td>rs1801133</td><td>fluorouracil</td><td>Colonic Neoplasms</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with genotype AG and colorectal neoplasms may have an increased response to fluorouracil, leucovorin and oxaliplatin (FOLFOX therapy) as compared to patients with the GG genotype. However, conflicting evidence exists.Other genetic and clinical factors may also influence a patient's response to FOLFOX therapy.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447813969>1855</a></td><td>MTHFR</td><td>rs1801133</td><td>leucovorin</td><td>Colonic Neoplasms</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with genotype AG and colorectal neoplasms may have an increased response to fluorouracil, leucovorin and oxaliplatin (FOLFOX therapy) as compared to patients with the GG genotype. However, conflicting evidence exists.Other genetic and clinical factors may also influence a patient's response to FOLFOX therapy.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447813969>1856</a></td><td>MTHFR</td><td>rs1801133</td><td>oxaliplatin</td><td>Colonic Neoplasms</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with genotype AG and colorectal neoplasms may have an increased response to fluorouracil, leucovorin and oxaliplatin (FOLFOX therapy) as compared to patients with the GG genotype. However, conflicting evidence exists.Other genetic and clinical factors may also influence a patient's response to FOLFOX therapy.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444607611>1857</a></td><td>CYP2D6</td><td>rs1065852</td><td>escitalopram</td><td>Depressive Disorder, Major</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype and depression may have an increased response and remission rate when treated with escitalopram as compared to patients with the AA genotype. This drug-variant pair has been assigned a no recommendation by DPWG, as it was determined to be not clinically actionable. Other genetic and clinical factors may also effect patients response.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444686868>1858</a></td><td>KDR</td><td>rs34231037</td><td>pazopanib</td><td>Kidney Neoplasms</td><td>3</td><td>AA</td><td>Efficacy</td><td>Patients with the AA genotype and Kidney Neoplasms may have increased steady state levels of KDR, possibly leading to increased metabolism of and decreased response to pazopanib as compared to patients with the AG or GG genotypes. Other clinical and genetic factors may also influence metabolism and response to pazopanib.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447814385>1859</a></td><td>ADCY9</td><td>rs1967309</td><td>dalcetrapib</td><td>Acute coronary syndrome</td><td>3</td><td>GG</td><td>Efficacy</td><td>Patients with the GG genotype may have increased risk of major adverse cardiac events (MACE) and decreased cholesterol efflux response when treated with delcetrapib in people with acute coronary syndrome as compared to patients with the AA and AG genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity. These results are from a stratified analysis of a trial that found patients taking dalcetrapib at increased risk for MACE compared to patients on placebo.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447943760>1860</a></td><td>NRG1</td><td>rs13250975</td><td>antipsychotics</td><td>Schizophrenia</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with AG genotype and schizophrenia may have increased response to antipsychotics compared to patients with the AA genotype. Other clinical and genetic factors may affect response to antipsychotics.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447943772>1861</a></td><td>ZMAT4</td><td>rs1367094</td><td>atenolol</td><td>Hypertension</td><td>3</td><td>TT</td><td>Efficacy</td><td>Patients with genotype TT and hypertension have increased response to atenolol compared to patients with the CC or CT genotypes. Other clinical and genetic factors may affect patient response to atenolol.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1445594498>1862</a></td><td>-</td><td>rs9285669</td><td>hydrochlorothiazide</td><td>Essential hypertension</td><td>3</td><td>TT</td><td>Efficacy</td><td>Patients with the TT genotype and essential hypertension may have an increased response when treated with hydrochlorothiazide as compared to patients with the AT and AA genotypes. Other genetic and clinical factors may also influence response to hydrochlorothiazide in patients with essential hypertension.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1445594505>1863</a></td><td>CSMD1</td><td>rs11993031</td><td>hydrochlorothiazide</td><td>Essential hypertension</td><td>3</td><td>AA</td><td>Efficacy</td><td>Patients with the AA genotype and essential hypertension may have an increased response when treated with hydrochlorothiazide as compared to patients with the AT and TT genotypes. Other genetic and clinical factors may also influence response to hydrochlorothiazide in patients with essential hypertension.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444686789>1864</a></td><td>CYP2B6</td><td>rs3745274</td><td>imatinib</td><td>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</td><td>3</td><td>GT</td><td>Efficacy</td><td>Patients with the GT genotype and chronic myeloid leukemia may have a 1) a better response to treatment with imatinib as compared to patients with the TT genotype, 2) a decreased risk of developing cytogenetic resistance to imatinib as compared to patients with the GG or TT genotype, and 3) a decreased risk for side effects as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response, resistance and risk of side effects in patients taking imatinib.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447945887>1865</a></td><td>FCGR3A</td><td>rs396991</td><td>infliximab</td><td>Arthritis, Rheumatoid</td><td>3</td><td>AC</td><td>Efficacy</td><td>Patients with the AC genotype and rheumatoid arthritis may have a better response when treated with infliximab as compared to patients with the CC genotype, or a poorer response as compared to patients with the AA genotype. However, contradictory evidence exists for this association. Other genetic and clinical factors may also influence a patient's response to infliximab.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447945958>1866</a></td><td>ATP2B1</td><td>rs12817819</td><td>Antihypertensives</td><td>Coronary Artery Disease;Hypertension</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype who are treated with antihypertensives may have an increased risk for resistant hypertension as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for resistant hypertension.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447945967>1867</a></td><td>GRM3</td><td>rs6465084</td><td>antipsychotics</td><td>Schizophrenia</td><td>3</td><td>GG</td><td>Efficacy</td><td>Patients with the GG genotype and schizophrenia who are treated with antipsychotics may have a poorer response according to the Brief Psychiatric Rating Scale (BPRS) negative symptoms subscale, as compared to patients with the AA genotype. However, a different study found that the GG genotype was associated with better response according to the clinical global impressions (CGI) score, though this association did not withstand correction for multiple testing. Other genetic and clinical factors may also influence a patient's response to antipsychotic treatment.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447945999>1868</a></td><td>HMGCR</td><td>rs17671591</td><td>atorvastatin</td><td>Hypercholesterolemia</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype and hypercholesterolemia who are treated with atorvastatin may have an increased drop in LDL-C levels and rise in HDL-C levels as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451648980>1869</a></td><td>ADH1C</td><td>rs698</td><td>naltrexone</td><td>Alcoholism</td><td>3</td><td>CC</td><td>Efficacy</td><td>Patients with alcoholism and the rs698 CC genotype may have an increased response to naltrexone as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to naltrexone.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444686893>1870</a></td><td>CHRNA7</td><td>rs6494223</td><td>donepezil</td><td>Alzheimer Disease</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype and Alzheimer's disease may be less likely to respond to treatment with cholinesterase inhibitors as compared to patients with the TT genotype, or more likely to respond as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to cholinesterase inhibitors.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444686893>1871</a></td><td>CHRNA7</td><td>rs6494223</td><td>galantamine</td><td>Alzheimer Disease</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype and Alzheimer's disease may be less likely to respond to treatment with cholinesterase inhibitors as compared to patients with the TT genotype, or more likely to respond as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to cholinesterase inhibitors.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444686893>1872</a></td><td>CHRNA7</td><td>rs6494223</td><td>rivastigmine</td><td>Alzheimer Disease</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype and Alzheimer's disease may be less likely to respond to treatment with cholinesterase inhibitors as compared to patients with the TT genotype, or more likely to respond as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to cholinesterase inhibitors.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447943753>1873</a></td><td>ABCB1</td><td>rs1128503</td><td>modafinil</td><td>Narcolepsy</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with AG genotype and narcolepsy may have increased response to modafinil compared to patients with AA or GG genotype. Other clinical and genetic factors may affect response to modafinil.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447944755>1874</a></td><td>DRD2</td><td>rs1079597</td><td>amisulpride</td><td>Schizophrenia</td><td>3</td><td>CC</td><td>Efficacy</td><td>Patients with the CC genotype and schizophrenia may have an increased response according to the PANSS negative symptoms scale when treated with amisulpride, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to amisulpride.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444686796>1875</a></td><td>HDAC1</td><td>rs1741981</td><td>corticosteroids</td><td>Asthma</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype and asthma may have a better response when treated with corticosteroids, either systemic or inhaled, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to corticosteroids in asthmatics.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444704392>1876</a></td><td>OPRD1</td><td>rs4654327</td><td>naltrexone</td><td>Alcoholism</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype and Alcoholism may have increased naltrexone-induced blunting of alcohol stimulation and alcohol craving when treated with naltrexone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to naltrexone.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444686907>1877</a></td><td>CYP3A4</td><td>rs4646437</td><td>cyclosporine</td><td>Kidney Transplantation</td><td>3</td><td>GG</td><td>Efficacy</td><td>Patients with the GG genotype who are undergoing kidney transplantation may have higher dose-adjusted trough concentrations of cyclosporine, and have a lower likelihood of experiencing biopsy-proven acute rejection, as compared to patients with the AA genotype. Other genetic and clinical factors may also influence concentrations of and response to cyclosporine.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444686921>1878</a></td><td>IL1B</td><td>rs4848306</td><td>Tumor necrosis factor alpha (TNF-alpha) inhibitors</td><td>Colitis, Ulcerative;Inflammatory Bowel Diseases</td><td>3</td><td>AA</td><td>Efficacy</td><td>Patients with the AA genotype and inflammatory bowel disease, or specifically Crohn's disease, may have a better response to anti-TNF therapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444687046>1879</a></td><td>IFNG</td><td>rs2430561</td><td>Tumor necrosis factor alpha (TNF-alpha) inhibitors</td><td>Crohn Disease;Inflammatory Bowel Diseases</td><td>3</td><td>AT</td><td>Efficacy</td><td>Patients with the AT genotype and inflammatory bowel disease, or specifically Crohn's disease, may have a better response to anti-TNF therapy as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444686935>1880</a></td><td>TLR9</td><td>rs352139</td><td>Tumor necrosis factor alpha (TNF-alpha) inhibitors</td><td>Crohn Disease;Inflammatory Bowel Diseases</td><td>3</td><td>CC</td><td>Efficacy</td><td>Patients with the CC genotype and inflammatory bowel disease, or specifically Crohn's disease, may have a better response to anti-TNF therapy as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448573300>1881</a></td><td>STX1B</td><td>rs4889606</td><td>warfarin</td><td></td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype may have increased dose of warfarin in African American patients as compared to patients with genotype AA. Other genetic and clinical factors may also influence the dose of warfarin.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448573615>1882</a></td><td>ABCB1</td><td>rs1128503</td><td>tacrolimus</td><td>Colitis, Ulcerative</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype and ulcerative colitis may have an increased response when treated with tacrolimus as compared to patients with the AA genotype. Other genetic and clinical factors may also influence tacrolimus response.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444607674>1883</a></td><td>HTR1A</td><td>rs6295</td><td>fluoxetine</td><td>Depressive Disorder, Major</td><td>3</td><td>CC</td><td>Efficacy</td><td>Patients with the CC genotype who are treated with fluoxetine may have an increased response as compared to patients with the GG or GC genotype. Other genetic and clinical factors may also influence a patient's response to fluoxetine.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444607851>1884</a></td><td>CXCL8</td><td>rs4073</td><td>bevacizumab</td><td>Macular Degeneration</td><td>3</td><td>AT</td><td>Efficacy</td><td>Patients with the AT genotype and age-related macular degeneration may have a better response when treated with bevacizumab as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to bevacizumab.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184986321>1885</a></td><td>BCL2L11</td><td>rs724710</td><td>imatinib</td><td>Neoplasms</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype and cancer may have a diminished response when treated with imatinib as compared to patients with the CC genotype and an improved response as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to imatinib.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444706810>1886</a></td><td>SLC1A1</td><td>rs301434</td><td>Selective serotonin reuptake inhibitors</td><td>Obsessive-Compulsive Disorder</td><td>3</td><td>TT</td><td>Efficacy</td><td>Patients with the TT genotype and Obsessive-Compulsive Disorder may have increased severity of pharmacological resistance when treated with Selective serotonin reuptake inhibitors as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to Selective serotonin reuptake inhibitors.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444706818>1887</a></td><td>SLC1A1</td><td>rs301435</td><td>Selective serotonin reuptake inhibitors</td><td>Obsessive-Compulsive Disorder</td><td>3</td><td>CC</td><td>Efficacy</td><td>Patients with the CC genotype and Obsessive-Compulsive Disorder may have increased severity of pharmacological resistance when treated with Selective serotonin reuptake inhibitors as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to Selective serotonin reuptake inhibitors.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1185000238>1888</a></td><td>CYP3A5</td><td>rs776746</td><td>tacrolimus</td><td>Colitis, Ulcerative</td><td>3</td><td>CC</td><td>Efficacy</td><td>Patients with the CC genotype (CYP3A5 *3/*3) and ulcerative colitis may have an increased chance of achieving remission when treated with tacrolimus as compared to patients with the CT (*1/*3) or TT (*1/*1) genotype. However, a couple studies have found no association with remission or response. Other genetic and clinical factors may also influence chance of remission from ulcerative colitis.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444607979>1889</a></td><td>RRM1</td><td>rs1042927</td><td>gemcitabine</td><td>Mesothelioma</td><td>3</td><td>AA</td><td>Efficacy</td><td>Patients with the AA genotype and Mesothelioma who are treated with gemcitabine and Platinum compounds may have an increased overall survival probability as compared to patients with the CC genotype. Other genetic and clinical factors may also influence patient's survival probability.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444607979>1890</a></td><td>RRM1</td><td>rs1042927</td><td>Platinum compounds</td><td>Mesothelioma</td><td>3</td><td>AA</td><td>Efficacy</td><td>Patients with the AA genotype and Mesothelioma who are treated with gemcitabine and Platinum compounds may have an increased overall survival probability as compared to patients with the CC genotype. Other genetic and clinical factors may also influence patient's survival probability.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444608491>1891</a></td><td>AREG</td><td>rs1353295</td><td>cetuximab</td><td>Colorectal Neoplasms</td><td>3</td><td>GG</td><td>Efficacy</td><td>Patients with the GG genotype and colorectal cancer may have a better response to anti-EGFR plus irinotecan treatment, as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence response to anti-EGFR plus irinotecan treatment.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444608491>1892</a></td><td>AREG</td><td>rs1353295</td><td>irinotecan</td><td>Colorectal Neoplasms</td><td>3</td><td>GG</td><td>Efficacy</td><td>Patients with the GG genotype and colorectal cancer may have a better response to anti-EGFR plus irinotecan treatment, as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence response to anti-EGFR plus irinotecan treatment.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444608491>1893</a></td><td>AREG</td><td>rs1353295</td><td>panitumumab</td><td>Colorectal Neoplasms</td><td>3</td><td>GG</td><td>Efficacy</td><td>Patients with the GG genotype and colorectal cancer may have a better response to anti-EGFR plus irinotecan treatment, as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence response to anti-EGFR plus irinotecan treatment.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444687025>1894</a></td><td>TLR4</td><td>rs5030728</td><td>Tumor necrosis factor alpha (TNF-alpha) inhibitors</td><td>Inflammatory Bowel Diseases</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype and inflammatory bowel diseases may have a better response to anti-TNF therapy as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to anti-TNF therapy.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1445556297>1895</a></td><td>CYP2B6</td><td>rs3211371</td><td>bupropion</td><td>Tobacco Use Disorder</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype who are smokers may have a better chance of smoking cessation when treated with bupropion as compared to patients with the CC genotype, although this is contradicted in one study. Other genetic and clinical factors may also influence likelihood of smoking cessation.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444666738>1896</a></td><td>NEDD4L</td><td>rs520210</td><td>citalopram</td><td>Depression</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype and depression may have a better response when treated with citalopram as compared to patients with the GG genotype, or a poorer response as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to citalopram.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444608377>1897</a></td><td>IL11</td><td>rs1126757</td><td>escitalopram</td><td>Depression</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype and depression may respond better to treatment with escitalopram, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to escitalopram.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444667902>1898</a></td><td>ADIPOQ</td><td>rs2241766</td><td>pioglitazone</td><td>Diabetes Mellitus</td><td>3</td><td>GT</td><td>Efficacy</td><td>Patients with the GT genotype and diabetes mellitus may have an increased response to pioglitazone as compared to patients with the TT genotype. Other clinical and genetic factors also influence response to pioglitazone in people with diabetes mellitus. *Please note: in the single study referenced here there were no individuals of genotype GG.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451683665>1899</a></td><td>SRD5A2</td><td>rs523349</td><td>abiraterone</td><td>Prostatic Neoplasms</td><td>3</td><td>CC</td><td>Efficacy</td><td>Patients with prostate cancer and the rs523349 CC genotype may have an increased response to abiraterone as compared to patients with the CG or GG genotypes. Other genetic and clinical factors may also influence response to abiraterone.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444607768>1900</a></td><td>HTR2A</td><td>rs6311</td><td>fluvoxamine</td><td>Depressive Disorder, Major</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype who are treated with fluvoxamine may have an increased risk of gastrointestinal side effects and decreased response as compared to patients with the TT genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to fluvoxamine.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444666763>1901</a></td><td>MTHFR</td><td>rs1801133</td><td>pemetrexed</td><td>Carcinoma, Non-Small-Cell Lung;Mesothelioma</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype and lung cancer may be associated with overall survival when treated with pemetrexed as compared to patients with the GG genotype. However, contradictory findings (better and poorer responses) have been reported. Other genetic and clinical factors may also influence overall survival.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444666796>1902</a></td><td>SLC19A1</td><td>rs1051298</td><td>pemetrexed</td><td>Carcinoma, Non-Small-Cell Lung;Mesothelioma</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype and lung cancer may have shorter overall and progression-free survival times when treated with pemetrexed as compared to patients with the GG genotype, and a longer overall survival time as compared to patients with the AA genotype. Other genetic and clinical factors may also influence survival time.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444666818>1903</a></td><td>SLC19A1</td><td>rs914232</td><td>pemetrexed</td><td>Carcinoma, Non-Small-Cell Lung;Mesothelioma</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype and lung cancer may have a longer overall survival time when treated with pemetrexed as compared to patients with the TT genotype. Other genetic and clinical factors may also influence overall survival time.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449003829>1904</a></td><td>ABCB1</td><td>rs1128503</td><td>clopidogrel</td><td></td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype who are taking clopidogrel may have increased resistance to clopidogrel as compared to patients with the GG genotype. Other genetic and clinical factors may also influence resistance to clopidogrel in patients.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449003869>1905</a></td><td>STAT4</td><td>rs7574865</td><td>etanercept</td><td>Arthritis, Rheumatoid</td><td>3</td><td>GG</td><td>Efficacy</td><td>Patients with the GG genotype may have an increased response to etanercept treatment in patients with rheumatoid arthritis as compared to patients with the GT or TT genotypes. Other genetic and clinical factors may also influence response to etanercept in patients.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444703537>1906</a></td><td>EIF2AK4</td><td>rs2412459</td><td>haloperidol</td><td>Schizophrenia</td><td>3</td><td>TT</td><td>Efficacy</td><td>Patients with the TT genotype and Schizophrenia may have increased response to haloperidol as compared to patients with the CT genotype. Other genetic and clinical factors may also influence a patient's response to haloperidol.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444704328>1907</a></td><td>TNFRSF1B</td><td>rs3397</td><td>Tumor necrosis factor alpha (TNF-alpha) inhibitors</td><td>Arthritis, Rheumatoid</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype and Rheumatoid Arthritis may have increased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to tumor necrosis factor alpha (TNF-alpha) inhibitors.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444607796>1908</a></td><td>SLC6A2</td><td>rs3785143</td><td>atomoxetine</td><td>Attention Deficit Disorder with Hyperactivity</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype and attention deficit hyperactivity disorder (ADHD) may have a better response to treatment with atomoxetine as compared to patients with the TT genotype or a poorer response to treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to atomoxetine.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444608027>1909</a></td><td>BDNF</td><td>rs7124442</td><td>citalopram</td><td>Depressive Disorder, Major</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype and major depressive disorder may have a better response when treated with citalopram as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to citalopram.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444608291>1910</a></td><td>CA10</td><td>rs967676</td><td>fluticasone propionate</td><td>Asthma</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype and asthma may have a better response to treatment with fluticasone propionate or montelukast, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to fluticasone propionate or montelukast.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444608291>1911</a></td><td>CA10</td><td>rs967676</td><td>montelukast</td><td>Asthma</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype and asthma may have a better response to treatment with fluticasone propionate or montelukast, as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to fluticasone propionate or montelukast.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444667222>1912</a></td><td>EXO1</td><td>rs1047840</td><td>capecitabine</td><td>Neoplasm Metastasis</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with metastasized cancer and the AG genotype may have improved response to capecitabine or fluorouracil as compared to people with the GG genotype and worse response as compared to people with the AA genotype. Other genetic and clinical factors may also influence a patient's response to capecitabine and fluorouracil.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444667222>1913</a></td><td>EXO1</td><td>rs1047840</td><td>fluorouracil</td><td>Neoplasm Metastasis</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with metastasized cancer and the AG genotype may have improved response to capecitabine or fluorouracil as compared to people with the GG genotype and worse response as compared to people with the AA genotype. Other genetic and clinical factors may also influence a patient's response to capecitabine and fluorouracil.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1446903310>1914</a></td><td>LGR5</td><td>rs17109924</td><td>fluorouracil</td><td>Colonic Neoplasms</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype and colon cancer may have a longer time to tumor recurrence when treated with fluorouracil-based chemotherapy as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to fluorouracil.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444608040>1915</a></td><td>BDNF</td><td>rs7103411</td><td>citalopram</td><td>Depressive Disorder, Major</td><td>4</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype and major depressive disorder may have a better response when treated with citalopram as compared to patients with the TT genotype, or a poorer response when treated with citalopram as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to citalopram.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444666674>1916</a></td><td>WNT5B</td><td>rs12819505</td><td>Platinum compounds</td><td>Carcinoma, Non-Small-Cell Lung</td><td>3</td><td>AA</td><td>Efficacy</td><td>Patients with the AA genotype and non-small-cell lung cancer may have a longer survival time when treated with platinum-based chemotherapy as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence survival time in patients receiving platinum-based chemotherapy.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444694602>1917</a></td><td>ABCB1</td><td>rs1045642</td><td>tacrolimus</td><td>Colitis, Ulcerative</td><td>3</td><td>AA</td><td>Efficacy</td><td>Patients with the AA genotype and ulcerative colitis may have a better chance at achieving remission when treated with tacrolimus as compared to patients with the AG or GG genotype. However, a different study contradicts this finding. Other genetic and clinical factors may also influence likelihood of ulcerative colitis remission.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444704118>1918</a></td><td>ADAMTS1</td><td>rs402007</td><td>hmg coa reductase inhibitors</td><td></td><td>3</td><td>CG</td><td>Efficacy</td><td>Patients with the CG genotype who are treated with hmg coa reductase inhibitors may have more benefit from statin treatment in reducing the risk of myocardial infarction as compared to patients with the GG genotype or may have less benefit from statin treatment in reducing the risk of myocardial infarction as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to hmg coa reductase inhibitors.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444608132>1919</a></td><td>VEGFA</td><td>rs2010963</td><td>bevacizumab</td><td>Choroidal Neovascularization</td><td>3</td><td>GG</td><td>Efficacy</td><td>Patients with the GG genotype and choroidal neovascularization may have a better response to anti-VEGF treatment, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to anti-VEGF treatment.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444608132>1920</a></td><td>VEGFA</td><td>rs2010963</td><td>pegaptanib</td><td>Choroidal Neovascularization</td><td>3</td><td>GG</td><td>Efficacy</td><td>Patients with the GG genotype and choroidal neovascularization may have a better response to anti-VEGF treatment, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to anti-VEGF treatment.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444608132>1921</a></td><td>VEGFA</td><td>rs2010963</td><td>ranibizumab</td><td>Choroidal Neovascularization</td><td>3</td><td>GG</td><td>Efficacy</td><td>Patients with the GG genotype and choroidal neovascularization may have a better response to anti-VEGF treatment, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to anti-VEGF treatment.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444667322>1922</a></td><td>DLG5</td><td>rs2289310</td><td>capecitabine</td><td>Neoplasm Metastasis</td><td>3</td><td>GT</td><td>Efficacy</td><td>"Patients with metastasized cancer and the GT genotype may have improved response to capecitabine or fluorouracil as compared to people with the GG genotype and worse response as compared to people with the TT genotype. Other genetic and clinical factors may also influence a patient's response to capecitabine and fluorouracil. Please note: the single statistically significant association was for a haplotype that included five SNPs (rs2289310 G>T; rs1047840 G>A; rs17431184 T>C; rs17160359 G>T; rs2236722 A>G) that distinguished the ""non-responder"" phenotype from the ""responder"" phenotype when using a logistic regression multivariate model."</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444667322>1923</a></td><td>DLG5</td><td>rs2289310</td><td>fluorouracil</td><td>Neoplasm Metastasis</td><td>3</td><td>GT</td><td>Efficacy</td><td>"Patients with metastasized cancer and the GT genotype may have improved response to capecitabine or fluorouracil as compared to people with the GG genotype and worse response as compared to people with the TT genotype. Other genetic and clinical factors may also influence a patient's response to capecitabine and fluorouracil. Please note: the single statistically significant association was for a haplotype that included five SNPs (rs2289310 G>T; rs1047840 G>A; rs17431184 T>C; rs17160359 G>T; rs2236722 A>G) that distinguished the ""non-responder"" phenotype from the ""responder"" phenotype when using a logistic regression multivariate model."</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1446904604>1924</a></td><td>FNTB</td><td>rs11623866</td><td>carboplatin</td><td>Ovarian Neoplasms</td><td>3</td><td>CG</td><td>Efficacy</td><td>Patients with ovarian cancer and the CG genotype may have an increased response to carboplatin, lonafarnib, and paclitaxel as compared to patients with the GG genotype. Other clinical and genetic factors may also influence response to carboplatin, lonafarnib, and paclitaxel in patients with ovarian cancer. Please note, the treatment arm that included paclitaxel and carboplatin WITHOUT lonafarnib showed no significant differences in treatment outcome when comparing between genotypes.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1446904604>1925</a></td><td>FNTB</td><td>rs11623866</td><td>lonafarnib</td><td>Ovarian Neoplasms</td><td>3</td><td>CG</td><td>Efficacy</td><td>Patients with ovarian cancer and the CG genotype may have an increased response to carboplatin, lonafarnib, and paclitaxel as compared to patients with the GG genotype. Other clinical and genetic factors may also influence response to carboplatin, lonafarnib, and paclitaxel in patients with ovarian cancer. Please note, the treatment arm that included paclitaxel and carboplatin WITHOUT lonafarnib showed no significant differences in treatment outcome when comparing between genotypes.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1446904604>1926</a></td><td>FNTB</td><td>rs11623866</td><td>paclitaxel</td><td>Ovarian Neoplasms</td><td>3</td><td>CG</td><td>Efficacy</td><td>Patients with ovarian cancer and the CG genotype may have an increased response to carboplatin, lonafarnib, and paclitaxel as compared to patients with the GG genotype. Other clinical and genetic factors may also influence response to carboplatin, lonafarnib, and paclitaxel in patients with ovarian cancer. Please note, the treatment arm that included paclitaxel and carboplatin WITHOUT lonafarnib showed no significant differences in treatment outcome when comparing between genotypes.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1446908543>1927</a></td><td>CHRNA4</td><td>rs1044396</td><td>varenicline</td><td>Tobacco Use Disorder</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype and Tobacco Use Disorder who are treated with varenicline may have an increased response to varenicline as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to varenicline.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1446908603>1928</a></td><td>AGT</td><td>rs11122576</td><td>amlodipine</td><td></td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype may have an increased risk for Coronary Disease when treated with chlorthalidone or lisinopril as compared to patients with the CT genotype who are treated with amlodipine. Other genetic and clinical factors may also influence a patient's response to treatment and risk for Coronary Disease.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1446908603>1929</a></td><td>AGT</td><td>rs11122576</td><td>chlorthalidone</td><td></td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype may have an increased risk for Coronary Disease when treated with chlorthalidone or lisinopril as compared to patients with the CT genotype who are treated with amlodipine. Other genetic and clinical factors may also influence a patient's response to treatment and risk for Coronary Disease.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1446908603>1930</a></td><td>AGT</td><td>rs11122576</td><td>lisinopril</td><td></td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype may have an increased risk for Coronary Disease when treated with chlorthalidone or lisinopril as compared to patients with the CT genotype who are treated with amlodipine. Other genetic and clinical factors may also influence a patient's response to treatment and risk for Coronary Disease.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444668298>1931</a></td><td>AMHR2</td><td>rs784892</td><td>metformin</td><td>Diabetes Mellitus</td><td>3</td><td>GG</td><td>Efficacy</td><td>In healthy volunteers the GG genotype may be associated with decreased secretory clearance of metformin, and in patients with diabetes mellitus may result in an increase efficacy (decreased HbA1c levels) as compared to patients with the AG or AA genotypes. Other clinical and genetic factors may also influence metformin clearance and efficacy in patients with diabetes mellitus.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444668306>1932</a></td><td>PPARA</td><td>rs149711321</td><td>metformin</td><td>Diabetes Mellitus</td><td>3</td><td>TT</td><td>Efficacy</td><td>In healthy volunteers as well as patients with diabetes mellitus the TT genotype may be associated with a decreased secretory clearance of metformin, leading to increased exposure and a corresponding decrease in HbA1c levels, which is indicative of improved metformin efficacy, as compared to patients with the CC genotype. Other clinical and genetic factors may also influence metformin clearance and efficacy in patients with diabetes mellitus.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444673197>1933</a></td><td>VEGFA</td><td>rs13207351</td><td>docetaxel</td><td>Breast Neoplasms</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype and breast cancer may have a longer progression-free survival time when treated with docetaxel as compared to patients with the GG genotype. Other genetic and clinical factors may also influence progression-free survival time.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444673209>1934</a></td><td>VEGFA</td><td>rs1570360</td><td>docetaxel</td><td>Breast Neoplasms</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype and breast cancer may have a better response to docetaxel treatment as compared to patients with the GG genotype. However, contradictory evidence exists when considering progression-free survival. Other genetic and clinical factors may also influence response to docetaxel.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444668477>1935</a></td><td>SLC30A8</td><td>rs13266634</td><td>insulin recombinant</td><td></td><td>3</td><td>TT</td><td>Efficacy</td><td>Individuals with the TT genotype may have an increased response to insulin supplemented with zinc acetate as compared to individuals with the CC genotypes. Other clinical and genetic factors may also affect response to insulin and zinc acetate.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444668477>1936</a></td><td>SLC30A8</td><td>rs13266634</td><td>zinc acetate</td><td></td><td>3</td><td>TT</td><td>Efficacy</td><td>Individuals with the TT genotype may have an increased response to insulin supplemented with zinc acetate as compared to individuals with the CC genotypes. Other clinical and genetic factors may also affect response to insulin and zinc acetate.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444700860>1937</a></td><td>ABCG2</td><td>rs7699188</td><td>fluorouracil</td><td>Colorectal Neoplasms</td><td>3</td><td>AA</td><td>Efficacy</td><td>Patients with the AA genotype may have increased tumor response rate and increased risk of grade 3-4 nonhematological toxicity when treated with fluorouracil, irinotecan and leucovorin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to fluorouracil, irinotecan and leucovorin.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444700860>1938</a></td><td>ABCG2</td><td>rs7699188</td><td>irinotecan</td><td>Colorectal Neoplasms</td><td>3</td><td>AA</td><td>Efficacy</td><td>Patients with the AA genotype may have increased tumor response rate and increased risk of grade 3-4 nonhematological toxicity when treated with fluorouracil, irinotecan and leucovorin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to fluorouracil, irinotecan and leucovorin.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444700860>1939</a></td><td>ABCG2</td><td>rs7699188</td><td>leucovorin</td><td>Colorectal Neoplasms</td><td>3</td><td>AA</td><td>Efficacy</td><td>Patients with the AA genotype may have increased tumor response rate and increased risk of grade 3-4 nonhematological toxicity when treated with fluorouracil, irinotecan and leucovorin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to fluorouracil, irinotecan and leucovorin.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1445401325>1940</a></td><td>ATG16L1</td><td>rs10210302</td><td>adalimumab</td><td>Crohn Disease</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype and Crohn's disease may have a better response to treatment with adalimumab as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to adalimumab.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444702725>1941</a></td><td>CFH</td><td>rs1061170</td><td>bevacizumab</td><td>Macular Degeneration</td><td>4</td><td>TT</td><td>Efficacy</td><td>Patients with the TT genotype and macular degeneration may have a greater improvement in visual acuity when treated with ranibizumab or bevacizumab as compared to patients with the CC genotype. However, some studies have found no association with response to ranibizumab or bevacizumab. Other genetic and clinical factors may also influence response to ranibizumab or bevacizumab.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444702725>1942</a></td><td>CFH</td><td>rs1061170</td><td>ranibizumab</td><td>Macular Degeneration</td><td>4</td><td>TT</td><td>Efficacy</td><td>Patients with the TT genotype and macular degeneration may have a greater improvement in visual acuity when treated with ranibizumab or bevacizumab as compared to patients with the CC genotype. However, some studies have found no association with response to ranibizumab or bevacizumab. Other genetic and clinical factors may also influence response to ranibizumab or bevacizumab.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1445401193>1943</a></td><td>MVK</td><td>rs10161126</td><td>alendronate</td><td>Bone Diseases</td><td>3</td><td>GG</td><td>Efficacy</td><td>Patients with the GG genotype and osteoporosis or osteopenia may have a better response when treated with alendronate as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence response to alendronate.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1445402033>1944</a></td><td>ABCB1</td><td>rs1128503</td><td>cytarabine</td><td>Leukemia, Myeloid, Acute</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype and acute myeloid leukemia may have a better response when treated with cytarabine, alone or in combination with daunorubicin, or dexrazoxane as compared to patients with the GG genotype, however some evidence contradicts this. Other genetic and clinical factors may also influence response to cytarabine.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1446898016>1945</a></td><td>GLP1R</td><td>rs6923761</td><td>liraglutide</td><td>Obesity;Polycystic Ovary Syndrome</td><td>3</td><td>AG</td><td>Efficacy</td><td>Women with obesity and polycystic ovarian syndrome (PCOS) and the AG genotype may have an increased response to liraglutide as compared to women with the GG genotype. Other clinical and genetic factors may also influence response to liraglutide in women with obesity and PCOS.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448613363>1946</a></td><td>PEAR1</td><td>rs57731889</td><td>clopidogrel</td><td></td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype may have higher on-treatment platelet reactivity in patients with coronary heart disease (CHD) who underwent percutaneous coronary intervention (PCI) treated with aspirin and clopidogrel as compared to patients with genotype TT. Other genetic and clinical factors may also influence the response to clopidogrel.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448522754>1947</a></td><td>CTNNA2</td><td>rs11126740</td><td>Tumor necrosis factor alpha (TNF-alpha) inhibitors</td><td>Psoriasis</td><td>3</td><td>GG</td><td>Efficacy</td><td>Patients with the GG genotype and psoriasis may have a better response to treatment with anti-TNF drugs as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to anti-TNF drugs.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448600720>1948</a></td><td>SLC26A9</td><td>rs7512462</td><td>ivacaftor</td><td>Cystic Fibrosis</td><td>3</td><td>CT</td><td>Efficacy</td><td>Children with the CT genotype and gating mutations in cystic fibrosis may have increased response to ivacaftor compared to children with the TT genotypes. Other clinical and genetic factors may affect response to ivacaftor.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448427833>1949</a></td><td>ABCB1</td><td>rs1045642</td><td>granisetron</td><td>Neoplasms</td><td>3</td><td>AA</td><td>Efficacy</td><td>Patients with the AA genotype and cancer may have a greater likelihood of avoiding chemotherapy-induced nausea and vomiting (CINV) when treated with granisetron as compared to patients with the AG or GG genotype, although this is contradicted in one study. Other genetic and clinical factors may also influence response to granisetron.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448615153>1950</a></td><td>CYP19A1</td><td>rs727479</td><td>anastrozole</td><td>Breast Neoplasms</td><td>3</td><td>AA</td><td>Efficacy</td><td>Postmenopausal women with HR+ breast cancer and the AA genotype may have decreased likelihood of breast cancer recurrence (increased recurrence free survival) when treated with anastrozole as compared to women with the AC or CC genotype. Other clinical and genetic factors may also influence the likelihood of breast cancer recurrence in postmenopausal women with HR+ breast cancer who are treated with anastrozole.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450374895>1951</a></td><td>TH</td><td>rs2070762</td><td>methylphenidate</td><td>Attention Deficit Disorder with Hyperactivity</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype and attention deficit hyperactivity disorder (ADHD) may have a increased treatment response (based on the Improvement subscale of the Clinical Global Impression scale (CGI-I)) when treated with methylphenidate as compared to patients with the GG genotype who started from a lower Clinical Global Impressions-Severity scale (CGI-S) score. Other genetic and clinical factors may also influence response to methylphenidate.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449166396>1952</a></td><td>ABCB1</td><td>rs1045642</td><td>omeprazole</td><td>Gastroesophageal Reflux</td><td>3</td><td>AA</td><td>Efficacy</td><td>Patients with the AA genotype and gastroesophageal reflux may have increased absorption rate and response to omeprazole compared to patients with the AG and GG genotypes. Other clinical and genetic factors may also influence absorption rate and response to omeprazole in patients.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448617231>1953</a></td><td>TBXA2R</td><td>rs1131882</td><td>aspirin</td><td>Diabetes Mellitus, Type 2</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype may have increased risk of mortality when treated with aspirin in people with Diabetes Mellitus, Type 2 as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to aspirin.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447953250>1954</a></td><td>ABCB1</td><td>rs2032582</td><td>modafinil</td><td>Narcolepsy</td><td>3</td><td>AC</td><td>Efficacy</td><td>Patients with the AC genotype and narcolepsy may have an increased response to modafinil as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to modafinil.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447961122>1955</a></td><td>-</td><td>rs1419555</td><td>salbutamol</td><td>Asthma</td><td>3</td><td>TT</td><td>Efficacy</td><td>Patients with the TT genotype and asthma may have a better response to salbutamol treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to salbutamol.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447962843>1956</a></td><td>ABCB1</td><td>rs1128503</td><td>simvastatin</td><td>Hypercholesterolemia</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype and hypercholesterolemia may greater reduction in LDL and total cholesterol when treated with simvastatin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence cholesterol levels.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447964236>1957</a></td><td>ADGRL3</td><td>rs6551665</td><td>methylphenidate</td><td>Attention Deficit Disorder with Hyperactivity</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype and ADHD may have a better response when treated with methylphenidate as compared to patients with the AA genotype. However, other studies have failed to find this association or have found contradictory evidence. Other genetic and clinical factors may also influence response to methylphenidate.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447987113>1958</a></td><td>CYP2A6</td><td>rs4803381</td><td>bupropion</td><td>Tobacco Use Disorder</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype and tobacco use disorder may have a worse response (abstinence from tobacco) to bupropion and drugs used in nicotine replacement therapy as compared to patients with the TT genotype and an improved response (abstinence from tobacco) to bupropion and drugs used in nicotine replacement therapy compared to patients with the CC genotype. Other clinical and genetic factors may also influence response to bupropion in people with tobacco use disorder.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447987113>1959</a></td><td>CYP2A6</td><td>rs4803381</td><td>Drugs used in nicotine dependence</td><td>Tobacco Use Disorder</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype and tobacco use disorder may have a worse response (abstinence from tobacco) to bupropion and drugs used in nicotine replacement therapy as compared to patients with the TT genotype and an improved response (abstinence from tobacco) to bupropion and drugs used in nicotine replacement therapy compared to patients with the CC genotype. Other clinical and genetic factors may also influence response to bupropion in people with tobacco use disorder.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448522772>1960</a></td><td>CDKAL1</td><td>rs6908425</td><td>Tumor necrosis factor alpha (TNF-alpha) inhibitors</td><td>Psoriasis</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype and psoriasis may have a better response to treatment with anti-TNF drugs as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to anti-TNF drugs.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448522778>1961</a></td><td>HLA-C</td><td>rs12191877</td><td>Tumor necrosis factor alpha (TNF-alpha) inhibitors</td><td>Psoriasis</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype and psoriasis may have a better response to treatment with anti-TNF drugs as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to anti-TNF drugs.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448099568>1962</a></td><td>SLCO1B1</td><td>rs2291075</td><td>cytarabine</td><td>Leukemia, Myeloid, Acute</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype may have more favorable event-free and overall survival in children with de novo acute myeloid leukemia (AML) treated with cytarabine, daunorubicin, etoposide and mitoxantrone as compared to patients with genotype CC. Other genetic and clinical factors may also influence the treatment outcome in acute myeloid leukemia.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448099568>1963</a></td><td>SLCO1B1</td><td>rs2291075</td><td>daunorubicin</td><td>Leukemia, Myeloid, Acute</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype may have more favorable event-free and overall survival in children with de novo acute myeloid leukemia (AML) treated with cytarabine, daunorubicin, etoposide and mitoxantrone as compared to patients with genotype CC. Other genetic and clinical factors may also influence the treatment outcome in acute myeloid leukemia.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448099568>1964</a></td><td>SLCO1B1</td><td>rs2291075</td><td>etoposide</td><td>Leukemia, Myeloid, Acute</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype may have more favorable event-free and overall survival in children with de novo acute myeloid leukemia (AML) treated with cytarabine, daunorubicin, etoposide and mitoxantrone as compared to patients with genotype CC. Other genetic and clinical factors may also influence the treatment outcome in acute myeloid leukemia.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448099568>1965</a></td><td>SLCO1B1</td><td>rs2291075</td><td>mitoxantrone</td><td>Leukemia, Myeloid, Acute</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype may have more favorable event-free and overall survival in children with de novo acute myeloid leukemia (AML) treated with cytarabine, daunorubicin, etoposide and mitoxantrone as compared to patients with genotype CC. Other genetic and clinical factors may also influence the treatment outcome in acute myeloid leukemia.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449576307>1966</a></td><td>ALDH1A2</td><td>rs261316</td><td>atenolol</td><td>Hypertension</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype may have a decreased response to treatment with atenolol and hydrochlorothiazide, resulting in an increased risk of having uncontrolled blood pressure, as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to treatment with atenolol and hydrochlorothiazide.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449576307>1967</a></td><td>ALDH1A2</td><td>rs261316</td><td>hydrochlorothiazide</td><td>Hypertension</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype may have a decreased response to treatment with atenolol and hydrochlorothiazide, resulting in an increased risk of having uncontrolled blood pressure, as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to treatment with atenolol and hydrochlorothiazide.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447954525>1968</a></td><td>IRS1</td><td>rs13431554</td><td>clopidogrel</td><td>Coronary Artery Disease;Diabetes Mellitus, Type 2</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype may have higher platelet reactivity when treated with aspirin and clopidogrel in people with Coronary Artery Disease and Diabetes Mellitus, Type 2 as compared to patients with genotype AA. Other genetic and clinical factors may also influence the efficacy of clopidogrel.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447959724>1969</a></td><td>-</td><td>rs1448673</td><td>interferon beta-1a</td><td>Multiple Sclerosis</td><td>3</td><td>GG</td><td>Efficacy</td><td>Patients with the GG genotype and multiple sclerosis may have an increased response to treatment with interferon-beta as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to interferon-beta treatment.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447959724>1970</a></td><td>-</td><td>rs1448673</td><td>interferon beta-1b</td><td>Multiple Sclerosis</td><td>3</td><td>GG</td><td>Efficacy</td><td>Patients with the GG genotype and multiple sclerosis may have an increased response to treatment with interferon-beta as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to interferon-beta treatment.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447960623>1971</a></td><td>AGTR1</td><td>rs5186</td><td>losartan</td><td></td><td>3</td><td>AC</td><td>Efficacy</td><td>Patients with the AC genotype may have better humoral and renal hemodynamic responses when treated with losartan as compared to patients with the AA genotype. Other genetic and clinical factors may also influence humoral and renal hemodynamic responses.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447962620>1972</a></td><td>VDR</td><td>rs1544410</td><td>conjugated estrogens</td><td></td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CC genotype may have a lesser increase in bone mineral density when treated with hormone replacement therapy as compared to patients with the TT genotype, or a greater increase as compared to patients with the CC genotype. Other genetic and clinical factors may also influence changes in bone mineral density.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447962620>1973</a></td><td>VDR</td><td>rs1544410</td><td>medroxyprogesterone</td><td></td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CC genotype may have a lesser increase in bone mineral density when treated with hormone replacement therapy as compared to patients with the TT genotype, or a greater increase as compared to patients with the CC genotype. Other genetic and clinical factors may also influence changes in bone mineral density.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447962768>1974</a></td><td>PON1</td><td>rs705379</td><td>atorvastatin</td><td>Hypercholesterolemia</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype and hypercholesterolemia who have high baseline HDL levels may have a greater increase in HDL cholesterol when treated with atorvastatin or simvastatin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence HDL cholesterol levels.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447962768>1975</a></td><td>PON1</td><td>rs705379</td><td>simvastatin</td><td>Hypercholesterolemia</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype and hypercholesterolemia who have high baseline HDL levels may have a greater increase in HDL cholesterol when treated with atorvastatin or simvastatin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence HDL cholesterol levels.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448102306>1976</a></td><td>CYBA</td><td>rs4673</td><td>doxorubicin</td><td>Neoplasms</td><td>3</td><td>AG</td><td>Efficacy</td><td>Cancer patients with the AG genotype may have a longer overall and event-free survival time as compared to patients with the AA genotype when treated with anthracyclines. Other genetic and clinical factors may also influence survival times.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448102306>1977</a></td><td>CYBA</td><td>rs4673</td><td>idarubicin</td><td>Neoplasms</td><td>3</td><td>AG</td><td>Efficacy</td><td>Cancer patients with the AG genotype may have a longer overall and event-free survival time as compared to patients with the AA genotype when treated with anthracyclines. Other genetic and clinical factors may also influence survival times.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448101408>1978</a></td><td>UGT1A3</td><td>rs3806596</td><td>deferasirox</td><td>beta-Thalassemia</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype and beta-thalassemia may have worse response to, and decreased concentrations of deferasirox and increased risk of iron overload as compared to patients with the CC genotype. Other clinical and genetic factors may also influence concentrations of and response to deferasirox in patients with beta-thalassemia.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447979500>1979</a></td><td>-</td><td>rs4604006</td><td>sorafenib</td><td>Carcinoma, Hepatocellular</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype may have increased progression-free survival and increased overall survival when treated with sorafenib in people with Hepatocellular Carcinoma as compared to patients with genotype CC. Other genetic and clinical factors may also influence the response to sorafenib.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447979507>1980</a></td><td>NOS3</td><td>rs2070744</td><td>sorafenib</td><td>Carcinoma, Hepatocellular</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype may have increased progression-free survival and increased overall survival when treated with sorafenib in people with Hepatocellular Carcinoma as compared to patients with genotype TT. Other genetic and clinical factors may also influence the response to sorafenib.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447961108>1981</a></td><td>-</td><td>rs17701271</td><td>salbutamol</td><td>Asthma</td><td>3</td><td>AC</td><td>Efficacy</td><td>Patients with the AC genotype and asthma may have a better response to salbutamol treatment as compared to patients with the CC genotype, or a poorer response as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to salbutamol.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447964278>1982</a></td><td>ADGRL3</td><td>rs1355368</td><td>methylphenidate</td><td>Attention Deficit Disorder with Hyperactivity</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype and ADHD may have a faster response when treated with methylphenidate as compared to patients with the AA genotype. Other genetic and clinical factors may also influence the speed of efficacy of methylphenidate.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447946233>1983</a></td><td>DHFR</td><td>rs1053129</td><td>methotrexate</td><td>Osteosarcoma</td><td>3</td><td>CC</td><td>Efficacy</td><td>Patients with the CC genotype and osteosarcoma who are receiving methotrexate may have an increased risk for metastasis, as compared to patients with the AC genotype. Other genetic and clinical factors may also influence risk for metastasis in patients receiving methotrexate.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447960649>1984</a></td><td>AGTR1</td><td>rs5186</td><td>perindopril</td><td>Hypertension</td><td>3</td><td>AC</td><td>Efficacy</td><td>Patients with the AC genotype and hypertension may have a greater reduction in blood pressure and pulse wave velocity when treated with perindopril as compared to patients with the AA genotype. Other genetic and clinical factors may also influence blood pressure and pulse wave velocity.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447960850>1985</a></td><td>GGH</td><td>rs3780126</td><td>bevacizumab</td><td>Carcinoma, Non-Small-Cell Lung</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype and non-small-cell lung cancer may have longer overall survival times when treated with pemetrexed and bevacizumab as compared to patients with the AA genotype, and shorter overall survival times as compared to patients with the GG genotype. Other genetic and clinical factors may also influence survival time.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447960850>1986</a></td><td>GGH</td><td>rs3780126</td><td>pemetrexed</td><td>Carcinoma, Non-Small-Cell Lung</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype and non-small-cell lung cancer may have longer overall survival times when treated with pemetrexed and bevacizumab as compared to patients with the AA genotype, and shorter overall survival times as compared to patients with the GG genotype. Other genetic and clinical factors may also influence survival time.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447962751>1987</a></td><td>PON1</td><td>rs662</td><td>atorvastatin</td><td>Hypercholesterolemia</td><td>3</td><td>CC</td><td>Efficacy</td><td>Patients with the CC genotype and hypercholesterolemia may have a greater increase in HDL cholesterol when treated with simvastatin or atorvastatin as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence HDL cholesterol levels.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447962751>1988</a></td><td>PON1</td><td>rs662</td><td>simvastatin</td><td>Hypercholesterolemia</td><td>3</td><td>CC</td><td>Efficacy</td><td>Patients with the CC genotype and hypercholesterolemia may have a greater increase in HDL cholesterol when treated with simvastatin or atorvastatin as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence HDL cholesterol levels.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447981070>1989</a></td><td>CFH</td><td>rs800292</td><td>bevacizumab</td><td></td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype and age-related macular degeneration may have a better improvement in visual acuity when treated with bevacizumab as compared to patients with the GG genotype, and a poorer improvement as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to bevacizumab.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448423795>1990</a></td><td>COMT</td><td>rs4818</td><td>quetiapine</td><td>Schizophrenia</td><td>3</td><td>GG</td><td>Efficacy</td><td>Patients with the GG genotype and schizophrenia may have a better response to treatment with quetiapine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence quetiapine response.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448103963>1991</a></td><td>IGF2BP2</td><td>rs4402960</td><td>repaglinide</td><td>Diabetes Mellitus, Type 2</td><td>3</td><td>GT</td><td>Efficacy</td><td>Patients with the GT genotype and type 2 diabetes may have an increased response to treatment with repaglinide as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to repaglinide.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448104022>1992</a></td><td>CRP</td><td>rs1205</td><td>rosuvastatin</td><td>Coronary Disease</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype and coronary disease may have better cardiovascular outcomes when treated with rosuvastatin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence cardiovascular outcomes.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447982723>1993</a></td><td>TOLLIP</td><td>rs3750920</td><td>acetylcysteine</td><td>Pulmonary Fibrosis</td><td>3</td><td>TT</td><td>Efficacy</td><td>Patients with the TT genotype and pulmonary fibrosis may have increased response to N-acetylcysteine compared to patients with the CC and CT genotypes. Other genetic and clinical factors may affect response to N-acetylcysteine.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447953162>1994</a></td><td>-</td><td>rs2513265</td><td>antipsychotics</td><td>Schizophrenia</td><td>3</td><td>AA</td><td>Efficacy</td><td>Patients with the AA genotype and schizophrenia may have an increased response to antipsychotics as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to antipsychotics.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447953192>1995</a></td><td>ADRA2A</td><td>rs1800544</td><td>Selective serotonin reuptake inhibitors</td><td>Depressive Disorder, Major</td><td>3</td><td>CG</td><td>Efficacy</td><td>Patients with the CG genotype and major depressive disorder may have an increased response to selective serotonin reuptake inhibitors as compared to patients with the CC and GG genotypes. Other genetic and clinical factors may also influence a patient's response to SSRIs.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447953212>1996</a></td><td>-</td><td>rs6983267</td><td>Platinum compounds</td><td>Lung Neoplasms</td><td>3</td><td>GT</td><td>Efficacy</td><td>Patients with the GT genotype and lung cancer may have an increased response to platinum compounds as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to platinum compounds.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447959731>1997</a></td><td>GAPVD1</td><td>rs10819043</td><td>interferon beta-1a</td><td>Multiple Sclerosis</td><td>3</td><td>TT</td><td>Efficacy</td><td>Patients with the TT genotype and multiple sclerosis may have an increased response to treatment with interferon-beta as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to interferon-beta treatment.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447959731>1998</a></td><td>GAPVD1</td><td>rs10819043</td><td>interferon beta-1b</td><td>Multiple Sclerosis</td><td>3</td><td>TT</td><td>Efficacy</td><td>Patients with the TT genotype and multiple sclerosis may have an increased response to treatment with interferon-beta as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to interferon-beta treatment.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447959738>1999</a></td><td>GAPVD1</td><td>rs2291858</td><td>interferon beta-1a</td><td>Multiple Sclerosis</td><td>3</td><td>GG</td><td>Efficacy</td><td>Patients with the GG genotype and multiple sclerosis may have an increased response to treatment with interferon-beta as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to interferon-beta treatment.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447959738>2000</a></td><td>GAPVD1</td><td>rs2291858</td><td>interferon beta-1b</td><td>Multiple Sclerosis</td><td>3</td><td>GG</td><td>Efficacy</td><td>Patients with the GG genotype and multiple sclerosis may have an increased response to treatment with interferon-beta as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to interferon-beta treatment.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447964331>2001</a></td><td>IGFBP3</td><td>rs2854744</td><td>fluorouracil</td><td>Stomach Neoplasms</td><td>3</td><td>TT</td><td>Efficacy</td><td>Patients with the TT genotype and stomach cancer may have a better survival outcomes when treated with fluorouracil as compared to patients with the GG genotype. Other genetic and clinical factors may also influence survival outcome.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447983163>2002</a></td><td>NRP1</td><td>rs2070296</td><td>ranibizumab</td><td>Macular Degeneration</td><td>3</td><td>CC</td><td>Efficacy</td><td>Patients with the CC genotype and Macular Degeneration who are treated with ranibizumab may have an increased response as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's response to treatment.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/982045465>2003</a></td><td>VKORC1</td><td>rs9934438</td><td>warfarin</td><td></td><td>3</td><td>AG</td><td>Efficacy</td><td>Subjects with AG genotypes may have increased ratio of (R)-warfarin / (S)-warfarin AUC prothrombin time when compared to subjects with GG genotypes. Other genetic and clinical factors may also influence a subject's response to therapy.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447960484>2004</a></td><td>NOS3</td><td>rs2070744</td><td>enalapril</td><td>Hypertension</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype and hypertension may have a greater reduction in blood pressure when treated with enalapril as compared to patients with the TT genotype. Other genetic and clinical factors may also influence blood pressure reduction in patients receiving enalapril.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447960663>2005</a></td><td>AGT</td><td>rs699</td><td>quinapril</td><td>Coronary Artery Disease</td><td>3</td><td>GG</td><td>Efficacy</td><td>Patients with the GG genotype and coronary artery disease may have a better response when treated with quinapril as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence response to quinapril.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447962710>2006</a></td><td>LIPC</td><td>rs1800588</td><td>fluvastatin</td><td></td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype may have a greater increase in HDL cholesterol when treated with fluvastatin or simvastatin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence HDL cholesterol response.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447962710>2007</a></td><td>LIPC</td><td>rs1800588</td><td>simvastatin</td><td></td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype may have a greater increase in HDL cholesterol when treated with fluvastatin or simvastatin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence HDL cholesterol response.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447962723>2008</a></td><td>LIPC</td><td>rs1800588</td><td>pravastatin</td><td></td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype may have a greater increase in HDL cholesterol when treated with pravastatin as compared to patients with the CC genotype. However, a different study finds no association with HDL cholesterol levels. Other genetic and clinical factors may also influence HDL cholesterol response.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447981430>2009</a></td><td>CMPK1</td><td>rs7543016</td><td>gemcitabine</td><td>Pancreatic Neoplasms</td><td>3</td><td>CC</td><td>Efficacy</td><td>Patients with the CC genotype and pancreatic cancer may have a longer time to progression when treated with gemcitabine as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence time to progression in patients with pancreatic cancer.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447981465>2010</a></td><td>TENT4A</td><td>rs274717</td><td>gemcitabine</td><td>Pancreatic Neoplasms</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype and pancreatic cancer may have a longer overall survival time when treated with gemcitabine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence overall survival time in patients with pancreatic cancer.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448123001>2011</a></td><td>ABCB1</td><td>rs1045642</td><td>losartan</td><td>Hypertension</td><td>3</td><td>AA</td><td>Efficacy</td><td>Patients with the AA genotype may have better response to losartan in people with hypertension as compared to patients with the GG genotype. Other genetic and clinical factors may also influence the response to losartan.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447990902>2012</a></td><td>VEGFA</td><td>rs699947</td><td>enalapril</td><td>Hypertension</td><td>3</td><td>AC</td><td>Efficacy</td><td>Patients with hypertension and the AC genotype may have an improved response to enalapril as compared to patients with the CC genotype. Other clinical and geneticc factors may also influence response to enalapril in patients with hypertension.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447980724>2013</a></td><td>OR52E2</td><td>rs16909440</td><td>lithium</td><td>Bipolar Disorder</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype and bipolar disorder may have a poorer response to treatment with lithium as compared to patients with the TT genotype, and a better response as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to lithium treatment.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447980740>2014</a></td><td>ASIC2</td><td>rs11869731</td><td>lithium</td><td>Bipolar Disorder</td><td>3</td><td>CC</td><td>Efficacy</td><td>Patients with the CC genotype and bipolar disorder may have a better response to treatment with lithium as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence response to lithium treatment.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447980753>2015</a></td><td>-</td><td>rs16973410</td><td>lithium</td><td>Bipolar Disorder</td><td>3</td><td>CC</td><td>Efficacy</td><td>Patients with the CC genotype and bipolar disorder may have a better response to treatment with lithium as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence response to lithium treatment.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448276370>2016</a></td><td>-</td><td>rs3759467</td><td>rituximab</td><td>Vasculitis</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype and ANCA-associated vasculitis may have longer time to failure when treated with rituximab compared to patients with the CC genotype. Other clinical and genetic factors may affect response to rituximab.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447963821>2017</a></td><td>APOA1</td><td>rs2727786</td><td>fenofibrate</td><td>Hypertriglyceridemia</td><td>3</td><td>CC</td><td>Efficacy</td><td>Patients with the CC genotype and hypertriglyceridemia may have a greater decrease in triglycerides when treated with fenofibrate as compared to patients with the CG genotype. Other genetic and clinical factors may also influence response to fenofibrate.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447963829>2018</a></td><td>LPL</td><td>rs320</td><td>fenofibrate</td><td>Hypertriglyceridemia</td><td>3</td><td>GT</td><td>Efficacy</td><td>Patients with the GT genotype and hypertriglyceridemia may have a greater decrease in triglycerides when treated with fenofibrate as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to fenofibrate.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447964164>2019</a></td><td>PON1</td><td>rs705379</td><td>atorvastatin</td><td>Hypercholesterolemia</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype and hypercholesterolemia may have increased oxidative stress in response to treatment with atorvastatin as compared to patients with the GG genotype, or decreased oxidative stress as compared to patients with the AA genotype. Other genetic and clinical factors may also influence oxidative stress response to lipid-lowering drugs.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447989803>2020</a></td><td>TYMS</td><td>rs2847153</td><td>fluorouracil</td><td>Pancreatic Neoplasms</td><td>3</td><td>AA</td><td>Efficacy</td><td>Patients with the AA genotype and pancreatic cancer may have an increased chance of survival when treated with fluorouracil as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence chance of survival in patients receiving fluorouracil.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447953199>2021</a></td><td>ADRA2A</td><td>rs1800544</td><td>milnacipran</td><td>Depressive Disorder</td><td>3</td><td>CG</td><td>Efficacy</td><td>Patients with the CG genotype and depressive disorder may have an increased response to milnacipran as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of side effects when treated with milnacipran</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447953354>2022</a></td><td>REV1</td><td>rs3087403</td><td>cisplatin</td><td>Osteosarcoma</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype and osteosarcoma may have an increased response to cisplatin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to cisplatin.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448262537>2023</a></td><td>B4GALT2</td><td>rs1061781</td><td>clopidogrel</td><td></td><td>3</td><td>CC</td><td>Efficacy</td><td>Patients with the CC genotype may have higher on-treatment platelet reactivity when treated with aspirin and clopidogrel in people with Coronary Artery Disease as compared to patients with genotype TT or CT. Other genetic and clinical factors may also influence the response to clopidogrel.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447960245>2024</a></td><td>SLC28A2</td><td>rs1060896</td><td>gemcitabine</td><td>Neoplasms</td><td>3</td><td>AC</td><td>Efficacy</td><td>Patients with the AC genotype and cancer may have increased survival time and an increased risk for hematologic toxicity when treated with gemcitabine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence toxicity and response in patients receiving gemcitabine.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447964264>2025</a></td><td>ADGRL3</td><td>rs6813183</td><td>methylphenidate</td><td>Attention Deficit Disorder with Hyperactivity</td><td>3</td><td>CG</td><td>Efficacy</td><td>Patients with the CG genotype and ADHD may show faster improvement of symptoms when treated with methylphenidate as compared to patients with the GG genotype. Other genetic and clinical factors may also influence the speed of efficacy of methylphenidate.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448423763>2026</a></td><td>COMT</td><td>rs5993883</td><td>quetiapine</td><td>Schizophrenia</td><td>3</td><td>GT</td><td>Efficacy</td><td>Patients with the GT genotype and schizophrenia may have a better response to treatment with quetiapine as compared to patients with the TT genotype, or a poorer response as compared to patients with the GG genotype. Other genetic and clinical factors may also influence quetiapine response.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448423788>2027</a></td><td>COMT</td><td>rs6269</td><td>quetiapine</td><td>Schizophrenia</td><td>3</td><td>GG</td><td>Efficacy</td><td>Patients with the GG genotype and schizophrenia may have a better response to treatment with quetiapine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence quetiapine response.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447990050>2028</a></td><td>BCHE</td><td>rs1803274</td><td>rivastigmine</td><td>Alzheimer Disease;Lewy Body Disease</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype and Lewy Body disease or Alzheimer's disease may have an improved response to rivastigmine as compared to patients with the TT genotype, although some studies show contradictory results. Other clinical and genetic factors may also influence response to rivastigmine in patients with Lewy Body disease or Alzheimer's disease.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448256689>2029</a></td><td>SLC2A2</td><td>rs8192675</td><td>metformin</td><td>Diabetes Mellitus</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype may have increased response to metformin in people with Diabetes Mellitus as compared to patients with genotype TT. Other genetic and clinical factors may also influence the response to metformin.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448266663>2030</a></td><td>-</td><td>rs247616</td><td>hmg coa reductase inhibitors</td><td></td><td>3</td><td>TT</td><td>Efficacy</td><td>Patients with the TT genotype may have a better response to statin therapy compared to patients with the CC genotype. Other clinical and genetic factors may affect response to statins.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447980968>2031</a></td><td>SLC22A1</td><td>rs594709</td><td>metformin</td><td>Diabetes Mellitus, Type 2</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype and Type 2 Diabetes may have improved response to metformin compared to patients with the GG genotype. Other genetic and clinical factors may affects response to metformin.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447960403>2032</a></td><td>GPX5</td><td>rs451774</td><td>carboplatin</td><td>Carcinoma, Non-Small-Cell Lung</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype and non-small-cell lung cancer may have longer overall survival times when treated with platinum agents in combination with gemcitabine, as compared to patients with the AA genotype. Other genetic and clinical factors may also influence overall survival times in non-small-cell lung cancer patients.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447960403>2033</a></td><td>GPX5</td><td>rs451774</td><td>cisplatin</td><td>Carcinoma, Non-Small-Cell Lung</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype and non-small-cell lung cancer may have longer overall survival times when treated with platinum agents in combination with gemcitabine, as compared to patients with the AA genotype. Other genetic and clinical factors may also influence overall survival times in non-small-cell lung cancer patients.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447960403>2034</a></td><td>GPX5</td><td>rs451774</td><td>gemcitabine</td><td>Carcinoma, Non-Small-Cell Lung</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype and non-small-cell lung cancer may have longer overall survival times when treated with platinum agents in combination with gemcitabine, as compared to patients with the AA genotype. Other genetic and clinical factors may also influence overall survival times in non-small-cell lung cancer patients.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447963049>2035</a></td><td>LEPR</td><td>rs1805094</td><td>atorvastatin</td><td>Acute coronary syndrome</td><td>3</td><td>GG</td><td>Efficacy</td><td>Patients with the GG genotype and acute coronary syndrome who are treated with atorvastatin may have an increase in lumbar bone marrow density as compared to patients with the CG genotype. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447963442>2036</a></td><td>ULK3</td><td>rs2290573</td><td>imatinib</td><td>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype and chronic myeloid leukemia may have a higher rate of major cytogenetic response when treated with imatinib as compared to patients with the GG genotype. Other genetic and clinical factors may also influence major cytogenetic response rate.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447990224>2037</a></td><td>RRM1</td><td>rs12806698</td><td>gemcitabine</td><td>Carcinoma, Non-Small-Cell Lung</td><td>3</td><td>AC</td><td>Efficacy</td><td>Patients with the AC genotype and Non-small-cell-lung cancer may have an increased response to platinum compounds and gemcitabine as compared to patients with the AA and CC genotypes, however this is contradicted in two studies. Other clinical and genetic factors may also influence response to platinum compounds and gemcitabine in patients with non-small-cell lung cancer.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447990224>2038</a></td><td>RRM1</td><td>rs12806698</td><td>Platinum compounds</td><td>Carcinoma, Non-Small-Cell Lung</td><td>3</td><td>AC</td><td>Efficacy</td><td>Patients with the AC genotype and Non-small-cell-lung cancer may have an increased response to platinum compounds and gemcitabine as compared to patients with the AA and CC genotypes, however this is contradicted in two studies. Other clinical and genetic factors may also influence response to platinum compounds and gemcitabine in patients with non-small-cell lung cancer.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448423436>2039</a></td><td>PRORP</td><td>rs12436663</td><td>zileuton</td><td>Asthma</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype and asthma may have a better response when treated with zileuton as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to zileuton treatment.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447960443>2040</a></td><td>ADRB1</td><td>rs1801253</td><td>Ace Inhibitors, Plain</td><td>Heart Failure</td><td>3</td><td>CG</td><td>Efficacy</td><td>Patients with the rs1801253 CG genotype and heart failure may have increased emergency department utilization when treated with cardiovascular drugs as compared to patients with the GG genotype. Other genetic and clinical factors may also influence efficacy of cardiovascular drugs.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447960443>2041</a></td><td>ADRB1</td><td>rs1801253</td><td>Angiotensin II Antagonists</td><td>Heart Failure</td><td>3</td><td>CG</td><td>Efficacy</td><td>Patients with the rs1801253 CG genotype and heart failure may have increased emergency department utilization when treated with cardiovascular drugs as compared to patients with the GG genotype. Other genetic and clinical factors may also influence efficacy of cardiovascular drugs.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447960443>2042</a></td><td>ADRB1</td><td>rs1801253</td><td>Beta Blocking Agents</td><td>Heart Failure</td><td>3</td><td>CG</td><td>Efficacy</td><td>Patients with the rs1801253 CG genotype and heart failure may have increased emergency department utilization when treated with cardiovascular drugs as compared to patients with the GG genotype. Other genetic and clinical factors may also influence efficacy of cardiovascular drugs.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447960443>2043</a></td><td>ADRB1</td><td>rs1801253</td><td>digoxin</td><td>Heart Failure</td><td>3</td><td>CG</td><td>Efficacy</td><td>Patients with the rs1801253 CG genotype and heart failure may have increased emergency department utilization when treated with cardiovascular drugs as compared to patients with the GG genotype. Other genetic and clinical factors may also influence efficacy of cardiovascular drugs.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447960443>2044</a></td><td>ADRB1</td><td>rs1801253</td><td>diuretics</td><td>Heart Failure</td><td>3</td><td>CG</td><td>Efficacy</td><td>Patients with the rs1801253 CG genotype and heart failure may have increased emergency department utilization when treated with cardiovascular drugs as compared to patients with the GG genotype. Other genetic and clinical factors may also influence efficacy of cardiovascular drugs.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447960443>2045</a></td><td>ADRB1</td><td>rs1801253</td><td>spironolactone</td><td>Heart Failure</td><td>3</td><td>CG</td><td>Efficacy</td><td>Patients with the rs1801253 CG genotype and heart failure may have increased emergency department utilization when treated with cardiovascular drugs as compared to patients with the GG genotype. Other genetic and clinical factors may also influence efficacy of cardiovascular drugs.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447959745>2046</a></td><td>GAPVD1</td><td>rs10760397</td><td>interferon beta-1a</td><td>Multiple Sclerosis</td><td>3</td><td>CC</td><td>Efficacy</td><td>Patients with the CC genotype and multiple sclerosis may have an increased response to treatment with interferon-beta as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to interferon-beta treatment.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447959745>2047</a></td><td>GAPVD1</td><td>rs10760397</td><td>interferon beta-1b</td><td>Multiple Sclerosis</td><td>3</td><td>CC</td><td>Efficacy</td><td>Patients with the CC genotype and multiple sclerosis may have an increased response to treatment with interferon-beta as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to interferon-beta treatment.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448102324>2048</a></td><td>IL18</td><td>rs187238</td><td>interferons</td><td>Hepatitis C, Chronic</td><td>3</td><td>CG</td><td>Efficacy</td><td>Patients with the CG genotype and chronic hepatitis C may have a poorer response to treatment with interferons and ribavirin as compared to patients with the GG genotype, or a better response as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to interferon and ribavirin therapy.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448102324>2049</a></td><td>IL18</td><td>rs187238</td><td>ribavirin</td><td>Hepatitis C, Chronic</td><td>3</td><td>CG</td><td>Efficacy</td><td>Patients with the CG genotype and chronic hepatitis C may have a poorer response to treatment with interferons and ribavirin as compared to patients with the GG genotype, or a better response as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to interferon and ribavirin therapy.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448102337>2050</a></td><td>IL18</td><td>rs1946518</td><td>interferons</td><td>Hepatitis C, Chronic</td><td>3</td><td>GT</td><td>Efficacy</td><td>Patients with the GT genotype and chronic hepatitis C may have a poorer response to treatment with interferons and ribavirin as compared to patients with the TT genotype, or a better response as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to interferon and ribavirin therapy.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448102337>2051</a></td><td>IL18</td><td>rs1946518</td><td>ribavirin</td><td>Hepatitis C, Chronic</td><td>3</td><td>GT</td><td>Efficacy</td><td>Patients with the GT genotype and chronic hepatitis C may have a poorer response to treatment with interferons and ribavirin as compared to patients with the TT genotype, or a better response as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to interferon and ribavirin therapy.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448265266>2052</a></td><td>IL12B</td><td>rs3213094</td><td>ustekinumab</td><td>Psoriasis</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype and Psoriasis may have increased response to ustekinumab compared to patients with the CC genotype. Other clinical and genetic factors may affect response to ustekinumab.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447953291>2053</a></td><td>GSTA1</td><td>rs3957356</td><td>cyclophosphamide</td><td>Lupus Nephritis</td><td>3</td><td>CC</td><td>Efficacy</td><td>Patients with the CC genotype and lupus nephritis may have an increased response to cyclophosphamide as compared to patients with the CT genotype. Other genetic and clinical factors may also influence a patient's response to cyclophosphamide.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447953304>2054</a></td><td>HTR1A</td><td>rs6295</td><td>milnacipran</td><td>Depressive Disorder</td><td>3</td><td>CC</td><td>Efficacy</td><td>Patients with the CC genotype and depressive disorder may have an increased response to milnacipran as compared to patients with the GG genotype. However, results conflict. Other genetic and clinical factors may also influence a patient's response to milnacipran.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447960335>2055</a></td><td>SLC28A2</td><td>rs11854484</td><td>gemcitabine</td><td>Carcinoma, Non-Small-Cell Lung</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype and non-small-cell lung cancer may have a longer median survival time when treated with gemcitabine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence survival.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447964346>2056</a></td><td>-</td><td>rs2960436</td><td>fluorouracil</td><td>Stomach Neoplasms</td><td>3</td><td>AA</td><td>Efficacy</td><td>Patients with the AA genotype and stomach cancer may have better survival outcomes when treated with fluorouracil as compared to patients with the GG genotype. Other genetic and clinical factors may also influence survival outcome.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447960191>2057</a></td><td>ADRB2</td><td>rs1042714</td><td>terbutaline</td><td></td><td>3</td><td>CG</td><td>Efficacy</td><td>Patients with the CG genotype may experience faster desensitization to effects of terbutaline as compared to patients with the GG genotype. Other genetic and clinical factors may also influence desensitization to terbutaline.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447961329>2058</a></td><td>DUSP1</td><td>rs881152</td><td>salbutamol</td><td>Asthma</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype and asthma may have a poorer response to salbutamol treatment as compared to patients with the GG genotype, or a better response as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to salbutamol.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447964292>2059</a></td><td>ADGRL3</td><td>rs734644</td><td>methylphenidate</td><td>Attention Deficit Disorder with Hyperactivity</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype and ADHD may have a faster response when treated with methylphenidate as compared to patients with the TT genotype. Other genetic and clinical factors may also influence the speed of efficacy of methylphenidate.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448525395>2060</a></td><td>IL17RA</td><td>rs4819554</td><td>Tumor necrosis factor alpha (TNF-alpha) inhibitors</td><td>Psoriasis</td><td>3</td><td>AA</td><td>Efficacy</td><td>Patients with the AA genotype and psoriasis may have a better response to treatment with anti-TNF drugs as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence response to anti-TNF drugs.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448100630>2061</a></td><td>DRD2</td><td>rs6277</td><td>methadone</td><td>Substance-Related Disorders</td><td>4</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype may have a better response to treatment with methadone as compared to patients with the GG genotype, or a poorer response as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to methadone.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447987227>2062</a></td><td>ERICH3</td><td>rs11580409</td><td>citalopram</td><td>Depressive Disorder</td><td>3</td><td>AC</td><td>Efficacy</td><td>Patients with depressive disorder and the AC genotype may have improved response to citalopram or escitalopram as compared to patients with the CC genotypes and worse response as compared to patients with the AA genotype. Other clinical and genetic factors may also influence response to citalopram and escitalopram in patients with depressive disorder.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447987227>2063</a></td><td>ERICH3</td><td>rs11580409</td><td>escitalopram</td><td>Depressive Disorder</td><td>3</td><td>AC</td><td>Efficacy</td><td>Patients with depressive disorder and the AC genotype may have improved response to citalopram or escitalopram as compared to patients with the CC genotypes and worse response as compared to patients with the AA genotype. Other clinical and genetic factors may also influence response to citalopram and escitalopram in patients with depressive disorder.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447990925>2064</a></td><td>MGAT4A</td><td>rs885036</td><td>bevacizumab</td><td>Colorectal Neoplasms</td><td>3</td><td>GG</td><td>Efficacy</td><td>The GG genotype in patients with colorectal cancer who are treated with bevacizumab, capecitabine, oxaliplatin AND cetuximab may be associated with increased progression-free survival as compared to patients with the AG or AA genotypes. Other clinical and genetic factors may also influence length of progression-free survival in patients with colorectal cancer.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447990925>2065</a></td><td>MGAT4A</td><td>rs885036</td><td>capecitabine</td><td>Colorectal Neoplasms</td><td>3</td><td>GG</td><td>Efficacy</td><td>The GG genotype in patients with colorectal cancer who are treated with bevacizumab, capecitabine, oxaliplatin AND cetuximab may be associated with increased progression-free survival as compared to patients with the AG or AA genotypes. Other clinical and genetic factors may also influence length of progression-free survival in patients with colorectal cancer.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447990925>2066</a></td><td>MGAT4A</td><td>rs885036</td><td>cetuximab</td><td>Colorectal Neoplasms</td><td>3</td><td>GG</td><td>Efficacy</td><td>The GG genotype in patients with colorectal cancer who are treated with bevacizumab, capecitabine, oxaliplatin AND cetuximab may be associated with increased progression-free survival as compared to patients with the AG or AA genotypes. Other clinical and genetic factors may also influence length of progression-free survival in patients with colorectal cancer.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447990925>2067</a></td><td>MGAT4A</td><td>rs885036</td><td>oxaliplatin</td><td>Colorectal Neoplasms</td><td>3</td><td>GG</td><td>Efficacy</td><td>The GG genotype in patients with colorectal cancer who are treated with bevacizumab, capecitabine, oxaliplatin AND cetuximab may be associated with increased progression-free survival as compared to patients with the AG or AA genotypes. Other clinical and genetic factors may also influence length of progression-free survival in patients with colorectal cancer.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448100695>2068</a></td><td>GALR1</td><td>rs2717162</td><td>nicotine</td><td>Tobacco Use Disorder</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype who are addicted to smoking and are trying to quit may have a greater cravings for nicotine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence nicotine cravings.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448100751>2069</a></td><td>DOT1L</td><td>rs2269879</td><td>hydrochlorothiazide</td><td>Hypertension</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype and hypertension may have better blood pressure response to treatment with hydrochlorothiazide as compared to patients with the CC genotype. However, this was not significantly replicated in a second cohort. Other genetic and clinical factors may also influence blood pressure response to hydrochlorothiazide.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447979272>2070</a></td><td>ESR1</td><td>rs2234693</td><td>leflunomide</td><td>Arthritis, Rheumatoid</td><td>3</td><td>CT</td><td>Efficacy</td><td>Female patients with the CT genotype and rheumatoid arthritis may have a poorer response when treated with leflunomide as compared to patients with the TT genotype, or a better response as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to leflunomide.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448568152>2071</a></td><td>VASP</td><td>rs10995</td><td>hydrochlorothiazide</td><td>Hypertension</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with AG genotype may have increased blood pressure response to hydrochlorothiazide in people with Hypertension as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to hydrochlorothiazide.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447990940>2072</a></td><td>ERICH3</td><td>rs696692</td><td>citalopram</td><td>Depressive Disorder</td><td>3</td><td>CT</td><td>Efficacy</td><td>The CT genotype in patients with depressive disorder who are taking citalopram or escitalopram may may be associated with higher baseline serotonin levels and greater decreases in serotonin levels as compared to the CC genotype and lower baseline and smaller decreases in serotonin levels as compared to the TT genotype. This variant was not associated with response to citalopram or escitalopram despite being associated with plasma serotonin levels, biomarkers associated with response. Other clinical and genetic factors may also influence plasma levels of serotonin in patients with depressive disorder. Other clinical and genetic factors may also influence plasma levels of serotonin in patients with depressive disorder.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447990940>2073</a></td><td>ERICH3</td><td>rs696692</td><td>escitalopram</td><td>Depressive Disorder</td><td>3</td><td>CT</td><td>Efficacy</td><td>The CT genotype in patients with depressive disorder who are taking citalopram or escitalopram may may be associated with higher baseline serotonin levels and greater decreases in serotonin levels as compared to the CC genotype and lower baseline and smaller decreases in serotonin levels as compared to the TT genotype. This variant was not associated with response to citalopram or escitalopram despite being associated with plasma serotonin levels, biomarkers associated with response. Other clinical and genetic factors may also influence plasma levels of serotonin in patients with depressive disorder. Other clinical and genetic factors may also influence plasma levels of serotonin in patients with depressive disorder.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448100514>2074</a></td><td>ACY3</td><td>rs2514036</td><td>bisoprolol</td><td>Hypertension</td><td>3</td><td>TT</td><td>Efficacy</td><td>Men with the TT genotype and hypertension may have increased response to bisoprolol compared to men with the CC and CT genotypes. Other factors may affect response to bisoprolol.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448101114>2075</a></td><td>APOB</td><td>rs676210</td><td>fenofibrate</td><td>Hypertriglyceridemia</td><td>3</td><td>AA</td><td>Efficacy</td><td>Patients with the AA genotype and hypertriglyceridemia may have greater decreases in triglyceride levels when treated with fenofibrate as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence response to fenofibrate.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448104353>2076</a></td><td>VEGFA</td><td>rs2010963</td><td>capecitabine</td><td>Colorectal Neoplasms</td><td>3</td><td>GG</td><td>Efficacy</td><td>Patients with the GG genotype and colorectal cancer may have a better response when treated with capecitabine and oxaliplatin (XELOX) as compared to patients with the CG genotype. Other genetic and clinical factors may also influence response to XELOX treatment.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448104353>2077</a></td><td>VEGFA</td><td>rs2010963</td><td>oxaliplatin</td><td>Colorectal Neoplasms</td><td>3</td><td>GG</td><td>Efficacy</td><td>Patients with the GG genotype and colorectal cancer may have a better response when treated with capecitabine and oxaliplatin (XELOX) as compared to patients with the CG genotype. Other genetic and clinical factors may also influence response to XELOX treatment.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448266599>2078</a></td><td>KLRD1</td><td>rs2302489</td><td>adalimumab</td><td>Arthritis, Rheumatoid</td><td>3</td><td>AT</td><td>Efficacy</td><td>Patients with the AT genotype and rheumatoid arthritis may have better response to EULAR therapy after 12 weeks of treatment compared to patients with the TT genotype. Other clinical and genetic factors may affect EULAR response.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448266599>2079</a></td><td>KLRD1</td><td>rs2302489</td><td>certolizumab pegol</td><td>Arthritis, Rheumatoid</td><td>3</td><td>AT</td><td>Efficacy</td><td>Patients with the AT genotype and rheumatoid arthritis may have better response to EULAR therapy after 12 weeks of treatment compared to patients with the TT genotype. Other clinical and genetic factors may affect EULAR response.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448266599>2080</a></td><td>KLRD1</td><td>rs2302489</td><td>etanercept</td><td>Arthritis, Rheumatoid</td><td>3</td><td>AT</td><td>Efficacy</td><td>Patients with the AT genotype and rheumatoid arthritis may have better response to EULAR therapy after 12 weeks of treatment compared to patients with the TT genotype. Other clinical and genetic factors may affect EULAR response.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448266599>2081</a></td><td>KLRD1</td><td>rs2302489</td><td>glucocorticoids</td><td>Arthritis, Rheumatoid</td><td>3</td><td>AT</td><td>Efficacy</td><td>Patients with the AT genotype and rheumatoid arthritis may have better response to EULAR therapy after 12 weeks of treatment compared to patients with the TT genotype. Other clinical and genetic factors may affect EULAR response.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448266599>2082</a></td><td>KLRD1</td><td>rs2302489</td><td>infliximab</td><td>Arthritis, Rheumatoid</td><td>3</td><td>AT</td><td>Efficacy</td><td>Patients with the AT genotype and rheumatoid arthritis may have better response to EULAR therapy after 12 weeks of treatment compared to patients with the TT genotype. Other clinical and genetic factors may affect EULAR response.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448266599>2083</a></td><td>KLRD1</td><td>rs2302489</td><td>methotrexate</td><td>Arthritis, Rheumatoid</td><td>3</td><td>AT</td><td>Efficacy</td><td>Patients with the AT genotype and rheumatoid arthritis may have better response to EULAR therapy after 12 weeks of treatment compared to patients with the TT genotype. Other clinical and genetic factors may affect EULAR response.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448266609>2084</a></td><td>KLRC1</td><td>rs7301582</td><td>adalimumab</td><td>Arthritis, Rheumatoid</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype and rheumatoid arthritis may have better response to EULAR therapy compared to patients with the CC genotypes. Other clinical and genetic factors may affect response to EULAR therapy.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448266609>2085</a></td><td>KLRC1</td><td>rs7301582</td><td>certolizumab pegol</td><td>Arthritis, Rheumatoid</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype and rheumatoid arthritis may have better response to EULAR therapy compared to patients with the CC genotypes. Other clinical and genetic factors may affect response to EULAR therapy.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448266609>2086</a></td><td>KLRC1</td><td>rs7301582</td><td>etanercept</td><td>Arthritis, Rheumatoid</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype and rheumatoid arthritis may have better response to EULAR therapy compared to patients with the CC genotypes. Other clinical and genetic factors may affect response to EULAR therapy.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448266609>2087</a></td><td>KLRC1</td><td>rs7301582</td><td>glucocorticoids</td><td>Arthritis, Rheumatoid</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype and rheumatoid arthritis may have better response to EULAR therapy compared to patients with the CC genotypes. Other clinical and genetic factors may affect response to EULAR therapy.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448266609>2088</a></td><td>KLRC1</td><td>rs7301582</td><td>infliximab</td><td>Arthritis, Rheumatoid</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype and rheumatoid arthritis may have better response to EULAR therapy compared to patients with the CC genotypes. Other clinical and genetic factors may affect response to EULAR therapy.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448266609>2089</a></td><td>KLRC1</td><td>rs7301582</td><td>methotrexate</td><td>Arthritis, Rheumatoid</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype and rheumatoid arthritis may have better response to EULAR therapy compared to patients with the CC genotypes. Other clinical and genetic factors may affect response to EULAR therapy.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447960238>2090</a></td><td>EPHX1</td><td>rs1051740</td><td>phenprocoumon</td><td></td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype may have a reduced likelihood of being overanticoagulated when treated with phenprocoumon, and may require an increased dose, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to and dose of phenprocoumon.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447960930>2091</a></td><td>DRD2</td><td>rs1799732</td><td>bupropion</td><td>Tobacco Use Disorder</td><td>3</td><td>GG</td><td>Efficacy</td><td>Patients with the GG genotype who are tobacco dependent may have a greater likelihood of abstinence when treated with bupropion as compared to patients with the G/del or del/del genotype. Other genetic and clinical factors may also influence smoking cessation.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448100242>2092</a></td><td>LDLR</td><td>rs2738466</td><td>pravastatin</td><td>Vascular Diseases</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype and vascular diseases may have a poorer response to pravastatin treatment as compared to patients with the GG genotype, or a better response as compared to patients with the AA genotype. Other genetic and clinical factors may also influence pravastatin response.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449146840>2093</a></td><td>SLC29A1</td><td>rs760370</td><td>tipiracil hydrochloride</td><td>Colorectal Neoplasms</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with colorectal cancer and the AG genotype may have an improved response to tipiracil hydrochloride and trifluridine as compared to patients with the AA genotypes. Other clinical and genetic factors may also have an influence on response to tipiracil hydrochloride and trifluridine in patients with colorectal cancer.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449146840>2094</a></td><td>SLC29A1</td><td>rs760370</td><td>trifluridine</td><td>Colorectal Neoplasms</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with colorectal cancer and the AG genotype may have an improved response to tipiracil hydrochloride and trifluridine as compared to patients with the AA genotypes. Other clinical and genetic factors may also have an influence on response to tipiracil hydrochloride and trifluridine in patients with colorectal cancer.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449147022>2095</a></td><td>IFNL3</td><td>rs12979860</td><td>sofosbuvir</td><td>Hepatitis C, Chronic</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with genotypes CT may have increased likelihood of virological relapse when treated with sofosbuvir, velpatasvir and voxilaprevir for 8 weeks in people with Hepatitis C as compared to patients with genotype CC.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449147022>2096</a></td><td>IFNL4</td><td>rs12979860</td><td>sofosbuvir</td><td>Hepatitis C, Chronic</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with genotypes CT may have increased likelihood of virological relapse when treated with sofosbuvir, velpatasvir and voxilaprevir for 8 weeks in people with Hepatitis C as compared to patients with genotype CC.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449147022>2097</a></td><td>IFNL3</td><td>rs12979860</td><td>velpatasvir</td><td>Hepatitis C, Chronic</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with genotypes CT may have increased likelihood of virological relapse when treated with sofosbuvir, velpatasvir and voxilaprevir for 8 weeks in people with Hepatitis C as compared to patients with genotype CC.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449147022>2098</a></td><td>IFNL4</td><td>rs12979860</td><td>velpatasvir</td><td>Hepatitis C, Chronic</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with genotypes CT may have increased likelihood of virological relapse when treated with sofosbuvir, velpatasvir and voxilaprevir for 8 weeks in people with Hepatitis C as compared to patients with genotype CC.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449147022>2099</a></td><td>IFNL3</td><td>rs12979860</td><td>voxilaprevir</td><td>Hepatitis C, Chronic</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with genotypes CT may have increased likelihood of virological relapse when treated with sofosbuvir, velpatasvir and voxilaprevir for 8 weeks in people with Hepatitis C as compared to patients with genotype CC.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449147022>2100</a></td><td>IFNL4</td><td>rs12979860</td><td>voxilaprevir</td><td>Hepatitis C, Chronic</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with genotypes CT may have increased likelihood of virological relapse when treated with sofosbuvir, velpatasvir and voxilaprevir for 8 weeks in people with Hepatitis C as compared to patients with genotype CC.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448099065>2101</a></td><td>NUMA1</td><td>rs10898815</td><td>calcium channel blockers</td><td>Hypertension</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype and hypertension may have a smaller decrease in diastolic blood pressure when treated with calcium channel blockers as compared to patients with the GG genotype, or a greater decrease as compared to those with the AA genotype. Other genetic and clinical factors may also influence blood pressure response to calcium channel blockers.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448099080>2102</a></td><td>PICALM</td><td>rs588076</td><td>calcium channel blockers</td><td>Hypertension</td><td>3</td><td>CG</td><td>Efficacy</td><td>Patients with the CG genotype and hypertension may have a smaller decrease in blood pressure when treated with calcium channel blockers as compared to patients with the GG genotype, or a greater decrease as compared to patients with the CC genotype. Other genetic and clinical factors may also influence blood pressure response to calcium channel blockers.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448264186>2103</a></td><td>SCARB1</td><td>rs10846744</td><td>peginterferon alfa-2a</td><td>Hepatitis C, Chronic</td><td>3</td><td>CG</td><td>Efficacy</td><td>Patients with the CG genotype may have increased sustained virological response (svr) when treated with peginterferon alpha and ribavirin in people with Hepatitis C, Chronic as compared to patients with genotypes GG. Other genetic and clinical factors may also influence peginterferon response.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448264186>2104</a></td><td>SCARB1</td><td>rs10846744</td><td>ribavirin</td><td>Hepatitis C, Chronic</td><td>3</td><td>CG</td><td>Efficacy</td><td>Patients with the CG genotype may have increased sustained virological response (svr) when treated with peginterferon alpha and ribavirin in people with Hepatitis C, Chronic as compared to patients with genotypes GG. Other genetic and clinical factors may also influence peginterferon response.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448103935>2105</a></td><td>NOS1AP</td><td>rs10494366</td><td>repaglinide</td><td>Diabetes Mellitus, Type 2</td><td>3</td><td>GT</td><td>Efficacy</td><td>Patients with the GT genotype and type 2 diabetes may have a poorer response to treatment with repaglinide as compared to patients with the TT genotype, or a better response as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to repaglinide.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450933001>2106</a></td><td>GC</td><td>rs7041</td><td>deferasirox</td><td>beta-Thalassemia</td><td>3</td><td>AC</td><td>Efficacy</td><td>Patients with beta-thalassemia and the AC genotype may have a decreased response to deferasirox, as measured by higher liver stiffness values, as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to deferasirox.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450933052>2107</a></td><td>TNFAIP3</td><td>rs610604</td><td>Tumor necrosis factor alpha (TNF-alpha) inhibitors</td><td>Arthritis, Psoriatic;Psoriasis</td><td>3</td><td>GT</td><td>Efficacy</td><td>Patients with the GT genotype may have an increased response to anti-TNF drugs, as measured by an increase in quality of life scores, as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to anti-TNF drugs.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1043880143>2108</a></td><td>CETP</td><td>rs708272</td><td>hmg coa reductase inhibitors</td><td>Coronary Artery Disease</td><td>3</td><td>AA</td><td>Efficacy</td><td>Patients with the rs708272 AA genotype and Coronary Artery Disease who are treated with statins may have a greater reduction in cardiovascular events as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence response to statin treatment.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448100132>2109</a></td><td>RGS17</td><td>rs672170</td><td>antidepressants</td><td>Depressive Disorder, Major</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype and major depressive disorder may have increased response to antidepressants compared to patients with the GG genotype. Other factors may affect response to antidepressants.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448100146>2110</a></td><td>PON2</td><td>rs2299267</td><td>antidepressants</td><td>Depressive Disorder, Major</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype and major depressive disorder may have increased response to antidepressants compared to patients with the GG genotype. Other factors may affect response to antidepressants.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448532313>2111</a></td><td>IFNL3</td><td>rs12979860</td><td>ledipasvir</td><td>Hepatitis C, Chronic;Recurrence</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with genotype CT may have increased likelihood of relapse when treated with ledipasvir and sofosbuvir in people with Hepatitis C, Chronic as compared to patients with genotype CC. Other genetic and clinical factors may also influences response to ledipasvir/sofosbuvir therapy.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448532313>2112</a></td><td>IFNL4</td><td>rs12979860</td><td>ledipasvir</td><td>Hepatitis C, Chronic;Recurrence</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with genotype CT may have increased likelihood of relapse when treated with ledipasvir and sofosbuvir in people with Hepatitis C, Chronic as compared to patients with genotype CC. Other genetic and clinical factors may also influences response to ledipasvir/sofosbuvir therapy.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448532313>2113</a></td><td>IFNL3</td><td>rs12979860</td><td>sofosbuvir</td><td>Hepatitis C, Chronic;Recurrence</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with genotype CT may have increased likelihood of relapse when treated with ledipasvir and sofosbuvir in people with Hepatitis C, Chronic as compared to patients with genotype CC. Other genetic and clinical factors may also influences response to ledipasvir/sofosbuvir therapy.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448532313>2114</a></td><td>IFNL4</td><td>rs12979860</td><td>sofosbuvir</td><td>Hepatitis C, Chronic;Recurrence</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with genotype CT may have increased likelihood of relapse when treated with ledipasvir and sofosbuvir in people with Hepatitis C, Chronic as compared to patients with genotype CC. Other genetic and clinical factors may also influences response to ledipasvir/sofosbuvir therapy.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448276473>2115</a></td><td>SLCO1B1</td><td>rs4149056</td><td>rosiglitazone</td><td>Diabetes Mellitus, Type 2</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype may have increased response to rosiglitazone in people with type II Diabetes Mellitus as compared to patients with genotype TT. Other genetic and clinical factors may also influence the response to rosiglitazone.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448099149>2116</a></td><td>ABCB1</td><td>rs2032582</td><td>tramadol</td><td>Fractures, Bone;Pain;Pain, Postoperative</td><td>3</td><td>AC</td><td>Efficacy</td><td>Patients with the rs2032582 AC genotype may be more likely to respond to tramadol treatment as compared to patients with the CC genotype, or less likely as compared to those with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to tramadol.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183491175>2117</a></td><td>CYP3A5</td><td>rs776746</td><td>rosuvastatin</td><td>Myocardial Infarction</td><td>3</td><td>CC</td><td>Efficacy</td><td>Patients with the CC genotype and Myocardial Infarction who are treated with rosuvastatin may be more likely to achieve target LDL levels as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to rosuvastatin treatment.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444843613>2118</a></td><td>IFNL3</td><td>rs12980275</td><td>peginterferon alfa-2a</td><td>Hepatitis C, Chronic</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype may have decreased response (higher SVR rate) to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin (PEG-IFN/RBV) in people with chronic Hepatitis C as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to PEG-IFN/RBV therapy.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444843613>2119</a></td><td>IFNL3</td><td>rs12980275</td><td>peginterferon alfa-2b</td><td>Hepatitis C, Chronic</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype may have decreased response (higher SVR rate) to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin (PEG-IFN/RBV) in people with chronic Hepatitis C as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to PEG-IFN/RBV therapy.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444843613>2120</a></td><td>IFNL3</td><td>rs12980275</td><td>ribavirin</td><td>Hepatitis C, Chronic</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype may have decreased response (higher SVR rate) to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin (PEG-IFN/RBV) in people with chronic Hepatitis C as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to PEG-IFN/RBV therapy.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448099784>2121</a></td><td>GALNT14</td><td>rs12613732</td><td>cisplatin</td><td>Carcinoma, Hepatocellular</td><td>3</td><td>GT</td><td>Efficacy</td><td>Patients with the GT genotype and hepatocellular carcinoma may have a better response when treated with cisplatin, fluorouracil and mitoxantrone combination therapy as compared to patients with the TT genotype, or a poorer response as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to cisplatin, fluorouracil and mitoxantrone combination therapy.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448099784>2122</a></td><td>GALNT14</td><td>rs12613732</td><td>fluorouracil</td><td>Carcinoma, Hepatocellular</td><td>3</td><td>GT</td><td>Efficacy</td><td>Patients with the GT genotype and hepatocellular carcinoma may have a better response when treated with cisplatin, fluorouracil and mitoxantrone combination therapy as compared to patients with the TT genotype, or a poorer response as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to cisplatin, fluorouracil and mitoxantrone combination therapy.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448099784>2123</a></td><td>GALNT14</td><td>rs12613732</td><td>mitoxantrone</td><td>Carcinoma, Hepatocellular</td><td>3</td><td>GT</td><td>Efficacy</td><td>Patients with the GT genotype and hepatocellular carcinoma may have a better response when treated with cisplatin, fluorouracil and mitoxantrone combination therapy as compared to patients with the TT genotype, or a poorer response as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to cisplatin, fluorouracil and mitoxantrone combination therapy.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448103867>2124</a></td><td>TAAR6</td><td>rs4305746</td><td>aripiprazole</td><td>Schizophrenia</td><td>3</td><td>AA</td><td>Efficacy</td><td>Patients with the AA genotype and schizophrenia may have faster improvement in Brief Psychiatric Rating Scale (BPRS) scores when treated with aripiprazole as compared to patients with the GG genotype. Other genetic and clinical factors may also influence improvement in BPRS scores.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448522748>2125</a></td><td>PGLYRP4</td><td>rs2916205</td><td>Tumor necrosis factor alpha (TNF-alpha) inhibitors</td><td>Psoriasis</td><td>3</td><td>TT</td><td>Efficacy</td><td>Patients with the TT genotype and psoriasis may have a better response to treatment with anti-TNF drugs as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence response to anti-TNF drugs.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1445400672>2126</a></td><td>TLR4</td><td>rs2770150</td><td>Pertussis vaccines</td><td></td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype may have a better response to the pertussis vaccine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence efficacy of the pertussis vaccine.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1446897383>2127</a></td><td>CYP19A1</td><td>rs4646</td><td>tamoxifen</td><td>Breast Neoplasms;Menopause</td><td>3</td><td>CC</td><td>Efficacy</td><td>Post-menopausal women with the CC genotype and breast cancer may have increased disease free survival when treated with tamoxifen as compared to patients with the AA genotypes. Other genetic and clinical factors may also influence response to tamoxifen.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447952831>2128</a></td><td>HLA-E</td><td>rs1264457</td><td>adalimumab</td><td>Arthritis, Rheumatoid</td><td>3</td><td>AA</td><td>Efficacy</td><td>Women with the AA genotype and rheumatoid arthritis may have a better response when treated with dalimumab, certolizumab pegol, etanercept, glucocorticoids, infliximab or methotrexate as compared to women with the GG genotype. Other genetic and clinical factors may also influence a patient's response to adalimumab, certolizumab pegol, etanercept, glucocorticoids, infliximab or methotrexate.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447952831>2129</a></td><td>HLA-E</td><td>rs1264457</td><td>certolizumab pegol</td><td>Arthritis, Rheumatoid</td><td>3</td><td>AA</td><td>Efficacy</td><td>Women with the AA genotype and rheumatoid arthritis may have a better response when treated with dalimumab, certolizumab pegol, etanercept, glucocorticoids, infliximab or methotrexate as compared to women with the GG genotype. Other genetic and clinical factors may also influence a patient's response to adalimumab, certolizumab pegol, etanercept, glucocorticoids, infliximab or methotrexate.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447952831>2130</a></td><td>HLA-E</td><td>rs1264457</td><td>etanercept</td><td>Arthritis, Rheumatoid</td><td>3</td><td>AA</td><td>Efficacy</td><td>Women with the AA genotype and rheumatoid arthritis may have a better response when treated with dalimumab, certolizumab pegol, etanercept, glucocorticoids, infliximab or methotrexate as compared to women with the GG genotype. Other genetic and clinical factors may also influence a patient's response to adalimumab, certolizumab pegol, etanercept, glucocorticoids, infliximab or methotrexate.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447952831>2131</a></td><td>HLA-E</td><td>rs1264457</td><td>glucocorticoids</td><td>Arthritis, Rheumatoid</td><td>3</td><td>AA</td><td>Efficacy</td><td>Women with the AA genotype and rheumatoid arthritis may have a better response when treated with dalimumab, certolizumab pegol, etanercept, glucocorticoids, infliximab or methotrexate as compared to women with the GG genotype. Other genetic and clinical factors may also influence a patient's response to adalimumab, certolizumab pegol, etanercept, glucocorticoids, infliximab or methotrexate.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447952831>2132</a></td><td>HLA-E</td><td>rs1264457</td><td>infliximab</td><td>Arthritis, Rheumatoid</td><td>3</td><td>AA</td><td>Efficacy</td><td>Women with the AA genotype and rheumatoid arthritis may have a better response when treated with dalimumab, certolizumab pegol, etanercept, glucocorticoids, infliximab or methotrexate as compared to women with the GG genotype. Other genetic and clinical factors may also influence a patient's response to adalimumab, certolizumab pegol, etanercept, glucocorticoids, infliximab or methotrexate.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447952831>2133</a></td><td>HLA-E</td><td>rs1264457</td><td>methotrexate</td><td>Arthritis, Rheumatoid</td><td>3</td><td>AA</td><td>Efficacy</td><td>Women with the AA genotype and rheumatoid arthritis may have a better response when treated with dalimumab, certolizumab pegol, etanercept, glucocorticoids, infliximab or methotrexate as compared to women with the GG genotype. Other genetic and clinical factors may also influence a patient's response to adalimumab, certolizumab pegol, etanercept, glucocorticoids, infliximab or methotrexate.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448099574>2134</a></td><td>SLCO1B1</td><td>rs2291075</td><td>cytarabine</td><td>Leukemia, Myeloid, Acute</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype may have more favorable event-free and overall survival in children with de novo acute myeloid leukemia (AML) treated with cytarabine, daunorubicin, etoposide and mitoxantrone as compared to patients with genotype CC. Other genetic and clinical factors may also influence the treatment outcome in acute myeloid leukemia.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448099574>2135</a></td><td>SLCO1B1</td><td>rs2291075</td><td>daunorubicin</td><td>Leukemia, Myeloid, Acute</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype may have more favorable event-free and overall survival in children with de novo acute myeloid leukemia (AML) treated with cytarabine, daunorubicin, etoposide and mitoxantrone as compared to patients with genotype CC. Other genetic and clinical factors may also influence the treatment outcome in acute myeloid leukemia.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448099574>2136</a></td><td>SLCO1B1</td><td>rs2291075</td><td>etoposide</td><td>Leukemia, Myeloid, Acute</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype may have more favorable event-free and overall survival in children with de novo acute myeloid leukemia (AML) treated with cytarabine, daunorubicin, etoposide and mitoxantrone as compared to patients with genotype CC. Other genetic and clinical factors may also influence the treatment outcome in acute myeloid leukemia.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448099574>2137</a></td><td>SLCO1B1</td><td>rs2291075</td><td>mitoxantrone</td><td>Leukemia, Myeloid, Acute</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype may have more favorable event-free and overall survival in children with de novo acute myeloid leukemia (AML) treated with cytarabine, daunorubicin, etoposide and mitoxantrone as compared to patients with genotype CC. Other genetic and clinical factors may also influence the treatment outcome in acute myeloid leukemia.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1043872988>2138</a></td><td>KLC1</td><td>rs861539</td><td>fluorouracil</td><td>Colorectal Neoplasms</td><td>3</td><td>AA</td><td>Efficacy</td><td>Patients with the AA genotype may have increased progression free survival in people with colorectal cancer when treated with fluorouracil, irinotecan and leucovorin as compared to patients with the GG genotype. Other clinical or genetic factors may also influence a patient's response.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1043872988>2139</a></td><td>XRCC3</td><td>rs861539</td><td>fluorouracil</td><td>Colorectal Neoplasms</td><td>3</td><td>AA</td><td>Efficacy</td><td>Patients with the AA genotype may have increased progression free survival in people with colorectal cancer when treated with fluorouracil, irinotecan and leucovorin as compared to patients with the GG genotype. Other clinical or genetic factors may also influence a patient's response.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1043872988>2140</a></td><td>KLC1</td><td>rs861539</td><td>irinotecan</td><td>Colorectal Neoplasms</td><td>3</td><td>AA</td><td>Efficacy</td><td>Patients with the AA genotype may have increased progression free survival in people with colorectal cancer when treated with fluorouracil, irinotecan and leucovorin as compared to patients with the GG genotype. Other clinical or genetic factors may also influence a patient's response.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1043872988>2141</a></td><td>XRCC3</td><td>rs861539</td><td>irinotecan</td><td>Colorectal Neoplasms</td><td>3</td><td>AA</td><td>Efficacy</td><td>Patients with the AA genotype may have increased progression free survival in people with colorectal cancer when treated with fluorouracil, irinotecan and leucovorin as compared to patients with the GG genotype. Other clinical or genetic factors may also influence a patient's response.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1043872988>2142</a></td><td>KLC1</td><td>rs861539</td><td>leucovorin</td><td>Colorectal Neoplasms</td><td>3</td><td>AA</td><td>Efficacy</td><td>Patients with the AA genotype may have increased progression free survival in people with colorectal cancer when treated with fluorouracil, irinotecan and leucovorin as compared to patients with the GG genotype. Other clinical or genetic factors may also influence a patient's response.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1043872988>2143</a></td><td>XRCC3</td><td>rs861539</td><td>leucovorin</td><td>Colorectal Neoplasms</td><td>3</td><td>AA</td><td>Efficacy</td><td>Patients with the AA genotype may have increased progression free survival in people with colorectal cancer when treated with fluorouracil, irinotecan and leucovorin as compared to patients with the GG genotype. Other clinical or genetic factors may also influence a patient's response.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183605989>2144</a></td><td>CACNA1C</td><td>rs2239128</td><td>calcium channel blockers</td><td>Hypertension</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype and hypertension may have a better blood pressure response when treated with calcium channel blockers, including amlodipine, felodipine, lacidipine, nifedipine or nitrendipine, as compared to patients with the TT genotype, or a poorer blood pressure response compared to patients with the CC genotype. Other genetic and clinical factors may also influence blood pressure response.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448125499>2145</a></td><td>SLC15A2</td><td>rs2257212</td><td>sorafenib</td><td>Carcinoma, Hepatocellular</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with genotype CT have longer progression-free survival time when treated with sorafenib as compared to patients with CC genotype. Other genetic and clinical factors may also influence the response to sorafenib.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449167245>2146</a></td><td>ALDH1L1</td><td>rs2886059</td><td>methylphenidate</td><td>Attention Deficit Disorder with Hyperactivity</td><td>3</td><td>AC</td><td>Efficacy</td><td>Patients with the AC genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to methylphenidate.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448531101>2147</a></td><td>CES1</td><td>rs8192950</td><td>clopidogrel</td><td>Constriction, Pathologic;Ischemic Attack, Transient;Stroke</td><td>3</td><td>GT</td><td>Efficacy</td><td>Patients with the GT genotype and stenosis may be less likely to suffer from a transient ischemic attack as compared to patients with the TT genotypes when taking clopidogrel. Other clinical and genetic factors affect response to clopidogrel.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655386075>2148</a></td><td>ABCB1</td><td>rs1045642</td><td>cytarabine</td><td>Leukemia, Myeloid, Acute</td><td>3</td><td>AA</td><td>Efficacy</td><td>Patients with the AA genotype may have increased response to cytarabine regimens as compared to patients with the GG genotype, however the evidence is highly contradictory. Other genetic and clinical factors may also influence response to cytarabine regimens.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183684172>2149</a></td><td>ABCB1</td><td>rs2032582</td><td>cytarabine</td><td>Leukemia, Myeloid, Acute</td><td>3</td><td>AC</td><td>Efficacy</td><td>Patients with the AC genotype and acute myeloid leukemia who are treated with cytarabine, idarubicin, or cytrarabine, daunorubicin and dexrazoxane may have an increased response as compared to the CC, CT, or TT genotypes. Some contradictory evidence exists for these associations. Other genetic and clinical factors may also influence a patient's response to cytarabine and idarubicin or cytarabine, daunorubicin and dexrazoxane treatment.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183684172>2150</a></td><td>ABCB1</td><td>rs2032582</td><td>daunorubicin</td><td>Leukemia, Myeloid, Acute</td><td>3</td><td>AC</td><td>Efficacy</td><td>Patients with the AC genotype and acute myeloid leukemia who are treated with cytarabine, idarubicin, or cytrarabine, daunorubicin and dexrazoxane may have an increased response as compared to the CC, CT, or TT genotypes. Some contradictory evidence exists for these associations. Other genetic and clinical factors may also influence a patient's response to cytarabine and idarubicin or cytarabine, daunorubicin and dexrazoxane treatment.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183684172>2151</a></td><td>ABCB1</td><td>rs2032582</td><td>dexrazoxane</td><td>Leukemia, Myeloid, Acute</td><td>3</td><td>AC</td><td>Efficacy</td><td>Patients with the AC genotype and acute myeloid leukemia who are treated with cytarabine, idarubicin, or cytrarabine, daunorubicin and dexrazoxane may have an increased response as compared to the CC, CT, or TT genotypes. Some contradictory evidence exists for these associations. Other genetic and clinical factors may also influence a patient's response to cytarabine and idarubicin or cytarabine, daunorubicin and dexrazoxane treatment.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183684172>2152</a></td><td>ABCB1</td><td>rs2032582</td><td>idarubicin</td><td>Leukemia, Myeloid, Acute</td><td>3</td><td>AC</td><td>Efficacy</td><td>Patients with the AC genotype and acute myeloid leukemia who are treated with cytarabine, idarubicin, or cytrarabine, daunorubicin and dexrazoxane may have an increased response as compared to the CC, CT, or TT genotypes. Some contradictory evidence exists for these associations. Other genetic and clinical factors may also influence a patient's response to cytarabine and idarubicin or cytarabine, daunorubicin and dexrazoxane treatment.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451100007>2153</a></td><td>PTPRD</td><td>rs324498</td><td>Antihypertensives</td><td>Hypertension</td><td>3</td><td>AA</td><td>Efficacy</td><td>Patients with the AA genotype and hypertension may be more likely to respond to antihypertensives than patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's response to antihypertensives.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451100053>2154</a></td><td>-</td><td>rs11749255</td><td>Antihypertensives</td><td>Hypertension</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype and hypertension may be more likely to respond to antihypertensives than patients with the AA genotype, but less likely to respond than patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to antihypertensives.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451103240>2155</a></td><td>SLCO1B3</td><td>rs4149117</td><td>mycophenolic acid</td><td>lung transplantation;overall survival</td><td>3</td><td>GG</td><td>Efficacy</td><td>Patients with the GG genotype who are treated with mycophenolic acid following lung transplantation may have increased survival rates as compared to patients with the GT or TT genotypes. Other genetic and clinical factors may also affect response to mycophenolic acid. in lung transplant patients.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451117640>2156</a></td><td>C5orf56</td><td>rs12521868</td><td>hydrochlorothiazide</td><td>Hypertension</td><td>3</td><td>GT</td><td>Efficacy</td><td>Patients with hypertension and the GT genotype may have a decreased response to hydrochlorothiazide, as measured by an increase in systolic blood pressure, as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to hydrochlorothiazide.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451117646>2157</a></td><td>KCNK3</td><td>rs1275988</td><td>candesartan</td><td>Hypertension</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with hypertension and the CT genotype may have an increased response to candesartan, as measured by a decrease in systolic blood pressure, as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to candesartan.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451118241>2158</a></td><td>CSK</td><td>rs1378942</td><td>hydrochlorothiazide</td><td>Hypertension</td><td>3</td><td>AC</td><td>Efficacy</td><td>Patients with hypertension and the AC genotype may have a decreased response to hydrochlorothiazide, as measured by an increase in systolic blood pressure, as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to hydrochlorothiazide.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451118277>2159</a></td><td>PDE3A</td><td>rs12579720</td><td>hydrochlorothiazide</td><td>Hypertension</td><td>3</td><td>GG</td><td>Efficacy</td><td>Patients with hypertensions and the GG genotype may have a decreased response to hydrochlorothiazide, as measured by an increase in systolic blood pressure, as compared to patients with the CC or CG genotypes. Other genetic and clincial factors may also affect a patient's response to hydrochlorothiazide.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451118326>2160</a></td><td>STN1</td><td>rs4387287</td><td>atenolol</td><td>Hypertension</td><td>3</td><td>CC</td><td>Efficacy</td><td>Patients with hypertension and the CC genotype may have an increased response to atenolol, as measured by a decrease in systolic blood pressure, as compared to patient with the AA or AC genotypes. Other genetic and clinical factors may also affect a patient's response to atenolol.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451118332>2161</a></td><td>TBX2</td><td>rs8068318</td><td>atenolol</td><td>Hypertension</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with hypertension and the CT genotype may have a decreased response to atenolol, as measured by an increase in systolic blood pressure, as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to atenolol.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450811948>2162</a></td><td>OPRM1</td><td>rs524731</td><td>ethanol</td><td></td><td>3</td><td>AC</td><td>Efficacy</td><td>Patients with the AC genotype may have increased subjective responses to alcohol as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to alcohol.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449167200>2163</a></td><td>SPSB2</td><td>rs12302749</td><td>methylphenidate</td><td>Attention Deficit Disorder with Hyperactivity</td><td>3</td><td>CC</td><td>Efficacy</td><td>Patients with the CC genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to methylphenidate.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449168656>2164</a></td><td>-</td><td>rs7316769</td><td>duloxetine</td><td>Depressive Disorder, Major</td><td>3</td><td>TT</td><td>Efficacy</td><td>Patients with the TT genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the GG or GT genotypes. Other genetic and clinical factors may also affect a patient's response to duloxetine.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449168663>2165</a></td><td>-</td><td>rs7306991</td><td>duloxetine</td><td>Depressive Disorder, Major</td><td>3</td><td>TT</td><td>Efficacy</td><td>Patients with the TT genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the AA or AT genotypes. Other genetic and clinical factors may also affect a patient's response to duloxetine.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449167469>2166</a></td><td>SENP3</td><td>rs11552708</td><td>methylphenidate</td><td>Attention Deficit Disorder with Hyperactivity</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to methylphenidate.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449167480>2167</a></td><td>ESYT2</td><td>rs1061735</td><td>methylphenidate</td><td>Attention Deficit Disorder with Hyperactivity</td><td>3</td><td>GG</td><td>Efficacy</td><td>Patients with the GG genotype and Attention Deficit Disorder with Hyperactivity may have an increased response to treatment with methylphenidate as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to methylphenidate.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449168350>2168</a></td><td>ZNF385D</td><td>rs9819548</td><td>duloxetine</td><td>Depressive Disorder, Major</td><td>3</td><td>GG</td><td>Efficacy</td><td>Patients with the GG genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449168357>2169</a></td><td>ZNF385D</td><td>rs13093500</td><td>duloxetine</td><td>Depressive Disorder, Major</td><td>3</td><td>TT</td><td>Efficacy</td><td>Patients with the TT genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449168475>2170</a></td><td>INVS</td><td>rs10123866</td><td>duloxetine</td><td>Depressive Disorder, Major</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449168482>2171</a></td><td>TEX10</td><td>rs7472</td><td>duloxetine</td><td>Depressive Disorder, Major</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449168489>2172</a></td><td>TEX10</td><td>rs10124893</td><td>duloxetine</td><td>Depressive Disorder, Major</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449168496>2173</a></td><td>TEX10</td><td>rs7035619</td><td>duloxetine</td><td>Depressive Disorder, Major</td><td>3</td><td>AT</td><td>Efficacy</td><td>Patients with the AT genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449168503>2174</a></td><td>TEX10</td><td>rs6479008</td><td>duloxetine</td><td>Depressive Disorder, Major</td><td>3</td><td>AC</td><td>Efficacy</td><td>Patients with the AC genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449168510>2175</a></td><td>TEX10</td><td>rs10989064</td><td>duloxetine</td><td>Depressive Disorder, Major</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to duloxetine.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449168691>2176</a></td><td>ATP10A</td><td>rs12595802</td><td>duloxetine</td><td>Depressive Disorder, Major</td><td>3</td><td>AA</td><td>Efficacy</td><td>Patients with the AA genotype may have an increased response to treatment with duloxetine for major depressive disorder as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's response to duloxetine.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450814430>2177</a></td><td>MTHFR</td><td>rs1801133</td><td>l-methylfolate</td><td>Depressive Disorder, Major</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype may show improved response to pharmacotherapy for depression when given folate supplements. Please note that there is currently no evidence regarding the association between the GG genotype and response to folate supplementation. Other genetic and clinical factors may also affect a patient's response to folate supplementation.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450814430>2178</a></td><td>MTHFR</td><td>rs1801133</td><td>Vitamin B-complex, Incl. Combinations</td><td>Depressive Disorder, Major</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype may show improved response to pharmacotherapy for depression when given folate supplements. Please note that there is currently no evidence regarding the association between the GG genotype and response to folate supplementation. Other genetic and clinical factors may also affect a patient's response to folate supplementation.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449715590>2179</a></td><td>UGT2B7</td><td>rs7439366</td><td>fentanyl</td><td>Pain, Postoperative</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype may have an increased response to fentanyl as compared to patients with the TT genotype. However, another study failed to find this association. Other genetic and clinical factors may also affect a patient's response to fentanyl.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449748202>2180</a></td><td>KIF6</td><td>rs20455</td><td>rosuvastatin</td><td>Hypercholesterolemia</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype may have an increased lipid-lowering response to rosuvastatin as compared to patients with the GG genotype. However, one study found no association between this variant and response to rosuvastatin. Other genetic and clinical factors may also affect a patient's response to rosuvastatin.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450811942>2181</a></td><td>OPRM1</td><td>rs553202</td><td>ethanol</td><td></td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype may have increased subjective responses to alcohol as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to alcohol.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450933023>2182</a></td><td>VDR</td><td>rs1544410</td><td>deferasirox</td><td>beta-Thalassemia</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with beta-thalassemia and the CT genotype may have a decreased response to deferasirox, as measured by higher liver stiffness values, as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to deferasirox.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450811966>2183</a></td><td>OPRM1</td><td>rs3778148</td><td>ethanol</td><td></td><td>3</td><td>GT</td><td>Efficacy</td><td>Patients with the GT genotype may have increased subjective responses to alcohol as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to alcohol.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450815172>2184</a></td><td>PPA2</td><td>rs2636719</td><td>risperidone</td><td>Schizophrenia</td><td>3</td><td>CC</td><td>Efficacy</td><td>Patients with schizophrenia and the CC genotype may have an increased response to risperidone as compared to patients with the AA or AC genotypes. Other genetic or clinical factors may also affect a patient's response to risperidone.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450933011>2185</a></td><td>UGT1A3</td><td>rs1983023</td><td>deferasirox</td><td>beta-Thalassemia</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with beta-thalassemia and the CT genotype may have a decreased response to deferasirox, as measured by higher liver stiffness values, as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's response to deferasirox.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450812410>2186</a></td><td>CACNA1C</td><td>rs2239128</td><td>nimodipine</td><td></td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype may have increased systolic blood pressure following nimodipine administration as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's blood pressure following nimodipine administration.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451103280>2187</a></td><td>SLCO1B3</td><td>rs7311358</td><td>mycophenolic acid</td><td>lung transplantation;overall survival</td><td>3</td><td>AA</td><td>Efficacy</td><td>Patients with the AA genotype who are treated with mycophenolic acid following lung transplantation may have increased survival rates as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect response to mycophenolic acid in lung transplant patients.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451117590>2188</a></td><td>RRP1B</td><td>rs9306160</td><td>atenolol</td><td>Hypertension</td><td>3</td><td>CC</td><td>Efficacy</td><td>Patients with hypertension and the CC genotype may have a decreased response to atenolol, as measured by an increase in systolic blood pressure, as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's response to atenolol.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451117620>2189</a></td><td>SH2B3</td><td>rs3184504</td><td>candesartan</td><td>Hypertension</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with hypertension and the CT genotype may have an increased response to candesartan, as measured by. a decrease in systolic blood pressure, as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's response to candesartan.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451118766>2190</a></td><td>ABCB1</td><td>rs1045642</td><td>remifentanil</td><td></td><td>3</td><td>AA</td><td>Efficacy</td><td>Patients with the AA genotype may have show increased anesthesia efficacy of remifentanil as compared to patients with the GG genotype. Other genetic and clinical factors may also affect efficacy of remifentanil in a patient.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451120561>2191</a></td><td>BST1</td><td>rs28404156</td><td>Beta blocking agents, selective</td><td>Hypertension</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with hypertension and the AG genotype may have an increased response to selective beta blockers, as measured by systolic blood pressure response, as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's response to selective beta blockers.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451121805>2192</a></td><td>-</td><td>rs6848893</td><td>oxycodone</td><td></td><td>3</td><td>TT</td><td>Efficacy</td><td>Patients with the TT genotype may have increased subjective positive effects from oxycodone as compared to patients with the CT genotype. Other genetic and clinical factors may also affect a patient's subjective response to oxycodone.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451129880>2193</a></td><td>HTR1A</td><td>rs6295</td><td>lurasidone</td><td>Schizophrenia</td><td>3</td><td>CC</td><td>Efficacy</td><td>Patients with schizophrenia and the CC genotype may have an increased response to lurasidone as compared to patients with the CG or GG genotypes. Note that this association was only found in patients of European ancestry. Other genetic and clinical factors may also affect a patient's response to lurasidone.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451130640>2194</a></td><td>RORA</td><td>rs4774388</td><td>interferon beta-1a</td><td>Multiple Sclerosis</td><td>3</td><td>TT</td><td>Efficacy</td><td>Patients with multiple sclerosis and the TT genotype may have an increased response to interferon-beta as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect a patient's response to interferon-beta.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451151920>2195</a></td><td>HTR2A</td><td>rs6313</td><td>olanzapine</td><td>Schizophrenia</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with schizophrenia and the AG genotype may have an increased response to olanzapine as compared to patients with the AA genotype. However, this was based on a subanalysis of symptom scores and the opposite association was found when analyzing a different score in the same dataset. Additionally, another study failed to find an association. Other genetic and clinical factors may also affect a patient's response to olanzapine.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451285000>2196</a></td><td>VDR</td><td>rs1544410</td><td>clodronate</td><td></td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype may have increased likelihood of resistance when treated with clodronate in people with Osteitis Deformans as compared to patients with the TT genotype. Other genetic and clinical factors may also influence the response to clodronate.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451551426>2197</a></td><td>ERCC1</td><td>rs11615</td><td>cisplatin</td><td>Carcinoma, Non-Small-Cell Lung</td><td>3</td><td>AA</td><td>Efficacy</td><td>Patients with the rs11615 AA genotype may have an increased response to treatment with cisplatin and gemcitabine as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence response to treatment with cisplatin and gemcitabine</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451551426>2198</a></td><td>ERCC1</td><td>rs11615</td><td>gemcitabine</td><td>Carcinoma, Non-Small-Cell Lung</td><td>3</td><td>AA</td><td>Efficacy</td><td>Patients with the rs11615 AA genotype may have an increased response to treatment with cisplatin and gemcitabine as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence response to treatment with cisplatin and gemcitabine</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451551460>2199</a></td><td>ERCC1</td><td>rs11615</td><td>cisplatin</td><td>Pancreatic Neoplasms</td><td>3</td><td>AA</td><td>Efficacy</td><td>Patients with the rs11615 AA genotype may have an increased response to treatment with capecitabine, cisplatin, docetaxel, epirubicin and gemcitabine as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also influence response to chemotherapy.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451551846>2200</a></td><td>GGH</td><td>rs11545077</td><td>methotrexate</td><td>Precursor Cell Lymphoblastic Leukemia-Lymphoma</td><td>3</td><td>CC</td><td>Efficacy</td><td>Patients with acute lymphoblastic leukemia (ALL) and the rs11545077 CC genotype may have an increased response to methotrexate as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to methotrexate.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451226200>2201</a></td><td>PNOC</td><td>rs4732636</td><td>buprenorphine</td><td>Neonatal Abstinence Syndrome</td><td>3</td><td>AA</td><td>Toxicity</td><td>Infants who have been exposed to buprenorphine in utero and who have the AA genotype may be more likely to require medication to treat neonatal abstinence syndrome as compared to infants with the CC genotype. However, this was not a statistically significant association. Other genetic and clinical factors may also affect severity of neonatal abstinence syndrome.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451226206>2202</a></td><td>PNOC</td><td>rs4732636</td><td>methadone</td><td>Neonatal Abstinence Syndrome</td><td>3</td><td>AA</td><td>Toxicity</td><td>Infants who have been exposed to methadone in utero and who have the AA genotype may be more likely to require medication to treat neonatal abstinence syndrome as compared to infants with the CC genotype. However, this was not a statistically significant association. Other genetic and clinical factors may also affect severity of neonatal abstinence syndrome.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451121880>2203</a></td><td>ERCC1</td><td>rs11615</td><td>cisplatin</td><td>Drug Toxicity</td><td>3</td><td>AA</td><td>Toxicity</td><td>Patients with the AA genotype may have an increased risk for toxicity when treated with cisplatin chemotherapy regimens as compared to patients with the GG genotype. However, some studies find no association with drug toxicity. Other genetic and clinical factors may also influence a patient's response to platinum-based chemotherapy.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451357200>2204</a></td><td>SLCO1B1</td><td>rs4149056</td><td>rosuvastatin</td><td>statin-related myopathy</td><td>1A</td><td>CT</td><td>Toxicity</td><td>Patients with the rs4149056 CT genotype may have increased risk of statin-related myopathy or myalgia when treated with rosuvastatin as compared to patients with genotype TT. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect risk to rosuvastatin.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451244720>2205</a></td><td>SLCO1B1</td><td>rs4149056</td><td>fluvastatin</td><td>statin-related myopathy</td><td>1A</td><td>CT</td><td>Toxicity</td><td>Patients with the rs4149056 CT genotype may have an increased risk of developing myopathy when treated with fluvastatin as compared to patients with the TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect a patient's risk of developing fluvastatin-induced myopathy.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451238365>2206</a></td><td>OPRM1</td><td>rs495491</td><td>heroin</td><td>Heroin Dependence</td><td>3</td><td>AG</td><td>Toxicity</td><td>Patients with the AG genotype may be at an increased risk of developing heroin dependence as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of developing heroin dependence.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450377208>2207</a></td><td>NAT2</td><td>rs1799930</td><td>isoniazid</td><td>Drug interaction with drug;Drug Toxicity</td><td>3</td><td>AG</td><td>Toxicity</td><td>Patients with the AG genotype who are receiving concomitant phenytoin and isoniazid may be at an increased risk of phenytoin toxicity resulting from isoniazid-phenytoin interaction as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing phenytoin toxicity when treated with both isoniazid and phenytoin.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450377208>2208</a></td><td>NAT2</td><td>rs1799930</td><td>phenytoin</td><td>Drug interaction with drug;Drug Toxicity</td><td>3</td><td>AG</td><td>Toxicity</td><td>Patients with the AG genotype who are receiving concomitant phenytoin and isoniazid may be at an increased risk of phenytoin toxicity resulting from isoniazid-phenytoin interaction as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing phenytoin toxicity when treated with both isoniazid and phenytoin.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/981238234>2209</a></td><td>FKBP5</td><td>rs1360780</td><td>clomipramine</td><td>Depression</td><td>3</td><td>CT</td><td>Toxicity</td><td>Patients with the CT genotype and depression who are treated with paroxetine, venlafaxine, clomipramine or nefazodone may have an increased risk of suicidal ideation as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to paroxetine, venlafaxine, clomipramine or nefazodone.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/981238234>2210</a></td><td>FKBP5</td><td>rs1360780</td><td>nefazodone</td><td>Depression</td><td>3</td><td>CT</td><td>Toxicity</td><td>Patients with the CT genotype and depression who are treated with paroxetine, venlafaxine, clomipramine or nefazodone may have an increased risk of suicidal ideation as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to paroxetine, venlafaxine, clomipramine or nefazodone.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/981238234>2211</a></td><td>FKBP5</td><td>rs1360780</td><td>paroxetine</td><td>Depression</td><td>3</td><td>CT</td><td>Toxicity</td><td>Patients with the CT genotype and depression who are treated with paroxetine, venlafaxine, clomipramine or nefazodone may have an increased risk of suicidal ideation as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to paroxetine, venlafaxine, clomipramine or nefazodone.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/981238234>2212</a></td><td>FKBP5</td><td>rs1360780</td><td>venlafaxine</td><td>Depression</td><td>3</td><td>CT</td><td>Toxicity</td><td>Patients with the CT genotype and depression who are treated with paroxetine, venlafaxine, clomipramine or nefazodone may have an increased risk of suicidal ideation as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to paroxetine, venlafaxine, clomipramine or nefazodone.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451337885>2213</a></td><td>NAT2</td><td>rs1041983</td><td>isoniazid</td><td>Toxic liver disease;Tuberculosis</td><td>3</td><td>CT</td><td>Toxicity</td><td>Patients with the rs1041983 CT genotype and tuberculosis may have an increased risk of developing toxic liver disease when treated with isoniazid, pyrazinamide and rifampin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of toxic liver disease when treated with isoniazid, pyrazinamide and rifampin.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451337885>2214</a></td><td>NAT2</td><td>rs1041983</td><td>pyrazinamide</td><td>Toxic liver disease;Tuberculosis</td><td>3</td><td>CT</td><td>Toxicity</td><td>Patients with the rs1041983 CT genotype and tuberculosis may have an increased risk of developing toxic liver disease when treated with isoniazid, pyrazinamide and rifampin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of toxic liver disease when treated with isoniazid, pyrazinamide and rifampin.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451337885>2215</a></td><td>NAT2</td><td>rs1041983</td><td>rifampin</td><td>Toxic liver disease;Tuberculosis</td><td>3</td><td>CT</td><td>Toxicity</td><td>Patients with the rs1041983 CT genotype and tuberculosis may have an increased risk of developing toxic liver disease when treated with isoniazid, pyrazinamide and rifampin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of toxic liver disease when treated with isoniazid, pyrazinamide and rifampin.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/981201770>2216</a></td><td>SLCO1B3</td><td>rs4149117</td><td>mycophenolate mofetil</td><td>Kidney Transplantation</td><td>3</td><td>GG</td><td>Toxicity</td><td>Patients with the GG genotype who are renal transplant recipients and are treated with mycophenolate mofetil: 1) may have an increased risk of adverse drug reactions 2) may have decreased exposure to active mycophenolic acid as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for drug-induced toxicity and exposure to mycophenolic acid.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/827848732>2217</a></td><td>CCND1</td><td>rs9344</td><td>methotrexate</td><td>Lymphoma;Osteosarcoma;Precursor Cell Lymphoblastic Leukemia-Lymphoma</td><td>3</td><td>AG</td><td>Toxicity</td><td>Patients with the rs9344 AG genotype may be at an increased risk of experiencing drug toxicity when treated with methotrexate as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of experiencing drug toxicity when treated with methotrexate.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450373589>2218</a></td><td>SLC22A1</td><td>rs628031</td><td>imatinib</td><td>Neoplasms</td><td>3</td><td>AG</td><td>Toxicity</td><td>Patients with the AG genotype and cancer may have increased clearance of imatinib, as well as a decreased response and decreased risk for toxicity when treated with imatinib as compared to patients with the GG genotype. However, one study failed to find an association between this variant and imatinib toxicity. Other genetic and clinical factors may also influence clearance, response, and risk for toxicity in patients receiving imatinib.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450814557>2219</a></td><td>OPRM1</td><td>rs2236256</td><td>cocaine</td><td>Cocaine-Related Disorders</td><td>3</td><td>AA</td><td>Toxicity</td><td>Patients with cocaine dependence and the AA genotype may have increased cocaine cue-reactivity as compared to patients with the AC or CC genotypes. Other genetic or clinical factors may also affect cocaine cue-reactivity in a patient with cocaine dependence.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449718259>2220</a></td><td>SLC22A16</td><td>rs714368</td><td>cyclophosphamide</td><td>Breast Neoplasms</td><td>3</td><td>CT</td><td>Toxicity</td><td>Patients with the CT genotype may have increased risk for nausea, but a decreased likelihood of dose delay, when treated with cyclophosphamide, doxorubicin and fluorouracil, as compared to patients with TT genotype. Other genetic and clinical factors may also influence risk for dose delay and toxicity in patients taking cyclophosphamide, doxorubicin and fluorouracil.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449718259>2221</a></td><td>SLC22A16</td><td>rs714368</td><td>doxorubicin</td><td>Breast Neoplasms</td><td>3</td><td>CT</td><td>Toxicity</td><td>Patients with the CT genotype may have increased risk for nausea, but a decreased likelihood of dose delay, when treated with cyclophosphamide, doxorubicin and fluorouracil, as compared to patients with TT genotype. Other genetic and clinical factors may also influence risk for dose delay and toxicity in patients taking cyclophosphamide, doxorubicin and fluorouracil.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449718259>2222</a></td><td>SLC22A16</td><td>rs714368</td><td>fluorouracil</td><td>Breast Neoplasms</td><td>3</td><td>CT</td><td>Toxicity</td><td>Patients with the CT genotype may have increased risk for nausea, but a decreased likelihood of dose delay, when treated with cyclophosphamide, doxorubicin and fluorouracil, as compared to patients with TT genotype. Other genetic and clinical factors may also influence risk for dose delay and toxicity in patients taking cyclophosphamide, doxorubicin and fluorouracil.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451244740>2223</a></td><td>SLCO1B1</td><td>rs4149056</td><td>pravastatin</td><td>statin-related myopathy</td><td>1A</td><td>CT</td><td>Toxicity</td><td>Patients with the rs4149056 CT genotype may have an increased risk of developing myopathy when treated with pravastatin as compared to patients with the TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect a patient's risk of experiencing pravastatin-induced myopathy.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449167086>2224</a></td><td>OPRL1</td><td>rs6090041</td><td>opioids</td><td>Opioid-Related Disorders</td><td>3</td><td>AG</td><td>Toxicity</td><td>Caucasian patients with the AG genotype may be at an increased risk of developing opioid dependence as compared to Caucasian patients with the AA genotype. Please note that this association was not observed in Hispanic or African American patients. Other genetic and clinical factors may also affect a patient's risk of developing opioid dependence.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449167086>2225</a></td><td>RGS19</td><td>rs6090041</td><td>opioids</td><td>Opioid-Related Disorders</td><td>3</td><td>AG</td><td>Toxicity</td><td>Caucasian patients with the AG genotype may be at an increased risk of developing opioid dependence as compared to Caucasian patients with the AA genotype. Please note that this association was not observed in Hispanic or African American patients. Other genetic and clinical factors may also affect a patient's risk of developing opioid dependence.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449167093>2226</a></td><td>LKAAEAR1</td><td>rs6090043</td><td>opioids</td><td>Opioid-Related Disorders</td><td>3</td><td>CT</td><td>Toxicity</td><td>Caucasian patients with the CT genotype may have an increased risk of developing opioid dependence as compared to Caucasian patients with the TT genotype. Please note that this association was not seen in Hispanic or African American patients. Other genetic and clinical factors may also affect a patient's risk of developing opioid dependence.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449167093>2227</a></td><td>OPRL1</td><td>rs6090043</td><td>opioids</td><td>Opioid-Related Disorders</td><td>3</td><td>CT</td><td>Toxicity</td><td>Caucasian patients with the CT genotype may have an increased risk of developing opioid dependence as compared to Caucasian patients with the TT genotype. Please note that this association was not seen in Hispanic or African American patients. Other genetic and clinical factors may also affect a patient's risk of developing opioid dependence.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449753234>2228</a></td><td>UGT1A1</td><td>rs887829</td><td>risperidone</td><td>Hyperprolactinemia</td><td>3</td><td>CT</td><td>Toxicity</td><td>Patients with the CT genotype and autism may have an increased risk for hyperprolactinemia when treated with risperidone as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for hyperprolactinemia.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/981478131>2229</a></td><td>NOS1AP</td><td>rs10919035</td><td>amiodarone</td><td>Long QT Syndrome</td><td>3</td><td>CT</td><td>Toxicity</td><td>Patients with the CT genotype may have increased risk of drug-induced ventricular arrhythmia and QT prolongation when treated with amiodarone as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of drug-induced ventricular arrhythmia and QT prolongation.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450932697>2230</a></td><td>OPRD1</td><td>rs2234918</td><td>buprenorphine</td><td>Opioid-Related Disorders;Sexual Dysfunctions, Psychological</td><td>3</td><td>TT</td><td>Toxicity</td><td>Patients with the TT genotype and who are being treated with buprenorphine with optional fentanyl and tramadol for prescription opioid dependence may more likely to experience sexual dysfunction or reproductive system disorders as compared to patients with the CT genotype. Other genetic and clinical factors may also affect the incidence of adverse events during treatment for opioid dependence.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450932697>2231</a></td><td>OPRD1</td><td>rs2234918</td><td>fentanyl</td><td>Opioid-Related Disorders;Sexual Dysfunctions, Psychological</td><td>3</td><td>TT</td><td>Toxicity</td><td>Patients with the TT genotype and who are being treated with buprenorphine with optional fentanyl and tramadol for prescription opioid dependence may more likely to experience sexual dysfunction or reproductive system disorders as compared to patients with the CT genotype. Other genetic and clinical factors may also affect the incidence of adverse events during treatment for opioid dependence.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450932697>2232</a></td><td>OPRD1</td><td>rs2234918</td><td>tramadol</td><td>Opioid-Related Disorders;Sexual Dysfunctions, Psychological</td><td>3</td><td>TT</td><td>Toxicity</td><td>Patients with the TT genotype and who are being treated with buprenorphine with optional fentanyl and tramadol for prescription opioid dependence may more likely to experience sexual dysfunction or reproductive system disorders as compared to patients with the CT genotype. Other genetic and clinical factors may also affect the incidence of adverse events during treatment for opioid dependence.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450936563>2233</a></td><td>AQP1</td><td>rs1049305</td><td>cisplatin</td><td>Leukopenia;Mesothelioma</td><td>3</td><td>CG</td><td>Toxicity</td><td>Patients with malignant mesothelioma and the CG genotype may be at an increased risk of developing leukopenia when treated with cisplatin-based chemotherapy as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing leukopenia when treated with cisplatin-based chemotherapy.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1043880476>2234</a></td><td>AGTR1</td><td>rs5186</td><td>Ace Inhibitors, Plain</td><td>Coronary Artery Disease</td><td>3</td><td>CA</td><td>Toxicity</td><td>Patients with the CA genotype and Coronary Artery Disease may have an increased major cardiovascular events rate when treated with Ace Inhibitors as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for major cardiovascular events.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1043880293>2235</a></td><td>CYP2B6</td><td>rs3211371</td><td>cyclophosphamide</td><td>Breast Neoplasms</td><td>3</td><td>TC</td><td>Toxicity</td><td>Patients withe the TC genotype may have increased likelihood of dose delay when treated with cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to patients with the CC genotype. Leucopenia and neutropenia were the most common reasons for dose delay. Other clinical or genetic factors may also influence a patient's response.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1043880293>2236</a></td><td>CYP2B6</td><td>rs3211371</td><td>doxorubicin</td><td>Breast Neoplasms</td><td>3</td><td>TC</td><td>Toxicity</td><td>Patients withe the TC genotype may have increased likelihood of dose delay when treated with cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to patients with the CC genotype. Leucopenia and neutropenia were the most common reasons for dose delay. Other clinical or genetic factors may also influence a patient's response.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1140655380>2237</a></td><td>ABCB1</td><td>rs1045642</td><td>atorvastatin</td><td>Coronary Artery Disease;Myalgia unspecified</td><td>3</td><td>AA</td><td>Toxicity</td><td>Patients with the AA genotype and Coronary Artery Disease who are treated with atorvastatin may have a higher likelihood of developing myalgia as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of atorvastatin-induced myalgia.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1152661500>2238</a></td><td>ABCB1</td><td>rs2032582</td><td>simvastatin</td><td>Hypercholesterolemia;Myalgia unspecified</td><td>3</td><td>AC</td><td>Toxicity</td><td>Patients with the AC genotype and Hypercholesterolemia who are treated with simvastatin may have an increased risk of developing myalgia as compared to patients with the AA or TT genotype. Other genetic and clinical factors may also influence a patient's risk of simvastatin-induced adverse drug reactions.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183490952>2239</a></td><td>CES1</td><td>rs2244613</td><td>Dabigatran</td><td>Atrial Fibrillation</td><td>3</td><td>TT</td><td>Toxicity</td><td>Patients with the TT genotype and Atrial Fibrillation may have an increased risk for bleeding when treated with dabigatran as compared to patients with the GT or GG genotype. Other genetic and clinical factors may also influence a patient's risk for bleeding.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183615135>2240</a></td><td>HTR2C</td><td>rs1414334</td><td>olanzapine</td><td>Mental Disorders</td><td>3</td><td>GG</td><td>Toxicity</td><td>Women with the GG genotype and mental disorders (excluding schizophrenia) may have greater weight gain when treated with olanzapine as compared to women with the CC genotype. Other genetic and clinical factors may also influence weight gain.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183697557>2241</a></td><td>CDA</td><td>rs602950</td><td>capecitabine</td><td>Neoplasms</td><td>3</td><td>AG</td><td>Toxicity</td><td>Cancer patients with the AG genotype may have an increased risk of diarrhea or dehydration when treated with capecitabine-based therapy as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of diarrhea and dehydration.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183679122>2242</a></td><td>-</td><td>rs1719247</td><td>hmg coa reductase inhibitors</td><td></td><td>3</td><td>CT</td><td>Toxicity</td><td>Patients with the CT genotype may be less likely to experience myopathy when treated with statins as compared to patients with the CC genotype, and more likely to experience myopathy when treated with statins as compared to patients with the TT genotype. Other genetic and clinical factors may also influence the likelihood of myopathy when a patient is treated with statins.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183693443>2243</a></td><td>NT5C2</td><td>rs11191561</td><td>didanosine</td><td>HIV Infections</td><td>3</td><td>CG</td><td>Toxicity</td><td>Patients with the CG genotype and HIV may have an increased risk of developing noncirrhotic portal hypertension when treated with didanosine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of noncirrhotic portal hypertension.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183700279>2244</a></td><td>ABCC11</td><td>rs7194667</td><td>fluorouracil</td><td>Leukopenia;Neoplasms</td><td>3</td><td>GT</td><td>Toxicity</td><td>Patients with the GT genotype and cancer who are treated with fluorouracil may have an increased risk of leukopenia as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of adverse reactions when treated with fluorouracil.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183603764>2245</a></td><td>HTR2C</td><td>rs2497538</td><td>olanzapine</td><td>Weight gain</td><td>3</td><td>CC</td><td>Toxicity</td><td>Patients with two X-chromosomes, the CC genotype, and mental disorders may have increased weight gain when treated with olanzapine as compared to patients with the AA genotype. No significant results were seen for men. Other genetic and clinical factors may also influence weight gain. This gene is on the X chromosome therefore some individuals may have only one allele.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183632165>2246</a></td><td>GIPR</td><td>rs10423928</td><td>olanzapine</td><td>Schizophrenia</td><td>3</td><td>AA</td><td>Toxicity</td><td>Patients with the AA genotype may have increased plasma insulin levels and increased severity of weight gain when treated with olanzapine in people with Schizophrenia as compared to patients with the genotype TT. Other genetic and clinical factors may also influence a patient's response to olanzapine.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183679135>2247</a></td><td>-</td><td>rs1346268</td><td>simvastatin</td><td></td><td>3</td><td>CT</td><td>Toxicity</td><td>Patients with the CT genotype may be less likely to experience myopathy when treated with statins as compared to patients with the TT genotype, and more likely to experience myopathy when treated with statins as compared to patients with the CC genotype. Other genetic and clinical factors may also influence the likelihood of myopathy when a patient is treated with statins.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183602560>2248</a></td><td>SACM1L</td><td>rs2742435</td><td>bupropion</td><td>Depressive Disorder, Major</td><td>3</td><td>AA</td><td>Toxicity</td><td>Patients with the AA genotype and major depressive disorder may have increased sexual side-effects when treated with bupropion as compared to patients with the GG genotype. Other genetic and clinical factors may also influence sexual side-effects.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/982031767>2249</a></td><td>CYP1A2</td><td>rs762551</td><td>paroxetine</td><td>Depressive Disorder, Major</td><td>3</td><td>AC</td><td>Toxicity</td><td>Patients with AT genotype may require an increased dose of paroxetine and may have an increased risk of fatigue when treated with paroxetine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence patient's response to paroxetine.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1043858656>2250</a></td><td>IL4</td><td>rs2243250</td><td>aspirin</td><td>Asthma</td><td>3</td><td>CC</td><td>Toxicity</td><td>Patients with the CC genotype and asthma may have a higher aspirin-induced decline in forced expiratory volume in 1 s (FEV1) after aspirin provocation as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183631536>2251</a></td><td>OPRM1</td><td>rs544093</td><td>carboplatin</td><td>Ovarian Neoplasms</td><td>3</td><td>TT</td><td>Toxicity</td><td>Patients with the TT genotype and ovarian cancer may have an increased risk of neurotoxicity when treated with carboplatin in combination with either docetaxel or paclitaxel, as compared to patients with the GG or GT genotype. Other genetic and clinical factors may also influence risk of neurotoxicity.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183631536>2252</a></td><td>OPRM1</td><td>rs544093</td><td>docetaxel</td><td>Ovarian Neoplasms</td><td>3</td><td>TT</td><td>Toxicity</td><td>Patients with the TT genotype and ovarian cancer may have an increased risk of neurotoxicity when treated with carboplatin in combination with either docetaxel or paclitaxel, as compared to patients with the GG or GT genotype. Other genetic and clinical factors may also influence risk of neurotoxicity.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183631536>2253</a></td><td>OPRM1</td><td>rs544093</td><td>paclitaxel</td><td>Ovarian Neoplasms</td><td>3</td><td>TT</td><td>Toxicity</td><td>Patients with the TT genotype and ovarian cancer may have an increased risk of neurotoxicity when treated with carboplatin in combination with either docetaxel or paclitaxel, as compared to patients with the GG or GT genotype. Other genetic and clinical factors may also influence risk of neurotoxicity.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183684144>2254</a></td><td>CYP2E1</td><td>rs2070673</td><td>cytarabine</td><td>Leukemia, Myeloid, Acute</td><td>3</td><td>TT</td><td>Toxicity</td><td>Patients with the TT genotype may have an increased likelihood of toxic liver disease when treated with cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183684144>2255</a></td><td>CYP2E1</td><td>rs2070673</td><td>fludarabine</td><td>Leukemia, Myeloid, Acute</td><td>3</td><td>TT</td><td>Toxicity</td><td>Patients with the TT genotype may have an increased likelihood of toxic liver disease when treated with cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183684144>2256</a></td><td>CYP2E1</td><td>rs2070673</td><td>gemtuzumab ozogamicin</td><td>Leukemia, Myeloid, Acute</td><td>3</td><td>TT</td><td>Toxicity</td><td>Patients with the TT genotype may have an increased likelihood of toxic liver disease when treated with cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183684144>2257</a></td><td>CYP2E1</td><td>rs2070673</td><td>idarubicin</td><td>Leukemia, Myeloid, Acute</td><td>3</td><td>TT</td><td>Toxicity</td><td>Patients with the TT genotype may have an increased likelihood of toxic liver disease when treated with cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183693448>2258</a></td><td>NT5C2</td><td>rs11598702</td><td>didanosine</td><td>HIV Infections</td><td>3</td><td>CT</td><td>Toxicity</td><td>Patients with the CT genotype and HIV may have a increased risk of developing noncirrhotic portal hypertension when treated with didanosine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of noncirrhotic portal hypertension.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183630271>2259</a></td><td>SLC31A1</td><td>rs10981694</td><td>cisplatin</td><td>Carcinoma, Non-Small-Cell Lung</td><td>3</td><td>GT</td><td>Toxicity</td><td>Patients with the GT genotype and NSCLC who are treated with cisplatin may have an increased risk of severe ototoxicity as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of cisplatin-induced ototoxicity.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183632160>2260</a></td><td>GABRG3</td><td>rs2061051</td><td>antipsychotics</td><td>Schizophrenia</td><td>3</td><td>AA</td><td>Toxicity</td><td>Patients with the AA genotype may have increased severity of tardive dyskinesia when treated with antipsychotics in people with Schizophrenia as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to antipsychotics.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183679775>2261</a></td><td>CYP1A2</td><td>rs762551</td><td>antipsychotics</td><td>Schizophrenia</td><td>3</td><td>AC</td><td>Toxicity</td><td>Patients with the AC genotype may have increased QT interval when treated with antipsychotics, chlorpromazine, fluphenazine, thioridazine and trifluoperazine in people with Schizophrenia as compared to patients with genotype AA. Other genetic and clinical factors may also influence a patient's response to antipsychotics.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183679775>2262</a></td><td>CYP1A2</td><td>rs762551</td><td>chlorpromazine</td><td>Schizophrenia</td><td>3</td><td>AC</td><td>Toxicity</td><td>Patients with the AC genotype may have increased QT interval when treated with antipsychotics, chlorpromazine, fluphenazine, thioridazine and trifluoperazine in people with Schizophrenia as compared to patients with genotype AA. Other genetic and clinical factors may also influence a patient's response to antipsychotics.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183679775>2263</a></td><td>CYP1A2</td><td>rs762551</td><td>fluphenazine</td><td>Schizophrenia</td><td>3</td><td>AC</td><td>Toxicity</td><td>Patients with the AC genotype may have increased QT interval when treated with antipsychotics, chlorpromazine, fluphenazine, thioridazine and trifluoperazine in people with Schizophrenia as compared to patients with genotype AA. Other genetic and clinical factors may also influence a patient's response to antipsychotics.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183679775>2264</a></td><td>CYP1A2</td><td>rs762551</td><td>thioridazine</td><td>Schizophrenia</td><td>3</td><td>AC</td><td>Toxicity</td><td>Patients with the AC genotype may have increased QT interval when treated with antipsychotics, chlorpromazine, fluphenazine, thioridazine and trifluoperazine in people with Schizophrenia as compared to patients with genotype AA. Other genetic and clinical factors may also influence a patient's response to antipsychotics.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183679775>2265</a></td><td>CYP1A2</td><td>rs762551</td><td>trifluoperazine</td><td>Schizophrenia</td><td>3</td><td>AC</td><td>Toxicity</td><td>Patients with the AC genotype may have increased QT interval when treated with antipsychotics, chlorpromazine, fluphenazine, thioridazine and trifluoperazine in people with Schizophrenia as compared to patients with genotype AA. Other genetic and clinical factors may also influence a patient's response to antipsychotics.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183679808>2266</a></td><td>MEX3C</td><td>rs17751934</td><td>Bisphosphonates</td><td>Osteonecrosis</td><td>3</td><td>CT</td><td>Toxicity</td><td>Patients with the CT genotype may have increased likelihood of Osteonecrosis when treated with Bisphosphonates as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity to bisphosphonates.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183615268>2267</a></td><td>ERCC1</td><td>rs11615</td><td>fluorouracil</td><td>Colonic Neoplasms</td><td>3</td><td>AA</td><td>Toxicity</td><td>Patients with the AA genotype and colon cancer may have an increased risk of neutropenia when treated with FOLFOX (fluorouracil, leucovorin, oxaliplatin) as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence risk of neutropenia.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183615268>2268</a></td><td>ERCC1</td><td>rs11615</td><td>leucovorin</td><td>Colonic Neoplasms</td><td>3</td><td>AA</td><td>Toxicity</td><td>Patients with the AA genotype and colon cancer may have an increased risk of neutropenia when treated with FOLFOX (fluorouracil, leucovorin, oxaliplatin) as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence risk of neutropenia.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183615268>2269</a></td><td>ERCC1</td><td>rs11615</td><td>oxaliplatin</td><td>Colonic Neoplasms</td><td>3</td><td>AA</td><td>Toxicity</td><td>Patients with the AA genotype and colon cancer may have an increased risk of neutropenia when treated with FOLFOX (fluorouracil, leucovorin, oxaliplatin) as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence risk of neutropenia.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451403476>2270</a></td><td>ZNF804A</td><td>rs7597593</td><td>opioids</td><td>Opioid-Related Disorders</td><td>3</td><td>CC</td><td>Toxicity</td><td>Patients with the rs7597593 CC genotype may have an increased risk of developing opioid dependence when exposed to opioids as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence risk of developing opioid dependence.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183614860>2271</a></td><td>UGT1A</td><td>rs1042640</td><td>acetaminophen</td><td>Liver Failure, Acute</td><td>3</td><td>CC</td><td>Toxicity</td><td>Patients with the CC genotype may have an increased risk of liver failure due to unintentional acetaminophen overdose as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence risk of liver failure due to unintentional acetaminophen overdose.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183619225>2272</a></td><td>BDNF</td><td>rs6265</td><td>fluoxetine</td><td>Depressive Disorder, Major</td><td>4</td><td>CT</td><td>Toxicity</td><td>Patients with the CT genotype and major depressive disorder who are treated with fluoxetine may have a higher likelihood of side effects as compared to patients with the TT genotype or may have a reduced likelihood of side effects as compared to patients with the CC genotype. This SNP was not associated with response to fluoxetine. Other genetic and clinical factors may also influence a patient's risk of fluoxetine-induced side effects.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451403608>2273</a></td><td>DRD3</td><td>rs6280</td><td>opioids</td><td>Opioid-Related Disorders</td><td>3</td><td>CT</td><td>Toxicity</td><td>Patients with the rs6280 CT genotype may have an increased risk of developing opioid dependence when exposed to opioids as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of developing opioid dependence.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451403720>2274</a></td><td>TACR3</td><td>rs1384401</td><td>opioids</td><td>Opioid-Related Disorders</td><td>3</td><td>GG</td><td>Toxicity</td><td>Patients with the rs1384401 GG genotype may have an increased risk of developing opioid dependence when exposed to opioids as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of developing opioid dependence.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450377339>2275</a></td><td>TCF7L2</td><td>rs290487</td><td>tacrolimus</td><td>liver transplantation</td><td>3</td><td>CT</td><td>Toxicity</td><td>Patients who are undergoing liver transplantation and receive a donor liver with the CT genotype may have an increased risk for new-onset diabetes mellitus (NODM) when treated with tacrolimus as compared to patients who receive a donor liver with the TT genotype. Other genetic and clinical factors may also influence risk for NODM.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451403680>2276</a></td><td>DRD3</td><td>rs324029</td><td>opioids</td><td>Opioid-Related Disorders</td><td>3</td><td>AG</td><td>Toxicity</td><td>Patients with the rs324029 AG genotype may have an increased risk of developing opioid dependence when exposed to opioids as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of developing opioid dependence.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451403687>2277</a></td><td>EXOC4</td><td>rs718656</td><td>opioids</td><td>Opioid-Related Disorders</td><td>3</td><td>TT</td><td>Toxicity</td><td>Patients with the rs718656 TT genotype may have an increased risk of developing opioid dependence when exposed to opioids as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also influence risk of developing opioid dependence.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1043858845>2278</a></td><td>VEGFA</td><td>rs833061</td><td>sunitinib</td><td></td><td>3</td><td>CT</td><td>Toxicity</td><td>Patients with the CT genotype may be associated with a higher increase in systolic blood pressure and increased risk of developing grade 3 hypertension when treated with sunitinib as compared to patients with the TT genotype. Other clinical and genetic factors may also influence a patient's response to sunitinib.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1043880750>2279</a></td><td>FAAH</td><td>rs324420</td><td>aripiprazole</td><td>Psychotic Disorders</td><td>3</td><td>AC</td><td>Toxicity</td><td>Patients with the AC genotype and Psychotic Disorders who are treated with aripiprazole, clozapine, haloperidol, olanzapine, quetiapine or risperidone may have an increased likelihood of weight gain of more than 7% of baseline body weight as compared to patients with the CC genotype. However, this is contradicted in one study with risperidone. Other genetic and clinical factors may also influence a patient's risk for treatment-induced weight gain.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1043880750>2280</a></td><td>FAAH</td><td>rs324420</td><td>clozapine</td><td>Psychotic Disorders</td><td>3</td><td>AC</td><td>Toxicity</td><td>Patients with the AC genotype and Psychotic Disorders who are treated with aripiprazole, clozapine, haloperidol, olanzapine, quetiapine or risperidone may have an increased likelihood of weight gain of more than 7% of baseline body weight as compared to patients with the CC genotype. However, this is contradicted in one study with risperidone. Other genetic and clinical factors may also influence a patient's risk for treatment-induced weight gain.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1043880750>2281</a></td><td>FAAH</td><td>rs324420</td><td>haloperidol</td><td>Psychotic Disorders</td><td>3</td><td>AC</td><td>Toxicity</td><td>Patients with the AC genotype and Psychotic Disorders who are treated with aripiprazole, clozapine, haloperidol, olanzapine, quetiapine or risperidone may have an increased likelihood of weight gain of more than 7% of baseline body weight as compared to patients with the CC genotype. However, this is contradicted in one study with risperidone. Other genetic and clinical factors may also influence a patient's risk for treatment-induced weight gain.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1043880750>2282</a></td><td>FAAH</td><td>rs324420</td><td>olanzapine</td><td>Psychotic Disorders</td><td>3</td><td>AC</td><td>Toxicity</td><td>Patients with the AC genotype and Psychotic Disorders who are treated with aripiprazole, clozapine, haloperidol, olanzapine, quetiapine or risperidone may have an increased likelihood of weight gain of more than 7% of baseline body weight as compared to patients with the CC genotype. However, this is contradicted in one study with risperidone. Other genetic and clinical factors may also influence a patient's risk for treatment-induced weight gain.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1043880750>2283</a></td><td>FAAH</td><td>rs324420</td><td>quetiapine</td><td>Psychotic Disorders</td><td>3</td><td>AC</td><td>Toxicity</td><td>Patients with the AC genotype and Psychotic Disorders who are treated with aripiprazole, clozapine, haloperidol, olanzapine, quetiapine or risperidone may have an increased likelihood of weight gain of more than 7% of baseline body weight as compared to patients with the CC genotype. However, this is contradicted in one study with risperidone. Other genetic and clinical factors may also influence a patient's risk for treatment-induced weight gain.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1043880750>2284</a></td><td>FAAH</td><td>rs324420</td><td>risperidone</td><td>Psychotic Disorders</td><td>3</td><td>AC</td><td>Toxicity</td><td>Patients with the AC genotype and Psychotic Disorders who are treated with aripiprazole, clozapine, haloperidol, olanzapine, quetiapine or risperidone may have an increased likelihood of weight gain of more than 7% of baseline body weight as compared to patients with the CC genotype. However, this is contradicted in one study with risperidone. Other genetic and clinical factors may also influence a patient's risk for treatment-induced weight gain.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1043880900>2285</a></td><td>SLCO1B1</td><td>rs2306283</td><td>hmg coa reductase inhibitors</td><td>Coronary Artery Disease;Diabetes Mellitus;Hypercholesterolemia</td><td>3</td><td>AG</td><td>Toxicity</td><td>Patients with the AG genotype who are treated with statins (hmg coa reductase inhibitors) may have increased creatine kinase levels, and an increased risk of adverse events in response to treatment as compared to patients with the GG genotype, but a lower creatine kinase levels and lower risk of intolerance as compared to the AA genotype, although this is contradicted in some studies. Other genetic and clinical factors may also influence a patient's response to statin treatment.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451403740>2286</a></td><td>-</td><td>rs4530637</td><td>opioids</td><td>Opioid-Related Disorders</td><td>3</td><td>AG</td><td>Toxicity</td><td>Patients with the rs4530637 AG genotype may have an increased risk of developing opioid dependence when exposed to opioids as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of developing opioid dependence.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183549413>2287</a></td><td>UGT1A</td><td>rs8330</td><td>acetaminophen</td><td>Liver Failure, Acute</td><td>3</td><td>CC</td><td>Toxicity</td><td>Patients with the CC genotype may have an increased risk of liver failure due to unintentional acetaminophen overdose as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence risk of liver failure due to unintentional acetaminophen overdose.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183549413>2288</a></td><td>UGT1A9</td><td>rs8330</td><td>acetaminophen</td><td>Liver Failure, Acute</td><td>3</td><td>CC</td><td>Toxicity</td><td>Patients with the CC genotype may have an increased risk of liver failure due to unintentional acetaminophen overdose as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence risk of liver failure due to unintentional acetaminophen overdose.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183614825>2289</a></td><td>UGT1A</td><td>rs10929303</td><td>acetaminophen</td><td>Liver Failure, Acute</td><td>3</td><td>CC</td><td>Toxicity</td><td>Patients with the CC genotype may have an increased risk of liver failure due to unintentional acetaminophen overdose as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence risk of liver failure due to unintentional acetaminophen overdose.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183679117>2290</a></td><td>GATM</td><td>rs9806699</td><td>hmg coa reductase inhibitors</td><td>Myocardial Infarction</td><td>4</td><td>AG</td><td>Toxicity</td><td>Patients with the AG genotype may be less likely to experience myopathy when treated with statins as compared to patients with the GG genotype, and more likely to experience myopathy when treated with statins as compared to patients with the AA genotype. This association has not been found consistently in replication studies. Other genetic and clinical factors may also influence the likelihood of myopathy when a patient is treated with statins.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183679117>2291</a></td><td>GATM</td><td>rs9806699</td><td>simvastatin</td><td>Myocardial Infarction</td><td>4</td><td>AG</td><td>Toxicity</td><td>Patients with the AG genotype may be less likely to experience myopathy when treated with statins as compared to patients with the GG genotype, and more likely to experience myopathy when treated with statins as compared to patients with the AA genotype. This association has not been found consistently in replication studies. Other genetic and clinical factors may also influence the likelihood of myopathy when a patient is treated with statins.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183614676>2292</a></td><td>MC4R</td><td>rs17782313</td><td>antipsychotics</td><td>Weight gain</td><td>3</td><td>CT</td><td>Toxicity</td><td>Patients with the rs17782313 CT genotype may have increased likelihood of weight gain when treated with antipsychotics as compared to patients with the TT genotype. Other genetic and clinical factors may also influence weight gain.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/982030757>2293</a></td><td>FDPS</td><td>rs2297480</td><td>zoledronate</td><td>Neoplasms;Osteonecrosis</td><td>3</td><td>TG</td><td>Toxicity</td><td>Patients with genotype TG may have increased likelihood of osteonecrosis when treated with zoledronate in people with Neoplasms as compared to patients with genotype GG. Other genetic and clinical factors may also influence a patient's chance of response.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183632180>2294</a></td><td>HSPA1A</td><td>rs1043620</td><td>carbamazepine</td><td></td><td>3</td><td>CC</td><td>Toxicity</td><td>Patients with the CC genotype may have increased risk of severe hypersensitivity when treated with carbamazepine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to carbamazepine.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183632180>2295</a></td><td>HSPA1L</td><td>rs1043620</td><td>carbamazepine</td><td></td><td>3</td><td>CC</td><td>Toxicity</td><td>Patients with the CC genotype may have increased risk of severe hypersensitivity when treated with carbamazepine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to carbamazepine.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/981238415>2296</a></td><td>ITPA</td><td>rs1127354</td><td>methotrexate</td><td>Arthritis, Rheumatoid;Precursor Cell Lymphoblastic Leukemia-Lymphoma</td><td>3</td><td>CC</td><td>Toxicity</td><td>Patients with the CC genotype and with Rheumatoid Arthritis who are treated with methotrexate may have 1) a decreased, but not absent, risk for gastrointestinal toxicities 2) an increased response to folic acid and methotrexate as compared to patients with the AA and AC genotype. However, this association is contradicted in other studies that show the CC genotype may have decreased response to methotrexate as compared to patients with the AC and AA genotype or show no association of the allele with response to methotrexate. Children with Precursor Cell Lymphoblastic Leukemia-Lymphomathe and the CC genotype may have increased event free survival when treated with mercaptopurine and methotrexate as compared to children with the AA or AC genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/981478113>2297</a></td><td>NOS1AP</td><td>rs10800397</td><td>amiodarone</td><td>Long QT Syndrome</td><td>3</td><td>TT</td><td>Toxicity</td><td>Patients with the TT genotype may have increased risk of drug-induced ventricular arrhythmia and QT prolongation when treated with amiodarone as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of drug-induced ventricular arrhythmia and QT prolongation.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/982032743>2298</a></td><td>ABCB1</td><td>rs2032582</td><td>clomipramine</td><td>Depression</td><td>3</td><td>AC</td><td>Toxicity</td><td>Patients with the AC genotype and depression may have an increased risk of suicidal ideation when treated with clomipramine, liothyronine, Lithium, nefazodone, paroxetine or venlafaxine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to clomipramine, liothyronine, Lithium, nefazodone, paroxetine or venlafaxine.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/982032743>2299</a></td><td>ABCB1</td><td>rs2032582</td><td>lithium</td><td>Depression</td><td>3</td><td>AC</td><td>Toxicity</td><td>Patients with the AC genotype and depression may have an increased risk of suicidal ideation when treated with clomipramine, liothyronine, Lithium, nefazodone, paroxetine or venlafaxine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to clomipramine, liothyronine, Lithium, nefazodone, paroxetine or venlafaxine.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/982032743>2300</a></td><td>ABCB1</td><td>rs2032582</td><td>nefazodone</td><td>Depression</td><td>3</td><td>AC</td><td>Toxicity</td><td>Patients with the AC genotype and depression may have an increased risk of suicidal ideation when treated with clomipramine, liothyronine, Lithium, nefazodone, paroxetine or venlafaxine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to clomipramine, liothyronine, Lithium, nefazodone, paroxetine or venlafaxine.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/982032743>2301</a></td><td>ABCB1</td><td>rs2032582</td><td>paroxetine</td><td>Depression</td><td>3</td><td>AC</td><td>Toxicity</td><td>Patients with the AC genotype and depression may have an increased risk of suicidal ideation when treated with clomipramine, liothyronine, Lithium, nefazodone, paroxetine or venlafaxine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to clomipramine, liothyronine, Lithium, nefazodone, paroxetine or venlafaxine.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/982032743>2302</a></td><td>ABCB1</td><td>rs2032582</td><td>venlafaxine</td><td>Depression</td><td>3</td><td>AC</td><td>Toxicity</td><td>Patients with the AC genotype and depression may have an increased risk of suicidal ideation when treated with clomipramine, liothyronine, Lithium, nefazodone, paroxetine or venlafaxine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to clomipramine, liothyronine, Lithium, nefazodone, paroxetine or venlafaxine.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1043858642>2303</a></td><td>FSIP1</td><td>rs7179742</td><td>aspirin</td><td>Asthma</td><td>3</td><td>AG</td><td>Toxicity</td><td>Patients with the AG genotype and asthma may have an increased risk for aspirin-intolerant asthma as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for aspirin-intolerant asthma.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183490999>2304</a></td><td>NOS1AP</td><td>rs10494366</td><td>dolasetron</td><td></td><td>3</td><td>TG</td><td>Toxicity</td><td>Patients with the TG genotype undergoing surgery who are exposed to dolasetron or granisetron as part of anesthetic management may have an increased risk for QTc interval prolongation as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for QTc interval prolongation.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183490999>2305</a></td><td>NOS1AP</td><td>rs10494366</td><td>granisetron</td><td></td><td>3</td><td>TG</td><td>Toxicity</td><td>Patients with the TG genotype undergoing surgery who are exposed to dolasetron or granisetron as part of anesthetic management may have an increased risk for QTc interval prolongation as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for QTc interval prolongation.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1043880447>2306</a></td><td>BDKRB2</td><td>rs8016905</td><td>Ace Inhibitors, Plain</td><td>Cough</td><td>3</td><td>AG</td><td>Toxicity</td><td>Patients with the AG genotype may have an increased risk for angiotensin-converting enzyme inhibitors-induced cough when treated with Ace Inhibitors, Plain as compared to patients with the AA or GG genotype. Other genetic and clinical factors may also influence a patient's risk for angiotensin-converting enzyme inhibitors-induced cough.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1043880818>2307</a></td><td>SLCO1B1</td><td>rs4149056</td><td>atorvastatin</td><td>statin-related myopathy</td><td>1A</td><td>CT</td><td>Toxicity</td><td>Patients with the rs4149056 CT genotype may have an increased risk of myopathy when treated with atorvastatin as compared to patients with the TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of developing myopathy when treated with atorvastatin.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1043880192>2308</a></td><td>CETP</td><td>rs708272</td><td>atorvastatin</td><td></td><td>4</td><td>AA</td><td>Toxicity</td><td>Patients with the AA genotype who are treated with atorvastatin may have a decreased response to treatment and an increased risk of cardiovascular disease events as compared to patients with the GG genotype. However, these results were not statistically significant and there are contradictory studies. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1043880783>2309</a></td><td>NR1H3</td><td>rs11039149</td><td>atenolol</td><td>Coronary Artery Disease;Hypertension</td><td>3</td><td>GG</td><td>Toxicity</td><td>Patients with the GG genotype and hypertension and coronary artery disease who are treated with atenolol and verapamil may have an increased risk for cardiovascular events as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for cardiovascular events.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1043880783>2310</a></td><td>NR1H3</td><td>rs11039149</td><td>verapamil</td><td>Coronary Artery Disease;Hypertension</td><td>3</td><td>GG</td><td>Toxicity</td><td>Patients with the GG genotype and hypertension and coronary artery disease who are treated with atenolol and verapamil may have an increased risk for cardiovascular events as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for cardiovascular events.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183614840>2311</a></td><td>ABCB1</td><td>rs1045642</td><td>sirolimus</td><td>Kidney Transplantation</td><td>3</td><td>AA</td><td>Toxicity</td><td>Patients with the AA genotype who underwent kidney transplantation may have increased total and low-density lipoprotein cholesterol when treated with sirolimus as compared to patients with the GG genotype. Other genetic and clinical factors may also influence total and low-density lipoprotein cholesterol levels.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183615186>2312</a></td><td>SLCO1B1</td><td>rs4149056</td><td>irinotecan</td><td>Neoplasms</td><td>3</td><td>CT</td><td>Toxicity</td><td>Patients with the CT genotype and cancer may have an increased risk of neutropenia when treated with irinotecan or irinotecan-based regimens, as compared to patients with the TT genotype. However, a different study of similar size found no association between the CT genotype and neutropenia. No significant results have been seen for diarrhea. Other genetic and clinical factors may also influence risk of neutropenia or diarrhea.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183613866>2313</a></td><td>SACM1L</td><td>rs1969624</td><td>bupropion</td><td>Depressive Disorder, Major</td><td>3</td><td>CC</td><td>Toxicity</td><td>Patients with the CC genotype and major depressive disorder may have increased sexual side-effects when treated with bupropion as compared to patients with the TT genotype. Other genetic and clinical factors may also influence sexual side-effects.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/982030948>2314</a></td><td>BDNF</td><td>rs962369</td><td>escitalopram</td><td>Depressive Disorder, Major</td><td>3</td><td>CT</td><td>Toxicity</td><td>Patients with the CT genotype and depression may have increased likelihood of suicide ideation with escitalopram or nortriptyline as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to antidepressants.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/982030948>2315</a></td><td>BDNF</td><td>rs962369</td><td>nortriptyline</td><td>Depressive Disorder, Major</td><td>3</td><td>CT</td><td>Toxicity</td><td>Patients with the CT genotype and depression may have increased likelihood of suicide ideation with escitalopram or nortriptyline as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to antidepressants.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451407348>2316</a></td><td>HTR2A</td><td>rs6311</td><td>sertraline</td><td>Depressive Disorder, Major;Sexual Dysfunctions, Psychological</td><td>3</td><td>CT</td><td>Toxicity</td><td>Patients with the rs6311 CT genotype and major depressive disorder may be more likely to develop sexual dysfunction when treated with sertraline as compared to patients with the CC genotype. Other genetic and clinical factors may also influence likelihood of developing sexual dysfunction when treated with sertraline.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451407321>2317</a></td><td>HTR2A</td><td>rs6313</td><td>sertraline</td><td>Depressive Disorder, Major;Sexual Dysfunctions, Psychological</td><td>3</td><td>AG</td><td>Toxicity</td><td>Patients with the rs6313 AG genotype and major depressive disorder may be less likely to develop sexual dysfunction when treated with sertraline as compared to patients with the AA genotype. Other genetic and clinical factors may also influence likelihood of developing sexual dysfunction when treated with sertraline.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451407329>2318</a></td><td>HTR2A</td><td>rs6313</td><td>citalopram</td><td>Depressive Disorder, Major;Sexual Dysfunctions, Psychological</td><td>3</td><td>AG</td><td>Toxicity</td><td>Patients with the rs6313 AG genotype and major depressive disorder may be less likely to develop sexual dysfunction when treated with citalopram as compared to patients with the AA genotype. Other genetic and clinical factors may also influence likelihood of developing sexual dysfunction when treated with citalopram.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451407341>2319</a></td><td>HTR2A</td><td>rs6311</td><td>citalopram</td><td>Depressive Disorder, Major;Sexual Dysfunctions, Psychological</td><td>3</td><td>CT</td><td>Toxicity</td><td>Patients with the rs6311 CT genotype and major depressive disorder may be more likely to develop sexual dysfunction when treated with citalopram as compared to patients with the CC genotype. Other genetic and clinical factors may also influence likelihood of developing sexual dysfunction when treated with citalopram.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450810236>2320</a></td><td>OPRM1</td><td>rs511435</td><td>heroin</td><td>Heroin Dependence;Opioid-Related Disorders</td><td>3</td><td>CT</td><td>Toxicity</td><td>Patients with the CT genotype may be at an increased risk of developing heroin dependence or opioid dependence as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of developing opioid dependence.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450810236>2321</a></td><td>OPRM1</td><td>rs511435</td><td>opioids</td><td>Heroin Dependence;Opioid-Related Disorders</td><td>3</td><td>CT</td><td>Toxicity</td><td>Patients with the CT genotype may be at an increased risk of developing heroin dependence or opioid dependence as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of developing opioid dependence.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450931416>2322</a></td><td>PIP5K1C</td><td>rs4807493</td><td>ethanol</td><td>Alcoholism</td><td>3</td><td>GG</td><td>Toxicity</td><td>Patients with the GG genotype may be at an increased risk of developing alcoholism as compared to patients with the AA or AG genotypes. This association was found in patients of African ancestry in the discovery cohort and was not replicated in either the replication cohort or in patients or European ancestry. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450810381>2323</a></td><td>OPRM1</td><td>rs495491</td><td>cocaine</td><td>Cocaine-Related Disorders</td><td>3</td><td>AG</td><td>Toxicity</td><td>Patients with the AG genotype may be at an increased risk of developing cocaine dependence as compared to patients with the AA genotype. Other genetic or clinical factors may also affect a patient's risk of developing cocaine dependence.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449566673>2324</a></td><td>SLC31A1</td><td>rs4979223</td><td>Platinum compounds</td><td>overall survival;Thrombocytopenia</td><td>3</td><td>AC</td><td>Toxicity</td><td>Patients with the AC genotype and non-small cell lung cancer who are treated with platinum compounds may have increased severity of thrombocytopenia, and decresed likelihood of overall survival as compared to patients with the AC genotype. Other clinical and genetic factors may also influence severity of thrombocytopenia and overall survival in patients with non-small lung cancer.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449157530>2325</a></td><td>PSORS1C1</td><td>rs3131003</td><td>allopurinol</td><td>severe cutaneous adverse reactions</td><td>3</td><td>AG</td><td>Toxicity</td><td>Patients with the AG genotype who are administered allopurinol may have an increased risk of severe cutaneous adverse reactions (SCAR) as compared to patients with the AA genotype. Other clinical and genetic factors may also influence risk of SCAR in patients administered allopurinol.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449156029>2326</a></td><td>CHRNA5</td><td>rs503464</td><td>bupropion</td><td>Tobacco Use Disorder</td><td>3</td><td>AT</td><td>Toxicity</td><td>Patients with the AT genotype may have 1) an increased risk of nicotine dependence and 2) an increased response to smoking cessation therapies as compared to patients with the TT genotype. Other genetic and clinical factors may also affect nicotine dependence and smoking cessation.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449156029>2327</a></td><td>CHRNA5</td><td>rs503464</td><td>nicotine</td><td>Tobacco Use Disorder</td><td>3</td><td>AT</td><td>Toxicity</td><td>Patients with the AT genotype may have 1) an increased risk of nicotine dependence and 2) an increased response to smoking cessation therapies as compared to patients with the TT genotype. Other genetic and clinical factors may also affect nicotine dependence and smoking cessation.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449156029>2328</a></td><td>CHRNA5</td><td>rs503464</td><td>varenicline</td><td>Tobacco Use Disorder</td><td>3</td><td>AT</td><td>Toxicity</td><td>Patients with the AT genotype may have 1) an increased risk of nicotine dependence and 2) an increased response to smoking cessation therapies as compared to patients with the TT genotype. Other genetic and clinical factors may also affect nicotine dependence and smoking cessation.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450377187>2329</a></td><td>NAT2</td><td>rs1801280</td><td>isoniazid</td><td>Drug interaction with drug;Drug Toxicity</td><td>3</td><td>CT</td><td>Toxicity</td><td>Patients with the CT genotype who are receiving concomitant phenytoin and isoniazid may be at an increased risk of phenytoin toxicity resulting from isoniazid-phenytoin interaction as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's risk of developing phenytoin toxicity when treated with both isoniazid and phenytoin.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450377187>2330</a></td><td>NAT2</td><td>rs1801280</td><td>phenytoin</td><td>Drug interaction with drug;Drug Toxicity</td><td>3</td><td>CT</td><td>Toxicity</td><td>Patients with the CT genotype who are receiving concomitant phenytoin and isoniazid may be at an increased risk of phenytoin toxicity resulting from isoniazid-phenytoin interaction as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's risk of developing phenytoin toxicity when treated with both isoniazid and phenytoin.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450810255>2331</a></td><td>OPRM1</td><td>rs524731</td><td>cocaine</td><td>Cocaine-Related Disorders</td><td>3</td><td>AC</td><td>Toxicity</td><td>Patients with the AC genotype may be at an increased risk of developing cocaine dependence as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of developing cocaine dependence.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450930470>2332</a></td><td>OPRD1</td><td>rs4654327</td><td>heroin</td><td>Heroin Dependence</td><td>3</td><td>AG</td><td>Toxicity</td><td>Patients with the AG genotype may be at an increased risk of developing heroin dependence as compared to patients with the AA genotype. However, another study did not find an association between this variant and heroin dependence. Other genetic and clinical factors may also affect a patient's risk of developing heroin dependence.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449171162>2333</a></td><td>SOD2</td><td>rs5746136</td><td>heroin</td><td>Heroin Dependence</td><td>3</td><td>TT</td><td>Toxicity</td><td>Patients with the TT genotype may be at an increased risk of developing heroin dependence as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of developing heroin dependence.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450810228>2334</a></td><td>OPRM1</td><td>rs511435</td><td>ethanol</td><td>Alcoholism</td><td>3</td><td>CT</td><td>Toxicity</td><td>Patients with the CT genotype may be at an increased risk of developing alcoholism as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450810283>2335</a></td><td>OPRM1</td><td>rs3823010</td><td>ethanol</td><td>Alcoholism</td><td>3</td><td>AG</td><td>Toxicity</td><td>Patients with the AG genotype may be at an increased risk of developing alcoholism as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450810289>2336</a></td><td>OPRM1</td><td>rs3823010</td><td>cocaine</td><td>Cocaine-Related Disorders</td><td>3</td><td>AG</td><td>Toxicity</td><td>Patients with the AG genotype may be at an increased risk of developing cocaine dependence as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing cocaine dependence.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450810393>2337</a></td><td>OPRM1</td><td>rs548646</td><td>opioids</td><td>Opioid-Related Disorders</td><td>3</td><td>CC</td><td>Toxicity</td><td>Patients with the CC genotype may be at an increased risk of developing opioid dependence as compared to patients with the CT or TT genotypes. Other genetic or clinical factors may also affect a patient's risk of developing opioid dependence.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449753229>2338</a></td><td>UGT1A1</td><td>rs1976391</td><td>risperidone</td><td>Hyperprolactinemia</td><td>3</td><td>AG</td><td>Toxicity</td><td>Patients with the AG genotype and autism may have an increased risk for hyperprolactinemia when treated with risperidone as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk for hyperprolactinemia.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449718271>2339</a></td><td>CYP2C19</td><td>rs4244285</td><td>cyclophosphamide</td><td>Breast Neoplasms</td><td>3</td><td>AA</td><td>Toxicity</td><td>Patients with AA genotype and breast cancer may have an increased risk of neutropenia when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the GG genotype. Other genetic and clinical factors may also affect the risk for neutropenia in patients taking FAC chemotherapy.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449718271>2340</a></td><td>CYP2C19</td><td>rs4244285</td><td>doxorubicin</td><td>Breast Neoplasms</td><td>3</td><td>AA</td><td>Toxicity</td><td>Patients with AA genotype and breast cancer may have an increased risk of neutropenia when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the GG genotype. Other genetic and clinical factors may also affect the risk for neutropenia in patients taking FAC chemotherapy.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449718271>2341</a></td><td>CYP2C19</td><td>rs4244285</td><td>fluorouracil</td><td>Breast Neoplasms</td><td>3</td><td>AA</td><td>Toxicity</td><td>Patients with AA genotype and breast cancer may have an increased risk of neutropenia when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the GG genotype. Other genetic and clinical factors may also affect the risk for neutropenia in patients taking FAC chemotherapy.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449718331>2342</a></td><td>XRCC1</td><td>rs25487</td><td>cyclophosphamide</td><td>Breast Neoplasms</td><td>3</td><td>CT</td><td>Toxicity</td><td>Patients with the CT genotype and breast cancer may have an increased risk for nausea when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for nausea in patients taking FAC chemotherapy.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449718331>2343</a></td><td>XRCC1</td><td>rs25487</td><td>doxorubicin</td><td>Breast Neoplasms</td><td>3</td><td>CT</td><td>Toxicity</td><td>Patients with the CT genotype and breast cancer may have an increased risk for nausea when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for nausea in patients taking FAC chemotherapy.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449718331>2344</a></td><td>XRCC1</td><td>rs25487</td><td>fluorouracil</td><td>Breast Neoplasms</td><td>3</td><td>CT</td><td>Toxicity</td><td>Patients with the CT genotype and breast cancer may have an increased risk for nausea when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC) as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for nausea in patients taking FAC chemotherapy.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450375080>2345</a></td><td>ERCC1</td><td>rs11615</td><td>bleomycin</td><td>febrile neutropenia;Testicular Neoplasms</td><td>3</td><td>AA</td><td>Toxicity</td><td>Patients with testicular cancer and the AA genotype may have an increased risk of developing febrile neutropenia as a result of treatment with bleomycin, cisplatin and etoposide as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's risk of febrile neutropenia as a result of treatment with bleomycin, cisplatin and etoposide.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450375080>2346</a></td><td>ERCC1</td><td>rs11615</td><td>cisplatin</td><td>febrile neutropenia;Testicular Neoplasms</td><td>3</td><td>AA</td><td>Toxicity</td><td>Patients with testicular cancer and the AA genotype may have an increased risk of developing febrile neutropenia as a result of treatment with bleomycin, cisplatin and etoposide as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's risk of febrile neutropenia as a result of treatment with bleomycin, cisplatin and etoposide.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450375080>2347</a></td><td>ERCC1</td><td>rs11615</td><td>etoposide</td><td>febrile neutropenia;Testicular Neoplasms</td><td>3</td><td>AA</td><td>Toxicity</td><td>Patients with testicular cancer and the AA genotype may have an increased risk of developing febrile neutropenia as a result of treatment with bleomycin, cisplatin and etoposide as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's risk of febrile neutropenia as a result of treatment with bleomycin, cisplatin and etoposide.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451413082>2348</a></td><td>NOS1AP</td><td>rs10494366</td><td>glibenclamide</td><td>Diabetes Mellitus, Type 2;Hypoglycemia</td><td>3</td><td>GT</td><td>Toxicity</td><td>Patients with the rs10494366 GT genotype and type 2 diabetes may have an increased risk of hypoglycemia when treated with glibenclamide as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of hypoglycemia when treated with glibenclamide.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451413140>2349</a></td><td>NOS1AP</td><td>rs10494366</td><td>glipizide</td><td>Diabetes Mellitus, Type 2;Hypoglycemia</td><td>3</td><td>GT</td><td>Toxicity</td><td>Patients with the rs10494366 GT genotype and type 2 diabetes may have an increased risk of hypoglycemia when treated with glipizide as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of hypoglycemia when treated with glipizide.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451413120>2350</a></td><td>NOS1AP</td><td>rs10494366</td><td>glimepiride</td><td>Diabetes Mellitus, Type 2;Hypoglycemia</td><td>3</td><td>GT</td><td>Toxicity</td><td>Patients with the rs10494366 GT genotype and type 2 diabetes may have an increased risk of hypoglycemia when treated with glimepiride as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of hypoglycemia when treated with glimepiride.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450812235>2351</a></td><td>HTR3B</td><td>rs3758987</td><td>heroin</td><td>Heroin Dependence</td><td>3</td><td>CT</td><td>Toxicity</td><td>Patients with the CT genotype may be at an increased risk of developing heroin dependence as compared to patients with the TT genotype. Other genetic and clinical factors may also affect a patient's risk of developing heroin dependence.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655385388>2352</a></td><td>CYP1A2</td><td>rs762551</td><td>caffeine</td><td>Myocardial Infarction</td><td>3</td><td>AC</td><td>Toxicity</td><td>Patients with the AC genotype may have an increased risk of nonfatal myocardial infarction with increased coffee consumption as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of myocardial infarction.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655385491>2353</a></td><td>DRD2</td><td>rs6277</td><td>antipsychotics</td><td>Schizophrenia</td><td>3</td><td>AG</td><td>Toxicity</td><td>Patients with the AG genotype may have an increased risk for weight gain when treated with clozapine or olanzepine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of side-effects.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655385491>2354</a></td><td>DRD2</td><td>rs6277</td><td>clozapine</td><td>Schizophrenia</td><td>3</td><td>AG</td><td>Toxicity</td><td>Patients with the AG genotype may have an increased risk for weight gain when treated with clozapine or olanzepine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of side-effects.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655385491>2355</a></td><td>DRD2</td><td>rs6277</td><td>olanzapine</td><td>Schizophrenia</td><td>3</td><td>AG</td><td>Toxicity</td><td>Patients with the AG genotype may have an increased risk for weight gain when treated with clozapine or olanzepine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of side-effects.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655385701>2356</a></td><td>ABCB1</td><td>rs1045642</td><td>efavirenz</td><td>HIV Infections</td><td>3</td><td>AA</td><td>Toxicity</td><td>Patients with the AA genotype and HIV who are treated with nelfinavir and efavirenz: 1) May have increased CD4-cell count as compared to patients with the GA and GG genotype 2) May have increased virologic response as compared to patients with the GA and GG genotype 3) May have an increased risk for toxicity-related failure as compared to patients with the GA and GG genotype 4) May have a decreased, but not absent, risk of hepatotoxicity as compared to patients with the GA and GG genotype. Other genetic and clinical factors may also influence a patient's drug response or risk for toxicity.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655385701>2357</a></td><td>ABCB1</td><td>rs1045642</td><td>nelfinavir</td><td>HIV Infections</td><td>3</td><td>AA</td><td>Toxicity</td><td>Patients with the AA genotype and HIV who are treated with nelfinavir and efavirenz: 1) May have increased CD4-cell count as compared to patients with the GA and GG genotype 2) May have increased virologic response as compared to patients with the GA and GG genotype 3) May have an increased risk for toxicity-related failure as compared to patients with the GA and GG genotype 4) May have a decreased, but not absent, risk of hepatotoxicity as compared to patients with the GA and GG genotype. Other genetic and clinical factors may also influence a patient's drug response or risk for toxicity.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655385985>2358</a></td><td>CYBA</td><td>rs4673</td><td>doxorubicin</td><td>Neoplasms</td><td>3</td><td>AG</td><td>Toxicity</td><td>Cancer patients with the AG genotype who are treated with doxorubicin may have an increased risk for cardiotoxicity as compared to patients with the GG genotype. However, conflicting evidence exists for patients treated with idarubicin, a different anthracycline. Other genetic and clinical factors may also influence a patient's risk for cardiotoxicity.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655385985>2359</a></td><td>CYBA</td><td>rs4673</td><td>idarubicin</td><td>Neoplasms</td><td>3</td><td>AG</td><td>Toxicity</td><td>Cancer patients with the AG genotype who are treated with doxorubicin may have an increased risk for cardiotoxicity as compared to patients with the GG genotype. However, conflicting evidence exists for patients treated with idarubicin, a different anthracycline. Other genetic and clinical factors may also influence a patient's risk for cardiotoxicity.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655385989>2360</a></td><td>EPHX1</td><td>rs1051740</td><td>phenytoin</td><td>Congenital Abnormalities;Craniofacial Abnormalities</td><td>3</td><td>CT</td><td>Toxicity</td><td>Patients with the CT genotype who use phenytoin during the first trimester of pregnancy may be more likely to have a child with a craniofacial abnormality as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655385814>2361</a></td><td>ABCC2</td><td>rs2273697</td><td>antiepileptics</td><td>Epilepsy</td><td>4</td><td>AG</td><td>Toxicity</td><td>Patients with the AG genotype and epilepsy who are treated with antiepileptic drugs may have an increased likelihood of resistance to treatment as compared to patients with the GG genotype. Note; most studies find no association with response, and one study finds the A allele to be associated with better response. Other genetic and clinical factors may also influence a patient's response to treatment.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655385814>2362</a></td><td>ABCC2</td><td>rs2273697</td><td>carbamazepine</td><td>Epilepsy</td><td>4</td><td>AG</td><td>Toxicity</td><td>Patients with the AG genotype and epilepsy who are treated with antiepileptic drugs may have an increased likelihood of resistance to treatment as compared to patients with the GG genotype. Note; most studies find no association with response, and one study finds the A allele to be associated with better response. Other genetic and clinical factors may also influence a patient's response to treatment.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655385814>2363</a></td><td>ABCC2</td><td>rs2273697</td><td>oxcarbazepine</td><td>Epilepsy</td><td>4</td><td>AG</td><td>Toxicity</td><td>Patients with the AG genotype and epilepsy who are treated with antiepileptic drugs may have an increased likelihood of resistance to treatment as compared to patients with the GG genotype. Note; most studies find no association with response, and one study finds the A allele to be associated with better response. Other genetic and clinical factors may also influence a patient's response to treatment.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655386114>2364</a></td><td>CHST3</td><td>rs4148950</td><td>docetaxel</td><td>Prostatic Neoplasms</td><td>3</td><td>AG</td><td>Toxicity</td><td>Patients with the AG genotype may have an 1) increased chance of response to treatment with docetaxel and thalidomide 2) increased risk of toxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence treatment response.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655386114>2365</a></td><td>CHST3</td><td>rs4148950</td><td>thalidomide</td><td>Prostatic Neoplasms</td><td>3</td><td>AG</td><td>Toxicity</td><td>Patients with the AG genotype may have an 1) increased chance of response to treatment with docetaxel and thalidomide 2) increased risk of toxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence treatment response.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655386126>2366</a></td><td>CHST3</td><td>rs4148945</td><td>docetaxel</td><td>Prostatic Neoplasms</td><td>3</td><td>CT</td><td>Toxicity</td><td>Patients with the CT genotype may have an 1) increased chance of response to treatment with docetaxel and thalidomide 2) increased risk of toxicity as compared to patients with the TT genotype. Other genetic and clinical factors may also influence treatment response.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655386126>2367</a></td><td>CHST3</td><td>rs4148945</td><td>thalidomide</td><td>Prostatic Neoplasms</td><td>3</td><td>CT</td><td>Toxicity</td><td>Patients with the CT genotype may have an 1) increased chance of response to treatment with docetaxel and thalidomide 2) increased risk of toxicity as compared to patients with the TT genotype. Other genetic and clinical factors may also influence treatment response.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655386141>2368</a></td><td>SLC10A2</td><td>rs2301159</td><td>docetaxel</td><td>Prostatic Neoplasms</td><td>3</td><td>AG</td><td>Toxicity</td><td>Patients with the AG genotype may have an increased risk of toxicity with docetaxel and thalidomide as compared to patients with the GG genotype. Other genetic and clinical factors may also influence treatment response.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655386141>2369</a></td><td>SLC10A2</td><td>rs2301159</td><td>thalidomide</td><td>Prostatic Neoplasms</td><td>3</td><td>AG</td><td>Toxicity</td><td>Patients with the AG genotype may have an increased risk of toxicity with docetaxel and thalidomide as compared to patients with the GG genotype. Other genetic and clinical factors may also influence treatment response.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655386146>2370</a></td><td>SPG7</td><td>rs2292954</td><td>docetaxel</td><td>Prostatic Neoplasms</td><td>3</td><td>AG</td><td>Toxicity</td><td>Patients with the AG genotype may have an increased risk of toxicity with docetaxel and thalidomide as compared to patients with the GG genotype. Other genetic and clinical factors may also influence treatment response.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655386146>2371</a></td><td>SPG7</td><td>rs2292954</td><td>thalidomide</td><td>Prostatic Neoplasms</td><td>3</td><td>AG</td><td>Toxicity</td><td>Patients with the AG genotype may have an increased risk of toxicity with docetaxel and thalidomide as compared to patients with the GG genotype. Other genetic and clinical factors may also influence treatment response.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655386151>2372</a></td><td>ABCC6</td><td>rs2238472</td><td>docetaxel</td><td>Prostatic Neoplasms</td><td>3</td><td>CT</td><td>Toxicity</td><td>Patients with the CT genotype may have an increased risk of toxicity with docetaxel and thalidomide as compared to patients with the TT genotype. Other genetic and clinical factors may also influence treatment response.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655386151>2373</a></td><td>ABCC6</td><td>rs2238472</td><td>thalidomide</td><td>Prostatic Neoplasms</td><td>3</td><td>CT</td><td>Toxicity</td><td>Patients with the CT genotype may have an increased risk of toxicity with docetaxel and thalidomide as compared to patients with the TT genotype. Other genetic and clinical factors may also influence treatment response.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655386171>2374</a></td><td>CHST3</td><td>rs1871450</td><td>docetaxel</td><td>Prostatic Neoplasms</td><td>3</td><td>AG</td><td>Toxicity</td><td>Patients with the AA genotype may have an 1) increased chance of response to treatment with docetaxel and thalidomide 2) increased risk of toxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence treatment response.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655386171>2375</a></td><td>CHST3</td><td>rs1871450</td><td>thalidomide</td><td>Prostatic Neoplasms</td><td>3</td><td>AG</td><td>Toxicity</td><td>Patients with the AA genotype may have an 1) increased chance of response to treatment with docetaxel and thalidomide 2) increased risk of toxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence treatment response.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655386186>2376</a></td><td>RPL13</td><td>rs12960</td><td>docetaxel</td><td>Prostatic Neoplasms</td><td>3</td><td>AG</td><td>Toxicity</td><td>Patients with the AG genotype may have an increased risk of toxicity with docetaxel and thalidomide as compared to patients with the AA genotype. Other genetic and clinical factors may also influence treatment response.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655386186>2377</a></td><td>SNORD68</td><td>rs12960</td><td>docetaxel</td><td>Prostatic Neoplasms</td><td>3</td><td>AG</td><td>Toxicity</td><td>Patients with the AG genotype may have an increased risk of toxicity with docetaxel and thalidomide as compared to patients with the AA genotype. Other genetic and clinical factors may also influence treatment response.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655386186>2378</a></td><td>SPG7</td><td>rs12960</td><td>docetaxel</td><td>Prostatic Neoplasms</td><td>3</td><td>AG</td><td>Toxicity</td><td>Patients with the AG genotype may have an increased risk of toxicity with docetaxel and thalidomide as compared to patients with the AA genotype. Other genetic and clinical factors may also influence treatment response.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655386186>2379</a></td><td>RPL13</td><td>rs12960</td><td>thalidomide</td><td>Prostatic Neoplasms</td><td>3</td><td>AG</td><td>Toxicity</td><td>Patients with the AG genotype may have an increased risk of toxicity with docetaxel and thalidomide as compared to patients with the AA genotype. Other genetic and clinical factors may also influence treatment response.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655386186>2380</a></td><td>SNORD68</td><td>rs12960</td><td>thalidomide</td><td>Prostatic Neoplasms</td><td>3</td><td>AG</td><td>Toxicity</td><td>Patients with the AG genotype may have an increased risk of toxicity with docetaxel and thalidomide as compared to patients with the AA genotype. Other genetic and clinical factors may also influence treatment response.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655386186>2381</a></td><td>SPG7</td><td>rs12960</td><td>thalidomide</td><td>Prostatic Neoplasms</td><td>3</td><td>AG</td><td>Toxicity</td><td>Patients with the AG genotype may have an increased risk of toxicity with docetaxel and thalidomide as compared to patients with the AA genotype. Other genetic and clinical factors may also influence treatment response.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655386550>2382</a></td><td>CLCN6</td><td>rs1801133</td><td>antipsychotics</td><td>Schizophrenia</td><td>3</td><td>AG</td><td>Toxicity</td><td>Patients with the AG genotype treated with antipsychotics may have increased risk for metabolic syndrome as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655386550>2383</a></td><td>MTHFR</td><td>rs1801133</td><td>antipsychotics</td><td>Schizophrenia</td><td>3</td><td>AG</td><td>Toxicity</td><td>Patients with the AG genotype treated with antipsychotics may have increased risk for metabolic syndrome as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655386589>2384</a></td><td>COMT</td><td>rs4646316</td><td>cisplatin</td><td>Drug Toxicity;Neoplasms;Ototoxicity</td><td>3</td><td>CT</td><td>Toxicity</td><td>Children with the CT genotype and cancer who are treated with cisplatin may have an increased risk for hearing loss as compared to children with the TT genotype. A separate independent study found no association between this SNP and risk of cisplatin-induced ototoxicity. Other genetic and clinical factors may also influence a patient's risk for hearing loss with cisplatin treatment.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655386639>2385</a></td><td>ERCC1</td><td>rs11615</td><td>carboplatin</td><td>Neoplasms</td><td>3</td><td>AA</td><td>Toxicity</td><td>Patients with the AA genotype may have an increased risk for toxicity when treated with platinum-based chemotherapy as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's response to platinum-based chemotherapy.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655386639>2386</a></td><td>ERCC1</td><td>rs11615</td><td>cisplatin</td><td>Neoplasms</td><td>3</td><td>AA</td><td>Toxicity</td><td>Patients with the AA genotype may have an increased risk for toxicity when treated with platinum-based chemotherapy as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's response to platinum-based chemotherapy.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655386639>2387</a></td><td>ERCC1</td><td>rs11615</td><td>oxaliplatin</td><td>Neoplasms</td><td>3</td><td>AA</td><td>Toxicity</td><td>Patients with the AA genotype may have an increased risk for toxicity when treated with platinum-based chemotherapy as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's response to platinum-based chemotherapy.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655386639>2388</a></td><td>ERCC1</td><td>rs11615</td><td>platinum</td><td>Neoplasms</td><td>3</td><td>AA</td><td>Toxicity</td><td>Patients with the AA genotype may have an increased risk for toxicity when treated with platinum-based chemotherapy as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's response to platinum-based chemotherapy.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655386639>2389</a></td><td>ERCC1</td><td>rs11615</td><td>Platinum compounds</td><td>Neoplasms</td><td>3</td><td>AA</td><td>Toxicity</td><td>Patients with the AA genotype may have an increased risk for toxicity when treated with platinum-based chemotherapy as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's response to platinum-based chemotherapy.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655386990>2390</a></td><td>CYP2B6</td><td>rs2279343</td><td>cyclophosphamide</td><td>Transplantation</td><td>3</td><td>AG</td><td>Toxicity</td><td>Patients with the AG genotype who have received a hematopoietic stem cell transplant and are treated with cyclophosphamide may have an increased risk for oral mucositis as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for oral mucositis.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655386995>2391</a></td><td>CYP3A4</td><td>rs2740574</td><td>cyclophosphamide</td><td>Breast Neoplasms</td><td>3</td><td>TT</td><td>Toxicity</td><td>Premenopausal patients with the TT genotype and breast cancer who are treated with cyclophosphamide may have a shorter period of time before chemotherapy-induced ovarian failure compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence time to chemotherapy-induced ovarian failure.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655387023>2392</a></td><td>CDA</td><td>rs2072671</td><td>cytarabine</td><td>Leukemia;Lymphoma</td><td>3</td><td>AC</td><td>Toxicity</td><td>Patients with the AC genotype who are treated with cytarabine may have an increased risk of toxicity as compared to patients with the the AA genotype. Other genetic and clinical factors may also influence a patient's risk for drug-induced toxicity.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655387835>2393</a></td><td>MTHFR</td><td>rs1801133</td><td>nitrous oxide</td><td></td><td>3</td><td>AG</td><td>Toxicity</td><td>Patients with the GA genotype who undergo elective surgery with nitrous oxide anesthesia may have higher plasma total homocysteine concentrations as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's homocysteine levels after nitrous oxide anesthesia.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655387876>2394</a></td><td>DRD3</td><td>rs167771</td><td>risperidone</td><td>Bipolar Disorder;Schizophrenia</td><td>3</td><td>AG</td><td>Toxicity</td><td>Patients with the AG genotype may have increased risk for extrapyramidal symptoms in psychiatric patients receiving risperidone as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/699639328>2395</a></td><td>CYP2C8</td><td>rs1113129</td><td>paclitaxel</td><td></td><td>3</td><td>CC</td><td>Toxicity</td><td>Patients with the CC genotype may have increased risk of neurotoxicity in people with neoplasms treated with paclitaxel as compared to patients with the CG or GG genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655387938>2396</a></td><td>SLCO1B1</td><td>rs4149081</td><td>methotrexate</td><td>Precursor Cell Lymphoblastic Leukemia-Lymphoma</td><td>3</td><td>AG</td><td>Toxicity</td><td>Patients with the AG genotype and precursor cell lymphoblastic leukemia-lymphoma who are treated with methotrexate: 1) may have increased clearance of methotrexate and 2) may have an increased risk of GI toxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of GI toxicity.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655386961>2397</a></td><td>ADORA2A</td><td>rs2298383</td><td>methotrexate</td><td>Arthritis, Rheumatoid</td><td>3</td><td>CT</td><td>Toxicity</td><td>Patients with the rs2298383 CT genotype and Rheumatoid Arthritis who are treated with methotrexate may have a decreased, but not absent, risk for adverse events as compared to patients with the TT genotype or may have an increased risk for adverse events as compared to patients with the CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk for adverse events when treated with methotrexate.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/613977037>2398</a></td><td>HSPA1L</td><td>rs2227956</td><td>carbamazepine</td><td>Epilepsy</td><td>3</td><td>AA</td><td>Toxicity</td><td>Patients with the AA genotype may have an increased chance of severe hypersensitivity to carbamazepine treatment as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's chance of adverse response.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/619523400>2399</a></td><td>RRM1</td><td>rs9937</td><td>gemcitabine</td><td>Neoplasms</td><td>3</td><td>AG</td><td>Toxicity</td><td>Patients with the AG genotype with cancer who are treated with gemcitabine 1) may be less likely to experience neutropenia and 2) may have increased progression-free survival (PFS) as compared to patients with the AA genotype. However, one study found no association with PFS for this variant. Other genetic and clinical factors may also influence a patient's risk of toxicity and response to gemcitabine.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/637879864>2400</a></td><td>ADORA2A</td><td>rs5760410</td><td>methotrexate</td><td>Arthritis, Rheumatoid</td><td>3</td><td>AG</td><td>Toxicity</td><td>Patients with the AG genotype who are treated with methotrexate may have an increased risk of gastrointestinal adverse events as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events with methotrexate treatment.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/637879864>2401</a></td><td>SPECC1L</td><td>rs5760410</td><td>methotrexate</td><td>Arthritis, Rheumatoid</td><td>3</td><td>AG</td><td>Toxicity</td><td>Patients with the AG genotype who are treated with methotrexate may have an increased risk of gastrointestinal adverse events as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events with methotrexate treatment.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/613979643>2402</a></td><td>LTC4S</td><td>rs730012</td><td>aspirin</td><td>Urticaria</td><td>3</td><td>AC</td><td>Toxicity</td><td>Patients with the rs730012 AC genotype who are treated with aspirin may have an increased risk of urticaria as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk for urticaria.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/637880014>2403</a></td><td>ABCB1</td><td>rs2032582</td><td>Platinum compounds</td><td>Ovarian Neoplasms</td><td>3</td><td>AC</td><td>Toxicity</td><td>Patients with the AC genotype may have increased risk for gastrointestinal toxicity with taxane and platinum regimens as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for gastrointestinal toxicity with taxane and platinum regimens.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/637880014>2404</a></td><td>ABCB1</td><td>rs2032582</td><td>taxanes</td><td>Ovarian Neoplasms</td><td>3</td><td>AC</td><td>Toxicity</td><td>Patients with the AC genotype may have increased risk for gastrointestinal toxicity with taxane and platinum regimens as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for gastrointestinal toxicity with taxane and platinum regimens.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655384011>2405</a></td><td>SLCO1B1</td><td>rs4149056</td><td>simvastatin</td><td>statin-related myopathy</td><td>1A</td><td>CT</td><td>Toxicity</td><td>Patients with the rs4149056 CT genotype may have a higher risk of simvastatin-related myopathy when treated with simvastatin as compared to patients with the TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of toxicity to simvastatin.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655384670>2406</a></td><td>APOE</td><td>rs7412</td><td>Antivirals for treatment of HIV infections, combinations</td><td>HIV Infections;Hyperlipidemias;Hypertriglyceridemia</td><td>3</td><td>CT</td><td>Toxicity</td><td>Patients with the CT genotype may have increased risk for elevated triglycerides in response to ritonavir containing antiretroviral therapy as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655384670>2407</a></td><td>APOE</td><td>rs7412</td><td>ritonavir</td><td>HIV Infections;Hyperlipidemias;Hypertriglyceridemia</td><td>3</td><td>CT</td><td>Toxicity</td><td>Patients with the CT genotype may have increased risk for elevated triglycerides in response to ritonavir containing antiretroviral therapy as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655384813>2408</a></td><td>ADRB1</td><td>rs1801253</td><td>muraglitazar</td><td>Diabetes Mellitus;Edema;Hyperlipidemias</td><td>3</td><td>CG</td><td>Toxicity</td><td>Patients with the CG genotype and Diabetes Mellitus who are treated with muraglitazar may have an increased risk of edema as compared to patients with the CC genotype.Other genetic and clinical factors may also influence a patient's risk for edema with muraglitazar treatment.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655384597>2409</a></td><td>CYP2C8</td><td>rs1934951</td><td>Bisphosphonates</td><td>Multiple Myeloma;Osteonecrosis</td><td>4</td><td>TT</td><td>Toxicity</td><td>Patients with the TT genotype may have increased risk for osteonecrosis of the jaw in response to bisphosphonates as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence adverse responses to bisphosphonates.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655384597>2410</a></td><td>CYP2C8</td><td>rs1934951</td><td>pamidronate</td><td>Multiple Myeloma;Osteonecrosis</td><td>4</td><td>TT</td><td>Toxicity</td><td>Patients with the TT genotype may have increased risk for osteonecrosis of the jaw in response to bisphosphonates as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence adverse responses to bisphosphonates.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655384597>2411</a></td><td>CYP2C8</td><td>rs1934951</td><td>zoledronate</td><td>Multiple Myeloma;Osteonecrosis</td><td>4</td><td>TT</td><td>Toxicity</td><td>Patients with the TT genotype may have increased risk for osteonecrosis of the jaw in response to bisphosphonates as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence adverse responses to bisphosphonates.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655384966>2412</a></td><td>HTR2C</td><td>rs518147</td><td>olanzapine</td><td>Schizophrenia;Weight gain</td><td>3</td><td>G</td><td>Toxicity</td><td>Patients with one X-chromosome, the G genotype and schizophrenia who are treated with olanzapine may have an increased risk of weight gain as compared to patients with the C genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's risk of weight gain with olanzapine.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655384966>2413</a></td><td>HTR2C</td><td>rs518147</td><td>olanzapine</td><td>Schizophrenia;Weight gain</td><td>3</td><td>GG</td><td>Toxicity</td><td>Patients with two X-chromosomes, the GG genotype and schizophrenia who are treated with olanzapine may have an increased risk of weight gain as compared to patients with the CC genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's risk of weight gain with olanzapine. This gene is on the X chromosome therefore some individuals may have only one allele.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655384846>2414</a></td><td>ABCB1</td><td>rs1045642</td><td>nortriptyline</td><td>Depression;Depressive Disorder;Depressive Disorder, Major;Hypotension</td><td>3</td><td>AA</td><td>Toxicity</td><td>Patients with the AA genotype and depression who are treated with nortriptyline may have a higher likelihood to develop postural hypotension as compared to patients with the GG or GA genotype. Other genetic and clinical factors may also influence a patient's risk for postural hypotension with nortriptyline treatment.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655384878>2415</a></td><td>NRG3</td><td>rs4933824</td><td>iloperidone</td><td>Acquired Long QT Syndrome (aLQTS)</td><td>3</td><td>GG</td><td>Toxicity</td><td>Patients with the GG genotype who are treated with iloperidone may have increased risk for adverse cardiovascular events as compared to patients with the TT or GT genotype. Other genetic and clinical factors may also influence a patient's response.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655384882>2416</a></td><td>NUBPL</td><td>rs7142881</td><td>iloperidone</td><td>Acquired Long QT Syndrome (aLQTS)</td><td>3</td><td>AG</td><td>Toxicity</td><td>Patients with the AG genotype who are treated with iloperidone may have increased risk for adverse cardiovascular events as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655384886>2417</a></td><td>CELF4</td><td>rs4799915</td><td>iloperidone</td><td>Acquired Long QT Syndrome (aLQTS)</td><td>3</td><td>TT</td><td>Toxicity</td><td>Patients with the TT genotype who are treated with iloperidone may have increased risk for adverse cardiovascular events as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655384890>2418</a></td><td>CERKL</td><td>rs993648</td><td>iloperidone</td><td>Acquired Long QT Syndrome (aLQTS)</td><td>3</td><td>CC</td><td>Toxicity</td><td>Patients with the CC genotype who are treated with iloperidone may have increased risk for adverse cardiovascular events as compared to patients with the CT genotype. Other genetic and clinical factors may also influence a patient's response.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655384894>2419</a></td><td>NOS1AP</td><td>rs10918594</td><td>verapamil</td><td>Acquired Long QT Syndrome (aLQTS)</td><td>3</td><td>CG</td><td>Toxicity</td><td>While patients with the GG genotype may have an increased risk for QTc prolongation during verapamil treatment as compared to patients with the CC genotype, it was not shown conclusively if heterzygous (GC) individuals are affected. Other genetic and clinical factors may also influence a patient's QTc prolongation risk.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655384898>2420</a></td><td>NOS1AP</td><td>rs10494366</td><td>verapamil</td><td>Acquired Long QT Syndrome (aLQTS)</td><td>3</td><td>GT</td><td>Toxicity</td><td>While patients with the GG genotype may have an increased risk for QTc prolongation during verapamil treatment as compared to patients with the TT genotype, it was not shown conclusively if heterzygous (GT) individuals are affected. Other genetic and clinical factors may also influence a patient's QTc prolongation risk.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655384918>2421</a></td><td>PICK1</td><td>rs2076369</td><td>methamphetamine</td><td>Psychotic Disorders;Substance-Related Disorders</td><td>3</td><td>TT</td><td>Toxicity</td><td>Patients with the TT genotype who are methamphetamine abusers may have an increased risk for spontaneous relapse of psychosis as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for spontaneous relapse of psychosis with methamphetamine abuse.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655384922>2422</a></td><td>DTNBP1</td><td>rs3213207</td><td>methamphetamine</td><td>Psychotic Disorders</td><td>3</td><td>CT</td><td>Toxicity</td><td>Patients with the CT genotype who are exposed to methamphetamine may have an increased risk for psychosis as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for psychosis with methamphetamine exposure.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655384926>2423</a></td><td>DTNBP1</td><td>rs2619538</td><td>methamphetamine</td><td>Psychotic Disorders</td><td>3</td><td>AT</td><td>Toxicity</td><td>Patients with the AT genotype may have an increased risk for methamphetamine psychosis compared to patients with the TT genotype. Please note this associated did not remain significant after Bonferroni correction and was comparing allele frequencies in healthy controls and those with methamphetamine psychosis, not comparing frequencies in individuals exposed to methamphetamine. Other genetic and clinical factors may also influence a patient's risk to methamphetamine psychosis.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655384946>2424</a></td><td>HTR2A</td><td>rs6313</td><td>olanzapine</td><td>Schizophrenia;Weight gain</td><td>3</td><td>AG</td><td>Toxicity</td><td>Patients with the GA genotype and schizophrenia who are treated with olanzapine may have an increased risk of weight gain as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for weight gain with olanzapine treatment.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655384954>2425</a></td><td>HTR2C</td><td>rs6318</td><td>risperidone</td><td>Schizophrenia;Weight gain</td><td>3</td><td>G</td><td>Toxicity</td><td>Patients with one X-chromosome, the G genotype and schizophrenia, treated with risperidone, may have an increased likelihood of antipsychotic-induced weight as compared to patients the genotype C. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's risk for antipsychotic-induced weight gain.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655384954>2426</a></td><td>HTR2C</td><td>rs6318</td><td>risperidone</td><td>Schizophrenia;Weight gain</td><td>3</td><td>GG</td><td>Toxicity</td><td>Patients with two X-chromosomes, the GG genotype and schizophrenia, treated with risperidone, may have an increased likelihood of antipsychotic-induced weight as compared to patients the genotype CC. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's risk for antipsychotic-induced weight gain. This gene is on the X chromosome therefore some individuals may have only one allele.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655385033>2427</a></td><td>ERBB2</td><td>rs1136201</td><td>trastuzumab</td><td>Breast Neoplasms;Drug Toxicity</td><td>3</td><td>AG</td><td>Toxicity</td><td>Patients with the AG genotype may have increased risk of cardiotoxicity in breast cancer patients treated with trastuzumab as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655385087>2428</a></td><td>APOC3</td><td>rs2854116</td><td>ritonavir</td><td>HIV Infections;Hyperlipidemias</td><td>3</td><td>TT</td><td>Toxicity</td><td>Patients with the TT genotype and HIV who are treated with ritonavir may have increased severity of triglyceride elevation as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence a patient's triglyceride levels.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655385092>2429</a></td><td>APOC3</td><td>rs5128</td><td>ritonavir</td><td>HIV Infections;Hyperlipidemias</td><td>3</td><td>CC</td><td>Toxicity</td><td>Patients with the CC genotype and HIV who are treated with ritonavir may have an increased risk of triglyceride elevation as compared to patients with the CG or GG genotype.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655385149>2430</a></td><td>ESR2</td><td>rs4986938</td><td>tamoxifen</td><td></td><td>3</td><td>TT</td><td>Toxicity</td><td>Patients with the TT genotype may have lower tamoxifen-induced increase in triglycerides in postmenopausal woman as compared to patients with the CC genotype. Other genetic and clinical factors may influence the response to tamoxifen.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655385262>2431</a></td><td>ABCC1</td><td>rs2238476</td><td>methotrexate</td><td>Psoriasis</td><td>3</td><td>GG</td><td>Toxicity</td><td>Patients with the GG genotype and psoriasis who are treated with methotrexate: 1) may be more likely to have a reduction in psoriasis area or disease severity 2) may have an increased risk of toxicity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate and risk of toxicity.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655385333>2432</a></td><td>-</td><td>rs4888024</td><td>methotrexate</td><td>Neoplasm, Residual;Precursor Cell Lymphoblastic Leukemia-Lymphoma</td><td>3</td><td>AG</td><td>Toxicity</td><td>Patients with the AG genotype and childhood acute lymphoblastic leukemia who are treated with methotrexate may have an increased risk of end-of-induction minimal residual disease (MRD) as compared to patients with the AA genotype.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/981344897>2433</a></td><td>SLCO1B1</td><td>rs4149056</td><td>cerivastatin</td><td>Rhabdomyolysis</td><td>3</td><td>CT</td><td>Toxicity</td><td>Patients with the CT genotype may have a higher risk of cerivastatin-related rhabdomyolysis as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity. Cerivastatin was withdrawn from the market because of 52 deaths attributed to drug-related rhabdomyolysis that lead to kidney failure.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/827849095>2434</a></td><td>HLA-DQB1</td><td>rs9274407</td><td>amoxicillin</td><td>Drug Toxicity</td><td>3</td><td>AT</td><td>Toxicity</td><td>Patients with the AT genotype may have increased risk of drug induced liver injury in response to amoxicillin or clavulanate as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk for drug induced liver injury.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/827849095>2435</a></td><td>HLA-DQB1</td><td>rs9274407</td><td>clavulanate</td><td>Drug Toxicity</td><td>3</td><td>AT</td><td>Toxicity</td><td>Patients with the AT genotype may have increased risk of drug induced liver injury in response to amoxicillin or clavulanate as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk for drug induced liver injury.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/981201399>2436</a></td><td>ABCC2</td><td>rs2273697</td><td>tenofovir</td><td>HIV Infections;Kidney Diseases</td><td>4</td><td>AG</td><td>Toxicity</td><td>Patients with the AG genotype may have increased risk of renal proximal tubulopathy, but may not be associated with changes in glomerular filtration rate, or risk of Fanconi syndrome when treated with tenofovir as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/981202068>2437</a></td><td>PON1</td><td>rs662</td><td>clopidogrel</td><td>Angina Pectoris;Coronary Artery Disease;Myocardial Infarction;Myocardial Ischemia;Thrombosis</td><td>4</td><td>CC</td><td>Toxicity</td><td>Patients with the CC genotype who are treated with clopidogrel 1) may have higher levels of active metabolite, resulting in increased platelet inhibition and better response 2) may have a decreased, but not absent, risk of stent thrombosis, target vessel revascularization or cardiovascular secondary events, as compared to patients with the CT or TT genotype. A large number of studies report contradictory findings. Other genetic and clinical factors may also influence a patient's response to clopidogrel.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/827923042>2438</a></td><td>CYP2B6</td><td>rs3745274</td><td>efavirenz</td><td>HIV Infections</td><td>1A</td><td>GT</td><td>Toxicity</td><td>Patients with the rs3745274 GT genotype may have an increased risk of efavirenz-induced side effects, including sleep- and central nervous system-related side effects, as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of efavirenz toxicity.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/981203854>2439</a></td><td>CYP3A5</td><td>rs776746</td><td>tacrolimus</td><td>Hyperlipidemias</td><td>3</td><td>CC</td><td>Toxicity</td><td>Patients with the CC genotype and recipients of kidney transplant who are treated with tacrolimus may have an increased risk of developing hyperlipidemia as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence a patient's risk for hyperlipidemia.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/981204258>2440</a></td><td>ABCB1</td><td>rs1045642</td><td>paclitaxel</td><td>Neoplasms;Neurotoxicity Syndromes</td><td>3</td><td>AA</td><td>Toxicity</td><td>Patients with the AA genotype and cancer may have an increased risk of neuropathy when treated with paclitaxel as compared to patients with the AG and GG genotypes. Other genetic and clinical factors may influence the risk of neuropathy.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/981345382>2441</a></td><td>SLCO1B1</td><td>rs4149056</td><td>hmg coa reductase inhibitors</td><td>statin-related myopathy</td><td>2A</td><td>CT</td><td>Toxicity</td><td>Patients with the rs4149056 CT genotype may have an increased risk of developing myopathy when treated with statins as compared to patients with the TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect risk of statin-induced myopathy.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/981203532>2442</a></td><td>CDA</td><td>rs602950</td><td>cytarabine</td><td></td><td>3</td><td>AG</td><td>Toxicity</td><td>Patients with the AG genotype who are treated with cytarabine may have higher levels of toxicity as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for cytarabine-induced toxicity.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/981204361>2443</a></td><td>ABCB1</td><td>rs1045642</td><td>clopidogrel</td><td>Acute coronary syndrome;Myocardial Infarction</td><td>3</td><td>AA</td><td>Toxicity</td><td>People with AA genotype may have an increased risk of major adverse cardiovascular events (MACE such as cardiovascular death, myocardial infarction, or stroke) when treated with clopidogrel in people with Acute coronary syndrome or myocardial Infarction as compared to people with genotypes GG or AG. Contradictory findings have been reported in the literature. Other genetic and clinical factors may also impact the response to clopidogrel.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/981204414>2444</a></td><td>ABCB1</td><td>rs1045642</td><td>fluorouracil</td><td>Colorectal Neoplasms</td><td>4</td><td>AA</td><td>Toxicity</td><td>Patients with AA genotype may have increased risk of diarrhea when treated with fluorouracil in people with Colorectal Neoplasms as compared to patients with genotype GG. Other genetic and clinical factors may also impact a patients response to fluorouracil.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/981204975>2445</a></td><td>MTHFR</td><td>rs1801133</td><td>mercaptopurine</td><td>Precursor Cell Lymphoblastic Leukemia-Lymphoma</td><td>4</td><td>AG</td><td>Toxicity</td><td>Patients with the AG genotype may have increased likelihood of treatment interruptions when treated with mercaptopurine in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to patients with genotype GG. However, contradictory finding has been reported. Other genetic and clinical factors may also influence a patient's risk for toxicity to mercaptopurine.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449005066>2446</a></td><td>CYP3A</td><td>rs2740574</td><td>cyclosporine</td><td>Kidney Transplantation;transplant rejection</td><td>3</td><td>TT</td><td>Toxicity</td><td>Recipients of kidney transplants who are administered cyclosporine or tacrolimus and who receive kidneys from donors with the rs2740574 TT genotype (CYP3A4 *1A/*1A) may have a greater likelihood of transplant rejection as compared to kidneys from donors with the rs2740574 CT genotype (CYP3A4 *1A/*1B). Other clinical and genetic factors may also influence risk of transplant rejection in recipients of kidneys.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449005066>2447</a></td><td>CYP3A4</td><td>rs2740574</td><td>cyclosporine</td><td>Kidney Transplantation;transplant rejection</td><td>3</td><td>TT</td><td>Toxicity</td><td>Recipients of kidney transplants who are administered cyclosporine or tacrolimus and who receive kidneys from donors with the rs2740574 TT genotype (CYP3A4 *1A/*1A) may have a greater likelihood of transplant rejection as compared to kidneys from donors with the rs2740574 CT genotype (CYP3A4 *1A/*1B). Other clinical and genetic factors may also influence risk of transplant rejection in recipients of kidneys.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449005066>2448</a></td><td>CYP3A</td><td>rs2740574</td><td>tacrolimus</td><td>Kidney Transplantation;transplant rejection</td><td>3</td><td>TT</td><td>Toxicity</td><td>Recipients of kidney transplants who are administered cyclosporine or tacrolimus and who receive kidneys from donors with the rs2740574 TT genotype (CYP3A4 *1A/*1A) may have a greater likelihood of transplant rejection as compared to kidneys from donors with the rs2740574 CT genotype (CYP3A4 *1A/*1B). Other clinical and genetic factors may also influence risk of transplant rejection in recipients of kidneys.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449005066>2449</a></td><td>CYP3A4</td><td>rs2740574</td><td>tacrolimus</td><td>Kidney Transplantation;transplant rejection</td><td>3</td><td>TT</td><td>Toxicity</td><td>Recipients of kidney transplants who are administered cyclosporine or tacrolimus and who receive kidneys from donors with the rs2740574 TT genotype (CYP3A4 *1A/*1A) may have a greater likelihood of transplant rejection as compared to kidneys from donors with the rs2740574 CT genotype (CYP3A4 *1A/*1B). Other clinical and genetic factors may also influence risk of transplant rejection in recipients of kidneys.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449164752>2450</a></td><td>SLC22A1</td><td>rs683369</td><td>imatinib</td><td>Gastrointestinal Stromal Tumors</td><td>3</td><td>CG</td><td>Toxicity</td><td>Patients with the CG genotype and gastrointestinal stromal tumors (GIST) may have an increased risk for conjunctival hemorrhage when treated with imatinib as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for conjunctival hemorrhage.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450822470>2451</a></td><td>OPRD1</td><td>rs2298897</td><td>heroin</td><td>Heroin Dependence</td><td>3</td><td>CG</td><td>Toxicity</td><td>Patients with the CG genotype may be at an increased risk of developing heroin dependence as compared to patients with the GG genotype. Other genetic or clinical factors may also affect a patient's risk of developing heroin dependence.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449565072>2452</a></td><td>POLR2A</td><td>rs2228130</td><td>gemcitabine</td><td>Carcinoma, Non-Small-Cell Lung</td><td>3</td><td>CC</td><td>Toxicity</td><td>Patients with the CC genotype and non-small cell lung cancer who are treated with gemcitabine may have increased severity of thrombocytopenia as compared to patients with the CT genotype. There was no association with neutropenia, or progression-free and overall survival. Other clinical and genetic factors may also influence response to gemcitabine and adverse events in patients with non-small cell lung cancer.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450810266>2453</a></td><td>OPRM1</td><td>rs524731</td><td>heroin</td><td>Heroin Dependence;Opioid-Related Disorders</td><td>3</td><td>AC</td><td>Toxicity</td><td>Patients with the AC genotype may be at an increased risk of developing heroin dependence or opioid dependence as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of developing heroin dependence or opioid dependence.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450810266>2454</a></td><td>OPRM1</td><td>rs524731</td><td>opioids</td><td>Heroin Dependence;Opioid-Related Disorders</td><td>3</td><td>AC</td><td>Toxicity</td><td>Patients with the AC genotype may be at an increased risk of developing heroin dependence or opioid dependence as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of developing heroin dependence or opioid dependence.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450823109>2455</a></td><td>OPRM1</td><td>rs3778150</td><td>heroin</td><td>Heroin Dependence</td><td>3</td><td>CT</td><td>Toxicity</td><td>Patients with the CT genotype may be at an increased risk of developing heroin dependence as compared to patients with the TT genotype. Other genetic or clinical factors may also affect a patient's risk of developing heroin dependence.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449269910>2456</a></td><td>VKORC1</td><td>rs9923231</td><td>warfarin</td><td>Hemorrhage</td><td>2A</td><td>CT</td><td>Toxicity</td><td>Patients with the rs9923231 CT genotype may have an increased risk of bleeding when treated with warfarin as compared to patients with the CC genotypes. However, conflicting evidence has been reported. Other clinical and genetic factors may also influence risk of warfarin-induced bleeding.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450377214>2457</a></td><td>NAT2</td><td>rs1208</td><td>isoniazid</td><td>Drug interaction with drug;Drug Toxicity</td><td>3</td><td>AG</td><td>Toxicity</td><td>Patients with the AG genotype who are receiving concomitant phenytoin and isoniazid may be at an increased risk of phenytoin toxicity resulting from isoniazid-phenytoin interaction as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of developing phenytoin toxicity when treated with both isoniazid and phenytoin.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450377214>2458</a></td><td>NAT2</td><td>rs1208</td><td>phenytoin</td><td>Drug interaction with drug;Drug Toxicity</td><td>3</td><td>AG</td><td>Toxicity</td><td>Patients with the AG genotype who are receiving concomitant phenytoin and isoniazid may be at an increased risk of phenytoin toxicity resulting from isoniazid-phenytoin interaction as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of developing phenytoin toxicity when treated with both isoniazid and phenytoin.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448636814>2459</a></td><td>RPTOR</td><td>rs9906827</td><td>everolimus</td><td>pneumonitis;progression-free survival</td><td>3</td><td>TT</td><td>Toxicity</td><td>Patients with the TT genotype and breast cancer who are treated with everolimus may have increased likelihood of progression-free survival and decreased likelihood of pneumonitis as compared to patients with the CC genotypes. Other clinical and genetic factors may also influence the likelihood of progression-free survival or pneumonitis in women with breast cancer who are treated with everolimus.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448636848>2460</a></td><td>ABCB1</td><td>rs1045642</td><td>everolimus</td><td>Breast Neoplasms;mucositis</td><td>3</td><td>AA</td><td>Toxicity</td><td>Patients with the AA genotype and breast cancer who are treated with everolimus may have increased likelihood of Mucositis as compared to patients with the AG or GG genotypes. Other clinical and genetic factors may also influence likelihood of mucositis in patients with breast cancer who are treated with everolimus.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450375024>2461</a></td><td>ABCB1</td><td>rs1045642</td><td>bleomycin</td><td>Testicular Neoplasms;Vomiting</td><td>3</td><td>AA</td><td>Toxicity</td><td>Patients with testicular cancer and the AA genotype may be at an increased risk of vomiting as a result of treatment with bleomycin, cisplatin and etoposide as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's risk of vomiting as a result of treatment with bleomycin, cisplatin and etoposide.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450375024>2462</a></td><td>ABCB1</td><td>rs1045642</td><td>cisplatin</td><td>Testicular Neoplasms;Vomiting</td><td>3</td><td>AA</td><td>Toxicity</td><td>Patients with testicular cancer and the AA genotype may be at an increased risk of vomiting as a result of treatment with bleomycin, cisplatin and etoposide as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's risk of vomiting as a result of treatment with bleomycin, cisplatin and etoposide.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450375024>2463</a></td><td>ABCB1</td><td>rs1045642</td><td>etoposide</td><td>Testicular Neoplasms;Vomiting</td><td>3</td><td>AA</td><td>Toxicity</td><td>Patients with testicular cancer and the AA genotype may be at an increased risk of vomiting as a result of treatment with bleomycin, cisplatin and etoposide as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect a patient's risk of vomiting as a result of treatment with bleomycin, cisplatin and etoposide.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449270901>2464</a></td><td>PERP</td><td>rs78428806</td><td>cyclophosphamide</td><td>Breast Neoplasms;Neutropenia</td><td>3</td><td>GG</td><td>Toxicity</td><td>Patients with breast cancer and the GG genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449270901>2465</a></td><td>PERP</td><td>rs78428806</td><td>epirubicin</td><td>Breast Neoplasms;Neutropenia</td><td>3</td><td>GG</td><td>Toxicity</td><td>Patients with breast cancer and the GG genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449270901>2466</a></td><td>PERP</td><td>rs78428806</td><td>fluorouracil</td><td>Breast Neoplasms;Neutropenia</td><td>3</td><td>GG</td><td>Toxicity</td><td>Patients with breast cancer and the GG genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449270907>2467</a></td><td>PERP</td><td>rs117101815</td><td>cyclophosphamide</td><td>Breast Neoplasms;Neutropenia</td><td>3</td><td>GG</td><td>Toxicity</td><td>Patients with breast cancer and the GG genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the GT or TT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449270907>2468</a></td><td>PERP</td><td>rs117101815</td><td>epirubicin</td><td>Breast Neoplasms;Neutropenia</td><td>3</td><td>GG</td><td>Toxicity</td><td>Patients with breast cancer and the GG genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the GT or TT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449270907>2469</a></td><td>PERP</td><td>rs117101815</td><td>fluorouracil</td><td>Breast Neoplasms;Neutropenia</td><td>3</td><td>GG</td><td>Toxicity</td><td>Patients with breast cancer and the GG genotype may have an increased risk of developing neutropenia when treated with cyclophosphamide, epirubicin and fluorouracil as compared to patients with the GT or TT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing neutropenia.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450373610>2470</a></td><td>CHST1</td><td>rs9787901</td><td>imatinib</td><td>Gastrointestinal Stromal Tumors</td><td>3</td><td>AG</td><td>Toxicity</td><td>Patients with the AG genotype and gastrointestinal stromal tumors may have an increased risk for toxicity when treated with imatinib as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for toxicity in patients receiving imatinib.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450377181>2471</a></td><td>NAT2</td><td>rs1041983</td><td>isoniazid</td><td>Drug interaction with drug;Drug Toxicity</td><td>3</td><td>CT</td><td>Toxicity</td><td>Patients with the CT genotype who are receiving concomitant phenytoin and isoniazid may be at an increased risk of phenytoin toxicity resulting from isoniazid-phenytoin interaction as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of developing phenytoin toxicity when treated with both isoniazid and phenytoin.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450377181>2472</a></td><td>NAT2</td><td>rs1041983</td><td>phenytoin</td><td>Drug interaction with drug;Drug Toxicity</td><td>3</td><td>CT</td><td>Toxicity</td><td>Patients with the CT genotype who are receiving concomitant phenytoin and isoniazid may be at an increased risk of phenytoin toxicity resulting from isoniazid-phenytoin interaction as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of developing phenytoin toxicity when treated with both isoniazid and phenytoin.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450377193>2473</a></td><td>NAT2</td><td>rs1799929</td><td>isoniazid</td><td>Drug interaction with drug;Drug Toxicity</td><td>3</td><td>CT</td><td>Toxicity</td><td>Patients with the CT genotype who are receiving concomitant phenytoin and isoniazid may be at an increased risk of phenytoin toxicity resulting from isoniazid-phenytoin interaction as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of developing phenytoin toxicity when treated with both isoniazid and phenytoin.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450377193>2474</a></td><td>NAT2</td><td>rs1799929</td><td>phenytoin</td><td>Drug interaction with drug;Drug Toxicity</td><td>3</td><td>CT</td><td>Toxicity</td><td>Patients with the CT genotype who are receiving concomitant phenytoin and isoniazid may be at an increased risk of phenytoin toxicity resulting from isoniazid-phenytoin interaction as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of developing phenytoin toxicity when treated with both isoniazid and phenytoin.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450931422>2475</a></td><td>PIP5K1C</td><td>rs10432303</td><td>ethanol</td><td>Alcoholism</td><td>3</td><td>AA</td><td>Toxicity</td><td>Patients with the AA genotype may be at an increased risk of developing alcoholism as compared to patients with the GG genotype. This association was found in patients of African ancestry in the discovery cohort and was not replicated in either the replication cohort or in patients or European ancestry. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450931440>2476</a></td><td>PIP5K1C</td><td>rs10405681</td><td>ethanol</td><td>Alcoholism</td><td>3</td><td>TT</td><td>Toxicity</td><td>Patients with the TT genotype may be at an increased risk of developing alcoholism as compared to patients with the CC or CT genotype. This association was found in patients of African ancestry in the discovery cohort and was not replicated in either the replication cohort or in patients or European ancestry. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451615920>2477</a></td><td>-</td><td>rs2736308</td><td>Bisphosphonates</td><td>osteonecrosis of jaw caused by drug</td><td>3</td><td>CT</td><td>Toxicity</td><td>Patients with the rs2736308 CT genotype may have an increased risk of Medication-related osteonecrosis of the jaw (MRONJ) when treated with bisphosphonates as compared to patients with the TT genotype. Other genetic and clinical factors may also influence the risk of toxicity to bisphosphonates.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450813554>2478</a></td><td>CYP2A6</td><td>rs28399433</td><td>nicotine</td><td>Tobacco Use Disorder</td><td>3</td><td>AA</td><td>Toxicity</td><td>Patients with the AA genotype may have more severe nicotine dependence as measured by Fagerstrom Test Nicotine dependence score as compared to patients with the CC genotype. However, analysis of other measurements did not find a significant association. Other genetic or clinical factors may also affect severity of nicotine dependence.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450810387>2479</a></td><td>OPRM1</td><td>rs495491</td><td>opioids</td><td>Opioid-Related Disorders</td><td>3</td><td>AG</td><td>Toxicity</td><td>Patients with the AG genotype may be at an increased risk of developing opioid dependence as compared to patients with the AA genotype. Other genetic or clinical factors may also affect a patient's risk of developing opioid dependence.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450810247>2480</a></td><td>OPRM1</td><td>rs524731</td><td>ethanol</td><td>Alcoholism</td><td>3</td><td>AC</td><td>Toxicity</td><td>Patients with the AC genotype may be at an increased risk of developing alcoholism as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450810295>2481</a></td><td>OPRM1</td><td>rs3823010</td><td>heroin</td><td>Heroin Dependence;Opioid-Related Disorders</td><td>3</td><td>AG</td><td>Toxicity</td><td>Patients with the AG genotype may be at an increased risk of developing heroin dependence or opioid dependence as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing opioid dependence.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450810295>2482</a></td><td>OPRM1</td><td>rs3823010</td><td>opioids</td><td>Heroin Dependence;Opioid-Related Disorders</td><td>3</td><td>AG</td><td>Toxicity</td><td>Patients with the AG genotype may be at an increased risk of developing heroin dependence or opioid dependence as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing opioid dependence.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451621726>2483</a></td><td>ABCB1</td><td>rs1128503</td><td>methotrexate</td><td>Lymphoma;mucositis;Osteosarcoma;Precursor Cell Lymphoblastic Leukemia-Lymphoma</td><td>3</td><td>AG</td><td>Toxicity</td><td>Patients with the rs1128503 AG genotype may be at an increased risk of experiencing side effects when treated with methotrexate as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of side effects when treated with methotrexate.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450930827>2484</a></td><td>CHRNA3</td><td>rs3743075</td><td>nicotine</td><td>Tobacco Use Disorder</td><td>3</td><td>CT</td><td>Toxicity</td><td>Patients with the CT genotype may have increased severity of nicotine dependence, as measured by FTND score, as compared to patients with the CC genotype. Other genetic and clinical factors may also affect severity of nicotine dependence.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449310013>2485</a></td><td>-</td><td>rs12046844</td><td>gemcitabine</td><td>Leukopenia;Neoplasms</td><td>3</td><td>AG</td><td>Toxicity</td><td>Patients with cancer and the AG genotype who are treated with gemcitabine may have a increased risk of leukopenia as compared to patients with the AA genotype. Other clinical and genetic factors may also influence risk of of leukopenia in patients with cancer.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449716392>2486</a></td><td>ABCB1</td><td>rs2032582</td><td>fentanyl</td><td>Neoplasms;Pain</td><td>3</td><td>AC</td><td>Toxicity</td><td>Patients with the AC genotype may have an increased likelihood of experiencing constipation when taking fentanyl as compared to patients with the AA, AT or TT genotypes. However, this association was not significant. Other genetic and clinical factors may also affect a patient's likelihood of experiencing constipation when taking fentanyl.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450822476>2487</a></td><td>OPRD1</td><td>rs2236855</td><td>heroin</td><td>Heroin Dependence</td><td>3</td><td>AC</td><td>Toxicity</td><td>Patients with the AC genotype may be at an increased risk of developing heroin dependence as compared to patients with the CC genotype. Other genetic or clinical factors may also affect a patient's risk of developing heroin dependence.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450823115>2488</a></td><td>-</td><td>rs9384169</td><td>heroin</td><td>Heroin Dependence</td><td>3</td><td>CT</td><td>Toxicity</td><td>Patients with the CT genotype may be at an increased risk of developing heroin dependence as compared to patients with the TT genotype. Other genetic or clinical factors may also affect a patient's risk of developing heroin dependence.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449005393>2489</a></td><td>ABCB1</td><td>rs1128503</td><td>remifentanil</td><td>tonsillectomy</td><td>3</td><td>AG</td><td>Toxicity</td><td>Pediatric patients undergoing surgery with the AG genotype may have an increased likelihood of adverse events, as well as a worse response to sevoflurane and remifentanil as compared to patients with the GG genotype. Other clinical and genetic factors may also influence response to sevoflurane and remifentanil.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449005393>2490</a></td><td>ABCB1</td><td>rs1128503</td><td>sevoflurane</td><td>tonsillectomy</td><td>3</td><td>AG</td><td>Toxicity</td><td>Pediatric patients undergoing surgery with the AG genotype may have an increased likelihood of adverse events, as well as a worse response to sevoflurane and remifentanil as compared to patients with the GG genotype. Other clinical and genetic factors may also influence response to sevoflurane and remifentanil.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184348731>2491</a></td><td>NAT2</td><td>rs1801280</td><td>cisplatin</td><td>Ovarian Neoplasms</td><td>3</td><td>CT</td><td>Toxicity</td><td>Patients with the CT genotype and ovarian cancer who are treated with chemotherapy involving cisplatin and cyclophosphamide may have an increased risk of grade 2-4 anemia as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity when treated with chemotherapy.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184348731>2492</a></td><td>NAT2</td><td>rs1801280</td><td>cyclophosphamide</td><td>Ovarian Neoplasms</td><td>3</td><td>CT</td><td>Toxicity</td><td>Patients with the CT genotype and ovarian cancer who are treated with chemotherapy involving cisplatin and cyclophosphamide may have an increased risk of grade 2-4 anemia as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity when treated with chemotherapy.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184472737>2493</a></td><td>ESR1</td><td>rs2234693</td><td>anastrozole</td><td>Neoplasms</td><td>3</td><td>CT</td><td>Toxicity</td><td>Patients with cancer and the CT genotype may have an increased risk of musculoskeletal pain when exposed to anastrozole and letrozole as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of musculoskeletal pain.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184472737>2494</a></td><td>ESR1</td><td>rs2234693</td><td>letrozole</td><td>Neoplasms</td><td>3</td><td>CT</td><td>Toxicity</td><td>Patients with cancer and the CT genotype may have an increased risk of musculoskeletal pain when exposed to anastrozole and letrozole as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of musculoskeletal pain.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183704321>2495</a></td><td>VEGFA</td><td>rs699947</td><td>sunitinib</td><td></td><td>3</td><td>AC</td><td>Toxicity</td><td>Patients with the AC genotype may have higher increase in systolic blood pressure and increased risk of developing grade 3 hypertension when treated with sunitinib as compared to patients with genotype CC. Other genetic and clinical factors may also influence the response to sunitinib.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183704277>2496</a></td><td>ADH7</td><td>rs729147</td><td>anthracyclines and related substances</td><td></td><td>4</td><td>AG</td><td>Toxicity</td><td>Patients with the AG genotype may have increased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with genotype AA, although this is contradicted in one study. Other genetic and clinical factors may also influence the risk of toxicity to anthracyclines.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183704399>2497</a></td><td>KCNJ1</td><td>rs658903</td><td>hydrochlorothiazide</td><td>Diabetes Mellitus;Hypertension</td><td>3</td><td>TT</td><td>Toxicity</td><td>Patients with the TT genotype may have increased likelihood of Diabetes Mellitus when treated with hydrochlorothiazide in people with Hypertension as compared to patients with genotype AA or AT. Other genetic and clinical factors may also influence the risk of toxicity to hydrochlorothiazide.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184348708>2498</a></td><td>EPHX1</td><td>rs1051740</td><td>cisplatin</td><td>Ovarian Neoplasms</td><td>3</td><td>CT</td><td>Toxicity</td><td>Patients with the CT genotype and ovarian cancer who are treated with chemotherapy involving cisplatin and cyclophosphamide may have an increased risk of grade 1-4 nephrotoxicity as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity when treated with chemotherapy.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184348708>2499</a></td><td>EPHX1</td><td>rs1051740</td><td>cyclophosphamide</td><td>Ovarian Neoplasms</td><td>3</td><td>CT</td><td>Toxicity</td><td>Patients with the CT genotype and ovarian cancer who are treated with chemotherapy involving cisplatin and cyclophosphamide may have an increased risk of grade 1-4 nephrotoxicity as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of toxicity when treated with chemotherapy.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184134170>2500</a></td><td>DCK</td><td>rs4694362</td><td>gemcitabine</td><td>Pancreatic Neoplasms</td><td>3</td><td>TT</td><td>Toxicity</td><td>Patients with TT genotype and pancreatic cancer who are treated with gemcitabine may have an increased risk of neutropenia compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of neutropenia when treated with gemcitabine.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183704248>2501</a></td><td>SEMA3C</td><td>rs7779029</td><td>irinotecan</td><td>Carcinoma, Non-Small-Cell Lung</td><td>3</td><td>CT</td><td>Toxicity</td><td>Patients with the CT genotype may have increased severity of Neutropenia when treated with irinotecan in people with Carcinoma, Non-Small-Cell Lung as compared to patients with genotype TT. Other genetic or clinical factors may also influence the toxicity to irinotecan.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183863785>2502</a></td><td>CYP19A1</td><td>rs7176005</td><td>exemestane</td><td>Breast Neoplasms</td><td>3</td><td>TT</td><td>Toxicity</td><td>Patients with the TT genotype may have a higher odds of vasomotor symptoms (VMSs) in postmenopausal hormone receptor (HR)-positive breast cancer patients when treated with exemestane as compared to patients with genotype CC or CT. Other genetic and clinical factors may also influence a patient's risk of toxicity to exemestane.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451636580>2503</a></td><td>SLCO1B1</td><td>rs11045879</td><td>mercaptopurine</td><td>gastrointestinal toxicity;Precursor Cell Lymphoblastic Leukemia-Lymphoma</td><td>3</td><td>CT</td><td>Toxicity</td><td>Patients with acute lymphoblastic leukemia (ALL) and the rs11045879 CT genotype may be at an increased risk of experiencing toxicity when treated with mercaptopurine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of toxicity when treated with mercaptopurine.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183704262>2504</a></td><td>-</td><td>rs7325568</td><td>fluorouracil</td><td>Colorectal Neoplasms</td><td>3</td><td>CT</td><td>Toxicity</td><td>Patients with the CT genotype may have increased likelihood of Drug Toxicity when treated with fluorouracil and oxaliplatin in people with Colorectal Neoplasms as compared to patients with genotype CC. Other genetic and clinical factors may also influence the toxicity to fluorouracil and oxaliplatin.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183704262>2505</a></td><td>-</td><td>rs7325568</td><td>oxaliplatin</td><td>Colorectal Neoplasms</td><td>3</td><td>CT</td><td>Toxicity</td><td>Patients with the CT genotype may have increased likelihood of Drug Toxicity when treated with fluorouracil and oxaliplatin in people with Colorectal Neoplasms as compared to patients with genotype CC. Other genetic and clinical factors may also influence the toxicity to fluorouracil and oxaliplatin.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444700881>2506</a></td><td>-</td><td>rs16947</td><td>timolol</td><td>Bradycardia</td><td>3</td><td>AG</td><td>Toxicity</td><td>Patients with the AG genotype and open-angle glaucoma who are treated with timolol may have an increased risk for bradycardia as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for bradycardia.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1445401317>2507</a></td><td>FAAH</td><td>rs2295632</td><td>opioids</td><td></td><td>3</td><td>GT</td><td>Toxicity</td><td>Children with the GT genotype who are undergoing a tonsillectomy may have an increased risk for respiratory depression when treated with opioids as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of respiratory depression.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1446898857>2508</a></td><td>CNR1</td><td>rs806378</td><td>clozapine</td><td>Autism Spectrum Disorder;Schizophrenia</td><td>3</td><td>CT</td><td>Toxicity</td><td>Patients with schizophrenia, or autism spectrum disorder (ASD) and the CT genotype, may have an increased likelihood of weight gain as compared to patients with the CC genotypes when taking risperidone, clozapine, or olanzapine. Other clinical and genetic factors may also influence risk of weight gain in patients taking risperidone, clozapine, or olanzapine.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1446898857>2509</a></td><td>CNR1</td><td>rs806378</td><td>olanzapine</td><td>Autism Spectrum Disorder;Schizophrenia</td><td>3</td><td>CT</td><td>Toxicity</td><td>Patients with schizophrenia, or autism spectrum disorder (ASD) and the CT genotype, may have an increased likelihood of weight gain as compared to patients with the CC genotypes when taking risperidone, clozapine, or olanzapine. Other clinical and genetic factors may also influence risk of weight gain in patients taking risperidone, clozapine, or olanzapine.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1446898857>2510</a></td><td>CNR1</td><td>rs806378</td><td>risperidone</td><td>Autism Spectrum Disorder;Schizophrenia</td><td>3</td><td>CT</td><td>Toxicity</td><td>Patients with schizophrenia, or autism spectrum disorder (ASD) and the CT genotype, may have an increased likelihood of weight gain as compared to patients with the CC genotypes when taking risperidone, clozapine, or olanzapine. Other clinical and genetic factors may also influence risk of weight gain in patients taking risperidone, clozapine, or olanzapine.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444700605>2511</a></td><td>ALOX12</td><td>rs11078659</td><td>celecoxib</td><td>Colorectal Neoplasms</td><td>3</td><td>AA</td><td>Toxicity</td><td>Patients with the AA genotype with colorectal neoplasms who are treated with celecoxib may have an increased risk of adenoma recurrence as compared to patients with the GG genotype. Other genetic and clinical factors may also effect patients' risk for adenoma recurrence.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444701017>2512</a></td><td>KCNT2</td><td>rs1886629</td><td>Bisphosphonates</td><td>Osteonecrosis</td><td>3</td><td>TT</td><td>Toxicity</td><td>Patients with the TT genotype may have increased likelihood of Osteonecrosis when treated with Bisphosphonates as compared to patients with genotype CC. Other genetic and clinical factors may also influence the toxicity to Bisphosphonates.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444700748>2513</a></td><td>-</td><td>rs11719165</td><td>gemcitabine</td><td>Neoplasms</td><td>3</td><td>CC</td><td>Toxicity</td><td>Patients with the CC genotype and neoplasms who are treated with gemcitabine may have an increased risk for leukopenia as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for leukopenia.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1446906439>2514</a></td><td>ABCB1</td><td>rs2032582</td><td>capecitabine</td><td>Colorectal Neoplasms;hand-foot syndrome</td><td>3</td><td>AC</td><td>Toxicity</td><td>Patients with genotype AC may have increased risk of hand-foot syndrome when treated with capecitabine in people with Colorectal Neoplasms as compared to patients with genotype AA. Other genetic and clinical factors may also influence the response to capecitabine.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1446906446>2515</a></td><td>IL10</td><td>rs1800896</td><td>efavirenz</td><td>HIV Infections</td><td>3</td><td>TT</td><td>Toxicity</td><td>Patients with genotype TT may have increased likelihood of Drug Hypersensitivity when treated with efavirenz in people with HIV Infections as compared to patients with genotype CC or CT. Other genetic and clinical factors may also influence the toxicity to efavirenz.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1446905691>2516</a></td><td>ITPA</td><td>rs1127354</td><td>peginterferon alfa-2b</td><td>Anemia;Hepatitis C, Chronic</td><td>2B</td><td>CC</td><td>Toxicity</td><td>Patients with the rs1127354 CC genotype and chronic hepatitis C may have an increased risk of anemia as compared to patients with the AA or AC genotype when treated with peginterferon alfa-2b and ribavirin. However, conflicting evidence has been reported. Other clinical and genetic factors may influence risk of anemia when treated with peginterferon alfa-2b and ribavirin.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1446905691>2517</a></td><td>ITPA</td><td>rs1127354</td><td>ribavirin</td><td>Anemia;Hepatitis C, Chronic</td><td>2B</td><td>CC</td><td>Toxicity</td><td>Patients with the rs1127354 CC genotype and chronic hepatitis C may have an increased risk of anemia as compared to patients with the AA or AC genotype when treated with peginterferon alfa-2b and ribavirin. However, conflicting evidence has been reported. Other clinical and genetic factors may influence risk of anemia when treated with peginterferon alfa-2b and ribavirin.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449753224>2518</a></td><td>UGT1A1</td><td>rs10929302</td><td>risperidone</td><td>Hyperprolactinemia</td><td>3</td><td>AG</td><td>Toxicity</td><td>Patients with the AG genotype and autism may have an increased risk for hyperprolactinemia when treated with risperidone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for hyperprolactinemia.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451465324>2519</a></td><td>SLCO1B1</td><td>rs4149056</td><td>lovastatin</td><td>statin-related myopathy</td><td>1A</td><td>CT</td><td>Toxicity</td><td>TPatients with the rs4149056 CT genotype may have an increased risk of lovastatin-related myopathy when treated with lovastatin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of toxicity to lovastatin.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444607730>2520</a></td><td>TBC1D1</td><td>rs9852</td><td>clozapine</td><td>Schizophrenia</td><td>3</td><td>CT</td><td>Toxicity</td><td>Patients with the CT genotype and schizophrenia may experience less of a weight gain when treated with clozapine or olanzapine, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence weight gain when receiving clozapine or olanzapine.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444607730>2521</a></td><td>TBC1D1</td><td>rs9852</td><td>olanzapine</td><td>Schizophrenia</td><td>3</td><td>CT</td><td>Toxicity</td><td>Patients with the CT genotype and schizophrenia may experience less of a weight gain when treated with clozapine or olanzapine, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence weight gain when receiving clozapine or olanzapine.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444704784>2522</a></td><td>GRK4</td><td>rs1024323</td><td>atenolol</td><td>Coronary Artery Disease;Hypertension</td><td>3</td><td>TT</td><td>Toxicity</td><td>Patients with the TT genotype and hypertension and coronory artery disease may have increased risk for adverse cardiovascular outcomes when treated with atenolol or verapamil as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence a patient's response to atenolol or verapamil.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444704784>2523</a></td><td>GRK4</td><td>rs1024323</td><td>verapamil</td><td>Coronary Artery Disease;Hypertension</td><td>3</td><td>TT</td><td>Toxicity</td><td>Patients with the TT genotype and hypertension and coronory artery disease may have increased risk for adverse cardiovascular outcomes when treated with atenolol or verapamil as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence a patient's response to atenolol or verapamil.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444706876>2524</a></td><td>DRD2</td><td>rs2734842</td><td>olanzapine</td><td></td><td>3</td><td>CG</td><td>Toxicity</td><td>Female patients with the CG genotype may have increased prolactin when treated with olanzapine as compared to patients with the CC genotype or may have decreased prolactin when treated with olanzapine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to olanzapine.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447678614>2525</a></td><td>-</td><td>rs9346455</td><td>antipsychotics</td><td>Schizophrenia</td><td>3</td><td>GT</td><td>Toxicity</td><td>Patients with the GT genotype and schizophrenia may greater weight gain when treated with antipsychotics as compared to patients with the TT genotype. Other genetic and clinical factors may also influence weight gain in patients taking antipsychotics.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451476564>2526</a></td><td>CLCN6</td><td>rs1801133</td><td>cisplatin</td><td>nephrotoxicity;Osteosarcoma</td><td>3</td><td>AG</td><td>Toxicity</td><td>Patients with osteosarcoma and the rs1801133 AG genotype may be at an increased risk of developing nephrotoxicity when treated with cisplatin, doxorubicin and methotrexate as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of developing nephrotoxicity when treated with cisplatin, doxorubicin and methotrexate.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451476564>2527</a></td><td>MTHFR</td><td>rs1801133</td><td>cisplatin</td><td>nephrotoxicity;Osteosarcoma</td><td>3</td><td>AG</td><td>Toxicity</td><td>Patients with osteosarcoma and the rs1801133 AG genotype may be at an increased risk of developing nephrotoxicity when treated with cisplatin, doxorubicin and methotrexate as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of developing nephrotoxicity when treated with cisplatin, doxorubicin and methotrexate.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451476564>2528</a></td><td>CLCN6</td><td>rs1801133</td><td>doxorubicin</td><td>nephrotoxicity;Osteosarcoma</td><td>3</td><td>AG</td><td>Toxicity</td><td>Patients with osteosarcoma and the rs1801133 AG genotype may be at an increased risk of developing nephrotoxicity when treated with cisplatin, doxorubicin and methotrexate as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of developing nephrotoxicity when treated with cisplatin, doxorubicin and methotrexate.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451476564>2529</a></td><td>MTHFR</td><td>rs1801133</td><td>doxorubicin</td><td>nephrotoxicity;Osteosarcoma</td><td>3</td><td>AG</td><td>Toxicity</td><td>Patients with osteosarcoma and the rs1801133 AG genotype may be at an increased risk of developing nephrotoxicity when treated with cisplatin, doxorubicin and methotrexate as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of developing nephrotoxicity when treated with cisplatin, doxorubicin and methotrexate.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451476564>2530</a></td><td>CLCN6</td><td>rs1801133</td><td>methotrexate</td><td>nephrotoxicity;Osteosarcoma</td><td>3</td><td>AG</td><td>Toxicity</td><td>Patients with osteosarcoma and the rs1801133 AG genotype may be at an increased risk of developing nephrotoxicity when treated with cisplatin, doxorubicin and methotrexate as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of developing nephrotoxicity when treated with cisplatin, doxorubicin and methotrexate.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451476564>2531</a></td><td>MTHFR</td><td>rs1801133</td><td>methotrexate</td><td>nephrotoxicity;Osteosarcoma</td><td>3</td><td>AG</td><td>Toxicity</td><td>Patients with osteosarcoma and the rs1801133 AG genotype may be at an increased risk of developing nephrotoxicity when treated with cisplatin, doxorubicin and methotrexate as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of developing nephrotoxicity when treated with cisplatin, doxorubicin and methotrexate.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1446906399>2532</a></td><td>SCNN1B</td><td>rs889299</td><td>Farglitazar</td><td>Diabetes Mellitus, Type 2</td><td>3</td><td>AG</td><td>Toxicity</td><td>Patients with genotype AG may have increased risk of oedema when treated with Farglitazar and glibenclamide in people with Diabetes Mellitus, Type 2 as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to Farglitazar.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1446906399>2533</a></td><td>SCNN1B</td><td>rs889299</td><td>glibenclamide</td><td>Diabetes Mellitus, Type 2</td><td>3</td><td>AG</td><td>Toxicity</td><td>Patients with genotype AG may have increased risk of oedema when treated with Farglitazar and glibenclamide in people with Diabetes Mellitus, Type 2 as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to Farglitazar.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444667461>2534</a></td><td>SLC30A9</td><td>rs1047626</td><td>aspirin</td><td>aspirin-induced asthma</td><td>3</td><td>GG</td><td>Toxicity</td><td>Patients with asthma and the GG genotype may have an increased risk of aspirin induced asthma as compared to people with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's risk of asthma.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444700815>2535</a></td><td>-</td><td>rs1495741</td><td>Drugs For Treatment Of Tuberculosis</td><td>Tuberculosis</td><td>3</td><td>AA</td><td>Toxicity</td><td>Patients with the AA genotype who are treated with drugs for treatment of tuberculosis may have increased risk for toxic liver disease or abnormal liver-function tests as compared to patients with GG genotype. Other genetic and clinical factors may also influence a patient's risk for toxic liver disease.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447814178>2536</a></td><td>VEGFA</td><td>rs2010963</td><td>sorafenib</td><td>Carcinoma, Renal Cell;hand-foot syndrome</td><td>3</td><td>GG</td><td>Toxicity</td><td>Patients with the GG genotype may have increased risk of hand-foot syndrome when treated with sorafenib in people with Carcinoma, Renal Cell as compared to patients with genotype CC. Other genetic and clinical factors may also influence the toxicity to sorafenib.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447814185>2537</a></td><td>ABCB1</td><td>rs1045642</td><td>sorafenib</td><td>Carcinoma, Renal Cell;Hypertension</td><td>3</td><td>AA</td><td>Toxicity</td><td>Patients with the AA genotype may have increased risk of hypertension when treated with sorafenib in people with Carcinoma, Renal Cell as compared to patients with genotype GG. Other genetic and clinical factors may also influence the toxicity to sorafenib.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447814385>2538</a></td><td>ADCY9</td><td>rs1967309</td><td>dalcetrapib</td><td>Acute coronary syndrome</td><td>3</td><td>GG</td><td>Toxicity</td><td>Patients with the GG genotype may have increased risk of major adverse cardiac events (MACE) and decreased cholesterol efflux response when treated with delcetrapib in people with acute coronary syndrome as compared to patients with the AA and AG genotype. Other genetic and clinical factors may also influence a patient's risk for toxicity. These results are from a stratified analysis of a trial that found patients taking dalcetrapib at increased risk for MACE compared to patients on placebo.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444706869>2539</a></td><td>DRD2</td><td>rs2734841</td><td>olanzapine</td><td></td><td>3</td><td>AC</td><td>Toxicity</td><td>Female patients with the AC genotype may have increased prolactin when treated with olanzapine as compared to patients with the CC genotype or may have decreased prolactin when treated with olanzapine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to olanzapine.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447945978>2540</a></td><td>GRM3</td><td>rs1468412</td><td>antipsychotics</td><td>Schizophrenia</td><td>3</td><td>TT</td><td>Toxicity</td><td>Patients with the TT genotype and schizophrenia who are treated with antipsychotics may have an increased risk for worsening of working memory as compared to patients with the AA or AT genotype. Other genetic and clinical factors may also influence a patient's risk for worsening working memory.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1185000052>2541</a></td><td>CYP3A5</td><td>rs776746</td><td>tacrolimus</td><td>Kidney Failure</td><td>3</td><td>CC</td><td>Toxicity</td><td>Patients with the CC genotype (CYP3A5 *3/*3) undergoing liver transplantation may have an increased risk for renal dysfunction when treated with tacrolimus as compared to patients with the CT or TT genotype (*1/*3 or *1/*1). Other genetic and clinical factors may also influence risk for renal dysfunction.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448602689>2542</a></td><td>DPYS</td><td>rs2669429</td><td>atenolol</td><td>Hyperglycemia;Hypertension</td><td>3</td><td>AG</td><td>Toxicity</td><td>Patients with the AG genotype and hypertension may be at increased risk of developing hyperglycemia when taking atenolol compared to patients with the AA genotype. Other clinical and genetic factors may affect severity of hyperglycemia when taking atenolol for hypertension.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448602865>2543</a></td><td>CES1</td><td>rs2244614</td><td>capecitabine</td><td>Drug Toxicity</td><td>3</td><td>AG</td><td>Toxicity</td><td>Patients with the AG genotype may have increased risk of overall capecitabine-related toxicity in cancer patients as compared to patients with the AA genotype. Other genetic and clinical factors may also influence the toxicity to capecitabine.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1296599132>2544</a></td><td>ABCB1</td><td>rs1045642</td><td>methotrexate</td><td>Burkitt Lymphoma;Drug Toxicity;Lymphoma, T-Cell;Precursor Cell Lymphoblastic Leukemia-Lymphoma</td><td>3</td><td>AA</td><td>Toxicity</td><td>Patients with the rs1045642 AA genotype and cancer who are treated with methotrexate may have increased risk of toxicity as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of methotrexate-induced toxicities.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448603297>2545</a></td><td>FAAH</td><td>rs4141964</td><td>morphine</td><td></td><td>3</td><td>CT</td><td>Toxicity</td><td>Children with the CT genotype who are undergoing a tonsillectomy may have an increased risk for post-operative nausea and vomiting (PONV) when treated with morphine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of PONV.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448603303>2546</a></td><td>FAAH</td><td>rs3766246</td><td>morphine</td><td></td><td>3</td><td>AG</td><td>Toxicity</td><td>Children with the AG genotype who are undergoing a tonsillectomy may have an increased risk for post-operative nausea and vomiting (PONV) when treated with morphine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of PONV.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444700423>2547</a></td><td>SLC22A2</td><td>rs316019</td><td>cisplatin</td><td>Ototoxicity</td><td>3</td><td>AC</td><td>Toxicity</td><td>Patients with the AC genotype may have increased risk of cisplatin-induced ototoxicity as compared to patients with AA genotype. However, other studies have failed to find an association. Other clinical and genetic factors may also influence the risk of toxicity to cisplatin.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444704818>2548</a></td><td>ABCB1</td><td>rs1045642</td><td>codeine</td><td></td><td>3</td><td>AA</td><td>Toxicity</td><td>Patients with the AA genotype may have increased likelihood of CNS depression in breast-feeding infants as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to codeine.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184764189>2549</a></td><td>-</td><td>rs2844665</td><td>allopurinol</td><td>Epidermal Necrolysis, Toxic;severe cutaneous adverse reactions;Stevens-Johnson Syndrome</td><td>3</td><td>CC</td><td>Toxicity</td><td>Patients with genotype CC may have an increased risk of severe cutaneous adverse reactions (such as Stevens Johnson Syndrome or Toxic Epidermal Necrolysis) when treated with allopurinol as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of allopurinol-induced adverse reactions.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444703502>2550</a></td><td>ACE</td><td>rs4291</td><td>aspirin</td><td>Asthma</td><td>3</td><td>AT</td><td>Toxicity</td><td>Patients with the AT genotype and asthma who are treated with aspirin may have increased risk for aspirin intolerance as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444705236>2551</a></td><td>HTR2A</td><td>rs6313</td><td>citalopram</td><td>Depressive Disorder</td><td>3</td><td>AG</td><td>Toxicity</td><td>Patients with the AG genotype and major depression may have decreased, but not absent, risk of heart palpitations when treated with citalopram as compared to patients with the GG genotype or may have increased risk of heart palpitations when treated with citalopram as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to citalopram.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1185000097>2552</a></td><td>ABCC2</td><td>rs2273697</td><td>carbamazepine</td><td>Epilepsy</td><td>3</td><td>AG</td><td>Toxicity</td><td>Patients with the AG genotype and epilepsy who are treated with carbamazepine may have an increased risk of neurological adverse drug reactions as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk of carbamazepine-induced adverse reactions.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444607697>2553</a></td><td>ABCC2</td><td>rs12762549</td><td>docetaxel</td><td></td><td>3</td><td>CG</td><td>Toxicity</td><td>Patients with the CG genotype who are treated with docetaxel may have a decreased clearance and increased risk of leukopenia as compared to patients with the CC genotype. However the association for clearance of docetaxel was not significant and no association was found with risk for neutropenia. Other genetic and clinical factors may also influence a patient's response to docetaxel.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444607768>2554</a></td><td>HTR2A</td><td>rs6311</td><td>fluvoxamine</td><td>Depressive Disorder, Major</td><td>3</td><td>CT</td><td>Toxicity</td><td>Patients with the CT genotype who are treated with fluvoxamine may have an increased risk of gastrointestinal side effects and decreased response as compared to patients with the TT genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to fluvoxamine.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444703401>2555</a></td><td>CEP72</td><td>rs924607</td><td>vincristine</td><td>Precursor Cell Lymphoblastic Leukemia-Lymphoma</td><td>3</td><td>TT</td><td>Toxicity</td><td>Patients with the rs924607 TT genotype may have increased risk of peripheral nervous system diseases when treated with vincristine may have as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence risk of peripheral nervous system diseases when treated with vincristine.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444667175>2556</a></td><td>CYP2D6</td><td>rs28360521</td><td>aspirin</td><td></td><td>3</td><td>CT</td><td>Toxicity</td><td>Patients with the CT genotype who are treated with aspirin may have an increased risk of gastrointestinal bleeding as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of gastrointestinal bleeding when administered aspirin.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444700667>2557</a></td><td>HTR1B</td><td>rs11568817</td><td>escitalopram</td><td>Anxiety Disorders</td><td>3</td><td>AC</td><td>Toxicity</td><td>Patients with the AC genotype and anxiety disorder who are treated with escitalopram may have increased risk of adverse cognitive effects as compared to patients with the AA genotype. Other genetic and clinical factors may also effect patients' response to escitalopram.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444700675>2558</a></td><td>HTR2A</td><td>rs6311</td><td>escitalopram</td><td>Anxiety Disorders</td><td>3</td><td>CT</td><td>Toxicity</td><td>Patients with the CT genotype and anxiety disorder who are treated with escitalopram may have increased risk of adverse cognitive effects as compared to patients with the CC genotype. Other genetic and clinical factors may also effect patients' response to escitalopram.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184764194>2559</a></td><td>PSORS1C3</td><td>rs3094188</td><td>allopurinol</td><td>Epidermal Necrolysis, Toxic;severe cutaneous adverse reactions;Stevens-Johnson Syndrome</td><td>3</td><td>AA</td><td>Toxicity</td><td>Patients with genotype AA may have an increased risk of severe cutaneous adverse reactions (such as Stevens Johnson Syndrome or Toxic Epidermal Necrolysis) when treated with allopurinol as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of allopurinol-induced adverse reactions.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184764199>2560</a></td><td>POU5F1</td><td>rs3130501</td><td>allopurinol</td><td>Epidermal Necrolysis, Toxic;severe cutaneous adverse reactions;Stevens-Johnson Syndrome</td><td>3</td><td>GG</td><td>Toxicity</td><td>Patients with genotype GG may have an increased risk of severe cutaneous adverse reactions (such as Stevens Johnson Syndrome or Toxic Epidermal Necrolysis) when treated with allopurinol as compared to patients with the AA genotype. This association was significant for haplotype analysis with other alleles. Other genetic and clinical factors may also influence a patient's risk of allopurinol-induced adverse reactions.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184764204>2561</a></td><td>POU5F1</td><td>rs3130931</td><td>allopurinol</td><td>Epidermal Necrolysis, Toxic;severe cutaneous adverse reactions;Stevens-Johnson Syndrome</td><td>3</td><td>CT</td><td>Toxicity</td><td>Patients with genotype CT may have an increased risk of severe cutaneous adverse reactions (such as Stevens Johnson Syndrome or Toxic Epidermal Necrolysis) when treated with allopurinol as compared to patients with the TT genotype, or may have a decreased, but not absent risk of severe cutaneous adverse reactions (such as Stevens Johnson Syndrome or Toxic Epidermal Necrolysis) when treated with allopurinol as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of allopurinol-induced adverse reactions.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444704763>2562</a></td><td>CACNA1C</td><td>rs1006737</td><td>citalopram</td><td>Depressive Disorder, Major</td><td>3</td><td>AA</td><td>Toxicity</td><td>Patients with the AA genotype and major depression may have increased risk for suicide when treated with citalopram as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response citalopram.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1446898992>2563</a></td><td>MC4R</td><td>rs489693</td><td>antipsychotics</td><td>Weight gain</td><td>3</td><td>AC</td><td>Toxicity</td><td>Patients with the rs489693 AC genotype may have increased likelihood of weight gain when treated with antipsychotics as compared to patients with the CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence weight gain.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184764213>2564</a></td><td>PSORS1C1</td><td>rs3815087</td><td>allopurinol</td><td>Epidermal Necrolysis, Toxic;severe cutaneous adverse reactions;Stevens-Johnson Syndrome</td><td>4</td><td>AG</td><td>Toxicity</td><td>Patients with genotype AG may have an increased risk of severe cutaneous adverse reactions (such as Stevens Johnson Syndrome or Toxic Epidermal Necrolysis) when treated with allopurinol as compared to patients with the GG genotype, or may have a decreased, but not absent risk of severe cutaneous adverse reactions (such as Stevens Johnson Syndrome or Toxic Epidermal Necrolysis) when treated with allopurinol as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of allopurinol-induced adverse reactions.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444666855>2565</a></td><td>ABCB1</td><td>rs1045642</td><td>risperidone</td><td>Schizophrenia</td><td>3</td><td>AA</td><td>Toxicity</td><td>Patients with the AA genotype and schizophrenia may have a longer QTc interval when treated with risperidone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence QTc interval in patients taking risperidone.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1446904693>2566</a></td><td>UGT1A1</td><td>rs4124874</td><td>deferasirox</td><td>Drug Toxicity;Thalassemia</td><td>3</td><td>GT</td><td>Toxicity</td><td>Patients with major thalassemia and the GT genotype may have an increased risk of adverse reactions when administered deferasirox as compared to patients with the TT genotype. Other clinical and genetic factors may also influence risk of adverse reactions.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184987062>2567</a></td><td>FTO</td><td>rs9940629</td><td>atenolol</td><td>Hypertension</td><td>3</td><td>AA</td><td>Toxicity</td><td>Patients with genotype AA and hypertension may have a smaller reduction in HDL-C when administered atenolol as compared to patients with the AG and GG genotypes. Other clinical and genetic factors may also influence risk of hypercholesteremia upon administration of atenolol in patients with hypertension.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184987556>2568</a></td><td>HTR2A</td><td>rs6305</td><td>Analgesics</td><td></td><td>3</td><td>AG</td><td>Toxicity</td><td>Patients with the AG genotype with substance withdrawal syndrome may have an increased likelihood of headache when discontinuing the use of analgesics (such as opioids, NSAIDs, triptans, ergot) as compared to patients with the GG genotype. Other clinical and genetic factors may also influence likelihood of headache in patients with withdrawal syndrome who discontinue the use of analgesics.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184987556>2569</a></td><td>HTR2A</td><td>rs6305</td><td>Antiinflammatory agents, non-steroids</td><td></td><td>3</td><td>AG</td><td>Toxicity</td><td>Patients with the AG genotype with substance withdrawal syndrome may have an increased likelihood of headache when discontinuing the use of analgesics (such as opioids, NSAIDs, triptans, ergot) as compared to patients with the GG genotype. Other clinical and genetic factors may also influence likelihood of headache in patients with withdrawal syndrome who discontinue the use of analgesics.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184987556>2570</a></td><td>HTR2A</td><td>rs6305</td><td>Ergot alkaloids</td><td></td><td>3</td><td>AG</td><td>Toxicity</td><td>Patients with the AG genotype with substance withdrawal syndrome may have an increased likelihood of headache when discontinuing the use of analgesics (such as opioids, NSAIDs, triptans, ergot) as compared to patients with the GG genotype. Other clinical and genetic factors may also influence likelihood of headache in patients with withdrawal syndrome who discontinue the use of analgesics.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184987556>2571</a></td><td>HTR2A</td><td>rs6305</td><td>opioids</td><td></td><td>3</td><td>AG</td><td>Toxicity</td><td>Patients with the AG genotype with substance withdrawal syndrome may have an increased likelihood of headache when discontinuing the use of analgesics (such as opioids, NSAIDs, triptans, ergot) as compared to patients with the GG genotype. Other clinical and genetic factors may also influence likelihood of headache in patients with withdrawal syndrome who discontinue the use of analgesics.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184987556>2572</a></td><td>HTR2A</td><td>rs6305</td><td>sumatriptan</td><td></td><td>3</td><td>AG</td><td>Toxicity</td><td>Patients with the AG genotype with substance withdrawal syndrome may have an increased likelihood of headache when discontinuing the use of analgesics (such as opioids, NSAIDs, triptans, ergot) as compared to patients with the GG genotype. Other clinical and genetic factors may also influence likelihood of headache in patients with withdrawal syndrome who discontinue the use of analgesics.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184989651>2573</a></td><td>-</td><td>rs2647087</td><td>azathioprine</td><td>Drug Toxicity;Inflammatory Bowel Diseases;Pancreatitis</td><td>3</td><td>AC</td><td>Toxicity</td><td>Patients with the AC genotype and inflammatory bowel disease who are treated with azathioprine or mercaptopurine may have an increased risk of pancreatitis as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of pancreatitis.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184989651>2574</a></td><td>-</td><td>rs2647087</td><td>mercaptopurine</td><td>Drug Toxicity;Inflammatory Bowel Diseases;Pancreatitis</td><td>3</td><td>AC</td><td>Toxicity</td><td>Patients with the AC genotype and inflammatory bowel disease who are treated with azathioprine or mercaptopurine may have an increased risk of pancreatitis as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of pancreatitis.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1446908580>2575</a></td><td>ABCC5</td><td>rs10937158</td><td>fluorouracil</td><td>Colorectal Neoplasms</td><td>3</td><td>CC</td><td>Toxicity</td><td>Patients with the CC genotype and Colorectal Neoplasms who are treated with fluorouracil, irinotecan and leucovorin may have an increased risk for grade 34 severe diarrhea as compared to patients with the CT + TT genotype. Other genetic and clinical factors may also influence a patient's risk for grade 34 severe diarrhea.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1446908580>2576</a></td><td>ABCC5</td><td>rs10937158</td><td>irinotecan</td><td>Colorectal Neoplasms</td><td>3</td><td>CC</td><td>Toxicity</td><td>Patients with the CC genotype and Colorectal Neoplasms who are treated with fluorouracil, irinotecan and leucovorin may have an increased risk for grade 34 severe diarrhea as compared to patients with the CT + TT genotype. Other genetic and clinical factors may also influence a patient's risk for grade 34 severe diarrhea.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1446908580>2577</a></td><td>ABCC5</td><td>rs10937158</td><td>leucovorin</td><td>Colorectal Neoplasms</td><td>3</td><td>CC</td><td>Toxicity</td><td>Patients with the CC genotype and Colorectal Neoplasms who are treated with fluorouracil, irinotecan and leucovorin may have an increased risk for grade 34 severe diarrhea as compared to patients with the CT + TT genotype. Other genetic and clinical factors may also influence a patient's risk for grade 34 severe diarrhea.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1446908622>2578</a></td><td>ABCC5</td><td>rs3749438</td><td>fluorouracil</td><td>Colorectal Neoplasms</td><td>3</td><td>AG</td><td>Toxicity</td><td>Patients with the AG genotype and Colorectal Neoplasms who are treated with fluorouracil, irinotecan and leucovorin may have an increased risk for grade 34 severe diarrhea as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for grade 34 severe diarrhea.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1446908622>2579</a></td><td>ABCC5</td><td>rs3749438</td><td>irinotecan</td><td>Colorectal Neoplasms</td><td>3</td><td>AG</td><td>Toxicity</td><td>Patients with the AG genotype and Colorectal Neoplasms who are treated with fluorouracil, irinotecan and leucovorin may have an increased risk for grade 34 severe diarrhea as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for grade 34 severe diarrhea.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1446908622>2580</a></td><td>ABCC5</td><td>rs3749438</td><td>leucovorin</td><td>Colorectal Neoplasms</td><td>3</td><td>AG</td><td>Toxicity</td><td>Patients with the AG genotype and Colorectal Neoplasms who are treated with fluorouracil, irinotecan and leucovorin may have an increased risk for grade 34 severe diarrhea as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for grade 34 severe diarrhea.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1446908672>2581</a></td><td>PLA2G4A</td><td>rs12746200</td><td>acetaminophen</td><td></td><td>3</td><td>AG</td><td>Toxicity</td><td>Patients with the AG genotype who are treated with acetaminophen, aspirin, diclofenac, propionic acid derivatives or Pyrazolones may have an increased risk of urticaria as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for urticaria.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1446908672>2582</a></td><td>PLA2G4A</td><td>rs12746200</td><td>aspirin</td><td></td><td>3</td><td>AG</td><td>Toxicity</td><td>Patients with the AG genotype who are treated with acetaminophen, aspirin, diclofenac, propionic acid derivatives or Pyrazolones may have an increased risk of urticaria as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for urticaria.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1446908672>2583</a></td><td>PLA2G4A</td><td>rs12746200</td><td>diclofenac</td><td></td><td>3</td><td>AG</td><td>Toxicity</td><td>Patients with the AG genotype who are treated with acetaminophen, aspirin, diclofenac, propionic acid derivatives or Pyrazolones may have an increased risk of urticaria as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for urticaria.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1446908672>2584</a></td><td>PLA2G4A</td><td>rs12746200</td><td>propionic acid derivatives</td><td></td><td>3</td><td>AG</td><td>Toxicity</td><td>Patients with the AG genotype who are treated with acetaminophen, aspirin, diclofenac, propionic acid derivatives or Pyrazolones may have an increased risk of urticaria as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for urticaria.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1446908672>2585</a></td><td>PLA2G4A</td><td>rs12746200</td><td>Pyrazolones</td><td></td><td>3</td><td>AG</td><td>Toxicity</td><td>Patients with the AG genotype who are treated with acetaminophen, aspirin, diclofenac, propionic acid derivatives or Pyrazolones may have an increased risk of urticaria as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for urticaria.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1446908679>2586</a></td><td>TNFRSF11A</td><td>rs1805034</td><td>acetaminophen</td><td></td><td>3</td><td>CT</td><td>Toxicity</td><td>Patients with the CT genotype who are treated with acetaminophen, aspirin, diclofenac, propionic acid derivatives or Pyrazolones may have an increased risk of urticaria and Angioedema as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for urticaria and Angioedema.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1446908679>2587</a></td><td>TNFRSF11A</td><td>rs1805034</td><td>aspirin</td><td></td><td>3</td><td>CT</td><td>Toxicity</td><td>Patients with the CT genotype who are treated with acetaminophen, aspirin, diclofenac, propionic acid derivatives or Pyrazolones may have an increased risk of urticaria and Angioedema as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for urticaria and Angioedema.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1446908679>2588</a></td><td>TNFRSF11A</td><td>rs1805034</td><td>diclofenac</td><td></td><td>3</td><td>CT</td><td>Toxicity</td><td>Patients with the CT genotype who are treated with acetaminophen, aspirin, diclofenac, propionic acid derivatives or Pyrazolones may have an increased risk of urticaria and Angioedema as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for urticaria and Angioedema.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1446908679>2589</a></td><td>TNFRSF11A</td><td>rs1805034</td><td>propionic acid derivatives</td><td></td><td>3</td><td>CT</td><td>Toxicity</td><td>Patients with the CT genotype who are treated with acetaminophen, aspirin, diclofenac, propionic acid derivatives or Pyrazolones may have an increased risk of urticaria and Angioedema as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for urticaria and Angioedema.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1446908679>2590</a></td><td>TNFRSF11A</td><td>rs1805034</td><td>Pyrazolones</td><td></td><td>3</td><td>CT</td><td>Toxicity</td><td>Patients with the CT genotype who are treated with acetaminophen, aspirin, diclofenac, propionic acid derivatives or Pyrazolones may have an increased risk of urticaria and Angioedema as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for urticaria and Angioedema.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451506746>2591</a></td><td>-</td><td>rs139945292</td><td>Beta Blocking Agents</td><td></td><td>3</td><td>CT</td><td>Toxicity</td><td>Patients with the rs139945292 CT genotype may have increased adverse cardiovascular risk after treatment with the beta blocking agents as compared to patients with the CC genotype. Other genetic and clinical factors may also influence the toxicity to beta-blocking agents.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444700452>2592</a></td><td>TAPBP</td><td>rs1059288</td><td>aspirin</td><td>Asthma</td><td>3</td><td>AG</td><td>Toxicity</td><td>Patients with the AG genotype and Asthma may have a higher aspirin-induced decline in forced expiratory volume in 1 s (FEV1) after aspirin provocation as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444700466>2593</a></td><td>TAPBP</td><td>rs2071888</td><td>aspirin</td><td>Asthma</td><td>3</td><td>CG</td><td>Toxicity</td><td>Patients with the CG genotype and Asthma may have a higher aspirin-induced decline in forced expiratory volume in 1 s (FEV1) after aspirin provocation as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444700950>2594</a></td><td>CDK1</td><td>rs10711</td><td>radiotherapy</td><td>pneumonitis</td><td>3</td><td>GT</td><td>Toxicity</td><td>Patients with the GT genotype may have increased risk of pneumonitis when treated with radiotherapy as compared to patients with genotype TT. Other genetic or clinical factors may also influence the risk of toxicity to radiotherapy.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444700860>2595</a></td><td>ABCG2</td><td>rs7699188</td><td>fluorouracil</td><td>Colorectal Neoplasms</td><td>3</td><td>AA</td><td>Toxicity</td><td>Patients with the AA genotype may have increased tumor response rate and increased risk of grade 3-4 nonhematological toxicity when treated with fluorouracil, irinotecan and leucovorin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to fluorouracil, irinotecan and leucovorin.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444700860>2596</a></td><td>ABCG2</td><td>rs7699188</td><td>irinotecan</td><td>Colorectal Neoplasms</td><td>3</td><td>AA</td><td>Toxicity</td><td>Patients with the AA genotype may have increased tumor response rate and increased risk of grade 3-4 nonhematological toxicity when treated with fluorouracil, irinotecan and leucovorin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to fluorouracil, irinotecan and leucovorin.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444700860>2597</a></td><td>ABCG2</td><td>rs7699188</td><td>leucovorin</td><td>Colorectal Neoplasms</td><td>3</td><td>AA</td><td>Toxicity</td><td>Patients with the AA genotype may have increased tumor response rate and increased risk of grade 3-4 nonhematological toxicity when treated with fluorouracil, irinotecan and leucovorin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to fluorouracil, irinotecan and leucovorin.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1445401389>2598</a></td><td>LEPR</td><td>rs1137101</td><td>valproic acid</td><td>Epilepsy</td><td>3</td><td>AG</td><td>Toxicity</td><td>Patients with the AG genotype and epilepsy may have greater weight gain when treated with valproic acid as compared to patients with the GG genotype. Other genetic and clinical factors may also influence weight gain.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1445401817>2599</a></td><td>CYP2C8</td><td>rs1934951</td><td>paclitaxel</td><td>Breast Neoplasms</td><td>4</td><td>TT</td><td>Toxicity</td><td>Patients with the TT genotype and breast cancer may have an increased risk for anemia, but not neuropathy, when treated with paclitaxel as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for anemia.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444703438>2600</a></td><td>OCRL</td><td>rs757639</td><td>tenofovir</td><td>HIV Infections</td><td>3</td><td>CC</td><td>Toxicity</td><td>Patients with the CC genotype and HIV who are treated with tenofovir may have increased creatinine clearance as compared to patients with the CT genotype. Other genetic and clinical factors may also influence a patient's response to tenofovir.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444703495>2601</a></td><td>ACE</td><td>rs4292</td><td>aspirin</td><td>Asthma</td><td>3</td><td>CT</td><td>Toxicity</td><td>Patients with the CT genotype and asthma who are treated with aspirin may have increased risk for aspirin intolerance as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1445401804>2602</a></td><td>SOD2</td><td>rs4880</td><td>paclitaxel</td><td>Breast Neoplasms</td><td>3</td><td>AA</td><td>Toxicity</td><td>Patients with the AA genotype and breast cancer may have an increased risk for neuropathy when treated with paclitaxel as compared to patients with the AG or GG genotype. This association was only found in individuals who are CYP3A4 and CYP3A5 non-expressers (CYP3A4 *1/*1 and CYP3A5 *3/*3). Other genetic and clinical factors may also influence risk for neuropathy.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1445401853>2603</a></td><td>ERCC1</td><td>rs11615</td><td>docetaxel</td><td>Breast Neoplasms</td><td>3</td><td>AA</td><td>Toxicity</td><td>Patients with the AA genotype and breast cancer may have an increased risk for mucositis when treated with docetaxel as compared to patients with the AG or GG genotype. This association was only found in individuals who are CYP3A4 and CYP3A5 non-expressers (CYP3A4 *1/*1 and CYP3A5 *3/*3). Other genetic and clinical factors may also influence risk for mucositis.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448258741>2604</a></td><td>SLCO1B1</td><td>rs4149056</td><td>sorafenib</td><td>Thrombocytopenia</td><td>3</td><td>CT</td><td>Toxicity</td><td>Patients with the CT genotype may have increased likelihood of developing Thrombocytopenia when treated with sorafenib as compared to patients with genotype CC. Other genetic and clinical factors may also influence the response to sorafenib.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448423689>2605</a></td><td>CTLA4</td><td>rs3087243</td><td>Tumor necrosis factor alpha (TNF-alpha) inhibitors</td><td>Psoriasis</td><td>3</td><td>AA</td><td>Toxicity</td><td>Patients with the AA genotype and psoriasis may have an increased risk for paradoxical psoriasiform reactions when treated with TNF-inhibitors as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence risk for paradoxical psoriasiform reactions.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448423696>2606</a></td><td>SLC12A8</td><td>rs651630</td><td>Tumor necrosis factor alpha (TNF-alpha) inhibitors</td><td>Psoriasis</td><td>3</td><td>AG</td><td>Toxicity</td><td>Patients with the AG genotype and psoriasis may have an increased risk for paradoxical psoriasiform reactions when treated with TNF-inhibitors as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk for paradoxical psoriasiform reactions.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448525458>2607</a></td><td>DRD2</td><td>rs1799732</td><td>levodopa</td><td>Parkinson Disease</td><td>3</td><td>GG</td><td>Toxicity</td><td>Patients with the GG genotype and Parkinson's Disease may have an increased risk for gastrointestinal toxicities when treated with levodopa as compared to patients with the G/del or del/del genotype. Other genetic and clinical factors may also influence gastrointestinal toxicity risk.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448617146>2608</a></td><td>ABCB1</td><td>rs2032582</td><td>atazanavir</td><td>HIV Infections</td><td>3</td><td>AC</td><td>Toxicity</td><td>Patients with the AC genotype who are administered atazanavir may have an increased risk of hyperbilirubinemia as compared to patients with the CC genotype. Other clinical and genetic factors may also influence risk of hyperbilirubinemia in patients who are taking atazanavir.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448616855>2609</a></td><td>CDA</td><td>rs1048977</td><td>capecitabine</td><td>Hyperbilirubinemia;Neoplasms</td><td>3</td><td>TT</td><td>Toxicity</td><td>Patients with cancer and the TT genotype who are treated with capecitabine may have increased risk of hyperbilirubinemia as compared to patients with the CC genotype. Other clinical and genetic factors may also influence risk of hyperbilirubinemia in patients with cancer who are treated with capecitabine.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448624874>2610</a></td><td>N6AMT1</td><td>rs2254638</td><td>clopidogrel</td><td>major adverse cardiac events (mace)</td><td>3</td><td>AG</td><td>Toxicity</td><td>Patients with the AG genotype may have decreased metabolism and increased risk of major adverse cardiac events (mace) when treated with clopidogrel in people with Coronary Artery Disease as compared patients with genotype AA. Other genetic and clinical factors may also influence the response to clopidogrel.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448428030>2611</a></td><td>SLCO1B1</td><td>rs2306283</td><td>irinotecan</td><td>Neoplasms</td><td>4</td><td>AG</td><td>Toxicity</td><td>Patients with the AG genotype and solid tumors may experience increased risk of neutropenia compared to patients with the AA genotype. However, studies conflict as to this association. Other clinical and genetic factors may affect risk of neutropenia with irinotecan therapy.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448617231>2612</a></td><td>TBXA2R</td><td>rs1131882</td><td>aspirin</td><td>Diabetes Mellitus, Type 2</td><td>3</td><td>AG</td><td>Toxicity</td><td>Patients with the AG genotype may have increased risk of mortality when treated with aspirin in people with Diabetes Mellitus, Type 2 as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to aspirin.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449190339>2613</a></td><td>PDYN</td><td>rs1997794</td><td>opioids</td><td>Opioid-Related Disorders</td><td>3</td><td>CT</td><td>Toxicity</td><td>Patients with the CT genotype may have an increased likelihood of developing opioid dependence as compared to patients with the CC genotype. However, a meta-analysis failed to replicate this association. Other genetic and clinical factors may also affect a patient's likelihood of developing opioid dependence.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447953109>2614</a></td><td>CYP19A1</td><td>rs6493497</td><td>exemestane</td><td>Breast Neoplasms</td><td>3</td><td>AA</td><td>Toxicity</td><td>Women with the AA genotype and breast cancer may have an increased risk of bone density loss when treated with exemestane and letrozole, or exemestane alone, as compared to patients with the AG and GG genotypes. Other genetic and clinical factors may also influence a patient's risk of bone mineral density loss when treated with exemestane and letrozole.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447953109>2615</a></td><td>CYP19A1</td><td>rs6493497</td><td>letrozole</td><td>Breast Neoplasms</td><td>3</td><td>AA</td><td>Toxicity</td><td>Women with the AA genotype and breast cancer may have an increased risk of bone density loss when treated with exemestane and letrozole, or exemestane alone, as compared to patients with the AG and GG genotypes. Other genetic and clinical factors may also influence a patient's risk of bone mineral density loss when treated with exemestane and letrozole.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447953130>2616</a></td><td>SLCO1B1</td><td>rs4149056</td><td>enalapril</td><td>Essential hypertension</td><td>3</td><td>CT</td><td>Toxicity</td><td>Patients with the CT genotype and essential hypertension may have an increased likelihood of cough when treated with enalapril as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of cough when treated with enalapril.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448099745>2617</a></td><td>DRD2</td><td>rs1799732</td><td>antipsychotics</td><td>Psychotic Disorders</td><td>3</td><td>GG</td><td>Toxicity</td><td>Patients with the GG genotype and psychotic disorders may have an increased risk for side effects when treated with antipsychotics as compared to patients with the del/del genotype. However, contradictory evidence exists. Other genetic and clinical factors may also influence risk for side effects.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448603291>2618</a></td><td>FAAH</td><td>rs2295632</td><td>morphine</td><td></td><td>3</td><td>GT</td><td>Toxicity</td><td>Children with the GT genotype who are undergoing a tonsillectomy may have an increased risk for post-operative nausea and vomiting (PONV) when treated with morphine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of PONV.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449715913>2619</a></td><td>ABCB1</td><td>rs1045642</td><td>fentanyl</td><td>Pain, Postoperative;Respiratory Insufficiency</td><td>3</td><td>AA</td><td>Toxicity</td><td>Patients with the AA genotype may have an increased likelihood of experiencing respiratory depression as a result of fentanyl as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect the likelihood of a patient developing respiratory depression as a result of fentanyl.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448109754>2620</a></td><td>SLC28A1</td><td>rs2305364</td><td>anthracyclines and related substances</td><td>Neoplasms</td><td>4</td><td>TT</td><td>Toxicity</td><td>Patients with the TT genotype may have an increased likelihood of cardiotoxicity when exposed to anthracyclines for pediatric cancer as compared to patients with the CT or CC genotypes, although this is contradicted in one study. Other genetic and clinical factors may also influence risk for cardiotoxicity.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447980904>2621</a></td><td>ABCB1</td><td>rs1045642</td><td>Antivirals for treatment of HIV infections, combinations</td><td>HIV Infections;Tuberculosis</td><td>3</td><td>AA</td><td>Toxicity</td><td>Patients with the AA genotype who are co-infected with HIV and tuberculosis (TB) may have an increased risk for hepatotoxicity when treated with anti-tubercular and antiretroviral drugs as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of hepatotoxicity.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447980904>2622</a></td><td>ABCB1</td><td>rs1045642</td><td>Drugs For Treatment Of Tuberculosis</td><td>HIV Infections;Tuberculosis</td><td>3</td><td>AA</td><td>Toxicity</td><td>Patients with the AA genotype who are co-infected with HIV and tuberculosis (TB) may have an increased risk for hepatotoxicity when treated with anti-tubercular and antiretroviral drugs as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of hepatotoxicity.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183679785>2623</a></td><td>CCHCR1</td><td>rs746647</td><td>nevirapine</td><td>HIV Infections</td><td>3</td><td>AG</td><td>Toxicity</td><td>Patients with the AG genotype may have increased risk of Nevirapine-induced rash when treated with nevirapine in people with HIV as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to nevirapine.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447961178>2624</a></td><td>EGFR</td><td>rs712830</td><td>cetuximab</td><td>Colorectal Neoplasms</td><td>3</td><td>CC</td><td>Toxicity</td><td>Patients with the CC genotype and colorectal cancer may have an increased risk for toxicity when treated with 5-fluorouracil-based therapy together with cetuximab-irinotecan as compared to patients with the AC genotype. Other genetic and clinical factors may also influence drug toxicity.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447961178>2625</a></td><td>EGFR</td><td>rs712830</td><td>irinotecan</td><td>Colorectal Neoplasms</td><td>3</td><td>CC</td><td>Toxicity</td><td>Patients with the CC genotype and colorectal cancer may have an increased risk for toxicity when treated with 5-fluorouracil-based therapy together with cetuximab-irinotecan as compared to patients with the AC genotype. Other genetic and clinical factors may also influence drug toxicity.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447961178>2626</a></td><td>EGFR</td><td>rs712830</td><td>leucovorin</td><td>Colorectal Neoplasms</td><td>3</td><td>CC</td><td>Toxicity</td><td>Patients with the CC genotype and colorectal cancer may have an increased risk for toxicity when treated with 5-fluorouracil-based therapy together with cetuximab-irinotecan as compared to patients with the AC genotype. Other genetic and clinical factors may also influence drug toxicity.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447961178>2627</a></td><td>EGFR</td><td>rs712830</td><td>tegafur</td><td>Colorectal Neoplasms</td><td>3</td><td>CC</td><td>Toxicity</td><td>Patients with the CC genotype and colorectal cancer may have an increased risk for toxicity when treated with 5-fluorouracil-based therapy together with cetuximab-irinotecan as compared to patients with the AC genotype. Other genetic and clinical factors may also influence drug toxicity.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448112147>2628</a></td><td>SLCO1B1</td><td>rs4149056</td><td>cyclophosphamide</td><td>Breast Neoplasms</td><td>3</td><td>CT</td><td>Toxicity</td><td>Patients with the CT genotype and hormone insensitive breast cancer may experience lower risk of chemotherapy-induced amenorrhea when treated with goserelin or combinations of cyclophosphamide, docetaxel, doxorubicin, epirubicin, and fluorouracil compared to patients with the TT genotype. Other clinical and genetic factors may affect a patient's risk of chemotherapy-induced amenorrhea.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448112147>2629</a></td><td>SLCO1B1</td><td>rs4149056</td><td>docetaxel</td><td>Breast Neoplasms</td><td>3</td><td>CT</td><td>Toxicity</td><td>Patients with the CT genotype and hormone insensitive breast cancer may experience lower risk of chemotherapy-induced amenorrhea when treated with goserelin or combinations of cyclophosphamide, docetaxel, doxorubicin, epirubicin, and fluorouracil compared to patients with the TT genotype. Other clinical and genetic factors may affect a patient's risk of chemotherapy-induced amenorrhea.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448112147>2630</a></td><td>SLCO1B1</td><td>rs4149056</td><td>doxorubicin</td><td>Breast Neoplasms</td><td>3</td><td>CT</td><td>Toxicity</td><td>Patients with the CT genotype and hormone insensitive breast cancer may experience lower risk of chemotherapy-induced amenorrhea when treated with goserelin or combinations of cyclophosphamide, docetaxel, doxorubicin, epirubicin, and fluorouracil compared to patients with the TT genotype. Other clinical and genetic factors may affect a patient's risk of chemotherapy-induced amenorrhea.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448112147>2631</a></td><td>SLCO1B1</td><td>rs4149056</td><td>epirubicin</td><td>Breast Neoplasms</td><td>3</td><td>CT</td><td>Toxicity</td><td>Patients with the CT genotype and hormone insensitive breast cancer may experience lower risk of chemotherapy-induced amenorrhea when treated with goserelin or combinations of cyclophosphamide, docetaxel, doxorubicin, epirubicin, and fluorouracil compared to patients with the TT genotype. Other clinical and genetic factors may affect a patient's risk of chemotherapy-induced amenorrhea.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448112147>2632</a></td><td>SLCO1B1</td><td>rs4149056</td><td>fluorouracil</td><td>Breast Neoplasms</td><td>3</td><td>CT</td><td>Toxicity</td><td>Patients with the CT genotype and hormone insensitive breast cancer may experience lower risk of chemotherapy-induced amenorrhea when treated with goserelin or combinations of cyclophosphamide, docetaxel, doxorubicin, epirubicin, and fluorouracil compared to patients with the TT genotype. Other clinical and genetic factors may affect a patient's risk of chemotherapy-induced amenorrhea.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448256864>2633</a></td><td>ERCC2</td><td>rs50872</td><td>Platinum compounds</td><td>Carcinoma, Non-Small-Cell Lung</td><td>3</td><td>GG</td><td>Toxicity</td><td>Patients with the GG genotype and non-small cell lung cancer may have increased risk of toxicities when treated with platinum-based chemotherapy compared to patients with the AA and AG genotypes. Other clinical and genetic factors may affect risk of toxicities in response to platinum-based chemotherapies.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448256872>2634</a></td><td>IL16</td><td>rs7170924</td><td>Platinum compounds</td><td>Carcinoma, Non-Small-Cell Lung</td><td>3</td><td>GT</td><td>Toxicity</td><td>Patients with the GT genotype and non-small cell lung cancer may have increased risk of drug toxicity when treated with platinum based chemotherapy compared to patients with the GG genotype. Other clinical and genetic factors may affect risk of toxicities when treated with platinum compound chemotherapies.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447953263>2635</a></td><td>OPRM1</td><td>rs2075572</td><td>methadone</td><td>Opioid-Related Disorders</td><td>3</td><td>CC</td><td>Toxicity</td><td>Patients with the rs2075572 CC genotype and opioid dependence may have an increased severity of sleep disorders when treated with methadone as compared to patients with the CG genotype. This drug-variant pair has been assigned a no recommendation by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also influence severity of sleep disorders when treated with methadone.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447953277>2636</a></td><td>ESR1</td><td>rs2813543</td><td>exemestane</td><td>Breast Neoplasms</td><td>3</td><td>GG</td><td>Toxicity</td><td>Patients with the GG genotype and breast cancer may have an increased risk of bone density loss when treated with exemestane as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of bone mineral density loss when treated with exemestane.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447963070>2637</a></td><td>CHRNB4</td><td>rs2869950</td><td>nicotine</td><td>Tobacco Use Disorder</td><td>3</td><td>CT</td><td>Toxicity</td><td>Patients with the CT genotype who smoke tobacco may have a lower body mass index as compared to patients with the TT genotype, or a greater body mass index as compared to patients with the CC genotype. Other genetic and clinical factors may also influence body mass index.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447960502>2638</a></td><td>SLC28A1</td><td>rs2242046</td><td>gemcitabine</td><td>Carcinoma, Non-Small-Cell Lung</td><td>3</td><td>AG</td><td>Toxicity</td><td>Patients with the AG genotype and non-small-cell lung cancer may have an increased risk of hematologic toxicity when treated with gemcitabine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of hematologic toxicity.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448107270>2639</a></td><td>HCG22</td><td>rs2523864</td><td>triamcinolone</td><td>Retinal Diseases</td><td>3</td><td>TT</td><td>Toxicity</td><td>Patients with retinal disease and the TT genotype may have increased intraocular pressure when treated with triamcinolone as compared to patients with the CT or CC genotypes. Other clinical and genetic factors may also influence changes in intraocular pressure in patients with retinal disease.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448263285>2640</a></td><td>ADRB2</td><td>rs1042718</td><td>fentanyl</td><td>Hypotension</td><td>3</td><td>AC</td><td>Toxicity</td><td>Patients undergoing neurosurgery and with the AC genotype may experience greater severity of hypotension when treated with combinations of fentanyl, propofol, remifentanil, and sevoflurane compared to patients with the CC genotype. Other genetic and clinical factors may affect response to fentanyl, propofol, remifentanil, and sevoflurane.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448263285>2641</a></td><td>ADRB2</td><td>rs1042718</td><td>propofol</td><td>Hypotension</td><td>3</td><td>AC</td><td>Toxicity</td><td>Patients undergoing neurosurgery and with the AC genotype may experience greater severity of hypotension when treated with combinations of fentanyl, propofol, remifentanil, and sevoflurane compared to patients with the CC genotype. Other genetic and clinical factors may affect response to fentanyl, propofol, remifentanil, and sevoflurane.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448263285>2642</a></td><td>ADRB2</td><td>rs1042718</td><td>remifentanil</td><td>Hypotension</td><td>3</td><td>AC</td><td>Toxicity</td><td>Patients undergoing neurosurgery and with the AC genotype may experience greater severity of hypotension when treated with combinations of fentanyl, propofol, remifentanil, and sevoflurane compared to patients with the CC genotype. Other genetic and clinical factors may affect response to fentanyl, propofol, remifentanil, and sevoflurane.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448263285>2643</a></td><td>ADRB2</td><td>rs1042718</td><td>sevoflurane</td><td>Hypotension</td><td>3</td><td>AC</td><td>Toxicity</td><td>Patients undergoing neurosurgery and with the AC genotype may experience greater severity of hypotension when treated with combinations of fentanyl, propofol, remifentanil, and sevoflurane compared to patients with the CC genotype. Other genetic and clinical factors may affect response to fentanyl, propofol, remifentanil, and sevoflurane.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447963688>2644</a></td><td>FAAH</td><td>rs324420</td><td>cannabinoids</td><td>Substance-Related Disorders</td><td>3</td><td>AC</td><td>Toxicity</td><td>Patients with the AC genotype may be more likely to be tetrahydrocannabinol (THC) dependent as compared to patients with the AA genotype. Other genetic and clinical factors may also influence THC dependency.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448259025>2645</a></td><td>KDR</td><td>rs1870377</td><td>sorafenib</td><td>hand-foot syndrome;Hypertension</td><td>3</td><td>AT</td><td>Toxicity</td><td>Patients with the AT genotype may have increased risk of Hypertension and hand-foot skin reactions when treated with sorafenib as compared to patients with genotype AA.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447960245>2646</a></td><td>SLC28A2</td><td>rs1060896</td><td>gemcitabine</td><td>Neoplasms</td><td>3</td><td>AC</td><td>Toxicity</td><td>Patients with the AC genotype and cancer may have increased survival time and an increased risk for hematologic toxicity when treated with gemcitabine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence toxicity and response in patients receiving gemcitabine.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447960795>2647</a></td><td>POLR3G</td><td>rs2562519</td><td>nevirapine</td><td>HIV Infections</td><td>3</td><td>TT</td><td>Toxicity</td><td>Patients with the TT genotype and HIV infection who are treated with nevirapine may have an increased risk of drug-induced rash as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for nevirapine-induced rash.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447963681>2648</a></td><td>ARRB2</td><td>rs4790694</td><td>methamphetamine</td><td>Substance-Related Disorders</td><td>3</td><td>CC</td><td>Toxicity</td><td>Patients with the CC genotype who take methamphetamine may have an increased likelihood of addiction as compared to patients with the AA genotype. Other genetic and clinical factors may also influence methamphetamine addiction.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447964025>2649</a></td><td>ABCB1</td><td>rs1045642</td><td>Drugs For Treatment Of Tuberculosis</td><td>Tuberculosis</td><td>3</td><td>AA</td><td>Toxicity</td><td>Patients with the AA genotype and tuberculosis (TB) may have an increased risk for hepatotoxicity when treated with anti-TB drugs as compared to patients with the GG genotype. Other genetic and clinical factors may also influence hepatotoxicity.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447964025>2650</a></td><td>ABCB1</td><td>rs1045642</td><td>isoniazid</td><td>Tuberculosis</td><td>3</td><td>AA</td><td>Toxicity</td><td>Patients with the AA genotype and tuberculosis (TB) may have an increased risk for hepatotoxicity when treated with anti-TB drugs as compared to patients with the GG genotype. Other genetic and clinical factors may also influence hepatotoxicity.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448103818>2651</a></td><td>NOS1AP</td><td>rs10494366</td><td>Dihydropyridine derivatives</td><td></td><td>3</td><td>GT</td><td>Toxicity</td><td>Patients with the GT genotype and hypertension may have an increased risk for cardiovascular and all-cause mortality when treated with dihydropyridine derivatives as compared to patients with the TT genotype. Other genetic and clinical factors may also influence mortality risk in patients taking dihydropyridine derivatives.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448422846>2652</a></td><td>TGFBR2</td><td>rs3087465</td><td>irinotecan</td><td>Colorectal Neoplasms</td><td>3</td><td>GG</td><td>Toxicity</td><td>Patients with the GG genotype and colorectal cancer may have an increased risk for diarrhea when treated with irinotecan as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence risk for diarrhea in patients taking irinotecan.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448427972>2653</a></td><td>NTRK2</td><td>rs1439050</td><td>antidepressants</td><td>Depressive Disorder, Major</td><td>3</td><td>GT</td><td>Toxicity</td><td>Patients with the GT genotype and depression may have increased risk of suicidal thoughts when taking antidepressants compared to patients with the TT genotype. Other clinical and genetic factors may affect risk of suicidal thoughts when taking antidepressants.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448428151>2654</a></td><td>HTR2A</td><td>rs9567733</td><td>antipsychotics</td><td>Psychotic Disorders</td><td>3</td><td>AG</td><td>Toxicity</td><td>Patients with the AG genotype and first episode psychosis (FEP) may have an increased risk for extrapyramidal symptoms when treated with antipsychotics as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of extrapyramidal symptoms.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448098299>2655</a></td><td>NR1I3</td><td>rs75114882</td><td>docetaxel</td><td>Nasopharyngeal Neoplasms;Neutropenia</td><td>3</td><td>AG</td><td>Toxicity</td><td>Patients with nasopharyngeal cancer and the AG genotype may have a increased severity of neutropenia when treated with docetaxel as compared to patients with the AA genotype. Other clinical and genetic factors may also influence severity of neutropenia in patients with nasopharyngeal cancer who are treated with docetaxel.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448102407>2656</a></td><td>DRD3</td><td>rs6280</td><td>methamphetamine</td><td>HIV Infections</td><td>3</td><td>CT</td><td>Toxicity</td><td>Patients with the CT genotype and HIV may have increased cognitive impairment when taking methamphetamines as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk for cognitive impairment in patients taking methamphetamines.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448615167>2657</a></td><td>CYP19A1</td><td>rs1008805</td><td>anastrozole</td><td>Breast Neoplasms</td><td>3</td><td>AA</td><td>Toxicity</td><td>Postmenopausal women with HR+breast cancer and the AA genotype may have an increased likelihood of experiencing arthralgia when treated with anastrozole as compared to women with the GG genotype. Other clinical and genetic factors may also influence likelihood of arthralgia in postmenopausal women with HR+ breast cancer who are treated with anastrozole.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448265565>2658</a></td><td>RIPOR2</td><td>rs10946739</td><td>rifampin</td><td>Tuberculosis</td><td>3</td><td>CT</td><td>Toxicity</td><td>Patients with the CT genotype and tuberculosis may be at increased risk of drug-induced liver toxicity when taking rifampicin compared to patients with the TT genotype. This SNP was identified in a GWAS study and maintained significance in combination with a replication study. Other genetic and clinical factors may affect response to rifampicin.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448265573>2659</a></td><td>RIPOR2</td><td>rs10946737</td><td>Drugs For Treatment Of Tuberculosis</td><td>Tuberculosis</td><td>3</td><td>AG</td><td>Toxicity</td><td>Patients with the AG genotype and tuberculosis may be at increased risk of drug-induced liver toxicity when taking drugs for treatment of tuberculosis, e.g. rifampicin, compared to patients with the GG genotype. Other genetic and clinical factors may affect response to rifampicin or other drugs for treatment of tuberculosis.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448265573>2660</a></td><td>RIPOR2</td><td>rs10946737</td><td>rifampin</td><td>Tuberculosis</td><td>3</td><td>AG</td><td>Toxicity</td><td>Patients with the AG genotype and tuberculosis may be at increased risk of drug-induced liver toxicity when taking drugs for treatment of tuberculosis, e.g. rifampicin, compared to patients with the GG genotype. Other genetic and clinical factors may affect response to rifampicin or other drugs for treatment of tuberculosis.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448265598>2661</a></td><td>AGBL4</td><td>rs319952</td><td>rifampin</td><td>Tuberculosis</td><td>3</td><td>AG</td><td>Toxicity</td><td>Patients with the AG genotype and tuberculosis may be at increased risk of drug-induced liver toxicity when taking rifampicin compared to patients with the GG genotype. This SNP was identified in a GWAS study and maintained significance in combination with a replication study. Other genetic and clinical factors may affect response to rifampicin.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448427559>2662</a></td><td>ABCB1</td><td>rs1045642</td><td>clozapine</td><td></td><td>3</td><td>AA</td><td>Toxicity</td><td>Patients with the AA genotype may have increased clozapine plasma concentrations, as well as an increased risk for clozapine-induced agranulocytosis or neutropenia, as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence concentrations and risk of clozapine-induced toxicity.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447963853>2663</a></td><td>AGTR1</td><td>rs5186</td><td>Thiazides, plain</td><td></td><td>3</td><td>AC</td><td>Toxicity</td><td>Patients with the AC genotype who are taking thiazide diuretics may have an increased risk of developing diabetes mellitus as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of diabetes.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447982768>2664</a></td><td>SLCO1B3</td><td>rs7311358</td><td>carboplatin</td><td>Carcinoma, Non-Small-Cell Lung</td><td>3</td><td>AA</td><td>Toxicity</td><td>Patients with the AA genotype and Non-Small-Cell Lung Carcinoma who are treated with carboplatin and paclitaxel may have an increased risk for anemia as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's risk for anemia.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447982768>2665</a></td><td>SLCO1B3</td><td>rs7311358</td><td>paclitaxel</td><td>Carcinoma, Non-Small-Cell Lung</td><td>3</td><td>AA</td><td>Toxicity</td><td>Patients with the AA genotype and Non-Small-Cell Lung Carcinoma who are treated with carboplatin and paclitaxel may have an increased risk for anemia as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's risk for anemia.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448101059>2666</a></td><td>SLC6A12</td><td>rs557881</td><td>aspirin</td><td>Asthma</td><td>3</td><td>GG</td><td>Toxicity</td><td>Patients with the GG genotype may have an increased risk for aspirin-intolerant asthma as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk for aspirin-intolerant asthma.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448100249>2667</a></td><td>SERPINE1</td><td>rs6092</td><td>dexamethasone</td><td>Precursor Cell Lymphoblastic Leukemia-Lymphoma</td><td>3</td><td>AG</td><td>Toxicity</td><td>Pediatric patients with the AG genotype and acute lymphoblastic leukemia may have an increased risk of osteonecrosis when treated with dexamethasone as compared to patients with the GG genotype. Other genetic and clinical factors may also influence osteonecrosis risk.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448100257>2668</a></td><td>IL6</td><td>rs1800795</td><td>peginterferon alfa-2b</td><td>Hepatitis C, Chronic</td><td>3</td><td>CG</td><td>Toxicity</td><td>Patients with the CG genotype and chronic hepatitis C may have an increased risk for depression when treated with peginterferon alfa-2b and ribavirin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence depression in patients receiving peginterferon alfa-2b and ribavirin treatment.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448100257>2669</a></td><td>IL6</td><td>rs1800795</td><td>ribavirin</td><td>Hepatitis C, Chronic</td><td>3</td><td>CG</td><td>Toxicity</td><td>Patients with the CG genotype and chronic hepatitis C may have an increased risk for depression when treated with peginterferon alfa-2b and ribavirin as compared to patients with the CC genotype. Other genetic and clinical factors may also influence depression in patients receiving peginterferon alfa-2b and ribavirin treatment.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448099100>2670</a></td><td>SREBF1</td><td>rs11868035</td><td>hmg coa reductase inhibitors</td><td>Schizophrenia</td><td>3</td><td>AG</td><td>Toxicity</td><td>Patients with the AG genotype and schizophrenia may have a greater increase in total cholesterol levels when treated with HMG-CoA reductase inhibitors as compared to patients with the GG genotype. Other genetic and clinical factors may also influence total cholesterol levels.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448124216>2671</a></td><td>PTGS1</td><td>rs1330344</td><td>clopidogrel</td><td>major adverse cardiac events (mace)</td><td>3</td><td>TT</td><td>Toxicity</td><td>Patients with the TT genotype may have increased the risk of recurrent clinical events when treated with clopidogrel as compared to patients with genotype CC. Other genetic and clinical factors may also influence the response to clopidogrel.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448124242>2672</a></td><td>P2RY12</td><td>rs2046934</td><td>clopidogrel</td><td>major adverse cardiac events (mace)</td><td>3</td><td>AA</td><td>Toxicity</td><td>Patients with the AA genotype may have increased risk of adverse cardiac events when treated with clopidogrel as compared to patients with genotype GG. Other genetic and clinical factors may also influence the response to clopidogrel.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447982797>2673</a></td><td>SLCO1B3</td><td>rs4149117</td><td>carboplatin</td><td>Lung Neoplasms</td><td>3</td><td>GG</td><td>Toxicity</td><td>Patients with the GG genotype and Lung Neoplasms who are treated with carboplatin and paclitaxel may have an increased risk for anemia and thrombocytopenia as compared to patients with the GT and TT genotype. Other genetic and clinical factors may also influence a patient's risk for anemia and thrombocytopenia.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447982797>2674</a></td><td>SLCO1B3</td><td>rs4149117</td><td>paclitaxel</td><td>Lung Neoplasms</td><td>3</td><td>GG</td><td>Toxicity</td><td>Patients with the GG genotype and Lung Neoplasms who are treated with carboplatin and paclitaxel may have an increased risk for anemia and thrombocytopenia as compared to patients with the GT and TT genotype. Other genetic and clinical factors may also influence a patient's risk for anemia and thrombocytopenia.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448265605>2675</a></td><td>AGBL4</td><td>rs393994</td><td>rifampin</td><td>Tuberculosis</td><td>3</td><td>AG</td><td>Toxicity</td><td>Patients with the AG genotype and tuberculosis may be at increased risk of drug-induced liver toxicity when taking rifampicin compared to patients with the GG genotype. This SNP was identified in a GWAS study and maintained significance in combination with a replication study. Other genetic and clinical factors may affect response to rifampicin.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450933110>2676</a></td><td>ADGRL3</td><td>rs2271339</td><td>nicotine</td><td>Tobacco Use Disorder</td><td>3</td><td>AG</td><td>Toxicity</td><td>Patients with ADHD and the AG genotype may be at an increased risk of developing nicotine dependence as compared to patients with the AA or GG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing nicotine dependence.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447990932>2677</a></td><td>DHFR</td><td>rs442767</td><td>methotrexate</td><td>Precursor Cell Lymphoblastic Leukemia-Lymphoma</td><td>3</td><td>GT</td><td>Toxicity</td><td>The GT genotype in patients with precursor cell lymphoblastic leukemia-lymphoma may be associated with an increased risk of leukopenia when treated with methotrexate as compared to the TT genotype. Other clinical and genetic factors may also influence risk of leukopenia in patients with precursor cell lymphoblastic leukemia-lymphoma.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447961028>2678</a></td><td>NAT2</td><td>rs1799929</td><td>Drugs For Treatment Of Tuberculosis</td><td>Tuberculosis</td><td>3</td><td>CT</td><td>Toxicity</td><td>Patients with the CT genotype and tuberculosis (TB) may have an increased risk for hepatotoxicity when treated with anti-TB drugs as compared to patients with the CC genotype. This SNP is present in a variety of NAT2 * alleles resulting in different NAT2 acetylator phenotypes, and is the signature SNP of NAT2*11. Other genetic and clinical factors may also influence hepatotoxicity.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449156815>2679</a></td><td>TH</td><td>rs2070762</td><td>opioids</td><td>Opioid-Related Disorders</td><td>3</td><td>AG</td><td>Toxicity</td><td>Patients with the AG genotype may have an increased risk of developing opioid dependence as compared to patients with the AA genotype. However, another study failed to find an association. Other genetic and clinical factors may also affect a patient's risk of developing opioid dependence.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448098287>2680</a></td><td>NR1I3</td><td>rs2501873</td><td>docetaxel</td><td>Anemia;Nasopharyngeal Neoplasms</td><td>3</td><td>CT</td><td>Toxicity</td><td>Patients with nasopharyngeal cancer and the CT genotype may have an increased severity of anemia when treated with docetaxel as compared to patients with the CC genotypes. Other clinical and genetic factors may also influence the severity of anemia in patients with nasopharyngeal cancer who are administered docetaxel.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448098354>2681</a></td><td>RXRA</td><td>rs1536475</td><td>docetaxel</td><td>Nasopharyngeal Neoplasms</td><td>3</td><td>AG</td><td>Toxicity</td><td>Patients with nasopharyngeal cancer and the AG genotype who are treated with docetaxel may have more severe anemia as compared to patients with the AA genotype. Other clinical and genetic factors may also influence severity of anemia in patients with nasopharyngeal cancer who are treated with docetaxel.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448099320>2682</a></td><td>RXRA</td><td>rs2234753</td><td>docetaxel</td><td>Anemia;Nasopharyngeal Neoplasms</td><td>3</td><td>AG</td><td>Toxicity</td><td>Patients with nasopharyngeal cancer and the AG genotype who are treated with docetaxel may have more severe anemia as compared to patients with the AA genotype. Other clinical and genetic factors may also influence severity of anemia in patients with nasopharyngeal cancer who are administered docetaxel.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451704127>2683</a></td><td>NAT2</td><td>rs1799930</td><td>sulfamethoxazole / trimethoprim</td><td>adverse events;Hypersensitivity</td><td>3</td><td>AG</td><td>Toxicity</td><td>Patients with infections and the rs1799930 AG genotype may be at an increased risk of experiencing adverse events when treated with sulfamethoxazole/trimethoprim as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of adverse events when treated with sulfamethoxazole/trimethoprim.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447949305>2684</a></td><td>ABCB1</td><td>rs1045642</td><td>tacrolimus</td><td>Kidney Transplantation</td><td>3</td><td>AA</td><td>Toxicity</td><td>Patients who receive a kidney with the AA genotype may have decreased estimated glomerular filtration rate (eGFR) when treated with tacrolimus as compared to patients with the AG or GG genotype. No significant results were seen when recipient genotype was considered. Other genetic and clinical factors may also influence eGFR.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448098344>2685</a></td><td>RXRA</td><td>rs62576288</td><td>docetaxel</td><td>Nasopharyngeal Neoplasms</td><td>3</td><td>GG</td><td>Toxicity</td><td>Patients with nasopharyngeal cancer and the GG genotype who are treated with docetaxel may have more severe anemia as compared to the AA genotype. Other clinical and genetic factors may also influence severity of anemia in patients with nasopharyngeal cancer who are treated with doxetaxel.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448615319>2686</a></td><td>ABCB1</td><td>rs1045642</td><td>clopidogrel</td><td>Coronary Disease;Hemorrhage</td><td>3</td><td>AA</td><td>Toxicity</td><td>Patients with coronary disease and the AA genotype who are treated with clopidogrel may have an increased risk of hemorrhage as compared to patients with the AG or GG genotypes. Other clinical and genetic factors may also influence risk of hemorrhage in patients with coronary disease who are treated with clopidogrel.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444706245>2687</a></td><td>SLCO1B1</td><td>rs4363657</td><td>simvastatin</td><td>Muscular Diseases</td><td>4</td><td>CT</td><td>Toxicity</td><td>Patients with the CT genotype may be at increased risk of myopathy when treated with simvastatin as compared to patients with the TT genotype. Other genetic and clinical factors may influence also a patient's risk of myopathy.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1446899702>2688</a></td><td>KCNIP4</td><td>rs7661530</td><td>Ace Inhibitors, Plain</td><td></td><td>4</td><td>CC</td><td>Toxicity</td><td>Patients with the CC genotype may be more likely to experience ACE inhibitor induced cough when taking ACE inhibitors as compared to patients with the CT and TT genotype, although this is contradicted in one study. Other clinical and genetic factors may also influence likelihood of ACE inhibitor induced cough in patients who are taking ACE inhibitors.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448616922>2689</a></td><td>TYMS</td><td>rs699517</td><td>capecitabine</td><td>Asthenia;Nausea;Neoplasms;Vomiting</td><td>3</td><td>TT</td><td>Toxicity</td><td>Patients with the TT genotype and cancer who are treated with Capecitabine may have an increased risk of of nausea and vomiting as compared to patients with the CC or CT genotypes and a decreased likelihood of asthenia as compared to the CC genotype. Other clinical and genetic factors may also influence nausea and vomiting in patients with cancer who are treated with Capecitabine.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450812229>2690</a></td><td>OPRD1</td><td>rs2236857</td><td>heroin</td><td>Heroin Dependence</td><td>3</td><td>CT</td><td>Toxicity</td><td>Patients with the rs2236857 CT genotype may be at an increased risk of developing heroin dependence as compared to patients with the TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect risk of developing heroin dependence.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450813775>2691</a></td><td>DRD2</td><td>rs1799732</td><td>ethanol</td><td>Alcoholism</td><td>3</td><td>GG</td><td>Toxicity</td><td>Patients with the GG genotype and alcohol dependence may more likely to drink > 36 drinks in 24 hours as compared to patients with the del/del or G/del genotypes. However, this association lost its significance when other measures of alcohol consumption were analyzed. Other genetic and clinical factors may also affect severity of alcohol dependence.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448266986>2692</a></td><td>SLC22A2</td><td>rs316019</td><td>Platinum compounds</td><td>Carcinoma, Non-Small-Cell Lung</td><td>3</td><td>AC</td><td>Toxicity</td><td>Patients with the AC genotype and non-small cell lung cancer may have increased severity of toxicity, specifically hepatotoxicity, when taking platinum-based compounds compared to patients with the CC genotype. Other clinical and genetic factors may affect risk of toxicity.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447673005>2693</a></td><td>VKORC1</td><td>rs9923231</td><td>warfarin</td><td>over-anticoagulation</td><td>1B</td><td>CT</td><td>Toxicity</td><td>Patients with the rs9923231 CT genotype may have increased risk of over-anticoagulation when treated with warfarin as compared with patients with genotype CC. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence the toxicity to warfarin.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450811261>2694</a></td><td>ADH1B</td><td>rs1229984</td><td>ethanol</td><td>Alcoholism</td><td>3</td><td>CC</td><td>Toxicity</td><td>Patients with the CC genotype may be at an increased risk of developing alcoholism as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451110320>2695</a></td><td>SLC19A1</td><td>rs2838956</td><td>methotrexate</td><td>adverse events;Arthritis, Rheumatoid</td><td>3</td><td>AG</td><td>Toxicity</td><td>Patients with rheumatoid arthritis and the AG genotype may have an increased risk of experiencing adverse events as compared to patients with the GG genotype. However, this association did not reach statistical significance. Other genetic and clinical factors may also affect a patient's risk of experiencing methotrexate-related adverse events.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451120960>2696</a></td><td>ANKS1B</td><td>rs2133896</td><td>ethanol</td><td>Alcoholism</td><td>3</td><td>GT</td><td>Toxicity</td><td>Patients with the GT genotype may be at an increased risk of developing alcohol dependence as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing alcohol dependence.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451120980>2697</a></td><td>ANKS1B</td><td>rs2133896</td><td>heroin</td><td>Heroin Dependence</td><td>3</td><td>GT</td><td>Toxicity</td><td>Patients with the GT genotype may be at an increased risk of developing heroin dependence as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing heroin dependence.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451125512>2698</a></td><td>ATAT1</td><td>rs9262132</td><td>carboplatin</td><td>Carcinoma, Non-Small-Cell Lung;Thrombocytopenia</td><td>3</td><td>CC</td><td>Toxicity</td><td>Patients with non-small cell lung cancer and the CC genotype may experience an increased severity of thrombocytopenia when treated with carboplatin and gemcitabine as compared to patients with the AA genotype. Other genetic and clinical factors may also affect severity of thrombocytopenia.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451125512>2699</a></td><td>ATAT1</td><td>rs9262132</td><td>gemcitabine</td><td>Carcinoma, Non-Small-Cell Lung;Thrombocytopenia</td><td>3</td><td>CC</td><td>Toxicity</td><td>Patients with non-small cell lung cancer and the CC genotype may experience an increased severity of thrombocytopenia when treated with carboplatin and gemcitabine as compared to patients with the AA genotype. Other genetic and clinical factors may also affect severity of thrombocytopenia.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451125538>2700</a></td><td>HLA-C</td><td>rs1049709</td><td>carboplatin</td><td>Carcinoma, Non-Small-Cell Lung;Thrombocytopenia</td><td>3</td><td>TT</td><td>Toxicity</td><td>Patients with non-small cell lung cancer and the TT genotype may experience a decreased severity of thrombocytopenia when treated with carboplatin and gemcitabine as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect severity of thrombocytopenia.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451125538>2701</a></td><td>HLA-C</td><td>rs1049709</td><td>gemcitabine</td><td>Carcinoma, Non-Small-Cell Lung;Thrombocytopenia</td><td>3</td><td>TT</td><td>Toxicity</td><td>Patients with non-small cell lung cancer and the TT genotype may experience a decreased severity of thrombocytopenia when treated with carboplatin and gemcitabine as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect severity of thrombocytopenia.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451125544>2702</a></td><td>MUCL3</td><td>rs3094086</td><td>carboplatin</td><td>Carcinoma, Non-Small-Cell Lung;Thrombocytopenia</td><td>3</td><td>AG</td><td>Toxicity</td><td>Patients with non-small cell lung cancer and the AG genotype may experience an increased severity of thrombocytopenia when treated with carboplatin and gemcitabine as compared to patients with the GG genotype. Other genetic and clinical factors may also affect severity of thrombocytopenia.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451125544>2703</a></td><td>MUCL3</td><td>rs3094086</td><td>gemcitabine</td><td>Carcinoma, Non-Small-Cell Lung;Thrombocytopenia</td><td>3</td><td>AG</td><td>Toxicity</td><td>Patients with non-small cell lung cancer and the AG genotype may experience an increased severity of thrombocytopenia when treated with carboplatin and gemcitabine as compared to patients with the GG genotype. Other genetic and clinical factors may also affect severity of thrombocytopenia.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451125570>2704</a></td><td>PRRC2A</td><td>rs11229</td><td>carboplatin</td><td>Carcinoma, Non-Small-Cell Lung;Thrombocytopenia</td><td>3</td><td>AG</td><td>Toxicity</td><td>Patients with non-small cell lung cancer and the AG genotype may experience an increased severity of thrombocytopenia when treated with carboplatin and gemcitabine as compared to patients with the AA genotype. Other genetic and clinical factors may also affect severity of thrombocytopenia.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451125570>2705</a></td><td>PRRC2A</td><td>rs11229</td><td>gemcitabine</td><td>Carcinoma, Non-Small-Cell Lung;Thrombocytopenia</td><td>3</td><td>AG</td><td>Toxicity</td><td>Patients with non-small cell lung cancer and the AG genotype may experience an increased severity of thrombocytopenia when treated with carboplatin and gemcitabine as compared to patients with the AA genotype. Other genetic and clinical factors may also affect severity of thrombocytopenia.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451125600>2706</a></td><td>PRRC2A</td><td>rs10885</td><td>carboplatin</td><td>Carcinoma, Non-Small-Cell Lung;Thrombocytopenia</td><td>3</td><td>CT</td><td>Toxicity</td><td>Patients with non-small cell lung cancer and the CT genotype may experience an increased severity of thrombocytopenia when treated with carboplatin and gemcitabine as compared to patients with the CC genotype. Other genetic and clinical factors may also affect severity of thrombocytopenia.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451125600>2707</a></td><td>PRRC2A</td><td>rs10885</td><td>gemcitabine</td><td>Carcinoma, Non-Small-Cell Lung;Thrombocytopenia</td><td>3</td><td>CT</td><td>Toxicity</td><td>Patients with non-small cell lung cancer and the CT genotype may experience an increased severity of thrombocytopenia when treated with carboplatin and gemcitabine as compared to patients with the CC genotype. Other genetic and clinical factors may also affect severity of thrombocytopenia.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451125646>2708</a></td><td>CYP2C8</td><td>rs1058932</td><td>carboplatin</td><td>Carcinoma, Non-Small-Cell Lung;Thrombocytopenia</td><td>3</td><td>AA</td><td>Toxicity</td><td>Patients with non-small cell lung cancer and the AA genotype may experience a decreased severity of thrombocytopenia when treated with carboplatin and gemcitabine as compared to patients with the GG genotype. Other genetic and clinical factors may also affect severity of thrombocytopenia.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451125646>2709</a></td><td>CYP2C8</td><td>rs1058932</td><td>gemcitabine</td><td>Carcinoma, Non-Small-Cell Lung;Thrombocytopenia</td><td>3</td><td>AA</td><td>Toxicity</td><td>Patients with non-small cell lung cancer and the AA genotype may experience a decreased severity of thrombocytopenia when treated with carboplatin and gemcitabine as compared to patients with the GG genotype. Other genetic and clinical factors may also affect severity of thrombocytopenia.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451125660>2710</a></td><td>CYP2C8</td><td>rs11572078</td><td>carboplatin</td><td>Carcinoma, Non-Small-Cell Lung;Thrombocytopenia</td><td>3</td><td>AA</td><td>Toxicity</td><td>Patients with non-small cell lung cancer and the AA genotype may experience a decreased severity of thrombocytopenia when treated with carboplatin and gemcitabine as compared to patients with the del/del genotype. Other genetic and clinical factors may also affect severity of thrombocytopenia.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451125660>2711</a></td><td>CYP2C8</td><td>rs11572078</td><td>gemcitabine</td><td>Carcinoma, Non-Small-Cell Lung;Thrombocytopenia</td><td>3</td><td>AA</td><td>Toxicity</td><td>Patients with non-small cell lung cancer and the AA genotype may experience a decreased severity of thrombocytopenia when treated with carboplatin and gemcitabine as compared to patients with the del/del genotype. Other genetic and clinical factors may also affect severity of thrombocytopenia.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451125672>2712</a></td><td>XYLT2</td><td>rs6504649</td><td>carboplatin</td><td>Carcinoma, Non-Small-Cell Lung;Thrombocytopenia</td><td>3</td><td>CG</td><td>Toxicity</td><td>Patients with non-small cell lung cancer and the CG genotype may experience an increased severity of thrombocytopenia when treated with carboplatin and gemcitabine as compared to patients with the CC genotype. Other genetic and clinical factors may also affect severity of thrombocytopenia.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451125672>2713</a></td><td>XYLT2</td><td>rs6504649</td><td>gemcitabine</td><td>Carcinoma, Non-Small-Cell Lung;Thrombocytopenia</td><td>3</td><td>CG</td><td>Toxicity</td><td>Patients with non-small cell lung cancer and the CG genotype may experience an increased severity of thrombocytopenia when treated with carboplatin and gemcitabine as compared to patients with the CC genotype. Other genetic and clinical factors may also affect severity of thrombocytopenia.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451125687>2714</a></td><td>SERPINA5</td><td>rs6118</td><td>carboplatin</td><td>Carcinoma, Non-Small-Cell Lung;Thrombocytopenia</td><td>3</td><td>CC</td><td>Toxicity</td><td>Patients with non-small cell lung cancer and the CC genotype may experience a decreased severity of thrombocytopenia when treated with carboplatin and gemcitabine as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect severity of thrombocytopenia.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451125687>2715</a></td><td>SERPINA5</td><td>rs6118</td><td>gemcitabine</td><td>Carcinoma, Non-Small-Cell Lung;Thrombocytopenia</td><td>3</td><td>CC</td><td>Toxicity</td><td>Patients with non-small cell lung cancer and the CC genotype may experience a decreased severity of thrombocytopenia when treated with carboplatin and gemcitabine as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect severity of thrombocytopenia.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451243628>2716</a></td><td>VKORC1</td><td>rs9923231</td><td>acenocoumarol</td><td>Hemorrhage</td><td>3</td><td>CT</td><td>Toxicity</td><td>Patients with the CT genotype who are treated with acenocoumarol may have an increased risk of Hemorrhage as compared to the CC genotypes. Other clinical and genetic factors may also influence risk of hemorrhage in patients administered acetacoumarol.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451243676>2717</a></td><td>VKORC1</td><td>rs9923231</td><td>phenprocoumon</td><td>Hemorrhage;over-anticoagulation;time above therapeutic range</td><td>2A</td><td>CT</td><td>Toxicity</td><td>Patients with the CT genotype may have an increased risk of adverse events (bleeding, over-anticoagulation or increased time above therapeutic range) when treated with phenprocoumon as compared to patients with the CC genotype. Other clinical and genetic factors may also influence risk of adverse events to phenprocoumon.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450812260>2718</a></td><td>OPRD1</td><td>rs2236861</td><td>heroin</td><td>Heroin Dependence</td><td>3</td><td>AG</td><td>Toxicity</td><td>Patients with the AG genotype may be at an increased risk of developing heroin dependence as compared to patients with the GG genotype. However, another study did not find an association between this variant and heroin dependence. Other genetic and clinical factors may also affect a patient's risk of developing heroin dependence.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449003966>2719</a></td><td>MAFK</td><td>rs4720833</td><td>isoniazid</td><td>drug-induced liver injury;Toxic liver disease</td><td>3</td><td>AG</td><td>Toxicity</td><td>Patients with the AG genotype who are taking isoniazid may have an increased risk of drug-induced liver injury as compared to patients with the GG genotype. However, another study found no association between this variant and the risk of drug-induced liver injury when taking isoniazid. Other genetic and clinical factors may also influence risk of drug-induced liver injury in patients taking isoniazid.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449715840>2720</a></td><td>OPRM1</td><td>rs540825</td><td>fentanyl</td><td>Vomiting</td><td>3</td><td>TT</td><td>Toxicity</td><td>Patients with the rs540825 TT genotype may have an increased likelihood of experiencing vomiting as a result of taking fentanyl as compared to patients with the AA or AT genotypes. This drug-variant pair has been assigned a no recommendation by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect likelihood of vomiting as a result of taking fentanyl.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450814563>2721</a></td><td>GABRA2</td><td>rs11503014</td><td>cocaine</td><td>Cocaine-Related Disorders</td><td>3</td><td>CG</td><td>Toxicity</td><td>Patients with cocaine dependence and the CG genotype may have increased cocaine cue-reactivity as compared to patients with the CC genotype. Other genetic or clinical factor may also affect cocaine cue-reactivity in patients with cocaine dependence.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449161121>2722</a></td><td>IL10</td><td>rs1800896</td><td>Antiinflammatory agents, non-steroids</td><td></td><td>3</td><td>TT</td><td>Toxicity</td><td>Patients with the TT genotype may have an increased risk of experiencing a hypersensitivity reaction to NSAIDs as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of developing NSAID hypersensitivity.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450810375>2723</a></td><td>OPRM1</td><td>rs495491</td><td>ethanol</td><td>Alcoholism</td><td>3</td><td>AG</td><td>Toxicity</td><td>Patients with the AG genotype may be at an increased risk of developing alcoholism as compared to patients with the AA genotype. Other genetic or clinical factors may also affect a patient's risk of developing alcoholism.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450936577>2724</a></td><td>AQP1</td><td>rs28362731</td><td>cisplatin</td><td>Thrombocytopenia</td><td>3</td><td>AG</td><td>Toxicity</td><td>Patients with malignant mesothelioma and the AG genotype may be at an increased risk of developing thrombocytopenia when treated with cisplatin-based chemotherapy as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing thromobocytopenia when treated with cisplatin-based chemotherapy.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449003805>2725</a></td><td>ABO</td><td>rs56392308</td><td>hormonal contraceptives for systemic use</td><td></td><td>3</td><td>GG</td><td>Toxicity</td><td>Patients with the GG genotype who are taking oral contraceptives may have an increased risk of venous thrombosis as compared to patients with the G/del or del/del genotypes. Other genetic and clinical factors may also influence risk for venous thrombosis in patients taking oral contraceptives.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450375065>2726</a></td><td>ERCC2</td><td>rs238406</td><td>bleomycin</td><td>Leukopenia;Testicular Neoplasms</td><td>3</td><td>GT</td><td>Toxicity</td><td>Patients with testicular cancer and the GT genotype may have an increased risk of developing leukopenia as a result of treatment with bleomycin, cisplatin and etoposide as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of leukopenia as a result of treatment with bleomycin, cisplatin and etoposide.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450375065>2727</a></td><td>ERCC2</td><td>rs238406</td><td>cisplatin</td><td>Leukopenia;Testicular Neoplasms</td><td>3</td><td>GT</td><td>Toxicity</td><td>Patients with testicular cancer and the GT genotype may have an increased risk of developing leukopenia as a result of treatment with bleomycin, cisplatin and etoposide as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of leukopenia as a result of treatment with bleomycin, cisplatin and etoposide.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450375065>2728</a></td><td>ERCC2</td><td>rs238406</td><td>etoposide</td><td>Leukopenia;Testicular Neoplasms</td><td>3</td><td>GT</td><td>Toxicity</td><td>Patients with testicular cancer and the GT genotype may have an increased risk of developing leukopenia as a result of treatment with bleomycin, cisplatin and etoposide as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of leukopenia as a result of treatment with bleomycin, cisplatin and etoposide.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450812210>2729</a></td><td>OPRM1</td><td>rs510769</td><td>heroin</td><td>Heroin Dependence</td><td>3</td><td>CT</td><td>Toxicity</td><td>Patients with the rs510769 CT genotype may be at an increased risk of developing heroin dependence as compared to patients with the CC genotype. Other genetic and clinical factors may also affect risk of developing heroin dependence.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450812223>2730</a></td><td>OPRD1</td><td>rs3766951</td><td>heroin</td><td>Heroin Dependence</td><td>3</td><td>CT</td><td>Toxicity</td><td>Patients with the rs3766951 CT genotype may be at an increased risk of developing heroin dependence as compared to patients with the TT genotype. Other genetic and clinical factors may also affect risk of developing heroin dependence.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450936557>2731</a></td><td>AQP1</td><td>rs1049305</td><td>cisplatin</td><td>Mesothelioma;Thrombocytopenia</td><td>3</td><td>CG</td><td>Toxicity</td><td>Patients with malignant mesothelioma and the CG genotype may be at an increased risk of developing thromobocytopenia when treated with cisplatin-based chemotherapy as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of developing thromobocytopenia when treated with cisplatin-based chemotherapy.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450936586>2732</a></td><td>AQP1</td><td>rs1049305</td><td>cisplatin</td><td>Alopecia;Mesothelioma</td><td>3</td><td>CG</td><td>Toxicity</td><td>Patients with malignant mesothelioma and the CG genotype may be at an increased risk of developing alopecia when treated with cisplatin-based chemotherapy as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing alopecia when treated with cisplatin-based chemotherapy.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451105228>2733</a></td><td>DRD2</td><td>rs12364283</td><td>heroin</td><td>Heroin Dependence</td><td>3</td><td>AG</td><td>Toxicity</td><td>Patients with the AG genotype may have an increased risk of developing heroin dependence as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of developing heroin dependence.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451106460>2734</a></td><td>SYT1</td><td>rs2251214</td><td>cocaine</td><td>Cocaine-Related Disorders</td><td>3</td><td>GG</td><td>Toxicity</td><td>Patients with the GG genotype may have an increased risk of developing cocaine dependence as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of developing cocaine dependence.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451120359>2735</a></td><td>CHRNA4</td><td>rs2229959</td><td>nicotine</td><td></td><td>3</td><td>AA</td><td>Toxicity</td><td>Patients with the AA genotype may be less likely to successfully quit smoking following a diagnosis of lung cancer as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's likelihood of successfully quitting smoking.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451120421>2736</a></td><td>CHRNA3</td><td>rs578776</td><td>nicotine</td><td></td><td>3</td><td>AG</td><td>Toxicity</td><td>Patients with the AG genotype may be less likely to successfully quit smoking following a diagnosis of lung cancer as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's likelihood of successfully quitting smoking.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451120421>2737</a></td><td>CHRNA5</td><td>rs578776</td><td>nicotine</td><td></td><td>3</td><td>AG</td><td>Toxicity</td><td>Patients with the AG genotype may be less likely to successfully quit smoking following a diagnosis of lung cancer as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's likelihood of successfully quitting smoking.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451120427>2738</a></td><td>CHRNA4</td><td>rs1044396</td><td>nicotine</td><td></td><td>3</td><td>AG</td><td>Toxicity</td><td>Patients with the AG genotype may be less likely to successfully quit smoking following a diagnosis of lung cancer as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's likelihood of successfully quitting smoking.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451120986>2739</a></td><td>ANKS1B</td><td>rs2133896</td><td>methamphetamine</td><td>methamphetamine dependence</td><td>3</td><td>GT</td><td>Toxicity</td><td>Patients with the GT genotype may be at an increased risk of developing methamphetamine dependence as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing methamphetamine dependence.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451125500>2740</a></td><td>C6orf15</td><td>rs2233980</td><td>carboplatin</td><td>Carcinoma, Non-Small-Cell Lung;Thrombocytopenia</td><td>3</td><td>GG</td><td>Toxicity</td><td>Patients with non-small cell lung cancer and the GG genotype may experience a decreased severity of thrombocytopenia when treated with carboplatin and gemcitabine as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect severity of thrombocytopenia.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451125500>2741</a></td><td>C6orf15</td><td>rs2233980</td><td>gemcitabine</td><td>Carcinoma, Non-Small-Cell Lung;Thrombocytopenia</td><td>3</td><td>GG</td><td>Toxicity</td><td>Patients with non-small cell lung cancer and the GG genotype may experience a decreased severity of thrombocytopenia when treated with carboplatin and gemcitabine as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect severity of thrombocytopenia.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451126020>2742</a></td><td>SLC28A2</td><td>rs11854484</td><td>tenofovir disoproxil fumarate</td><td>HIV Infections;nephrotoxicity</td><td>3</td><td>CT</td><td>Toxicity</td><td>Patients with HIV and the CT genotype may experience an increased severity of nephrotoxicity when treated with tenofovir disoproxil fumarate as compared to patients with the CC genotype. Other genetic and clinical factors may also affect severity of nephrotoxicity.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451126040>2743</a></td><td>CYP24A1</td><td>rs2248359</td><td>tenofovir disoproxil fumarate</td><td>HIV Infections;nephrotoxicity</td><td>3</td><td>TT</td><td>Toxicity</td><td>Patients with HIV and the TT genotype may experience an increased severity of nephrotoxicity when treated with tenofovir disoproxil fumarate as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect severity of nephrotoxicity.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451127140>2744</a></td><td>HRH1</td><td>rs901865</td><td>desloratadine</td><td>sedation;Urticaria</td><td>3</td><td>CT</td><td>Toxicity</td><td>Patients with the CT genotype may experience a decreased severity of sedation during treatment with desloratadine as compared to patients with the CC genotype. Note that there are potential inconsistencies with the data presented in the study supporting this association. Other genetic and clinical factors may also affect the severity of sedation. inpatients treated with desloratadine.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451131846>2745</a></td><td>NFKBIB</td><td>rs2053071</td><td>gefitinib</td><td>Toxic liver disease</td><td>3</td><td>GG</td><td>Toxicity</td><td>Patients with non-small cell lung cancer and the GG genotype may be at an increased risk of developing hepatotoxicity when treated with gefitinib as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of gefitinib-induced hepatotoxicity.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451131846>2746</a></td><td>SIRT2</td><td>rs2053071</td><td>gefitinib</td><td>Toxic liver disease</td><td>3</td><td>GG</td><td>Toxicity</td><td>Patients with non-small cell lung cancer and the GG genotype may be at an increased risk of developing hepatotoxicity when treated with gefitinib as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of gefitinib-induced hepatotoxicity.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451131852>2747</a></td><td>NR1H2</td><td>rs2695121</td><td>gefitinib</td><td>Carcinoma, Non-Small-Cell Lung;Diarrhea</td><td>3</td><td>CT</td><td>Toxicity</td><td>Patients with non-small cell lung cancer and the CT genotype may be at an increased risk of developing diarrhea when treated with gefitinib as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of gefitinib-induced diarrhea.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451131860>2748</a></td><td>NFKBIA</td><td>rs8904</td><td>gefitinib</td><td>Carcinoma, Non-Small-Cell Lung;Exanthema</td><td>3</td><td>AG</td><td>Toxicity</td><td>Patients with non-small cell lung cancer and the AG genotype may be at an increased risk of developing skin rash when treated with gefitinib as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's risk of gefitinib-induced skin rash.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451139960>2749</a></td><td>CRYBG2</td><td>rs36024412</td><td>opioids</td><td>Nausea;Vomiting</td><td>3</td><td>TT</td><td>Toxicity</td><td>Patients with the TT genotype may experience a decreased severity of nausea and vomiting when treated with opioids as compared to people with the GG genotype. Other genetic and clinical factors may also affect the severity of nausea and vomiting in patients treated with opioids.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451141146>2750</a></td><td>POM121L2</td><td>rs41269255</td><td>opioids</td><td>Nausea;Vomiting</td><td>3</td><td>CT</td><td>Toxicity</td><td>Patients with the CT genotype may experience an increased severity of nausea and vomiting when treated with opioids as compared to patients with the CC genotype. Other genetic and clinical factors may also affect severity of opioid-induced nausea and vomiting.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451146160>2751</a></td><td>TH</td><td>rs10770140</td><td>opioids</td><td>Opioid-Related Disorders</td><td>3</td><td>TT</td><td>Toxicity</td><td>Patients with the TT genotype may be at an increased risk of developing opioid dependence as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's risk of developing opioid dependence.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451150080>2752</a></td><td>-</td><td>rs13129401</td><td>ethanol</td><td>Alcoholism</td><td>3</td><td>GG</td><td>Toxicity</td><td>Patients with the GG genotype may be at an increased risk of developing alcoholism as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451150086>2753</a></td><td>ADH1C</td><td>rs13125415</td><td>ethanol</td><td>Alcoholism</td><td>3</td><td>GG</td><td>Toxicity</td><td>Patients with the GG genotype may be at an increased risk of developing alcoholism as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451151478>2754</a></td><td>-</td><td>rs56722963</td><td>ethanol</td><td>Alcoholism</td><td>3</td><td>CC</td><td>Toxicity</td><td>Patients with the CC genotype may be at an increased risk of developing alcoholism as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451151490>2755</a></td><td>-</td><td>rs1783835</td><td>ethanol</td><td>Alcoholism</td><td>3</td><td>GG</td><td>Toxicity</td><td>Patients with the GG genotype may be at an increased risk of developing alcoholism as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451151522>2756</a></td><td>TNRC6A</td><td>rs72768626</td><td>ethanol</td><td>Alcoholism</td><td>3</td><td>AA</td><td>Toxicity</td><td>Patients with the AA genotype may be at an increased risk of developing alcoholism as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451151540>2757</a></td><td>FTO</td><td>rs9937709</td><td>ethanol</td><td>Alcoholism</td><td>3</td><td>AG</td><td>Toxicity</td><td>Patients with the AG genotype may be at an increased risk of developing alcoholism as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's risk of developing alcoholism.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451223540>2758</a></td><td>CYP2B6</td><td>rs2279343</td><td>methadone</td><td>Neonatal Abstinence Syndrome</td><td>3</td><td>AG</td><td>Toxicity</td><td>Infants who have been been exposed to methadone in utero and who have the AG genotype may been less likely to require treatment for neonatal abstinence syndrome as compared to infants with the AA genotype. Other genetic and clinical factors may also affect severity of neonatal abstinence syndrome.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451223592>2759</a></td><td>CYP2A7P1</td><td>rs3745274</td><td>methadone</td><td>Neonatal Abstinence Syndrome</td><td>3</td><td>GT</td><td>Toxicity</td><td>Infants who have been exposed to methadone in utero and who have the GT genotype may be less likely to require treatment for neonatal abstinence syndrome as compared to infants with the GG genotype. Other genetic and clinical factors may also affect severity of neonatal abstinence syndrome.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451223592>2760</a></td><td>CYP2B6</td><td>rs3745274</td><td>methadone</td><td>Neonatal Abstinence Syndrome</td><td>3</td><td>GT</td><td>Toxicity</td><td>Infants who have been exposed to methadone in utero and who have the GT genotype may be less likely to require treatment for neonatal abstinence syndrome as compared to infants with the GG genotype. Other genetic and clinical factors may also affect severity of neonatal abstinence syndrome.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451340320>2761</a></td><td>SLCO1B3</td><td>rs60140950</td><td>telmisartan</td><td></td><td>3</td><td>CG</td><td>Metabolism/PK</td><td>Patients with the CG genotype may have increased concentrations of telmisartan as compared to patients with the GG genotype. Other genetic and clinical factors may also influence metabolism of telmisartan. This annotation only covers the pharmacokinetic relationship between SLCO1B3 and telmisartan and does not include evidence about clinical outcomes.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451244680>2762</a></td><td>SLCO1B1</td><td>rs4149056</td><td>lovastatin acid</td><td></td><td>3</td><td>CT</td><td>Metabolism/PK</td><td>Patients with the CT genotype may have increased concentrations of lovastatin acid as compared to patients with the TT genotype. Other genetic and clinical factors may also affect metabolism of lovastatin acid. This annotation only covers the pharmacokinetic relationship between rs4149056 and lovastatin acid and does not include evidence about clinical outcomes.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451336026>2763</a></td><td>ABCB1</td><td>rs3842</td><td>olanzapine</td><td></td><td>3</td><td>CT</td><td>Metabolism/PK</td><td>Patients with the rs3842 CT genotype may have increased clearance of olanzapine as compared to patients with the CC genotype. This annotation only covers the pharmacokinetic relationship between rs3842 and olanzapine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence clearance of olanzapine.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451254580>2764</a></td><td>SLCO1B1</td><td>rs11045879</td><td>methotrexate</td><td>Neoplasms</td><td>3</td><td>CT</td><td>Metabolism/PK</td><td>Patients with the CT genotype and neoplasms who are treated with methotrexate may have increased clearance of methotrexate as compared to patients with the CC genotype. However, contradictory findings have been reported. Other genetic and clinical factors may also influence a patient's responds to methotrexate. This annotation only covers the pharmacokinetic relationship between rs11045879 and methotrexate and does not include evidence about clinical outcomes.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/981345311>2765</a></td><td>SLCO1B1</td><td>rs4149056</td><td>atorvastatin</td><td></td><td>3</td><td>CT</td><td>Metabolism/PK</td><td>Patients with the CT genotype may have decreased plasma concentration of atorvastatin when treated concomitantly with rifampin as compared to patients with the TT genotypes. Other genetic and clinical factors may also influence a patient's metabolism and response to atorvastatin.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/981345311>2766</a></td><td>SLCO1B1</td><td>rs4149056</td><td>rifampin</td><td></td><td>3</td><td>CT</td><td>Metabolism/PK</td><td>Patients with the CT genotype may have decreased plasma concentration of atorvastatin when treated concomitantly with rifampin as compared to patients with the TT genotypes. Other genetic and clinical factors may also influence a patient's metabolism and response to atorvastatin.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450373589>2767</a></td><td>SLC22A1</td><td>rs628031</td><td>imatinib</td><td>Neoplasms</td><td>3</td><td>AG</td><td>Metabolism/PK</td><td>Patients with the AG genotype and cancer may have increased clearance of imatinib, as well as a decreased response and decreased risk for toxicity when treated with imatinib as compared to patients with the GG genotype. However, one study failed to find an association between this variant and imatinib toxicity. Other genetic and clinical factors may also influence clearance, response, and risk for toxicity in patients receiving imatinib.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449005047>2768</a></td><td>CYP3A4</td><td>rs2740574</td><td>lumefantrine</td><td>Malaria</td><td>3</td><td>TT</td><td>Metabolism/PK</td><td>Pregnant patients with malaria and the TT genotype may have lower concentrations and worse response to lumefantrine as compared to patients with the CT or CC genotypes. Other clinical and genetic factors may also influence concentrations and response to lumefantrine.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449645474>2769</a></td><td>SULT1A3</td><td>rs553050853</td><td>acetaminophen</td><td></td><td>3</td><td>GG</td><td>Metabolism/PK</td><td>Patients with the GG genotype may have a decreased rate of sulfation of acetaminophen as compared to patients with the TT genotype. Other genetic and clinical factors may also affect acetaminophen sulfation in patients.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449645480>2770</a></td><td>SULT1A3</td><td>rs553050853</td><td>morphine</td><td></td><td>3</td><td>GG</td><td>Metabolism/PK</td><td>Patients with the GG genotype may have a decreased rate of sulfation of morphine as compared to patients with the TT genotype. Other genetic and clinical factors may also affect morphine sulfation in patients.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449645486>2771</a></td><td>SULT1A3</td><td>rs553050853</td><td>tapentadol</td><td></td><td>3</td><td>GG</td><td>Metabolism/PK</td><td>Patients with the GG genotype may have a decreased rate of sulfation of tapentadol as compared to patients with the TT genotype. Other genetic and clinical factors may also affect tapentadol sulfation in patients.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449645492>2772</a></td><td>SULT1A3</td><td>rs553050853</td><td>o-desmethyltramadol</td><td></td><td>3</td><td>GG</td><td>Metabolism/PK</td><td>Patients with the GG genotype may have a decreased rate of sulfation of O-desmethyl-tramadol, a metabolite of tramadol, as compared to patients with the TT genotype. Other genetic and clinical factors may also affect O-desmethyl-tramadol sulfation in patients.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449645492>2773</a></td><td>SULT1A3</td><td>rs553050853</td><td>tramadol</td><td></td><td>3</td><td>GG</td><td>Metabolism/PK</td><td>Patients with the GG genotype may have a decreased rate of sulfation of O-desmethyl-tramadol, a metabolite of tramadol, as compared to patients with the TT genotype. Other genetic and clinical factors may also affect O-desmethyl-tramadol sulfation in patients.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449645507>2774</a></td><td>SULT1A3</td><td>rs751527244</td><td>morphine</td><td></td><td>3</td><td>CC</td><td>Metabolism/PK</td><td>Patients with the CC genotype may have a decreased rate of sulfation of morphine as compared to patients with the AA or AC genotypes. Other genetic and clinical factors may also affect morphine sulfation in patients.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450936747>2775</a></td><td>ADH1A</td><td>rs1229976</td><td>acetaldehyde</td><td></td><td>3</td><td>TT</td><td>Metabolism/PK</td><td>Patients with the TT genotype may have decreased blood concentrations of acetaldehyde, a metabolite of ethanol, as compared to patients with the CT genotype. Other genetic and clinical factors may also affect acetaldehyde blood concentrations.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449171120>2776</a></td><td>CYP2B6</td><td>rs3211371</td><td>methadone</td><td></td><td>3</td><td>CT</td><td>Metabolism/PK</td><td>Patients with the CT genotype may have decreased serum concentrations of methadone as compared to patients with the TT genotype. Other genetic and clinical factors may also affect serum concentrations of methadone in patients.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449732040>2777</a></td><td>ABCB1</td><td>rs1045642</td><td>risperidone</td><td>Bipolar Disorder;Depression;Psychotic Disorders;Schizophrenia;Substance-Related Disorders</td><td>4</td><td>AA</td><td>Metabolism/PK</td><td>Patients with the AA genotype may have decreased exposure to risperidone as compared to patients with the GG genotype. However other studies have found no association between this variant and risperidone pharmacokinetics. Other genetic and clinical factors may also affect a patient's exposure to risperidone.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450042856>2778</a></td><td>SORCS2</td><td>rs73208473</td><td>atazanavir</td><td>HIV Infections</td><td>3</td><td>AC</td><td>Metabolism/PK</td><td>Patients with the AC genotype may have decreased exposure to atazanavir as compared to patients with the CC genotype. Other genetic and clinical factors may also influence the pharmacokinetics of atazanavir.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451411286>2779</a></td><td>SLCO2B1</td><td>rs3781727</td><td>voriconazole</td><td></td><td>3</td><td>CT</td><td>Metabolism/PK</td><td>Patients with the rs3781727 CT genotype may have decreased exposure to voriconazole as compared to patients with the TT genotype. This annotation only covers the pharmacokinetic relationship between rs3781727 and voriconazole and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence exposure to voriconazole.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449171933>2780</a></td><td>ABCC2</td><td>rs3740066</td><td>tacrolimus</td><td>Kidney Transplantation</td><td>3</td><td>CT</td><td>Metabolism/PK</td><td>Patients with the CT genotype who are undergoing kidney transplantation may have increased concentrations of tacrolimus, and require a decreased dose, as compared to patients with the CC genotype. Other genetic and clinical factors may also influence tacrolimus concentrations and dose.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449269830>2781</a></td><td>CYP3A5</td><td>rs776746</td><td>apixaban</td><td>Atrial Fibrillation</td><td>3</td><td>CC</td><td>Metabolism/PK</td><td>Patients with atrial fibrillation and the CC genotype may have increased concentrations of apixaban as compared to patients with the TT genotype, although this is contraindicated by another study which found that the CC genotype was associated with increased clearance of apixaban as compared to the CT and TT genotypes. Other clinical and genetic factors may also influence concentrations and clearance of apixaban in patients with atrial fibrillation.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449188673>2782</a></td><td>OPRM1</td><td>rs1074287</td><td>cotinine</td><td></td><td>3</td><td>AG</td><td>Metabolism/PK</td><td>Patients with the AG genotype and receiving methadone maintenance therapy may have increased plasma concentrations of cotinine, a metabolite of nicotine, as compared to patients with the AA genotype. Other genetic and clinical factors may also affect plasma concentrations of cotinine in patients receiving methadone maintenance therapy.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449188673>2783</a></td><td>OPRM1</td><td>rs1074287</td><td>nicotine</td><td></td><td>3</td><td>AG</td><td>Metabolism/PK</td><td>Patients with the AG genotype and receiving methadone maintenance therapy may have increased plasma concentrations of cotinine, a metabolite of nicotine, as compared to patients with the AA genotype. Other genetic and clinical factors may also affect plasma concentrations of cotinine in patients receiving methadone maintenance therapy.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449188701>2784</a></td><td>OPRM1</td><td>rs510769</td><td>cotinine</td><td></td><td>3</td><td>CT</td><td>Metabolism/PK</td><td>Patients with the CT genotype and receiving methadone maintenance therapy may have increased plasma concentrations of cotinine, a metabolite of nicotine, as compared to patients with the CC genotype. Other genetic and clinical factors may also affect plasma concentrations of cotinine in patients receiving methadone maintenance therapy.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449188701>2785</a></td><td>OPRM1</td><td>rs510769</td><td>nicotine</td><td></td><td>3</td><td>CT</td><td>Metabolism/PK</td><td>Patients with the CT genotype and receiving methadone maintenance therapy may have increased plasma concentrations of cotinine, a metabolite of nicotine, as compared to patients with the CC genotype. Other genetic and clinical factors may also affect plasma concentrations of cotinine in patients receiving methadone maintenance therapy.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449188707>2786</a></td><td>OPRM1</td><td>rs3798676</td><td>cotinine</td><td></td><td>3</td><td>CC</td><td>Metabolism/PK</td><td>Patients with the CC genotype and receiving methadone maintenance therapy may have decreased plasma concentrations of cotinine, a metabolite of nicotine, as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect plasma concentrations of cotinine in patients receiving methadone maintenance therapy.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449188707>2787</a></td><td>OPRM1</td><td>rs3798676</td><td>nicotine</td><td></td><td>3</td><td>CC</td><td>Metabolism/PK</td><td>Patients with the CC genotype and receiving methadone maintenance therapy may have decreased plasma concentrations of cotinine, a metabolite of nicotine, as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also affect plasma concentrations of cotinine in patients receiving methadone maintenance therapy.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449188713>2788</a></td><td>OPRM1</td><td>rs553202</td><td>cotinine</td><td></td><td>3</td><td>CT</td><td>Metabolism/PK</td><td>Patients with the CT genotype and receiving methadone maintenance therapy may have increased plasma concentrations of cotinine, a metabolite of nicotine, as compared to patients with the CC genotype. Other genetic and clinical factors may also affect plasma concentrations of cotinine in patients receiving methadone maintenance therapy.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449188713>2789</a></td><td>OPRM1</td><td>rs553202</td><td>nicotine</td><td></td><td>3</td><td>CT</td><td>Metabolism/PK</td><td>Patients with the CT genotype and receiving methadone maintenance therapy may have increased plasma concentrations of cotinine, a metabolite of nicotine, as compared to patients with the CC genotype. Other genetic and clinical factors may also affect plasma concentrations of cotinine in patients receiving methadone maintenance therapy.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449188719>2790</a></td><td>OPRM1</td><td>rs7748401</td><td>cotinine</td><td></td><td>3</td><td>TT</td><td>Metabolism/PK</td><td>Patients with the TT genotype and receiving methadone maintenance therapy may have decreased plasma concentrations of cotinine, a metabolite of nicotine, as compared to patients with the GG or GT genotypes. Other genetic and clinical factors may also affect plasma concentrations of cotinine in patients receiving methadone maintenance therapy.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449188719>2791</a></td><td>OPRM1</td><td>rs7748401</td><td>nicotine</td><td></td><td>3</td><td>TT</td><td>Metabolism/PK</td><td>Patients with the TT genotype and receiving methadone maintenance therapy may have decreased plasma concentrations of cotinine, a metabolite of nicotine, as compared to patients with the GG or GT genotypes. Other genetic and clinical factors may also affect plasma concentrations of cotinine in patients receiving methadone maintenance therapy.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449188725>2792</a></td><td>OPRM1</td><td>rs495491</td><td>cotinine</td><td></td><td>3</td><td>AG</td><td>Metabolism/PK</td><td>Patients with the AG genotype and receiving methadone maintenance therapy may have increased plasma concentrations of cotinine, a metabolite of nicotine, as compared to patients with the AA genotype. Other genetic and clinical factors may also affect plasma concentrations of cotinine in patients receiving methadone maintenance therapy.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449188725>2793</a></td><td>OPRM1</td><td>rs495491</td><td>nicotine</td><td></td><td>3</td><td>AG</td><td>Metabolism/PK</td><td>Patients with the AG genotype and receiving methadone maintenance therapy may have increased plasma concentrations of cotinine, a metabolite of nicotine, as compared to patients with the AA genotype. Other genetic and clinical factors may also affect plasma concentrations of cotinine in patients receiving methadone maintenance therapy.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655384850>2794</a></td><td>ABCB1</td><td>rs1045642</td><td>lansoprazole</td><td>Gastroesophageal Reflux;Transplantation</td><td>3</td><td>AA</td><td>Metabolism/PK</td><td>Patients with the AA genotype who are CYP2C19 extensive metabolizers and are receiving tacrolimus after renal transplantation may have decreased plasma concentrations of (R)-lansoprazole but no significant differences in the frequency of gastroesophageal symptoms as compared to patients with the GG or AG genotype. Other genetic and clinical factors may also influence lansoprazole clearance.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655384850>2795</a></td><td>ABCB1</td><td>rs1045642</td><td>tacrolimus</td><td>Gastroesophageal Reflux;Transplantation</td><td>3</td><td>AA</td><td>Metabolism/PK</td><td>Patients with the AA genotype who are CYP2C19 extensive metabolizers and are receiving tacrolimus after renal transplantation may have decreased plasma concentrations of (R)-lansoprazole but no significant differences in the frequency of gastroesophageal symptoms as compared to patients with the GG or AG genotype. Other genetic and clinical factors may also influence lansoprazole clearance.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655385004>2796</a></td><td>UGT2B10</td><td>rs61750900</td><td>nicotine</td><td></td><td>3</td><td>GG</td><td>Metabolism/PK</td><td>Patients with the GG genotype may have an increased metabolism of nicotine as compared to patients with the TT genotype. Other genetic and clinical factors may also effect patients' response to nicotine. This annotation only covers the pharmacokinetic relationship between rs61750900 and nicotine and does not include evidence about clinical outcomes.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655385144>2797</a></td><td>ABCC2</td><td>rs2273697</td><td>talinolol</td><td></td><td>3</td><td>AG</td><td>Metabolism/PK</td><td>People with the rs2273697 AG genotype may have increased clearance of talinolol as compared to people with the GG genotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs2273697 and talinolol and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence the clearance of talinolol.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655385159>2798</a></td><td>ABCC4</td><td>rs1751034</td><td>tenofovir</td><td>HIV Infections</td><td>3</td><td>TT</td><td>Metabolism/PK</td><td>Patients with the TT genotype carriers may have increased tenofovir renal clearance, and lower AUC as compared to patients with CC or CT genotype. Contradictory evidence has been reported for this association. This annotation only covers the pharmacokinetic relationship between rs1751034 and tenofovir and does not include evidence about clinical outcomes.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/827923032>2799</a></td><td>CYP2B6</td><td>rs3745274</td><td>efavirenz</td><td>HIV Infections</td><td>1A</td><td>GT</td><td>Metabolism/PK</td><td>Patients with the rs3745274 GT genotype and HIV infection may have increased plasma concentrations and decreased clearance of efavirenz as compared to patients with the GG genotype. Other genetic and clinical factors may also influence the metabolism of efavirenz. This annotation only covers the pharmacokinetic relationship between rs3745274 and efavirenz and does not include evidence about clinical outcomes.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/981202294>2800</a></td><td>CYP2B6</td><td>rs3745274</td><td>nevirapine</td><td>HIV Infections</td><td>2A</td><td>GT</td><td>Metabolism/PK</td><td>Patients with the rs3745274 GT genotype and HIV infection may have decreased clearance of and increased exposure to nevirapine as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence clearance of nevirapine and exposure to drug. This annotation only covers the pharmacokinetic relationship between rs3745274 and nevirapine and does not include evidence about clinical outcomes.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451417123>2801</a></td><td>ABCB1</td><td>rs1128503</td><td>temozolomide</td><td>Glioma</td><td>3</td><td>AG</td><td>Metabolism/PK</td><td>Patients with glioma and the rs1128503 AG genotype may have decreased concentrations of temozolomide as compared to patients with the GG genotype. This annotation only covers the pharmacokinetic relationship between rs1128503 and temozolomide and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence temozolomide concentrations.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/981345293>2802</a></td><td>SLCO1B1</td><td>rs4149056</td><td>pravastatin</td><td></td><td>1A</td><td>CT</td><td>Metabolism/PK</td><td>Patients with the rs4149056 CT genotype may have increased plasma concentrations of pravastatin as compared to patients with the TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence a patient's metabolism of pravastatin. This annotation only covers the pharmacokinetic relationship between rs4149056 and pravastatin and does not include evidence about clinical outcomes.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/981204372>2803</a></td><td>ABCB1</td><td>rs1045642</td><td>digoxin</td><td></td><td>3</td><td>AA</td><td>Metabolism/PK</td><td>Patients with AA genotype may have decreased metabolism and increased serum concentration of digoxin as compared to patients with the GG genotype. Other genetic and clinical factors may also impact the metabolism of digoxin. This annotation only covers the pharmacokinetic relationship between rs1045642 and digoxin and does not include evidence about clinical outcomes.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/981345350>2804</a></td><td>SLCO1B1</td><td>rs4149056</td><td>rosuvastatin</td><td>Hypercholesterolemia</td><td>1A</td><td>CT</td><td>Metabolism/PK</td><td>Patients with the rs4149056 CT genotype may have higher plasma concentrations of rosuvastatin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence metabolism of rosuvastatin. This annotation only covers the pharmacokinetic relationship between rs4149056 and rosuvastatin and does not include evidence about clinical outcomes.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449004567>2805</a></td><td>ABCB1</td><td>rs1045642</td><td>oxcarbazepine</td><td>Epilepsy</td><td>3</td><td>AA</td><td>Metabolism/PK</td><td>Patients with epilepsy and the AA genotype may have decreased concentrations of oxcarbazepine and worse response as compared to patients with the AG and GG genotypes. Other clinical and genetic factors may also influence exposure to and response to oxcarbazepine in patients with epilepsy.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449645378>2806</a></td><td>SULT1A3</td><td>rs767263838</td><td>o-desmethyltramadol</td><td></td><td>3</td><td>TT</td><td>Metabolism/PK</td><td>Patients with the TT genotype may have an increased rate of sulfation of O-desmethyl-tramadol, a metabolite of tramadol, as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect O-desmethyl-tramadol sulfation in patients.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449645378>2807</a></td><td>SULT1A3</td><td>rs767263838</td><td>tramadol</td><td></td><td>3</td><td>TT</td><td>Metabolism/PK</td><td>Patients with the TT genotype may have an increased rate of sulfation of O-desmethyl-tramadol, a metabolite of tramadol, as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also affect O-desmethyl-tramadol sulfation in patients.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449157951>2808</a></td><td>CYP24A1</td><td>rs927650</td><td>deferasirox</td><td>beta-Thalassemia</td><td>3</td><td>CC</td><td>Metabolism/PK</td><td>Patients with the CC genotype and beta-thalassemia may have increased metabolism of deferasirox as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence deferasirox metabolism.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450936741>2809</a></td><td>SRPRB</td><td>rs17376019</td><td>ethanol</td><td></td><td>3</td><td>CT</td><td>Metabolism/PK</td><td>Patients with the CT genotype may have a decreased blood alcohol concentration (BAC) as compared to patients with the CC genotype. Note that this association was not consistently observed over all timepoints studied. Other genetic and clinical factors may also affect BAC.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449005031>2810</a></td><td>CYP3A5</td><td>rs10264272</td><td>lumefantrine</td><td>Malaria</td><td>3</td><td>CC</td><td>Metabolism/PK</td><td>Pregnant patients infected with malaria and the CC genotype may have lower concentrations of lumefantrine as compared to patients with the CT or TT genotypes. There is no association with response. Other clinical and genetic factors may also influence concentrations of lumefantrine in pregnant patients infected with malaria.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184472764>2811</a></td><td>NT5C2</td><td>rs11598702</td><td>gemcitabine</td><td>Neoplasms</td><td>3</td><td>CT</td><td>Metabolism/PK</td><td>Patients with the CT genotype may have increased clearance of gemcitabine as compared to patients with the TT genotype. Other genetic and clinical factors may also affect clearance of gemcitabine. This annotation only covers the pharmacokinetic relationship between rs11598702 and gemcitabine and does not include evidence about clinical outcomes.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183705010>2812</a></td><td>CYP2B6</td><td>rs2279345</td><td>efavirenz</td><td>HIV Infections;Tuberculosis</td><td>3</td><td>CC</td><td>Metabolism/PK</td><td>Patients with the rs2279345 CC genotype and HIV may have increased metabolism of efavirenz resulting in lower efavirenz plasma levels as compared to patients with the TT genotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs2279345 and efavirenz and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism of efavirenz.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444704025>2813</a></td><td>CYP2B6</td><td>rs2279343</td><td>nicotine</td><td>Tobacco Use Disorder</td><td>3</td><td>AG</td><td>Metabolism/PK</td><td>Patients with the AG genotype may have increased metabolism of nicotine as compared to patients with the AA genotype. Other genetic and clinical factors may also affect nicotine metabolism.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444704040>2814</a></td><td>SLCO2B1</td><td>rs2306168</td><td>fexofenadine</td><td></td><td>3</td><td>CC</td><td>Metabolism/PK</td><td>Patients with the CC genotype who are treated with fexofenadine may have increased area under the plasma concentration-time curve as compared to patients with the TT or CT genotype. Other genetic and clinical factors may also influence a patient's metabolism of fexofenadine.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1446899616>2815</a></td><td>CYP3A5</td><td>rs776746</td><td>cyclosporine</td><td>liver transplantation</td><td>3</td><td>CC</td><td>Metabolism/PK</td><td>Patients who are recipients of a liver transplantation from a donor with the CC (CYP3A5 *3/*3) genotype who is also CYP3A4 low or intermediate expressers may have decreased metabolism of cyclosporine resulting in increased exposure, and may require a lower dose as compared to patients who receive a liver transplantation from a donor with the CT or TT (*1/*3 or *1/*1) genotype, regardless of CYP3A4 expresser status. However, this is contradicted in one study. Other genetic and clinical factors, such as recipient genotype, may also influence a patient's cyclosporine dose requirement.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1445401413>2816</a></td><td>UGT1A</td><td>rs11563250</td><td>bilirubin</td><td>Colorectal Neoplasms</td><td>3</td><td>AG</td><td>Metabolism/PK</td><td>Patients with the AG genotype and metastatic colorectal cancer may have reduced concentrations of bilirubin, possibly indicating increased UGT1A1 activity, as compared to patients with the AA genotype. Other genetic and clinical factors, such as rs8175347, may also influence bilirubin concentrations.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1446908002>2817</a></td><td>CYP2B6</td><td>rs4802101</td><td>cyclophosphamide</td><td>Lupus erythematosus</td><td>3</td><td>CC</td><td>Metabolism/PK</td><td>Patients with the CC genotype may have decreased metabolism of cyclophosphamide, resulting in decreased concentrations of active cyclophosphamide metabolites, and decreased risk of gastrointestinal toxicity, or leukopenia, as compared to patients with the CT or TT genotypes. Other clinical and genetic factors may also influence metabolism of cyclophosphamide, as well as risk of toxicity in patients with lupus.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1446905231>2818</a></td><td>CYP2B6</td><td>rs4803419</td><td>efavirenz</td><td>HIV Infections</td><td>3</td><td>CT</td><td>Metabolism/PK</td><td>Patients with HIV and the CT genotype may have higher plasma concentrations of efavirenz as compared to patients with the CC genotype and lower plasma concentrations as compared to patients with the TT genotype. However, other studies have failed to find this association. Other clinical and genetic factors may also influence plasma concentrations of efavirenz in patients with HIV. This annotation only covers the pharmacokinetic relationship between rs4803419 and efavirenz and does not include evidence about clinical outcomes.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444666543>2819</a></td><td>-</td><td>rs887829</td><td>deferasirox</td><td>beta-Thalassemia</td><td>3</td><td>CT</td><td>Metabolism/PK</td><td>Patients with the CT genotype and beta-thalassemia may have decreased concentrations of deferasirox as compared to patients with the TT genotype. Other genetic and clinical factors may also influence concentrations of deferasirox.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444686868>2820</a></td><td>KDR</td><td>rs34231037</td><td>pazopanib</td><td>Kidney Neoplasms</td><td>3</td><td>AA</td><td>Metabolism/PK</td><td>Patients with the AA genotype and Kidney Neoplasms may have increased steady state levels of KDR, possibly leading to increased metabolism of and decreased response to pazopanib as compared to patients with the AG or GG genotypes. Other clinical and genetic factors may also influence metabolism and response to pazopanib.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444686880>2821</a></td><td>UGT1A9</td><td>rs2741049</td><td>SN-38</td><td></td><td>3</td><td>CT</td><td>Metabolism/PK</td><td>In human liver microsomes, the CT genotype was associated with increased glucuronidation of SN-38, as compared to the CC genotype. SN-38 is the active metabolite of irinotecan. Other genetic and clinical factors, such as the UGT1A1*28 allele, may also influence glucuronidation of SN-38.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444667758>2822</a></td><td>IL18</td><td>rs1946518</td><td>tacrolimus</td><td>Kidney Transplantation;lung transplantation</td><td>3</td><td>GT</td><td>Metabolism/PK</td><td>Patients with the GT genotype and kidney or lung transplantation may experience decreased metabolism of tacrolimus resulting in increased exposure as compared to patients with the TT genotype. Other genetic and clinical factors may also influence the metabolism of tacrolimus.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447943713>2823</a></td><td>ABCB1</td><td>rs1045642</td><td>silibinin</td><td></td><td>3</td><td>AA</td><td>Metabolism/PK</td><td>People with genotype AA may have decreased exposure to silibinin compared to people with genotypes AG or GG. Other clinical and genetic factors may affect a person's exposure to silibinin.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444686907>2824</a></td><td>CYP3A4</td><td>rs4646437</td><td>cyclosporine</td><td>Kidney Transplantation</td><td>3</td><td>GG</td><td>Metabolism/PK</td><td>Patients with the GG genotype who are undergoing kidney transplantation may have higher dose-adjusted trough concentrations of cyclosporine, and have a lower likelihood of experiencing biopsy-proven acute rejection, as compared to patients with the AA genotype. Other genetic and clinical factors may also influence concentrations of and response to cyclosporine.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444686914>2825</a></td><td>NR1I2</td><td>rs2276707</td><td>tacrolimus</td><td>Kidney Transplantation</td><td>3</td><td>CT</td><td>Metabolism/PK</td><td>Patients with the CT genotype who are undergoing kidney transplantation may have decreased dose-adjusted trough concentrations of tacrolimus as compared to patients with the CC genotype. Other genetic and clinical factors may also influence concentrations of tacrolimus.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1445401274>2826</a></td><td>UGT2B7</td><td>rs7438135</td><td>morphine</td><td></td><td>3</td><td>AG</td><td>Metabolism/PK</td><td>Patients with the AG genotype may have lower levels of morphine as compared to patients with the GG genotype. However, another study found no association with allele and the pharmacokinetics measures AUC, clearance, Cmax, and volume of distribution in healthy controls. Other genetic and clinical factors may also influence morphine concentrations.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448573506>2827</a></td><td>CYP2B6</td><td>rs3745274</td><td>3,4-methylenedioxymethamphetamine</td><td></td><td>3</td><td>GT</td><td>Metabolism/PK</td><td>Patients with the GT genotype may have deceased concentrations of 3,4-methylenedioxymethamphetamine compared to patients with the TT genotype. Other clinical and genetic factors may affect concentrations of 3,4-methylenedioxymethamphetamine.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1445585156>2828</a></td><td>ABCB1</td><td>rs1045642</td><td>daptomycin</td><td></td><td>3</td><td>AA</td><td>Metabolism/PK</td><td>Patients with the AA genotype may decreased clearance of daptomycin, resulting in increased concentrations of the drug, as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence clearance of daptomycin.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444607737>2829</a></td><td>ADH1B</td><td>rs1229984</td><td>ethanol</td><td></td><td>3</td><td>CC</td><td>Metabolism/PK</td><td>Patients with the CC genotype may have a lower maximal rate (Vmax) of ethanol as compared to patients with the TT genotype. Other genetic and clinical factors may also influence Vmax of ethanol.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444607697>2830</a></td><td>ABCC2</td><td>rs12762549</td><td>docetaxel</td><td></td><td>3</td><td>CG</td><td>Metabolism/PK</td><td>Patients with the CG genotype who are treated with docetaxel may have a decreased clearance and increased risk of leukopenia as compared to patients with the CC genotype. However the association for clearance of docetaxel was not significant and no association was found with risk for neutropenia. Other genetic and clinical factors may also influence a patient's response to docetaxel.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1185000534>2831</a></td><td>NR1I2</td><td>rs2472677</td><td>atazanavir</td><td>Acquired Immunodeficiency Syndrome;HIV Infections;nephrolithiasis</td><td>3</td><td>TT</td><td>Metabolism/PK</td><td>Patients with the TT genotype and HIV may have decreased exposure to atazanavir as compared to patients with the CT and TT genotypes, although this is contradicted in some studies. Other clinical and genetic factors may also influence exposure to atazanavir in patients with HIV.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1185235008>2832</a></td><td>CYP2B6</td><td>rs35303484</td><td>efavirenz</td><td>HIV Infections</td><td>3</td><td>AA</td><td>Metabolism/PK</td><td>Patients with the AA genotype and HIV who are treated with efavirenz may have decreased efavirenz plasma concentrations as compared to patients with the GG genotype. Evidence is conflicting as to this association.Other genetic and clinical factors may also influence a patient's metabolism of efavirenz. Evidence is conflicting as to this association.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1446903556>2833</a></td><td>CYP2A6</td><td>rs56113850</td><td>nicotine</td><td>Tobacco Use Disorder</td><td>3</td><td>CT</td><td>Metabolism/PK</td><td>Individuals who smoke and have the CT genotype may have increased rates of nicotine clearance, and as a consequence may smoke more when compared to individuals who smoke with the TT genotypes. Other clinical and genetic factors may also influence nicotine clearance rates in smokers.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1445401915>2834</a></td><td>ABCB1</td><td>rs1045642</td><td>carbamazepine</td><td>Epilepsy</td><td>4</td><td>AA</td><td>Metabolism/PK</td><td>Patients with the AA genotype and epilepsy may need a decreased dose carbamazepine as compared to patients with the AG genotype. However, multiple studies have shown no association with dose or concentrations of carbamazepine. Other genetic and clinical factors may also influence dose requirements and concentrations of carbamazepine.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444668298>2835</a></td><td>AMHR2</td><td>rs784892</td><td>metformin</td><td>Diabetes Mellitus</td><td>3</td><td>GG</td><td>Metabolism/PK</td><td>In healthy volunteers the GG genotype may be associated with decreased secretory clearance of metformin, and in patients with diabetes mellitus may result in an increase efficacy (decreased HbA1c levels) as compared to patients with the AG or AA genotypes. Other clinical and genetic factors may also influence metformin clearance and efficacy in patients with diabetes mellitus.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444668306>2836</a></td><td>PPARA</td><td>rs149711321</td><td>metformin</td><td>Diabetes Mellitus</td><td>3</td><td>TT</td><td>Metabolism/PK</td><td>In healthy volunteers as well as patients with diabetes mellitus the TT genotype may be associated with a decreased secretory clearance of metformin, leading to increased exposure and a corresponding decrease in HbA1c levels, which is indicative of improved metformin efficacy, as compared to patients with the CC genotype. Other clinical and genetic factors may also influence metformin clearance and efficacy in patients with diabetes mellitus.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444672993>2837</a></td><td>ABCB1</td><td>rs1128503</td><td>tacrolimus</td><td>Transplantation</td><td>4</td><td>AG</td><td>Metabolism/PK</td><td>Patients with the AG genotype who are undergoing organ transplantation may have increased concentrations of tacrolimus as compared to patients with the GG genotype. However, the majority of the literature evidence shows no association between this variant and tacrolimus concentrations, clearance or dose. Other genetic and clinical factors may also influence concentrations of tacrolimus.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1445401880>2838</a></td><td>CYP3A5</td><td>rs776746</td><td>carbamazepine</td><td>Epilepsy</td><td>3</td><td>CC</td><td>Metabolism/PK</td><td>Patients with the CC genotype (CYP3A5 *3/*3) and epilepsy may have decreased clearance and increased concentrations of carbamazepine, and require lower doses of the drug, as compared to patients with the CT (*1/*3) or TT (*1/*1) genotype. Other genetic and clinical factors may also influence dose or concentrations of carbamazepine.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451678112>2839</a></td><td>SLCO1B1</td><td>rs4149056</td><td>lovastatin</td><td></td><td>1A</td><td>CT</td><td>Metabolism/PK</td><td>Patients with the rs4149056 CT genotype may have increased concentration of lovastatin acid as compared to patients with the TT genotype. Other genetic and clinical factors may also influence the metabolism of lovastatin. This annotation only covers the pharmacokinetic relationship between rs4149056 and lovastatin acid or lovastatin and does not include evidence about clinical outcomes.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451678112>2840</a></td><td>SLCO1B1</td><td>rs4149056</td><td>lovastatin acid</td><td></td><td>1A</td><td>CT</td><td>Metabolism/PK</td><td>Patients with the rs4149056 CT genotype may have increased concentration of lovastatin acid as compared to patients with the TT genotype. Other genetic and clinical factors may also influence the metabolism of lovastatin. This annotation only covers the pharmacokinetic relationship between rs4149056 and lovastatin acid or lovastatin and does not include evidence about clinical outcomes.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451678210>2841</a></td><td>SLCO1B1</td><td>rs4149056</td><td>pitavastatin</td><td></td><td>1A</td><td>CT</td><td>Metabolism/PK</td><td>Patients with the rs4149056 CT genotype may have increased concentrations of pitavastatin when treated with pitavastatin as compared to patients with TT genotype. Other genetic and clinical factors may also influence the metabolism of pitavastatin. This annotation only covers the pharmacokinetic relationship between rs4149056 and pitavastatin and does not include evidence about clinical outcomes.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449166396>2842</a></td><td>ABCB1</td><td>rs1045642</td><td>omeprazole</td><td>Gastroesophageal Reflux</td><td>3</td><td>AA</td><td>Metabolism/PK</td><td>Patients with the AA genotype and gastroesophageal reflux may have increased absorption rate and response to omeprazole compared to patients with the AG and GG genotypes. Other clinical and genetic factors may also influence absorption rate and response to omeprazole in patients.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448604251>2843</a></td><td>ABCB1</td><td>rs2032582</td><td>methadone</td><td>Opioid-Related Disorders</td><td>3</td><td>AC</td><td>Metabolism/PK</td><td>Patients with the rs2032582 AC genotype may have increased clearance of methadone compared to patients with the CC genotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs2032582 and methadone and does not include evidence about clinical outcomes. Other clinical and genetic factors may affect methadone clearance.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447987005>2844</a></td><td>NR1I3</td><td>rs2307424</td><td>efavirenz</td><td>HIV Infections</td><td>3</td><td>AG</td><td>Metabolism/PK</td><td>Patients with the AG genotype and HIV who do not have the rs3745274 TT genotype may have increased concentrations of efavirenz as compared to patients with the AA genotype. Other genetic and clinical factors, such as rs3745274, may also influence metabolism of efavirenz.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447987030>2845</a></td><td>NR1I3</td><td>rs3003596</td><td>efavirenz</td><td>HIV Infections</td><td>3</td><td>AG</td><td>Metabolism/PK</td><td>Patients with the AG genotype and HIV may have decreased concentrations of efavirenz as compared to patients with the AA genotype. Other genetic and clinical factors, such as rs3745274, may also influence concentrations of efavirenz.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447987052>2846</a></td><td>NR1I2</td><td>rs2461817</td><td>carbamazepine</td><td>Epilepsy</td><td>3</td><td>CC</td><td>Metabolism/PK</td><td>Patients with the CC genotype and epilepsy may have increased metabolism of carbamazepine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence metabolism of carbamazepine.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447987066>2847</a></td><td>UGT2B7</td><td>rs28365063</td><td>carbamazepine</td><td>Epilepsy</td><td>3</td><td>AG</td><td>Metabolism/PK</td><td>Patients with the AG genotype and epilepsy may have increased clearance of carbamazepine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence clearance of carbamazepine.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447987073>2848</a></td><td>CYP2A6</td><td>rs4803381</td><td>nicotine</td><td></td><td>3</td><td>CT</td><td>Metabolism/PK</td><td>Patients with the CT genotype may metabolize nicotine more rapidly as compared to patients with the TT genotype. Other clinical and genetic factors may also influence the metabolism of nicotine.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447987101>2849</a></td><td>CYP3A4</td><td>rs2740574</td><td>carbamazepine</td><td>Epilepsy</td><td>3</td><td>TT</td><td>Metabolism/PK</td><td>Patients with the TT genotype and epilepsy may have increased clearance of carbamazepine as compared to patients with the CC or CT genotype. Other genetic and clinical factors may also influence clearance of carbamazepine.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447987094>2850</a></td><td>ABCB1</td><td>rs1128503</td><td>carbamazepine</td><td>Epilepsy</td><td>4</td><td>AG</td><td>Metabolism/PK</td><td>African American and white patients with the AG genotype and epilepsy may have increased clearance of carbamazepine as compared to patients with the GG genotype. This association was not found in Chinese patients. Other genetic and clinical factors may also influence clearance of carbamazepine.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449576551>2851</a></td><td>UGT1A3</td><td>rs7604115</td><td>montelukast</td><td>Asthma</td><td>3</td><td>CT</td><td>Metabolism/PK</td><td>Patients with the CT genotype may have decreased plasma concentrations of montelukast as compared to patients with the CC genotype. Other genetic and clinical factors may also influence the metabolism of montelukast.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447960874>2852</a></td><td>ABCB1</td><td>rs1128503</td><td>tipifarnib</td><td>Neoplasms</td><td>3</td><td>AG</td><td>Metabolism/PK</td><td>Patients with the AG genotype and cancer may have decreased exposure to tipifarnib as compared to patients with the AA genotype. Other genetic and clinical factors may also influence exposure to tipifarnib.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447962874>2853</a></td><td>CYP2C19</td><td>rs4244285</td><td>nelfinavir</td><td>HIV Infections;Pancreatic Neoplasms</td><td>3</td><td>AA</td><td>Metabolism/PK</td><td>Patients with the AA genotype and pancreatic cancer or HIV may have decreased metabolism and increased concentrations of nelfinavir as compared to patients with the GG genotype. Other genetic and clinical factors may also influence metabolism and concentration of nelfinavir.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448101408>2854</a></td><td>UGT1A3</td><td>rs3806596</td><td>deferasirox</td><td>beta-Thalassemia</td><td>3</td><td>CT</td><td>Metabolism/PK</td><td>Patients with the CT genotype and beta-thalassemia may have worse response to, and decreased concentrations of deferasirox and increased risk of iron overload as compared to patients with the CC genotype. Other clinical and genetic factors may also influence concentrations of and response to deferasirox in patients with beta-thalassemia.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447962661>2855</a></td><td>UGT1A9</td><td>rs72551344</td><td>SN-38</td><td></td><td>3</td><td>TT</td><td>Metabolism/PK</td><td>Cells with the TT genotype may have increased enzymatic activity toward SN-38 as compared to cells with the GG genotype. Other genetic and clinical factors may also influence enzymatic activity toward SN-38.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451511344>2856</a></td><td>SLC19A1</td><td>rs1051296</td><td>methotrexate</td><td>Precursor Cell Lymphoblastic Leukemia-Lymphoma</td><td>3</td><td>AC</td><td>Metabolism/PK</td><td>Patients with acute lymphoblastic leukemia and the rs1051296 AC genotype may have decreased concentrations of methotrexate as compared to patients with the AA genotype. This annotation only covers the pharmacokinetic relationship between rs1051296 and methotrexate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence methotrexate concentrations.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447986925>2857</a></td><td>CHRNB4</td><td>rs10851907</td><td>cotinine</td><td>Tobacco Use Disorder</td><td>3</td><td>GG</td><td>Metabolism/PK</td><td>Individuals with Tobacco Use Disorder and the GG genotype may have decreased concentrations of cotinine, a metabolite of nicotine, as compared to individuals with the AG or AA genotype. Other clinical and genetic factors may also contribute to cotinine concentrations in individuals with Tobacco Use Disorder.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447946169>2858</a></td><td>CYP3A4</td><td>rs4646437</td><td>voriconazole</td><td>Mycoses</td><td>3</td><td>GG</td><td>Metabolism/PK</td><td>Patients with the GG genotype who have invasive fungal infections may have decreased concentrations of voriconazole, as compared to patients with the AG genotype. Other genetic and clinical factors, such as variants in the CYP2C19 gene, may also influence plasma concentrations of voriconazole.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448266429>2859</a></td><td>NR1I2</td><td>rs2276707</td><td>risperidone</td><td>Bipolar Disorder;Depression;Substance-Related Disorders</td><td>3</td><td>CT</td><td>Metabolism/PK</td><td>Patients with the CT genotype and psychiatric disorders may have increased clearance of risperidone compared to patients with the CC genotypes. Other clinical and genetic factors may affect clearance of risperidone.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448099125>2860</a></td><td>SLCO1B1</td><td>rs2306283</td><td>rifampin</td><td></td><td>3</td><td>AG</td><td>Metabolism/PK</td><td>Patients with the AG genotype may have increased clearance of rifampin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence rifampin clearance.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448098947>2861</a></td><td>ABCC2</td><td>rs4148386</td><td>carbamazepine</td><td>Epilepsy</td><td>3</td><td>AG</td><td>Metabolism/PK</td><td>Patients with the AG genotype and epilepsy may have increased clearance of carbamazepine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence carbamazepine clearance.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448531674>2862</a></td><td>ABCC1</td><td>rs35621</td><td>SN-38</td><td>Colorectal Neoplasms</td><td>3</td><td>CC</td><td>Metabolism/PK</td><td>Patients with the CC genotype and colorectal neoplasms may have decreased exposure to SN-38 compared to patients with the CT and TT genotypes. Other clinical and genetic factors may affect exposure to SN-38.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448100567>2863</a></td><td>ABCC2</td><td>rs3740066</td><td>mycophenolic acid</td><td>Organ Transplantation</td><td>3</td><td>CT</td><td>Metabolism/PK</td><td>Patients with the CT genotype and organ transplantation may have decreased concentrations of mycophenolic acid compared to patients with CC and TT genotypes. However, other studies do not find an association. Other factors may affect the concentration of mycophenolic acid after organ transplantation.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448100942>2864</a></td><td>ABCB1</td><td>rs4148738</td><td>Dabigatran</td><td>Atrial Fibrillation</td><td>3</td><td>CT</td><td>Metabolism/PK</td><td>Patients with genotype CT and atrial fibrillation may have decreased trough plasma concentrations of dabigatran compared to patients with the CC genotype. Other factors may affect dabigatran plasma concentrations.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448617757>2865</a></td><td>CYP3A</td><td>rs2740574</td><td>atazanavir</td><td></td><td>3</td><td>TT</td><td>Metabolism/PK</td><td>Patients with the TT genotype may have increased clearance of atazanavir as compared to patients with the CT or CC genotypes. Other clinical and genetic factors may also influence clearance of atazanavir.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448617757>2866</a></td><td>CYP3A4</td><td>rs2740574</td><td>atazanavir</td><td></td><td>3</td><td>TT</td><td>Metabolism/PK</td><td>Patients with the TT genotype may have increased clearance of atazanavir as compared to patients with the CT or CC genotypes. Other clinical and genetic factors may also influence clearance of atazanavir.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448615147>2867</a></td><td>ABCB1</td><td>rs2032582</td><td>anastrozole</td><td>Breast Neoplasms</td><td>3</td><td>AC</td><td>Metabolism/PK</td><td>Postmenopausal women with HR+ breast cancer and the AC genotype may have decreased plasma concentrations of anastrozole as compared to women with the AA genotype. Other clinical and genetic factors may also affect plasma concentrations of anastrozole in postmenopausal women with HR+ breast cancer.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448567993>2868</a></td><td>IL10</td><td>rs1800896</td><td>sirolimus</td><td>Kidney Transplantation</td><td>3</td><td>TT</td><td>Metabolism/PK</td><td>Patients with the TT genotype who underwent kidney transplantation may have decreased dose-adjusted trough concentrations of sirolimus as compared to patients with the CC genotype. Other genetic and clinical factors may also influence sirolimus dose-adjusted trough concentrations.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449140069>2869</a></td><td>NR1I2</td><td>rs6785049</td><td>sirolimus</td><td>gastrointestinal toxicity;Myelosuppression;Urinary Bladder Neoplasms</td><td>3</td><td>AG</td><td>Metabolism/PK</td><td>Patients with the AG genotype and bladder cancer who are treated with temsirolimus may have decreased exposure to temsirolimus or sirolimus as compared to patients with the GG genotype, and decreased likelihood of bone marrow and gastrointestinal toxicities, or other adverse events as compared to patients with the AA genotypes. Other clinical and genetic factors may also influence metabolism of and likelihood of adverse events with temsirolimus or sirolimus in patients with bladder cancer.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449140069>2870</a></td><td>NR1I2</td><td>rs6785049</td><td>temsirolimus</td><td>gastrointestinal toxicity;Myelosuppression;Urinary Bladder Neoplasms</td><td>3</td><td>AG</td><td>Metabolism/PK</td><td>Patients with the AG genotype and bladder cancer who are treated with temsirolimus may have decreased exposure to temsirolimus or sirolimus as compared to patients with the GG genotype, and decreased likelihood of bone marrow and gastrointestinal toxicities, or other adverse events as compared to patients with the AA genotypes. Other clinical and genetic factors may also influence metabolism of and likelihood of adverse events with temsirolimus or sirolimus in patients with bladder cancer.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450936735>2871</a></td><td>ADH1B</td><td>rs1229984</td><td>acetaldehyde</td><td></td><td>3</td><td>CC</td><td>Metabolism/PK</td><td>Patients with the CC genotype may have decreased blood concentrations of acetaldehyde, a metabolite of ethanol, as compared to patients with the CT genotype. Note that this association was not seen at all timepoints studied. Other genetic and clinical factors may also affect blood concentrations of acetaldehyde.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451674308>2872</a></td><td>CYP2A6</td><td>rs145157460</td><td>nicotine</td><td></td><td>3</td><td>GG</td><td>Metabolism/PK</td><td>Patients with the rs145157460 GG genotype may have increased metabolism of nicotine as compared to patients with the GT or TT genotypes. This annotation only covers the pharmacokinetic relationship between rs145157460 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450959466>2873</a></td><td>PAH</td><td>rs76394784</td><td>carbocisteine</td><td></td><td>3</td><td>TT</td><td>Metabolism/PK</td><td>Patients with the TT genotype may have increased metabolism of carbocisteine as compared to patients with the AA or AT genotypes. Other genetic and clinical factors may also affect metabolism of carbocisteine.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451674360>2874</a></td><td>CYP2A6</td><td>rs1303839356</td><td>nicotine</td><td></td><td>3</td><td>CC</td><td>Metabolism/PK</td><td>Patients with the rs1303839356 CC genotype may have increased metabolism of nicotine as compared to patients with the CT or TT genotypes. This annotation only covers the pharmacokinetic relationship between rs1303839356 and nicotine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence nicotine metabolism.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451100100>2875</a></td><td>CYP3A</td><td>rs2740574</td><td>fentanyl</td><td></td><td>3</td><td>TT</td><td>Metabolism/PK</td><td>Patients with the rs2740574 TT genotype may have increased clearance of fentanyl as compared to patients with the rs2740574 CT genotype (CYP3A4*1B allele). This annotation only covers the pharmacokinetic relationship between rs2740574 and fentanyl and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect clearance of fentanyl in a patient.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451100100>2876</a></td><td>CYP3A4</td><td>rs2740574</td><td>fentanyl</td><td></td><td>3</td><td>TT</td><td>Metabolism/PK</td><td>Patients with the rs2740574 TT genotype may have increased clearance of fentanyl as compared to patients with the rs2740574 CT genotype (CYP3A4*1B allele). This annotation only covers the pharmacokinetic relationship between rs2740574 and fentanyl and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect clearance of fentanyl in a patient.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451116100>2877</a></td><td>SLCO1B1</td><td>rs4149056</td><td>amprenavir</td><td>HIV Infections</td><td>3</td><td>CT</td><td>Metabolism/PK</td><td>Patients with HIV infections and the CT genotype may have decreased trough concentrations of amprenavir as compared to patients with the TT genotype. Note that this association was only found in patients of European descent, and not in African American or Hispanic patients. Other genetic and clinical factors may also affect concentrations of amprenavir in patients.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449188755>2878</a></td><td>OPRM1</td><td>rs2075572</td><td>cotinine</td><td></td><td>3</td><td>CC</td><td>Metabolism/PK</td><td>Patients with the CC genotype and receiving methadone maintenance therapy may have decreased plasma concentrations of cotinine, a metabolite of nicotine, as compared to patients with the CG or GG genotypes. Other genetic and clinical factors may also affect plasma concentrations of cotinine in patients receiving methadone maintenance therapy.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449188755>2879</a></td><td>OPRM1</td><td>rs2075572</td><td>nicotine</td><td></td><td>3</td><td>CC</td><td>Metabolism/PK</td><td>Patients with the CC genotype and receiving methadone maintenance therapy may have decreased plasma concentrations of cotinine, a metabolite of nicotine, as compared to patients with the CG or GG genotypes. Other genetic and clinical factors may also affect plasma concentrations of cotinine in patients receiving methadone maintenance therapy.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449266588>2880</a></td><td>ABCB1</td><td>rs1045642</td><td>methadone</td><td>Opioid-Related Disorders</td><td>3</td><td>AA</td><td>Metabolism/PK</td><td>Patients with the rs1045642 AA genotype who are receiving methadone maintenance therapy may have increased clearance of methadone, leading to decreased plasma concentration of methadone as compared to patients with the AG and GG genotypes. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect methadone clearance and plasma concentrations. This annotation only covers the pharmacokinetic relationship between rs1045642 and methadone and does not include evidence about clinical outcomes.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450959506>2881</a></td><td>PAH</td><td>rs5030858</td><td>l-phenylalanine</td><td></td><td>3</td><td>GG</td><td>Metabolism/PK</td><td>Patients with the GG genotype may have increased metabolism of phenylalanine as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect metabolism of phenylalanine.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450959524>2882</a></td><td>PAH</td><td>rs5030858</td><td>carbocisteine</td><td></td><td>3</td><td>GG</td><td>Metabolism/PK</td><td>Patients with the GG genotype may have increased metabolism of carbocisteine as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect metabolism of carbocisteine.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450959560>2883</a></td><td>PAH</td><td>rs76394784</td><td>l-phenylalanine</td><td></td><td>3</td><td>TT</td><td>Metabolism/PK</td><td>Patients with the TT genotype may have increased metabolism of phenylalanine as compared to patients with the AA or AT genotypes. Other genetic and clinical factors may also affect metabolism of phenylalanine.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451101225>2884</a></td><td>-</td><td>rs72732317</td><td>o-desmethyltramadol</td><td></td><td>3</td><td>GG</td><td>Metabolism/PK</td><td>Patients with the GG genotype may have increased conversion of tramadol to O-desmethyltramadol (M1) as compared to patients with the GT or TT genotypes. Other genetic and clinical factors may also affect tramadol metabolism in a patient.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451101225>2885</a></td><td>-</td><td>rs72732317</td><td>tramadol</td><td></td><td>3</td><td>GG</td><td>Metabolism/PK</td><td>Patients with the GG genotype may have increased conversion of tramadol to O-desmethyltramadol (M1) as compared to patients with the GT or TT genotypes. Other genetic and clinical factors may also affect tramadol metabolism in a patient.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451101400>2886</a></td><td>PGM1</td><td>rs4643</td><td>acetaldehyde</td><td></td><td>3</td><td>AC</td><td>Metabolism/PK</td><td>Patients with the AC genotype may have increased blood alcohol concentrations (BAC) and decreased concentrations. of acetaldehyde, a metabolite of ethanol, as compared to patients with the CC genotype. Other genetic and clinical factors may also affect ethanol metabolism.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451124500>2887</a></td><td>UGT2B7</td><td>rs7439366</td><td>morphine</td><td></td><td>3</td><td>CT</td><td>Metabolism/PK</td><td>Patients with the CT genotype may have decreased plasma concentrations of morphine as compared to patients with the CC genotype. However, one study has failed to find this association and another has reported this opposite association. Other genetic and clinical factors may also affect plasma concentrations of morphine in a patient.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451129680>2888</a></td><td>CYP2B6</td><td>rs3211371</td><td>efavirenz</td><td></td><td>4</td><td>CT</td><td>Metabolism/PK</td><td>Patients with the CT genotype may have decreased exposure to efavirenz as compared to patients with the CC genotype. However, the majority of studies have failed to find this association. Other genetic and clinical factors may also affect a patient's exposure to efavirenz.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451138560>2889</a></td><td>OPRD1</td><td>rs204047</td><td>methadone</td><td></td><td>3</td><td>GT</td><td>Metabolism/PK</td><td>Patients with the GT genotype may have decreased plasma concentrations of methadone when undergoing methadone maintenance treatment (MMT) as compared to patients with the GG genotype. Other genetic and clinical factors may also affect plasma concentrations of methadone in patients receiving MMT.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451148780>2890</a></td><td>CYP2C9</td><td>rs780801862</td><td>naproxen</td><td></td><td>3</td><td>AA</td><td>Metabolism/PK</td><td>Patients with the AA genotype may have increased metabolism of naproxen as compared to patients with the AT or TT genotypes. This drug-variant pair has been assigned a no recommendation by CPIC, as it was determined to be not clinically actionable. Other genetic and clinical factors may also affect naproxen metabolism. This annotation only covers the pharmacokinetic relationship between rs780801862 and naproxen and does not include evidence about clinical outcomes.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451148820>2891</a></td><td>CYP2C9</td><td>rs780801862</td><td>phenytoin</td><td></td><td>3</td><td>AA</td><td>Metabolism/PK</td><td>Patients with the AA genotype may have increased metabolism of phenytoin as compared to patients with the AT or TT genotypes. Other genetic and clinical factors may also affect phenytoin metabolism. This annotation only covers the pharmacokinetic relationship between rs780801862 and phenytoin and does not include evidence about clinical outcomes.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451148840>2892</a></td><td>CYP2C9</td><td>rs780801862</td><td>warfarin</td><td></td><td>3</td><td>AA</td><td>Metabolism/PK</td><td>Patients with the AA genotype may have increased metabolism of warfarin as compared to patients with the AT or TT genotypes. Other genetic and clinical factors may also affect warfarin metabolism. This annotation only covers the pharmacokinetic relationship between rs780801862 and warfarin and does not include evidence about clinical outcomes.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451148762>2893</a></td><td>CYP2C9</td><td>rs780801862</td><td>flurbiprofen</td><td></td><td>3</td><td>AA</td><td>Metabolism/PK</td><td>Patients with the rs780801862 AA genotype may have increased metabolism of flurbiprofen as compared to patients with the AT or TT genotypes. Other genetic and clinical factors may also affect flurbiprofen metabolism. This annotation only covers the pharmacokinetic relationship between rs780801862 and flurbiprofen and does not include evidence about clinical outcomes.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451207020>2894</a></td><td>ABCB1</td><td>rs1128503</td><td>morphine</td><td></td><td>3</td><td>AG</td><td>Metabolism/PK</td><td>Patients with the AG genotype may have decreased concentrations of morphine as compared to patients with the AA genotype. However, one study failed to find this association. Other genetic and clinical factors may also affect morphine concentrations in a patient.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451552587>2895</a></td><td>CYP2A7P1</td><td>rs3745274</td><td>tramadol</td><td></td><td>3</td><td>GT</td><td>Metabolism/PK</td><td>Patients with the rs3745274 GT genotype may have a decreased exposure to tramadol as compared to patients with the TT genotype. This annotation only covers the pharmacokinetic relationship between rs3745274 and tramadol and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence exposure to tramadol.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451552587>2896</a></td><td>CYP2B6</td><td>rs3745274</td><td>tramadol</td><td></td><td>3</td><td>GT</td><td>Metabolism/PK</td><td>Patients with the rs3745274 GT genotype may have a decreased exposure to tramadol as compared to patients with the TT genotype. This annotation only covers the pharmacokinetic relationship between rs3745274 and tramadol and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence exposure to tramadol.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451356380>2897</a></td><td>NECTIN4</td><td>rs11265549</td><td>methadone</td><td>Opioid-Related Disorders</td><td>3</td><td>GG</td><td>Dosage</td><td>Patients with opioid dependence and the rs11265549 GG genotype may require increased doses of methadone when receiving methadone maintenance therapy (MMT) as compared to patients with the AA genotype. Other genetic and clinical factors may also influence methadone dosage requirements.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/981237878>2898</a></td><td>UGT1A6</td><td>rs1105879</td><td>valproic acid</td><td>Epilepsy</td><td>3</td><td>AC</td><td>Dosage</td><td>Patients with the AC genotype and Epilepsy who are treated with valproic acid may require an increased dose as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to valproic acid.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451354647>2899</a></td><td>OPRL1</td><td>rs2229205</td><td>methadone</td><td>Heroin Dependence</td><td>3</td><td>CT</td><td>Dosage</td><td>Patients with heroin dependence and the rs2229205 CT genotype may require increased doses of methadone as compared to patients with the CC genotype. Other genetic and clinical factors may also influence methadone dosage requirements.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451354700>2900</a></td><td>CYP2B6</td><td>rs16974799</td><td>methadone</td><td>Heroin Dependence</td><td>3</td><td>CT</td><td>Dosage</td><td>Patients with heroin dependence and the rs16974799 CT genotype may require increased doses of methadone as compared to patients with the CC genotype. Other genetic and clinical factors may also influence methadone dosage requirements.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451354560>2901</a></td><td>CNR1</td><td>rs806368</td><td>methadone</td><td>Heroin Dependence</td><td>3</td><td>CT</td><td>Dosage</td><td>Patients with heroin dependence and the rs806368 CT genotype may require increased doses of methadone as compared to patients with the CC genotype. Other genetic and clinical factors may also influence methadone dosage requirements.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/981238092>2902</a></td><td>ABCB1</td><td>rs2032582</td><td>antiepileptics</td><td>Epilepsy</td><td>3</td><td>AC</td><td>Dosage</td><td>Patients with genotype AC may have increased likelihood of drug resistance when treated with antiepileptics and carbamazepine in people with Epilepsy as compared to patients with genotype CC. However, contradictory findings have been reported. Genotype AC is not associated with dose of carbamazepine. Other genetic and clinical factors may also influence a patient's response to carbamazepine.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/981238092>2903</a></td><td>ABCB1</td><td>rs2032582</td><td>carbamazepine</td><td>Epilepsy</td><td>3</td><td>AC</td><td>Dosage</td><td>Patients with genotype AC may have increased likelihood of drug resistance when treated with antiepileptics and carbamazepine in people with Epilepsy as compared to patients with genotype CC. However, contradictory findings have been reported. Genotype AC is not associated with dose of carbamazepine. Other genetic and clinical factors may also influence a patient's response to carbamazepine.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449575745>2904</a></td><td>ABCB1</td><td>rs1045642</td><td>warfarin</td><td></td><td>4</td><td>AA</td><td>Dosage</td><td>Patients with the AA genotype may require an increased dose of warfarin as compared to patients with the AG or GG genotypes, although this is contradicted in one study which found the opposite (the GG genotype was associated with a higher dose as compared to the AA or AG genotypes), as well as two studies which found no association. Other clinical and genetic factors may also influence warfarin dose.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1043880402>2905</a></td><td>VKORC1</td><td>rs61162043</td><td>warfarin</td><td></td><td>3</td><td>AG</td><td>Dosage</td><td>Patients with the AG genotype may require increased dose of warfarin as compared to patients with the AA genotype. Other clinical or genetic factors may also influence warfarin dose.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/982031767>2906</a></td><td>CYP1A2</td><td>rs762551</td><td>paroxetine</td><td>Depressive Disorder, Major</td><td>3</td><td>AC</td><td>Dosage</td><td>Patients with AT genotype may require an increased dose of paroxetine and may have an increased risk of fatigue when treated with paroxetine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence patient's response to paroxetine.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/982032442>2907</a></td><td>NTRK2</td><td>rs4358872</td><td>methadone</td><td>Heroin Dependence;Opioid-Related Disorders</td><td>3</td><td>TT</td><td>Dosage</td><td>Patients with the TT genotype and heroin addiction may require a higher dose of methadone when undergoing methadone maintenance treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence methadone dose required for effective treatment.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/982032672>2908</a></td><td>NGF</td><td>rs2239622</td><td>methadone</td><td>Heroin Dependence;Opioid-Related Disorders</td><td>3</td><td>GG</td><td>Dosage</td><td>Patients with the GG genotype and heroin addiction may require a higher dose of methadone when undergoing methadone maintenance treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence methadone dose required for effective treatment.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/982032306>2909</a></td><td>BDNF</td><td>rs1491850</td><td>methadone</td><td>Heroin Dependence;Opioid-Related Disorders</td><td>3</td><td>CT</td><td>Dosage</td><td>Patients with the CT genotype and heroin addiction may require a higher dose of methadone when undergoing methadone maintenance treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence methadone dose required for effective treatment.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/982035703>2910</a></td><td>VKORC1</td><td>rs2884737</td><td>warfarin</td><td></td><td>2A</td><td>AC</td><td>Dosage</td><td>Patients with the rs2884737 AC genotype may require higher dose of warfarin as compared to patients with the CC genotype. Other clinical and genetic factors may also influence warfarin dosage requirements.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451404219>2911</a></td><td>IAPP</td><td>rs11045995</td><td>rocuronium</td><td></td><td>3</td><td>TT</td><td>Dosage</td><td>Patients with the rs11045995 TT genotype may require increased doses of rocuronium as compared to patients with the CC genotype. Other genetic and clinical factors may also influence rocuronium dosage requirements.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451404219>2912</a></td><td>SLCO1A2</td><td>rs11045995</td><td>rocuronium</td><td></td><td>3</td><td>TT</td><td>Dosage</td><td>Patients with the rs11045995 TT genotype may require increased doses of rocuronium as compared to patients with the CC genotype. Other genetic and clinical factors may also influence rocuronium dosage requirements.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1043880337>2913</a></td><td>CYP2C9</td><td>rs10509680</td><td>warfarin</td><td></td><td>3</td><td>GG</td><td>Dosage</td><td>Patients with the GG genotype may require increased dose of warfarin when treated with warfarin as compared to patients with the TT or TG genotype. Other clinical or genetic factors may also influence the dose of warfarin.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1043859108>2914</a></td><td>SLCO1B1</td><td>rs4149056</td><td>SN-38</td><td>Carcinoma, Non-Small-Cell Lung</td><td>3</td><td>CT</td><td>Dosage</td><td>Patients with the CT genotype and non-small cell lung cancer may receive an increased dose of SN-38 (as shown by an increased area under the concentration curve) when treated with irinotecan as compared to patients with the TT genotype. SN-38 is the active metabolite of irinotecan. Other genetic and clinical factors may also influence dose of SN-38.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450824479>2915</a></td><td>OPRM1</td><td>rs3778150</td><td>ethanol</td><td></td><td>3</td><td>CT</td><td>Dosage</td><td>Patients with the CT genotype may have increased levels of alcohol consumption as compared to patients with the TT genotype. Other genetic or clinical factors may also affect a patient's levels of alcohol consumption.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655386315>2916</a></td><td>PRDX4</td><td>rs518329</td><td>docetaxel</td><td>Carcinoma, Non-Small-Cell Lung</td><td>3</td><td>CC</td><td>Dosage</td><td>Patients with the CC genotype may have increased clearance of docetaxel compared to patients with the TT genotype. Other genetic and clinical factors may also influence docetaxel clearance.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/613978937>2917</a></td><td>SCN1A</td><td>rs3812718</td><td>phenytoin</td><td>Epilepsy</td><td>3</td><td>CT</td><td>Dosage</td><td>Patients with the CT genotype who are treated with phenytoin may require a higher dose as compared to patients with the CC genotype. Other genetic and clinical factors may also influence dose of phenytoin.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655384592>2918</a></td><td>CYP3A</td><td>rs12721627</td><td>paclitaxel</td><td>Carcinoma, Non-Small-Cell Lung;Neoplasms</td><td>3</td><td>GG</td><td>Dosage</td><td>Patients with the GG genotype may have increased metabolism of paclitaxel as compared to patients with the CC or CG genotypes. Other genetic and clinical factors may also influence paclitaxel metabolism.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655384592>2919</a></td><td>CYP3A4</td><td>rs12721627</td><td>paclitaxel</td><td>Carcinoma, Non-Small-Cell Lung;Neoplasms</td><td>3</td><td>GG</td><td>Dosage</td><td>Patients with the GG genotype may have increased metabolism of paclitaxel as compared to patients with the CC or CG genotypes. Other genetic and clinical factors may also influence paclitaxel metabolism.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451415425>2920</a></td><td>UGT2B7</td><td>rs7668258</td><td>lamotrigine</td><td>Epilepsy</td><td>3</td><td>CT</td><td>Dosage</td><td>Patients with the rs7668258 CT genotype and epilepsy may require increased doses of lamotrigine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence lamotrigine dosage requirements.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/981203641>2921</a></td><td>UGT1A10</td><td>rs6759892</td><td>valproic acid</td><td>Epilepsy</td><td>3</td><td>GT</td><td>Dosage</td><td>Patients with the GT genotype and Epilepsy who are treated with valproic acid may require a higher dose as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's valproic acid dose requirement.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/981203641>2922</a></td><td>UGT1A6</td><td>rs6759892</td><td>valproic acid</td><td>Epilepsy</td><td>3</td><td>GT</td><td>Dosage</td><td>Patients with the GT genotype and Epilepsy who are treated with valproic acid may require a higher dose as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's valproic acid dose requirement.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/981203641>2923</a></td><td>UGT1A7</td><td>rs6759892</td><td>valproic acid</td><td>Epilepsy</td><td>3</td><td>GT</td><td>Dosage</td><td>Patients with the GT genotype and Epilepsy who are treated with valproic acid may require a higher dose as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's valproic acid dose requirement.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/981203641>2924</a></td><td>UGT1A8</td><td>rs6759892</td><td>valproic acid</td><td>Epilepsy</td><td>3</td><td>GT</td><td>Dosage</td><td>Patients with the GT genotype and Epilepsy who are treated with valproic acid may require a higher dose as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's valproic acid dose requirement.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/981203641>2925</a></td><td>UGT1A9</td><td>rs6759892</td><td>valproic acid</td><td>Epilepsy</td><td>3</td><td>GT</td><td>Dosage</td><td>Patients with the GT genotype and Epilepsy who are treated with valproic acid may require a higher dose as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's valproic acid dose requirement.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/981204317>2926</a></td><td>ABCB1</td><td>rs1045642</td><td>phenytoin</td><td></td><td>3</td><td>AA</td><td>Dosage</td><td>Patients with genotype AA may have increased plasma drug levels of phenytoin in people with no disease as compared to genotype GG. However, another study reported no association between this variant and increased dose of phenytoin in people with Epilepsy. Other genetic and clinical factors may influence a patient's dose of phenytoin.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451592476>2927</a></td><td>ASTN2</td><td>rs7858836</td><td>fentanyl</td><td>Pain, Postoperative</td><td>3</td><td>CC</td><td>Dosage</td><td>Patients with postoperative pain and the rs7858836 CC genotype may have increased fentanyl dose requirements as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence fentanyl dose requirements.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449270486>2928</a></td><td>KLB</td><td>rs11940694</td><td>ethanol</td><td>Alcoholism</td><td>3</td><td>GG</td><td>Dosage</td><td>Patients with the GG genotype may have increased alcohol consumption as compared to patients with the AA or AG genotypes. Other genetic and clinical factors may also affect a patient's level of alcohol consumption.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444694562>2929</a></td><td>IL10</td><td>rs1800872</td><td>tacrolimus</td><td>liver transplantation</td><td>3</td><td>GT</td><td>Dosage</td><td>Patients undergoing liver transplantation who receive a donor liver with the GT genotype and who are also homozygous for CYP3A5*3 may require increased doses of tacrolimus as compared to patients with the TT genotype. Other genetic and clinical factors, such as CYP3A5*3, may also influence dose of tacrolimus.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444694574>2930</a></td><td>IL10</td><td>rs1800871</td><td>tacrolimus</td><td>liver transplantation</td><td>3</td><td>AG</td><td>Dosage</td><td>Patients undergoing liver transplantation who receive a donor liver with the AG genotype and who are also homozygous for CYP3A5*3 may require increased doses of tacrolimus as compared to patients with the AA genotype. Other genetic and clinical factors, such as CYP3A5*3, may also influence dose of tacrolimus.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444686836>2931</a></td><td>IL10</td><td>rs1800871</td><td>tacrolimus</td><td>Kidney Transplantation</td><td>3</td><td>AG</td><td>Dosage</td><td>Patients with the AG genotype who are undergoing kidney transplantation may have a lower chance of achieving target concentrations of tacrolimus as compared to patients with the AA genotype. Other genetic and clinical factors, such as the CYP3A5*3 allele, may also influence a patient achieving target concentrations of tacrolimus.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444700550>2932</a></td><td>STX4</td><td>rs10871454</td><td>phenprocoumon</td><td></td><td>3</td><td>CT</td><td>Dosage</td><td>Patients with the CT genotype who are treated with phenprocoumon may require a increased dose as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's required phenprocoumon dosage.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444672993>2933</a></td><td>ABCB1</td><td>rs1128503</td><td>tacrolimus</td><td>Transplantation</td><td>4</td><td>AG</td><td>Dosage</td><td>Patients with the AG genotype who are undergoing organ transplantation may have increased concentrations of tacrolimus as compared to patients with the GG genotype. However, the majority of the literature evidence shows no association between this variant and tacrolimus concentrations, clearance or dose. Other genetic and clinical factors may also influence concentrations of tacrolimus.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448267397>2934</a></td><td>DNMT3A</td><td>rs2304429</td><td>warfarin</td><td>heart valve replacement</td><td>3</td><td>TT</td><td>Dosage</td><td>Patients with the TT genotype and heart valve replacement may require higher warfarin dose compared to patients with the CC and CT genotypes. Other genetic and clinical factors may affect warfarin dose.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448431545>2935</a></td><td>UGT1A1</td><td>rs887829</td><td>warfarin</td><td>heart valve replacement</td><td>3</td><td>CT</td><td>Dosage</td><td>Patients with the CT genotype and heart valve replacement may require a larger stable dose of warfarin compared to patients with the CC genotypes, although this is contradicted in one study. Other clinical and genetic factors affect stable dose of warfarin.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449164133>2936</a></td><td>VDR</td><td>rs11168292</td><td>warfarin</td><td></td><td>3</td><td>GG</td><td>Dosage</td><td>Patients with the GG genotype may require increased doses of warfarin as compared to patients with the CC or CG genotype. Other genetic and clinical factors may also influence warfarin dose, such as variations in the CYP2C9 and VKORC1 genes.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449164149>2937</a></td><td>VDR</td><td>rs11168293</td><td>warfarin</td><td></td><td>3</td><td>TT</td><td>Dosage</td><td>Patients with the TT genotype may require increased doses of warfarin as compared to patients with the GG or GT genotype. Other genetic and clinical factors may also influence warfarin dose, such as variations in the CYP2C9 and VKORC1 genes.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449164155>2938</a></td><td>VDR</td><td>rs4760658</td><td>warfarin</td><td></td><td>3</td><td>GG</td><td>Dosage</td><td>Patients with the GG genotype may require increased doses of warfarin as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence warfarin dose, such as variations in the CYP2C9 and VKORC1 genes.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447960948>2939</a></td><td>GRIN2B</td><td>rs1019385</td><td>valproic acid</td><td>Epilepsy</td><td>3</td><td>AA</td><td>Dosage</td><td>Patients with the AA genotype and epilepsy may require an increased dose of valproic acid as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence dose of valproic acid.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655384733>2940</a></td><td>VKORC1</td><td>rs7294</td><td>warfarin</td><td></td><td>1B</td><td>CT</td><td>Dosage</td><td>Patients with the rs7294 CT genotype may require a higher dose of warfarin as compared to patients with the CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect warfarin dose requirements.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451135400>2941</a></td><td>ABCB1</td><td>rs1128503</td><td>sufentanil</td><td></td><td>3</td><td>AG</td><td>Dosage</td><td>Patients with the AG genotype may have increased sufentanil dose requirements as compared to patients with the GG genotype. Other genetic and clinical factors may also affect a patient's sufentantil dose requirements.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451138166>2942</a></td><td>GAD1</td><td>rs3762556</td><td>methadone</td><td>Heroin Dependence</td><td>3</td><td>CG</td><td>Dosage</td><td>Patients with heroin dependence and the CG genotype may require increased doses of methadone when treated with methadone maintenance therapy (MMT) as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's methadone dose requirements in MMT.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451138140>2943</a></td><td>GAD1</td><td>rs3762555</td><td>methadone</td><td>Heroin Dependence</td><td>3</td><td>GG</td><td>Dosage</td><td>Patients with heroin dependence and the rs3762555 GG genotype may require increased doses of methadone when treated with methadone maintenance therapy (MMT) as compared to patients with the CC genotype. Other genetic and clinical factors may also affect methadone dose requirements in MMT.</td><td>Increased</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449566379>2944</a></td><td>-</td><td>rs11065987</td><td>hydrochlorothiazide</td><td>Hypertension</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype and hypertension may have an increased response to hydrochlorothiazide treatment, as measured by decreases in systolic and diastolic blood pressure, as compared to patients with the GG genotype, but a decreased response as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to hydrochlorothiazide.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451223506>2945</a></td><td>MTHFR</td><td>rs1801133</td><td>methotrexate</td><td>Precursor Cell Lymphoblastic Leukemia-Lymphoma</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the rs1801133 AG genotype may have a decreased response to methotrexate as compared to patients with the GG genotype but an increased response compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to methotrexate. This drug-variant pair has been assigned a no recommendation by DPWG, as it was determined to be not clinically actionable.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/827863928>2946</a></td><td>CACNA1C</td><td>rs1051375</td><td>atenolol</td><td>Coronary Artery Disease;Hypertension</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype, hypertension and stable coronary artery disease, may respond similarily to treatment with atenolol or verapamil. Other genetic and clinical factors may also influence a patient's response to treatment.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/827863928>2947</a></td><td>CACNA1C</td><td>rs1051375</td><td>verapamil</td><td>Coronary Artery Disease;Hypertension</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype, hypertension and stable coronary artery disease, may respond similarily to treatment with atenolol or verapamil. Other genetic and clinical factors may also influence a patient's response to treatment.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449144376>2948</a></td><td>ADCY1</td><td>rs1521470</td><td>lithium</td><td>Bipolar Disorder</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype and bipolar affective disorder may have a decreased response to lithium as compared to patients with the GG genotype, but an increased response as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to lithium when treating bipolar affective disorder.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449144382>2949</a></td><td>FAM177A1</td><td>rs79403677</td><td>lithium</td><td>Bipolar Disorder</td><td>3</td><td>GT</td><td>Efficacy</td><td>Patients with the GT genotype and bipolar affective disorder may have a decreased response to lithium as compared to patients with the TT genotype, but an increased response as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to lithium when treating bipolar affective disorder.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450815166>2950</a></td><td>-</td><td>rs7395555</td><td>risperidone</td><td>Schizophrenia</td><td>3</td><td>CG</td><td>Efficacy</td><td>Patients with schizophrenia and the CG genotype may have a decreased response to risperidone as compared to patients with the CC genotype but an increased response as compared to patients with the GG genotype. Other genetic or clinical factors may also affect a patient's response to risperidone.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1043880205>2951</a></td><td>CETP</td><td>rs708272</td><td>lovastatin</td><td></td><td>3</td><td>AA</td><td>Efficacy</td><td>Patients with the AA genotype may have an increased response to lovastatin as compared to patients with the GG genotype or may have a decreased response to lovastatin as compared to patients with the AG genotype. Other genetic and clinical factors may also influence a patient's response to lovastatin treatment.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1148995043>2952</a></td><td>ABCB1</td><td>rs2032582</td><td>atorvastatin</td><td>Hypercholesterolemia</td><td>3</td><td>AC</td><td>Efficacy</td><td>Patients with the rs2032582 AC genotype who are treated with atorvastatin may have a decreased response (as measured by lower reductions in LDL-cholesterol) as compared to patients with the CC genotype or may have an increased response (as measured by higher reductions in LDL-cholesterol) as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to atorvastatin treatment.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/982036604>2953</a></td><td>ABCB1</td><td>rs1128503</td><td>cisplatin</td><td>Osteosarcoma</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype and osteosarcoma may have a decreased risk of death when treated with cisplatin, cyclophosphamide, doxorubicin, methotrexate, and vincristine as compared to patients with the GG genotype, but an increased risk of death as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/982036604>2954</a></td><td>ABCB1</td><td>rs1128503</td><td>cyclophosphamide</td><td>Osteosarcoma</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype and osteosarcoma may have a decreased risk of death when treated with cisplatin, cyclophosphamide, doxorubicin, methotrexate, and vincristine as compared to patients with the GG genotype, but an increased risk of death as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/982036604>2955</a></td><td>ABCB1</td><td>rs1128503</td><td>doxorubicin</td><td>Osteosarcoma</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype and osteosarcoma may have a decreased risk of death when treated with cisplatin, cyclophosphamide, doxorubicin, methotrexate, and vincristine as compared to patients with the GG genotype, but an increased risk of death as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/982036604>2956</a></td><td>ABCB1</td><td>rs1128503</td><td>methotrexate</td><td>Osteosarcoma</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype and osteosarcoma may have a decreased risk of death when treated with cisplatin, cyclophosphamide, doxorubicin, methotrexate, and vincristine as compared to patients with the GG genotype, but an increased risk of death as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/982036604>2957</a></td><td>ABCB1</td><td>rs1128503</td><td>vincristine</td><td>Osteosarcoma</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype and osteosarcoma may have a decreased risk of death when treated with cisplatin, cyclophosphamide, doxorubicin, methotrexate, and vincristine as compared to patients with the GG genotype, but an increased risk of death as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1158793019>2958</a></td><td>SLCO1B1</td><td>rs4149081</td><td>rosuvastatin</td><td>Coronary Disease</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype and Coronary Disease may have an increased response to rosuvastatin as compared to patients with the GG genotype and a decreased response to rosuvastatin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to rosuvastatin.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183632117>2959</a></td><td>-</td><td>rs4815273</td><td>hydrochlorothiazide</td><td>Hypertension</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype and hypertension who are treated with hydrochlorothiazide may have decreased reduction of systolic blood pressure as compared to patients with the TT genotype and increased reduction of systolic blood pressure as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to hydrochlorothiazide treatment.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/981238415>2960</a></td><td>ITPA</td><td>rs1127354</td><td>methotrexate</td><td>Arthritis, Rheumatoid;Precursor Cell Lymphoblastic Leukemia-Lymphoma</td><td>3</td><td>CC</td><td>Efficacy</td><td>Patients with the CC genotype and with Rheumatoid Arthritis who are treated with methotrexate may have 1) a decreased, but not absent, risk for gastrointestinal toxicities 2) an increased response to folic acid and methotrexate as compared to patients with the AA and AC genotype. However, this association is contradicted in other studies that show the CC genotype may have decreased response to methotrexate as compared to patients with the AC and AA genotype or show no association of the allele with response to methotrexate. Children with Precursor Cell Lymphoblastic Leukemia-Lymphomathe and the CC genotype may have increased event free survival when treated with mercaptopurine and methotrexate as compared to children with the AA or AC genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/982036595>2961</a></td><td>ABCB1</td><td>rs4148737</td><td>cisplatin</td><td>Osteosarcoma</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype and osteosarcoma may have a decreased risk of death when treated with cisplatin, cyclophosphamide, doxorubicin, methotrexate, and vincristine as compared to patients with the CC genotype, but an increased risk of death as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/982036595>2962</a></td><td>ABCB1</td><td>rs4148737</td><td>cyclophosphamide</td><td>Osteosarcoma</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype and osteosarcoma may have a decreased risk of death when treated with cisplatin, cyclophosphamide, doxorubicin, methotrexate, and vincristine as compared to patients with the CC genotype, but an increased risk of death as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/982036595>2963</a></td><td>ABCB1</td><td>rs4148737</td><td>doxorubicin</td><td>Osteosarcoma</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype and osteosarcoma may have a decreased risk of death when treated with cisplatin, cyclophosphamide, doxorubicin, methotrexate, and vincristine as compared to patients with the CC genotype, but an increased risk of death as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/982036595>2964</a></td><td>ABCB1</td><td>rs4148737</td><td>methotrexate</td><td>Osteosarcoma</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype and osteosarcoma may have a decreased risk of death when treated with cisplatin, cyclophosphamide, doxorubicin, methotrexate, and vincristine as compared to patients with the CC genotype, but an increased risk of death as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/982036595>2965</a></td><td>ABCB1</td><td>rs4148737</td><td>vincristine</td><td>Osteosarcoma</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype and osteosarcoma may have a decreased risk of death when treated with cisplatin, cyclophosphamide, doxorubicin, methotrexate, and vincristine as compared to patients with the CC genotype, but an increased risk of death as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655385856>2966</a></td><td>ABCB1</td><td>rs2032582</td><td>paclitaxel</td><td>Breast Neoplasms;Ovarian Neoplasms</td><td>3</td><td>CA</td><td>Efficacy</td><td>Patients with the CA or CT genotype may have increased response to paclitaxel as compared to the CC genotype, but decreased response as compared to patients with other genotypes. Other genetic and clinical factors may also influence a patient's response to paclitaxel. Note that rs2032582 is a tri-allelic snp.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655384645>2967</a></td><td>SLCO1B1</td><td>rs4149056</td><td>repaglinide</td><td></td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype may have decreased exposure of repaglinide and decreased response to repaglinide as compared to patients with the CC genotype and increased exposure as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a exposure of and response to repaglinide.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655384804>2968</a></td><td>ARG1</td><td>rs2781659</td><td>selective beta-2-adrenoreceptor agonists</td><td>Asthma</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype and asthma who are treated with selective beta-2-adenoreceptor agonists may have increased improvement in forced expiratory volume (FEV) as compared to patients with the GG genotype or may have decreased improvement in forced expiratory volume (FEV) as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to beta-2-adenoreceptor agonist treatment.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655385041>2969</a></td><td>SLCO1B1</td><td>rs2306283</td><td>pravastatin</td><td></td><td>4</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype may have decreased pravastatin plasma concentrations as compared to patients with the AA genotype, or may have increased pravastatin plasma concentrations as compared to patients with the GG genotype. This does not seem to have an affect on response. Other genetic and clinical factors may also influence a patient's pravastatin pharmacokinetics.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655385299>2970</a></td><td>ATIC</td><td>rs2372536</td><td>methotrexate</td><td>Arthritis, Rheumatoid</td><td>3</td><td>CG</td><td>Efficacy</td><td>Patients with the CG genotype and rheumatoid arthritis who are treated with methotrexate may have a poorer response to the drug and a decreased risk for toxicity as compared to those with the GG genotype, and an increased risk for toxicity as compared to the CC genotype. However, conflicting evidence exists for both response and toxicity associations. Other genetic and clinical factors may also influence methotrexate response and toxicity.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/981237900>2971</a></td><td>ATM</td><td>rs11212617</td><td>metformin</td><td>Diabetes Mellitus, Type 2</td><td>4</td><td>AC</td><td>Efficacy</td><td>Patients with the AC genotype with diabetes mellitus, or polycystic ovarian syndrome who are treated with metformin may have an increased response to metformin as compared to patients with the AA genotype or may have a decreased response to metformin as compared to patients with the CC genotype. An association with increased/decreased response to metformin was not seen in people with impaired glucose tolerance. Other genetic and clinical factors may also influence a patient's response to metformin.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/981237900>2972</a></td><td>C11orf65</td><td>rs11212617</td><td>metformin</td><td>Diabetes Mellitus, Type 2</td><td>4</td><td>AC</td><td>Efficacy</td><td>Patients with the AC genotype with diabetes mellitus, or polycystic ovarian syndrome who are treated with metformin may have an increased response to metformin as compared to patients with the AA genotype or may have a decreased response to metformin as compared to patients with the CC genotype. An association with increased/decreased response to metformin was not seen in people with impaired glucose tolerance. Other genetic and clinical factors may also influence a patient's response to metformin.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449144310>2973</a></td><td>EPHX2</td><td>rs59724122</td><td>lithium</td><td>Bipolar Disorder</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype and bipolar affective disorder may have a decreased response to lithium as compared to patients with the TT genotype, but an increased response as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to lithium when treating bipolar affective disorder.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449144316>2974</a></td><td>GRAMD1B</td><td>rs61123830</td><td>lithium</td><td>Bipolar Disorder</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype and bipolar affective disorder may have a decreased response to lithium as compared to patients with the GG genotype, but an increased response as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to lithium when treating bipolar affective disorder.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/827864159>2975</a></td><td>GRK4</td><td>rs1024323</td><td>metoprolol</td><td>Hypertension;Kidney Diseases;Nephrosclerosis</td><td>3</td><td>TT</td><td>Efficacy</td><td>In male patients with the rs1024323 TT genotype and hypertensive nephrosclerosis 1) those who also have the rs2960306 TC or TT genotype may have a better response to metoprolol compared to those with rs1024323 genotype CT and TT, 2) those who also have the rs2960306 GG genotype may have a similar response to metoprolol compared to genotype CT and TT. No association was found in women with hypertensive nephrosclerosis. Other genetic and clinical factors may also influence a patient's response to metoprolol treatment.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/827862764>2976</a></td><td>IFNL3</td><td>rs12979860</td><td>peginterferon alfa-2a</td><td>Hepatitis C</td><td>1A</td><td>CT</td><td>Efficacy</td><td>Patients with the rs12979860 CT genotype and hepatitis C infection may have decreased response (typically assayed as sustained virological response, SVR) when administered peg interferon alpha 2a or 2b in combination with ribavirin as compared to patients with the CC genotype, but an increased response as compared to patients with the TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to peginterferon alpha and ribavirin.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/827862764>2977</a></td><td>IFNL4</td><td>rs12979860</td><td>peginterferon alfa-2a</td><td>Hepatitis C</td><td>1A</td><td>CT</td><td>Efficacy</td><td>Patients with the rs12979860 CT genotype and hepatitis C infection may have decreased response (typically assayed as sustained virological response, SVR) when administered peg interferon alpha 2a or 2b in combination with ribavirin as compared to patients with the CC genotype, but an increased response as compared to patients with the TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to peginterferon alpha and ribavirin.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/827862764>2978</a></td><td>IFNL3</td><td>rs12979860</td><td>peginterferon alfa-2b</td><td>Hepatitis C</td><td>1A</td><td>CT</td><td>Efficacy</td><td>Patients with the rs12979860 CT genotype and hepatitis C infection may have decreased response (typically assayed as sustained virological response, SVR) when administered peg interferon alpha 2a or 2b in combination with ribavirin as compared to patients with the CC genotype, but an increased response as compared to patients with the TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to peginterferon alpha and ribavirin.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/827862764>2979</a></td><td>IFNL4</td><td>rs12979860</td><td>peginterferon alfa-2b</td><td>Hepatitis C</td><td>1A</td><td>CT</td><td>Efficacy</td><td>Patients with the rs12979860 CT genotype and hepatitis C infection may have decreased response (typically assayed as sustained virological response, SVR) when administered peg interferon alpha 2a or 2b in combination with ribavirin as compared to patients with the CC genotype, but an increased response as compared to patients with the TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to peginterferon alpha and ribavirin.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/827862764>2980</a></td><td>IFNL3</td><td>rs12979860</td><td>ribavirin</td><td>Hepatitis C</td><td>1A</td><td>CT</td><td>Efficacy</td><td>Patients with the rs12979860 CT genotype and hepatitis C infection may have decreased response (typically assayed as sustained virological response, SVR) when administered peg interferon alpha 2a or 2b in combination with ribavirin as compared to patients with the CC genotype, but an increased response as compared to patients with the TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to peginterferon alpha and ribavirin.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/827862764>2981</a></td><td>IFNL4</td><td>rs12979860</td><td>ribavirin</td><td>Hepatitis C</td><td>1A</td><td>CT</td><td>Efficacy</td><td>Patients with the rs12979860 CT genotype and hepatitis C infection may have decreased response (typically assayed as sustained virological response, SVR) when administered peg interferon alpha 2a or 2b in combination with ribavirin as compared to patients with the CC genotype, but an increased response as compared to patients with the TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to peginterferon alpha and ribavirin.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184472708>2982</a></td><td>SLC29A1</td><td>rs747199</td><td>gemcitabine</td><td>Breast Neoplasms</td><td>3</td><td>CG</td><td>Efficacy</td><td>Patients with breast cancer and the CG genotype may have a decreased response to gemcitabine and paclitaxel as compared to patients with the CC genotypes, and an increased response as compared to patients with the GG genotype when part of a haplotype with the rs760370 A allele. Other genetic and clinical factors may influence the response to gemcitabine and paclitaxel.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184472708>2983</a></td><td>SLC29A1</td><td>rs747199</td><td>paclitaxel</td><td>Breast Neoplasms</td><td>3</td><td>CG</td><td>Efficacy</td><td>Patients with breast cancer and the CG genotype may have a decreased response to gemcitabine and paclitaxel as compared to patients with the CC genotypes, and an increased response as compared to patients with the GG genotype when part of a haplotype with the rs760370 A allele. Other genetic and clinical factors may influence the response to gemcitabine and paclitaxel.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444703178>2984</a></td><td>IL6</td><td>rs1800795</td><td>Tumor necrosis factor alpha (TNF-alpha) inhibitors</td><td>Psoriasis</td><td>3</td><td>CG</td><td>Efficacy</td><td>Patients with the CG genotype and psoriasis who are treated with tumor necrosis factor alpha (TNF-alpha) inhibitors may have decreased response as compared to patients with CC genotype or may have increased response as compared to patients with GG genotype. Other genetic and clinical factors may also influence a patient's response to tumor necrosis factor alpha (TNF-alpha) inhibitors.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444703195>2985</a></td><td>-</td><td>rs342293</td><td>clopidogrel</td><td>Coronary Artery Disease</td><td>3</td><td>CG</td><td>Efficacy</td><td>Patients with the CG genotype and Coronary Artery Disease may have increased platelet reactivity when treated with clopidogrel as compared to patients with the CC genotype or may have decreased platelet reactivity when treated with clopidogrel as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to clopidogrel.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1445401247>2986</a></td><td>ABCB1</td><td>rs1128503</td><td>rocuronium</td><td></td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype who are placed under anesthesia may have an increased response to rocuronium as compared to patients with the AA genotype but a decreased response as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to rocuronium.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1445594352>2987</a></td><td>TET2</td><td>rs12505746</td><td>hydrochlorothiazide</td><td>Essential hypertension</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype and essential hypertension may have a decreased response when treated with hydrochlorothiazide as compared to patients with the GG genotype and an increased response as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to hydrochlorothiazide in patients with essential hypertension.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1445594359>2988</a></td><td>FBXL17</td><td>rs7706429</td><td>hydrochlorothiazide</td><td>Essential hypertension</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype and essential hypertension may have a decreased response when treated with hydrochlorothiazide as compared to patients with the AA genotype and an increased response as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to hydrochlorothiazide in patients with essential hypertension.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451648374>2989</a></td><td>-</td><td>rs6973474</td><td>buprenorphine</td><td>Opioid-Related Disorders</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with opioid dependence and the rs6973474 CT genotype may have a decreased response to buprenorphine therapy as compared to patients with the TT genotype but an increased response as compared to the CC genotype. Other genetic and clinical factors may also influence response to buprenorphine.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451648382>2990</a></td><td>-</td><td>rs13169373</td><td>buprenorphine</td><td>Opioid-Related Disorders</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with opioid dependence and the rs13169373 CT genotype may have a decreased response to buprenorphine therapy as compared to patients with the TT genotype but an increased response as compared to the CC genotype. Other genetic and clinical factors may also influence response to buprenorphine.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183632200>2991</a></td><td>ABCB1</td><td>rs2032582</td><td>ondansetron</td><td>Postoperative Nausea and Vomiting;Vomiting</td><td>3</td><td>AC</td><td>Efficacy</td><td>Patients with the rs2032582 AC genotype may have increased likelihood of nausea and vomiting shortly after being treated with ondansetron as compared to patients with the AA genotype but a decreased likelihood of nausea and vomiting shortly after being treated with ondansetron as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to ondansetron.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444668457>2992</a></td><td>SLCO1B1</td><td>rs2900478</td><td>hmg coa reductase inhibitors</td><td></td><td>3</td><td>AT</td><td>Efficacy</td><td>Patients with the AT genotype may have a decreased response to hmg coa reductase inhibitors as compared to patients with the TT genotypes and an increased response to hmg coa reductase inhibitors as compared to patients with the AA genotype. Other clinical and genetic factors may also influence a patient's response to hmg coa reductase inhibitors.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444668468>2993</a></td><td>-</td><td>rs445925</td><td>hmg coa reductase inhibitors</td><td></td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype may have an increased response to hmg coa reductase inhibitors as compared to patients with the GG genotypes and a decreased response to hmg coa reductase inhibitors as compared to patients with the AA genotype. Other clinical and genetic factors may also influence a patient's response to hmg coa reductase inhibitors.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444706854>2994</a></td><td>IL1A</td><td>rs11677416</td><td>olanzapine</td><td>Schizophrenia</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype and Schizophrenia may have increased response to olanzapine as compared to patients with the TT genotype or may have decreased response to olanzapine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to olanzapine.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1445594491>2995</a></td><td>FBXL17</td><td>rs4431329</td><td>hydrochlorothiazide</td><td>Essential hypertension</td><td>3</td><td>AT</td><td>Efficacy</td><td>Patients with the AT genotype and essential hypertension may have an increased response when treated with hydrochlorothiazide as compared to patients with TT genotypes and a decreased response when treated with hydrochlorothiazide as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to hydrochlorothiazide in patients with essential hypertension.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444667661>2996</a></td><td>CAPN10</td><td>rs3792269</td><td>metformin</td><td>Diabetes Mellitus</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype and diabetes mellitus may have a decreased response when treated with metformin as compared to patients with the AA genotypes and an increased response to metformin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence response to metformin.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444668402>2997</a></td><td>CELSR2</td><td>rs646776</td><td>hmg coa reductase inhibitors</td><td></td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype may have an increased response to hmg coa reductase inhibitors as compared to patients with the TT genotype and a decreased response to hmg coa reductase inhibitors as compared to patients with the CC genotype. Other clinical and genetic factors may also influence response to hmg coa reductase inhibitors.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184988860>2998</a></td><td>GRIN2B</td><td>rs2058878</td><td>acamprosate</td><td>Alcoholism</td><td>3</td><td>AT</td><td>Efficacy</td><td>Patients with the AT genotype and alcoholism may have an increased response to acamprosate as compared to patients with the TT genotype and a decreased response as compared to patients with the AA genotype. Other clinical and genetic factors may also influence response to acamprosate in patients with alcoholism.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444703639>2999</a></td><td>SLC16A7</td><td>rs3763980</td><td>methotrexate</td><td>Arthritis, Juvenile Rheumatoid</td><td>3</td><td>AT</td><td>Efficacy</td><td>Patients with the AA genotype may have decreased response to methotrexate as compared to TT genotype or may have increased response to methotrexate as compared to AA genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444607634>3000</a></td><td>SLC22A1</td><td>rs628031</td><td>metformin</td><td>Diabetes Mellitus, Type 2</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype who are treated with metformin may have a decreased response and increased risk for gastrointestinal side effects as compared to patients with the GG genotype and increased response and decreased risk for gastrointestinal side effects as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to metformin.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444700767>3001</a></td><td>IL6R</td><td>rs12083537</td><td>tocilizumab</td><td>Arthritis, Rheumatoid</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype and rheumatoid arthritis who are treated with tocilizumab may have increased response to tocilizumab as compared to patients with the AA genotype. However, a different study found a decreased response to tocilizumab for patients with the AG genotype. Other genetic and clinical factors may also influence a patient's response to tocilizumab.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444703100>3002</a></td><td>-</td><td>rs1703794</td><td>methotrexate</td><td>Arthritis, Rheumatoid</td><td>4</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype and Rheumatoid Arthritis may have a decreased response to methotrexate as compared to patients with the CC genotype or may have an increased response to methotrexate as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444705198>3003</a></td><td>GLDC</td><td>rs10975641</td><td>citalopram</td><td>Depressive Disorder, Major</td><td>3</td><td>CG</td><td>Efficacy</td><td>Patients with the CG genotype and major depression may have increased response to citalopram and escitalopram as compared to patients with the CC genotype or may have decreased response to citalopram and escitalopram as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to citalopram and escitalopram.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444705198>3004</a></td><td>GLDC</td><td>rs10975641</td><td>escitalopram</td><td>Depressive Disorder, Major</td><td>3</td><td>CG</td><td>Efficacy</td><td>Patients with the CG genotype and major depression may have increased response to citalopram and escitalopram as compared to patients with the CC genotype or may have decreased response to citalopram and escitalopram as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to citalopram and escitalopram.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444705243>3005</a></td><td>-</td><td>rs6966038</td><td>citalopram</td><td>Depressive Disorder, Major</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the GG genotype and major depression may have increased response to citalopram as compared to patients with the AA genotype or may have decreased response to citalopram as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to citalopram.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451640212>3006</a></td><td>-</td><td>rs77583603</td><td>acamprosate</td><td>Alcoholism</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with alcoholism and the rs77583603 AG genotype may have an increased response to acamprosate treatment as compared to patients with the GG genotype but a decreased response as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to acamprosate.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444703086>3007</a></td><td>SLC6A2</td><td>rs12708954</td><td>atomoxetine</td><td>Attention Deficit Disorder with Hyperactivity</td><td>3</td><td>AC</td><td>Efficacy</td><td>Patients with the AC genotype and Attention Deficit Disorder with Hyperactivity who are treated with atomoxetine may have increased response as compared to patients with the CC genotype or may have decreased response as compared to patients with the AA genotype. However, contradictory findings exist. Other genetic and clinical factors may also influence a patient's response to atomoxetine..</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444703230>3008</a></td><td>ABCB1</td><td>rs2032582</td><td>fluoxetine</td><td>Depressive Disorder</td><td>3</td><td>AC</td><td>Efficacy</td><td>Patients with the AA genotype and Depressive Disorder may have increased response to fluoxetine as compared to patients with the CC genotype or may have decreased response to fluoxetine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to fluoxetine.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1445594556>3009</a></td><td>CSMD1</td><td>rs7387065</td><td>hydrochlorothiazide</td><td>Essential hypertension</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype and essential hypertension may have a decreased response when treated with hydrochlorothiazide as compared to patients with GG genotype and an increased response as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to hydrochlorothiazide in patients with essential hypertension.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444608384>3010</a></td><td>FCGR3A</td><td>rs396991</td><td>rituximab</td><td>Arthritis, Rheumatoid;Neuromyelitis Optica</td><td>2B</td><td>AC</td><td>Efficacy</td><td>Patients with the rs396991 AC genotype may have a decreased response to rituximab, as compared to patients with the CC genotype but an increased response as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to rituximab.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444703171>3011</a></td><td>IL6</td><td>rs1800795</td><td>adalimumab</td><td>Arthritis, Rheumatoid</td><td>3</td><td>CG</td><td>Efficacy</td><td>Patients with the GG genotype and Rheumatoid Arthritis who are treated with adalimumab, etanercept or infliximab may have increased response as compared to patients with the CC genotype or may have decreased response as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to adalimumab, etanercept or infliximab.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444703171>3012</a></td><td>IL6</td><td>rs1800795</td><td>etanercept</td><td>Arthritis, Rheumatoid</td><td>3</td><td>CG</td><td>Efficacy</td><td>Patients with the GG genotype and Rheumatoid Arthritis who are treated with adalimumab, etanercept or infliximab may have increased response as compared to patients with the CC genotype or may have decreased response as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to adalimumab, etanercept or infliximab.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444703171>3013</a></td><td>IL6</td><td>rs1800795</td><td>infliximab</td><td>Arthritis, Rheumatoid</td><td>3</td><td>CG</td><td>Efficacy</td><td>Patients with the GG genotype and Rheumatoid Arthritis who are treated with adalimumab, etanercept or infliximab may have increased response as compared to patients with the CC genotype or may have decreased response as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to adalimumab, etanercept or infliximab.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444705174>3014</a></td><td>DTNBP1</td><td>rs760761</td><td>citalopram</td><td>Depressive Disorder, Major</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype and major depression may have increased response to citalopram as compared to patients with the GG genotype or may have decreased response to citalopram as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to citalopram.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444703480>3015</a></td><td>-</td><td>rs7624766</td><td>methotrexate</td><td>Arthritis, Rheumatoid</td><td>4</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype and Rheumatoid Arthritis may have decreased response to methotrexate as compared to patients with the AA genotype or may have increased response to methotrexate as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448615575>3016</a></td><td>ABCB1</td><td>rs1045642</td><td>clopidogrel</td><td>platelet reactivity</td><td>4</td><td>AA</td><td>Efficacy</td><td>Patients with the AA genotype may have a decreased response to clopidogrel (increased platelet reactivity) as compared to patients with the GG genotype, although most studies find no association between the allele and treatment response. One study reports a decreased response for the AG genotype versus the AA and GG genotypes, and another reports decreased response for the GG genotype versus the AA genotype. Other clinical and genetic factors may also influence response to clopidogrel.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448102490>3017</a></td><td>IFNL3</td><td>rs4803217</td><td>peginterferon alfa-2a</td><td>Hepatitis C;HIV Infections</td><td>3</td><td>AC</td><td>Efficacy</td><td>Patients with the AC genotype and hepatitis C or HIV may have a decreased response to peginterferon-alpha and ribavirin treatment as compared to patients with the CC genotype, or an increased response as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to peginterferon-alpha and ribavirin treatment.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448102490>3018</a></td><td>IFNL3</td><td>rs4803217</td><td>peginterferon alfa-2b</td><td>Hepatitis C;HIV Infections</td><td>3</td><td>AC</td><td>Efficacy</td><td>Patients with the AC genotype and hepatitis C or HIV may have a decreased response to peginterferon-alpha and ribavirin treatment as compared to patients with the CC genotype, or an increased response as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to peginterferon-alpha and ribavirin treatment.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448102490>3019</a></td><td>IFNL3</td><td>rs4803217</td><td>ribavirin</td><td>Hepatitis C;HIV Infections</td><td>3</td><td>AC</td><td>Efficacy</td><td>Patients with the AC genotype and hepatitis C or HIV may have a decreased response to peginterferon-alpha and ribavirin treatment as compared to patients with the CC genotype, or an increased response as compared to patients with the AA genotype. Other genetic and clinical factors may also influence response to peginterferon-alpha and ribavirin treatment.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449716035>3020</a></td><td>ATF2</td><td>rs7583431</td><td>fentanyl</td><td>Pain, Postoperative</td><td>3</td><td>AC</td><td>Efficacy</td><td>Patients with the AC genotype may have an increased response to fentanyl as compared to patients with the CC genotype, but a decreased response as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's response to fentanyl.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447959694>3021</a></td><td>-</td><td>rs4278350</td><td>interferon beta-1a</td><td>Multiple Sclerosis</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype and multiple sclerosis may have a decreased response to treatment with interferon-beta as compared to patients with the TT genotype, or an increased response to treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to interferon-beta treatment.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447959694>3022</a></td><td>-</td><td>rs4278350</td><td>interferon beta-1b</td><td>Multiple Sclerosis</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype and multiple sclerosis may have a decreased response to treatment with interferon-beta as compared to patients with the TT genotype, or an increased response to treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to interferon-beta treatment.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447959717>3023</a></td><td>FHIT</td><td>rs760316</td><td>interferon beta-1a</td><td>Multiple Sclerosis</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype and multiple sclerosis may have an increased response to treatment with interferon-beta as compared to patients with the TT genotype, or a decreased response to treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to interferon-beta treatment.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447959717>3024</a></td><td>FHIT</td><td>rs760316</td><td>interferon beta-1b</td><td>Multiple Sclerosis</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the CT genotype and multiple sclerosis may have an increased response to treatment with interferon-beta as compared to patients with the TT genotype, or a decreased response to treatment as compared to patients with the CC genotype. Other genetic and clinical factors may also influence response to interferon-beta treatment.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447963991>3025</a></td><td>ABCB1</td><td>rs3789243</td><td>antiepileptics</td><td>Epilepsy</td><td>3</td><td>AG</td><td>Efficacy</td><td>Male patients with the AG genotype and specifically localization-related epilepsy syndrome may have a decreased risk for resistance to antiepileptic treatment as compared to patients with the GG genotype, or an increased risk for resistance as compared to patients with the AA genotype. However, one study found no association between this variant and resistance to antiepileptic treatment. Other genetic and clinical factors may also influence resistance to antiepileptics.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448102432>3026</a></td><td>-</td><td>rs10853728</td><td>peginterferon alfa-2b</td><td>Hepatitis C, Chronic</td><td>3</td><td>CG</td><td>Efficacy</td><td>Patients with the CG genotype and chronic hepatitis C may have an increased likelihood of sustained virological response when treated with peginterferon alfa-2b and ribavirin as compared to patients with the GG genotype, and a decreased likelihood as compared to patients with the CC genotype. Other genetic and clinical factors may also influence likelihood of sustained virological response.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448102432>3027</a></td><td>-</td><td>rs10853728</td><td>ribavirin</td><td>Hepatitis C, Chronic</td><td>3</td><td>CG</td><td>Efficacy</td><td>Patients with the CG genotype and chronic hepatitis C may have an increased likelihood of sustained virological response when treated with peginterferon alfa-2b and ribavirin as compared to patients with the GG genotype, and a decreased likelihood as compared to patients with the CC genotype. Other genetic and clinical factors may also influence likelihood of sustained virological response.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447963078>3028</a></td><td>CHRNA3</td><td>rs578776</td><td>nicotine</td><td>Tobacco Use Disorder</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the rs578776 AG genotype may have a decreased risk for nicotine dependence as compared to patients with the GG genotype, or an increased risk as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk for nicotine dependence and cotinine levels.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447963979>3029</a></td><td>ABCB1</td><td>rs1128503</td><td>antiepileptics</td><td>Epilepsy</td><td>4</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype and specifically localization-related epilepsy syndrome may have an increased risk for resistance to antiepileptic treatment as compared to patients with the GG genotype, or a decreased risk as compared to patients with the AA genotype. However, all other studies of people with epilepsy have found no association between this variant and antiepileptic resistance. Other genetic and clinical factors may also influence resistance to antiepileptics.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450815130>3030</a></td><td>TNFRSF11A</td><td>rs2980976</td><td>risperidone</td><td>Schizophrenia</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with schizophrenia and the AG genotype may have an increased response to risperidone as compared to patients with the AA genotype but a decreased response as compared to patients with the GG genotype. Other genetic or clinical factors may also affect a patient's response to risperidone.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451151857>3031</a></td><td>HTR2A</td><td>rs6313</td><td>risperidone</td><td>Schizophrenia</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with schizophrenia and the AG genotype may have an increased response to risperidone as compared to patients with the GG genotype but a decreased response as compared to patients with the AA genotype. However, this association was only found in a subanalysis of symptoms scores while another study failed to find an association. Other genetic and clinical factors may also affect a patient's response to risperidone.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/827848365>3032</a></td><td>MTHFR</td><td>rs1801133</td><td>methotrexate</td><td>Drug Toxicity;hematotoxicity;Leukopenia;Lymphoma;mucositis;Neoplasms;Neutropenia;Osteosarcoma;Precursor Cell Lymphoblastic Leukemia-Lymphoma;primary central nervous system lymphoma;Thrombocytopenia;Toxic liver disease</td><td>2A</td><td>AG</td><td>Toxicity</td><td>Patients with the rs1801133 AG genotype and cancer who are treated with methotrexate may be at increased risk of toxicity as compared to patients with the GG genotype, and may be at decreased risk of toxicity compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of toxicity following methotrexate treatment. This drug-variant pair has been assigned a no recommendation by DPWG, as it was determined to be not clinically actionable.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448624459>3033</a></td><td>PIGB</td><td>rs12050587</td><td>cyclophosphamide</td><td>Breast Neoplasms;Leukopenia;Neutropenia</td><td>3</td><td>AG</td><td>Toxicity</td><td>Patients with the AG genotype and breast cancer who are treated with fluorouracil, epirubicin, and cyclophosphamide (FEC) may have increased likelihood of neutropenia or leukopenia as compared to patients with the AA genotype, and decreased likelihood of neutropenia or leukopenia as compared to patients wth the GG genotype. Other clinical and genetic factors may also influence likelihood of neutropenia or leukopenia in patients with breast cancer who are treated with FEC. The SNP is not associated with neutropenia or leukopenia when patients are treated with docetaxel (+/-gemcitabine).</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448624459>3034</a></td><td>PIGB</td><td>rs12050587</td><td>epirubicin</td><td>Breast Neoplasms;Leukopenia;Neutropenia</td><td>3</td><td>AG</td><td>Toxicity</td><td>Patients with the AG genotype and breast cancer who are treated with fluorouracil, epirubicin, and cyclophosphamide (FEC) may have increased likelihood of neutropenia or leukopenia as compared to patients with the AA genotype, and decreased likelihood of neutropenia or leukopenia as compared to patients wth the GG genotype. Other clinical and genetic factors may also influence likelihood of neutropenia or leukopenia in patients with breast cancer who are treated with FEC. The SNP is not associated with neutropenia or leukopenia when patients are treated with docetaxel (+/-gemcitabine).</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448624459>3035</a></td><td>PIGB</td><td>rs12050587</td><td>fluorouracil</td><td>Breast Neoplasms;Leukopenia;Neutropenia</td><td>3</td><td>AG</td><td>Toxicity</td><td>Patients with the AG genotype and breast cancer who are treated with fluorouracil, epirubicin, and cyclophosphamide (FEC) may have increased likelihood of neutropenia or leukopenia as compared to patients with the AA genotype, and decreased likelihood of neutropenia or leukopenia as compared to patients wth the GG genotype. Other clinical and genetic factors may also influence likelihood of neutropenia or leukopenia in patients with breast cancer who are treated with FEC. The SNP is not associated with neutropenia or leukopenia when patients are treated with docetaxel (+/-gemcitabine).</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183684153>3036</a></td><td>SULT2B1</td><td>rs2302948</td><td>cytarabine</td><td>Leukemia, Myeloid, Acute</td><td>3</td><td>CT</td><td>Toxicity</td><td>Patients with the CT genotype may have a decreased likelihood of fever when treated with cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin as compared to patients with the CC genotype and an increased likelihood of fever as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183684153>3037</a></td><td>SULT2B1</td><td>rs2302948</td><td>fludarabine</td><td>Leukemia, Myeloid, Acute</td><td>3</td><td>CT</td><td>Toxicity</td><td>Patients with the CT genotype may have a decreased likelihood of fever when treated with cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin as compared to patients with the CC genotype and an increased likelihood of fever as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183684153>3038</a></td><td>SULT2B1</td><td>rs2302948</td><td>gemtuzumab ozogamicin</td><td>Leukemia, Myeloid, Acute</td><td>3</td><td>CT</td><td>Toxicity</td><td>Patients with the CT genotype may have a decreased likelihood of fever when treated with cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin as compared to patients with the CC genotype and an increased likelihood of fever as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183684153>3039</a></td><td>SULT2B1</td><td>rs2302948</td><td>idarubicin</td><td>Leukemia, Myeloid, Acute</td><td>3</td><td>CT</td><td>Toxicity</td><td>Patients with the CT genotype may have a decreased likelihood of fever when treated with cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin as compared to patients with the CC genotype and an increased likelihood of fever as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183684167>3040</a></td><td>SLCO1B1</td><td>rs4149056</td><td>cytarabine</td><td>Leukemia, Myeloid, Acute</td><td>3</td><td>CT</td><td>Toxicity</td><td>Patients with the CT genotype may have a decreased likelihood of toxic liver disease when treated with cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin as compared to patients with the CC genotype and an increased likelihood of toxic liver disease as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183684167>3041</a></td><td>SLCO1B1</td><td>rs4149056</td><td>fludarabine</td><td>Leukemia, Myeloid, Acute</td><td>3</td><td>CT</td><td>Toxicity</td><td>Patients with the CT genotype may have a decreased likelihood of toxic liver disease when treated with cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin as compared to patients with the CC genotype and an increased likelihood of toxic liver disease as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183684167>3042</a></td><td>SLCO1B1</td><td>rs4149056</td><td>gemtuzumab ozogamicin</td><td>Leukemia, Myeloid, Acute</td><td>3</td><td>CT</td><td>Toxicity</td><td>Patients with the CT genotype may have a decreased likelihood of toxic liver disease when treated with cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin as compared to patients with the CC genotype and an increased likelihood of toxic liver disease as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183684167>3043</a></td><td>SLCO1B1</td><td>rs4149056</td><td>idarubicin</td><td>Leukemia, Myeloid, Acute</td><td>3</td><td>CT</td><td>Toxicity</td><td>Patients with the CT genotype may have a decreased likelihood of toxic liver disease when treated with cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin as compared to patients with the CC genotype and an increased likelihood of toxic liver disease as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183603970>3044</a></td><td>DRD2</td><td>rs2440390</td><td>olanzapine</td><td>Mental Disorders</td><td>3</td><td>CT</td><td>Toxicity</td><td>Patients with the CT genotype and mental disorders may have increased weight gain when treated with olanzapine as compared to patients with the CC genotype, or decreased weight gain when treated with olanzapine as compared to patients with the TT genotype. Other genetic and clinical factors may also influence weight gain.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/981237930>3045</a></td><td>ERCC1</td><td>rs11615</td><td>cisplatin</td><td>Ovarian Neoplasms</td><td>3</td><td>AA</td><td>Toxicity</td><td>Genotype AA is not associated with decreased risk of Drug Toxicity when treated with cisplatin and cyclophosphamide as compared to genotypes AG and GG. Please note, patients with the AG genotype and Ovarian Neoplasms who are treated with cisplatin and cyclophosphamide may have an increased risk of nephrotoxicity as compared to patients with the GG genotype. This association has been contradicted in some studies. Other genetic and clinical factors may also influence a patient's risk for adverse events with cisplatin and cyclophosphamide treatment.No result</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/981237930>3046</a></td><td>ERCC1</td><td>rs11615</td><td>cyclophosphamide</td><td>Ovarian Neoplasms</td><td>3</td><td>AA</td><td>Toxicity</td><td>Genotype AA is not associated with decreased risk of Drug Toxicity when treated with cisplatin and cyclophosphamide as compared to genotypes AG and GG. Please note, patients with the AG genotype and Ovarian Neoplasms who are treated with cisplatin and cyclophosphamide may have an increased risk of nephrotoxicity as compared to patients with the GG genotype. This association has been contradicted in some studies. Other genetic and clinical factors may also influence a patient's risk for adverse events with cisplatin and cyclophosphamide treatment.No result</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183624421>3047</a></td><td>HTR1B</td><td>rs130058</td><td>clomipramine</td><td>Depression</td><td>3</td><td>AT</td><td>Toxicity</td><td>Patients with the AT genotype and Depression who are treated with clomipramine, liothyronine, lithium, nefazodone or venlafaxine may have an increased risk for suicidal ideation as compared to patients with the TT genotype and a decreased, but not absent, risk for suicidal ideation as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for suicidal ideation.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183624421>3048</a></td><td>HTR1B</td><td>rs130058</td><td>liothyronine</td><td>Depression</td><td>3</td><td>AT</td><td>Toxicity</td><td>Patients with the AT genotype and Depression who are treated with clomipramine, liothyronine, lithium, nefazodone or venlafaxine may have an increased risk for suicidal ideation as compared to patients with the TT genotype and a decreased, but not absent, risk for suicidal ideation as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for suicidal ideation.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183624421>3049</a></td><td>HTR1B</td><td>rs130058</td><td>lithium</td><td>Depression</td><td>3</td><td>AT</td><td>Toxicity</td><td>Patients with the AT genotype and Depression who are treated with clomipramine, liothyronine, lithium, nefazodone or venlafaxine may have an increased risk for suicidal ideation as compared to patients with the TT genotype and a decreased, but not absent, risk for suicidal ideation as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for suicidal ideation.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183624421>3050</a></td><td>HTR1B</td><td>rs130058</td><td>nefazodone</td><td>Depression</td><td>3</td><td>AT</td><td>Toxicity</td><td>Patients with the AT genotype and Depression who are treated with clomipramine, liothyronine, lithium, nefazodone or venlafaxine may have an increased risk for suicidal ideation as compared to patients with the TT genotype and a decreased, but not absent, risk for suicidal ideation as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for suicidal ideation.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183624421>3051</a></td><td>HTR1B</td><td>rs130058</td><td>venlafaxine</td><td>Depression</td><td>3</td><td>AT</td><td>Toxicity</td><td>Patients with the AT genotype and Depression who are treated with clomipramine, liothyronine, lithium, nefazodone or venlafaxine may have an increased risk for suicidal ideation as compared to patients with the TT genotype and a decreased, but not absent, risk for suicidal ideation as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for suicidal ideation.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449718283>3052</a></td><td>ABCC2</td><td>rs3740066</td><td>cyclophosphamide</td><td>Breast Neoplasms</td><td>3</td><td>CT</td><td>Toxicity</td><td>Patients with CT genotype and breast cancer may have an increased risk of nausea as compared to the CC genotype, and a decreased risk of neutropenia as compared to the TT genotype, when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC). Other genetic and clinical factors may also affect the risk for nausea and neutropenia in patients taking FAC chemotherapy.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449718283>3053</a></td><td>ABCC2</td><td>rs3740066</td><td>doxorubicin</td><td>Breast Neoplasms</td><td>3</td><td>CT</td><td>Toxicity</td><td>Patients with CT genotype and breast cancer may have an increased risk of nausea as compared to the CC genotype, and a decreased risk of neutropenia as compared to the TT genotype, when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC). Other genetic and clinical factors may also affect the risk for nausea and neutropenia in patients taking FAC chemotherapy.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449718283>3054</a></td><td>ABCC2</td><td>rs3740066</td><td>fluorouracil</td><td>Breast Neoplasms</td><td>3</td><td>CT</td><td>Toxicity</td><td>Patients with CT genotype and breast cancer may have an increased risk of nausea as compared to the CC genotype, and a decreased risk of neutropenia as compared to the TT genotype, when treated with cyclophosphamide, doxorubicin and fluorouracil (FAC). Other genetic and clinical factors may also affect the risk for nausea and neutropenia in patients taking FAC chemotherapy.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655385379>3055</a></td><td>HTR3B</td><td>rs2276307</td><td>atorvastatin</td><td>Myalgia unspecified</td><td>3</td><td>AG</td><td>Toxicity</td><td>Patients with the AG genotype and Hypercholesterolemia may have an increased risk of statin-related myalgia as compared to patients with the AA genotype, or may have a decreased, but not absent, risk statin-related myalgia as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for myalgia.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655385379>3056</a></td><td>HTR3B</td><td>rs2276307</td><td>pravastatin</td><td>Myalgia unspecified</td><td>3</td><td>AG</td><td>Toxicity</td><td>Patients with the AG genotype and Hypercholesterolemia may have an increased risk of statin-related myalgia as compared to patients with the AA genotype, or may have a decreased, but not absent, risk statin-related myalgia as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for myalgia.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655385379>3057</a></td><td>HTR3B</td><td>rs2276307</td><td>simvastatin</td><td>Myalgia unspecified</td><td>3</td><td>AG</td><td>Toxicity</td><td>Patients with the AG genotype and Hypercholesterolemia may have an increased risk of statin-related myalgia as compared to patients with the AA genotype, or may have a decreased, but not absent, risk statin-related myalgia as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for myalgia.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655386421>3058</a></td><td>SLC19A1</td><td>rs1051266</td><td>methotrexate</td><td>Arthritis, Rheumatoid;Drug Toxicity</td><td>3</td><td>CT</td><td>Toxicity</td><td>Patients with the rs1051266 CT genotype and rheumatoid arthritis may have increased likelihood of toxicity when treated with methotrexate as compared to patients with the TT genotype but a decreased likelihood as compared to patients with the CC genotype. Other genetic and clinical factors may also influence methotrexate toxicity.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655386969>3059</a></td><td>ADORA2A</td><td>rs3761422</td><td>methotrexate</td><td>Arthritis, Rheumatoid</td><td>3</td><td>CT</td><td>Toxicity</td><td>Patients with the CT genotype and Rheumatoid Arthritis who are treated with methotrexate may have an increased risk of adverse events as compared to patients with the CC genotype or may have a decreased, but not absent, risk of adverse events as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events when treated with methotrexate.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655386981>3060</a></td><td>ADORA2A</td><td>rs2267076</td><td>methotrexate</td><td>Arthritis, Rheumatoid</td><td>3</td><td>CT</td><td>Toxicity</td><td>Patients with the CT genotype and Rheumatoid Arthritis who are treated with methotrexate may have an increased risk for adverse events as compared to patients with the CC genotype or may have a decreased, but not absent, risk for adverse events as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for adverse events when treated with methotrexate.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655386985>3061</a></td><td>ADORA2A</td><td>rs2236624</td><td>methotrexate</td><td>adverse events;Arthritis, Rheumatoid</td><td>3</td><td>CT</td><td>Toxicity</td><td>Patients with the rs2236624 CT genotype and Rheumatoid Arthritis who are treated with methotrexate may have an increased risk for an adverse event as compared to patients with the CC genotype or may have a decreased, but not absent, risk for an adverse event as compared to patients with the TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence a patient's risk for an adverse event.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655385307>3062</a></td><td>MTHFR</td><td>rs1801133</td><td>methotrexate</td><td>Arthritis, Juvenile Rheumatoid;Arthritis, Psoriatic;Arthritis, Rheumatoid;Drug Toxicity</td><td>2A</td><td>AG</td><td>Toxicity</td><td>Patients with the rs1801133 AG genotype and Arthritis who are treated with methotrexate may have an increased risk of toxicity as compared to patients with the GG genotype, or may have a decreased risk of adverse events as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence methotrexate toxicity. This drug-variant pair has been assigned a no recommendation by DPWG, as it was determined to be not clinically actionable.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/827831021>3063</a></td><td>CDA</td><td>rs532545</td><td>cytarabine</td><td>Leukemia, Myeloid</td><td>3</td><td>CT</td><td>Toxicity</td><td>Patients with the CT genotype and Myeloid Leukemia who are treated with cytarabine may have a decreased survival time and an increased risk of death as compared to patients with the CC genotype or may have an increased survival time and a decreased risk for death as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's survival when treated with cytarabine.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/981204912>3064</a></td><td>MTHFR</td><td>rs1801133</td><td>capecitabine</td><td>Neoplasms</td><td>4</td><td>AG</td><td>Toxicity</td><td>Cancer patients with the AG genotype may have increased risk of drug toxicities when treated with fluorouracil- or capecitabine-based therapy as compared to patients with the GG genotype, or a decreased risk of drug toxicities as compared to patients with the AA genotype. This has been contradicted in some studies. Other genetic and clinical factors may also influence a patient's risk of toxicities when taking these drugs.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/981204912>3065</a></td><td>MTHFR</td><td>rs1801133</td><td>fluorouracil</td><td>Neoplasms</td><td>4</td><td>AG</td><td>Toxicity</td><td>Cancer patients with the AG genotype may have increased risk of drug toxicities when treated with fluorouracil- or capecitabine-based therapy as compared to patients with the GG genotype, or a decreased risk of drug toxicities as compared to patients with the AA genotype. This has been contradicted in some studies. Other genetic and clinical factors may also influence a patient's risk of toxicities when taking these drugs.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/981203709>3066</a></td><td>APOE</td><td>rs7412</td><td>Antivirals for treatment of HIV infections, combinations</td><td>HIV Infections;Hypertriglyceridemia</td><td>3</td><td>CT</td><td>Toxicity</td><td>Patients with the CT genotype and HIV infection who are treated with antiretroviral regimens containing ritonavir may have an increased risk of hypertriglyceridemia as compared to patients with the CC genotype or may have a decreased risk of hypertriglyceridemia as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's triglyceride levels.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/981203709>3067</a></td><td>APOE</td><td>rs7412</td><td>ritonavir</td><td>HIV Infections;Hypertriglyceridemia</td><td>3</td><td>CT</td><td>Toxicity</td><td>Patients with the CT genotype and HIV infection who are treated with antiretroviral regimens containing ritonavir may have an increased risk of hypertriglyceridemia as compared to patients with the CC genotype or may have a decreased risk of hypertriglyceridemia as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's triglyceride levels.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448636842>3068</a></td><td>ABCB1</td><td>rs2032582</td><td>everolimus</td><td>Breast Neoplasms;Lymphopenia</td><td>3</td><td>AC</td><td>Toxicity</td><td>Patients with the AC genotype and breast cancer who are treated with everolimus may have increased likelihood of Lymphopenia as compared to patients with the CC genotype, and decreased likelihood as compared to patients with the AA genotype. Other clinical and genetic factors may also influence likelihood of lymphopenia in patients with breast cancer who are treated with everolimus.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449003729>3069</a></td><td>-</td><td>rs1056854</td><td>glatiramer acetate</td><td></td><td>3</td><td>AG</td><td>Toxicity</td><td>Patients with the AG genotype may have increased risk of coronary artery disease in multiple sclerosis patients treated with glatiramer acetate as compared to patients with the GG genotype or a decreased risk of coronary artery disease compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of coronary artery disease.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449003741>3070</a></td><td>-</td><td>rs75041078</td><td>glatiramer acetate</td><td></td><td>3</td><td>AG</td><td>Toxicity</td><td>Patients with the AG genotype may have increased risk of coronary artery disease in multiple sclerosis patients treated with glatiramer acetate as compared to patients with the GG genotype or a decreased risk of coronary artery disease compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of coronary artery disease.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183704367>3071</a></td><td>UGT1A6</td><td>rs6759892</td><td>anthracyclines and related substances</td><td></td><td>4</td><td>GT</td><td>Toxicity</td><td>Patients with the GT genotype may have increased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with genotype TT and decreased likelihood as compared to patients with the GG genotype, although this has been contradicted in one study. Other genetic and clinical factors may also influence the risk of toxicity to anthracyclines and related substances.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184513880>3072</a></td><td>BCHE</td><td>rs1803274</td><td>succinylcholine</td><td>postanesthesia apnea</td><td>3</td><td>CT</td><td>Toxicity</td><td>Patients with the CT genotype have a decreased risk of post anesthesia apnea when treated with succinylcholine as compared to patients with the TT genotype and an increased risk of post anesthesia apnea as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of post anesthesia apnea.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444704141>3073</a></td><td>PTGER4</td><td>rs4133101</td><td>celecoxib</td><td>Colorectal Neoplasms</td><td>3</td><td>CT</td><td>Toxicity</td><td>Patients with the CT genotype and Colorectal Neoplasms who are treated with celecoxib may have increased risk of gastrointestinal toxicities as compared to patients with the CC genotype or may have decreased, but not absent, risk of gastrointestinal toxicities as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to celecoxib.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444700597>3074</a></td><td>RRM1</td><td>rs11030918</td><td>gemcitabine</td><td>Mesothelioma</td><td>3</td><td>CT</td><td>Toxicity</td><td>Patients with the CT genotype who are treated with gemcitabine and platinum compounds may have a decreased risk for nausea as compared to patients with the TT genotype or may have an increased risk for nausea as compared to patients with the CC genotype. Other genetic and clinical factors may also effect patients' risk for nausea.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444700597>3075</a></td><td>RRM1</td><td>rs11030918</td><td>Platinum compounds</td><td>Mesothelioma</td><td>3</td><td>CT</td><td>Toxicity</td><td>Patients with the CT genotype who are treated with gemcitabine and platinum compounds may have a decreased risk for nausea as compared to patients with the TT genotype or may have an increased risk for nausea as compared to patients with the CC genotype. Other genetic and clinical factors may also effect patients' risk for nausea.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444700740>3076</a></td><td>PAPLN</td><td>rs11628713</td><td>citalopram</td><td>Depressive Disorder, Major</td><td>3</td><td>CT</td><td>Toxicity</td><td>Patients with the TT genotype and major depression who are treated with citalopram may have an increased risk for suicidal ideation as compared to patients with the CC genotype or may have a decreased, but not absent, risk for suicidal ideation as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for suicidal ideation.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1446897675>3077</a></td><td>ABCB1</td><td>rs1128503</td><td>sunitinib</td><td>Carcinoma, Renal Cell</td><td>3</td><td>AG</td><td>Toxicity</td><td>Patients with renal cell carcinoma and the AG genotype who are treated with sunitinib may have an increased risk of neutropenia, leukopenia as compared to patients with the AA genotypes and a decreased risk of diarrhea as compared to patients with the GG genotype, although this has been contradicted by some studies. Other clinical and genetic factors may also influence risk of toxicity in patients with renal cell carcinoma who are administered sunitinib.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447813539>3078</a></td><td>ABCC4</td><td>rs1059751</td><td>tenofovir</td><td>HIV Infections</td><td>3</td><td>AG</td><td>Toxicity</td><td>Individuals with the AG genotype and HIV may have a decreased risk of developing Kidney disease when treated with tenofovir as compared to those with the GG genotype and an increased risk as compared to those with the AA genotype. Other clinical and genetic may affect risk of developing kidney disease in individuals with HIV who are taking tenofovir.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448603309>3079</a></td><td>FAAH</td><td>rs324420</td><td>morphine</td><td>Constipation;Delirium;Lung Neoplasms;Nausea;Pain;Postoperative Nausea and Vomiting;Pruritus;Respiratory Insufficiency;somnolence;Urinary Retention</td><td>3</td><td>AC</td><td>Toxicity</td><td>Patients with the rs324420 AC genotype may be at an increased risk of experiencing adverse events when treated with morphine as compared to patients with the CC genotype but a decreased risk as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of adverse events when treated with morphine.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444694504>3080</a></td><td>KCNQ1</td><td>rs2237895</td><td>tacrolimus</td><td>Kidney Transplantation</td><td>3</td><td>AC</td><td>Toxicity</td><td>Patients with the AC genotype who are undergoing kidney transplantation may have a decreased risk of experiencing new-onset diabetes after transplantation when treated with tacrolimus as compared to patients with the CC genotype, or an increased risk as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of new-onset diabetes after transplantation.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444705191>3081</a></td><td>CACNA1C</td><td>rs10848635</td><td>citalopram</td><td>Depressive Disorder, Major</td><td>3</td><td>AT</td><td>Toxicity</td><td>Patients with the AT genotype and major depression may have increased risk of suicide when treated with citalopram as compared to patients with the TT genotype or may have decreased, but not absent, risk of suicide when treated with citalopram as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to citalopram.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444667578>3082</a></td><td>-</td><td>rs1074373</td><td>aspirin</td><td>aspirin-induced asthma;Asthma</td><td>3</td><td>AC</td><td>Toxicity</td><td>Patients with asthma and the AC genotype may have an increased risk of aspirin induced asthma as compared to patients with the CC genotype and a decreased risk of aspirin induced asthma as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk of asthma.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1445556405>3083</a></td><td>POLG</td><td>rs3087374</td><td>valproic acid</td><td>Toxic liver disease</td><td>3</td><td>AC</td><td>Toxicity</td><td>Patients with the AC genotype who are treated with valproic acid may have an increased risk of hepatotoxicity as compared to patients with the CC genotype, or a decreased risk of hepatotoxicity as compared to patients with the AA genotype. This variation is commonly referred to as Q1236H within the literature. Other genetic and clinical factors may also influence risk of hepatotoxicity.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444607782>3084</a></td><td>SLCO1B1</td><td>rs4149056</td><td>mycophenolate mofetil</td><td>Kidney Transplantation</td><td>3</td><td>CT</td><td>Toxicity</td><td>Patients with the CT genotype and Kidney Transplantation who are treated with mycophenolate mofetil may have an increased risk of adverse drug reaction as compared to patients with the CC genotype and may have a decreased risk of adverse drug reaction as compared to patients with the TT genotype. However no association is found with increased risk of diarrhea or leukopenia. Other genetic and clinical factors may also influence a patient's risk for adverse drug reaction.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444667549>3085</a></td><td>HLA-DPB2</td><td>rs3129294</td><td>aspirin</td><td>aspirin-induced asthma;Asthma</td><td>3</td><td>AC</td><td>Toxicity</td><td>Patients with asthma and the AC genotype may have an increased risk of aspirin induced asthma as compared to patients with the AA genotype and a decreased risk of aspirin induced asthma as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of asthma.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444667566>3086</a></td><td>ZBTB22</td><td>rs3130100</td><td>aspirin</td><td>aspirin-induced asthma;Asthma</td><td>3</td><td>CT</td><td>Toxicity</td><td>Patients with asthma and the CT genotype may have an increased risk of aspirin induced asthma as compared to patients with the TT genotype and a decreased risk of aspirin induced asthma as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of asthma.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444703422>3087</a></td><td>TCF7L2</td><td>rs7917983</td><td>hydrochlorothiazide</td><td>Hypertension</td><td>3</td><td>CT</td><td>Toxicity</td><td>Patients with the CT genotype and Hypertension who are treated with hydrochlorothiazide may have increased risk for diabetes mellitus as compared to patients with the CC genotype or may have decreased, but not absent, risk for diabetes mellitus as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for diabetes mellitus.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444703552>3088</a></td><td>UGT2B7</td><td>rs7438135</td><td>mycophenolate mofetil</td><td>Kidney Transplantation</td><td>3</td><td>AG</td><td>Toxicity</td><td>Patients with the AG genotype and kidney transplantation may have increased risk for anemia when treated with mycophenolate mofetil as compared to patients with the AA genotype or may have decreased, but not absent, risk for anemia when treated with mycophenolate mofetil as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to mycophenolate mofetil.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444703215>3089</a></td><td>-</td><td>rs1901440</td><td>gemcitabine</td><td>Neoplasms</td><td>3</td><td>AC</td><td>Toxicity</td><td>Patients with the AC genotype and Neoplasms who are treated with gemcitabine may have an increased risk for leukopenia as compared to patients with the AA genotype or may have a decreased, but not absent, risk for leukopenia as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to gemcitabine.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444608182>3090</a></td><td>DPYD</td><td>rs12022243</td><td>capecitabine</td><td>Colorectal Neoplasms</td><td>3</td><td>CT</td><td>Toxicity</td><td>Patients with the CT genotype and colorectal cancer may have a decreased risk for experiencing drug toxicity, particularly diarrhea, when treated with capecitabine as compared to patients with the TT genotype, or an increased risk for toxicity as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for experiencing drug toxicity when treated with capecitabine.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444667585>3091</a></td><td>TSC1</td><td>rs7862221</td><td>aspirin</td><td>aspirin-induced asthma;Asthma</td><td>3</td><td>CT</td><td>Toxicity</td><td>Patients with asthma and the CT genotype may have an increased risk of aspirin induced asthma as compared to patients with the TT genotype and a decreased risk of aspirin induced asthma as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk of asthma.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1446903240>3092</a></td><td>NR1I2</td><td>rs6785049</td><td>sunitinib</td><td>Neoplasms</td><td>3</td><td>AG</td><td>Toxicity</td><td>Patients with the AG genotype and cancer may have an increased risk for hypertension when treated with sunitinib as compared to patients with the GG genotype, or a decreased risk as compare to patients with the AA genotype. Other genetic and clinical factors may also influence risk for hypertension in patients receiving sunitinib.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444673032>3093</a></td><td>CYP2B6</td><td>rs2054675</td><td>nevirapine</td><td>HIV Infections</td><td>3</td><td>CT</td><td>Toxicity</td><td>Patients with the CT genotype and HIV may be at an increased risk for experiencing severe cutaneous adverse events when treated with nevirapine, as compared to patients with the TT genotype, or a decreased risk as compared to patients with the CC genotype. Other genetic and clinical factors may also influence nevirapine-related adverse reactions.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444673039>3094</a></td><td>CYP2B6</td><td>rs3786547</td><td>nevirapine</td><td>HIV Infections</td><td>3</td><td>CT</td><td>Toxicity</td><td>Patients with the CT genotype and HIV may be at an increased risk for experiencing severe cutaneous adverse events when treated with nevirapine, as compared to patients with the TT genotype, or a decreased risk as compared to patients with the CC genotype. Other genetic and clinical factors may also influence nevirapine-related adverse reactions.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444700808>3095</a></td><td>RRM1</td><td>rs12806698</td><td>gemcitabine</td><td>Mesothelioma</td><td>3</td><td>AC</td><td>Toxicity</td><td>Patients with the AC genotype who are treated gemcitabine and platinum compounds may have decreased risk for nausea as compared to patients with the CC genotype or may have increased risk for nausea as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for nausea.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444700808>3096</a></td><td>RRM1</td><td>rs12806698</td><td>Platinum compounds</td><td>Mesothelioma</td><td>3</td><td>AC</td><td>Toxicity</td><td>Patients with the AC genotype who are treated gemcitabine and platinum compounds may have decreased risk for nausea as compared to patients with the CC genotype or may have increased risk for nausea as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for nausea.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448525452>3097</a></td><td>DRD3</td><td>rs6280</td><td>levodopa</td><td>gastrointestinal toxicity;Hallucinations;Parkinson Disease</td><td>3</td><td>CT</td><td>Toxicity</td><td>Patients with the CT genotype and Parkinson's Disease may have a decreased risk of adverse events when treated with levodopa as compared to patients with the TT genotype but an increased risk as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of adverse events when treated with levodopa.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448635585>3098</a></td><td>CYP2B6</td><td>rs3745274</td><td>nevirapine</td><td>drug reaction with eosinophilia and systemic symptoms;HIV Infections;Stevens-Johnson Syndrome;Toxic liver disease</td><td>4</td><td>GT</td><td>Toxicity</td><td>Individuals with HIV and the GT genotype may have a decreased risk of SJS/TEN and DRESS Syndrome when treated with nevirapine as compared to patients with the TT genotype and an increased risk as compared to patients with the GG genotype, but may not be associated with hepatotoxicity. Please note: in two studies, it was the combination of rs28399499 and rs3745274 that was significantly associated with toxicity. Other clinical and genetic factors may also influence risk of SJS/TEN or DRESS Syndrome in patients with HIV who are administered nevirapine.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447962855>3099</a></td><td>ABCB1</td><td>rs1128503</td><td>simvastatin</td><td>Hypercholesterolemia</td><td>3</td><td>AG</td><td>Toxicity</td><td>Patients with the AG genotype and hypercholesterolemia may have a decreased risk for myalgia when treated with simvastatin as compared to patients with the GG genotype, or an increased risk as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk for myalgia.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448109591>3100</a></td><td>SLC22A2</td><td>rs316019</td><td>anthracyclines and related substances</td><td>Neoplasms</td><td>4</td><td>AC</td><td>Toxicity</td><td>Patients with the AC genotype may have decreased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with genotype CC and increased likelihood as compared to patients with the AA genotype, although this has been contradicted in one study. Other genetic and clinical factors may also influence the risk of toxicity to anthracyclines and related substances.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447964041>3101</a></td><td>NAT2</td><td>rs1041983</td><td>ethambutol</td><td>Toxic liver disease;Tuberculosis</td><td>3</td><td>CT</td><td>Toxicity</td><td>Patients with the rs1041983 CT genotype and tuberculosis (TB) may have a decreased risk for hepatotoxicity when treated with ethambutol, isoniazid, pyrazinamide and rifampin as compared to patients with the TT genotype, or an increased risk as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for hepatotoxicity.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447964041>3102</a></td><td>NAT2</td><td>rs1041983</td><td>isoniazid</td><td>Toxic liver disease;Tuberculosis</td><td>3</td><td>CT</td><td>Toxicity</td><td>Patients with the rs1041983 CT genotype and tuberculosis (TB) may have a decreased risk for hepatotoxicity when treated with ethambutol, isoniazid, pyrazinamide and rifampin as compared to patients with the TT genotype, or an increased risk as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for hepatotoxicity.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447964041>3103</a></td><td>NAT2</td><td>rs1041983</td><td>pyrazinamide</td><td>Toxic liver disease;Tuberculosis</td><td>3</td><td>CT</td><td>Toxicity</td><td>Patients with the rs1041983 CT genotype and tuberculosis (TB) may have a decreased risk for hepatotoxicity when treated with ethambutol, isoniazid, pyrazinamide and rifampin as compared to patients with the TT genotype, or an increased risk as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for hepatotoxicity.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447964041>3104</a></td><td>NAT2</td><td>rs1041983</td><td>rifampin</td><td>Toxic liver disease;Tuberculosis</td><td>3</td><td>CT</td><td>Toxicity</td><td>Patients with the rs1041983 CT genotype and tuberculosis (TB) may have a decreased risk for hepatotoxicity when treated with ethambutol, isoniazid, pyrazinamide and rifampin as compared to patients with the TT genotype, or an increased risk as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for hepatotoxicity.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448101278>3105</a></td><td>CHRNA5</td><td>rs684513</td><td>nicotine</td><td>Tobacco Use Disorder</td><td>3</td><td>CG</td><td>Toxicity</td><td>Patients with the CG genotype may have an increased likelihood of smoking addiction as compared to patients with the GG genotype, or a decreased likelihood as compared to patients with the CC genotype. Other genetic and clinical factors may also influence smoking addiction.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447980911>3106</a></td><td>CYP2B6</td><td>rs3745274</td><td>Antivirals for treatment of HIV infections, combinations</td><td>HIV Infections;Tuberculosis</td><td>3</td><td>GT</td><td>Toxicity</td><td>Patients with the GT genotype who are co-infected with HIV and tuberculosis (TB) may have a decreased risk for hepatotoxicity when treated with anti-tubercular and antiretroviral drugs as compared to patients with the TT genotype, and an increased risk as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of hepatotoxicity.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447980911>3107</a></td><td>CYP2B6</td><td>rs3745274</td><td>Drugs For Treatment Of Tuberculosis</td><td>HIV Infections;Tuberculosis</td><td>3</td><td>GT</td><td>Toxicity</td><td>Patients with the GT genotype who are co-infected with HIV and tuberculosis (TB) may have a decreased risk for hepatotoxicity when treated with anti-tubercular and antiretroviral drugs as compared to patients with the TT genotype, and an increased risk as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of hepatotoxicity.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448100712>3108</a></td><td>ABCB1</td><td>rs1128503</td><td>codeine</td><td>Pain</td><td>3</td><td>AG</td><td>Toxicity</td><td>Breast-feeding infants whose mothers have the AG genotype and are taking codeine may be at increased risk for CNS depression as compared to those whose mothers have the GG genotype, or at decreased risk as compared to those whose mothers have the AA genotype. Other genetic and clinical factors may also influence the risk of CNS depression in breast-feeding infants.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448101271>3109</a></td><td>CHRNA5</td><td>rs637137</td><td>nicotine</td><td>Tobacco Use Disorder</td><td>3</td><td>AT</td><td>Toxicity</td><td>Patients with the AT genotype may have a decreased likelihood of smoking addiction as compared to patients with the TT genotype, or an increased likelihood as compared to patients with the AA genotype. Other genetic and clinical factors may also influence smoking addiction.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447964324>3110</a></td><td>NAT2</td><td>rs4271002</td><td>aspirin</td><td>Asthma</td><td>3</td><td>CG</td><td>Toxicity</td><td>Patients with the CG genotype and asthma may have an increased risk of aspirin intolerance as compared to patients with the GG genotype, or a decreased risk as compared to patients with the CC genotype. Other genetic and clinical factors may also influence aspirin-intolerant asthma.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448109812>3111</a></td><td>CYP4F2</td><td>rs2108623</td><td>anthracyclines and related substances</td><td>Neoplasms</td><td>4</td><td>AG</td><td>Toxicity</td><td>Patients with the AG genotype may have decreased likelihood of cardiotoxicity when exposed to anthracyclines for pediatric cancer as compared to patients with the AA genotype and increased likelihood as compared to patients with the GG genotype, although this is contradicted in one study. Other genetic and clinical factors may also influence risk for cardiotoxicity.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448109578>3112</a></td><td>UGT1A6</td><td>rs17863783</td><td>anthracyclines and related substances</td><td>Neoplasms</td><td>4</td><td>GT</td><td>Toxicity</td><td>Patients with the GT genotype may have increased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with genotype GG and decreased likelihood as compared to patients with the TT genotype, although this has been contradicted in one study. Other genetic and clinical factors may also influence the risk of toxicity to anthracyclines and related substances.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448109598>3113</a></td><td>ABCB4</td><td>rs1149222</td><td>anthracyclines and related substances</td><td>Neoplasms</td><td>4</td><td>GT</td><td>Toxicity</td><td>Patients with the GT genotype may have increased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with genotype TT and decreased likelihood as compared to patients with the GG genotype, although this has been contradicted in one study. Other genetic and clinical factors may also influence the risk of toxicity to anthracyclines and related substances.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448109605>3114</a></td><td>ABCB4</td><td>rs4148808</td><td>anthracyclines and related substances</td><td>Neoplasms</td><td>4</td><td>CT</td><td>Toxicity</td><td>Patients with the CT genotype may have increased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with genotype CC and decreased likelihood as compared to patients with the TT genotype, although this is contradicted in one study. Other genetic and clinical factors may also influence the risk of toxicity to anthracyclines and related substances.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448109802>3115</a></td><td>SPG7</td><td>rs2019604</td><td>anthracyclines and related substances</td><td>Neoplasms</td><td>4</td><td>GT</td><td>Toxicity</td><td>Patients with the GT genotype may have decreased likelihood of cardiotoxicity when exposed to anthracyclines for pediatric cancer as compared to patients with the TT genotype and increased likelihood as compared to patients with the GG genotype, although this is contradicted in one study. Other genetic and clinical factors may also influence risk for cardiotoxicity.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447960731>3116</a></td><td>CCHCR1</td><td>rs1265112</td><td>nevirapine</td><td>HIV Infections</td><td>3</td><td>CT</td><td>Toxicity</td><td>Patients with the CT genotype and HIV infection who are treated with nevirapine may have an increased risk of drug-induced rash as compared to patients with the TT genotype or may have a decreased risk of drug-induced rash as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for nevirapine-induced rash.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447987124>3117</a></td><td>RYR2</td><td>rs2819742</td><td>atorvastatin</td><td>Cardiovascular Diseases</td><td>3</td><td>AG</td><td>Toxicity</td><td>Patients with the AG genotype and cardiovascular disease who are taking a statin may have an increased likelihood of statin-associated myopathy and myalgia as compared with patients with the GG genotypes and decreased likelihood as compared to patients with the AA genotype. Other clinical and genetic factors may also influence the likelihood of developing statin-associated myopathy and myalgia in patients with cardiovascular disease who are taking atorvastatin or simvastatin, although the evidence is contradictory. Other clinical and genetic factors may also influence the likelihood of developing statin-associated myopathy and myalgia in patients who are taking statins.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447987124>3118</a></td><td>RYR2</td><td>rs2819742</td><td>simvastatin</td><td>Cardiovascular Diseases</td><td>3</td><td>AG</td><td>Toxicity</td><td>Patients with the AG genotype and cardiovascular disease who are taking a statin may have an increased likelihood of statin-associated myopathy and myalgia as compared with patients with the GG genotypes and decreased likelihood as compared to patients with the AA genotype. Other clinical and genetic factors may also influence the likelihood of developing statin-associated myopathy and myalgia in patients with cardiovascular disease who are taking atorvastatin or simvastatin, although the evidence is contradictory. Other clinical and genetic factors may also influence the likelihood of developing statin-associated myopathy and myalgia in patients who are taking statins.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447963078>3119</a></td><td>CHRNA3</td><td>rs578776</td><td>nicotine</td><td>Tobacco Use Disorder</td><td>3</td><td>AG</td><td>Toxicity</td><td>Patients with the rs578776 AG genotype may have a decreased risk for nicotine dependence as compared to patients with the GG genotype, or an increased risk as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk for nicotine dependence and cotinine levels.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447963713>3120</a></td><td>PMCH</td><td>rs7973796</td><td>olanzapine</td><td>Schizophrenia</td><td>3</td><td>AG</td><td>Toxicity</td><td>Patients with the AG genotype and schizophrenia may have a decreased likelihood of obesity when treated with olanzapine as compared to patients with the GG genotype, and an increased likelihood as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of weight gain while receiving olanzapine.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448605477>3121</a></td><td>CRTC2</td><td>rs8450</td><td>cyclosporine</td><td>Transplantation</td><td>3</td><td>AG</td><td>Toxicity</td><td>Patients with the AG genotype who are undergoing organ transplantation may have a decreased risk for new-onset diabetes after transplantation (NODAT) when treated with tacrolimus or cyclosporine as compared to patients with the AA genotype, or increased risk as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for NODAT.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448605477>3122</a></td><td>CRTC2</td><td>rs8450</td><td>tacrolimus</td><td>Transplantation</td><td>3</td><td>AG</td><td>Toxicity</td><td>Patients with the AG genotype who are undergoing organ transplantation may have a decreased risk for new-onset diabetes after transplantation (NODAT) when treated with tacrolimus or cyclosporine as compared to patients with the AA genotype, or increased risk as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk for NODAT.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447963674>3123</a></td><td>ARRB2</td><td>rs2036657</td><td>methamphetamine</td><td>Substance-Related Disorders</td><td>3</td><td>AG</td><td>Toxicity</td><td>Patients with the AG genotype who take methamphetamine may have an increased likelihood of addiction as compared to patients with the GG genotype, or a decreased risk as compared to patients with the AA genotype. Other genetic and clinical factors may also influence methamphetamine addiction.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448101260>3124</a></td><td>CHRNA3</td><td>rs3743078</td><td>nicotine</td><td>Tobacco Use Disorder</td><td>3</td><td>CG</td><td>Toxicity</td><td>Patients with the CG genotype may have a decreased likelihood of smoking addiction as compared to patients with the GG genotype, or an increased likelihood as compared to patients with the CC genotype. Other genetic and clinical factors may also influence smoking addiction.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447990283>3125</a></td><td>DROSHA</td><td>rs639174</td><td>cyclophosphamide</td><td>Precursor Cell Lymphoblastic Leukemia-Lymphoma</td><td>3</td><td>CT</td><td>Toxicity</td><td>Pediatric patients with precursor cell lymphoblastic leukemia-lymphoma and the CT genotype may have a decreased risk of drug toxicity when treated with chemotherapy that includes cyclophosphamide, cytarabine, daunorubicin, mercaptopurine, methotrexate, prednisone and vincristine as compared to patients with the TT genotype and an increased risk of drug toxicity as compared to patients with the CC genotype. Other clinical and genetic factors may also influence the risk of drug toxicity in pediatric patients with precursor cell lymphoblastic leukemia-lymphoma who are administered chemotherapy.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447990283>3126</a></td><td>DROSHA</td><td>rs639174</td><td>cytarabine</td><td>Precursor Cell Lymphoblastic Leukemia-Lymphoma</td><td>3</td><td>CT</td><td>Toxicity</td><td>Pediatric patients with precursor cell lymphoblastic leukemia-lymphoma and the CT genotype may have a decreased risk of drug toxicity when treated with chemotherapy that includes cyclophosphamide, cytarabine, daunorubicin, mercaptopurine, methotrexate, prednisone and vincristine as compared to patients with the TT genotype and an increased risk of drug toxicity as compared to patients with the CC genotype. Other clinical and genetic factors may also influence the risk of drug toxicity in pediatric patients with precursor cell lymphoblastic leukemia-lymphoma who are administered chemotherapy.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447990283>3127</a></td><td>DROSHA</td><td>rs639174</td><td>daunorubicin</td><td>Precursor Cell Lymphoblastic Leukemia-Lymphoma</td><td>3</td><td>CT</td><td>Toxicity</td><td>Pediatric patients with precursor cell lymphoblastic leukemia-lymphoma and the CT genotype may have a decreased risk of drug toxicity when treated with chemotherapy that includes cyclophosphamide, cytarabine, daunorubicin, mercaptopurine, methotrexate, prednisone and vincristine as compared to patients with the TT genotype and an increased risk of drug toxicity as compared to patients with the CC genotype. Other clinical and genetic factors may also influence the risk of drug toxicity in pediatric patients with precursor cell lymphoblastic leukemia-lymphoma who are administered chemotherapy.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447990283>3128</a></td><td>DROSHA</td><td>rs639174</td><td>mercaptopurine</td><td>Precursor Cell Lymphoblastic Leukemia-Lymphoma</td><td>3</td><td>CT</td><td>Toxicity</td><td>Pediatric patients with precursor cell lymphoblastic leukemia-lymphoma and the CT genotype may have a decreased risk of drug toxicity when treated with chemotherapy that includes cyclophosphamide, cytarabine, daunorubicin, mercaptopurine, methotrexate, prednisone and vincristine as compared to patients with the TT genotype and an increased risk of drug toxicity as compared to patients with the CC genotype. Other clinical and genetic factors may also influence the risk of drug toxicity in pediatric patients with precursor cell lymphoblastic leukemia-lymphoma who are administered chemotherapy.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447990283>3129</a></td><td>DROSHA</td><td>rs639174</td><td>methotrexate</td><td>Precursor Cell Lymphoblastic Leukemia-Lymphoma</td><td>3</td><td>CT</td><td>Toxicity</td><td>Pediatric patients with precursor cell lymphoblastic leukemia-lymphoma and the CT genotype may have a decreased risk of drug toxicity when treated with chemotherapy that includes cyclophosphamide, cytarabine, daunorubicin, mercaptopurine, methotrexate, prednisone and vincristine as compared to patients with the TT genotype and an increased risk of drug toxicity as compared to patients with the CC genotype. Other clinical and genetic factors may also influence the risk of drug toxicity in pediatric patients with precursor cell lymphoblastic leukemia-lymphoma who are administered chemotherapy.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447990283>3130</a></td><td>DROSHA</td><td>rs639174</td><td>prednisone</td><td>Precursor Cell Lymphoblastic Leukemia-Lymphoma</td><td>3</td><td>CT</td><td>Toxicity</td><td>Pediatric patients with precursor cell lymphoblastic leukemia-lymphoma and the CT genotype may have a decreased risk of drug toxicity when treated with chemotherapy that includes cyclophosphamide, cytarabine, daunorubicin, mercaptopurine, methotrexate, prednisone and vincristine as compared to patients with the TT genotype and an increased risk of drug toxicity as compared to patients with the CC genotype. Other clinical and genetic factors may also influence the risk of drug toxicity in pediatric patients with precursor cell lymphoblastic leukemia-lymphoma who are administered chemotherapy.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447990283>3131</a></td><td>DROSHA</td><td>rs639174</td><td>vincristine</td><td>Precursor Cell Lymphoblastic Leukemia-Lymphoma</td><td>3</td><td>CT</td><td>Toxicity</td><td>Pediatric patients with precursor cell lymphoblastic leukemia-lymphoma and the CT genotype may have a decreased risk of drug toxicity when treated with chemotherapy that includes cyclophosphamide, cytarabine, daunorubicin, mercaptopurine, methotrexate, prednisone and vincristine as compared to patients with the TT genotype and an increased risk of drug toxicity as compared to patients with the CC genotype. Other clinical and genetic factors may also influence the risk of drug toxicity in pediatric patients with precursor cell lymphoblastic leukemia-lymphoma who are administered chemotherapy.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447979279>3132</a></td><td>TBXAS1</td><td>rs6962291</td><td>aspirin</td><td>Asthma</td><td>3</td><td>AT</td><td>Toxicity</td><td>Patients with the AT genotype and asthma may have a decreased risk for aspirin-intolerant asthma as compared to patients with the TT genotype, or an increased risk as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk for aspirin-intolerant asthma.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448109565>3133</a></td><td>UGT1A6</td><td>rs4261716</td><td>anthracyclines and related substances</td><td>Neoplasms</td><td>4</td><td>GT</td><td>Toxicity</td><td>Patients with the GT genotype may have increased likelihood of cardiotoxicity when exposed to anthracyclines and related substances in children with Neoplasms as compared to patients with the GG genotype and decreased likelihood as compared to patients with the TT genotype, although this is contradicted in one study. Other genetic and clinical factors may also influence the toxicity to anthracyclines.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448101086>3134</a></td><td>SLC22A1</td><td>rs622342</td><td>amantadine</td><td>Parkinson Disease</td><td>3</td><td>AC</td><td>Toxicity</td><td>Patients with the AC genotype and Parkinson disease may require increased doses of anti-Parkinsonian drugs and may have an increased risk of mortality as compared to patients with the AA genotype, and require decreased doses and have a decreased risk of mortality as compared to patients with the CC genotype. Other genetic and clinical factors may also influence dose of anti-Parkinsonian drugs and risk of mortality.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448101086>3135</a></td><td>SLC22A1</td><td>rs622342</td><td>Anticholinergics</td><td>Parkinson Disease</td><td>3</td><td>AC</td><td>Toxicity</td><td>Patients with the AC genotype and Parkinson disease may require increased doses of anti-Parkinsonian drugs and may have an increased risk of mortality as compared to patients with the AA genotype, and require decreased doses and have a decreased risk of mortality as compared to patients with the CC genotype. Other genetic and clinical factors may also influence dose of anti-Parkinsonian drugs and risk of mortality.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448101086>3136</a></td><td>SLC22A1</td><td>rs622342</td><td>Dopamine agonists</td><td>Parkinson Disease</td><td>3</td><td>AC</td><td>Toxicity</td><td>Patients with the AC genotype and Parkinson disease may require increased doses of anti-Parkinsonian drugs and may have an increased risk of mortality as compared to patients with the AA genotype, and require decreased doses and have a decreased risk of mortality as compared to patients with the CC genotype. Other genetic and clinical factors may also influence dose of anti-Parkinsonian drugs and risk of mortality.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448101086>3137</a></td><td>SLC22A1</td><td>rs622342</td><td>levodopa</td><td>Parkinson Disease</td><td>3</td><td>AC</td><td>Toxicity</td><td>Patients with the AC genotype and Parkinson disease may require increased doses of anti-Parkinsonian drugs and may have an increased risk of mortality as compared to patients with the AA genotype, and require decreased doses and have a decreased risk of mortality as compared to patients with the CC genotype. Other genetic and clinical factors may also influence dose of anti-Parkinsonian drugs and risk of mortality.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448101086>3138</a></td><td>SLC22A1</td><td>rs622342</td><td>selegiline</td><td>Parkinson Disease</td><td>3</td><td>AC</td><td>Toxicity</td><td>Patients with the AC genotype and Parkinson disease may require increased doses of anti-Parkinsonian drugs and may have an increased risk of mortality as compared to patients with the AA genotype, and require decreased doses and have a decreased risk of mortality as compared to patients with the CC genotype. Other genetic and clinical factors may also influence dose of anti-Parkinsonian drugs and risk of mortality.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448101252>3139</a></td><td>CHRNB4</td><td>rs3813567</td><td>nicotine</td><td>Tobacco Use Disorder</td><td>3</td><td>AG</td><td>Toxicity</td><td>Patients with the AG genotype may have a decreased likelihood of smoking addiction as compared to patients with the GG genotype, or an increased likelihood as compared to patients with the AA genotype. Other genetic and clinical factors may also influence smoking addiction.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448624484>3140</a></td><td>-</td><td>rs11636687</td><td>cyclophosphamide</td><td>Breast Neoplasms;Leukopenia;Neutropenia</td><td>3</td><td>CT</td><td>Toxicity</td><td>Patients with the CT genotype and breast cancer who are treated with fluorouracil, epirubicin, and cyclophosphamide (FEC) may have increased likelihood of neutropenia or leukopenia as compared to patients with the TT genotype, and decreased likelihood of neutropenia or leukopenia as compared to patients wth the CC genotype. Other clinical and genetic factors may also influence likelihood of neutropenia or leukopenia in patients with breast cancer who are treated with FEC. The SNP is not associated with neutropenia or leukopenia when patients are treated with docetaxel (+/-gemcitabine).</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448624484>3141</a></td><td>-</td><td>rs11636687</td><td>epirubicin</td><td>Breast Neoplasms;Leukopenia;Neutropenia</td><td>3</td><td>CT</td><td>Toxicity</td><td>Patients with the CT genotype and breast cancer who are treated with fluorouracil, epirubicin, and cyclophosphamide (FEC) may have increased likelihood of neutropenia or leukopenia as compared to patients with the TT genotype, and decreased likelihood of neutropenia or leukopenia as compared to patients wth the CC genotype. Other clinical and genetic factors may also influence likelihood of neutropenia or leukopenia in patients with breast cancer who are treated with FEC. The SNP is not associated with neutropenia or leukopenia when patients are treated with docetaxel (+/-gemcitabine).</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448624484>3142</a></td><td>-</td><td>rs11636687</td><td>fluorouracil</td><td>Breast Neoplasms;Leukopenia;Neutropenia</td><td>3</td><td>CT</td><td>Toxicity</td><td>Patients with the CT genotype and breast cancer who are treated with fluorouracil, epirubicin, and cyclophosphamide (FEC) may have increased likelihood of neutropenia or leukopenia as compared to patients with the TT genotype, and decreased likelihood of neutropenia or leukopenia as compared to patients wth the CC genotype. Other clinical and genetic factors may also influence likelihood of neutropenia or leukopenia in patients with breast cancer who are treated with FEC. The SNP is not associated with neutropenia or leukopenia when patients are treated with docetaxel (+/-gemcitabine).</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448616381>3143</a></td><td>SLC16A5</td><td>rs4788863</td><td>cisplatin</td><td>Neoplasms;Ototoxicity;Testicular Neoplasms</td><td>3</td><td>CT</td><td>Toxicity</td><td>Patients with the CT genotype and cancer may have an increased likelihood of ototoxicity when treated with cisplatin as compared to patients with the TT genotype, and a decreased risk as compared to patients with the CC genotype. However, one study failed to find an association. Other clinical and genetic factors may also influence likelihood of ototoxicity in patients with cancer who are treated with cisplatin.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447964542>3144</a></td><td>ABCB1</td><td>rs1128503</td><td>capecitabine</td><td>Colorectal Neoplasms</td><td>3</td><td>AG</td><td>Toxicity</td><td>Patients with the AG genotype and colorectal cancer may have a decreased risk of neutropenia or hand-foot syndrome when treated with capecitabine as compared to patients with the GG genotype, or an increased risk as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of neutropenia or hand-foot syndrome.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447979295>3145</a></td><td>LEPR</td><td>rs1137101</td><td>antipsychotics</td><td></td><td>3</td><td>AG</td><td>Toxicity</td><td>Female patients with the AG genotype may have a decreased likelihood of weight gain when treated with antipsychotics as compared to patients with the GG genotype, or an increased likelihood as compared to patients with the AA genotype. In males, this association may be in the opposite direction. Other genetic and clinical factors may also influence weight gain in patients receiving antipsychotics.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448100826>3146</a></td><td>EPHA5</td><td>rs7349683</td><td>paclitaxel</td><td>Breast Neoplasms;Ovarian Neoplasms;Peripheral Nervous System Diseases</td><td>3</td><td>CT</td><td>Toxicity</td><td>Women with the CT genotype and breast or ovarian cancer may have an increased risk for peripheral neuropathy when treated with paclitaxel as compared to women with the CC genotype, and a decreased risk as compared to women with the TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk for peripheral neuropathy.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450810975>3147</a></td><td>PLIN1</td><td>rs894160</td><td>rosiglitazone</td><td>Diabetes Mellitus, Type 2;Weight gain</td><td>3</td><td>CT</td><td>Toxicity</td><td>Patients with the CT genotype may experience increased weight gain when treated with rosiglitazone as compared to patients with TT genotype, but decreased weight gain as compared to patients with the CC genotype. Other genetic and clinical factors may also affect a patient's weight gain during rosiglitazone treatment.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449003759>3148</a></td><td>KNG1</td><td>rs710446</td><td>hormonal contraceptives for systemic use</td><td></td><td>3</td><td>CT</td><td>Toxicity</td><td>Patients with the CT genotype who are taking oral contraceptives may have an increased risk of venous thrombosis as compared to patients with the TT genotype or a decreased risk of venous thrombosis compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk for venous thrombosis in patients taking oral contraceptives.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449003777>3149</a></td><td>F11</td><td>rs2289252</td><td>hormonal contraceptives for systemic use</td><td></td><td>3</td><td>CT</td><td>Toxicity</td><td>Patients with the CT genotype who are taking oral contraceptives may have an increased risk of venous thrombosis as compared to patients with the CC genotype or a decreased risk for venous thrombosis compared to the TT genotype. Other genetic and clinical factors may also influence risk for venous thrombosis in patients taking oral contraceptives.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451135574>3150</a></td><td>ADGRV1</td><td>rs2366929</td><td>opioids</td><td>Opioid-Related Disorders</td><td>3</td><td>CT</td><td>Toxicity</td><td>African American male patients with the CT genotype may be at an increased risk of developing opioid dependence as compared to patients with the TT genotype, but a decreased risk as compared to patients with the CC genotype. Note that this association was not found in female patients or in European Americans. Other genetic and clinical factors may also affect a patient's risk of developing opioid dependence.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449645498>3151</a></td><td>SULT1A3</td><td>rs751527244</td><td>acetaminophen</td><td></td><td>3</td><td>CC</td><td>Metabolism/PK</td><td>Patients with the CC genotype may have an increased rate of sulfation of acetaminophen as compared to patients with the CT or TT genotypes, but a decreased rate of acetaminophen sulfation as compared to patients with the AA or AC genotypes. Other genetic and clinical factors may also affect acetaminophen sulfation in patients.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449645513>3152</a></td><td>SULT1A3</td><td>rs751527244</td><td>tapentadol</td><td></td><td>3</td><td>CC</td><td>Metabolism/PK</td><td>Patients with the CC genotype may have an increased rate of sulfation of tapentadol as compared to patients with the CT or TT genotypes, but a decreased rate of tapentadol sulfation as compared to patients with the AA or AC genotypes. Other genetic and clinical factors may also affect tapentadol sulfation in patients.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449645522>3153</a></td><td>SULT1A3</td><td>rs751527244</td><td>o-desmethyltramadol</td><td></td><td>3</td><td>CC</td><td>Metabolism/PK</td><td>Patients with the CC genotype may have an increased rate of sulfation of O-desmethyl-tramadol as compared to patients with the CT or TT genotypes, but a decreased rate of O-desmethyl-tramadol sulfation as compared to patients with the AA or AC genotypes. Other genetic and clinical factors may also affect O-desmethyl-tramadol sulfation in patients.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449645522>3154</a></td><td>SULT1A3</td><td>rs751527244</td><td>tramadol</td><td></td><td>3</td><td>CC</td><td>Metabolism/PK</td><td>Patients with the CC genotype may have an increased rate of sulfation of O-desmethyl-tramadol as compared to patients with the CT or TT genotypes, but a decreased rate of O-desmethyl-tramadol sulfation as compared to patients with the AA or AC genotypes. Other genetic and clinical factors may also affect O-desmethyl-tramadol sulfation in patients.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451401800>3155</a></td><td>SLCO1B1</td><td>rs4149081</td><td>methotrexate</td><td>Osteosarcoma;Precursor Cell Lymphoblastic Leukemia-Lymphoma</td><td>3</td><td>AG</td><td>Metabolism/PK</td><td>Patients with the rs4140981 AG genotype may have increased clearance of methotrexate as compared to patients with the AA genotype but decreased clearance of methotrexate as compared to patients with the GG genotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs4149081 and methotrexate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence methotrexate clearance.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183682148>3156</a></td><td>UGT2B7</td><td>rs7668258</td><td>lamotrigine</td><td>Epilepsy</td><td>3</td><td>CT</td><td>Metabolism/PK</td><td>Patients with the rs7668258 CT genotype may have decreased clearance of lamotrigine as compared to patients with the CC genotype but increased clearance as compared to patients with the TT genotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs7668258 and lamotrigine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence lamotrigine clearance.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/981238550>3157</a></td><td>EPHX1</td><td>rs1051740</td><td>carbamazepine</td><td>Epilepsy</td><td>3</td><td>CT</td><td>Metabolism/PK</td><td>Patients with the CT genotype and Epilepsy may have decreased metabolism of carbamazepine as compared to patients with the the CC genotype, or an increased metabolism as compared to patients with the the TT genotype. This annotation only covers the pharmacokinetic relationship between rs1051740 and carbamazepine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence metabolism and dose of carbamazepine.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449163934>3158</a></td><td>CYP1A2</td><td>rs762551</td><td>caffeine</td><td></td><td>3</td><td>AC</td><td>Metabolism/PK</td><td>Patients with the AC genotype may have increased metabolism of caffeine as compared to patients with the CC genotype, or decreased metabolism as compared to patients with the AA genotype. Other genetic and clinical factors may also influence CYP1A2 activity and resultant changes in caffeine metabolism, such as smoking.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449565184>3159</a></td><td>-</td><td>rs1976391</td><td>oxazepam</td><td></td><td>3</td><td>AG</td><td>Metabolism/PK</td><td>The AG genotype is associated with decreased concentrations of UGT1A1 and decreased glucoronidation of oxazepam as compared to the GG genotypes, and increased concentrations of UGT1A1 and increased glucoronidation of oxazepam. Other clinical and genetic factors may also influence concentrations of UGT1A1 and glucoronidation of oxazepam.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449556772>3160</a></td><td>SLCO1B1</td><td>rs4149056</td><td>simvastatin</td><td></td><td>1A</td><td>CT</td><td>Metabolism/PK</td><td>Patients with the rs4149056 CT genotype may have increased serum concentrations of simvastatin acid as compared to patients with the TT genotype, but decreased concentrations as compared to patients with the CC genotype. This annotation only covers the pharmacokinetic relationship between rs4149056 and simvastatin acid and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect serum concentrations of simvastatin acid.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449556772>3161</a></td><td>SLCO1B1</td><td>rs4149056</td><td>simvastatin acid</td><td></td><td>1A</td><td>CT</td><td>Metabolism/PK</td><td>Patients with the rs4149056 CT genotype may have increased serum concentrations of simvastatin acid as compared to patients with the TT genotype, but decreased concentrations as compared to patients with the CC genotype. This annotation only covers the pharmacokinetic relationship between rs4149056 and simvastatin acid and does not include evidence about clinical outcomes. Other genetic and clinical factors may also affect serum concentrations of simvastatin acid.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444703791>3162</a></td><td>SLC47A2</td><td>rs34834489</td><td>metformin</td><td></td><td>3</td><td>AG</td><td>Metabolism/PK</td><td>Patients with the AG genotype who are treated with metformin may have increased renal clearance and secretion clearance of metformin as compared to patients with the GG genotype or may have decreased renal clearance and secretion clearance of metformin but no differences in the plasma metformin concentration and no association with glucose-lowering effect as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to metformin.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1446907957>3163</a></td><td>CYP2B6</td><td>rs7254579</td><td>cyclophosphamide</td><td>Lupus erythematosus</td><td>3</td><td>CT</td><td>Metabolism/PK</td><td>Patients with lupus and the CT genotype may have decreased metabolism of cyclophosphamide resulting in decreased concentrations of active cyclophosphamide metabolite as compared to patients with the TT genotypes and increased metabolism of cyclophosphamide and increased concentrations of cyclophosphide metabolite as compared to patients with the CC genotype. Other clinical and genetic factors may also influence metabolism of cyclophosphamide in patients with lupus.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451504901>3164</a></td><td>MTHFR</td><td>rs1801133</td><td>methotrexate</td><td>Burkitt Lymphoma;Leukemia;Lymphoma;Lymphoma, T-Cell;Precursor Cell Lymphoblastic Leukemia-Lymphoma</td><td>3</td><td>AG</td><td>Metabolism/PK</td><td>Patients with the rs1801133 AG genotype may have increased concentrations of methotrexate as compared to the GG genotype but decreased concentrations as compared to the AA genotype. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs1801133 and methotrexate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence methotrexate concentrations. This drug-variant pair has been assigned a no recommendation by DPWG, as it was determined to be not clinically actionable.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447963096>3165</a></td><td>GSTM1</td><td>rs3754446</td><td>busulfan</td><td>Leukemia, Myeloid, Acute</td><td>3</td><td>AC</td><td>Metabolism/PK</td><td>Patients with the AC genotype and acute myeloid leukemia may have decreased clearance of busulfan as compared to patients with the CC genotype, or increased clearance as compared to patients with the AA genotype. Other genetic and clinical factors may also influence clearance of busulfan.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447987059>3166</a></td><td>NR1I2</td><td>rs7643645</td><td>carbamazepine</td><td>Epilepsy</td><td>3</td><td>AG</td><td>Metabolism/PK</td><td>Patients with the AG genotype and epilepsy may have decreased metabolism of carbamazepine as compared to patients with the GG genotype, or increased metabolism as compared to patients with the AA genotype. Other genetic and clinical factors may also influence metabolism of carbamazepine.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447986910>3167</a></td><td>CHRNA3</td><td>rs7170068</td><td>cotinine</td><td>Tobacco Use Disorder</td><td>3</td><td>AG</td><td>Metabolism/PK</td><td>Individuals with Tobacco Use Disorder and the AG genotype may have increased concentrations of cotinine, a metabolite of nicotine, as compared to individuals with the GG genotype, and decreased concentrations as compared to the AA genotype. Other clinical and genetic factors may also contribute to cotinine concentrations in individuals with Tobacco Use Disorder.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447963004>3168</a></td><td>ABCB1</td><td>rs2032582</td><td>cyclosporine</td><td>Cystic Fibrosis</td><td>3</td><td>AC</td><td>Metabolism/PK</td><td>Patients with the AC genotype and cystic fibrosis may have decreased clearance of dicloxacillin, when it is coadministered with cyclosporine, as compared to patients with the CC genotype, or increased clearance as compared to patients with the AA genotype. Other genetic and clinical factors may also influence clearance of dicloxacillin.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447963004>3169</a></td><td>ABCB1</td><td>rs2032582</td><td>dicloxacillin</td><td>Cystic Fibrosis</td><td>3</td><td>AC</td><td>Metabolism/PK</td><td>Patients with the AC genotype and cystic fibrosis may have decreased clearance of dicloxacillin, when it is coadministered with cyclosporine, as compared to patients with the CC genotype, or increased clearance as compared to patients with the AA genotype. Other genetic and clinical factors may also influence clearance of dicloxacillin.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448100887>3170</a></td><td>ARID5B</td><td>rs10994982</td><td>methotrexate</td><td>Precursor Cell Lymphoblastic Leukemia-Lymphoma</td><td>3</td><td>AG</td><td>Metabolism/PK</td><td>Patients with the AG genotype and acute lymphoblastic leukemia may have decreased clearance of methotrexate as compared to patients with the GG genotype, or increased clearance as compared to patients with the AA genotype. Other genetic and clinical factors may also influence clearance of methotrexate.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448100777>3171</a></td><td>VDR</td><td>rs1544410</td><td>midazolam</td><td></td><td>3</td><td>CT</td><td>Metabolism/PK</td><td>Patients with the CT genotype may have increased clearance of midazolam as compared to patients with the TT genotype, and decreased clearance as compared to patients with the CC genotype. This SNP is present in the VDR gene, and the VDR protein is known to transcriptionally regulate intestinal CYP3A4 expression. Other genetic and clinical factors may also influence clearance of midazolam.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447981385>3172</a></td><td>NT5C3A</td><td>rs3750117</td><td>gemcitabine</td><td>Neoplasms</td><td>3</td><td>GG</td><td>Metabolism/PK</td><td>Patients with the GG genotype and cancer may have decreased clearance of gemcitabine as compared to patients with the AA genotype, and increased elimination clearance of dFdU (the main metabolite of gemcitabine) as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence gemcitabine clearance.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448634752>3173</a></td><td>ABCC2</td><td>rs2273697</td><td>cyclosporine</td><td>Kidney Transplantation</td><td>3</td><td>AG</td><td>Metabolism/PK</td><td>Patients with the AG genotype and kidney transplantation who are treated with mycophenolic acid and cyclosporine may have decreased exposure of mycophenolic acid as compared to patients with the GG genotype, and increased exposure as compared to patients with the AA genotype, however the evidence is contradictory. In one study, the A allele was associated with decreased AUC and increased clearance in both kidney donors AND kidney recipients, but increased Cmax in kidney donors. Other clinical and genetic factors may also influence mycophenolic acid exposure in patients with kidney transplantation who are treated with mycophenolic acid and cyclosporine.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448634752>3174</a></td><td>ABCC2</td><td>rs2273697</td><td>mycophenolic acid</td><td>Kidney Transplantation</td><td>3</td><td>AG</td><td>Metabolism/PK</td><td>Patients with the AG genotype and kidney transplantation who are treated with mycophenolic acid and cyclosporine may have decreased exposure of mycophenolic acid as compared to patients with the GG genotype, and increased exposure as compared to patients with the AA genotype, however the evidence is contradictory. In one study, the A allele was associated with decreased AUC and increased clearance in both kidney donors AND kidney recipients, but increased Cmax in kidney donors. Other clinical and genetic factors may also influence mycophenolic acid exposure in patients with kidney transplantation who are treated with mycophenolic acid and cyclosporine.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444704359>3175</a></td><td>SLCO1B1</td><td>rs4149056</td><td>lopinavir</td><td>HIV Infections</td><td>3</td><td>CT</td><td>Metabolism/PK</td><td>Patients with HIV and the CT genotype may have decreased plasma levels of lopinavir as compared to patients with the CC genotype, but increased plasma levels as compared to patients with the TT genotype. However, one study failed to find this association. Other genetic and clinical factors may also influence lopinavir concentrations in a patients. This annotation only covers the pharmacokinetic relationship between rs4149056 and lopinavir and does not include evidence about clinical outcomes.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449003881>3176</a></td><td>-</td><td>rs12459249</td><td>nicotine</td><td></td><td>3</td><td>CT</td><td>Metabolism/PK</td><td>Patients with the CT genotype may have decreased metabolism of nicotine as compared to patients with the TT genotype, or increased metabolism compared to patients with the CC genotype. Other genetic and clinical factors may also influence metabolism of nicotine in patients.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/981202356>3177</a></td><td>CYP2B6</td><td>rs3745274</td><td>cyclophosphamide</td><td>Breast Neoplasms</td><td>3</td><td>GT</td><td>Dosage</td><td>Patients with the GT genotype and Breast Cancer who are treated with cyclophosphamide and doxorubicin may be more likely to require a reduction in dose as compared to patients with the TT genotype, or may be less likely to require a reduction in dose as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's dose requirements.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/981202356>3178</a></td><td>CYP2B6</td><td>rs3745274</td><td>doxorubicin</td><td>Breast Neoplasms</td><td>3</td><td>GT</td><td>Dosage</td><td>Patients with the GT genotype and Breast Cancer who are treated with cyclophosphamide and doxorubicin may be more likely to require a reduction in dose as compared to patients with the TT genotype, or may be less likely to require a reduction in dose as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's dose requirements.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449716056>3179</a></td><td>IL17A</td><td>rs2275913</td><td>opioids</td><td>Pain, Postoperative</td><td>3</td><td>AG</td><td>Dosage</td><td>Patients with the AG genotype may require an increased dose of opioids as compared to patients with the GG genotype, but a decreased dose as compared to patients with the AA genotype. Other genetic and clinical factors may also affect a patient's opioids dose requirements.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183702975>3180</a></td><td>CYP2B6</td><td>rs3745274</td><td>methadone</td><td>Heroin Dependence;Opioid-Related Disorders</td><td>3</td><td>GT</td><td>Dosage</td><td>Patients with the rs3745274 GT genotype may have increased methadone dose requirements as compared to patients with the TT genotype but decreased dose requirements as compared to the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence dose of methadone.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183702981>3181</a></td><td>CYP2B6</td><td>rs2279343</td><td>methadone</td><td>Heroin Dependence</td><td>3</td><td>AG</td><td>Dosage</td><td>Patients with the rs2279343 AG genotype may have increased methadone dose requirements as compared to patients with the GG genotype but decreased dose requirements as compared to the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence methadone dose requirements.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1445585748>3182</a></td><td>VKORC1</td><td>rs7294</td><td>acenocoumarol</td><td></td><td>3</td><td>CT</td><td>Dosage</td><td>Patients with the CT genotype may require a increased dose of phenprocoumon or acenocoumarol as compared to patients with the CC genotype and a decreased dose as compared to the TT genotype, although this has been contradicted in some studies. Other genetic and clinical factors may also influence a patient's phenprocoumon or acenocoumarol dose requirement.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1445585748>3183</a></td><td>VKORC1</td><td>rs7294</td><td>phenprocoumon</td><td></td><td>3</td><td>CT</td><td>Dosage</td><td>Patients with the CT genotype may require a increased dose of phenprocoumon or acenocoumarol as compared to patients with the CC genotype and a decreased dose as compared to the TT genotype, although this has been contradicted in some studies. Other genetic and clinical factors may also influence a patient's phenprocoumon or acenocoumarol dose requirement.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184986386>3184</a></td><td>VKORC1</td><td>rs7196161</td><td>warfarin</td><td></td><td>3</td><td>AG</td><td>Dosage</td><td>Patients with the AG genotype may require an increased dose of warfarin as compared to patients with the GG genotype and a decreased dose of warfarin as compared to patients with the AA genotype. Other clinical and genetic factors may also influence the dose of warfarin.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451646580>3185</a></td><td>DRD1</td><td>rs5326</td><td>methadone</td><td>Heroin Dependence</td><td>3</td><td>CT</td><td>Dosage</td><td>Patients with heroin dependence and the rs5326 CT genotype may have decreased methadone dose requirements as compared to patients with the TT genotype but increased dose requirements as compared to the CC genotype. Other genetic and clinical factors may also influence methadone dose requirements.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451244040>3186</a></td><td>VKORC1</td><td>rs9934438</td><td>phenprocoumon</td><td></td><td>2A</td><td>AG</td><td>Dosage</td><td>Patients with the rs9934438 AG genotype may require a decreased dose of phenprocoumon as compared to patients with the GG genotype, but an increased dose as compared to patients with the AA genotype. Other genetic and clinical factors may also influence dose of phenprocoumon.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451135380>3187</a></td><td>ABCB1</td><td>rs2032582</td><td>sufentanil</td><td>Pain, Postoperative</td><td>3</td><td>AC</td><td>Dosage</td><td>Patients with the rs2032582 AC genotype may have increased dose requirements of sufentanil as compared to patients with the CC genotype but decreased dose requirements as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also affect dose requirements of sufentanil.</td><td>Moderate</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183700258>3188</a></td><td>RRM1</td><td>rs1042919</td><td>cladribine</td><td>Leukemia, Myeloid, Acute</td><td>3</td><td>TT</td><td>Efficacy</td><td>Patients with the TT genotype were not studied. Patients with the AT genotype and acute myeloid leukemia who are treated with cytarabine and cladribine may have poorer event-free survival as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine and cladribine treatment.</td><td>Unknown</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183700258>3189</a></td><td>RRM1</td><td>rs1042919</td><td>cytarabine</td><td>Leukemia, Myeloid, Acute</td><td>3</td><td>TT</td><td>Efficacy</td><td>Patients with the TT genotype were not studied. Patients with the AT genotype and acute myeloid leukemia who are treated with cytarabine and cladribine may have poorer event-free survival as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to cytarabine and cladribine treatment.</td><td>Unknown</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1043858675>3190</a></td><td>GP6</td><td>rs1613662</td><td>aspirin</td><td>Coronary Artery Disease</td><td>3</td><td>AA</td><td>Efficacy</td><td>Patients with the AA genotype were not studied but patients with the AG genotype who are treated with aspirin may have an increased risk for non-response to aspirin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to aspirin.</td><td>Unknown</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449191407>3191</a></td><td>CFTR</td><td>rs113993958</td><td>ivacaftor</td><td>Cystic Fibrosis</td><td>1A</td><td>GG</td><td>Efficacy</td><td>Patients with the GG genotype (do not have a copy of the CFTR D110H variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including D110H. Other genetic and clinical factors may also influence response to ivacaftor.</td><td>Unknown</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449191413>3192</a></td><td>CFTR</td><td>rs77834169</td><td>ivacaftor</td><td>Cystic Fibrosis</td><td>1A</td><td>CC</td><td>Efficacy</td><td>Patients with the CC genotype (do not have a copy of the CFTR R117C variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including R117C. Other genetic and clinical factors may also influence response to ivacaftor.</td><td>Unknown</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449191430>3193</a></td><td>CFTR</td><td>rs121908752</td><td>ivacaftor</td><td>Cystic Fibrosis</td><td>1A</td><td>TT</td><td>Efficacy</td><td>Patients with the TT genotype (do not have a copy of the CFTR L206W variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including L206W. Other genetic and clinical factors may also influence response to ivacaftor.</td><td>Unknown</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655385257>3194</a></td><td>ABCC1</td><td>rs28364006</td><td>methotrexate</td><td>Psoriasis</td><td>3</td><td>AA</td><td>Efficacy</td><td>Patients with the AA genotype were not studied, and so conclusions cannot be made in regard to response to methotrexate. However, patients with the GA genotype and psoriasis who are treated with methotrexate may be less likely to have improvement in psoriasis area and severity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.</td><td>Unknown</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655385272>3195</a></td><td>ABCG2</td><td>rs17731538</td><td>methotrexate</td><td>Psoriasis</td><td>3</td><td>AA</td><td>Efficacy</td><td>Patients with the AA genotype were not studied. However, patients with the AG genotype and psoriasis who are treated with methotrexate may be less likely to have improvement in psoriasis area or severity as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to methotrexate.</td><td>Unknown</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183960805>3196</a></td><td>CFTR</td><td>rs80282562</td><td>ivacaftor</td><td>Cystic Fibrosis</td><td>1A</td><td>GG</td><td>Efficacy</td><td>Patients with the rs80282562 GG genotype (do not have a copy of the CFTR G178R variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including G178R. Other genetic and clinical factors may also influence response to ivacaftor.</td><td>Unknown</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444705222>3197</a></td><td>-</td><td>rs585719</td><td>citalopram</td><td>Depressive Disorder</td><td>3</td><td>TT</td><td>Efficacy</td><td>Patients with the TT genotype were not studied. However, patients with the CT genotype and major depression may have increased response to citalopram as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to citalopram.</td><td>Unknown</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449191574>3198</a></td><td>CFTR</td><td>rs77409459</td><td>ivacaftor</td><td>Cystic Fibrosis</td><td>3</td><td>CC</td><td>Efficacy</td><td>Patients with the rs77409459 CC genotype (do not have a copy of the CFTR T338I variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. Other genetic and clinical factors may also influence response to ivacaftor.</td><td>Unknown</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447964180>3199</a></td><td>CYP19A1</td><td>rs6493497</td><td>anastrozole</td><td>Breast Neoplasms</td><td>3</td><td>AA</td><td>Efficacy</td><td>No patients with the AA genotype were available for analysis, but women with the AG genotype and breast cancer may have greater aromatase (CYP19A1) inhibition when treated with aromatase inhibitors as compared to patients with the GG genotype. Other genetic and clinical factors may also influence efficacy.</td><td>Unknown</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447964180>3200</a></td><td>CYP19A1</td><td>rs6493497</td><td>exemestane</td><td>Breast Neoplasms</td><td>3</td><td>AA</td><td>Efficacy</td><td>No patients with the AA genotype were available for analysis, but women with the AG genotype and breast cancer may have greater aromatase (CYP19A1) inhibition when treated with aromatase inhibitors as compared to patients with the GG genotype. Other genetic and clinical factors may also influence efficacy.</td><td>Unknown</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447964180>3201</a></td><td>CYP19A1</td><td>rs6493497</td><td>letrozole</td><td>Breast Neoplasms</td><td>3</td><td>AA</td><td>Efficacy</td><td>No patients with the AA genotype were available for analysis, but women with the AG genotype and breast cancer may have greater aromatase (CYP19A1) inhibition when treated with aromatase inhibitors as compared to patients with the GG genotype. Other genetic and clinical factors may also influence efficacy.</td><td>Unknown</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450814424>3202</a></td><td>MTHFR</td><td>rs1801131</td><td>l-methylfolate</td><td>Depressive Disorder, Major</td><td>3</td><td>TT</td><td>Efficacy</td><td>There is currently no evidence regarding the association between the TT genotype and response to folate supplementation in the context of pharmacotherapy for depression.</td><td>Unknown</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450814424>3203</a></td><td>MTHFR</td><td>rs1801131</td><td>Vitamin B-complex, Incl. Combinations</td><td>Depressive Disorder, Major</td><td>3</td><td>TT</td><td>Efficacy</td><td>There is currently no evidence regarding the association between the TT genotype and response to folate supplementation in the context of pharmacotherapy for depression.</td><td>Unknown</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449191758>3204</a></td><td>CFTR</td><td>rs75541969</td><td>ivacaftor</td><td>Cystic Fibrosis</td><td>1A</td><td>GG</td><td>Efficacy</td><td>Patients with the rs75541969 GG genotype (do not have a copy of the CFTR D1152H variant) and cystic fibrosis have an unknown response to ivacaftor treatment, as response may depend on the presence of other CFTR variants. FDA-approved drug labeling information and CPIC guidelines indicate use of ivacaftor in cystic fibrosis patients with at least one copy of a list of 33 CFTR genetic variants, including D1152H. Other genetic and clinical factors may also influence response to ivacaftor.</td><td>Unknown</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/699639343>3205</a></td><td>MME</td><td>rs2016848</td><td>Ace Inhibitors, Plain</td><td>Cough;Hypertension</td><td>3</td><td>AG</td><td>Toxicity</td><td>Patients with the AG genotype who are treated with ACE inhibitors may have an increased risk for cough as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for cough with ACE inhibitor treatment. Patients with this genotype were not studied directly.</td><td>Unknown</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/699639347>3206</a></td><td>PTGER3</td><td>rs11209716</td><td>Ace Inhibitors, Plain</td><td>Cough;Hypertension</td><td>3</td><td>CT</td><td>Toxicity</td><td>Patients with the genotype have not been studied.</td><td>Unknown</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/699639351>3207</a></td><td>BDKRB2</td><td>rs8012552</td><td>Ace Inhibitors, Plain</td><td>Cough;Hypertension</td><td>3</td><td>CT</td><td>Toxicity</td><td>Patients with the CT genotype and hypertension who are treated with ACE-inhibitors may have an increased risk of cough as compared to patients with the TT genotype. (please note that patients with this genotype were not studied directly). Other genetic and clinical factors may also influence a patient's risk of cough with ACE-inhibitors.</td><td>Unknown</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450933116>3208</a></td><td>ADGRL3</td><td>rs1456862</td><td>nicotine</td><td>Tobacco Use Disorder</td><td>3</td><td>TT</td><td>Toxicity</td><td>There is currently no available evidence regarding the association of the TT genotype and a patient's risk of developing nicotine dependence.</td><td>Unknown</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444703063>3209</a></td><td>CYP2C19</td><td>rs4244285</td><td>venlafaxine</td><td>Depression</td><td>3</td><td>AA</td><td>Toxicity</td><td>Patients with the AA genotype were not studied. Other genetic and clinical factors may also influence a patient's risk for treatment side effects.</td><td>Unknown</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444703430>3210</a></td><td>ABCC2</td><td>rs7917432</td><td>tenofovir</td><td>HIV Infections</td><td>3</td><td>TT</td><td>Toxicity</td><td>Patients with the TT genotype were not studied. However, patients with the CT genotype and HIV who are treated with tenofovir may have decreased creatinine clearance as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to tenofovir.</td><td>Unknown</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451120280>3211</a></td><td>MTHFR</td><td>rs1801133</td><td>phenobarbital</td><td>Epilepsy;Psychotic Disorders</td><td>3</td><td>AG</td><td>Toxicity</td><td>There is currently no available evidence regarding the association between the AG genotype and a patient's rick of developing psychosis following phenytoin and phenobarbital treatment.</td><td>Unknown</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451120280>3212</a></td><td>MTHFR</td><td>rs1801133</td><td>phenytoin</td><td>Epilepsy;Psychotic Disorders</td><td>3</td><td>AG</td><td>Toxicity</td><td>There is currently no available evidence regarding the association between the AG genotype and a patient's rick of developing psychosis following phenytoin and phenobarbital treatment.</td><td>Unknown</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451336060>3213</a></td><td>APOC3</td><td>rs5128</td><td>olanzapine</td><td></td><td>3</td><td>CC</td><td>Metabolism/PK</td><td>There is currently no available evidence regarding the association between the rs5128 CC genotype and exposure to olanzapine. However, patients with the rs5128 CG genotype may have increased exposure to olanzapine as compared to patients with the GG genotype. This annotation only covers the pharmacokinetic relationship between rs5128 and olanzapine and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence exposure to olanzapine.</td><td>Unknown</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/981204361>3214</a></td><td>ABCB1</td><td>rs1045642</td><td>clopidogrel</td><td>Acute coronary syndrome;Myocardial Infarction</td><td>3</td><td>AA</td><td>Metabolism/PK</td><td>People with AA genotype may have an increased risk of major adverse cardiovascular events (MACE such as cardiovascular death, myocardial infarction, or stroke) when treated with clopidogrel in people with Acute coronary syndrome or myocardial Infarction as compared to people with genotypes GG or AG. Contradictory findings have been reported in the literature. Other genetic and clinical factors may also impact the response to clopidogrel.</td><td>Unknown</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449162899>3215</a></td><td>ABCB1</td><td>rs2032582</td><td>tramadol</td><td></td><td>3</td><td>AC</td><td>Metabolism/PK</td><td>There is currently no evidence to show whether the AC genotype affects a patient's exposure to tramadol.</td><td>Unknown</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449162912>3216</a></td><td>ABCB1</td><td>rs1128503</td><td>tramadol</td><td></td><td>3</td><td>AG</td><td>Metabolism/PK</td><td>There is currently no evidence to show whether the AG genotype affects a patient's exposure to tramadol.</td><td>Unknown</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444607318>3217</a></td><td>NR1I2</td><td>rs7643645</td><td>risperidone</td><td>Psychotic Disorders</td><td>3</td><td>AG</td><td>Metabolism/PK</td><td>No information available.</td><td>Unknown</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451398000>3218</a></td><td>ADRB1</td><td>rs1801253</td><td>carvedilol</td><td>Heart Failure</td><td>3</td><td>CG</td><td>Dosage</td><td>There is currently no available evidence regarding the association between the rs1801253 CG genotype and carvedilol dosage requirements. However, patients with heart failure and the CC genotype may require decreased doses of carvedilol as compared to patients with the GG genotype. Other genetic and clinical factors may also affect carvedilol dosage requirements.</td><td>Unknown</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1446903007>3219</a></td><td>UGT2B7</td><td>rs7439366</td><td>codeine</td><td></td><td>3</td><td>CT</td><td>Dosage</td><td>No information is available for the CT genotype.</td><td>Unknown</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449163324>3220</a></td><td>UGT2B7</td><td>rs7439366</td><td>morphine</td><td></td><td>4</td><td>CT</td><td>Dosage</td><td>There is currently no evidence to show the effect of the CT genotype on a patient's morphine dose requirements.</td><td>Unknown</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451138182>3221</a></td><td>GAD1</td><td>rs769404</td><td>methadone</td><td>Heroin Dependence</td><td>3</td><td>CT</td><td>Dosage</td><td>There is currently no studies which have found an association between the CT genotype and methadone dose requirements in patients with heroin dependence receiving methadone maintenance therapy (MMT).</td><td>Unknown</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184986770>3222</a></td><td>GAL</td><td>rs948854</td><td>opioids</td><td>Opioid-Related Disorders</td><td>3</td><td>TT</td><td>Other</td><td>The TT genotype was not evaluated for its influence on risk of opioid dependence upon exposure to opioids.Other clinical and genetic factors may also influence the risk of opioid dependence upon exposure to opioids.</td><td>Unknown</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655386869>3223</a></td><td>VDR</td><td>rs1544410</td><td>alendronate</td><td>Osteoporosis</td><td>3</td><td>CT</td><td>Efficacy</td><td>Patients with the rs1544410 CT genotype who are treated with alendronate have an undocumented response compared to that of patients with the CC or the TT genotype.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655384906>3224</a></td><td>DHODH</td><td>rs3213422</td><td>leflunomide</td><td>Arthritis, Rheumatoid</td><td>3</td><td>AC</td><td>Efficacy</td><td>It is not clear how patients with the AC genotype who are treated with leflunomide respond as compared to patients with the AA or the CC genotype.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444607641>3225</a></td><td>XBP1</td><td>rs2269577</td><td>Platinum compounds</td><td>Carcinoma, Non-Small-Cell Lung</td><td>3</td><td>CG</td><td>Efficacy</td><td>No significant findings available.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449191716>3226</a></td><td>CFTR</td><td>rs397508510</td><td>ivacaftor</td><td>Cystic Fibrosis</td><td>3</td><td>CC</td><td>Efficacy</td><td>Patients with the rs397508510 CC genotype (two copies of the CFTR H1054D variant) and cystic fibrosis may respond to ivacaftor treatment. Other genetic and clinical factors may also influence response to ivacaftor.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448265280>3227</a></td><td>TNFAIP3</td><td>rs610604</td><td>ustekinumab</td><td>Psoriasis</td><td>4</td><td>GT</td><td>Efficacy</td><td>Patients with the GT genotype and psoriasis do not seem to have different response to ustekinumab compared to patients with the TT genotype. Other clinical and genetic factors may affect response to ustekinumab.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183491446>3228</a></td><td>KIF6</td><td>rs20455</td><td>atorvastatin</td><td>Coronary Disease;Hypercholesterolemia;Myocardial Infarction</td><td>3</td><td>AG</td><td>Efficacy</td><td>Patients with the AG genotype may have response to atorvastatin treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to atorvastatin.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448266008>3229</a></td><td>CFTR</td><td>rs77010898</td><td>ivacaftor</td><td>Cystic Fibrosis</td><td>3</td><td>GG</td><td>Efficacy</td><td>Patients with the rs77010898 GG genotype and cystic fibrosis may not respond to ivacaftor treatment, as response may depend on the presence of other CFTR variants. Other clinical and genetic factors may affect response to ivacaftor.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1043858685>3230</a></td><td>IL1B</td><td>rs1143627</td><td>aspirin</td><td></td><td>3</td><td>AA</td><td>Toxicity</td><td>Patients with the AA genotype and Cardiovascular Diseases may have a risk for peptic ulcer as compared to patients with the GG genotype. The study did not discuss the direction of the association but it might be a protective effect. Other genetic and clinical factors may also influence a patient's risk for peptic ulcer.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444607641>3231</a></td><td>XBP1</td><td>rs2269577</td><td>Platinum compounds</td><td>Carcinoma, Non-Small-Cell Lung</td><td>3</td><td>CG</td><td>Toxicity</td><td>No significant findings available.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451141166>3232</a></td><td>PDE3A</td><td>rs12305038</td><td>opioids</td><td>Nausea;Vomiting</td><td>3</td><td>AG</td><td>Toxicity</td><td>The association between the AG genotype and severity of opioid-induced nausea and vomiting is currently unclear. One study investigated this variant in two cohorts and found significant associations going in opposite directions. Other genetic and clinical factors may also affect severity of opioid-induced nausea and vomiting.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/981201788>3233</a></td><td>CYP3A</td><td>rs2740574</td><td>efavirenz</td><td>HIV Infections</td><td>3</td><td>TT</td><td>Other</td><td>Patients with the TT genotype may have decreased plasma drug exposure when treated with efavirenz as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also influence a patient's drug metabolism.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/981201788>3234</a></td><td>CYP3A4</td><td>rs2740574</td><td>efavirenz</td><td>HIV Infections</td><td>3</td><td>TT</td><td>Other</td><td>Patients with the TT genotype may have decreased plasma drug exposure when treated with efavirenz as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also influence a patient's drug metabolism.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/981201797>3235</a></td><td>CYP2A6</td><td>rs28399433</td><td>nicotine</td><td></td><td>3</td><td>AA</td><td>Other</td><td>Patients with the AA genotype may have increased metabolism of nicotine as compared to patients with the AC or CC genotypes. Other genetic and clinical factors may also influence a patient's drug metabolism.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/981201805>3236</a></td><td>CYP2A6</td><td>rs28399433</td><td>coumarin</td><td></td><td>3</td><td>AA</td><td>Other</td><td>Patients with the AA genotype may have increased metabolism of coumarin as compared to patients with the AC or CC genotypes. Other genetic and clinical factors may also influence a patient's drug metabolism.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/981238057>3237</a></td><td>ABCB1</td><td>rs2032582</td><td>doxorubicin</td><td>Breast Neoplasms</td><td>3</td><td>AC</td><td>Other</td><td>Patients with the AC genotype may have decreased metabolism of doxorubicin in people with Breast Neoplasms as compared to patients with genotype CC. Other genetic and clinical factors may also influence the metabolism of doxorubicin.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/981238108>3238</a></td><td>ABCB1</td><td>rs2032582</td><td>digoxin</td><td></td><td>3</td><td>AC</td><td>Other</td><td>Patients with genotype AC may have increased metabolism of digoxin as compared to patients with genotype AA. Other genetic and clinical factors may also influence the metabolism of digoxin.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183631480>3239</a></td><td>ABCB1</td><td>rs1045642</td><td>talinolol</td><td></td><td>3</td><td>AA</td><td>Other</td><td>Patients with the AA genotype may have increased clearance of talinolol as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence clearance of talinolol.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183697752>3240</a></td><td>SLC22A2</td><td>rs316019</td><td>metformin</td><td></td><td>3</td><td>AC</td><td>Other</td><td>Patients with the AC genotype may have decreased clearance of metformin as compared to patients with the CC genotype, however this is contradicted by one study. Other genetic and clinical factors may also influence clearance of metformin.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183700891>3241</a></td><td>BDNF</td><td>rs6265</td><td>heroin</td><td>Substance-Related Disorders</td><td>4</td><td>CT</td><td>Other</td><td>Patients with the CT genotype may have a greater risk of dependence on methamphetamine or heroin as compared to patients with the CC genotype or may have a lower risk of dependence on methamphetamine or heroin as compared to patients with the TT genotype. However, contradictory evidence exists. Other genetic and clinical factors may also influence a patient's risk of addiction to methamphetamine or heroin.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183700891>3242</a></td><td>BDNF</td><td>rs6265</td><td>methamphetamine</td><td>Substance-Related Disorders</td><td>4</td><td>CT</td><td>Other</td><td>Patients with the CT genotype may have a greater risk of dependence on methamphetamine or heroin as compared to patients with the CC genotype or may have a lower risk of dependence on methamphetamine or heroin as compared to patients with the TT genotype. However, contradictory evidence exists. Other genetic and clinical factors may also influence a patient's risk of addiction to methamphetamine or heroin.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1043880098>3243</a></td><td>SLCO1B3</td><td>rs7311358</td><td>mycophenolate mofetil</td><td>Kidney Transplantation</td><td>3</td><td>AA</td><td>Other</td><td>Patients with the AA genotype and Kidney Transplantation may have a decreased clearance of mycophenolate mofetil as compared to patients with the GG genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to mycophenolate mofetil.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183689987>3244</a></td><td>CYP3A4</td><td>rs2740574</td><td>sirolimus</td><td>Kidney Transplantation</td><td>3</td><td>TT</td><td>Other</td><td>Transplant recipients with the TT (CYP3A4 *1/*1) genotype may require a decreased dose of sirolimus as compared to patients with the CC (*1B/*1B) or CT (*1B/*1) genotype. Other genetic and clinical factors, such as CYP3A5 *3 (rs776746), may also influence a patient's dose requirements.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183614855>3245</a></td><td>UGT1A</td><td>rs1042640</td><td>acetaminophen</td><td></td><td>3</td><td>CC</td><td>Other</td><td>Human liver microsomes with the CC genotype may have decreased activity of UGT1A proteins when exposed to acetaminophen as compared to human liver microsomes with the CG or GG genotype. SNP was specified as being in the UGT1A-3'UTR. Other genetic and clinical factors may also influence activity of UGT1A proteins.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1043880433>3246</a></td><td>SCAP</td><td>rs12487736</td><td>atorvastatin</td><td></td><td>4</td><td>CT</td><td>Other</td><td>Patients with the CT genotype who are treated with atorvastatin may have higher expression of SCAP as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183491162>3247</a></td><td>CYP3A5</td><td>rs776746</td><td>simvastatin</td><td>Hypercholesterolemia;Myalgia unspecified</td><td>4</td><td>CC</td><td>Other</td><td>Patients with the CC genotype may have higher plasma concentrations and reduced clearance of simvastatin as compared to patients with the TT genotype. This does not seem to affect response to treatment or risk of myalgia or myopathy. Other genetic and clinical factors may also influence a patient's metabolism of simvastatin and response to treatment.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183700812>3248</a></td><td>CYP2D6</td><td>rs1080985</td><td>debrisoquine</td><td></td><td>3</td><td>CG</td><td>Other</td><td>Patients with the CG genotype may have increased metabolism of debrisoquine as compared to patients with the GG genotype or may have decreased metabolism of debrisoquine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's metabolism of debrisoquine.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183701068>3249</a></td><td>CYP2D6</td><td>rs1080985</td><td>thioridazine</td><td></td><td>3</td><td>CG</td><td>Other</td><td>Patients with the CG genotype may have a lower thioridazine:mesoridazine ratio when treated with thioridazine as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's metabolism of thioridazine.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1043880303>3250</a></td><td>FMO1</td><td>rs12720462</td><td>olanzapine</td><td></td><td>3</td><td>AC</td><td>Other</td><td>Patients with AC genotype may have increased dose-adjusted serum olanzapine concentrations when treated with olanzapine as compared to patients with the CC genotype. Other clinical or genetic factors may also influence olanzapine metabolism.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183697278>3251</a></td><td>CYP2C9</td><td>rs1934969</td><td>losartan</td><td></td><td>3</td><td>TT</td><td>Other</td><td>Patients with the TT genotype may have decreased metabolism of losartan as compared to patients with the AA genotype. No association was seen in Korean subjects, and a seperate study in Ecuadorian subjects found contradictory results. Other genetic and clinical factors may also influence a patient's losartan metabolism.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183634192>3252</a></td><td>CYP2A6</td><td>rs28399433</td><td>efavirenz</td><td>HIV Infections</td><td>3</td><td>AA</td><td>Other</td><td>Patients with the AA genotype and HIV may have decreased plasma concentrations of efavirenz as compared to patients with the AC or CC genotype. However, one study failed to find this association. Other genetic and clinical factors may also influence plasma concentrations of efavirenz.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183491044>3253</a></td><td>CYP2B6</td><td>rs3745274</td><td>mitotane</td><td>Adrenocortical Carcinoma</td><td>3</td><td>TG</td><td>Other</td><td>Patients with the TG genotype and Adrenocortical Carcinoma who are treated with mitotane may have higher mitotane plasma concentrations as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's metabolism of mitotane.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183615317>3254</a></td><td>ABCC2</td><td>rs2273697</td><td>irinotecan</td><td>Colorectal Neoplasms</td><td>3</td><td>AG</td><td>Other</td><td>Patients with the AG genotype and colorectal cancer may have increased metabolism of irinotecan as compared to patients with the GG genotype. Other genetic and clinical factors may also influence metabolism of irinotecan.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183693527>3255</a></td><td>DRD2</td><td>rs1124493</td><td>olanzapine</td><td></td><td>3</td><td>GT</td><td>Other</td><td>Female patients with the GT genotype may have increased prolactin serum concentration when treated with olanzapine as compared to female patients with the GG genotype and decreased prolactin serum concentration when treated with olanzapine as compared to female patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to olanzapine.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183697628>3256</a></td><td>CYP3A5</td><td>rs776746</td><td>nifedipine</td><td>Pregnancy</td><td>3</td><td>CC</td><td>Other</td><td>Pregnant women with the CC genotype may have decreased clearance of nifedipine as compared to women with the CT or TT genotype. Other genetic and clinical factors may also influence clearance of nifedipine.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1043880567>3257</a></td><td>SLCO1B1</td><td>rs2306283</td><td>pitavastatin</td><td></td><td>3</td><td>AG</td><td>Other</td><td>Patients with the AG genotype may have increased pitavastatin plasma concentrations as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's pitavastatin pharmacokinetics.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183631460>3258</a></td><td>NR1I2</td><td>rs1523130</td><td>memantine</td><td>Dementia</td><td>3</td><td>CC</td><td>Other</td><td>Patients with the CC genotype and dementia may have increased clearance of memantine as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence clearance of memantine.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183490957>3259</a></td><td>PRKCB</td><td>rs9922316</td><td>dexmedetomidine</td><td></td><td>3</td><td>TG</td><td>Other</td><td>Patients with the TG genotype may have increased dexmedetomidine ED50 values for drug-induced dorsal hand vein constriction as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to dexmedetomidine.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183614816>3260</a></td><td>UGT1A</td><td>rs10929303</td><td>acetaminophen</td><td></td><td>3</td><td>CC</td><td>Other</td><td>Human liver microsomes with the CC genotype may have decreased activity of UGT1A proteins when exposed to acetaminophen as compared to human liver microsomes with the CT or TT genotype. SNP was specified as being in the UGT1A-3'UTR. Other genetic and clinical factors may also influence activity of UGT1A proteins.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183631422>3261</a></td><td>SLC22A2</td><td>rs316019</td><td>l-tryptophan</td><td></td><td>3</td><td>AC</td><td>Other</td><td>Patients with the AC genotype may have decreased clearance of L-tryptophan as compared to patients with the CC genotype, but an increased clearance as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183491333>3262</a></td><td>CYBA</td><td>rs4673</td><td>simvastatin</td><td>Hypercholesterolemia</td><td>3</td><td>AG</td><td>Other</td><td>Patients with the AG genotype and Hypercholesterolemia may benefit more from simvastatin treatment due to an increased reduction in DNA damage as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183547855>3263</a></td><td>UGT1A</td><td>rs8330</td><td>acetaminophen</td><td></td><td>3</td><td>CC</td><td>Other</td><td>Human liver microsomes with the CC genotype may have decreased activity of UGT1A proteins when exposed to acetaminophen as compared to human liver microsomes with the CG or GG genotype. SNP was specified as being in the UGT1A-3'UTR. Other genetic and clinical factors may also influence activity of UGT1A proteins.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183615535>3264</a></td><td>ABCB1</td><td>rs1128503</td><td>digoxin</td><td></td><td>3</td><td>AG</td><td>Other</td><td>Patients with the AA genotype may have increased serum concentrations of digoxin as compared to patients with the GG genotype, or decreased serum concentrations of digoxin as compared to patients with the AA genotype. Other genetic and clinical factors may also impact serum concentrations of digoxin.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449164857>3265</a></td><td>SLC6A2</td><td>rs2242446</td><td>3,4-methylenedioxymethamphetamine</td><td></td><td>3</td><td>CT</td><td>Other</td><td>Individuals with the CT genotype who are exposed to (3,4-methylenedioxymethamphetamine) MDMA may have an increased response, specifically an increased heart rate, as compared to patients with the TT genotype. Other clinical and genetic factors may also influence an individual's response to MDMA.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/982029652>3266</a></td><td>FAAH</td><td>rs324420</td><td>methamphetamine</td><td>Substance-Related Disorders</td><td>3</td><td>AC</td><td>Other</td><td>Patients with the AC genotype may have an increased risk for dependence on methamphetamine as compared to men with the CC genotype, or a decreased risk for dependence on methamphetamine as compared to men with the AA genotype. Genotype was not associated with risk of methamphetamine-induced pyschosis or panic disorder. Other genetic and clinical factors may also influence dependence on methamphetamine and methamphetamine-induced side effects.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/982036238>3267</a></td><td>ABCB1</td><td>rs1045642</td><td>verapamil</td><td></td><td>3</td><td>AA</td><td>Other</td><td>Patients with the AA genotype may have increased metabolism of verapamil as compared to patients with the GG genotype. Other genetic and clinical factors may also impact the metabolism of verapamil.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1043880313>3268</a></td><td>FMO1</td><td>rs7877</td><td>olanzapine</td><td></td><td>3</td><td>CT</td><td>Other</td><td>Patients with CT genotype may have increased dose-adjusted serum olanzapine concentrations when treated with olanzapine as compared to patients with the CC genotype. Other clinical or genetic factors may also influence olanzapine metabolism.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183574180>3269</a></td><td>-</td><td>rs2952768</td><td>opioids</td><td></td><td>3</td><td>CT</td><td>Other</td><td>Patients with the CT genotype may have more vulnerability to severe drug dependence in patients with methamphetamine dependence, alcohol dependence, and eating disorders and a lower 'Reward Dependence' score on a personality questionnaire when treated with opioids as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to opioids.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183617565>3270</a></td><td>HTR1B</td><td>rs130058</td><td>paroxetine</td><td>Depression</td><td>3</td><td>AT</td><td>Other</td><td>Patients with the AT genotype and depression who are treated with paroxetine may have an increased risk of suicidal ideation as compared to patients with the TT genotype or may have a decreased risk of suicidal ideation as compared to patients with the AA genotype. Please note; alleles are complemented to the plus chromosomal strand. Other genetic and clinical factors may also influence a patient's risk of suicidal ideation.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183556815>3271</a></td><td>CYP3A5</td><td>rs776746</td><td>ondansetron</td><td></td><td>3</td><td>CC</td><td>Other</td><td>Patients with the CC genotype may have decreased metabolism of ondansetron as compared to patients with the CT or TT genotype. Other genetic and clinical factors may also influence metabolism of ondansetron.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/982036249>3272</a></td><td>ABCB1</td><td>rs2032582</td><td>verapamil</td><td></td><td>3</td><td>AC</td><td>Other</td><td>Patients with the AC genotype may have increased metabolism of verapamil as compared to patients with the CC genotype. Other genetic and clinical factors may also impact the metabolism of verapamil.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183490962>3273</a></td><td>ADRA2A</td><td>rs1800544</td><td>dexmedetomidine</td><td></td><td>3</td><td>GC</td><td>Other</td><td>Patients with the GC genotype may have a decreased sedative response to dexmedetomidine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to dexmedetomidine.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183533592>3274</a></td><td>HMGCR</td><td>rs12654264</td><td>hmg coa reductase inhibitors</td><td>Colonic Neoplasms</td><td>3</td><td>AT</td><td>Other</td><td>Patients with the AT genotype may have a higher reduction in the risk of colon cancer when treated with statins as compared to patients with the TT genotype or may have a lower reduction in the risk of colon cancer when treated with statins as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for colon cancer and response to statin treatment.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183615410>3275</a></td><td>CDA</td><td>rs60369023</td><td>cytarabine</td><td></td><td>3</td><td>GG</td><td>Other</td><td>Purified CDA proteins with the GG genotype may have increased catalytic activity when exposed to cytarabine as compared to those proteins with the AA or AG genotype. Other genetic and clinical factors may also influence catalytic activity of the CDA protein.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449188545>3276</a></td><td>VKORC1</td><td>rs7294</td><td>acenocoumarol</td><td></td><td>3</td><td>CT</td><td>Other</td><td>Patients with the CT genotype may have a decreased likelihood of hemorrhage when treated with acenocoumarol as compared to patients with the TT genotypes and increased likelihood as compared to patients with the CC genotypes. Other clinical and genetic factors may also influence risk of hemorrhage in patients administered acenocoumarol.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655385471>3277</a></td><td>ARID5B</td><td>rs10821936</td><td>methotrexate</td><td>Precursor Cell Lymphoblastic Leukemia-Lymphoma</td><td>3</td><td>CT</td><td>Other</td><td>Pediatric patients with the CT genotype and B-hyperdiploid acute lymphoblastic leukemia who are treated with methotrexate may have greater methotrexate polyglutamate accumulation as compared to patients with the TT genotype. Other genetic and clinical factors may also influence methotrexate polyglutamate accumulation.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655385749>3278</a></td><td>CYP3A4</td><td>rs12721627</td><td>midazolam</td><td></td><td>3</td><td>GG</td><td>Other</td><td>The expression of a construct caring the G variant is not associated with decreased clearance of midazolam in transfected cells.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655386083>3279</a></td><td>SLC22A16</td><td>rs714368</td><td>doxorubicin</td><td>Breast Neoplasms</td><td>3</td><td>CT</td><td>Other</td><td>Patients with the CT genotype may have decreased exposure to doxorubicin and its metabolite doxorubicinol compared to patients with the genotype CC. Other genetic and clinical factors may also influence exposure to doxorubicin and doxorubicinol.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655386083>3280</a></td><td>SLC22A16</td><td>rs714368</td><td>doxorubicinol</td><td>Breast Neoplasms</td><td>3</td><td>CT</td><td>Other</td><td>Patients with the CT genotype may have decreased exposure to doxorubicin and its metabolite doxorubicinol compared to patients with the genotype CC. Other genetic and clinical factors may also influence exposure to doxorubicin and doxorubicinol.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655388022>3281</a></td><td>ABCB1</td><td>rs1045642</td><td>prednisone</td><td>Organ Transplantation;Transplantation</td><td>3</td><td>AA</td><td>Other</td><td>Pediatric patients with the AA genotype who are treated with prednisone and tacrolimus may have a decreased risk of remaining on steroids 1 year after heart transplantation compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of remaining on steroids 1 year after transplantation.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655388022>3282</a></td><td>ABCB1</td><td>rs1045642</td><td>tacrolimus</td><td>Organ Transplantation;Transplantation</td><td>3</td><td>AA</td><td>Other</td><td>Pediatric patients with the AA genotype who are treated with prednisone and tacrolimus may have a decreased risk of remaining on steroids 1 year after heart transplantation compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of remaining on steroids 1 year after transplantation.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/613977064>3283</a></td><td>CHRNA4</td><td>rs2236196</td><td>nicotine</td><td>Tobacco Use Disorder</td><td>3</td><td>AA</td><td>Other</td><td>Patients with the AA genotype may have an increased risk for nicotine dependence as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for nicotine dependence.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/618376538>3284</a></td><td>CHRNA4</td><td>rs2236196</td><td>nicotine</td><td>Tobacco Use Disorder</td><td>3</td><td>AA</td><td>Other</td><td>Patients with the AA genotype may have a decreased, but not absent, risk for nicotine dependence as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's risk for nicotine dependence.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655384821>3285</a></td><td>SLCO1B1</td><td>rs2306283</td><td>repaglinide</td><td></td><td>3</td><td>AG</td><td>Other</td><td>While the GG genotype is associated with reduced plasma concentrations of repaglinide, no results are shown for the GA genotype.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655384854>3286</a></td><td>CYP3A4</td><td>rs2740574</td><td>indinavir</td><td>HIV Infections</td><td>3</td><td>TT</td><td>Other</td><td>Patients with the TT genotype and HIV infection may have increased metabolism of indinavir compared to patients with the CC genotype. Other genetic and clinical factors may also influence indinavir metabolism.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655385045>3287</a></td><td>NR1I2</td><td>rs2472677</td><td>rifampin</td><td></td><td>3</td><td>TT</td><td>Other</td><td>Genotype TT is associated with lower CYP3A4 acitvity induced by rifampin compared with genotype CC, particularly in livers from male subjects.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655385361>3288</a></td><td>CHRNA4</td><td>rs1044396</td><td>nicotine</td><td>Tobacco Use Disorder</td><td>3</td><td>AG</td><td>Other</td><td>The AG genotype was found more often in smokers as compared to the AA genotype (smoker OR = 1.13). In the White population the association with nicotine dependence based on the Fagerstrom test for nicotine dependence was not significant and only included male subjects in the study with Asian population. Other genetic and clinical factors may also influence a patient's risk for nicotine dependence.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449575633>3289</a></td><td>DPYD</td><td>rs188052243</td><td>fluorouracil</td><td></td><td>3</td><td>TT</td><td>Other</td><td>The TT genotype is associated with increased catalytic activity of DPYD as compared to the CT or CC genotypes. Other clinical and genetic factors may also influence catalytic activity of DPYD.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449575696>3290</a></td><td>DPYD</td><td>rs1212037891</td><td>fluorouracil</td><td></td><td>3</td><td>AA</td><td>Other</td><td>The AA genotype is associated with decreased expression of DPYD as compared to the AT or TT genotypes. Other clinical and genetic factors may also influence DPYD protein expression.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/981237922>3291</a></td><td>ABCB1</td><td>rs1128503</td><td>phenytoin</td><td></td><td>3</td><td>AG</td><td>Other</td><td>Patients with the AG genotype who receive phenytoin may have increased plasma drug levels of phenytoin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to phenytoin.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/981204444>3292</a></td><td>ABCB1</td><td>rs1045642</td><td>rhodamine 123</td><td></td><td>3</td><td>AA</td><td>Other</td><td>Genotype AA may be associated with decreased efflux of rhodamine from CD56+ natural killer cells when exposed to rhodamine 123 as compared to genotypes GG. However, contradictory finding has been reported.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/981203886>3293</a></td><td>CYP3A5</td><td>rs776746</td><td>nevirapine</td><td>HIV Infections</td><td>4</td><td>CC</td><td>Other</td><td>Patients with the CC genotype and HIV infection who are treated with nevirapine may have increased clearance of the drug as compared to patients with the CT and TT genotype. Association with clearance was not found in a larger cohort in a separate study. Patients may also have differences in alanine aminotransferase levels, but association with toxicity has not been reported. Other genetic and clinical factors may also influence clearance of nevirapine.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/981203954>3294</a></td><td>UGT2B7</td><td>rs7439366</td><td>efavirenz</td><td>HIV Infections</td><td>4</td><td>CT</td><td>Other</td><td>Patients with the CT genotype and HIV infection who are treated with efavirenz may have higher plasma concentrations of the drug as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's exposure to efavirenz.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/981204455>3295</a></td><td>ABCB1</td><td>rs1045642</td><td>dicloxacillin</td><td></td><td>3</td><td>AA</td><td>Other</td><td>Genotype AA may be associated with decreased clearance of dicloxacillin when treated with dicloxacillin and probenecid as compared to genotype GG. however, another report showed no association between this variant and PK of dicloxacillin. Other genetic and clinical factors may also influence the pharmacokinetics of dicloxacillin.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/981203918>3296</a></td><td>CYP3A5</td><td>rs776746</td><td>efavirenz</td><td>HIV Infections</td><td>4</td><td>CC</td><td>Other</td><td>Patients with the CC genotype and HIV infection who are treated with efavirenz may have decreased exposure to drug as compared to patients with the TT genotype. Please note; an association with efavirenz exposure and this genetic variant was not found in the majority of studies. Other genetic and clinical factors may also influence a patient's exposure to efavirenz.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451274045>3297</a></td><td>DPYD</td><td>rs67376798</td><td>fluorouracil</td><td></td><td>1A</td><td>TT</td><td>Other</td><td>The A allele of this variant, when measured on plus chromosomal strand, is assigned decreased function by CPIC. Patients with the TT genotype may have increased activity of DPYD as compared to patients with the AT or AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence catalytic activity of DPYD.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449164863>3298</a></td><td>SLC6A2</td><td>rs36029</td><td>3,4-methylenedioxymethamphetamine</td><td></td><td>3</td><td>AG</td><td>Other</td><td>Individuals with the AG genotype who are exposed to (3,4-methylenedioxymethamphetamine) MDMA may have a decreased response, specifically mean arterial pressure, as compared to patients with the AA genotype. Other clinical and genetic factors may also influence an individual's response to MDMA.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449164869>3299</a></td><td>SLC6A2</td><td>rs1861647</td><td>3,4-methylenedioxymethamphetamine</td><td></td><td>3</td><td>AG</td><td>Other</td><td>Individuals with the AG genotype who are exposed to (3,4-methylenedioxymethamphetamine) MDMA may have a decreased response, specifically a decreased heart rate, as compared to patients with the GG genotype. Other clinical and genetic factors may also influence an individual's response to MDMA.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1451608148>3300</a></td><td>AKR1C3</td><td>rs1937840</td><td>doxorubicin</td><td>Breast Neoplasms</td><td>3</td><td>CG</td><td>Other</td><td>Patients with breast cancer and the rs1937840 CG genotype may have increased absolute leucocyte and neutrophil counts when treated with doxorubicin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence absolute leucocyte and neutrophil counts when treated with doxorubicin.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1450931815>3301</a></td><td>ADRB2</td><td>rs1042718</td><td>fentanyl</td><td></td><td>3</td><td>AC</td><td>Other</td><td>Patients with the AC genotype may be more likely to experience a reduction in systolic blood pressure following fentanyl administration as compared to patients with the AA or CC genotypes. Note that this association was not significant. Other genetic and clinical factors may also affect a patient's response to fentanyl.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449005382>3302</a></td><td>RABEP1</td><td>rs1000940</td><td>amisulpride</td><td>Bipolar Disorder;Depressive Disorder;Psychotic Disorders;schizoaffective disorder</td><td>3</td><td>AA</td><td>Other</td><td>Patients with bipolar, depressive, psychotic, or schizoaffective disorders and the AA genotype who are administered amisulpride, aripiprazole, clozapine, olanzapine, quetiapine, paliperidone, risperidone, lithium, valproate or/and mirtazapine may have greater elevations of fasting glucose concentrations as compared to patients with the AG or GG genotypes. Other clinical and genetic factors may also influence fasting glucose concentrations in patients administered these medications.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449005382>3303</a></td><td>RABEP1</td><td>rs1000940</td><td>aripiprazole</td><td>Bipolar Disorder;Depressive Disorder;Psychotic Disorders;schizoaffective disorder</td><td>3</td><td>AA</td><td>Other</td><td>Patients with bipolar, depressive, psychotic, or schizoaffective disorders and the AA genotype who are administered amisulpride, aripiprazole, clozapine, olanzapine, quetiapine, paliperidone, risperidone, lithium, valproate or/and mirtazapine may have greater elevations of fasting glucose concentrations as compared to patients with the AG or GG genotypes. Other clinical and genetic factors may also influence fasting glucose concentrations in patients administered these medications.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449005382>3304</a></td><td>RABEP1</td><td>rs1000940</td><td>clozapine</td><td>Bipolar Disorder;Depressive Disorder;Psychotic Disorders;schizoaffective disorder</td><td>3</td><td>AA</td><td>Other</td><td>Patients with bipolar, depressive, psychotic, or schizoaffective disorders and the AA genotype who are administered amisulpride, aripiprazole, clozapine, olanzapine, quetiapine, paliperidone, risperidone, lithium, valproate or/and mirtazapine may have greater elevations of fasting glucose concentrations as compared to patients with the AG or GG genotypes. Other clinical and genetic factors may also influence fasting glucose concentrations in patients administered these medications.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449005382>3305</a></td><td>RABEP1</td><td>rs1000940</td><td>lithium</td><td>Bipolar Disorder;Depressive Disorder;Psychotic Disorders;schizoaffective disorder</td><td>3</td><td>AA</td><td>Other</td><td>Patients with bipolar, depressive, psychotic, or schizoaffective disorders and the AA genotype who are administered amisulpride, aripiprazole, clozapine, olanzapine, quetiapine, paliperidone, risperidone, lithium, valproate or/and mirtazapine may have greater elevations of fasting glucose concentrations as compared to patients with the AG or GG genotypes. Other clinical and genetic factors may also influence fasting glucose concentrations in patients administered these medications.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449005382>3306</a></td><td>RABEP1</td><td>rs1000940</td><td>mirtazapine</td><td>Bipolar Disorder;Depressive Disorder;Psychotic Disorders;schizoaffective disorder</td><td>3</td><td>AA</td><td>Other</td><td>Patients with bipolar, depressive, psychotic, or schizoaffective disorders and the AA genotype who are administered amisulpride, aripiprazole, clozapine, olanzapine, quetiapine, paliperidone, risperidone, lithium, valproate or/and mirtazapine may have greater elevations of fasting glucose concentrations as compared to patients with the AG or GG genotypes. Other clinical and genetic factors may also influence fasting glucose concentrations in patients administered these medications.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449005382>3307</a></td><td>RABEP1</td><td>rs1000940</td><td>olanzapine</td><td>Bipolar Disorder;Depressive Disorder;Psychotic Disorders;schizoaffective disorder</td><td>3</td><td>AA</td><td>Other</td><td>Patients with bipolar, depressive, psychotic, or schizoaffective disorders and the AA genotype who are administered amisulpride, aripiprazole, clozapine, olanzapine, quetiapine, paliperidone, risperidone, lithium, valproate or/and mirtazapine may have greater elevations of fasting glucose concentrations as compared to patients with the AG or GG genotypes. Other clinical and genetic factors may also influence fasting glucose concentrations in patients administered these medications.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449005382>3308</a></td><td>RABEP1</td><td>rs1000940</td><td>paliperidone</td><td>Bipolar Disorder;Depressive Disorder;Psychotic Disorders;schizoaffective disorder</td><td>3</td><td>AA</td><td>Other</td><td>Patients with bipolar, depressive, psychotic, or schizoaffective disorders and the AA genotype who are administered amisulpride, aripiprazole, clozapine, olanzapine, quetiapine, paliperidone, risperidone, lithium, valproate or/and mirtazapine may have greater elevations of fasting glucose concentrations as compared to patients with the AG or GG genotypes. Other clinical and genetic factors may also influence fasting glucose concentrations in patients administered these medications.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449005382>3309</a></td><td>RABEP1</td><td>rs1000940</td><td>quetiapine</td><td>Bipolar Disorder;Depressive Disorder;Psychotic Disorders;schizoaffective disorder</td><td>3</td><td>AA</td><td>Other</td><td>Patients with bipolar, depressive, psychotic, or schizoaffective disorders and the AA genotype who are administered amisulpride, aripiprazole, clozapine, olanzapine, quetiapine, paliperidone, risperidone, lithium, valproate or/and mirtazapine may have greater elevations of fasting glucose concentrations as compared to patients with the AG or GG genotypes. Other clinical and genetic factors may also influence fasting glucose concentrations in patients administered these medications.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449005382>3310</a></td><td>RABEP1</td><td>rs1000940</td><td>risperidone</td><td>Bipolar Disorder;Depressive Disorder;Psychotic Disorders;schizoaffective disorder</td><td>3</td><td>AA</td><td>Other</td><td>Patients with bipolar, depressive, psychotic, or schizoaffective disorders and the AA genotype who are administered amisulpride, aripiprazole, clozapine, olanzapine, quetiapine, paliperidone, risperidone, lithium, valproate or/and mirtazapine may have greater elevations of fasting glucose concentrations as compared to patients with the AG or GG genotypes. Other clinical and genetic factors may also influence fasting glucose concentrations in patients administered these medications.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449005382>3311</a></td><td>RABEP1</td><td>rs1000940</td><td>valproic acid</td><td>Bipolar Disorder;Depressive Disorder;Psychotic Disorders;schizoaffective disorder</td><td>3</td><td>AA</td><td>Other</td><td>Patients with bipolar, depressive, psychotic, or schizoaffective disorders and the AA genotype who are administered amisulpride, aripiprazole, clozapine, olanzapine, quetiapine, paliperidone, risperidone, lithium, valproate or/and mirtazapine may have greater elevations of fasting glucose concentrations as compared to patients with the AG or GG genotypes. Other clinical and genetic factors may also influence fasting glucose concentrations in patients administered these medications.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183704272>3312</a></td><td>SLCO1B3</td><td>rs7311358</td><td>docetaxel</td><td></td><td>3</td><td>AA</td><td>Other</td><td>Patients with the AA genotype may have increased AUC and decreased clearance of docetaxel in people with Nasopharyngeal Neoplasms as compared to patients with genotype GG. Other genetic and clinical factors may also influence the clearance of docetaxel.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184514449>3313</a></td><td>GRM3</td><td>rs274618</td><td>heroin</td><td>Heroin Dependence</td><td>3</td><td>AA</td><td>Other</td><td>Patients with the AA genotype may have a decreased risk of Heroin Dependence when exposed to heroin as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk of Heroin Dependence.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184514458>3314</a></td><td>GRM3</td><td>rs1990040</td><td>heroin</td><td>Heroin Dependence</td><td>3</td><td>AG</td><td>Other</td><td>Patients with the AG genotype may have a decreased risk of Heroin Dependence when exposed to heroin as compared to patients with the AA genotype and an increased risk of Heroin Dependence when exposed to heroin as compared to patients with the GG genotype. Other genetic and clinical factors may also influence risk of Heroin Dependence.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184514464>3315</a></td><td>GRM3</td><td>rs13242038</td><td>heroin</td><td>Heroin Dependence</td><td>3</td><td>CT</td><td>Other</td><td>Patients with the CT genotype may have a decreased risk of Heroin Dependence when exposed to heroin as compared to patients with the TT genotype and an increased risk of Heroin Dependence as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of Heroin Dependence.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184514469>3316</a></td><td>GRM3</td><td>rs724226</td><td>heroin</td><td>Heroin Dependence</td><td>3</td><td>GG</td><td>Other</td><td>Patients with the GG genotype may have a decreased risk of Heroin Dependence when exposed to heroin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of Heroin Dependence.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184514474>3317</a></td><td>GRM3</td><td>rs2189814</td><td>heroin</td><td>Heroin Dependence</td><td>3</td><td>CT</td><td>Other</td><td>Patients with the CT genotype may have a decreased risk of Heroin Dependence as compared to patients with the TT genotype and an increased risk of Heroin Dependence as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of Heroin Dependence.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184472550>3318</a></td><td>ABCB1</td><td>rs1045642</td><td>hmg coa reductase inhibitors</td><td></td><td>3</td><td>AA</td><td>Other</td><td>Patients with the AA genotype may have increased serum creatine kinase levels when treated with hmg CoA reductase inhibitors as compared to patients with the AG, or GG genotype. Other genetic and clinical factors may also influence serum creatine kinase levels.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184472555>3319</a></td><td>ABCB1</td><td>rs1128503</td><td>hmg coa reductase inhibitors</td><td></td><td>3</td><td>AG</td><td>Other</td><td>Patients with the rs1128503 AG genotype may have decreased serum creatine kinase levels when treated with hmg CoA reductase inhibitors as compared to patients with the AA genotype. Other genetic and clinical factors may also influence serum creatine kinase levels.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184472751>3320</a></td><td>CDA</td><td>rs1048977</td><td>gemcitabine</td><td>Neoplasms</td><td>3</td><td>TT</td><td>Other</td><td>Patients with cancer and the TT genotype may have decreased metabolism of gemcitabine as compared to patients with the CC genotype. However, this has been contradicted by some studies. Other genetic and clinical factors may also influence metabolism of gemcitabine.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184233711>3321</a></td><td>ABCB1</td><td>rs1045642</td><td>efavirenz</td><td>HIV Infections</td><td>3</td><td>AA</td><td>Other</td><td>Patients with the AA genotype and HIV infection who are treated with efavirenz may have increased clearance of efavirenz as compared to patients with the AG or GG genotype. Some studies have shown no association between this polymorphism and efavirenz clearance, plasma concentrations or exposure, or PBMC concentrations. Other genetic and clinical factors may also influence efavirenz pharmacokinetics.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184133889>3322</a></td><td>ABCB1</td><td>rs3842</td><td>efavirenz</td><td>HIV Infections</td><td>3</td><td>CT</td><td>Other</td><td>Patients with the CT genotype, and HIV infection, may have increased exposure to efavirenz compared to patients with the TT genotype. Other genetic and clinical factors may also influence metabolism of efavirenz and patient's exposure to the drug.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1183863836>3323</a></td><td>UGT1A1</td><td>rs887829</td><td>atazanavir</td><td>HIV Infections</td><td>3</td><td>CT</td><td>Other</td><td>Patients infected with the human immunodeficiency virus (HIV) and the CT genotype who are treated with atazanavir may have a decreased, but not absent, risk of hyperbilirubinemia and bilirubin-related drug discontinuation as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for hyperbilirubinemia, or drug discontinuation.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184233486>3324</a></td><td>COMT</td><td>rs6269</td><td>opioids</td><td>Pain</td><td>3</td><td>GG</td><td>Other</td><td>Patients with the GG genotype may be more likely to require postoperative intervention with opioids after adenotonsillectomy as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's requirement for pain management.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184233517>3325</a></td><td>COMT</td><td>rs4818</td><td>opioids</td><td>Pain</td><td>3</td><td>GG</td><td>Other</td><td>Patients with the GG genotype may be more likely to require postoperative intervention with opioids after adenotonsillectomy as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's requirement for pain management.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184986744>3326</a></td><td>OPRD1</td><td>rs2236861</td><td>opioids</td><td>Opioid-Related Disorders</td><td>3</td><td>AG</td><td>Other</td><td>Patients with the AG genotype may have a decreased risk of opioid dependence when exposed to opioids as compared to patients with the GG genotype and an increased risk of opioid dependence when exposed to opioids as compared to patients with the AA genotype. Other clinical and genetic factors may influence risk of opioid dependence when exposed to opioids.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444703884>3327</a></td><td>CA12</td><td>rs4984241</td><td>topiramate</td><td></td><td>3</td><td>AG</td><td>Other</td><td>Patients with the AG genotype who are treated with topiramate or zonisamide may have decreased serum bicarbonate levels as compared to patients with the GG genotype or may have increased serum bicarbonate levels as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to topiramate or zonisamide.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444703884>3328</a></td><td>CA12</td><td>rs4984241</td><td>zonisamide</td><td></td><td>3</td><td>AG</td><td>Other</td><td>Patients with the AG genotype who are treated with topiramate or zonisamide may have decreased serum bicarbonate levels as compared to patients with the GG genotype or may have increased serum bicarbonate levels as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to topiramate or zonisamide.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1446905759>3329</a></td><td>FDPS</td><td>rs2297480</td><td>atorvastatin</td><td>Coronary Disease</td><td>3</td><td>GT</td><td>Other</td><td>Patients with the GT genotype may have decreased bone density when treated with atorvastatin in people with Coronary Disease as compared to patients with genotype TT. Other genetic and clinical factors may also influence the bone response to atorvastatin.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447681808>3330</a></td><td>CYP19A1</td><td>rs10046</td><td>hdl cholesterol</td><td>Breast Neoplasms;Menopause</td><td>3</td><td>AA</td><td>Other</td><td>Post-menopausal women with the AA genotype and breast cancer, who are taking letrozole may have decreased plasma concentrations of triglycerides and elevated concentrations of hdl cholsterol as compared to women with the AG or GG genotypes. Other clinical and genetic factors may also influence triglyceride levels in postmenopausal women with breast cancer who are taking letrozole.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447681808>3331</a></td><td>CYP19A1</td><td>rs10046</td><td>letrozole</td><td>Breast Neoplasms;Menopause</td><td>3</td><td>AA</td><td>Other</td><td>Post-menopausal women with the AA genotype and breast cancer, who are taking letrozole may have decreased plasma concentrations of triglycerides and elevated concentrations of hdl cholsterol as compared to women with the AG or GG genotypes. Other clinical and genetic factors may also influence triglyceride levels in postmenopausal women with breast cancer who are taking letrozole.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447681808>3332</a></td><td>CYP19A1</td><td>rs10046</td><td>triglycerides</td><td>Breast Neoplasms;Menopause</td><td>3</td><td>AA</td><td>Other</td><td>Post-menopausal women with the AA genotype and breast cancer, who are taking letrozole may have decreased plasma concentrations of triglycerides and elevated concentrations of hdl cholsterol as compared to women with the AG or GG genotypes. Other clinical and genetic factors may also influence triglyceride levels in postmenopausal women with breast cancer who are taking letrozole.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444700474>3333</a></td><td>ABCG2</td><td>rs45605536</td><td>dasatinib</td><td></td><td>3</td><td>CC</td><td>Other</td><td>Patients with CC genotype may have a decreased sensitivity to dasatinib or imatinib as compared to patients with TT genotype. The association is based on in-vitro finding in K562 cells. Other genetic and clinical factors may also influence a patient's response to dasatinib or imatinib.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444700474>3334</a></td><td>ABCG2</td><td>rs45605536</td><td>imatinib</td><td></td><td>3</td><td>CC</td><td>Other</td><td>Patients with CC genotype may have a decreased sensitivity to dasatinib or imatinib as compared to patients with TT genotype. The association is based on in-vitro finding in K562 cells. Other genetic and clinical factors may also influence a patient's response to dasatinib or imatinib.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444700495>3335</a></td><td>ABCG2</td><td>rs41282401</td><td>dasatinib</td><td></td><td>3</td><td>CC</td><td>Other</td><td>Patients with CC genotype may have an increased sensitivity to dasatinib or imatinib or nilotinib as compared to patients with GG genotype. The association is based on in-vitro finding in K562 cells. Other genetic and clinical factors may also influence a patient's response to dasatinib, imatinib or nilotinib.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444700495>3336</a></td><td>ABCG2</td><td>rs41282401</td><td>imatinib</td><td></td><td>3</td><td>CC</td><td>Other</td><td>Patients with CC genotype may have an increased sensitivity to dasatinib or imatinib or nilotinib as compared to patients with GG genotype. The association is based on in-vitro finding in K562 cells. Other genetic and clinical factors may also influence a patient's response to dasatinib, imatinib or nilotinib.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444700495>3337</a></td><td>ABCG2</td><td>rs41282401</td><td>nilotinib</td><td></td><td>3</td><td>CC</td><td>Other</td><td>Patients with CC genotype may have an increased sensitivity to dasatinib or imatinib or nilotinib as compared to patients with GG genotype. The association is based on in-vitro finding in K562 cells. Other genetic and clinical factors may also influence a patient's response to dasatinib, imatinib or nilotinib.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444704810>3338</a></td><td>ARRB2</td><td>rs1045280</td><td>methamphetamine</td><td>Substance-Related Disorders</td><td>3</td><td>CT</td><td>Other</td><td>Patients with the TT genotype may have increased likelihood of Substance-Related Disorders when exposed to methamphetamine as compared to CC genotype or may have decreased likelihood of Substance-Related Disorders when exposed to methamphetamine as compared to TT genotype. Other genetic and clinical factors may also influence a patient's response to methamphetamine.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447680068>3339</a></td><td>CYP19A1</td><td>rs4646</td><td>letrozole</td><td>Breast Neoplasms;Menopause</td><td>3</td><td>CC</td><td>Other</td><td>Post-menopausal women with the CC genotype and breast cancer, who are taking letrozole, alone or with a statin may have increased plasma concentrations of hdl cholesterol as compared to women with the AA or AC genotypes. Other clinical and genetic factors may also influence hdl cholesterol levels in post-menopausal women with breast cancer who are taking letrozole alone or in combination with a statin.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447681831>3340</a></td><td>CYP19A1</td><td>rs2289105</td><td>hdl cholesterol</td><td>Breast Neoplasms;Menopause</td><td>3</td><td>CC</td><td>Other</td><td>Post-menopausal women with the CC genotype and breast cancer, who are taking letrozole may have decreased plasma concentrations of triglycerides and increased plasma concentrations of hdl cholsterol as compared to patients with the CT or TT genotypes. Other clinical and genetic factors may also influence plasma triglyceride or cholesterol concentrations in postmenopausal women with breast cancer who are taking letrozole.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447681831>3341</a></td><td>CYP19A1</td><td>rs2289105</td><td>letrozole</td><td>Breast Neoplasms;Menopause</td><td>3</td><td>CC</td><td>Other</td><td>Post-menopausal women with the CC genotype and breast cancer, who are taking letrozole may have decreased plasma concentrations of triglycerides and increased plasma concentrations of hdl cholsterol as compared to patients with the CT or TT genotypes. Other clinical and genetic factors may also influence plasma triglyceride or cholesterol concentrations in postmenopausal women with breast cancer who are taking letrozole.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447681831>3342</a></td><td>CYP19A1</td><td>rs2289105</td><td>triglycerides</td><td>Breast Neoplasms;Menopause</td><td>3</td><td>CC</td><td>Other</td><td>Post-menopausal women with the CC genotype and breast cancer, who are taking letrozole may have decreased plasma concentrations of triglycerides and increased plasma concentrations of hdl cholsterol as compared to patients with the CT or TT genotypes. Other clinical and genetic factors may also influence plasma triglyceride or cholesterol concentrations in postmenopausal women with breast cancer who are taking letrozole.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447681869>3343</a></td><td>CYP19A1</td><td>rs3759811</td><td>letrozole</td><td>Breast Neoplasms;Menopause</td><td>3</td><td>CT</td><td>Other</td><td>Post-menopausal women with breast cancer and the CT genotype who are taking letrozole, with or without a statin, may have decreased plasma concentrations of triglycerides as compared to women with the TT genotypes and increased concentrations as compared to women with the CC genotype. Other clinical and genetic factors may also influence plasma concentrations of triglycerides in post-menopausal women with breast cancer.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447681876>3344</a></td><td>CYP19A1</td><td>rs4775936</td><td>letrozole</td><td>Breast Neoplasms;Menopause</td><td>3</td><td>CT</td><td>Other</td><td>Post-menopausal women with the CT genotype and breast cancer, who are taking letrozole, alone or with a statin may have decreased plasma concentrations of triglycerides as compared to women with TT genotypes and increased levels as compared to women with the CC genotype. Other clinical and genetic factors may also influence triglyceride levels in postmenopausal women with breast cancer who are taking letrozole alone or in combination with a statin.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447681883>3345</a></td><td>CYP19A1</td><td>rs1008805</td><td>hmg coa reductase inhibitors</td><td>Breast Neoplasms;Menopause</td><td>3</td><td>AA</td><td>Other</td><td>Post-menopausal women with the AA genotype and breast cancer, who are taking letrozole with a statin may have increased plasma concentrations of hdl cholesterol as compared to women with the AG or GG genotypes. Other clinical and genetic factors may also influence hdl cholesterol levels in post-menopausal women with breast cancer who are taking letrozole alone in combination with a statin.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447681883>3346</a></td><td>CYP19A1</td><td>rs1008805</td><td>letrozole</td><td>Breast Neoplasms;Menopause</td><td>3</td><td>AA</td><td>Other</td><td>Post-menopausal women with the AA genotype and breast cancer, who are taking letrozole with a statin may have increased plasma concentrations of hdl cholesterol as compared to women with the AG or GG genotypes. Other clinical and genetic factors may also influence hdl cholesterol levels in post-menopausal women with breast cancer who are taking letrozole alone in combination with a statin.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447681902>3347</a></td><td>CYP19A1</td><td>rs749292</td><td>letrozole</td><td>Breast Neoplasms;Menopause</td><td>3</td><td>AA</td><td>Other</td><td>Post-menopausal women with the AA genotype and breast cancer, who are taking letrozole, alone or with a statin, may have decreased plasma concentrations of triglycerides as compared to women with the AG or GG genotypes. Other clinical and genetic factors may also influence triglyceride levels in postmenopausal women with breast cancer who are taking letrozole alone or in combination with a statin.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447682300>3348</a></td><td>CYP19A1</td><td>rs1062033</td><td>hmg coa reductase inhibitors</td><td>Breast Neoplasms;Menopause</td><td>3</td><td>CG</td><td>Other</td><td>Post-menopausal women with breast cancer and the CG genotype may have increased concentrations of plasma HDL cholesterol when taking letrozole in combination with a statin, as compared to women with the CC genotypes and decreased concentrations as compared to women with the GG genotype. Other clinical and genetic factors may also influence plasma triglyceride levels in post-menopausal women with breast cancer.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447682300>3349</a></td><td>CYP19A1</td><td>rs1062033</td><td>letrozole</td><td>Breast Neoplasms;Menopause</td><td>3</td><td>CG</td><td>Other</td><td>Post-menopausal women with breast cancer and the CG genotype may have increased concentrations of plasma HDL cholesterol when taking letrozole in combination with a statin, as compared to women with the CC genotypes and decreased concentrations as compared to women with the GG genotype. Other clinical and genetic factors may also influence plasma triglyceride levels in post-menopausal women with breast cancer.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184998947>3350</a></td><td>ABCB1</td><td>rs1045642</td><td>morphine</td><td>Pain</td><td>3</td><td>AA</td><td>Other</td><td>Patients with the AA genotype who are treated with morphine may have higher levels of morphine-3-glucuronide formation as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's metabolism of morphine.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184986491>3351</a></td><td>PPARA</td><td>rs4823613</td><td>tacrolimus</td><td>Organ Transplantation</td><td>3</td><td>AA</td><td>Other</td><td>Patients with the AA genotype and organ transplantation administered tacrolimus may have increased metabolism of tacrolimus as compared to patients with the GG genotype. Other genetic and clinical factors may affect metabolism of tacrolimus in organ transplant patients administered tacrolimus.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184986763>3352</a></td><td>ABCB1</td><td>rs1045642</td><td>opioids</td><td>Opioid-Related Disorders</td><td>3</td><td>AA</td><td>Other</td><td>Patients with the AA genotype may have a decreased risk of opioid dependence when exposed to opioids as compared to patients with the AG or GG genotypes. Other clinical and genetic factors may also influence risk of opioid dependence upon exposure to opioids.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444607295>3353</a></td><td>CNR1</td><td>rs806368</td><td>cocaine</td><td>Cocaine-Related Disorders</td><td>3</td><td>CT</td><td>Other</td><td>Individuals with the CT genotype may have a decreased risk of cocaine dependence as compared to those with the TT genotype. Other genetic and clinical factors may also influence risk of cocaine dependence.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444607302>3354</a></td><td>CNR1</td><td>rs6454674</td><td>cocaine</td><td>Cocaine-Related Disorders</td><td>3</td><td>GT</td><td>Other</td><td>Individuals with the GT genotype may have an increased risk of cocaine dependence as compared to individuals with the GG genotype. Other genetic and clinical factors may also influence risk of cocaine dependence.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184986567>3355</a></td><td>TLR4</td><td>rs1927907</td><td>tacrolimus</td><td>Organ Transplantation</td><td>3</td><td>CC</td><td>Other</td><td>Organ transplant patients with the CC genotype who are administered tacrolimus may have increased dose adjusted trough concentration of tacrolimus as compared to organ transplant patients with the CT and TT genotypes. Other clinical and genetic factors may also influence dose adjusted trough concentration of tacrolimus in organ transplant patients.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184986654>3356</a></td><td>NR1I2</td><td>rs3814058</td><td>repaglinide</td><td></td><td>3</td><td>CT</td><td>Other</td><td>The CT genotype did not differ significantly in metabolism of repaglinide as compared to patients with the CC or TT genotypes. Other clinical and genetic factors may also influence metabolism of repaglinide.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184986643>3357</a></td><td>NR1I2</td><td>rs2276706</td><td>repaglinide</td><td></td><td>3</td><td>GG</td><td>Other</td><td>Patients with the GG genotype may have decreased metabolism of repaglinide as compared to patients with the AA genotype. Other clinical and genetic factors may also influence metabolism of repaglinide.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444704775>3358</a></td><td>GRIN3A</td><td>rs10121600</td><td>nicotine</td><td>Tobacco Use Disorder</td><td>3</td><td>CC</td><td>Other</td><td>Patients with the CC genotype may have with increased risk for Tobacco Use Disorder when exposed to nicotine as compared to patients with TT genotype. Other genetic and clinical factors may also influence a patient's response to nicotine.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444704861>3359</a></td><td>-</td><td>rs11849538</td><td>estradiol</td><td></td><td>3</td><td>CG</td><td>Other</td><td>Patients with the GG genotype may have increased expression of TCL1A, IL17RA and decreased expression of IL17A, IL12RB2, and IL1R2 when treated with estradiol as compared to patients with the CC genotype or may have decreased expression of TCL1A, IL17RA and increased expression of IL17A, IL12RB2, and IL1R2 when treated with estradiol as compared to patients with the GG genotype based on in-vitro results. Other genetic and clinical factors may also influence a patient's response to estradiol.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444704869>3360</a></td><td>CHRNA4</td><td>rs1044397</td><td>nicotine</td><td>Tobacco Use Disorder</td><td>3</td><td>CT</td><td>Other</td><td>Male patients with the CT genotype may have increased likelihood of Tobacco Use Disorder when exposed to nicotine as compared to patients with the TT genotype or may have decreased likelihood of Tobacco Use Disorder when exposed to nicotine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to nicotine.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444607803>3361</a></td><td>ABCB1</td><td>rs1045642</td><td>olanzapine</td><td>Psychotic Disorders</td><td>3</td><td>AA</td><td>Other</td><td>Patients with the AA genotype and Psychotic Disorders who are treated with olanzapine may have increased social and clinical needs as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence patient's response to olanzapine.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1185000522>3362</a></td><td>ABCB1</td><td>rs1045642</td><td>atazanavir</td><td>HIV Infections</td><td>4</td><td>AA</td><td>Other</td><td>Patients with the AA genotype and HIV may have decreased concentrations of atazanavir as compared to patients with the GG genotypes, and may require dose alteration, although this is contradicted in most studies. There is no evidence that the AA genotype is associated with hyperbilirubinemia, drug discontinuation, treatment failure, or nephrolithiasis. Other clinical and genetic factors may also influence the concentrations of atazanavir in patients with HIV.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1185000522>3363</a></td><td>ABCB1</td><td>rs1045642</td><td>ritonavir</td><td>HIV Infections</td><td>4</td><td>AA</td><td>Other</td><td>Patients with the AA genotype and HIV may have decreased concentrations of atazanavir as compared to patients with the GG genotypes, and may require dose alteration, although this is contradicted in most studies. There is no evidence that the AA genotype is associated with hyperbilirubinemia, drug discontinuation, treatment failure, or nephrolithiasis. Other clinical and genetic factors may also influence the concentrations of atazanavir in patients with HIV.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184987397>3364</a></td><td>-</td><td>rs6901146</td><td>anastrozole</td><td>Breast Neoplasms</td><td>3</td><td>CC</td><td>Other</td><td>Patients with the CC genotype and ER and/or PR positive breast cancer may have a decreased risk of bone fractures when exposed to the aromatase inhibitors anastrazole and exemestane as compared to patients with the CT or TT genotypes. Other clinical and genetic factors may also influence risk of bone fractures in people with ER and/or PR positive breast cancer when exposed to exemestane or anastrazole.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184987397>3365</a></td><td>-</td><td>rs6901146</td><td>exemestane</td><td>Breast Neoplasms</td><td>3</td><td>CC</td><td>Other</td><td>Patients with the CC genotype and ER and/or PR positive breast cancer may have a decreased risk of bone fractures when exposed to the aromatase inhibitors anastrazole and exemestane as compared to patients with the CT or TT genotypes. Other clinical and genetic factors may also influence risk of bone fractures in people with ER and/or PR positive breast cancer when exposed to exemestane or anastrazole.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184987471>3366</a></td><td>DBH</td><td>rs1611115</td><td>Analgesics</td><td>Substance Withdrawal Syndrome</td><td>3</td><td>CC</td><td>Other</td><td>Patients with the CC genotype with substance withdrawal syndrome may have an increased likelihood of headache when discontinuing the use of analgesics (such as opioids, NSAIDs, triptans, ergot) as compared to patients with the TT genotype. Other clinical and genetic factors may also influence likelihood of headache in patients with withdrawal syndrome who discontinue the use of analgesics.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184987471>3367</a></td><td>DBH</td><td>rs1611115</td><td>Antiinflammatory agents, non-steroids</td><td>Substance Withdrawal Syndrome</td><td>3</td><td>CC</td><td>Other</td><td>Patients with the CC genotype with substance withdrawal syndrome may have an increased likelihood of headache when discontinuing the use of analgesics (such as opioids, NSAIDs, triptans, ergot) as compared to patients with the TT genotype. Other clinical and genetic factors may also influence likelihood of headache in patients with withdrawal syndrome who discontinue the use of analgesics.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184987471>3368</a></td><td>DBH</td><td>rs1611115</td><td>Ergot alkaloids</td><td>Substance Withdrawal Syndrome</td><td>3</td><td>CC</td><td>Other</td><td>Patients with the CC genotype with substance withdrawal syndrome may have an increased likelihood of headache when discontinuing the use of analgesics (such as opioids, NSAIDs, triptans, ergot) as compared to patients with the TT genotype. Other clinical and genetic factors may also influence likelihood of headache in patients with withdrawal syndrome who discontinue the use of analgesics.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184987471>3369</a></td><td>DBH</td><td>rs1611115</td><td>opioids</td><td>Substance Withdrawal Syndrome</td><td>3</td><td>CC</td><td>Other</td><td>Patients with the CC genotype with substance withdrawal syndrome may have an increased likelihood of headache when discontinuing the use of analgesics (such as opioids, NSAIDs, triptans, ergot) as compared to patients with the TT genotype. Other clinical and genetic factors may also influence likelihood of headache in patients with withdrawal syndrome who discontinue the use of analgesics.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184987471>3370</a></td><td>DBH</td><td>rs1611115</td><td>sumatriptan</td><td>Substance Withdrawal Syndrome</td><td>3</td><td>CC</td><td>Other</td><td>Patients with the CC genotype with substance withdrawal syndrome may have an increased likelihood of headache when discontinuing the use of analgesics (such as opioids, NSAIDs, triptans, ergot) as compared to patients with the TT genotype. Other clinical and genetic factors may also influence likelihood of headache in patients with withdrawal syndrome who discontinue the use of analgesics.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184987488>3371</a></td><td>BDNF</td><td>rs6265</td><td>Analgesics</td><td></td><td>3</td><td>CT</td><td>Other</td><td>Patients with the CT genotype with substance withdrawal syndrome may have a decreased likelihood of headache when discontinuing the use of analgesics (such as opioids, NSAIDs, triptans, ergot) as compared to patients with the CC genotype. Other clinical and genetic factors may also influence likelihood of headache in patients with withdrawal syndrome who discontinue the use of analgesics.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184987488>3372</a></td><td>BDNF</td><td>rs6265</td><td>Antiinflammatory agents, non-steroids</td><td></td><td>3</td><td>CT</td><td>Other</td><td>Patients with the CT genotype with substance withdrawal syndrome may have a decreased likelihood of headache when discontinuing the use of analgesics (such as opioids, NSAIDs, triptans, ergot) as compared to patients with the CC genotype. Other clinical and genetic factors may also influence likelihood of headache in patients with withdrawal syndrome who discontinue the use of analgesics.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184987488>3373</a></td><td>BDNF</td><td>rs6265</td><td>Ergot alkaloids</td><td></td><td>3</td><td>CT</td><td>Other</td><td>Patients with the CT genotype with substance withdrawal syndrome may have a decreased likelihood of headache when discontinuing the use of analgesics (such as opioids, NSAIDs, triptans, ergot) as compared to patients with the CC genotype. Other clinical and genetic factors may also influence likelihood of headache in patients with withdrawal syndrome who discontinue the use of analgesics.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184987488>3374</a></td><td>BDNF</td><td>rs6265</td><td>opioids</td><td></td><td>3</td><td>CT</td><td>Other</td><td>Patients with the CT genotype with substance withdrawal syndrome may have a decreased likelihood of headache when discontinuing the use of analgesics (such as opioids, NSAIDs, triptans, ergot) as compared to patients with the CC genotype. Other clinical and genetic factors may also influence likelihood of headache in patients with withdrawal syndrome who discontinue the use of analgesics.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184987488>3375</a></td><td>BDNF</td><td>rs6265</td><td>sumatriptan</td><td></td><td>3</td><td>CT</td><td>Other</td><td>Patients with the CT genotype with substance withdrawal syndrome may have a decreased likelihood of headache when discontinuing the use of analgesics (such as opioids, NSAIDs, triptans, ergot) as compared to patients with the CC genotype. Other clinical and genetic factors may also influence likelihood of headache in patients with withdrawal syndrome who discontinue the use of analgesics.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184987503>3376</a></td><td>DRD2</td><td>rs6275</td><td>Analgesics</td><td></td><td>3</td><td>AG</td><td>Other</td><td>Patients with the AG genotype with substance withdrawal syndrome may have an increased likelihood of headache when discontinuing the use of analgesics (such as opioids, NSAIDs, triptans, ergot) as compared to patients with the AA genotype. Other clinical and genetic factors may also influence likelihood of headache in patients with withdrawal syndrome who discontinue the use of analgesics.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184987503>3377</a></td><td>DRD2</td><td>rs6275</td><td>Antiinflammatory agents, non-steroids</td><td></td><td>3</td><td>AG</td><td>Other</td><td>Patients with the AG genotype with substance withdrawal syndrome may have an increased likelihood of headache when discontinuing the use of analgesics (such as opioids, NSAIDs, triptans, ergot) as compared to patients with the AA genotype. Other clinical and genetic factors may also influence likelihood of headache in patients with withdrawal syndrome who discontinue the use of analgesics.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184987503>3378</a></td><td>DRD2</td><td>rs6275</td><td>Ergot alkaloids</td><td></td><td>3</td><td>AG</td><td>Other</td><td>Patients with the AG genotype with substance withdrawal syndrome may have an increased likelihood of headache when discontinuing the use of analgesics (such as opioids, NSAIDs, triptans, ergot) as compared to patients with the AA genotype. Other clinical and genetic factors may also influence likelihood of headache in patients with withdrawal syndrome who discontinue the use of analgesics.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184987503>3379</a></td><td>DRD2</td><td>rs6275</td><td>opioids</td><td></td><td>3</td><td>AG</td><td>Other</td><td>Patients with the AG genotype with substance withdrawal syndrome may have an increased likelihood of headache when discontinuing the use of analgesics (such as opioids, NSAIDs, triptans, ergot) as compared to patients with the AA genotype. Other clinical and genetic factors may also influence likelihood of headache in patients with withdrawal syndrome who discontinue the use of analgesics.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1184987503>3380</a></td><td>DRD2</td><td>rs6275</td><td>sumatriptan</td><td></td><td>3</td><td>AG</td><td>Other</td><td>Patients with the AG genotype with substance withdrawal syndrome may have an increased likelihood of headache when discontinuing the use of analgesics (such as opioids, NSAIDs, triptans, ergot) as compared to patients with the AA genotype. Other clinical and genetic factors may also influence likelihood of headache in patients with withdrawal syndrome who discontinue the use of analgesics.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444704105>3381</a></td><td>FCGR3A</td><td>rs396991</td><td>antithymocyte globulin</td><td>Kidney Transplantation</td><td>3</td><td>AC</td><td>Other</td><td>Patients with the AC genotype and Kidney Transplantation may have increased sensitivity to antilymphocyte serum when treated with antithymocyte globulin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to antithymocyte globulin.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444700566>3382</a></td><td>FMO1</td><td>rs10912675</td><td>nicotine</td><td></td><td>3</td><td>CT</td><td>Other</td><td>Patients with the CT genotype may have an increased risk for nicotine dependence or heavy smoking when exposed to nicotine as compared to patients with the TT genotype and may have a decreased risk for nicotine dependence or heavy smoking when exposed to nicotine as compared to patients with the CC genotype. Other genetic and clinical factors may also effect patients' risk for nicotine dependence.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1444700574>3383</a></td><td>FMO1</td><td>rs7877</td><td>nicotine</td><td></td><td>3</td><td>CT</td><td>Other</td><td>Patients with the CT genotype may have an increased risk for nicotine dependence or heavy smoking when exposed to nicotine as compared to patients with the CC genotype and may have a decreased risk for nicotine dependence or heavy smoking when exposed to nicotine as compared to patients with the TT genotype. Other genetic and clinical factors may also effect patients' risk for nicotine dependence.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447990846>3384</a></td><td>-</td><td>rs2965667</td><td>Antiinflammatory agents, non-steroids</td><td>Colorectal Neoplasms</td><td>3</td><td>TT</td><td>Other</td><td>Individuals with the TT genotype who take non-steroidal anti-inflammatory (NSAID) agents or aspirin were less likely to develop colorectal cancer as compared to patients with the AA or TT genotypes. Other clinical and genetic factors may also influence the likelihood of developing colorectal cancer in individuals taking NSAIDs or aspirin.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447990846>3385</a></td><td>-</td><td>rs2965667</td><td>aspirin</td><td>Colorectal Neoplasms</td><td>3</td><td>TT</td><td>Other</td><td>Individuals with the TT genotype who take non-steroidal anti-inflammatory (NSAID) agents or aspirin were less likely to develop colorectal cancer as compared to patients with the AA or TT genotypes. Other clinical and genetic factors may also influence the likelihood of developing colorectal cancer in individuals taking NSAIDs or aspirin.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1449575674>3386</a></td><td>DPYD</td><td>rs1184321568</td><td>fluorouracil</td><td></td><td>3</td><td>TT</td><td>Other</td><td>The TT genotype is associated with increased catalytic activity of DPYD as compared to the del/del or del/T genotypes. Other clinical and genetic factors may also influence catalytic activity of DPYD.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447954397>3387</a></td><td>CFTR</td><td>rs77010898</td><td>ataluren</td><td>Cystic Fibrosis</td><td>3</td><td>GG</td><td>Other</td><td>Patients with the rs77010898 GG genotype and cystic fibrosis may not have improvement in chloride transport when treated with ataluren. Randomized clinical trials did not find improvement in chloride transport or improved pulmonary function after 2 rounds of 2 weeks of treatment. Other genetic and clinical factors may also influence changes in chloride transport and improvement of pulmonary symptoms in patients with cystic fibrosis.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448103882>3388</a></td><td>DRD2</td><td>rs12364283</td><td>amphetamine</td><td></td><td>3</td><td>AG</td><td>Other</td><td>Patients with the AG genotype who are given amphetamine may have increased stop reaction time, or greater impulsivity, as compared to patients with the AA genotype. Other genetic and clinical factors may also influence stop reaction time.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448103889>3389</a></td><td>GRIN3A</td><td>rs11788456</td><td>nicotine</td><td>Tobacco Use Disorder</td><td>3</td><td>AG</td><td>Other</td><td>Patients with the AG genotype may have a decreased risk for nicotine dependence as compared to patients with the GG genotype, or an increased risk as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk for nicotine dependence.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448103910>3390</a></td><td>KCNJ6</td><td>rs2070995</td><td>methadone</td><td>Heroin Dependence</td><td>3</td><td>CC</td><td>Other</td><td>Patients with the CC genotype who are addicted to heroin may have increased withdrawal symptoms when treated with methadone as compared to patients with the TT genotype. Other genetic and clinical factors may also influence withdrawal symptoms in patients treated with methadone.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448103942>3391</a></td><td>CHRNA3</td><td>rs578776</td><td>ethanol</td><td>Alcoholism</td><td>3</td><td>AG</td><td>Other</td><td>Patients with the AG genotype may have an increased risk for alcoholism as compared to patients with the GG genotype, or a decreased risk as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of alcoholism.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448103949>3392</a></td><td>CHRNA5</td><td>rs615470</td><td>ethanol</td><td>Alcoholism</td><td>3</td><td>CT</td><td>Other</td><td>Patients with the CT genotype may have an increased risk for alcoholism as compared to patients with the TT genotype, or a decreased risk as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of alcoholism.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448103956>3393</a></td><td>CHRNA5</td><td>rs684513</td><td>cocaine</td><td>Cocaine-Related Disorders</td><td>3</td><td>CG</td><td>Other</td><td>Patients with the CG genotype may have a decreased risk for cocaine addiction as compared to patients with the GG genotype, or an increased risk as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of cocaine addiction.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448104043>3394</a></td><td>DRD2</td><td>rs6279</td><td>olanzapine</td><td>Bipolar Disorder;Depression</td><td>3</td><td>CG</td><td>Other</td><td>Female patients with the CG genotype may have decreased prolactin concentrations when treated with olanzapine as compared to patients with the GG genotype, or increased concentrations as compared to patients with the CC genotype. Other genetic and clinical factors may also influence prolactin concentrations.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448104050>3395</a></td><td>DRD2</td><td>rs6275</td><td>olanzapine</td><td>Bipolar Disorder;Depression</td><td>3</td><td>AG</td><td>Other</td><td>Female patients with the AG genotype may have increased prolactin concentrations when treated with olanzapine as compared to patients with the GG genotype, or decreased concentrations as compared to patients with the AA genotype. Other genetic and clinical factors may also influence prolactin concentrations.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447979532>3396</a></td><td>CYP2A6</td><td>rs8192725</td><td>tegafur</td><td></td><td>3</td><td>AG</td><td>Other</td><td>Hepatic cells with the AG genotype may have increased expression of the CYP2A6 gene, resulting in increased metabolism of tegafur, as compared to those with the AA genotype. Other genetic and clinical factors may also influence CYP2A6 expression and tegafur metabolism.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447979548>3397</a></td><td>CYP2A6</td><td>rs28399433</td><td>tegafur</td><td></td><td>3</td><td>AA</td><td>Other</td><td>Hepatic cells with the AA genotype may have increased expression of the CYP2A6 gene, resulting in increased metabolism of tegafur, as compared to those with the AC or CC genotype. Other genetic and clinical factors may also influence CYP2A6 expression and tegafur metabolism.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447989796>3398</a></td><td>DPYD</td><td>rs72728438</td><td>fluorouracil</td><td></td><td>3</td><td>CT</td><td>Other</td><td>Patients with the CT genotype may have decreased DPYD activity when exposed to fluorouracil as compared to patients with the TT genotype. Other genetic and clinical factors may also influence DPYD activity in patients exposed to fluorouracil.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448101220>3399</a></td><td>CHRNA4</td><td>rs2229959</td><td>nicotine</td><td>Tobacco Use Disorder</td><td>3</td><td>AA</td><td>Other</td><td>Patients with the AA genotype who are smokers may have decreased physical responses to smoking as compared to patients with the CC genotype. No association with nicotine addiction has been seen. Other genetic and clinical factors may also influence physical responses to smoking.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448100874>3400</a></td><td>CHRM2</td><td>rs324650</td><td>nicotine</td><td>Tobacco Use Disorder</td><td>3</td><td>AT</td><td>Other</td><td>Patients with the AT genotype may have a decreased risk of becoming addicted to nicotine as compared to patients with the TT genotype, or an increased risk as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of nicotine addiction.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448097837>3401</a></td><td>BCHE</td><td>rs1803274</td><td>cocaine</td><td>Cocaine-Related Disorders</td><td>3</td><td>CT</td><td>Other</td><td>Patients with the CT genotype may be less likely to develop an addiction to crack cocaine as compared to patients with the TT genotype. Other clinical and genetic factors may also be associated with addiction to crack cocaine.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448100201>3402</a></td><td>DRD1</td><td>rs4532</td><td>nicotine</td><td>Tobacco Use Disorder</td><td>3</td><td>CT</td><td>Other</td><td>Patients with the CT genotype may be at decreased risk for nicotine dependence as compared to patients with the TT genotype, or increased risk as compared to patients with the CC genotype. Other genetic and clinical factors may also influence risk of nicotine dependence.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1448100208>3403</a></td><td>DRD1</td><td>rs686</td><td>nicotine</td><td>Tobacco Use Disorder</td><td>3</td><td>AG</td><td>Other</td><td>Patients with the AG genotype may be at increased risk for nicotine dependence as compared to patients with the GG genotype, or decreased risk as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk of nicotine dependence.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447954378>3404</a></td><td>CFTR</td><td>rs113993959</td><td>ataluren</td><td>Cystic Fibrosis</td><td>3</td><td>GG</td><td>Other</td><td>Patients with the rs113993959 GG genotype and cystic fibrosis may not have improvement in chloride transport when treated with ataluren. Randomized clinical trials did not find improvement in chloride transport or improved pulmonary function after 2 rounds of 2 weeks of treatment. Other genetic and clinical factors may also influence changes in chloride transport and improvement of pulmonary symptoms in patients with cystic fibrosis.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/982042110>3405</a></td><td>WNT5B</td><td>rs2010851</td><td>fluorouracil</td><td>Colonic Neoplasms</td><td>3</td><td>AA</td><td>Other</td><td>Colon cancer patients with AA genotype may have longer time to tumor recurrence when treated 5-fluorouracil compared to patients with CC genotypes. Other genetic and clinical factors may also influence the tumor recurrence time.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447990271>3406</a></td><td>GRM3</td><td>rs274622</td><td>heroin</td><td>Heroin Dependence</td><td>3</td><td>TT</td><td>Other</td><td>Patients with the TT genotype may have an decreased risk of addiction to heroin when using heroin as compared to patients with the CT or CC genotype. Other clinical and genetic factors may also influence risk of heroin addiction in individuals who use heroin.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/1447990789>3407</a></td><td>SOD2</td><td>rs4880</td><td>methotrexate</td><td></td><td>3</td><td>AA</td><td>Other</td><td>Peripheral blood mononuclear cells (PBMC) from individuals with the rs4880 AA genotype may be more sensitive to methotrexate as compared to PBMCs from individuals with the AG and GG genotypes. Other clinical and genetic factors may also influence sensitivity to methotrexate in PBMCs.</td><td>Uncertain</td></tr>
<tr><td><a href=https://www.pharmgkb.org/clinicalAnnotation/655385129>3408</a></td><td>HMGCR</td><td>rs3846662</td><td>simvastatin</td><td>Cardiovascular Diseases</td><td>3</td><td>AG</td><td>Other</td><td>The AG genotype may be associated with decreased induction of full-length transcripts and increased expression of spliced HMGCRv_1 transcript as compared to AA genotype.</td><td>Uncertain</td></tr>
</table>
</blockquote>

  <h2>Disclaimers</h2>
  <p>The report incorporates analyses of peer-reviewed studies and other publicly available information identified by CPAT by State Key Laboratory of Genetic Engineering from the School of Life Sciences and Human Phenome Institute, Fudan University, Shanghai, China. These analyses and information may include associations between a molecular alteration (or lack of alteration) and one or more drugs with potential clinical benefit (or potential lack of clinical benefit), including drug candidates that are being studied in clinical research.</p>
  <p>Note: A finding of biomarker alteration does not necessarily indicate pharmacologic effectiveness (or lack thereof) of any drug or treatment regimen; a finding of no biomarker alteration does not necessarily indicate lack of pharmacologic effectiveness (or effectiveness) of any drug or treatment regimen.</p>
  <p>No Guarantee of Clinical Benefit: This Report makes no promises or guarantees that a particular drug will be effective in the treatment of disease in any patient. This report also makes no promises or guarantees that a drug with a potential lack of clinical benefit will provide no clinical benefit.</p>
  <p>Treatment Decisions are Responsibility of Physician: Drugs referenced in this report may not be suitable for a particular patient. The selection of any, all, or none of the drugs associated with potential clinical benefit (or potential lack of clinical benefit) resides entirely within the discretion of the treating physician. Indeed, the information in this report must be considered in conjunction with all other relevant information regarding a particular patient, before the patient's treating physician recommends a course of treatment. Decisions on patient care and treatment must be based on the independent medical judgment of the treating physician, taking into consideration all applicable information concerning the patient's condition, such as patient and family history, physical examinations, information from other diagnostic tests, and patient preferences, following the standard of care in a given community. A treating physician's decisions should not be based on a single test, such as this test or the information contained in this report.</p>
  <p>When using results obtained from CPAT, you agree to cite CPAT.</p>
  
</body>
</html>
